<SEC-DOCUMENT>0001493152-23-010029.txt : 20230331
<SEC-HEADER>0001493152-23-010029.hdr.sgml : 20230331
<ACCEPTANCE-DATETIME>20230331115519
ACCESSION NUMBER:		0001493152-23-010029
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		119
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230331
DATE AS OF CHANGE:		20230331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Agape ATP Corp
		CENTRAL INDEX KEY:			0001713210
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HEALTH SERVICES [8000]
		IRS NUMBER:				364838886
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-220144
		FILM NUMBER:		23785182

	BUSINESS ADDRESS:	
		STREET 1:		1705-1708 LEVEL 17, TOWER 2, FABER TOWER
		STREET 2:		JALAN DESA BAHAGIA, TAMAN DESA
		CITY:			KUALA LUMPUR
		STATE:			N8
		ZIP:			58100
		BUSINESS PHONE:		(603) 27325716

	MAIL ADDRESS:	
		STREET 1:		1705-1708 LEVEL 17, TOWER 2, FABER TOWER
		STREET 2:		JALAN DESA BAHAGIA, TAMAN DESA
		CITY:			KUALA LUMPUR
		STATE:			N8
		ZIP:			58100
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:AATP="http://agapeatp.com/20221231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_03E_AATP_agapeatp.com_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20220101_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0001713210 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_067_RM_0_iso4217%2D%2DMYR -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityCentralIndexKey">0001713210</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0033" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0034" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0059" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AATP:InvestmentInNonMarketableSecuritiesNoncurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0095" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0117" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccountsPayableOtherCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0133" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0144" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="AsOf2022-12-31" id="xdx2ixbrl0147" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0150" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31" id="xdx2ixbrl0159" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-12-31" id="xdx2ixbrl0160" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0236" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AATP:PreferredStockDividendIncomeStatementImpact" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0257" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0312" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0320" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0321" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AATP:ContributionsFromNoncontrollingInterestShareholders" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AATP:ContributionsFromNoncontrollingInterestShareholders" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0325" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AATP:ContributionsFromNoncontrollingInterestShareholders" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0326" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AATP:ContributionsFromNoncontrollingInterestShareholders" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0332" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0349" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0361" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AATP:PreferredStockDividendIncomeStatementImpact" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0397" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0406" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0428" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0431" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToOtherRelatedPartiesCurrent" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0443" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0458" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0469" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AATP:ChangesInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseModifications" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0496" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0585" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0587" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0589" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AATP:InventoryWriteOff" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0599" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0607" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_custom_EnergizedMineralConcentrateMember" id="xdx2ixbrl0666" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_custom_VegeFruitFiberMember" id="xdx2ixbrl0678" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_custom_OrganicYouthCarCleansingBarMember" id="xdx2ixbrl0687" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_custom_LipomaskMember" id="xdx2ixbrl0693" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-12-31_custom_ProductHealthTherapiesMember" id="xdx2ixbrl0703" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-12-31_custom_OthersMember" id="xdx2ixbrl0706" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-12-31_us-gaap_VariableIncomeInterestRateMember" id="xdx2ixbrl0857" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-12-31_us-gaap_VariableIncomeInterestRateMember" id="xdx2ixbrl0858" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2022-01-012022-12-31_us-gaap_VariableIncomeInterestRateMember" id="xdx2ixbrl0860" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2021-01-012021-12-31_us-gaap_VariableIncomeInterestRateMember" id="xdx2ixbrl0861" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccountsReceivableGrossCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0896" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0898" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0899" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0902" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AATP:InventoryWriteOff" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0917" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" contextRef="AsOf2022-12-31" id="xdx2ixbrl0932" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2020-12-31" id="xdx2ixbrl0941" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0943" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0947" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2022-12-31" id="xdx2ixbrl0952" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AATP:TransferFromNonmarketableSecurity" contextRef="AsOf2021-12-31" id="xdx2ixbrl1063" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AATP:InvestmentsIncomeDividend" contextRef="AsOf2022-12-31" id="xdx2ixbrl1065" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AATP:TransferToInvestmentInMarketableSecurities" contextRef="AsOf2021-12-31_custom_PhoenixPlusCorpMember" id="xdx2ixbrl1093" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AATP:InvestmentInNonMarketableSecuritiesNoncurrent" contextRef="AsOf2022-12-31_custom_PhoenixPlusCorpMember" id="xdx2ixbrl1095" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DueFromRelatedParties" contextRef="AsOf2021-12-31_custom_TH3TechnologySdnBhdMember" id="xdx2ixbrl1154" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DueFromRelatedParties" contextRef="AsOf2021-12-31_custom_DSYBeautySdnBhdMember" id="xdx2ixbrl1162" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DueFromRelatedParties" contextRef="AsOf2022-12-31_custom_AgapeATPAsiaLimitedMember" id="xdx2ixbrl1172" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DueFromRelatedParties" contextRef="AsOf2022-12-31_custom_HostastaySdnBhdMember" id="xdx2ixbrl1184" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="AsOf2021-12-31_custom_CTANutriceuticalsSdnBhdMember" id="xdx2ixbrl1202" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="AsOf2021-12-31_custom_DSYBeautySdnBhdMember" id="xdx2ixbrl1212" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl1216" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2021-12-31_custom_CTANutriceuticalsAsiaSdnBhdOneMember" id="xdx2ixbrl1228" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2021-12-31_custom_DSYBeautySdnBhdOneMember" id="xdx2ixbrl1240" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2021-12-31_custom_HowKokChoongMember" id="xdx2ixbrl1252" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl1256" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2021-01-012021-12-31_custom_CTANutriceuticalsSdnBhdMember" id="xdx2ixbrl1268" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2021-01-012021-12-31_custom_DSYWellnessandLongevityCenterSdnBhdTwoMember" id="xdx2ixbrl1292" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AATP:RelatedPartyOtherIncome" contextRef="From2022-01-012022-12-31_custom_HostastaySdnBhdHostastayMember" id="xdx2ixbrl1302" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AATP:RelatedPartyOtherIncome" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1306" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AATP:RelatedPartyTransactionOtherPurchasesFromRelatedParty" contextRef="From2021-01-012021-12-31_custom_CTANutriceuticalsAsiaSdnBhdMember" id="xdx2ixbrl1320" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AATP:RelatedPartyTransactionOtherPurchasesFromRelatedParty" contextRef="From2021-01-012021-12-31_custom_DSYBeautySdnBhdMember" id="xdx2ixbrl1332" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AATP:RelatedPartyTransactionOtherPurchasesFromRelatedParty" contextRef="From2021-01-012021-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdMember" id="xdx2ixbrl1344" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AATP:RelatedPartyTransactionOtherPurchasesFromRelatedParty" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AATP:RelatedPartyOtherExpenses" contextRef="From2021-01-012021-12-31_custom_TH3TechnologySdnBhdMember" id="xdx2ixbrl1376" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AATP:RelatedPartyOtherExpenses" contextRef="From2021-01-012021-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdThreeMember" id="xdx2ixbrl1400" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AATP:NonControllingInterestAsl" contextRef="AsOf2022-12-31" id="xdx2ixbrl1464" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AATP:NonControllingInterestAsl" contextRef="AsOf2021-12-31" id="xdx2ixbrl1465" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1494" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl1503" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1504" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AATP:DeferredTaxLiabilitiesDepreciation" contextRef="AsOf2022-12-31" id="xdx2ixbrl1606" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2022-12-31" id="xdx2ixbrl1609" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2021-10-01" id="xdx2ixbrl1669" name="us-gaap:LesseeOperatingLeaseTermOfContract">P2Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2021-11-01" id="xdx2ixbrl1677" name="us-gaap:LesseeOperatingLeaseTermOfContract">P2Y</ix:nonNumeric>
  <ix:nonFraction name="AATP:LesseeOperatingLeaseLiabilityPaymentsDueAfterNextTwelveMonths" contextRef="AsOf2022-12-31" id="xdx2ixbrl1691" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="aatp-20221231.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-01-01to2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-23">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_AgapeATPInternationalHoldingLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:AgapeATPInternationalHoldingLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-072020-05-08_custom_ShareExchangeAgreementMember_custom_MrHowKokChoongMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AATP:ShareExchangeAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AATP:MrHowKokChoongMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-07</xbrli:startDate>
        <xbrli:endDate>2020-05-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-05-08_custom_SubsidiaryCompanyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:SubsidiaryCompanyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-05-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-11_custom_SubsidiaryCompanyFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:SubsidiaryCompanyFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SubsidiaryCompanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:SubsidiaryCompanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SubsidiaryCompanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:SubsidiaryCompanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SubsidiaryCompanyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:SubsidiaryCompanyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SubsidiaryCompanyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:SubsidiaryCompanyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SubsidiaryCompanyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:SubsidiaryCompanyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SubsidiaryCompanyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:SubsidiaryCompanyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SubsidiaryCompanyThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:SubsidiaryCompanyThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SubsidiaryCompanyFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:SubsidiaryCompanyFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SubsidiaryCompanyFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:SubsidiaryCompanyFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SubsidiaryCompanyFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:SubsidiaryCompanyFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SubsidiaryCompanyFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:SubsidiaryCompanyFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_HealthAndWellnessServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:HealthAndWellnessServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_HealthAndWellnessServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:HealthAndWellnessServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ShippingAndHandlingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ShippingAndHandlingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SocialSecurityOrganizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:SocialSecurityOrganizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EmployeesProvidentFundMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:EmployeesProvidentFundMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EmployeesProvidentFundMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:EmployeesProvidentFundMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EmploymentInsuranceSystemMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:EmploymentInsuranceSystemMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_HumanResourceDevelopmentFundMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:HumanResourceDevelopmentFundMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_VehiclesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SurvivorSelectMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:SurvivorSelectMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SurvivorSelectMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:SurvivorSelectMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EnergizedMineralConcentrateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:EnergizedMineralConcentrateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_EnergizedMineralConcentrateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:EnergizedMineralConcentrateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_IonizedCalMagMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:IonizedCalMagMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_IonizedCalMagMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:IonizedCalMagMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_OmegaBlendMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:OmegaBlendMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_OmegaBlendMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:OmegaBlendMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_BetaMaxxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:BetaMaxxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_BetaMaxxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:BetaMaxxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_VegeFruitFiberMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:VegeFruitFiberMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_VegeFruitFiberMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:VegeFruitFiberMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_IronMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:IronMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_IronMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:IronMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_YoungFormulaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:YoungFormulaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_YoungFormulaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:YoungFormulaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_OrganicYouthCarCleansingBarMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:OrganicYouthCarCleansingBarMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_OrganicYouthCarCleansingBarMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:OrganicYouthCarCleansingBarMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ATPRMITOPlusMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:ATPRMITOPlusMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ATPRMITOPlusMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:ATPRMITOPlusMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_LipomaskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:LipomaskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_LipomaskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:LipomaskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EnergetiqueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:EnergetiqueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_EnergetiqueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:EnergetiqueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_TrimPlusMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:TrimPlusMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_TrimPlusMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:TrimPlusMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ProductHealthTherapiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:ProductHealthTherapiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ProductHealthTherapiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:ProductHealthTherapiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_OthersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:OthersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_OthersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:OthersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PeriodEndMYRMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">AATP:PeriodEndMYRMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_PeriodEndMYRMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">AATP:PeriodEndMYRMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PeriodEndHKDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">AATP:PeriodEndHKDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_PeriodEndHKDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">AATP:PeriodEndHKDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PeriodAverageMYRMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">AATP:PeriodAverageMYRMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_PeriodAverageMYRMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">AATP:PeriodAverageMYRMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PeriodAverageHKDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">AATP:PeriodAverageHKDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_PeriodAverageHKDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">AATP:PeriodAverageHKDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SubsidiaryCompanyThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:SubsidiaryCompanyThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_VariableIncomeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">us-gaap:VariableIncomeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_VariableIncomeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">us-gaap:VariableIncomeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_VariableIncomeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">us-gaap:VariableIncomeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_VariableIncomeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">us-gaap:VariableIncomeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ComputerAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">AATP:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ComputerAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">AATP:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_VehicleMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">AATP:VehicleMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_VehicleMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">AATP:VehicleMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-05-17_custom_GreenproCapitalCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:GreenproCapitalCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-05-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-30_custom_GreenproCapitalCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:GreenproCapitalCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-10-16_custom_GreenproCapitalCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:GreenproCapitalCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-10-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-182022-07-19">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-18</xbrli:startDate>
        <xbrli:endDate>2022-07-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_GreenproCapitalCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:GreenproCapitalCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-19_custom_GreenproCapitalCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:GreenproCapitalCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-11-03_custom_DSwissIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:DSwissIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-11-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-09_custom_DSwissIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:DSwissIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-27_custom_SEATechVenturesCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:SEATechVenturesCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-03_custom_PhoenixPlusCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:PhoenixPlusCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-03_us-gaap_CommonStockMember_custom_PhoenixPlusCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:PhoenixPlusCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-182023-03-09_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-18</xbrli:startDate>
        <xbrli:endDate>2023-03-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PhoenixPlusCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:PhoenixPlusCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_PhoenixPlusCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:PhoenixPlusCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_TH3TechnologySdnBhdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:TH3TechnologySdnBhdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_TH3TechnologySdnBhdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:TH3TechnologySdnBhdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TH3TechnologySdnBhdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:TH3TechnologySdnBhdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_TH3TechnologySdnBhdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:TH3TechnologySdnBhdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_DSYBeautySdnBhdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYBeautySdnBhdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_DSYBeautySdnBhdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYBeautySdnBhdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_DSYBeautySdnBhdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYBeautySdnBhdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_DSYBeautySdnBhdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYBeautySdnBhdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_AgapeATPAsiaLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:AgapeATPAsiaLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_AgapeATPAsiaLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:AgapeATPAsiaLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_AgapeATPAsiaLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:AgapeATPAsiaLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_AgapeATPAsiaLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:AgapeATPAsiaLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_HostastaySdnBhdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HostastaySdnBhdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_HostastaySdnBhdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HostastaySdnBhdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_HostastaySdnBhdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HostastaySdnBhdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_HostastaySdnBhdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HostastaySdnBhdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CTANutriceuticalsSdnBhdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:CTANutriceuticalsSdnBhdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_CTANutriceuticalsSdnBhdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:CTANutriceuticalsSdnBhdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_CTANutriceuticalsSdnBhdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:CTANutriceuticalsSdnBhdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CTANutriceuticalsSdnBhdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:CTANutriceuticalsSdnBhdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CTANutriceuticalsAsiaSdnBhdOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:CTANutriceuticalsAsiaSdnBhdOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_CTANutriceuticalsAsiaSdnBhdOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:CTANutriceuticalsAsiaSdnBhdOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_CTANutriceuticalsAsiaSdnBhdOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:CTANutriceuticalsAsiaSdnBhdOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CTANutriceuticalsAsiaSdnBhdOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:CTANutriceuticalsAsiaSdnBhdOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_DSYBeautySdnBhdOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYBeautySdnBhdOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_DSYBeautySdnBhdOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYBeautySdnBhdOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_DSYBeautySdnBhdOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYBeautySdnBhdOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_DSYBeautySdnBhdOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYBeautySdnBhdOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_HowKokChoongMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HowKokChoongMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_HowKokChoongMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HowKokChoongMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_HowKokChoongMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HowKokChoongMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_HowKokChoongMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HowKokChoongMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_DSYWellnessandLongevityCenterSdnBhdTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYWellnessandLongevityCenterSdnBhdTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_DSYWellnessandLongevityCenterSdnBhdTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYWellnessandLongevityCenterSdnBhdTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_HostastaySdnBhdHostastayMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HostastaySdnBhdHostastayMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_HostastaySdnBhdHostastayMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HostastaySdnBhdHostastayMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CTANutriceuticalsAsiaSdnBhdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:CTANutriceuticalsAsiaSdnBhdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_CTANutriceuticalsAsiaSdnBhdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:CTANutriceuticalsAsiaSdnBhdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYWellnessAndLongevityCenterSdnBhdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYWellnessAndLongevityCenterSdnBhdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYWellnessAndLongevityCenterSdnBhdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYWellnessAndLongevityCenterSdnBhdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_HowKokChoongMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HowKokChoongMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_HowKokChoongMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HowKokChoongMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_RedboyPictureSdnBhdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:RedboyPictureSdnBhdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_RedboyPictureSdnBhdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:RedboyPictureSdnBhdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYWellnessAndLongevityCenterSdnBhdThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYWellnessAndLongevityCenterSdnBhdThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ShareForfeitureAgreementsMember_custom_HowKokChoongTalentLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AATP:ShareForfeitureAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HowKokChoongTalentLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ShareForfeitureAgreementsMember_custom_HowKokChoongTalentLimitedMember_custom_ShareholdersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AATP:ShareForfeitureAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HowKokChoongTalentLimitedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AATP:ShareholdersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ShareForfeitureAgreementsMember_custom_HKCHoldingsSdnBhdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AATP:ShareForfeitureAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HKCHoldingsSdnBhdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ShareForfeitureAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AATP:ShareForfeitureAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ShareForfeitureAgreementsMember_custom_HowKokChoongTalentLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AATP:ShareForfeitureAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HowKokChoongTalentLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ShareForfeitureAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AATP:ShareForfeitureAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_country_MY">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MY</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_country_MY">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MY</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_country_HK">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_country_HK">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-12-282019-01-02_custom_LabuanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">AATP:LabuanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-12-28</xbrli:startDate>
        <xbrli:endDate>2019-01-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_country_MY">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MY</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_country_MY">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MY</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TwoThousandTwentyEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">AATP:TwoThousandTwentyEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TwoThousandTwentyNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">AATP:TwoThousandTwentyNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TwoThousandThirtyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">AATP:TwoThousandThirtyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_AATPLBASLSEAAndWATPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">AATP:AATPLBASLSEAAndWATPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_AATPHKMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">AATP:AATPHKMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_AATPLBASLSEAWATPAndDSYMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">AATP:AATPLBASLSEAWATPAndDSYMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_NoCustomerMember_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:NoCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_NoCustomerMember_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:NoCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_FiveIndividualCustomersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:FiveIndividualCustomersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_VendorOneMember_us-gaap_CostOfGoodsTotalMember_us-gaap_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:VendorOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_VendorTwoMember_us-gaap_CostOfGoodsTotalMember_us-gaap_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:VendorTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_VendorThreeMember_us-gaap_CostOfGoodsTotalMember_us-gaap_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:VendorThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_VendorOneMember_us-gaap_CostOfGoodsTotalMember_us-gaap_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:VendorOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_VendorTwoMember_us-gaap_CostOfGoodsTotalMember_us-gaap_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:VendorTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_DSwissIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:DSwissIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_DSwissIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:DSwissIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfGoodsTotalMember_custom_VendorOneMember_custom_DSwissIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:VendorOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:DSwissIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfGoodsTotalMember_custom_VendorOneMember_custom_DSwissIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:VendorOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:DSwissIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_VendorOneMember_us-gaap_AccountsPayableMember_us-gaap_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:VendorOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_VendorTwoMember_us-gaap_AccountsPayableMember_us-gaap_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:VendorTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_VendorThreeMember_us-gaap_AccountsPayableMember_us-gaap_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:VendorThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_VendorMember_us-gaap_AccountsPayableMember_us-gaap_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:VendorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_SupplierConcentrationRiskMember_us-gaap_AccountsPayableMember_custom_OneVendorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:OneVendorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfGoodsTotalMember_custom_OneSalesDistributorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:OneSalesDistributorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfGoodsTotalMember_custom_OneSalesDistributorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:OneSalesDistributorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-01_custom_AgapeSuperiorLivingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">AATP:AgapeSuperiorLivingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-302021-05-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-30</xbrli:startDate>
        <xbrli:endDate>2021-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-302021-05-31_custom_TrainingCenterMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">AATP:TrainingCenterMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-30</xbrli:startDate>
        <xbrli:endDate>2021-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-31_custom_AgapeSuperiorLivingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">AATP:AgapeSuperiorLivingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-10-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-10-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_AgapeSuperiorLivingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001713210</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">AATP:AgapeSuperiorLivingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="RM">
      <xbrli:measure>iso4217:MYR</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact001577" toRefs="Footnote001582"></ix:relationship>
  <ix:relationship fromRefs="Fact001578" toRefs="Footnote001585"></ix:relationship>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_906_edei--DocumentType_c20220101__20221231_z9QHXjDOzesc"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--DocumentAnnualReport_c20220101__20221231_zaAwJuflWM64"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANNUAL
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
The Fiscal Year Ended <span id="xdx_909_edei--DocumentPeriodEndDate_c20220101__20221231_zh3V6tcusDXh"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><span id="xdx_908_edei--CurrentFiscalYearEndDate_c20220101__20221231_zbhXLcWla639"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, <span id="xdx_90E_edei--DocumentFiscalYearFocus_c20220101__20221231_z7nEMrKgfby6"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>or</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--DocumentTransitionReport_c20220101__20221231_zIyrwmIbAOV2"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the transition period from _____________________________</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
File Number <span id="xdx_908_edei--EntityFileNumber_c20220101__20221231_zszZykL7bBqb"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityFileNumber">333-220144</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90E_edei--EntityRegistrantName_c20220101__20221231_zBeaHI5iw9R2"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityRegistrantName">AGAPE
ATP CORPORATION</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant issuer as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20220101__20221231_zYSWtudeenl3"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--EntityTaxIdentificationNumber_c20220101__20221231_zLmCw6HTfh23"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityTaxIdentificationNumber">36-4838886</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other jurisdiction of</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation
    or organization)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
                                            Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--EntityAddressAddressLine1_c20220101__20221231_zii97prVU9m1"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressAddressLine1">1705
&#8211; 1708, Level 17, Tower 2</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressAddressLine2_c20220101__20221231_zUckQKGmmwbc"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressAddressLine2">Faber Towers</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressAddressLine3_c20220101__20221231_zXqGRF2YD0Vh"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressAddressLine3">Jalan Desa Bahagia</ix:nonNumeric></span>,</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Taman
Desa, <span id="xdx_901_edei--EntityAddressPostalZipCode_c20220101__20221231_zpHiPOwM0raf"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressPostalZipCode">58100</ix:nonNumeric></span> <span id="xdx_902_edei--EntityAddressCityOrTown_c20220101__20221231_ztWkZPepLeQk"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressCityOrTown">Kuala Lumpur</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressCountry_c20220101__20221231_zBptkZJIIZ7b"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">Malaysia</ix:nonNumeric></span>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices, including zip code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&#8217;s
phone number, including area code</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--CityAreaCode_c20220101__20221231_zer8ihEYmGXj"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:CityAreaCode">(60)</ix:nonNumeric></span>
<span id="xdx_900_edei--LocalPhoneNumber_c20220101__20221231_zRr6OOqMjVfk"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:LocalPhoneNumber">192230099</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Securities Exchange Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_90F_edei--Security12bTitle_c20220101__20221231_zQ3d0epIYAf6"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:Security12bTitle">Common
Stock, $0.0001 par value</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Title
of Class)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">The
OTC Market &#8211; Pink Sheets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
of exchange on which registered)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(g) of the Securities Exchange Act: <b><span style="text-decoration: underline">None</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <span id="xdx_905_edei--EntityWellKnownSeasonedIssuer_c20220101__20221231_z0XMTvyglbs"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <span id="xdx_901_edei--EntityVoluntaryFilers_c20220101__20221231_zfhMKyauR2Yg"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_909_edei--EntityCurrentReportingStatus_c20220101__20221231_zQs8I7SpoVxj"><span style="-sec-ix-hidden: xdx2ixbrl0033">YES</span></span> &#9746; NO &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (section 232.405 of this chapter) during the preceding twelve months (or shorter period that the registrant was
required to submit and post such files). <span id="xdx_904_edei--EntityInteractiveDataCurrent_c20220101__20221231_zIsEDvdzKHai"><span style="-sec-ix-hidden: xdx2ixbrl0034">YES</span></span> &#9746; NO &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (&#167; 229.405 of this chapter) is not contained
herein, and will not be contained, to the best of registrant&#8217;s knowledge, in definitive proxy or information statements incorporated
by reference in Part III of this Form 10-K or any amendment to this Form 10-K. &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting
company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221;
in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
Accelerated Filer &#9744; Accelerated Filer &#9744; <span id="xdx_901_edei--EntityFilerCategory_c20220101__20221231_zzpmZkaAXrPe"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated Filer</ix:nonNumeric></span> &#9746; Smaller reporting company <span id="xdx_900_edei--EntitySmallBusiness_c20220101__20221231_zLJVI4tPvJDc"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; <span id="xdx_90F_edei--EntityShellCompany_c20220101__20221231_zCjwSCMFG2Tk"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth Company <span id="xdx_909_edei--EntityEmergingGrowthCompany_c20220101__20221231_zC6VINbJ1aZh"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate market value of the Company&#8217;s common stock held by non-affiliates computed by reference to the closing bid price of the
Company&#8217;s common stock, as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">$<span id="xdx_90B_edei--EntityPublicFloat_iI_pdp0_c20220630_zz3k8ZXMAo8h"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">293,809,710</ix:nonFraction></span></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
    at March 23, 2023</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock, $0.0001 par value</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--EntityCommonStockSharesOutstanding_iI_pid_c20230323_zaZclg2oAMKf"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-03-23" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,452,012</ix:nonFraction></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
10-K</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the Fiscal Year Ended December 31, 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Index</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.6in; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
    #</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#m_001">PART I</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#m_002">Business</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#m_003">Risk Factors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#m_004">Unresolved Staff Comments</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#m_005">Properties</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#m_006">Legal Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">40</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#m_007">Mine Safety Disclosure</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#m_008">PART II</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#m_009">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">41</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#m_010">Selected Financial Data</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">41</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#m_011">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">42</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ap_001">Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ap_002">Financial Statements and Supplementary Data</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ap_003">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">51</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ap_004">Controls and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ap_005">Other Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">53</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ap_006">PART III</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ap_007">Directors, Executive Officers and Corporate Governance</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ap_008">Executive Compensation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">57</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ap_009">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ap_010">Certain Relationships and Related Transactions, and Director Independence</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ap_011">Principal Accounting Fees and Services</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ap_012">PART IV</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ap_013">Exhibits, Financial Statement Schedules</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">66</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ap_014">SIGNATURES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>This
Annual Report on Form 10-K contains forward-looking statements. These forward-looking statements are not historical facts but rather
are based on current expectations, estimates and projections. We may use words such as &#8220;anticipate,&#8221; &#8220;expect,&#8221;
&#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;foresee,&#8221; &#8220;estimate&#8221; and variations of these
words and similar expressions to identify forward-looking statements. These statements are not guarantees of future performance and are
subject to certain risks, uncertainties and other factors, some of which are beyond our control, are difficult to predict and could cause
actual results to differ materially from those expressed or forecasted. These risks and uncertainties include the following:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#9679;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
    availability and adequacy of our cash flow to meet our requirements;</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#9679;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Economic,
    competitive, demographic, business and other conditions in our local and regional markets;</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#9679;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Changes
    or developments in laws, regulations or taxes in our industry;</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#9679;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Actions
    taken or omitted to be taken by third parties including our suppliers and competitors, as well as legislative, regulatory, judicial
    and other governmental authorities;</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#9679;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Competition
    in our industry;</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#9679;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
    loss of or failure to obtain any license or permit necessary or desirable in the operation of our business;</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#9679;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Changes
    in our business strategy, capital improvements or development plans;</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#9679;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
    availability of additional capital to support capital improvements and development; and</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#9679;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
    risks identified in this report and in our other filings with the Securities and Exchange Commission or the SEC.</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>This
report should be read completely and with the understanding that actual future results may be materially different from what we expect.
The forward-looking statements included in this report are made as of the date of this report and should be evaluated with consideration
of any changes occurring after the date of this Report. We will not update forward-looking statements even though our situation may change
in the future and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events
or otherwise.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
of Defined Terms</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise indicated by the context, references in this Report to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our,&#8221; &#8220;Agape&#8221; are references to Agape ATP
    Corporation, a Nevada corporation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Common
    Stock&#8221; refers to the common stock, par value $0.0001, of the Company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Malaysia&#8221;
    is Malaysia;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;U.S.
    dollar,&#8221; &#8220;$&#8221; and &#8220;US$&#8221; refer to the legal currency of the United States;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;RM&#8221;
    and &#8220;Ringgit&#8221; are to the legal currency of Malaysia;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Securities
    Act&#8221; refers to the Securities Act of 1933, as amended; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Exchange
    Act&#8221; refers to the Securities Exchange Act of 1934, as amended.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="m_001"></span>PART
I</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="m_002"></span>ITEM
1. BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
ORGANIZATION AND BUSINESS BACKGROUND</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
ATP Corporation, a Nevada corporation (&#8220;the Company&#8221;) was incorporated under the laws of the State of Nevada on June 1, 2016.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
ATP Corporation operates through its subsidiaries, namely, Agape ATP Corporation (&#8220;AATP LB&#8221;), a company incorporated in Labuan,
Malaysia, and Agape Superior Living Sdn. Bhd. (&#8220;ASL&#8221;), a company incorporated in Malaysia. .</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
ATP Corporation, incorporated in Labuan, Malaysia, is an investment holding company with 100% equity interest in Agape ATP International
Holding Limited (&#8220;AATP HK&#8221;), a company incorporated in Hong Kong.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 8, 2020, the Company entered into a Share Exchange Agreement with Mr. How Kok Choong, CEO and director of the Company to acquire
9,590,596 ordinary shares, no par value, equivalent to approximately 99.99% of the equity interest in Agape Superior Living Sdn. Bhd.,
a network marketing entity incorporated in Malaysia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
Superior Living Sdn. Bhd. is a limited company incorporated on August 8, 2003, under the laws of Malaysia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 11, 2020, the Company incorporated Wellness ATP International Holdings Sdn, Bhd. (&#8220;WATP&#8221;), a wholly owned subsidiary
under the laws of Malaysia, to pursue the business of promoting wellness and wellbeing lifestyle of the community by providing services
that includes online editorials, programs, events and campaigns on how to achieve positive wellness and lifestyle.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 11, 2021, Agape ATP Corporation (Labuan) formed a joint-venture entity, DSY Wellness International Sdn. Bhd. (&#8220;DSY Wellness&#8221;)
with an independent third party which Agape ATP Corporation (Labuan) owns 60% of the equity interest, to pursue the business of providing
complementary health therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and its subsidiaries are principally engaged in the Health and Wellness Industry. The principal activity of the Company is to
supply high-quality health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation,
anti-aging and products designed to improve the overall health system of the human body and various wellness programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements reflect the activities of the Company, AATP LB, AATP HK, WATP, ASL and its variable interest
entity (&#8220;VIE&#8221;), Agape S.E.A. Sdn. Bhd. (&#8220;SEA&#8221;) (See Note 3), and DSY Wellness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details
of the Company&#8217;s subsidiaries:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Subsidiary company name</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Place and date of incorporation</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Particulars of issued capital</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Principal activities</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Proportional of ownership interest and voting power held</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 3%; text-align: left">1.</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 17%; text-align: left">Agape ATP Corporation</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 17%; text-align: center">Labuan, <br /> March 6, 2017</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 17%; text-align: center">100 shares of ordinary share of US$1 each</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 17%; text-align: center">Investment holding</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 17%; text-align: right">100</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">2.</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Agape ATP International Holding Limited</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Hong Kong,<br /> June 1, 2017</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">1,000,000 shares of ordinary share of HK$1 each</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Wholesaling of health and wellness products; and health solution advisory services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">3.</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Agape Superior Living Sdn. Bhd.</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Malaysia, <br /> August 8, 2003</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">9,590,598 shares of ordinary share of RM1 each</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Health and wellness products and health solution advisory services via network marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">99.99</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">4.</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Agape S.E.A. Sdn. Bhd.</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Malaysia, <br /> March 4, 2004</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">2 shares of ordinary share of RM1 each</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">VIE of Agape Superior Living Sdn. Bhd.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VIE</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">5.</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Wellness ATP International Holdings Sdn, Bhd</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Malaysia, <br /> September 11, 2020</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">100 shares of ordinary share of RM1 each</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">The promotion of wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">6.</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">DSY Wellness International Sdn Bhd.</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Malaysia, <br /> November 11, 2021</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">1,000 shares of ordinary share of RM1 each</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Provision of complementary health therapies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60</td><td style="text-align: left">%</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a provider of health and wellness products and advisory services in the Malaysian market. We pursue our mission of helping people
to create health and wealth by providing a financially rewarding business opportunity to distributors and quality products to distributors
and customers who seek a healthy lifestyle. We believe the quality of our products coupled with the effectiveness of our distribution
network have been the primary reasons for our success and will allow us to pursue future business expansion. In order to further our
supply chain, on May 8, 2020, we acquired 99.99% of Agape Superior Living Sdn Bhd, with the goal of securing an established network marketing
sales channel that has been in existence in Malaysia for the past 15 years. On September 11, 2020, the Company incorporated Wellness
ATP International Holdings Sdn. Bhd., a wholly owned subsidiary in Malaysia, with the aim to pursue the business of promoting wellness
and wellbeing lifestyle of the community through the provision of services including online editorials, programs, events and campaigns
on how to achieve positive wellness and lifestyle.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 15, 2020, Wellness ATP International Holdings Sdn. Bhd. entered into a business collaboration agreement with ASL to carry out
certain wellness programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently offer three series of products: ATP Zeta Health Program, &#201;NERG&#201;TIQUE and BEAUNIQUE. Our ATP Zeta Health Program
is a health program designed to assist in the elimination of various diseases caused by environmental pollutants, unhealthy dietary intake
and unhealthy lifestyles. The program aims to promote improved health and longevity through a combination of modern health supplements,
proper nutrition and advice from skilled dieticians. Our &#201;NERG&#201;TIQUE series aims to provide a total dermal solution for
healthy skin beginning from the cellular level. The series is comprised of the Energy Mask series, Hyaluronic Acid and Mousse Facial
Cleanser. Our BEAUNIQUE product series focuses on the research of our diet&#8217;s impact on modifying gene expressions to address genetic
variations and deliver a personalized nutrigenomic solution for every individual.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 11, 2021, Agape ATP Corporation (Labuan) formed a joint-venture entity, DSY Wellness International Sdn. Bhd. (&#8220;DSY Wellness&#8221;)
with Mr. Steve Yap, following which Agape ATP Corporation (Labuan) owns 60% of the equity interest, to pursue the business of providing
complementary health therapies. The establishment of DSY Wellness is a further expansion of our business into the health and wellness
industry. Mr. Steve Yap readily owns 33 proprietary formulas for treating non-communicable disease which he has agreed to bring into
the company for joint commercialization. Mr. Steve Yap also has existing clients receiving traditional complimentary medicine or &#8220;TCM&#8221;
in Indonesia and China.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Products</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
offer three series of products: (i) ATP Zeta Health Program, (ii) &#201;NERG&#201;TIQUE and (iii) BEAUNIQUE.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ATP Zeta Health Program is a health program designed to promote health and general wellbeing, as well as to prevent diseases caused by
polluted environments, unhealthy dietary intake and unhealthy lifestyles. At its core, the ATP Zeta Super Health Program is focused upon
biological energy, Adenosine Triphosphate (ATP), at the cellular level. The stimulation of ATP production at the cellular level can increase
an individual&#8217;s metabolic rate in order to promote and maintain normal and healthy functioning of the body&#8217;s systems. Our
program emphasizes nutrient absorption through the membrane ion channel in order to provide complete and balanced nutrients to improve
cellular health. Thus, ATP Zeta Super Health Program provides ionized and high zeta potential (high bioavailability) nutrients to enhance
the absorption at the cellular level.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
&#201;NERG&#201;TIQUE product series is comprised of &#201;NERG&#201;TIQUE Mask series, Hyaluronic Acid Serum and Mousse Facial
Cleanser.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
&#201;NERG&#201;TIQUE Mask series is formulated with triple action natural ingredients and advanced technology. The innovative combination
of award-winning patented liposome encapsulating the customized fast acting patented essence, produces micro-particle liposome which,
when combined with collagen peptide Tencel film, creates an effective formulation that benefits the skin at the cellular level. The &#201;NERG&#201;TIQUE
series aims to provide a total dermal solution for healthy skin beginning at the cellular level. There are three types of face masks
in the &#201;NERG&#201;TIQUE Mask Series, each addressing a specific skin condition. They are: N&#176;1 Med-Hydration, N&#176;2 Med-Whitening
and N&#176;3 Med-Firming. Advanced genetic analysis and clinical trials conducted revealed the benefits and efficacy of the patented functional
essence. The &#201;NERG&#201;TIQUE Mask Series has clinically shown deep penetration of liposomal essence into deep skin layers within
5 minutes application, in order to deliver immediate, deep-reaching and long-lasting benefits of skin hydration, whitening, and firming.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
&#201;NERG&#201;TIQUE Hyaluronic Acid Serum is formulated with four functional hyaluronic acid and a unique peptide. It is a scientifically
advanced and intensive quintuple action serum designed to promote skin hydration, reparation and regeneration to enhance skin viscoelasticity
for improved skin firmness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
&#201;NERG&#201;TIQUE Mousse Facial Cleanser is formulated with the mildest surface-active agents available on the market. It takes
the form of a unique mousse like-foam that delivers a comfortable and soft feeling to the skin during and after use without compromising
the moisturizing level and viscoelastic properties of the skin. Its PH-balanced formula is suitable for all skin types for an effortless
cleansing routine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
BEAUNIQUE product series focuses on the research of our diet&#8217;s impact on modifying gene expressions in order to address genetic
variations and deliver a personalized nutrigenomic solution for every individual.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ATP
Zeta Health Program</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a list of our ATP Zeta Health Program products:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">ATP1s
Survivor Select</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATP1s
Survivor Select contains various essential nutrients required by the human body to maintain the normal metabolism, which includes productions
of biological energy (ATP). Effective production of ATP enhances both physical as well as mental health, and helps the body to build
up resistance to diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_001.jpg" alt="" style="width: 170px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stimulates
    instant bio-energy production at the cellular level to ensure sufficient supply of bio energy for body cell.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promotes
    better metabolism at the cellular level.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promotes
    healthy and optimal growth of bones system, teeth structure and muscle tissue of children.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improves
    the digestion and nutrient absorption powers of body cell.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promotes
    cell detoxification and repair capabilities in order to enhance cell self-healing ability.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">ATP2
Energized Mineral Concentrate</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATP2
is a nutritional supplement made from the finest plant substances and also is a proprietary formulation of a super-energized colloidal
concentrate developed from a dibase solution. Its formula supports and enhances nutritional biochemical activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_002.jpg" alt="" style="height: 311px; width: 143px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supports
    and enhance nutritional biochemical activities (nutrient absorption and waste metabolism). </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Breaks
    down or oxidised toxins and waste material to promote cellular detoxification and improve blood circulation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increases
    cellular respiration and energy production to reduce fatigue and maintain energy level.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increases
    oxygen level in body cells to create a high oxygen environment in the body, which possibly help to prevent the growth of harmful
    pathogens that contribute to diseases.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provides
    sufficient antioxidants that act as a superior scavenger of free radicals, to strengthen the body cells resistance against oxidative
    damages.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">ATP3
Ionized Cal-Mag</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATP3
Ionized Cal-Mag is a specialized calcium and magnesium minerals supplement that is designed to transform into ionic form completely before
entering the body. This is compatible to the cellular ion channel theory, that all cellular metabolisms are dependent on ionic transmission
to achieve the highest absorption rate. This product was tested for its nanoparticle by the National Measurement Institute of Australian
Government, with proven content of nanosized calcium and magnesium that has better absorption and bio-availability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_003.jpg" alt="" style="width: 150px" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strengthens
    the bone system and promote better bone development.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strengthens
    the teeth structure and prevent teeth damages.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provides
    abundant of ionic calcium and magnesium to prevent chronic diseases through better blood circulation and acid-base regulation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promotes
    better relaxing of nervous system and regulations of neurotransmitters which helps to enhance sleep quality.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promotes
    better relaxing of muscle to prevent muscle soreness and cramps.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">ATP4
Omega Blend</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATP4
Omega Blend is a proprietary oil blend that is rich in undamaged polyunsaturated essential fatty acid, which is fully extracted from
plant-based ingredients. It provides a bio-effective balance of both essential fatty acids, Omega 3 and Omega 6 which are the important
structural components of cell membranes that cannot be synthesized by humans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_004.jpg" alt="" style="width: 133px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulates
    cholesterol and triglycerides levels to promote better blood circulation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulates
    inflammation, the unifying component of many diseases, and enhance cell repairing activities. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulates
    hormones production and functions in the body through supplies of the balanced ratio of Omega 3 and Omega 6.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promotes
    healthy functioning of the brain through the maintenance of healthy impulse transmission in brain cells that is crucial for memory
    and learning ability.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">ATP5
BetaMaxx</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATP5
BetaMaxx is derived from the cell wall of premium food-grade baker&#8217;s yeast and is a medical breakthrough result of more than 50
years of intensive research and studies by scientists and physicians. This product combines the immunostimulatory properties of perfectly
molecularly structured beta 1-3, 1-6-D-glucan with other immunomodulating compounds that work in perfect synergy to make ATP5 a unique
and effective natural product. It is a 100% natural immune enhancer, safe and does not cause any allergic reactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><img src="form10-k_005.jpg" alt="" style="width: 150px" /><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strengthens
    the function of immune cells to build up a better immune response of body for external and internal protections</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promotes
    better cell repairing and regulate inflammatory responses in wound healing. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enhances
    the function of immune cell against damages caused by radiation. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Helps
    to normalize blood sugar levels. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">AGN-Vege
Fruit Fiber</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AGN-Vege
Fruit Fiber is the special nutrition-based formula for intestines and stomach. It consists of four most essential components for gastrointestinal
health effects such as fiber, probiotic the &#8220;friendly bacteria&#8221;, prebiotic fructooligosaccharides (FOS) as well as digestive
enzymes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_006.jpg" alt="" style="width: 170px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promotes
    better bowel movement and prevent low-fiber diet-induced constipation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maintains
    bowel health. FOS helps increase intestinal bifidobacteria and helps maintain a good intestinal environment.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Slows
    the absorption of sugar and lipid into the bloodstream which helps improve blood sugar and cholesterol level.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Induces
    better satiety, which results in reduced total food intake and helps in achieving an ideal weight management.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">AGP1-Iron</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AGP1-Iron
is the purest and most advanced Colloidal Iron that is sourced from the remains of an ancient rainforest which contains the most active
plant-based element from nature. The colloidal nanosized iron provides high zeta potential promotes better absorptivity and cellular
iron uptake through the ion channel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><img src="form10-k_007.jpg" alt="" style="width: 150px" /><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promotes
    better hemoglobin production to improve iron deficiency anemia.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Iron
    is a component of hemoglobin in red blood cell which carries oxygen to all part of the body. Therefore, it helps to improve blood
    circulation and prevent some oxygen deficiency symptoms through enhancement of oxygen delivery and nutrient circulation as well as
    toxins excretion.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Iron
    is a factor in red blood cell formation. It promotes hemoglobin production hence is suitable especially for women and individual
    who experienced accidental bleedings.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">YFA-Young
Formula</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">YFA-Young
Formula is a 100% natural unique formula, a combination of amino acid, vitamins, and minerals and is the best anti-aging and youthful
maintenance supplement. It stimulates the pituitary gland to release endocrine hormones such as human growth hormone (HGH) to stimulate
synergies thus achieving the efficacy of anti-ageing through the promotion of cells vitality and strengthening of organ function.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><img src="form10-k_008.jpg" alt="" style="width: 200px" /><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enhances
    the production of bio-energy ATP and metabolism, which aids in reducing body fat accumulation and promote strong muscles building.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stimulates
    the production of collagen to restore skin elasticity and reduce wrinkles.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduces
    pigmentation and dark spots on face caused by hormonal imbalances.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HGH
    builds and repairs tissues and thus has an effect on hair cells at the hair root to promote healthy hair growth. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enhances
    memory and cardiovascular function and prevent various chronic diseases due to HGH deficiency.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">BEAUNIQUE
Mito+ and Mitogize</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
discontinued ATP Regal Mitogize on October 1, 2019. In its stead, an enhanced formula, the BEAUNIQUE Mito+ was introduced in November
2019. As a strong antioxidant drink with great flavor and taste, the preeminence of BEAUNIQUE Mito+ is its ability to further protect
and stimulate mitochondria (the membrane-bound organelles which produces energy for cells) in cellular energy (ATP) production with the
added advantage of fewer total sugars and calories. The new formula is comprised of 11 food groups, including potent mangosteen skin
extract. Backed by advanced scientific research and tested on 88 nutrigenomic profiles, the new formulation revealed enhanced antioxidant
properties. 96.34% DPPH Radical Scavenging activity, an approximate 22% increase compared to Mitogize.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><img src="form10-k_009.jpg" alt="" style="height: 400px; width: 100px" /><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cellular
    health</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
    antioxidants to protect from cellular oxidative damages.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Immune
    health</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enhanced
    adaptive immune response.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provides
    anti-inflammatory functionality.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strengthens
    immunity against bacteria and viruses.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Metabolic
    health</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduces
    the risk of obesity.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduces
    the risk of vascular diseases.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduces
    the risk of Type II Diabetic.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Brain
    health</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduces
    the risk of neurodegenerative diseases.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Skin
    health</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Systemic
    photoprotection.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduces
    dark spot formation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alleviates
    skin wrinkle and inflammation induced by UV-B irradiation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">ORYC-Organic
Youth Care Cleansing Bar</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ORYC-Organic
Youth Care Cleansing Bar is a natural, organic cleansing soap for skin. It contains pure Australian-accredited natural and organic plant
oils acting as a high quality and natural skin lubricant. It maintains the softness of the skin while promoting skin beauty and radiance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_010.jpg" alt="" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
    its biodynamic avocado oil and vanilla extract, remove impurities, leaving skin clear, fresh and clean.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
    its biodynamic, coconut, almond and olive oil, moisturize and texturize the skin to prevent skin drying.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    acting as natural anti-bacterial and anti-inflammatory agents, reduce the risks of skin infections and allergies. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*References
alluding to the efficacy and effects of our products are based on client testimonials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#201;NERG&#201;TIQUE</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following is a list of our &#201;NERG&#201;TIQUE products:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N&#176;1
Med-Hydration</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Formulated
with the patented Sea Grape (Caulerpa lentillifera) extract, the <b>N&#176;1 Med-Hydration </b>enhances skin moisture and luminosity.
This treatment effectively improves the moisture content of the inner skin layer and rejuvenate the skin barrier function to avoid moisture
loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_011.jpg" alt="" style="width: 200px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Locking
    the skin moisture and nutrients, strengthening the skin barrier function and boosting the skin&#8217;s moisture level.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increases
    the skin&#8217;s natural moisturizing factor (PCA) and skin layer glycoprotein connectivity to maintain the skin&#8217;s moisture.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effectively
    retains water, provides moisturization, restores skin elasticity, and promotes the growth of fibroblasts for moisturization, removes
    dryness, regains skin&#8217;s elasticity and smoothness.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delivers
    an instant boost of skin moisture content up to 45.7% in just 5 minutes of application and synergistically ensuring a profound and
    long-lasting skin moisturization and hydratio n.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N&#176;2
Med-Whitening</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Formulated
with patented Peach Blossom Stem Cell Extract, the <b>N&#176;2 Med-Whitening</b> has clinically shown its efficacy in inhibiting the melanin
synthesis, down-regulating the melanin synthesis gene, boosting skin moisture level and protecting skin against UV radiation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_012.jpg" alt="" style="width: 200px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suppresses
    melanin production and fight against UV radiation to protect skin cells and result in whitening effect.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stimulates
    interstitial hyperplasia cell and helps in increasing the moisturizing ceramide by 7.4 times in order to remove skin roughness and
    smoothing skin.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enhances
    the skin brightness up to 6.3% in just 5 minutes of application and synergistically rejuvenate a profound and long-lasting skin ability
    in anti-UV damage.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N&#176;3
Med-Firming</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Formulated
with the patented Djulis (Chenopodium formosanum Koidz) Seed Extract, the native cereal plant in Taiwan and traditionally called &#8220;ruby
of cereals.&#8221; The formulation is clinically proven to be effective in stimulation of collagen secretion and anti-advances glycation
end-products (AGEs) reducing the glycation of skin collagen, provide protection and maintenance of the basal skin collagen production.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><img src="form10-k_013.jpg" alt="" style="width: 200px" /><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suppresses
    the skin collagen glycation process, reduces collagen loss, and enhancing collagen secretion.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repairs
    the dead skin tissue, smooth wrinkles to restore the smoothness and health of the skin.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prevents
    wrinkles formation and providing the essential skin moisture content.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boosts
    skin elasticity by up to 14.4%. and improve sagging skin by 135 in just 5 minutes of application.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#201;NERG&#201;TIQUE
Hyaluronic Acid (HA) Serum</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Formulated
with four functional hyaluronic acid and a unique peptide, this scientifically advanced and intensive quintuple action serum proven to
deliver 5Rs dermal benefits. Filled in an innovative yet convenient and hygienics syringe packaging, this HA serum also ensure consumer-perceivable
benefits for every skin type.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_014.jpg" alt="" style="width: 400px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Benefits:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">REBALANCE
    - Hydrates the skin surface by forming a protection layer and keep skin moisturized even after cleansing</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RECOVER
    &#8211; Repairs the out-balanced lamellar layer to act as barrier to prevent skin moisture from evaporation</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">REGENERATE
    - Promotes the production of Type I pro-collagen and boost skin&#8217;s own production of Hyaluronic Acid up to 3 times</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">REHYDRATE
    - Nano-sized particles with high capacity of water-holding allow deep penetration and bestows moisture from inside the skin. Long-lasting
    moisture retention up to 72 hours</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">REMODELLING
    - Proven to increase skin firmness +200% (cheek, under-eye and neck). Enhance skin viscoelasticity to improves skin roughness</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#201;NERG&#201;TIQUE
Mousse Facial Cleanser</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Formulated
with the mildest surface-active agents available on the market, this facial cleanser was designed to deliver a distinct A to E cleansing
benefits to consumers. The unique mousse like-foam delivers a comfortable and soft feeling of the skin during and after use without compromising
the moisturizing level and viscoelastic properties of the skin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_015.jpg" alt="" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Benefits:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All
    Skin Type</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hypoallergenic</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-comedogenic</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pH-balanced
    formula with buffer capacity at pH 5.5 of the skin.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comfortable</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mild
    to skin and eyes without irritating or drying your skin</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comfortable
    and soft feeling <b>&#8211; </b>prolonged comfortable to skin before and after use. Accidental consuming would not be harmful to
    your body.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.</b></span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dense</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mousse-like
    foam very fine porous foam and smooth skin-feel during use</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.</b></span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effortlessly</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Easily
    remove light makeup, dirt and impurities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Easy
    to rinse with no residual.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>BEAUNIQUE</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s BEAUNIQUE product series focuses on the research of our diet&#8217;s impact on modifying gene expressions in order to
address genetic variations and deliver personalized nutrigenomic solutions for every individual.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trim+</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trim+
is the first product launched under this series, which utilizes advanced technology to extract patented active ingredients in foods.
Trim+ has been scientifically proven to be effective in inhibiting the activities of carbohydrates digestive enzymes, which results in
a reduction of the breakdown and absorption of sugars.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_016.jpg" alt="" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Benefits:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduces
    total carbohydrates calories intake with scientifically proven effect on weight management.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulates
    blood sugar levels with scientifically proven efficacy.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improves
    cellular uptake of sugars for bioenergy ATP production.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maintains
    insulin hormone balance and helps prevent diabetes.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improves
    blood lipids compositions and helps prevent cardiovascular disease.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DSY
Wellness</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 11, 2021, Agape ATP Corporation (Labuan) formed a joint-venture entity, DSY Wellness with Mr. Steve Yap following which Agape
ATP Corporation (Labuan) owns 60% of the equity interest, to pursue the business of providing complementary health therapies. The establishment
of DSY Wellness is a further expansion of our business into the health and wellness industry. DSY Wellness offers health consultancy
and advice, as well as nutritional supplements at medical dosages, as prescribed by in-house nutritional practitioners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Business Model</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the direct-selling channel is ideally suited to marketing our products, because sales of health solution and personal care
products are strengthened by ongoing personal contact between retail consumers and distributors. This personal contact may enhance consumers&#8217;
nutritional and health education and motivate consumers to begin and maintain wellness and weight management programs. In addition, by
using our products themselves, distributors can provide first-hand testimonials of product effectiveness, which can serve as a powerful
sales tool.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are focused on building and maintaining our distributor network by offering financially rewarding and flexible career opportunities through
the sale of quality, innovative products to health-conscious consumers. We believe the income opportunity provided by our bonus program
appeals to a broad cross-section of our members, particularly those seeking to supplement family income, start a home business or pursue
entrepreneurial, full and part-time, employment opportunities. Our distributors, who are all independent third parties, profit from selling
our products and also earning bonuses through performance of their network group, the establishment of their own network group and the
performance of distributors recruited under their own network group. Top performing distributors with their own physical stores may also
become stockists of the company, whereby they enjoy benefits such as maintaining a certain amount of the Company&#8217;s inventory in
their store premises, with the requirement that all product sales are monitored through our centralized stock tracking system and accounted
back to us. The stockists have the option of returning or exchanging any unsold inventory consigned to them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
enable distributors to maximize their potential by providing a broad array of motivational, educational and support services. We motivate
our distributors through our performance-based compensation plan, product-training seminars, workshops and participation in routine promotional
activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are committed to providing professionally designed educational training materials that our distributors can use to enhance recruitment
and to maximize their sales. We conduct several training sessions per year to motivate our distributors. These training events teach
our distributors not only how to develop invaluable business-building and leadership skills, but also how to differentiate our products
with their consumers, including information sessions presented by in-house nutritional consultants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate-sponsored training events provide a forum for distributors, who otherwise operate independently, to share ideas with us and
each other. In addition, we are also developing an e-marketing and e-trading platform allowing for marketing and trading of products
to members, as well as online recruitment of new members and to provide direct sales to customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are committed to providing our distributors with quality products to help them increase sales and recruit additional distributors. We
leverage our team of in-house nutritional consultants with rich experience gained in the area of nutrition, in collaborating with our
customers and clients to understand the health and wellness market via a process of consultative review. This review team is headed by
the Head of Product Development. We then communicate our findings and proposals to third-party suppliers to improve formulations, to
bring about new products for distributors and members who are ready to market to end-users.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
place a strong emphasis on the science of nutrition. We have obtained the appropriate authorizations from the Food Safety and Quality
Division, and the National Pharmaceutical Regulatory Agency of the Ministry of Health, Malaysia for all our products. Whenever products
are purchased for inventory replenishment, samples are randomly selected from every batch for testing at laboratories registered with
the Ministry of Health Malaysia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Customers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
provide health and wellness products and advisory services to health-conscious customers in the Malaysian market. Such customers are
able to enjoy membership discounts across all our products by becoming a member.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
distributors enjoy further discounts on all of our products. Besides our three sales branches located in Kuala Lumpur, Johor Bahru and
Ipoh, our products are all distributed to customers and members by our distributor&#8217;s networks, which are comprised of three stockists
who are also independent distributors, whose store premises are located in two other locations in Malaysia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our products are particularly well-suited for direct distribution because the sale of health and nutrition products are
strengthened by ongoing personal contact between retail customers and distributors. We believe our continued commitment to source quality
science-based products will enhance our ability to attract new customer, as well as increase the productivity and retention of our distributors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Structure
of the membership program</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
customers are able to become lifetime members by paying a one-time membership fee with the purchase of specific products. Doing so allows
the customer to enjoy membership discounts on all our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Members
who accumulate a predetermined number of purchases are automatically promoted to become a distributor of the Company. Other than helping
distributors achieve physical health and wellness through the use of our products, we offer our distributors, who are independent third
parties, bonuses based on various performance factors. Distributors are required to maintain a predetermined number of purchases per
year in order to maintain their distributor status.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Top
performing distributors with their own physical stores may also become stockists of the Company, whereby they enjoy benefits such as
maintaining a certain amount of the Company&#8217;s inventory in their store premises. The stockists shall account to the Company for
all products sales from their store premises as monitored through the Company&#8217;s centralized stock tracking system. The stockists
shall have the option to either return or exchange the Company&#8217;s inventory consigned to them that are unsold.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the number of members and distributors at the date indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Distributors</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Members</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total Number of Distributors and Members</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">As at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">56,459</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">72,160</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">128,619</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Distributors&#8217;
and members&#8217; earnings</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distributors
and members earn profits from the sales of our products to customers. Distributors enjoy additional discounts compared to members, allowing
them to earn higher direct profits through the differences in pricing when selling products they bought at distributors&#8217; prices
which are more favorable than member&#8217;s prices to customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Members
are encouraged to build their respective network group. Members are promoted to distributors if they manage to recruit the requisite
number of members; and the network group is able to achieve set sales targets. Other than preferential distributor pricing for the purchase
of the Company&#8217;s products, distributors enjoy bonuses from the collective performance of their network group. There are several
levels of distributors depending on the size and the collective sales performance of their respective network group. Each level affords
bonus benefits in a different form in ascending order. A higher-level distributor will be compensated with higher returns in the form
of bonus entitlements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Distributors
and members motivation and training</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that motivation, inspiration and training are key elements in the success of sales via network group marketing. Together with
our distributors and members, we have established a consistent schedule of gatherings to support those needs. We conduct several training
sessions per year to educate and motivate our distributors and members. The training sessions are typically presented by in-house staff
with suitable background in nutrition, in order to provide key nutrition information about our products, as well as providing workshops
to promote presentation skills to attending participants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Suppliers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
all of our products are acquired from unrelated third parties located in Australia, the United States, Germany and Malaysia, and rebranded
by us. Due to the high costs associated with research and development of nutrition and health products, we do not maintain any facilities
to produce our products. We have no expenditures or expenses relating to research and development of our product. We leverage our team
of in-house nutritional consultants with rich experience gained in the area of nutritionist work, in collaborating with our customers
and clients to understand the health and wellness market via a process of consultative review. We then communicate our findings and proposals
to third-party suppliers to improve formulations and to bring about new products for distributors and members who are ready to market
to end-users.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up
to the year ended December 31, 2020, we purchased from Agape S.E.A. Sdn Bhd, one of our largest suppliers, through the SEA Supply Agreement.
For more information, please see &#8220;The SEA Supply Agreement&#8221; below. For the year ended December 31, 2022, we purchased from
our three largest suppliers through purchase order forms which included customary terms including unit price, quantity, total price of
the orders, and order lead times. We did not enter into any long term supply agreements with our major suppliers for the years ended December
31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
SEA Supply Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
S.E.A Sdn Bhd is a dietary supplement company founded in Malaysia. We originally entered into the SEA Supply Agreement with Agape S.E.A.
Sdn Bhd, in May 2018, which was one of our largest suppliers at the time. Under the SEA Supply Agreement we purchased dietary supplement
products and skincare products from Agape S.E.A.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
following summarizes the major terms of the SEA Supply Agreement:</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sales
    of Goods:</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    agreement stipulates the type of goods sold, transported and delivered, with a minimum quantity per order between 5,000 to 10,000
    units per order. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Purchase
    price:</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    agreement stipulates that the Company shall place order for goods using a purchase order. The purchase prices under the SEA Supply
    Agreement are based on and in accordance with each purchase order. Agape S.E.A shall be responsible for all taxes in connection with
    the purchase of goods under the SEA Supply Agreement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Payment:</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
    for goods is due within seven days of the date of the Agape S.E.A&#8217;s invoice, which date will not be before the date of delivery
    of goods.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Delivery:</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    delivery date and delivery destination of each purchase shall be determined by both parties in a purchase order. Agape S.E.A. shall
    deliver the goods in accordance with the terms and conditions specified separately in each purchase order, including without limitation
    the quantity and delivery date. The Company is responsible for freight insurance arising from shipment to a single delivery destination.
    For destinations outside of Malaysia, the Company is also responsible for freight, freight insurance, tariffs and custom clearance
    fees.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk
    of Loss:</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    to and risk of loss of the goods shall pass to the Company upon shipment of the goods.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Right
    of Inspection</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company shall be allowed to examine the goods once received and shall do so within fourteen days after the receipt of the goods.
    In the event the Company discovers any damages, shortages or other nonconformance of the goods, the Company shall notify Agape S.E.A
    within fourteen days specifying the basis of the claim. In the event of nonconformance, the Company has the following options: </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-retuning
    the goods for a replacement at Agape S.E.A&#8217;s expense;-returning the goods at Agape S.E.A&#8217;s expense for a credit of the
    full purchase price on future transactions; or-returning the goods at Agape S.E.A&#8217;s expense for a full refund of the purchase
    price.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warranties:</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    buyer acknowledges that it has not relied on, and that Agape S.E.A has not made any representations or warranties with respect to
    the quality or condition of the goods, and is purchasing the goods on an &#8220;as is&#8221; basis.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Security
    Interest:</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company grants Agape S.E.A a security interest in the goods, until the Company has paid the seller in full for the goods. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Seller
    Representations and Warranties:</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
    S.E.A warrants that the goods are free, and at the time of delivery will be free, from any security interest or other liens or encumbrances,
    and there are no outstanding titles or claims of title hostile to the rights of Agape S.E.A in the goods.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Limitation
    of Liability:</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
    S.E.A will not be liable for any indirect, special, consequential or punitive damages (including lost profits) arising out of or
    relating to this agreement or the transactions contemplated by it contemplates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Assignment:</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
    party may not assign any of its rights or delegate any performance under the agreement, except with prior consent from the other
    party</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Governing
    Law:</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    terms of the agreement shall be governed by and construed in accordance with the laws of the State of England.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Breach/
    Termination:</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    party has an obligation to notify the other party of any breach, and where the breach is rectifiable, the breaching party has 21
    days from the date of notification of its breach to rectify. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Quality
Control</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
present, our products are predominately sold in Malaysia. As the contents and combination of the main ingredients in our ATP Zeta Health
Program and BEAUNIQUE series are categorized as health food rather than medicines or drugs, all of our products require authorization
from the Food Safety and Quality Division of the Ministry of Health, Malaysia according to the Food Act 1983 (ACT 281) &amp; Regulations
in order to be sold in the country. Accordingly, we have obtained the appropriate authorizations from the Food Safety and Quality Division
of the Ministry of Health, Malaysia for all products in our ATP Zeta Health Program and BEAUNIQUE series.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
&#201;NERG&#201;TIQUE series is regulated under the Control of Drugs and Cosmetics Regulations 1984, the Ministry of Health, Malaysia.
We have also obtained the appropriate authorizations for distribution and sale of the products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inventory</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates a central warehouse at its head office in Kuala Lumpur, Malaysia, which typically maintains an inventory reserve of
up to 6 months per product. Inventory is transferred to the Company&#8217;s sales branches via ordering through the Company&#8217;s centralized
stock tracking system. Stockists of the Company are required to have physical stores, and enjoys the benefit of being able to store certain
amount of inventory in their stores for convenience. The stockists shall account to the Company for all products sales from their store
premises as monitored through the Company&#8217;s centralized stock tracking system. The stockists shall have the option to either return
or exchange the Company&#8217;s inventory consigned to them that are unsold.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Seasonality</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s business is generally not subject to any seasonality factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warranty</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products include a customer satisfaction guarantee. Under this guarantee, within 90 days of purchase, any customer who is not satisfied
with our product for any reason may return it or any unused portion of it to the distributor from whom it was purchased for a full refund
from the Company or credit toward the purchase of another product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
product returns have not been significant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E-commerce
system</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to facilitate our continued growth and to support distributor activities, we continually invest and upgrade our platforms. In 2019,
we invested in an initiative to establish e-commerce through the setup of e-trading of our products on an existing Malaysian e-commerce
trading platform. Our e-trading initiative will be actively promoted for online recruitment of new members by existing distributors and
to provide direct sales to customers. Once the E-trading platform has provided tangible results in the Malaysia market, we intend to
expand the platform to other geographic markets in order to duplicate its success. We also intend to approach online social influencers
as part of our marketing strategy to promote our products and our e-commerce platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consider trademarks, patents and copyrights to protect our intellectual property rights critical to our success. We are the registered
owner of five registered trademarks and with 1 trademark pending registration in Malaysia. We have one applied to register an additional
one trademarks in Malaysia. We are also the registered owner of five domain names, namely &#8220;agapeatpgroup.com&#8221;, &#8220;agapeatpcorporation.com&#8221;,
&#8220;atpsummit.com&#8221;, &#8220;agapeatpgroup.my&#8221; and &#8220;agapeatpgroup.com.my.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Category</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
    Number</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 28%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
    Marks Logo</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ownership</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Country</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
    Date and Duration</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trademark</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">06010456</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_017.jpg" alt="" /></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
    Superior Living Sdn. Bhd.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malaysia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
                                            20, 2016</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    10 Years</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>[Class
    30]</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trademark</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017005364</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_018.jpg" alt="" style="width: 150px" /></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
    ATP Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malaysia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    5, 2017<br />
    For 10 Years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>[Class
    35]</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trademark</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019023588</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_019.jpg" alt="" /><b></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
    ATP Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malaysia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
                                            3, 2019</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    10 Years</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>[Class
    3]</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trademark</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019023590</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_020.jpg" alt="" /></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
    ATP Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malaysia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
                                            3, 2019</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    10 Years</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>[Class
    5]</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trademark</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019023589</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_020.jpg" alt="" /></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
    ATP Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malaysia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    3, 2019<br />
    For 10 Years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>[Class
    16]</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trademark</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019036886</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_021.jpg" alt="" /></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
    Superior Living Sdn. Bhd.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malaysia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    3, 2019<br />
    For 10 Years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>[Class
    5]</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
at December 31, 2022, we had 30 employees (excluding our Directors). The following table sets forth the number of employees by function:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Function</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>employees</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Senior Management</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">1</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Business Development Department</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Corporate Affairs Department</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance Department</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Human Resources Department</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operations Department</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Product Development Department</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Sales &amp; Marketing Department</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">30</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Insurance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Employees&#8217; Social Security Act, 1969, Malaysia mandates employers and employees to make a monthly contribution to the Social Security
Organisation, Malaysia, (&#8220;SOCSO&#8221;) for any employee who is employed for wages paid under a contract of service or apprenticeship
with an employer for the purpose of providing social security protection to employees and their dependents against occupational injuries,
including industrial accident, accident during emergency at the employers&#8217; premises, occupational diseases and commuting accidents.
Depending on the monthly wages earned by the employee, employers shall cause to be deducted from the respective employee&#8217;s wages,
amounts that ranges between RM0.10 to RM19.75 for monthly wages between RM30 to RM4,000. The employers&#8217; contribution corresponds
to the said rates are between RM0.4 to RM69.05. Rates applicable to both the employee and employer are fixed at the maximum rate of RM19.75
and RM69.05 respectively. Employees who have attained 60 years of age are not required to contribute to the scheme. The employer&#8217;s
responsibility towards this group shall be at a reduced rate which ranges between MYR0.30 to RM49.40 for the said wage band.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than SOCSO, effective January 1, 2018, employees and employers in the private sector are mandated to contribute to an employment insurance
system, (&#8220;EIS&#8221;) under the Employment Insurance System Act, 2017. Both the employee and employer shall contribute at an equal
rate at 0.2% of the employee&#8217;s wages under the scheme, subject to a maximum monthly wage rate of RM4,000. No further contribution
to the scheme is required from the employee or the employer for employees who have attained 60 years of age; and employees aged 57 and
above who have no prior contributions are exempted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any third-party liability insurance to cover claims in respect of personal injury or property or environmental damage arising
from accidents on our property or relating to our operations. Such insurance is not mandatory according to the laws and regulations of
Malaysia. We typically do not require our distributors to purchase insurance regarding their operations. We believe this practice is
consistent with customary industry standards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
present, our products are predominately sold in Malaysia. As the contents and combination of the main ingredients in our ATP Zeta Health
Program and BEAUNIQUE series are categorized as health food rather than medicines or drugs, all of our products require authorization
from the Food Safety and Quality Division of the Ministry of Health, Malaysia according to the Food Act 1983 (ACT 281) &amp; Regulations
in order to be sold in the country. Accordingly, we have obtained the appropriate authorizations from the Food Safety and Quality Division
of the Ministry of Health, Malaysia for all products in our ATP Zeta Health Program and BEAUNIQUE series.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
&#201;NERG&#201;TIQUE series is regulated under the Control of Drugs and Cosmetics Regulations 1984, the Ministry of Health, Malaysia.
We have also obtained the appropriate authorizations for distribution and sale of the products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="m_003"></span>ITEM
1A. RISK FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
are exposed to concentration risk of heavy reliance on our three largest suppliers for the supply of our products, and any shortage of,
or delay in, the supply may significantly impact on our business and results of operation.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2022, we purchased $198,376, $82,434 and $79,365 from three of our major suppliers, represented approximately
53%, 22% and 21%, respectively, of our total purchases. Our business, financial condition and operating results depend on the continuous
supply of products from our major suppliers and our continuous supplier-customer relationships with them. Our heavy reliance on our major
suppliers for the supply of our products will have significant impact on our business and results of operation in the event of any shortage
of, or delay in the supply.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently do not have long term supply agreements with our three largest suppliers for the year ended December 31, 2022, and we typically
make ad hoc purchases through submission of purchase order forms. There is no assurance that our major suppliers will continue to supply
their products in the quantities and timeframes required by us to meet the needs of our customers or comply with their supply agreements
with us. Our product supply may also be disrupted by potential labor disputes, strike action, natural disasters or other accidents, epidemic
and pandemic affecting the supplier. If our major suppliers do not supply products to us in a timely manner or in sufficient quantities,
our business, financial condition and operating results may be materially and adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
in the event of any delay in delivery of the products to us, our cash flow or working capital may be materially and adversely affected
as a result of the corresponding delay in delivery of our products to our customers, and hence the delay in our receipt of payment from
our customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
major suppliers may change their existing sales or marketing strategy in respect of the products supplied to us by changing their export
strategy, reducing its sales or production volume or changing its selling prices. Consequently, there are no assurances that our major
suppliers will not appoint other dealers or distributors which may compete with us in the market where we operate. Furthermore, any significant
increase in the selling prices of the products which we source from our suppliers will increase our costs and may adversely affect our
profit margin if we are not able to pass the increased costs on to our customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no assurances that there will be no deterioration in our relationships with our major suppliers which could affect our ability to
secure sufficient supply of products for our business. In the event that our major suppliers change their sales or marketing strategy
or otherwise appoint other dealers or distributors who may compete with us, our business, financial condition and operating results may
be materially and adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
could be adversely affected by a change in consumer preferences, perception and spending habits and failure to develop or enrich our
product offering or gain market acceptance of our new products could have a negative effect on our business.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market we operate is subject to changes in consumer preference, perception and spending habits. Our performance depends significantly
on factors which may affect the level and pattern of consumer spending in the market we operate. Such factors include consumer preference,
consumer confidence, consumer income and consumer perception of the safety and quality of our products. Media coverage regarding the
safety or quality of, or diet or health issues relating to, our products or the raw materials, ingredients or processes involved in their
manufacturing, may damage consumer confidence in our products. A general decline in the consumption of our products could occur as a
result of change in consumer preference, perception and spending habits at any time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
failure to adapt our product offering to respond to such changes may result in a decrease in our sales if such changes are related to
certain of our products. Any changes in consumer preference could result in lower sales of our products, put pressure on pricing or lead
to increased levels of selling and promotional expenses. In any event a decrease in customer demand on our products may also result in
lower sales and slow down the consumption of our inventory to a low inventory turnover level. Any of these changes could result in a
material adverse effect on our business, financial conditions or results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
success of our products depends on a number of factors including our ability to accurately anticipate changes in market demand and consumer
preferences, our ability to differentiate the quality of our products from those of our competitors, and the effectiveness of our marketing
and advertising campaigns for our products. We may not be successful in identifying trends in consumer preferences and developing products
that respond to such trends in a timely manner. We also may not be able to effectively promote our products by our marketing and advertising
campaigns and gain market acceptance. If our products fail to gain market acceptance, are restricted by regulatory requirements, or have
quality problems, we may not be able to fully recover our costs and expenses incurred in our operation, and our business prospects, financial
condition or results of operations may be materially and adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
we fail to maintain quality products and value, our sales are likely to be negatively affected.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends on the safety and quality of products that we obtain from our suppliers for our customers. Our future customers will
identify our brand name with a certain level of quality and value. If we cannot meet this perceived value or level of quality, we may
be negatively affected and our operating results may suffer. In addition, any failure on the part of our suppliers to maintain the quality
of their products, will in turn substantially harm the results of our business operations, potentially forcing us to identify other suppliers
or alter our business strategy significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
we are unable to create brand influence, we may not be able to maintain current or attract new users and customers for our products.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operational and financial performance is highly dependent on the strength of our brand. We believe brand familiarity and preference will
continue to have a significant role in winning customers as the decision to buy our products and services. In order to further expand
our customer base, we may need to substantially increase our marketing expenditures to enhance brand awareness through various online
and offline means. Moreover, negative coverage in the media of our company could threaten the perception of our brand, and we cannot
assure you that we will be able to defuse negative press coverage about our company to the satisfaction of our investors, customers and
suppliers. If we are unable to defuse negative press coverage about our company, our brand may suffer in the marketplace, our operational
and financial performance may be negatively impacted and the price of our shares may decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
we sell our products, with or without customization, under our brand name &#8220;ATP&#8221;, to domestic customers in Malaysia and to
overseas customers. However, if our competitors initiate a lawsuit against us for infringing their trademark, we may be forced to adopt
a new brand name for our products. As a result, we may incur additional marketing cost to raise awareness of such new brand name. We
may also be ordered to pay a significant amount of damages, and our business, results of operations and financial condition could be
materially and adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
may be unable to protect our intellectual property rights.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on intellectual property laws in Malaysia and other jurisdictions to protect our trademarks. We are the registered owner of two
trademarks. We have recently applied to register an additional three trademarks in Malaysia. We cannot assure you that counterfeiting
or imitation of our products will not occur in the future or, if it does occur, that we will be able to address the problem in a timely
and effective manner. Any occurrence of counterfeiting or imitation of our products or other infringement of our intellectual property
rights could negatively affect our brand and our reputation, which in turn adversely affects the results of our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation
to prosecute infringement of our intellectual property rights could be costly and lengthy and will divert our managerial and financial
resources. We will have to bear costs of the intellectual property litigation and may be unable to recover such costs from our opposite
parties. Protracted litigation could also result in our customers deferring or limiting their purchase or use of or products until such
litigation is resolved. The occurrence of any of the foregoing will have a material adverse effect on our business, financial condition
and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
may incur losses resulting from product liability claims or product recalls or adverse publicity relating to our products.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may incur losses resulting from product liability claims with respect to our products supplied by our supplier. We may face claims or
liabilities which may arise if there exist any defects in quality of these products or any of these products are deemed or proven to
be unsafe, defective or contaminated. In the event that the use or misuse of any product distributed by us results in personal injury
or death, product liability and/or indemnity claims may be brought against us, in addition to our product recalls, and the relevant regulatory
authorities in the market we operate may close down some of our related operations and take administrative actions against us. If we
experience any business disruption and litigation, we may incur additional costs and have to divert our management&#8217;s attention
and resources on such matters, which may adversely affect our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
operate in a heavily regulated industry.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is principally regulated by various laws and regulations in the market we operate, such as in Malaysia the Food Act of 1983
(Act 281) and Regulations, Control of Drugs and Cosmetics Regulations 1984 mandate authorization from the Food Safety and Quality Division
and National Pharmaceutical Regulatory Agency of the Ministry of Health for our Company&#8217;s products to be sold in the country. Various
registrations, certificates and/or licenses for the conduct of our business are required under the above laws, which also contain provisions
for requirements on the storage, labelling, advertising and importation of some of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on our experience, some of the laws and regulations of the place where we operate our business are subject to amendments, uncertainty
in interpretation and administrative actions from time to time. Therefore, we cannot assure you that, for the implementation of our business
plans and the introduction of any new product, we will be able to obtain all the necessary registrations, certificates and/or licenses.
Any failure to comply with the above laws and regulations may give rise to fines, administrative penalties and/or prosecution against
us, which may adversely affect our reputation, financial condition or results of operation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
had previously relied on our variable interest entity, Agape S.E.A. Sdn Bhd, in Malaysia for our business operations, which may not be
as effective in providing operational control or enabling us to derive economic benefits as through ownership of controlling equity interests.
While we no longer rely on Agape S.E.A. Sdn Bhd for our operations, we may do so in the future.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
S.E.A. Sdn Bhd&#8217;s equity at risk was insufficient to finance its business activities and it provided all of the Company&#8217;s
purchases during the fiscal years ended December 31, 2020 and 2019. As a result, it is considered to be a variable interest entity
(&#8220;VIE&#8221;) and the Company is the primary beneficiary since it has both of the following characteristics, (a) the power to
direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance; and (b) the obligation to
absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could
potentially be significant to the VIE. However, the Company no longer relied on the VIE after the fiscal year ended December 31,
2020. For the years ended December 31, 2022 and 2021, Agape S.E.A. Sdn Bhd did not provide any purchase to the Company. In addition, Agape S.E.A.&#8217;s impact to our consolidated
financial statements constitutes less than 1% of our total consolidated assets. While the Company have not made any purchases from the VIE for the year ended December 31, 2022, we may expect to continue to
rely on ASL&#8217;s beneficiary ownership structure with Agape S.E.A. to operate our business. If we fail to continue our
beneficiary ownership structure with Agape S.E.A. in the future, it could have a material adverse effect on our financial condition
and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
internal controls may be inadequate, which could cause our financial reporting to be unreliable and lead to misinformation being disseminated
to the public.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over our financial reporting. As defined in Exchange
Act Rule 13a-15(f), internal control over financial reporting is a process designed by, or under the supervision of, the principal executive
and principal financial officer and effected by the board of directors, management and other personnel, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with
generally accepted accounting principles and includes those policies and procedures that: pertain to the maintenance of records in reasonable
detail accurately and fairly reflect the transactions and dispositions of the assets of the Company; provide reasonable assurance that
transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting
principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and/or
directors of the Company; and provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use
or disposition of the Company&#8217;s assets that could have a material effect on the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the audit of our consolidated financial statements as of December 31, 2022, we identified three &#8220;material
weaknesses&#8221;, and other control deficiencies including significant deficiencies in our internal control over financial
reporting. A &#8220;material weakness&#8221; is a deficiency, or a combination of deficiencies, in internal control over financial
reporting, such that there is a reasonable possibility that a material misstatement of the company&#8217;s annual or interim
financial statements will not be prevented or detected on a timely basis. The material weaknesses identified related to the Company
were: (i) insufficient full-time personnel with appropriate levels of accounting knowledge and experience to monitor the daily
recording of transactions, address complex U.S. GAAP accounting issues and to prepare and review financial statements and related
disclosures under U.S. GAAP; (ii) lack of a functional internal audit department or personnel that monitors the consistencies of the
preventive internal control procedures and lack of adequate policies and procedures in internal audit function to ensure that the
Company&#8217;s policies and procedures have been carried out as planned; (iii) lack of proper IT policies and procedures developed
for system change management, user access management, backup management and service organization management. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have taken measures and plan to continue to take measures to remedy these material weaknesses. The measures that we are planning to
take include, but not limited to, hiring of suitable IT personnel to develop and implement proper IT policies and procedures for
system change management, user access management, backup management and service organization management, form an internal audit
function and have plans to hire internal auditors to strengthen our overall governance. All internal auditors will be independent of
our operations and will report directly to the audit committee. The implementation of these measures may not fully address the
material weaknesses in our internal control over financial reporting, and we cannot conclude that they have been fully remedied. Our
failure to correct theses material weaknesses or our failure to discover and address any other material weaknesses could result in
inaccuracies in our financial statements and could also impair our ability to comply with applicable financial reporting
requirements and related regulatory filings on a timely basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we will become subject to the Sarbanes-Oxley Act of 2002. Section 404 of the Sarbanes-Oxley Act, or SOX 404, will require
that we include a report from management on the effectiveness of our internal control over financial reporting in our annual report on
Form 10-K and in our quarterly report on Form 10-Q if we are qualified as an accelerated filer. Our management may conclude that our
internal control over financial reporting is not effective. Moreover, even if our management concludes that our internal control over
financial reporting is effective, our independent registered public accounting firm, after conducting its own independent testing, may
issue a report that is qualified if it is not satisfied with our internal controls or the level at which our controls are documented,
designed, operated or reviewed, or if it interprets the relevant requirements differently from us. In addition, after we become a public
company, our reporting obligations may place a significant strain on our management, operational and financial resources and systems
for the foreseeable future. We may be unable to timely complete our evaluation testing and any required remediation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the course of documenting and testing our internal control procedures, in order to satisfy the requirements of SOX 404, we may identify
other weaknesses and deficiencies in our internal control over financial reporting. In addition, if we fail to maintain the adequacy
of our internal control over financial reporting, as these standards are modified, supplemented or amended from time to time, we may
not be able to conclude on an ongoing basis that we have effective internal control over financial reporting in accordance with SOX 404.
If we fail to achieve and maintain an effective internal control environment, we could suffer material misstatements in our financial
statements and fail to meet our reporting obligations, which would likely cause investors to lose confidence in our reported financial
information. This could in turn limit our access to capital markets, harm our results of operations, and lead to a decline in the trading
price of our shares. Additionally, ineffective internal control over financial reporting could expose us to increased risk of fraud or
misuse of corporate assets and subject us to potential delisting from the stock exchange on which we list, regulatory investigations
and civil or criminal sanctions. We may also be required to restate our financial statements from prior periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal
disputes or proceedings could expose us to liability, divert our management&#8217;s attention and negatively impact our reputation.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may at times be involved in potential legal disputes or proceedings during the ordinary course of business operations relating to product
or other types of liability, employees&#8217; claims, labor disputes or contract disputes that could have a material and adverse effect
on our reputation, operation and financial condition. If we become involved in material or protracted legal proceedings or other legal
disputes in the future, the outcome of such proceedings could be uncertain and could result in settlements or outcomes which adversely
affect our financial condition. In addition, any litigation or legal proceedings could incur substantial legal expenses as well as significant
time and attention of our management, diverting their attention from our business and operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
failure to comply with anti-corruption laws and regulations, or effectively manage our employees, customers and business partners, could
severely damage our reputation, and materially and adversely affect our business, financial condition, results of operations and prospects.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to risks in relation to actions taken by us, our employees, third-party customers or third-party suppliers that constitute
violations of the anti-corruption laws and regulations. While we adopt strict internal procedures and work closely with relevant government
agencies to ensure compliance of our business operations with relevant laws and regulations, our efforts may not be sufficient to ensure
that we comply with relevant laws and regulations at all times. If we, our employees, third-party customers or third-party suppliers
violate these laws, rules or regulations, we could be subject to fines and/or other penalties. Actions by Malaysia regulatory authorities
or the courts to provide an alternative interpretation of the laws and regulations or to adopt additional anti-bribery or anti-corruption
related regulations could also require us to make changes to our operations. Our reputation, corporate image, and business operations
may be materially and adversely affected if we fail to comply with these measures or become the target of any negative publicity as a
result of actions taken by us, our employees, third-party customers or third-party suppliers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
we are unable to successfully develop and timely introduce new products or services or enhance existing products or services, our business,
financial condition and results of operations may be materially and adversely affected.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
must continually source, develop and introduce new products and services as well as improve and enhance our existing products and services
to maintain or increase our sales. The success of new or enhanced products or services may depend on a number of factors including, anticipating
and effectively addressing user preferences and demand, the success of our sales and marketing efforts, effective forecasting and management
of products and services demands, purchase commitments, and the quality of or defects in our products. The risk of not meeting our customers&#8217;
preferences and demands through our products and services may result in a shift in market shares, as customers instead choose products
and services offered by our competitors. This may result in lower sales revenue, materially and adversely affecting our business, financial
condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
may not be able to manage the growth of our business and our expansion plans and operations or implement our business strategies on schedule
or within our budget, or at all.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are continually executing a number of growth initiatives, strategies and operating plans designed to enhance our business. In 2023 we
plan to increase our revenue stream from health solution advisory services from our &#8220;ATP Zeta Health Program&#8221;, &#8220;ENERGETIQUE&#8221;
and &#8220;BEAUNIQUE&#8221; series to align with our growth strategies. Any expansion may increase the complexity of our operations and
place a significant strain on our managerial, operational, financial and human resources. Our current and planned personnel, systems,
procedures and controls may not be adequate to support our future operations. We cannot assure you that we will be able to effectively
manage our growth or to implement all these systems, procedures and control measures successfully. Furthermore, the anticipated benefits
from these growth initiatives, strategies and operating plans are based on assumptions that may prove to be inaccurate. Moreover, we
may not be able to successfully complete these growth initiatives, strategies and operating plans and realize all of the benefits that
we expect to achieve or it may be more costly to do so than we anticipate. If, for any reason, we are not able to manage our growth effectively,
the benefits we realize are less than our estimates or the implementation of these growth initiatives, strategies and operating plans
adversely affects our operations or costs more or takes longer to effectuate than we expect, and/or if our assumptions prove to be inaccurate,
our business and prospects may be materially and adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may seek and pursue opportunities through joint ventures or strategic partnerships for expansion from time to time, and
we may face similar risks and uncertainties as listed above. Failure to properly address these risks and uncertainties may materially
and adversely affect our ability to carry out acquisitions and other expansion plans, integrate and consolidate newly acquired or newly
formed businesses, and realize all or any of the anticipated benefits of such expansion, which may have a material adverse effect on
our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
have a limited operating history in the Malaysia health and wellness industry, which makes it difficult to evaluate our future prospects.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
launched our ATP Zeta Super Health Program business in June 2016, the same month in which our Company was incorporated, followed by our
ENERGETIQUE&#8221; and &#8220;BEAUNIQUE&#8221; series in July 2018 and March 2019, respectively, and thus, we have a limited operating
history. We have limited experience in most aspects of our business operation, such as sourcing products for and offering advisory services
on all the three programs. As our business develops and as we respond to competition, we may continue to introduce new product and services
offerings and make adjustments to our existing product line and services and to our business operation in general. Any significant change
to our business model that does not achieve expected results may have a material and adverse impact on our financial condition and results
of operations. It is therefore difficult to effectively assess our future prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Malaysia health and wellness industry may not develop as expected. Prospective retail and corporate customers may not be familiar with
the development of the market and may have difficulties distinguishing our products from those of our competitors. Convincing prospective
customers or distributors of the value of our products or services is important to the success of our business. The risk of failing to
convince potential customers or distributors to purchase products or services from us may result in the failure of our business plan.
Many customers or distributors may not be interested in purchasing products and services we sell because there is no certainty that our
business will succeed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should consider our business and prospects in light of the risks and challenges we encounter or may encounter given the rapidly evolving
market in which we operate and our limited operating history. These risks and challenges include our ability to, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manage
                                            our future growth;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase
                                            the utilization of our products by existing and new customers;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain
                                            and enhance our relationships with customers and distributors;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">improve
                                            our operational efficiency;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract,
                                            retain and motivate talented employees;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cope
                                            with economic fluctuations;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">navigate
                                            the evolving regulatory environment; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">defend
                                            ourselves against legal and regulatory actions.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
historical growth rates may not be indicative of our future growth. If we are unable to manage the growth and increased complexity of
our business, fail to control our costs and expenses, or fail to execute our strategies effectively, our business and business prospects
may be materially and adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
historical growth rates may not be indicative of our future growth, and we may not be able to generate similar growth rates in future
periods. Our revenue growth may slow, or our total revenues may decline for a number of possible reasons, including change in consumers&#8217;
preferences, changes in regulations and government policies, increasing competition, emergence of alternative business models, and general
economic conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
total revenues increased by approximately 82.6% from approximately $1.0 million for the year ended December 31, 2021 to approximately
$1.9 million for the year ended December 31, 2022. Our gross profit increased by
approximately 65.4% from approximately $0.7 million for the year ended December 31, 2021 to approximately $1.2 million for the year ended
December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our growth rate declines, investors&#8217; perceptions of our business and business prospects may be materially and adversely affected
and the market price of our shares could decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
lack of insurance could expose us to significant costs and business disruption.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
health and wellness industry in Malaysia is a mature market. We currently do not have any product liability or disruption insurance to
cover our operations in Malaysia or overseas, which, based on public information available to us relating to Malaysia-based health and
wellness companies, is consistent with customary industry practice in Malaysia. We have determined that the costs of insuring for these
risks and the difficulties associated with acquiring such insurance on commercially reasonable terms make it impractical for us to have
such insurance. If we suffer any losses, damages or liabilities in the course of our business operations, we may not have adequate insurance
coverage to provide sufficient funds to cover any such losses, damages or product claim liabilities. Therefore, there may be instances
when we will sustain losses, damages and liabilities because of our lack of insurance coverage, which may in turn materially and adversely
affect our financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A
decline in general economic condition could lead to reduced consumer demand and could negatively impact our business operation and financial
condition, which in turn could have a material adverse effect on our business, financial condition and results of operations.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating and financial performance may be adversely affected by a variety of factors that influence the general economy. Consumer spending
habits, including spending for health-related products and services we sell, are affected by, among other things, prevailing economic
conditions, levels of unemployment, salaries and wage rates, prevailing interest rates, income tax rates and policies, consumer confidence
and consumer perception of economic conditions. In addition, consumer purchasing patterns may be influenced by consumers&#8217; disposable
income. In the event of an economic slowdown, consumer spending habits could be adversely affected and we could experience lower net
sales than expected on a quarterly or annual basis which could have a material adverse effect on our business, financial condition and
results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
may be adversely affected by the performance of third-party contractors.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
engaged third-party contractors to carry out logistics services. We endeavor to engage third-party companies with a strong reputation
and track record, high performance reliability and adequate financial resources. However, any such third-party contractor may still fail
to provide satisfactory logistics services at the level of quality or within the timeframe required by us or our customers. While we
generally require our logistics contractors to fully reimburse us for any losses arising from delay in delivery or non-delivery, our
results of operation and financial condition may be adversely affected if any of the losses are not borne by them. If the performance
of any third-party contractor is not satisfactory, we may need to replace such contractor or take other remedial actions, which could
adversely affect the cost structure and delivery schedule of our products and services and thus have a negative impact on our reputation,
financial position and business operations. In addition, as we expand our business into overseas markets, there may be a shortage of
third-party contractors that meet our quality standards and other selection criteria in such locations and, as a result, we may not be
able to engage a sufficient number of high-quality third-party contractors in a timely manner, which may adversely affect our delivery
schedules and delivery costs and hence our business, results of operations and financial conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
may need additional capital, and financing may not be available on terms acceptable to us, or at all.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no guarantee that in the future we will generate enough profits to support our business. Although we believe that our anticipated
cash flows from operating activities together with cash on hand will be sufficient to meet our anticipated working capital requirements
and capital expenditures in the ordinary course of business for the next twelve months, we cannot assure you this will be the case. We
may need additional cash resources in the future if we experience changes in business conditions or other developments. We may also need
additional cash resources in the future if we find and wish to pursue opportunities for investment, acquisition, capital expenditure
or similar actions. If we determine that our cash requirements exceed the amount of cash and cash equivalents we have on hand at the
time, we may seek to issue equity or debt securities or obtain credit facilities. The issuance and sale of additional equity would result
in further dilution to our stockholders. The incurrence of indebtedness would result in increased fixed obligations and could result
in operating covenants that would restrict our operations. We cannot assure you that financing will be available in amounts or on terms
acceptable to us, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Adverse
developments in our existing areas of operation could adversely impact our results of business, results of operations and financial condition.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations are focused on utilizing our sales efforts which are principally located in Malaysia. As a result, our results of operations,
cash flows and financial condition depend upon the demand for our products in Malaysia. Due to the lack of broad diversification in industry
type and geographic location, adverse developments in our current segment of the industry, or our existing areas of operation, could
have a significantly greater impact on our business, results of operations and financial condition than if our operations were more diversified.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>An
overall decline in the health of the economy and other factors impacting consumer spending, such as natural disasters, outbreak of viruses,
illnesses, infectious diseases, contagions and the occurrence of unforeseen epidemics may affect consumer purchases, reduce demand for
our products and materially harm our business, results of operations and financial condition.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business depends on consumer demand for our products and, consequently, is sensitive to a number of factors that influence consumer confidence
and spending, including but not limited to, general current and future economic and political conditions, consumer disposable income,
recession and fears of recession, unemployment, minimum wages, availability of consumer credit, consumer debt levels, interest rates,
tax rates and policies, inflation, war and fears of war, inclement weather, natural disasters, terrorism, active shooter situations,
outbreak of viruses, illnesses, infectious diseases, contagions and the occurrence of unforeseen epidemics (including the outbreak of
the coronavirus and its potential impact on our financial results) and consumer perceptions of personal well-being and security. For
example, in recent years, there have been outbreaks of epidemics in various countries, including Malaysia. Recently, there was an outbreak
of a novel strain of coronavirus (COVID-19), which has spread rapidly to many parts of the world, including Malaysia. In March 2020,
the World Health Organization declared the COVID-19 a pandemic. The epidemic has resulted in intermittent quarantines, travel restrictions,
and the temporary closure of stores and facilities in Malaysia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantially
all of our revenues are concentrated in Malaysia. Consequently, our results of operations were adversely affected as a result of the
implementation of Movement Control Order (MCO) by the Malaysian government. The impact on the company as a result of the MCO includes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">temporary
                                            closure of offices and travel restrictions prevented the company and our distributors from
                                            organizing offline events, which in turn stalled our marketing effort;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">temporary
                                            suspension of product supplies to our distributors and members due supply chain disruption
                                            as our suppliers and logistics providers faced disruption and delay in their operation; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            COVID-19 outbreak has resulted in a decline in overall economic environment, which in turn
                                            lower the spending power of the consumer and consequently, the revenue of the company.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the uncertainty surrounding the COVID-19 outbreak, the financial impact related to the outbreak of and response to the coronavirus
cannot be reasonably estimated at this time. There is no guarantee that our total revenues will grow or remain at the similar level year
over year in the fiscal year 2023. We may have to record downward adjustments or impairment in the fair value of investments in the fiscal
year 2023, if conditions have not been significantly improved and global stock markets have not recovered from recent declines.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, our business could be adversely affected by the effects of epidemics, pandemic or, including, but not limited to, the COVID-19,
avian influenza, severe acute respiratory syndrome (SARS), the influenza A virus, Ebola virus, severe weather conditions such as flood
or hazardous air pollution, or other outbreaks. In response to an epidemic, severe weather conditions, or other outbreaks, government
and other organizations may adopt regulations and policies that could lead to severe disruption to our daily operations, including temporary
closure of our offices and other facilities. These severe conditions may cause us and/or our partners to make internal adjustments, including
but not limited to, temporarily closing down business, limiting business hours, and setting restrictions on travel and/or visits with
clients and partners for a prolonged period of time. Various impact arising from a severe condition may cause business disruption, resulting
in material, adverse impact to our financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fluctuations
in foreign currency exchange rates could have a material adverse effect on our financial results.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
earn revenues, pay expenses, own assets and incur liabilities in countries using currencies other than the U.S. dollar, including Australian
Dollar, Malaysian Ringgit and the Hong Kong Dollar. Because our consolidated financial statements are presented in U.S. dollars, we must
translate revenues, income and expenses, as well as assets and liabilities, into U.S. dollars at exchange rates in effect during or at
the end of each reporting period. Therefore, increases or decreases in the value of the U.S. dollar against other currencies affect our
net operating revenues, operating income and the value of balance sheet items denominated in foreign currencies. We cannot assure you
that fluctuations in foreign currency exchange rates, particularly the strengthening of the U.S. dollar against major currencies would
not materially affect our financial results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
business depends on the continued contributions made by Mr. How Kok Choong, as our key executive officer, the loss of who may result
in a severe impediment to our business.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success is dependent upon the continued contributions made by our CEO and President, Mr. How Kok Choong. We rely on his expertise in
business operations when we are developing our business. We have no &#8220;Key Man&#8221; insurance to cover the resulting losses in
the event that any of our officer or directors should die or resign.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Mr. How Kok Choong cannot serve the Company or is no longer willing to do so, the Company may not be able to find alternatives in a timely
manner or at all. This would likely result in a severe damage to our business operations and would have an adverse material impact on
our financial position and operating results. To continue as a viable operation, the Company may have to recruit and train replacement
personnel at a higher cost. Additionally, if Mr. How Kok Choong joins our competitors or develops similar businesses that are in competition
with our Company, our business may also be negatively impacted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future success depends on our ability to attract and retain qualified long-term staff to fill management, technology, sales, marketing,
and customer services positions. We have a great need for qualified talent, but we may not be successful in attracting, hiring, developing,
and retaining the talent required for our success.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
we are not able to achieve our overall long-term growth objectives, the value of an investment in our Company could be negatively affected.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established and publicly announced certain long-term growth objectives. These objectives were based on, among other things, our
evaluation of our growth prospects, which are generally driven by the sales potential of many product types, some of which are more profitable
than others, and on an assessment of the potential price and product mix. There can be no assurance that we will realize the sales potential
and the price and product mix necessary to achieve our long-term growth objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
face risks related to health epidemics, severe weather conditions and other outbreaks.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
recent years, there have been outbreaks of epidemics in various countries, including Malaysia. Recently, there was an outbreak of a novel
strain of coronavirus (COVID-19), which has spread rapidly to many parts of the world, including Malaysia. In March 2020, the World Health
Organization declared the COVID-19 a pandemic. The epidemic has resulted in quarantines, travel restrictions, and the temporary closure
of stores and facilities in Malaysia for prolong periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantially
all of our revenues are concentrated in Malaysia. Consequently, our results of operations will likely be adversely, and may be materially,
affected, to the extent that the COVID-19 or any other epidemic harms the Malaysia and global economy in general. Any potential impact
to our results will depend on, to a large extent, future developments and new information that may emerge regarding the duration and
severity of the COVID-19 and the actions taken by government authorities and other entities to contain the COVID-19 or treat its impact,
almost all of which are beyond our control. Potential impacts include, but are not limited to, the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">temporary
    closure of offices, travel restrictions, financial impact of our customers or suspension supplies may negatively affect, and could
    continue to negatively affect, the demand for our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    customer may require additional time to pay us or fail to pay us at all, which could significantly increase the amount of accounts
    receivable and require us to record additional allowances for doubtful accounts. We may have to provide significant sales incentives
    to our sole customer during the outbreak, which may in turn materially adversely affect our financial condition and operating results;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    disruption of our supply chain, logistics providers or customers could adversely impact our business and results of operations, including
    causing us or our suppliers to cease manufacturing for a period of time or materially delay delivery to our customers, which may
    also lead to loss of our customers; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    global stock markets have experienced, and may continue to experience, significant decline from the COVID-19 outbreak and the marketable
    securities that we have invested in could be materially adversely affected, which may lead to significant impairment in the fair
    values of our investments and in turn materially adversely affect our financial condition and operating results.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to our Industry</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
business and reputation may be affected by product liability claims, litigation, customer complaints, product tampering, food safety
issues, food-borne illnesses, health threats, quality control concerns or adverse publicity relating to our products. Product liability
insurance of our supplier may not cover our liability sufficiently or at all.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Like
other consumer product manufacturers, sale of our products involves an inherent risk of our products being found to be unfit for consumption
or cause illness. Products may be rendered unfit for consumption due to raw materials or product contamination or degeneration, presence
of microbials, illegal tampering of products by unauthorized third parties or other problems arising during the various stages of the
procurement, production, transportation and storage processes. The occurrence of such problems may result in customer complaints, fines,
penalties or adverse publicity causing serious damage to our reputation and brand, as well as product liability claims, other legal disputes
and loss of revenues. Under certain circumstances, we may be required to recall our products. Even if a situation does not necessitate
a product recall, we cannot assure you that product liability claims or other legal disputes will not be asserted against us as a result.
Product liability insurance of our supplier may not cover our liability sufficiently or at all and will not cover liability that arises
out of our default such as mishandling, poor storage condition and/or contamination of the products by us. As a result, a product liability
or other judgment against us, or a product recall, could have a material adverse effect on our business, financial condition or results
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is susceptible to food-borne illnesses. We cannot assure you that we are able to effectively prevent all diseases or illnesses
caused by our products or contamination of our products. Furthermore, our reliance on third-party product suppliers means that food-borne
illness incidents could be caused by our suppliers outside of our control. New illnesses may develop in the future, or diseases with
long incubation periods could arise that could give rise to claims or allegations on a retroactive basis. Reports in the media of instances
of food-borne illnesses or health threats of our products or any of their major ingredients could adversely and significantly affect
our sales, and have significant negative impact on our results of operations. This risk exists even if it were later determined that
the illness or health threat in fact was not caused by our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, adverse publicity about health and safety concerns, whether unfounded or not, may discourage consumers from buying our products.
Even if a product liability claim is unsuccessful or is not fully pursued, the negative publicity surrounding any assertion that our
products caused personal injury or illness could adversely affect our reputation and our corporate and brand image. If consumers were
to lose confidence in our brand and reputation, we could suffer long-term or even permanent declines in our sales and results of operation.
The amount of negative news, customers complaints and claims against us may also be very costly and may divert our management&#8217;s
attention from our business operation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
operate in a highly competitive market. If we do not compete effectively, our prospects, operating results, and financial condition could
be materially and adversely affected</i>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
health and wellness market in Malaysia is a mature and a highly competitive market, with companies offering a variety of competitive
products and services. We expect competition in our market to intensify in the future as new and existing competitors introduce new or
enhanced products and services that are potentially more competitive than our products and services. The health and wellness market has
a multitude of participants in the domestic market, including, but not limited, to retail health supplement providers, pharmaceutical
companies, and network marketing company which supply health supplement products, such as Elken Group, USANA Group, NHF Group, Young
Living, Jeunesse Global Holdings LLC, USA, Shaklee Corporation, VASAYO LLC, Amway Corporation, Sami Direct, Ky&#228;ni, Inc., Melaleuca,
Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe many of our competitors and potential competitors may have significant competitive advantages, including but not limited to,
longer operating histories, ability to leverage their sales efforts and marketing expenditures across a broader portfolio of products
and services, larger and broader customer bases, more established relationships with a larger number of suppliers, greater brand recognition,
ability to leverage stores which they may operate, and greater financial, research and development, marketing, distribution, and other
capabilities and resources than we do. Our competitors and potential competitors may also be able to develop products and services that
are equal or more superior to ours, achieve greater market acceptance of their products and services, and increase sales by utilizing
different distribution channels than we do. Some of our competitors may aggressively discount their products in order to gain market
share, which could result in pricing pressures, reduced profit margins, lost market share, or a failure to grow market share for us.
If we are not able to compete effectively against our current or potential competitors, our prospects, operating results, and financial
condition could be materially and adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Doing Business in Malaysia</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Developments
in the social, political, regulatory and economic environment in Malaysia may have a material adverse impact on us.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business, prospects, financial condition and results of operations may be adversely affected by social, political, regulatory and economic
developments in Malaysia. Such political and economic uncertainties include, but are not limited to, the risks of war, terrorism, nationalism,
nullification of contract, changes in interest rates, imposition of capital controls and methods of taxation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Negative
developments in Malaysia&#8217;s socio-political environment may adversely affect our business, financial condition, results of
operations and prospects. The Malaysian economy registered modest growth of approximately 8.7% and 3.1% in 2022 and 2021 respectively, according to the Department of Statistics Malaysia. Although the overall Malaysian economic environment
(in which we predominantly operate) appears to be positive, there can be no assurance that this will continue to prevail in the
future. Economic growth is determined by countless factors, and it is extremely difficult to predict with any level of absolute
certainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
on March 11, 2020, the World Health Organization or WHO declared the corona virus or COVID-19 a pandemic. To help counter the
transmission of COVID-19, from March 18, 2020 to April 26, 2022, the government of Malaysia initiated (i) Movement control orders
(&#8220;MCO&#8221;), . The MCO had resulted in quarantines, travel restrictions, and the temporary closure of stores and facilities
in Malaysia. (ii) Conditional Movement Control Order (&#8220;CMCO&#8221;) where most business sectors were allowed to operate under
strict rules and Standard Operating Procedures mandated by the government of Malaysia. (iii) Recovery Movement Control Order
(&#8220;RMCO&#8221;). At the height of the pandemic, on January 12, 2021, the Malaysian government even declared a state of
emergency nationwide to combat COVID-19. On April 27, 2022, the Malaysian government announced the country had entered into the
endemic phase with further easing of restrictions. We are witnessing the adverse impact on the purchasing power of consumers in
Malaysia, where our products are mainly sold as a direct result of the prolonged pandemic. A such, the extent to which the
coronavirus may continue to adversely impact the Malaysian economy is uncertain. In the event that the Malaysia economy suffers,
demand for our products may diminish, which would in turn result in our profitability. This could in turn result in a substantial
need for restructuring of our business objectives and could result in a partial or entire loss of an investment in our
Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
are subject to foreign exchange control policies in Malaysia.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of our subsidiaries to pay dividends or make other payments to us may be restricted by the foreign exchange control policies
in the countries where we operate. For example, there are foreign exchange policies in Malaysia which support the monitoring of capital
flows into and out of the country in order to preserve its financial and economic stability. The foreign exchange policies are administered
by the Foreign Exchange Administration, an arm of Bank Negara Malaysia (&#8220;BNM&#8221;), the central bank of Malaysia. The foreign
exchange policies monitor and regulate both residents and non-residents. Under the current Foreign Exchange Administration rules issued
by BNM, non-residents are free to repatriate any amount of funds from Malaysia in foreign currency other than the currency of Israel
at any time (subject to limited exceptions), including capital, divestment proceeds, profits, dividends, rental, fees and interest arising
from investment in Malaysia, subject to any withholding tax. In the event BNM or any other country where we operate introduces any restrictions
in the future, we may be affected in our ability to repatriate dividends or other payments from our subsidiaries in Malaysia or in such
other countries. Since we are a holding company and rely principally on dividends and other payments from our subsidiaries for our cash
requirements, any restrictions on such dividends or other payments could materially and adversely affect our liquidity, financial condition
and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Economic,
market and political developments in the countries where we operate could have a material and adverse effect on our business.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
with all organizations that seek to reduce business risks via geographical expansion, the economic, market and political conditions in
other countries, particularly emerging market conditions in Southeast Asia, could have an influence on our business. Any widespread global
financial instability or a significant loss of investor confidence in emerging market economies may materially and adversely affect our
business, financial condition, results of operations, prospects or reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Examples
of such external factors or conditions that are outside our control include, but are not limited to the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
                                            economic, political and social conditions in Southeast Asian markets;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consumer
                                            spending patterns in our key markets;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">currency
                                            and interest rate fluctuations;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">international
                                            events and circumstances such as wars, terrorist attacks, natural disasters and political
                                            instability; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in legal regimes and governmental regulations, such as licensing and approvals, taxation,
                                            duties and tariffs, in key markets and abroad.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, the global financial markets experienced significant disruptions in 2008 and the United States, Europe and other economies went
into recession. The recovery from the lows of 2008 and 2009 was uneven and the global economy has continued to face new challenges. There
is considerable uncertainty over the long-term effects of the expansionary monetary and fiscal policies that have been adopted by the
central banks and financial authorities of some of the world&#8217;s leading economies, including the United States. For example, in
2013, the Federal Reserve Bank in the United States announced the tapering of its bond-buying program which led to a high degree of volatility
in equity markets and substantial devaluations in the currencies of many emerging economies, including markets where we operate. Economic
conditions in the countries where we operate might be sensitive to global economic conditions, as well as changes in domestic economic
and political policies and the expected or perceived overall economic growth rate in emerging markets. Furthermore, the outbreak of coronavirus
disease 2019 was first reported in December 2019 in Wuhan, China. As of November 2022, Malaysia ranks #27 in the list of countries with
the highest COVID-19 cases as recorded under the coronavirus statistics of the &#8220;worldometer&#8221;. Total COVID-19 cases in Malaysia
hit approximately 4.9 million and associated fatality of 36,566. These figures are huge relative to the small size economy of the country.
We are witnessing the adverse impact on the purchasing power of consumers in Malaysia, where our products are mainly sold as a direct
result of the prolonged pandemic.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to our Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Volatility
in our shares price may subject us to securities litigation.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market for our shares may have, when compared to seasoned issuers, significant price volatility and we expect that our share price may
continue to be more volatile than that of a seasoned issuer for the indefinite future. In the past, plaintiffs have often initiated securities
class action litigation against a company following periods of volatility in the market price of its securities. We may, in the future,
be the target of similar litigation. Securities litigation could result in substantial costs and liabilities and could divert management&#8217;s
attention and resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
may never be able to pay dividends and are unlikely to do so.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not paid, nor do we intend to pay in the foreseeable future, dividends on our common stock, even if we become profitable.
Earnings, if any, are expected to be used to advance our activities and for working capital and general corporate purposes, rather than
to make distributions to stockholders. Since we are not in a financial position to pay dividends on our common stock and future dividends
are not presently being contemplated, investors are advised that return on investment in our common stock is restricted to an appreciation
in the share price. The potential or likelihood of an increase in share price is uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under Nevada law, we may only pay dividends subject to our ability to service our debts as they become due and provided that
our assets will exceed our liabilities after the dividend. Our ability to pay dividends will therefore depend on our ability to generate
sufficient profits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shareholders
may be diluted significantly through our efforts to obtain financing and satisfy obligations through the issuance of securities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wherever
possible, our board of directors will attempt to use non-cash consideration to satisfy obligations. In many instances, we believe that
the non-cash consideration will consist of shares of our common stock, warrants to purchase shares of our common stock or other securities.
In the future, we may issue our authorized but previously unissued equity securities, resulting in the dilution of the ownership interests
of our stockholders. We are authorized to issue an aggregate of 1,000,000,000 shares of common stock and 200,000,000 shares of preferred
stock. We may issue additional shares of common stock or other securities that are convertible into or exercisable for our common stock
in connection with hiring or retaining employees, future acquisitions, future sales of our securities for capital raising purposes, or
for other business purposes. The future issuance of any such additional shares of our common stock may create downward pressure on the
trading price of the common stock. We expect we will need to raise additional capital in the near future to meet our working capital
needs, and there can be no assurance that we will not be required to issue additional shares, warrants or other convertible securities
in the future in conjunction with these capital-raising efforts, including at a price (or exercise prices) below the price you paid for
your stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
are a &#8220;smaller reporting company,&#8221; and we cannot be certain if the reduced disclosure requirements applicable to smaller
reporting companies will make our common stock less attractive to investors.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently a &#8220;smaller reporting company&#8221;, meaning that we are not an investment company, an asset- backed issuer, or a
majority-owned subsidiary of a parent company that is not a smaller reporting company and annual revenues of less than $50.0 million
during the most recently completed fiscal year. In the event that we are still considered a &#8220;smaller reporting company,&#8221;
at such time as we cease being an &#8220;emerging growth company,&#8221; we will be required to provide additional disclosure in our
SEC filings. However, similar to an &#8220;emerging growth companies&#8221;, &#8220;smaller reporting companies&#8221; are able to provide
simplified executive compensation disclosures in their filings; are exempt from the provisions of Section 404(b) of the Sarbanes-Oxley
Act requiring that independent registered public accounting firms provide an attestation report on the effectiveness of internal control
over financial reporting; and have certain other decreased disclosure obligations in their SEC filings, including, among other things,
only being required to provide two years of audited financial statements in annual reports. Decreased disclosures in our SEC filings
due to our status as a &#8220;smaller reporting company&#8221; may make it harder for investors to analyze our results of operations
and financial prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="m_004"></span>ITEM
1B. UNRESOLVED STAFF COMMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="m_005"></span>ITEM
2. PROPERTIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently lease 6 properties ranging from approximately 2,500 to 11,900 square feet in Kuala Lumpur, Johor Bahru and Ipoh which
primarily carry out the functions of a staff accommodation, warehouse, office, service centers and sales branches in different
regions of Malaysia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business
support services are primarily rendered from:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            principal executive office at</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1705
    &#8211; 1708, Level 17, Tower 2,</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Faber
    Towers, Jalan Desa Bahagia,</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taman
    Desa, 58100 Kuala Lumpur, Malaysia.</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Room
                                            2708-9, 2F,</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Metropolis Tower,</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10
    Metropolis Drive, Hunghom,</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kowloon,
    Hong Kong.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="m_006"></span>ITEM
3. LEGAL PROCEEDINGS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation
is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.
There are currently no pending legal proceedings or claims that we believe will have a material adverse effect on our business, financial
condition or operating results. None of our directors, officers or affiliates is involved in a proceeding adverse to our business or
has a material interest adverse to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="m_007"></span>ITEM
4. MINE SAFETY DISCLOSURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="m_008"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">PART
II</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span id="m_009"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Common Stock is currently listed on the OTC Markets &#8211; Pink Sheets under the trading symbol &#8220;ATTP.&#8221; There is no active
trading market in the Company&#8217;s securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Holders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, we had 75,452,012 shares of our Common Stock par value, $0.0001 issued and outstanding. There were 1,296 record
holders of our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transfer
Agent and Registrar</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
transfer agent is VStock Transfer, LLC, with an address at 18, Lafayette Place, Woodmere, New York 11598 and telephone number is +1 (212)
828-843.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividend
Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
future determination as to the declaration and payment of dividends on shares of our Common Stock will be made at the discretion of our
board of directors out of funds legally available for such purpose. We are under no contractual obligations or restrictions to declare
or pay dividends on our shares of Common Stock. In addition, we currently have no plans to pay such dividends. Our board of directors
currently intends to retain all earnings for use in the business for the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity
Compensation Plan Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
there are no equity compensation plan in place.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unregistered
Sales of Equity Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Purchases
of Equity Securities by the Registrant and Affiliated Purchasers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not repurchased any shares of our common stock during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="m_010"></span>ITEM
6. SELECTED FINANCIAL DATA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth selected financial data as of December 31, 2022 and 2021 and for the years ended December 31, 2022 and 2021.
This selected financial data should be read in conjunction with the consolidated financial statements and related notes included in Item
15 of this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; padding-bottom: 2.5pt">Revenue</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">1,856,564</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">1,016,962</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss attributable to Agape ATP Corporation</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,686,899</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,524,244</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"> Loss per share &#8211; (basic and diluted)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.02</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.01</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">2,791,749</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">4,724,535</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,229,295</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,411,899</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="m_011"></span>ITEM
7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following discussion of our financial condition and results of operations should be read in conjunction with our audited consolidated
financial statements and the notes to those financial statements appearing elsewhere in this Report.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Certain
statements in this Report constitute forward-looking statements. These forward-looking statements include statements, which involve risks
and uncertainties, regarding, among other things, (a) our projected sales, profitability, and cash flows, (b) our growth strategy, (c)
anticipated trends in our industry, (d) our future financing plans, and (e) our anticipated needs for, and use of, working capital. They
are generally identifiable by use of the words &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;anticipate,&#8221;
&#8220;estimate,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;project,&#8221; &#8220;continuing,&#8221; &#8220;ongoing,&#8221;
&#8220;expects,&#8221; &#8220;management believes,&#8221; &#8220;we believe,&#8221; &#8220;we intend,&#8221; or the negative of these
words or other variations on these words or comparable terminology. In light of these risks and uncertainties, there can be no assurance
that the forward-looking statements contained in this filing will in fact occur. You should not place undue reliance on these forward-looking
statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
forward-looking statements speak only as of the date on which they are made, and, except to the extent required by federal securities
laws, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date on which
the statements are made or to reflect the occurrence of unanticipated events.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Overview</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
ATP Corporation, a Nevada corporation (&#8220;the Company&#8221;) was incorporated under the laws of the State of Nevada on June 1, 2016.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
ATP Corporation operates through its subsidiaries, namely, Agape ATP Corporation (&#8220;AATP LB&#8221;), a company incorporated in Labuan,
Malaysia, and Agape Superior Living Sdn. Bhd. (&#8220;ASL&#8221;), a company incorporated in Malaysia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
ATP Corporation, incorporated in Labuan, Malaysia, is an investment holding company with 100% equity interest in Agape ATP International
Holding Limited (&#8220;AATP HK&#8221;), a company incorporated in Hong Kong.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 8, 2020, the Company entered into a Share Exchange Agreement with Mr. How Kok Choong, CEO and director of the Company to acquire
9,590,596 ordinary shares, no par value, equivalent to approximately 99.99% of the equity interest in Agape Superior Living Sdn. Bhd.,
a network marketing entity incorporated in Malaysia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
Superior Living Sdn. Bhd. is a limited company incorporated on August 8, 2003, under the laws of Malaysia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 11, 2020, the Company incorporated Wellness ATP International Holdings Sdn, Bhd. (&#8220;WATP&#8221;), a wholly owned subsidiary
under the laws of Malaysia, to pursue the business of promoting wellness and wellbeing lifestyle of the community by providing services
that includes online editorials, programs, events and campaigns on how to achieve positive wellness and lifestyle.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 11, 2021, Agape ATP Corporation (Labuan) formed a joint-venture entity, DSY Wellness International Sdn. Bhd. (&#8220;DSY Wellness&#8221;)
with an independent third party which Agape ATP Corporation (Labuan) owns 60% of the equity interest, to pursue the business of providing
complementary health therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and its subsidiaries are principally engaged in the Health and Wellness Industry. The principal activity of the Company is to
supply high-quality health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation,
anti-aging and products designed to improve the overall health system of the human body and various wellness programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
ATP Corporation is a company that provides health and wellness products and health solution advisory services to our clients. The Company
primarily focus its efforts on attracting customers in Malaysia. Its advisory services center on the &#8220;ATP Zeta Health Program&#8221;,
which is a health program designed to effectively prevent diseases caused by polluted environments, unhealthy dietary intake and unhealthy
lifestyles, and promotion of health. The program aims to promote improved health and longevity in our clients through a combination of
modern medicine, proper nutrition and advice from skilled nutritionists and/or dieticians.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to strengthen the Company&#8217;s supply chain, on May 8, 2020, the Company has successfully acquired approximately 99.99% of ASL,
with the goal of securing an established network marketing sales channel that has been established in Malaysia for the past 15 years.
ASL has been offering the Company&#8217;s ATP Zeta Health Program as part of its product lineup. As such, the acquisition creates synergy
in the Company&#8217;s operation by boosting the Company&#8217;s retail and marketing capabilities. The newly acquired subsidiary allows
the Company to fulfill its mission of &#8220;helping people to create health and wealth&#8221; by providing a financially rewarding business
opportunity to distributors and quality products to distributors and customers who seek a healthy lifestyle.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Via
ASL, the Company offers three series of programs which consist of different services and products: ATP Zeta Health Program, &#201;NERG&#201;TIQUE
and BEAUNIQUE.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ATP Zeta Health Program is a health program designed to promote health and general wellbeing designed to prevent health diseases caused
by polluted environments, unhealthy dietary intake and unhealthy lifestyles. The program aims to promote improved health and longevity
through a combination of modern health supplements, proper nutrition and advice from skilled dieticians as well as trained members and
distributors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
&#201;NERG&#201;TIQUE series aims to provide a total dermal solution for a healthy skin beginning from the cellular level. The series
is comprised of the Energy Mask series, Hyaluronic Acid Serum and Mousse Facial Cleanser.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
BEAUNIQUE product series focuses on the research of our diet&#8217;s impact on modifying gene expressions in order to address genetic
variations and deliver a nutrigenomic solution for every individual.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company deems creating public awareness on wellness and wellbeing lifestyle as essential to enhance the provision of its health solution
advisory services; and therefore, incorporated WATP. Upon its establishment, WATP started collaborating with ASL to carry out various
wellness programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
further its reach in the Health and Wellness Industry, on November 11, 2021, Agape ATP Corporation (Labuan) formed a joint-venture entity,
DSY Wellness International Sdn. Bhd. (&#8220;DSY Wellness&#8221;) with an independent third party which Agape ATP Corporation (Labuan)
owns 60% of the equity interest, to pursue the business of providing complementary health therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Results
of Operation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">For
the years ended December 31, 2022 and 2021</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Revenue</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
generated revenue of $1,856,564, which comprised of revenue from the Company&#8217;s network marketing business of $1,141,307
(approximately 61.5%); and revenue from the Company&#8217;s operations in the provision of complementary health therapies of
$715,257 (approximately 38.5%) for the year ended December 31, 2022 as compared to $1,016,962, which the amount was solely
attributable to revenue from the Company&#8217;s network marketing business for the year ended December 31, 2021. Revenue from the
Company&#8217;s network marketing business increased by $124,345 or approximately 12.2%. Total revenue increased by a
significant $839,602 or approximately 82.6%. The increase was predominately due to: (i) the recovery from COVID-19 in Malaysia after
April 2022. The Company made progress in revenue generating as Malaysia, where the Company&#8217;s operations predominantly reside,
has moved to a COVID-19 endemic phase with minimal restrictions on businesses and people movements in the country; and (ii) the
Company&#8217;s operations in the provision of complementary health therapies since February 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Cost
of Revenue</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
of revenue for the year ended December 31, 2022 amounted to $666,042 as compared to $297,333 for the year ended December 31, 2021, representing
a significant increase of $368,709 or approximately 124.0%. The significant increase was in line with the increase in revenue as explained
in the above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
of revenue typically comprise of freight-in, cost of goods purchased, packing materials and services acquired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Gross
Profit</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
profit for the year ended December 31, 2022 amounted to $1,190,522, represented a gross margin of approximately 64.1%, as compared
to $719,629 for the year ended December 31, 2021, which was equivalent to a gross margin of approximately 70.8%. The decrease in gross
margin was predominantly due to a lower gross margin associated with the provision of complementary health therapies as compared to
the Company&#8217;s network marketing business; and promotional activities undertaken by the Company to increase revenue from its
network marketing business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Operating
Expenses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating expenses consist of selling expenses, commission expenses, general and administrative expenses and provision for doubtful accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Selling
expenses</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling
expenses for the year ended December 31, 2022 amounted to $361,414 as compared to $394,682 for the year ended December 31, 2021, a decrease
of $33,268 or approximately 8.4%. The Company&#8217;s selling expenses typically comprise salaries and benefits expenses, credit card
processing fees and promotional expenses. The decrease in selling expenses was predominantly due to decrease in salaries and benefits
expenses. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Commission
expenses</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
expenses were $405,351 and $316,267 for the years ended December 31, 2022 and 2021, respectively, representing an increase of $89,084
or approximately 28.2%. The increase in commission expenses was in line with the increase in revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">General
and administrative expenses (&#8220;G&amp;A expenses&#8221;)</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G&amp;A
expenses for the year ended December 31, 2022 amounted to $1,957,023, as compared to $1,745,734 for the year ended December 31, 2021,
representing an increase of $211,289, or approximately 12.1%. The increase in G&amp;A expenses was mainly due to G&amp;A expenses associated
with the provision of complementary health therapies. The Company&#8217;s G&amp;A expenses typically comprise of salaries and benefits
expenses, rental expenses, professional expenses and depreciation expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Provision
for doubtful accounts</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision
for doubtful accounts were $0 and $121,514 for the year ended December 31, 2022 and 2021, respectively. The provision for doubtful accounts was in respect of prepayments to a supplier. As the Company&#8217;s attempts to recover the prepayments were futile,
the entire provision for doubtful accounts of $121,514 was written-off during the year ended December 31, 2022.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Other
(Expenses) Income</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2022, we recorded an amount of $136,868 as other expenses, net as compared to $529,045 other expenses,
net for the year ended December 31, 2021, representing a significant decrease of $392,177, or approximately 74.1%, in other expenses, net.
The net other expenses of $136,868 incurred during the year ended December 31, 2022 comprised of other expenses of $79,539,
interest income of $16,190 and unrealized holding loss on marketable securities of $73,519. The net other expenses of $529,405
incurred during the year ended December 31, 2021 comprised of other expense of $68,323, interest income of $25,570, unrealized
holding loss on marketable securities of $505,231 and dividend income from marketable securities of $18,939. The significant decrease of other expenses, net was mainly due to the decrease of unrealized holding loss on marketable
securities as a result of market price changes during the year of those investments held by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Benefit of (Provision
for) Income Taxes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had benefits of income taxes of $4,055 and provision for income taxes of $137,067 for the years ended December 31, 2022 and 2021,
respectively. During the year ended December 31, 2022, our operations in Malaysia recorded benefits of income taxes due to reversal
of overprovision of taxes in prior years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, we had provision for income taxes of $114,862 due to certain permanent items required for the income
taxes provision in Malaysia jurisdiction after our Malaysia local tax audit and had provision for income taxes of $22,205 on U.S. GILTI
taxes provision.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Net Loss</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
generated a net loss of $1,666,079 for the year ended December 31, 2022, as compared to $2,524,680 for the year ended
December 31, 2021, a decrease of $858,601 or approximately 34.0%, predominately due to reasons as discussed above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Liquidity
and Capital Resources</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malaysia,
where the operations of the Company predominantly reside, officially transitioned to the endemic phase of COVID-19 effective April 1,
2022. Restrictions on businesses and people are minimal. Meanwhile, the government continues to encourage inoculation for those between
the ages of 5 to 11 years and its adolescent group which comprised those between the ages 12 and 17. Adults who have been fully vaccinated,
i.e. received two doses of the COVID-19 vaccine are encouraged to take booster shots.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantially
all of our revenues are concentrated in Malaysia. Consequently, our results of operations will likely be adversely, and may be materially,
affected, to the extent that the COVID-19 or any other epidemic harms the Malaysia and global economy in general. Any potential impact
to our results will depend on, to a large extent, future developments and new information that may emerge regarding the duration and
severity of the COVID-19 and the actions taken by government authorities and other entities to contain the COVID-19 or treat its impact,
almost all of which are beyond our control. Potential impacts include, but are not limited to, the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">temporary
    closure of offices, travel restrictions, disruption or suspension of supplies, our customers may be negatively impacted financially
    resulting in which the demand for our products may be adversely affected;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may have to provide significant sales incentives to our customers during the outbreak, which may in turn materially adversely affect
    our financial condition and operating results; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    disruption of our supply chain, logistics providers or customers could adversely impact our business and results of operations, including
    causing us or our suppliers to cease manufacturing for a period of time or materially delay delivery to our customers, which may
    also lead to loss of our customers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Albeit
a lengthy 3 years in the COVID-19 pandemic and living alongside COVID-19, there could still be supply chain disruptions. From our experiences
operating under the much-restricted COVID-19 environment, we have modified our methods of operations, to build in sufficient buffer in
the management of inventories. We may experience slight delay in products delivery lead time but barring unforeseen circumstances, the
setback should be temporary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently operating primarily in Malaysia and anticipate expanding into the Asian markets in the future, with a particular focus,
at least initially, on expanding into Thailand, Indonesia and Taiwan. We will explore expansion via e-commerce. Now that most nations
are living alongside COVID-19, we will re-assess our plans to set up offices in the countries in which we operate to better service our
customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the uncertainty surrounding the COVID-19 outbreak, the financial impact related to the outbreak of and response to the COVID-19 cannot
be reasonably estimated at this time. There is no guarantee that the Company&#8217;s total revenues will grow or remain at similar levels
year over year in 2023 and beyond.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, we had working capital of $799,239 consisting of cash and cash in bank of $523,619 and time deposits of
$914,811 as compared to working capital of $2,599,281 consisting of cash and cash in bank of $622,501 and time deposits of
$1,975,347 as of December 31, 2021. The Company had a net loss of $1,666,079 for the year ended December 31, 2022 and accumulated
deficits of $4,945,586 as of December 31, 2022 as compared to net loss of $2,524,680 for the year ended December 31, 2021 and
accumulated deficits of $3,258,687 as of December 31, 2021. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
assessing our liquidity and going concern, management is projecting that the company&#8217;s revenue will revert to pre-pandemic level,
generating sufficient cash therefrom to cover our operating expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our Company is unable to generate sufficient cash flow within the normal operating cycle of a twelve-month period to pay for its future
payment obligations, we may have to consider supplementing our available sources of funds through the following sources:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    available sources of financing from Malaysia banks and other financial institutions; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial
    support from our related parties and shareholders.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the above initiatives, management is of the opinion that the Company shall have sufficient funds to meet its working capital
requirements and debt obligations as they become due in the foreseeable future twelve months from the date of issuance of this
Annual Report. However, there is no assurance that management will be successful in its plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summarizes the key components of our cash flows for the years ended December 31, 2022 and 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Net cash used in operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(811,683</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(845,842</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(32,119</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,959</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash used in financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(234,466</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19,061</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of exchange rate on cash and cash equivalents</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(81,150</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(50,890</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net change in cash and cash equivalents</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,159,418</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(919,752</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities for the year ended December 31, 2022 was $811,683 and were mainly comprised of the net loss of
$1,666,079, the non-cash deferred tax benefit of $14,751, the increase in accounts receivables of $2,824, the increase in amount due
from related parties of $3,786, the payment of operating lease liabilities of $145,197 and the decrease in other payables (including
related parties) and accrued liabilities of $115,085. The net cash used in operating activities was mainly offset by the non-cash
depreciation and amortization expense of $73,876, amortization of operating right-of-use assets of $144,064, the unrealized holding
loss on marketable securities of $73,519, inventory write-downs of $5,307, the decrease in inventories of $343,483, the refund in
prepaid taxes of $263,404, the decrease in prepayments and deposits of $89,113, the increase in accounts payable (including related
parties) of $41,422, increase in customer deposits of $94,877 and increase in income tax payables of $6,974.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities for the year ended December 31, 2021 was $845,842 and were mainly comprised of the net loss of $2,524,680,
dividend income from marketable securities of $18,939, the increase in prepayments and deposits of $128,363, and the payment of operating
lease liabilities of $138,143. The net cash used in operating activities was mainly offset by the non-cash depreciation and amortization
expense of $77,758, amortization of operating right-of-use assets of $139,451, the unrealized holding loss on marketable securities of
$505,231, the non-cash deferred tax expense of $10,127, inventories write-down of $36,241, provision for doubtful accounts of $121,514,
the decrease of accounts receivables of $167,566, the decrease in inventories of $192,713, the refund in prepaid taxes of $430,062, the
increase in customer deposits of $52,981, the increase in income tax payables of $3,988, and the increase in other payables and accrued
liabilities of $226,651.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Investing
activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities for the year ended December 31, 2022 was $32,119, the amount entirely for the purchase of equipment
and intangible assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities for the year ended December 31, 2021 was $3,959, the amount entirely for the purchase of equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financing
activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in financing activities for the year ended December 31, 2022 was $234,466, the amount entirely payment of deferred offering
cost.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in financing activities for the year ended December 31, 2021 was $19,061, mainly comprised of payment of deferred offering
cost of $15,210 and advances to related parties of $3,851.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Credit
Facilities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any credit facilities or other access to bank credit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Off-Balance
Sheet Arrangements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, we have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future
effect on our financial condition, changes in our financial condition, revenues or expenses, results of operations, liquidity, capital
expenditures or capital resources that are material to our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Critical
Accounting Estimates</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make
estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and
liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the
periods presented. Significant accounting estimates reflected in the Company&#8217;s consolidated financial statements include
allowance for inventories obsolescence, impairment of long-lived assets, allowance for deferred tax assets. Following
are the methods and assumptions used in determining our estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Estimated
allowance for inventories obsolescence</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
reviews inventory on hand for estimated obsolescence or unmarketable items, as compared to future demand requirements and the shelf life
of the various products. Based on the review, the Company records inventory write-downs, when necessary, when costs exceed expected net
realizable value. For the years ended December 31, 2022 and 2021, the Company recognize an inventory write-downs of $5,307 and $36,241,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impairment
of long-lived assets</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
right-of-use assets and property, plant and equipment are stated at costs less accumulated depreciation and impairment, if any. In determining
whether an asset is impaired, the Company has to exercise judgment and make estimation, particularly in assessing: (1) whether an event
has occurred or any indicators that may affect the asset value; (2) whether the carrying value of an asset can be supported by the recoverable
amount, in the case of value in use, the present value of future cash flows which are estimating the recoverable amounts including cash
flow projections and an appropriate discount rate. Changing the assumptions and estimates, including the discount rates or the growth
rate in the cash flow projections, could materially affect the net present value used in the impairment test.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 and 2021, the carrying amounts of operating right-of-use assets and property, plant and equipment is amounted to
$81,133 and $142,149 (December 31, 2021: $237,718 and $215,799), respectively. No impairment losses on operating right-of-use assets
and property, plant and equipment were recognized as of December 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recognition
of income taxes and allowance for deferred tax assets/liabilities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company conducts much of its business activities in Malaysia and Hong Kong and is subject to tax in each of these jurisdictions. Significant
estimates are required in determining the provision for income taxes. There are many transactions and calculations for which the ultimate
tax determination is uncertain during the ordinary course of business. Where the final tax outcome of these matters is different from
the amounts that were initially recorded, such differences will impact the income tax and deferred tax provisions in the period in which
such determination is made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets relating to certain temporary differences and tax losses are recognized as management considers it is probable that future
taxable profit will be available against which the temporary differences or tax losses can be utilized. Where the expectation is different
from the original estimate, such differences will impact the recognition of deferred taxation assets and taxation in the periods in which
such estimate is changed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 48; Options: NewSection; Value: 48 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Critical
Accounting Policies</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue
recognition</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers (ASC Topic 606). The core
principle underlying the revenue recognition of this ASU allows the Company to recognize - revenue that represents the transfer of goods
and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange.
This will require the Company to identify contractual performance obligations and determine whether revenue should be recognized at a
point in time or over time, based on when control of goods and services transfers to a customer. The Company&#8217;s revenue streams
are recognized at a point in time for the Company&#8217;s sale of health and wellness products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ASU requires the use of a new five-step model to recognize revenue from customer contracts. The five-step model requires that the Company
(i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction
price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate
the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies
the performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for a contract with a customer when the contract is committed in writing, the rights of the parties, including payment
terms, are identified, the contract has commercial substance and consideration is probable of substantially collection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sales
of Health and Wellness products</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>-
Performance obligations satisfied at a point in time</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company derives its revenues from sales contracts with its customers with revenues being recognized when control of the health and wellness
products are transferred to its customer at the Company&#8217;s office or shipment of the goods. The revenue is recorded net of estimated
discounts and return allowances. Products are given 60 days for returns or exchanges from the date of purchase. Historically, there were
insignificant sales returns.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Under the Company&#8217;s network marketing business, the Company issues
product coupons to members and distributors when these customers made purchases above certain thresholds set by the Company. Depending
on the type of product coupons issued, the coupons carry varying values and can be used by the customers for reduction in the transaction
price of product purchases within the coupon validity period. The value of the product coupons issued is recorded as a reduction of the
Company&#8217;s revenue account upon issuance; the corresponding amount credited to the customer deposits account. Amounts in customer
deposits will be reversed when the coupons are used. The Company&#8217;s coupons have a validity period of between six and twelve months.
If the Company&#8217;s customers did not utilize the coupons after the validity period, the Company would recognize the forfeiture of
the originated sales value of the coupons as net revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Provision
of Health and Wellness services</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
<i>Performance obligations satisfied at a point in time</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company carries out its Wellness program, where the Company&#8217;s products are bundled with health screening test and a health camp
program. The health screening test and the health camp programs are considered as separate performance obligations. The promises to deliver
the health screening test report and the attendance at the health camp are separately identifiable, which are evidenced by the fact that
the Company provides separate services of delivering the health screening test report and allowing admission of the customers to attend
the health camp. The Company derives its revenues from sales contracts with its customers with revenues being recognized when the test
reports are completed and delivered to its customers during the consultation section in person. The Company also separately derives its
revenues from sales contracts with its customers with revenues being recognized when the health camp program was completed in the final
day of the health camp.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 49; Value: 48 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
value of financial instruments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting standard regarding fair value of financial instruments and related fair value measurements defines financial instruments and
requires disclosure of the fair value of financial instruments held by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting standards define fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance
disclosure requirements for fair value measures. The three levels are defined as follow:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that
    are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 inputs to the valuation methodology are unobservable and significant to the fair value.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments included in current assets and current liabilities are reported in the consolidated balance sheets at face value or cost,
which approximate fair value because of the short period of time between the origination of such instruments and their expected realization
and their current market rates of interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Recent
accounting pronouncements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has reviewed all recently issued, but not yet effective, considers the applicability and impact of all accounting standards updates
(&#8220;ASUs&#8221;). Management periodically reviews new accounting standards that are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2019, the FASB issued ASU No. 2019-10, which to update the effective date of ASU No. 2016-13 for private companies, not-for-profit
organizations and certain smaller reporting companies applying for credit losses, leases, and hedging standard. The new effective date
for these preparers is for fiscal years beginning after December 15, 2022. ASU 2019-05 is effective for the Company for annual and interim
reporting periods beginning January 1, 2023 as the Company is qualified as a smaller reporting company. The Company is currently evaluating
the impact ASUs 2016-13 and 2019-05 may have on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for the above-mentioned pronouncements, there are no new recent issued accounting standards that will have a material impact on the consolidated
financial position, statements of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ap_001"></span>ITEM
7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Foreign
exchange risk</i>. Substantially most of our revenues are denominated in the Malaysian Ringgit while most of our expenses are denominated
in Malaysian Ringgit, U.S. dollar and Hong Kong Dollar. We do not believe that we currently have any significant direct foreign exchange
risk and have not hedged exposures denominated in foreign currencies or any other derivative financial instruments. Although in general,
our exposure to foreign exchange risks should be limited, the value of an investment in our Common Stock may be affected by the foreign
exchange rate between U.S. dollar and Malaysian Ringgit; and U.S. dollar and Hong Kong Dollar because the value of our business is effectively
denominated in Malaysian Ringgit and Hong Kong Dollar, while the Common Stock is traded in U.S. dollars.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Credit
risk</i>. Financial instruments that are potentially subject to credit risk consist principally of accounts receivable. The Company believes
the concentration of credit risk in its trade receivables is substantially mitigated by its ongoing credit evaluation process and relatively
short collection terms. The Company does not generally require collateral from customers. The Company evaluates the need for an allowance
for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 50; Value: 48 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ap_002"></span>ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements required by this item are located in PART IV of this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ap_003"></span>ITEM
9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ap_004"></span>ITEM
9A. CONTROLS AND PROCEDURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Evaluation
of Disclosure Controls and Procedures</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the end of the period covered by this Report, we carried out an evaluation, under the supervision and with the participation of our
management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our
disclosure controls and procedures(as defined in the Exchange Act Rules 13a-15(e) and 15d-15(e)). Based on the foregoing evaluation,
our chief executive officer and chief financial officer concluded that, as of December 31, 2022, our disclosure controls and procedures
were not effective at the reasonable assurance level due to the material weaknesses described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Internal
Control Over Financial Reporting</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management, including our chief executive officer and chief financial officer, is responsible for establishing and maintaining adequate
internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated
under the Exchange Act as a process designed by, or under the supervision of, the company&#8217;s chief executive officer and chief financial
officer and effected by the company&#8217;s board of directors, management and other personnel, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting
principles generally accepted in the United States of America and includes those policies and procedures that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pertain
    to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets
    of the company;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
    reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with
    accounting principles generally accepted in the United States of America and that receipts and expenditures of the company are being
    made only in accordance with authorizations of management and directors of the company; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
    reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company&#8217;s
    assets that could have a material effect on the financial statements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 51; Value: 48 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of its inherent limitations, internal control over financial reporting may not prevent or detect all misstatements. Projections of any
evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions,
or that the degree of compliance with the policies or procedures may deteriorate. All internal control systems, no matter how well designed,
have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect
to financial statement preparation and presentation. Because of the inherent limitations of internal control, there is a risk that material
misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent
limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to
reduce, though not eliminate, this risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, our management, including our chief executive officer and chief financial officer, assessed the effectiveness of
our internal control over financial reporting based on the criteria for effective internal control over financial reporting established
in Internal Control&#8212;Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission
(&#8220;COSO&#8221;) and SEC guidance on conducting such assessments. Based on such evaluation, the Company&#8217;s management, including
our chief executive officer and chief financial officer, concluded that, during the period covered by this Report, internal controls
and procedures over financial reporting were not effective. This was due to deficiencies that existed in the design or operation of our
internal controls over financial reporting that adversely affected our internal controls and that may be considered to be material weaknesses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Identified
Material Weakness</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
material weakness in internal control over financial reporting is a control deficiency, or combination of control deficiencies, that
results in more than a remote likelihood that a material misstatement of the financial statements will not be prevented or detected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management,
including our chief executive officer and chief financial officer, identified the following material weakness during its assessment of
internal controls over financial reporting as of December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
insufficient full-time personnel with appropriate levels of accounting knowledge and experience to monitor the daily recording of transactions,
address complex U.S. GAAP accounting issues and to prepare and review financial statements and related disclosures under U.S. GAAP; (ii)
lack of a functional internal audit department or personnel that monitors the consistencies of the preventive internal control procedures
and lack of adequate policies and procedures in internal audit function to ensure that the Company&#8217;s policies and procedures have
been carried out as planned; (iii) lack of proper IT policies and procedures developed for system change management, backup management, user access management and service organization
management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 52; Value: 48 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
the Company concluded that these control deficiencies resulted in a reasonable possibility that a material misstatement of the annual
or interim financial statements will not be prevented or detected on a timely basis by the company&#8217;s internal controls.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Management&#8217;s
Remediation Initiatives</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
an effort to remediate the identified material weaknesses and other deficiencies and enhance our internal controls, we will prepare written
policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC
guidelines, to establish a formal process to close our books monthly on an accrual basis and account for all transactions, including
equity and debt transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
further strengthen the Company&#8217;s internal controls, we plan to initiate the following measures going forward:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    intend to establish an internal audit function with assessment of Sarbanes-Oxley compliance requirements and improvement of overall
    internal control.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
    we hire additional employees, we intend to initiate a comprehensive training program and development plan to provide ongoing company-wide
    trainings regarding internal control and requirements of U.S. GAAP financial statements and related disclosures, with particular
    emphasis on our accounting staff.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="margin: 0">Hire suitable IT personnel to develop and implement proper IT policies
and procedures for system change management, backup management and service organization management.</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that these initiatives will be at least partially, if not fully, implemented by the end of fiscal year 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Changes
in internal controls over financial reporting</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no significant changes in our internal controls over financial reporting that occurred during the period covered by this Report,
which has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
annual report does not include an attestation report of the Company&#8217;s registered independent public accounting firm regarding internal
control over financial reporting. Management&#8217;s report was not subject to attestation by the Company&#8217;s registered independent
public accounting firm pursuant to rules of the Securities and Exchange Commission that permit the Company to provide only management&#8217;s
report in this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ap_005"></span>ITEM
9B. OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53; Value: 48 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="ap_006"></span>PART
III</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ap_007"></span>ITEM
10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
executive officer&#8217;s and director&#8217;s and their respective ages as of the date hereof are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NAME</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGE</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>POSITION</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">How
    Kok Choong</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, President, Director, Chief Operating Officer, Chairman of the board of Directors and Secretary</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
    Lee Kam Fan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below is a brief description of the background and business experience of our executive officer and director for the past five
years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
How Kok Choong</i></b> is our founder and serves as our Chief Executive Officer, President, Director Chief Operating Officer, Chairman
of the Board of Directors and Secretary since 2016. Dr. How is primarily responsible for overall development and business strategies,
financial, administrative and human resources affairs of the Company. Dr. How has more than 20 years of experience in the senior management
roles in the health and wellness industry. From 1987 to 2016, Dr. How was with the San Hin Group of Companies and his last position held
was the group chief executive officer for the group. Since August 2003, Dr. How began to work for AGAPE Superior Living International
Group as the global president and continues to hold this position. Further, since September 2009, Dr. How has worked for TH3 Holdings
Sdn Bhd as president. Dr. How obtained a master&#8217;s degree and a doctorate degree in Business Administrative from Newport University,
USA in December 1997 and December 2000, respectively. In Malaysia, Dr. How Kok Choong was recognized by the Junior Chamber Malaysia (JCM)
as an Outstanding Young Malaysian 2003, and was awarded the title of Justice of Peace of Malaysia since 2005. Dr. How Kok Choong received
the Outstanding Asian Community Contribution Award in 2011, Malaysia Top Team 50 Enterprise Award in 2011 and 2016, The Contributor Award
(Medical and Health Research) in 2012, &#8220;Man of The Year&#8221; in Worldwide Excellence Award in 2015, &#8220;Man of The Year&#8221;
in McMillan Global Award in 2016, The Distinguished Asia Pacific Outstanding Entrepreneur Lifetime Achievement Award in 2019, World Outstanding
Chinese Entrepreneur Lifetime Award in 2019 and Certified Professional Trainer of The International Professional Managers Association
in 2019.</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 54; Value: 48 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Mr.
Lee Kam Fan</i></b>, Andrew serves as our chief financial officer of the Company. Prior to joining the Company in January 2021, Mr. Lee
has approximately 38 years of accounting and finance related experience. Since July 2014, Mr. Lee has been the proprietor of Andrew Lee
&amp; Company. Since June 2010, Mr. Lee served as an adjunct lecturer of the HKICPA Professional Examinations Preparatory Programme at
HKU Space. From January 2011 to October 2015, Mr. Lee served as the managing director at ANSA CPA Limited. From September 2010 to October
2012, Mr. Lee served as an independent non-executive director at Sunrise (China) Technology Group Limited (currently referred to as KOALA
Financial Group Limited (Hong Kong stock code: 08226)). From March 2006 to April 2017, Mr. Lee was in cooperation with Friedman LLP to
oversee financial statements are prepared in accordance with U.S. GAAP. From October 2000 to December 2010, Mr. Lee served as an audit
manager and subsequently a partner at Clodick &amp; Company. From April 1998 to September 2000, Mr. Lee served as a director at Nitwell
Business Services Limited. From August 1994 to April 1998, Mr. Lee was an assistant audit manager at Cheng, Kwok &amp; Chang. From July
1990 to July 1994, Mr. Lee served as an accountant at K.C. Manufacturing Company. From April 1989 to July 1990, Mr. Lee served as an
accountant at Haldane, Midgley &amp; Booth. From January 1987 to April 1989, Mr. Lee served as an audit senior at RSM Nelson Wheeler.
From October 1985 to December 1986, Mr. Lee served as an audit assistant at Andrew Ma &amp; Company. From April 1983 to September 1985,
Mr. Lee served as an audit Clerk at Anthony Y.T. Tse &amp; Company. Mr. Lee is an associate member of the Institute of Chartered Accountants
in England and Wales since April 2019, a certified public accountant (practicing) of the Hong Kong Institute of Certified Public Accountants
since May 2010, a fellow member of the Association of International Accountants since December 2006, and an associate member and chartered
tax advisor of the Tax Institute of Hong Kong since July 2010. Mr. Lee received his bachelor&#8217;s degree in business administration
at the Open University of Hong Kong (currently referred to as Hong Kong Metropolitan University) in June 2004 and his master&#8217;s
degree in professional accounting from the Hong Kong Polytechnic University in November 2010.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Corporate
Governance</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company promotes accountability for adherence to honest and ethical conduct; endeavors to provide full, fair, accurate, timely and understandable
disclosure in reports and documents that the Company files with the Securities and Exchange Commission (the &#8220;SEC&#8221;) and in
other public communications made by the Company; and strives to be compliant with applicable governmental laws, rules and regulations.
The Company has not formally adopted a written code of business conduct and ethics that governs the Company&#8217;s employees, officers
and Directors as the Company is not required to do so.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
lieu of an Audit Committee, the Company&#8217;s Board of Directors, is responsible for reviewing and making recommendations concerning
the selection of outside auditors, reviewing the scope, results and effectiveness of the annual audit of the Company&#8217;s financial
statements and other services provided by the Company&#8217;s independent public accountants. The Board of Directors and the Chief Executive
Officer of the Company review the Company&#8217;s internal accounting controls, practices and policies with advice from third party consultants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Committees
of the Board</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Company currently does not have nominating, compensation, or audit committees or committees performing similar functions nor does our
Company have a written nominating, compensation or audit committee charter. We will establish the nominating, compensation, and audit
committees under the board of directors immediately upon the effectiveness of our registration statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Audit
Committee Financial Expert</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has determined that we do not have a board member that qualifies as an &#8220;audit committee financial expert&#8221;
as defined in Item 407(D)(5) of Regulation S-K, nor do we have a Board member that qualifies as &#8220;independent&#8221; as the term
is used in Item 7(d)(3)(iv)(B) of Schedule 14A under the Securities Exchange Act of 1934, as amended, and as defined by Rule 4200(a)(14)
of the FINRA Rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to maintain good corporate governance and in view of the Company&#8217;s planned expansion, the Company plans to establish a full
board comprising the nominating, compensation, and audit committees during the year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 55; Value: 48 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Involvement
in Certain Legal Proceedings</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Directors and our Executive officers have not been involved in any of the following events during the past ten years:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bankruptcy
    petition filed by or against any business of which such person was a general partner or executive officer either at the time of the
    bankruptcy or within two years prior to that time;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor
    offenses);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Being
    subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction,
    permanently or temporarily enjoining, barring, suspending or otherwise limiting his/her involvement in any type of business, securities
    or banking activities; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Being
    found by a court of competent jurisdiction (in a civil action), the Commission or the Commodity Futures Trading Commission to have
    violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
    person was found by a court of competent jurisdiction in a civil action or by the Commission to have violated any Federal or State
    securities law, and the judgment in such civil action or finding by the Commission has not been subsequently reversed, suspended,
    or vacated;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
    person was found by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated
    any Federal commodities law, and the judgment in such civil action or finding by the Commodity Futures Trading Commission has not
    been subsequently reversed, suspended or vacated;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
    person was the subject of, or a party to, any Federal or State judicial or administrative order, judgment, decree, or finding, not
    subsequently reversed, suspended or vacated, relating to an alleged violation of:</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    Federal or State securities or commodities law or regulation; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent
    injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal
    or prohibition order; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
    person was the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory
    organization (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section
    1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that
    has disciplinary authority over its members or persons associated with a member.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Code
of Ethics</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a code of ethics that applies to all of our employees, including our principal executive officer, principal financial officer and
principal accounting officer, and the Board. A copy of this code is available in our employee handbook and under the &#8220;About Us
&#8211; Code of Conduct&#8221; section of our website at www.agapeatpgroup.com. In addition, we intend to post on our website all disclosures
that are required by law or the listing standards of our applicable trading market concerning any amendments to, or waivers from, any
provision of the code. The reference to our website address does not constitute incorporation by reference of the information contained
at or available through our website, and you should not consider it to be a part of this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 56; Value: 48 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Shareholder
Proposals</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Company does not have any defined policy or procedural requirements for shareholders to submit recommendations or nominations for Directors.
The Board of Directors believes that, given the stage of our development, a specific nominating policy would be premature and of little
assistance until our business operations develop to a more advanced level. Our Company does not currently have any specific or minimum
criteria for the election of nominees to the Board of Directors and we do not have any specific process or procedure for evaluating such
nominees. The Board of Directors will assess all candidates, whether submitted by management or shareholders, and make recommendations
for election or appointment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
shareholder who wishes to communicate with our Board of Directors may do so by directing a written request addressed to our President,
at the address appearing on the first page of this Information Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ap_008"></span>ITEM
11. EXECUTIVE COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
How Kok Choong, the Chief Executive Officer, President, Director Chief Operating Officer, Chairman of the Board of Directors and Secretary
received $289,957 and $275,210 as total salaries for the years ended December 31, 2022 and 2021 respectively. Mr. How Kok Choong had
not received any (i) Stock compensation; (ii) Option awards, (iii) Non-equity incentive plan compensation, (iv) Non-qualified deferred
compensation earnings and (v) Any other compensations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Mohd Shaharuddin Bin Abdullah was appointed and entered into an employment agreement with the Company on January 12, 2021 and the employment
agreement will take effect on the listing of our stock on NASDAQ Capital Market. In March 2023, Mr. Mohd Shaharuddin Bin Abdullah resigned
from the Company and his employment agreement terminated with immediate effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Andrew Lee Kam Fan was appointed and entered into an employment agreement with the Company on January 12, 2021. Mr. Andrew Lee Kam Fan
received $46,440 and $46,988 as total salaries for the year ended December 31, 2022 and 2021 respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Stock
Option Grants</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not granted any stock options to our executive officers since our incorporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Employment
Agreements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Save
except for Mr. Mohd Shaharuddin Bin Abdullah and Mr. Andrew Lee Kam Fan for the year ended December 31, 2022, we do not have an employment
or consulting agreement with any officers or Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
Discussion and Analysis</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Chief Executive Officer, President, Director Chief Operating Officer, Chairman of the Board of Directors and Secretary, Mr. How Kok
Choong is paid a monthly salary of $21,552 (RM 95,000). His salary shall accrue on a day-to-day basis, payable in arrears on the last
day of each calendar month, provided that if his employment is terminated prior to the end of a calendar month, his compensation for
the month shall be pro-rated to reflect his period of service up to the date of termination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
Prior to Mr. Mohd Shaharuddin Bin Abdullah resignation in March 2023, as an executive director of the Company, Mr. Mohd Shaharuddin
Bin Abdullah will be paid a monthly salary of $3,000. He is also entitled to receive a stock-based compensation of $60,000 per
annum. His compensation, i.e., salary and stock-based compensation shall accrue on a day-to-day basis, payable in arrears on the
last day of each calendar month, provided that if his employment is terminated prior to the end of a calendar month, his
compensation for the month shall be pro-rated to reflect his period of service up to the date of termination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 57; Value: 48 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
Chief Financial Officer of the Company, Mr. Andrew Lee Kam Fan is paid a monthly salary of $3,870. His salary shall accrue on a day-to-day
basis, payable in arrears on the last day of each calendar month, provided that if his employment is terminated prior to the end of a
calendar month, his compensation for the month shall be pro-rated to reflect his period of service up to the date of termination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive
Compensation Philosophy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors determines the compensation given to our executive officers in their sole determination. Our Board of Directors reserves
the right to pay our executive or any future executives a salary, and/or issue them shares of common stock in consideration for services
rendered and/or to award incentive bonuses which are linked to our performance, as well as to the individual executive officer&#8217;s
performance. This package may also include long-term stock-based compensation to certain executives, which is intended to align the performance
of our executives with our long-term business strategies. Additionally, while our Board of Directors has not granted any performance
base stock options to date, the Board of Directors reserves the right to grant such options in the future, if the Board in its sole determination
believes such grants would be in the best interests of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incentive
Bonus</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors may grant incentive bonuses to our executive officer and/or future executive officers in its sole discretion, if the
Board of Directors believes such bonuses are in the Company&#8217;s best interest, after analyzing our current business objectives and
growth, if any, and the amount of revenue we are able to generate each month, which revenue is a direct result of the actions and ability
of such executives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Long-term,
Stock Based Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to attract, retain and motivate executive talent necessary to support the Company&#8217;s long-term business strategy we may award
our executive and any future executives with long-term, stock-based compensation in the future, at the sole discretion of our Board of
Directors, which we do not currently have any immediate plans to award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ap_009"></span>ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company has 72,452,012 shares of common stock issued and outstanding, which number of issued and outstanding
shares of common stock have been used throughout this report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Name and Address of<br /> Beneficial Owner</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares of Common Stock Beneficially Owned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock Voting Percentage Beneficially Owned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Voting <br /> Shares of Preferred Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Preferred Stock Voting Percentage Beneficially Owned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total <br /> Voting Percentage Beneficially Owned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Executive Officers and Directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 35%; text-align: left">How Kok Choong, Chief Executive Officer, President, Director Chief Operating Officer, Chairman of the Board of Directors and Secretary; collectively this includes HKC Holdings Sdn. Bhd.*</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">19,608,998</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">25.99</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">25.99</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Mohd Shaharuddin Bin Abdullah</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Andrew Lee Kam Fan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58; Value: 48 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership has been determined in accordance with Rule 13d-3 under the Exchange Act. Under this rule, certain shares may be deemed to
be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares).
In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire shares (for example, upon
exercise of a<span style="background-color: white">n option or warrant) within 60 days of the date as of which the information is provided.
In computing the percentage ownership of any person, the amount of shares is deemed to include the amount of shares beneficially owned
by such person by reason of such acquisition rights. As a result, the percentage of outstanding shares of any person as shown in the
following table does not necessarily reflect the person&#8217;s actual voting power at any particular date.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ap_010"></span>ITEM
13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, DIRECTOR INDEPENDENCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 8, 2020, the Company acquired approximately 99.99% of the issued share capital of Agape Superior Living Sdn Bhd from Dr. How Kok
Choong. Dr. How received an aggregate consideration of $1,714,003, which was determined based on the net asset carrying value of ASL
as at March 31, 2020. The aggregate consideration was satisfied by (i) the offset of the consideration whereby the Company has a loan
receivable of $656,495 as of March 31, 2020 due from Dr. How; and (ii) the allotment and issue of the common stock of the Company. The
Company allotted and issued 162,694 shares of the Company&#8217;s common stock, each with a par value $0.0001, representing approximately
0.0432% of the total issued and outstanding shares in the Company after the issuance of the shares, which was valued at $1,057,508 based
on the closing price of $6.50 of the Company as quoted on the OTC Market on March 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 1, 2020, the Company and Dr. How Kok Choong agreed to amend the Share Exchange agreement and enter into a supplemental agreement
share exchange agreement (the &#8220;<b>Supplemental Share Exchange Agreement</b>&#8221;). In accordance with Supplemental Share Exchange
Agreement, Dr. How received an aggregate consideration of $1,804,046, which was determined based on the net asset carrying value of ASL
as at March 31, 2020. The aggregate consideration shall be satisfied by (i) the offset of the consideration whereby the Company has a
loan receivable of $656,495 as of March 31, 2020 due from Dr. How; and (ii) the allotment and issuance of common stock of the Company.
The Company allotted and issued 176,547 shares of the Company&#8217;s common stock, par value $0.0001 (the &#8220;<b>Shares</b>&#8221;),
representing approximately 0.0469% of the total issued and outstanding shares in the Company after the issuance of the Shares, which
is valued at $1,147,551 based on the closing price of $6.50 of the Company as quoted on the OTC Market on March 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 1, 2021, Dr. How Kok Choong, our CEO and director, was appointed as the non-executive Chairman of Vettons. Vettons Sdn Bhd (&#8220;Vettons&#8221;)
is an e-commerce company through which ASL conducts some of its distribution activities to its members. As of December 31, 2020, the
Company has accounts receivable of $172,757 from Vettons, representing 100% of our accounts receivable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2021, there were share forfeiture agreements (the &#8220;Share Forfeiture Agreements&#8221;) between the Company and (i) HKC
Talent Limited; (ii) various stockholders of the Company (the &#8220;Forfeiting Stockholders&#8221;), pursuant to which:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
HKC Talent Limited had agreed to forfeiture of 41,750,000 shares of common stock of the Company, and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
the Forfeiting Stockholders had agreed to forfeiture, in aggregate, 44,242,000 shares of common stock of the Company. Included in (ii)
is 11,242,000 shares forfeited from HKC Holdings Sdn. Bhd, a company in which Dr. How Kok Choong, is a stockholder. As a result, the
outstanding shares was reduced by 85,992,000 shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 20, 2022, a share forfeiture agreement (the &#8220;Share Forfeiture Agreement&#8221;) was entered between the Company and Dr.
How Kok Choong, pursuant to which Dr. How agreed to forfeit 215,008,035 shares of common stock of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*HKC
Holdings Sdn Bhd is owned and controlled by How Kok Choong who is our executive officer and director. As such, HKC Holdings Sdn Bhd.
is regarded a related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
regards to all of the above transactions we claim an exemption from registration afforded by Section 4a(2) and/or Regulation S of the
Securities Act of 1933, as amended (&#8220;Regulation S&#8221;) due to the fact that all sales of stock were made to non-U.S. persons
(as defined under Rule 902 section (k)(2)(i) of Regulation S), pursuant to offshore transactions, and no directed selling efforts were
made in the United States by the issuer, a distributor, any of their respective affiliates, or any person acting on behalf of any of
the foregoing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 59; Value: 48 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
Party Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Company&#8217;s related party list and relationship are as follows:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
    parties</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 2%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationships</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Agape
    ATP (Asia) Limited</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Mr.
    How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of Agape ATP (Asia) Limited.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">CTA
    Nutriceuticals (Asia) Sdn Bhd</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">The
    directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness
    Sdn Bhd.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">DSY
    Beauty Sdn Bhd</span></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">The
    directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International
    Sdn Bhd</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">DSY
    Wellness &amp; Longevity Center Sdn Bhd</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Mr.
    Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSY Wellness &amp; Longevity Center
    Sdn Bhd.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">TH3
    Technology Sdn Bhd</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Mr.
How Kok Choong, the CEO and director of the Company is also a director of TH3 Technology Sdn Bhd.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Redboy
    Picture Sdn Bhd</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Mr.
    How Kok Choong, the CEO and director of the Company is also a director of Redboy Picture Sdn Bhd.</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
party balances as of December 31, 2022 and 2021 are as per table below:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount
due from related parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Name of Related</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Party</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nature</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 22%; text-align: left">TH3 Technology Sdn Bhd (&#8220;TH3&#8221;)</td><td style="width: 2%">&#160;</td>
    <td style="width: 22%; text-align: center">Mr. How Kok Choong, the CEO and director of the Company is also a director of TH3</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center">Prepayment of IT expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,273</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">DSY Beauty Sdn Bhd (&#8220;DSY Beauty&#8221;)</td><td>&#160;</td>
    <td style="text-align: center">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Deposits for products purchases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,261</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Agape ATP (Asia) Limited (&#8220;AATP Asia&#8221;)</td><td>&#160;</td>
    <td style="text-align: center">Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of AATP Asia</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Expenses paid for AATP Asia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,214</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">Hostastay Sdn. Bhd. &#8220;Hostastay&#8221;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt">Sublease rent due from Hostastay</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,790</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,534</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,004</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 60; Value: 48 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
party balances as of December 31, 2022 and 2021 are as per table below:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accounts
payable &#8211; related parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center">Name of Related</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: top; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: top; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Party</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nature</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="text-align: center; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 22%; text-align: left">CTA Nutriceuticals (Asia) Sdn Bhd (&#8220;CTA&#8221;)</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 22%; text-align: center">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center">Purchases of products for the provision of complementary health therapies</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">25,387</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">DSY Beauty Sdn Bhd (&#8220;DSY Beauty&#8221;)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt">Purchases of beauty products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">224</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">25,611</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 61; Value: 48 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
party balances as of December 31, 2022 and 2021 are as per table below:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other payable &#8211; related parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Name of Related</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Party</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Relationship</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nature</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="text-align: center; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 22%; text-align: left">CTA Nutriceuticals (Asia) Sdn Bhd (&#8220;CTA&#8221;)</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 22%; text-align: center">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center">Purchase of products for general use</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,149</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">DSY Beauty Sdn Bhd (&#8220;DSY Beauty&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Purchase of products for general use</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,147</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">Mr. How Kok Choong</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt">Mr. How Kok Choong, the CEO and director of the Company</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt">Commission expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">584</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,880</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
party transactions for years ended December 31, 2022 and 2021, are as per table below:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Purchases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Name of Related</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Party</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Relationship</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nature</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 22%; text-align: left">CTA Nutriceuticals (Asia) Sdn Bhd (&#8220;CTA&#8221;)</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 22%; text-align: center">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center">Purchases of products for the provision of complementary health therapies</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">198,376</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">DSY Beauty Sdn Bhd (&#8220;DSY Beauty&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Purchases of beauty products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,975</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">718</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">DSY Wellness &amp; Longevity Center Sdn Bhd (&#8220;DSYWLC&#8221;)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt">Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt">Purchases of products for the provision of complementary health therapies</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">124</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">202,475</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">718</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 62; Value: 48 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
party transactions for years ended December 31, 2022 and 2021, are as per table below:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
income</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Name of Related</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Party</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Relationship</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nature</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 22%; text-align: left; padding-bottom: 1.5pt">Hostastay
    Sdn. Bhd.</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; width: 22%; text-align: center; padding-bottom: 1.5pt">Mr.
    How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director
    of Hostastay as of April 21, 2021</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center; padding-bottom: 1.5pt">Sublease
    rental income due from Hostastay</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">&#160;&#160;&#160;&#160;-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">4,345</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,345</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
purchases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Name of Related</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Party</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Relationship</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nature</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 22%; text-align: left">CTA Nutriceuticals (Asia) Sdn Bhd (&#8220;CTA&#8221;)</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 22%; text-align: center">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center">Purchases of products for the provision of complementary health therapies</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,431</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">DSY Beauty Sdn Bhd (&#8220;DSY Beauty&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Purchases of beauty products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,888</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">DSY Wellness &amp; Longevity Center Sdn Bhd (&#8220;DSYWLC&#8221;)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt">Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt">Purchases of products for the provision of complementary health therapies</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,323</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 63; Value: 48 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
party transactions for years ended December 31, 2022 and 2021, are as per table below:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
expense</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Name of Related</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Party</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Relationship</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nature</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 22%; text-align: left; padding-bottom: 1.5pt">Mr. How Kok Choong</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; width: 22%; text-align: center; padding-bottom: 1.5pt">Mr. How Kok Choong, the CEO and director of the Company</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center; padding-bottom: 1.5pt">Commission expense</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">16,590</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">12,758</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">16,590</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,758</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Name of Related</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Party</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Relationship</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nature</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 22%; text-align: left">TH3 Technology Sdn Bhd (&#8220;TH3&#8221;)</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 22%; text-align: center">Mr. How Kok Choong, the CEO and director of the Company is also a director of TH3</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center">IT support services fee</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">56,450</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">Redboy Picture Sdn Bhd (&#8220;Redboy&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Mr. How Kok Choong, the CEO and director of the Company is also the director of Redboy</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Sponsorship fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,686</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">718</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">DSY Wellness &amp; Longevity Center Sdn Bhd (&#8220;DSYWLC&#8221;)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt">Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt">Office rental expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,779</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">100,915</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">718</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Review,
Approval and Ratification of Related Party Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
our small size and limited financial resources, we have not adopted formal policies and procedures for the review, approval or ratification
of transactions, such as those described above, with our executive officer(s), Director(s) and significant stockholders. We intend to
establish formal policies and procedures in the future, once we have sufficient resources and have appointed additional Directors, so
that such transactions will be subject to the review, approval or ratification of our Board of Directors, or an appropriate committee
thereof. Until formal policies and procedures are put in place, our Directors will continue to approve any related party transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 64; Value: 48 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ap_011"></span>ITEM
14. PRINCIPAL ACCOUNTING FEES AND SERVICES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective September 1, 2022, Friedman LLP, our then
independent registered public accounting firm, combined with Marcum LLP and continued to operate as an independent registered public accounting
firm. On October 20, 2022, our Board of Directors approved the dismissal of Friedman and the engagement of Marcum Asia CPAs LLP (&#8220;Marcum
Asia&#8221;) to serve as our independent registered public accounting firm. The services previously provided by Friedman LLP are now provided
by Marcum Asia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Marcum LLP is our tax accountant for the year ended
December 31, 2022. Friedman LLP is our tax accountant for the year ended December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is the aggregate amount of fees billed for professional services rendered by our principal accountants with respect to our last two fiscal
years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Audit fees</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">402,200</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">395,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Tax fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,350</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">432,550</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">411,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
category of &#8220;Audit fees&#8221; includes fees for our annual audit, quarterly reviews and services rendered in connection with regulatory
filings with the SEC, such as the issuance of comfort letters and consents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
category of &#8220;Tax fees&#8221; includes professional services rendered by our principal accountant for tax compliance, tax advice,
and tax planning.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the professional services rendered by principal accountants for the audit of our annual financial statements that are normally provided
by the accountant in connection with statutory and regulatory filings or engagements for last two fiscal years were approved by our board
of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 65; Value: 48 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="ap_012"></span>PART
IV</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ap_013"></span>ITEM
15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)
Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are filed as part of this report:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following financial statements of AGAPE ATP Corporation. and Report of Independent Registered Public Accounting Firm are presented in
the &#8220;F&#8221; pages of this Report:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ap_021">Index</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Fin_001">Reports of Independent Registered Public Accounting Firm</a> </span> (PCAOB ID 5395)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#ap_015">Reports of Independent Registered Public Accounting Firm</a> (PCAOB ID 711)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">F-3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Financial Statements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ap_016">Consolidated Balance Sheets</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ap_017">Consolidated Statements of Operations and Comprehensive Loss</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ap_018">Consolidated Statements of Changes in Stockholders&#8217; Equity</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ap_019">Consolidated Statements of Cash Flows</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ap_020">Notes to Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8
    &#8211; F-33</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)
Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following exhibits are filed or &#8220;furnished&#8221; herewith:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.65in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1713210/000169082417000101/certofinc.htm" style="-sec-extract: exhibit">Articles of Incorporation**</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1713210/000169082417000101/bylaws.htm" style="-sec-extract: exhibit">Bylaws**</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Rule 13(a)-14(a)/15(d)-14(a) Certification of principal executive officer and principal financial officer*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Section 1350 Certification of principal executive officer and principal financial officer*</a></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.65in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)*</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Filed herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**
As filed in the Registrant&#8217;s Registration Statement on Form S-1 Amendment No.2 (File No. 333-220144) on October 26, 2017.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 66; Value: 48 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ap_014"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AGAPE
    ATP CORPORATION.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
    of Registrant)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 31, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>/s/
    How Kok Choong</i></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HOW
    KOK CHOONG</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, President, Director Chief Operating Officer, Chairman of the Board of Directors and Secretary</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 31, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Andrew Lee Kam Fan</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEE
    KAM FAN</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 67; Value: 48 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ap_021"></span>INDEX
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.75in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
    Statements</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Fin_001">Report
of Independent Registered Public Accounting Firm</a> (PCAOB ID: <span id="xdx_902_edei--AuditorFirmId_c20220101__20221231_zoIpBK8wAWge"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorFirmId">5395</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#ap_015">Report of Independent Registered Public Accounting Firm</a> <span style="font-family: Times New Roman, Times, Serif">(PCAOB
ID: 711)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">F-3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ap_016">Consolidated Balance Sheets</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ap_017">Consolidated Statements of Operations and Comprehensive Loss</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ap_018">Consolidated Statements of Changes in Stockholders&#8217; Equity</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ap_019">Consolidated Statements of Cash Flows</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ap_020">Notes to Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8
    - F-33</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 68; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Fin_001"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Shareholders and Board of Directors of</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
ATP Corporation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheet of Agape ATP Corporation (the &#8220;Company&#8221;) as of December 31, 2022,
the related consolidated statement of operation, comprehensive loss, stockholders&#8217; equity and cash flows for the year then ended,
and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements
present fairly, in all material respects, the financial position of the Company as of December 31, 2022, and the results of its operations
and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides
a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Audit Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Critical
audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be
communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and
(2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Marcum Asia CPAs <span style="font-variant: small-caps">LLP</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcum
Asia CPAs <span style="font-variant: small-caps">LLP</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2019 (such date takes into account the acquisition of certain assets of Friedman LLP
by Marcum Asia CPAs LLP effective September 1, 2022)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York<br />
March 31, 2023</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 69 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_022.jpg" alt="" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ap_015"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
of Agape ATP Corporation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheet of Agape ATP Corporation (the &#8220;Company&#8221;) as of December 31, 2021,
and the related consolidated statement of operations and comprehensive loss, changes in stockholders&#8217; equity and cash flow for
the year ended December 31, 2021, and the related notes (collectively referred to as the consolidated financial statements). In our opinion,
the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2021, and the result of its operations and its cash flow for the year ended December 31, 2021, in conformity with accounting principles
generally accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion
on the Company&#8217;s consolidated financial statements based on our audit. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part
of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing
an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due
to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audit provide a reasonable basis for our opinion.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<span id="xdx_902_edei--AuditorName_c20220101__20221231_zwhaN2n3EtB8"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorName">Friedman LLP</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2019 through 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--AuditorLocation_c20220101__20221231_zxlkLZFLYnTc"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorLocation">New
York, New York</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
28, 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img src="form10-k_023.jpg" alt="" style="height: 77px; width: 670px" /><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 70 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ap_016"></span>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_301_111_zfg34WE7PNFb" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20221231_zJmVMkRrClne" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20211231_z64cp4fUfJi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AssetsAbstract_iB_zbf52aLw9q5c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B_zui3laEl4cHi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">CURRENT ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACzCse_zvRIQcYk0ig2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Cash and cash equivalents (Included $<span id="xdx_900_ecustom--VariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents_iI_pp0p0_c20221231_z8G2iYgplUzd" title="VIE consolidated amount of cash and cash equivalents"><ix:nonFraction name="AATP:VariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,609</ix:nonFraction></span> and $<span id="xdx_90E_ecustom--VariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents_iI_pp0p0_c20211231_zWkqvxdmCo78" title="VIE consolidated amount of cash and cash equivalents"><ix:nonFraction name="AATP:VariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,493</ix:nonFraction></span> in the consolidated VIE that can be used only to settle obligations of the consolidated VIE as of December 31, 2022 and 2021, respectively.)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,438,430</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,597,848</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccountsReceivableNetCurrent_i02I_maACzCse_zMzG4IqgU6Cb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,826</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0059">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DueFromRelatedPartiesCurrent_i02I_maACzCse_zaVnBwlrkRF2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Amount due from related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,534</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,004</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--InventoryNet_i02I_maACzCse_zKNVbO8mtNki" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,277</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">375,535</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PrepaidTaxes_i02I_maACzCse_z8ldn3ovZo03" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Prepaid taxes (Included $<span id="xdx_909_ecustom--VariableInterestEntityConsolidatedAmountOfPrepaidTaxes_iI_pp0p0_c20221231_zIO6JR1Ko2a9" title="VIE consolidated amount of prepaid taxes"><ix:nonFraction name="AATP:VariableInterestEntityConsolidatedAmountOfPrepaidTaxes" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,741</ix:nonFraction></span> and $<span id="xdx_907_ecustom--VariableInterestEntityConsolidatedAmountOfPrepaidTaxes_iI_pp0p0_c20211231_zeUvm38pBmoi" title="VIE consolidated amount of prepaid taxes"><ix:nonFraction name="AATP:VariableInterestEntityConsolidatedAmountOfPrepaidTaxes" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,357</ix:nonFraction></span> in the consolidated VIE that can be used only to settle obligations of the consolidated VIE as of December 31, 2022 and 2021, respectively.)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidTaxes" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">339,367</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidTaxes" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">636,218</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maACzCse_z6vF0nxBuQW2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Prepayments and deposits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">191,100</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,517</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsCurrent_i02TI_mtACzCse_maAzw32_zWULp5DrRVP3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Current Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,028,534</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,912,122</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsNoncurrentAbstract_i01B_zG9x1Nqx4VXf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">OTHER ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentNet_i02I_maANzQ9i_z0cWMvxovPT8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142,149</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">215,799</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i02I_maANzQ9i_zMlKX97GQOxh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,044</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,660</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_maANzQ9i_ziS9JmGKRmof" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,133</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">237,718</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--MarketableSecuritiesNoncurrent_i02I_maANzQ9i_zz8DRGtZVEne" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Investment in marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,687</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,001</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--InvestmentInNonMarketableSecuritiesNoncurrent_i02I_maANzQ9i_zgukrrNZDsd8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Investment in non-marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0095">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AATP:InvestmentInNonMarketableSecuritiesNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredCosts_i02I_maANzQ9i_ztVSzSqluwy2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Deferred offering costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">499,202</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">264,735</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsNoncurrent_i02TI_mtANzQ9i_maAzw32_zxnkDdUHF9m9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">763,215</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">812,413</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Assets_i01TI_mtAzw32_zrZOupJeNYmj" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,791,749</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,724,535</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zVm4UAgSTSyf" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesCurrentAbstract_i01B_zwqxlyKKYrSc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">CURRENT LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccountsPayableTradeCurrent_i02I_maLCz1lC_zkRjmiqVYILa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,833</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,715</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccountsPayableRelatedPartiesCurrent_i02I_pp0p0_maLCz1lC_z2qnELLsYcZg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable &#8211; related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,611</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0117">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ContractWithCustomerLiabilityCurrent_i02I_maLCz1lC_zEogzGH8jwe9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Customer deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">363,018</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">279,689</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCz1lC_zUVMlerlyHib" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,708</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,094</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OtherAccountsPayableAndAccruedLiabilities_i02I_maLCz1lC_zQgg8JDzvQmf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other payables and accrued liabilities ($<span id="xdx_90E_ecustom--VariableInterestEntityConsolidatedAmountOfOtherPayablesAndAccruedLiabilities_iI_pp0p0_c20221231_zJEvmuVZWlPc" title="VIE consolidated amount of other payables and accrued liabilities"><ix:nonFraction name="AATP:VariableInterestEntityConsolidatedAmountOfOtherPayablesAndAccruedLiabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,090</ix:nonFraction></span> and $<span id="xdx_900_ecustom--VariableInterestEntityConsolidatedAmountOfOtherPayablesAndAccruedLiabilities_iI_pp0p0_c20211231_zBkaQRbeecL6" title="VIE consolidated amount of other payables and accrued liabilities"><ix:nonFraction name="AATP:VariableInterestEntityConsolidatedAmountOfOtherPayablesAndAccruedLiabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,548</ix:nonFraction></span> are included in the consolidated VIE that are without recourse to the credit of Agape ATP Corporation as of December 31, 2022 and 2021, respectively.)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">713,277</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">858,355</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccountsPayableOtherCurrent_i02I_pp0p0_maLCz1lC_zqIHxTL9B3jh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Other payable &#8211; related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableOtherCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,880</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0133">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--TaxesPayableCurrent_i02I_maLCz1lC_zmCH6p9viot8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Income tax payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:TaxesPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,968</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:TaxesPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,988</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesCurrent_i02TI_mtLCz1lC_maLzYAs_zQIsnjlRJPdb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Current Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,229,295</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,312,841</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_zriERwGej2T3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">NON-CURRENT LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maLNzbeD_z01yphlEgO58" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0144">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83,484</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredIncomeTaxLiabilitiesNet_i02I_maLNzbeD_zfiVgfeUHWR9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0147">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,574</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesNoncurrent_i02TI_mtLNzbeD_maLzYAs_zFMtgL7eXun1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Non-current Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0150">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,058</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--Liabilities_i01TI_mtLzYAs_maLASEz8Bt_zLriCz5yMKp" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL LIABILITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,229,295</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,411,899</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--StockholdersEquityAbstract_i01B_zf4yePWWolx7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PreferredStockValue_i02I_maSEzF36_z1OSx9GisHPb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Preferred stock, $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231_zqAcBlSoDf7e" title="Preferred stock, par value"><span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20211231_z3bAJ3TJHUR9" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_z2eI1Pq11e9h" title="Preferred stock, shares authorized"><span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231_zhlwpkXNZXXd" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_dn_c20221231_z0sD8bp7VvLd" title="Preferred stock, shares issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20221231_zwCrzUf5dcV3" title="Preferred stock, shares outstanding"><span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_dn_c20211231_zAYoegOWPEDa" title="Preferred stock, shares issued"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20211231_zFFgORCX9uNd" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">None</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> issued and outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0159">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0160">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CommonStockValue_i02I_maSEzF36_zX2DszyHwA7l" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common Stock, par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231_zZO3pREabNc1" title="Common stock, par value"><span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20211231_zmQZVM2rpY6" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span>; <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zh6ozLaQr9bc" title="Common stock, shares authorized"><span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zyfpPSahhue7" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_c20221231_zb9xnn9ily1g" title="Common stock, shares issued"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_z6BU7vlAzn2e" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,452,012</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_c20211231_zOzPD3EfVT5a" title="Common stock, shares issued"><span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_zn6OFzO3OXsl" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">290,460,047</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of December 31, 2022 and 2021, respectively.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,545</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,046</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AdditionalPaidInCapital_i02I_maSEzF36_ziko0tmNx9v" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Additional paid in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,470,716</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,449,215</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzF36_zMMWN2JJPyhg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,945,586</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,258,687</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_maSEzF36_zKm65syVs8C4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accumulated other comprehensive income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,266</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,398</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--StockholdersEquity_i02TI_pp0p0_mtSEzF36_maSEIPAzGMc_zIIIKhDETeQk" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">TOTAL AGAPE CORPORATION STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,541,941</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,312,972</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--MinorityInterest_i02I_maSEIPAzGMc_zV03141LMIRf" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">NON-CONTROLLING INTERESTS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,513</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">336</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_i02TI_mtSEIPAzGMc_maLASEz8Bt_zsky8x2hieOl" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL EQUITY</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,562,454</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,312,636</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_mtLASEz8Bt_zSvCgBURGJN6" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,791,749</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,724,535</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 71 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ap_017"></span>CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_113_z2NjQ2ucvtyj" summary="xdx: Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_zO6vkJKncPKd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20211231_zA5A7lds0b44" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maGPzmxQ_zU5hGGKCE895" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">REVENUE</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,856,564</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,016,962</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CostOfGoodsAndServicesSold_iN_di_msGPzmxQ_zpz0VcdXl0Mf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">COST OF REVENUE</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">666,042</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">297,333</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--GrossProfit_iT_mtGPzmxQ_maOILzCrc_zEU4uwuVFyx9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">GROSS PROFIT</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,190,522</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">719,629</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--SellingExpense_iN_di_maOEzDbx_zHWEyrc4IT5k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>SELLING</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:SellingExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">361,414</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:SellingExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">394,682</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--SalesCommissionsAndFees_iN_di_maOEzDbx_zxrCrQuNmtZc" style="vertical-align: bottom; background-color: White">
    <td>COMMISSION</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:SalesCommissionsAndFees" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">405,351</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:SalesCommissionsAndFees" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">316,267</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--GeneralAndAdministrativeExpense_iN_di_maOEzDbx_zZaELx8Yv6W5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">GENERAL AND ADMINISTRATIVE</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,957,023</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,745,734</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--ProvisionForDoubtfulAccounts_iN_di_maOEzDbx_zMojXQ05zk4c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">PROVISION FOR DOUBTFUL ACCOUNTS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0236">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,514</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingExpenses_iNT_di_msOILzCrc_mtOEzDbx_zt0MHScbwIO1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL OPERATING EXPENSES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,723,788</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,578,197</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingIncomeLoss_iT_mtOILzCrc_maILFCOzIhE_znmFbsjfGtmj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">LOSS FROM OPERATIONS</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,533,266</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,858,568</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zL4aeAOz7gJ5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">OTHER INCOME (EXPENSES)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherNonoperatingIncomeExpense_i01_pp0p0_maNIEzhGL_zP8joFfoz7J4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other expenses, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">79,539</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">68,323</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--InvestmentIncomeInterest_i01_maNIEzhGL_zX1vff3UaFdl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,190</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,570</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_i01_pp0p0_maNIEzhGL_zu2lx3Udlkq1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Unrealized holding loss on marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">73,519</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">505,231</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--PreferredStockDividendIncomeStatementImpact_i01N_pp0p0_di_msNIEzhGL_zij93bP3U2H" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Dividend income from marketable securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0257">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="AATP:PreferredStockDividendIncomeStatementImpact" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">18,939</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NonoperatingIncomeExpense_i01T_pp0p0_mtNIEzhGL_maILFCOzIhE_zO3ful9tQCj6" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL OTHER EXPENSES, NET</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">136,868</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">529,045</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOzIhE_maPLzPS1_zdKwbNLz64o3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">LOSS BEFORE INCOME TAXES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,670,134</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,387,613</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msPLzPS1_zuQQfRM72QL8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">BENEFIT OF (PROVISION FOR) INCOME TAXES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,055</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">137,067</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ProfitLoss_iT_mtPLzPS1_maNILz6V5_zgL9FotYuMh5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">NET LOSS</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,666,079</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,524,680</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_iN_di_msNILz6V5_z7Jmtf4SxtYh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">NET (INCOME) LOSS ATTRIBUTABLE TO NON-CONTROLLING INTERESTS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,820</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">436</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_iT_mtNILz6V5_zLohkZbcBlf9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET LOSS ATTRIBUTABLE TO AGAPE ATP CORPORATION</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,686,899</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,524,244</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_maCINOTzSav_zrd7YkGvm9j7" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">NET LOSS</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,666,079</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,524,680</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_iB_z3V1gWjBGbSj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">OTHER COMPREHENSIVE LOSS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_i01_maCINOTzSav_zUxq87u2HrBg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">84,132</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">87,615</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_i01T_mtCINOTzSav_maCINOTzN32_z3sT8VshQs27" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">TOTAL COMPREHENSIVE LOSS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,750,211</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,612,295</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_i01_pp0p0_msCINOTzN32_zweco6cx61Qh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: Comprehensive income (loss) attributable to non-controlling interests</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,849</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">433</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ComprehensiveIncomeNetOfTax_i01T_mtCINOTzN32_zzuP4C4WmkH7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">COMPREHENSIVE LOSS ATTRIBUTABLE TO AGAPE ATP CORPORATION</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,771,060</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,611,862</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--EarningsPerShareBasicAbstract_iB_z2sw6JekEOIh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">LOSS PER SHARE</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--EarningsPerShareBasic_i01_zKpg2ek0AIM2" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.02</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.01</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--EarningsPerShareBasicOtherDisclosuresAbstract_iB_zBjypdMHM9T" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_zRdKo9Sy2gKd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Basic and diluted</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">87,822,337</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">376,216,452</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 72 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ap_018"></span>CONSOLIDATED
STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_114_zbDZplc3BQXj" summary="xdx: Statement - Consolidated Statements of Changes in Stockholders&apos; Equity" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 8pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zpVA4ZtkfH1g" style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zK8kjMlvpWik" style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zVzR08J0sqNb" style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zar8BwY4mxwg" style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--NoncontrollingInterestMember_zkPDOfMRJnt9" style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td id="xdx_4BA_z09vzFCes7r9" style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td></tr>
<tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><b>&#160;</b></td><td colspan="5" style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><b>COMMON
                                            STOCK</b></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><b>ADDITIONAL</b></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><b>ACCUMULATED
                                            OTHER</b></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><b>NON-</b></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><b>TOTAL</b></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><b>&#160;</b></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><b>Number
                                            of shares</b></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><b>Par
                                            value</b></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>PAID
                                            IN CAPITAL</b></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><b>ACCUMULATED<br />
                                            DEFICIT</b></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><b>COMPREHENSIVE
                                            INCOME</b></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><b>CONTROLLING
                                            INTERESTS</b></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><b>&#160;</b></td>
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><b>STOCKHOLDERS&#8217;<br />

                                            EQUITY</b></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"><b>&#160;</b></td></tr>
  <tr id="xdx_435_c20210101__20211231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zYiboGgeMdok" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance
    as of December 31, 2020</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJqTac15xpwa" style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">376,452,047</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,645</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,440,616</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">734,443</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181,016</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0312">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,924,834</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationForfeited_zk9lp6FfXrdi" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Forfeiture
    of common stock</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_iN_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4AcY51Vzyx7" style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">85,992,000</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,599</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,599</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0318">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0319">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0320">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0321">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--ContributionsFromNoncontrollingInterestShareholders_zaTnXiqy2uJf" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Contributions
    from non-controlling interest shareholders</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0324">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0325">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0326">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0327">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="AATP:ContributionsFromNoncontrollingInterestShareholders" contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="AATP:ContributionsFromNoncontrollingInterestShareholders" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zGMVTow3VTY6" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net
    loss</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0331">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0332">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,524,244</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0334">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">436</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,524,680</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Foreign
    currency translation adjustment</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(87,618</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(87,615</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr id="xdx_434_c20220101__20221231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_z6bKqb8eOxoc" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance
    as of December 31, 2021</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z48YzrKFCSll" style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">290,460,047</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,046</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,449,215</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,258,687</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,398</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">336</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,312,636</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationForfeited_zZLnhk5rEUOb" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Forfeiture
    of common stock</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEVf06ZQBoyh" style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">218,008,035</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,501</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,501</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0348">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0349">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0350">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0351">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zSwEuCO5oRZ9" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net
    loss</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0354">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0355">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,686,899</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0357">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,820</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,666,079</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_zKBHFSXl2cVh" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Foreign
    currency translation adjustment</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0361">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0362">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0363">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">84,132</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">84,103</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr id="xdx_43F_c20220101__20221231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zFtrrj8o4Vri" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance
    as of December 31, 2022</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAfBUTIO1cMb" style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">72,452,012</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,545</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,470,716</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,945,586</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,266</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,513</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,562,454</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 73 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ap_019"></span>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_112_zKlxaDf5YI5i" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20220101__20221231_zxUOvSfs5b82" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20210101__20211231_zbWoKBcf45L8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zg32dY6r7vJd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_i01_maNCPBUzWx7_zwMcY2zuh4Li" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,666,079</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,524,680</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zGXNA8DZYjrf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Depreciation_i02_maNCPBUzWx7_zJR4uRGOSIIh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,754</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,797</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CostOfGoodsAndServicesSoldAmortization_i02_maNCPBUzWx7_zbIP5XeA8QCg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSoldAmortization" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,122</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSoldAmortization" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,961</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_i02_maNCPBUzWx7_zJrouefhj6t1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Amortization of operating right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">144,064</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,451</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_i02N_pp0p0_di_msNCPBUzWx7_zT5rLCQTJQx6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Unrealized holding loss on marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">73,519</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">505,231</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--PreferredStockDividendIncomeStatementImpact_i02_pp0p0_maNCPBUzWx7_zs4FMCfMuema" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Dividend income from marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0397">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="AATP:PreferredStockDividendIncomeStatementImpact" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">18,939</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_i02_maNCPBUzWx7_zCWEGOcXENzf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Deferred tax (benefit) expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,751</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,127</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--InventoryWriteDown_i02_pp0p0_maNCPBUzWx7_zoPZWDxOIJcj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Inventory write-down</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,307</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">36,241</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProvisionForDoubtfulAccounts_i02_pp0p0_maNCPBUzWx7_zYvjDYUs9Gpf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Provision for doubtful accounts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0406">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">121,514</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zuXKfqv20mW8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_di_msNCPBUzWx7_zGke4QpR4FT9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,824</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">167,566</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent_i03N_di_msNCPBUzWx7_z6htaePG0f5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Amount due from related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,786</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInInventories_i03N_di_msNCPBUzWx7_zGqfqMl8dJIb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">343,483</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">192,713</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInPrepaidTaxes_i03N_di_msNCPBUzWx7_zRdjErSV2vqk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Prepaid taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidTaxes" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">263,404</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidTaxes" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">430,062</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInPrepaidExpensesOther_i03N_di_msNCPBUzWx7_zP0sF4wLKb2b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Prepayments and deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">89,113</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">128,363</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInOtherAccountsPayable_i03_maNCPBUzWx7_z7y7h8kkrvd8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,825</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0428">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInAccountsPayableRelatedParties_i03_pp0p0_maNCPBUzWx7_zqLA39zjCFUc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable &#8211; related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,597</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0431">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInContractWithCustomerLiability_i03_maNCPBUzWx7_zPGak2NjIWG1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Customer deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,877</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,981</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_maNCPBUzWx7_zqrrURmAN4Z7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">145,197</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">138,143</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_i03_maNCPBUzWx7_zrc4guk5WBx3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other payables and accrued liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">119,963</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">226,651</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInDueToOtherRelatedPartiesCurrent_i03_pp0p0_maNCPBUzWx7_zVeI9JEb6b7c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Other payables &#8211; related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToOtherRelatedPartiesCurrent" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,878</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0443">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInAccruedIncomeTaxesPayable_i03_maNCPBUzWx7_zHYjpKnu9IT5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Income tax payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,974</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,988</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i02T_mtNCPBUzWx7_maCCERCzFvG_zh8ZKekqDTLe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">811,683</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">845,842</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_znKr1zyUEjq" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PaymentsToAcquireMachineryAndEquipment_i01N_di_msNCPBUzifK_zKPDxfZAnmtd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Purchase of equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMachineryAndEquipment" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,433</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMachineryAndEquipment" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,959</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_pp0p0_di_msNCPBUzifK_zCNEHkPWnZjf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Purchase of intangible assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,686</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0458">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUzifK_maCCERCzFvG_zLtBYxdB5ITj" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">32,119</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,959</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zp0mRNZBoGq7" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PaymentsOfDebtIssuanceCosts_i01N_di_msNCPBUzRmY_z4phnBflNXN2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">234,466</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,210</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_i01_maNCPBUzRmY_zv3i1naPxMa4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Advances to related parties</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0469">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,851</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzRmY_maCCERCzFvG_zktRarRsvss5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash used in financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">234,466</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,061</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_maCCERCzFvG_zvxG432VxzP4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">81,150</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">50,890</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzFvG_zKjLPz5pG605" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">DECREASE IN CASH AND CASH EQUIVALENTS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,159,418</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">919,752</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_pp0p0_zif4ELDMyX62" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">CASH AND CASH EQUIVALENTS, beginning of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,597,848</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,517,600</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_pp0p0_znvZr94IgW57" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">CASH AND CASH EQUIVALENTS, end of year</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,438,430</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,597,848</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zZfkKeQG1Qoi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">SUPPLEMENTAL CASH FLOWS INFORMATION</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxesPaidNet_i01_zKHldZe0jw9e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Income taxes paid</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,511</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">326,838</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zAo2Vhkn43E8" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">SUPPLEMENTAL NON-CASH FLOWS INFORMATION</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--ChangesInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseModifications_i01_z3NsMMQS1zya" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Changes in right-of-use assets and lease liabilities due to lease modifications</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0496">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="AATP:ChangesInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseModifications" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,250</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 74 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ap_020"></span>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock"><p id="xdx_803_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zR6JjLOESEf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
<span id="xdx_82D_ztREWQUryuRe">ORGANIZATION AND BUSINESS BACKGROUND</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
ATP Corporation, a Nevada corporation (&#8220;the Company&#8221;) was incorporated under the laws of the State of Nevada on June 1, 2016.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
ATP Corporation operates through its subsidiaries, namely, Agape ATP Corporation (&#8220;AATP LB&#8221;), a company incorporated in Labuan,
Malaysia, and Agape Superior Living Sdn. Bhd. (&#8220;ASL&#8221;), a company incorporated in Malaysia. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
ATP Corporation, incorporated in Labuan, Malaysia, is an investment holding company with <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AgapeATPInternationalHoldingLimitedMember_zc7eTvCZ2HD5" title="Ownership interest percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-31_custom_AgapeATPInternationalHoldingLimitedMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% equity interest in Agape ATP International
Holding Limited (&#8220;AATP HK&#8221;), a company incorporated in Hong Kong.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 8, 2020, the Company entered into a Share Exchange Agreement with Mr. How Kok Choong, CEO and director of the Company to acquire
<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20200507__20200508__us-gaap--TypeOfArrangementAxis__custom--ShareExchangeAgreementMember__srt--TitleOfIndividualAxis__custom--MrHowKokChoongMember_z802G6v5C9f9" title="Stock issued during period acquisitions, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2020-05-072020-05-08_custom_ShareExchangeAgreementMember_custom_MrHowKokChoongMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,590,596</ix:nonFraction></span> ordinary shares, no par value, equivalent to approximately <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20200508__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zfnUebdMNK4j" title="Ownership interest percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2020-05-08_custom_SubsidiaryCompanyTwoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">99.99</ix:nonFraction></span>% of the equity interest in Agape Superior Living Sdn. Bhd.,
a network marketing entity incorporated in Malaysia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
Superior Living Sdn. Bhd. is a limited company incorporated on August 8, 2003, under the laws of Malaysia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 11, 2020, the Company incorporated Wellness ATP International Holdings Sdn, Bhd. (&#8220;WATP&#8221;), a wholly owned subsidiary
under the laws of Malaysia, to pursue the business of promoting wellness and wellbeing lifestyle of the community by providing services
that includes online editorials, programs, events and campaigns on how to achieve positive wellness and lifestyle.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
November 11, 2021, Agape ATP Corporation (Labuan) formed a joint-venture entity, DSY Wellness International Sdn. Bhd. (&#8220;DSY Wellness&#8221;)
with an independent third party which Agape ATP Corporation (Labuan) owns <span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20211111__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zqShoCpWyng9" title="Ownership interest percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2021-11-11_custom_SubsidiaryCompanyFiveMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">60</ix:nonFraction></span>% of the equity interest, to pursue the business of providing
complementary health therapies</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and its subsidiaries are principally engaged in the Health and Wellness Industry. The principal activity of the Company is to
supply high-quality health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation,
anti-aging and products designed to improve the overall health system of the human body and various wellness programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements reflect the activities of the Company, AATP LB, AATP HK, WATP, ASL and its variable interest
entity (&#8220;VIE&#8221;), Agape S.E.A. Sdn. Bhd. (&#8220;SEA&#8221;) (See Note 3), and DSY Wellness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_z6jBKz43mij3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details
of the Company&#8217;s subsidiaries:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_z4U5U8Q2bO8b" style="display: none">SCHEDULE OF SUBSIDIARIES AND ASSOCIATES</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Subsidiary company name</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Place and date of incorporation</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Particulars of issued capital</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Principal activities</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Proportional of ownership interest and voting power held</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 4%; vertical-align: top">1.</td>
    <td id="xdx_98F_ecustom--NameOftheCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_z2wgyn1Dpdoi" title="Subsidiary company name" style="vertical-align: top; width: 16%; text-align: center"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyMember" name="AATP:NameOftheCompany">Agape ATP Corporation</ix:nonNumeric></td><td style="width: 2%">&#160;</td>
    <td id="xdx_98A_ecustom--PlaceAndDateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_zOH5MKL1PLkj" title="Place and date of incorporation" style="vertical-align: top; width: 16%; text-align: center"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyMember" name="AATP:PlaceAndDateOfIncorporation">Labuan, <br /> March 6, 2017</ix:nonNumeric></td><td style="width: 2%">&#160;</td>
    <td id="xdx_98C_ecustom--ParticularsOfIssuedCapital_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_zU2TJAdQCsg1" title="Particulars of issued capital" style="vertical-align: top; width: 20%; text-align: center"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyMember" name="AATP:ParticularsOfIssuedCapital">100 shares of ordinary share of US$1 each</ix:nonNumeric></td><td style="width: 2%">&#160;</td>
    <td id="xdx_984_ecustom--PrincipalActivities_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_z0yc20sqe4e5" title="Principal activities" style="vertical-align: top; width: 18%; text-align: center"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyMember" name="AATP:PrincipalActivities">Investment holding</ix:nonNumeric></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_zlXDpPQbfo4c" title="Proportional of ownership interest and voting power held" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-31_custom_SubsidiaryCompanyMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">2.</td>
    <td id="xdx_988_ecustom--NameOftheCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_zwISC4Dfxule" title="Subsidiary company name" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyOneMember" name="AATP:NameOftheCompany">Agape ATP International Holding Limited</ix:nonNumeric></td><td>&#160;</td>
    <td id="xdx_980_ecustom--PlaceAndDateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_zKZuiXDJIJO9" title="Place and date of incorporation" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyOneMember" name="AATP:PlaceAndDateOfIncorporation">Hong Kong,<br /> June 1, 2017</ix:nonNumeric></td><td>&#160;</td>
    <td id="xdx_987_ecustom--ParticularsOfIssuedCapital_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_z1C2yO2Krxjf" title="Particulars of issued capital" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyOneMember" name="AATP:ParticularsOfIssuedCapital">1,000,000 shares of ordinary share of HK$1 each</ix:nonNumeric></td><td>&#160;</td>
    <td id="xdx_98A_ecustom--PrincipalActivities_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_ztkuR8UgE2Ga" title="Principal activities" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyOneMember" name="AATP:PrincipalActivities">Wholesaling of health and wellness products; and health solution advisory services</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_zhrHuElxQgUb" title="Proportional of ownership interest and voting power held" style="text-align: right"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-31_custom_SubsidiaryCompanyOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">3.</td>
    <td id="xdx_986_ecustom--NameOftheCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zWPZEeulGIaj" title="Subsidiary company name" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyTwoMember" name="AATP:NameOftheCompany">Agape Superior Living Sdn. Bhd.</ix:nonNumeric></td><td>&#160;</td>
    <td id="xdx_989_ecustom--PlaceAndDateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_z2vG4JESWMse" title="Place and date of incorporation" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyTwoMember" name="AATP:PlaceAndDateOfIncorporation">Malaysia, <br /> August 8, 2003</ix:nonNumeric></td><td>&#160;</td>
    <td id="xdx_98F_ecustom--ParticularsOfIssuedCapital_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zlxQ0wCJyced" title="Particulars of issued capital" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyTwoMember" name="AATP:ParticularsOfIssuedCapital">9,590,598 shares of ordinary share of RM1 each</ix:nonNumeric></td><td>&#160;</td>
    <td id="xdx_98F_ecustom--PrincipalActivities_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zaWmlnQpMVlk" title="Principal activities" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyTwoMember" name="AATP:PrincipalActivities">Health and wellness products and health solution advisory services via network marketing</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zRDu6wC8Y65g" title="Proportional of ownership interest and voting power held" style="text-align: right"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-31_custom_SubsidiaryCompanyTwoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">99.99</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">4.</td>
    <td id="xdx_983_ecustom--NameOftheCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_zCQSxQOdMDV6" title="Subsidiary company name" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyThreeMember" name="AATP:NameOftheCompany">Agape S.E.A. Sdn. Bhd.</ix:nonNumeric></td><td>&#160;</td>
    <td id="xdx_989_ecustom--PlaceAndDateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_zJkdhPBAnCx6" title="Place and date of incorporation" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyThreeMember" name="AATP:PlaceAndDateOfIncorporation">Malaysia, <br /> March 4, 2004</ix:nonNumeric></td><td>&#160;</td>
    <td id="xdx_981_ecustom--ParticularsOfIssuedCapital_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_zQVikuygSc68" title="Particulars of issued capital" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyThreeMember" name="AATP:ParticularsOfIssuedCapital">2 shares of ordinary share of RM1 each</ix:nonNumeric></td><td>&#160;</td>
    <td id="xdx_98B_ecustom--PrincipalActivities_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_zx9nzdHshE9" title="Principal activities" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyThreeMember" name="AATP:PrincipalActivities">VIE of Agape Superior Living Sdn. Bhd.</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VIE</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">5.</td>
    <td id="xdx_988_ecustom--NameOftheCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_zVyxdcbNtEw4" title="Subsidiary company name" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyFourMember" name="AATP:NameOftheCompany">Wellness ATP International Holdings Sdn, Bhd</ix:nonNumeric></td><td>&#160;</td>
    <td id="xdx_98A_ecustom--PlaceAndDateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_zQzORBPslp6b" title="Place and date of incorporation" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyFourMember" name="AATP:PlaceAndDateOfIncorporation">Malaysia, <br /> September 11, 2020</ix:nonNumeric></td><td>&#160;</td>
    <td id="xdx_98F_ecustom--ParticularsOfIssuedCapital_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_zzCN2vTm0Nrj" title="Particulars of issued capital" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyFourMember" name="AATP:ParticularsOfIssuedCapital">100 shares of ordinary share of RM1 each</ix:nonNumeric></td><td>&#160;</td>
    <td id="xdx_980_ecustom--PrincipalActivities_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_z4w9BFgkjcaf" title="Principal activities" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyFourMember" name="AATP:PrincipalActivities">The promotion of wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_zrwhNipqlX5h" title="Proportional of ownership interest and voting power held" style="text-align: right"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-31_custom_SubsidiaryCompanyFourMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">6.</td>
    <td id="xdx_981_ecustom--NameOftheCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zPNDKJMYKVCf" title="Subsidiary company name" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyFiveMember" name="AATP:NameOftheCompany">DSY Wellness International Sdn Bhd.</ix:nonNumeric></td><td>&#160;</td>
    <td id="xdx_987_ecustom--PlaceAndDateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zkpqjGWY6Im9" title="Place and date of incorporation" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyFiveMember" name="AATP:PlaceAndDateOfIncorporation">Malaysia, <br /> November 11, 2021</ix:nonNumeric></td><td>&#160;</td>
    <td id="xdx_989_ecustom--ParticularsOfIssuedCapital_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zSsNZhMC3uab" title="Particulars of issued capital" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyFiveMember" name="AATP:ParticularsOfIssuedCapital">1,000 shares of ordinary share of RM1 each</ix:nonNumeric></td><td>&#160;</td>
    <td id="xdx_982_ecustom--PrincipalActivities_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_z5jZwgR6At6a" title="Principal activities" style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyFiveMember" name="AATP:PrincipalActivities">Provision of complementary health therapies</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zWZ4bln97jE8" title="Proportional of ownership interest and voting power held" style="text-align: right"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-31_custom_SubsidiaryCompanyFiveMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">60</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zodYUjrS2ead" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 75 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
ORGANIZATION AND BUSINESS BACKGROUND (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
ATP Corporation is a company that provides health and wellness products and health solution advisory services to our clients. The Company
primarily focus its efforts on attracting customers in Malaysia. Its advisory services center on the &#8220;ATP Zeta Health Program&#8221;,
which is a health program designed to effectively prevent diseases caused by polluted environments, unhealthy dietary intake and unhealthy
lifestyles, and promotion of health. The program aims to promote improved health and longevity in our clients through a combination of
modern medicine, proper nutrition and advice from skilled nutritionists and/or dieticians.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to strengthen the Company&#8217;s supply chain, on May 8, 2020, the Company has successfully acquired approximately <span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20200508__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zWwMZGl7fYI9" title="Ownership interest percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2020-05-08_custom_SubsidiaryCompanyTwoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">99.99</ix:nonFraction></span>% of ASL,
with the goal of securing an established network marketing sales channel that has been established in Malaysia for the past 15 years.
ASL has been offering the Company&#8217;s ATP Zeta Health Program as part of its product lineup. As such, the acquisition creates synergy
in the Company&#8217;s operation by boosting the Company&#8217;s retail and marketing capabilities. The newly acquired subsidiary allows
the Company to fulfill its mission of &#8220;helping people to create health and wealth&#8221; by providing a financially rewarding business
opportunity to distributors and quality products to distributors and customers who seek a healthy lifestyle.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Via
ASL, the Company offers three series of programs which consist of different services and products: ATP Zeta Health Program, &#201;NERG&#201;TIQUE
and BEAUNIQUE.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ATP Zeta Health Program is a health program designed to promote health and general wellbeing designed to prevent health diseases caused
by polluted environments, unhealthy dietary intake and unhealthy lifestyles. The program aims to promote improved health and longevity
through a combination of modern health supplements, proper nutrition and advice from skilled dieticians as well as trained members and
distributors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
&#201;NERG&#201;TIQUE series aims to provide a total dermal solution for a healthy skin beginning from the cellular level. The series
is comprised of the Energy Mask series, Hyaluronic Acid Serum and Mousse Facial Cleanser.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
BEAUNIQUE product series focuses on the research of our diet&#8217;s impact on modifying gene expressions in order to address genetic
variations and deliver a nutrigenomic solution for every individual.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company deems creating public awareness on wellness and wellbeing lifestyle as essential to enhance the provision of its health solution
advisory services; and therefore, incorporated WATP. Upon its establishment, WATP started collaborating with ASL to carry out various
wellness programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">To
further its reach in the Health and Wellness Industry, on November 11, 2021, Agape ATP Corporation (Labuan) formed a joint-venture entity,
DSY Wellness International Sdn. Bhd. (&#8220;DSY Wellness&#8221;) with an independent third party which Agape ATP Corporation (Labuan)
owns <span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20211111__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zwAGvqoA2HP9" title="Ownership interest percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2021-11-11_custom_SubsidiaryCompanyFiveMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">60</ix:nonFraction></span>% of the equity interest, to pursue the business of providing complementary health therapies</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_z6WrXQERQkr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span id="xdx_823_zkfU5HXXyal3">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_844_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zNyP0JyAjBg1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86B_zswr0mP2xvua">Basis
of presentation</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#8220;U.S. GAAP&#8221;) for information pursuant to the rules and regulations of the Securities Exchange Commission
(&#8220;SEC&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the financial statements of the Company, its subsidiaries and its VIE over which the Company
exercises control and, where applicable, entities for which the Company has a controlling financial interest or is the primary beneficiary.
All transactions and balances among the Company, its subsidiaries and its VIE have been eliminated upon consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 76 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_zjSzSQwxiDdi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86B_zL3GCcj9fsy3">Principles
of consolidation</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries
are those entities in which the Company, directly or indirectly, controls more than one half of the voting power; or has the power to
govern the financial and operating policies, to appoint or remove the majority of the members of the board of directors, or to cast a
majority of votes at the meeting of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
VIE is an entity that has either a total equity investment that is insufficient to permit the entity to finance its activities without
additional subordinated financial support, or whose equity investors lack the characteristics of a controlling financial interest, such
as through voting rights, right to receive the expected residual returns of the entity or obligation to absorb the expected losses of
the entity. The variable interest holder, if any, that has a controlling financial interest in a VIE is deemed to be the primary beneficiary
and must consolidate the VIE. As of and for the year ended December 31, 2022, SEA, the only VIE of the Company has no significant operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_847_eus-gaap--UseOfEstimates_zkjAIul2wCT" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86C_zVJBrVh7U4Aj">Use
of estimates</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of
the consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant
accounting estimates reflected in the Company&#8217;s consolidated financial statements include allowance for inventories
obsolescence, impairment of long-lived assets, allowance for deferred tax assets. Actual results could differ from
these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6f6d91OK2Rc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86B_zsTXHABZLZv4">Cash
and cash equivalents</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents represent cash on hand, time deposits placed with banks or other financial institutions and all highly liquid investments
with an original maturity of three months or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:TradeAndOtherAccountsReceivablePolicy"><p id="xdx_847_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z3H4czMnpm65" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zzkCSgBX4RR5">Accounts
receivable</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable are recorded at the invoiced amount less an allowance for any uncollectible accounts and do not bear interest, which are due
on credit term. Management reviews the adequacy of the allowance for doubtful accounts on an ongoing basis,
using historical collection trends and aging of receivables. Management also periodically evaluates individual customer&#8217;s financial
condition, credit history, and the current economic conditions to make adjustments in the allowance when it is considered necessary.
Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery
is considered remote. The Company&#8217;s management continues to evaluate the reasonableness of the valuation allowance policy and update
it if necessary. As of December 31, 2022 and 2021, <span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_pp0p0_doxL_c20221231_zhiOqmrcPqr8" title="Accounts receivable, allowance for credit loss::XDX::-"><span id="xdx_901_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_pp0p0_doxL_c20221231_zIRpLQV9Lc8j" title="Accounts receivable, allowance for credit loss::XDX::-"><span id="xdx_90B_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_pp0p0_doxL_c20211231_zjYfB6tYQihl" title="Accounts receivable, allowance for credit loss::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0585"><span style="-sec-ix-hidden: xdx2ixbrl0587"><span style="-sec-ix-hidden: xdx2ixbrl0589">no</span></span></span></span></span></span> allowance of doubtful accounts was recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 77 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p id="xdx_844_eus-gaap--InventoryPolicyTextBlock_zroHu3uZnh9c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86E_zb5B0Zq2D3Jc">Inventories</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
consist of finished goods and are stated at the lower of cost or net realizable value using the first-in first-out method. Management
reviews inventory on hand for estimated obsolescence or unmarketable items, as compared to future demand requirements and the shelf life
of the various products. Based on the review, the Company records inventory write-downs, when necessary, when costs exceed expected net
realizable value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2022 and 2021, the Company recognized $<span id="xdx_90F_ecustom--InventriesWriteDown_pp0p0_c20220101__20221231_zkXsJJfxpgR3" title="Inventories write-down"><ix:nonFraction name="AATP:InventriesWriteDown" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,307</ix:nonFraction></span> and $<span id="xdx_902_ecustom--InventriesWriteDown_pp0p0_c20210101__20211231_zViMsjV0vVu5" title="Inventories write-down"><ix:nonFraction name="AATP:InventriesWriteDown" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">36,241</ix:nonFraction></span> inventory write-down; and $<span id="xdx_902_ecustom--InventoryWriteOff_c20220101__20221231_z1Nv38Qn2qsf" title="Inventories write off"><ix:nonFraction name="AATP:InventoryWriteOff" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142,466</ix:nonFraction></span> and $<span id="xdx_905_ecustom--InventoryWriteOff_dxL_c20210101__20211231_zGY4zxAPf0Q1" title="Inventories write off::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0599">0</span></span> inventory
write-off, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="AATP:PrepaidTaxesPolicyTextBlock"><p id="xdx_84E_ecustom--PrepaidTaxesPolicyTextBlock_z8UDeXO0uIVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_865_zJcRJJhWLRv">Prepaid
taxes</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Prepaid
taxes include prepaid income taxes that will either be refunded or utilized to offset future income tax</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="AATP:PrepaymentsAndDepositsPolicyTextBlock"><p id="xdx_841_ecustom--PrepaymentsAndDepositsPolicyTextBlock_zvFkVXX4W746" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_z2uvTEKsIbGb">Prepayments
and deposits</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepayments
and deposits are mainly cash deposited or advanced to suppliers for future inventory purchases or service providers for future
services. This amount is refundable and bears no interest. For any prepayments and deposits determined by management that such
advances will not be in receipts of inventories, services, or refundable, the Company will recognize an allowance account to reserve
such balances. Management reviews its prepayments and deposits on a regular basis to determine if the allowance is adequate, and
adjusts the allowance when necessary. Delinquent account balances are written-off against allowance for doubtful accounts after
management has determined that the likelihood of collection is not probable. The Company&#8217;s management continues to evaluate
the reasonableness of the allowance policy and update it if necessary. For the years ended December 31, 2022 and 2021, the Company
wrote-off allowance for doubtful accounts of $<span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_c20220101__20221231_zW6bV9v1bfo2" title="Wrote-off allowance for doubtful accounts"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,372</ix:nonFraction></span>
and $<span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_dxL_c20210101__20211231_zFMULrNMoPne" title="Wrote-off allowance for doubtful accounts::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0607">0</span></span>,
respectively. As of December 31, 2022 and 2021, there was $<span id="xdx_907_ecustom--AllowanceForDoubtfulAccountsReceivablesCurrent_iI_pp0p0_do_c20221231_zGvdFOudWL7c" title="Allowance for doubtful accounts"><ix:nonFraction name="AATP:AllowanceForDoubtfulAccountsReceivablesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span>
and $<span id="xdx_905_ecustom--AllowanceForDoubtfulAccountsReceivablesCurrent_iI_pp0p0_do_c20211231_zv10kvuHJ4n3" title="Allowance for doubtful accounts"><ix:nonFraction name="AATP:AllowanceForDoubtfulAccountsReceivablesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">121,514</ix:nonFraction></span>
allowance for the doubtful accounts recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zgg3hTGkHmZf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_zpVTMf0SNNfe">Property
and equipment, net</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated
useful lives of the assets with no residual value. The estimated useful lives are as follows:</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="AATP:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock"><p id="xdx_892_ecustom--ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_zxSyuQKO7vsa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zOyq8RivGFR9" style="display: none">SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT</span></span></span></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful
    Life</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    and office equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zRaLyCBNVncf" title="Estimated Useful Life of Property and Equipment"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span>-<span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zKSowKihepnf" title="Estimated Useful Life of Property and Equipment"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">7</ix:nonNumeric></span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    &amp; fixtures</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zbVjqFcoASWf" title="Estimated Useful Life of Property and Equipment"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">6</ix:nonNumeric></span>-<span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_z0vZeH6V7xCf" title="Estimated Useful Life of Property and Equipment"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">7</ix:nonNumeric></span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_ziqFH0okZyU7" title="Property and equipment, useful lives"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_LeaseholdImprovementsMember" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives">Lease
    Term</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vehicle</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zP2bWwILT46e" title="Property and equipment, estimated useful life"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_VehiclesMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span>
    years</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A4_zbgOBOvXHTH4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cost and related accumulated depreciation of assets sold or otherwise retired are eliminated from the accounts and any gain or loss is
included in the consolidated statements of income and comprehensive income. Expenditures for maintenance and repairs are charged to earnings
as incurred, while additions, renewals and betterments, which are expected to extend the useful life of assets, are capitalized. The
Company also re-evaluates the periods of depreciation to determine whether subsequent events and circumstances warrant revised estimates
of useful lives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 78 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_84D_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zBv5uUAm31Fa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zDVA3pZbA5M9">Intangible
assets, net</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="AATP:ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock"><p id="xdx_89B_ecustom--ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock_zaVytQwRId14" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets, net, are stated at cost, less accumulated amortization. Amortization expense is recognized on the straight-line basis over the
estimated useful lives of the assets as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zDzRO3Dcan" style="display: none">SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET</span></span></span></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 80%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Classification</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful
    Life</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    software</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zRsBzurNO1nc" title="Estimated useful lives of intangible assets"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">5</ix:nonNumeric></span>
    years</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A4_zLUo8k4t2rki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_84D_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zTvfaNfOGHP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_zuAN8gurejM7">Impairment
for long-lived assets</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived
assets, including property and equipment, and intangible assets with finite lives are reviewed for impairment whenever events or changes
in circumstances (such as a significant adverse change to market conditions that will impact the future use of the assets) indicate that
the carrying value of an asset may not be recoverable. The Company assesses the recoverability of the assets based on the undiscounted
future cash flows the assets are expected to generate and recognize an impairment loss when estimated undiscounted future cash flows
expected to result from the use of the asset plus net proceeds expected from disposition of the asset, if any, are less than the carrying
value of the asset. If an impairment is identified, the Company would reduce the carrying amount of the asset to its estimated fair value
based on a discounted cash flows approach or, when available and appropriate, to comparable market values. As of December 31, 2022 and
2021, <span id="xdx_90D_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20220101__20221231_zRooauhLHRQ6" title="Impairment of long-lived assets"><span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20210101__20211231_zlATP8y30Bn4" title="Impairment of long-lived assets"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" contextRef="From2022-01-01to2022-12-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" contextRef="From2021-01-012021-12-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> impairment of long-lived assets was recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:DeferredChargesPolicyTextBlock"><p id="xdx_842_eus-gaap--DeferredChargesPolicyTextBlock_zMw2aKdMtLE7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_zx7gkumGIB5b">Deferred
offering costs</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
offering costs represents costs associated with the Company&#8217;s current offering which will be netted against the proceeds from the
Company&#8217;s current offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:MarketableSecuritiesPolicy"><p id="xdx_848_eus-gaap--MarketableSecuritiesPolicy_z8aS297zZ9zi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zLchEfqtIIXg">Investment
in marketable equity securities</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company follows the provisions of ASU 2016-01, <i>Financial Instruments &#8211; Overall (Subtopic 825-10): Recognition and Measurement
of Financial Assets and Financial Liabilities</i>. Investments in marketable equity securities (non-current) are reported at fair value
with changes in fair value recognized in the Company&#8217;s consolidated statements of operations and comprehensive income (loss) in
the caption of &#8220;unrealized holding gain loss on marketable securities&#8221; in each reporting period</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="AATP:NonMarketableSecuritiesPolicyTextBlock"><p id="xdx_84F_ecustom--NonMarketableSecuritiesPolicyTextBlock_zYzL1EUXi7gk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_zhnw5Q0KKIYd">Investment
in non-marketable equity securities</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the provisions of ASU 2016-01, <i>Financial Instruments &#8211; Overall (Subtopic 825-10): Recognition and Measurement
of Financial Assets and Financial Liabilities</i>. Due to the Company&#8217;s non-marketable equity securities (non-current) does not
qualify for the practical expedient to estimate fair value in accordance with ASC 820-10-35-59, the Company has selected to record its
investments in non-marketable equity securities (non-current) at cost minus impairment, if any, plus or minus changes resulting from
observable price changes in orderly transactions for the identical or a similar investment of the same issue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
each reporting period, the Company will make a qualitative assessment considering impairment indicators to evaluate whether the investment
is impaired. The qualitative assessment indicators include, but are not limited to: (1) A significant deterioration in the earnings performance,
credit rating, asset quality, or business prospects of the investee; (ii) A significant adverse change in the regulatory, economic, or
technological environment of the investee; (iii) A significant adverse change in the general market condition of either the geographical
area or the industry in which the investee operates; (iv) A bona fide offer to purchase, an offer by the investee to sell, or a completed
auction process for the same or similar investment for an amount less than the carrying amount of that investment; and (v) Factors that
raise significant concerns about the investee&#8217;s ability to continue as a going concern, such as negative cash flows from operations,
working capital deficiencies, or noncompliance with statutory capital requirements or debt covenants. If the qualitative assessment indicators
indicated that the non-marketable equity securities (non-current) is deemed to be impaired, the Company would recognize the impairment
loss equal to the difference between the fair value of the investment and its carrying amount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 79 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p id="xdx_84D_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z3SZaMEFApKc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_869_zgCWme2SuQRb">Customer
deposits</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
deposits represent amounts advanced by customers on product orders and unapplied unexpired coupons. Customer deposits are reduced
when the related sale is recognized in accordance with the Company&#8217;s revenue recognition policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zl9XzPhLY6W4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_zL1ebv1bxSTe">Revenue
recognition</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers (ASC Topic 606). The core
principle underlying the revenue recognition of this ASU allows the Company to recognize - revenue that represents the transfer of goods
and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange.
This will require the Company to identify contractual performance obligations and determine whether revenue should be recognized at a
point in time or over time, based on when control of goods and services transfers to a customer. The Company&#8217;s revenue streams
are recognized at a point in time for the Company&#8217;s sale of health and wellness products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ASU requires the use of a new five-step model to recognize revenue from customer contracts. The five-step model requires that the Company
(i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction
price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate
the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies
the performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for a contract with a customer when the contract is committed in writing, the rights of the parties, including payment
terms, are identified, the contract has commercial substance and consideration is probable of substantially collection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sales
of Health and Wellness products</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
<i>Performance obligations satisfied at a point in time</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company derives its revenues from sales contracts with its customers with revenues being recognized when control of the health and wellness
products are transferred to its customer at the Company&#8217;s office or shipment of the goods. The revenue is recorded net of estimated
discounts and return allowances. Products are given 60 days for returns or exchanges from the date of purchase. Historically, there were
insignificant sales returns.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the Company&#8217;s network marketing business, the Company issues
product coupons to members and distributors when these customers made purchases above certain thresholds set by the Company. Depending
on the type of product coupons issued, the coupons carry varying values and can be used by the customers for reduction in the transaction
price of product purchases within the coupon validity period. The value of the product coupons issued is recorded as a reduction of the
Company&#8217;s revenue account upon issuance; the corresponding amount credited to the customer deposits account. Amounts in customer
deposits will be reversed when the coupons are used. The Company&#8217;s coupons have a validity period of between six and twelve months.
If the Company&#8217;s customers did not utilize the coupons after the validity period, the Company would recognize the forfeiture of
the originated sales value of the coupons as net revenues. For the years ended December 31, 2022 and 2021, the Company
recognized $<span id="xdx_905_ecustom--ForfeitedCouponIncome_pp0p0_c20220101__20221231_z1fGausFuaig" title="Value of coupons"><ix:nonFraction name="AATP:ForfeitedCouponIncome" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,543</ix:nonFraction></span> and $<span id="xdx_90A_ecustom--ForfeitedCouponIncome_pp0p0_c20210101__20211231_zH33eqi84eae" title="Value of coupons"><ix:nonFraction name="AATP:ForfeitedCouponIncome" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,209</ix:nonFraction></span> as forfeited coupon income, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company had contracts for the sales of health and wellness products amounting to $<span id="xdx_909_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20220101__20221231__srt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_zQlULzaPfKO" title="Cost of revenue"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2022-01-012022-12-31_custom_HealthAndWellnessServicesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,912</ix:nonFraction></span> which it is expected
to fulfill within 12 months from December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sales of products for the provision of complementary
health therapies</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Products for the provision of complementary health
therapies are predominantly Chinese herbs in different forms, processed or otherwise, for prescriptions for treating non-communicable
diseases.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 80 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Provision
of Health and Wellness services</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
<i>Performance obligations satisfied at a point in time</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company carries out its Wellness program, where the Company&#8217;s products are bundled with health screening test and a health camp
program. The health screening test and the health camp programs are considered as separate performance obligations. The promises to deliver
the health screening test report and the attendance at the health camp are separately identifiable, which are evidenced by the fact that
the Company provides separate services of delivering the health screening test report and allowing admission of the customers to attend
the health camp. The Company derives its revenues from sales contracts with its customers with revenues being recognized when the test
reports are completed and delivered to its customers during the consultation section in person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also separately derives its revenues from sales contracts with its customers with revenues being recognized when the health
camp program is completed in the final day of the health camp. For the years ended December 31, 2022 and 2021, revenues from
providing health and wellness services are $<span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220101__20221231__srt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_zC5UZ5MD7tQ" title="Revenues"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-12-31_custom_HealthAndWellnessServicesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">145,510</ix:nonFraction></span>
and $<span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210101__20211231__srt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_zOxTFwz9GRPe" title="Revenues"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-12-31_custom_HealthAndWellnessServicesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,543</ix:nonFraction></span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:DisaggregationOfRevenueTableTextBlock"><p id="xdx_899_eus-gaap--DisaggregationOfRevenueTableTextBlock_zL1STfYdysn6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disaggregated
information of revenues by products and services are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zSBL4CN1dXei" style="display: none">SCHEDULE OF DIS-AGGREGATED INFORMATION OF REVENUES</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_z21abgegsA4l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20211231_z7xtVmlVkoNi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--SurvivorSelectMember_z5LWKevPxJmd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Survivor Select</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_custom_SurvivorSelectMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,470</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-12-31_custom_SurvivorSelectMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83,904</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--EnergizedMineralConcentrateMember_zr0zkyHoLKi8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Energized Mineral Concentrate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0666">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-12-31_custom_EnergizedMineralConcentrateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,047</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--IonizedCalMagMember_zcbfX7scUGK5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Ionized Cal-Mag</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_custom_IonizedCalMagMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,219</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-12-31_custom_IonizedCalMagMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,527</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--OmegaBlendMember_zslpoCg1cIPh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Omega Blend</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_custom_OmegaBlendMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">272,332</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-12-31_custom_OmegaBlendMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">222,718</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--BetaMaxxMember_zFBHCEibRUgg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>BetaMaxx</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_custom_BetaMaxxMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">137,447</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-12-31_custom_BetaMaxxMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">208,043</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--VegeFruitFiberMember_zKD0P0DckIMb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Vege Fruit Fiber</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0678">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-12-31_custom_VegeFruitFiberMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,757</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--IronMember_zqKvQRKr7jQc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Iron</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_custom_IronMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,697</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-12-31_custom_IronMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,114</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--YoungFormulaMember_zwDXHSYIX4Rj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Young Formula</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_custom_YoungFormulaMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,403</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-12-31_custom_YoungFormulaMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,425</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--OrganicYouthCarCleansingBarMember_zhkQlF7fn2S8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Organic Youth Care Cleansing Bar</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0687">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-12-31_custom_OrganicYouthCarCleansingBarMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,137</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--ATPRMITOPlusMember_z3Dq7VueuIXa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">ATPR Mito+</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_custom_ATPRMITOPlusMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">271,493</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-12-31_custom_ATPRMITOPlusMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">183,800</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--LipomaskMember_zHMa8egFj19d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Lipomask</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0693">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-12-31_custom_LipomaskMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,331</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--EnergetiqueMember_zIfNeHxtjAlg" style="vertical-align: bottom; background-color: White">
    <td>Energetique</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_custom_EnergetiqueMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,089</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-12-31_custom_EnergetiqueMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,574</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--TrimPlusMember_zkwcgP3YRps5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Trim+</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_custom_TrimPlusMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">88,613</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-12-31_custom_TrimPlusMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,042</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--ProductHealthTherapiesMember_zCHcL6QqgpEh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Others &#8211; Products for the provision of complementary health therapies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_custom_ProductHealthTherapiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">569,823</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0703">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--OthersMember_zDHxgz4Dsps5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_custom_OthersMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,468</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0706">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zrDljTyzVArc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total revenues &#8211; products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_us-gaap_ProductMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,711,054</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-12-31_us-gaap_ProductMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,009,419</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_z2YRBKYgeNg4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Health and Wellness services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_custom_HealthAndWellnessServicesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,510</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-12-31_custom_HealthAndWellnessServicesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,543</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--Revenues_zUKQbvvSwePf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total revenues &#8211; products and services</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,856,564</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,016,962</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zE1GaDUQw54k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 81 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CostOfSalesPolicyTextBlock"><p id="xdx_843_eus-gaap--CostOfSalesPolicyTextBlock_z6hmnXy5OW45" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zskQLX6oS36d">Cost
of revenue</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Cost
of revenue comprised freight-in, the purchase cost of manufactured goods for sale to customers </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
products for the provision of complementary health therapies. <span style="background-color: white">Cost of revenue amounted to $<span id="xdx_90A_eus-gaap--CostOfGoodsAndServicesSold_c20220101__20221231_zJWOrBaL3rZb" title="Cost of revenue"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">666,042</ix:nonFraction></span>
(including inventory write-downs of $<span id="xdx_903_ecustom--InventriesWriteDown_pp0p0_c20220101__20221231_zRagiINTU2v3" title="Inventories write-down"><ix:nonFraction name="AATP:InventriesWriteDown" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,307</ix:nonFraction></span> and inventory written-off of $<span id="xdx_90A_ecustom--InventoryWriteOff_c20220101__20221231_zfIQAT5Y3WE9" title="Inventories write off"><ix:nonFraction name="AATP:InventoryWriteOff" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142,466</ix:nonFraction></span>) and $<span id="xdx_901_eus-gaap--CostOfGoodsAndServicesSold_c20210101__20211231_zy3tBqIOa1G8" title="Cost of revenue"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">297,333</ix:nonFraction></span> (including inventory write-downs of $<span id="xdx_906_ecustom--InventriesWriteDown_pp0p0_c20210101__20211231_zB1oBXGY34X2" title="Inventories write-down"><ix:nonFraction name="AATP:InventriesWriteDown" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">36,241</ix:nonFraction></span>)
for the years ended December 31, 2022 and 2021, respectively</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="AATP:ShippingAndHandlingPolicyTextBlock"><p id="xdx_845_ecustom--ShippingAndHandlingPolicyTextBlock_zvpO8NKxWZUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_865_z0aGmeBeTpgc">Shipping
and handling</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shipping
and handling charges amounted to $<span id="xdx_90C_eus-gaap--SellingExpense_pp0p0_c20220101__20221231__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_z6kvkMl8C7zf" title="Selling expenses"><ix:nonFraction name="us-gaap:SellingExpense" contextRef="From2022-01-012022-12-31_us-gaap_ShippingAndHandlingMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,585</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--SellingExpense_pp0p0_c20210101__20211231__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zlMEsfQKQ5A9" title="Selling expenses"><ix:nonFraction name="us-gaap:SellingExpense" contextRef="From2021-01-012021-12-31_us-gaap_ShippingAndHandlingMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,054</ix:nonFraction></span> for the years ended December 31, 2022 and 2021, respectively. Shipping and handling
charges are expensed as incurred and included in selling expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:AdvertisingCostsPolicyTextBlock"><p id="xdx_84B_eus-gaap--AdvertisingCostsPolicyTextBlock_zPT6muVeN732" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_z7Es73GdWP47">Advertising
costs</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising
costs amounted to $<span id="xdx_90F_eus-gaap--AdvertisingExpense_pp0p0_c20220101__20221231_zYDnt2NU8M2f" title="Advertising costs"><ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,688</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--AdvertisingExpense_pp0p0_c20210101__20211231_zuP4dGeRsy0c" title="Advertising costs"><ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,218</ix:nonFraction></span> for the years ended December 31, 2022 and 2021, respectively. Advertising costs are expensed as
incurred and included in selling expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CommissionsExpensePolicyPolicyTextBlock"><p id="xdx_84F_eus-gaap--CommissionsExpensePolicyPolicyTextBlock_z9Mv3yTzzq3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86C_zZMSQOUlDMA2">Commission
expenses</span> </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
expenses are the Company&#8217;s most significant expenses. As with all companies in the network marketing industry, the Company&#8217;s
sales channel is external to the Company. The Company&#8217;s &#8220;external sales force&#8221; is stratified into two levels based
on priority recruitment. First, there are sales distributors. Second, all members recruited by a sales distributor, directly or indirectly,
are referred to as &#8220;sales network members&#8221;. The Company pays commission to every sales distributor based on purchases made
by its sales network members which includes the independent direct sales members. Top performing distributors with their own physical
stores may also become stockists of the Company, whereby they enjoy benefits such as maintaining a certain amount of the Company&#8217;s
inventory on their store premises. The stockists shall account to the Company for all products sales from their store premises as monitored
through the Company&#8217;s centralized stock tracking system. The Company pays a separate commission to stockists based on revenue generated
from the stockists&#8217; physical stores. Commission expenses amounted to $<span id="xdx_90B_eus-gaap--SalesCommissionsAndFees_pp0p0_c20220101__20221231_zX3h03VVO6v1" title="Commission expenses"><ix:nonFraction name="us-gaap:SalesCommissionsAndFees" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">405,351</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--SalesCommissionsAndFees_pp0p0_c20210101__20211231_zp2dghig06Jl" title="Commission expenses"><ix:nonFraction name="us-gaap:SalesCommissionsAndFees" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">316,267</ix:nonFraction></span> for the years ended December 31, 2022
and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="AATP:DefinedContributionPlanPolicyTextBlock"><p id="xdx_84A_ecustom--DefinedContributionPlanPolicyTextBlock_zzTqGCuRJEU3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration: underline"><span id="xdx_862_z5HFBg68sykk">Defined
contribution plan</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
full-time employees of the Company are entitled to the government mandated defined contribution plan. The Company is required to accrue
and pay for these benefits based on certain percentages of the employees&#8217; respective salaries, subject to certain ceilings, in
accordance with the relevant government regulations, and make cash contributions to the government mandated defined contribution plan</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Total expenses for the plans were $<span id="xdx_906_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pp0p0_c20220101__20221231_zVicH7EgFDLa" title="Defined contribution plan expense"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">133,489</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pp0p0_c20210101__20211231_zfGWX5OFpjta" title="Defined contribution plan expense"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">99,488</ix:nonFraction></span> for the years ended December 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
related contribution plans include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Social
    Security Organization (&#8220;SOSCO&#8221;) &#8211; <span id="xdx_90A_ecustom--SalaryPercentage_pid_dp_c20220101__20221231__dei--LegalEntityAxis__custom--SocialSecurityOrganizationMember_zBxcFz5qfd16" title="Salary percentage"><ix:nonFraction name="AATP:SalaryPercentage" contextRef="From2022-01-012022-12-31_custom_SocialSecurityOrganizationMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.75</ix:nonFraction></span>% based on employee&#8217;s monthly salary capped of RM <span id="xdx_90E_ecustom--MonthlySalary_uRM_c20220101__20221231__dei--LegalEntityAxis__custom--SocialSecurityOrganizationMember_zF3FRUewo47b" title="Monthly salary"><ix:nonFraction name="AATP:MonthlySalary" contextRef="From2022-01-012022-12-31_custom_SocialSecurityOrganizationMember" format="ixt:numdotdecimal" decimals="0" unitRef="RM">5,000</ix:nonFraction></span>;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employees
    Provident Fund (&#8220;EPF&#8221;) &#8211;based on employee&#8217;s monthly salary, <span id="xdx_90D_ecustom--SalaryPercentage_pid_dp_c20220101__20221231__dei--LegalEntityAxis__custom--EmployeesProvidentFundMember__srt--RangeAxis__srt--MinimumMember_zQriZXqhOcEf" title="Salary percentage"><ix:nonFraction name="AATP:SalaryPercentage" contextRef="From2022-01-012022-12-31_custom_EmployeesProvidentFundMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">13</ix:nonFraction></span>% for employee earning RM<span id="xdx_90E_ecustom--MonthlySalary_uRM_c20220101__20221231__dei--LegalEntityAxis__custom--EmployeesProvidentFundMember__srt--RangeAxis__srt--MinimumMember_zhjGzhzfJlAc" title="Monthly salary"><ix:nonFraction name="AATP:MonthlySalary" contextRef="From2022-01-012022-12-31_custom_EmployeesProvidentFundMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" unitRef="RM">5,000</ix:nonFraction></span> and below; and
    <span id="xdx_90E_ecustom--SalaryPercentage_pid_dp_c20220101__20221231__dei--LegalEntityAxis__custom--EmployeesProvidentFundMember__srt--RangeAxis__srt--MinimumMember__srt--RangeAxis__srt--MaximumMember_z2esrfOwXpSb" title="Salary percentage"><ix:nonFraction name="AATP:SalaryPercentage" contextRef="From2022-01-012022-12-31_custom_EmployeesProvidentFundMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>% for employee earning RM<span id="xdx_906_ecustom--MonthlySalary_uRM_c20220101__20221231__dei--LegalEntityAxis__custom--EmployeesProvidentFundMember__srt--RangeAxis__srt--MaximumMember_zWZBWgz0MTwk" title="Monthly salary"><ix:nonFraction name="AATP:MonthlySalary" contextRef="From2022-01-012022-12-31_custom_EmployeesProvidentFundMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" unitRef="RM">5,001</ix:nonFraction></span> and above.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment
    Insurance System (&#8220;EIS&#8221;) &#8211; <span id="xdx_90C_ecustom--SalaryPercentage_pid_dp_c20220101__20221231__dei--LegalEntityAxis__custom--EmploymentInsuranceSystemMember_zRHbOFUNH1f1" title="Salary percentage"><ix:nonFraction name="AATP:SalaryPercentage" contextRef="From2022-01-012022-12-31_custom_EmploymentInsuranceSystemMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.2</ix:nonFraction></span>% based on employee&#8217;s monthly salary capped of RM <span id="xdx_90E_ecustom--MonthlySalary_uRM_c20220101__20221231__dei--LegalEntityAxis__custom--EmploymentInsuranceSystemMember_ztc1arIXPmgb" title="Monthly salary"><ix:nonFraction name="AATP:MonthlySalary" contextRef="From2022-01-012022-12-31_custom_EmploymentInsuranceSystemMember" format="ixt:numdotdecimal" decimals="0" unitRef="RM">5,000</ix:nonFraction></span>;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
    Resource Development Fund (&#8220;HRDF&#8221;) &#8211; <span id="xdx_907_ecustom--SalaryPercentage_pid_dp_c20220101__20221231__dei--LegalEntityAxis__custom--HumanResourceDevelopmentFundMember_zZfEeTcMmTd6" title="Salary percentage"><ix:nonFraction name="AATP:SalaryPercentage" contextRef="From2022-01-012022-12-31_custom_HumanResourceDevelopmentFundMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction></span>% based on employee&#8217;s monthly salary</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 82 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zZdZiC8AkEH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_zCkcAvFtpGea">Income
taxes</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes in accordance with U.S. GAAP for income taxes. The charge for taxation is based on the results for
the fiscal year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted
or substantively enacted by the balance sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
taxes is accounted for using the asset and liability method in respect of temporary differences arising from differences between the
carrying amount of assets and liabilities in the consolidated financial statements and the corresponding tax basis used in the computation
of assessable tax profit. In principle, deferred tax liabilities are recognized for all taxable temporary differences. Deferred tax assets
are recognized to the extent that it is probable that taxable profit will be available against which deductible temporary differences
can be utilized. Deferred tax is calculated using tax rates that are expected to apply to the period when the asset is realized or the
liability is settled. Deferred tax is charged or credited in the income statement, except when it is related to items credited or charged
directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets are reduced by a valuation allowance
when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.
Current income taxes are provided for in accordance with the laws of the relevant taxing authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
uncertain tax position is recognized as a benefit only if it is &#8220;more likely than not&#8221; that the tax position would be sustained
in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that
is <span id="xdx_90F_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20220101__20221231_zridEaAy3q5d" title="Income tax description"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement">greater than 50%</ix:nonNumeric></span> likely of being realized on examination. For tax positions not meeting the &#8220;more likely than not&#8221; test,
no tax benefit is recorded. $<span id="xdx_905_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_pp0p0_c20220101__20221231_zPKdG0hn2bma" title="Income tax examination, penalties and interest expense"><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_pp0p0_c20210101__20211231_zSFYTL7JYgi1" title="Income tax examination, penalties and interest expense"><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">395</ix:nonFraction></span> penalties and interest incurred related to underpayment of income tax for the years ended December
31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company conducts much of its business activities in Hong Kong and Malaysia and is subject to tax in each of their jurisdictions. As a
result of its business activities, the Company will file separate tax returns that are subject to examination by the foreign tax authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p id="xdx_841_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zAIQ7gf36Ghj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_868_zwYFtkBQLvFa">Comprehensive
income (loss)</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
income (loss) consists of two components, net income (loss) and other comprehensive income (loss). Net income (loss) refers to revenue,
expenses, gains and losses that under GAAP are recorded as an element of stockholders&#8217; equity but are excluded from net income.
Other comprehensive income (loss) consists of a foreign currency translation adjustment resulting from the Company not using the U.S.
dollar as its functional currencies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="AATP:NoncontrollingInterestPolicyTextBlock"><p id="xdx_848_ecustom--NoncontrollingInterestPolicyTextBlock_zUmxJoS2Nq6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_z3pSSXQCI64h">Non-controlling
interest</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--MinorityInterestDescription_c20220101__20221231_z3bBup5MmeXk" title="Noncontrolling interest, description"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="us-gaap:MinorityInterestDescription">Non-controlling
interest consists of 40% of the equity interests of DSY Wellness held by an individual and approximately 0.01% (2 ordinary shares out
of 9,590,598 shares) of the equity interests of ASL held by two individuals</ix:nonNumeric></span>. The non-controlling interests are presented in the consolidated
balance sheets, separately from equity attributable to the shareholders of the Company. Non-controlling interests in the results of the
Company are presented on the face of the consolidated statements of operations as an allocation of the total income or loss for the periods
between non-controlling interest holders and the shareholders of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 83 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zYeCXifgtjIc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_z17u0oqw1S65">Earnings
(loss) per share</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company computes earnings (loss) per share (&#8220;EPS&#8221;) in accordance with ASC 260, &#8220;Earnings per Share&#8221;. ASC 260
requires companies to present basic and diluted EPS. Basic EPS is measured as net income divided by the weighted average ordinary share
outstanding for the period. Diluted EPS presents the dilutive effect on a per share basis of the potential ordinary shares (e.g., convertible
securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later.
Potential ordinary shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are
excluded from the calculation of diluted EPS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. For the
years ended December 31, 2022 and 2021, there were <span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20220101__20221231_zZU9VYbmnxme" title="Potentially dilutive securities outstanding"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20210101__20211231_zTFE6S4QfcGg" title="Potentially dilutive securities outstanding"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-01to2022-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> dilutive shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zpmvue0RnR04" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86F_zeX8FIyxsbb9">Foreign
currencies translation and transaction</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing
at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated
into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded
in the consolidated statements of operations and comprehensive income (loss).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reporting currency of the Company is United States Dollars (&#8220;US$&#8221;) and the accompanying financial statements have been expressed
in US$. The Company&#8217;s subsidiary in Labuan maintains its books and record in United States Dollars (&#8220;US$&#8221;) albeit its
functional currency being the primary currency of the economic environment in which the entity operates, which is the Malaysian Ringgit
(&#8220;MYR&#8221; or &#8220;RM&#8221;). The Company&#8217;s subsidiary in Hong Kong maintains its books and record in Hong Kong Dollars
(&#8220;HK$&#8221;), similar to its functional currency. The Company&#8217;s subsidiary and VIE in Malaysia conducts its businesses and
maintains its books and record in the local currency, Malaysian Ringgit (&#8220;MYR&#8221; or &#8220;RM&#8221;), as its functional currency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into
US$, in accordance with ASC Topic 830-30, &#8220;<i>Translation of Financial Statement&#8221;</i>, using the exchange rate on the balance
sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation
of financial statements of foreign subsidiary are recorded as a separate component of accumulated other comprehensive income within the
statements of stockholders&#8217; equity. Cash flows are also translated at average translation rates for the periods, therefore, amounts
reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance
sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_zTYA4P9FOinb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Translation
of foreign currencies into US$1 have been made at the following exchange rates for the respective periods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zdv4I7CXhGol" style="display: none">SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zgy5lSiaUnqg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20211231_zsVB6e9RZDpg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hus-gaap--VariableRateAxis__custom--PeriodEndMYRMember_zFRhCxqqi3Eh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Period-end MYR : US$1 exchange rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextRef="AsOf2022-12-31_custom_PeriodEndMYRMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.41</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextRef="AsOf2021-12-31_custom_PeriodEndMYRMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.18</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hus-gaap--VariableRateAxis__custom--PeriodEndHKDMember_zLYf4zb3Voe5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Period-end HKD : US$1 exchange rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextRef="AsOf2022-12-31_custom_PeriodEndHKDMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">7.80</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextRef="AsOf2021-12-31_custom_PeriodEndHKDMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">7.80</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hus-gaap--VariableRateAxis__custom--PeriodEndHKDMember_ziM6JpnK0o6" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign currency exchange
    rate, translation</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextRef="AsOf2022-12-31_custom_PeriodEndHKDMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">7.80</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextRef="AsOf2021-12-31_custom_PeriodEndHKDMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">7.80</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20220101__20221231_zu9ykfzTy0w3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20210101__20211231_zaKDMyylVgMj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_405_ecustom--ForeignCurrencyExchangeRateAverage_hus-gaap--VariableRateAxis__custom--PeriodAverageMYRMember_zqsIpHu1yyE" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Period-average MYR : US$1 exchange rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="AATP:ForeignCurrencyExchangeRateAverage" contextRef="From2022-01-012022-12-31_custom_PeriodAverageMYRMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.41</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="AATP:ForeignCurrencyExchangeRateAverage" contextRef="From2021-01-012021-12-31_custom_PeriodAverageMYRMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.14</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ForeignCurrencyExchangeRateAverage_hus-gaap--VariableRateAxis__custom--PeriodAverageHKDMember_zecoVeo3Tg3a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Period-average HKD : US$1 exchange rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AATP:ForeignCurrencyExchangeRateAverage" contextRef="From2022-01-012022-12-31_custom_PeriodAverageHKDMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">7.83</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AATP:ForeignCurrencyExchangeRateAverage" contextRef="From2021-01-012021-12-31_custom_PeriodAverageHKDMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">7.77</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ForeignCurrencyExchangeRateAverage_hus-gaap--VariableRateAxis__custom--PeriodAverageHKDMember_zCDRKLJohb0b" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign currency exchange
    rate period average</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AATP:ForeignCurrencyExchangeRateAverage" contextRef="From2022-01-012022-12-31_custom_PeriodAverageHKDMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">7.83</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AATP:ForeignCurrencyExchangeRateAverage" contextRef="From2021-01-012021-12-31_custom_PeriodAverageHKDMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">7.77</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zR6kyPJj6KLc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 84 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="AATP:RelatedPartiesPolicyTextBlock"><p id="xdx_840_ecustom--RelatedPartiesPolicyTextBlock_zI7d5N4JYGed" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zRTbziKHfAwb">Related
parties</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parties,
which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control
the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also
considered to be related if they are subject to common control or common significant influence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_844_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zE82vognobm5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_864_zepRYIYYprik">Fair
value of financial instruments</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting standard regarding fair value of financial instruments and related fair value measurements defines financial instruments and
requires disclosure of the fair value of financial instruments held by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting standards define fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance
disclosure requirements for fair value measures. The three levels are defined as follow:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that
    are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 inputs to the valuation methodology are unobservable and significant to the fair value.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments included in current assets and current liabilities are reported in the consolidated balance sheets at face value or cost,
which approximate fair value because of the short period of time between the origination of such instruments and their expected realization
and their current market rates of interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_84F_eus-gaap--LesseeLeasesPolicyTextBlock_z3UFyt6sece6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_zibQIkWeu1wg">Leases</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted ASU 2016-02, &#8220;Leases&#8221; (Topic 842), and elected the practical expedients that does not require the Company
to reassess: (1) whether any expired or existing contracts are, or contain, leases, (2) lease classification for any expired or existing
leases and (3) initial direct costs for any expired or existing leases. For lease terms of twelve months or fewer, a lessee is permitted
to make an accounting policy election not to recognize lease assets and liabilities. The Company also adopts the practical expedient
that allows lessees to treat the lease and non-lease components of a lease as a single lease component. Some of the Company&#8217;s leases
include one or more options to renew, which is typically at the Company&#8217;s sole discretion. The Company regularly evaluates the
renewal options, and, when it is reasonably certain of exercise, it will include the renewal period in its lease term. New lease modifications
result in re-measurement of the right of use (&#8220;ROU&#8221;) assets and lease liabilities. Operating ROU assets and lease liabilities
are recognized at the commencement date, based on the present value of lease payments over the lease term. Since the implicit rate for
the Company&#8217;s leases is not readily determinable, the Company use its incremental borrowing rate based on the information available
at the commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that
the Company would have to pay to borrow, on a collateralized basis, an amount equal to the lease payments, in a similar economic environment
and over a similar term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 85 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
terms used to calculate the present value of lease payments generally do not include any options to extend, renew, or terminate the lease,
as the Company does not have reasonable certainty at lease inception that these options will be exercised. The Company generally considers
the economic life of its operating lease ROU assets to be comparable to the useful life of similar owned assets. The Company has elected
the short-term lease exception, therefore operating lease ROU assets and liabilities do not include leases with a lease term of twelve
months or less. Its leases generally do not provide a residual guarantee. The operating lease ROU asset also excludes lease incentives.
Lease expense is recognized on a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews the impairment of its ROU assets consistent with the approach applied for its other long-lived assets. The Company reviews
the recoverability of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the
asset may not be recoverable. The assessment of possible impairment is based on its ability to recover the carrying value of the asset
from the expected undiscounted future pre-tax cash flows of the related operations. The Company has elected to include the carrying amount
of operating lease liabilities in any tested asset group and includes the associated operating lease payments in the undiscounted future
pre-tax cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zOEqo9L2pkTk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86C_zkQqYFp7vst4">Recent
accounting pronouncements</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has reviewed all recently issued, but not yet effective, considers the applicability and impact of all accounting standards updates
(&#8220;ASUs&#8221;). Management periodically reviews new accounting standards that are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2019, the FASB issued ASU No. 2019-10, which to update the effective date of ASU No. 2016-13 for private companies, not-for-profit
organizations and certain smaller reporting companies applying for credit losses, leases, and hedging standard. The new effective date
for these preparers is for fiscal years beginning after December 15, 2022. ASU 2019-05 is effective for the Company for annual and interim
reporting periods beginning January 1, 2023 as the Company is qualified as a smaller reporting company. The Company is currently evaluating
the impact ASUs 2016-13 and 2019-05 may have on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for the above-mentioned pronouncements, there are no new recent issued accounting standards that will have a material impact on the consolidated
financial position, statements of operations and cash flows.</span></p>

</ix:nonNumeric><p id="xdx_85D_zpd7CU8LeYd4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:VariableInterestEntityDisclosureTextBlock"><p id="xdx_802_eus-gaap--VariableInterestEntityDisclosureTextBlock_zFRxQR1FO7hi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
<span id="xdx_824_zj2d1J3GbxTf">VARIABLE INTEREST ENTITY (&#8220;VIE&#8221;)</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEA
is a trading company incorporated on March 4, 2004, under the laws of Malaysia. SEA provided majority of ASL&#8217;s purchases. Its equity
at risk was insufficient to finance its activities and <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_zBAHgxlBLbg4" title="Ownership interest percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-31_custom_SubsidiaryCompanyThreeMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of its business is transacted with ASL. Therefore, it was considered to be
a VIE and ASL is the primary beneficiary since it has both of the following characteristics:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
    power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
    obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the
    VIE that could potentially be significant to the VIE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
the accounts of SEA is consolidated in the accompanying financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 86 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
VARIABLE INTEREST ENTITY (&#8220;VIE&#8221;) (CONT&#8217;D)</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfVariableInterestEntitiesTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfVariableInterestEntitiesTextBlock_zNdRAR4wzbY5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amount of the VIE&#8217;s assets and liabilities were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zQFexFWDKz4c" style="display: none">SCHEDULE OF VARIABLE INTEREST ENTITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_49A_20221231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_z5lVlw6Fn3tc" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_493_20211231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zI4DBiW68nWg" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsCurrent_iI_zUmQYchAUCB5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Current assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31_us-gaap_VariableIncomeInterestRateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,350</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31_us-gaap_VariableIncomeInterestRateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,850</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesCurrent_iNI_di_zZSjd8BHuSs8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31_us-gaap_VariableIncomeInterestRateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,512</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-12-31_us-gaap_VariableIncomeInterestRateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,272</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--StockholdersEquity_iI_z24RgFPig1Bj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deficit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_VariableIncomeInterestRateMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">40,162</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_VariableIncomeInterestRateMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">32,422</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20221231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zIZ5onYFsdw1" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20211231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zEYYv5IBQbTb" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_ztcWNesxOZqa" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31_us-gaap_VariableIncomeInterestRateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,609</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31_us-gaap_VariableIncomeInterestRateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,493</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidTaxes_iI_z00YJcaIpYid" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Prepaid taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidTaxes" contextRef="AsOf2022-12-31_us-gaap_VariableIncomeInterestRateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,741</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidTaxes" contextRef="AsOf2021-12-31_us-gaap_VariableIncomeInterestRateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,357</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsCurrent_iI_zUgacGYqQEni" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31_us-gaap_VariableIncomeInterestRateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,350</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31_us-gaap_VariableIncomeInterestRateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,850</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iI_zSSpL7fZ4Wy3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts payable &#8211; intercompany</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31_us-gaap_VariableIncomeInterestRateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,422</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31_us-gaap_VariableIncomeInterestRateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,724</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--OtherPayablesRelatedPartyCurrent_iI_zCiPzH9XUjbi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other payables and accrued liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="AATP:OtherPayablesRelatedPartyCurrent" contextRef="AsOf2022-12-31_us-gaap_VariableIncomeInterestRateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,090</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="AATP:OtherPayablesRelatedPartyCurrent" contextRef="AsOf2021-12-31_us-gaap_VariableIncomeInterestRateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,548</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesCurrent_iI_zRheyKpvRmF7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31_us-gaap_VariableIncomeInterestRateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,512</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-12-31_us-gaap_VariableIncomeInterestRateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,272</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockholdersEquity_iI_zKO7drUZdXNc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deficit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_VariableIncomeInterestRateMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">40,162</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_VariableIncomeInterestRateMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">32,422</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
summarized operating results of the VIE&#8217;s are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_49D_20220101__20221231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zxKoIUlQxhh4" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_495_20210101__20211231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_z0QiRSbSOepl" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_z2Fz4S6CfAZ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 2.5pt">Operating revenues</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0857">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0858">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--GrossProfit_zkzi7RwfRXOj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Gross profit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0860">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0861">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingIncomeLoss_ztX6z0oXxJq4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Loss from operations</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_VariableIncomeInterestRateMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,432</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_VariableIncomeInterestRateMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,966</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLoss_zV42ojDKQhxc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_VariableIncomeInterestRateMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,432</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_VariableIncomeInterestRateMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">27,966</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zHMnheaZyNnd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock"><p id="xdx_80C_eus-gaap--CashAndCashEquivalentsDisclosureTextBlock_zujFwGP2qic1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
<span id="xdx_821_z5dqFc3yMcj7">CASH AND CASH EQUIVALENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
of December 31, 2022 and 2021 the Company had $<span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20221231_zoEHWX9rirq" title="Cash and cash equivalents"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,438,430</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20211231_zVjM6SiekJTc" title="Cash and cash equivalents"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,597,848</ix:nonFraction></span>, respectively, of cash and cash equivalents, which consisted of
$<span id="xdx_90B_eus-gaap--Cash_iI_pp0p0_c20221231_z71GEdb78pQ8" title="Cash in bank"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">513,152</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--Cash_iI_pp0p0_c20211231_zDOvVNzzIluj" title="Cash in bank"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">554,864</ix:nonFraction></span>, respectively, of cash in banks and </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90A_eus-gaap--TimeDeposits_iI_pp0p0_c20221231_zW7yV59dKgF2" title="Time deposits"><ix:nonFraction name="us-gaap:TimeDeposits" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">914,811</ix:nonFraction></span>
<span style="background-color: white">and $</span><span id="xdx_90B_eus-gaap--TimeDeposits_iI_pp0p0_c20211231_zYIsVeV1EV43" title="Time deposits"><ix:nonFraction name="us-gaap:TimeDeposits" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,975,347</ix:nonFraction></span><span style="background-color: white">, respectively, of time deposits placed
with banks or other financial institutions and are all highly liquid investments with an original maturity of three months or less. The
effective interest rate for the time deposits ranges between <span id="xdx_90E_eus-gaap--PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits_iI_pid_dp_uPure_c20221231__srt--RangeAxis__srt--MinimumMember_zR1NmRU1EC6l" title="Percentage of Interest rate for time deposits"><ix:nonFraction name="us-gaap:PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits" contextRef="AsOf2022-12-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.10</ix:nonFraction></span>% to <span id="xdx_902_eus-gaap--PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits_iI_pid_dp_uPure_c20221231__srt--RangeAxis__srt--MaximumMember_zMZ80BAaKbdj" title="Percentage of Interest rate for time deposits"><ix:nonFraction name="us-gaap:PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits" contextRef="AsOf2022-12-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.88</ix:nonFraction></span>% per annum. As of December 31, 2022 and 2021, $<span id="xdx_90D_eus-gaap--TimeDepositLiabilityUninsured_iI_c20221231_zJ1saXAIpPp3" title="Time deposit uninsured"><ix:nonFraction name="us-gaap:TimeDepositLiabilityUninsured" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">231,187</ix:nonFraction></span> and
$<span id="xdx_90C_eus-gaap--TimeDepositLiabilityUninsured_iI_c20211231_zbUkhuYIUSC4" title="Time deposit uninsured"><ix:nonFraction name="us-gaap:TimeDepositLiabilityUninsured" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,761</ix:nonFraction></span> of these balances are not covered by deposit insurance, respectively.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 87 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"><p id="xdx_800_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_z5Q2QJxfsYv4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>5.
<span id="xdx_82E_zelRnHFzaVRk">ACCOUNTS RECEIVABLE </span></b></span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zovZssHaUBh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span id="xdx_8B8_z2Lb6cEO3jPb" style="display: none">SCHEDULE OF ACCOUNTS RECEIVABLES - RELATED PARTY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_498_20221231_zhuxswMdXScl" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_49A_20211231_z4sPQYFIQRLk" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccountsReceivableGrossCurrent_iI_pp0p0_maARAARzRRC_zWvEKK9iCda2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Accounts receivable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableGrossCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,826</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0896">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_pp0p0_msARAARzRRC_zGbqLTZYDSq7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0898">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0899">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsReceivableNetCurrent_iTI_pp0p0_mtARAARzRRC_zbtUjgGqE52" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,826</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0902">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zGmGdYx9q2ai" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:InventoryDisclosureTextBlock"><p id="xdx_808_eus-gaap--InventoryDisclosureTextBlock_zr9utPAPg9zl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
<span id="xdx_82B_z3iOu7BmGgsd">INVENTORIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zotCKPgQXxv4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zU8B3QydgPDg" style="display: none">SCHEDULE OF INVENTORIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td id="xdx_49A_20221231_zBaRxb2sOesg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td id="xdx_49E_20211231_zRW16l6SN7Ne" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; width: 64%; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; width: 2%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 14%; font-weight: bold; text-align: center">2022</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 2%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 14%; font-weight: bold; text-align: center">2021</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InventoryFinishedGoods_iI_zyTB0EwcnZd5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Finished goods</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,277</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">375,535</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zEjWgesrU6ha" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2022 and 2021, the Company recognized $<span id="xdx_907_ecustom--InventriesWriteDown_c20220101__20221231_z7U9hW7hyrbl" title="Inventory write-down"><ix:nonFraction name="AATP:InventriesWriteDown" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,307</ix:nonFraction></span> and $<span id="xdx_90A_ecustom--InventriesWriteDown_c20210101__20211231_zViZNDF5OAfg" title="Inventory write-down"><ix:nonFraction name="AATP:InventriesWriteDown" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,241</ix:nonFraction></span> inventory write-down; and $<span id="xdx_907_ecustom--InventoryWriteOff_pp0p0_c20220101__20221231_zsc1Be2WkdCl" title="Inventory write-off"><ix:nonFraction name="AATP:InventoryWriteOff" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">142,466</ix:nonFraction></span> and $<span id="xdx_907_ecustom--InventoryWriteOff_pp0p0_dxL_c20210101__20211231_zarA66562s99" title="Inventory write- off::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0917">0</span></span> inventory
write-off, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="AATP:PrepaymentsAndDepositsTextBlock"><p id="xdx_80E_ecustom--PrepaymentsAndDepositsTextBlock_zL7cdHSwwqG2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>7.
<span id="xdx_82B_zwdyY1bfdqs3">PREPAYMENTS AND DEPOSITS</span></b></span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"><p id="xdx_89F_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zjdtaEGFgsBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_z5pL7RUdAnWe" style="display: none">SCHEDULE OF PREPAID EXPENSES AND DEPOSITS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_49F_20221231_zR4XRYcqQTfj" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_498_20211231_znAMLzPN5TLh" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ReceivablesFromSalesDistributors_iI_maCzFPV_zCUi5vUgbfJh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Receivables from sales distributors</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="AATP:ReceivablesFromSalesDistributors" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,596</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="AATP:ReceivablesFromSalesDistributors" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">115,379</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DepositsToSupplier_iI_maCzFPV_zi1WAsQlc8J2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Deposits to suppliers</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="AATP:DepositsToSupplier" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">147,504</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="AATP:DepositsToSupplier" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">301,233</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--PrepaidExpensesGross_iTI_maCzxAt_mtCzFPV_zx851PNPzPR4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AATP:PrepaidExpensesGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">191,100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AATP:PrepaidExpensesGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">416,612</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iNI_di_msCzxAt_ztK47EHkLdij" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Provision for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0932">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,095</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtCzxAt_zh5aznB2iZWf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">191,100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,517</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_z4IuqImDPMVa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock"><p id="xdx_89D_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zRnLg89Y2iH2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Movements
of allowance for doubtful accounts are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zIuXxCkXFkB3" style="display: none">SCHEDULE OF CHANGES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_499_20220101__20221231_zIMzlTah3pX8" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_494_20210101__20211231_zjYgUiIl1ba1" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_z8IiVjZTcvd4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Beginning balance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,095</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0941">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_zjRhyxAeJhv8" style="vertical-align: bottom; background-color: White">
    <td>Addition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0943">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,514</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_di_zhkfGqoOLAC9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Write off</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,372</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0947">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AllowanceForDoubtfulAccountsReceivableExchangeRateEffect_zkAodHvfNy97" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange rate effect</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="AATP:AllowanceForDoubtfulAccountsReceivableExchangeRateEffect" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">723</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="AATP:AllowanceForDoubtfulAccountsReceivableExchangeRateEffect" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">419</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_zXdLcLP2wUDh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0952">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,095</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zSoJ7RFXnWj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 88 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_802_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zrLPbDAFgTHk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
<span id="xdx_820_ztxby9rdsA99">PROPERTY AND EQUIPMENT, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_89D_eus-gaap--PropertyPlantAndEquipmentTextBlock_zmRWPBeyI347" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment, net consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B0_zJYY8Y96jaqi" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT, NET</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_490_20221231_zmnDw4egigNj" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_494_20211231_zGSBwYf9jRr2" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerAndOfficeEquipmentMember_zJTZVLonUMl7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Computer and office equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_custom_ComputerAndOfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,428</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_custom_ComputerAndOfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,298</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zT3bDv62yQu" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture &amp; fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">115,789</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,185</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z7Y6kVTFQ22b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">191,965</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">202,570</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--VehicleMember_zP6q3kqDHDz3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Vehicle</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_custom_VehicleMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,535</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_custom_VehicleMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,702</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENz5ZB_zuXLsaldfBp1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">488,717</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">505,755</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENz5ZB_zNaotftUy1eb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">346,568</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">289,956</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz5ZB_zrGBUIeqXFsg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142,149</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">215,799</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zD5zv4BXkAT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense for the years ended December 31, 2022 and 2021 amounted to $<span id="xdx_90F_eus-gaap--Depreciation_pp0p0_c20220101__20221231_zM1cQJCYtDqb" title="Depreciation"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">71,754</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--Depreciation_pp0p0_c20210101__20211231_zo7fj0jzidFd" title="Depreciation"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">75,797</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p id="xdx_804_eus-gaap--IntangibleAssetsDisclosureTextBlock_zOgdM8JyWVQ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
<span id="xdx_824_zz8jNBrDFqp3">INTANGIBLE ASSETS, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zm6UnzTggnt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets, net, consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B7_zKqIDuKePe73" style="display: none">SCHEDULE OF INTANGIBLE ASSETS, NET</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_493_20221231_zd7VedRq0D5k" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_493_20211231_zZxbckCQ0w9a" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CapitalizedComputerSoftwareGross_iI_maCzFod_zrusbEBApco5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Computer software</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,348</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,453</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msCzFod_z66goRzTWTG3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,304</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,793</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtCzFod_z4FectFsIhM8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,044</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,660</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zB0qHIgrTsH7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
expense for the years ended December 31, 2022 and 2021 amounted to $<span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20220101__20221231_zIgF3JYdbu8e" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,122</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20210101__20211231_zqKFeWR6wLd" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,961</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="AATP:InvestmentInMarketableSecuritiesTextBlock"><p id="xdx_807_ecustom--InvestmentInMarketableSecuritiesTextBlock_z0A1AgtbWSb9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
<span id="xdx_825_zQvuOqi8GWOf">INVESTMENT IN MARKETABLE SECURITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    May 17, 2018, the Company purchased <span id="xdx_90F_eus-gaap--InvestmentOwnedBalanceShares_iI_c20180517__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zm3gQDiLDcnd" title="Investment owned, balance, shares"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2018-05-17_custom_GreenproCapitalCorpMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">83,333</ix:nonFraction></span> shares of common stock in Greenpro Capital Corp. for $<span id="xdx_901_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20180517__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zPpH4oOHXtm5" title="Investment owned, balance, value"><ix:nonFraction name="us-gaap:InvestmentOwnedAtCost" contextRef="AsOf2018-05-17_custom_GreenproCapitalCorpMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000</ix:nonFraction></span> at a purchase price of $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20180517__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zaXyI8H7SnVi" title="Shares issued, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2018-05-17_custom_GreenproCapitalCorpMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6</ix:nonFraction></span>
    per share.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    July 30, 2018, the Company disposed <span id="xdx_909_eus-gaap--InvestmentOwnedBalanceShares_iI_c20180730__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zvuOhS2JZVSl" title="Investment owned, balance, shares"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2018-07-30_custom_GreenproCapitalCorpMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20</ix:nonFraction></span> shares of common stock in Greenpro Capital Corp. for $<span id="xdx_90A_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20180730__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zdZKwuzNtYd8" title="Investment owned, balance, value"><ix:nonFraction name="us-gaap:InvestmentOwnedAtCost" contextRef="AsOf2018-07-30_custom_GreenproCapitalCorpMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">125</ix:nonFraction></span> at a purchase price of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20180730__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zgN0fw7pBxag" title="Shares issued, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2018-07-30_custom_GreenproCapitalCorpMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.2613</ix:nonFraction></span> per
    share.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    October 16, 2018, the Company purchased <span id="xdx_90C_eus-gaap--InvestmentOwnedBalanceShares_iI_c20181016__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zDqIWuJmaEa3" title="Investment owned, balance, shares"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2018-10-16_custom_GreenproCapitalCorpMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">33,333</ix:nonFraction></span> shares of common stock in Greenpro Capital Corp. for $<span id="xdx_902_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20181016__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zPi6lcUs4Eil" title="Investment owned, balance, value"><ix:nonFraction name="us-gaap:InvestmentOwnedAtCost" contextRef="AsOf2018-10-16_custom_GreenproCapitalCorpMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,000</ix:nonFraction></span> at a purchase price of
    $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20181016__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zXS2rwZJaCV1" title="Shares issued, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2018-10-16_custom_GreenproCapitalCorpMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.03</ix:nonFraction></span> per share.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    July 19, 2022, Greenpro Capital Corp. filed a certificate of change with the Secretary of State of Nevada to effect a reverse split
    of <span id="xdx_907_eus-gaap--StockholdersEquityReverseStockSplit_c20220718__20220719_zwSn4r44Kra3" title="Stockholders equity reverse stock split"><ix:nonNumeric contextRef="From2022-07-182022-07-19" name="us-gaap:StockholdersEquityReverseStockSplit">the
    company&#8217;s common stock at the ratio of 10-for-1 effective July 28, 2022. Under the reverse stock split, each 10 pre-split
    share of common stock outstanding will automatically combine into 1 new share of common stock of the company. As at July 28, 2022,
    the Company has an investment of <span id="xdx_90B_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20221231__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zTMsWNH24c05" title="Investment owned, balance shares"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2022-12-31_custom_GreenproCapitalCorpMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">116,646</ix:nonFraction></span>
    common stock of Greenpro Capital Corp. The Company&#8217;s investment of <span id="xdx_908_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20221231__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zQRIGxFVY9ee" title="Investment owned, balance shares"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2022-12-31_custom_GreenproCapitalCorpMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">116,646</ix:nonFraction></span>
    common stock of Greenpro Capital Corp. was reduced to <span id="xdx_90D_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220719__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zCB09Nfj7Ke8" title="Investment owned, balance shares"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2022-07-19_custom_GreenproCapitalCorpMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,665</ix:nonFraction></span>
    subsequent to the reverse stock split.</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    November 3, 2020, the Company received dividend of <span id="xdx_904_eus-gaap--InvestmentOwnedBalanceShares_iI_c20201103__dei--LegalEntityAxis__custom--DSwissIncMember_zMIsUacusxo1" title="Investment owned, balance shares"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2020-11-03_custom_DSwissIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,667</ix:nonFraction></span> shares of common stock in DSwiss, Inc. for $<span id="xdx_900_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20201103__dei--LegalEntityAxis__custom--DSwissIncMember_zi5CkLRH6nM" title="Investment amount"><ix:nonFraction name="us-gaap:InvestmentOwnedAtCost" contextRef="AsOf2020-11-03_custom_DSwissIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">76,671</ix:nonFraction></span> at fair value of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20201103__dei--LegalEntityAxis__custom--DSwissIncMember_zK1owfLgr3l9" title="Shares issued, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2020-11-03_custom_DSwissIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.50</ix:nonFraction></span>
    per share from Greenpro Capital Corporation as result of its Spin-off of DSwiss, Inc.&#8217;s shares</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    December 9, 2020, the Company received dividend of <span id="xdx_90B_eus-gaap--InvestmentOwnedBalanceShares_iI_c20201209__dei--LegalEntityAxis__custom--DSwissIncMember_zdoG7Jk99tql" title="Investment owned, balance shares"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2020-12-09_custom_DSwissIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,663</ix:nonFraction></span> shares of common stock in DSwiss, Inc. for $<span id="xdx_902_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20201209__dei--LegalEntityAxis__custom--DSwissIncMember_zFaH5SRmUoFg" title="Investment owned, balance, value"><ix:nonFraction name="us-gaap:InvestmentOwnedAtCost" contextRef="AsOf2020-12-09_custom_DSwissIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">83,315</ix:nonFraction></span> at fair value of $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_c20201209__dei--LegalEntityAxis__custom--DSwissIncMember_zDAfYwC4oh0h" title="Shares issued, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2020-12-09_custom_DSwissIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5</ix:nonFraction></span>
    per share from Greenpro Capital Corporation as result of its Spin-off of DSwiss, Inc.&#8217;s shares.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    September 27, 2021, the Company received dividend of <span id="xdx_906_eus-gaap--InvestmentOwnedBalanceShares_iI_c20210927__dei--LegalEntityAxis__custom--SEATechVenturesCorpMember_zlPcAJsUNjok" title="Investment in securities, shares"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2021-09-27_custom_SEATechVenturesCorpMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,665</ix:nonFraction></span> shares of common stock in SEATech Ventures Corp. for $<span id="xdx_903_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20210927__dei--LegalEntityAxis__custom--SEATechVenturesCorpMember_z2f9vVLdWhfj" title="Investment amount"><ix:nonFraction name="us-gaap:InvestmentOwnedAtCost" contextRef="AsOf2021-09-27_custom_SEATechVenturesCorpMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,874</ix:nonFraction></span> at fair
    value of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20210927__dei--LegalEntityAxis__custom--SEATechVenturesCorpMember_zYfgGzL5GgNd" title="Purchased price per shares"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2021-09-27_custom_SEATechVenturesCorpMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.62</ix:nonFraction></span> per share from Greenpro Capital Corp as a dividend income since Greenpro Capital Corp previously owned these shares.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    April 3, 2019, the Company purchased a <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20190403__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PhoenixPlusCorpMember_zEurJrkWfvL3" title="Equity interest percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2019-04-03_custom_PhoenixPlusCorpMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>%
    of stock or <span id="xdx_904_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20190403__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PhoenixPlusCorpMember_zsZQVTglfUF9" title="Shares purchased during period"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2019-04-03_us-gaap_CommonStockMember_custom_PhoenixPlusCorpMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000,000</ix:nonFraction></span>
    shares of common stock in Phoenix Plus Corp. (a non-marketable security) for $<span id="xdx_909_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20190403__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PhoenixPlusCorpMember_zOek7wSfajpe" title="Investment amount"><ix:nonFraction name="us-gaap:InvestmentOwnedAtCost" contextRef="AsOf2019-04-03_custom_PhoenixPlusCorpMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,500</ix:nonFraction></span>
    at purchase price of $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20190403__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PhoenixPlusCorpMember_z97OVMGsYqx8" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2019-04-03_custom_PhoenixPlusCorpMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span>
    per share. Phoenix Plus Corp. obtained approval for Depository Trust Company eligibility on April 26, 2022. Since the commencement of trading of common stock of Phoenix Plus Corp. on May 18, 2022, to March 9, 2023,
    there were only <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210518__20230309__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zyLc59iB1OHd" title="Stock issued during peirod shares new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-05-182023-03-09_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200</ix:nonFraction></span> shares of common stock of the company traded. The Company deems there is an absence of a readily determinable
    fair value of the common stock of Phoenix Plus Corp. and has continued to value its investment in the company Phoenix Plus
    Corp. at cost.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 89 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
INVESTMENT IN MARKETABLE SECURITIES (CONT&#8217;D)</b></span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:MarketableSecuritiesTextBlock"><p id="xdx_895_eus-gaap--MarketableSecuritiesTextBlock_zuGzrtr9rAUc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;<span id="xdx_8B0_zN99PDRxKP02" style="display: none">SCHEDULE OF INVESTMENT IN MARKETABLE SECURITIES</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20221231_z4RIpzJXVA29" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20211231_z8xbbM4gX3Kf" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_maMSNzd9C_zzkch15ow0Z2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Cost of investment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:InvestmentOwnedAtCost" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">89,001</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:InvestmentOwnedAtCost" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">577,035</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--TransferFromNonmarketableSecurity_iNI_pp0p0_di_msMSNzd9C_z4pyxkB70cWa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Transfer from non-marketable security</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AATP:TransferFromNonmarketableSecurity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1063">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--InvestmentsIncomeDividend_iNI_pp0p0_di_msMSNzd9C_z4XWyTJDvR08" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend income from Greenpro Capital Corp.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1065">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AATP:InvestmentsIncomeDividend" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">18,939</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--MarketableSecuritiesUnrealizedHoldingLoss_iNI_pp0p0_di_msMSNzd9C_z67Y6b3K59S7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Unrealized holding loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="AATP:MarketableSecuritiesUnrealizedHoldingLoss" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">73,519</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="AATP:MarketableSecuritiesUnrealizedHoldingLoss" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">505,231</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--ExchangeRateEffectOnInvestmentInMarketableSecurites_iI_pp0p0_maMSNzd9C_zA1iT4Zoqkrc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange rate effect</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="AATP:ExchangeRateEffectOnInvestmentInMarketableSecurites" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">295</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="AATP:ExchangeRateEffectOnInvestmentInMarketableSecurites" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,742</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--MarketableSecuritiesNoncurrent_iTI_pp0p0_mtMSNzd9C_zQpdBZmA4Cng" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Investment in marketable securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,687</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">89,001</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zJcQxpLuKbL1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="AATP:InvestmentInNonMarketableSecuritiesTextBlock"><p id="xdx_80E_ecustom--InvestmentInNonMarketableSecuritiesTextBlock_zkjqdsvXMPd4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.
<span id="xdx_823_zaEyLiz194h2">INVESTMENT IN NON-MARKETABLE SECURITIES</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 3, 2019, the Company purchased a <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20190403__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PhoenixPlusCorpMember_zPQsOu2Iphhc" title="Equity interest percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2019-04-03_custom_PhoenixPlusCorpMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% of stock or <span id="xdx_903_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20190403__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PhoenixPlusCorpMember_zG44J5ACcI84" title="Shares purchased during period"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2019-04-03_us-gaap_CommonStockMember_custom_PhoenixPlusCorpMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000,000</ix:nonFraction></span> shares of common stock in Phoenix Plus Corp. for $<span id="xdx_909_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20190403__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PhoenixPlusCorpMember_zyyjs0mRv6ef" title="Investment amount"><ix:nonFraction name="us-gaap:InvestmentOwnedAtCost" contextRef="AsOf2019-04-03_custom_PhoenixPlusCorpMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,500</ix:nonFraction></span> at purchase
price of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20190403__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PhoenixPlusCorpMember_zzAKlWVf0qhc" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2019-04-03_custom_PhoenixPlusCorpMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share. Phoenix Plus Corp. attained its effective date with the Securities Exchange Commission for listing on OTC (Pink Sheet),
U.S. on March 12, 2021, and obtained approval for Depository trust Company (&#8220;DTC&#8221;)
eligibility on April 26, 2022. Accordingly, stocks of Phoenix Plus Corp. can be traded on OTC. As such the investment in Phoenix Plus Corp. was transferred to marketable securities.</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="AATP:NonMarketableSecuritiesTableTextBlock"><p id="xdx_89E_ecustom--NonMarketableSecuritiesTableTextBlock_zBFVNM9h6jw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zsjdkcg96i46" style="display: none">SCHEDULE OF INVESTMENT IN NON MARKETABLE SECURITIES</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Phoenix Plus Corporation</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20221231__dei--LegalEntityAxis__custom--PhoenixPlusCorpMember_zXXHcTFvwT4a" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20211231__dei--LegalEntityAxis__custom--PhoenixPlusCorpMember_zdReaiw7n5o9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Phoenix Plus Corporation</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InvestmentOwnedAtCost_iI_maIINMSz0ls_zigDTIRmqOR9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Cost of investment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:InvestmentOwnedAtCost" contextRef="AsOf2022-12-31_custom_PhoenixPlusCorpMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:InvestmentOwnedAtCost" contextRef="AsOf2021-12-31_custom_PhoenixPlusCorpMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--TransferToInvestmentInMarketableSecurities_iNI_di_msIINMSz0ls_zpVXZpw00J8a" style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left; padding-bottom: 1.5pt">Less: Transfer to investment in marketable securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="AATP:TransferToInvestmentInMarketableSecurities" contextRef="AsOf2022-12-31_custom_PhoenixPlusCorpMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1093">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--InvestmentInNonMarketableSecuritiesNoncurrent_iTI_mtIINMSz0ls_z1Uxjbfm9Z17" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Investment in non-marketable securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1095">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="AATP:InvestmentInNonMarketableSecuritiesNoncurrent" contextRef="AsOf2021-12-31_custom_PhoenixPlusCorpMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_z76k0VA2FEzk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="AATP:CustomerDepositsTextBlock"><p id="xdx_809_ecustom--CustomerDepositsTextBlock_zBHnnqeVa9Ch" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>12. <span id="xdx_826_zQES4THSnK8l">CUSTOMER DEPOSITS</span></b></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="AATP:CustomerDepositsTableTextBlock"><p id="xdx_89D_ecustom--CustomerDepositsTableTextBlock_zHhQaYUa9k5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF CUSTOMER DEPOSITS</span></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221231_zow2nIkKZI36" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20211231_zTv7W3RRpuqb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--CustomerDeposits_iI_zwD3eV7Y1YXi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Customer deposits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="AATP:CustomerDeposits" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">289,487</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="AATP:CustomerDeposits" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">273,581</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--UnexpiredProductCoupons_iI_zpZlYuDLeHh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Unexpired product coupons</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="AATP:UnexpiredProductCoupons" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,531</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="AATP:UnexpiredProductCoupons" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,108</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DepositLiabilityCurrent_iI_zI1umsyIVJ32" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DepositLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">363,018</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DepositLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">279,689</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A5_zFeI1mPtS7X2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Customer deposits represent amounts advanced by customers
on product orders and unexpired product coupons issued to the Company&#8217;s members and distributors of its network marketing business.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:OtherLiabilitiesDisclosureTextBlock"><p id="xdx_806_eus-gaap--OtherLiabilitiesDisclosureTextBlock_zgP6LWKYW1vf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.
<span id="xdx_820_zPzlrUUAodIl">OTHER PAYABLES AND ACCRUED LIABILITIES</span></b></span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="AATP:ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock"><p id="xdx_899_ecustom--ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock_z0fAGKnF5AM" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zeSWMrAQEuWa" style="display: none">SCHEDULE OF OTHER PAYABLES AND ACCRUED LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_49C_20221231_zQIWaMMhHL12" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_49C_20211231_z45F1OSPJsFf" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maOAPAAz1Ku_zI8xwdf6tNn" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Professional fees</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">324,629</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">436,541</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--AccruedPromotionExpensesCurrent_iI_pp0p0_maOAPAAz1Ku_zK1vqfScw7Ti" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Promotion expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AATP:AccruedPromotionExpensesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38,583</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AATP:AccruedPromotionExpensesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">36,024</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_maOAPAAz1Ku_zTU3Vl05AfI1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Payroll</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedPayrollTaxesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,164</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedPayrollTaxesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,669</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccruedSalesCommissionCurrent_iI_pp0p0_maOAPAAz1Ku_zBf7jn2I9sS" style="vertical-align: bottom; background-color: White">
    <td>Amounts held in eWallets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedSalesCommissionCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">216,049</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedSalesCommissionCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">223,781</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--AccruedTaxPenaltyCurrent_iI_pp0p0_maOAPAAz1Ku_zCTg4hKcqDfa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax penalty</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AATP:AccruedTaxPenaltyCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">75,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AATP:AccruedTaxPenaltyCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">75,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iI_pp0p0_maOAPAAz1Ku_zXbRWJ730LGf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">37,852</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">64,340</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--OtherAccountPayableAndAccruedLiabilities_iTI_pp0p0_mtOAPAAz1Ku_zooHneFb6om8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="AATP:OtherAccountPayableAndAccruedLiabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">713,277</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="AATP:OtherAccountPayableAndAccruedLiabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">858,355</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zRI6cdAor1X9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company requires all members and distributors of its network marketing business to maintain an electronic wallet (eWallet) account with
the Company. <span id="xdx_90D_ecustom--CommissionPaymentsDescriptions_c20220101__20221231_zMUgKigPDTa4" title="Commission payments descriptions"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="AATP:CommissionPaymentsDescriptions">The eWallet is primarily for the crediting of any commission payment that falls below RM<span id="xdx_909_eus-gaap--CommissionsPayableToBrokerDealersAndClearingOrganizations_iI_uRM_c20221231_zv5mLNWiWRxk" title="Comission payable"><ix:nonFraction name="us-gaap:CommissionsPayableToBrokerDealersAndClearingOrganizations" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="RM">100</ix:nonFraction></span> (or $22.70).</ix:nonNumeric></span> Commission payment
exceeding the RM<span id="xdx_90F_eus-gaap--ContractWithCustomerAssetGross_iI_uRM_c20221231_zk9aTMMaZ3w4" title="Comission payable, threshold"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="RM">100</ix:nonFraction></span> threshold shall only be credited into the member&#8217;s or distributor&#8217;s eWallet upon request. The eWallet
functionality allows the members to place new product orders utilizing eWallet available balance and/or request commission payout via
multiple payment methods provided that each of the withdrawal amount exceeds RM<span id="xdx_904_eus-gaap--ContractWithCustomerAssetGross_iI_uRM_c20221231__srt--RangeAxis__srt--MaximumMember_zWQ98f2Fse27" title="Comission payable, threshold"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetGross" contextRef="AsOf2022-12-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" unitRef="RM">100</ix:nonFraction></span>. Amounts held in eWallets are reflected on the balance
sheet as a current liability.</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 90 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_803_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zaYfTMIgUOEj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.
<span id="xdx_826_zBglaasqwYCi">RELATED PARTY BALANCES AND TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related
party balances</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount
due from related parties</b></span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zl0oYWLAAj4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_z727ztZuIZn6" style="display: none">SCHEDULE OF RELATED PARTIES</span></span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center">Name of Related</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Party</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Relationship</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nature</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 22%; text-align: left">TH3 Technology Sdn Bhd (&#8220;TH3&#8221;)</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 22%; text-align: center"><span id="xdx_904_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_ziLC6cF8O0Hb" title="Relationship"><span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_zzSz5d5bIqm9" title="Relationship"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_TH3TechnologySdnBhdMember" name="AATP:RelatedPartiesRelationshipsDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_TH3TechnologySdnBhdMember" name="AATP:RelatedPartiesRelationshipsDescription">Mr. How Kok Choong, the CEO and director of the Company is also a director of TH3</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center">Prepayment of IT expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_zZAUIMTT8fOj" title="Due from related parties" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DueFromRelatedParties" contextRef="AsOf2022-12-31_custom_TH3TechnologySdnBhdMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,273</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_zukwEs1YngT4" title="Due from related parties" style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1154">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">DSY Beauty Sdn Bhd (&#8220;DSY Beauty&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_903_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_z0694WTKbtY1" title="Relationship"><span id="xdx_901_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zeZmlYSi7375" title="Relationship"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_DSYBeautySdnBhdMember" name="AATP:RelatedPartiesRelationshipsDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_DSYBeautySdnBhdMember" name="AATP:RelatedPartiesRelationshipsDescription">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Deposits for products</p>
                                                        <p style="margin-top: 0; margin-bottom: 0">purchases</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zwDZUnOh83dc" title="Due from related parties" style="text-align: right"><ix:nonFraction name="us-gaap:DueFromRelatedParties" contextRef="AsOf2022-12-31_custom_DSYBeautySdnBhdMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,261</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zByqRivjGxmc" title="Due from related parties" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1162">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Agape ATP (Asia) Limited (&#8220;AATP Asia&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_900_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zHWmYpA622q9" title="Relationship"><span id="xdx_902_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zP3giNs1HF4d" title="Relationship"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_AgapeATPAsiaLimitedMember" name="AATP:RelatedPartiesRelationshipsDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_AgapeATPAsiaLimitedMember" name="AATP:RelatedPartiesRelationshipsDescription">Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of AATP Asia</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90B_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zvM7Hh1mF5pj" title="Nature"><span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zJUFhY5rF4V1" title="Nature"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_AgapeATPAsiaLimitedMember" name="AATP:RelatedPartiesNatureDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_AgapeATPAsiaLimitedMember" name="AATP:RelatedPartiesNatureDescription">Expenses paid for AATP Asia</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zybPyNfOgw56" title="Due from related parties" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1172">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_ziSokE5HMXP7" title="Due from related parties" style="text-align: right"><ix:nonFraction name="us-gaap:DueFromRelatedParties" contextRef="AsOf2021-12-31_custom_AgapeATPAsiaLimitedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,214</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">Hostastay Sdn. Bhd. <br />&#8220;Hostastay&#8221;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_904_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_z9WLCOVt2aPa" title="Relationship"><span id="xdx_90F_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_z3VsvnIpOAm2" title="Relationship"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_HostastaySdnBhdMember" name="AATP:RelatedPartiesRelationshipsDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_HostastaySdnBhdMember" name="AATP:RelatedPartiesRelationshipsDescription">Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_903_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zdj7boQy7Z08" title="Nature"><span id="xdx_906_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zUYOiG4dFOU3" title="Nature"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_HostastaySdnBhdMember" name="AATP:RelatedPartiesNatureDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_HostastaySdnBhdMember" name="AATP:RelatedPartiesNatureDescription">Sublease rent due from Hostastay</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zpXdWXaREyb2" title="Due from related parties" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1184">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zXiuGQBFncKe" title="Due from related parties" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DueFromRelatedParties" contextRef="AsOf2021-12-31_custom_HostastaySdnBhdMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,790</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20221231_zF4oFTU7cPKd" title="Due from related parties" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DueFromRelatedParties" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,534</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20211231_z5LEII8mzdAe" title="Due from related parties" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DueFromRelatedParties" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,004</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accounts
payable &#8211; related parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center">Name of Related</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Party</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Relationship</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nature</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="text-align: center; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 22%; text-align: left">CTA Nutriceuticals (Asia) Sdn Bhd (&#8220;CTA&#8221;)</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 22%; text-align: center"><span id="xdx_906_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zerXYsBJD1ta" title="Relationship"><span id="xdx_90E_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zqorjRRHLqeh" title="Relationship"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_CTANutriceuticalsSdnBhdMember" name="AATP:RelatedPartiesRelationshipsDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_CTANutriceuticalsSdnBhdMember" name="AATP:RelatedPartiesRelationshipsDescription">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center"><span id="xdx_900_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zIWoggCpvyz9" title="Nature"><span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zHhxRv48SPpb" title="Nature"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_CTANutriceuticalsSdnBhdMember" name="AATP:RelatedPartiesNatureDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_CTANutriceuticalsSdnBhdMember" name="AATP:RelatedPartiesNatureDescription">Purchases of products for the provision of complementary health therapies</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zPFD76jbZAm2" title="Accounts payable, related parties, current" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="AsOf2022-12-31_custom_CTANutriceuticalsSdnBhdMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,387</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zNdbULlh8yt8" title="Accounts payable, related parties, current" style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1202">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">DSY Beauty Sdn Bhd (&#8220;DSY Beauty&#8221;)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_908_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zM1z2HcEGkuj" title="Relationship"><span id="xdx_906_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_z8IOZfRRQTP2" title="Relationship"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_DSYBeautySdnBhdMember" name="AATP:RelatedPartiesRelationshipsDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_DSYBeautySdnBhdMember" name="AATP:RelatedPartiesRelationshipsDescription">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_904_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zc7oweQDOY3f" title="Nature"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_DSYBeautySdnBhdMember" name="AATP:RelatedPartiesNatureDescription">Purchases of beauty products</ix:nonNumeric></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zfU3NUY42Nfb" title="Accounts payable, related parties, current" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="AsOf2022-12-31_custom_DSYBeautySdnBhdMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">224</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zV5eQ932Q825" title="Accounts payable, related parties, current" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1212">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20221231_zGBB1JB6CVq4" title="Accounts payable, related parties, current" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,611</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20211231_zZAdIF7v7Zaa" title="Accounts payable, related parties, current" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1216">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 91 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.
RELATED PARTY BALANCES AND TRANSACTIONS (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related
party balances</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other payable - related parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Name of Related</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">As of December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Party</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Relationship</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nature</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="text-align: center; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 22%; text-align: left">CTA Nutriceuticals (Asia) Sdn Bhd (&#8220;CTA&#8221;)</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 22%; text-align: center"><span id="xdx_906_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdOneMember_zRZjLu2pyuSk" title="Relationship"><span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdOneMember_zC9td5yiQjm1" title="Relationship"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_CTANutriceuticalsAsiaSdnBhdOneMember" name="AATP:RelatedPartiesRelationshipsDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_CTANutriceuticalsAsiaSdnBhdOneMember" name="AATP:RelatedPartiesRelationshipsDescription">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center"><span id="xdx_901_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdOneMember_zz6M3NDzdZ5d" title="Nature"><span id="xdx_90A_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdOneMember_zzwxLVUhJ7Gj" title="Nature"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_CTANutriceuticalsAsiaSdnBhdOneMember" name="AATP:RelatedPartiesNatureDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_CTANutriceuticalsAsiaSdnBhdOneMember" name="AATP:RelatedPartiesNatureDescription">Purchase of products for general use</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdOneMember_z4MvZfHbEqh5" title="Due to related parties" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2022-12-31_custom_CTANutriceuticalsAsiaSdnBhdOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,149</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdOneMember_zEE4fagrL1fd" title="Due to related parties" style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1228">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">DSY Beauty Sdn Bhd (&#8220;DSY Beauty&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_900_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_zjX7ki6BoTY1" title="Relationship"><span id="xdx_903_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_zztblYDJrAed" title="Relationship"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_DSYBeautySdnBhdOneMember" name="AATP:RelatedPartiesRelationshipsDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_DSYBeautySdnBhdOneMember" name="AATP:RelatedPartiesRelationshipsDescription">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_901_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_z0iOuRmJMVBf" title="Nature"><span id="xdx_904_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_zHVZ5TNJC34l" title="Nature"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_DSYBeautySdnBhdOneMember" name="AATP:RelatedPartiesNatureDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_DSYBeautySdnBhdOneMember" name="AATP:RelatedPartiesNatureDescription">Purchase of products for general use</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_z8Wmhm3hUI43" title="Due to related parties" style="text-align: right"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2022-12-31_custom_DSYBeautySdnBhdOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,147</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_zah7ZUjUINIk" title="Due to related parties" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1240">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">Mr. How Kok Choong</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_901_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zzfHYp7VfMm6" title="Relationship"><span id="xdx_90C_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zXbRwDLsk895" title="Relationship"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_HowKokChoongMember" name="AATP:RelatedPartiesRelationshipsDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_HowKokChoongMember" name="AATP:RelatedPartiesRelationshipsDescription">Mr. How Kok Choong, the CEO and director of the Company</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_909_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_z6dwnfOeuOqg" title="Nature"><span id="xdx_907_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zGwXo2mC8cKd" title="Nature"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_HowKokChoongMember" name="AATP:RelatedPartiesNatureDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_HowKokChoongMember" name="AATP:RelatedPartiesNatureDescription">Commission expense</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zH4Rwm5s39Og" title="Due to related parties" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2022-12-31_custom_HowKokChoongMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">584</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zjnTizCPpH8g" title="Due to related parties" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1252">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pdp0_c20221231_zJbx1u9mu5C9" title="Due to related parties" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,880</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pdp0_c20211231_zS1BhyQ3Bi9i" title="Due to related parties" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1256">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related
party transactions </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Purchases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Name of Related</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Party</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Relationship</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nature</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 22%; text-align: left">CTA Nutriceuticals (Asia) Sdn Bhd (&#8220;CTA&#8221;)</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 22%; text-align: center"><span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zG9btHnwadC2" title="Relationship"><span id="xdx_908_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zauLz8fCZTk7" title="Relationship"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_CTANutriceuticalsSdnBhdMember" name="AATP:RelatedPartiesRelationshipsDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_CTANutriceuticalsSdnBhdMember" name="AATP:RelatedPartiesRelationshipsDescription">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center"><span id="xdx_90A_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zwQlhwdt3st7" title="Nature"><span id="xdx_90C_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zUTGwGNmJzUi" title="Nature"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_CTANutriceuticalsSdnBhdMember" name="AATP:RelatedPartiesNatureDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_CTANutriceuticalsSdnBhdMember" name="AATP:RelatedPartiesNatureDescription">Purchases of products for the provision of complementary health therapies</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zEDJpcz6QUD3" title="Purchases" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2022-01-012022-12-31_custom_CTANutriceuticalsSdnBhdMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">198,376</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zjNU7dGm447l" title="Purchases" style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1268">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">DSY Beauty Sdn Bhd (&#8220;DSY Beauty&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_908_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zIGdx9Bw1blh" title="Relationship"><span id="xdx_90C_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zPFuB2i5T166" title="Relationship"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_DSYBeautySdnBhdMember" name="AATP:RelatedPartiesRelationshipsDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_DSYBeautySdnBhdMember" name="AATP:RelatedPartiesRelationshipsDescription">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90B_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zPv0pPRzwuc6" title="Nature"><span id="xdx_908_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zYrKqkNdAo55" title="Nature"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_DSYBeautySdnBhdMember" name="AATP:RelatedPartiesNatureDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_DSYBeautySdnBhdMember" name="AATP:RelatedPartiesNatureDescription">Purchases of beauty products</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zugqbvRWvu3l" title="Purchases" style="text-align: right"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2022-01-012022-12-31_custom_DSYBeautySdnBhdMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,975</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zu6p5YJuNohk" title="Purchases" style="text-align: right"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2021-01-012021-12-31_custom_DSYBeautySdnBhdMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">718</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">DSY Wellness &amp; Longevity Center Sdn Bhd (&#8220;DSYWLC&#8221;)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_906_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zbVboKp0GiI5" title="Relationship"><span id="xdx_903_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_ziSDJiKeBjU6" title="Relationship"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_DSYWellnessandLongevityCenterSdnBhdTwoMember" name="AATP:RelatedPartiesRelationshipsDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_DSYWellnessandLongevityCenterSdnBhdTwoMember" name="AATP:RelatedPartiesRelationshipsDescription">Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC</ix:nonNumeric></ix:nonNumeric></span></span>.</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_900_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zUuiIpm9PQeb" title="Nature"><span id="xdx_900_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zZRPuzBVaJBf" title="Nature"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_DSYWellnessandLongevityCenterSdnBhdTwoMember" name="AATP:RelatedPartiesNatureDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_DSYWellnessandLongevityCenterSdnBhdTwoMember" name="AATP:RelatedPartiesNatureDescription">Purchases of products for the provision of complementary health therapies</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zjB80Z6q022f" title="Purchases" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2022-01-012022-12-31_custom_DSYWellnessandLongevityCenterSdnBhdTwoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">124</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zUPPsxbNbbu7" title="Purchases" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1292">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220101__20221231_zIZqZ8Ed99Nd" title="Purchases" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">202,475</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210101__20211231_zx3eXt89sgO2" title="Purchases" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">718</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 92 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.
RELATED PARTY BALANCES AND TRANSACTIONS (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related
party transactions</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
income</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Name
    of Related</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the years ended December 31,</span></td>
    <td>&#160;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Party</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Relationship</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Nature</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td>
    <td>&#160;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td>&#160;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 26%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Hostastay
    Sdn. Bhd.</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_900_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zqcHbYBaJJmd" style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_z2EvLexgEEyc"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_HostastaySdnBhdHostastayMember" name="AATP:RelatedPartiesRelationshipsDescription"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_HostastaySdnBhdHostastayMember" name="AATP:RelatedPartiesRelationshipsDescription">Mr.
    How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director
    of Hostastay as of April 21, 2021</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 14%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_900_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_z1nEmOAMZg66" style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zAKIFOJ42Gng"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_HostastaySdnBhdHostastayMember" name="AATP:RelatedPartiesNatureDescription"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_HostastaySdnBhdHostastayMember" name="AATP:RelatedPartiesNatureDescription">Sublease
    rental income due from Hostastay</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--RelatedPartyOtherIncome_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_z6RcmQ3ozwGh" title="Other income" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1302">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_ecustom--RelatedPartyOtherIncome_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_z7nXSW3qZRa4" title="Other income" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="AATP:RelatedPartyOtherIncome" contextRef="From2021-01-012021-12-31_custom_HostastaySdnBhdHostastayMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,345</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_ecustom--RelatedPartyOtherIncome_pp0p0_c20220101__20221231_zuRLWr8prJsl" title="Other income" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1306">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_ecustom--RelatedPartyOtherIncome_pp0p0_c20210101__20211231_z1H0garr44X9" title="Other income" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="AATP:RelatedPartyOtherIncome" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,345</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
purchases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Name of Related</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Party</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Relationship</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nature</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 22%; text-align: left">CTA Nutriceuticals (Asia) Sdn Bhd (&#8220;CTA&#8221;)</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 22%; text-align: center"><span id="xdx_901_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdMember_zQpS1MGX9God" title="Relationship"><span id="xdx_904_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdMember_zQ7tlyF1WxH8" title="Relationship"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_CTANutriceuticalsAsiaSdnBhdMember" name="AATP:RelatedPartiesRelationshipsDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_CTANutriceuticalsAsiaSdnBhdMember" name="AATP:RelatedPartiesRelationshipsDescription">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center"><span id="xdx_90A_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdMember_zOB0wRP6Zbwk" title="Nature"><span id="xdx_904_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdMember_zKuywerER7I5" title="Nature"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_CTANutriceuticalsAsiaSdnBhdMember" name="AATP:RelatedPartiesNatureDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_CTANutriceuticalsAsiaSdnBhdMember" name="AATP:RelatedPartiesNatureDescription">Purchases of products for the provision of complementary health therapies</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdMember_zHyk1uIlG5X7" title="Other purchases" style="width: 14%; text-align: right"><ix:nonFraction name="AATP:RelatedPartyTransactionOtherPurchasesFromRelatedParty" contextRef="From2022-01-012022-12-31_custom_CTANutriceuticalsAsiaSdnBhdMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,431</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdMember_zOJhGebFBwke" title="Other purchases" style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1320">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">DSY Beauty Sdn Bhd (&#8220;DSY Beauty&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zzmSc7AiZDU9" title="Relationship"><span id="xdx_90D_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zZszxc9zLCci" title="Relationship"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_DSYBeautySdnBhdMember" name="AATP:RelatedPartiesRelationshipsDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_DSYBeautySdnBhdMember" name="AATP:RelatedPartiesRelationshipsDescription">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_z0Wk8Ark1EC9" title="Nature"><span id="xdx_90C_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zhWXpNnpqXsj" title="Nature"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_DSYBeautySdnBhdMember" name="AATP:RelatedPartiesNatureDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_DSYBeautySdnBhdMember" name="AATP:RelatedPartiesNatureDescription">Purchases of beauty products</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_z2yPLa3DzNw9" title="Other purchases" style="text-align: right"><ix:nonFraction name="AATP:RelatedPartyTransactionOtherPurchasesFromRelatedParty" contextRef="From2022-01-012022-12-31_custom_DSYBeautySdnBhdMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,888</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zXmRjMkWYmi7" title="Other purchases" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1332">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">DSY Wellness &amp; Longevity Center Sdn Bhd (&#8220;DSYWLC&#8221;)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_908_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z5Y8L65Fxfw5" title="Relationship"><span id="xdx_90E_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zCZxtEuEhEu8" title="Relationship"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdMember_srt_ChiefExecutiveOfficerMember" name="AATP:RelatedPartiesRelationshipsDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdMember_srt_ChiefExecutiveOfficerMember" name="AATP:RelatedPartiesRelationshipsDescription">Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_901_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdMember_z9Arjnl5Pz17" title="Nature"><span id="xdx_903_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdMember_z6pp5SD6xYf5" title="Nature"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdMember" name="AATP:RelatedPartiesNatureDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdMember" name="AATP:RelatedPartiesNatureDescription">Purchases of products for the provision of complementary health therapies</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdMember_zhkqEQynYhXg" title="Other purchases" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="AATP:RelatedPartyTransactionOtherPurchasesFromRelatedParty" contextRef="From2022-01-012022-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdMember_z9pDuZhyXAAd" title="Other purchases" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1344">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20220101__20221231_z76MRFD0m2B9" title="Other purchases" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="AATP:RelatedPartyTransactionOtherPurchasesFromRelatedParty" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,323</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20210101__20211231_zkBH9qsQYILf" title="Other purchases" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1348">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 93 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.
RELATED PARTY BALANCES AND TRANSACTIONS (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related
party transactions</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
expense</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Name of Related</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Party</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Relationship</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nature</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 22%; text-align: left; padding-bottom: 1.5pt">Mr. How Kok Choong</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; width: 22%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_90C_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zu0Whq1PIPL8" title="Relationship"><span id="xdx_903_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_ziKt3iMOZKOf" title="Relationship"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_HowKokChoongMember" name="AATP:RelatedPartiesRelationshipsDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_HowKokChoongMember" name="AATP:RelatedPartiesRelationshipsDescription">Mr. How Kok Choong, the CEO and director of the Company</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_900_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zwKUCUPMtWLb" title="Nature"><span id="xdx_904_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_z8acQHVXjMAf" title="Nature"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_HowKokChoongMember" name="AATP:RelatedPartiesNatureDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_HowKokChoongMember" name="AATP:RelatedPartiesNatureDescription">Commission expense</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--SalesCommissionsAndFees_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zDVS0V5gpANk" title="Commission expense" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:SalesCommissionsAndFees" contextRef="From2022-01-012022-12-31_custom_HowKokChoongMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,590</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--SalesCommissionsAndFees_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_znsRavhRLPGj" title="Commission expense" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:SalesCommissionsAndFees" contextRef="From2021-01-012021-12-31_custom_HowKokChoongMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,758</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--SalesCommissionsAndFees_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zLYgWsHkbrUl" title="Commission expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SalesCommissionsAndFees" contextRef="From2022-01-012022-12-31_custom_HowKokChoongMember_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,590</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--SalesCommissionsAndFees_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zoRsvIlllO4i" title="Commission expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SalesCommissionsAndFees" contextRef="From2021-01-012021-12-31_custom_HowKokChoongMember_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,758</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Name of Related</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Party</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Relationship</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nature</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 22%; text-align: left">TH3 Technology Sdn Bhd (&#8220;TH3&#8221;)</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 22%; text-align: center"><span id="xdx_90E_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_z4iv32kYvk1l" title="Relationship"><span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_z0xuXefakGMb" title="Relationship"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_TH3TechnologySdnBhdMember" name="AATP:RelatedPartiesRelationshipsDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_TH3TechnologySdnBhdMember" name="AATP:RelatedPartiesRelationshipsDescription">Mr. How Kok Choong, the CEO and director of the Company is also a director of TH3</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center"><span id="xdx_90E_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_zQ6QjExXo1U7" title="Nature"><span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_zXGYWHCDNtCh" title="Nature"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_TH3TechnologySdnBhdMember" name="AATP:RelatedPartiesNatureDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_TH3TechnologySdnBhdMember" name="AATP:RelatedPartiesNatureDescription">IT support services fee</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--RelatedPartyOtherExpenses_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_z8z2j3a0nVPd" title="Other expenses" style="width: 14%; text-align: right"><ix:nonFraction name="AATP:RelatedPartyOtherExpenses" contextRef="From2022-01-012022-12-31_custom_TH3TechnologySdnBhdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,450</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--RelatedPartyOtherExpenses_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_zABwXOfX473k" title="Other expenses" style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1376">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">Redboy Picture Sdn Bhd (&#8220;Redboy&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_908_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RedboyPictureSdnBhdMember_zTlZ7u9rRIy7" title="Relationship"><span id="xdx_907_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RedboyPictureSdnBhdMember_zi3zgmDv7iKd" title="Relationship"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_RedboyPictureSdnBhdMember" name="AATP:RelatedPartiesRelationshipsDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_RedboyPictureSdnBhdMember" name="AATP:RelatedPartiesRelationshipsDescription">Mr. How Kok Choong, the CEO and director of the Company is also the director of Redboy</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90B_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RedboyPictureSdnBhdMember_z5yIEWjsXqtd" title="Nature"><span id="xdx_906_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RedboyPictureSdnBhdMember_zBJEOcGeyzn" title="Nature"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_RedboyPictureSdnBhdMember" name="AATP:RelatedPartiesNatureDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_RedboyPictureSdnBhdMember" name="AATP:RelatedPartiesNatureDescription">Sponsorship fee</ix:nonNumeric></ix:nonNumeric></span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--RelatedPartyOtherExpenses_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RedboyPictureSdnBhdMember_zQ3qYXMAmiBj" title="Other expenses" style="text-align: right"><ix:nonFraction name="AATP:RelatedPartyOtherExpenses" contextRef="From2022-01-012022-12-31_custom_RedboyPictureSdnBhdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,686</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--RelatedPartyOtherExpenses_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RedboyPictureSdnBhdMember_z09R8ZOGeew9" title="Other expenses" style="text-align: right"><ix:nonFraction name="AATP:RelatedPartyOtherExpenses" contextRef="From2021-01-012021-12-31_custom_RedboyPictureSdnBhdMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">718</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">DSY Wellness &amp; Longevity Center Sdn Bhd (&#8220;DSYWLC&#8221;)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_90C_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zcFhJLetkZFb" title="Relationship"><span id="xdx_901_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zK7nMlKX00y3" title="Relationship"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdThreeMember" name="AATP:RelatedPartiesRelationshipsDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdThreeMember" name="AATP:RelatedPartiesRelationshipsDescription">Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_z7juN7qEQtMg" title="Nature"><span id="xdx_90C_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_z82d28JtijVi" title="Nature"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdThreeMember" name="AATP:RelatedPartiesNatureDescription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdThreeMember" name="AATP:RelatedPartiesNatureDescription">Office rental expenses</ix:nonNumeric></ix:nonNumeric></span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--RelatedPartyOtherExpenses_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zW53VjqvfB7a" title="Other expenses" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="AATP:RelatedPartyOtherExpenses" contextRef="From2022-01-012022-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdThreeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,779</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--RelatedPartyOtherExpenses_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zHVhurNTFL4a" title="Other expenses" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1400">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--RelatedPartyOtherExpenses_c20220101__20221231_zVoXaAlg39Lf" title="Other expenses" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="AATP:RelatedPartyOtherExpenses" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,915</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--RelatedPartyOtherExpenses_c20210101__20211231_zLvySw9yI4bi" title="Other expenses" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="AATP:RelatedPartyOtherExpenses" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">718</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zI0eiSIdihIi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 94 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80D_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zrxrGEATJSG7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15.
<span id="xdx_828_z7H1JaGpStBb">STOCKHOLDERS&#8217; EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Preferred
stock</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 and 2021, there were <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_zty6O6HQbxW1" title="Preferred stock, shares authorized"><span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231_z9ul9eaResr2" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000,000</ix:nonFraction></ix:nonFraction></span></span> preferred stocks authorized but <span id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_dn_c20221231_zdiZyFzKB8yf" title="Preferred stock, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20221231_zdVAv5pFAaTd" title="Preferred stock, shares outstanding"><span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_dn_c20221231_z4GT5rfxaZz" title="Preferred stock, shares issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20211231_zW5jdvfloTRd" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> were issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Common
stock</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 and 2021, there were <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zNbnPSp1kgW9" title="Common stock, shares authorized"><span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zSTJp5umnSw" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000,000</ix:nonFraction></ix:nonFraction></span></span> common stocks authorized, <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20221231_zQBtTzjRuTH3" title="Common stock, shares issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_z5pPYvDUOk1a" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,452,012</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_c20211231_zMHzMgcbEL9d" title="Common stock, shares issued"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_zYAyTYa7hJok" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">290,460,047</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2021, there were share forfeiture agreements (the &#8220;<b>Share Forfeiture Agreements</b>&#8221;) between the Company and
(i) HKC Talent Limited; (ii) various shareholders of the Company (the &#8220;<b>Forfeiting Shareholders</b>&#8221;), pursuant to which:
(i) HKC Talent Limited had agreed to forfeiture of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ShareForfeitureAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongTalentLimitedMember_zm04t01nvDPl" title="Share- based payment arrangement, forfeited"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="From2021-01-012021-12-31_custom_ShareForfeitureAgreementsMember_custom_HowKokChoongTalentLimitedMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">41,750,000</ix:nonFraction></span> shares of common stock of the Company, and (ii) the Forfeiting Shareholders
had agreed to forfeiture, in aggregate, <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ShareForfeitureAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongTalentLimitedMember__srt--TitleOfIndividualAxis__custom--ShareholdersMember_zN9m5lnyt6ih" title="Share- based payment arrangement, forfeited"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="From2021-01-012021-12-31_custom_ShareForfeitureAgreementsMember_custom_HowKokChoongTalentLimitedMember_custom_ShareholdersMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">44,242,000</ix:nonFraction></span> shares of common stock of the Company. Included in (ii) is <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ShareForfeitureAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HKCHoldingsSdnBhdMember_zko4kprwOe7g" title="Share- based payment arrangement, forfeited"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="From2021-01-012021-12-31_custom_ShareForfeitureAgreementsMember_custom_HKCHoldingsSdnBhdMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,242,000</ix:nonFraction></span> shares forfeited
from HKC Holdings Sdn. Bhd, a company in which <span style="background-color: white">Mr. How Kok Choong, </span>the CEO and director
of the Company, is a shareholder. As a result, the outstanding shares was reduced by <span id="xdx_90C_ecustom--ReductionInCommonStockOutstanding_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ShareForfeitureAgreementsMember_zHPpq9P03LB2" title="Reduction in outstanding shares"><ix:nonFraction name="AATP:ReductionInCommonStockOutstanding" contextRef="From2021-01-012021-12-31_custom_ShareForfeitureAgreementsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">85,992,000</ix:nonFraction></span> shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
share forfeiture agreement (the &#8220;Share Forfeiture Agreement&#8221;) dated January 20, 2022, between the Company and Mr. How Kok
Choong, the CEO and director of the Company, pursuant to which Mr. How Kok Choong agreed to forfeit <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--ShareForfeitureAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongTalentLimitedMember_zY1VZhyWHbJl" title="Number of shares forfeited"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="From2022-01-012022-12-31_custom_ShareForfeitureAgreementsMember_custom_HowKokChoongTalentLimitedMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">215,008,035</ix:nonFraction></span> shares of common stock
of the Company. As a result, the outstanding shares was reduced by <span id="xdx_903_ecustom--ReductionInCommonStockOutstanding_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--ShareForfeitureAgreementsMember_zBgiQdmVV7u2" title="Reduction in outstanding shares"><ix:nonFraction name="AATP:ReductionInCommonStockOutstanding" contextRef="From2022-01-012022-12-31_custom_ShareForfeitureAgreementsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">215,008,035</ix:nonFraction></span> shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_do_c20220101__20221231_z6TOREpaB1j8" title="Potentially dilutive securities outstanding"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_do_c20210101__20211231_zzmSUykSSlS9" title="Potentially dilutive securities outstanding"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-01to2022-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> stock options, warrants or other potentially dilutive securities outstanding as of December 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:MinorityInterestDisclosureTextBlock"><p id="xdx_80A_eus-gaap--MinorityInterestDisclosureTextBlock_zRMcY1MqRNO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16.
<span id="xdx_820_zLo6yEndAVUb">NON-CONTROLLING INTEREST</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="AATP:ScheduleOfNonControllingInterestTableTextBlock"><p id="xdx_89E_ecustom--ScheduleOfNonControllingInterestTableTextBlock_zItFSSqNjvNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s non-controlling interest consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zWLqh61alVOc" style="display: none">SCHEDULE OF NON CONTROLLING INTEREST</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_496_20221231_z8n1xYUN2KRc" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_497_20211231_zLxvsRVAtnza" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">DSY Wellness:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--NonControllingInterestPaidinCapital_iI_maNCINCzwzX_maNCINCzgCA_ztnQP5spxhD7" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Paid-in capital</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="AATP:NonControllingInterestPaidinCapital" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="AATP:NonControllingInterestPaidinCapital" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--NonControllingInterestAccumulatedDeficit_iI_maNCINCzwzX_maNCINCzgCA_zdhlZiZBS117" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accumulated surplus (deficit)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AATP:NonControllingInterestAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,384</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="AATP:NonControllingInterestAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">436</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--NonControllingInterestAccumulatedOtherComprehensiveIncome_iI_maNCINCzwzX_maNCINCzgCA_zamMSBSCAIV8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated other comprehensive income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="AATP:NonControllingInterestAccumulatedOtherComprehensiveIncome" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="AATP:NonControllingInterestAccumulatedOtherComprehensiveIncome" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--NonControllingInterestNonControllingInterestGross_iTI_mtNCINCzgCA_zFjLER4eaPU1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Non Controlling interest Gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AATP:NonControllingInterestNonControllingInterestGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,513</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="AATP:NonControllingInterestNonControllingInterestGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">336</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--NonControllingInterestAsl_iI_maMIzbTf_zhASwFT68lgk" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">ASL</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1464">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1465">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--MinorityInterest_iI_zHlazE5YlbS3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,513</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">336</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_ztCYbvXrAQb5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 95 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_804_eus-gaap--IncomeTaxDisclosureTextBlock_znvIM9XybCJa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17.
<span id="xdx_829_zeAaJlP7VpZe">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zbYrNSfpqOqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
United States and foreign components of loss before income taxes were comprised of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BC_zbw9RcdCJECe" style="display: none">SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAX</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20220101__20221231_zILNGugjEUVd" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20210101__20211231_zJModJ8xjfzb" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax jurisdictions from:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_zEfm59KnFAFd" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Local &#8211; United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">736,946</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">706,659</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_hsrt--StatementGeographicalAxis__country--MY_zKjnqwH7pae9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign &#8211; Malaysia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2022-01-012022-12-31_country_MY" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">864,794</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2021-01-012021-12-31_country_MY" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,064,314</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_hsrt--StatementGeographicalAxis__country--HK_zEcVHq1RW1wl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign &#8211; Hong Kong</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2022-01-012022-12-31_country_HK" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">68,394</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2021-01-012021-12-31_country_HK" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">616,640</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_hsrt--StatementGeographicalAxis__country--HK_zQZ4XU7Pz09d" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign, Tax jurisdictions</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2022-01-012022-12-31_country_HK" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">68,394</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2021-01-012021-12-31_country_HK" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">616,640</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ze9d2YDOMzhe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Loss before income tax</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,670,134</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,387,613</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zuOOqa94XT0b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zvnkRDjToTH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
benefit of (provision for) income taxes consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zd1FtMJnpQK1" style="display: none">SCHEDULE OF PROVISION FOR INCOME TAX</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20220101__20221231_zyjO9HHS05l5" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20210101__20211231_zaZTlg3JC3n7" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zMK5QD2RIBb5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Current:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_iN_di_maITEBzQW2_z60POG4Cj7X3" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%">- Local</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1494">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,205</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--CurrentForeignTaxExpenseBenefit_iN_di_maITEBzQW2_zx6jaeMCGMG5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>- Foreign</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,962</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,735</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zf5oiH7PaL34" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Deferred:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_iN_di_maITEBzQW2_zYXpTW31pcRa" style="vertical-align: bottom; background-color: White">
    <td>- Local</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1503">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1504">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_iN_di_maITEBzQW2_zyDwuD45MHn9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">- Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,017</ix:nonFraction></p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,127</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_iNT_pp0p0_di_mtITEBzQW2_zJnYG9RGYQ28" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Benefit of (Provision for) income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">4,055</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">137,067</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zLpr1cFDX1Z3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
effective tax rate in the periods presented is the result of the mix of income earned in various tax jurisdictions that apply a broad
range of income tax rates. The Company and its subsidiary that operate in various countries: United States, Malaysia (including Labuan)
and Hong Kong that are subject to taxes in the jurisdictions in which they operate, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>United
States of America</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
ATP Corporation was incorporated in the State of Nevada and is subject to the tax laws of the United States of America with a corporate
tax rate of <span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zgJNy2t1B1ze" title="Tax percentage"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-012022-12-31_us-gaap_StateAndLocalJurisdictionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></span>% on its taxable income. Agape ATP Corporation also subject to controlled foreign corporations Subpart F income (&#8220;Subpart
F&#8221;) tax, which is a tax primarily on passive income from controlled foreign corporations with a tax rate of <span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zz8ClLj2ufX1" title="Tax percentage"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-012022-12-31_us-gaap_ForeignCountryMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">35</ix:nonFraction></span>%. <span id="xdx_902_ecustom--TaxRateDescription_c20220101__20221231_ze4PeMh6BJud" title="Tax rate description"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="AATP:TaxRateDescription">In addition, the
Tax Cuts and Jobs Act imposed a global intangible low-taxed income (&#8220;GILTI&#8221;) tax, which is a tax on certain off-shore earnings
at an effective rate of 10.5% for tax years (50% deduction of the current enacted tax rate of 21%) with a partial offset for 80% foreign
tax credits. If the foreign tax rate is 13.125% or higher, there will be no U.S. corporate tax after the 80% foreign tax credits are
applied.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2022 and 2021, the Company&#8217;s foreign subsidiaries did not generate any income that were subject to Subpart F
tax and GILTI tax.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 96 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17.
INCOME TAXES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 and 2021, the operations in the United States of America incurred approximately $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20221231__srt--StatementGeographicalAxis__country--US_zkoq4MMBUwha" title="Operating loss"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31_country_US" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,357,000</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__srt--StatementGeographicalAxis__country--US_zWOT89Pcrepf" title="Operating loss"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2021-12-31_country_US" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">620,000</ix:nonFraction></span>, respectively,
of cumulative net operating losses (&#8220;NOL&#8221;) which can be carried forward to offset future taxable income or Subpart F and
GILTI taxes. These balances can be carried forward indefinitely. The deferred tax valuation allowance as of December 31, 2022 and 2021
were approximately $<span id="xdx_901_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pp0p0_c20221231__srt--StatementGeographicalAxis__country--US_zRO6KfP9duZ3" title="Deferred tax valuation allowance"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-12-31_country_US" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">285,000</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pp0p0_c20211231__srt--StatementGeographicalAxis__country--US_zEoT3y5h8boh" title="Deferred tax valuation allowance"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2021-12-31_country_US" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">130,000</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2021, the Company re-visited its fiscal 2020 U.S. income taxes and determined its stock dividend from Greenpro
Capital Corp as a result of its Spin-off of DSwiss Inc.&#8217;s shares in 2020 were subject to Subpart F and GILTI taxes. As a result,
the Company incurred additional income taxes expenses of $<span id="xdx_909_eus-gaap--IncomeTaxExpenseBenefit_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zcsImL44TVba" title="Income tax expense benefit"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,205</ix:nonFraction></span>, including interest and penalty of $<span id="xdx_902_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_c20210101__20211231_zmMMvEdraQ5g" title="Income tax  examination penalties and interest expense"><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">395</ix:nonFraction></span>, for the year ended December
31, 2021, after utilizing its estimated cumulative net operating losses (&#8220;NOL&#8221;) of $<span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_iI_c20201231_zE6NfjrRcXk1" title="Cumulative net operating loss"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">312,608</ix:nonFraction></span> as of December 31, 2020. As a
result, the Company&#8217;s deferred tax assets of estimated NOL of $<span id="xdx_90C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20211231_zsP4YJOKxmHl" title="Deferred tax assets operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,648</ix:nonFraction></span> were fully utilized and reduced to $<span id="xdx_900_ecustom--DeferredTaxAssetsOperatingLossCarryforwardsReducedAmount_iI_c20211231_ztjakd3u7C47" title="Deferred tax assets operating loss carryforwards reduced amount"><ix:nonFraction name="AATP:DeferredTaxAssetsOperatingLossCarryforwardsReducedAmount" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Malaysia</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
to the Labuan Business Activity Tax Act (LBATA) 1990 which was gazetted and came into operation on January 1, 2019 mandate companies
incorporated in Labuan to satisfy the &#8220;substantial activity requirements&#8221; to qualify for the preferential tax rate of <span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20181228__20190102__srt--StatementGeographicalAxis__custom--LabuanMember_zIRsUgxuLdag" title="Effective tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2018-12-282019-01-02_custom_LabuanMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction></span>%
on net audited profit. Subsequently, on April 29, 2020, a circular setting out revisions to the &#8220;substantial activity requirements&#8221;
was issued. As Agape ATP Corporation did not maintain a permanent establishment in Labuan, and therefore did not satisfy the said requirements,
the company was subjected to tax at <span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20181228__20190102__srt--StatementGeographicalAxis__custom--LabuanMember_zk0ogbKW0V3l" title="Taxp percentage"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2018-12-282019-01-02_custom_LabuanMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">24</ix:nonFraction></span>% on its net audited profit. On June 11, 2021, Agape ATP Corporation made an irrevocable election
to be taxed under the Malaysian Income Tax Act 1967 as the elected tax regime is more tax efficient to the entity compare to LBATA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
Superior Living Sdn Bhd, Agape S.E.A Sdn Bhd and Wellness ATP International Holdings Sdn Bhd. are governed by the income taxes laws of
Malaysia and the income taxes provision in respect of operations in Malaysia is calculated at the applicable tax rates on the taxable
income for the periods based on existing legislation, interpretations and practices in respect thereof. Under the Income Tax Act of Malaysia,
enterprises that incorporated in Malaysia are usually subject to a unified 24% enterprise income taxes rate while preferential tax rates,
tax holidays and even tax exemption may be granted on case-by-case basis. <span id="xdx_90D_eus-gaap--IncomeTaxExaminationDescription_c20220101__20221231__srt--StatementGeographicalAxis__country--MY_zNZZZmJheaGc" title="Income tax examination, description"><ix:nonNumeric contextRef="From2022-01-012022-12-31_country_MY" name="us-gaap:IncomeTaxExaminationDescription">The tax rate for small and medium sized companies (generally
companies incorporated in Malaysia with paid-in capital of RM <span id="xdx_903_eus-gaap--AdditionalPaidInCapitalCommonStock_iI_uRM_c20221231__srt--StatementGeographicalAxis__country--MY_zbKPsZfgFsXl" title="Paid in capital"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2022-12-31_country_MY" format="ixt:numdotdecimal" decimals="0" unitRef="RM">2,500,000</ix:nonFraction></span> or less) is <span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231__srt--StatementGeographicalAxis__country--MY_zZ62Snk1qEg1" title="Tax percentage"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-012022-12-31_country_MY" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">17</ix:nonFraction></span>% for the first RM <span id="xdx_905_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockSplit_uRM_c20220101__20221231__srt--StatementGeographicalAxis__country--MY_zBNTbf6oiRb1" title="Additional paid in capital stock split"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" contextRef="From2022-01-012022-12-31_country_MY" format="ixt:numdotdecimal" decimals="0" unitRef="RM">600,000</ix:nonFraction></span> (or approximately $<span id="xdx_903_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockSplit_c20220101__20221231__srt--StatementGeographicalAxis__country--MY_zygUhR4xo3nh" title="Additional paid in capital stock split"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" contextRef="From2022-01-012022-12-31_country_MY" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span>)
for the year ended December 31, 2022 and 2021, with the remaining balance being taxed at the 24% rate.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 and 2021, the operations in the Malaysia incurred approximately $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20221231__srt--StatementGeographicalAxis__country--MY_zDl4zfqro5ll" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31_country_MY" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,723,000</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__srt--StatementGeographicalAxis__country--MY_zmekVsOtcVJ2" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2021-12-31_country_MY" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">946,000</ix:nonFraction></span>, respectively, of cumulative
net operating losses (&#8220;NOL&#8221;) which can be carried forward to offset future taxable income. Approximately $<span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_c20221231__srt--StatementScenarioAxis__custom--TwoThousandTwentyEightMember_zShKKzS5sOMj" title="Net operating loss carryforward"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31_custom_TwoThousandTwentyEightMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">790,000</ix:nonFraction></span>, $<span id="xdx_907_eus-gaap--OperatingLossCarryforwards_iI_c20221231__srt--StatementScenarioAxis__custom--TwoThousandTwentyNineMember_z4R1I2LYn4i7" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31_custom_TwoThousandTwentyNineMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">897,000</ix:nonFraction></span>
and $<span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_c20221231__srt--StatementScenarioAxis__custom--TwoThousandThirtyMember_zYdQzWPGiCtf" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31_custom_TwoThousandThirtyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,000</ix:nonFraction></span> of the net operating loss carry forwards will expire in 2028, 2029 and 2030, respectively, if unutilized. The deferred tax
valuation allowance as of December 31, 2022 and 2021 were approximately $<span id="xdx_904_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pp0p0_c20221231__srt--StatementGeographicalAxis__country--MY_zkNcrZV4Sqqd" title="Deferred tax valuation allowance"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-12-31_country_MY" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">408,000</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pp0p0_c20211231__srt--StatementGeographicalAxis__country--MY_zIIliFXylte7" title="Deferred tax valuation allowance"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2021-12-31_country_MY" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">217,000</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Hong
Kong</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
ATP International Holding (HK) Limited is subject to Hong Kong Profits Tax, which is charged at the statutory income rate of <span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231__srt--StatementGeographicalAxis__country--HK_z0iE2ahYAfTl" title="Tax percentage"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-012022-12-31_country_HK" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">16.5</ix:nonFraction></span>% on
its assessable income derived from Hong Kong. Business income derived or business expenses incurred outside the Special Administrative
Region is not subject to Hong Kong Profits Tax or deduction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 97 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17.
INCOME TAXES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zs7koufBlsPe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table reconciles the local (United States) statutory rates to the Company&#8217;s effective tax rate for the periods indicated
below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_ztzQ54IozAzh" style="display: none">SCHEDULE OF EFFECTIVE INCOME TAX RATE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20220101__20221231_zHCxR3XC3b55" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20210101__20211231_zgGgyOd8ejc8" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_zYddPEdno3Oc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">U.S. statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="width: 3%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="width: 3%; text-align: left">%</td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_z5DvnDY0tKVa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">22.9</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">17.0</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_dp_uPure_zQNCTYXfjhb5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Differential tax rate in Malaysia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_uPure_zsrG7A1gpjp3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Permanent difference</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2022-01-01to2022-12-31" id="Fact001577" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.2</ix:nonFraction></p></td><td style="padding-bottom: 1.5pt; text-align: left">%<span id="xdx_F27_zatEtQtRgLT8" style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2021-01-012021-12-31" id="Fact001578" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">12.7</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)%<span id="xdx_F2B_zOwAJzLC1RXf" style="font-family: Times New Roman, Times, Serif">(2)</span></td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_uPure_zXyJa4KL4mx9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Effective tax rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.3</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">5.7</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)%&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    amount comprised:</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F03_zytERM4xm703" style="display: none; font-family: Times New Roman, Times, Serif">(1)</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zOWyPY8rPQ44" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001582" xml:lang="en-US">The
    amount comprised:  (1.0)% being expenses
    incurred in AATP LB, ASL, SEA and WATP that are not deductible in the Malaysia tax return.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dp_uPure_c20220101__20221231__srt--ConsolidatedEntitiesAxis__custom--AATPLBASLSEAAndWATPMember_zi6DGrGLC2ag" title="Tax percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtICBTQ0hFRFVMRSBPRiBFRkZFQ1RJVkUgSU5DT01FIFRBWCBSQVRFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="From2022-01-012022-12-31_custom_AATPLBASLSEAAndWATPMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.2</ix:nonFraction></span>%
    being expenses incurred in AATP LB, ASL, SEA and WATP that are not deductible in the Malaysia tax return.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    amount comprised:</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F05_z2wAecmBq731" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zWKUhUXw4cdk" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001585" xml:lang="en-US">The
    amount comprised: 6.2% being income derived in AATP HK that were not taxable in the Malaysia tax returns; and 6.7% being expenses
    incurred in AATP LB, ASL, SEA, WATP, and DSY Wellness that are not deductible in the Malaysia tax return.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dp_uPure_c20210101__20211231__srt--ConsolidatedEntitiesAxis__custom--AATPHKMember_z6xpV1RMQVUj" title="Tax percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtICBTQ0hFRFVMRSBPRiBFRkZFQ1RJVkUgSU5DT01FIFRBWCBSQVRFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="From2021-01-012021-12-31_custom_AATPHKMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.2</ix:nonFraction></span>%
    being income derived in AATP HK that were not taxable in the Malaysia tax returns; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dp_uPure_c20210101__20211231__srt--ConsolidatedEntitiesAxis__custom--AATPLBASLSEAWATPAndDSYMember_zbGeGh7tMbTi" title="Tax percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtICBTQ0hFRFVMRSBPRiBFRkZFQ1RJVkUgSU5DT01FIFRBWCBSQVRFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="From2021-01-012021-12-31_custom_AATPLBASLSEAWATPAndDSYMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.5</ix:nonFraction></span>%
    being expenses incurred in AATP LB, ASL, SEA, WATP, and DSY Wellness that are not deductible in the Malaysia tax return.</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AA_zNnq9UE82us8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zfEpPIcQn1Lf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the significant components of the aggregate deferred tax assets of the Company as of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zWpLBFPc1Dkb" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_49A_20221231_zn52KdWrhKTj" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_490_20211231_z0VTgYqVbouf" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_hsrt--StatementGeographicalAxis__country--US_zVEaoySimCW6" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Net operating loss carry forwards in U.S.</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" contextRef="AsOf2022-12-31_country_US" format="ixt:numdotdecimal" decimals="0" unitRef="USD">284,959</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" contextRef="AsOf2021-12-31_country_US" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,061</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_hsrt--StatementGeographicalAxis__country--MY_zKdi2QR162R4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net operating loss carry forwards in Malaysia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" contextRef="AsOf2022-12-31_country_MY" format="ixt:numdotdecimal" decimals="0" unitRef="USD">408,226</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" contextRef="AsOf2021-12-31_country_MY" format="ixt:numdotdecimal" decimals="0" unitRef="USD">227,106</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_hsrt--StatementGeographicalAxis__country--MY_z1c62vy6Wc2h" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net operating loss carry forwards in Malaysia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" contextRef="AsOf2022-12-31_country_MY" format="ixt:numdotdecimal" decimals="0" unitRef="USD">408,226</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" contextRef="AsOf2021-12-31_country_MY" format="ixt:numdotdecimal" decimals="0" unitRef="USD">227,106</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_c20221231_zoFkfth0N4jk" title="Less: valuation allowance" style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">693,185</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_c20211231_zHah2jn5TAA3" title="Less: valuation allowance" style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">380,167</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DeferredTaxLiabilitiesDepreciation_iI_zz9ivyR9T0h9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1606">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="AATP:DeferredTaxLiabilitiesDepreciation" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,574</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iNI_di_zrvCGHXA3RVl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Deferred tax liabilities, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1609">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,574</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zUlQheZGTDob" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Uncertain
tax positions</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company evaluates each uncertain tax position (including the potential application of interest and penalties) based on the technical
merits, and measure the unrecognized benefits associated with the tax positions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
As of December 31, 2022 and 2021, the Company did not have any significant unrecognized uncertain tax positions. The Company did not
incur interest and penalties tax for the years ended December 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 98 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:ConcentrationRiskDisclosureTextBlock"><p id="xdx_80B_eus-gaap--ConcentrationRiskDisclosureTextBlock_zROLBkIHSamd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>18.
<span id="xdx_821_zlvbAJHpNgn5">CONCENTRATIONS OF RISKS</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Major customers</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2022 and 2021, no customer accounted for <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--NoCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWKJc4bsj6Uc" title="Concentrations of risk percentage"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--NoCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zAONw3R7qX0b" title="Concentrations of risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_custom_NoCustomerMember_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-01-012021-12-31_custom_NoCustomerMember_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10.0</ix:nonFraction></ix:nonFraction></span></span>% or more of the Company&#8217;s total revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, five individual customers accounted for approximately <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--FiveIndividualCustomersMember_zBwk0nuBy2zc" title="Concentrations of risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_FiveIndividualCustomersMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">72.0</ix:nonFraction></span>% of the Company&#8217;s balance of accounts receivable.
There was no accounts receivable balance as of December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Major vendors</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2022, three vendors accounted for approximately <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zfuoGkoRdPA3" title="Concentrations of risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_custom_VendorOneMember_us-gaap_CostOfGoodsTotalMember_us-gaap_SupplierConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">53.3</ix:nonFraction></span>%, <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zoZqGJPNUz78" title="Concentrations of risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_custom_VendorTwoMember_us-gaap_CostOfGoodsTotalMember_us-gaap_SupplierConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">22.1</ix:nonFraction></span>% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zDnV58Jej51h" title="Concentrations of risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_custom_VendorThreeMember_us-gaap_CostOfGoodsTotalMember_us-gaap_SupplierConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.3</ix:nonFraction></span>% of the Company&#8217;s total purchases.
For the year ended December 31, 2021, two vendors accounted for approximately <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zQPkwlZce1Z9" title="Concentrations of risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-01-012021-12-31_custom_VendorOneMember_us-gaap_CostOfGoodsTotalMember_us-gaap_SupplierConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">47.3</ix:nonFraction></span>% and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_ziDzEcL0CCl2" title="Concentrations of risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-01-012021-12-31_custom_VendorTwoMember_us-gaap_CostOfGoodsTotalMember_us-gaap_SupplierConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">45.2</ix:nonFraction></span>% of the Company&#8217;s total purchases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Via a dividend distribution, the Company acquired <span id="xdx_90E_ecustom--DividendShareForCommonStock_pid_c20210101__20211231__dei--LegalEntityAxis__custom--DSwissIncMember_zca4wE7CywH" title="Dividend share for common stock"><ix:nonFraction name="AATP:DividendShareForCommonStock" contextRef="From2021-01-012021-12-31_custom_DSwissIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,330</ix:nonFraction></span> shares of common stock of DSwiss, Inc., represents approximately <span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20211231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DSwissIncMember_zleAnAUhNaJ2" title="Equity method investment ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2021-12-31_custom_DSwissIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.01</ix:nonFraction></span>% ownership,
that the Company accounted for as investment in marketable securities (See Note 11). DSwiss, Inc.&#8217;s wholly owned subsidiary is
the vendor that accounted for the Company&#8217;s total purchases of approximately <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__srt--MajorCustomersAxis__custom--VendorOneMember__dei--LegalEntityAxis__custom--DSwissIncMember_zusE8A7Yki5d" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfGoodsTotalMember_custom_VendorOneMember_custom_DSwissIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">22.1</ix:nonFraction></span>% and <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__srt--MajorCustomersAxis__custom--VendorOneMember__dei--LegalEntityAxis__custom--DSwissIncMember_z5Lx7iFKKLlh" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-01-012021-12-31_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfGoodsTotalMember_custom_VendorOneMember_custom_DSwissIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">47.3</ix:nonFraction></span>% for the years ended December 31, 2022
and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, three vendors accounted for approximately <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zBdUEcqmBp4i"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_custom_VendorOneMember_us-gaap_AccountsPayableMember_us-gaap_SupplierConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">46.6</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
<span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zsDL8yJK0zxh"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_custom_VendorTwoMember_us-gaap_AccountsPayableMember_us-gaap_SupplierConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25.8</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_z7gJ9lvHSQf2"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_custom_VendorThreeMember_us-gaap_AccountsPayableMember_us-gaap_SupplierConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">23.9</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the Company&#8217;s total balance of accounts payable, respectively. CTA Nutriceuticals (Asia) Sdn Bhd, a related company, accounted
for approximately <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zk63rwWeuecd"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_custom_VendorMember_us-gaap_AccountsPayableMember_us-gaap_SupplierConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">47</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the Company&#8217;s total balance of accounts payable. As of December 31, 2021, one vendor accounted for <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__srt--MajorCustomersAxis__custom--OneVendorMember_zhnOu5e2jfLl"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_us-gaap_SupplierConcentrationRiskMember_us-gaap_AccountsPayableMember_custom_OneVendorMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the total balance of accounts payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Commission Expenses to Sales Distributors and Stockists</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2022, one sales distributor accounted for approximately <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__srt--MajorCustomersAxis__custom--OneSalesDistributorMember_zJL3nnPr6syj" title="Concentrations of risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfGoodsTotalMember_custom_OneSalesDistributorMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10.3</ix:nonFraction></span>%
of the Company&#8217;s total commission expense. For the year ended December 2021, one sales distributor accounted for approximately <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__srt--MajorCustomersAxis__custom--OneSalesDistributorMember_zhaCbealWL3l" title="Concentrations of risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2021-01-012021-12-31_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfGoodsTotalMember_custom_OneSalesDistributorMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">17.9</ix:nonFraction></span>%
of the Company&#8217;s total commission expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Credit risk</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. As of December
31, 2022 and 2021, $<span id="xdx_901_eus-gaap--Deposits_iI_pp0p0_c20221231_z6mGVwNczc65" title="Deposits"><ix:nonFraction name="us-gaap:Deposits" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">513,152</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--Deposits_iI_pp0p0_c20211231_z7vQs6ijMMzl" title="Deposits"><ix:nonFraction name="us-gaap:Deposits" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">554,864</ix:nonFraction></span> were deposited with financial institutions, respectively, $<span id="xdx_908_ecustom--DepositForInsurance_iI_pp0p0_c20221231_zeLPRNuQv3p" title="Deposit for insurance"><ix:nonFraction name="AATP:DepositForInsurance" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">231,187</ix:nonFraction></span> and $<span id="xdx_900_ecustom--DepositForInsurance_iI_pp0p0_c20211231_zrvdO8zk80Ag" title="Deposit for insurance"><ix:nonFraction name="AATP:DepositForInsurance" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">295,761</ix:nonFraction></span> of these balances
are not covered by deposit insurance. While management believes that these financial institutions are of high credit quality, it also
continually monitors their credit worthiness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that are potentially subject to credit risk consist principally of accounts receivable. The Company believes the concentration
of credit risk in its account receivable is substantially mitigated by its ongoing credit evaluation process and relatively short collection
terms. The Company does not generally require collateral from customers. The Company evaluates the need for an allowance for doubtful
accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information. Historically,
the Company did not have any bad debt on its account receivable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Exchange rate risk</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company cannot guarantee that the current exchange rate will remain steady; therefore, there is a possibility that the Company could
post the same amount of profit for two comparable periods and because of the fluctuating exchange rate actually post higher or lower
profit depending on exchange rate of RM and HK$ converted to US$ on that date. The exchange rate could fluctuate depending on changes
in political and economic environments without notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 99 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80C_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z69LD8AdR3ud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>19.
<span id="xdx_822_zheUq6pXeslf">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Lease
commitments</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 1, 2020, the Company adopted ASC 842 for ASL&#8217;s office space lease and sales and training center as the lease commencement
date upon the acquisition of ASL. The Company recognized lease liabilities of approximately $<span id="xdx_905_eus-gaap--OperatingLeaseLiability_iI_c20200401__us-gaap--BusinessAcquisitionAxis__custom--AgapeSuperiorLivingMember_zHEG7ffirE7f" title="Operating lease liability"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2020-04-01_custom_AgapeSuperiorLivingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">490,000</ix:nonFraction></span>, with a corresponding right-of-use
(&#8220;ROU&#8221;) asset in the same amount based on the present value of the future minimum rental payments of the lease, using an
effective interest rate of <span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20200401__us-gaap--BusinessAcquisitionAxis__custom--AgapeSuperiorLivingMember_zsfc97PkyXX" title="Operating lease effective interest rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2020-04-01_custom_AgapeSuperiorLivingMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.5</ix:nonFraction></span>%, which was determined using the Company&#8217;s estimated incremental borrowing rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 31, 2021, the Company entered into two separate two-year leases extension with the modified lease expiring <span id="xdx_902_ecustom--LeaseExpirationTerm_dd_c20210530__20210531_z5HRcpGjQYe4" title="Lease expiration term"><ix:nonNumeric contextRef="From2021-05-302021-05-31" format="ixt:datemonthdayyearen" name="AATP:LeaseExpirationTerm">May 31, 2023</ix:nonNumeric></span> for its office
space and expiring <span id="xdx_906_ecustom--LeaseExpirationTerm_dd_c20210530__20210531__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--TrainingCenterMember_zgWo3XXLKBk4" title="Lease expiration term"><ix:nonNumeric contextRef="From2021-05-302021-05-31_custom_TrainingCenterMember" format="ixt:datemonthdayyearen" name="AATP:LeaseExpirationTerm">August 31, 2023</ix:nonNumeric></span> for its training center. The lease modification required the Company to re-measure the ROU assets
and lease liabilities based on the modified leases. The Company recognized a reduction of $<span id="xdx_907_ecustom--IncreaseDecreaseInROUAssetsAndLiabilities_iI_c20210531_zMm1KiV1UOf5" title="Reduction in ROU assets and liabilities"><ix:nonFraction name="AATP:IncreaseDecreaseInROUAssetsAndLiabilities" contextRef="AsOf2021-05-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,250</ix:nonFraction></span> in ROU assets and lease liabilities
upon lease modifications based on the present value of the future minimum rental payments of the lease, using an effective interest rate
of <span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20210531__us-gaap--BusinessAcquisitionAxis__custom--AgapeSuperiorLivingMember_zZFVSgvwkURl" title="Operating lease effective interest rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2021-05-31_custom_AgapeSuperiorLivingMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.5</ix:nonFraction></span>%, which was determined using the Company&#8217;s estimated incremental borrowing rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 1, 2021, the Company entered into a <span id="xdx_90B_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dxL_c20211001_zwO49qHuz3n7" title="Operating lease term::XDX::P2Y"><span style="-sec-ix-hidden: xdx2ixbrl1669">two-years</span></span>
lease for an apartment to serve as staff accommodation. The Company recognized lease liabilities of approximately $<span id="xdx_908_eus-gaap--OperatingLeaseLiability_iI_c20211001_zQfxh8uQLN0i" title="Operating lease liability"><span id="xdx_905_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20211001_zoOOaZ2efkBe" title="Operating right-of-use assets"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2021-10-01" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-10-01" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,777</ix:nonFraction></ix:nonFraction></span></span>, with a corresponding
right-of-use (&#8220;ROU&#8221;) asset in the same amount based on the present value of the future minimum rental payments of the lease,
using an effective interest rate of <span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20211001_zi8zLBxgsmve" title="Operating lease effective interest rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2021-10-01" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.5</ix:nonFraction></span>%, which was determined using the Company&#8217;s estimated incremental borrowing rate.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">On November 1, 2021, the Company entered into a <span id="xdx_90A_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dxL_c20211101_zJeDmQwI3MWk" title="Lease term::XDX::P2Y"><span style="-sec-ix-hidden: xdx2ixbrl1677">two-years</span></span> lease for a branch
office and operating centre. The Company recognized lease liabilities of approximately $<span id="xdx_907_eus-gaap--OperatingLeaseLiability_iI_c20211101_zpBUZLZW2Lbh" title="Operating lease liability"><span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20211101_zgVkR9kWAfa4" title="Operating right-of-use assets"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2021-11-01" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-11-01" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,864</ix:nonFraction></ix:nonFraction></span></span>, with a corresponding right-of-use (&#8220;ROU&#8221;)
asset in the same amount based on the present value of the future minimum rental payments of the lease, using an effective interest rate
of <span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20211101_zUAmwGr4yWbi" title="Operating lease effective interest rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2021-11-01" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.5</ix:nonFraction></span>%, which was determined using the Company&#8217;s estimated incremental borrowing rate.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
of December 31, 2022, the weighted remaining term of the lease is approximately <span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231__us-gaap--BusinessAcquisitionAxis__custom--AgapeSuperiorLivingMember_zXR7UdCxOVR9" title="Operating lease, weighted average remaining lease term"><ix:nonNumeric contextRef="AsOf2022-12-31_custom_AgapeSuperiorLivingMember" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">0.54</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_894_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z19xei46SuY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
five-year maturity of the Company&#8217;s operating lease liabilities is as follow:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B8_zPzwct6CWzei" style="display: none">SCHEDULE OF LEASE COMMITMENTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_498_20221231_zelUUryFsmN9" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Twelve Months Ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating lease liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzA1T_znNAabTgceb9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">84,146</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterNextTwelveMonths_iI_pp0p0_maLOLLPzA1T_zVWVdRWGvhwa" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1691">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzA1T_zr1jivH6QUx5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">84,146</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zxPaMYfFvuCg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,439</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zbhS2P8SMYie" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">82,707</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zKoWpdy9tLcj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also leased one office and operation center, and one shophouse with an expiring term of twelve months or less, which were classified
as operation leases. Since the lease terms for these leases were twelve months or less, a lessee is permitted to elect not to recognize
lease assets and liabilities. The Company has elected not to recognize lease assets and liabilities on these leases. As of December 31,
2022, the Company&#8217;s commitment for minimum lease payment under these operating leases within the next twelve months were $<span id="xdx_906_eus-gaap--OperatingLeasePayments_c20220101__20221231_zGIFHSAk5Ky1" title="Operating lease payments"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">567</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent
expense for the years ended December 31, 2022 and 2021 was $<span id="xdx_90C_eus-gaap--OperatingLeaseExpense_pp0p0_c20220101__20221231_zcxO7WDxBHfd" title="Operating lease, expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">190,547</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--OperatingLeaseExpense_pp0p0_c20210101__20211231_z7CK0VXCjhHg" title="Operating lease, expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">179,562</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Contingencies</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Company is party to certain legal proceedings, as well as certain asserted and un-asserted claims. Amounts accrued,
as well as the total amount of reasonably possible losses with respect to such matters, individually and in the aggregate, are not deemed
to be material to the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COVID-19</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malaysia,
where the operations of the Company predominantly reside, officially transitioned to the endemic phase of COVID-19 effective April 1,
2022. Restrictions on businesses and people are minimal. Meanwhile, the government continues to encourage inoculation for those between
the ages of 5 and 11 years and its adolescent group which comprised those between the ages 12 and 17. Adults who have been fully vaccinated,
i.e. received two doses of the COVID-19 vaccine are encouraged to take booster shots.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantially
all of our revenues are concentrated in Malaysia. Consequently, our results of operations will likely be adversely, and may be materially,
affected, to the extent that the COVID-19 or any other epidemic harms the Malaysia and global economy in general. Any potential impact
to our results will depend on, to a large extent, future developments and new information that may emerge regarding the duration and
severity of the COVID-19 and the actions taken by government authorities and other entities to contain the COVID-19 or treat its impact,
almost all of which are beyond our control. Potential impacts include, but are not limited to, the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">temporary
    closure of offices, travel restrictions, disruption or suspension of supplies, our customers may be negatively impacted financially
    resulting in which the demand for our products may be adversely affected</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">we
    may have to provide significant sales incentives to our customers during the outbreak, which may in turn materially adversely affect
    our financial condition and operating results</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    disruption of our supply chain, logistics providers or customers could adversely impact our business and results of operations, including
    causing us or our suppliers to cease manufacturing for a period of time or materially delay delivery to our customers, which may
    also lead to loss of our customers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the uncertainty surrounding the COVID-19 outbreak, the financial impact related to the outbreak of and response to the COVID-19 cannot
be reasonably estimated at this time. There is no guarantee that the Company&#8217;s total revenues will grow or remain at similar levels
year over year in 2023 and beyond.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zyuucV8ANjb8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>20.
<span id="xdx_824_zM4zIO21U53c">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated subsequent events through the date of issuance of this consolidated financial statements,
and does not identify any events with material financial impact on the Company&#8217;s consolidated financial statements.</span></p>
</ix:nonNumeric><p id="xdx_815_zumU9J2639jd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 100; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>



</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!--  
       -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, HOW KOK CHOONG, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. I have reviewed this annual report on Form 10-K
of Agape ATP Corporation (the &ldquo;Company&rdquo;) for the year ended December 31, 2022;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2. Based on my knowledge, this annual report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of
the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4. The registrant&rsquo;s other certifying officer
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5. The registrant&rsquo;s other certifying officer
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 31, 2023</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ How Kok Choong</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HOW KOK CHOONG</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Chief Executive Officer,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">President, Director, Secretary, Treasurer</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, ANDREW LEE KAM FAN, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. I have reviewed this annual report on Form 10-K
of Agape ATP Corporation (the &ldquo;Company&rdquo;) for the year ended December 31, 2022;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2. Based on my knowledge, this annual report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of
the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4. The registrant&rsquo;s other certifying officer
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5. The registrant&rsquo;s other certifying officer
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 31, 2023</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Andrew Lee Kam Fan</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEE KAM FAN</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer,</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>3
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO<BR>
18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Annual Report of Agape ATP
Corporation (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December 31, 2022 as filed with the Securities and Exchange Commission
on the date hereof (the &ldquo;Report&rdquo;), The undersigned hereby certifies, pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant
to &sect; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(1) The Report fully complies
with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(2) The information contained
in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 31, 2023</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ How Kok Choong</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HOW KOK CHOONG</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Chief Executive Officer,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">President, Director, Secretary, Treasurer</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A signed original of this written statement required
by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within
the electronic version of this written statement has been provided to the Company and will be retained by the Company and will be retained
by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO<BR>
18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Annual Report of Agape ATP
Corporation (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December 31, 2022 as filed with the Securities and Exchange Commission
on the date hereof (the &ldquo;Report&rdquo;), The undersigned hereby certifies, pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant
to &sect; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(1) The Report fully complies
with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(2) The information contained
in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 31, 2023</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Andrew Lee Kam Fan</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEE KAM FAN</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A signed original of this written statement required
by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within
the electronic version of this written statement has been provided to the Company and will be retained by the Company and will be retained
by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>form10-k_001.jpg
<TEXT>
begin 644 form10-k_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (6 7,# 2(  A$! Q$!_\0
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MIVG_ #U/_?#?X4 6Z*KK?6K#(GC'^\<?SJ1)XI/]7*C?[K T 24444 %%%%
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MCN\:/*S6[-W 4UQ$NI+<PF*>1']&V8(_*FPW21V;6PDBVL<[L$&CE079WO\
MPF]]E &MB#U//%21^-[II&79:L%[A^M>;F-<CRYU)_WO_K5<B=8("L$"^8WW
MG:0$GZ>E'*@N>@)XWG,>][%&'3Y9 34X\9IE1)ILV6_NX;^5>9I'E3)<_:%
M/RJH.#^-()YKB7]Q.ENJ#@ESDT<H7/4X?&^G(S?\?$!'WOE(Q6A;>-+%_P#5
MZIC/]\Y_G7D:WMXJ,D,EQ<MW) VBI8[ZXV![R"S94Z;NOZ468[GM<'B;S%'E
MW-O+GUZ_H:O)KXR-\''<HV?TKP5;K3W<KY%Q$[<[[=R<?A5^WN)P2=-UY@0/
MEBFX.?2GJ%SW2/6K)Q\SM&?1E/\ 3-7(KF"?B*:-SUPK FO#3XD\1:;S=VL=
MQ&.KKQ5VR\?6$Q"74;VS_P"T,BB[ZCNCVJBN$T[Q*[H'MKP2Q\<%MP_^M71V
M7B""?"3CRF/\6<J?\*::8[&Q10"" 0<@]Z*8@HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** (;FYCM(#+(>!T'<GT%<_<WKW!,D[80<JG8?XU#JUX
MUQJ<B$_)"=BC^9_/^E<7X^U2>TT81PL5,S["P[#'-2QAXA^(<5F[6NF()YAP
M7_A4_P!:YN.TU?Q"WVG5+QA;]<;P ![ <5E>&;..ZOPSC.W'!*?R//Y5M^-;
MR6UL[:TA)1)2=V.X&./UHL3>Y1FU+2].<P:9:+<2_P#/63E<^V:HRW=[J)/V
MNZE0?W=AV_I5"PDB3)D^SAL\-*9,C_OFMJ/5+=(FQ=Q!@.BQ2<^P)84Q$*>4
M(A@6KXXPJD,??&::&MKF0+9VCO.>T9(4?6J>HWC3QIB5R#G(,A/Z;CBKVIDZ
M;HME!:?*EU'YDTHZN>.,^@STH$-FF6%/+N;L,1_RR@&['_ CP/UIB2P.H?\
M<1,>$:8F0GZCH/RK-MK;[2DC>=$A09VN^TM],]:N6,K6\RA;B,(P,;>=]T C
MV)/XT .9W9&5K]4*GE ,*1[8Z_I5>6.+89!=F0'A05(/XU9M3Y,TR-=1JLJ%
M&9]KKC\&)_G4<;!M/>W:]A56D)",AQQWR.1GZ4 1-:P;#BX.\#)+(=I^A_\
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M$3X-U^745N-EKN@8%8RDJQJ <A1\O3Z'O[U#/X&UV]N)[MQ &=V=AME'.<G
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M&@"4&G@U"I/>I : ) :=FF TX4"'"G"FBE% QW-+S2#%.XH .:.:.*7(H$(
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M6/!XDT*XD6.'6=/>1_NHMRA8_AG-:RL" 000>],HE%.%,!IP-,8\4X4P4X4
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M332:8#6-1/TJ1JADY4BF,[^BBBF 4444 %%%% !1110 4444 %%%% !1110
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MDK.1RSW+MOJC(!YZ$J3@.!6I;W,,X_=NK>W?\JBM"MWX/O+80EIH)/-1MO\
M#D;L'U Z^U<X&(.1Q28FVK'?Z0<7I_W#_,5T<?!%>?\ A6[N&U"52S2[86*H
M3R3D<9-=);>)[+SO(NDGM90P0K+&<;CT&1D5C)-O0UC)6.ECJRG:J\=6D' H
M2-42H.14R+S34'2IU6M$AB*M/ IP6G!:=@ #BG@4!:>!18!0*D%- IXJDAF'
MK<V9DB[*,GZUE%B!S5_75*W@/8J#6:3GN*\;$-^T9+W%W[9 _IS6S9ZU)Y1!
M4$ <9K#?!!QBI+-\(P-9PJ2@[Q8B\C_:'9I,$DDFK"S*B[(P/HHJ@N O+<>E
M2"=MNV-<#U I*3W"Y=R^ 68**FA82-MC)+5EL<<R2?@#6YI,&(O/88W#Y![>
MM;T(N<K(:+Z)LC"^E#4K,!4+RX'%>QL,4FHV8 <FHWE;/7%0,Q/4U#D3<F>8
M<XJ$R,3UIIII-+F8KD^=RBGVP)O;<#_GJO\ ,5#&?EJ:US]OML?\]4_F*T12
M.ZHHHJQA1110 4444 %%%% !1110 4444 %%%% !7)_$,9\-I_U\#_T%JZRN
M4^(7_(MK_P!=U_\ 06H \+U1<V[^W-<Y)UKJ+T;HY![5RTG6HD<]0W_#?B:/
M14>WGMS)"[[BRGD'&.G?I6XVB>&_$F9-/N5M[@\E8^/S0_TQ6'X8\/0:LD]S
M>R%+:([< XR>O)]*OZCX)0VYN]%NC,5Y\LL#G_=84:V"/-;NA-.T270/$WV:
M29)1);EU=01QN Y'X4[49K9=6EA_M2>S5I(VG46Y=2XVE<-_"<!:S?#MU=7&
MN 74TLC1Q,@\PDE1GIS6O<3+%K4S0ZA=VC;0TKF)9(>%!QCKG!!K'[01LUH=
ME#5R.J41Y-7(SFE$W1;0=*L**KH:KW-Q*C$*Q&*N=105V4:(8T\-7FM]K^N6
M1+I/N3IRH-9P\;ZJS?-<$>V!7/'&1DKI?D8.LET/7@U/!%>1)XWU=#Q,K#_:
M6K">/M4_B$9^@Q3^M+^5_@+ZQ$]8!%.R*\UMOB#.I_?0@CVK:M/'EE.X2165
MCZBFL73^TFBU6@^IT>IV(O8.#^\7E??VKA+G6[>TF>*2*<,C89=HR#^==U:Z
MM9W0'ES+D]LU4UOPS8:['ODS'/C"S1]?Q]145:4:WOTW<<KR7NLX9O%%GM.V
M&?/H0!_6IM%UUM4NI0+7RXH1EF9\?TJ"]^'6L0%VMIK>Y0<@$E6/X=/UK.\-
M:1?W\=]:VX5)MVUPY( QUS7%4I.,;6U.>]5-71H7/BMHY&%O C<\%B3FJ$WB
MK5)OEC:.+)X")G^>:WK;X97LN#>:JD8[I#%G]21_*NJT7P;I.BLLD<;3W _Y
M;3'<1]!T%;PPLNJ&J=66[L8'AOP[JE_(E[K-Q.L Y2#.TO\ [P'0>U=[@*H4
M# '04M-8UZ%.G&FK(Z(Q459#&-5W/%2.>M5W;BB3!C6/-1DTK'FHR>*R;('$
MTPF@GFFDT[@6(_N?C4]H?^)A:_\ 79/YBH$X05-9G_B8VO\ UV3^8K>)HCNZ
M***L84444 %%%% !1110 4444 %%%% !1110 5RWQ &?#8]IU_DU=37,^/!G
MPRY])%/\Z /#KD9+"N4G7;*P]#767/WC7,7Z[;N0>^:B1A,V]*WW7@W5;6')
ME1UE*CNO&?Y&L;2-7NM'OEGMY#MR-\>>''H:FT75)M'O5O%1G@)V2#L1Z?6N
MOAT7PMK<JWD$H3)W/$LFW\U/3\,4MR4N9*SU&ZC9)!XJMK^W 5+VW9\?[0QD
M_D1^M9UQ;37<ZS7VGR3!3M>33IP=^.Q0\^WK6CJ>JVU[XILK2T=7CM8G!9>1
MDXX_ **PWTN^LRSBPE=HU/DR6LN?WN<ARO!YX!X-0[<Q3WT/0XVY.>M7(C6?
M&>:N1-P*QB]35,T4/2J]VA#DDX5A^M21FII(A-$4/X'TK2I#GC8HX";8Y>,D
M]\ US=UH=TSL\2@@G. :ZB\LIENVBE7;(IQN'0CUJ5+8VK[99%+'^Z<BOGHS
ME2;L<CC?<X,VMS ^)(V'U%/5&)P.M=O>P[[<E0I/N*YN2VD2;F,#TQ73#$<^
MZ,9PL7-+T07&'G?"^E=-;V>E6:@% 3]*RK))C&J\@5JPVB\%\FN&I5DY:FU-
M=D,G>P9@8X'+=BM36UYJT!4V<KB,?P2C<#5R,VT6,I^.*NQSPL/E ITVT[QE
M9FJA=[C8/%4\9*7MF,@?>C/7\#_C6-HTSZ=JMY>(N?M4C.R>F3FKEX%;.T<U
M26*0-Q53QE9M7EL3*]]SJX=:DE'^K458346)&0*YN!Y%QFM33P;B8*1P.M=-
M#&5IR4;ZFRE<W]V5!]:C=J<W J%S7OME,C=N3S5=VXJ1SS4#'BL),S;$)YII
M-&>:58G;M@>]1JR1I-.2,LWM4RVZCKS3S@<"M5'N4D--269_XF-K_P!=D_\
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M- P=7M?^N@JX)J6I45J>D4445UFH4444 %%%% !1110 4444 %%%% !1110
M5A>,_P#D4K_Z)_Z&M;M8?C 9\*7X_P!E?_0A0!X#)SD>YJ ]:E<C+_[QJ(]:
M3,V6;."69;IK>[>VFCB+*5[XZ@USC>(=8/\ S$;C\'Q73Z1]G_M%3<2F)<$
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MBSIPL*+N-;^@.'\3PD<C<?Y&M;Z_,[8-W=^YZ-1116IL%%%% !1110 4444
M%%%% !1110 4444 %97B49\-:@/^F+&M6LWQ ,^'=1'_ $[O_*@#YND;&H3"
ME-1W1VZM(.F33\YI,S9:L7M4N@;R/?"00<#I[U9U+PC'JD:SZ5>(P'\#G/ZB
MG:CIUM96,#B0_:'(W MU&/2J:VNK1VIN["&93C*NF/F_#O28FNA8U30Y-/\
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MGE6E^(+O2K=88(X"H.<NI)_G6HOC[65&$^SK](__ *]>BK\+/#@ZK='ZS?\
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M )<T9J$R@=32IOD^XC,,XR!D4Q$FZD+T];.=^H"CW/\ A5A+! <NS-[#@46
MI;B3@ DGL*FCM)I.6^1??K^5:"1I&,(H7Z"G4Q$$5K%%@XW-ZM4]%% !1110
M 4444 %%%% !1110 4444 )12T4 %%%% !1110 4444 %%%% !1110 4444
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A% !1110 4444 %%%% !1110 4444 %%%% "8HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>form10-k_002.jpg
<TEXT>
begin 644 form10-k_002.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )3 0<# 2(  A$! Q$!_\0
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M&.1LLHS_  FO?- \0V/B73UN["82QGJO\2GT([&JN*QI4444Q!1110 4444
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MZ/G_ ($*J(CW9?NBEIJ?<7Z4ZMC,**** "BBB@ HHHH **** "BBB@ HHHH
M*\[^.W_(AR9_Y^(_ZUZ)7GGQU_Y$-_\ KXC_ *T ?/\ I_6M^U<+@GM7/V/W
M@<'!-;]JHK*1HC9M?N^O K6MQ_6L.QD((5N1@8-;EOVY[FH*+]N#M'TJ["/E
M'TJC"?NCVJ]#V^E2(LQ]!]*GC[5!'V^E3(.5YI@2KVIZTQ>U/H >O>G4T=Z=
MZTP'4QN:4TUJ &-4,E3-4,E %*?H:YZ^&W4+7WE7_P!"%=%<8^E<]J:_Z7:D
M'I*I_45:W$>Z1_ZM?H*=3(?]2G^Z*?6IF%%%% !1110 4444 %%%% !1110
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M)SMS\U9D6FK)C(J:/PZ&D$@RLG8KQ6,F,[>UQZ=JT[=>?7FN0LVU"R &[SD
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MDJ*Y?X?^*AXFT5?,?-[;XCG!QDGLV/?_ !KJ*L@**** "BBB@ HHHH ****
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M<UZY\&_AOJOC#5(3#;LEFI'F7##"@>WK7KGPQ_8Q@TEH;SQ9<K>2J0PLX/N
M^Y[U]#V.AV.@6,=K8V\=K!&,*D:XKR<PSJC&'L<-KY]/D>CEV3UG4]MB=/+K
M\ST[]F71X- TS4["W&$A6(?4_-S7MU>/_ %?FUMLY/[H?^A5[!7P<FY-MGWB
M5E9!1114C"BBB@ HHHH **** "ORC_:OR_QJ\4G/'VQOY"OU<K\GOVK,GXT>
M*3@X^UOC]*]O*?X[]#R<RUHGS#J2F+4IU[ELU2N&Z9ZUHZY_R%9JSIL[>>M?
MJ=+X4?E-16J-$:JK=14VP;5_*HHVQQC%=OX=\-Z3-X3O=:OWN+F2VD6/[';,
M%8*?XR?2M*E2-*/-)%0IRJ2Y4<@J]*GL=/N=2NDM[6![B>0X6.,9)_"NT\0^
M#=-C\"Z?XHTQKF&&YG-N;:X(8@C.6##MD5U7P"\)ZA;^+M"\02P(=*DG: 2[
M@</@\$5A4QE.-"59=+Z/NNAI#"U)5HTN]GIV?4\RN/"^L:?)LN-,NHF'9H6_
MPJ-89(^&1E([,#FOTMBTJTN-IEMHY/\ >0&FOX"\/W3;Y=&LV/?,*YKYFGQ0
ME\=+\3WZG#<I?#5_#_@GYNP@U8#'=SP*_1";X,>#+S)DT"TS[(!38_V?_ DB
MX_X1^V^;KQ77'BG#]:;_  .&7"V(>U1?B?GFW:A>:_0]?V=_ ;#!T"W'&.AJ
MQ'^SWX$5]W_"/VI.<]*T_P!:\+_)+\#/_57$_P \?Q/SNC7&!@U9^SR;0?+;
MYO\ 9-?HU:_!#P7:E2GA^TRO3Y,UNP_#_P .P(%71[, =/W*UG+BRC]FD_O1
MI'A&M)^_57W'YGVGAO5[QE\C3KN4-_<A8@_I75:+\%?&WB":*.UT&ZQ(<!Y$
MV@>Y)K]&K;1+&S4"&TAB'8*@&*MPJL/W5"CL!7#4XMJO^'22]7_PQWT^$:5_
MWE5OT27^9\%6?['_ (YOY1'<1VUDO=WDW5W/AO\ 82@WQR:YK3OQ\T5LN/U-
M?7^P#DC)IC<5XU;B+'U5924?1'M4.'<!0^RWZL\A\*_LR^ ?".QXM&CO)U S
M+=_O#GUP:]&CL+>QA$4$2P1+T6-0 /P%:+MUS528YR:\&MB*V(?-5DY/S/?I
M4*5!6I14?0J3?+G!R:RKQCZ5IRCJ>^*S+QOE;O7.=!ZC\ \;-9P/XH_Y&O7*
M\B^ +;H]:XQ\T?\ (UZ[4LU"BBBD 4444 %%%% !1110 5^4/[53*WQB\2$'
MK=R _I7ZO5^3/[4+$_%[Q.1C_C\<U[>4_P ?Y'EYC_!/FG7LKJ9[9%4)&9U-
M:?B1=MX&]?2LO)P!7ZE1^%'Y565JC&*Q9@,X_I7JGAGX<ZB?#%YKVD:O%-=0
M%0MO;L&$BG&58'^1KRQ%ZUW/A#PX+CPOJ&J7.MS:7I\4BQR) "S.QZ<"L\9S
M*FFI6U72]_(Z,+RRG9QO\[6\[FW>>.+IO#=OH.N^%0;&"3S4%N&A.\DY;CCG
M)KT#X5>*KO5M6\.Z5!X?.C^'([CS/.;+&20 X&X^]<A)X<U;1=/T_4=-\8VL
MMEJ&3:K?DHS@=?O @$5V?@63QLWC#P_9>(GA?1VEWQ?9W0H[ $@\=1Q7@U_9
M2HRY$NKW:UMK:+ZGLT/:1JQYV^BV3TTM=KH?75FW"5J0-ZBLBU_AZ?G6K"V"
M <&OSP^Y+RGY<U!9^(+:;69=,#*+F.,2;<\E3QFFW%P+>W>1CA5!)/I7RM<?
M&[[%^T#;WF)8=*D1;,^:F-RDD;_IFO0P>"GC'-0^RFSS\9CJ>"47/JTO^"?8
MRMM_K4BR<@XKYV^('[7F@^ /$=QH\NG7%_)"$_>V\J[6R,_I_2N&U#]N"2^N
MT2PT:2RL\_-)(P>7\!TK>ED^-K)2C3T?H95,XP=%N,YZKR9]D+*.I(^E5YM:
MM+:0)),BNW1<Y)KY(A_;,L[9'/\ 9%]>RY!#32JJY^@Z"J\_[:MRK%K?PO:@
MGG,DQSGUKHCD&/D_X?XK_,QEQ!E\5_$_!_Y'U:WB=9DE^S6EU=/&^QE1,$_3
M/:L"^UWQ1)XVT^UM=,VZ,T9:>=SRK=ABO'_A#^UL?&/BJWT;6M.AL1=,$MYH
M')&\]%;/K7T]" RYKS\5A*N GR5H6;7J>E@L=1QT'4HRNA2?E&>M1M]XBI'X
M]ZB=L@^M>78](@D^G-5I6XJ=S^-5I6_&F(J7'<=:R[OH>U:$Q/)S69=]Z8T>
MI_ #_5ZU_O1_R->O5Y#^S_CR=:]=\>?R->O5F]S4****0PHHHH **** "BBB
M@ K\E/VF ?\ A<'B@-R?MCXK]:Z_)7]J8'_A:OB&95.[[4^<=\&O;RG^._0\
MK,OX%T?./B!]S+WVG%9#?<!K6\08%P^!A0W'T-93?+QGZ5^HT?A1^6UOXC$0
M$+UKKO".DW6O:7J%C:7T\,[@,+54+1SXY SV:N03ZUZKX-\"VNH>%]1U/2/$
M3)JL&TQQB3R,>H;/\ZSQE94J>KMMK:Z^9KA:3JU+)7W\G\C%L?$@M=$_X1SQ
M)8SSV4,I:%A\DULQZ[<]1[5ZC\+_ !1X?FU?P]H6C1WMU>1W7F1W5Z #&F#N
M48[>U<%-J'C/3T0ZCIG]J0#A7FMQ.I]]R]:[+X5VUS+XNT35I/"JZ5;M=;#?
MQAE7)4C&T],FO,Q2A*C*3\WI+2]NVGW'?A^>-6*CY;Q=[7757/L^SSM7Z>E:
M43>]9=J3\OZ5%KWB*S\,Z3<ZCJ$RV]M;H7=V-?FJBY.R/T%R25V5?B-XJT[P
MWX=N'U'4$L8I%*!R<$\$D#U.*^(_C!J][X\FMM?TK19M+\/PXM8KYS@RXZ$"
MNKCNM3_:H^+8M-TD'AJP^=U_N19X'^\W\J^D_BA\-K34/A/J&B:?;+$MM;YM
MHXUZ%.1CW./UKZO#.&55:<9ZS>_]U/\ 4^8Q,9YI1J2@O=7P^;7Z'F'PA^%/
M@'QK\*X]7?2(I]5CB=+F:5R\GFJ.I.>_!_&O+OV<O"&D^*?BD=/U6S2^L4BE
M)AF7Y20>#6M^S+XX/A_5=9\/7DA2WU"%C'N. LR@\?B/Y"E_9=^7XU2J&^7R
MY^^<\U[DHUL-];BY.UKQUVO?8^>C4I8GZI+E5^:TM%K:VY]!>-O!_P (_AC9
M1WNL:'IMN78^6NPL[L!V&>>M<*/VA?A1HZ.FG^%E;:,+_H:8/YUQ?[95S/=_
M$?2K0RL8$L4*)C@,SL"?T'Y5Z]X%_9S^'UIX<TQM5BCNK^:)97:XG 8E@#@#
M/2O)4,/0PE/$8V<Y.?1,]>4\37Q=3#X&$(J&[:/ ?!,<GQ8^/MG?:-IG]GV;
M7:7!AB0!88TQDG' Z?F:_0F ;80,\@5RG@KP-X<\)V[?V#8V]M')PTD(!+?\
M"[UU:\+[5X6:8^..G!4XVC%65]SWLKP$L#";J2O.;N^PKL=O-0%NIJ1^O%0M
M]ZO&/;(7;GDXJO+WJ63J>*@EYH$4KCY>:RKQCR:T[AFR:P[YS,WEK]W^)J"X
MGL'[/G-KK+=C(G/X&O7J\C_9^ 6QU<#M(@_\=KURLI;G0%%%%( HHHH ****
M "BBB@ K\F?VFUW?$SQ("<YN7(_/%?K+7Y,?M+,O_"S]9R<*]U(#^9KVLJ_C
MGF9@KT3YPU;;-""3E@-I^HK&D^95:M/4V\JZE3^$G=66WRY';M7ZC27NJQ^5
MU7[[%CSP.M=QX#\+Z1KFEZM=:GJL]FMF@<V]NH+R+ZX[UPR8%=I\/8];CN)[
MS2+2WN(X5_?-= ; #Q@DT8KF]B^65F7A[>V7-&Z_KL7]*33+>;?HOC&ZTT@_
M*EXC)G\CBN_\!7GB2Z\:Z#%JWB./6=(^T@^3'<JPW8)4D=>M<;K-C;6]N+W6
M?"WV:VD?!OM,N 8RQ[ =*N_"^#PZ?B)H<FE7%T]Q]I'^BW48QC!YW#TKRJJC
M.C.5KZ/HGT[K8]&'-"I&.VJZM=>S/NVSP-OT[FO+?VBOASJGC?PO<2V%]<[K
M6,R)IT0&R9AW8]3Q7J%KCY.E<AXR\::KX>UZ%+;3I+S3DB+SNB]\' 'Y?K7P
M.$E4A64Z6Z/M<3&G.DXU5>+#]G;X5Q_"[P';VDJ[M4NC]IO9?[TA'3Z 8 ^E
M>KR0BXC*-RK#!!%>+6'Q^M3;QRO82RJPD.^W!*?(#GYB/]DBNJ\-_%NW\0:J
M=/AT^Z298S(TC#Y![9[U>)HXCFE6JKS9%&O025.G(\=U/]C_ %5O%-QJFEZ[
M:V4;7+2PQF-BT0)R/KBNM^#'[,^H?#?QHNNW>KV]Z/+=#'#$RG+=\FO8!XJM
MXXR70AP 2H%3P^*H74^7#(3C.<8%9SXCJU*;I2J*S5ME>WYG)#*<'"JJJCJG
M?=[^AYM\6/V<4^*7BVSUJ756LD@A6 QK'N) 8G/ZUW>H?#&VU*QM+<R^68+=
M8!,$!8;<8(]QBMFWU[[1)M2!O7<>!2G7IWC#0P&3/X8/>N"IFCJTH4Y2O&.V
MAZ=+#T:-2=:$;2ENRUX3\-P^%-%BTVW=GBC+%2W7DDX_6MS\:YC^VM0\Z!&M
MU02-@'DG%=%GY0#UK"G556_+T.RXK&HF^4GGBE9L'K36YY]JV @D856F;;WP
M*=>W,=I&SR, />LF5I=0;E3#;_\ CS4QI=1M^99%"Q'!)Y8]JH- (8PJ\_UK
M1DPJ@#I6?<D<]J"HRZ'L/P!7_B7ZL?\ IJH_\=KUFO)_V?\ ']EZKSG]\O\
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M-62]N)ITL;6PC$DDRJ3(<GC&*QK8CVE%PGIYFE&G*G64H:G+7VM+;W$L6O\
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M6(.<AG.!S4__  C.HP1EQ 9X_P"_"=X_2O?E["I;VMKGAQE6IQ;I[=3IX?$
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MT?PG?+=:/;-@H"HPI/2MRZP;>4D@@K7.>$X4@T&T13D; <BM:XN4M[60L^%
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MROO5V]:]7\"ZS)XDMC*T8CQUQVKR?1OAK8!GO-3OA;>7U7/%:6H_&[PW\/\
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M9/%:MO\ [1^<C&[8,T3_ !>\57$;))J+$$8^Z*B.48ERYFT$LUP_+RI/\/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
A110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>form10-k_003.jpg
<TEXT>
begin 644 form10-k_003.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (7 2D# 2(  A$! Q$!_\0
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MCO3[AED;O_*MV&W@N<$?*V >.OK_ $/Y"N<M<F;ZUN:;E-I'L/U-0RR^-+Z
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MRUNY"S1@?>7V]QU'_P!>O:()DN88YHF#QR*&5AW!&0:U3N9LDHHHIB"BBB@
MHI!GFEH *Y7XF^)CX5\'7UW&^RZD'DP<X.]N,CW RWX5U5>'_M':S^\TG2U=
M@ K7,B=N3M4_H_YT#1XS"#(^YNIYK3MT]*HVR],"M:WCZ>E9LLN6\?2M"&'%
M001GBM"&/I[5 R2*/VJTD?3-$4=68T'I2&+'&<BK,>5^E)&G%3QK0(DCJ>/Z
MU$L=2JO2@"='/8U*KFH46I%% $ZRM4HF:JRY_&I5H G68^M*LS;VYXP.*A&<
M4X*=V?SH L>>?6E\XU7\O<<U)S2 D\PTF\^M-YHVFF %O>F,W-/*T!#Z4 0M
MD]Z9Y=6?+H\N@"KY=-:/VJWY?%-:.@"BT7M5>6*M)DJ"2/VI@8EU;Y!KM_AC
MK7G6LVERGYX/WD7NA/(_ _\ H0]*Y:XCSFH]!OCH_B*SN VU#($?)P-K?*<_
M3.?PJX[B9[/1116AF%%%% #$<,SC^Z<?H*?442%9)3_>;/Z"I: "OF;XY:A)
M>?$"YB;&VVCCA3 [;=_\W-?3-?)_Q-O/MWC[67(^[<-'_P!\@+_2@J.YAP9R
M*U[7(QQ63!VK6M36++-6W'MQ6A"./2L^WQQ6E#VJ0+48[5;C7CI5>''I5N.E
M8":-:G1:CCJ>/ZTP'JM2JM,6IEH <JT]5'I0M2+0 BKS4BK2JO-2JM #-M/"
MU(J4X)0!&%I=M3;:41^U $06G;*E\NE\O':@"';2[>^*EV&EV^M $.RC94VV
MFE: (MM-9:F(IC"@"NRU#(E6F%0R#TI@4)UR#6)J4>4; [8K>G[]JQ-2/R&F
M![)H=ZVI:-8W;J$>>!)"HZ E0<5>KG/AW<-<^#=,9CDA"GX*Q _E71UL9!11
M10 4444 %?(?CC/_  FVM_\ 7[-_Z,:OKROC_P :2K+XYUX#JE],I_[[)_K0
M5$J0Y[=:U+6LVWS6A#6;+-:W;IS6E >E9%N?6M*!J@#4AJY&:SX6JY&WXTAE
MU#4RU60D8JQ&:!%A>GO4J5$M2IB@"=<8J=5Z5!'5B(]* )HXNE65A'I4<;#%
M6!(* %6 >E/^SK^AIGG8Z4]9MP/TIB'BW7TIWD+^%,6:I/-&*0Q/)'I3?*%2
M[P><4F[VI@1F+CUII3%2%N*C:@!C+32*=[FF,U #3BF&G,WX5&S4 ,:H)*E=
MNM5I&/- %6X:L34F^4UKW!^4UC:B0%.>E4!ZG\/+5K3P9I:-U:/S/^^B6_K7
M1UB>![A;KP;H<R_=DLH6'XH*VZU,@HHHH **:C;@3[D?K3J "OA7XD>+K+0?
MVC?%/ARZE6'[=*ES;/(<!I#&NY/J1@CUYK[JK\H_V_7:+X\:VZ,T<B>2RLIP
M0?*0Y![5<8\SL5'5GTG;]N]:$..*^0/A#^UXFFBWT?QP6*+A(]8C&>.G[Y>O
M_ AZ=*^L= US3_$-C%?:;>07]I(,I/;N'4_B._MUJ)PE!V:-+-;F[#U%7[?'
M%4(:T(N/SK$"_#FKD;52A^M6XN>O2D!<C;=R>M68VJI'^M6%YH$6HS4ZD?A5
M=?NU,E %I&J9&_ U60U*K4@+<<E3+)51<\5(I- %CS*<LF,U IIRTP)UD-/$
MAJ"G T@+(EI?,JOS2Y-,";S:0R9J(&DSSB@!^[M3&:BD-(!K-QS4;>U/:HVI
M@1MFH)#4[56F8*K,3@*,D^@]:8%2?O7DWQP^)EEX T%8/-5M8U ^1:6X/S<\
M%R/11^N!7"?'K]N#P;\,5GTOP]<0^*_$PRODVK[K:W;'620<'M\JYSZBODWP
M#KGB3XV_%"'5-;NY+^\D?S)9",)!&#]U1T4=@*VA3<M7L6HW/V%^'\/V;P+X
M=BQC9I]NOY1K6_5/1[<6>DV4 X$4")^2@5<H.<**** (X5VJ1_M$_K4E-0Y!
M^I_G3J "ORB_X* K_P 7TUXX'2'_ -%)7ZNU^4_[?_S?''Q$1_"L!/\ WZ2M
M:7Q%PW/C34OO$]^]3>$_B5XG^&VH"]\-ZS<Z9(&!>)&W12X.<.AX89[5!JF-
MQ[5@70W*WM7MQBI1LU<[4KJQ]=_#G_@H5=6IBMO&V@+<)E5;4-).U@/XF:(\
M$^@7%?3'P^_:@^&GQ"6-=.\4V=M=,GF-9ZDPMI4&<?-O^7/L&-?DXQZU#(H<
M ,H;_>&:YIX&$OA=@]E%^1^Y-K,DT*2QLKQ. 5=3E6'J#WJ_#T'-?BEX3^*G
MC+P+-++X>\5:MI+RJ$<V]VWS =!@DC'TKVSPI_P4(^*WA]XQJ$FE>(K:- @B
MN[41,<?Q-(F&8GUKCE@:J^'4AT9=#]2X^>E68Z^"/"__  5 @CM($\1^!)C>
M%OWDVE7JB!5]0K@L3^->M>'?^"B7P>UB\@M;B]U;2&DP&GO]/*P1GW<,?Y5R
MRP]6.\69NG-;H^I5[5*M>1^'_P!JSX0^)+[['IOQ"T6YN,@;3*T8Y]W51^M=
MY8_$;PGJ$HBMO%.AW,IZ1PZG [?D'K!Q:W1%FMSIUJ9:C@CDFC61(W>-AE65
M20?H:DY4_,"OUI")5J1:B5AV-2JP]: 'KVS3UIFX4Y6% #QZT[-,S[TJD<<T
M 24N:58W?[L;-]%)JEJFL6&A1^9J=]:Z;'_?O)EA7\V(H N4M</KWQR^'GA?
M3Y+W4O&^@06R<M(FH12D=_NH6/Z5YOX@_;Q^".A:>+N+QG'K?./(TFWDEE^N
MU@O'XU:A*6R+4)/9'O\ 32:^*O&7_!5+X?Z)-"FA>%=>\01N,L\QCLBG_ 6W
M9KQ#QE_P58\=ZI'>0>&_"VBZ&K-_HUY.SW,\:_[2,?+8_A6JP]3L7[&?8_4'
M.< <GL!7&^/OB]X)^&-O--XK\4Z7H(AVF2.[N )5ST)B&7P?7;7X[^.?VQ/C
M%\1/M,>J>.=0@M;F/RIK'32+2V=>_P B="?8UY(#>Z[J2+_I6J:C(,*"7N)V
M'H.K&MHX67VF7[!]6?IM\5/^"H7@K04N+3P1HM[XIOEWHEW=C[-:!@>&_O.A
M]1M-?&?Q<_; ^)GQJ:2#5]=?3-'8G&DZ3F"#&<@.1\SD=B35#P#^RA\1?'GD
MS#2/[#T^0!A=ZH?+RI.,JGWB1Z'%?3?P[_8M\)^"_*NM=E?Q/J*\[9EV6RM[
M)_$/3-;*%&EYL'[.!\N_"7X+^)/B9=HVGVC6VEJ?WFHW"E8AZ[?[Q^E?</P\
M\!Z3\,M-CM+!"[\&:Y<?/*W3G_"NS^PP:99I;01)#%&,+'$H55^@%5+>,7%W
M&A&5+?UJ)3<_0R<W(^^(O]6GT%/IL?\ JU^@IU<IS!1110 BC;2T44 %?E9^
MWU'_ ,7R\38Y/E0'Z?NHZ_5.ORT_;NC+_';Q0#S_ */$0/\ MBE:TOB+AN?$
MNI'YF^M8=QW-;6I??;MS6-/WXKW:9W1,R7Y2?2HBZMT&.*FNEP#SBM'P2MZW
MC/0!IR0RZBU_ +9+D9B:4R+L#C^Z3C-;7MJ:[:F-NW+D'</4&G*A+ =,G%?7
M?Q(\:?!/_A)KS0_&/AI9=:A 34=6T&V:,"< 92/D-@=,]L50/[-OPH\::0NM
M^$OB$VF6UQ((;>'4'5X8IL;MDC-A@< ]3V.,URK%1M>2:)]HMVCQS4OV=_&-
MK%)+##9WB+]V.&X'FO\ 12/ZURNM?"_Q?X?6)[_PWJ$"S<IMC\PG\$)K[4U/
M1]2\.W$0U**(PW7_ !ZZC9N)+:Y&W.5;^$D G:<\8YI]M=/'@J[*1_=./RK-
M8B4M3'VTCX'U"QN-,;R]0M)[)_[MW$T9_)@*K6[QPR>9;E8W[/"=I_,5^A#2
M17%PLES##<3 \27$:RGWQN!JKJW@OPSXHE$VL>'M/OI>I+VP'_H.*KVZZHU5
M?NCX7'B36&0!M9U3"] +Z8 ?^/5V>@_M"?$[PO"(-(\?:_I\>,!8KQC_ #S7
MU5>?!GX?7UJJ_P#"(:; I(&ZSC,;^G7-58?V5?AK-)YDNF:@4SG:FHR(,8[8
MJ?:4GO'\BO;0ZH^?%_:P^-'4_%'Q/_X&_P#UJLP_M=?&>W48^)?B!_>2Y#?T
MKZ(F_9/^&4R#R=)U*U]QJDK_ ,ZS3^Q3X.NF5HM5U6%2<[<JWX<T<V&^U'\"
M_;4>J_ \4B_;/^-4/'_"P=5?_?93_2EF_;,^-4S?\E#U>/\ ZYN%_I7M*_L(
M^&)WX\3ZN@[8BB/\Q5ZU_8'\*[OG\3ZQ*/\ KE$/Y"HY\+_+^ O;4%T_ ^?S
M^UI\:'8G_A:/B5,]DN\#\.*:_P"U9\8YLI)\3O$LJD<A[S.?TKZCM?V'OASI
M-I)+?RZKJ.U=VYKLPY_[YKQWX<_";P%\1-<UU(/#EU!I-K>M;65S'J\Y:95;
M!<AN.1CI6U-T)WY(;>2!XFA'I^!X?K7Q&\5^)KEKC4_$VL7MPQR9'OI03^3"
MLO4M=U"]MQ'=ZC>748&=MS<O(/R8FONO1/V<?AOI.M36T7AJ.^BA4;O[2=I\
MD\]3V]O:M;4_@_X!TV07=CX,T6PNH65HY+>#;@CH>214QQ-':,?R.J511LN4
M_.JSBCN+@):QI+,QX6!0S'\!S76Z5\._%NN7D%C9>&=7GNIN8T-E(@;WW, O
MZU]M2:Q WB71[=[.T):4)&5MXU923G P/7-?0*F1H4C:1V0+@ DX IU,6Z-O
M=)G6E%7L?FC9?LA_%;Q%=>0?#7]D,H.7U6X2%?P(+5W7AG_@GOXDNH[>;7O$
MVGZ9E\2VMI$T[A?59.%S]17W<\>W@?E354;?T%>;/%5*COL<4JLY,^<O"O["
M/P\T)PVI2:GXBE60.CW4PA3 _A*)PP^M>V^%?AKX7\#0^3X?T#3](CW[_P#1
MH%4[L=0QY'YUTD:L6)(PO:GGCKQ6//*6[.2<GU9!( J\Y]<UG[3)(7/0&K=U
M(9&V*>34$ZB*,*.U(SV,?4),YJ'1E,NK6J 99I%'YD47Q,CX!S["M#PS9AO$
MFD0EL/)=P@\]MZ\5IT+V1]Q)]Q?I3J3I2U@8A1110 BG*@TM(O"@>U+0 5^7
MO[<7[S]H+Q&N#@P0CC_K@E?J%7YA?MO#9^T)X@/;R;?_ -$I6M/XBX;GPOJR
M[9G[<UBS=#GI71>(H_*U"X4=I"/UKGIONFO<I['= SKE0RU-H.JW'AW6]/U2
MUV_:;&XCN8MPR-Z,&'ZBF2-SG'?O4FC:7<:]K%CIEHJO=WLZ6\*L< N[ #GZ
MFNAI6U-O4^D/%GPFT_\ :6?_ (37X>ZG9QZU=HIU/0+Z41O%* H9@>P[DX(.
M0>"36CX7^ &I_"7X6?$:\\>W&FQV-]IIBM]/643QO<*"89,D#]X&X4#U-4;?
M]C\VLY@TCXD65GXCM(_,O8_F3RTZY^5@P7./O<5S'Q*_9V^,5OIYU'69G\2:
M=;#>K0Z@9B(QSYGEG&!CG/->5S<R]G&HN7SW.?FNN52T/?=%N4?X<_$BT<K+
M#I>FIJ-K:2+\EO,JR,L@[XW1J<=/E]ZH1N<+N.XX'\N:R#=7%O;W]K#<2VD&
MH0I;WD<>-L\8;)##U(RI/]TD=ZLQ7.WGY5 /IV]*(TVFVSG(/$6O)X=MK2[>
M54B-U'$_H5.0?TY_"NRMY@T:MNVG'!QTX]/QKP?XKWT-PSO-=K#]E*I#!G_6
M-R6;'T*\^QJO:ZWXTU_04U33KK^S[&SA$,GES?O&*#.\J>^#S7NPR^-:A"?,
ME=N]_P #Y^IF;HXFI3<6TDK6W\SZ,LIC&N3SZ_2M2QU:S963[7;F4<%!,I/Y
M9KY6T:^\3:Y)+<PK/K<EN59C/\XC)SC R.O/Y5U,7CCQS:OYTFE1*Q/WSIB[
MO3L*N623A+D52/-VO8QCG]*<.?V<DN_+='T<OB/3X7"M<,K8'"HQ _(?6I6\
M?:'IMQ8PSW\<;WDGDP"0,#))Q\HX].>?0UX5HOQXUK2+R%-:TF,VK$;SY31.
M!W*]B<_S-?06EPZ?K"VFI"*.X5H@T,SIDA& (QFO,QF!J8/E]K'1]4TT>A@L
MPI8[F5*6JW5FF=79_P )SC-:]LW(K$LV+="/I6Q9\'DUX;/39S7QL\5-X/\
MAGK^J13K#/!:2-"S8XEVD1_7YROYUXS^S9X8&C>$=*24$NZ^?(&ZACECG\2:
MV?VQ=2D_X033M%CVN=5U&WM)$_B"9,A(^AC7\ZV? D:Z7X;N)8EP8+0^63S@
M@?SZUZ-+]WA92[F45SUH075G2>'5%P;Z\!)6:=G7/IT_I53Q),/LLHPV2I&>
MWM_GWK1T>'[+H]NK'=\@);U..M9>N?ZL@J=N,'OUYKDI4[V9[M76LTCQF\U
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MEU;PS++GS)(7!*@,-WS''>L^25_>,([L^B?BA###X+U)6,SO-&88UA7<Y=N
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M7[S;R@!'45W?]I2+'YGF,Q8\*W(Z],&MCX97;W&N&38D,;RR;5AC6-2 #V4
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M7QX;Z'^5>WI]U?I7CMA8_P!H:M:6Y0NLDJAE']W.6_3->Q].*TB9R%HHHJB
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M@QYC!EN6&'G?[Q]AZ#VK7K1*QFV%%%%,D**** $I:** "BBB@ HHHH ****
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M ?*T^YX_YZ((_P#T(BK%OX5URZB9F@AMFS@+/,,_7Y0W\Z?*%T(URH[U#)?
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>HHH **** "BBB@ HHHH **** &[?F)]J=110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>form10-k_004.jpg
<TEXT>
begin 644 form10-k_004.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *S 3 # 2(  A$! Q$!_\0
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M** "BBB@ HHHH **** "BBB@ HJCK6M6/AW2;K4M2N4M+&V3S)9I#PH_J2<
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M ?52/ZU^Q'[*=PLWP<TQ5_Y9L4_\<0_UI]!]#V"BBBD(**** "BBB@ HHHH
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M?#N]1A97&K6S=092A7\^M9^T?<V5%;V9!XZ\40>(M6FGMM-CTZ)N!%&0?Q.
M.:Y:/_6'*BI?MFFKPM]&Z_WF;DU7N-6TZ-28[E3EC\N"3[=L?KVI\WF+V=MD
M>R_!IM+:^BEU";[IPR,O YZ@@U]\_LI^)=*C^)?V#3[I+N*XL98(RO5<%9.3
MGGA#7Y16/CA]+?\ T'.\C[TO&#WX!YKU_P#9_P#CIJ?@/XB:-K@N-SVLH8HS
M$*RGAEX(X(X/K6\)+8YITFKL_<"BN4^'?Q-T#XGZ%!J>AWB3+(@9X&($L1XR
M&'X]1Q75UN<@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5D>*O%VC^"-&EU77=0ATS3XN&FF/4X)VJ!RS<'@ GBO)?C9^U9X:^%=I/;V4
MD>M:TH($,;_N8FQP78=><?*OH02#7YN?'/\ :/\ $'Q-U:2[U;4))AR(X5.V
M.->F$4< <?CU.:8['N_[3'[=EYXHANM$\+F;1M%9&CDD+ 3W(/\ >(^ZN.-H
M)SDY)X ^ O&GB^;5[J3=(79CN9B:K^(/$CS,Y+'\ZXBXNVFD9LGD]ZSG))6-
MJ<6W<ORW\L&&CD9&Z[E.*H3:Y>* #.SX.1O^;'YU T^Y-H-564%O>L+HZK/8
MEN==NVB(W\_05S4EW<AW&<;N#P*WF5:R9H0TAXXJ>9+8.1]64FGN&SF5B/J:
MGLW:!LGKW-2+"%QCFEDVJHSUJE)LRE%1>A:DNVF&&)ID6$;(JLC&ID.X^U+E
M3'S,U(;QE[U8^W$CGI64HR.M2J .]9.DC:-9Q-5;Y=H I/./4<UG18R035J%
MD"\'\Z7L[&GMG(O6]QN/H>U;NEWSV\JD''-<RC#=D&M"WF*\YYH^'8KXM&?4
M?P5_:!UOX?WEO+9WTT>U@?D<C_/%?I+\"OVNM$^(UM!9:S)'8:FP $W C<X_
MB_NG/?ISVK\5=)UAH2!NQBO3?!_CJYTJXCE@F9&7GJ:Z85$]SCG0:V/WE5@Z
MAE(96&01R#2U^??[.?[:5UH:6VEZ^S7NEYV\G]Y'GNI_7!XZ],YK[N\+^*M+
M\9:/#J>CWD=Y:2?Q(>5/=6'8^U=!QM6-:BBB@04444 %%%% !1110 4444 %
M%%% !114-Y>0:?:3W5U-';VT"-++-*P5$11DL2>@ !.: "[NX+"UEN;F:.WM
MX5+R2RL%5% R22>  *^(?VD/VT!="\T+PG,8-.YBEO!Q)<#H<?W4/IU(ZXR5
MKB?VMOVNI?&EU<^'_#UPUOX;MVVEQE6NV!^^PZ[?13]3SP/B7Q!XL>9I,R;B
MQ/>F5L;OC7X@3ZG*[RSL['N37E&M:^7W$MG-5=8ULMN^;.>V:YFXN#(2S&HE
M*VQI&+D[L?=WC7#$N?I5&23-,EN!GKGWJ$R;O>N:7<ZE*V@_>=QP:AFN60X!
MYI6<*N<]:J3R#!/>E%794G9"27CY/I4#,S&FJN:=Q6W*CC<Y/J,9V1>.M,4E
MN34K;:*+$W!3BI%D(S]*BQ3E_,U0^8G6;OFG&Y [\U74_+[4C T@N2_:6Y[T
M];IACG%5U49YP!24:$W9J0W3<<UIV]T&QDX.:Y^!MO%78W*]ZB44S6G5<3H8
M9MOS9Z5M:7JC1L,MP*Y.WN\<,.*T(9APP/-<[BT=\:BD>KZ!XD:(JP<J?45]
M'_ G]I;7?AGJD4UE=L86(\RWD.8I5ST8?GSU&>"*^,M/U)H6')XKL=%\0;"I
MWX'>KA4:W)J4E+5'[E?"#XV>'OC'HHNM*F$-_&@:YT^1@9(NQ(_O+G^(>V0"
M<5Z#7XI_"WXQ:IX#\066I:7?26=W;L&21#CZ@@\$$'!!X()!K]3_ -GW]H;2
M/CAH*[6CL]?MXP;JR!X8< R1YZKD].JYP>Q/8G=7/-E'E=CUVBBBF0%%%% !
M1110 4444 %%%% !7P5^V]^TTNH7,_@CP_=M_9EJY74)XS@7$RG[@]40_@6&
M?X5->]_M=_'0?"+P"UEIUP(_$.K*T<#(^'MXNCR^H/\ "O3DD@_+7Y)>,O$3
MW,\LLLA/)Y)]ZI 9GB;Q$TK2.SG\37FVKZ\9&;82WO4NK:I)>,<DB// ]?K7
M-73')':D 3W6X[B=S&J$UT6Z42'GT%5ROO4<J+YGL&XN<YH9PJTA^53Z]JA;
MU-9M7-%*R&2RLQZTS&[KS1UIRCVIZ$J\MQ-OIS1BG<=J"#WI7+Y1G2C]*=SF
MDQ3N3RC>:4+3L4;:5Q\HVD.:?MHP,47#E&#%+3M@% &*+BY6"?*<U=B;..]5
M0#]:F@]#2N5RV+:U8CE,8'K]:K*WO4H]VIBVU1IV]WN&#UK2M=5,.#G KG5F
M"]\U-',S$=Z7LTR_;-*QW.D^('\X/NYS7N7P>^+>I^"]>L=3TV\DM+NV</')
M&1P?H>".H(/!'!KYAM9VC8<_K77Z!K#0R+\Q'XUNM#F;N[G[N? ?XVZ;\:/"
MD=Y%MM]6@55O+5>@;^^G^R?3J.A[$^F5^0'[,OQTU#X<>++*^MICLW;98BWR
MRQGJC#T/Z$ ]0#7ZV^&_$%EXJT*RU?3Y/-L[N,21MW]P?<'(/N* -*BBB@04
M444 %%%% !5?4+^WTJPN;V[E6WM+:)III7^ZB*"68^P )JQ7SM^V_P#$IO!/
MPG_LJV<I>:Y(82PR"(4PTF"#P23&O.00S4 ? W[3_P 9+GXH>/\ 5=7D9UMF
M<Q6L+-_JH5R$7'0<<G'4ECWKY9\2ZFUU<,F1L7K[FNP\;:LW[U]V79N/K7F.
MH3;6QR:L"E=3;B1FLFX?<2<U8N)#SSQ5*0_-Q4@1/\V?6H&[5*S4QN>E(",M
MZU%,PQQ4U0NF:GE'=D"L,@9IZL.E-DA^7(J'=ZU/*6I6+.X4;O6JV\T*YI<K
M*]H6N* /SJL)/>G+,5Z?RI<K'[1$]':H?.:E,K4<K*YXDF,^]+MJ'SFQUQ0L
MS>M*S%[2)-MSVI0,5&MQ[4OV@Y^Z*+,KGB3*?EJ2-@OOFJWFD\=*FC]35*)$
MI=B=9#UIP8FHP<4X'%68WN2CJ:FC<U74\^E2*U4(O1R;<#.:U;&X,97GI6)&
MW3M6A;-[T >G^#=;:":,A^<\<U^GG[!/QK35X9_!=]-B62,W=CN/WF7B5![[
M=K#_ '6K\E=$O#%(IZ5],?L\>.IO"OC31-4A?;-9W*31GMUP0?8@D$>AH&NQ
M^S]%4M&U:#7=)LM1M23;W<*S1YQG:P! .._-7:!!1110 4444 %?FA^WWX\.
MO_%2[LH95:WTJ%+)2G=AEGS[AV9?^ U^E=Q/':P232L$BC4N[-T  R37XO?'
M3Q)-XB\8:QJ$[[Y[JYDFD/\ M,Q)_4U40/!?%EUYEP1V4>OK7%7DF[/-;^NW
M'F74QSR3C\N*YB;,CA0,L>@]:;V)*<K<U7=JEDQGWJ!F'>H*(VIO7WI[&F?A
M0 UO:FFDW;I,>@J&\NO)7@Y)H )KA8UQWJ@9-[9-0O(6)).:19*5[@60>E2K
MBJ2R5-')GBF!>1![4[RQP:CA?-2-VH D4+Z4[:I'2H,FG*_RT#'2QJRGC%4N
M<\=*O;P15=X]K''0T""$+NZ=JG\M.NT5#'CCUJWY>1ZFD/8KL@':IHUPN#S2
M^6?2G*M  *?2**>%'04Q !3U'3BF@&G _A2 G0].U6H'JDOYU8BQ]*8&Y8R;
M6'8^U>J?#[4C#<1$'E6!ZUY#:,1CGZ5W_@VY,<Z=N:: _:;]D/QE_P )5\(;
M.%W#S6#F+&,80_,N?QW?E7MU?%__  3P\02W%CK&FE_W7D+,5]U8 ?\ H1K[
M0H&PHHHI""BBB@#FOB9,;?X;^*Y02I32;M@0<$8A<U^*?Q"N3)J-R2<DL3^M
M?L[\;#=CX-^.S8)')?#0;XP)*2$:3[.^T,1T!.,U^*'BR^CU',\:LH;.5889
M6R<JP[,#D$=B#51?0;3Y;GD6KL6F<^YKGYV*L2#@CD8K>U<?OI/]X\5@7&,G
MM3D3U*<C<FH7J9P!FH6_.H&-_A(Q3&^Z33NM17#[(R<4 0>8(XRQZFLNXFWL
M2:?+,S #M5:1MQZ5%T VDHS2C\J- '*I9L#]:DC^5JA&0:?NI :$;?E5A3N]
M*S[>3MFKL;^O-,I6']CZT!3GUI^W.#1TI7+&E2.E'ELW09-2+SUJ]:*-W3\:
M$R.4K6NGM)("?E%:"V87O5U5"XP.:7:M:;(GJ9LMKM/!XJ,PBM.13QQTJM(N
M#Z5/,,J"/UH;Z5(RE>1S3#TYHU$+C@9IM-9L8IN[WIV L+S4\?XU53\_K5NW
MV;6##)P-I!Z'(_IFF!H6O'>NT\)R?Z0G/>N*MNU=GX3(6922 %Y)/&*+Z DV
MS])/^"<=TS>+=4AS_P P]W(Z=)(Q_45^@%?G?_P39T65OB)JNKS[D4Z)+#:Q
MMQ^[:> LY'^T47'H%!_B(K]$*F,E+5&M2G*D^6:LPHHHJC(**** .6^*G_)+
M_&';_B3WG_HAZ_&WXA^"QJ%_/>Z<ZPWC']]&_$<V. 3Z-C W=P #V(_9+XJ\
M?"_Q@<9_XDUYQ_VP>OR8UY1]ID)Z_E7EXVI*ERR@]3[#(<-2Q<:E*LKIV/EG
MQ%I]Q9ZA)!=0O;7!&X1R#!/X]".O(R#BN6N%ZG%?3_B+3+75;-H;JWCN(P<@
M,,E3Z@]0?I7E'B;X8PEC)I]P8L_\LI>5_ ]?YUA1S6G+W:NC_ [<=PGB*=YX
M1\Z[;/\ R?X>AY4W?BH'X^E=%JWA+5-+W&6U=HU/^LC^=<>O'3\:Y]@><C!K
MUX5(5%>#N?%5L/6P\N6M!Q?FB*JE_(%C^O%736?J +-&/4UH<YF.W6H:EE^4
MD5%68 <@4GUI:6GHP$7'TIRKGTIN*?&VULT*P#XXF!'%7X8V8=*9;[6(_.M*
M% PH*(E7:!36X;FI9E,=5I&+5)1/"K2' YXS5^UZ],UG6[$'.<=N*T+4_,.<
MTT!IJW8BGE?ESUIB]C3S]T8K2Y%B(L1]*KR$[LXJ=CCWJ+@G_P"O6-R^5D#+
MGG%1-Z59(W9J-U/I5IDM6*C+N-*L9ZX./6IECW5+%:RS,$16=B<!5%5>VXDF
M]$01U<@6M[1O &J:@R%H3:Q$\O,,$?AUKL-,^&=E9J'NY6N6_NK\B_X_RK@K
M8_#T='*[\M3Z'!\/YAC/>C3Y8]Y:?\'\#B])TVXU!PEO$TK]]HZ?4]J]F\ >
M!(;*XMY-1VW,GW_)ZHI]_P"]V]OKUINFVD%K%'#!"L$8_A10!]:]1^%_@C5O
M'&M1V&DVAN)N"[]$A7.-SMV'ZGMD\5XM7,*F(?)25D_O/M\+P]ALMC[?$RYI
M+OLOZ\SZZ_8/C9O'&L2[24&ENI;' )FB./KP?RK[<KP+]FKP#:?#V:73X&\Z
M=K5GN+@C!D?<@SCL/0?UR:]]KZ'#P=.FHO<_.LSQ$<3BIU(;= HHHKI/+"BB
MB@#E?BM_R2[QC_V!KS_T0]?DQKA/VB3ZXQ7ZU?%)=_PR\7+ZZ1>#_P @O7Y*
M:US</D5X^9?"C[CAC^)-'.ZB 8VW=<5@SJLRC(!'YBN@O<;#BL%@0ISQCBOC
MY'[+3V*'V?:QVCC%9FH>&].U12+FRAD8G[^T!OS'-?0_@GX!V7CSP-IVL0:G
M<6%_<"0.)$$D7RR,HPO!'"C^(US^N?LW^,='7=!;6^JQ#G=:2C./=6P<^PS7
M3]5Q--*I!;]CR8YQE5><L/6FDTVFI:+33KH?.NH?"?2[HDVTDUJ>WS!A^1Y_
M6N/USX4W-G+&8KN.89)&Y2I_K7O&K^'-4T*7R]1TZZL&Z#[3"R9^F1S7,:]"
M6B1CU!JH9AC*+Y7+[S+$\.Y3BJ;J0IKUB[?EH>!W_P /=7B9BL22CK^[<5DS
M>%-5@R'LI1[A<U[L8=WUIRV;,V.QKOCF]6/Q13/E:G".&E_#G)?<_P!#Y[DT
MRYC.&B=2/[P-1&W=?O*?RKZ6ATF.,AF19".=K(&'Y'K56?PW:3,VZU@8GLT2
M_P"%=$<ZC]J'XG#/@JK]BK]Z_P""?-[1D=:%4\XKZ$E\$:<RDMIL#<==M)#\
M/?#UQQ)IJ^9G^%F4#U[UJLYH=8LXY<&XU;3C^/\ D>$6>9"0!R*T8[@Q#&*^
MK/"'[/?@?7+/S9+&6.1  ZK<-ALGJO/X?C6I??LY^"4E*Q6]R% Z-<,:Q>?X
M2,N5I_=_P3T*?A_FM2'/&4/O?^1\@37!9?N_K55J^CO%?P>\.Z6P%M!(J#C!
MD)[5S'_"N=&"Y%JS8/\ $YK=9SAI*ZO]QY]7@S,J,N63C?U?^1XU&VTC-:ME
MF3IS7JEO\.]%<\V63_UT;_&NAT7X?:1'.O\ Q+XRGH6)_K4/.:"UL_Z^9I1X
M-QU1I.<5]_\ D>0*I"]*(]S$J!TKZ;T_P!H;1JHTZU1B."\0?\:Z?^PM*M;6
M*&"SMC*G\<=NJ9KCGQ#3CI&FV?0T?#O$3=ZE=+T3?^1\B1Z/>70S#:S2_P#7
M-":T?^%?Z\(?-DTRXMX^H:9-@/YU]5W5ND:KL55SV'&*?J7AFW\46\"W<T@C
M7D)&P&[ZUPSSZ;V@E^)[5/P]H134ZSD_1+_,^;-"^#^L:Y'(\36\2(A8[WR>
M.V *T[7X,CRP]U?_ %6./^I-?0^E>%;/0(9%M4VY7'S'-<#<3'8#@8_SQ7,\
MXQ59M1=EZ'IQX+RK"0BZL'*7FW^ECC]/^&VB6N"]NUPR]Y7)_0<5LKIMI8IL
MMK>*W7^ZB@5VOA?X6^-/&&PZ-X9U._BD(VS1VS"+G_IH0%'XFO7O"/["OC[7
MV1]:N+#P[;DX?S9/M$X'J$3Y3_WV*%#&XMZW?Y$SK9-E,;+DAZ6O^&I\T+A<
M ?I6OX?\,ZOXNU 6&C:9=:I>''[FSA:1@/4@ X'N>!7WIX%_82\"^&VCGUR>
M\\3W('*3OY%ON!ZA$PWX,["O>-!\)Z-X1T];'1=+M-*M%Y$%G"L29]<*!S[U
MZM'*:CUJNQ\EC>,,-"\<+!R?=Z+_ #_(^*?A3^P[K%\8K[QK>#2;;K_9MFZR
M7!]F?E%_X#NS[5]8>&/!&B> ](CTW0]/AT^T4YVQC)8XQN9CRQ]R2>*Z^;[I
MK-N37T%##4Z"M!'YUC\UQ68R_?RT[+1?UZFU\,?^1GN>/^71O_0TKU*O+/A@
M3_PDUR/^G5O_ $-*]3KOCL>++<****HD**** .>^(@W?#_Q,#T_LRZ_]%-7Y
M%:\^R>5@-P7)K]?/&T/VGP9KT.,^9I]PGYQL*_(37^+B; QDFO)S#X$?;<,_
MQ)_(U/&WPQUKPFK3/!]ML5&?MENI*J!G)=>2G Y/(YZUYI,"KL,=Z^@OA3\3
M]3N9Y-/U5X[S3[6V>XEO)FQ+%&@Y).#YG.WKSR22>E;4G@OX=?%Z26?39(X;
MX9,DEC^XFP3RS1,O<G[Q7)]:\J>"I8A*>'E:_1_H?74L]Q.7S=',:?,HV]^.
MJUVNNGX>AM? %O\ BU>BKW4S<=_]>YKTV'D#/%<+\,=!/A7PT-'\[[2+&>6,
M2[=NX%RP..><-7<0DXKU**<*<8O=(_-\QE&KBZM2&TI-KT;N75@AN%*/&KAA
MA@PR#[5SVK? WP)XEC87_AFP;=U:&/R7^NY,']:@\:>*(O"T.D74TA2.2_BM
MV&[ (<,I)]AG=_P&N]LY-R@Y_6NJ5*\%*:NF>?2Q%2E)JE-Q:[.QXEJO[%O@
M#4I-UI_:.E>UM<[A_P"1 U<OJO[!\,DC-IGBJ2)>RW-F)#^:LO\ *OJ2%NG:
MKL,@XYXKDEA,//>"/:I9YF5'X:S^=G^=SXKO?V'/&,#?Z'JVE7:=O,:2(D?0
M*W\ZY_5?V.?B19MNATZSO>/^7>[4?^A[:_0&*0>PJW',BXR0*YGEF&ET:^9Z
MM/B[,H;N+]5_E8_.*X_9A^)5K&-WA6X)''[N:)_Y/66?@3XZT^7]_P"$-4;L
M-EJSC] :_3Z/!%6$53V%9/)Z#VDSOAQMC8_'2@_O_P V?F=H_@;QQHJR"/PM
MK*#/W?[/E(_]!HN?#WCN29L^&]85CUQITO'X;:_398U_NBI5A3^Z/RK!Y%1;
MOS,]&/B#BXQY?8K[V?E9J7P]\77L>9_#6LMG_IPE_P#B:J0?"7Q5(!L\*:TP
M_P"P=-_\37ZQK"G78,U(L*9^Z/RJEDM-?;9A+CJO-\SH+[V?E78_!/QE(08_
M!VM'C(W:=*/YK73Z;^S_ /$"7:$\(:DGIYD/E_\ H1%?ID(U]/TJ54'I3_L6
MCUDQ?Z]XN/P48_C_ )H_/&Q_9E^)5P /^$:DBR>LES"/_9ZZO3?V0?'UQ'^\
M73+(GM-=$G_QU6K[F"@=J?5QR3"K>[^9E/C[-I*T8P7R?ZMGQK;?L0>(+[8+
MWQ'8V8_B\B%YOPY*UVNB_L4:5:M&=0\27UQM[6T*1#_Q[?7TJ!S2X%=4<JP<
M?L7^\\JMQCG=;_E_;T45^ESR/3/V6? =CM,]C<:BP_BN;E^?J%*C]*Z_P_\
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M1J0!>2V5 !DY&7@/;<3\R;=Q'WC7)%/>C*S['K591^'%PO#HU^O5%GP+]O\
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M01G:,'T'I7F5\=O(X;/!KL?AIXJM-2\6:E9>)Y5;3O$,9@NG*A%$V0T<AP,
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M/2<7[/=)(=S[G.YCCKG.:[\LA3P6&IPJTU>]^[^1]P\+)4_W;]ZWRN8_PO\
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MZLG.MJULNQX[\0/A;%X3CBOK8K#:DA)5!)^;VK9\)^'TNM+#+@KMX7KP,?\
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MVKR:?Y2%B=Y'RX/R_P">376>']4FG161B=QX]ZF_)JT<M:FY1W/2I-0"J$B
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M: L99(_X0/>OF:DY5)7J2;]6)X7#TM(:$^IOHMY$8FMU"'J&6CX6_"S0IO'
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M@8/SX9U Q[G'/(KSZS?.ET)E*='$PIU%[KZZ[^O?[CEY-'^QVL$D*_Z,R*5
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MM^6A=_LUVFT]%AFFMOM6+C9&Y7 8[& ['83N(X!Z>I5_[15WA07TKI%<D^9
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M9?,ED9N""22-N#]!R,9YSP!GV?PSU'3;:<PR6]S)-<"Y>(C:!(KLZD,0>/F
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M7Z3?!O\ X)^_"?X2QPSW&D_\)?JR@;KK7%62$-MPVR#&S!Z@.'([-7THJA5
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MJ*  /H*O444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
C%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>form10-k_005.jpg
<TEXT>
begin 644 form10-k_005.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )7 5L# 2(  A$! Q$!_\0
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MM<CA\P9\O:<CVZT<Z'RGT=<?$;PO;#+Z_IY'^Q<*W\C6=-\9/!T!PVMQ,?\
MIG&[?R6O#&\+^&(<>;K<CX_N#%*--\&6_P!ZZN9_Q I<Z#E9[:/C9X,/35S_
M . LW_Q%+_PNKP=N _M8Y_Z]9O\ XBOG?4=2T6WOF%G8>;#MV@R$C-4QK-I'
MY6W2XL(<C+$__KHYPY3Z4_X77X-V[O[7./7[+-_\10/C3X.,FS^UFW8SC[+-
M_P#$5\U-K4&UD&FPX9]QY/%*=>B:21AI\(+KMSSQ1S!RGTL/C-X0*[O[5.W.
M,_9IO_B*7_A<GA'<5_M1L@9/^BS?_$5\T+X@C4Q8T^'"#BE'B"/: ;"(\Y8[
MCDT<S[!RGTM_PN3PCM#?VHV#P/\ 19O_ (B@_&3PDK%3J;Y R?\ 1)O_ (BO
MFO\ X2&%MP^PJ,G(PW3Z5*OB*V^;-F1D<8:CF\@Y3Z1A^,/A";;C6%7=P#)#
M(@/YK6G#\0?#,ZDKKVGC'7?<*I_(FOF)?$=C\N;9Q@?K4T>O:61\R, WWN*.
M?R#E/J&S\6:)J$RQ6NL6-S*W1(KE&)_ &M3<OJ/SKY0CU#1IF0D(&'3<O2K%
MNFDLZM#(L3YR&C8J1^(YI\Z%RL^J:*^<[;5K^.17M_$&H(5Y5?MCLHQ[,2/S
M%;MGX]\46\PD&J1WB;?]5<6Z8SZ_(%/ZT^9,7*SV^BO*['XLZM#&!>:9:W3Y
MY:WE:+ _W2&R?QKH+'XK:/<%A<Q7=@5&<S0[P?H4+?KBG= =I152PU>QU12U
MG=P707KY,@;&?7'2K=,04444 %%%% !1110 4444 %%%% !1110 51U?6['0
M;4W%_<I;1=!N/+'T4#DGV%4_&7B(>%?#=YJ6T221J%B1NC.Q"J#STR1GVS7B
MEU'=:G(;^]G>[NI!\TS=N^U1_".>@I-V'8ZS7_B]>W6Z'1;5;53D?:+L;GZ=
M0@.!SZD_2N'U*ZU+7F9M2O[B^!(;RY9,(#C'"#"C\J1<;MHQGIC/-.O+G^S+
M%KAER<87(K)R9213&EI$H+;(57U[52NM:TJQRNXSL.R5RVJ:Q<ZC<,'9Q'UQ
MVJ@%SWS[U.Y1T<WC7;D6MI''_M-R:SY_$VHW&1]H:,>B#%9@49ZTNW/!-.R
M?)=SW&?,F=OJQJ+![G)^M/V\=<4;1Z\>N*8QNT4X?+2[?0TNWWYH :0/7O1M
M6GX]#1M'UH$1E11QCWJ3 ^E(N.HH CP/3 I=H[BE(/\ " ?J:W)M%LH_#T5V
MM^OVTMAK?'&/8T 8G&.:-HQP*=MXQGFD_G0&XW:,T;!SBG9%'O0 W9[4W;[<
M5)G\*09YSC':@9&8_FSGCTIVW'_UJ>.W^%!7=WP* %CFEC^Z[#Z&K<&M7</W
M9B1]:J<T=B318+LW[;QA=Q?>(<?[5;%IXTMYFQ/&4/\ >3D?E7$1D2*&&<'V
MQ4JK^8J; >IZ??6]T1-;2J[*00RG# @Y'/45U.F>.M4TW:IG^TQC/R7'S=_[
MW7]37A$<TUJXFMY#',G.1W]C7HWAR_.JZ5#<,N&8<BA-H32/9='\?:?J3".;
M-G,?[YRG?^+Z>N*Z96#*"#D'D$5X+(!&,YP*Z'PCXLOK.]2%9#<6['!CD;('
MJ1Z']*T4NY%CUJBDZTM:$A1110 4444 %%%% !1110!Y+^TI-);^"+-T#%5O
MD+8Z?=;&?QQ7G7A/Q9%=V\<1/G*RY,?\8[<>O\ZZO]HCXG:5;V$OA*.+[9J$
MVR21U8;;?# C/JQP>.V:\%T_='\J.4P3@KQU&*SD]2UL>S369>07-DZRV_\
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M*UQGM4;3')XYI-OO24 ,:1FS4;*:F)J-FIB('45!)BIG:JT\BQKEV"CIDG%
M%6X(K&U#E6SWK6F)92>@_O-6-J$@56"'G^\: /2OA6?^*9?':X8?^.K78UQ?
MPE!_X15L][F3^E=I70MC)[A1113$%%%% !1110 4444 >=?M!#/PCUWZ0G_R
M,E?$UOG'6OMOX_\ _))-?_W(S_Y%2OB2W!SUS42-([&Q93-'C!]N*V;<0R8+
M(4.<EHSM)_+M6#:@\5LVOO611N6L4F 8YQC/(D7MZ#%:L+7"*2UOY@[>2P8G
M\\8K&M#TK6MV/!SS2*-2&[16"L'1\="IX_'I6C:W44S$)(KE>H5@<5GVUTZK
MC=5Y)$E&)(D?/4%14@:D/:KD-94$-NJ;5B\H?],V*U<@BCC7"RS*?5FW_P Z
M!&G'5E&K/AC(_P"7IV_WU&/TJS&DYZ3PD>Z'_&@"_'FIU)JFGFXX\MS_ +V*
ME1KCO%'C_KK_ /6H NHU2JU54\W',8_!P:E4R#_EDQ^F*8%E34BM5422?\\'
M/Y?XU(LDG_/O)^G^- %E6IV[I5=6D_YX/^G^-/!EZ>4?S% $X:G!N*A_?<8C
M7\7%-5KG=CR8P/7S?_K4 6PQI=QJ#]YZQJ?KFF 3Y^::(K_LH<_SH LYHR:@
M9"W_ "W=?]U1_6AT1E&6E.#U5MO\J!$^:C:>-6"EUW_W2>:C*1-UB5_0MS2^
M8>P4?04 )]H\Q241W([;2/YTUS)Q\JH".K'D?A0TC-U<G\:B:F QL?Q2,Q]%
M&!5>1PO"HH]SR:E>J\E %2X8MG)R:Q=0;*L*V)ZQ=0Z-0!ZQ\,8?)\*I_M32
M-^M=96!X%C\KPM9#UW'_ ,>-;]="V,F%%%%,04444 %%%% !1110!YG^TEJ4
M6C_!/Q1>3[A## C.5&<#S%R?PKXGT^YCNH8YX)5EAD7<C(V00>XK[6_::L_M
MWP#\;Q8S_P 2V1O^^<'^E?COX;^+6K?#6\D$/^G:86S)92MP.>2A_A/Z52IN
M:NCEJXN&'DHU-F?9MGT'/%;%KT!KQ_X=_'KPGXU6.-+]=.OSP;2]81MGIA3T
M;\.?:O7K21#WKFE%Q=F=L)QFN:#NC9M>@YS6I#CCFLNUQP:U+=>@J&:&A;\5
MH0_6J$*]/2KL%(9?ASW-7(>W-4H>1UJY'^=(1<CS^%6HSVJG'VJU'3 MQMQ[
MU,C56C/2IU- BPK5*K5 M2J13 G5N*D5N.34"U(IH F#$]Z<IJ):D6@"0'-.
M!J,&G\4 .I131Q2T .S12<44 %)FEI.* &M43=ZEX-,9>: (&]J@DJPZU1O;
MJ&SMY9[B1(((AN>21@JJHZDD]!3 @N!UKF/$^L6NA:;<WUY*(;>WC:1W/8 9
MKR#XN?MO_#SX>QSVVEWG_"5ZPH(6VTU@8E; QOE^Z!S_  [J^+/&7[27C7XV
M>*[>WU*Z%GI+3CRM)L05BZ\!CU<_6MHT9RU."KCJ-)\M[OR/V+^"?B5?&'PM
M\/ZRL1A2\A:14)R0/,8#]!7<5YQ^SKIDNC_!/PE9S@":*T(8+T'SL?ZUZ/5G
M3ZA1110 4444 %%%% !1110!Q/QMMOM?P=\;1XS_ ,2:[;\HF/\ 2OPL\3*&
M\]3U!-?NW\7_ /DDOC7_ + E[_Z(>OPKUX?Z1,N.,FNS#]3YW-]HLX.3AE(X
M*\C':NW\&_'+QIX%5(=.UF62T7 %K=_OHP <X&[[N?45Q<B8G53_ '@#^=>^
MZI\ =&UB-9+&XETV5E!^7YTSCT/0?2NBHX;3/+PE*O4YI4'9HZ3PE^W1=6V(
M]?\ #<<P+X\W3YBNU?4J^<GZ$5[3X3_;!^&NO#$^JS:/)N"A-2MV0L?8KN&/
MJ17QYK7[._B?3][61M]3C7_GFVQS]%/^-<5J?@_7=#8B^TB\MPO5FA)7\QD5
MSO#TI_"ST/KN.P_\6-_E_D?JIX?^('AKQ%+'%I>OZ;?S2#<L-O=(\A'^Z#G]
M*ZV%QTS7XSI,UNY:&1H91_%&Q5A^(K4T/XL>-/":O%HOBK5]-1CDK!=N ?UK
MGEA6MF==+-U/XX6/V2BQQCI5V-1VK\H=$_;.^+FA6JP1>*!=*/X[ZTCG<_\
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M!7T?1I?$VH1'^U-5^9&DY9(<Y'XM]X^N16YXR\&6/CW0SIETZ0NSJZ2J!O\
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M7.]=@QP?<5CS8B*?-!/T?^9LI/L=-;Z+86]Z;R.SBCN7<RM,B89F*A2Q]3M
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M6%#MT$?8FGQF+3[9"<E8E'Y 58IJKM4+Z#%.J3,**** "BBB@ HHHH ****
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M@R>(?CA\1=%<_P"E1ZA)-;9[X/(K]6Z_'7]K;5)_#?[3_B^]AR'BU%GZ\,I
M./R-:0W.:O)0C=['F^D^,M7\)RE+2;?"I^:UGR5S[=Q6C;:R_B*[NKZ2(022
MO\T>=P'%)\0+&WU#38O%6F#?8W !N%3DQMZD?SJGX)C%W97-Q&ZE%.1S][CM
M6^C7-8\?WXS]DW==#I88^ #Z5:AC.<-P.E9L>J1A@"I(K8LY$N@K*<^U6DUN
M$HHFCA..!5R&,+@GUYH2W(QCI5R&WY'&:UYKHY)1U+FEVHN+J.,D$,<9K=O=
M#6WC65,E,X.:Q]/C:.0,F=RGBNADU![RU$;  CJ?6L6S>,8V=R_H\J16:K@;
MA]X?THB;]]E&"C/3'%9,*2*!@\>M:-D6W#(P*=Q2OHC66/9SCAA5JW8[OF&?
M0YJ&$EHSGTXIUOUSQ5(&[;&[9YQC'':K3+M7!JM;?=![^F>:N!MR\]:RDM3L
M6Q7= YQR/?-1R0_+@CBK4B=^])MSU_.LR9(HF/Y@"O&/SJ0+B/(&/K4S6_S+
MQCBC:0HX]JEF%K%;DYP*:['9Z'UJ1_ESP*KOCGN,4(QD-W?_ *ZL02%<YY&:
MI,3DXY&.PJ2,E5R/QK5&'-J7Q,=P)SBIXY>XY[UE,V#Q^M6(9&SCM3-(RUU-
MJ*;D \&K2S#OS6-#(RMTR*MB;YL5H;QF:XEXQUIZR'@#^=9T,I/>K,4I]:5C
MKA(N;NU&ZH/,RWU]Z9<7D5JI:618Q[U@T=D96W)6(KM?@G&LWQ&TXYSL60C_
M +YKRF?7OM#[(>$[D]37JO[.,8N/'RN3G9;2O_Z"/ZU$HM(Z*=6,G:)]3444
M5F;!1110 4444 %%%% !1110 5^9'[6_PNTS7OCIXEN;EI$>:17.QL#[HK]-
MZ_-K]O*WU>Q^*VIWNB73)-%!$\MNHSN!0<X]:N.YG42<?>5SR7PA\/K7PO#>
M6T=U+=:?=+M:UG 903W'X5YJMO#X+US6-,M1_HJ3916ZJ&&<?A7)W7Q@\5JQ
M5=1\LCCB, TNAZM>:XEW>W\YN+J63YI&')P.*Z8PDG=GC_6:-2484U9HZT_*
M00<YY%6[.\DLY%D0^Y6L.WO6^3GE:O\ V@LQ9NO?%=]DT$H/<]+TF1-2MUDC
M(ST(]*UH8<=!D]#7GWAO71IC,6#.C<;0>]=E;^+;-\!P\9/7(KEE%Q>ABY16
MDC>MX&#*< #H370V6C+=6N_.&[5RUKXBTZ:/!GV_45/;_%CP[HMV]A<:I'%+
M@?*X( ST.:YY7-82I)^\]/4VFMS&S#TZU2_MJ&*1HH_G*_Q'[OY]S6-K'Q"T
M2[M?*L=9M9IICCY9 #CO6-9:O!+<B-)HS_=VL#6E*/-N8U&OL:GH-IK$DW&%
M!]*U+63;(&QD>E<I8S!5'.#ZUOV[_P #,&8<Y7I75R);&&N[.OM6#*"#FKD>
M>3V'O6!IMT<+SQW&.M;Z,-@*]#7/)69VPE=$J_,M(RYZ>M,CD(;-6E4%.#Q6
M31:U*FTC&32,GR\'C/2K#+EO>HV&W-9M&92="H/>JTBX7CO5UUW9J"13T&,T
MD<TBHL>,^E&XQL0<$=:DDPJG.5[[CVK/FU:SASONX%QUW2J/ZUJCEEH7-QSG
MIG@"IUDV]2%^E<K=?$3PW9G9)K-JKCDJ'R:P;[XX>&K5'\J2XNG7H(XL!OH3
M5)7V1SRQ%*&LI)?,]-CF:I/..X5X=>?M##C[%I)88Y^T28_]!KF=2^-OB/4-
MZ)<1V<9Z>3& P_X%6L82?0Y:F:8>FM&WZ'T_]MBMUWR2K$O<LV!67>?$;1;!
MMOVP7#_W8?F-?*LWB?4=2D+7E[/<L3_&Y(_*M?2=2^91DG/>NJ-!?:9Q2SR3
MTIPMZGO=Q\2I;MMMI$L2G^-SEJH#59KUF>:1I">Y-<'I5X7"Y-=-ITAV]>35
M2A"&QK1QE6N[U)'6Z7(6 SBO??V8AGQM,3@D64O_ *%'7SSI;;2,G!ZU]"_L
MOL/^$SF_Z\I/_0HZ\VL?8X!MK4^HZ***Y#V@HHHH **** "BBB@ HHHH *_-
M#]M_Q>/"O[3ETMP?]!N-/M1)Z+\GWJ_2^ORD_P""EBX_:"F/KIMM_P"@FKCN
M<^(DX0YD>1?$'X0Q>(X&U?P\R">0;S I&R3W7WKA_"NBW5KHNH+/!)#<VMSB
M2-Q@@8J?P#\6+KP9,+2\#7>E$\H#\T7NOM[5Z38ZMIWBG6-3NK.5;FTG6/+>
MOR#(/O6[<H*SV/,I*A7J*K#275'G#MY<@(ZGK5RWG:FZIIOV>_E,7S1J^ /:
MIK?8Q^YDUU1G9&[E&2T-;2HVN+B) <;F KOIO#ID@0Q\..OS5RGA>QDFN$N7
M79#&<C/<UVT=[QM!Q42J-O0\^K%2UD9T/AVY')+'TQBO)/B1HEW'XLF_<LP\
MM.0OM7NEO?8X)KS'XC:EY?BB7YO^6:=_:FI.^QY6*A'V>C/+-7TF>&S#R(57
M/!(K,AN)K?YDD=&]48@_I7J$C0ZWI<MK+QN'WO0]C7F]]83:9=/#,F".GH?<
M5M3GJ<M#W8VO<NV/BK4K4C;J%R"/^FK?XUUFE_$[Q#;;1'K-PN!CJ#_2N ^S
MJPW [6JW;VSKT;I^M=JE%[HZ);:2:/7M-^+7B.%D;^TI)%/]Y01FO3/#/Q2U
MR\TKS'F5V#$;FC'.*\B\.V=M?:)L9,3;/W?8[O6NP\(W%L^EI;(VR>,?O$;@
MYJ9>S>ECS*M6K3^&;^\[B3XHZX.CVXQW\K_Z]6+7XL:VHV.UOSP#Y73]:X^X
MMRW8#N*:T)\M>XK7V-*2V/+EC<5%_P 1_>=???%#Q!%C;)!G'_/+_P"O6'=_
M%KQ+@A;N./GJL0S6.MP'4QR'# ?+ZFLJ\=-Q^O1JYW1@M'$PECL3O[1_>7KG
MXE^*9-P_MB=,C^ */Z5FWGC[Q%=1;)]8NF'3.X#^0JM-"K+N&/PK*O %6LW3
MA_*CF^M5W\51_>R"\U[59OOZC=L&/>=L?SK'E+RR%G9G;.26.35F3OD\9II@
M&"<\>W2LVK;$\W-N[D2L?E_6G,^WD'G.*:4(^E1MV'0FIO8?)<E:0\D&F+*2
MP)--92.AP*C/4\_A2YG<U4-#3MYSP&)K7T^\*2#!Q7-Q,2H]:T;-R6 R![5M
M&7<CEY=CT72=0;Y?3ZUUVGWC-&,'!]J\QTF[*MC./:NWTFX&Q.><TY,]/#RL
M>@Z/,79<Y]*^D/V6PW_";2G)(^PRYY_VHZ^9M#D&],FOIW]EF,_\)=,X!V_8
MY0?^^HZX*Y][E>NI]2T445Q'T(4444 %%%% !1110 4444 %?F!^W]X</BC]
MIH6/F&)6TRW+.!G VFOT_K\U?VYM0_LG]I*^O-@D:'187"YZD*:N.YC62E&T
MMCXG\>_#O4_"%PSR1M/8L?DN4''T/H:Z/X+W M]'U=_[K@_^.UZ]HOBK3/$5
MM9V5\(UNKRW$WV6495@>H&>M<=XDT'3O"$NK0Z;"+6.=%<QJ>,GCBMN=R7*S
MS%A(TZJK4WH4+&);TO(IW=2U=3H^A:==6:S?9E\Q>&//-4/A_8I);WDDNW8L
M6TLU6O#FK6D-Q<6TEPJG/RY/&142O>T3.G%Q:ET=S4N&$,>U<*HZ "HK1);N
MX6*+EV[5:NXA("RD$,."#6?$S6\@=&*,/0U=/S,:_F7V\R!F1A\RG!7TKR3X
MC3_\53+SSY:?RKU5;IKABS8+'J:\A^)2F/Q5(2,9C7D]^*[(GB8KX#.L=0:!
MOO5IR+;:M$J7"A\=&[BN97.X&K]O(5CW;NG:IE'J>6I<NJ+<G@CSF#6]RNW^
M[(*NZ9\/;B1OWMW$B]\9)J*#4BBBM6QUIE;.?S-1SSV-/;-[G2V7A)=-L?\
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M_7S&_P *YJOPJQ];AHRYN:6YWE%%%<IZ04444 %%%% !1110 4444 %?)/\
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M6_EDE74KV8'-:4VEL?.5J;NSH(\S-TR*]H\ VY7P[:\CN>GO7@EC>O:D'?E
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ME52?F!V@9_2O;]+C:'2[2-UV.L**5/8A1D5P?@7PV;J[-]<)^YB/R C[S?\
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MTTA/_?S<*[RB@#S:\^#8 C%AK4T6#\_VJ%9<_3;LQ5>Z^%.JPH#:ZG:W#_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>form10-k_006.jpg
<TEXT>
begin 644 form10-k_006.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )N :$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^^*,\47 [>/XP>)(_OW,+_[T"_TJW'\;-<3[T=F_UB;^C5YXQI-W>BX'H_\
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ME*B[Q!,LI7/WMISBFMQ'L=%1P3)<PQS1L'CD4,K#H01D&I*T)"BBB@ HHHH
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MFN6*LCWGX1_\D_TO_MI_Z,:NPKD?A0AC\ :4#W5V_-V-==5G2%%%% !1110
M4444 %%%% 'PW^W='_Q<326'?3$S_P!_):^:2HDCY["OIS]NY?\ BOM&/8Z:
MH_\ (DE?,V,QD@<=Z^*SKXSY_':5#B+P#[5+Z;S_ #JOMSGFK5Z/],N,?WC5
M?^%ATXKY*1Y$CM/"7PWM=6T5-:UO6/[&L)':.*,E(]_. 69^G(. .HK,\6>#
MO^$5URWTVTO7U,7CQK;O-M7F1@JC*C&,GK5OQZ\]QHGA8.\,]@NF*L3+@DR
M 2 _3"?C1XFN)(;/P9=0MMN8]*M;A)&&X;UY4D'KR*^CQ4<)&@Z7L_@Y&Y=7
M?<]&I&DJ;CR[6U]27X<V<EO\0K"UNX&AGBDD26&4<JVQN"*]VNO!&AZOEI].
MA9VZR*NUOS%<C;RVWBJ^\'^,%1;:[N&DLYXUC(\QU5^GL"KX/<8KTF#"]*];
M X6GAX3I?%!NZOV:1VX>A&*<=UT.,NO@?HEUS;S75G[!MX_6L#4OV>[V1&^Q
MZM%(,<)+&5/YYKV*'[W\ZN0]<UI/*L!5=Y4E\M/R-)8.C+[)\E:S^S=XUMG>
M2&TMKU220MO< M^1 KDM3^$?C#25)NO#E^@'.4C$G_H)-?=41QG-6X3SD' ^
MM)Y3AG\+:)>#CT9^=%QH.HV&6NM.N[8#O-;NG\Q58*HYSS]:_25K>*?/G11S
M#_IHH;^=5KKPCH6H1[+O1K&9&X(:!>?TK"63)_#4_#_@F+P;Z,_.<#;]*7&>
M3FOT D^!O@&ZR7\*Z:I/.Y8L&LJY_9A^'E\Q8Z1+#ST@NG0#\C7-+):WV9K\
M3)X.IW/A9?E//\JW]+C^V0E0N0!P,5]<7'[(?@.X)\M-1M_]VZ9L?G5W3?V2
M?"VFQD0:CJ'S#^,J?Z5Q8C(\7*-H6;]?^ 8RP=7HCYS^&-N+?Q!;@KCYO3FO
ML/<AT09&?D[#VKEM(_9ETC1]4CNX-7O6=.=LB)@_D*]-7P;_ *'Y(N>V Q6O
MD,9PKFE:ISQ@O_ D:T<-6A?F1Y+J$@CLYBJ[3C@5\Y^.KR;[8Q661>3]UB*^
MRKOX4_;('C^W[-PZA*\^US]DV'6I=YU]XSGM"#4X3A?-*-7FG!6_Q+_,QJ8:
MN[61\WW5U*WAO'FR<C^^:\WFDF:8@S2MSW8U]J-^R)%+8BU/B)P.FX0"LG_A
MAS3W;+>*+KU^6!:^AP>18^CS<T%J^Z)^JXCL?(UO&S$%G8]^2371:59K(V6
MQ[U]1V_[#^CQD;_$^HD^T,?^%;-G^QOH-OMW>(M3<#MY<0_I716R/'5%917W
MH7U.N^AY+\*+-%UFVV@9S@\4GC33HO!OQ O;!1OL]1)N54_\LW/WOP-?1_A?
M]GC0?#-PDL-[>3.O3S-H_D*T?$WP#\*>*M4AO]3ANIKB)=JM'<M&,?AUKPUP
M?F$ZC<G%)KN_\C:.#K**[W/CGQ%I>GWBLK*=P&=Z-@BI=/\ %<VCZ"L$*D+%
M_P M)R"6_*OKZW_9]\#0$%M(-QZBXF:0'ZY-:4'P3\"1.K+X4TLLIR&:#//K
M7H4^#L4Z:IU:RY4[VU?^1/\ 9U3G]HK)['Q5X?\ %FJV^J0ZI-<!O*?,<+#"
MGZCO5/XF>*?%?C[9#!IU[<VB\[+.UDDS[DJ#7Z#6_A;1[%56#2[.-5& %@7C
M]*OV]O%:_P"IBCB_ZYH%_E7KX;A&C1J*I.=[=H_\$/[,J/2573^O,_+[2/@3
M\0?$P2?3_"&J3QYSF2,1'\I"M>M>$_V4/B#]JMKF73K.S5,;DN[L(X_  _SK
M[KW,W)Y^M+MKZ"61X6HN6;;^?_ -XY72CNVSYXL?V7]1F6,WFM6T _BCBB9R
M/HV<?I71:7^RWX:M)M]]?7^HH1S$66(?FH!KV>BE1X?RRAK&BGZW?YG9'!4(
M_9N<9I/P?\'Z(T30:%;22Q'*37"F20?\"-=5#;16JE8(DA4]1&@4'\JG-,;F
MO<ITJ=%<M**BO)6.R-.$%:*L1M4;5*?I4;5J402=/:JDW2K<E4[CH:!F=<'J
M36-J'S)USS6S<#K6-?\ W3BF@1]#?#J+R? ^BKZVZM^?/]:Z.L3P2H7P=H@'
M_/E#_P"@"MND;!1110 4444 %%%% !1110!\2_MY)CQIH+XZV'\I&_QKYBC.
MZ,BOJW]OBW"ZMX7G[M;S+^3+_C7RC'_J^M?&9W\1X&.^,X_4$"ZA..G-0,JK
MU%7]<0+?.>,D9_I6?[]>*^-EL>,SN_ RZ;XOT)_".IR?9)D=KC3[A, @DG<%
MSU;))P>H/M6UXR^%?B"Z;0K;2([6]M;#3X;)YI[CR6RA(+;=IR,$5PUUX-MX
MO!.F^(+2[F+RW#I-'*Q(R&890]5(*@8Z8S6OHOQ6\3Z3#Y!O8]0B"A5-U&"Z
M^Y8<L?K7U?UG#4J*PN8*]TG==5NK]=#U8U*<8*GB%NEJNQZ7'H__  A6E>#-
M#>\CN+J.]DF?<-I8,LF\H/0/*HYYP:[Z'KS7SMX?U[4-=\;:=>:G=M=W+3HN
M\J% '0*H'"CDGCN37T1#BO2PN+IXKF=%6C&R7R1Z&'JQJ7Y%HM$:$##I5V,[
ME'/O5&'ITJ[">!D]J]),["U$P]*M1L%8 G!JI&0#ZUYS\9?B%%X"OO!<S3(@
MFU=4F5FQ^X:-U=C[ LI_ 5VX6C/%552ANS"M6CAZ;J3V1ZW&V/\ &K2?I5.%
M@RAARI[BK'F"./>S!4'5F. /QK/4UOU+T?%6EK*M=1MI@3'/'*!U*,&_E563
MQMI$%P8'N)1*&V$"VF(S]0F*WC";V0N9=SI(\;JOPM\M<K'XPTLE/W\OSD!?
M]&EYS_P&LO3_ (O:5=_$J;P2(+M-4BMQ=%Y(BL;(3@;6/!_#TK14JFN@*<7L
MST-6&ZKBGY>*HI]XU<096LKF@\8V^U)W% XXIH/S=*JXB5<&G=.E,7'TIP.>
MU.X$HJ1?FZ"HN<<5(OZTP)8_O5)-U'I4<?6I)EW8IC(A4BC%(JU)[T 'I3<4
M['RTW':J$+3MO>F^U2#.W% QM%'UI* $_G333C3&S0 QN.]1-ZU(W?O4;=/2
M@"&3I5.;H:N2+528=J ,VX[\UCZA\L?I_P#KK6O)%BX^\YZ*.M8U]G9DGG-4
MAGTCX+_Y$_1/^O*'_P! %;58O@O_ )$_1/\ KRA_] %;52:A1110 4444 %%
M%% !1110!\A?M_1[8?!\N<$_:5_(Q?XU\A0J.I)]N:^OO^"@#'[+X,'&,W9Y
M_P"V-?'T?08.?6OCLZ7O'@8_XSG]<7_303U*UG=_3M6KX@3;=1L#Q@CFLK.U
MB:^*EL>+(](\*^#-0\4?#Z:VDGA>+S_M.G#+*T+C*LC]B#SCTW&N U*QNM!N
M98-3MI;%XS@M.I5/0$/]TY^M:7A_QQKOA<[-/NU>USO-K<KO0GT!ZJ._%=_I
M_P =+.XMUAUS0F) 4EH0)HV8GG"-R .N237TG_"=F%&G"I/DG%)7_K_@'HKV
M%>$8RERR2.#\)LO_  DFDMG"FZC&?JPKZ;MQ@\'Z5XGXGD\&7VH>';SPN;6/
M4)-<A%TL 9&D!#$Y4@9&0.1P*]I@<=A7I8#"+ QE34U--WNCT<)2]C>-T_0T
M8B1_]>KD6./6J4+=!BKT+@]L'UKUTSO+,;8KY-_:OL;(6,WB.^U!(-1.H"VL
M[623#?940JQ"?]= QSW!%>V_&SXKVOPK\$W-_N!U*<-%9Q-CE\<N?]E>I_ =
MZ\3^%_P(N_BMX+UGQOXU,FH:WJ]H_P#8T-TQ(MDV_NY2.S-@8'9?J:^NR?\
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MK)=#CPL*=-/EES-N[?4^*?%<S_!G]I*>_BW);QWPNL ?>AE&751]&9?PK6^
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M [\>G)HRG,<3B*CI5I\R2TO\NIZ&55JE2OR2E=6_R.1\=076I6%PMNS1R-M
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M=)9_"N]\(Z8L^IW$4<TVWSXX>6SMZ9Z8Y_2OI?2]!M_!]O/ID$D4Z/+YAA1
M@7(YRH[UYY\7K.1+6WD:)4@9CM(ZGCO6\:?L8QI5'>Q\3A8K%5Z=.ILM#RR1
M8+2PC@BMXX_F)\P?>;/]X]S4D/G>;&(XV\UQ@#'6I-!T&;7;H6Z-DY&Q>Y/I
M7K47P=U2*9;UI8 8X^+?!+=/7UKUXXE12C$]/&55AY.DNA!\,;0JBM@ [P"#
MZXKZS^"$9D\60'^Y!(?T _K7R_X+M_L=Y'"%,;1O\P8Y.:^J/@2F[Q1(?[MH
MY_\ 'D_QKTL.[JY\[)W9[S1117<2%%%% !1110 4444 %%%% !7YE_&9?+^*
MGBU<_P#,5N3^<K'^M?II7YJ_'JW-O\7O%B-QG4)6_,Y_K7%BO@1R8GX4>>R_
M=(('(KE+E/+E/!4HQ*E3@CW!KJ9.G![^E<WJW[N\;/3J*^)S1-4U-=&?.XI>
MZF=/X=^*VJZ(JQ7JKJELO]X[95'H#T/;K77M-X.^*#QF>?[-J*KA0TAAF50>
M@SP1DUXQ)G=Q6@OAG46T!=:,,4NFB7:7#?-&P8*,@]R?3I6&#S;%SC*E4A[6
M*6J>]OU(HXNM;D:YUV9WFL?!76+4-)IEW#J4>.(YOW,AYZ9^[@#UJSX;L9]/
MT%K2\S!<1RLKJI!P>O-<?HGCS7_#<86RU*1H0/\ 470\Y.N21DYS^-=5HNL2
M:Y87EVX\HS3LS(O(!VC.*NA5RZI4]I@X.$K.ZZ?(]?+98>IB8NDK/J8^K74.
MD03SW+CR82"SQJ2<$XR .M</X9CEF\4ZE=:5=Z;-I]Q=HUQ<V]VOF'!E8J8C
M\Q;YT3(& %%=W<@QSAP[(=W!5B#^=<##8RWGBV&UM8M-FALM0FO'O)(]EW 7
M9BT97&9 <G:^2 ,=*]&C)6D?8XJG)RIM;7^9[#8IN7(X#$ 5JVMN9D.W@]">
MO-8VCW0^9" > 5S726;>1(TS'$?1#C[I]Z\F,4WJ?3RO'0 K)<"-UW)T! Z&
MK,=NRL0<CL<'CO5CRF95SB5N/N#@G/7-)N"Y8<X."P/6JG343.,N8\:U:XE@
M\1:F&E,-IYS;A!\I;G)S_CZUK?#O^RM<\7M?6NF27&IZ>A!-P^Y6CP>@(P2,
MC@]216'XLE:'7[UHP6)?<>>E6/"_B*;PVWF0^8P8XF\OAFR><>_)YKQ<%F2P
M>+DI[7L>MC<M]MAU."UL>K7DFIZA9"ZU*ZC?3O,$:64D 4#!^[LY'IUK/T[P
M[HWB2^2.?3@SVY(2.*806_EXZE#\N.,'U.:U;35-+U?3X$E<2QQC.&RH7G//
MO5U(=+UKRK=S&=.2?,T,;[-W&0N>I''/J"17Z#]:PLM/:K[T?"N$H_9L9-]X
M9MM-O)+BPBT_29[B14-K&//,JK@@$*?E]P#C"KT(K"UU)=6UBTL-4F33]-A5
MI9);>80PHHP/NJ>^3D'&1T]:]"FM;&\DC.G7\UH,[76,A@PSSVS^M,E\/6K0
MSQZR?-@;@PQHNZ5>YWG./YUK%0J*\))KRV)YFG=[G+6^@76GZ#;V/ARZBL?"
MDDAN;PI:9FE#<K+$A;JW''7'.*D\.^#;%=%BMY+J"Z-QSY>DQLR+'ZN6^Z2.
M3Z&NMATFV;3'S+)'*K'$;-E0"040CV4*/SK.T'25T6QGVP^2CRR/>+"IS(I)
M*A?11^O-<=6DKI/]27-V>IT'A?PJFBVJQZ?*SP\AIOE'/4].,US7QTU"U\+_
M  ^U/4-1TZ'6]/3:L]I,-RR*3@?3Y]O/;K7HMO+_ &:L$$840H@(V$<@]3]:
M-6T?3/$VCW6C:C;1W5C>*599%RK@]J\FMAJ=U?1I_P!?><D)J-:-2>R?3<_*
MLW C&<<^GI2?VHY0J&P*[;X[?!_4_@MXL?3[K=<:7<DOI]_C"S(,$J?1UR 1
M]#WKSUK&Z73EU PLMH9?)\QAC+8S@>O'>M?9M,_I#!YG3E1A4I2]UK0VO#NG
MRZM?;_+$D$.'D_H/QQ79WFG6^I6"2R1E6W&,L4"@XYSG\>U9'PJET^QOI;S4
MTF4,-D<RMP@[DI_$.G?M7L/A^S/CC]SHFG-=2VRILD:#"*-V"Q)XZ']*J$5>
MU]3\KXHS>K6S!1IS=H=GU/"]5\*W%O9R7%M;S,(2/-0 OM![D]NWYUS<TGEJ
M0WRGT-?:FA? "ZCDMI=3U/RF#;S!;C< ".['HWTS6?KOP!T+X=:>FI):0WA>
M0QK+< R2G=GEMW!^H%=4L/))RL>ODO$LJD?88N5Y='U9\BZ;HFIZM)LLK"XN
MGQNQ'&>GK79:?\(/%6H1Q.;..WC;_GO,JLOU7K7O=G&L4*&-51   HX ]L5I
M;F521V'%<<K'U<,RDGS11XW9?L^7<DA%]K,,<>,_Z+&6;_Q[ K:TOX$^';:6
M'[7)=7LJ,&.Z0(K>Q4#^M>C*&E#*JEB3GY>:TO#_ (/U'5-:;SO]&MHA@GJ7
MSZ4DK)R>AS8C-*U1J+D'A/P;X=T-B]GH]I"6()!CW]/][.*]4TOR)+)MR \=
M^WTJ&/PG9V=J%$;<?Q,<USNJW<FEY6%R4!P1GD>]<4)*,[O4Y:E9XI6<G<Z/
M4+F.SM%@CE$9+;L#HW7BNP\(ZQ%?6*VKM''.I^14  *\?K7@&H:U--,HWMZ#
MFHFUJYLYHY8;B2)U4[65B#S_ /JKT:.(=.5TCY;,LC6*G[2$K/KYL]=\6:[8
M7'BX00LIO(XMKLO(8\X&?48JOJ6DP^,M)-K-*H69<Q2 <QR+P?SR*\J\,W,K
M>(K:9MQ9Y1ENYSUKW;P3IH*7AF3="+A@F[U7C_$42;K5'-GR>.P<LM=.47KO
M?S,_X8_"N+PBK3W3)=7['_6*/E1>P7WQWKT*XA'EM@"IX5V1\5%.VV-\_A79
M&*MJ>)6K3K3=2;NV>/-:R:+XS=)6&R1S*-OH37TM^SS<?:O$-P_8VC_^AI7S
M7XNODC\0/>=1##_4XKZ%_9?D,FHL3U-DQ_\ 'TKV\*_=0F?1U%%%>B2%%%%
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M*X]*IZ?;L&B9MJJ[9; .$'K5^>.-5,D<X+)P#G@DCM7C5)RD[L]&,8QT.D\
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MHHH **** "BBB@ HHHH *^,/^"BT'F#P&X^\AO#^&8*^SZ^+_P#@HO=&S;P
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M_P")M*MHH6>25PB%APV3C'ZUDVNGR:A9VTBQ9MF)4A%/4#+8]2 ,GMR*]O\
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ML<RRG[S'^0]@*ZNOU3 87ZK04'OU]3W\)0^KTE%[]0HHHKT3L"BBB@ HHHH
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MWL3)07WO\-/Q.BCE%:7\1J/XL^3/"OP+\7^+&5QI[:=;,?\ 7WO[L?7:>3^
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MLV@SD[B-/8"%CC !B(*@=_E"D^M<1JGPG\6:+DVR6NOP@J ;=_L\QSU.QSM
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M?:,5.J*HP% 'L*=10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
A44 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form10-k_007.jpg
<TEXT>
begin 644 form10-k_007.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )' 0<# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M31YJ[(<U%Y)DZ"J&94D&YNE=!X'A\F_N?7RQD?C5)[<1J2>36AX+;=J5V?\
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MAE6%W'@_^/5H1^(M)E7*:K8/_NW49_\ 9JDXW"2W1I FG*:S_P"VM/\ ^?\
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MTO8YK'LU%%%9DA1110 4444 %%%% !1110 5#>#=:3#U1OY5-45S_P >\O\
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M+F2'KM-:=LSM;%5)V*0Y7/7M^=9<S)90L^=R*N<=R?2O;/!O[+]YXAT&UO\
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MO2O@7(C:IJR*,$1J6_.O5H['AXA\VI['1116YPA1110 4444 %%%% !1110
M5%=?\>LW^XW\JEJ.<;H9!_LG^5 'Y;?&Z9/[6O+>5QY<KEE+CH< 5\]>)/%
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MK:VV>6B0X]LFO4PE55+I;(YJL&H-L]XHHHKTSS@HHHH **** "BBB@ HHHH
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MO<7'58XT+G\A6UD]S[CEA.-JBNO,^@?!W[:GB?1%AAUO3+768E^])&3#*?\
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MFV3S0F46NS<X&#P2. >*I:EXOLK'2-)U7[#(NFZ@K_O)!L:-@/E7'?/K6O\
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M%7^.%U8'Z#.?TIL=S-''OFMKB)1U,D+*!^8KTJDZ]:6A5V>=0ZI!)TE4_P#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
5BB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>form10-k_008.jpg
<TEXT>
begin 644 form10-k_008.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )7 AX# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI"P7DG K#O/'?AV
MPC=YM;L0$.&59U9@?3 )- &[17":A\:O"UE#OCNIKPY^Y! P/URP4?K6'?\
M[0FEQJ#9:7=7![^<Z1@?D6H ]7HKP[4/VAKUU LM(MX#W:>5I/T 7^=9%_\
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M-Y"DT$J31.,K)&P92/4$4 2T444 %%%% !1110 4444 %%%% !1110 4444
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M8_&NSTK]HJZ3<-1TN&;)&UK=VCP.^0=V?S%>,YI:8'TOI?QR\+ZAN$TT]@5
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M_P :^A/A_P#%:P\9*EM.%LM3VC,9/R2'OL/]#S]>: .[HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4LEJ\> 5(JNT;+R2<&@!_6DVTS)VYZCO1YN..:=A#J:5I2W2C- #:3;3BRY
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M >!GMBI![TP<$5(!VH <!Z4]12+[\4]:0QP^E/I%_*I(QNIB 4^E\L 48Q3
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M_P".BK]>H>8%%%% !1110 4444 %%%% !7SE^WA;&;X*PR 9\G5(7_-)%_\
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MZ3]GVSE8XUFZ"]3B)*?)^SW9S*O_ !.;A7]3"AZ]:OV.([_B1]8PEO\ @?\
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M)K4CT'381E+.W4COL%6LMEUDB/[4IK:+/#)H7FC411,S8XV*2/TJQI>DW]T
MT-C/+Z90KW]_>O=8;6"'[D2*.VU0!5D?H*VCED;^],Q>:O[,#Q&W\"Z[=7@9
MM/DB7&<R$#_)K<C^&FL7*8D,%L03C<^_Z'BO4\8&.O%*<MTZ5TQRV@M[LYY9
MI7>R2^1YDWP5CO% N]3D7IN\E!S[<UHV'P9\-V9)D@ENB>,32$C\J[O&2>V:
M48QG^*NN.%H0V@CDEC,1/>;_ ",+2_!.A:(@6STNVBYR3Y88Y^IK;\I$P%4*
M%["E_AZ4UF[=*[(I15EH<DI2EK)W!N*:#QTR/2AN?I]:1N.AS5$B-T'--8C;
M[4K9ZYIK>O>@0WD'/>F-@Y'44KD+P3UJLTVYP%Y[9-/41DZC:7T>7LYL]_+<
MUQVM:A<74RBY&R2/CIBNXU74A9PD(N^9CA4'6N*U+39ENII)3O<#S),=L]J[
M*4NXC9\,?9?LN5<-,W+9Z_2M>9OE.>E94.@V_EQSPEHG(#?*:T"I"C+9('WJ
MRG)-W117F[_E50M_I,0QDLZX_.II<;B*32;?[1K6GQ==US&N/7+@418,^R8_
MN+]*=2+PHI:9(4444 %%%% !1110 4444 %<)\=K47GP9\:1GMI-Q)_WRA;^
ME=W7&_&;GX0^-@>G]BWG_HEZ3V&MT?D:^&=MK <XZT1M\V&'%)<#9,P!SR>:
M6+'7]<5\CB5[S/LL.]$6E52I;./>H;AMR].#Z5-&ORDYXZ8Q56Z8G)X]J\:6
MYZ:(4V#///H*V=#RUJ^3_$:QE;L!C(_'I6UH.!9D*0!N)Y&>]=.&^)G-6^$R
M]3B6*\8_=#<GWI(\'CKVSVJ]KT062.08&1C;CI5./[I[\5RXB*C-G12E>" X
M5L=NF.E' V@C*GKBD9 <G'ZT1X;@,0!UK"VAI>PK_*PYR#^=/8;>IR /7I2'
MY>1@BM;PCH5KXCUPV=]J']G1>29%F;&"P(XYXZ9ITZ;J245NQ3J*G%RELB_\
M,/$D'A/QE#<W9\NTN(VMY'ZA<D$'Z9'ZUN^.M!@\'^++'Q-;74<VGW5XMP!&
MV2#N!?GN.34DWP,OY-\NG:O9WL&/DW*0Q_$<5AZA\*?%5BNP:<]W".B6\P<+
MQZ'I7L>QQ-.C[*5.]M4UT?R/+5;#U*WM85$KJS3ZKYG0_&+P?=S:Y'XATVU>
MXMKJ%7>:URS(^,9X]1CI70?\([>:]X%\.ZSJ+3PZO8SQ;O,)!EC\T ;U]<8.
M>M<=X=\=>+_A_&-.?3Y9K:,'9!<PN=@XZ,HZ8[>]6]3^,>K>*KBQTZ>WM[2%
MKJ(RQQ;BS8<$ D]!FM75P]YU)73E]FW4B-/$I0IQLU%_%?IVL>YQ<XQS4Z-W
MSFJ<9# 8/8?6IMP7J>_2O04CP">ZOH;.UEGGE2"&)3(\CD!54<DD^E>%?!7X
MFVVI_%GQGIRW2O9WT[7%HV?E8IA25_WE /X5VWQAO%D\)RZ:+N.Q&I,+>6=\
M;8X.LK'/^P&'U(]:^.-6\76WA?XCW=[X'N=\4%P?LTI3"QJ1@@@_P\D#U%?;
M9'E\,90K1?Q25EV5FG^?X)GR&<8VIAJU%QVB[OOK=?E^:/T 'C#1%D:,ZO8+
M( 0RM<H&!&<@C-9]U\7?"EG=&V76(+JZ'!@LMT[Y[#" X/UKXX\;_ 7Q'I.A
MS^+K_4;+4K68+=22VS%-WF'J >2/F_6LOX;?#_Q#XNDOAX8/ERVZJ9MDYA9@
M3P,CKTKOH</X.I2E7>)]V._1)^;.*MGN*I5(TOJ^KV\UY'W98^++G5(YFM=!
MU)&0@#[=&+=7[Y4DG-26VO>()9/WOAZ.!,\,=01CCGG@?3\Z^-IOA-\5+&X/
MEV.K2%>C6]T2/_0JLPZ!\9].MO,C@\100Q@?-NSC@X[_ %J/[#PSUIXFF_5_
M\$/[:KKX\/-?+_@'V0NI^(7F0'2+98S]YOM8)_05Q-UX@^)"?%V#3K?2K'_A
M#S$KR7SN2003N  _B(/ /]T&O'_@)\?M<D\66N@^);V34[:^?RH[F<_O(I.P
M)[@XQ[$U]8@@@@?E7A9CA:F55?95H1=UHU>WJ>[EV+I9C2=2DWH[-.UT75<,
MH)_6D:X$9QD'Z5 LG4';C/I4%Y.(?F'('4^@KYN4[*Y[D8<SL6S<X]V[C^E3
MM.=P"D;<=_7-8]O<&53G:PX(P.E78LRS _B *YE6YMC:5/E+RS<G Z5(9NG
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M]_7'6L+5H/+O&<%MK<UO*0N>23C)YJAK4.8TD8'=T-9UX\T&52ERR1B,P))
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M'6IHR]]^858^ZO(WH6/!X]N*LQEMPSC%5H3E>.U68?FV\\]P178<YB>(+?\
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MK7[-1_XKJ\_Z\)/_ $9'7L8;<X*VQ]+T445Z)PA1110 4444 %%%% !1110
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M2=.GS/J?.XV:<N1=#IJ***],\P**** "BBB@ HHHH **** "BBB@#QO]J#P
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MF_PC\.E5FUJ=<%P8H 1VS\S?F,?@?6O2Z^IM;0^:;;U84444""BBB@ HHHH
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MT%>T^&?#5KX7TU;6W&YV^:68C!D;U^GH*]K8\C<TK6UBLK:*W@3RX8E"(H[
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>BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>form10-k_009.jpg
<TEXT>
begin 644 form10-k_009.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *M *\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH *BENH81F26-!_M,!7XE_M[?M-?%.Q_:5\=^&;#QUK6EZ#IUV+>V
ML=/NFMT1-BG'R8SR3UKY)OO''B37)LZEXAU6^)/)N+V1R?S- ']*]SXPT*S_
M ./C6M.@QU\R[C7^9K-F^*O@NWXE\7:''_O:C"/_ &:OYQM/TRVNVS.99#W+
M2MZCWKH[#POH\FSS+8G*Y.9&]O>@#^@YOC-X!7KXV\/#ZZI!_P#%4J_&/P')
M]WQKX?/TU.'_ .*K\ H_".A^63]CY\M3]]NN4]_<TC^%M(5@%MR/G8<2M_<8
M^OL* /Z"(?B?X.N/]5XKT63_ '=0B/\ [-6C;^+-#N\>1K.GS9Z>7=(W]:_G
MD_X1O30.$D7Y2>)F_O8]:S[[2;:V!:*2X1@H((G;T'O0!_1W'=0S#,<T;CU5
M@:FK^:I/%&O:.Q;3]?U2S8=#!>2)_(UT&@?M3?%_PI*O]F?$GQ)"$Z*^HR2+
MQ_LL2* /Z-:*^7_^"=7Q>\5?&S]F^S\0^,=1.JZPNH7%J;ID"LZ)MVYQP3SU
MKZ@H **** "BBB@ HHHH **** "BBB@#^?7]OIMW[8'Q//\ U$\?^0UKY_C_
M -8*]\_;T;=^UY\3_P#L*$?^.+7@(^\* .DTZXVX_P ^E=!9ZAMV<_PUQ]K-
MMQS_ )XK0@O",<]J .PCU3]WU_Y9K_-*235/F7G^(_\ H#5RZWQ"]?X0/U6A
MM0.1SW_]E- '2-JGR\'^$C_QZLV^U#>K#/\  /Y"LAKX_P![L?YU6FNRW<],
M4 %U-NS_ )[UC/\ ZPU;FESG_/>J;'+4 ?MU_P $EEQ^R-9'UU>\/ZK7V?7Q
MI_P2;7'[(>FGUU6\/_CPK[+H **** "BBB@ HHHH **** "BBB@#^>_]O Y_
M:\^*'_86;_T%:\#_ (J]Y_;J;=^UQ\43_P!1=_Y"O!6H M1R8J=9NAS_ )YJ
MBK8I_F4 75N#Z]A_2D:<^O\ G%5/,IID_P _A0!::<^M1M,3W_SBJYD_S^-&
MZ@"21JC7K2,U*M '[B?\$GUV_L?Z0?74[P_^/BOL:OCW_@E(NW]CS0SZZC>'
M_P B5]A4 %%%% !1110 4444 %%%% !117-?$KQ0G@KX>^)->D.U=-T^>ZS[
MJA(_7% 'X)_MJ+;:E^U9\3KA+Z!H&UF8!T;<#@X/2O&X['1PN9M4DSZ16Y/\
MR*DU&/4O$&J7E[]FN+J:ZG>9W"$EF9B2<TZ'P+XANO\ 5:/=-_VS(J'4BMVA
MI/L5Y8]"7[EW>R?]L5'_ +-5?=I2_P 5VX^BC^M;\/PA\9W/,?AZ[8?[M7K?
MX!?$"X(*>&KG'N5']:S=>DMY+[Q\LNQ@6::/(5WV]XX]F KH=-LO"38^TZ9J
MC_\ 7.=16]I_[.OQ"X_XIR8?]M%_QKH[']G7X@X'_%/28_ZZ+_C4_6:'\Z^\
M?)+L85KH_P ,Y% GTCQ$I]8[J,_TI+KPO\,I%/DKXDMC_M^6X_2NU@_9W^(&
M/^1?D_[^+_C45U\ _'T*DGPW=-_N[3_(U7UBB_MK[PY9=CS"_P#"/A#G[+K%
M_%[3VW^%85UX;L8\_9=8AF]%D4H?UKT35?A#XRM<F7PUJ*_2 FN*UKPCK6G[
MOM.CWT&.N^W8?TJU4A+:2^\7*^Q^SO\ P2OC$'[(&A1>9&[KJ%YNV,#@^:3S
M^%?7M?F;_P $8_&3MH_Q"\)RNR^3/!J$439&-P*-Q^"U^F5:$A1110 4444
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M;KI>#7OG[--P6\'ZA"?^65ZV/H47_"OH<CE;$M>1RXCX#U^BBBOOSS HHHH
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M%J,@5.HC2MQTJ[&*J6XSBKT?:F!*JTXKQ2JM.VT 59E^6M+X:7!L_B5H4F<
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M/*]S:M^U7H>U4;?MVK0AKRK,U)EJ3%-7BGU0B*05G7J_*:TWJA=K\IH ]Z^
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MWE'(>-6_, U^;,ENMG$NP<1]#[YK]%/!EU]L\)Z//UWVD3?F@KS,4MCXK/\
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M^""BBB@#Y=_;XU1;;X>Z%:%L"6_,I^B(1_[-7YJZM<-?74DC'ECP/05]X?\
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M:DUA%;VYG5?WS ;F-9D/RE:W9OFM67MMI:DN][F!<29S7HO[,=V(?BD8B?\
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M!>:/R4U2Y\V=F'"]OIVK/CB2.(W=R/W2G"1]W;T^E6O*%Q,Q<[88_FD(]/\
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M*BS5BE[5>MY"2!65;*TA&.GK6S:JL0XY/K6T5<ZH)LU+.(MM+G'^S6S;R!<
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M:WF_W&_E6-;*6K<M5'D2?[I'Z5E/8PJ79Y=8KMN$S_?'\Z_??X5_\DU\*_\
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MPN/^_1K]J/\ AV'X)_Z&K6_^^(_\*/\ AV'X)_Z&K6_^^(O\*/:L?M&?BO\
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K? WX#^%?V?/!,/AWPO9^7'_K+F\D ,]U)_?=N_L.@KT85A*7,S*4N8__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>form10-k_010.jpg
<TEXT>
begin 644 form10-k_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #/ 1\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z**:[K&
MK.[!549+,< #UH =45U=0V-O)/<S1P01C<\DC!54>I)Z5R]YX_AN)'@T6 ZE
M(IVM<GY;=3_O?Q?\!S]:PKS39-:D$NKW!OR#E82,0I]$_J<FFXNQ2C<UH_C+
MX)DR?^$CLT7=MW2$HOYL ,>]:5E\1O"FI ?9?$ND3^T=]$3^6ZN7FT73/)Q-
M:6Y0#HR#%<_>?#_PSJ3-YNCZ7*#_ 'H%S7'&.*^URO[U_F/E9[';WUM=\P7$
M4P_Z9N&_E4]>!2?!7PG(6:/288'Z@VTC1G/?[IHM_A:+,YLM7US3RO06VJRX
MXZ<%L5=ZZW@OD_\ -(7+(]]HKP5O"?BRS4?8_'?B",_]-VCG'_CRFG0R?$RS
MD"P^,H;L9.%OM)CP?Q3!I>UJ+>D_P_S)L^Q[Q17C,?B[XE60*R-X=OV4<[HI
MH2?R8U"WQ@\>6+A;CP?IE]QUM-4*$G/8,AJ/K45\49+_ +=?Z)AKV/;**\>3
MX^:G"V+WX?ZQ'CJ;:>&;^JU,O[26AQL5N_#_ (ELV&,[M.W@?BC'I1]<P_6=
MO73\Q7/6Z*\NA_:4\ LQ%QJ=U8,!DB[TZX3]=F*V+'XX> -08+#XOTG=P-LE
MRL9YZ<-BM8XBC/X9I_-!='<T5C6?C3P_J(!M==TVY&,_N;N-OY&M>.1)%W(R
MN/53FMQCJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YKQ/
MXR_L2\CTVRL9-2U>:$SI &$<:(&"[WD/ &3C !)]*Y>;3-3UUEE\07@N>XL+
M4%+5/J.K_5OR%0_$V\;3_&%G/&<.=.<'_OZO^-<)XN^)=YX1\-7NLO(\T=HH
M=HU R1G!^G6M8Z*Z-5%)<S/4H[<Q84!50<*JK@"G/%YBLN2/<5Y-X#^.D7CK
M39KNR;;Y! E29<;2??O751^/+@@[X(SD=5XJ8R4XJ47=,I>\KHZ:6&.U3]Y-
M( W ).:@,,%PK*EV 3U) SBLF'Q\H51):'(ZE6S5I?'6GR##PR*?=<UH/4LP
M:7&I;9=+)N&WJ,TG]ASJO[JX!/J<TV'Q%HC,7"K$[=6\O!J2&]T1F9DN%0MP
M<,10(=_9MXT+AY,MVVM@?2FPV]_;QHIRP5LX!&<9Z9JQ'_9[1NL5\ZACVFZ8
M],T]H6,&(K^3<O.YBIS]>.E,12D>^56W1%DZ\KD_I5#4-+BO%BF>T?*?+E2R
ME3WK=BAOMC!KF,D@8W1YQZ]#2LNHJH -M(._)0C^= '+-:PQR)OFN[=ONC$Y
MVGOWJ*YT%/G;[7=1R$[C(FU\D]!T]*["X:?Y0EHMR"N6PX'/IR.:KJ)&W"XT
MR39GA048=.N : .:L]"MOE\V:2X!XV2Q#/O69JW@32M0;?$MN&8X*S1Y7^7%
M=K<&#Y(T@:%\Y'FPMCIZ@\<556.W>-I5:+8!DL'=!Z=Q64J%*I\<4_5(1YU)
M\&-(NK<^=I6FM/(W+*%'RCN..]9K?!$6;^9I]M) 0V=MG>%,]NS"O5X;>.2%
MFC=49EQ^[F1MV.@YQZT2:3]JA 9)[9L#=@98G/7*GBN;ZAA7_P NU\E;\A67
M8XW3?AKJ=O:@+XBUVTD7_GTU*0^X&&8]*M-X4\;64F;/XA:RO.0+F"*=>>WS
M*:Z5HS:JP:7,S  /)&ZLQ'KQR?>CSYX8VB%PLDW ^689'YX_R*2R^BOANO24
MO\Q<J,.*Z^)UG'E?%>GWH5AG[3IBJ2!_NXY-6(_&WQ-M6Q)!X;O1R>DL3>W\
M1K9\S4%D/ER>?&,?/&RMG/M3GN+IEV&$OSPSQD9&?TQ2^I?RU)+YI_FF'*C/
MA^*WC2WQ]J\&VETF1\UGJ..._#(<U9C^-VH1'%YX&U>'C.89(I1_,4D&I239
M22S@X)  Z>OX<<T_[9')J.SS%C55_P"6>'7CTXS_ /JI?5:ZVK/YJ+_)(7)Y
MCU_:"T-/^/O2->LOFVDR6!8#CK\I-:%G\=_!5XHSJTENQ'W+BTFC(_-*PY+Y
M;:=DD8;UZ^8F>_7AOZ4;K>1"Q2-CT)D'W?S7^='L<6MJD7_VZ_\ Y(.5]SL;
M?XJ>#[K&SQ'IPR2!YDX3IU^]BMFS\2Z1J&/LNJV5SGIY-PC=?H:\ONM'TZ[7
M]]:6K C*;T1@1^E9[_#7PY?S&6+1;&,IR R;6S[%34\N,CO&+^;7Z,.5GN*L
M&&001ZBEKY_N_ /A[269LW.GE00[0WDT:+WX/2IK72=BHVG^+-;3T6+4A+^)
M4GFCFQ2WI7])+]4A<K/>J*\8BC\4Z>H\KQC>D8POVRSCD]\YVU:_M[QU;JIC
MUG2;W<"J^=;;"S_@1^59RQ-2/Q49?@_R;"S/7:*\H3QYX[M5_?:'IEZ5Z_9Y
M64GU[G%/D^,NIV*K]L\)W .W+>3< X/IRHKEEFV%I_Q>:/K&2_0+,]4HKRZU
M^.UM<-'GP]J?EL^UG0QDIZDJ6!X]J]*L[Z#4+9+BVE2>%QE70Y!KJPV/PN,N
ML/44FNV_W!9GCOQHD>/QMI8!P'TN?CW$T?\ C7E7Q(B-]\._$4 .2UE(1]0,
M_P!*].^.T@A\<>&V+$!M-O1M'?\ >0?XUYMXJ62;POJ\<8SNLY1UQSM->FMF
M;;T['BG[*FL/-I/B*)!YC1HK[-N[.">,=S7OGA_6CK5F9C!);D,5V2K@U\O_
M +&NL)+XBUVWWY;RACTX;FOJH9#$_A7!@+N@K]&S+#/]TDRSY@4D$X]STKE?
M'7Q$L_!]JRHJWFHD;EM]V !ZL>PJO\2/&47@SP_+<[BUTX9;=%/5\=?H*^7V
MUC4+ZXFNKQS//.2\Q;GD^GM7EYSFSP*]A0_B/=]O^"8XK%*@K+<]:\,_&K5M
M6^(&CV%PZ3VU[*RF)  D0(.,'N:]PFD:U\QBWG,6RD9(7VQG_&OF/X(^&SKO
MQ&2^>-5M-,3S<?\ 31A@#\J^GY9/F)ZUID4JM7#2J59.5WU=_4>$J2J0YI=1
MX)(PQS].*6.:2-<1NR =/F-5_,VG)(*TYGQC)XSUKZ2YV%R/5+V$ "ZE(Z\L
M:R=-\2>+_P"V-26YO%73U?,&,'S%(Z$]1C]<U:DF2%<N^WM2'$R-M(!Z98?T
MH:3!.QT$'C;5+?AI5F'^THJQ)\2I[./S)XHQ'D L<CKTKD[BWEF6)8YS;A3D
ME /F]N>U,C"R1^3+(MS+%C?Q_%U!Q0*QZ##\0A&,O;8W')PU6$^(-K(V'@95
M_O9S^E>?LV[Y.C8R..GO4<4HD4X)RIVDD$9(IV0K'I7_  E6AW.#+&I(.X>9
M%G!'>I7UO0KZ59GDB:3&-S9!]:\Q;MR<9I%PK=.:=B3U6.XTILI#=O&&^;*7
M!!!Z8'-311IM(CNVD1APTCJQ7\,5X[J$<\T>VWF^SR?\]-F[\,5+;R3QHFZ9
MLCDX8]:FSO8H]?\ [/F5RJ7,163E@UNOS8'<C%-DTABH;R;=I5. 49XQC'L:
M\M75KR';LNI,#^\YJS#XPU*W;:+Q\_[7>G9DGH_V.XCCW>7(#P L5R< 8QCD
M5%>6FT!FAD.3@JL"2?B3U]OPKAX?B)JJ+EBKC.,,N#5G_A95]'&2;.*1AR%!
MQFBS ZNZC#0L[*ID0 .\L#IN_N@;3T'-01K:3\;D$;#YR\C*2?0!ATZ?G6&O
MQ6$3 2V+=,_(<U>C^)FGS*#)!(N1Z T:A<O+:R38,GF3(GW%B>-L*.PP1UXJ
M-M+^SMD;R3R6,+$'/T)ID/C[0IF8,/*;I\Z ;A3HM<\-R,P6Z1#W7>PQ2U'<
MBALY0&CBN_,EQC;DKN.,\KQ6S:Z2IM0EVD5W(?O/(@.?IQTIMGJFGR-MBN@_
M .7?CZ<U;DF2XB98KA%?LW!P?I2=PN8.H6.C6<D-K))]D56,JQQLR $\'D=.
MGK4]I8V\TRR6VM7$VTY$)G251UXY!(_/M5UUU'RRHFMI<\?=*'^9K*D\-NL[
MRF#SVD7#Y$;YXZ<J#U]Z"KH?)H.I+*[B6PN0W ,L#PO@GG+(>?RJUIS:A]J,
M4\(\D\"5)A(BX[;6 ;)]>>E4+;2)I+X>7'-:MMPT@:2,@9YQ\Q7-=&C"SA6-
MI&E=% +2'YF]R:4I=QI7T,GQ58VRZ7<2I @ND1F1@OH.AK5^"963P-'*H ,E
MQ*[8]<X_I7.ZQ<2R&<%U:,QLI3'.2/7Z5T7P/Q_PK?3CC!9Y2?\ OXPKYF="
M,<UIU8JUX3O]\/\ ,TJ1Y:9YA^TYKQ\/_$'P'(UM-=1W%IJ,)6!=S YMR#CT
MXKE-=<#PWJA/'^B2'_QPUU7[5]U'I_BKX:W<G 6XO4+^@:..N1U>=9=%U';A
ME^RR'YNF-IKW,/44ZE2G_+;\5_P#*/P'QK^RGXN_X1OQGJXCL9+]IH]NR$'<
M/FY-?;'VY(]/2:>0PJ5\QF(Z #)S7Q3^Q>HD^*6J$[2?L\C 9_VJ^C?C=XK?
M3](BTBV;$UY_K2I^[&.WXFO,CBE@<)4Q$]5%Z+SLCEI5(PH\W8\T^(_B^;QE
MKTEPK%+2 ^7;Q=A[_4]:YB8+;QJ 096'<]Z56W'IQ&/OGIFKFFV+Z[K6GZ?&
M /M$ZQ],X7JQ_*ORBI6JXJLYS=Y29X<KU97ENSW3X%^%/^$?\*&_G+&\U(^>
MV[LO\('X5Z#M9FR.3G(/;(JNL+V=O;P6PC6.,*F&SPH&.*ECSP-V=IK]LPF'
M6%P\*"^ROQZ_B?24X*G!170D5"K.,\GT)/6I"W9CE<8QC!J%@,/D[0PP3WKD
MKK7M#^&R3OJNMLD4F##:SN9' ']U?O&MYRC3CS3=EW>A3:2NV=HD@;Y63#
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M8U>UU.#S+&SNW BTNPSE-O/^L=0"S=><"E_9L^-6F_$37_$7AOPQH<.D>#-
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M8HVP'@H.!T!'7KS7C?PO_8TN?"]B8_$GC"\FLI\2WFCZ,[002N. &D^\PQZ
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ME:3:V=OF8P5 P%* GU-,7F9G[27P=U#XS>%=.MM'FM+35].O!-%/=D@;",,
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M.V216VA/F)(/;)-=#H>DW>CZ<EO?3K<2QG"LO4KVS[U<FTB"\B<S1B1,Y*L
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+9$MMN["BBB@1_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>form10-k_011.jpg
<TEXT>
begin 644 form10-k_011.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (' 8D# 2(  A$! Q$!_\0
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MQED-2&4L>3S]:/?_ )A:=C]66_X*G>'UP/\ A'XBQ_Z?&'_LE21_\%2-"D;
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M[\\=JC9?F';B@#T7X2JS6/BXC&5TMZ\[5BN 3@YKT3X0C=IWC$YP!I;Y->>
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M_"/B2;4=2CEU>*2TDM6CDE(8!AU![5'<>)]$_M'3IX+&ZEBMGW/#<W!<,!T
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M\H[8I"K-P&YI>#@9I-N=W48YI )&6X!'/K3R"HR>IIL8*Y(.>U2#=W7GT[4
M>O?LB_+^T/X+<9S]L'\C7[YU^!O[(^4_:)\&9X!O!_(U^^5:0)D%%%%:$!2-
M]TTM(WW30!^"?[5"AOCYXU)YS>G&/]U:\B90HZXKUW]J;+?'GQDH&,7I!/\
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ME 'X(?M4.8_CUXV15)'VX\YS_"*\B2;=P>GO7KG[43-'\>?&V1C_ $\\_P#
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M+?LXV/BBSC^*'PMGAUC1=77[1>:;'.GFPL>2R@G./45KZ3XHT?\ :6_9IM/
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M0#D<FC[O)^:B/# ,1BF2)(I# !3_ +U,.0N.OM4Q8L1V%,VEB#CBG<>@W.,
MC'I0N5;IQBE91T/3M3E0<X_*DQ#5SY9SS[TSF/).2.U2E2!P.#3>=F<\>E 6
M&+^F*7'R[>W7-*F&I3&6)YI@,7/0$9HV \C@>U*8^V>>IIW?.,FF BKUXQ2C
MCG%/3DX(R>M#8!'/)J0&!MI]*8S;LU)Y6XXS]<T@'7IFF%B/;WR?I37)W$9(
MJ;9OP>F*;C:?<>O>@ #-TZBEV;LG.<4N[=U//?%$8./YTM@$4'ZTF!U[]JD9
M>P;'UI$^7- $>#T/-/"X7K2[?ESU!IK+V'6F%Q.>W"TI Y]:D11WZ]J;L+-G
M%+4+GI?PA4?\(OX\W=]/'\Z\O6%> #TZUZE\)HV_X17QW_=_L\=?K7E_DE>5
M.:ZZG\.'S_,XZ7\:I\OR(VCV]"<YII9XU'/&>:7+J3SD9J6%A(2",5RG6&Y6
M7)%#9;BDE@ !P<#]:1,C.> *>XQXC)Y6E!DR<?0T+(JMP>,5)C..Q/:D!]!?
ML$_\G->%>&XF/\C7[>U^)'[!.[_AI;PR.F),_7@U^V]:4]V3(****V,PI&^Z
M?I2TC?=- 'X-_M+_ /)=/&N?^?\ )_\ '17E;#</UKU/]ID$?'3QH!VOSS_P
M%:\K\L?>W8Q7//XF52_AQ]$-:-#R3GUS2,L;,0.F*7;YF><#L*/)5U'.*DU(
M6B5N1R>F*:T#*H )/I4TT)7&T]:B68J2,\>M%A"*SJRC) [UZO<8_P"&>[=@
MV1_:W ]\5Y?&PDR#T]:]/F4C]G> #&/[7ZGKTKHH_:]&<F)^Q;^9'F+$'.>G
M>DVC< ?NT;2A)J0?<R1@^AK ["'C;CIZ4\97W!% P<9(!I-^WY1U]Z6@"\-G
MG_@-1G\J>#P?TIO&W!YH)&E1N]J<OW3S]*&Z 8P*55VCGB@8=AGD4BD@D]J>
MX 'J*;QM///I3T&-V]#^M.;.#QTHCPW .#3FPORCD^M B+R^,^M*K;>@XIY!
MV<TGICCZT@$Z?6E)SP#FD4AL]J?Z=OPJ0&Y/RD_I28'MCI4GW5(%(R%<]S5
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MCTK,7QYXE+9_MR^_[^&HV^('B1&)&N7HS_TU-3S4.S!_6.Z_$U!\(_%K,/\
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ML;R$@_6LV-S&QSR#4U:D9*,8+8JC3E!RE-ZOMZ$1W+P32J0HY%+Y@YS^%/\
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MXSCO=)GNCB.^MSOMBQZ#(Z5MZE^SSX<L?B%:^%6.L,;A XU!%_<Y(S7IF_\
MX0-SX*\/1S>)]:?$R+J!WQ:>G7+D]Q2IXB\5>;'%/XQT!?$@0[+,*IB]OGIJ
MG!:-!]8JRU3M_6YXQXA^ NB0ZC+H&B3W^N^((@PF:'Y;>W_N[FK(M/V9?%%K
M,+B^LDN+2)<R06=PK2L/]D>M>^6]]/XC%[X+UV#_ (1/Q'J967^TK'B._ '.
MUO<=JR=!\ ^%=!NM5UN'5/$&DCPY<#[7+>2,5EP.53UR?YU/L8WT12Q%1:-_
MJ<)IOP+\$ZQX:U#7;._U.9=/B_TC3=A$Z2#^&HH_@7X07P7:^*+V^U33[28,
MOV.9#YS2?PJM>J6_B[Q/KC/K&G6FE^#O#ES]^;4%'G7([/M^E.F\4^++2);^
M+^Q_&_A^W ;R;50LRXZL%]JKV<'T)]M5O\7X_AM8\(?]G7Q'JR)=:3IOV6SD
M'R1ZE.J3?B*T=)^!^D6.H6^C^*VOM$U.? AO(_GMI6)Z BO4]<\'^&?%JP^*
M9M2UW5;?5KA88K>RD*FT8\%7'8 UI3:DWA.2/P+X<M7\3ZQ:GSOM&I'='8 ]
M"Q/I6?LH7NT4\3.UD_\ @?,\SE^ /AB+X@'P@TNK?:7B#QWY7]SDC.*BLO@7
MX6U#Q1#X=L+K4M3O(FV7UW N(;?ZFO5O^$A\722_+XJ\.OX@QA;;8NWZ;JU_
M!/B*2YUXZ'JMC'X7\0O*MP\D('E:@HZD'WK2-.D^AFZ]6,6^:_S_ !V.4_X8
ML\,LI!UF^W?WJ3_ABKPQM7.K7Q(_B]:^C?+ZX&*-I#8-=BP]+^4\SZ[B?YV?
M.R_L6^&.2=5O?IFHY/V*_#)_YB][^=?1^WU6FK'SS1]7I?RE?7<1_.SYS/[%
MGA<Y']J7O/?/2FC]BOPRO75KYA]:^D%3V%+L"]N*GZO2O\(?7<1_.SYQ;]B_
MPP<?\36^ZTW_ (8J\-.Q/]KWH_&OH\*&XQQ2&,!B!5_5Z7\HOKN(7VSYP'[%
M/A@*5_M:\!/?/-'_  Q3X97@ZO?$5](-&,>],8;N,<TOJU+^47UW$?SL^=!^
MQ3X7W\:M?$8Z9IZ_L7>&-N/[5O>M?1*H><#%*L8W<C H]A2_E']<Q'\[/G3_
M (8O\,*QQJ=Y1_PQ7X95LG5;XGTKZ,V[>O-.V_F:/J]'^47US$_SGS?_ ,,5
M^&>2-6OA^-*O[%?AE6!&K7Q/?FOHME*XR,4JJ:/J]'^4/KF(_G9\YK^Q9X:#
M,3JU[SZGI2M^Q9X9[:K>X],U]&M]W!'--6$MU%'U>E_*5]<Q'\Y\Z?\ #%_A
MK[PU6]SGUI\G[&/AB1?^0G>#'H:^ARF-WI2JIXS1]7I?RB^N5_YV?/,?[%_A
M9?\ F(WAY]:YSQ[^S+X8\"Z;;ZB$U+4K?S-L_D<F)/[Y'I7U3M.!S@5QWQ+\
M26OA'2[:\GCFNYGD,5O8PC/VER/ND>E3.C32V-:>+Q#DES-GS)X@^!OA#0=#
MT_5[4:IX@M=0E"Q"U4YB4D<M2^+?@3X.\+WEO9PRZGJVL7B*\.G0J=R ]V/:
MO3;K7O$5FL?]N:_HWA"WD;,&GH@=U]%8=C2MXTUOPW-]K\1QV>J:1>CR(M?T
MM1YD&>!NQ7)[.%]CN]M6_F_$\07]FGQ,9"W]GV6-V5MS<KOQ_C75>%_@/X2\
M374UA<1ZCHVMV*EYK&4']ZH'53WS7>/\'_#LFN?V?%>ZY]K:#[=_:OG'RE!Y
M!_\ K5<C\8:UK2@^&_LUAH^GK]FD\1:L!YD^!SMSUI^RC'XD-XBI)>[+]#S#
M2/@/X5\3Z3J=U-#JGAU=.EW2R7BG#QCJ161)\%(/$S+<>%=):+2%;8+W4Y/+
M\T#^)0>U>NV>N:_J$,L>A>*]*\6'.;C3YHPAD'=5]33=8CT'XD:-/KFH1:I9
M-H*>1=:#9DKL<'L!US2]G!JUA1K58N[>GY?D>6#X+VOA/]_XGT9KC2V8*;S3
M9-_E^[ 5T.H? OPCH']B+:Z9J7B*#5GRMU#G;$IZ;J[Z%=/^&UC;OH-IJ&JZ
MGXBB4V^D7A+)$,<N^>F*S=4UC5M/EM(M;\?Z;H%Z#E+"TC#(OH":/9PBM45*
MM4D[IG"^(?@SX7T75KCP_HME=^(=>?\ >;6RL5LI&0&:LVW_ &>]2CVL^G:9
M<R]9+..X&X?3WKUD:]JMJSZ5XE6&;3-;_P!'@\0Z./F!/17(Z9J)?A/X;TV_
MU&)_[7LQH2K<OJ1E)$X') ]:'2A+9$QQ$XJTI?J=+^QCX1\/:?\ '#2[_3+*
MZTK5+=C;7=C< _*2C'<#WZ5^FE?GQ^S'XDU7Q5\;M(U.:QBTS19F*V<<@Q<W
M 5&'F-[5^@]<]5)2T/1PTI2A>04445B=84R;_4R?[I_E3ZCG_P!3)_NG^5 '
MYF^-H_#_ (-\9W7CJX@N[;5UO)+*"PM22=1.!ABM84VN>,(X#*E]H/@%+B4S
M+9W!&^93_&P[&NF\:>(O%.@^*K^_GT*Q\2^'[.XW0K:X-U;''+D>U<)XHTGP
M8+&W\81:7>>.AK5V(O+FE)-HQ_AQ_#SQBO3]#YV,;VYE?\?E_P .:>J>+KS0
MUN[/Q9IT,>G:V@MAXIT;GS"?XF(Y%9;>"/"%OXSM/APGAJXGM[VV$ZZ[N.XD
MC.\-Z"MZ3^S/AC]I\+:)9W'BK4M2*W T69M\>GKC.6/\.#_*ECUCXIY1_,\*
MK>H"D<0=<A/3.?TI>H7:UAHO6WS_ *T(X=:N;=K'PQX4TY/$TF@,4EU[4SA+
M=L]%8]2!_*HX]4\:7D=[$NL^'?&@8[GTB,J">?UQ3I/*^(R1>#=8BN/!.K1S
M_:Y+:V;:FI(/O%6[D\\5SN@^'O _B!O$,T>DWW@<>&YQNU))65I<==WJ3CI1
MKW_K^NX[1MJM?O\ Z^1M:I:^'_']M>^(KW2KRZU;0(-D_ADL56)@?O@=QBJ^
ME_\ ".>&=/TGQ_'I%YI.J7@:.WT"W8G[6QX!V]A6K#XZ\4^)%.I>$=(T_3M/
M?$+:KK1"/>J!][!ZTZ3QAXST",:AX@T72==TJU/RS:00TML#_& /3FA6W_&P
M>];E_"_X?UJ1MKGC""".5;WP]X",\IE6PN"-\JG^(^AI+SQ-<V[7FE^+M.AT
MRUUL""/Q)I'(E/\ M$=,U@:]HW@N'3=-\1+IMYXY&O7?E"2:5F:U)ZC'8@UO
M6SV/PY:[\(Z!;W'BS5+MA.FG7;;XK =<L>V*6O7;^OZT'RQWMK]WX^7F8W_"
M!^$F\:+\/_\ A&;N!'@\Z/6PYR#C/F;O2NL\%ZTMUK&E>']%L3XBM=$<Q76O
M7PY0Y^ZA/4U7_MKXJ;DD)\*R7(788Q(N[;_=!S5OPAK]KXFUFTT.[MI/!^LV
M%Q]I:P7Y8KWGE@>]7&R>FGR,JCE*.NOS_$]F9>2>Q-)M^8U*>2?4TB_*V>M=
MYY&HW!.16I#8P7=B'5Q%-']\-_$/45G-]T_-C-+DXQSFLIQ<K<KL=%.487YE
M<V9-/M_[2LXE3]V\>YO>J$-NLE[%&1N5GP?I4?VZ=IHY/,/F1C"GT%(+J57\
MS=A@<@U@J<^KZ'5*M3>RMJ6X;&.::]CV[?+R5?TQVK/VJ8]Q;YO[M227DTD;
M#?P3EAZU"K?,.U;1C);LPJU(2V1?:R0Z=;38^=Y=K'VITEO;0:R8'BS$V% '
M8D=:I/=2>4D9<A%.Y5]#2/=223":1LOV/>H5.5]7W-/;T^5)+73_ ()?DT^.
MUU:.T;Y_GPS>N:LMI]NVJ75L8B(U!*O_ ':R3=2R7'VAG8R@YW4Z74;B7=OD
M)#GYO6DZ4W;4?MZ:OII?\.QHV^FPM##(R[DV,7V]3Z&J-C:K<76YP?(4\@4Q
M-0GA9-DA 087VJ/SGVL-Y 8Y..YHC3FKJ^Y,JU*7*U';\31CTL1ZTEM(N8V/
M'N*9;V\9O+Q#'\L:,1CVJJ-2N!-&_FG?&,*WH*;'>2QM(RN0T@PQ]:/9S>[Z
M%^VIQ>BTN79[**WCL-JES,,N?7VJ;['9VMY=12AFA& C#JA-9JWDJ*JAS\O*
M^U1M=-\X8DECEO>CV4NK#VU-:I?U8L7MG]DVHPYR2&]15/[Q%2R7#3*H<[]O
M"^U1>];P3BK,Y*DHRE>.B#&3R*XSXG:Q?^';&QU*PT1-<6VE+31\>9&N/O)[
MUVG'!!^M<5\3M?L/"]E8ZG>-<23Q2E;6SM^MS(PQL([BE-^Z533<T>0:GI_A
MBVTN/Q7I6@S>+)M9O-DR71+-;%C@I@]"*TYO[-\ WUSX8\*Z++K&J:@$N)=/
MN26MK4=?F)XJ_;Z]XUBW22+H'A2RE;S8+2<*90QZ;AZU'=^+M5TZ.6U\9V=O
M;6>K#R5\1:.1A?0,1TKCNE_PQZ=FU;?Y_P!;>11&J^-6OC ?&?AU&/R#2LC_
M +]Y_2I8EL?'U]9>&/%VDOH^I:=NFM;*V8K;7@QG (X/-4!\-_";^,)?#!\,
M2^0MI]I'B7SCG&,A\^M:5OXNU/48;6U\'VEO)IVD_P"C_P#"1:R1\^.NTGK3
M5UO_ )DN*O>._P!QAZ#I^@:U8W^OZOX?D\'-X>O,)<6N5,P!^Y@=<UJW'B;Q
M1K,$FJV;Z7X$T^\8-'-J&/.NE[%AZU?DUKQ==6^ZRN]!\66JMYES8PJJNV.<
M*.YK \1MX8\7:-JGCFXTN]URYL56WE\/R,0+9AP?E%'30OKKK^/YFA;^+O%&
M@V<FHWTVG^--(4&.XO--QY]NAX.*S[C0-%T5?#A\.^%5\4V&O2L;B^NP6>,'
MKR?NXJYI_P#87P]BTW6=+T.YBU[7K8"+P["Q,97KN8'I5S^W_%>FK!#J?B/0
M/#EPQS#I\:*<9Z ^AJ>FO]?>*SW6GX?D4[.9?"MQJ'A#P-IWVORIC/=WVHMF
MWLB>0%)[BF1:MXQNK@6Z^/M!U65^MD<8E_V:N7FJW-Y'_P (UXVM(K*QU>8"
M+6]).$F;/"L1ZUFQ> _"U_K'B#1KOPLWA^QT.,2G6HY&#,!SE3ZU27;_ "':
M*3YE?SW/5_V9=:3Q)\?-);5=.?2?$NF+]GDMU)\DQE&(9.V#BOT*K\^OV7O$
MU_XN^,VAWR:6NG:"H,5I-<#%S=!58!SWVU^@M<5;XCU,*K4^P4445@=@4R7_
M %;_ $-/IK_<;Z4 ?F3XIA\/^"O%VH>-[B^O=-E%_);SZ:K[AJ3  #:OIS5/
M2==\3-#-+:>'=%\*:=<3BXB74) &F)Y4D#HU?./[1&J7G_"Y/$\37,S1P7[>
M2I<XCX'0=J\^U#Q-JE\J"ZU*ZFQRH>4G%;2Q*BVDCSXX-RBFW<^R+OQ=-!=:
MGIWBG1U\)7NO?Z-'XCT]@ZN3C!+=L]JYF3X8^!;7Q]9^!I+35VUFXA\V/6/M
M!\MV*D[^OK7RU=^(-3OK58+G4;F>)2&"2RE@".A%-D\1:I)<QW+:C=/<Q#;'
M-YIW*/0'TJ?K"E\2N6L'*.TK'V;_ ,)&=).G^'?#VG-X\\0Z&<?VM=$".$YY
M4OW(%6]4U_Q?-;74;^'= \16\K[[RRM9?G'<YR>37Q/9^)-6T]76UU"XMO-<
MN_ERD%F/4FDM?$NJ6$S2V^IW44K'YF64@D^]5]:\A?4==&?8&NP^%OB5ILOB
M&Y34&MM#AV3>&8W\IH"/X\?2H/"\7@_P5I%GXVL6U/3;.^W11Z%))YC7N>!Q
MZ=:^1X]=U#SKB5=0N%DN!MF=9""X]#ZTR?6M0;R5:\G9;?\ U(WDB/Z>E+ZR
MK\UM0^INW*I:?I_74^UM$\1^*TM,VWA[0?"VFO+YMO#?2X>7/0X!X-1MXH:6
M:_T;Q/I*^#M2UL^2FNV+ I)Z9;L37QA>>)-4U)8S<:C<S^6?E\R4G'N*?>>(
M-3OX%BN=2N9T4@JLDA8 CH15?6_(7U%WNVOQ/J7_ (5MX*C\;)X'6PUA-8,7
MF+K'V@E,XSYG6N[\+ZY8OK^E>'K"SD\57ND'9<^()\ 1<\@-W(%?$?\ PDVK
M^;]I&I70N%7;YOFG=M],^E)9^)M6TU'6VU&YMPY+OY<A&XGN:%B4G=1'/!2F
MK.7_  _]=#]0689)WJ>?44G']]?^^A7YB-XTU_)(UF^^OG-_C2?\)QXB9MQU
MJ]!_Z[M6_P!?C_*>?_9,_P"?\#]/<J/X@?Q%*SJ#DLO_ 'T*_,%/&NOHIVZW
M?$9[SM3?^$TU[ ']MWW7./.;_&CZ]'^4K^R9?SGZ?;O]I<_44XLN,;E_[Z%?
ME_\ \)EKZ,/^)U? ^OGM_C4J^,M>?IK5\?3]^W^-#QT?Y1?V3/\ F/TX61>?
MF7\Q0S*/XA^8K\QO^$T\0KG.LWVT?]-VIO\ PG&O-@#6[SKVG;_&C^T(_P H
MO[(G_.?IR65FQN&?]X4ID'JI]\BOS&'C'7HV^76;TGN//;_&GKXTU_85;6KS
M![>>W^-/Z\OY0_LF?21^FRMN_B7_ +Z%*T@7^)3^(K\Q'\9^(%7+:U>X[?OV
M_P :5?'&O;O^0U>[O^N[?XTOKZ_E'_9,OYC].68'N!^(I-V.K+C_ 'A7YE-X
MYUY>&UN\ /\ TW/^-1MXTUZ-L_VS>#MDSM_C3_M"/\H?V3+^<_3G</[ZX^HH
MW KDLH_X$*_,4^-/$'5=:O<>TS8_G1_PFGB'D'6;P@_]-F_QI_7E_*']DR_G
M/T[\Q>/F7_OH4C,,YW+CZBOS&;QCKS*5_MF] QT\]J;'XRU_A5UJ^'_;=J/K
MZ_E%_94_Y_P/TZW+_>7_ +ZH\Y1_$I/IN%?F3_PFNNJO&LWN>Y\YJ9+XR\0=
MM9O?7_7-2^OK^4/[(E_/^!^G*L,_>7'^\*XWXF>('\-6]AJ@T5=;M[:0M-M(
M+VZX^^HK\^%\:Z\<#^V;[(_Z;M_C22>+-=F4I)J]X488(,S'-1+')K8VAE;B
MT^8^J-<L?!]C8VWB62UOO%XUVZ\H$R\VY8_<QV(_I6I,VD?#E;GPGHEC<>*+
M[4MMPND7,FZ*U'7YB>E?'4&N:A;Q+#%>SI"K>8JJY #>OUIK:]JJWC7@U"X2
MX;AIED.\CZUA]92U4=3J^IR>CE_70^U6UGQS)*T*7OAO'E>7_8OF?/C'W,YJ
MDHT7XF-:>&M>L)_#FHZ2&G.CP/MBN^,_*1UKXUAU:^^U&Z^US_:"<^;YAW?7
M-3-XBU1KV.Z.H7!NHQA9VD)8?C1]<\A+ M:II>A]6^$;;PCK5K=>)TMI_!I\
M/W7ER2I+Q*%/W,=R:V_^$K\2:Q'?:GH=EI/A'3KR0,+[5" ]R.Q9?6OC*;5+
M^2WDA:[G>"1M[H7.UFZY(]:+O7-2OK=(;J^N)XAC;&TA*C'M26*\BI8+F=V_
MO/LL^-O$?AN.'4?$%GIOB/3$C:&;6M)8>;;J?0>@Z\5BWVA^$O#=SH,=IHC^
M+XO$<A+:E++N9=WH3]W&:^4(=9U"WM7MX;^X2V?[T*R':?PI]OKNI6L<44-]
M<1)%S$JR'"?3TIO%)] C@G'9GV'%?6_A-IO!OA&S7Q)<03^?/)J$N8+ 'HH)
M[C^E/CU7QU<2744FO^&M;!!WZ6K &4?W<U\;KKFHVSS20WUQ&\S9E*2$;SZG
MUJ"#4+RWN/.BN)8I?^>B.0?SH^M=D'U+S/T7_9A\2:?XM^.VCS3VTFE>(-.0
MVDVF[LQHI5CN3M@XZU^A-?D%_P $Z;ZXOOVE;*6>X>>5K=MS2-DD!37Z^UFZ
MGM7<Z*5+V,>5!1112-0IDW^J?_=-/IDW^ID_W3_*@#\)OVAMR_&KQ:6YS>L1
MCTP*\RD!9CSSZ5Z1^T(V?C1XO[?Z>V ?3 KS5@S,<<$\5R3^-ET_@CZ(1@<]
M<]\4S=_$.#Z4\YCSQG'6G!@R 8 YYQ1<U(U9@V3^=2':<\<4DBCJ#SZ5&C$=
M30(>/FP>/3BI4Q^/O3 JX4CIV IV-O0]^E Q67^+&1TXI-W7BE5BIVXP,TQ9
M-N1U'>@!VYO7'M3A(=I'>HMW<=32K(67('>F AR?F/T-!7/?Z4OS<YZ4-AL@
MG-3<!&4*I&<^].QE012>2"!DTU0_8Y'O5 *W+9ZFG;@O/04H4[3W-,VEE(W
M8I-,#1T. 7>NZ?#)AXWN$5E[8+#(KT'X_7FCKXL_LW2+.*S2Q41NL=NL7.T'
MJ/O?4UYC"[0NA0D.IR&'&*N7%V]],T]S(TTS_>DD.2:G8+GL7B/1]&C^ ^DW
M*6$)U)TW">% )8SD9:1NX-87PS\%Z5J7AO4+S6;B*WDO@;;3_.4DNX_B3'>O
M.9-2N_LK0?:9?(*[?+WG;CTQ3(]2NHXK93<2!(&W0J&.(SZCTICOK<[[X0>'
M].D\=:C8^(+0W-K:VDS2POPP*CK]>]7/B5X4T7P_\-O#%YIDD,[WUS*_GK@R
M;.<*WTKS?^T+G[5+<+<2">0$/*K'<P/4$U7:>62WC@:1VA3E4W'"_04:MA<]
M2M#=Z+X!LCI'ABWUB.^B9KR^:V\]XOQQ^[J7]GC3]/U+QAJTFH:8-2BM;!YD
MMQ )FW ]D/WC7F^G^(-6TNUEMK._N+:VF&)(HY"JN/<5#IFM7^AW0N=-NYK*
MYQ@RPN5;'ID570+]2UXJE2;Q)J$D-N]LAD)$+Q"(K[%!T^E9>[=R!@8HN[JX
MO+B2YN)&FED.YW<Y+'U)H\SY2?2I$-)!R6XIO7&#@4YF^7CFHVZ$C&*.8"0J
M'Z?**3YMV"<^E-Y*C)X[T'Y5// -.UP'(H8$FEW'@$<=C0O9<X[TIQEO7M2
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MP4<TQ9&4'')Z5$&/ -.\PC[M3J*Y/YFX+G[U#-W_ )5&LP]LT%OP I@/D9F
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M_P ?4_\ \71_P[[^ ?\ T3ZU_P# J?\ ^+KZ(HHL@/G?_AWW\ C_ ,T^M?\
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MGUK_ .!4_P#\77T1119 ?.Y_X)]_ (KM_P"%?6F/^OJ?_P"+I?\ AW[\ _\
MHGUI_P"!,_\ \77T/118=SYV_P"'?7P"Y_XM]:_^!4__ ,72_P##OOX!;<?\
M*^M<?]?4_P#\77T1119 ?.X_X)^_ ,?\T^M?_ J?_P"+IW_#O_X"_P#1/[7_
M ,"9_P#XNOH:BBR$?/)_X)__  $;K\/[0_\ ;S/_ /%TG_#OWX!C_FGUI_X$
MS_\ Q=?0]%%D.Y\[M_P3[^ ;,"?A_:G'_3U/_P#%TO\ P[]^ >,?\*^M,?\
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M .*KVNBERKL',^YXG)^Q?\%Y&RW@+3<_\#'_ +-0?V+_ (+LI!\!:;@_[_\
M\57ME%'*NP<S[GAK?L1_!)F!/@#3L_[TG_Q5,;]AWX'NSL?A_IV6Z_-)_P#%
M5[K13LA79RGPY^%?A3X2Z-)I7A+1+71+&20RO';KR[>I8\GVR>*ZNBBF(***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
..HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>form10-k_012.jpg
<TEXT>
begin 644 form10-k_012.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )R <<# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIZT@$D:8J,MGU&::TDA48STXYYJ1ERQP<"D9A@'.&_6@ V[AER6_I4L;JN0
M1433A4'S9"^E0^:6 /<T;A<L-)_>.3FH&D>X;GD'WIT8.,L,=C3@RQ9-,8*B
M'@K\O?-2&Z\O.,>@-5?,:1C@A0W>D2UW1C=QDYHL(G-R[Y ' Z4JW4NW'?\
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MU)]HGW9'7Z<4K3+&W(^;OBF?:NH''O4V$+]HDW98?,:3<%!^8KGK]::+C!!
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M[*_B08S^^M__ $8*^FZ^9?\ @HPVW]E;Q+SM_>P<_P#;05G4^$N&Y^+<W[C
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M_-Q57< 6_&OTC_X) M_Q.O&JC./LPY[??CHZH:V9^G%%%%=!D%%%% !1110
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M3 C5V7V%65<.H!Z^]-*B3J >P-5V#QDD<_TH ?+;CJIRV>%IGGE5"L.:>LO
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M5,KJ+:+BE*23+,WP?\!+(\?_  M6P5HV*LIM6R"#@C]*%^$?@%0N?BI8+GD
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MOE^GI4FT,P ^4'M2<;N>.V,T#&)N;.3TXS3\'[W44<%<*.0:&8[>10+48N6
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M< >"*D9]V#TJ]@(TF.W;C([FG!@P(;Y3GBI"H8<$?04UH2?>D,#&NWT:N^^
M,AM_BQH9*GYBZY'^[7GJNR-CL.QKT?X!LG_"U-&/4YD&/JM9S^%E1^)'#:LK
M?VI?DYYN91TQCYS57KQ5W4AMU"[R23]HE[Y_C-4N%/O6D=A/=CF 9><9S2%0
MN2.>*=N*KM4<,,\CI3-V_(//TH):%1AO.3EL4K,?Q_E4>XKT/Z4Y\[<^W/-
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M,<8)-+'".3G S3/LY4$[OQ]*58V[-TIA85H1G):A8UVG)_"EVE6Y.:DCC##
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M$@8#).>,5I?$:&2']C#X80RJ\+QZ[J"R1R J58.<J0>01Z5ZI_P2^POC+QP
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MZLWKP<+WQ6IK7P_^&6CZ]+I#?$Z:\2&9H9M3MM$D:W5E.,K\V77/\0]*^O\
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M_.D7&X\XJ-I/>D!+M!;T4\<FOTL_X)"QJ$\:NI/101VZI7YE[&;G/ K],O\
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M#L+V.1^M)CYNPH*D*!U[4X<+R,@T &-Q !YQCBD(QUI2IQP-I[TY5/4\MUH
M3R]S #KZT,A!&..*=NZ,>".F*9NW$-@@^] A5'RGO^%)R6'7T.*7CG'3^=(N
M>@XYXH!"JN&'%.7*KDD8[4YMOM]*9]W QS0,]5^)$A7X&_#$L<AFN?J*\EDV
MMCZ5ZU\2/E^!?PPQ\Q/VGKTZUY"L@R."#C!]*RI;/U?YFE3=>B&E>PRIZ&D#
M.K8QD>]60H8 G&33?+(;Y6W>WK6QEJ,9V'RL/?BEW.PR%R,4XL^[E<_I09NK
M8((H&1*CR8!&/J:ECB"_>/X4>8<;L9'3FD9FDP!T[C% #RP7@8)S7Z7_ /!(
M/_CS\:-CJ5Y_[XK\TA;G<.,$COUK],?^"0^19>,E))"D#V_@J>J*6S/T>HHH
MKI, HHHH **** "O*OVIHQ+\ ?&:D9_T(GIG^(<UZK7DW[59Q^S[XT^9E_T(
M\J<'[PK*K\#-*?QH_!>1MR!023QVIJ1D'YCWZ8J5(CY:D]<9S44DVWN<9K$8
M\1H.I'TIK3%F("G)X--6,RMR?HQ%3^5M7GGMGO3&5O,9N%. .#Q2PK(5XY_G
M5C;M48!SW]*(SM8D<'W-%P(&5Q[8[5U_P<VCXG>'RR'/V@=#7+L RY&,9Y%=
MC\(5_P"+E:!CJ;A>W:HE\++BO>1S/B!0VO:D .!=2GW^^:S&!X&#QSFM?Q(%
MD\1:GM./]*DR._WC6:J[F(SP*4=D*7Q,BD 8X/!]:" N".?>EE^7M@8I&4;0
M%X%:$";0O.>*9MW=\>U2#.TY4#UIW502, = * &1\ YINW;NW#G.3Q3]IW'/
M2AG)'H*8$;$NV0!CKBCC<,C%+M.X<D#Z4 #N>*&(:WWL'D4N-HX'RT;2OI2E
MC@#./:D,]0_9;&/VB/AX!WU>%<YQC)-?9GQL\ ^%/VP-2\8Z;H?DZ/\ %+P;
M>RV2K*0!?Q)]T/Z@]F_A/'>OC3]E\!OVB/AUN!#+K4!R?J:V_C%XZUKX:?M9
M>-_$?AJ]>RU6SUZ=TD4_*PR,HX_B4]"*SE?F]TTC)*)] _LKZ/?^&_V7_CSH
M^JV<NGZG9_:8KBUF7:\;"WP<^WH>AKY>_9J^+4'P7^*6D>(;RU:ZTTHUI>I$
M!YJP2 !F3/1AUS]:^\O#'Q^\,_'[]G7XD:GI]O#I/BZ/0I_[9TS@/N$>%E!_
MCC., ]NE?E[#\L*D#^$4X^]<<NEC[$O/B+\&_@7IOC[5_ 7BF_\ '_B7QA!+
MIPM+J)XH[""7)9G8C+XSPW4FO"_V;_B]%\!_B9;>*GT[^UE@LI[06^=IRZ@!
MOPQ7FFXM\P&21SFNH^'?P[UKXH>+].\-^'K5[S4+M\#'"Q(/O2.?X54=31RZ
M.Y-VV?2'[(NL>-?C#^UA<>.&U2XBL8/,NM79Y66'[.00D![  X8 ]E)KQW]J
M_P 6:1XX_:$\7ZOH10Z:TZQ(R@;6=%".PQP06!Y[U]U^,O@GXT^&_P #[7X=
M_!G2-.DO-20KK.NW5]';NQ(P^ >69LD ] ,U^:/BOPI?^!_$%]H&IQQ1:A8/
MY,R1.)%##L&'7ZTHV;NAR5E9F,R[B0!D'K3?+/WNE2^4%Z=/K1G^\<^@-:F9
M$JGH3GN1WI_7) R1TQ2J 6(Z?I0L8'.,<XIW B^\OJ>F:<-V#CBG=%)Z"C&>
M,9!_6BX";2RMGIV&:1,R<!<#W[TNP] <'I2LO&&Z]<B@!A7*GGVH7L/7VI[9
MZC&.GUII;! Q^=*X#AA6^IZ&D7YNO.#WH&3D;<BA<A?2@5SU7XF/)-\"?A>!
MG;&;D D=LUX_N=< KGUKV+X@_P#)"?AIG(8M<GKFO)67Y>!T-947:+]7^9K4
MU:]$0K@-C[H[594*RKV/>HPJ<Y7''>G*K*, ;FQ6VIF*VY.I#BFM)GJOS?I3
MMK'@&F?,.O.: !F"\@<8I/.5>=O7THW1]QCUI0L;#L!0*P[>6Y[]LU^F?_!(
M9A_9WC0$8?>O\DK\T8?+VX(K]+?^"12G[+XS8'*Y _\ 0*E[KU+6S/T=HHHK
MJ, HHHH **** "O)?VKL_P##/GC3 R?L?3./XA7K5>4_M3*'^ 7C('./L9Z#
M_:%9U/@9I3^-'X+22;E7@@8P*:D6U07&3G.<5/Y8\O@;21QFA8_E(')Q6**&
M[@>0 /I4OF#R\XP.X]Z8O[L=1QUXIK,N[G))_*@=@ED4X"#)^M1.K[2=ISUY
MI_G#Y2JXYQ[4/,S2'^[[T"(MSJ6W#C&%&*[/X.R,/B9X=5EV[KE1S7'?:!NR
M<@>W-=K\(6S\2_#Q/_/RH.:F?PLN'Q(P?&$>WQ5K'4'[7(,=_O&LE>O('XUL
M>*'^T>(M6=!M'VJ3J>GS&L?&T<G'J:4?A0I?$Q9,Y'KC\:A:,\CDGM4S_."V
M?RIK-TX%62"KC _,T,Q"X/R^^*(U!SD9&,]:7)5<>_-(9&<\-GFD#;E!/XU)
MM^\,Y J-5Z8Z9JA#E7DBFR)P ",4XKS].N*3RSNZ]3G-(0SR]W '/2G^5@?,
M*7^(MTI,[ESGYNPH&6=+U"[TB\@O;&YEL[VW8213QG#QL.A!]:CU+4;K5-2N
M+N]G>[NKAS)+/(<L['J2?6HOO,#CZYI&7J1T]:0&AHNO:CX>EN)]+O9]/GG@
M>UFDA?:9(7&'C;U4CM5#RU/"C '%)MRV,G%.51TZ''2F W;T([5JZ'XJUCPO
M-)/HVHW&EW$HP\EH^PLOH3Z5E[#T/.*:LG5ORXIB.L_X7!XY+*3XNU9B.1FX
M/'O7-7M]<:A<275U*\]Q,Q>2:5LLY/<FHE5>K9!' ]*7=E0,_,:A12V0[L8>
M<C^+K4+*4P,Y.>35KR]RJW'/ZU$RA@<#!SZ\BJ0ABGJQ;K4BKUW')ZY-*H )
M4"D5RRY _.@"-T"OC((Z\4;06Z_+Z'I3INQSSV Z"FKANG3TIV -N&8$@TW+
M?@!WI^!R.N.?PH7C//&>E(!B*/3]:5L,P&.O6C;['Z4W&YCBF [:<C _#M0<
MEBH).*>JE8^, =32,._8TQGJOQ&W'X%_#-E&%W7.<UY"SLO&&()XKU_XC8C^
M!/PP#EFR;G;[<UY*S@C!.!65/9^K_,TJ;_<1+.VW:R@&I1(.BT[8DB].1UJ)
MX#'DH<EC6ID3KM7'8XXIDB_-COBFQL58 _2I-RGN6(_6D!7;N,<9Y(I?+1L#
M=@U::,') Q[BHA #G&1Z^M4 L<.5R&R*_3#_ ()$C;I_C,9)&]3C_OBOS1%N
M58<\=C7Z7_\ !(E]NF^,XB<D.I)_[XJ7NBELS]&J***Z3 **** "BBB@ KRW
M]J 9^ OC+C/^@MQ^(KU*O+/VH,_\*%\9;0"?L1ZG'<5G4^!EP^)'X-KN:-3@
M*N._4XI!\Q&T'-2K\L:@'+ =#3"P4@N<$]!6!H,E^Z,GGTJ)F3JIR.F:?\N0
M2>3[TK*O&.G>@0U95VY.3QQBD78<=^,X(ZTXPJRY)I&3@'<2>U V-,:MR!LX
MS]*[#X/HZ?$KP^48$_:EX]1Z5QN'C;!.!CDUV'PAG/\ PLKP^,8_TM<>G6E/
MX6./Q(Q_$JLOB#5"R$$W<ORL.1\QK(^Z,J-PK>\8R,WB;6-SY8W<F<]?O&L4
MY7CJ.U*/PH4MV1YV\=1V%(6^8'\,4^3G'S<9].U0EBIX7KU-62"LWL0#3VW*
MHSS2+]X!AD=>E2;<Y8?@*0$;+QG..,$TUCMP,$DU*B]21D=:C=,L<'I[T]"A
MGT)S^E.7G@GMV-&X.N.<THCQSR3]*!"JNT]=PI&![<FG_>.#P*:05 "],Y&*
M0";2,@'WH!"DG)%/8JO..#UI%C++V''%,09//.&-(>JK^?--8[>@VFDS\O V
MCIFBP"M(%4 GGK2*V%'R4Y8\-G'S=.:DCC.W(Y(Z^U(9 N57!Z>E.C&!UX[<
M=*FDCW*#R2:3 51QDBF!&W]T=1V%1OG&3TZ&I&3)Z9]\TYH\Q[AW--"(-K @
M@D'')IZ@ ''WB><FG/&S<$X &<^M&%VGWI 1LJM@#D]C3=N/E/3/ [T[ _.D
M:,+R#@^]4 FW'&""#S2G!_AY[T_JHSWZ^M')( _6@8U5^]@__7I-H5L@_45.
MP#+DC:<^E0>6&(/W>U "[LC@9%"J%ZY(Z].E(/3\1BA1\PR#CVI >K?$4QM\
M"?AL6;=\USU[5Y#L#[MIVCTS7K?Q*MO^+'?#$YSDW.*\B1BK<]>N,UG2V?J_
MS-*F_P D.&Z+YB<^@I?M'9C\Q.!4J[9E4 ?-WILEN% .,XK6YD(Z X920QIB
MJ4YQBEC9DVDG<,8YJ=&#$@\C- #/.W-AS@<5+N&/J>M,\I7R,]^N:38<_>Y[
M4#)MPW;1D#I[5^DW_!(UML/C.,#"_*?K]ROS26.1N^>>M?I7_P $B<+!XS'?
MY>?^^*5M44MF?H_11172<X4444 %%%% !7EG[40+? /QF%Z_86_F*]3KS']I
MA0_P)\9 G ^PMS^(K.I\#+I_&C\%UW"%&/)P,^M,FC!/][FGR*S*.>%QBHRA
M7 R?RKGL:"F,*O(^;T%-\DL/E_*D6-MV3S3V8QL#@XQTI@1/$0H7.23DX--9
MRH*\^U2O,6;. />GJ!+_  @CMFF#&;P\8X&?>NN^$EO_ ,7(\.%2?^/M>,>]
M<G)'MR0./Y5UWPC;;\2/#K$X#7:?SJ)WY6./Q(R_&4/D^+M8C8Y*W4G4Y_B-
M8;?-M)7/;=71^/E7_A-=< Y NY,-^-<X>&'.?04HKW4$MVB-26R#]W%)NY/'
M%*V22!@CUZ4<MGD =Q6EB1%8JP4YSVS0"=V"<+FG+MR<= ,@BC 7..3Z4@'+
MQG.#QWJ&0A..K=*D#=,XW>]-9@S9QGGM1:P#5P!ZEO4TOS<Y)%.RK=%R:0Y7
MH./2F(,;0!U_6@J4[9%&[&,#GJ*E5NG&3TJ1D.=HPHX]13RO4C''>D;Y6QC(
M[<TJL W)Y_2C4=ACYP,@9_E33G[V./2GR,O(!P<=!3%RK<=/2J$.3Y6W$9.*
M=N^0[3S35;Y@.H_K4FT+DALOZF@"/<?4GC%+(Q8##Y-)DKGN3^1H#?)_=YH$
M1XZ<T_)\P=N*<R[UXX [TT[G X!QWZ46"PF>N?FH., YZ=*-PZ$<TW<5W<>V
M*>HP8#MGFG;@W)/YTW<K= =O?%*N. . >:0","W8>YIRJ>G3O2?P\_>!Z4JD
M;2<YS0 IRV>>*C"Y8CH*<S#M^5"#"_K]*H0FWYN>0#TIS85B1GI2"0C@?=%.
M1LDGOG@5(SU3XC/Y?P+^&!Y;FY/X5Y(8UD] >N:]<^)"B3X$_"\J<MFYS[<]
M*\AW-'R1QTQ6='X7ZO\ ,UJ?%\E^0JJRL<G'X4J3#!S^%/616C..5SBD>W++
MN7 .*V,1&0,HY!IGDE<%3D4;6C4+G(IOF.N0>AXI *Q=2QSR?04Y)'X]#WQ3
M/,W8!'TJ3<W 7..F:8[CE\QBVTX].*_2K_@D9GR?&>3G[O/_ 'Q7YJ?/UR4]
MJ_2;_@D3G9XTSUPN<]SE*36J*Z,_2*BBBNDYPHHHH **** "O,_VE%W? OQD
M/^G!_P"E>F5YK^T@I?X&^,0#C_0'/\JRJ_PY>A=/XD?@I)N*I[*!QW-"J\:G
MC&.FZGMM*H>@QTS3MN[KG:?>L30A5FPV0OT-.+!H]V<9Z"G%2?E! ]?>HVCP
MN0.<T ,,"%C@[<]#F@(8FP/E_K2I(=VUE]LU(Q#\XSCO0(5<3+@@$^F>OM74
M?#&$?\+(\.G[@^VQ_P ZY3_5\J,5U'PP=V^(WAQ6.3]NC[>]1+9EQ^)%+QXO
ME^,M:0]5NY <?6L!E! !Y]SQ^%=9X_TR[_X3C7O]#GPUW)@K"QSS]*P&TJ^7
MC[#= _\ 7!_\*(M602W904 ,..G'UIXC^7L?<59_LN^P2+&ZVC[W[A\?RH73
M;W<,65TO_;N_^%7S"*NT)\H&3W/2F,O\6<XJY_9MTS#=9763Z0/_ (4Z32[U
M5P+*ZQ_>\A^?;I33%8I>7QC."W6F^4.06&,=:O\ ]EWC+N%A=#'7]PY_I36T
MN\SN-C=8[?N&']*7,%BBJ 9'4CTI) 0QQ^>>*O\ ]E7N"5LK@^WDM_A4?]F7
MC-_QYW*D]!Y#_P"%',38J!.N#GWIW')Z5;73[]6PMC='UQ _'Z4BZ7>29)L;
MG_OR^/Y4KCU*N0VT@#ITHX90 ./4U:32[R,8^PW7_?A_\*5M-O(QM:PN0>^8
M'_PIW'8ILO)(&:3HH! 'ZYJ\NFWF['V*Z_[\-_A2?V1>C)^PW!YS_J6_PI\P
MBJ%4JJC ]Z:(_F.&&15W^R[O+8L;D^H\E_\ "D_LF]X(L;GW_</_ (4N8-2@
M4W=N>^*1OFSS[\UI'2KUU_X\+I@#]X0/_A43:7>8W+870^L#_P"%.X[%15W8
M![]LTK#YNO08(JY_9=[NV_8KG)'.('S_ "H_LNZ^Z;&YR#_SP?\ PI<R"S,Y
M@%SR!35SG'7-:4VEWH^7[!=?7[._^%1KI=\1Q8W6.P\A_P#"GS(+,JJ-I]1V
M.:/O*,\<]JM?V3>\_P"A71[X\A_\*?\ V9=[2/L%WSW%L_\ A1<-2D/0TC(/
ME!R >AJVNEWK' L;S_P'?_"AM*O58$6%X?;[._\ A2N&I!CYB1@TW[P('3//
M%6O[)OEY_L^ZW'IBW?\ PH73;]CQ87>#Q_Q[O_A3N"14V[?I3=P$GO5Z32=0
M_P"@?=C'_3N_^%,_LC4%)/V&[]O]'?C]*+C/4/B.PC^!/PQST8W&?SKR38K=
M6S7K/Q&MW'P/^&J.KQ.C7 *R*58?4&O(\21\@8S^6*RHOW?F_P RJF^GE^0-
M&=N5[=!2K)MX/7N*59"B[B>:<TBNO. QZYK<S(68=*-Z8Y''K3L(N,XQ0?+"
M[1TH$(S#CCD^G/%*LF %/%."E=N%Q]?2I/)!8,3DXI $:="!FOTA_P""18./
M&O''R\YYSE*_.%@I'7:/05^CG_!(D;1XT!R> 0?Q2GU1?1GZ1T445T'.%%%%
M !1110 5YE^TLS+\"?&94X/V!Q_*O3:\R_:63S/@7XR7G_CQ;I]1657X)%T_
MC1^#4<86"+=R<=*7#9/?;^5(L;^6HSDXI51U4#)^E8[F@UF"R%F7)/I2,<<Y
MP,=J7#MDYR1QBH]^ 5QM"GK18!2O=>"*09"MC@?SJ90=V3U%#<C/&[.<$4"(
MEF&W!^M6]*U2;1M3M;ZQD6.ZMW$L4A&[:PZ''>JDJJOKENA]*C\G8H.=WTI;
MAZ'J#?M%>/9%W'5+</G.XV,9;^51M^T5X_9AG5[<E1_SXQ#GL>E>:JK?,!_$
M.#FFBW([GU-9^RAV-/:S[GI$?[1WC^-&5M8MI W!'V&,#\<"G+^TA\0&?Y-5
MM=F,X^PQXS^5>:J@VY/R_A4H4*H&,DC.*?LX=A^TGW/1U_:(\>[ ?[4M5DZE
MOL,?^%*?VCO'OW&U6WV^GV*/G]*\U9AY8 /&>E1E2Q.[Y1ZBG[*#Z"]I/N>D
M+^T=\0-^U-5MMA &T6,>/Y4\?M%_$#&'U"T;G*LUC%Q[=*\WV#;QRV.O3-(T
M@/&?J5I.E#L'M)]STH_M&>/NVJV:@]OL$?'Z4P_M#?$!<?\ $XMCC_J'Q<<_
M2O-BS8&T;O?%,".1R3C/Y4O90[![2?<]('[0OQ&W,4UNV^;D@6$7/Z4O_#1_
MC]>NIVNT_>46,8'\J\X\N0?=/'7-)RL>>N3WH5*'8/:3[GIB_M'^/9,*-4M1
M]+&/_"DD_:*\?RS;O[6M6/3YK&+_  KS'<R]L<<<5)$!MR?O=0:/90[![2?<
M]%D_:(^($<F1J]MM7G'V"+K^5$?[2GCU4^;4+1FQC)L8_P ^E>?$%5''/\ZA
M:-6YQ\V>:?LX/=![2?<]+7]H[QT8U:/4[6-^A;[#'R/3&*>_[2'CV3D:K:JS
M#!;[#'_A7F/D+P$Y%(UNW&&Y!YI>RAV#VDUU/3/^&AOB$C97781GJHT^(#^5
M._X:-\?J0'U>UD(ZJUA%@_I7FHAZ9/7FE$?3//UH]E!=!^UGW/2&_:0\?.Q*
M:I:J_K]ACZ?E3%_:(^(&[_D+6I#?>_T"/G]*\[D53@^AYQ2%QM(].M/V,'T'
M[2?<]'?]I#X@>6,:Q;X7UL8^1Z=*CD_:8\?J^5U2V#8X_P!"C/\ 2O,G!9EV
MG&?TI\,2JV2/F_G1[&"Z"]I/N>E+^TC\0VSC4K/+?].4?^%/C_:0^(RG<=9M
M\]0HLH^#Z]*\R,BJ#UR.@IGF,>>O\Q3]G#L3[2?<].7]I'XC(#_Q.;<GKG[#
M%D_I2M^TQ\0^#_;-N2?^G*/D_E7F0C9EP3_]>D:-E7>Q[<>U/V<.P<\^YZ=_
MPTM\0^3_ &I:_4V<?7\J6/\ :8^('W?[6MP#V^R1_P"%>6I&YP!ZU)QT906'
M<4>RAV#VD^YZ>O[2GQ D88U>WV]_]#C_  [5'-^TA\1<E_[9MS]+*/\ PKS;
M^'<./6G=QG=Z>U3[.'8/:3[G1>-/BEXD^(D=HGB&\2[6S9FA1(5CVD@ GCK7
M+;ST)J=55N3R/6HOLY91@]>:UBE%61#;>XQL-M P::T:\CD'VIRPG>>?R_E2
M>7CC=D>O2J 8\:],@$?ABGJ5C^Z,X_SFE\@+\QRS#T-2A1TQDT@&8.!GD'L:
M><9':DD?:NTG'.:8SLV. 6_*F%AY8;2 .!S7Z2?\$C&W1^- 3EN/YI7YNB(;
M<G(;KR:_2#_@D: W_":,"!@*N/Q2EU0ULS](****Z3 **** "BBB@ KS/]I7
M/_"B_&6,Y^P/T_"O3*\T_:2./@;XQXS_ * _]*RJ_!(NG\2/P<0^9&A'!QQ0
MTC%N.<=\5(L86%/FX'ZTYW 0,G/K6%S0K!OXL<GK2,I7DC(J1A[8#<TW<1G'
MTYJT,:JAVV@[:=@LN3QBD.#@#@4JMCEN12 C92N>OYT*&X' '7FI9.Y&>>GK
M4>[@%A0(8K#<21WQ2>9@-['BGM&"?7OUIK1KC&#C/- "Y''TI'1F P,'-2;?
ME7/) QBG;\ G@?KBF,K%.W?-/8>6IR.:1V*GY>1C.32[692>H[_XTB2+)+ L
M.AZ5+'#DX'/>GA=N.!BF&3YB!QZD4ACVC1<9! [*.]0M*!D$,#[TOS,O<8/'
M;%*RJ&ZG'<TP&^8SY.0!].E(T;G'H:?N3IR2>_:@YZY&32O88QN<Y'/:EX0#
M!VY-+SGG[OTHR&SN7CT'2@0Z3&WU'0'O4:Y20,.?3=2^8%8@'!]#0Q5NH//)
MJQB+(.>.U'#X;(R>OK3A^[P,AE].]&Y&XV[2!VJ1"\*HP?F[YHW#. 2>.33@
MHR"#]:'B49(Y [&@")^^.!CI4.T[FR",CG-6PI9"<^X%1LWF8&"1W-4&I'C;
MUZFF\DGOMZ^P^E3-%T([]/I2JJJN>U3<172 -QRN>@IS1A<9./3-3LRY !XS
M41C,C9;[M.XR'<<]./3T-*S'C@D>]2)'\HSR>OM3BVW#;<YH @YW#'<=3TI=
MSC&%Y^E3*X91QENWK36E?^X% Z\\TA"+APVX%32\*PR<@]*19-VWZYY[TF S
M<<'K[4Q"M'G)'USVI"S!CQVI0' P1^72G-&1]P8W>M R-9!EL' %'R[02>,4
MK;5X=>:-B*N,\&@8S<-V5ZGH:>3D]<GUIK(K9&>,\>M*OW<X&WZTF2"1LQ8-
MC\:%C"[EZD=#GI2^8%7;G+=,^E,R,D8YQ1J,=,XY '(K](/^"1653QJI'7:?
M_0*_.*&,+DXZ]*_1[_@D< ?^$U*G(&T?JE+JAK9GZ/T445UF 4444 %%%% !
M7F?[2F?^%%^,L=?L#_TKTRO,?VF#CX$^,N_^@L/U%9U/@9=/XT?A%"-T*D=:
M5E"D BE\P)#'@D<8&:;NQ@ -FL#4&91T^F:C;YL$8Q4JX!Z#'7%)PWW>:8#%
M(;&3CGI2-C(^7G-*VTX/ YXI!C.,Y(]>E2 O+9#?A2JF_<6XVU)]G:.W2=BR
M1N2J$]&QUP?:F*^' (R._- $<BC<05V^N!BF-']U1_CFIW7=G@D>HI@." ?E
M;J#ZTP&H@SCK[=Z<T2\@G:#Z_P J6//RG(-+);[SM# '[W)_K2N! J_,P/S<
M\'^E+N'&!3FC?;C(P:38%;(&TBF(56W*:3: V>E/(5< 8R1DU'DLQVL#QWH
M1N<#KZ8I%4R8#<"G",]^,YI_RKMX"Y]\TQ$:PX9B1W_"D95R3Z\U*SE5(/\
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M;HHHKJ.<**** "BBB@ K@/CS80:I\)_$%G=3?9[6>)8YI0<;$+J&.>W%=_7
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M6S8<J['FW_#._P -^0/!^G88YQANOYU)_P ,_P#PZP4/A#3L9'&UNWXUZ(P
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M)W\2;O\ X3/Q)?RM;V5J"9BEKG#2D,21\O\ @*/^$$^#.P?"C^T0?& 4R?\
M"6 KM^V=?+WYZ9XV]/>M&U^&GA?X&V9\2_&;4H_%6OW++9VUK(QF40C@84XS
M@<Y[=*+]+O7\?0=O3_(=#^S'X)U/4%\80>* /A2T?]I/IWGD1F0<X/. !Z8S
MVK-U7POX+_:3674OA;>+X7\7Z6PMC;\V_P!JM =H? (P0.?PP>M7;K]F?2KN
M\_M.T\:-!\%IF_M2>P^TGB3KY8[8]^HZ8J&3P#X0^-<3:Y\%KU?"_B;2Y/LD
MMI&WDB2'[I?:.Q!//?OBGYJ3_1>H<NEK;_CZ';_!F?X;?#CQI;?#?0V75O%(
MCDN+G6@@<RW 7]X-_4<=OZU] 8##UKYZ^#NC_#;X7_$"T\#61CUOQ\()+BXU
M?:'\M\?O(@^>..U?0G'7;Q7'5WN=%/:PWH3BC:>!G-2#)+#^5-V]!BLM38L6
M20-/LG0A9/D5QU1CT-7;'24,5^MTH:6&(LJYZ>_XUF_\LRH&3ZGK^%207DMN
MLXC;:94V.6&3BM(R2W1#4NA/'80OHR7.R))1(5+2/C('05%;Q13Z?>3-$#+'
MM*>BY-$=Y);VHMRL;Q[MX$B[L&F0WLL$<J!49)2-RD>_:G>(K,DFLTGTLWBC
MR61_+:-?NM[_ %J""%898)9MDL3$;DW<X]Z+B:2=@"0L><K&HPH_"H2I&2#Q
MZU+:Z%).VIJ#2(/,N[=F5IVRUN4)SC&0/H1Q5*2W2*:&%DRP($@;@Y)Y'TIG
MVR3S8I/,8O$ $)[4Q9&6429W.6W?-SS5-QZ(E)]32@TF$:A>1$1M"@DV('R1
M@'%0QVL/_".27+(//695W_[/<5"MY+'--."HDDR'^7UZXJ-;N5;-K0$>2S!B
M".<BFY1"SZ%];6S70XKP6R^8UPRLN3C&.E1W-G%'H]G.L:"5MQ?<WWL'BJSW
M4K6*6I8>0C[U '.?K3X]2E%O'"8XGCCR%W)GK4WCU%9B6L%M,BPS8CEESLF/
M\)'0'VJ27239RZ=#/'M>1R)5_O#=@?ABJIDW0A65<*20<<\_TJ1M0FDD@+R>
M88?]66&2.^#1S+8KE=QTD=K:ZK*'B#6ZR%2A)^4>HJ:;11;V^64,&G18K@'A
MD;K^-4I[@S22R.J%I>3QT^E+]JD^R_9B_P"Y#[PI[$=Q3O'J+4LW6G(VN?9;
M>W7"G:%=B-WU-9LD(CD</ABI(X.1UJ^NJSH=W[MI5X\UDRYX]:IL3N+>O-*7
M+T&DUN0''4"C![BI=O?&,]:-H'?&>E9[E$7\73 Z\U\G>(?@'X4^(?B*\\2>
M&?%"Z-X4^U2_\)':F4IY$B$[SMS_ !$'KGKFOK9E*J2J[^/N^OM7RMK'[-NC
M^/O$%WKGA;Q0UAX-OKB0^(+19B,21L2RGT^;/7IUYKHHM1;UL8U-;*URI#9_
M"[]H+3Y/"WA(+X3UW07*Z+J&/+DF0<;^,%@><\YZ<TLMI\)?@?#;^!O$I77M
M8UHXUG5"OF-;%NCLW5>?QQR:;>>%_AI\89WT3X8W:^&O&N@_+87T?[M;T+P>
M1RP]^OM4MOX;^%?PIDC\(>/+J/Q#XN\1<:GJDWS_ &9FZ#=_",]#Z\G%=.BT
MN_3J8;:Z>I3;X.^#_@3-)XP\7ZXOB;1[9L^'-)9_,#YY#8)P0 >W'K2CX/\
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MB;^V_"^AMMT2WDE,B3J1E7VYZD<;1UQZ4FJ_ BP^)<T'B;X8^)UT3POK3?\
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MV>34[>-KR^OM4O=7AM?$%_J,7E/=:HAE>(_WXSD;6]Z?LVM+Z%>U7;4^E_\
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M([V2Q1(?^6LBN5.WV."?I75_#_XNW/P]UC1;@62:GIEG,DEWIMT<PW6V0.I
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MEN:06)&;&3GCI4C * ^0%ZFH8V&[)X;&*FDPRY/X4P%8E< <GKP>E(PW-M.
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M\]_I2R2[2><U!N#< 8-/5?XCR?0TK%#XE5E!.?04]XU7D9]Z;)* H]:B;<S
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MWM(%QNQ^)IC2$IZL37TP?^"9_P =I&PVD68QW^TQ_P#Q=6%_X)D_'/< +"P
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
944 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>form10-k_013.jpg
<TEXT>
begin 644 form10-k_013.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (V <(# 2(  A$! Q$!_\0
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M2#_@JKJ6,GPWI./^NDO^-+VL1^S9^C5%?G9#_P %5+F3@^'--W>SR?XTK?\
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MN>U?LY_P3,B\K]FVQYR6G8UE+^)#U?Y,?V6?6E%%%=Q@%%%% !1110 4444
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M HHHH X[XQ,%^%?BLD9']FS_ /H!K^>^?"R-D8&[@"OZ#?C0Q3X3^+2!N/\
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MS4L:;L=NXI"*^UU]LT?-UVU8D7:P)Y.:3<5^GO3 ]C_9"8-\:[$,H'^C3?\
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MG@4*">.E<1WC6^]@'/K2E0WKZ9HQR2.O>E7[H(.!0 O3GMZTC-NQM')H4%>
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MM!QS3E7<,]*0]?6GJ!Q[4@/;?B%&&_9G\ A^GVF3^=>&-:IP4)S7N?Q,W?\
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M\#UIC*,D9Q[4-U/4'MQ77?$#3?"VBZ?X?M-$NI[S6A:"36IF(,"SMSY<6.H
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M&4@\=CUKSWP3\7O$GPS\72:]X0NAH$DDF6L[<EH"F<^60V<CMD\UQARIS^=
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M?[+!Q7B#7&[^# KR\M_@?.7YLWKKW_N_(/*VD;>O6G+(7R#Q]*19D^[S3E
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MC/:M-!",5W8<D\XH5@F=J[J<OEJQ')X[T[?'DF@1 LASN*\^E/\ .!;!%/\
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MGEE6]!]*7:_H:]N7]H_36R&^'FAD9Z;*D_X:.TQ8RP^'>A@'@?)TH^L8M?\
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MS1G('/MQ2,ISC^0KWM?VFM"8C'PNT,CO2K^TQH R3\+]$]L4_K.*_P"@=_\
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M'DTSS@,DG)Q4;;YB/0=:>L/- #&W2$8.14T<:X!/XTB_N\9XHY.03UI#&23
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M/_\  =:\/_6RG:[HO[SI^HO^8_'9;.Y4;S;S_3RF_P *?]FG&,6\X'_7)O\
M"OV&_P"$,T#)QHMAS_TP6E_X0[0.3_8FG_\ @.M+_6RDO^73^\7U%_S'X\_9
M;AN!;SD^GE-_A3X[&=5R]M-CWB;_  K]A#X/T'MHFGCT_P!'6D_X0K06X.BV
M&/\ K@M+_6ZF_P#ET_O']1?\Q^/7V.4\>1,?4>4W^%+):RQJ&\B8>@\IO\*_
M8-O!6@ _\@2P_P"_"TC>"]!X/]BZ?_X#K3_ULI_\^G]__ #ZB_YC\>7AF/'V
M6?'_ %R;_"C[-.N/]&F'K^Z;_"OV&'@O0F4_\273_P#P'6E_X0W0#R=$T\_]
MNZT?ZV4O^?3^\7U%_P Q^//V6=O^7:?\(F_PIHMK@,%^SS'G(_=-_A7[#_\
M"'Z#U&B:>/\ MW6D_P"$.T# SHFGY/\ T[K27%M+_GT_O#ZB_P"8_'UK.X.,
MV\V#R?W3?X5 ;28-DVLW_?IO\*_8H^#= _Z FGGO_J%H;P?X?D&#H=A_X#K5
M_P"ME*W\)_?_ , /J+_F/QY_L^48_<3 Y_YY-_A1]AFZB&;!/_/)O\*_8?\
MX0OP^W71+#_P'6D_X0?P_P!M#L,9S_J%IKBRE_SZ?WA]1?\ ,?CW]AF4']Q-
MG_KFW^%'V:7@>3-_WZ;_  K]@CX)\/?=_L.P_P"_"TG_  @OAUC_ ,@*P/\
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M>I\U-&%P,Y/2FK'ACG@5]*Z-H_PXT'X>:I87UM_:<D=['976MJ>8I&3.Y!Z
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M_M"L^W^*7B>X\%^-+I;8Z?+9ZA86EKHJ1_)%'YC#R]O?(Z^M>C^/--M/AO\
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MQ7JFBSPW$D8$]I  HOBA)#*/?O7*7WQ?U2X^'&EN^FQM8SZC)9'1A'P(@<!
M/[WO6W+*51QHW4E)<VN_]=&3LO>[:$WBKQUI?Q%\(^"=,UZR%K;7RL+&:!?F
MM6#848[C K8^(]CIGPA^)NDZK.WV_P 1WGV>.Q3:1'!&2!YA]_:K7Q,T/2_A
M!\._"VLV>E3WNI ;;03@-'8[VR2P_O#-9^I:Q)\2OC!9^%M:LWOE807,&H1K
M\UJW!))_NUG%)I.G?V?O7_7_ (/<IZ.SWT-32;'3OBU\;=7-LJV'BJRBGBD^
M7,=PC)@-[$5A_#OQ1I?PSO?%7AO1+4:B;>QFEU6YF!43R \H!V49-;^M:XOP
MU^,U_P"'M!M9+.6ZMKBYN]5F7+SL(\@(>RBJWP2TW3OB[9^(M>U&PGM;R*RE
MM;R:U7"WPSU3_:XYHE94TVG[+E6GS_+L&[LM]3"T7X9^'O%'PBUOQ!87LEIX
M8DU!+V\@929(-J8:-?7)Z4^\^)7AWQ!\']-TG5M+^S^%;B_DLK3RSF6UPHVR
M>_)YJC#\8[O2/ASK2Z=IL=CHFGZM'9)I,B??B,?S*X[L?YUUGB#POX?\'_!/
M3_%BZ'=74:W37EII4J_+;R.HYD']T'D5I)-3_>W:YERZ^7Y[:BT:]WMJ4/&7
M@71_ACJW@#7=8F_M)UMK2STJU12!*P8 R,>P&>E?K)X);?X/T9L8S:1'_P =
M%?DC=_$2[\8>*/ FA>(K+^U['4[&SNHEA7]Y:S;L[T]!QS7ZW^"U">$M'4=!
M:1@?]\BO;RE5%)^U^*S^ZYR8BUO=V-JBBBOIC@"BBB@ HHHH **** .(^-31
M+\*_$9GV^0+;]YNZ;=PSG\*_*;5[[Q!J%E\1%F1FTH:5"-#6P'[KRO/79LQ_
M%TSWS7ZH_'N,R_!OQ:@4NS6+J% R23C K\X/@M.OP?\ AKXGM?$FJ^9JC6JW
M2Z>%#_V9&[A5=O1LD-M]J^3S=\E3G6KLM/FST<-\-F7?"<%WH?P;U5]1&F/\
M2"MO^[N.J<GR"_;S<YZUY@L/C;5-/^'T5LL\FO23WYOFN_N*GF+O,N?X<4FF
M_#/Q;K'A#QI:I.VJ7>HW]A=0ZPLF8WB\QB92_; ZCM7HGQ(UJ#5OA!X?\(Z'
MXD\W6)XYX1JQ 07S1D!X0WH3T/?%>5I"7NM.\NVRY?R\O(Z?B7;09\:KR33?
M"_ABQ\ _9)+)HA_:$UB")S&)?G"]_+WYZ51\&Z;>7GQK\13Z[Y<7@>.\C$DE
MWWFV+M$7^UGTK'T;P3JVB7OP]US5+N3PUHND:<T=Y<3?>F<SG]RJ_P 1-:_Q
M<N[KXC?%ZSFT*X:6PT:^C6ZT91M96(!\[:/O9!'TK!<JBJ:=U:7O?/\ /MZE
M7UN_(;XNU37+GXH:_&HC3PQ'87HLEL,B(R;6W%O]O/K6O\$K.\L_AC?WOBI+
M ^)#89TZ&]^_Y..#-[>F:D^&<+?"WQAXUOO$]X?].:[N+/0\!F6-<DRL/X<B
MN!T'POXB\4)XVU"WGDUR/6K M87D;< 'HA_N[1_*J:4H^S;22Y=>_?\ X(EO
MS+?4S+^Z\<ZAX4C,GVAO$[>(%"QKG;MVG&.VS'X8KU/XK&]TGX2Z='X3_L]_
M$3*W]H-:_P"L3CY_*_7.*J/JD6A_ \>&5\2K)XC:Y%H=6P"D4I4_N@WZ9]ZX
MU_ OB'3_  WX.N;FZ;18])EDEOK^5OE"^@/\6[M5Z5)INT;2?ST_(3VTZE_P
MRNOW'Q9TE) LGAS^SK4Z@]\3Y0//(S_'FM[XG76JQ?&32H-+$:>$?,<^99]6
MEV'_ %OO3_BY?-\1?%WAB#PQ>,$L5MY[O3L!&N$/20 =>G3WI_@M9_!/QMU'
M5=>NS#I>H2E+;2VP6G(7E]IZ 5',VO:M)/E?N_UU[!\/N]!W[/\ ]LO]%\0K
MXP%K]E'G#3GO/]<5WG ;_IGFO:/V6(]?7PWKZZ^H29=086ZQ_P"J\K^'R_;%
M?/L'A[5/$7B/QIKNFWC:WI5_9R16AB_Y8-N(\LKV-?0G[(>GZCI?PR>PU+5!
MJ=Y;3E713N^S_P"QGOBO+S11="<[K7ET[?UU-Z6DDK'M7/I14QC;:2%/Y5%L
M?/W6/X5\1?H>B(W?BA:D$+[?NG\J3R6(^ZP_"A=T%QO/4=:16;<23S3_ "VX
MRK#\*3RVYPI_*FI3CJI"T$+%6R.M#,S#&<CK2A'_ +A_*@QOD?(<_2K]M.UK
MA9#-ORY/6EZ*1G@TIC?(!4C\*7:W]PU,926SL%D-4E<X.*,G:!Z'(IWEMUVD
M>V*0HY_A;\J?M)I6YF%AI8[CSUH5CS@XSP:=Y;'^!ORI?+9?X&/X4E4E>]PL
MAH/R[<_*.E*N5(8'FE$3<#:WY4&%O[K?E3YY-[_B%D(6Y..AHY8<]:%C?/W#
M^5'ER=-K8^E*52;5F] MU$"4*IIWER==K?E2B-S_  MGZ5&@Q,4WBG^6V?NM
M^5'DOV1ORI<O49R/Q:FNK7X9^(Y;(NMVMFYC:/[P.#TKXW\+WGB'4/B%X8LA
M"E_H<VEQ/J?V\_ND^8_-D]&K[<\:.UIX3U.=KE;!8X69KF5<K&.Y(KY1^-5P
M_CJ;PY#X,OHY%MUAN+[3X$$<MS'G_6#U&<G%?69-*RE!I:]7TT_JQPUU[R9D
M_%RXU#2?BAH=KX?@C@\*3W0,UW:'+RR 'B4]O:I_@7'>^(&\3S^+[6W?2H7G
MBL;J[;;-(-Q^3W3WIW@.WO?"_P 8M2U;Q%/]B\,7<JQ0Z?<+N:ZE"]44],>M
M96L:=KGB+QMXKU>QG.JZ!-82PV0M5PL#@D&,J.C9KW6_W?L=/A3YOT]?F<WV
MN;\#D=0\0>+8_P#A.$GBDL+BSCA33K2S_P!6J;OEV8ZYKT_4K&72_@W9:L-&
ML3X[!:9+0.#L8CYI-O\ ?]JB^%EU)X/^%^KZ9XEU6U3Q6L ^SM,@D-DK?<61
MO7^5>97/@[QXWAC0;56F&M'5IIY;]FS&J9)\PMTVXK5VJ2Y=(\K6NNNGY=R=
M4N_Z$FFZUXIUJW\"VJQ-JJZ@LAU*&\SY>W><LY/W<5VGQXDG\(^)M*@\*VL<
M=C?7%NFIZC;MN<,"/W6>RUH?&"\DUCX9Z+I?@W4[9M09=UX+>,))=@-\YC/I
MG/ K#T/1]5L_C%+J6J3_ &#PE$EO'=I>+\L\F!A$4]6SW%+FC-QJ-))<VG?^
MN@]4^5/L;'PQAN?&'Q.\26_B6U1_#MCYRP:E<-M9,KAD0]QBN2M_$&MZ;XH\
M4:;;V_\ 8NCZ;I4K:7#:GY&&1B0$?>)KH?B$NL:W\76NM.E6Y\*0V=W'';V:
MX$,GEG(=1_$?6K7[.Z7?AGP?J2^,KFVCNS;22:;;WB;Y;>//#2>BDXX-*ZC'
MVS2>B]W^NO<I7;Y5YZEGP?H8UCX/W?B#6=!MCXL>=+F'3Y'"_:I53".R>N.<
M=Z\\L_'?C&;P;HDX@DU35=0UB:WN=-F3Y'CV@%"O8 ?E5*^TKQS>^'=>5S<W
M7B"?7H'LYX"=C+Y?RLI' 7%>M>,+B_E^#/V+1+_3Y/&[[X[J>W4 S,%'F+$W
M]['7'6K?)2GK:7-+[M/R_P B4^9=K(I?%K2H_ -KX4O_  KIT+WEPMI9WMU$
M_F-8PAQA4] >>:_3SP/G_A#=$R<G['%S_P !%?D5X=L_$UKXV\#3Q^99Z7;Z
M19KJLUZ#Y1R<;6!ZMFOUX\&X_P"$3TC;]W[+'C'^Z*]W*8\E246[NV_S.3$N
MZ3V-FBBBOISSPHHHH **** "BBB@#SC]HR[DL?@?XQN(G,<L5BSJZ]5((P:_
M"^\\7:M<-JCM?S.VI\7C,Q)F ;(!]LU^Y'[3C;?@'XW/_4/;^8K\&IB6R,<@
MG^=<,XQE6;:Z+\V;Q^#^O(Z73?B1XGTGPU-H5IKEU;Z1,")+5'(5@>U9$FNW
M\UG86K7DA@L"S6R;C^Z+')(^I%9SJ0/?%0R;OE&[FI5."=U%:E<S.M\1?$GQ
M-XNALH-5UFZOHK+!@CD<XCQT.*K6/CO7])\1/KMKJD\&KL<M>*QWMQCG\*Y]
M&9%)/3N:/,SM.>#0J--+E45;T'S/<WKKQUK^H:Q=:I=ZK<3W]Q&8I;B1R6=2
M,%3[8JSH/Q'\2>%],GT[2M8N;&SN!B2&)R P]*YC;N. >:,%26 P!0Z--KE<
M5;T%=FK+X@U%M+_L_P"U2&S$WVCR=W'F?WOK6GJ_Q&\2Z_HT&DZCK-U=:=!S
M';.YVBN;5MQSV-.QN4MZ<4W3@W=Q"[-NV\9ZS:ZO;ZM%J,\6H6Z+'%.K$,JC
MH/I1JGCOQ!J^N+K-WJMQ<ZHGW;AW)9?I6#@GY=W)Z4-\H./O>M+V4+WY179T
M?AWXC>)/"T5Y'I6KW-BMUDSK&Y ?/6K_ (9^,WC+P?!/;Z/X@O+"":0RRK'(
M1N8]S7%>:=N2N*57&WYASU%1+#T9WYH)W\BE)K8].7]I/XEL-H\7Z@/^VAIC
M?M'?$QN/^$OU  ?]-#7FC EE=3\U.49'S'-9_4\-TIK[D'/)]3TM?VC/B4R[
M3XOU$=\>::63]I+XE\9\7ZCD#_GH:\UXR#GGTIK%FP#1]3PW_/M?<A\\NYZ:
MO[2'Q+[^+]1)(Z^:>*/^&B?B0N<>,-0R>_F&O-(T///6DW'<><&I^IX;_GW'
M[D'/+N>F?\-%?$M%(_X3'4?^_AYIG_#1GQ+7D^,-0)/?S36;\,?!\'C"ZU&.
M5H0]O 7C^U3"*,M[L:QM,\/F;QQ9:+<O&(Y;Z.VD:%PZ89P"5;O]:KZGAO\
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M]J^626Q3 0L<$"C<6X IF"PSGBG<\< $T@) P$?(S1D,O'%,YX!YHX(.!2N
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MS;FY.:0,I^\<#T[TP*<@$XI&C.3N/XT#)BR^M D"\$9IBJODY!.*<OR^F#0
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MG,Y$?#<Y]Z19-K=OPKHF^$_CH '_ (0[7%!_Z<)?_B:>OPI\<;?^1.UL>_\
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6BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>form10-k_014.jpg
<TEXT>
begin 644 form10-k_014.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (E QD# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@!I^E+G-9^L:U8:!9M=ZG>V]A:K]Z:ZE$:#\2:YK_A=/@'
M_H<]"_\ !A%_C3Y6]D2Y);L[7(HW5Q'_  NSX?\ _0Z:#_X,(O\ &E_X79\/
MO^ATT'_P8Q?XT^678.:/<[7=1FN'_P"%X?#O_H=O#_\ X,(O_BJ/^%X_#O\
MZ';0/_!A%_\ %4<K[!S1[G<Y]Z/QKA/^%Z?#L?\ ,\: /^XC%_C2M\=/AVO7
MQQX?'_<1B_\ BJ.678.:/<[K\:,UPG_"]?AVW3QSX?/_ '$8O_BJ&^.GPZ7[
MWCGP^/\ N(Q?_%4<LNPN>/<[K-%<)_PO?X<?]#UX?_\ !C%_\52?\+X^''?Q
MUX>_\&,7_P 51RR[#YH]SO=U)N]JX1?CQ\.&Z>.O#Y_[B,7_ ,51_P +X^''
M3_A.O#__ (,8O_BJ.678.:/<[S/O1GWKA/\ A>GPZ_Z'GP__ .#&+_XJF_\
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MWYI_6)=B?J\5L=:WB32L?-9''I2IKFDMS]@^G2N45%+99@/0>E.4*YP&C/\
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M-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXFU5FW-J5UGWE8_UJ_[4C_*3_9,OYS[2\U/[Z_G36N(T7)=0/7(KXN;Q%J;
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M0#;&H/[I#^9JO'E4/[QMOMD5)&HD4-V]ZV'(E5C@>6%C'J>M2_.S#YU8^AI
M#QC=_P !P:=G=C[LP[\8(JC!B#,;,&7'MVJS'MPI 7\5-1+\R$+F1/[O\0IZ
M1CC:[+QT(JNA+)U^;KND/90,"F-]_P";YV[(.@HY4$%V8GMTHBCVMT.?IFG$
ME;DBM)TW(@]*DPY4G"N/5>U-5BN,LR?[Z\4\##<@1GLZ_=-:(74?$ZL2& !]
MZM+A<X*K[@55*@M\RD-_>7H:GC#?PR'%49,F]P",]7?^E*&Q]U<_[;5%M,G&
MYFQWJ4953A6_ 9K6)):TYG:?&Y<UZ3X+4K*H9<9[5YKI[;K@8PQ_ND8->J>
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MZ,H-:(3)(_E;IL_X'Q4I;=D G'<DU NZ4_*-J_WB,58C4<@+OQU9NE,S8]6
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MXV]:]M^&/RN@*X.:]/"[GF8SX3]>/@",?"+PU_U[=_J:]"KS[X"#'PE\-_\
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MKW_2M:6M2)O2TC/T9['\&UV?"SPN.@%DF?RKKY7[5RWPG7ROAGX:7'/V&/\
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M",ESBIFD/E[5.3CGG(J.U9(V(+#)'?-5W,EL2>7MS@'\!3]W09 ;'W9!BF2
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M'!_T[C^9KO*^6K_Q)>I]-0_A1]!:***Q-PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!.]?#?[?5K)#XBTRX8#RI(T
M4'OPU?<E?%W_  4 4^=HS8SA!C_OJO(S17P[?8^AR&7+CHGQ'Y/F:S]_8GE.
M3ZGBNT\#[T\+^6Y X0J/S!_6N46:*#6H6E&Z-0VX#J>*VO \S?V?*@;?M&[;
MGH-U?'+5'ZGB7;4W'5HV4=MU=) H:% .OI63:E;Q1Q\V?Y5J0C& .G49[5SR
MET.)2TN6X6.'!/7H*NV\A4_3BJBIMD&1VZU)'C<V#WS6>@S15BS<#BK$0W#F
MJ<)RV2<5<C;+4Q,E1<&I<=^M1J:=UH))(U+L .6)QBM..WMK.-9+HN[GD1"J
M]O;K%9O<2C<""JKGO_2NJ\(^%1=0C4-0'G;^8XVYSCN?6NS#X>5>7+$\?,,=
M2P=)U:CT_,Q[9KV[A(M-.9X\#Y]OH>*29[JV>,W]@\<:MN)*8S[9]*]/5<+M
M& HZ#H!^%#Q+(I21 Z-U5AD&O?>4^[OJ?#QXI]^WL_=]3RJZM89%62UDW C)
M3N/6J2M75^(O#HT&<:C9IFT8XDB/(3/]*Y_4(4\Y)HVS',"PXQBO KX>5"7)
M(^[P6,IXNFJE-W7]:%?=[TJG<M)^- &VN-Z'IC\]!2JP_K3,]Z7_ /74B'-\
MPIC4YB/44W@5 Q.G7I7QA^T\Y;QG=(>ANH1^HK[/)/I7Q?\ M3*%^(07LUS
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M/4?]G4'NCYE^(7PRU70[-=4N-6AN&ED6'9%#Y?...*[+2?V4;S6]&T[5(?&
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M*CH!Z;\%<KIOQ%(QG_A&G^]_U\0URB?-R#O?NW85U?P7_P"0;\1\_P#0M/\
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M#^'(K[2;J3BOBO\ :68-\:;0$Y_TF'^8KJP?\1^A-?\ A_<?85K_ ,>=N/\
MIFN?RJ.:%9%.!BBW/^B1'IA%_E23R$0L<D\5X,K<USN?D?(_Q;GCM?BIJLSN
MR'S8P&V94D*/SKF?%7AF\\07PU:QA>Z;<OFQ1* 0".H%=!\9&^T?%&X4L2GR
M?*3P#M]*['P'&OV=V[Y4=/:OKEB)4Z4&NQ\Q]0A*I)R>IY _AW6%W+_9FI<K
MU\D$5U]MXLUL7$-S-ITP9;:.S>WFMG9&1.C' X/TYXKW*U15C!R1^-6E88ZX
M'UKG_M!KH4\M@]+GA$?C2]MIIY7L?,W0)!MEMY"!M8_,!CKSWJA?>,3NN\VB
MAKU&B9U1\1YQ@C(P ,5]$;<#Y3S69JGEG]VW(Z]J:S-K>)/]DQE]H\"C^(,M
MO'%'(L<R*L,*AR0$V!@6''!.<Y]JEU3XA1WDEBL)2)+9OE8RJ&EQMRTG'WCM
M^E>T+9VC9W01$?[2 TCZ;ITG#V=L5]?*7_"K6;)?8,WDJ;^(^8O%GC9=<\27
MVH0RR6D<SEO)W#"<]!CM6?9^*8XK@,=3V'.-Q<5[/\4+'38-:\,Q165NCR2D
ML%B4;OF YXY_&O;=4\!^&KW3YXAH.EP2SPL@E%FF4++C<..V:Z7FL(J+G'<Y
M7DTVWRRV/C.Q\201ZI-,\Z"-E WL0-V.]>Y?![Q88X[65)+1XYI@F[(QG.0/
MK2> _@DG@W3[V#5H['5I))MR/Y.X*@& /F'XFH_%7EV_B/P[9V]K;VD$3[A'
M;Q"-<Y/) [X[TJV.IU;PIFN'RVK2:J3/H"/QL48C-CG/]\9J;_A+'DZ"R_[_
M "UX,WS2.0%)W>E2QX9AD+CITKR>=GLJE%NUC@/VM+]]2\>:;(T47RV(!6-@
MW\77(KY^U?YG 4>='C[O<5ZQ\<F#>)[0D%"+; 9>G6O)=8PTB%MC'CY@<&OT
MO RYL%!L_+\?%1QTTNY7@A7(VLR>Q4U8:,#@DL:ACDQ@+DGM\V:F1E7JPSW.
M,T$#UCV\ 9)^E>I:5G_AFW41AO\ D:X>&_Z]Z\M&&. (W_V3P:]1TG'_  S9
MJ8 88\5PY5O^O?M4SV.K#?Q/D<&M.IJTZD=84444 %)2T4 6M/U>_P!'D=["
M]N+-Y!M<P2%=P]".A_&NMU[XF?\ "9*DGB"WO9KORUCFDLKYHXKC:,!WB^[N
M(')'7TKB** .JT+QX_@>\^W>$;-M"U;&%U7[0SW,7_7,C 7\0:]!MOVI=9UZ
MUAM?B'X?TGXAF%0D&K7BFTU>W Z%+N'#<=MP->*44"Y4SZ)M/VI+?38/*L]2
M\>?9@,"PU2YL=5@ [*'N%WX%<-\6/VAO$_Q3A@TQY(=(\-V\0BCTRQMXH1+R
M6+2LBC<2Q+8^[GM7E]% N1(****"@HHHH *;_%0S;>X![9I-PH ].^"__(-^
M(W./^*:?G_MXAKDE5PN3)Q[5UOP5.--^(Q[#PT__ *40UR$;;P"QPF.AKNP?
MVCRLQWAZ%B*,GG'%2S$!>21_P#-11R;N!L/MN(J20G:!DQG_ &CD&O1ZGBBV
M.&N!D*5)^_'Q7O/PGRRQ[OF&[AUKP73VV78_Y9/_ ..FO>OA/\JQ?+M^;)VM
MQ7IX3<\[&_"?KQ\"?^23^'/^O<?S-=[7 _ K_DE'AW_KW_K7?5\M7_BR]3Z3
M#_PH^B%HHHK$W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** $KR#]J;Q0_ACX/ZT4@\][R)K8<XV[@<FO7Z\+_:^C,O
MPJD 7/[T _\ ?)KBQDG&A-KL>AE\5+%4T^Y^7/BK/V6/ME1S^5:'@=?+\93V
MY/+0\_\ ? .:J>*8S]AC.,G;CGVJSX'B;_A-(9CN EA&-WKL _I7PJ?NZG[#
M45XH]"CA*N?8_C6OI-L]S=(GW><%L9 'K69)^YFV'[W6N@TVZCM=-F8/)'=$
M\#& 5/O7-K-G%*3BBZ)G:[2RTJ-I)7;8,#YFYZCWSWKT?1?A;$52;5KB2>=O
MF:*,X&?0GO4'PB\-K8Z3_:DZ?Z3<DB,MU"9[?4UZ)YT87[XX/.#TS7U&"P4.
M53JGYIG&=5HU7AL)I;=F-_P@^AF/;_9\?'?)S]:HK\.-*63.ZYQ_=\SBNF6Z
MA.TB12&'R\U$VI6\<(F9_P!V>C8XZX_G7J_5\++>)\O3S#,8WM4D)INCV>CQ
MA+6!85[L!R?J:J^(?$=MH</S'S+AA\D(ZGW/H*M:GJ2Z=IL]V5_U:DA3W/85
MY)=74M]=23SN7FD.3GM[5RXW%K"0]E26Y[&397+-:CQ&*;<5WZD^J:I<:Q=&
M>Y?<W\('11Z"JJ\=\T'YOIZT#C/-?'2DYOF;U9^L4Z<*4%""LD2;ABGJ>.O-
M:FAPZ='9W5WJ<,EQ"K+'&L;8)8\U-J5YHEU8L-/LWM9E<<RODL,<XJO9>[S-
MG(\3:I[-0;\^AB@GUIZLT;*ZG:RG(93@BF$9Z<4JYW'O65VFFCL<5)69W'AS
MQN6>*TU#DG"I/_\ %?XUVBGGL?QKQ1LA<]\<5ZM:F6[\/VK!\3-$I+'VQFOJ
M<MQ4JJ<)ZV/R_B++*.'G"M15N9V9K[O:E\Q>><$=:R+>,S%9(Y1(H#*_)P<G
M*_E3I-/9E823C&W9N'7 ;(S_ "KV(U96T1\A+"PC)J4S#\>:4K6\6IP* \3!
M9=O\2GO7%WQ#S;U7:C\J"*]+UR)(_#M^&;<&C9CZ<]A[5YI=2[K6T7C.T@\<
MX]Z^5S*FH5+VW/U'AW$2K8;E>O*[%9\=C7Q3^T2V_P".%J#C'VN$?J*^U1CO
MS7Q3^T-C_A>EDO\ T^0G]17%@_XC]&?45_X?S1]?Q2;;>+TV#^5074F86P?X
M3G\JC\XB-1V"@?I5"_O3'"X52Q((Q7SLG[QZEM#Y9^+T@7XFW9/1=F?^^*[/
MP'(K6+G/&X8_*N)^(FER>)/B%JQ&Z,I(L;*#SP *JQ^*#X5N396ZR7\S/L%O
M&>^.237V,:#G1BCY*6.A&K)+N>_0WD2H-S8XYI_]JVX&/,%?/I\<>(I)/+^Q
M7";CUX('ZU!)XHU[!/V:<C/]T?XURO RWN:_7HO8^A_[8MU7[P_.N<U?Q##]
MJ?:_MUKQ67Q1XCY'DW !Z?**RY]6UMVW&*X)/.3'5+ WZA]?BNA[@->60'#@
M?C4B:M'CYIQGZU\_R:YK6,;)\#OY9J%_$.KJ.DGT,;4?V=?9A_:4>QZ=X^U"
M&\\7>&%1]QC;&/<R"OIBX81KSQQ7P9#X@FC\3:;>78E%O#,C2-L8[5# FOH?
MQ1^TIX6ETN[;2]2WWJPM]GBD@?#/CC/XUAB\#5ER0@C7#YA17-*4K'I^I2!H
MW8<5Y'XHC,WC/18T!+;=W\\U6^'7QPAU?PJJ^*;Z&'6%8X(0JKQGH<#H:MZ?
MJ5IXD\<:7<:==QW:11E)&3. <5A3PU2A*2DMCH^MTJ\$XLMK:R^8?E/6K"V<
MBQ_=-=FN@EE!R-QZ\4Y] ?:0"A'TK!R?8Z%%'RS\<LP^)K3=O&;8?=Z=:\FU
MB1FF78KD_3%>U_M'V;Z;XRL$;@-:!L@_[5>,:P=TBC+D8[,!7ZGE_P#N,/0_
M)\P5L?/U*D"!6PW[R4_PCH/K5P-C )4'^XBYJI#^[&,K$OL<L:M;]B@X\J/_
M ,>:J,@DC##@$'UVXKU#1V<_LUZF'/3Q7#_Z3UY=P.<;1C^-N:]2TE@?V;=3
MY!_XJJ'GK_R[U,]CJPW\3Y'+>'?"^L^+]373="TRYU?47!*6EHF^5\#/"]Z[
M#QE\'-;\.0PO9:+K,\5K9+/JEQ=6RQK!-C]XJKG=L3(&XCFNZ_8)_P"3P/AI
MC.?MLO\ Z(DJK\<)]+T+XG_%&_T?Q;J$WB676KBU_LQ;5U1K>1V^T98D@A0$
MZ>M(WOK8\FO/!/B&P\,V_B.?1KV+P_<.(X=4,1-N['^$..,^U1+X5UEO#QUX
M:=/_ &*)/*-]@>7O_NYSU]J^J_A#\;]&^''P,^'G@[QSIXUGX7^+)-4M=:M-
MNY[8B?$=U$>H9#@\=A7._M"? F_^ OP;?33=QZOX:U/Q6M_H.LP.&CO[-K1=
MK^S#H1ZB@.;6S/%(_@WX[ET^WU!/">I?8;D;H+HQ@12C'5&)PWX51L?AGXMU
M+Q%/H%IX<U"YUR!!)+IT4.Z=5(R#M[\<\=J^K/C!::/>_L*_LUQZUKUQH=M]
MHNP98+=YBR\!N%(Q@<\U@?L)ZG-J?[<?AF>2]N-12.TNK>VNYU*R2V\<&V)B
M/]T"@.9VNCYI\0>!?$GA2WBN-9T._P!,MIF*1W$T)$;,.JAQE<^V<TOAGP+X
MB\9)<R:'HMYJ<-L1Y\T$?[J'/0,YPH/MFOK#QE;GX'?L;^*;-KP_$'2_B-K+
MRV.IV@9K#0Y(I#E6W_,EP2",  =:R/VI(X_"?[*/[/NC^'3]E\.:K83:E?&V
M8HM[>\;FE(^^PR>&Z9H!3N?,FL>"?$'AV-9-4T>[L86D$*RS1XC=SR%5NA/T
M-=;'\"_%4/AF>[O?#>N0ZK/)'_9]N;95AFA(R\I<GD=  OO71^+/A[XETC]E
M/P]XENO%]M?^"]2UF7[!HIAE,T%XJ;),,W"KA>W!->Z_MC6/A_4/!/[/"Z_X
MFNM!A_X15 ?L]N\I9>,G(. >W- ^;5'R)I_PW\6:KJVHZ99^'K^XU#376.]M
MEB^>V9B0JN#T)(.!WQ3_ !)\+O&'A"V:XUSPUJ.D0K(D3-=Q;-K/G8#SP3@X
MSUK9\-^//$FI?$RV6]U&Y9]:\1:;-J+2 H]RT5ROE,_0Y 8G\:]A_P""D&NZ
MA!^U5\1=+CNI/L%Y;:8T]N6.UREJI0X]06/YT!S.]CY^\2?#[Q/X/L;6\US0
MKW2K6[ :WFNH]BS \@IS\P]QQ5C2_A;XPUS3[6^L?#>H3VMWS;2>7M^T8Z^6
M&(+CZ5]>_M*:5I?B"\_8[TS767^Q;S1[&"]\QL*8FDC5@3V!!QGWKQ[]O76=
M4L_VKO%ELLTUE%H+6]MHUO QC2S@2)3$(5'"@\-D=233)C4ON>(:3X5UO7-?
M.AZ?I-Y=:T',?]GI$1/N'5=AP<CTHU#PCK>D^(!H5[I=S::SO"?89E"R[CT4
MCL?8U]^?$VRL;?\ ;7_9KUN58K/Q+K6FV%UK2J C-.595=_]IACKR:^7/VE%
M=OVR/&D6&\X^*B O\1)F7 'Z4AJ5SB?"_A'Q3:^)-4\-Q^%+G4]9EMO+?3!
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MVMK=+7Q]IR1E@OV$,=R ?Q5\[ZS^\F7/W?3UKWC]I_6-0U[QMI\M\\4TJV0
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M5^[ST#'%=1+^T/X:USXB?"SQUJFG7]OXA\+WB)JC6\:L+RSB<FWVMWD1<)]
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M/;R2BQ@6++09\K&.PW-QT.3FD7XO>*EA>#[;;- ;R34(XVM$*VUQ)]^2$?\
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MW!SRSG->V_"W_EF1SR,R&O1PFYYF,^ _8CX _P#)(?#/_7L/YFO0J\\^ /\
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MK_4UZ57F/[-S;_@IX4.<_P"B_P#LQKTZOG*_\67J?14/X4?0****Q-PHHHH
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MRVU".TO!AKIB6$9'7)''YUV?[-TXN+77I>@,R?RKVM<<5P5L=6H5913T.R&
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M $Z?^S&O7J\>_9%8M^SKX*)_Y]/_ &8U[#7BU?XDCV:/\./H+11161J%%%%
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M8VK;T\CMSWKS75/]9P*^YPG^ZQ1^78])8VI8KK@+G*CW5J3S"_RKR:8NUAG
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M<8R?KBI5(7IU]VJR6B9<_>8X%/.-O5L>M0JQSG.YO7L*4MN]6/Z4$%BU=UF
MSN7T->B>$9!A,'CC@UYQ;,JR=A]*[SPJVW::Z\/N<N(6A^Y_['WS?LW^"/\
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MZ>"S&_F)]F;:QE\WC>W\??ZU[/6CW/+W%HHHI""BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FFG4E 'CO[5-HEU\'
MM1=XBYBEC=<#[IW=?RK\H]>7R[^^!/)D;'YU^N7[1F?^%->(SQGR.,_45^1?
MB?Y=6OL\_O"!^=?)9G'_ &A/R/T/AV3^KR7F==X%O/W967@[1T_W17;+-COT
MKSOP?(L+1(&WEE4@XZ'!S7;^9EN.GM7S=2/O,^QZ%YK@=N:8T_6JZ[CCG;3G
M\I>K;C[5E8%V)%N-W%2*QV\'BJBW"KRJCK2?:&9N6_#-%@+GNQZT+/'&,#YO
MK5(W"KG)QCDFN;UKXC>'=!5C>ZK;K(.D<;>8Y]@!_6M84YU-(*YC4KTZ2O.2
M1US7SXV@!?>H&N&9N6)->*:U^T9:QY&EZ9+/MX62Z(4?D/\ &L/3?$'Q/^+5
MX;7PYIM_=]O)TBV;'/JX_J:]2EE5>IJU9'S^(X@P=%V@^9^1[IK/B"RT6/S+
MV\AM%(S^]D"_H:X#5_CIX>T_<MLUQJ,@Z>2-J_3)_P *Z[X9?\$VOB]\2YFN
MO$:Q^%+7/^LU:0R3-]$4G]2*^JOAK_P2G^'GAJ6*X\4ZMJ'BF91EK?/D0[OP
MY/YU[%+):<;<[N?.5N)*]3^#&Q^>%Y\;/$^OW/V;1-.6%F/RQP1-/+_G\*[K
MP7^R#\>/C?=13SZ/J%G928(NM8<V\2@]PIY/Y5^N_@'X#^ ?A?#L\,>%--TM
MMNTS1P!I"/=CDUWBKM7%>Q2PE&BK1B>#7QN)Q'\2;/SA^&?_  212-DG\>^+
MS*.OV/1XMOX%V_H*^I_AC^Q+\(?A3<0W>F>%8+W4(AQ>:E^_?/J-W'Z5[S1B
MNN,5'8X.57N06]M%:QB."&.",# 6-0H'X"IN!VIU%44)2T44 %%%% !1110
M4444 %%%% !1110 4E+10 GX44M% #.:7\*=10 QEW#!&0>N:S]4T#3M:LY+
M2_L+>[MI 5>*6)6!!^HK2I&[4!L?B9_P5E\!^'_ /Q\\.V7A_2X-+M9M$$KQ
M0+A6?S6&:^&;S&ZOT"_X++';^T5X8_[%]?\ T:U?GW>-\W0_G6J^$C5R*XQZ
M<4YN@X ^E,W>G%.#>^/PK,L7G;Z"D4#'0 >K4>XZTGN/S- #^/;ZXIHYZ\T#
M'JQH.?\ ]= #MH[<_C2@#^[N/IBFANW>G9)[D?A0 WC=R ?8"G?+Z+2'TZ4A
M_(50#MHZ@#\JZ'3? .N:MIEC?V6F275M?3RP6[0D,7>)-\@QG(PO/..*YW=M
M'&XUUOACXK>)?!L.GQ:-J;64=A/+=6ZK&IVR2*$<G(Y!4 8/I025]%\ :QKW
MA_4=;L+2.;3-.<1WDWFH&M\@E692<A3@@'H3QUIFD^!M9UK3;.^L++[7#>7J
MZ?$8F!8SM]U",\$C\*EL/B-X@T_^V#;W^W^V XOP8E(N5;J&&.0#R!V/(JSI
M'Q4\2:#I6F:?87D<-OILCRVFVVCWQ.S!BX?&=V0.>U [FW:?L\^/[Y[1;3PU
M/=K=7"VT4D3(R;VC\U<D'Y5* G)XX(ZC%<AXC\*W_A6\M[;5+=+>:XMDNXU5
M@VZ)QE&X]1736?QW\=V.H6UY;>(9K>:VP(EA550 +M"E0,$ =!VR:YOQ#XQU
M;Q5]E_M2X6X>VA2")_*57$:#"KD#D <<T]!&1M5?X!^5+M7^Y32WKG\:4$4P
M'D*.JJ!["G?+P< #M@<TS)[?RI1\O(&/<TR!^1QQ^9IS8QGC-1_08]Z7=[FJ
M D7;V&/I3\+G.W)]34.[WIZL/3]*"62@@G^]3LC&,9J+<._/L!2[NF>GI30M
M2>' D' ^N:ZC1& QTKE(FPPYP/2NDT>0*J]:Z*6YSU=C][_V&\?\,K?#['_/
MD?\ T-J]WKP7]A=MW[*7P\/_ $XG_P!#:O>JX*GQ,[8?"A:***DL**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /-/VC(WD^#/B8(-Q%OG]:_(CQA(!K5XN.=Y)K]@/C__ ,D=\5=O]#;I7X[?
M$"ZCM_$MY&SJIW<<^U?+YE'FQ$;=OU/O>'YJ-"=^YK>!]09Y(]PW;&*_D,UW
MGV_*G9P/45Y)X1\1:7I(DFO;ZW@# L"[^GM3M8^.&C6+&*T@FOW'\2_(A_$\
M_I7C2PM6I/W8GTE3'X?#PO4FD>JK>EN3GZTVZU6&SC,D\J0H.K2L%'ZU\\WW
MQ@\3^(IEL](M_LSR-A([6,R2M[9_P%=UX%_8_P#CA\9+J"1?#>HP6<[@?;M7
M;R8T'<D,<X_"NZGE-26L]#Y^MQ)1B[4HW\S<U;XU>%])WJMVU[)TV6J;OUZ5
MP6M?M#:C=,4TG3H[1>SSGS'^N.E?9?P__P""1L*K#-XS\9L[#[]KI$( ^F]O
M\*^L/AG^QG\)/A9' ^E^$;6YO8EP;W4!Y\K'U.[@?@*]>CE=&%FU<^?Q&>8R
MMI!\I^2'AOX4_&GXZO =+T+6M2L9CE)?*:&VP>X8X&*^EOAE_P $F_$VK(MQ
MXW\36VB1LO\ QZV*>?,&ST+' Q7ZA6EK#8VZ06\,=O#&,+'"H55'L!4VT>E>
MM"E"G\*/GYRJ57S59-L^7/AK_P $Y_@[\/VM;BZTB7Q-J$.#YVJ2;T+>NSI7
MT=H/A31_"MJ+;1M*L]+MQ_RSLX%C'Z"M;'M16Q*26PFW\:7'O2T4#"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FM
M3J:U 'XT?\%F/^3C/#'_ & %_P#1K5^?5T<GO7Z!_P#!9HX_:*\,?]@!?_1K
M5^?5Q6G0C[1%VH%-YHS[9K,L=GV%)U^E)U[4HSZXH =TZ&CG_P#73?R-'TY%
M4 X_D:%SZ9I/H>*%X]*D _#%.':F\TI8^OZ58#MQ]*.W/(IG;FG*?6@ 7*_=
MY%2<]QBF#'M2<DXS022;N?2E_#/XU&,CZ4X,#QD&@0_GUQ]:#UP>#3>>W-'L
M#Q[TT \;A3MWJ/SIF[_.:09)]J8$@YIV[ZU'N_SBE#>],"3=[Y]J4>H-1@_A
M[TN[\:HDF#<=#GZT@;\*CW4Y?>@1/#UKH=)D*J.U<W&W(Y%;FF/M'O6U-ZG/
M4/WX_81)/[)_P[/_ $XG_P!&-7OM> ?L&G/[)?PZ/_3B?_1C5[_7'/XF=D?A
M0M%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(/N*]-5=JXQ@>@Z4^BN@YQ*6BB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK4ZFOTH _&7
M_@LXQ'[17A?O_P 2!?\ T:]?GU,:_0/_ (+.G_C(KPQ_V %_]&O7Y^,NZM.A
M'4AH_E4GD^U'EU-BR/Z4F*E\OUX-'E^]%F!%2^E2>7^-'ETK,!F:,GO3_*_S
MFE\NG85R.C-/V#M2^6/:F%QG%%/\NCRQZT!<;FC(XIVVC9B@5Q*/;I[T[:*7
M:*!#03]:=NI-H-+M Z?K0 4HI/K2U0"[C1N!^OI2<4 4 .!]L4N[WYIM+0(<
MIIR_6HN>U.7/XTQ$\9YYK9T^3"UBQUH6;[>O%;0,9ZG] ?[!!S^R/\.3_P!.
M)_\ 1C5]!5\]?L!L&_9#^&Y_Z<3_ .C&KZ%%<DMSJCLA:***0PHHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
*444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>form10-k_015.jpg
<TEXT>
begin 644 form10-k_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #R .<# 2(  A$! Q$!_\0
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MKL#^N5-5(3^/KQ_,5<A8<52)-729!_:%L "?FX]*_<O]E]2GP$\%@]?L(_\
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M*GN:@FQM(/3%(9SEQ'GYK=A\W\/8ULV4;6MKOF."!T-4_L0CG\^%2RKRT?\
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M!>BZEIMY<3^)X]-DM]0^R!)F1B8]V/-P/X<<YH&4X?%7POU",1W'AR72+L'
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M^->E_ ']JCQ9^SMKXETNY>^\.7#@WNARN?*E'=D_NO[BM3$_;>/Q/!XDC::
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MXMY7@GB;='+$Q5E/J".E1.GS(Z*-9TI)VNC]E?%46E:Y'<Z%XKT*.]T69/\
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M !Z "O&/V0/V;M-_9A^#.E>%K94EU:11=:M>*.9[EA\W/HO0?2O;Z@H****
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M;P\.,8^V)C^=,7XW>!,*/^$I\/X'_3XGKGUI_6*@OJ-#^FC\QA_P3W^-+?\
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MC)M\TY))QVY->@T4 %%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH
B**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>form10-k_016.jpg
<TEXT>
begin 644 form10-k_016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $? 2H# 2(  A$! Q$!_\0
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M;T#<!BO8$@XKY7.:%*%53I;N[DNS/9P=24DXO96L^Z+]'-)3A7SAZ0E+110
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M3=B1LY7<.!@'D&O.? 3:A'XUT5-,U"32-0DNXHDNXV(\LLX&3ZCV[U]:^-O
MC*TVJZ4\EIJ!A:!Y(3@NAZJ?7_Z]>,7WA7PCH/@G4)-5:>S\71S)<V5Q;,2Y
M D V;?N@@ G!]CFM*U%/]Y'8];#XKG3A+5L_2B%UT74(-3O6BN;*WT'.N74G
MW[J$9V$(!@E,/SUYQ7AOQE^&D%U9KJ>F11W,D]OOTR_WG_4O@LAV,/FQCO\
MSK-_9U_:Z\,>-M/M/#GC&X2PUGR6L&DNL)#?0N,$;LX5CUP>^<=:Z/PS;O\
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M[0K7,\B2$1_:=A,C.N,EF8E^#@# KS[]K+X ^&ET'6/%\VJ2IXC^S0NLUS<
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MNY[U\+F,N:M\CZ7!1Y:;)<_-ZBCCU-5]U'F'TKRSO(TB'I4OE\4]8JF2'_\
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M]AVC4\[?]HUZYI6DVFAZ;;:?8P+;6=M&(XHD& JBN2E3>(Q'MVK0CI'S[O\
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MP"?O ^E>9?%5:_)C(JSV:V]#@Q558E*MS7:W3MM\B#Q-HLFFZ?;WEKNU"WD
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M(*$8WZGS$I-W70]"\/ZU+HOSV[[9@AA##D@$<UW/PILA=>)(I&'^J4OG\/\
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MRIV(>7<NS/EZX^"]R9,I=S$#'^156X^"M\V,WSA3QMYS7TY-HMDS'$\@_P"
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M6;/DFWG.GZ@MRZ-Y>"C[5)(R,9P*NZ?K&[!$4^5Y#"!_\*^KETNV'/D1C_@
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M-S>M'F4M>X71@>?>]!I=P?Q7_&CSK[_H%3_]]+_C70^91YAZYI.X[F!YE_\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>form10-k_017.jpg
<TEXT>
begin 644 form10-k_017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !C &H# 2(  A$! Q$!_\0
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MR2#K[@CL0>,5M[:\AU*L9-2;OLSV8PI5(IP6FZ!?NBG445@= A-)N-+2-VH
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MH%NYS^E?71RK+J,D^5)KNSY.6:9A633DVGY'L7[)&G2:E\<M$=$REK%/.Y]
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>form10-k_018.jpg
<TEXT>
begin 644 form10-k_018.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #L /P# 2(  A$! Q$!_\0
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M.FJB)&U&SFN]#EN8.(9<9D##(;*L%88Z8- +LSXD"Y9E+8(&:^R_ [7&G_\
M!,WQ#<74L9LKGQ+_ *)$(@ASO ;+9RQ)]>F,5\>^)M!O/"^O:CIFH1-;WMC,
M]K/"RE6#HQ4\'D=*^OIFCL?^"6FF1!@))?%1D6-_O,!*2V/H*"8]3X_L5,=P
MQ/)?BOI/_@G7&S_M=>&)=^Y!8W@V^AV"OF>&032*@#(3T;TKZL_X)NZ>M_\
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MD0M[U],VX98@&ZXZU\@? G51XH_;:^--X[2,;&R@LDW#@*&Z U]@0L64D^M
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MU)/O6EX)\%:-X#\/VFBZ)IR:?IMFJK'&B@9XQDXZGWKI54!LXY]:!BQQ"-<
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LY.::MPV/NC\ZED4%<=JY*\^&>DZK>3WLT^I)-<-YCB*_E5<X X ;CI0!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>form10-k_019.jpg
<TEXT>
begin 644 form10-k_019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #K '<# 2(  A$! Q$!_\0
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MA_3O"MOH^B:@B,;9+AI#%.O29"W\1'!KEO%WCJX\81Z"LMNMNVD6,=@C(>)
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MTU'*7=I;W*^DR Y_.JMMX1T>SD\R'2[6-UY!6%<_RJ[HQ7MHZ/5'!:QJ%O\
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M">]?:&TR*03_ /6KP;XG? F[T?QBGQ&^&Q@TOQBG_'_8L=EKJ\7=9 . _HU
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MB.XAR/F.W&<>E-OO'OA7XK>/+.^\$6WQ*UOQ'>7L9GT^:6:PL+) PWM+N&
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?H)^]QUJS10! D(63?L /]['/_P"JIZ** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>form10-k_020.jpg
<TEXT>
begin 644 form10-k_020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #K '<# 2(  A$! Q$!_\0
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MA_3O"MOH^B:@B,;9+AI#%.O29"W\1'!KEO%WCJX\81Z"LMNMNVD6,=@C(>)
MISO-:MV/.4:=[Q/HFX\&Z>OBO3]$TSX?:?J&G6]K:B_OIKHK( Z!F<Y/!'-?
M:7_!/W7+>3PCXO\ #>GW9OM&T/6I(K"=F+8B89V ^@Y%?EAXP\?:AXY\0#4I
MVDL&>VCA:.W<@$1J%#$#VK]*_P#@G/X73X>?L^ZQXEUIVL;;4+J2^:20[0(5
M& _/8@5G)W-L'*G&;L@_X*<>.I;/X?Z'X+TV7=J&N7:GR4/S%0>!^=>Z?LK?
M"A/A#\%= T22+;>R0BXO/>5QD_E7SA\&?!NH_M5?M#ZG\6M=MI%\':.YMO#]
MI<)\LQ3A9<'KZ_C7W%H>I1:E8K*F5VL8V5ARK X-1S65CTZ<74K>T?0U8ONC
M XJ2F+Q@"GUD>F%%%% !2&EI* (9L\8^]VKR[X2ZU+XHU?Q=J/RJ(]4:U'T0
M8Q7I]T&X*\$9-> ?L\:O_8_CSXE>#KIE6_M=5-_'&3@O#(,EQ[9JC*7Q(N?M
M'_ 6X\?V^F>*_#,B6'C_ ,.O]HTZ]''F@<M"WJ&'%>?>+?#&@_MN_!^YT35(
M_P"P/'.D$K+!*,36-P!S[E&_K7UGGS%':O)_B9\'VNO$$'C7PK*FE>+[4;3(
M!B*]3_GG,.X]^U/F9S5J.CMU/Q^^,'[._CSX/ZC-:^(M%FCM@<1WUO&7@=1W
M! XKRZ'3YYI8H8(9IY7Z(D3;C[8Q7[P^$?&EGXV@DTCQ%I4=AKUN-L^E72!P
M?]J,GAE/M70?\(;X5T3-T-!TNU6-2[3M:QJJ@=\XZUIS:'%' 127*S\I_P!F
M']A?Q1\5M9M-9\26$WA_PA"5EE-R-LMS@YVKGHI[U]D^.(3\=;RV^$?@0-IW
M@71RD&N:O:\1L$_Y=8R.IQU->D^(M7UWXP2'0?#._2?"+$Q7FM*-KS+T,< ]
M#_>KT[P3X!T;X>^'[31=#M$L[&W7 11\S'N6/<D]2:5[G33PT8>['[RSX1\)
MV'@S0+'1](MTM=-LXUBBA08  &*Y+P-X@=_'GC#0>L5C/&ZMZ;USBO0VD=,!
M>G^<UX1\#M8'B_XJ_$W7H3OT];]+"&9/NR/&N&P>^*SD=L8J.B/?XU*XSUJ2
MF*=V.U/J34**** "D-#':I-,\P^F/QH 21 QKY_^.WP?\12^+M/^(OP[GCMO
M&=@GD7%G*=L.IVV<F)CV/H:]^9L^AI,>9CC\::W,ZD.=:.S/"O"G[5.BRSII
MOB[3M1\':Y"F+F&^MF,&X?W90,$5VW_"[O ]SLV>(;6;>,JL89F/T&*["^T6
MTU'*7=I;W*^DR Y_.JMMX1T>SD\R'2[6-UY!6%<_RJ[HQ7MHZ/5'!:QJ%O\
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M">]?:&TR*03_ /6KP;XG? F[T?QBGQ&^&Q@TOQBG_'_8L=EKJ\7=9 . _HU
MFKZ'XQ_%#X&^.?A!K5WI_BCP[>:>MNQC6X\HO$^.A5P.17$VMC=WUQ';V]I/
M<3R\)"D18M^ %?OKX$^(GA[XP6[Z;JFF?8]<MQLOO#^K0J9(F[L P^9/1A6Z
M?!/@[PC'/JC:#H>DQQ*6:\%K'&8P/]HBG=D>SB?E1^R;^P'XM^*6MVWB#QC:
M3>&_!5JXFDCN_DGNBIS@*1PGJ:^O_&UC)^U=XDM_A7X+9K'X5>'I%77=8MQM
MBN9%X^R1'N..2.*[WQ%KWB+]HV9?#7A0W'A[P&)?+U'Q P,<M\H^]%;+C[IZ
M%Z]U\!_#_0_AOX:M-"\/6*:?IMLN$B7J?5F/=CW)I%J*CL3^'?"VF^#?#NGZ
M)I%LEAIUC&L,$4*X"J.,5YG\#=6'_"7_ !#\.;MT>EZH77C&W>,X%>PW!.WD
M@*!DDG&/4U\__LRZE#XL\>?%;Q+9'?IUWK'V>"9?NOY8VD@]^:!GT0G2G4U>
M@IU !1110 4444 0S0B12#TKY@^/7PC\8>$?B''\7/A3;K=^(5A6WUC0&8(F
MJ6XZ[3_ST'8FOJ3@CGD4F%/8$T ?.?@O]MKP'KS16/B&>Y\ :XO[N?2_$<#P
M%''7;(1M9?>N[O/V@?APMON?QII%R.JK;3>:_P""KR:[W6_"NB^)% U;2+#5
M O07ELDN/IN!JCI?P^\+Z/=K<V/AS2K*=>%EM[.-&'X@4 >*^+[C2_C(UK>>
M%O#6L'4[63_1O$4*_8?+QT^9QEU_V2,&L75_!?C9M3M;KXD1OXZTJV D33]'
M;RD3'\<T/_+4_0XKZF"J.P&*-BMC*@]QQ0!Y3X=^,W@*XM[>-M6M]#$:^6+7
M4$-IM _AVL ./:M;5/CI\/\ 2;&>[N?&^A10Q#+L;Z,X_4YKIO$'A71?%$+1
M:OH]AJT9& MY;I(/ID@UQ4?[.GPQM[I;F+X?Z ER.=S6:'!_$8H \+\??M(:
M]^T#)+X)^!5M<WZW(-OJ/C"ZMVBLK.(\.8V8#S&P3TKZ(^#7PMTSX._#S1?"
MFF;I(+&/#SM]Z:4\N['N6))KKM+TRTTFS2UL[2VL[9.%AMHU1%^@ Q5W:.P%
M "XI:*3- "T444 -;E3CFOF_XU?M3-\,?BYX8\,VEDNH:0SJ?$5X@+?V?'(=
ML9)[9)'6O>/%GB"+PKX:U/5I4DE2SMWF\N%2[N0. H'))-?%GP9\2^#?'GA'
MQ1I7C#3?$$?C'Q_=2_VA<7&F28@&2L"JY&%50%(]Z /I#XX?&B?X=6^C:/X:
MTP>(?&?B!_)T?3V;;"QQDR2M_"@'.:X&;QQ\?OAG/I^L>--&\.^)O#<\JQ7U
MOX9247=@&.-PW?ZP GG%>7:-=>/?#5OX4\3W>@WNOZA\-;F?0]6M;="\]Y9G
MB.XAR/F.W&<>E-OO'OA7XK>/+.^\$6WQ*UOQ'>7L9GT^:6:PL+) PWM+N&
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?H)^]QUJS10! D(63?L /]['/_P"JIZ** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>form10-k_021.jpg
<TEXT>
begin 644 form10-k_021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "0 *D# 2(  A$! Q$!_\0
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ML/$MO#Y-GJ&^6VSG+PARJ/S_ '@,_C775SOP]\*P>!_!&A^'[90L&F64-H@
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M>I#'[H/HN*]EC3;@=:0XKJQR+MR*=112- HHHH **** "BBB@ HHHH ****
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M1='U&>U3<>0IPX7\-QH"^MC[,HHHH&%%,D#'[IP<T^@ HHHH **** "BBB@
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M>'>(/V)?!NL?M!:?\6K2]O-)UBWG6ZFL;54^SW$JC&]LC()[XH XG]H25?\
MAN[X!(&!86]WE0>1G-8EUJ]O\*/^"DUU?>*)TM-/\7Z&EMI-Y<8"!U"CRP>V
M64CGU%?0OC3X Z7XX^-7@WXD76I75OJ'AB*2.WLX47RYM^>7)^;C/:M3XS_
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$@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>form10-k_022.jpg
<TEXT>
begin 644 form10-k_022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !( 7\# 2(  A$! Q$!_\0
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M'_$/7;[P[X>CO-/D1)FN$C)=-PP0>WX4GP[U^_\ $7A^6\U%T>9+AXP43:,
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 8OB/4+O3].5=.C1[^ZE6"V63[H8]
MS[  FIM"U-=9TJ*ZV[) 3'*A_AD4X8?F*R]7\.W6M:_#=/?W5E:VD.(#:R ,
MTC?>)R#V 'XFGZ#H=UH6IWL2W$MS87.)_-GD!D$W1AP!P0!0!&MWK6LW5W)I
MMW;6EE!*]NI>+S'ED7@D]@,\?A6M87%['ICRZO%%%/#NWF(Y5P/XAZ9]*PU7
M7/#][=P:=I45_I\\K3Q$7 C='?E@0>V><^];.F0ZC<:.\>MM#]HGW;XX/NQ*
M>-H/?'K0!D6\GBG4+--2M[BRA28"6&T>(G,?4 MZD?E6KJNKR:;HB7CVI-S(
M8XT@S_RU<@ $^F36+;R^+-.L5TR'2+:X>$"*"\-UM0QC@,RXSD#MWK7U729]
M4T)+5KC_ $R(QRK-C ,J$$''H2* ,VYG\3Z+;G4;RZL[V"/YKB"*$H47N4/?
M'O6KK6IR6 TTPA2+F]B@;/\ =;/^%8US_P )1KEHNF7.EVUA'-\MW<BY\T>7
MW$8P#D^_2M;Q#IES>Z=;_8#&+JTG2YA63[LA3^$GMGUH C\3:S<:.='^SJC?
M;-3AM)-_9'SG'OQ2^)-0U&PBL!I<,,MQ/<B,QRG 90CL0#Z_+Q6=-:ZMXBU+
M31J&E)8V=C<+>%C<"1GE0$*H '3G.:W-4LIKJ[TN2/&VWNO-DR>WEN/YD4 5
M(O$$5_8Z7>V#!H;NY$3;ARO#9!'8@BC7%UV)9+C3;VSB@BA+&.:$L21SUS52
M\\/72>)K2]L)(UL9+@3WD#<?O I =?<YP?H*Z"^A:XL+F%/OO$R#ZD4 9&@C
M7IDANM2OK.:":%7$<,!4@D ]<U4O/$MS;>)1!Y:#28I4M)ICU\Z097'L. ?K
M6]90RVNDV\)4&:.!4QGC('K7(+\/C<Z1-;W>MZD);MC-/%'*OE^:3DXXS@''
M?M0!U'B"]N-/T.ZN;3R_M" >7YGW<D@<_G62_B6<^&[ZY,"PZE8D1W%NYSM;
M(Y^A!R#5RXM-1U#PF+6XCB74'C02 -E<@C//X5G^+O#5UJB&]TDQ1Z@RB"42
M?=FAW D'W&,@T ;FI1:I-;QC2[NWMY<Y=IHC("/;FL/PW<>)=1"W=Y?6!M5F
MDBDBB@(8['*\'/M76C@"LCP]83Z;IC07 42&XEDX.>&D)'Z&@#+U?6;S_A(S
MI-O?VVFHD F\ZX7/G$DC"9XXQS]:V-%>_DLC_:$MM-(&(6:V/RN/7'8UGZR-
M76]7RM*M-5L'3!B9@DD3=S\W!!_"D\+:5=:<VH75S;1V0NY0Z64+[EA &,YZ
M9/4XH Z6N2U7Q1<V7B/R(K4/IMHT27\_=&EX7'L."?J*ZERRQL8QN8 X!/4U
MQ-MX'NKW39SJFM:A#=WQ:6ZAMY5\H,>P&.@&!^% '4ZW=366AWUU;;//AA9X
M]W3=CC-8J>);G_A']3-Q%%%K&G1GSX1RN<9##U4U;^QZE=>#6LKT1MJ+6[1,
MP;AFZ Y]^#57Q=X=N=5LS-ICK'J*Q&$EN!-$>J,?U'O0!<\0:C>66A0W%B8D
MN9IH8@\HRJ[V )Q^-4Q>:_H]W:G59K.[M+B9(";>(QM$S=#R3D9JUXBT^^NM
M AAL(8YKF":"41M)L#['!(SVZ52\C7];O+6/4K"WTZRMYEN'\NY\YIBIR%Z#
M SR: .MK*UV_FL-,=[94:[D80VROT,K'"Y]N_P"%:M<QKWAR?7]:LI)+R>UM
M;%3+$UM( [3'CG(/ '\Z -#0-2EU'3-UR$6]@D:"Z5.@D0X./8]1]:R3=>(M
M1UO5+?3[RRMH+*5(@)H"Q;,8;.<^]3:%X;FT'7+R>&\N;JWOT#SM<R NLJ\
MC '!'\JKF/Q%I>O:M/8Z/!>6UY+'*KO=B(C$84C&#Z4 :&BZM=:C%J%I<QQQ
M:E8R>3*5!\MB5RKCO@YIEOXC \)S:K<H#/:*Z7$2?\]D."H^IZ?45)X=TJXL
M1>7U^ZF^U"433(ARD>%"A%]0 .M4+OPW=MXKCFMW1-)N)5N[Q,\M-&,* /0\
M$_[M $/BS6]8T3X?#4P8H=4!M_, 3<JEI%##!]CBK_BC6KC28["*W*0M>S^2
M;N49C@XSD_7&!4'Q!TB^UOPA<6.GP^=<O-"P3<!P)%)Y/L#6GKHU3[(C:;;V
MMT5;][;3G E7T#=C^% $&C2:H]W(MSJ%CJ%J5RLL'RLA]"!P0:AO+W5-2UBY
MTW2)H;:.S"?:9Y8_,)9AD*@Z=.I/K5'2])OIO$T.IRZ1#I$%O&Z%8903<E\?
M>"C&!C-6KVTU72=<N=0TJQ2^M[[:;J%I_+9&48!7/!!'44 6]'O[\7MQI>JF
M%[N%1*DT(PLL9)&<=B".:QUU77=0U;58K74],LX+.Z,"QSQ98_*#G.1ZUK:)
M::C)J%SJVK0Q07$J"&*"-MWEQ D\GN235!/",-ZGB&+4[>(KJ-RS1.N"ZH5
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1** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>form10-k_023.jpg
<TEXT>
begin 644 form10-k_023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !< QX# 2(  A$! Q$!_\0
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M\O\ =;;][>E3:?\ $S6[%M+NO$-CIT6FZII<^HQKI[N\L'E1)*ZMN^5]RO\
MP^G\76NDL?AG96T>IO>ZIJ6K7NH6SV<M[?SHTJQ,#E(]JJJ_]\U:?P#I<O\
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M=7VIM^ZOWN:I?$3Q%K>M>%_B)%(MG;:+I3/9J8EE^U,X2*7?_=V_/^E=5/\
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MEUI-TMU;20OLY7^%O[R^U7+[P[:W_B+2M8=I/M>G1SQ1*K?+B79NW?\ ?"T
M+;Z.FD>'TTO1V6Q2W@\BV?;O$6%PK;?XJ\@F.I^$O#OQ+B.LWE[J*WUG$VH3
M-ME_>Q6ZNR[/N???;_=^6O=\US4_@K2[K_A(DN%DN(]>=6NX9'RGRQ)%\G]W
MY47_ (%0!Y;X^TF#X2L9O"P;1Q>:+J/GI'*[*SPQ*T4OS'_6+N;YJL^,-#L?
MA-_9>I>&8GTZZFM[V*YD>1G$^RREG5I=WWGWPK\WNU=KI?PQL+6:XDU*_P!1
M\1O-9MIX.K3K)Y<+??5-J+][^)C\QVBDT7X8V>F7D,MYJ>J:\MO$UO;1:I<+
M*ENK#:VW"KN^7Y=S[FQ0!QTOAK3_  ':^"]>TF-X-4O+A+>^GEF9GO%E@=V\
MW^_\Z(WX5B^&[6\A'A'Q7JFE2V4NJ36OFZY:WVZ]E>?;L2>+9M\AG;;M5MRI
ML^[MKTK1?A;8Z+?6,[:GJU_;:<7%C8W\ZRP6H9=OR_)N;:GRKO9L?K1I?PIT
M_3;ZRE_M'5+BQL)/-L]*N+@/:P/_  LJ[=WR_P .YFVT =UVKSRX\:ZU;6^I
MZH;2S;2=-NY8)$WL+B6-&V[E_A7_ -F_V:]"[5P.E^ _.N+R747NXXY=2GNC
M9K.#!.OF[HF9?H%^7_OK-;4N37G,*O-]DVO&7ANP\1:?#'JMP\.F0/Y]U;^;
MY<,Z*I^65O[JGYO^ UQO@WPW=7%CXC3PO?S>'_#M[+'_ &8_E^9MZ^?+"K?=
M5_X?==_\5=AXS\&0>.-/M[*>_OM/BBF6X_T)D'F;3\JN'1E9?]FK/AOPW<:#
M'<+/KNI:R)-NW^T/*_=_[OEHE8FYQ/P\\-)KGPP32[J_OE@_M"]6:5)SYMQ&
MM[+O1W^]\^/FV[>M2_#O1M/M/%VHW/A9/L_A3[,L4JPG=;W-YO\ ]9%Z;4^5
MF7Y6W_[%;MY\.;*X\'W'AV._U"TL9YY9Y9;>55E_>S/*ZAMOW=SGM]VET?P+
M/I-M<VZ>*-:GB>#[/&DWV=?(_P!J/9$N* /,O'^GW>N^(/%]U8:7=>(!9QI;
MQ:A'<M;OH\Z1!G^SI_RU;YTE^3;N;Y:=\5OB!:>(_"-]HFG:_##!%HG]I7EV
MTZQ33[HM]O;HN[=NE^\W^Q\O\=>C:K\-[?4M4N[RUUC5=)^VC_3;;3YD6*Y;
M&W>P9&*MM 7<A7[M6]8^'/A[6M!GTJ72[:&WDL_L22Q0+YL46S8NUF7Y=J]*
M .=\4Z!X2UC3;;7?$=Q_:]D]M';V-KYN^'<W_/!%^_*_']Y_E^6MOP;X=NF^
M']GI/B9&O998&6XCNF\QMC.=L3O_ !LJE4W?Q;<U6U3X7VU]JUKJ%MK>J:/)
M9VWV6"&Q^S^5$G<JKQ-M9JZ#2=#FTL0>;JU]J(CC:(_:VB_>;FW;VVHOS?PT
M >2GPSI&C77C/Q9X?TRUTR+P[I]U:V4D28$MTD3-+*W][;\L7_?VK.H^'+'X
M>6OA/6]#C>WU6YE\B\G>5G-XK6LLK>;_ 'FWHK?A7IV@^$['P_X?.C1[KFT8
MRF3[0=S2^8[,^_\ O??-86B_"NQT>]LYWU75-3ALHVCL;/4)UEBM0RE/EPN6
M^3*_.6PIH X?3?#]EX=\-^!O%=BLL?B#4;FP^W:A)([277VHJ)5E_O#YO^ [
M%JK::+9V?PWT#QXBNOBRXN+*[FU+S&WR>?<(LJ/_ -,]LA7;[+7H.C_"?3](
MU"R<:GJMY8:?(TMCI=W.CVMJW\.T;-[;=S;=[-MIMK\*-/M[ZW?^T=2?2K>Z
M-Y#HKSK]BCESN'R[-VU6^95W;0>U 'H%%)FC- "T4F:,T +129HS0 M%)FC-
M "T4F:,T +129HS0 M%)FC- &/XF:XC\/ZBUI(L5PL#LCM_"=M<#X/\ [6T>
MRT/3-.CTN&2^LFOYYVBDP<>4N?O?,WS_ *5Z9>6L=[:3V\A.R5&C;'HPQ69I
M_AFRT^XL)HGD+6-G]ACW/GY/D^]_M?(M=$)J,.5G/4IRE+F.$C^(5U9VMK96
M-O:V,S+//(QM9[B(?OY%7:D?S?/L=JUK+QGJVN0Z=;6%K%9:A-')/<M>I*4C
M17V913M9]S<KG;\M:)\ VMLL#65[?:?<PJR>?;R+O=6=GVMN4JWS-5FX\%VU
MQ%9F.[O;2YME8)=Q39E.[[V[=N5MQYY%;2G2Z1,8TZQR6AZ]K-G>3V4%M;?;
M+[6+F*3SI6=(]L2MO7_9_P!FKR^,->BLY[R:#31;V-[]BN5C:0M*WF*FY/[O
MWE^]NK?TOP)8:3<6\\4EPSP7,MT#)+NW/(FUMU2MX1LI+&_M!),(KR[^V2-O
M^;?O1L+_ +/RBE*I2E+X1QIU.4YG5/B!>:;K@C,NG21+=I ]I#YDLZJSA%9Y
M%^5/O;MK#I4VI>-=:MQK%W':6;:=I5WY,@9V\V==B'Y?[K?/6A)\.;28R1_;
M]02T-Q]IBM4G_=Q2;]^Y1MY^;^%MR^U:%UX/L;JQU>U=YO+U.;SY]K_,K;$7
MY?\ OA:.>E_*'+6.4U!F'C"7YF_Y#UMQN_Z<JL6/C/7/[%T_7;NUT]=,D94F
MBC9_-56;;YBG[OWMOR?^/5T<WA&PFU![[=-YK7D=[PWR[UB\I?\ @.VL'PK\
M/S9Z+ID>HRW68 LK:;Y^Z!90V[=^?\.[;[4^>G*/O$>SJ1E[IL^)]:OK"ZT_
M3]*@ADO[TL4>Y)\J-4 W,P7YC]X5F'Q!XD;4+;2!;V$>I,KS274C.T'E(57<
MJ?>W,S?=W?*!U-:^I>%8=4@M$EO;M;NUD:2"\B9%ECW9SCY=NW'R_=JJ?A[9
M@0RQ7MY:ZC&S,VHPN@GEW?>W?+M;^'^'^$5C&4.4UE&IS&3%XWUF=[&Q@L[5
M=1>[FL;@LS>4K1Q;O,3_ &?]GWJ+_A-O$$=G<WDUOIXAT^[^QW2QF0M,VY5W
M1_W?OK][=72:?X'T_36L'B>=I;226;S))=S322+M9Y/[QQ3YO!]C+I]_9&27
MRKZY^UR8?YM^Y6^7_OD57/3_ )2?9UOYCHJ6BBN4[1G:DX7K3OQKD/%WP_C\
M67D%PVL:IIOE1^7LT^X\I6ITTI2]Z1$FXQ]TZW ]:,#UKSC_ (4G!_T-7B3_
M ,#A_P#$T?\ "DX/^AJ\2?\ @</_ (FNGV='_GY^!ASUOY/Q/1\#UHP/6O./
M^%)P?]#5XD_\#A_\31_PI.#_ *&KQ)_X'#_XFCV='_GY^ <];^3\3T? ]:,#
MUKSC_A2<'_0U>)/_  .'_P 31_PI.#_H:O$G_@</_B:/9T?^?GX!SUOY/Q/1
M\#UHP/6O./\ A2<'_0U>)/\ P.'_ ,31_P *3@_Z&KQ)_P"!P_\ B:/9T?\
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MP/6O./\ A2<'_0U>)/\ P.'_ ,31_P *3@_Z&KQ)_P"!P_\ B:/9T?\ GY^
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M>)/_  .'_P 31_PI.#_H:O$G_@</_B:/9T?^?GX!SUOY/Q/1\#UHP/6O./\
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M^!1@>M><?\*3@_Z&KQ)_X'#_ .)H_P"%)P?]#5XD_P# X?\ Q-'LZ/\ S\_
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M6L5VK>:B,NV!MK+_ !;]JU<O[[5_$7CS3K:&^CLY[;Q%J-K!<"W5O*B%DO\
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M_LUZ#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK5.X\;:;#9ZY<*99DT<?Z2L*;F/R;OE_O<4 =)16%)XJL8]0TBR#--+J:-+
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M6-@OE++Y#JL2_(CLS-_N5IZW\.X/$_[1SZ'?6=W_ &.VV)I8E9/E6W^3Y_\
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M,;OL3S7W-\OU_P"^<UOT44 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ** ,*+198]A^WS>;MB#M_>V*RY_X%FJ<?AF_$,*_P!N7.Y;:6!OE'WGZ/\
M[RUU-% &9I]G<6TDOVBX^T(P0KQ\VX+M8UIT44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
'!1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>27
<FILENAME>aatp-20221231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWauPabP9z5Z8iekhvWB8bRkK7y0vD5I0QircCDdmkSYF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:AATP="http://agapeatp.com/20221231" elementFormDefault="qualified" targetNamespace="http://agapeatp.com/20221231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://agapeatp.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" id="StatementsOfOperationsAndComprehensiveIncomeLoss">
	  <link:definition>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity" id="StatementsOfChangesInStockholdersEquity">
	  <link:definition>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/OrganizationAndBusinessBackground" id="OrganizationAndBusinessBackground">
	  <link:definition>00000007 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/VariableInterestEntityVie" id="VariableInterestEntityVie">
	  <link:definition>00000009 - Disclosure - VARIABLE INTEREST ENTITY (&#8220;VIE&#8221;)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/CashAndCashEquivalents" id="CashAndCashEquivalents">
	  <link:definition>00000010 - Disclosure - CASH AND CASH EQUIVALENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/AccountsReceivable" id="AccountsReceivable">
	  <link:definition>00000011 - Disclosure - ACCOUNTS RECEIVABLE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/Inventories" id="Inventories">
	  <link:definition>00000012 - Disclosure - INVENTORIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/PrepaymentsAndDeposits" id="PrepaymentsAndDeposits">
	  <link:definition>00000013 - Disclosure - PREPAYMENTS AND DEPOSITS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
	  <link:definition>00000014 - Disclosure - PROPERTY AND EQUIPMENT, NET</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/IntangibleAssetsNet" id="IntangibleAssetsNet">
	  <link:definition>00000015 - Disclosure - INTANGIBLE ASSETS, NET</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/InvestmentInMarketableSecurities" id="InvestmentInMarketableSecurities">
	  <link:definition>00000016 - Disclosure - INVESTMENT IN MARKETABLE SECURITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/InvestmentInNon-marketableSecurities" id="InvestmentInNon-marketableSecurities">
	  <link:definition>00000017 - Disclosure - INVESTMENT IN NON-MARKETABLE SECURITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/CustomerDeposits" id="CustomerDeposits">
	  <link:definition>00000018 - Disclosure - CUSTOMER DEPOSITS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/OtherPayablesAndAccruedLiabilities" id="OtherPayablesAndAccruedLiabilities">
	  <link:definition>00000019 - Disclosure - OTHER PAYABLES AND ACCRUED LIABILITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/RelatedPartyBalancesAndTransactions" id="RelatedPartyBalancesAndTransactions">
	  <link:definition>00000020 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000021 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/Non-controllingInterest" id="Non-controllingInterest">
	  <link:definition>00000022 - Disclosure - NON-CONTROLLING INTEREST</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000023 - Disclosure - INCOME TAXES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/ConcentrationsOfRisks" id="ConcentrationsOfRisks">
	  <link:definition>00000024 - Disclosure - CONCENTRATIONS OF RISKS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000025 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000026 - Disclosure - SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/OrganizationAndBusinessBackgroundTables" id="OrganizationAndBusinessBackgroundTables">
	  <link:definition>00000028 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/VariableInterestEntityVieTables" id="VariableInterestEntityVieTables">
	  <link:definition>00000030 - Disclosure - VARIABLE INTEREST ENTITY (&#8220;VIE&#8221;) (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/AccountsReceivableTables" id="AccountsReceivableTables">
	  <link:definition>00000031 - Disclosure - ACCOUNTS RECEIVABLE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/InventoriesTables" id="InventoriesTables">
	  <link:definition>00000032 - Disclosure - INVENTORIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/PrepaymentsAndDepositsTables" id="PrepaymentsAndDepositsTables">
	  <link:definition>00000033 - Disclosure - PREPAYMENTS AND DEPOSITS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
	  <link:definition>00000034 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/IntangibleAssetsNetTables" id="IntangibleAssetsNetTables">
	  <link:definition>00000035 - Disclosure - INTANGIBLE ASSETS, NET (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/InvestmentInMarketableSecuritiesTables" id="InvestmentInMarketableSecuritiesTables">
	  <link:definition>00000036 - Disclosure - INVESTMENT IN MARKETABLE SECURITIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesTables" id="InvestmentInNon-marketableSecuritiesTables">
	  <link:definition>00000037 - Disclosure - INVESTMENT IN NON-MARKETABLE SECURITIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/CustomerDepositsTables" id="CustomerDepositsTables">
	  <link:definition>00000038 - Disclosure - CUSTOMER DEPOSITS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesTables" id="OtherPayablesAndAccruedLiabilitiesTables">
	  <link:definition>00000039 - Disclosure - OTHER PAYABLES AND ACCRUED LIABILITIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/RelatedPartyBalancesAndTransactionsTables" id="RelatedPartyBalancesAndTransactionsTables">
	  <link:definition>00000040 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/Non-controllingInterestTables" id="Non-controllingInterestTables">
	  <link:definition>00000041 - Disclosure - NON-CONTROLLING INTEREST (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000042 - Disclosure - INCOME TAXES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000043 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails" id="ScheduleOfSubsidiariesAndAssociatesDetails">
	  <link:definition>00000044 - Disclosure - SCHEDULE OF SUBSIDIARIES AND ASSOCIATES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative" id="OrganizationAndBusinessBackgroundDetailsNarrative">
	  <link:definition>00000045 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" id="ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails">
	  <link:definition>00000046 - Disclosure - SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetDetails" id="ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetDetails">
	  <link:definition>00000047 - Disclosure - SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails" id="ScheduleOfDis-aggregatedInformationOfRevenuesDetails">
	  <link:definition>00000048 - Disclosure - SCHEDULE OF DIS-AGGREGATED INFORMATION OF REVENUES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails" id="ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails">
	  <link:definition>00000049 - Disclosure - SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000050 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails" id="ScheduleOfVariableInterestEntityDetails">
	  <link:definition>00000051 - Disclosure - SCHEDULE OF VARIABLE INTEREST ENTITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/VariableInterestEntityVieDetailsNarrative" id="VariableInterestEntityVieDetailsNarrative">
	  <link:definition>00000052 - Disclosure - VARIABLE INTEREST ENTITY (&#8220;VIE&#8221;) (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative" id="CashAndCashEquivalentsDetailsNarrative">
	  <link:definition>00000053 - Disclosure - CASH AND CASH EQUIVALENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/ScheduleOfAccountsReceivables-RelatedPartyDetails" id="ScheduleOfAccountsReceivables-RelatedPartyDetails">
	  <link:definition>00000054 - Disclosure - SCHEDULE OF ACCOUNTS RECEIVABLES - RELATED PARTY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/ScheduleOfInventoriesDetails" id="ScheduleOfInventoriesDetails">
	  <link:definition>00000055 - Disclosure - SCHEDULE OF INVENTORIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/InventoriesDetailsNarrative" id="InventoriesDetailsNarrative">
	  <link:definition>00000056 - Disclosure - INVENTORIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/ScheduleOfPrepaidExpensesAndDepositsDetails" id="ScheduleOfPrepaidExpensesAndDepositsDetails">
	  <link:definition>00000057 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND DEPOSITS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/ScheduleOfChangesInAllowanceForDoubtfulAccountsDetails" id="ScheduleOfChangesInAllowanceForDoubtfulAccountsDetails">
	  <link:definition>00000058 - Disclosure - SCHEDULE OF CHANGES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails" id="ScheduleOfPropertyAndEquipmentNetDetails">
	  <link:definition>00000059 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/PropertyAndEquipmentNetDetailsNarrative" id="PropertyAndEquipmentNetDetailsNarrative">
	  <link:definition>00000060 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/ScheduleOfIntangibleAssetsNetDetails" id="ScheduleOfIntangibleAssetsNetDetails">
	  <link:definition>00000061 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS, NET (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/IntangibleAssetsNetDetailsNarrative" id="IntangibleAssetsNetDetailsNarrative">
	  <link:definition>00000062 - Disclosure - INTANGIBLE ASSETS, NET (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails" id="ScheduleOfInvestmentInMarketableSecuritiesDetails">
	  <link:definition>00000063 - Disclosure - SCHEDULE OF INVESTMENT IN MARKETABLE SECURITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative" id="InvestmentInMarketableSecuritiesDetailsNarrative">
	  <link:definition>00000064 - Disclosure - INVESTMENT IN MARKETABLE SECURITIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/ScheduleOfInvestmentInNonMarketableSecuritiesDetails" id="ScheduleOfInvestmentInNonMarketableSecuritiesDetails">
	  <link:definition>00000065 - Disclosure - SCHEDULE OF INVESTMENT IN NON MARKETABLE SECURITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative" id="InvestmentInNon-marketableSecuritiesDetailsNarrative">
	  <link:definition>00000066 - Disclosure - INVESTMENT IN NON-MARKETABLE SECURITIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/ScheduleOfCustomerDepositsDetails" id="ScheduleOfCustomerDepositsDetails">
	  <link:definition>00000067 - Disclosure -  SCHEDULE OF CUSTOMER DEPOSITS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails" id="ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails">
	  <link:definition>00000068 - Disclosure - SCHEDULE OF OTHER PAYABLES AND ACCRUED LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesDetailsNarrative" id="OtherPayablesAndAccruedLiabilitiesDetailsNarrative">
	  <link:definition>00000069 - Disclosure - OTHER PAYABLES AND ACCRUED LIABILITIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails" id="ScheduleOfRelatedPartiesDetails">
	  <link:definition>00000070 - Disclosure - SCHEDULE OF RELATED PARTIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000071 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/ScheduleOfNonControllingInterestDetails" id="ScheduleOfNonControllingInterestDetails">
	  <link:definition>00000072 - Disclosure - SCHEDULE OF NON CONTROLLING INTEREST (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails" id="ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails">
	  <link:definition>00000073 - Disclosure - SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAX (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails" id="ScheduleOfProvisionForIncomeTaxDetails">
	  <link:definition>00000074 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAX (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" id="ScheduleOfEffectiveIncomeTaxRateDetails">
	  <link:definition>00000075 - Disclosure - SCHEDULE OF EFFECTIVE INCOME TAX RATE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/ScheduleOfEffectiveIncomeTaxRateDetailsParenthetical" id="ScheduleOfEffectiveIncomeTaxRateDetailsParenthetical">
	  <link:definition>00000076 - Disclosure -  SCHEDULE OF EFFECTIVE INCOME TAX RATE (Details) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/ScheduleOfDeferredTaxAssetsDetails" id="ScheduleOfDeferredTaxAssetsDetails">
	  <link:definition>00000077 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000078 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" id="ConcentrationsOfRisksDetailsNarrative">
	  <link:definition>00000079 - Disclosure - CONCENTRATIONS OF RISKS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/ScheduleOfLeaseCommitmentsDetails" id="ScheduleOfLeaseCommitmentsDetails">
	  <link:definition>00000080 - Disclosure - SCHEDULE OF LEASE COMMITMENTS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000081 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="aatp-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="aatp-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="aatp-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="aatp-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
    <element id="AATP_AgapeATPInternationalHoldingLimitedMember" name="AgapeATPInternationalHoldingLimitedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_ShareExchangeAgreementMember" name="ShareExchangeAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_MrHowKokChoongMember" name="MrHowKokChoongMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_SubsidiaryCompanyTwoMember" name="SubsidiaryCompanyTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_SubsidiaryCompanyFiveMember" name="SubsidiaryCompanyFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_SubsidiaryCompanyMember" name="SubsidiaryCompanyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_SubsidiaryCompanyOneMember" name="SubsidiaryCompanyOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_SubsidiaryCompanyThreeMember" name="SubsidiaryCompanyThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_SubsidiaryCompanyFourMember" name="SubsidiaryCompanyFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_HealthAndWellnessServicesMember" name="HealthAndWellnessServicesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_SocialSecurityOrganizationMember" name="SocialSecurityOrganizationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_EmployeesProvidentFundMember" name="EmployeesProvidentFundMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_EmploymentInsuranceSystemMember" name="EmploymentInsuranceSystemMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_HumanResourceDevelopmentFundMember" name="HumanResourceDevelopmentFundMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_SurvivorSelectMember" name="SurvivorSelectMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_EnergizedMineralConcentrateMember" name="EnergizedMineralConcentrateMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_IonizedCalMagMember" name="IonizedCalMagMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_OmegaBlendMember" name="OmegaBlendMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_BetaMaxxMember" name="BetaMaxxMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_VegeFruitFiberMember" name="VegeFruitFiberMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_IronMember" name="IronMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_YoungFormulaMember" name="YoungFormulaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_OrganicYouthCarCleansingBarMember" name="OrganicYouthCarCleansingBarMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_ATPRMITOPlusMember" name="ATPRMITOPlusMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_LipomaskMember" name="LipomaskMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_EnergetiqueMember" name="EnergetiqueMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_TrimPlusMember" name="TrimPlusMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_ProductHealthTherapiesMember" name="ProductHealthTherapiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_OthersMember" name="OthersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_PeriodEndMYRMember" name="PeriodEndMYRMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_PeriodEndHKDMember" name="PeriodEndHKDMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_PeriodAverageMYRMember" name="PeriodAverageMYRMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_PeriodAverageHKDMember" name="PeriodAverageHKDMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_ComputerAndOfficeEquipmentMember" name="ComputerAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_VehicleMember" name="VehicleMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_GreenproCapitalCorpMember" name="GreenproCapitalCorpMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_DSwissIncMember" name="DSwissIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_SEATechVenturesCorpMember" name="SEATechVenturesCorpMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_PhoenixPlusCorpMember" name="PhoenixPlusCorpMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_TH3TechnologySdnBhdMember" name="TH3TechnologySdnBhdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_DSYBeautySdnBhdMember" name="DSYBeautySdnBhdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_AgapeATPAsiaLimitedMember" name="AgapeATPAsiaLimitedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_HostastaySdnBhdMember" name="HostastaySdnBhdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_CTANutriceuticalsSdnBhdMember" name="CTANutriceuticalsSdnBhdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_CTANutriceuticalsAsiaSdnBhdOneMember" name="CTANutriceuticalsAsiaSdnBhdOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_DSYBeautySdnBhdOneMember" name="DSYBeautySdnBhdOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_HowKokChoongMember" name="HowKokChoongMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_DSYWellnessandLongevityCenterSdnBhdTwoMember" name="DSYWellnessandLongevityCenterSdnBhdTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_HostastaySdnBhdHostastayMember" name="HostastaySdnBhdHostastayMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_CTANutriceuticalsAsiaSdnBhdMember" name="CTANutriceuticalsAsiaSdnBhdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_DSYWellnessAndLongevityCenterSdnBhdMember" name="DSYWellnessAndLongevityCenterSdnBhdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_RedboyPictureSdnBhdMember" name="RedboyPictureSdnBhdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_DSYWellnessAndLongevityCenterSdnBhdThreeMember" name="DSYWellnessAndLongevityCenterSdnBhdThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_ShareForfeitureAgreementsMember" name="ShareForfeitureAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_HowKokChoongTalentLimitedMember" name="HowKokChoongTalentLimitedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_ShareholdersMember" name="ShareholdersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_HKCHoldingsSdnBhdMember" name="HKCHoldingsSdnBhdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_LabuanMember" name="LabuanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_TwoThousandTwentyEightMember" name="TwoThousandTwentyEightMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_TwoThousandTwentyNineMember" name="TwoThousandTwentyNineMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_TwoThousandThirtyMember" name="TwoThousandThirtyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_AATPLBASLSEAAndWATPMember" name="AATPLBASLSEAAndWATPMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_AATPHKMember" name="AATPHKMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_AATPLBASLSEAWATPAndDSYMember" name="AATPLBASLSEAWATPAndDSYMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_NoCustomerMember" name="NoCustomerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_FiveIndividualCustomersMember" name="FiveIndividualCustomersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_VendorOneMember" name="VendorOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_VendorTwoMember" name="VendorTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_VendorThreeMember" name="VendorThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_VendorMember" name="VendorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_OneVendorMember" name="OneVendorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_OneSalesDistributorMember" name="OneSalesDistributorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_AgapeSuperiorLivingMember" name="AgapeSuperiorLivingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_TrainingCenterMember" name="TrainingCenterMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_InvestmentInNonMarketableSecuritiesNoncurrent" name="InvestmentInNonMarketableSecuritiesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_VariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents" name="VariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_VariableInterestEntityConsolidatedAmountOfPrepaidTaxes" name="VariableInterestEntityConsolidatedAmountOfPrepaidTaxes" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_VariableInterestEntityConsolidatedAmountOfOtherPayablesAndAccruedLiabilities" name="VariableInterestEntityConsolidatedAmountOfOtherPayablesAndAccruedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_PreferredStockDividendIncomeStatementImpact" name="PreferredStockDividendIncomeStatementImpact" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_ContributionsFromNoncontrollingInterestShareholders" name="ContributionsFromNoncontrollingInterestShareholders" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_ChangesInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseModifications" name="ChangesInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseModifications" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_DisclosurePrepaymentsAndDepositsAbstract" name="DisclosurePrepaymentsAndDepositsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_PrepaymentsAndDepositsTextBlock" name="PrepaymentsAndDepositsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_DisclosureInvestmentInMarketableSecuritiesAbstract" name="DisclosureInvestmentInMarketableSecuritiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_InvestmentInMarketableSecuritiesTextBlock" name="InvestmentInMarketableSecuritiesTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_DisclosureInvestmentInNonmarketableSecuritiesAbstract" name="DisclosureInvestmentInNonmarketableSecuritiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_InvestmentInNonMarketableSecuritiesTextBlock" name="InvestmentInNonMarketableSecuritiesTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_DisclosureCustomerDepositsAbstract" name="DisclosureCustomerDepositsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_CustomerDepositsTextBlock" name="CustomerDepositsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_PrepaidTaxesPolicyTextBlock" name="PrepaidTaxesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_PrepaymentsAndDepositsPolicyTextBlock" name="PrepaymentsAndDepositsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_NonMarketableSecuritiesPolicyTextBlock" name="NonMarketableSecuritiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_ShippingAndHandlingPolicyTextBlock" name="ShippingAndHandlingPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_DefinedContributionPlanPolicyTextBlock" name="DefinedContributionPlanPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_NoncontrollingInterestPolicyTextBlock" name="NoncontrollingInterestPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_RelatedPartiesPolicyTextBlock" name="RelatedPartiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" name="ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock" name="ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_NonMarketableSecuritiesTableTextBlock" name="NonMarketableSecuritiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_CustomerDepositsTableTextBlock" name="CustomerDepositsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock" name="ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_ScheduleOfNonControllingInterestTableTextBlock" name="ScheduleOfNonControllingInterestTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_NameOftheCompany" name="NameOftheCompany" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_PlaceAndDateOfIncorporation" name="PlaceAndDateOfIncorporation" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_ParticularsOfIssuedCapital" name="ParticularsOfIssuedCapital" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_PrincipalActivities" name="PrincipalActivities" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_ForeignCurrencyExchangeRateAverage" name="ForeignCurrencyExchangeRateAverage" nillable="true" xbrli:periodType="duration" type="xbrli:pureItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_InventriesWriteDown" name="InventriesWriteDown" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_InventoryWriteOff" name="InventoryWriteOff" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_AllowanceForDoubtfulAccountsReceivablesCurrent" name="AllowanceForDoubtfulAccountsReceivablesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_ForfeitedCouponIncome" name="ForfeitedCouponIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_SalaryPercentage" name="SalaryPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_MonthlySalary" name="MonthlySalary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_OtherPayablesRelatedPartyCurrent" name="OtherPayablesRelatedPartyCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_ReceivablesFromSalesDistributors" name="ReceivablesFromSalesDistributors" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_DepositsToSupplier" name="DepositsToSupplier" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_PrepaidExpensesGross" name="PrepaidExpensesGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_AllowanceForDoubtfulAccountsReceivableExchangeRateEffect" name="AllowanceForDoubtfulAccountsReceivableExchangeRateEffect" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_TransferFromNonmarketableSecurity" name="TransferFromNonmarketableSecurity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_InvestmentsIncomeDividend" name="InvestmentsIncomeDividend" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_MarketableSecuritiesUnrealizedHoldingLoss" name="MarketableSecuritiesUnrealizedHoldingLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_ExchangeRateEffectOnInvestmentInMarketableSecurites" name="ExchangeRateEffectOnInvestmentInMarketableSecurites" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_TransferToInvestmentInMarketableSecurities" name="TransferToInvestmentInMarketableSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_CustomerDeposits" name="CustomerDeposits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_UnexpiredProductCoupons" name="UnexpiredProductCoupons" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_AccruedPromotionExpensesCurrent" name="AccruedPromotionExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_AccruedTaxPenaltyCurrent" name="AccruedTaxPenaltyCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_OtherAccountPayableAndAccruedLiabilities" name="OtherAccountPayableAndAccruedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_CommissionPaymentsDescriptions" name="CommissionPaymentsDescriptions" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_RelatedPartiesRelationshipsDescription" name="RelatedPartiesRelationshipsDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_RelatedPartiesNatureDescription" name="RelatedPartiesNatureDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_RelatedPartyOtherIncome" name="RelatedPartyOtherIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_RelatedPartyTransactionOtherPurchasesFromRelatedParty" name="RelatedPartyTransactionOtherPurchasesFromRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_RelatedPartyOtherExpenses" name="RelatedPartyOtherExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_ReductionInCommonStockOutstanding" name="ReductionInCommonStockOutstanding" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_NonControllingInterestPaidinCapital" name="NonControllingInterestPaidinCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_NonControllingInterestAccumulatedDeficit" name="NonControllingInterestAccumulatedDeficit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_NonControllingInterestAccumulatedOtherComprehensiveIncome" name="NonControllingInterestAccumulatedOtherComprehensiveIncome" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_NonControllingInterestNonControllingInterestGross" name="NonControllingInterestNonControllingInterestGross" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_NonControllingInterestAsl" name="NonControllingInterestAsl" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_DeferredTaxLiabilitiesDepreciation" name="DeferredTaxLiabilitiesDepreciation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_TaxRateDescription" name="TaxRateDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_DeferredTaxAssetsOperatingLossCarryforwardsReducedAmount" name="DeferredTaxAssetsOperatingLossCarryforwardsReducedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_DividendShareForCommonStock" name="DividendShareForCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_DepositForInsurance" name="DepositForInsurance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_LesseeOperatingLeaseLiabilityPaymentsDueAfterNextTwelveMonths" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterNextTwelveMonths" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_LeaseExpirationTerm" name="LeaseExpirationTerm" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_IncreaseDecreaseInROUAssetsAndLiabilities" name="IncreaseDecreaseInROUAssetsAndLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AATP_AATPUSMember" name="AATPUSMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>28
<FILENAME>aatp-20221231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://agapeatp.com/role/Cover" xlink:href="aatp-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/BalanceSheets" xlink:href="aatp-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/BalanceSheetsParenthetical" xlink:href="aatp-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:href="aatp-20221231.xsd#StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="aatp-20221231.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/StatementsOfCashFlows" xlink:href="aatp-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/OrganizationAndBusinessBackground" xlink:href="aatp-20221231.xsd#OrganizationAndBusinessBackground" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="aatp-20221231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/VariableInterestEntityVie" xlink:href="aatp-20221231.xsd#VariableInterestEntityVie" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/CashAndCashEquivalents" xlink:href="aatp-20221231.xsd#CashAndCashEquivalents" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/AccountsReceivable" xlink:href="aatp-20221231.xsd#AccountsReceivable" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/Inventories" xlink:href="aatp-20221231.xsd#Inventories" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/PrepaymentsAndDeposits" xlink:href="aatp-20221231.xsd#PrepaymentsAndDeposits" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/PropertyAndEquipmentNet" xlink:href="aatp-20221231.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/IntangibleAssetsNet" xlink:href="aatp-20221231.xsd#IntangibleAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/InvestmentInMarketableSecurities" xlink:href="aatp-20221231.xsd#InvestmentInMarketableSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/InvestmentInNon-marketableSecurities" xlink:href="aatp-20221231.xsd#InvestmentInNon-marketableSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/CustomerDeposits" xlink:href="aatp-20221231.xsd#CustomerDeposits" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/OtherPayablesAndAccruedLiabilities" xlink:href="aatp-20221231.xsd#OtherPayablesAndAccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/RelatedPartyBalancesAndTransactions" xlink:href="aatp-20221231.xsd#RelatedPartyBalancesAndTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/StockholdersEquity" xlink:href="aatp-20221231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/Non-controllingInterest" xlink:href="aatp-20221231.xsd#Non-controllingInterest" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/IncomeTaxes" xlink:href="aatp-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ConcentrationsOfRisks" xlink:href="aatp-20221231.xsd#ConcentrationsOfRisks" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/CommitmentsAndContingencies" xlink:href="aatp-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/SubsequentEvents" xlink:href="aatp-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="aatp-20221231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/OrganizationAndBusinessBackgroundTables" xlink:href="aatp-20221231.xsd#OrganizationAndBusinessBackgroundTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="aatp-20221231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/VariableInterestEntityVieTables" xlink:href="aatp-20221231.xsd#VariableInterestEntityVieTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/AccountsReceivableTables" xlink:href="aatp-20221231.xsd#AccountsReceivableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/InventoriesTables" xlink:href="aatp-20221231.xsd#InventoriesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/PrepaymentsAndDepositsTables" xlink:href="aatp-20221231.xsd#PrepaymentsAndDepositsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/PropertyAndEquipmentNetTables" xlink:href="aatp-20221231.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/IntangibleAssetsNetTables" xlink:href="aatp-20221231.xsd#IntangibleAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/InvestmentInMarketableSecuritiesTables" xlink:href="aatp-20221231.xsd#InvestmentInMarketableSecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesTables" xlink:href="aatp-20221231.xsd#InvestmentInNon-marketableSecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/CustomerDepositsTables" xlink:href="aatp-20221231.xsd#CustomerDepositsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesTables" xlink:href="aatp-20221231.xsd#OtherPayablesAndAccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/RelatedPartyBalancesAndTransactionsTables" xlink:href="aatp-20221231.xsd#RelatedPartyBalancesAndTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/Non-controllingInterestTables" xlink:href="aatp-20221231.xsd#Non-controllingInterestTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/IncomeTaxesTables" xlink:href="aatp-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/CommitmentsAndContingenciesTables" xlink:href="aatp-20221231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails" xlink:href="aatp-20221231.xsd#ScheduleOfSubsidiariesAndAssociatesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative" xlink:href="aatp-20221231.xsd#OrganizationAndBusinessBackgroundDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:href="aatp-20221231.xsd#ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetDetails" xlink:href="aatp-20221231.xsd#ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails" xlink:href="aatp-20221231.xsd#ScheduleOfDis-aggregatedInformationOfRevenuesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails" xlink:href="aatp-20221231.xsd#ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="aatp-20221231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails" xlink:href="aatp-20221231.xsd#ScheduleOfVariableInterestEntityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/VariableInterestEntityVieDetailsNarrative" xlink:href="aatp-20221231.xsd#VariableInterestEntityVieDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative" xlink:href="aatp-20221231.xsd#CashAndCashEquivalentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfAccountsReceivables-RelatedPartyDetails" xlink:href="aatp-20221231.xsd#ScheduleOfAccountsReceivables-RelatedPartyDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfInventoriesDetails" xlink:href="aatp-20221231.xsd#ScheduleOfInventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/InventoriesDetailsNarrative" xlink:href="aatp-20221231.xsd#InventoriesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfPrepaidExpensesAndDepositsDetails" xlink:href="aatp-20221231.xsd#ScheduleOfPrepaidExpensesAndDepositsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfChangesInAllowanceForDoubtfulAccountsDetails" xlink:href="aatp-20221231.xsd#ScheduleOfChangesInAllowanceForDoubtfulAccountsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails" xlink:href="aatp-20221231.xsd#ScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="aatp-20221231.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfIntangibleAssetsNetDetails" xlink:href="aatp-20221231.xsd#ScheduleOfIntangibleAssetsNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/IntangibleAssetsNetDetailsNarrative" xlink:href="aatp-20221231.xsd#IntangibleAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails" xlink:href="aatp-20221231.xsd#ScheduleOfInvestmentInMarketableSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative" xlink:href="aatp-20221231.xsd#InvestmentInMarketableSecuritiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfInvestmentInNonMarketableSecuritiesDetails" xlink:href="aatp-20221231.xsd#ScheduleOfInvestmentInNonMarketableSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative" xlink:href="aatp-20221231.xsd#InvestmentInNon-marketableSecuritiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfCustomerDepositsDetails" xlink:href="aatp-20221231.xsd#ScheduleOfCustomerDepositsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails" xlink:href="aatp-20221231.xsd#ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesDetailsNarrative" xlink:href="aatp-20221231.xsd#OtherPayablesAndAccruedLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails" xlink:href="aatp-20221231.xsd#ScheduleOfRelatedPartiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/StockholdersEquityDetailsNarrative" xlink:href="aatp-20221231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfNonControllingInterestDetails" xlink:href="aatp-20221231.xsd#ScheduleOfNonControllingInterestDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails" xlink:href="aatp-20221231.xsd#ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails" xlink:href="aatp-20221231.xsd#ScheduleOfProvisionForIncomeTaxDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:href="aatp-20221231.xsd#ScheduleOfEffectiveIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfEffectiveIncomeTaxRateDetailsParenthetical" xlink:href="aatp-20221231.xsd#ScheduleOfEffectiveIncomeTaxRateDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:href="aatp-20221231.xsd#ScheduleOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/IncomeTaxesDetailsNarrative" xlink:href="aatp-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" xlink:href="aatp-20221231.xsd#ConcentrationsOfRisksDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfLeaseCommitmentsDetails" xlink:href="aatp-20221231.xsd#ScheduleOfLeaseCommitmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="aatp-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaapDueFromRelatedPartiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDueFromRelatedPartiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaapPrepaidTaxes" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="loc_us-gaapMarketableSecuritiesNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapMarketableSecuritiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_InvestmentInNonMarketableSecuritiesNoncurrent" xlink:label="loc_AATPInvestmentInNonMarketableSecuritiesNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_AATPInvestmentInNonMarketableSecuritiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapDeferredCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableTradeCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaapAccountsPayableOtherCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableOtherCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaapTaxesPayableCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapTaxesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilitiesNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilitiesNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingExpense" xlink:label="loc_us-gaapSellingExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="loc_us-gaapSalesCommissionsAndFees" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSalesCommissionsAndFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PreferredStockDividendIncomeStatementImpact" xlink:label="loc_AATPPreferredStockDividendIncomeStatementImpact" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_AATPPreferredStockDividendIncomeStatementImpact" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="loc_us-gaapCostOfGoodsAndServicesSoldAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapCostOfGoodsAndServicesSoldAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PreferredStockDividendIncomeStatementImpact" xlink:label="loc_AATPPreferredStockDividendIncomeStatementImpact" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_AATPPreferredStockDividendIncomeStatementImpact" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaapInventoryWriteDown" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapInventoryWriteDown" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent" xlink:label="loc_us-gaapIncreaseDecreaseInDueFromOtherRelatedPartiesCurrent" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDueFromOtherRelatedPartiesCurrent" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidTaxes" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidTaxes" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableRelatedParties" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent" xlink:label="loc_us-gaapIncreaseDecreaseInDueToOtherRelatedPartiesCurrent" />
      <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDueToOtherRelatedPartiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedIncomeTaxesPayable" />
      <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquireMachineryAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireMachineryAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/OrganizationAndBusinessBackground" xlink:title="00000007 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/VariableInterestEntityVie" xlink:title="00000009 - Disclosure - VARIABLE INTEREST ENTITY (&#8220;VIE&#8221;)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/CashAndCashEquivalents" xlink:title="00000010 - Disclosure - CASH AND CASH EQUIVALENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/AccountsReceivable" xlink:title="00000011 - Disclosure - ACCOUNTS RECEIVABLE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/Inventories" xlink:title="00000012 - Disclosure - INVENTORIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/PrepaymentsAndDeposits" xlink:title="00000013 - Disclosure - PREPAYMENTS AND DEPOSITS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/PropertyAndEquipmentNet" xlink:title="00000014 - Disclosure - PROPERTY AND EQUIPMENT, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/IntangibleAssetsNet" xlink:title="00000015 - Disclosure - INTANGIBLE ASSETS, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/InvestmentInMarketableSecurities" xlink:title="00000016 - Disclosure - INVESTMENT IN MARKETABLE SECURITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/InvestmentInNon-marketableSecurities" xlink:title="00000017 - Disclosure - INVESTMENT IN NON-MARKETABLE SECURITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/CustomerDeposits" xlink:title="00000018 - Disclosure - CUSTOMER DEPOSITS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/OtherPayablesAndAccruedLiabilities" xlink:title="00000019 - Disclosure - OTHER PAYABLES AND ACCRUED LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/RelatedPartyBalancesAndTransactions" xlink:title="00000020 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/StockholdersEquity" xlink:title="00000021 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/Non-controllingInterest" xlink:title="00000022 - Disclosure - NON-CONTROLLING INTEREST" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/IncomeTaxes" xlink:title="00000023 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ConcentrationsOfRisks" xlink:title="00000024 - Disclosure - CONCENTRATIONS OF RISKS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/CommitmentsAndContingencies" xlink:title="00000025 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/SubsequentEvents" xlink:title="00000026 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/OrganizationAndBusinessBackgroundTables" xlink:title="00000028 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/VariableInterestEntityVieTables" xlink:title="00000030 - Disclosure - VARIABLE INTEREST ENTITY (&#8220;VIE&#8221;) (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/AccountsReceivableTables" xlink:title="00000031 - Disclosure - ACCOUNTS RECEIVABLE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/InventoriesTables" xlink:title="00000032 - Disclosure - INVENTORIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/PrepaymentsAndDepositsTables" xlink:title="00000033 - Disclosure - PREPAYMENTS AND DEPOSITS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/PropertyAndEquipmentNetTables" xlink:title="00000034 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/IntangibleAssetsNetTables" xlink:title="00000035 - Disclosure - INTANGIBLE ASSETS, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/InvestmentInMarketableSecuritiesTables" xlink:title="00000036 - Disclosure - INVESTMENT IN MARKETABLE SECURITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesTables" xlink:title="00000037 - Disclosure - INVESTMENT IN NON-MARKETABLE SECURITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/CustomerDepositsTables" xlink:title="00000038 - Disclosure - CUSTOMER DEPOSITS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesTables" xlink:title="00000039 - Disclosure - OTHER PAYABLES AND ACCRUED LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/RelatedPartyBalancesAndTransactionsTables" xlink:title="00000040 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/Non-controllingInterestTables" xlink:title="00000041 - Disclosure - NON-CONTROLLING INTEREST (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/IncomeTaxesTables" xlink:title="00000042 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/CommitmentsAndContingenciesTables" xlink:title="00000043 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails" xlink:title="00000044 - Disclosure - SCHEDULE OF SUBSIDIARIES AND ASSOCIATES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative" xlink:title="00000045 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:title="00000046 - Disclosure - SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetDetails" xlink:title="00000047 - Disclosure - SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails" xlink:title="00000048 - Disclosure - SCHEDULE OF DIS-AGGREGATED INFORMATION OF REVENUES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails" xlink:title="00000049 - Disclosure - SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000050 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails" xlink:title="00000051 - Disclosure - SCHEDULE OF VARIABLE INTEREST ENTITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/VariableInterestEntityVieDetailsNarrative" xlink:title="00000052 - Disclosure - VARIABLE INTEREST ENTITY (&#8220;VIE&#8221;) (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative" xlink:title="00000053 - Disclosure - CASH AND CASH EQUIVALENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfAccountsReceivables-RelatedPartyDetails" xlink:title="00000054 - Disclosure - SCHEDULE OF ACCOUNTS RECEIVABLES - RELATED PARTY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaapAccountsReceivableGrossCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsReceivableNetCurrent" xlink:to="loc_us-gaapAccountsReceivableGrossCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsReceivableNetCurrent" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfInventoriesDetails" xlink:title="00000055 - Disclosure - SCHEDULE OF INVENTORIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/InventoriesDetailsNarrative" xlink:title="00000056 - Disclosure - INVENTORIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfPrepaidExpensesAndDepositsDetails" xlink:title="00000057 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND DEPOSITS (Details)">
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PrepaidExpensesGross" xlink:label="loc_AATPPrepaidExpensesGross" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ReceivablesFromSalesDistributors" xlink:label="loc_AATPReceivablesFromSalesDistributors" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AATPPrepaidExpensesGross" xlink:to="loc_AATPReceivablesFromSalesDistributors" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DepositsToSupplier" xlink:label="loc_AATPDepositsToSupplier" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AATPPrepaidExpensesGross" xlink:to="loc_AATPDepositsToSupplier" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_AATPPrepaidExpensesGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfChangesInAllowanceForDoubtfulAccountsDetails" xlink:title="00000058 - Disclosure - SCHEDULE OF CHANGES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails" xlink:title="00000059 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="00000060 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfIntangibleAssetsNetDetails" xlink:title="00000061 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="loc_us-gaapCapitalizedComputerSoftwareGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapCapitalizedComputerSoftwareGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/IntangibleAssetsNetDetailsNarrative" xlink:title="00000062 - Disclosure - INTANGIBLE ASSETS, NET (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails" xlink:title="00000063 - Disclosure - SCHEDULE OF INVESTMENT IN MARKETABLE SECURITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="loc_us-gaapMarketableSecuritiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtCost" xlink:label="loc_us-gaapInvestmentOwnedAtCost" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapMarketableSecuritiesNoncurrent" xlink:to="loc_us-gaapInvestmentOwnedAtCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_TransferFromNonmarketableSecurity" xlink:label="loc_AATPTransferFromNonmarketableSecurity" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapMarketableSecuritiesNoncurrent" xlink:to="loc_AATPTransferFromNonmarketableSecurity" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_InvestmentsIncomeDividend" xlink:label="loc_AATPInvestmentsIncomeDividend" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapMarketableSecuritiesNoncurrent" xlink:to="loc_AATPInvestmentsIncomeDividend" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_MarketableSecuritiesUnrealizedHoldingLoss" xlink:label="loc_AATPMarketableSecuritiesUnrealizedHoldingLoss" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapMarketableSecuritiesNoncurrent" xlink:to="loc_AATPMarketableSecuritiesUnrealizedHoldingLoss" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ExchangeRateEffectOnInvestmentInMarketableSecurites" xlink:label="loc_AATPExchangeRateEffectOnInvestmentInMarketableSecurites" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapMarketableSecuritiesNoncurrent" xlink:to="loc_AATPExchangeRateEffectOnInvestmentInMarketableSecurites" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative" xlink:title="00000064 - Disclosure - INVESTMENT IN MARKETABLE SECURITIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfInvestmentInNonMarketableSecuritiesDetails" xlink:title="00000065 - Disclosure - SCHEDULE OF INVESTMENT IN NON MARKETABLE SECURITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_InvestmentInNonMarketableSecuritiesNoncurrent" xlink:label="loc_AATPInvestmentInNonMarketableSecuritiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtCost" xlink:label="loc_us-gaapInvestmentOwnedAtCost" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AATPInvestmentInNonMarketableSecuritiesNoncurrent" xlink:to="loc_us-gaapInvestmentOwnedAtCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_TransferToInvestmentInMarketableSecurities" xlink:label="loc_AATPTransferToInvestmentInMarketableSecurities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AATPInvestmentInNonMarketableSecuritiesNoncurrent" xlink:to="loc_AATPTransferToInvestmentInMarketableSecurities" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative" xlink:title="00000066 - Disclosure - INVESTMENT IN NON-MARKETABLE SECURITIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfCustomerDepositsDetails" xlink:title="00000067 - Disclosure -  SCHEDULE OF CUSTOMER DEPOSITS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails" xlink:title="00000068 - Disclosure - SCHEDULE OF OTHER PAYABLES AND ACCRUED LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_OtherAccountPayableAndAccruedLiabilities" xlink:label="loc_AATPOtherAccountPayableAndAccruedLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AATPOtherAccountPayableAndAccruedLiabilities" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_AccruedPromotionExpensesCurrent" xlink:label="loc_AATPAccruedPromotionExpensesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AATPOtherAccountPayableAndAccruedLiabilities" xlink:to="loc_AATPAccruedPromotionExpensesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="loc_us-gaapAccruedPayrollTaxesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AATPOtherAccountPayableAndAccruedLiabilities" xlink:to="loc_us-gaapAccruedPayrollTaxesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalesCommissionCurrent" xlink:label="loc_us-gaapAccruedSalesCommissionCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AATPOtherAccountPayableAndAccruedLiabilities" xlink:to="loc_us-gaapAccruedSalesCommissionCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_AccruedTaxPenaltyCurrent" xlink:label="loc_AATPAccruedTaxPenaltyCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AATPOtherAccountPayableAndAccruedLiabilities" xlink:to="loc_AATPAccruedTaxPenaltyCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AATPOtherAccountPayableAndAccruedLiabilities" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesDetailsNarrative" xlink:title="00000069 - Disclosure - OTHER PAYABLES AND ACCRUED LIABILITIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails" xlink:title="00000070 - Disclosure - SCHEDULE OF RELATED PARTIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000071 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfNonControllingInterestDetails" xlink:title="00000072 - Disclosure - SCHEDULE OF NON CONTROLLING INTEREST (Details)">
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_NonControllingInterestNonControllingInterestGross" xlink:label="loc_AATPNonControllingInterestNonControllingInterestGross" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_NonControllingInterestPaidinCapital" xlink:label="loc_AATPNonControllingInterestPaidinCapital" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AATPNonControllingInterestNonControllingInterestGross" xlink:to="loc_AATPNonControllingInterestPaidinCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_NonControllingInterestAccumulatedDeficit" xlink:label="loc_AATPNonControllingInterestAccumulatedDeficit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AATPNonControllingInterestNonControllingInterestGross" xlink:to="loc_AATPNonControllingInterestAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_NonControllingInterestAccumulatedOtherComprehensiveIncome" xlink:label="loc_AATPNonControllingInterestAccumulatedOtherComprehensiveIncome" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AATPNonControllingInterestNonControllingInterestGross" xlink:to="loc_AATPNonControllingInterestAccumulatedOtherComprehensiveIncome" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails" xlink:title="00000073 - Disclosure - SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAX (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails" xlink:title="00000074 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAX (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentForeignTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentForeignTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:title="00000075 - Disclosure - SCHEDULE OF EFFECTIVE INCOME TAX RATE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfEffectiveIncomeTaxRateDetailsParenthetical" xlink:title="00000076 - Disclosure -  SCHEDULE OF EFFECTIVE INCOME TAX RATE (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:title="00000077 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000078 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" xlink:title="00000079 - Disclosure - CONCENTRATIONS OF RISKS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfLeaseCommitmentsDetails" xlink:title="00000080 - Disclosure - SCHEDULE OF LEASE COMMITMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_LesseeOperatingLeaseLiabilityPaymentsDueAfterNextTwelveMonths" xlink:label="loc_AATPLesseeOperatingLeaseLiabilityPaymentsDueAfterNextTwelveMonths" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_AATPLesseeOperatingLeaseLiabilityPaymentsDueAfterNextTwelveMonths" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000081 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>29
<FILENAME>aatp-20221231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://agapeatp.com/role/Cover" xlink:href="aatp-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/BalanceSheets" xlink:href="aatp-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/BalanceSheetsParenthetical" xlink:href="aatp-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:href="aatp-20221231.xsd#StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="aatp-20221231.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/StatementsOfCashFlows" xlink:href="aatp-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/OrganizationAndBusinessBackground" xlink:href="aatp-20221231.xsd#OrganizationAndBusinessBackground" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="aatp-20221231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/VariableInterestEntityVie" xlink:href="aatp-20221231.xsd#VariableInterestEntityVie" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/CashAndCashEquivalents" xlink:href="aatp-20221231.xsd#CashAndCashEquivalents" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/AccountsReceivable" xlink:href="aatp-20221231.xsd#AccountsReceivable" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/Inventories" xlink:href="aatp-20221231.xsd#Inventories" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/PrepaymentsAndDeposits" xlink:href="aatp-20221231.xsd#PrepaymentsAndDeposits" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/PropertyAndEquipmentNet" xlink:href="aatp-20221231.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/IntangibleAssetsNet" xlink:href="aatp-20221231.xsd#IntangibleAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/InvestmentInMarketableSecurities" xlink:href="aatp-20221231.xsd#InvestmentInMarketableSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/InvestmentInNon-marketableSecurities" xlink:href="aatp-20221231.xsd#InvestmentInNon-marketableSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/CustomerDeposits" xlink:href="aatp-20221231.xsd#CustomerDeposits" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/OtherPayablesAndAccruedLiabilities" xlink:href="aatp-20221231.xsd#OtherPayablesAndAccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/RelatedPartyBalancesAndTransactions" xlink:href="aatp-20221231.xsd#RelatedPartyBalancesAndTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/StockholdersEquity" xlink:href="aatp-20221231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/Non-controllingInterest" xlink:href="aatp-20221231.xsd#Non-controllingInterest" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/IncomeTaxes" xlink:href="aatp-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ConcentrationsOfRisks" xlink:href="aatp-20221231.xsd#ConcentrationsOfRisks" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/CommitmentsAndContingencies" xlink:href="aatp-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/SubsequentEvents" xlink:href="aatp-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="aatp-20221231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/OrganizationAndBusinessBackgroundTables" xlink:href="aatp-20221231.xsd#OrganizationAndBusinessBackgroundTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="aatp-20221231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/VariableInterestEntityVieTables" xlink:href="aatp-20221231.xsd#VariableInterestEntityVieTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/AccountsReceivableTables" xlink:href="aatp-20221231.xsd#AccountsReceivableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/InventoriesTables" xlink:href="aatp-20221231.xsd#InventoriesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/PrepaymentsAndDepositsTables" xlink:href="aatp-20221231.xsd#PrepaymentsAndDepositsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/PropertyAndEquipmentNetTables" xlink:href="aatp-20221231.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/IntangibleAssetsNetTables" xlink:href="aatp-20221231.xsd#IntangibleAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/InvestmentInMarketableSecuritiesTables" xlink:href="aatp-20221231.xsd#InvestmentInMarketableSecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesTables" xlink:href="aatp-20221231.xsd#InvestmentInNon-marketableSecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/CustomerDepositsTables" xlink:href="aatp-20221231.xsd#CustomerDepositsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesTables" xlink:href="aatp-20221231.xsd#OtherPayablesAndAccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/RelatedPartyBalancesAndTransactionsTables" xlink:href="aatp-20221231.xsd#RelatedPartyBalancesAndTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/Non-controllingInterestTables" xlink:href="aatp-20221231.xsd#Non-controllingInterestTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/IncomeTaxesTables" xlink:href="aatp-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/CommitmentsAndContingenciesTables" xlink:href="aatp-20221231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails" xlink:href="aatp-20221231.xsd#ScheduleOfSubsidiariesAndAssociatesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative" xlink:href="aatp-20221231.xsd#OrganizationAndBusinessBackgroundDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:href="aatp-20221231.xsd#ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetDetails" xlink:href="aatp-20221231.xsd#ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails" xlink:href="aatp-20221231.xsd#ScheduleOfDis-aggregatedInformationOfRevenuesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails" xlink:href="aatp-20221231.xsd#ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="aatp-20221231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails" xlink:href="aatp-20221231.xsd#ScheduleOfVariableInterestEntityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/VariableInterestEntityVieDetailsNarrative" xlink:href="aatp-20221231.xsd#VariableInterestEntityVieDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative" xlink:href="aatp-20221231.xsd#CashAndCashEquivalentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfAccountsReceivables-RelatedPartyDetails" xlink:href="aatp-20221231.xsd#ScheduleOfAccountsReceivables-RelatedPartyDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfInventoriesDetails" xlink:href="aatp-20221231.xsd#ScheduleOfInventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/InventoriesDetailsNarrative" xlink:href="aatp-20221231.xsd#InventoriesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfPrepaidExpensesAndDepositsDetails" xlink:href="aatp-20221231.xsd#ScheduleOfPrepaidExpensesAndDepositsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfChangesInAllowanceForDoubtfulAccountsDetails" xlink:href="aatp-20221231.xsd#ScheduleOfChangesInAllowanceForDoubtfulAccountsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails" xlink:href="aatp-20221231.xsd#ScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="aatp-20221231.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfIntangibleAssetsNetDetails" xlink:href="aatp-20221231.xsd#ScheduleOfIntangibleAssetsNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/IntangibleAssetsNetDetailsNarrative" xlink:href="aatp-20221231.xsd#IntangibleAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails" xlink:href="aatp-20221231.xsd#ScheduleOfInvestmentInMarketableSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative" xlink:href="aatp-20221231.xsd#InvestmentInMarketableSecuritiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfInvestmentInNonMarketableSecuritiesDetails" xlink:href="aatp-20221231.xsd#ScheduleOfInvestmentInNonMarketableSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative" xlink:href="aatp-20221231.xsd#InvestmentInNon-marketableSecuritiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfCustomerDepositsDetails" xlink:href="aatp-20221231.xsd#ScheduleOfCustomerDepositsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails" xlink:href="aatp-20221231.xsd#ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesDetailsNarrative" xlink:href="aatp-20221231.xsd#OtherPayablesAndAccruedLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails" xlink:href="aatp-20221231.xsd#ScheduleOfRelatedPartiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/StockholdersEquityDetailsNarrative" xlink:href="aatp-20221231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfNonControllingInterestDetails" xlink:href="aatp-20221231.xsd#ScheduleOfNonControllingInterestDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails" xlink:href="aatp-20221231.xsd#ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails" xlink:href="aatp-20221231.xsd#ScheduleOfProvisionForIncomeTaxDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:href="aatp-20221231.xsd#ScheduleOfEffectiveIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfEffectiveIncomeTaxRateDetailsParenthetical" xlink:href="aatp-20221231.xsd#ScheduleOfEffectiveIncomeTaxRateDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:href="aatp-20221231.xsd#ScheduleOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/IncomeTaxesDetailsNarrative" xlink:href="aatp-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" xlink:href="aatp-20221231.xsd#ConcentrationsOfRisksDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfLeaseCommitmentsDetails" xlink:href="aatp-20221231.xsd#ScheduleOfLeaseCommitmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="aatp-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapNoncontrollingInterestMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationForfeited_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationForfeited_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ContributionsFromNoncontrollingInterestShareholders" xlink:label="loc_AATPContributionsFromNoncontrollingInterestShareholders_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AATPContributionsFromNoncontrollingInterestShareholders_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_70" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/OrganizationAndBusinessBackground" xlink:title="00000007 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/VariableInterestEntityVie" xlink:title="00000009 - Disclosure - VARIABLE INTEREST ENTITY (&#8220;VIE&#8221;)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/CashAndCashEquivalents" xlink:title="00000010 - Disclosure - CASH AND CASH EQUIVALENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/AccountsReceivable" xlink:title="00000011 - Disclosure - ACCOUNTS RECEIVABLE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/Inventories" xlink:title="00000012 - Disclosure - INVENTORIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/PrepaymentsAndDeposits" xlink:title="00000013 - Disclosure - PREPAYMENTS AND DEPOSITS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/PropertyAndEquipmentNet" xlink:title="00000014 - Disclosure - PROPERTY AND EQUIPMENT, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/IntangibleAssetsNet" xlink:title="00000015 - Disclosure - INTANGIBLE ASSETS, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/InvestmentInMarketableSecurities" xlink:title="00000016 - Disclosure - INVESTMENT IN MARKETABLE SECURITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/InvestmentInNon-marketableSecurities" xlink:title="00000017 - Disclosure - INVESTMENT IN NON-MARKETABLE SECURITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/CustomerDeposits" xlink:title="00000018 - Disclosure - CUSTOMER DEPOSITS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/OtherPayablesAndAccruedLiabilities" xlink:title="00000019 - Disclosure - OTHER PAYABLES AND ACCRUED LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/RelatedPartyBalancesAndTransactions" xlink:title="00000020 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/StockholdersEquity" xlink:title="00000021 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/Non-controllingInterest" xlink:title="00000022 - Disclosure - NON-CONTROLLING INTEREST" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/IncomeTaxes" xlink:title="00000023 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ConcentrationsOfRisks" xlink:title="00000024 - Disclosure - CONCENTRATIONS OF RISKS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/CommitmentsAndContingencies" xlink:title="00000025 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/SubsequentEvents" xlink:title="00000026 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/OrganizationAndBusinessBackgroundTables" xlink:title="00000028 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/VariableInterestEntityVieTables" xlink:title="00000030 - Disclosure - VARIABLE INTEREST ENTITY (&#8220;VIE&#8221;) (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/AccountsReceivableTables" xlink:title="00000031 - Disclosure - ACCOUNTS RECEIVABLE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/InventoriesTables" xlink:title="00000032 - Disclosure - INVENTORIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/PrepaymentsAndDepositsTables" xlink:title="00000033 - Disclosure - PREPAYMENTS AND DEPOSITS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/PropertyAndEquipmentNetTables" xlink:title="00000034 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/IntangibleAssetsNetTables" xlink:title="00000035 - Disclosure - INTANGIBLE ASSETS, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/InvestmentInMarketableSecuritiesTables" xlink:title="00000036 - Disclosure - INVESTMENT IN MARKETABLE SECURITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesTables" xlink:title="00000037 - Disclosure - INVESTMENT IN NON-MARKETABLE SECURITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/CustomerDepositsTables" xlink:title="00000038 - Disclosure - CUSTOMER DEPOSITS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesTables" xlink:title="00000039 - Disclosure - OTHER PAYABLES AND ACCRUED LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/RelatedPartyBalancesAndTransactionsTables" xlink:title="00000040 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/Non-controllingInterestTables" xlink:title="00000041 - Disclosure - NON-CONTROLLING INTEREST (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/IncomeTaxesTables" xlink:title="00000042 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/CommitmentsAndContingenciesTables" xlink:title="00000043 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails" xlink:title="00000044 - Disclosure - SCHEDULE OF SUBSIDIARIES AND ASSOCIATES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SubsidiaryCompanyMember" xlink:label="loc_AATPSubsidiaryCompanyMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_AATPSubsidiaryCompanyMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SubsidiaryCompanyOneMember" xlink:label="loc_AATPSubsidiaryCompanyOneMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_AATPSubsidiaryCompanyOneMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SubsidiaryCompanyTwoMember" xlink:label="loc_AATPSubsidiaryCompanyTwoMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_AATPSubsidiaryCompanyTwoMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SubsidiaryCompanyThreeMember" xlink:label="loc_AATPSubsidiaryCompanyThreeMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_AATPSubsidiaryCompanyThreeMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SubsidiaryCompanyFourMember" xlink:label="loc_AATPSubsidiaryCompanyFourMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_AATPSubsidiaryCompanyFourMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SubsidiaryCompanyFiveMember" xlink:label="loc_AATPSubsidiaryCompanyFiveMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_AATPSubsidiaryCompanyFiveMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_NameOftheCompany" xlink:label="loc_AATPNameOftheCompany_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AATPNameOftheCompany_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PlaceAndDateOfIncorporation" xlink:label="loc_AATPPlaceAndDateOfIncorporation_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AATPPlaceAndDateOfIncorporation_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ParticularsOfIssuedCapital" xlink:label="loc_AATPParticularsOfIssuedCapital_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AATPParticularsOfIssuedCapital_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PrincipalActivities" xlink:label="loc_AATPPrincipalActivities_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AATPPrincipalActivities_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_120" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative" xlink:title="00000045 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_AgapeATPInternationalHoldingLimitedMember" xlink:label="loc_AATPAgapeATPInternationalHoldingLimitedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_AATPAgapeATPInternationalHoldingLimitedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SubsidiaryCompanyTwoMember" xlink:label="loc_AATPSubsidiaryCompanyTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_AATPSubsidiaryCompanyTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SubsidiaryCompanyFiveMember" xlink:label="loc_AATPSubsidiaryCompanyFiveMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_AATPSubsidiaryCompanyFiveMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ShareExchangeAgreementMember" xlink:label="loc_AATPShareExchangeAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AATPShareExchangeAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_MrHowKokChoongMember" xlink:label="loc_AATPMrHowKokChoongMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_AATPMrHowKokChoongMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:title="00000046 - Disclosure - SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember" xlink:label="loc_us-gaapVehiclesMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapVehiclesMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaapPropertyPlantAndEquipmentEstimatedUsefulLives_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentEstimatedUsefulLives_70" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetDetails" xlink:title="00000047 - Disclosure - SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails" xlink:title="00000048 - Disclosure - SCHEDULE OF DIS-AGGREGATED INFORMATION OF REVENUES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SurvivorSelectMember" xlink:label="loc_AATPSurvivorSelectMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPSurvivorSelectMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_EnergizedMineralConcentrateMember" xlink:label="loc_AATPEnergizedMineralConcentrateMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPEnergizedMineralConcentrateMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_IonizedCalMagMember" xlink:label="loc_AATPIonizedCalMagMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPIonizedCalMagMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_OmegaBlendMember" xlink:label="loc_AATPOmegaBlendMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPOmegaBlendMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_BetaMaxxMember" xlink:label="loc_AATPBetaMaxxMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPBetaMaxxMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_VegeFruitFiberMember" xlink:label="loc_AATPVegeFruitFiberMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPVegeFruitFiberMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_IronMember" xlink:label="loc_AATPIronMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPIronMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_YoungFormulaMember" xlink:label="loc_AATPYoungFormulaMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPYoungFormulaMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_OrganicYouthCarCleansingBarMember" xlink:label="loc_AATPOrganicYouthCarCleansingBarMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPOrganicYouthCarCleansingBarMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ATPRMITOPlusMember" xlink:label="loc_AATPATPRMITOPlusMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPATPRMITOPlusMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_LipomaskMember" xlink:label="loc_AATPLipomaskMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPLipomaskMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_EnergetiqueMember" xlink:label="loc_AATPEnergetiqueMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPEnergetiqueMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_TrimPlusMember" xlink:label="loc_AATPTrimPlusMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPTrimPlusMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ProductHealthTherapiesMember" xlink:label="loc_AATPProductHealthTherapiesMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPProductHealthTherapiesMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_OthersMember" xlink:label="loc_AATPOthersMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPOthersMember_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_HealthAndWellnessServicesMember" xlink:label="loc_AATPHealthAndWellnessServicesMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPHealthAndWellnessServicesMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenues_370" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails" xlink:title="00000049 - Disclosure - SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaapVariableRateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapVariableRateAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PeriodEndMYRMember" xlink:label="loc_AATPPeriodEndMYRMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_AATPPeriodEndMYRMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PeriodEndHKDMember" xlink:label="loc_AATPPeriodEndHKDMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_AATPPeriodEndHKDMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PeriodAverageMYRMember" xlink:label="loc_AATPPeriodAverageMYRMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_AATPPeriodAverageMYRMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PeriodAverageHKDMember" xlink:label="loc_AATPPeriodAverageHKDMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_AATPPeriodAverageHKDMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="loc_us-gaapForeignCurrencyExchangeRateTranslation1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapForeignCurrencyExchangeRateTranslation1_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ForeignCurrencyExchangeRateAverage" xlink:label="loc_AATPForeignCurrencyExchangeRateAverage_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_AATPForeignCurrencyExchangeRateAverage_90" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000050 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_HealthAndWellnessServicesMember" xlink:label="loc_AATPHealthAndWellnessServicesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPHealthAndWellnessServicesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShippingAndHandlingMember" xlink:label="loc_us-gaapShippingAndHandlingMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapShippingAndHandlingMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SocialSecurityOrganizationMember" xlink:label="loc_AATPSocialSecurityOrganizationMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_AATPSocialSecurityOrganizationMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_EmployeesProvidentFundMember" xlink:label="loc_AATPEmployeesProvidentFundMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_AATPEmployeesProvidentFundMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_EmploymentInsuranceSystemMember" xlink:label="loc_AATPEmploymentInsuranceSystemMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_AATPEmploymentInsuranceSystemMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_HumanResourceDevelopmentFundMember" xlink:label="loc_AATPHumanResourceDevelopmentFundMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_AATPHumanResourceDevelopmentFundMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_InventriesWriteDown" xlink:label="loc_AATPInventriesWriteDown_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_AATPInventriesWriteDown_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_InventoryWriteOff" xlink:label="loc_AATPInventoryWriteOff_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_AATPInventoryWriteOff_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableWriteOffs_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableWriteOffs_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_AllowanceForDoubtfulAccountsReceivablesCurrent" xlink:label="loc_AATPAllowanceForDoubtfulAccountsReceivablesCurrent_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_AATPAllowanceForDoubtfulAccountsReceivablesCurrent_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ForfeitedCouponIncome" xlink:label="loc_AATPForfeitedCouponIncome_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_AATPForfeitedCouponIncome_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold_140" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_140" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingExpense" xlink:label="loc_us-gaapSellingExpense_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapSellingExpense_140" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaapAdvertisingExpense_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAdvertisingExpense_140" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="loc_us-gaapSalesCommissionsAndFees_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapSalesCommissionsAndFees_140" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount_140" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SalaryPercentage" xlink:label="loc_AATPSalaryPercentage_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_AATPSalaryPercentage_140" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_MonthlySalary" xlink:label="loc_AATPMonthlySalary_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_AATPMonthlySalary_140" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="loc_us-gaapIncomeTaxExaminationLikelihoodOfUnfavorableSettlement_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationLikelihoodOfUnfavorableSettlement_140" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestExpense_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestExpense_140" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDescription" xlink:label="loc_us-gaapMinorityInterestDescription_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapMinorityInterestDescription_140" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_140" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails" xlink:title="00000051 - Disclosure - SCHEDULE OF VARIABLE INTEREST ENTITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingActivityGainsAndLossesLineItems" xlink:label="loc_us-gaapTradingActivityGainsAndLossesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingActivitiesGainLossByTypeTable" xlink:label="loc_us-gaapTradingActivitiesGainLossByTypeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTradingActivityGainsAndLossesLineItems" xlink:to="loc_us-gaapTradingActivitiesGainLossByTypeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingActivityByTypeAxis" xlink:label="loc_us-gaapTradingActivityByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapTradingActivitiesGainLossByTypeTable" xlink:to="loc_us-gaapTradingActivityByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingActivityByTypeDomain" xlink:label="loc_us-gaapTradingActivityByTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTradingActivityByTypeAxis" xlink:to="loc_us-gaapTradingActivityByTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingActivityByTypeDomain" xlink:label="loc_us-gaapTradingActivityByTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTradingActivityByTypeAxis" xlink:to="loc_us-gaapTradingActivityByTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableIncomeInterestRateMember" xlink:label="loc_us-gaapVariableIncomeInterestRateMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTradingActivityByTypeDomain" xlink:to="loc_us-gaapVariableIncomeInterestRateMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTradingActivityGainsAndLossesLineItems" xlink:to="loc_us-gaapAssetsCurrent_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTradingActivityGainsAndLossesLineItems" xlink:to="loc_us-gaapLiabilitiesCurrent_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTradingActivityGainsAndLossesLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTradingActivityGainsAndLossesLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaapPrepaidTaxes_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTradingActivityGainsAndLossesLineItems" xlink:to="loc_us-gaapPrepaidTaxes_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTradingActivityGainsAndLossesLineItems" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_OtherPayablesRelatedPartyCurrent" xlink:label="loc_AATPOtherPayablesRelatedPartyCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTradingActivityGainsAndLossesLineItems" xlink:to="loc_AATPOtherPayablesRelatedPartyCurrent_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTradingActivityGainsAndLossesLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTradingActivityGainsAndLossesLineItems" xlink:to="loc_us-gaapGrossProfit_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTradingActivityGainsAndLossesLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTradingActivityGainsAndLossesLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/VariableInterestEntityVieDetailsNarrative" xlink:title="00000052 - Disclosure - VARIABLE INTEREST ENTITY (&#8220;VIE&#8221;) (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SubsidiaryCompanyThreeMember" xlink:label="loc_AATPSubsidiaryCompanyThreeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_AATPSubsidiaryCompanyThreeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative" xlink:title="00000053 - Disclosure - CASH AND CASH EQUIVALENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCash_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TimeDeposits" xlink:label="loc_us-gaapTimeDeposits_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTimeDeposits_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits" xlink:label="loc_us-gaapPercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TimeDepositLiabilityUninsured" xlink:label="loc_us-gaapTimeDepositLiabilityUninsured_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTimeDepositLiabilityUninsured_50" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfAccountsReceivables-RelatedPartyDetails" xlink:title="00000054 - Disclosure - SCHEDULE OF ACCOUNTS RECEIVABLES - RELATED PARTY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfInventoriesDetails" xlink:title="00000055 - Disclosure - SCHEDULE OF INVENTORIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/InventoriesDetailsNarrative" xlink:title="00000056 - Disclosure - INVENTORIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfPrepaidExpensesAndDepositsDetails" xlink:title="00000057 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND DEPOSITS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfChangesInAllowanceForDoubtfulAccountsDetails" xlink:title="00000058 - Disclosure - SCHEDULE OF CHANGES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails" xlink:title="00000059 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ComputerAndOfficeEquipmentMember" xlink:label="loc_AATPComputerAndOfficeEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_AATPComputerAndOfficeEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_VehicleMember" xlink:label="loc_AATPVehicleMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_AATPVehicleMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_110" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="00000060 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfIntangibleAssetsNetDetails" xlink:title="00000061 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS, NET (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/IntangibleAssetsNetDetailsNarrative" xlink:title="00000062 - Disclosure - INTANGIBLE ASSETS, NET (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails" xlink:title="00000063 - Disclosure - SCHEDULE OF INVESTMENT IN MARKETABLE SECURITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative" xlink:title="00000064 - Disclosure - INVESTMENT IN MARKETABLE SECURITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_GreenproCapitalCorpMember" xlink:label="loc_AATPGreenproCapitalCorpMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_AATPGreenproCapitalCorpMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DSwissIncMember" xlink:label="loc_AATPDSwissIncMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_AATPDSwissIncMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SEATechVenturesCorpMember" xlink:label="loc_AATPSEATechVenturesCorpMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_AATPSEATechVenturesCorpMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PhoenixPlusCorpMember" xlink:label="loc_AATPPhoenixPlusCorpMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_AATPPhoenixPlusCorpMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaapInvestmentOwnedBalanceShares_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentOwnedBalanceShares_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtCost" xlink:label="loc_us-gaapInvestmentOwnedAtCost_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentOwnedAtCost_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_130" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfInvestmentInNonMarketableSecuritiesDetails" xlink:title="00000065 - Disclosure - SCHEDULE OF INVESTMENT IN NON MARKETABLE SECURITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PhoenixPlusCorpMember" xlink:label="loc_AATPPhoenixPlusCorpMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_AATPPhoenixPlusCorpMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtCost" xlink:label="loc_us-gaapInvestmentOwnedAtCost_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentOwnedAtCost_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_TransferToInvestmentInMarketableSecurities" xlink:label="loc_AATPTransferToInvestmentInMarketableSecurities_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AATPTransferToInvestmentInMarketableSecurities_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_InvestmentInNonMarketableSecuritiesNoncurrent" xlink:label="loc_AATPInvestmentInNonMarketableSecuritiesNoncurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AATPInvestmentInNonMarketableSecuritiesNoncurrent_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative" xlink:title="00000066 - Disclosure - INVESTMENT IN NON-MARKETABLE SECURITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PhoenixPlusCorpMember" xlink:label="loc_AATPPhoenixPlusCorpMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_AATPPhoenixPlusCorpMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaapInvestmentOwnedBalanceShares_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentOwnedBalanceShares_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtCost" xlink:label="loc_us-gaapInvestmentOwnedAtCost_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentOwnedAtCost_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_30" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfCustomerDepositsDetails" xlink:title="00000067 - Disclosure -  SCHEDULE OF CUSTOMER DEPOSITS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails" xlink:title="00000068 - Disclosure - SCHEDULE OF OTHER PAYABLES AND ACCRUED LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesDetailsNarrative" xlink:title="00000069 - Disclosure - OTHER PAYABLES AND ACCRUED LIABILITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_CommissionPaymentsDescriptions" xlink:label="loc_AATPCommissionPaymentsDescriptions_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AATPCommissionPaymentsDescriptions_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommissionsPayableToBrokerDealersAndClearingOrganizations" xlink:label="loc_us-gaapCommissionsPayableToBrokerDealersAndClearingOrganizations_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommissionsPayableToBrokerDealersAndClearingOrganizations_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetGross" xlink:label="loc_us-gaapContractWithCustomerAssetGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapContractWithCustomerAssetGross_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails" xlink:title="00000070 - Disclosure - SCHEDULE OF RELATED PARTIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_TH3TechnologySdnBhdMember" xlink:label="loc_AATPTH3TechnologySdnBhdMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPTH3TechnologySdnBhdMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DSYBeautySdnBhdMember" xlink:label="loc_AATPDSYBeautySdnBhdMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPDSYBeautySdnBhdMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_AgapeATPAsiaLimitedMember" xlink:label="loc_AATPAgapeATPAsiaLimitedMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPAgapeATPAsiaLimitedMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_HostastaySdnBhdMember" xlink:label="loc_AATPHostastaySdnBhdMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPHostastaySdnBhdMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_CTANutriceuticalsSdnBhdMember" xlink:label="loc_AATPCTANutriceuticalsSdnBhdMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPCTANutriceuticalsSdnBhdMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_CTANutriceuticalsAsiaSdnBhdOneMember" xlink:label="loc_AATPCTANutriceuticalsAsiaSdnBhdOneMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPCTANutriceuticalsAsiaSdnBhdOneMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DSYBeautySdnBhdOneMember" xlink:label="loc_AATPDSYBeautySdnBhdOneMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPDSYBeautySdnBhdOneMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_HowKokChoongMember" xlink:label="loc_AATPHowKokChoongMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPHowKokChoongMember_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DSYWellnessandLongevityCenterSdnBhdTwoMember" xlink:label="loc_AATPDSYWellnessandLongevityCenterSdnBhdTwoMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPDSYWellnessandLongevityCenterSdnBhdTwoMember_340" xlink:type="arc" order="341" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_HostastaySdnBhdHostastayMember" xlink:label="loc_AATPHostastaySdnBhdHostastayMember_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPHostastaySdnBhdHostastayMember_380" xlink:type="arc" order="381" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_CTANutriceuticalsAsiaSdnBhdMember" xlink:label="loc_AATPCTANutriceuticalsAsiaSdnBhdMember_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPCTANutriceuticalsAsiaSdnBhdMember_400" xlink:type="arc" order="401" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DSYWellnessAndLongevityCenterSdnBhdMember" xlink:label="loc_AATPDSYWellnessAndLongevityCenterSdnBhdMember_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPDSYWellnessAndLongevityCenterSdnBhdMember_420" xlink:type="arc" order="421" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_RedboyPictureSdnBhdMember" xlink:label="loc_AATPRedboyPictureSdnBhdMember_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPRedboyPictureSdnBhdMember_480" xlink:type="arc" order="481" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DSYWellnessAndLongevityCenterSdnBhdThreeMember" xlink:label="loc_AATPDSYWellnessAndLongevityCenterSdnBhdThreeMember_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPDSYWellnessAndLongevityCenterSdnBhdThreeMember_500" xlink:type="arc" order="501" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_420" xlink:type="arc" order="422" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_RelatedPartiesRelationshipsDescription" xlink:label="loc_AATPRelatedPartiesRelationshipsDescription_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_AATPRelatedPartiesRelationshipsDescription_530" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaapDueFromRelatedParties_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDueFromRelatedParties_530" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_RelatedPartiesNatureDescription" xlink:label="loc_AATPRelatedPartiesNatureDescription_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_AATPRelatedPartiesNatureDescription_530" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrent_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrent_530" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrentAndNoncurrent_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDueToRelatedPartiesCurrentAndNoncurrent_530" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty_530" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_RelatedPartyOtherIncome" xlink:label="loc_AATPRelatedPartyOtherIncome_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_AATPRelatedPartyOtherIncome_530" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_RelatedPartyTransactionOtherPurchasesFromRelatedParty" xlink:label="loc_AATPRelatedPartyTransactionOtherPurchasesFromRelatedParty_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_AATPRelatedPartyTransactionOtherPurchasesFromRelatedParty_530" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="loc_us-gaapSalesCommissionsAndFees_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSalesCommissionsAndFees_530" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_RelatedPartyOtherExpenses" xlink:label="loc_AATPRelatedPartyOtherExpenses_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_AATPRelatedPartyOtherExpenses_530" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000071 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ShareForfeitureAgreementsMember" xlink:label="loc_AATPShareForfeitureAgreementsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AATPShareForfeitureAgreementsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_HowKokChoongTalentLimitedMember" xlink:label="loc_AATPHowKokChoongTalentLimitedMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPHowKokChoongTalentLimitedMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_HKCHoldingsSdnBhdMember" xlink:label="loc_AATPHKCHoldingsSdnBhdMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPHKCHoldingsSdnBhdMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ShareholdersMember" xlink:label="loc_AATPShareholdersMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_AATPShareholdersMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ReductionInCommonStockOutstanding" xlink:label="loc_AATPReductionInCommonStockOutstanding_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_AATPReductionInCommonStockOutstanding_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfNonControllingInterestDetails" xlink:title="00000072 - Disclosure - SCHEDULE OF NON CONTROLLING INTEREST (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails" xlink:title="00000073 - Disclosure - SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAX (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MY" xlink:label="loc_countryMY_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryMY_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_HK" xlink:label="loc_countryHK_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryHK_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails" xlink:title="00000074 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAX (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:title="00000075 - Disclosure - SCHEDULE OF EFFECTIVE INCOME TAX RATE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfEffectiveIncomeTaxRateDetailsParenthetical" xlink:title="00000076 - Disclosure -  SCHEDULE OF EFFECTIVE INCOME TAX RATE (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_AATPLBASLSEAAndWATPMember" xlink:label="loc_AATPAATPLBASLSEAAndWATPMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_AATPAATPLBASLSEAAndWATPMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_AATPHKMember" xlink:label="loc_AATPAATPHKMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_AATPAATPHKMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_AATPLBASLSEAWATPAndDSYMember" xlink:label="loc_AATPAATPLBASLSEAWATPAndDSYMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_AATPAATPLBASLSEAWATPAndDSYMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:title="00000077 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_countryUS_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MY" xlink:label="loc_countryMY_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryMY_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsForeign_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsForeign_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DeferredTaxLiabilitiesDepreciation" xlink:label="loc_AATPDeferredTaxLiabilitiesDepreciation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AATPDeferredTaxLiabilitiesDepreciation_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000078 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_countryUS_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_LabuanMember" xlink:label="loc_AATPLabuanMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_AATPLabuanMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MY" xlink:label="loc_countryMY_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryMY_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_HK" xlink:label="loc_countryHK_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryHK_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_TwoThousandTwentyEightMember" xlink:label="loc_AATPTwoThousandTwentyEightMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_AATPTwoThousandTwentyEightMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_TwoThousandTwentyNineMember" xlink:label="loc_AATPTwoThousandTwentyNineMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_AATPTwoThousandTwentyNineMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_TwoThousandThirtyMember" xlink:label="loc_AATPTwoThousandThirtyMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_AATPTwoThousandThirtyMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_180" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_TaxRateDescription" xlink:label="loc_AATPTaxRateDescription_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_AATPTaxRateDescription_180" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_180" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_180" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_180" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestExpense_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestExpense_180" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_180" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DeferredTaxAssetsOperatingLossCarryforwardsReducedAmount" xlink:label="loc_AATPDeferredTaxAssetsOperatingLossCarryforwardsReducedAmount_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_AATPDeferredTaxAssetsOperatingLossCarryforwardsReducedAmount_180" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations_180" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaapIncomeTaxExaminationDescription_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationDescription_180" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock_180" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockSplit_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockSplit_180" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" xlink:title="00000079 - Disclosure - CONCENTRATIONS OF RISKS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_NoCustomerMember" xlink:label="loc_AATPNoCustomerMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_AATPNoCustomerMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_FiveIndividualCustomersMember" xlink:label="loc_AATPFiveIndividualCustomersMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_AATPFiveIndividualCustomersMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_VendorOneMember" xlink:label="loc_AATPVendorOneMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_AATPVendorOneMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_VendorTwoMember" xlink:label="loc_AATPVendorTwoMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_AATPVendorTwoMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_VendorThreeMember" xlink:label="loc_AATPVendorThreeMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_AATPVendorThreeMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_VendorMember" xlink:label="loc_AATPVendorMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_AATPVendorMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_OneVendorMember" xlink:label="loc_AATPOneVendorMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_AATPOneVendorMember_160" xlink:type="arc" order="163" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_OneSalesDistributorMember" xlink:label="loc_AATPOneSalesDistributorMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_AATPOneSalesDistributorMember_170" xlink:type="arc" order="173" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaapRevenueFromContractWithCustomerMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapRevenueFromContractWithCustomerMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsTotalMember" xlink:label="loc_us-gaapCostOfGoodsTotalMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapCostOfGoodsTotalMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember" xlink:label="loc_us-gaapAccountsPayableMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsPayableMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaapSupplierConcentrationRiskMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapSupplierConcentrationRiskMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DSwissIncMember" xlink:label="loc_AATPDSwissIncMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_AATPDSwissIncMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DSwissIncMember" xlink:label="loc_AATPDSwissIncMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_AATPDSwissIncMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_220" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DividendShareForCommonStock" xlink:label="loc_AATPDividendShareForCommonStock_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_AATPDividendShareForCommonStock_220" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_220" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Deposits" xlink:label="loc_us-gaapDeposits_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapDeposits_220" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DepositForInsurance" xlink:label="loc_AATPDepositForInsurance_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_AATPDepositForInsurance_220" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfLeaseCommitmentsDetails" xlink:title="00000080 - Disclosure - SCHEDULE OF LEASE COMMITMENTS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000081 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaapRestructuringCostAndReserveLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_AgapeSuperiorLivingMember" xlink:label="loc_AATPAgapeSuperiorLivingMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_AATPAgapeSuperiorLivingMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_TrainingCenterMember" xlink:label="loc_AATPTrainingCenterMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_AATPTrainingCenterMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_LeaseExpirationTerm" xlink:label="loc_AATPLeaseExpirationTerm_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_AATPLeaseExpirationTerm_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_IncreaseDecreaseInROUAssetsAndLiabilities" xlink:label="loc_AATPIncreaseDecreaseInROUAssetsAndLiabilities_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_AATPIncreaseDecreaseInROUAssetsAndLiabilities_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapOperatingLeasePayments_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense_110" xlink:type="arc" order="8" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>30
<FILENAME>aatp-20221231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_AgapeATPInternationalHoldingLimitedMember" xlink:label="AATP_AgapeATPInternationalHoldingLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_AgapeATPInternationalHoldingLimitedMember" xlink:to="AATP_AgapeATPInternationalHoldingLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_AgapeATPInternationalHoldingLimitedMember_lbl" xml:lang="en-US">Agape ATP International Holding Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ShareExchangeAgreementMember" xlink:label="AATP_ShareExchangeAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ShareExchangeAgreementMember" xlink:to="AATP_ShareExchangeAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_ShareExchangeAgreementMember_lbl" xml:lang="en-US">Share Exchange Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_MrHowKokChoongMember" xlink:label="AATP_MrHowKokChoongMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_MrHowKokChoongMember" xlink:to="AATP_MrHowKokChoongMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_MrHowKokChoongMember_lbl" xml:lang="en-US">Mr.How Kok Choong [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SubsidiaryCompanyTwoMember" xlink:label="AATP_SubsidiaryCompanyTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_SubsidiaryCompanyTwoMember" xlink:to="AATP_SubsidiaryCompanyTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_SubsidiaryCompanyTwoMember_lbl" xml:lang="en-US">Subsidiary Company Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SubsidiaryCompanyFiveMember" xlink:label="AATP_SubsidiaryCompanyFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_SubsidiaryCompanyFiveMember" xlink:to="AATP_SubsidiaryCompanyFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_SubsidiaryCompanyFiveMember_lbl" xml:lang="en-US">Subsidiary Company Five [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SubsidiaryCompanyMember" xlink:label="AATP_SubsidiaryCompanyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_SubsidiaryCompanyMember" xlink:to="AATP_SubsidiaryCompanyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_SubsidiaryCompanyMember_lbl" xml:lang="en-US">Subsidiary Company [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SubsidiaryCompanyOneMember" xlink:label="AATP_SubsidiaryCompanyOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_SubsidiaryCompanyOneMember" xlink:to="AATP_SubsidiaryCompanyOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_SubsidiaryCompanyOneMember_lbl" xml:lang="en-US">Subsidiary Company One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SubsidiaryCompanyThreeMember" xlink:label="AATP_SubsidiaryCompanyThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_SubsidiaryCompanyThreeMember" xlink:to="AATP_SubsidiaryCompanyThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_SubsidiaryCompanyThreeMember_lbl" xml:lang="en-US">Subsidiary Company Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SubsidiaryCompanyFourMember" xlink:label="AATP_SubsidiaryCompanyFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_SubsidiaryCompanyFourMember" xlink:to="AATP_SubsidiaryCompanyFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_SubsidiaryCompanyFourMember_lbl" xml:lang="en-US">Subsidiary Company Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_HealthAndWellnessServicesMember" xlink:label="AATP_HealthAndWellnessServicesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_HealthAndWellnessServicesMember" xlink:to="AATP_HealthAndWellnessServicesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_HealthAndWellnessServicesMember_lbl" xml:lang="en-US">Health and Wellness Services [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShippingAndHandlingMember" xlink:label="us-gaap_ShippingAndHandlingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShippingAndHandlingMember" xlink:to="us-gaap_ShippingAndHandlingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShippingAndHandlingMember_lbl" xml:lang="en-US">Shipping and Handling [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SocialSecurityOrganizationMember" xlink:label="AATP_SocialSecurityOrganizationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_SocialSecurityOrganizationMember" xlink:to="AATP_SocialSecurityOrganizationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_SocialSecurityOrganizationMember_lbl" xml:lang="en-US">Social Security Organization [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_EmployeesProvidentFundMember" xlink:label="AATP_EmployeesProvidentFundMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_EmployeesProvidentFundMember" xlink:to="AATP_EmployeesProvidentFundMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_EmployeesProvidentFundMember_lbl" xml:lang="en-US">Employees Provident Fund [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_EmploymentInsuranceSystemMember" xlink:label="AATP_EmploymentInsuranceSystemMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_EmploymentInsuranceSystemMember" xlink:to="AATP_EmploymentInsuranceSystemMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_EmploymentInsuranceSystemMember_lbl" xml:lang="en-US">Employment Insurance System [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_HumanResourceDevelopmentFundMember" xlink:label="AATP_HumanResourceDevelopmentFundMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_HumanResourceDevelopmentFundMember" xlink:to="AATP_HumanResourceDevelopmentFundMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_HumanResourceDevelopmentFundMember_lbl" xml:lang="en-US">Human Resource Development Fund [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VehiclesMember_lbl" xml:lang="en-US">Vehicles [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SurvivorSelectMember" xlink:label="AATP_SurvivorSelectMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_SurvivorSelectMember" xlink:to="AATP_SurvivorSelectMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_SurvivorSelectMember_lbl" xml:lang="en-US">Survivor Select [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_EnergizedMineralConcentrateMember" xlink:label="AATP_EnergizedMineralConcentrateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_EnergizedMineralConcentrateMember" xlink:to="AATP_EnergizedMineralConcentrateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_EnergizedMineralConcentrateMember_lbl" xml:lang="en-US">Energized Mineral Concentrate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_IonizedCalMagMember" xlink:label="AATP_IonizedCalMagMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_IonizedCalMagMember" xlink:to="AATP_IonizedCalMagMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_IonizedCalMagMember_lbl" xml:lang="en-US">Ionized Cal Mag [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_OmegaBlendMember" xlink:label="AATP_OmegaBlendMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_OmegaBlendMember" xlink:to="AATP_OmegaBlendMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_OmegaBlendMember_lbl" xml:lang="en-US">Omega Blend [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_BetaMaxxMember" xlink:label="AATP_BetaMaxxMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_BetaMaxxMember" xlink:to="AATP_BetaMaxxMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_BetaMaxxMember_lbl" xml:lang="en-US">Beta Maxx [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_VegeFruitFiberMember" xlink:label="AATP_VegeFruitFiberMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_VegeFruitFiberMember" xlink:to="AATP_VegeFruitFiberMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_VegeFruitFiberMember_lbl" xml:lang="en-US">Vege Fruit Fiber [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_IronMember" xlink:label="AATP_IronMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_IronMember" xlink:to="AATP_IronMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_IronMember_lbl" xml:lang="en-US">Iron [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_YoungFormulaMember" xlink:label="AATP_YoungFormulaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_YoungFormulaMember" xlink:to="AATP_YoungFormulaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_YoungFormulaMember_lbl" xml:lang="en-US">Young Formula [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_OrganicYouthCarCleansingBarMember" xlink:label="AATP_OrganicYouthCarCleansingBarMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_OrganicYouthCarCleansingBarMember" xlink:to="AATP_OrganicYouthCarCleansingBarMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_OrganicYouthCarCleansingBarMember_lbl" xml:lang="en-US">Organic Youth Car Cleansing Bar [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ATPRMITOPlusMember" xlink:label="AATP_ATPRMITOPlusMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ATPRMITOPlusMember" xlink:to="AATP_ATPRMITOPlusMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_ATPRMITOPlusMember_lbl" xml:lang="en-US">A T P R M I T O Plus [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_LipomaskMember" xlink:label="AATP_LipomaskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_LipomaskMember" xlink:to="AATP_LipomaskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_LipomaskMember_lbl" xml:lang="en-US">Lipomask [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_EnergetiqueMember" xlink:label="AATP_EnergetiqueMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_EnergetiqueMember" xlink:to="AATP_EnergetiqueMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_EnergetiqueMember_lbl" xml:lang="en-US">Energetique [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_TrimPlusMember" xlink:label="AATP_TrimPlusMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_TrimPlusMember" xlink:to="AATP_TrimPlusMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_TrimPlusMember_lbl" xml:lang="en-US">Trim Plus [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ProductHealthTherapiesMember" xlink:label="AATP_ProductHealthTherapiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ProductHealthTherapiesMember" xlink:to="AATP_ProductHealthTherapiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_ProductHealthTherapiesMember_lbl" xml:lang="en-US">Product Health Therapies [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_OthersMember" xlink:label="AATP_OthersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_OthersMember" xlink:to="AATP_OthersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_OthersMember_lbl" xml:lang="en-US">Others [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Product [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US">Variable Rate [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PeriodEndMYRMember" xlink:label="AATP_PeriodEndMYRMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_PeriodEndMYRMember" xlink:to="AATP_PeriodEndMYRMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_PeriodEndMYRMember_lbl" xml:lang="en-US">Period End M Y R [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PeriodEndHKDMember" xlink:label="AATP_PeriodEndHKDMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_PeriodEndHKDMember" xlink:to="AATP_PeriodEndHKDMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_PeriodEndHKDMember_lbl" xml:lang="en-US">Period End H K D [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PeriodAverageMYRMember" xlink:label="AATP_PeriodAverageMYRMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_PeriodAverageMYRMember" xlink:to="AATP_PeriodAverageMYRMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_PeriodAverageMYRMember_lbl" xml:lang="en-US">Period Average M Y R [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PeriodAverageHKDMember" xlink:label="AATP_PeriodAverageHKDMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_PeriodAverageHKDMember" xlink:to="AATP_PeriodAverageHKDMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_PeriodAverageHKDMember_lbl" xml:lang="en-US">Period-average HKD [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingActivityByTypeAxis" xlink:label="us-gaap_TradingActivityByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradingActivityByTypeAxis" xlink:to="us-gaap_TradingActivityByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradingActivityByTypeAxis_lbl" xml:lang="en-US">Trading Activity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableIncomeInterestRateMember" xlink:label="us-gaap_VariableIncomeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableIncomeInterestRateMember" xlink:to="us-gaap_VariableIncomeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableIncomeInterestRateMember_lbl" xml:lang="en-US">Variable Income Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ComputerAndOfficeEquipmentMember" xlink:label="AATP_ComputerAndOfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ComputerAndOfficeEquipmentMember" xlink:to="AATP_ComputerAndOfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_ComputerAndOfficeEquipmentMember_lbl" xml:lang="en-US">Computer And Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_VehicleMember" xlink:label="AATP_VehicleMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_VehicleMember" xlink:to="AATP_VehicleMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_VehicleMember_lbl" xml:lang="en-US">Vehicle [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_GreenproCapitalCorpMember" xlink:label="AATP_GreenproCapitalCorpMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_GreenproCapitalCorpMember" xlink:to="AATP_GreenproCapitalCorpMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_GreenproCapitalCorpMember_lbl" xml:lang="en-US">Greenpro Capital Corp. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DSwissIncMember" xlink:label="AATP_DSwissIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DSwissIncMember" xlink:to="AATP_DSwissIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_DSwissIncMember_lbl" xml:lang="en-US">DSwiss Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SEATechVenturesCorpMember" xlink:label="AATP_SEATechVenturesCorpMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_SEATechVenturesCorpMember" xlink:to="AATP_SEATechVenturesCorpMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_SEATechVenturesCorpMember_lbl" xml:lang="en-US">SEATech Ventures Corp. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PhoenixPlusCorpMember" xlink:label="AATP_PhoenixPlusCorpMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_PhoenixPlusCorpMember" xlink:to="AATP_PhoenixPlusCorpMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_PhoenixPlusCorpMember_lbl" xml:lang="en-US">Phoenix Plus Corporation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_TH3TechnologySdnBhdMember" xlink:label="AATP_TH3TechnologySdnBhdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_TH3TechnologySdnBhdMember" xlink:to="AATP_TH3TechnologySdnBhdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_TH3TechnologySdnBhdMember_lbl" xml:lang="en-US">TH3 Technology Sdn Bhd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DSYBeautySdnBhdMember" xlink:label="AATP_DSYBeautySdnBhdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DSYBeautySdnBhdMember" xlink:to="AATP_DSYBeautySdnBhdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_DSYBeautySdnBhdMember_lbl" xml:lang="en-US">DSY Beauty Sdn Bhd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_AgapeATPAsiaLimitedMember" xlink:label="AATP_AgapeATPAsiaLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_AgapeATPAsiaLimitedMember" xlink:to="AATP_AgapeATPAsiaLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_AgapeATPAsiaLimitedMember_lbl" xml:lang="en-US">Agape ATP (Asia) Limited ("AATP Asia") [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_HostastaySdnBhdMember" xlink:label="AATP_HostastaySdnBhdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_HostastaySdnBhdMember" xlink:to="AATP_HostastaySdnBhdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_HostastaySdnBhdMember_lbl" xml:lang="en-US">Hostastay Sdn. Bhd. (&#147;Hostastay&#148;) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_CTANutriceuticalsSdnBhdMember" xlink:label="AATP_CTANutriceuticalsSdnBhdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_CTANutriceuticalsSdnBhdMember" xlink:to="AATP_CTANutriceuticalsSdnBhdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_CTANutriceuticalsSdnBhdMember_lbl" xml:lang="en-US">CTA Nutriceuticals Sdn Bhd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_CTANutriceuticalsAsiaSdnBhdOneMember" xlink:label="AATP_CTANutriceuticalsAsiaSdnBhdOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_CTANutriceuticalsAsiaSdnBhdOneMember" xlink:to="AATP_CTANutriceuticalsAsiaSdnBhdOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_CTANutriceuticalsAsiaSdnBhdOneMember_lbl" xml:lang="en-US">CTA Nutriceuticals Asia Sdn Bhd One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DSYBeautySdnBhdOneMember" xlink:label="AATP_DSYBeautySdnBhdOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DSYBeautySdnBhdOneMember" xlink:to="AATP_DSYBeautySdnBhdOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AATP_DSYBeautySdnBhdOneMember_lbl" xml:lang="en-US">DSY Beauty Sdn Bhd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_HowKokChoongMember" xlink:label="AATP_HowKokChoongMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_HowKokChoongMember" xlink:to="AATP_HowKokChoongMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_HowKokChoongMember_lbl" xml:lang="en-US">How Kok Choong [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DSYWellnessandLongevityCenterSdnBhdTwoMember" xlink:label="AATP_DSYWellnessandLongevityCenterSdnBhdTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DSYWellnessandLongevityCenterSdnBhdTwoMember" xlink:to="AATP_DSYWellnessandLongevityCenterSdnBhdTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_DSYWellnessandLongevityCenterSdnBhdTwoMember_lbl" xml:lang="en-US">DSY Wellness and Longevity Center Sdn Bhd ("DSYWLC") [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_HostastaySdnBhdHostastayMember" xlink:label="AATP_HostastaySdnBhdHostastayMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_HostastaySdnBhdHostastayMember" xlink:to="AATP_HostastaySdnBhdHostastayMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_HostastaySdnBhdHostastayMember_lbl" xml:lang="en-US">Hostastay Sdn. Bhd. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_CTANutriceuticalsAsiaSdnBhdMember" xlink:label="AATP_CTANutriceuticalsAsiaSdnBhdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_CTANutriceuticalsAsiaSdnBhdMember" xlink:to="AATP_CTANutriceuticalsAsiaSdnBhdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_CTANutriceuticalsAsiaSdnBhdMember_lbl" xml:lang="en-US">CTA Nutriceuticals Asia Sdn Bhd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DSYWellnessAndLongevityCenterSdnBhdMember" xlink:label="AATP_DSYWellnessAndLongevityCenterSdnBhdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DSYWellnessAndLongevityCenterSdnBhdMember" xlink:to="AATP_DSYWellnessAndLongevityCenterSdnBhdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_DSYWellnessAndLongevityCenterSdnBhdMember_lbl" xml:lang="en-US">DSY Wellness &amp; Longevity Center Sdn Bhd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_RedboyPictureSdnBhdMember" xlink:label="AATP_RedboyPictureSdnBhdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_RedboyPictureSdnBhdMember" xlink:to="AATP_RedboyPictureSdnBhdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_RedboyPictureSdnBhdMember_lbl" xml:lang="en-US">Redboy Picture Sdn Bhd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DSYWellnessAndLongevityCenterSdnBhdThreeMember" xlink:label="AATP_DSYWellnessAndLongevityCenterSdnBhdThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DSYWellnessAndLongevityCenterSdnBhdThreeMember" xlink:to="AATP_DSYWellnessAndLongevityCenterSdnBhdThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AATP_DSYWellnessAndLongevityCenterSdnBhdThreeMember_lbl" xml:lang="en-US">DSY Wellness and Longevity Center Sdn Bhd ("DSYWLC") [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ShareForfeitureAgreementsMember" xlink:label="AATP_ShareForfeitureAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ShareForfeitureAgreementsMember" xlink:to="AATP_ShareForfeitureAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_ShareForfeitureAgreementsMember_lbl" xml:lang="en-US">Share Forfeiture Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_HowKokChoongTalentLimitedMember" xlink:label="AATP_HowKokChoongTalentLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_HowKokChoongTalentLimitedMember" xlink:to="AATP_HowKokChoongTalentLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_HowKokChoongTalentLimitedMember_lbl" xml:lang="en-US">How Kok Choong Talent Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ShareholdersMember" xlink:label="AATP_ShareholdersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ShareholdersMember" xlink:to="AATP_ShareholdersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_ShareholdersMember_lbl" xml:lang="en-US">Shareholders [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_HKCHoldingsSdnBhdMember" xlink:label="AATP_HKCHoldingsSdnBhdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_HKCHoldingsSdnBhdMember" xlink:to="AATP_HKCHoldingsSdnBhdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_HKCHoldingsSdnBhdMember_lbl" xml:lang="en-US">HKC Holdings Sdn Bhd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MY" xlink:label="country_MY" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_MY" xlink:to="country_MY_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_MY_lbl" xml:lang="en-US">MALAYSIA</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_HK" xlink:label="country_HK" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_HK" xlink:to="country_HK_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_HK_lbl" xml:lang="en-US">HONG KONG</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_LabuanMember" xlink:label="AATP_LabuanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_LabuanMember" xlink:to="AATP_LabuanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_LabuanMember_lbl" xml:lang="en-US">Labuan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_TwoThousandTwentyEightMember" xlink:label="AATP_TwoThousandTwentyEightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_TwoThousandTwentyEightMember" xlink:to="AATP_TwoThousandTwentyEightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_TwoThousandTwentyEightMember_lbl" xml:lang="en-US">2028 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_TwoThousandTwentyNineMember" xlink:label="AATP_TwoThousandTwentyNineMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_TwoThousandTwentyNineMember" xlink:to="AATP_TwoThousandTwentyNineMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_TwoThousandTwentyNineMember_lbl" xml:lang="en-US">2029 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_TwoThousandThirtyMember" xlink:label="AATP_TwoThousandThirtyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_TwoThousandThirtyMember" xlink:to="AATP_TwoThousandThirtyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_TwoThousandThirtyMember_lbl" xml:lang="en-US">2030 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_AATPLBASLSEAAndWATPMember" xlink:label="AATP_AATPLBASLSEAAndWATPMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_AATPLBASLSEAAndWATPMember" xlink:to="AATP_AATPLBASLSEAAndWATPMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_AATPLBASLSEAAndWATPMember_lbl" xml:lang="en-US">AATP LB, ASL, SEA and WATP [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_AATPHKMember" xlink:label="AATP_AATPHKMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_AATPHKMember" xlink:to="AATP_AATPHKMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_AATPHKMember_lbl" xml:lang="en-US">AATP HK [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_AATPLBASLSEAWATPAndDSYMember" xlink:label="AATP_AATPLBASLSEAWATPAndDSYMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_AATPLBASLSEAWATPAndDSYMember" xlink:to="AATP_AATPLBASLSEAWATPAndDSYMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_AATPLBASLSEAWATPAndDSYMember_lbl" xml:lang="en-US">AATP LB, ASL, SEA, WATP, and DSY [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_NoCustomerMember" xlink:label="AATP_NoCustomerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_NoCustomerMember" xlink:to="AATP_NoCustomerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_NoCustomerMember_lbl" xml:lang="en-US">No Customer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerMember" xlink:to="us-gaap_RevenueFromContractWithCustomerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerMember_lbl" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_FiveIndividualCustomersMember" xlink:label="AATP_FiveIndividualCustomersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_FiveIndividualCustomersMember" xlink:to="AATP_FiveIndividualCustomersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_FiveIndividualCustomersMember_lbl" xml:lang="en-US">Five Individual Customers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_VendorOneMember" xlink:label="AATP_VendorOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_VendorOneMember" xlink:to="AATP_VendorOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_VendorOneMember_lbl" xml:lang="en-US">Vendor One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsTotalMember" xlink:label="us-gaap_CostOfGoodsTotalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsTotalMember" xlink:to="us-gaap_CostOfGoodsTotalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsTotalMember_lbl" xml:lang="en-US">Cost of Goods and Service Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xml:lang="en-US">Supplier Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_VendorTwoMember" xlink:label="AATP_VendorTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_VendorTwoMember" xlink:to="AATP_VendorTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_VendorTwoMember_lbl" xml:lang="en-US">Vendor Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_VendorThreeMember" xlink:label="AATP_VendorThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_VendorThreeMember" xlink:to="AATP_VendorThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_VendorThreeMember_lbl" xml:lang="en-US">Vendor Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableMember_lbl" xml:lang="en-US">Accounts Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_VendorMember" xlink:label="AATP_VendorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_VendorMember" xlink:to="AATP_VendorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_VendorMember_lbl" xml:lang="en-US">Vendor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_OneVendorMember" xlink:label="AATP_OneVendorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_OneVendorMember" xlink:to="AATP_OneVendorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_OneVendorMember_lbl" xml:lang="en-US">One Vendor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_OneSalesDistributorMember" xlink:label="AATP_OneSalesDistributorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_OneSalesDistributorMember" xlink:to="AATP_OneSalesDistributorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_OneSalesDistributorMember_lbl" xml:lang="en-US">One Sales Distributor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_AgapeSuperiorLivingMember" xlink:label="AATP_AgapeSuperiorLivingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_AgapeSuperiorLivingMember" xlink:to="AATP_AgapeSuperiorLivingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_AgapeSuperiorLivingMember_lbl" xml:lang="en-US">ASL [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_TrainingCenterMember" xlink:label="AATP_TrainingCenterMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_TrainingCenterMember" xlink:to="AATP_TrainingCenterMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_TrainingCenterMember_lbl" xml:lang="en-US">Training Center [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents (Included $1,609 and $17,493 in the consolidated VIE that can be used only to settle obligations of the consolidated VIE as of December 31, 2022 and 2021, respectively.)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xml:lang="en-US">Amount due from related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes" xlink:label="us-gaap_PrepaidTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidTaxes" xlink:to="us-gaap_PrepaidTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidTaxes_lbl" xml:lang="en-US">Prepaid taxes (Included $1,741 and $1,357 in the consolidated VIE that can be used only to settle obligations of the consolidated VIE as of December 31, 2022 and 2021, respectively.)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepayments and deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">OTHER ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xml:lang="en-US">Investment in marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_InvestmentInNonMarketableSecuritiesNoncurrent" xlink:label="AATP_InvestmentInNonMarketableSecuritiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_InvestmentInNonMarketableSecuritiesNoncurrent" xlink:to="AATP_InvestmentInNonMarketableSecuritiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_InvestmentInNonMarketableSecuritiesNoncurrent_lbl" xml:lang="en-US">Investment in non-marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCosts_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xml:lang="en-US">Accounts payable &#8211; related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Customer deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Other payables and accrued liabilities ($1,090 and $1,548 are included in the consolidated VIE that are without recourse to the credit of Agape ATP Corporation as of December 31, 2022 and 2021, respectively.)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other payable &#8211; related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Income tax payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US">Deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total Non-current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.0001 par value; 200,000,000 shares authorized; None issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, par value $0.0001; 1,000,000,000 shares authorized, 75,452,012 and 290,460,047 shares issued and outstanding as of December 31, 2022 and 2021, respectively.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL AGAPE CORPORATION STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">NON-CONTROLLING INTERESTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">TOTAL EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_VariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents" xlink:label="AATP_VariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_VariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents" xlink:to="AATP_VariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_VariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents_lbl" xml:lang="en-US">VIE consolidated amount of cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_VariableInterestEntityConsolidatedAmountOfPrepaidTaxes" xlink:label="AATP_VariableInterestEntityConsolidatedAmountOfPrepaidTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_VariableInterestEntityConsolidatedAmountOfPrepaidTaxes" xlink:to="AATP_VariableInterestEntityConsolidatedAmountOfPrepaidTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_VariableInterestEntityConsolidatedAmountOfPrepaidTaxes_lbl" xml:lang="en-US">VIE consolidated amount of prepaid taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_VariableInterestEntityConsolidatedAmountOfOtherPayablesAndAccruedLiabilities" xlink:label="AATP_VariableInterestEntityConsolidatedAmountOfOtherPayablesAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_VariableInterestEntityConsolidatedAmountOfOtherPayablesAndAccruedLiabilities" xlink:to="AATP_VariableInterestEntityConsolidatedAmountOfOtherPayablesAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_VariableInterestEntityConsolidatedAmountOfOtherPayablesAndAccruedLiabilities_lbl" xml:lang="en-US">VIE consolidated amount of other payables and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">REVENUE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">COST OF REVENUE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">GROSS PROFIT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingExpense" xlink:label="us-gaap_SellingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingExpense" xlink:to="us-gaap_SellingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingExpense_lbl" xml:lang="en-US">SELLING</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="us-gaap_SalesCommissionsAndFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesCommissionsAndFees" xlink:to="us-gaap_SalesCommissionsAndFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SalesCommissionsAndFees_lbl" xml:lang="en-US">COMMISSION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">GENERAL AND ADMINISTRATIVE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">PROVISION FOR DOUBTFUL ACCOUNTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">TOTAL OPERATING EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">LOSS FROM OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">OTHER INCOME (EXPENSES)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other expenses, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xml:lang="en-US">Unrealized holding loss on marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PreferredStockDividendIncomeStatementImpact" xlink:label="AATP_PreferredStockDividendIncomeStatementImpact" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_PreferredStockDividendIncomeStatementImpact" xlink:to="AATP_PreferredStockDividendIncomeStatementImpact_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="AATP_PreferredStockDividendIncomeStatementImpact_lbl" xml:lang="en-US">Dividend income from marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">TOTAL OTHER EXPENSES, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">LOSS BEFORE INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">BENEFIT OF (PROVISION FOR) INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">NET LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">NET (INCOME) LOSS ATTRIBUTABLE TO NON-CONTROLLING INTERESTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS ATTRIBUTABLE TO AGAPE ATP CORPORATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">NET LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US">OTHER COMPREHENSIVE LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">Foreign currency translation adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">TOTAL COMPREHENSIVE LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Less: Comprehensive income (loss) attributable to non-controlling interests</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">COMPREHENSIVE LOSS ATTRIBUTABLE TO AGAPE ATP CORPORATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US">LOSS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl" xml:lang="en-US">Forfeiture of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ContributionsFromNoncontrollingInterestShareholders" xlink:label="AATP_ContributionsFromNoncontrollingInterestShareholders" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ContributionsFromNoncontrollingInterestShareholders" xlink:to="AATP_ContributionsFromNoncontrollingInterestShareholders_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_ContributionsFromNoncontrollingInterestShareholders_lbl" xml:lang="en-US">Contributions from non-controlling interest shareholders</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Foreign currency translation adjustment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Shares, Outstanding, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:to="us-gaap_CostOfGoodsAndServicesSoldAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization_lbl" xml:lang="en-US">Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of operating right-of-use assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_2_lbl" xml:lang="en-US">Unrealized holding loss on marketable securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_PreferredStockDividendIncomeStatementImpact" xlink:to="AATP_PreferredStockDividendIncomeStatementImpact_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_PreferredStockDividendIncomeStatementImpact_2_lbl" xml:lang="en-US">Dividend income from marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred tax (benefit) expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US">Inventory write-down</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_2_lbl" xml:lang="en-US">Provision for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent_lbl" xml:lang="en-US">Amount due from related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:label="us-gaap_IncreaseDecreaseInPrepaidTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:to="us-gaap_IncreaseDecreaseInPrepaidTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidTaxes_lbl" xml:lang="en-US">Prepaid taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xml:lang="en-US">Prepayments and deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" xml:lang="en-US">Accounts payable &#8211; related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Customer deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Other payables and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent_lbl" xml:lang="en-US">Other payables &#8211; related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xml:lang="en-US">Income tax payables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:to="us-gaap_PaymentsToAcquireMachineryAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment_lbl" xml:lang="en-US">Purchase of equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Purchase of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Advances to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash used in financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">DECREASE IN CASH AND CASH EQUIVALENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS, beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS, end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL CASH FLOWS INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL NON-CASH FLOWS INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ChangesInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseModifications" xlink:label="AATP_ChangesInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseModifications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ChangesInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseModifications" xlink:to="AATP_ChangesInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseModifications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_ChangesInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseModifications_lbl" xml:lang="en-US">Changes in right-of-use assets and lease liabilities due to lease modifications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND BUSINESS BACKGROUND</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="us-gaap_VariableInterestEntityDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="us-gaap_VariableInterestEntityDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableInterestEntityDisclosureTextBlock_lbl" xml:lang="en-US">VARIABLE INTEREST ENTITY (&#8220;VIE&#8221;)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesAbstract_lbl" xml:lang="en-US">Receivables [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">ACCOUNTS RECEIVABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DisclosurePrepaymentsAndDepositsAbstract" xlink:label="AATP_DisclosurePrepaymentsAndDepositsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DisclosurePrepaymentsAndDepositsAbstract" xlink:to="AATP_DisclosurePrepaymentsAndDepositsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_DisclosurePrepaymentsAndDepositsAbstract_lbl" xml:lang="en-US">Prepayments And Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PrepaymentsAndDepositsTextBlock" xlink:label="AATP_PrepaymentsAndDepositsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_PrepaymentsAndDepositsTextBlock" xlink:to="AATP_PrepaymentsAndDepositsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_PrepaymentsAndDepositsTextBlock_lbl" xml:lang="en-US">PREPAYMENTS AND DEPOSITS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DisclosureInvestmentInMarketableSecuritiesAbstract" xlink:label="AATP_DisclosureInvestmentInMarketableSecuritiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DisclosureInvestmentInMarketableSecuritiesAbstract" xlink:to="AATP_DisclosureInvestmentInMarketableSecuritiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_DisclosureInvestmentInMarketableSecuritiesAbstract_lbl" xml:lang="en-US">Investment In Marketable Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_InvestmentInMarketableSecuritiesTextBlock" xlink:label="AATP_InvestmentInMarketableSecuritiesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_InvestmentInMarketableSecuritiesTextBlock" xlink:to="AATP_InvestmentInMarketableSecuritiesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_InvestmentInMarketableSecuritiesTextBlock_lbl" xml:lang="en-US">INVESTMENT IN MARKETABLE SECURITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DisclosureInvestmentInNonmarketableSecuritiesAbstract" xlink:label="AATP_DisclosureInvestmentInNonmarketableSecuritiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DisclosureInvestmentInNonmarketableSecuritiesAbstract" xlink:to="AATP_DisclosureInvestmentInNonmarketableSecuritiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_DisclosureInvestmentInNonmarketableSecuritiesAbstract_lbl" xml:lang="en-US">Investment In Non-marketable Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_InvestmentInNonMarketableSecuritiesTextBlock" xlink:label="AATP_InvestmentInNonMarketableSecuritiesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_InvestmentInNonMarketableSecuritiesTextBlock" xlink:to="AATP_InvestmentInNonMarketableSecuritiesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_InvestmentInNonMarketableSecuritiesTextBlock_lbl" xml:lang="en-US">INVESTMENT IN NON-MARKETABLE SECURITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DisclosureCustomerDepositsAbstract" xlink:label="AATP_DisclosureCustomerDepositsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DisclosureCustomerDepositsAbstract" xlink:to="AATP_DisclosureCustomerDepositsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_DisclosureCustomerDepositsAbstract_lbl" xml:lang="en-US">Customer Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_CustomerDepositsTextBlock" xlink:label="AATP_CustomerDepositsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_CustomerDepositsTextBlock" xlink:to="AATP_CustomerDepositsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_CustomerDepositsTextBlock_lbl" xml:lang="en-US">CUSTOMER DEPOSITS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">OTHER PAYABLES AND ACCRUED LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY BALANCES AND TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="us-gaap_NoncontrollingInterestAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestAbstract" xlink:to="us-gaap_NoncontrollingInterestAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestAbstract_lbl" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDisclosureTextBlock" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_lbl" xml:lang="en-US">NON-CONTROLLING INTEREST</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">CONCENTRATIONS OF RISKS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PrepaidTaxesPolicyTextBlock" xlink:label="AATP_PrepaidTaxesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_PrepaidTaxesPolicyTextBlock" xlink:to="AATP_PrepaidTaxesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_PrepaidTaxesPolicyTextBlock_lbl" xml:lang="en-US">Prepaid taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PrepaymentsAndDepositsPolicyTextBlock" xlink:label="AATP_PrepaymentsAndDepositsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_PrepaymentsAndDepositsPolicyTextBlock" xlink:to="AATP_PrepaymentsAndDepositsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AATP_PrepaymentsAndDepositsPolicyTextBlock_lbl" xml:lang="en-US">Prepayments and deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment for long-lived assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US">Investment in marketable equity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_NonMarketableSecuritiesPolicyTextBlock" xlink:label="AATP_NonMarketableSecuritiesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_NonMarketableSecuritiesPolicyTextBlock" xlink:to="AATP_NonMarketableSecuritiesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_NonMarketableSecuritiesPolicyTextBlock_lbl" xml:lang="en-US">Investment in non-marketable equity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Customer deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ShippingAndHandlingPolicyTextBlock" xlink:label="AATP_ShippingAndHandlingPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ShippingAndHandlingPolicyTextBlock" xlink:to="AATP_ShippingAndHandlingPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_ShippingAndHandlingPolicyTextBlock_lbl" xml:lang="en-US">Shipping and handling</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Advertising costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommissionsExpensePolicyPolicyTextBlock" xlink:label="us-gaap_CommissionsExpensePolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommissionsExpensePolicyPolicyTextBlock" xlink:to="us-gaap_CommissionsExpensePolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommissionsExpensePolicyPolicyTextBlock_lbl" xml:lang="en-US">Commission expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DefinedContributionPlanPolicyTextBlock" xlink:label="AATP_DefinedContributionPlanPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DefinedContributionPlanPolicyTextBlock" xlink:to="AATP_DefinedContributionPlanPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_DefinedContributionPlanPolicyTextBlock_lbl" xml:lang="en-US">Defined contribution plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_NoncontrollingInterestPolicyTextBlock" xlink:label="AATP_NoncontrollingInterestPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_NoncontrollingInterestPolicyTextBlock" xlink:to="AATP_NoncontrollingInterestPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_NoncontrollingInterestPolicyTextBlock_lbl" xml:lang="en-US">Non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings (loss) per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign currencies translation and transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_RelatedPartiesPolicyTextBlock" xlink:label="AATP_RelatedPartiesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_RelatedPartiesPolicyTextBlock" xlink:to="AATP_RelatedPartiesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_RelatedPartiesPolicyTextBlock_lbl" xml:lang="en-US">Related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair value of financial instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent accounting pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl" xml:lang="en-US">SCHEDULE OF SUBSIDIARIES AND ASSOCIATES</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:label="AATP_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:to="AATP_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock" xlink:label="AATP_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock" xlink:to="AATP_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DIS-AGGREGATED INFORMATION OF REVENUES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:to="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_lbl" xml:lang="en-US">SCHEDULE OF VARIABLE INTEREST ENTITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ACCOUNTS RECEIVABLES - RELATED PARTY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INVENTORIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PREPAID EXPENSES AND DEPOSITS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF CHANGES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROPERTY AND EQUIPMENT, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INTANGIBLE ASSETS, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INVESTMENT IN MARKETABLE SECURITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_NonMarketableSecuritiesTableTextBlock" xlink:label="AATP_NonMarketableSecuritiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_NonMarketableSecuritiesTableTextBlock" xlink:to="AATP_NonMarketableSecuritiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_NonMarketableSecuritiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INVESTMENT IN NON MARKETABLE SECURITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_CustomerDepositsTableTextBlock" xlink:label="AATP_CustomerDepositsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_CustomerDepositsTableTextBlock" xlink:to="AATP_CustomerDepositsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_CustomerDepositsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF CUSTOMER DEPOSITS</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock" xlink:label="AATP_ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock" xlink:to="AATP_ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF OTHER PAYABLES AND ACCRUED LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RELATED PARTIES</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ScheduleOfNonControllingInterestTableTextBlock" xlink:label="AATP_ScheduleOfNonControllingInterestTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ScheduleOfNonControllingInterestTableTextBlock" xlink:to="AATP_ScheduleOfNonControllingInterestTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_ScheduleOfNonControllingInterestTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF NON CONTROLLING INTEREST</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAX</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROVISION FOR INCOME TAX</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF EFFECTIVE INCOME TAX RATE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DEFERRED TAX ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF LEASE COMMITMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_NameOftheCompany" xlink:label="AATP_NameOftheCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_NameOftheCompany" xlink:to="AATP_NameOftheCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_NameOftheCompany_lbl" xml:lang="en-US">Subsidiary company name</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PlaceAndDateOfIncorporation" xlink:label="AATP_PlaceAndDateOfIncorporation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_PlaceAndDateOfIncorporation" xlink:to="AATP_PlaceAndDateOfIncorporation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_PlaceAndDateOfIncorporation_lbl" xml:lang="en-US">Place and date of incorporation</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ParticularsOfIssuedCapital" xlink:label="AATP_ParticularsOfIssuedCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ParticularsOfIssuedCapital" xlink:to="AATP_ParticularsOfIssuedCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_ParticularsOfIssuedCapital_lbl" xml:lang="en-US">Particulars of issued capital</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PrincipalActivities" xlink:label="AATP_PrincipalActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_PrincipalActivities" xlink:to="AATP_PrincipalActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_PrincipalActivities_lbl" xml:lang="en-US">Principal activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Proportional of ownership interest and voting power held</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_2_lbl" xml:lang="en-US">Ownership interest percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Stock issued during period acquisitions, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property and equipment, estimated useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xml:lang="en-US">Property and equipment, useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Estimated useful lives of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:label="us-gaap_ProductInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductInformationLineItems_lbl" xml:lang="en-US">Product Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total revenues &#8211; products and services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl" xml:lang="en-US">Foreign currency exchange rate, translation</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ForeignCurrencyExchangeRateAverage" xlink:label="AATP_ForeignCurrencyExchangeRateAverage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ForeignCurrencyExchangeRateAverage" xlink:to="AATP_ForeignCurrencyExchangeRateAverage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_ForeignCurrencyExchangeRateAverage_lbl" xml:lang="en-US">Foreign currency exchange rate period average</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Accounts receivable, allowance for credit loss</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_InventriesWriteDown" xlink:label="AATP_InventriesWriteDown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_InventriesWriteDown" xlink:to="AATP_InventriesWriteDown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_InventriesWriteDown_lbl" xml:lang="en-US">Inventories write-down</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_InventoryWriteOff" xlink:label="AATP_InventoryWriteOff" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_InventoryWriteOff" xlink:to="AATP_InventoryWriteOff_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_InventoryWriteOff_lbl" xml:lang="en-US">Inventories write off</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_lbl" xml:lang="en-US">Wrote-off allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_AllowanceForDoubtfulAccountsReceivablesCurrent" xlink:label="AATP_AllowanceForDoubtfulAccountsReceivablesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_AllowanceForDoubtfulAccountsReceivablesCurrent" xlink:to="AATP_AllowanceForDoubtfulAccountsReceivablesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_AllowanceForDoubtfulAccountsReceivablesCurrent_lbl" xml:lang="en-US">Allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xml:lang="en-US">Impairment of long-lived assets</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ForfeitedCouponIncome" xlink:label="AATP_ForfeitedCouponIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ForfeitedCouponIncome" xlink:to="AATP_ForfeitedCouponIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_ForfeitedCouponIncome_lbl" xml:lang="en-US">Value of coupons</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_2_lbl" xml:lang="en-US">Cost of revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xml:lang="en-US">Revenues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingExpense" xlink:to="us-gaap_SellingExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingExpense_2_lbl" xml:lang="en-US">Selling expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US">Advertising costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesCommissionsAndFees" xlink:to="us-gaap_SalesCommissionsAndFees_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SalesCommissionsAndFees_2_lbl" xml:lang="en-US">Commission expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US">Defined contribution plan expense</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SalaryPercentage" xlink:label="AATP_SalaryPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_SalaryPercentage" xlink:to="AATP_SalaryPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_SalaryPercentage_lbl" xml:lang="en-US">Salary percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_MonthlySalary" xlink:label="AATP_MonthlySalary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_MonthlySalary" xlink:to="AATP_MonthlySalary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_MonthlySalary_lbl" xml:lang="en-US">Monthly salary</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl" xml:lang="en-US">Income tax description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xml:lang="en-US">Income tax examination, penalties and interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDescription" xlink:label="us-gaap_MinorityInterestDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestDescription" xlink:to="us-gaap_MinorityInterestDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestDescription_lbl" xml:lang="en-US">Noncontrolling interest, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Potentially dilutive securities outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingActivitiesGainLossByTypeTable" xlink:label="us-gaap_TradingActivitiesGainLossByTypeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradingActivitiesGainLossByTypeTable" xlink:to="us-gaap_TradingActivitiesGainLossByTypeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradingActivitiesGainLossByTypeTable_lbl" xml:lang="en-US">Trading Activities, Gain and Losses, by Type, by Income Statement Location [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingActivityGainsAndLossesLineItems" xlink:label="us-gaap_TradingActivityGainsAndLossesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradingActivityGainsAndLossesLineItems" xlink:to="us-gaap_TradingActivityGainsAndLossesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradingActivityGainsAndLossesLineItems_lbl" xml:lang="en-US">Trading Activity, Gains and Losses, Net [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Net deficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidTaxes" xlink:to="us-gaap_PrepaidTaxes_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidTaxes_2_lbl" xml:lang="en-US">Prepaid taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable &#8211; intercompany</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_OtherPayablesRelatedPartyCurrent" xlink:label="AATP_OtherPayablesRelatedPartyCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_OtherPayablesRelatedPartyCurrent" xlink:to="AATP_OtherPayablesRelatedPartyCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AATP_OtherPayablesRelatedPartyCurrent_lbl" xml:lang="en-US">Other payables and accrued liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_3_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3_lbl" xml:lang="en-US">Operating revenues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash in bank</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TimeDeposits" xlink:label="us-gaap_TimeDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TimeDeposits" xlink:to="us-gaap_TimeDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TimeDeposits_lbl" xml:lang="en-US">Time deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits" xlink:label="us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits" xlink:to="us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits_lbl" xml:lang="en-US">Percentage of Interest rate for time deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TimeDepositLiabilityUninsured" xlink:label="us-gaap_TimeDepositLiabilityUninsured" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TimeDepositLiabilityUninsured" xlink:to="us-gaap_TimeDepositLiabilityUninsured_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TimeDepositLiabilityUninsured_lbl" xml:lang="en-US">Time deposit uninsured</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2_lbl" xml:lang="en-US">Allowance for doubtful accounts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_InventriesWriteDown" xlink:to="AATP_InventriesWriteDown_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AATP_InventriesWriteDown_2_lbl" xml:lang="en-US">Inventory write-down</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_InventoryWriteOff" xlink:to="AATP_InventoryWriteOff_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AATP_InventoryWriteOff_2_lbl" xml:lang="en-US">Inventory write- off</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DisclosurePrepaymentsAndDepositsAbstract" xlink:to="AATP_DisclosurePrepaymentsAndDepositsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AATP_DisclosurePrepaymentsAndDepositsAbstract_2_lbl" xml:lang="en-US">Schedule Of Prepaid Expenses And Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ReceivablesFromSalesDistributors" xlink:label="AATP_ReceivablesFromSalesDistributors" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ReceivablesFromSalesDistributors" xlink:to="AATP_ReceivablesFromSalesDistributors_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_ReceivablesFromSalesDistributors_lbl" xml:lang="en-US">Receivables from sales distributors</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DepositsToSupplier" xlink:label="AATP_DepositsToSupplier" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DepositsToSupplier" xlink:to="AATP_DepositsToSupplier_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_DepositsToSupplier_lbl" xml:lang="en-US">Deposits to suppliers</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PrepaidExpensesGross" xlink:label="AATP_PrepaidExpensesGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_PrepaidExpensesGross" xlink:to="AATP_PrepaidExpensesGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="AATP_PrepaidExpensesGross_lbl" xml:lang="en-US">Subtotal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:to="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_lbl" xml:lang="en-US">Less: Provision for doubtful accounts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DisclosurePrepaymentsAndDepositsAbstract" xlink:to="AATP_DisclosurePrepaymentsAndDepositsAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="AATP_DisclosurePrepaymentsAndDepositsAbstract_3_lbl" xml:lang="en-US">Schedule Of Changes In Allowance For Doubtful Accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_lbl" xml:lang="en-US">Addition</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_2_lbl" xml:lang="en-US">Write off</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_AllowanceForDoubtfulAccountsReceivableExchangeRateEffect" xlink:label="AATP_AllowanceForDoubtfulAccountsReceivableExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_AllowanceForDoubtfulAccountsReceivableExchangeRateEffect" xlink:to="AATP_AllowanceForDoubtfulAccountsReceivableExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_AllowanceForDoubtfulAccountsReceivableExchangeRateEffect_lbl" xml:lang="en-US">Exchange rate effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_2_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Subtotal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="us-gaap_CapitalizedComputerSoftwareGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareGross" xlink:to="us-gaap_CapitalizedComputerSoftwareGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_lbl" xml:lang="en-US">Computer software</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Less: accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DisclosureInvestmentInMarketableSecuritiesAbstract" xlink:to="AATP_DisclosureInvestmentInMarketableSecuritiesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AATP_DisclosureInvestmentInMarketableSecuritiesAbstract_2_lbl" xml:lang="en-US">Schedule Of Investment In Marketable Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtCost" xlink:label="us-gaap_InvestmentOwnedAtCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedAtCost" xlink:to="us-gaap_InvestmentOwnedAtCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedAtCost_lbl" xml:lang="en-US">Cost of investment</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_TransferFromNonmarketableSecurity" xlink:label="AATP_TransferFromNonmarketableSecurity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_TransferFromNonmarketableSecurity" xlink:to="AATP_TransferFromNonmarketableSecurity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="AATP_TransferFromNonmarketableSecurity_lbl" xml:lang="en-US">Transfer from non-marketable security</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_InvestmentsIncomeDividend" xlink:label="AATP_InvestmentsIncomeDividend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_InvestmentsIncomeDividend" xlink:to="AATP_InvestmentsIncomeDividend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="AATP_InvestmentsIncomeDividend_lbl" xml:lang="en-US">Dividend income from Greenpro Capital Corp.</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_MarketableSecuritiesUnrealizedHoldingLoss" xlink:label="AATP_MarketableSecuritiesUnrealizedHoldingLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_MarketableSecuritiesUnrealizedHoldingLoss" xlink:to="AATP_MarketableSecuritiesUnrealizedHoldingLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="AATP_MarketableSecuritiesUnrealizedHoldingLoss_lbl" xml:lang="en-US">Unrealized holding loss</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ExchangeRateEffectOnInvestmentInMarketableSecurites" xlink:label="AATP_ExchangeRateEffectOnInvestmentInMarketableSecurites" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ExchangeRateEffectOnInvestmentInMarketableSecurites" xlink:to="AATP_ExchangeRateEffectOnInvestmentInMarketableSecurites_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AATP_ExchangeRateEffectOnInvestmentInMarketableSecurites_lbl" xml:lang="en-US">Exchange rate effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_2_lbl" xml:lang="en-US">Investment in marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="us-gaap_InvestmentOwnedBalanceShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedBalanceShares" xlink:to="us-gaap_InvestmentOwnedBalanceShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedBalanceShares_lbl" xml:lang="en-US">Shares purchased during period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedAtCost" xlink:to="us-gaap_InvestmentOwnedAtCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentOwnedAtCost_2_lbl" xml:lang="en-US">Investment amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares issued price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Stockholders equity reverse stock split</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_3_lbl" xml:lang="en-US">Equity interest percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock issued during peirod shares new issues</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_TransferToInvestmentInMarketableSecurities" xlink:label="AATP_TransferToInvestmentInMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_TransferToInvestmentInMarketableSecurities" xlink:to="AATP_TransferToInvestmentInMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="AATP_TransferToInvestmentInMarketableSecurities_lbl" xml:lang="en-US">Less: Transfer to investment in marketable securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_InvestmentInNonMarketableSecuritiesNoncurrent" xlink:to="AATP_InvestmentInNonMarketableSecuritiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="AATP_InvestmentInNonMarketableSecuritiesNoncurrent_2_lbl" xml:lang="en-US">Investment in non-marketable securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DisclosureCustomerDepositsAbstract" xlink:to="AATP_DisclosureCustomerDepositsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AATP_DisclosureCustomerDepositsAbstract_2_lbl" xml:lang="en-US">Schedule Of Customer Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_CustomerDeposits" xlink:label="AATP_CustomerDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_CustomerDeposits" xlink:to="AATP_CustomerDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AATP_CustomerDeposits_lbl" xml:lang="en-US">Customer deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_UnexpiredProductCoupons" xlink:label="AATP_UnexpiredProductCoupons" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_UnexpiredProductCoupons" xlink:to="AATP_UnexpiredProductCoupons_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_UnexpiredProductCoupons_lbl" xml:lang="en-US">Unexpired product coupons</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositLiabilityCurrent" xlink:label="us-gaap_DepositLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositLiabilityCurrent" xlink:to="us-gaap_DepositLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositLiabilityCurrent_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_AccruedPromotionExpensesCurrent" xlink:label="AATP_AccruedPromotionExpensesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_AccruedPromotionExpensesCurrent" xlink:to="AATP_AccruedPromotionExpensesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_AccruedPromotionExpensesCurrent_lbl" xml:lang="en-US">Promotion expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedPayrollTaxesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedPayrollTaxesCurrent_lbl" xml:lang="en-US">Payroll</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalesCommissionCurrent" xlink:label="us-gaap_AccruedSalesCommissionCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalesCommissionCurrent" xlink:to="us-gaap_AccruedSalesCommissionCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalesCommissionCurrent_lbl" xml:lang="en-US">Amounts held in eWallets</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_AccruedTaxPenaltyCurrent" xlink:label="AATP_AccruedTaxPenaltyCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_AccruedTaxPenaltyCurrent" xlink:to="AATP_AccruedTaxPenaltyCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_AccruedTaxPenaltyCurrent_lbl" xml:lang="en-US">Tax penalty</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xml:lang="en-US">Others</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_OtherAccountPayableAndAccruedLiabilities" xlink:label="AATP_OtherAccountPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_OtherAccountPayableAndAccruedLiabilities" xlink:to="AATP_OtherAccountPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="AATP_OtherAccountPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_CommissionPaymentsDescriptions" xlink:label="AATP_CommissionPaymentsDescriptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_CommissionPaymentsDescriptions" xlink:to="AATP_CommissionPaymentsDescriptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_CommissionPaymentsDescriptions_lbl" xml:lang="en-US">Commission payments descriptions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommissionsPayableToBrokerDealersAndClearingOrganizations" xlink:label="us-gaap_CommissionsPayableToBrokerDealersAndClearingOrganizations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommissionsPayableToBrokerDealersAndClearingOrganizations" xlink:to="us-gaap_CommissionsPayableToBrokerDealersAndClearingOrganizations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommissionsPayableToBrokerDealersAndClearingOrganizations_lbl" xml:lang="en-US">Comission payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetGross" xlink:label="us-gaap_ContractWithCustomerAssetGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetGross" xlink:to="us-gaap_ContractWithCustomerAssetGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetGross_lbl" xml:lang="en-US">Comission payable, threshold</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_RelatedPartiesRelationshipsDescription" xlink:label="AATP_RelatedPartiesRelationshipsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_RelatedPartiesRelationshipsDescription" xlink:to="AATP_RelatedPartiesRelationshipsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_RelatedPartiesRelationshipsDescription_lbl" xml:lang="en-US">Relationship</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedParties" xlink:label="us-gaap_DueFromRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedParties" xlink:to="us-gaap_DueFromRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromRelatedParties_lbl" xml:lang="en-US">Due from related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_RelatedPartiesNatureDescription" xlink:label="AATP_RelatedPartiesNatureDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_RelatedPartiesNatureDescription" xlink:to="AATP_RelatedPartiesNatureDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_RelatedPartiesNatureDescription_lbl" xml:lang="en-US">Nature</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_2_lbl" xml:lang="en-US">Accounts payable, related parties, current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Due to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xml:lang="en-US">Purchases</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_RelatedPartyOtherIncome" xlink:label="AATP_RelatedPartyOtherIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_RelatedPartyOtherIncome" xlink:to="AATP_RelatedPartyOtherIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_RelatedPartyOtherIncome_lbl" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_RelatedPartyTransactionOtherPurchasesFromRelatedParty" xlink:label="AATP_RelatedPartyTransactionOtherPurchasesFromRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_RelatedPartyTransactionOtherPurchasesFromRelatedParty" xlink:to="AATP_RelatedPartyTransactionOtherPurchasesFromRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_RelatedPartyTransactionOtherPurchasesFromRelatedParty_lbl" xml:lang="en-US">Other purchases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesCommissionsAndFees" xlink:to="us-gaap_SalesCommissionsAndFees_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesCommissionsAndFees_3_lbl" xml:lang="en-US">Commission expense</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_RelatedPartyOtherExpenses" xlink:label="AATP_RelatedPartyOtherExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_RelatedPartyOtherExpenses" xlink:to="AATP_RelatedPartyOtherExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_RelatedPartyOtherExpenses_lbl" xml:lang="en-US">Other expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_2_lbl" xml:lang="en-US">Number of shares forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ReductionInCommonStockOutstanding" xlink:label="AATP_ReductionInCommonStockOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ReductionInCommonStockOutstanding" xlink:to="AATP_ReductionInCommonStockOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_ReductionInCommonStockOutstanding_lbl" xml:lang="en-US">Reduction in outstanding shares</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_NonControllingInterestPaidinCapital" xlink:label="AATP_NonControllingInterestPaidinCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_NonControllingInterestPaidinCapital" xlink:to="AATP_NonControllingInterestPaidinCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_NonControllingInterestPaidinCapital_lbl" xml:lang="en-US">Paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_NonControllingInterestAccumulatedDeficit" xlink:label="AATP_NonControllingInterestAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_NonControllingInterestAccumulatedDeficit" xlink:to="AATP_NonControllingInterestAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_NonControllingInterestAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated surplus (deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_NonControllingInterestAccumulatedOtherComprehensiveIncome" xlink:label="AATP_NonControllingInterestAccumulatedOtherComprehensiveIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_NonControllingInterestAccumulatedOtherComprehensiveIncome" xlink:to="AATP_NonControllingInterestAccumulatedOtherComprehensiveIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AATP_NonControllingInterestAccumulatedOtherComprehensiveIncome_lbl" xml:lang="en-US">Accumulated other comprehensive income</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_NonControllingInterestNonControllingInterestGross" xlink:label="AATP_NonControllingInterestNonControllingInterestGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_NonControllingInterestNonControllingInterestGross" xlink:to="AATP_NonControllingInterestNonControllingInterestGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="AATP_NonControllingInterestNonControllingInterestGross_lbl" xml:lang="en-US">Non Controlling interest Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_NonControllingInterestAsl" xlink:label="AATP_NonControllingInterestAsl" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_NonControllingInterestAsl" xlink:to="AATP_NonControllingInterestAsl_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_NonControllingInterestAsl_lbl" xml:lang="en-US">ASL</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MinorityInterest_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">Local &#8211; United States</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Foreign, Tax jurisdictions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Loss before income tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Current:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">- Local</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US">- Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Deferred:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">- Local</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">- Foreign</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Benefit of (Provision for) income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U.S. statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Differential tax rate in Malaysia</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Permanent difference</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Tax percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xml:lang="en-US">Net operating loss carry forwards in Malaysia</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DeferredTaxLiabilitiesDepreciation" xlink:label="AATP_DeferredTaxLiabilitiesDepreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DeferredTaxLiabilitiesDepreciation" xlink:to="AATP_DeferredTaxLiabilitiesDepreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AATP_DeferredTaxLiabilitiesDepreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Deferred tax liabilities, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">Tax percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_TaxRateDescription" xlink:label="AATP_TaxRateDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_TaxRateDescription" xlink:to="AATP_TaxRateDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_TaxRateDescription_lbl" xml:lang="en-US">Tax rate description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carryforwards</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred tax valuation allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xml:lang="en-US">Income tax expense benefit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_2_lbl" xml:lang="en-US">Income tax examination penalties and interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Deferred tax assets operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DeferredTaxAssetsOperatingLossCarryforwardsReducedAmount" xlink:label="AATP_DeferredTaxAssetsOperatingLossCarryforwardsReducedAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DeferredTaxAssetsOperatingLossCarryforwardsReducedAmount" xlink:to="AATP_DeferredTaxAssetsOperatingLossCarryforwardsReducedAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_DeferredTaxAssetsOperatingLossCarryforwardsReducedAmount_lbl" xml:lang="en-US">Deferred tax assets operating loss carryforwards reduced amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationDescription" xlink:to="us-gaap_IncomeTaxExaminationDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xml:lang="en-US">Income tax examination, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl" xml:lang="en-US">Additional paid in capital stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US">Concentration Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentrations of risk percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DividendShareForCommonStock" xlink:label="AATP_DividendShareForCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DividendShareForCommonStock" xlink:to="AATP_DividendShareForCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_DividendShareForCommonStock_lbl" xml:lang="en-US">Dividend share for common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Deposits" xlink:label="us-gaap_Deposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Deposits" xlink:to="us-gaap_Deposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Deposits_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DepositForInsurance" xlink:label="AATP_DepositForInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DepositForInsurance" xlink:to="AATP_DepositForInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_DepositForInsurance_lbl" xml:lang="en-US">Deposit for insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_LesseeOperatingLeaseLiabilityPaymentsDueAfterNextTwelveMonths" xlink:label="AATP_LesseeOperatingLeaseLiabilityPaymentsDueAfterNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_LesseeOperatingLeaseLiabilityPaymentsDueAfterNextTwelveMonths" xlink:to="AATP_LesseeOperatingLeaseLiabilityPaymentsDueAfterNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_LesseeOperatingLeaseLiabilityPaymentsDueAfterNextTwelveMonths_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating lease effective interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_LeaseExpirationTerm" xlink:label="AATP_LeaseExpirationTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_LeaseExpirationTerm" xlink:to="AATP_LeaseExpirationTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_LeaseExpirationTerm_lbl" xml:lang="en-US">Lease expiration term</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_IncreaseDecreaseInROUAssetsAndLiabilities" xlink:label="AATP_IncreaseDecreaseInROUAssetsAndLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_IncreaseDecreaseInROUAssetsAndLiabilities" xlink:to="AATP_IncreaseDecreaseInROUAssetsAndLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_IncreaseDecreaseInROUAssetsAndLiabilities_lbl" xml:lang="en-US">Reduction in ROU assets and liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating lease, weighted average remaining lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease, expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_InvestmentInNonMarketableSecuritiesNoncurrent" xlink:to="AATP_InvestmentInNonMarketableSecuritiesNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_InvestmentInNonMarketableSecuritiesNoncurrent_doc" xml:lang="en-US">Investment in non-marketable securities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_VariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents" xlink:to="AATP_VariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_VariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents_doc" xml:lang="en-US">VIE consolidated amount of cash and cash equivalents.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_VariableInterestEntityConsolidatedAmountOfPrepaidTaxes" xlink:to="AATP_VariableInterestEntityConsolidatedAmountOfPrepaidTaxes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_VariableInterestEntityConsolidatedAmountOfPrepaidTaxes_doc" xml:lang="en-US">VIE consolidated amount of Prepaid taxes .</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_VariableInterestEntityConsolidatedAmountOfOtherPayablesAndAccruedLiabilities" xlink:to="AATP_VariableInterestEntityConsolidatedAmountOfOtherPayablesAndAccruedLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_VariableInterestEntityConsolidatedAmountOfOtherPayablesAndAccruedLiabilities_doc" xml:lang="en-US">VIE consolidated amount of other payables and accrued liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_PreferredStockDividendIncomeStatementImpact" xlink:to="AATP_PreferredStockDividendIncomeStatementImpact_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_PreferredStockDividendIncomeStatementImpact_doc" xml:lang="en-US">The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ContributionsFromNoncontrollingInterestShareholders" xlink:to="AATP_ContributionsFromNoncontrollingInterestShareholders_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_ContributionsFromNoncontrollingInterestShareholders_doc" xml:lang="en-US">Contributions from non controlling interest shareholders.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ChangesInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseModifications" xlink:to="AATP_ChangesInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseModifications_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_ChangesInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseModifications_doc" xml:lang="en-US">Changes in right of use asset and lease liabilities due to lease modifications.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_AgapeATPInternationalHoldingLimitedMember" xlink:to="AATP_AgapeATPInternationalHoldingLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_AgapeATPInternationalHoldingLimitedMember_doc" xml:lang="en-US">Agape ATP International Holding Limited [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ShareExchangeAgreementMember" xlink:to="AATP_ShareExchangeAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_ShareExchangeAgreementMember_doc" xml:lang="en-US">Share Exchange Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_MrHowKokChoongMember" xlink:to="AATP_MrHowKokChoongMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_MrHowKokChoongMember_doc" xml:lang="en-US">Mr.How Kok Choong [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_SubsidiaryCompanyTwoMember" xlink:to="AATP_SubsidiaryCompanyTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_SubsidiaryCompanyTwoMember_doc" xml:lang="en-US">Subsidiary Company Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_SubsidiaryCompanyFiveMember" xlink:to="AATP_SubsidiaryCompanyFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_SubsidiaryCompanyFiveMember_doc" xml:lang="en-US">Subsidiary Company Five [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_NameOftheCompany" xlink:to="AATP_NameOftheCompany_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_NameOftheCompany_doc" xml:lang="en-US">Name of the company name.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_SubsidiaryCompanyMember" xlink:to="AATP_SubsidiaryCompanyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_SubsidiaryCompanyMember_doc" xml:lang="en-US">Subsidiary Company [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_SubsidiaryCompanyOneMember" xlink:to="AATP_SubsidiaryCompanyOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_SubsidiaryCompanyOneMember_doc" xml:lang="en-US">Subsidiary Company One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_SubsidiaryCompanyThreeMember" xlink:to="AATP_SubsidiaryCompanyThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_SubsidiaryCompanyThreeMember_doc" xml:lang="en-US">Subsidiary Company Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_SubsidiaryCompanyFourMember" xlink:to="AATP_SubsidiaryCompanyFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_SubsidiaryCompanyFourMember_doc" xml:lang="en-US">Subsidiary Company Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_PlaceAndDateOfIncorporation" xlink:to="AATP_PlaceAndDateOfIncorporation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_PlaceAndDateOfIncorporation_doc" xml:lang="en-US">Place and date of incorporation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ParticularsOfIssuedCapital" xlink:to="AATP_ParticularsOfIssuedCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_ParticularsOfIssuedCapital_doc" xml:lang="en-US">Particulars of issued capital.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_PrincipalActivities" xlink:to="AATP_PrincipalActivities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_PrincipalActivities_doc" xml:lang="en-US">Principal activities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_InventoryWriteOff" xlink:to="AATP_InventoryWriteOff_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_InventoryWriteOff_doc" xml:lang="en-US">Inventory write off.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_PrepaidTaxesPolicyTextBlock" xlink:to="AATP_PrepaidTaxesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_PrepaidTaxesPolicyTextBlock_doc" xml:lang="en-US">Prepaid Taxes [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_PrepaymentsAndDepositsPolicyTextBlock" xlink:to="AATP_PrepaymentsAndDepositsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_PrepaymentsAndDepositsPolicyTextBlock_doc" xml:lang="en-US">Prepayments And Deposits [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_AllowanceForDoubtfulAccountsReceivablesCurrent" xlink:to="AATP_AllowanceForDoubtfulAccountsReceivablesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_AllowanceForDoubtfulAccountsReceivablesCurrent_doc" xml:lang="en-US">Allowance for doubtful accounts,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:to="AATP_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_doc" xml:lang="en-US">Schedule Of Estimated Useful Lives Of Property And Equipment [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock" xlink:to="AATP_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock_doc" xml:lang="en-US">Schedule of Estimated Useful Lives of Intangible Assets Net [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_NonMarketableSecuritiesPolicyTextBlock" xlink:to="AATP_NonMarketableSecuritiesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_NonMarketableSecuritiesPolicyTextBlock_doc" xml:lang="en-US">Non Marketable Securities [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ForfeitedCouponIncome" xlink:to="AATP_ForfeitedCouponIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_ForfeitedCouponIncome_doc" xml:lang="en-US">Forfeited coupon income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_HealthAndWellnessServicesMember" xlink:to="AATP_HealthAndWellnessServicesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_HealthAndWellnessServicesMember_doc" xml:lang="en-US">Health and Wellness Services [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_LipomaskMember" xlink:to="AATP_LipomaskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_LipomaskMember_doc" xml:lang="en-US">Lipomask [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_EnergetiqueMember" xlink:to="AATP_EnergetiqueMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_EnergetiqueMember_doc" xml:lang="en-US">Energetique [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ShippingAndHandlingPolicyTextBlock" xlink:to="AATP_ShippingAndHandlingPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_ShippingAndHandlingPolicyTextBlock_doc" xml:lang="en-US">Shipping and Handling [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DefinedContributionPlanPolicyTextBlock" xlink:to="AATP_DefinedContributionPlanPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_DefinedContributionPlanPolicyTextBlock_doc" xml:lang="en-US">Defined Contribution Plan [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_SalaryPercentage" xlink:to="AATP_SalaryPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_SalaryPercentage_doc" xml:lang="en-US">Salary percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_SocialSecurityOrganizationMember" xlink:to="AATP_SocialSecurityOrganizationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_SocialSecurityOrganizationMember_doc" xml:lang="en-US">Social Security Organization [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_EmployeesProvidentFundMember" xlink:to="AATP_EmployeesProvidentFundMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_EmployeesProvidentFundMember_doc" xml:lang="en-US">Employees Provident Fund [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_EmploymentInsuranceSystemMember" xlink:to="AATP_EmploymentInsuranceSystemMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_EmploymentInsuranceSystemMember_doc" xml:lang="en-US">Employment Insurance System [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_HumanResourceDevelopmentFundMember" xlink:to="AATP_HumanResourceDevelopmentFundMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_HumanResourceDevelopmentFundMember_doc" xml:lang="en-US">Human Resource Development Fund [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_NoncontrollingInterestPolicyTextBlock" xlink:to="AATP_NoncontrollingInterestPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_NoncontrollingInterestPolicyTextBlock_doc" xml:lang="en-US">Noncontrolling Interest [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ForeignCurrencyExchangeRateAverage" xlink:to="AATP_ForeignCurrencyExchangeRateAverage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_ForeignCurrencyExchangeRateAverage_doc" xml:lang="en-US">Foreign currency exchange rate period average.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_PeriodAverageHKDMember" xlink:to="AATP_PeriodAverageHKDMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_PeriodAverageHKDMember_doc" xml:lang="en-US">Period-average HKD [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_RelatedPartiesPolicyTextBlock" xlink:to="AATP_RelatedPartiesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_RelatedPartiesPolicyTextBlock_doc" xml:lang="en-US">Related Parties [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_OtherPayablesRelatedPartyCurrent" xlink:to="AATP_OtherPayablesRelatedPartyCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_OtherPayablesRelatedPartyCurrent_doc" xml:lang="en-US">Other payables - related party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_PrepaymentsAndDepositsTextBlock" xlink:to="AATP_PrepaymentsAndDepositsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_PrepaymentsAndDepositsTextBlock_doc" xml:lang="en-US">Prepayments and Deposits [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ReceivablesFromSalesDistributors" xlink:to="AATP_ReceivablesFromSalesDistributors_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_ReceivablesFromSalesDistributors_doc" xml:lang="en-US">Receivables from sales distributors.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DepositsToSupplier" xlink:to="AATP_DepositsToSupplier_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_DepositsToSupplier_doc" xml:lang="en-US">Deposits to supplier.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_PrepaidExpensesGross" xlink:to="AATP_PrepaidExpensesGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_PrepaidExpensesGross_doc" xml:lang="en-US">Prepaid expenses gross.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_AllowanceForDoubtfulAccountsReceivableExchangeRateEffect" xlink:to="AATP_AllowanceForDoubtfulAccountsReceivableExchangeRateEffect_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_AllowanceForDoubtfulAccountsReceivableExchangeRateEffect_doc" xml:lang="en-US">Allowance for doubtful accounts receivable exchange rate effect.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_InvestmentInMarketableSecuritiesTextBlock" xlink:to="AATP_InvestmentInMarketableSecuritiesTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_InvestmentInMarketableSecuritiesTextBlock_doc" xml:lang="en-US">Investment In Marketable Securities [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_GreenproCapitalCorpMember" xlink:to="AATP_GreenproCapitalCorpMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_GreenproCapitalCorpMember_doc" xml:lang="en-US">Greenpro Capital Corp. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DSwissIncMember" xlink:to="AATP_DSwissIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_DSwissIncMember_doc" xml:lang="en-US">DSwiss Inc. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_SEATechVenturesCorpMember" xlink:to="AATP_SEATechVenturesCorpMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_SEATechVenturesCorpMember_doc" xml:lang="en-US">SEATech Ventures Corp. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_PhoenixPlusCorpMember" xlink:to="AATP_PhoenixPlusCorpMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_PhoenixPlusCorpMember_doc" xml:lang="en-US">Phoenix Plus Corporation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_InvestmentsIncomeDividend" xlink:to="AATP_InvestmentsIncomeDividend_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_InvestmentsIncomeDividend_doc" xml:lang="en-US">Dividend income .</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ExchangeRateEffectOnInvestmentInMarketableSecurites" xlink:to="AATP_ExchangeRateEffectOnInvestmentInMarketableSecurites_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_ExchangeRateEffectOnInvestmentInMarketableSecurites_doc" xml:lang="en-US">Exchange rate effect.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_InvestmentInNonMarketableSecuritiesTextBlock" xlink:to="AATP_InvestmentInNonMarketableSecuritiesTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_InvestmentInNonMarketableSecuritiesTextBlock_doc" xml:lang="en-US">Investment In Non Marketable Securities [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_NonMarketableSecuritiesTableTextBlock" xlink:to="AATP_NonMarketableSecuritiesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_NonMarketableSecuritiesTableTextBlock_doc" xml:lang="en-US">Non Marketable Securities [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_TransferToInvestmentInMarketableSecurities" xlink:to="AATP_TransferToInvestmentInMarketableSecurities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_TransferToInvestmentInMarketableSecurities_doc" xml:lang="en-US">Transfer to investment in marketable securities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock" xlink:to="AATP_ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock_doc" xml:lang="en-US">Schedule Of Other Payables And Accrued Liabilities [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_OtherAccountPayableAndAccruedLiabilities" xlink:to="AATP_OtherAccountPayableAndAccruedLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_OtherAccountPayableAndAccruedLiabilities_doc" xml:lang="en-US">Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_AccruedTaxPenaltyCurrent" xlink:to="AATP_AccruedTaxPenaltyCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_AccruedTaxPenaltyCurrent_doc" xml:lang="en-US">Accrued tax penalty, current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_RelatedPartiesRelationshipsDescription" xlink:to="AATP_RelatedPartiesRelationshipsDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_RelatedPartiesRelationshipsDescription_doc" xml:lang="en-US">Related parties relationships description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_CTANutriceuticalsSdnBhdMember" xlink:to="AATP_CTANutriceuticalsSdnBhdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_CTANutriceuticalsSdnBhdMember_doc" xml:lang="en-US">CTA Nutriceuticals Sdn Bhd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DSYBeautySdnBhdMember" xlink:to="AATP_DSYBeautySdnBhdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_DSYBeautySdnBhdMember_doc" xml:lang="en-US">DSY Beauty Sdn Bhd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_RelatedPartiesNatureDescription" xlink:to="AATP_RelatedPartiesNatureDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_RelatedPartiesNatureDescription_doc" xml:lang="en-US">Related parties nature description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_TH3TechnologySdnBhdMember" xlink:to="AATP_TH3TechnologySdnBhdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_TH3TechnologySdnBhdMember_doc" xml:lang="en-US">TH3 Technology Sdn Bhd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_AgapeATPAsiaLimitedMember" xlink:to="AATP_AgapeATPAsiaLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_AgapeATPAsiaLimitedMember_doc" xml:lang="en-US">Agape ATP (Asia) Limited ("AATP Asia") [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_HostastaySdnBhdMember" xlink:to="AATP_HostastaySdnBhdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_HostastaySdnBhdMember_doc" xml:lang="en-US">Hostastay Sdn. Bhd. (&#8220;Hostastay&#8221;) [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DSYBeautySdnBhdOneMember" xlink:to="AATP_DSYBeautySdnBhdOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_DSYBeautySdnBhdOneMember_doc" xml:lang="en-US">DSY Beauty Sdn Bhd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_HowKokChoongMember" xlink:to="AATP_HowKokChoongMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_HowKokChoongMember_doc" xml:lang="en-US">How Kok Choong [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_CTANutriceuticalsAsiaSdnBhdOneMember" xlink:to="AATP_CTANutriceuticalsAsiaSdnBhdOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_CTANutriceuticalsAsiaSdnBhdOneMember_doc" xml:lang="en-US">CTA Nutriceuticals Asia Sdn Bhd One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DSYWellnessandLongevityCenterSdnBhdTwoMember" xlink:to="AATP_DSYWellnessandLongevityCenterSdnBhdTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_DSYWellnessandLongevityCenterSdnBhdTwoMember_doc" xml:lang="en-US">DSY Wellness and Longevity Center Sdn Bhd ("DSYWLC") [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_HostastaySdnBhdHostastayMember" xlink:to="AATP_HostastaySdnBhdHostastayMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_HostastaySdnBhdHostastayMember_doc" xml:lang="en-US">Hostastay Sdn. Bhd. (&#8220;Hostastay&#8221;) [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_RelatedPartyOtherIncome" xlink:to="AATP_RelatedPartyOtherIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_RelatedPartyOtherIncome_doc" xml:lang="en-US">Related party other income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_RelatedPartyTransactionOtherPurchasesFromRelatedParty" xlink:to="AATP_RelatedPartyTransactionOtherPurchasesFromRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_RelatedPartyTransactionOtherPurchasesFromRelatedParty_doc" xml:lang="en-US">Related party transaction other purchases from related party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_CTANutriceuticalsAsiaSdnBhdMember" xlink:to="AATP_CTANutriceuticalsAsiaSdnBhdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_CTANutriceuticalsAsiaSdnBhdMember_doc" xml:lang="en-US">CTA Nutriceuticals Asia Sdn Bhd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DSYWellnessAndLongevityCenterSdnBhdMember" xlink:to="AATP_DSYWellnessAndLongevityCenterSdnBhdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_DSYWellnessAndLongevityCenterSdnBhdMember_doc" xml:lang="en-US">DSY Wellness &amp; Longevity Center Sdn Bhd [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_RelatedPartyOtherExpenses" xlink:to="AATP_RelatedPartyOtherExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_RelatedPartyOtherExpenses_doc" xml:lang="en-US">Related party other expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_RedboyPictureSdnBhdMember" xlink:to="AATP_RedboyPictureSdnBhdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_RedboyPictureSdnBhdMember_doc" xml:lang="en-US">Redboy Picture Sdn Bhd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DSYWellnessAndLongevityCenterSdnBhdThreeMember" xlink:to="AATP_DSYWellnessAndLongevityCenterSdnBhdThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_DSYWellnessAndLongevityCenterSdnBhdThreeMember_doc" xml:lang="en-US">DSY Wellness and Longevity Center Sdn Bhd ("DSYWLC") [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ShareForfeitureAgreementsMember" xlink:to="AATP_ShareForfeitureAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_ShareForfeitureAgreementsMember_doc" xml:lang="en-US">Share Forfeiture Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_HowKokChoongTalentLimitedMember" xlink:to="AATP_HowKokChoongTalentLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_HowKokChoongTalentLimitedMember_doc" xml:lang="en-US">How Kok Choong Talent Limited [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ShareholdersMember" xlink:to="AATP_ShareholdersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_ShareholdersMember_doc" xml:lang="en-US">Shareholders [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_HKCHoldingsSdnBhdMember" xlink:to="AATP_HKCHoldingsSdnBhdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_HKCHoldingsSdnBhdMember_doc" xml:lang="en-US">HKC Holdings Sdn Bhd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ReductionInCommonStockOutstanding" xlink:to="AATP_ReductionInCommonStockOutstanding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_ReductionInCommonStockOutstanding_doc" xml:lang="en-US">Reduction in common stock outstanding during period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ScheduleOfNonControllingInterestTableTextBlock" xlink:to="AATP_ScheduleOfNonControllingInterestTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_ScheduleOfNonControllingInterestTableTextBlock_doc" xml:lang="en-US">Schedule of Non Controlling Interest [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_NonControllingInterestPaidinCapital" xlink:to="AATP_NonControllingInterestPaidinCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_NonControllingInterestPaidinCapital_doc" xml:lang="en-US">Non controlling interest paid in capital.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_NonControllingInterestAccumulatedDeficit" xlink:to="AATP_NonControllingInterestAccumulatedDeficit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_NonControllingInterestAccumulatedDeficit_doc" xml:lang="en-US">Non controlling interest accumulated deficit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_NonControllingInterestAccumulatedOtherComprehensiveIncome" xlink:to="AATP_NonControllingInterestAccumulatedOtherComprehensiveIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_NonControllingInterestAccumulatedOtherComprehensiveIncome_doc" xml:lang="en-US">Non controlling interest accumulated other comprehensive income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_NonControllingInterestAsl" xlink:to="AATP_NonControllingInterestAsl_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_NonControllingInterestAsl_doc" xml:lang="en-US">Non controlling interest ASL.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_NonControllingInterestNonControllingInterestGross" xlink:to="AATP_NonControllingInterestNonControllingInterestGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_NonControllingInterestNonControllingInterestGross_doc" xml:lang="en-US">Non-Controlling interest non controlling interest gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_TaxRateDescription" xlink:to="AATP_TaxRateDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_TaxRateDescription_doc" xml:lang="en-US">Tax rate description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_LabuanMember" xlink:to="AATP_LabuanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_LabuanMember_doc" xml:lang="en-US">Labuan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_TwoThousandTwentyEightMember" xlink:to="AATP_TwoThousandTwentyEightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_TwoThousandTwentyEightMember_doc" xml:lang="en-US">2028 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_TwoThousandTwentyNineMember" xlink:to="AATP_TwoThousandTwentyNineMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_TwoThousandTwentyNineMember_doc" xml:lang="en-US">2029 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_TwoThousandThirtyMember" xlink:to="AATP_TwoThousandThirtyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_TwoThousandThirtyMember_doc" xml:lang="en-US">2030 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_AATPHKMember" xlink:to="AATP_AATPHKMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_AATPHKMember_doc" xml:lang="en-US">AATP HK [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_AATPUSMember" xlink:label="AATP_AATPUSMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_AATPUSMember" xlink:to="AATP_AATPUSMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_AATPUSMember_doc" xml:lang="en-US">AATP US [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_AATPLBASLSEAWATPAndDSYMember" xlink:to="AATP_AATPLBASLSEAWATPAndDSYMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_AATPLBASLSEAWATPAndDSYMember_doc" xml:lang="en-US">AATP LB, ASL, SEA, WATP, and DSY [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_AATPLBASLSEAAndWATPMember" xlink:to="AATP_AATPLBASLSEAAndWATPMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_AATPLBASLSEAAndWATPMember_doc" xml:lang="en-US">AATP LB, ASL, SEA and WATP [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DeferredTaxLiabilitiesDepreciation" xlink:to="AATP_DeferredTaxLiabilitiesDepreciation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_DeferredTaxLiabilitiesDepreciation_doc" xml:lang="en-US">Deferred tax liabilities, depreciation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_NoCustomerMember" xlink:to="AATP_NoCustomerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_NoCustomerMember_doc" xml:lang="en-US">No Customer [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_VendorOneMember" xlink:to="AATP_VendorOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_VendorOneMember_doc" xml:lang="en-US">Vendor One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_VendorTwoMember" xlink:to="AATP_VendorTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_VendorTwoMember_doc" xml:lang="en-US">Vendor Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_VendorThreeMember" xlink:to="AATP_VendorThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_VendorThreeMember_doc" xml:lang="en-US">Vendor Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DividendShareForCommonStock" xlink:to="AATP_DividendShareForCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_DividendShareForCommonStock_doc" xml:lang="en-US">Dividend share for common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_VendorMember" xlink:to="AATP_VendorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_VendorMember_doc" xml:lang="en-US">Vendor [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_OneVendorMember" xlink:to="AATP_OneVendorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_OneVendorMember_doc" xml:lang="en-US">One Vendor [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_OneSalesDistributorMember" xlink:to="AATP_OneSalesDistributorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_OneSalesDistributorMember_doc" xml:lang="en-US">One Sales Distributor [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DepositForInsurance" xlink:to="AATP_DepositForInsurance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_DepositForInsurance_doc" xml:lang="en-US">Deposit for insurance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_AgapeSuperiorLivingMember" xlink:to="AATP_AgapeSuperiorLivingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_AgapeSuperiorLivingMember_doc" xml:lang="en-US">ASL [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_LeaseExpirationTerm" xlink:to="AATP_LeaseExpirationTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_LeaseExpirationTerm_doc" xml:lang="en-US">Lease expiration term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_TrainingCenterMember" xlink:to="AATP_TrainingCenterMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_TrainingCenterMember_doc" xml:lang="en-US">Training Center [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_IncreaseDecreaseInROUAssetsAndLiabilities" xlink:to="AATP_IncreaseDecreaseInROUAssetsAndLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_IncreaseDecreaseInROUAssetsAndLiabilities_doc" xml:lang="en-US">Reduction in ROU assets and liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_TransferFromNonmarketableSecurity" xlink:to="AATP_TransferFromNonmarketableSecurity_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_TransferFromNonmarketableSecurity_doc" xml:lang="en-US">Transfer from non marketable security.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_AccruedPromotionExpensesCurrent" xlink:to="AATP_AccruedPromotionExpensesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_AccruedPromotionExpensesCurrent_doc" xml:lang="en-US">Accrued promotion expenses current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DeferredTaxAssetsOperatingLossCarryforwardsReducedAmount" xlink:to="AATP_DeferredTaxAssetsOperatingLossCarryforwardsReducedAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_DeferredTaxAssetsOperatingLossCarryforwardsReducedAmount_doc" xml:lang="en-US">Deferred tax assets operating loss carryforwards reduced amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_FiveIndividualCustomersMember" xlink:to="AATP_FiveIndividualCustomersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_FiveIndividualCustomersMember_doc" xml:lang="en-US">Five Individual Customers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_LesseeOperatingLeaseLiabilityPaymentsDueAfterNextTwelveMonths" xlink:to="AATP_LesseeOperatingLeaseLiabilityPaymentsDueAfterNextTwelveMonths_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_LesseeOperatingLeaseLiabilityPaymentsDueAfterNextTwelveMonths_doc" xml:lang="en-US">Lessee operating lease liability payments due after next twelve months.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_MonthlySalary" xlink:to="AATP_MonthlySalary_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_MonthlySalary_doc" xml:lang="en-US">Monthly salary.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_InventriesWriteDown" xlink:to="AATP_InventriesWriteDown_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_InventriesWriteDown_doc" xml:lang="en-US">Inventries write down.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_MarketableSecuritiesUnrealizedHoldingLoss" xlink:to="AATP_MarketableSecuritiesUnrealizedHoldingLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_MarketableSecuritiesUnrealizedHoldingLoss_doc" xml:lang="en-US">Unrealized holding (loss) gain.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_CustomerDepositsTextBlock" xlink:to="AATP_CustomerDepositsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_CustomerDepositsTextBlock_doc" xml:lang="en-US">Customer Deposits [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_UnexpiredProductCoupons" xlink:to="AATP_UnexpiredProductCoupons_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_UnexpiredProductCoupons_doc" xml:lang="en-US">Unexpired product coupons.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_CustomerDeposits" xlink:to="AATP_CustomerDeposits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_CustomerDeposits_doc" xml:lang="en-US">Customer deposits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_CommissionPaymentsDescriptions" xlink:to="AATP_CommissionPaymentsDescriptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AATP_CommissionPaymentsDescriptions_doc" xml:lang="en-US">Commission payments descriptions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DSYBeautySdnBhdOneMember" xlink:to="AATP_DSYBeautySdnBhdOneMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_DSYBeautySdnBhdOneMember_3_lbl" xml:lang="en-US">DSY Beauty Sdn Bhd [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DSYWellnessAndLongevityCenterSdnBhdThreeMember" xlink:to="AATP_DSYWellnessAndLongevityCenterSdnBhdThreeMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_DSYWellnessAndLongevityCenterSdnBhdThreeMember_3_lbl" xml:lang="en-US">DSY Wellness and Longevity Center Sdn Bhd ("DSYWLC") [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_3_lbl" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">General and Administrative Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_2_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent_2_lbl" xml:lang="en-US">Increase (Decrease) in Due from Other Related Parties, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:to="us-gaap_IncreaseDecreaseInPrepaidTaxes_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidTaxes_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Taxes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Related Parties</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2_lbl" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:to="us-gaap_PaymentsToAcquireMachineryAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Machinery and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_2_lbl" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_2_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_PrepaymentsAndDepositsPolicyTextBlock" xlink:to="AATP_PrepaymentsAndDepositsPolicyTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_PrepaymentsAndDepositsPolicyTextBlock_3_lbl" xml:lang="en-US">PrepaymentsAndDepositsPolicyTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_2_lbl" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_2_lbl" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2_lbl" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingExpense_2_lbl" xml:lang="en-US">Advertising Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_OtherPayablesRelatedPartyCurrent" xlink:to="AATP_OtherPayablesRelatedPartyCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_OtherPayablesRelatedPartyCurrent_3_lbl" xml:lang="en-US">OtherPayablesRelatedPartyCurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableGrossCurrent_2_lbl" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_PrepaidExpensesGross" xlink:to="AATP_PrepaidExpensesGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_PrepaidExpensesGross_3_lbl" xml:lang="en-US">Prepaid expenses gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:to="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_2_lbl" xml:lang="en-US">Allowance for Doubtful Accounts, Premiums and Other Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_3_lbl" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_TransferFromNonmarketableSecurity" xlink:to="AATP_TransferFromNonmarketableSecurity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_TransferFromNonmarketableSecurity_3_lbl" xml:lang="en-US">TransferFromNonmarketableSecurity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_InvestmentsIncomeDividend" xlink:to="AATP_InvestmentsIncomeDividend_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_InvestmentsIncomeDividend_3_lbl" xml:lang="en-US">Dividend income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_MarketableSecuritiesUnrealizedHoldingLoss" xlink:to="AATP_MarketableSecuritiesUnrealizedHoldingLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_MarketableSecuritiesUnrealizedHoldingLoss_3_lbl" xml:lang="en-US">MarketableSecuritiesUnrealizedHoldingLoss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_ExchangeRateEffectOnInvestmentInMarketableSecurites" xlink:to="AATP_ExchangeRateEffectOnInvestmentInMarketableSecurites_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_ExchangeRateEffectOnInvestmentInMarketableSecurites_3_lbl" xml:lang="en-US">Exchange rate effect [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_TransferToInvestmentInMarketableSecurities" xlink:to="AATP_TransferToInvestmentInMarketableSecurities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_TransferToInvestmentInMarketableSecurities_3_lbl" xml:lang="en-US">TransferToInvestmentInMarketableSecurities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_CustomerDeposits" xlink:to="AATP_CustomerDeposits_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_CustomerDeposits_3_lbl" xml:lang="en-US">CustomerDeposits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_OtherAccountPayableAndAccruedLiabilities" xlink:to="AATP_OtherAccountPayableAndAccruedLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_OtherAccountPayableAndAccruedLiabilities_3_lbl" xml:lang="en-US">OtherAccountPayableAndAccruedLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_NonControllingInterestAccumulatedOtherComprehensiveIncome" xlink:to="AATP_NonControllingInterestAccumulatedOtherComprehensiveIncome_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_NonControllingInterestAccumulatedOtherComprehensiveIncome_3_lbl" xml:lang="en-US">NonControllingInterestAccumulatedOtherComprehensiveIncome</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_NonControllingInterestNonControllingInterestGross" xlink:to="AATP_NonControllingInterestNonControllingInterestGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_NonControllingInterestNonControllingInterestGross_3_lbl" xml:lang="en-US">NonControllingInterestNonControllingInterestGross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AATP_DeferredTaxLiabilitiesDepreciation" xlink:to="AATP_DeferredTaxLiabilitiesDepreciation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AATP_DeferredTaxLiabilitiesDepreciation_3_lbl" xml:lang="en-US">DeferredTaxLiabilitiesDepreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>31
<FILENAME>aatp-20221231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://agapeatp.com/role/Cover" xlink:href="aatp-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/BalanceSheets" xlink:href="aatp-20221231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/BalanceSheetsParenthetical" xlink:href="aatp-20221231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:href="aatp-20221231.xsd#StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="aatp-20221231.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/StatementsOfCashFlows" xlink:href="aatp-20221231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/OrganizationAndBusinessBackground" xlink:href="aatp-20221231.xsd#OrganizationAndBusinessBackground" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="aatp-20221231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/VariableInterestEntityVie" xlink:href="aatp-20221231.xsd#VariableInterestEntityVie" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/CashAndCashEquivalents" xlink:href="aatp-20221231.xsd#CashAndCashEquivalents" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/AccountsReceivable" xlink:href="aatp-20221231.xsd#AccountsReceivable" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/Inventories" xlink:href="aatp-20221231.xsd#Inventories" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/PrepaymentsAndDeposits" xlink:href="aatp-20221231.xsd#PrepaymentsAndDeposits" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/PropertyAndEquipmentNet" xlink:href="aatp-20221231.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/IntangibleAssetsNet" xlink:href="aatp-20221231.xsd#IntangibleAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/InvestmentInMarketableSecurities" xlink:href="aatp-20221231.xsd#InvestmentInMarketableSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/InvestmentInNon-marketableSecurities" xlink:href="aatp-20221231.xsd#InvestmentInNon-marketableSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/CustomerDeposits" xlink:href="aatp-20221231.xsd#CustomerDeposits" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/OtherPayablesAndAccruedLiabilities" xlink:href="aatp-20221231.xsd#OtherPayablesAndAccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/RelatedPartyBalancesAndTransactions" xlink:href="aatp-20221231.xsd#RelatedPartyBalancesAndTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/StockholdersEquity" xlink:href="aatp-20221231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/Non-controllingInterest" xlink:href="aatp-20221231.xsd#Non-controllingInterest" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/IncomeTaxes" xlink:href="aatp-20221231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ConcentrationsOfRisks" xlink:href="aatp-20221231.xsd#ConcentrationsOfRisks" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/CommitmentsAndContingencies" xlink:href="aatp-20221231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/SubsequentEvents" xlink:href="aatp-20221231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="aatp-20221231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/OrganizationAndBusinessBackgroundTables" xlink:href="aatp-20221231.xsd#OrganizationAndBusinessBackgroundTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="aatp-20221231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/VariableInterestEntityVieTables" xlink:href="aatp-20221231.xsd#VariableInterestEntityVieTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/AccountsReceivableTables" xlink:href="aatp-20221231.xsd#AccountsReceivableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/InventoriesTables" xlink:href="aatp-20221231.xsd#InventoriesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/PrepaymentsAndDepositsTables" xlink:href="aatp-20221231.xsd#PrepaymentsAndDepositsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/PropertyAndEquipmentNetTables" xlink:href="aatp-20221231.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/IntangibleAssetsNetTables" xlink:href="aatp-20221231.xsd#IntangibleAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/InvestmentInMarketableSecuritiesTables" xlink:href="aatp-20221231.xsd#InvestmentInMarketableSecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesTables" xlink:href="aatp-20221231.xsd#InvestmentInNon-marketableSecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/CustomerDepositsTables" xlink:href="aatp-20221231.xsd#CustomerDepositsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesTables" xlink:href="aatp-20221231.xsd#OtherPayablesAndAccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/RelatedPartyBalancesAndTransactionsTables" xlink:href="aatp-20221231.xsd#RelatedPartyBalancesAndTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/Non-controllingInterestTables" xlink:href="aatp-20221231.xsd#Non-controllingInterestTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/IncomeTaxesTables" xlink:href="aatp-20221231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/CommitmentsAndContingenciesTables" xlink:href="aatp-20221231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails" xlink:href="aatp-20221231.xsd#ScheduleOfSubsidiariesAndAssociatesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative" xlink:href="aatp-20221231.xsd#OrganizationAndBusinessBackgroundDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:href="aatp-20221231.xsd#ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetDetails" xlink:href="aatp-20221231.xsd#ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails" xlink:href="aatp-20221231.xsd#ScheduleOfDis-aggregatedInformationOfRevenuesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails" xlink:href="aatp-20221231.xsd#ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="aatp-20221231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails" xlink:href="aatp-20221231.xsd#ScheduleOfVariableInterestEntityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/VariableInterestEntityVieDetailsNarrative" xlink:href="aatp-20221231.xsd#VariableInterestEntityVieDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative" xlink:href="aatp-20221231.xsd#CashAndCashEquivalentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfAccountsReceivables-RelatedPartyDetails" xlink:href="aatp-20221231.xsd#ScheduleOfAccountsReceivables-RelatedPartyDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfInventoriesDetails" xlink:href="aatp-20221231.xsd#ScheduleOfInventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/InventoriesDetailsNarrative" xlink:href="aatp-20221231.xsd#InventoriesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfPrepaidExpensesAndDepositsDetails" xlink:href="aatp-20221231.xsd#ScheduleOfPrepaidExpensesAndDepositsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfChangesInAllowanceForDoubtfulAccountsDetails" xlink:href="aatp-20221231.xsd#ScheduleOfChangesInAllowanceForDoubtfulAccountsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails" xlink:href="aatp-20221231.xsd#ScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="aatp-20221231.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfIntangibleAssetsNetDetails" xlink:href="aatp-20221231.xsd#ScheduleOfIntangibleAssetsNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/IntangibleAssetsNetDetailsNarrative" xlink:href="aatp-20221231.xsd#IntangibleAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails" xlink:href="aatp-20221231.xsd#ScheduleOfInvestmentInMarketableSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative" xlink:href="aatp-20221231.xsd#InvestmentInMarketableSecuritiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfInvestmentInNonMarketableSecuritiesDetails" xlink:href="aatp-20221231.xsd#ScheduleOfInvestmentInNonMarketableSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative" xlink:href="aatp-20221231.xsd#InvestmentInNon-marketableSecuritiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfCustomerDepositsDetails" xlink:href="aatp-20221231.xsd#ScheduleOfCustomerDepositsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails" xlink:href="aatp-20221231.xsd#ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesDetailsNarrative" xlink:href="aatp-20221231.xsd#OtherPayablesAndAccruedLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails" xlink:href="aatp-20221231.xsd#ScheduleOfRelatedPartiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/StockholdersEquityDetailsNarrative" xlink:href="aatp-20221231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfNonControllingInterestDetails" xlink:href="aatp-20221231.xsd#ScheduleOfNonControllingInterestDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails" xlink:href="aatp-20221231.xsd#ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails" xlink:href="aatp-20221231.xsd#ScheduleOfProvisionForIncomeTaxDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:href="aatp-20221231.xsd#ScheduleOfEffectiveIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfEffectiveIncomeTaxRateDetailsParenthetical" xlink:href="aatp-20221231.xsd#ScheduleOfEffectiveIncomeTaxRateDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:href="aatp-20221231.xsd#ScheduleOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/IncomeTaxesDetailsNarrative" xlink:href="aatp-20221231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" xlink:href="aatp-20221231.xsd#ConcentrationsOfRisksDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/ScheduleOfLeaseCommitmentsDetails" xlink:href="aatp-20221231.xsd#ScheduleOfLeaseCommitmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="aatp-20221231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaapDueFromRelatedPartiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDueFromRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaapPrepaidTaxes" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="loc_us-gaapMarketableSecuritiesNoncurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapMarketableSecuritiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_InvestmentInNonMarketableSecuritiesNoncurrent" xlink:label="loc_AATPInvestmentInNonMarketableSecuritiesNoncurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_AATPInvestmentInNonMarketableSecuritiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapDeferredCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableTradeCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaapAccountsPayableOtherCurrent" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableOtherCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaapTaxesPayableCurrent" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapTaxesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilitiesNet" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilitiesNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_VariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents" xlink:label="loc_AATPVariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_AATPVariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_VariableInterestEntityConsolidatedAmountOfPrepaidTaxes" xlink:label="loc_AATPVariableInterestEntityConsolidatedAmountOfPrepaidTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_AATPVariableInterestEntityConsolidatedAmountOfPrepaidTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_VariableInterestEntityConsolidatedAmountOfOtherPayablesAndAccruedLiabilities" xlink:label="loc_AATPVariableInterestEntityConsolidatedAmountOfOtherPayablesAndAccruedLiabilities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_AATPVariableInterestEntityConsolidatedAmountOfOtherPayablesAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingExpense" xlink:label="loc_us-gaapSellingExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapSellingExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="loc_us-gaapSalesCommissionsAndFees" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapSalesCommissionsAndFees" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PreferredStockDividendIncomeStatementImpact" xlink:label="loc_AATPPreferredStockDividendIncomeStatementImpact" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_AATPPreferredStockDividendIncomeStatementImpact" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicOtherDisclosuresAbstract" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicOtherDisclosuresAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapNoncontrollingInterestMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationForfeited" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ContributionsFromNoncontrollingInterestShareholders" xlink:label="loc_AATPContributionsFromNoncontrollingInterestShareholders" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AATPContributionsFromNoncontrollingInterestShareholders" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:label="loc_us-gaapCostOfGoodsAndServicesSoldAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapCostOfGoodsAndServicesSoldAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PreferredStockDividendIncomeStatementImpact" xlink:label="loc_AATPPreferredStockDividendIncomeStatementImpact" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_AATPPreferredStockDividendIncomeStatementImpact" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaapInventoryWriteDown" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapInventoryWriteDown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent" xlink:label="loc_us-gaapIncreaseDecreaseInDueFromOtherRelatedPartiesCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDueFromOtherRelatedPartiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidTaxes" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidTaxes" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableRelatedParties" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent" xlink:label="loc_us-gaapIncreaseDecreaseInDueToOtherRelatedPartiesCurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDueToOtherRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedIncomeTaxesPayable" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquireMachineryAndEquipment" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireMachineryAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ChangesInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseModifications" xlink:label="loc_AATPChangesInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseModifications" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_AATPChangesInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseModifications" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/OrganizationAndBusinessBackground" xlink:title="00000007 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/VariableInterestEntityVie" xlink:title="00000009 - Disclosure - VARIABLE INTEREST ENTITY (&#8220;VIE&#8221;)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaapVariableInterestEntityDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapVariableInterestEntityDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/CashAndCashEquivalents" xlink:title="00000010 - Disclosure - CASH AND CASH EQUIVALENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/AccountsReceivable" xlink:title="00000011 - Disclosure - ACCOUNTS RECEIVABLE">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaapReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="loc_us-gaapLoansNotesTradeAndOtherReceivablesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapLoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/Inventories" xlink:title="00000012 - Disclosure - INVENTORIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/PrepaymentsAndDeposits" xlink:title="00000013 - Disclosure - PREPAYMENTS AND DEPOSITS">
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DisclosurePrepaymentsAndDepositsAbstract" xlink:label="loc_AATPDisclosurePrepaymentsAndDepositsAbstract" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PrepaymentsAndDepositsTextBlock" xlink:label="loc_AATPPrepaymentsAndDepositsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AATPDisclosurePrepaymentsAndDepositsAbstract" xlink:to="loc_AATPPrepaymentsAndDepositsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/PropertyAndEquipmentNet" xlink:title="00000014 - Disclosure - PROPERTY AND EQUIPMENT, NET">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/IntangibleAssetsNet" xlink:title="00000015 - Disclosure - INTANGIBLE ASSETS, NET">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/InvestmentInMarketableSecurities" xlink:title="00000016 - Disclosure - INVESTMENT IN MARKETABLE SECURITIES">
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DisclosureInvestmentInMarketableSecuritiesAbstract" xlink:label="loc_AATPDisclosureInvestmentInMarketableSecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_InvestmentInMarketableSecuritiesTextBlock" xlink:label="loc_AATPInvestmentInMarketableSecuritiesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AATPDisclosureInvestmentInMarketableSecuritiesAbstract" xlink:to="loc_AATPInvestmentInMarketableSecuritiesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/InvestmentInNon-marketableSecurities" xlink:title="00000017 - Disclosure - INVESTMENT IN NON-MARKETABLE SECURITIES">
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DisclosureInvestmentInNonmarketableSecuritiesAbstract" xlink:label="loc_AATPDisclosureInvestmentInNonmarketableSecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_InvestmentInNonMarketableSecuritiesTextBlock" xlink:label="loc_AATPInvestmentInNonMarketableSecuritiesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AATPDisclosureInvestmentInNonmarketableSecuritiesAbstract" xlink:to="loc_AATPInvestmentInNonMarketableSecuritiesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/CustomerDeposits" xlink:title="00000018 - Disclosure - CUSTOMER DEPOSITS">
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DisclosureCustomerDepositsAbstract" xlink:label="loc_AATPDisclosureCustomerDepositsAbstract" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_CustomerDepositsTextBlock" xlink:label="loc_AATPCustomerDepositsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AATPDisclosureCustomerDepositsAbstract" xlink:to="loc_AATPCustomerDepositsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/OtherPayablesAndAccruedLiabilities" xlink:title="00000019 - Disclosure - OTHER PAYABLES AND ACCRUED LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/RelatedPartyBalancesAndTransactions" xlink:title="00000020 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/StockholdersEquity" xlink:title="00000021 - Disclosure - STOCKHOLDERS&#8217; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/Non-controllingInterest" xlink:title="00000022 - Disclosure - NON-CONTROLLING INTEREST">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="loc_us-gaapNoncontrollingInterestAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDisclosureTextBlock" xlink:label="loc_us-gaapMinorityInterestDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncontrollingInterestAbstract" xlink:to="loc_us-gaapMinorityInterestDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/IncomeTaxes" xlink:title="00000023 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ConcentrationsOfRisks" xlink:title="00000024 - Disclosure - CONCENTRATIONS OF RISKS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaapConcentrationRiskDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/CommitmentsAndContingencies" xlink:title="00000025 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/SubsequentEvents" xlink:title="00000026 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PrepaidTaxesPolicyTextBlock" xlink:label="loc_AATPPrepaidTaxesPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_AATPPrepaidTaxesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PrepaymentsAndDepositsPolicyTextBlock" xlink:label="loc_AATPPrepaymentsAndDepositsPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_AATPPrepaymentsAndDepositsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaapDeferredChargesPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDeferredChargesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaapMarketableSecuritiesPolicy" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_NonMarketableSecuritiesPolicyTextBlock" xlink:label="loc_AATPNonMarketableSecuritiesPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_AATPNonMarketableSecuritiesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="loc_us-gaapCostOfSalesPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCostOfSalesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ShippingAndHandlingPolicyTextBlock" xlink:label="loc_AATPShippingAndHandlingPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_AATPShippingAndHandlingPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaapAdvertisingCostsPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAdvertisingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommissionsExpensePolicyPolicyTextBlock" xlink:label="loc_us-gaapCommissionsExpensePolicyPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCommissionsExpensePolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DefinedContributionPlanPolicyTextBlock" xlink:label="loc_AATPDefinedContributionPlanPolicyTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_AATPDefinedContributionPlanPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_NoncontrollingInterestPolicyTextBlock" xlink:label="loc_AATPNoncontrollingInterestPolicyTextBlock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_AATPNoncontrollingInterestPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_RelatedPartiesPolicyTextBlock" xlink:label="loc_AATPRelatedPartiesPolicyTextBlock" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_AATPRelatedPartiesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/OrganizationAndBusinessBackgroundTables" xlink:title="00000028 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:label="loc_us-gaapScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:label="loc_AATPScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_AATPScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock" xlink:label="loc_AATPScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_AATPScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaapDisaggregationOfRevenueTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:label="loc_us-gaapScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/VariableInterestEntityVieTables" xlink:title="00000030 - Disclosure - VARIABLE INTEREST ENTITY (&#8220;VIE&#8221;) (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:label="loc_us-gaapScheduleOfVariableInterestEntitiesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfVariableInterestEntitiesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/AccountsReceivableTables" xlink:title="00000031 - Disclosure - ACCOUNTS RECEIVABLE (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaapReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/InventoriesTables" xlink:title="00000032 - Disclosure - INVENTORIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/PrepaymentsAndDepositsTables" xlink:title="00000033 - Disclosure - PREPAYMENTS AND DEPOSITS (Tables)">
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DisclosurePrepaymentsAndDepositsAbstract" xlink:label="loc_AATPDisclosurePrepaymentsAndDepositsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AATPDisclosurePrepaymentsAndDepositsAbstract" xlink:to="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:label="loc_us-gaapAccountsReceivableAllowanceForCreditLossTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AATPDisclosurePrepaymentsAndDepositsAbstract" xlink:to="loc_us-gaapAccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/PropertyAndEquipmentNetTables" xlink:title="00000034 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/IntangibleAssetsNetTables" xlink:title="00000035 - Disclosure - INTANGIBLE ASSETS, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/InvestmentInMarketableSecuritiesTables" xlink:title="00000036 - Disclosure - INVESTMENT IN MARKETABLE SECURITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DisclosureInvestmentInMarketableSecuritiesAbstract" xlink:label="loc_AATPDisclosureInvestmentInMarketableSecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="loc_us-gaapMarketableSecuritiesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AATPDisclosureInvestmentInMarketableSecuritiesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesTables" xlink:title="00000037 - Disclosure - INVESTMENT IN NON-MARKETABLE SECURITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DisclosureInvestmentInNonmarketableSecuritiesAbstract" xlink:label="loc_AATPDisclosureInvestmentInNonmarketableSecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_NonMarketableSecuritiesTableTextBlock" xlink:label="loc_AATPNonMarketableSecuritiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AATPDisclosureInvestmentInNonmarketableSecuritiesAbstract" xlink:to="loc_AATPNonMarketableSecuritiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/CustomerDepositsTables" xlink:title="00000038 - Disclosure - CUSTOMER DEPOSITS (Tables)">
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DisclosureCustomerDepositsAbstract" xlink:label="loc_AATPDisclosureCustomerDepositsAbstract" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_CustomerDepositsTableTextBlock" xlink:label="loc_AATPCustomerDepositsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AATPDisclosureCustomerDepositsAbstract" xlink:to="loc_AATPCustomerDepositsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesTables" xlink:title="00000039 - Disclosure - OTHER PAYABLES AND ACCRUED LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_AATPScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_AATPScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/RelatedPartyBalancesAndTransactionsTables" xlink:title="00000040 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/Non-controllingInterestTables" xlink:title="00000041 - Disclosure - NON-CONTROLLING INTEREST (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="loc_us-gaapNoncontrollingInterestAbstract" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ScheduleOfNonControllingInterestTableTextBlock" xlink:label="loc_AATPScheduleOfNonControllingInterestTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncontrollingInterestAbstract" xlink:to="loc_AATPScheduleOfNonControllingInterestTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/IncomeTaxesTables" xlink:title="00000042 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/CommitmentsAndContingenciesTables" xlink:title="00000043 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails" xlink:title="00000044 - Disclosure - SCHEDULE OF SUBSIDIARIES AND ASSOCIATES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SubsidiaryCompanyMember" xlink:label="loc_AATPSubsidiaryCompanyMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_AATPSubsidiaryCompanyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SubsidiaryCompanyOneMember" xlink:label="loc_AATPSubsidiaryCompanyOneMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_AATPSubsidiaryCompanyOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SubsidiaryCompanyTwoMember" xlink:label="loc_AATPSubsidiaryCompanyTwoMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_AATPSubsidiaryCompanyTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SubsidiaryCompanyThreeMember" xlink:label="loc_AATPSubsidiaryCompanyThreeMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_AATPSubsidiaryCompanyThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SubsidiaryCompanyFourMember" xlink:label="loc_AATPSubsidiaryCompanyFourMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_AATPSubsidiaryCompanyFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SubsidiaryCompanyFiveMember" xlink:label="loc_AATPSubsidiaryCompanyFiveMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_AATPSubsidiaryCompanyFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_NameOftheCompany" xlink:label="loc_AATPNameOftheCompany" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AATPNameOftheCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PlaceAndDateOfIncorporation" xlink:label="loc_AATPPlaceAndDateOfIncorporation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AATPPlaceAndDateOfIncorporation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ParticularsOfIssuedCapital" xlink:label="loc_AATPParticularsOfIssuedCapital" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AATPParticularsOfIssuedCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PrincipalActivities" xlink:label="loc_AATPPrincipalActivities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AATPPrincipalActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative" xlink:title="00000045 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_AgapeATPInternationalHoldingLimitedMember" xlink:label="loc_AATPAgapeATPInternationalHoldingLimitedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_AATPAgapeATPInternationalHoldingLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SubsidiaryCompanyTwoMember" xlink:label="loc_AATPSubsidiaryCompanyTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_AATPSubsidiaryCompanyTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SubsidiaryCompanyFiveMember" xlink:label="loc_AATPSubsidiaryCompanyFiveMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_AATPSubsidiaryCompanyFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ShareExchangeAgreementMember" xlink:label="loc_AATPShareExchangeAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AATPShareExchangeAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_MrHowKokChoongMember" xlink:label="loc_AATPMrHowKokChoongMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_AATPMrHowKokChoongMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:title="00000046 - Disclosure - SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember" xlink:label="loc_us-gaapVehiclesMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapVehiclesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaapPropertyPlantAndEquipmentEstimatedUsefulLives" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetDetails" xlink:title="00000047 - Disclosure - SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails" xlink:title="00000048 - Disclosure - SCHEDULE OF DIS-AGGREGATED INFORMATION OF REVENUES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SurvivorSelectMember" xlink:label="loc_AATPSurvivorSelectMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPSurvivorSelectMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_EnergizedMineralConcentrateMember" xlink:label="loc_AATPEnergizedMineralConcentrateMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPEnergizedMineralConcentrateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_IonizedCalMagMember" xlink:label="loc_AATPIonizedCalMagMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPIonizedCalMagMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_OmegaBlendMember" xlink:label="loc_AATPOmegaBlendMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPOmegaBlendMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_BetaMaxxMember" xlink:label="loc_AATPBetaMaxxMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPBetaMaxxMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_VegeFruitFiberMember" xlink:label="loc_AATPVegeFruitFiberMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPVegeFruitFiberMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_IronMember" xlink:label="loc_AATPIronMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPIronMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_YoungFormulaMember" xlink:label="loc_AATPYoungFormulaMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPYoungFormulaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_OrganicYouthCarCleansingBarMember" xlink:label="loc_AATPOrganicYouthCarCleansingBarMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPOrganicYouthCarCleansingBarMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ATPRMITOPlusMember" xlink:label="loc_AATPATPRMITOPlusMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPATPRMITOPlusMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_LipomaskMember" xlink:label="loc_AATPLipomaskMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPLipomaskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_EnergetiqueMember" xlink:label="loc_AATPEnergetiqueMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPEnergetiqueMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_TrimPlusMember" xlink:label="loc_AATPTrimPlusMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPTrimPlusMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ProductHealthTherapiesMember" xlink:label="loc_AATPProductHealthTherapiesMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPProductHealthTherapiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_OthersMember" xlink:label="loc_AATPOthersMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPOthersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_HealthAndWellnessServicesMember" xlink:label="loc_AATPHealthAndWellnessServicesMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPHealthAndWellnessServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails" xlink:title="00000049 - Disclosure - SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaapVariableRateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapVariableRateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PeriodEndMYRMember" xlink:label="loc_AATPPeriodEndMYRMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_AATPPeriodEndMYRMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PeriodEndHKDMember" xlink:label="loc_AATPPeriodEndHKDMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_AATPPeriodEndHKDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PeriodAverageMYRMember" xlink:label="loc_AATPPeriodAverageMYRMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_AATPPeriodAverageMYRMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PeriodAverageHKDMember" xlink:label="loc_AATPPeriodAverageHKDMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_AATPPeriodAverageHKDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="loc_us-gaapForeignCurrencyExchangeRateTranslation1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapForeignCurrencyExchangeRateTranslation1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ForeignCurrencyExchangeRateAverage" xlink:label="loc_AATPForeignCurrencyExchangeRateAverage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_AATPForeignCurrencyExchangeRateAverage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000050 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_HealthAndWellnessServicesMember" xlink:label="loc_AATPHealthAndWellnessServicesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AATPHealthAndWellnessServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShippingAndHandlingMember" xlink:label="loc_us-gaapShippingAndHandlingMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapShippingAndHandlingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SocialSecurityOrganizationMember" xlink:label="loc_AATPSocialSecurityOrganizationMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_AATPSocialSecurityOrganizationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_EmployeesProvidentFundMember" xlink:label="loc_AATPEmployeesProvidentFundMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_AATPEmployeesProvidentFundMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_EmploymentInsuranceSystemMember" xlink:label="loc_AATPEmploymentInsuranceSystemMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_AATPEmploymentInsuranceSystemMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_HumanResourceDevelopmentFundMember" xlink:label="loc_AATPHumanResourceDevelopmentFundMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_AATPHumanResourceDevelopmentFundMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_InventriesWriteDown" xlink:label="loc_AATPInventriesWriteDown" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_AATPInventriesWriteDown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_InventoryWriteOff" xlink:label="loc_AATPInventoryWriteOff" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_AATPInventoryWriteOff" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableWriteOffs" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_AllowanceForDoubtfulAccountsReceivablesCurrent" xlink:label="loc_AATPAllowanceForDoubtfulAccountsReceivablesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_AATPAllowanceForDoubtfulAccountsReceivablesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ForfeitedCouponIncome" xlink:label="loc_AATPForfeitedCouponIncome" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_AATPForfeitedCouponIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingExpense" xlink:label="loc_us-gaapSellingExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapSellingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaapAdvertisingExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAdvertisingExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="loc_us-gaapSalesCommissionsAndFees" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapSalesCommissionsAndFees" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SalaryPercentage" xlink:label="loc_AATPSalaryPercentage" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_AATPSalaryPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_MonthlySalary" xlink:label="loc_AATPMonthlySalary" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_AATPMonthlySalary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="loc_us-gaapIncomeTaxExaminationLikelihoodOfUnfavorableSettlement" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestExpense" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDescription" xlink:label="loc_us-gaapMinorityInterestDescription" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapMinorityInterestDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails" xlink:title="00000051 - Disclosure - SCHEDULE OF VARIABLE INTEREST ENTITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingActivitiesGainLossByTypeTable" xlink:label="loc_us-gaapTradingActivitiesGainLossByTypeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapTradingActivitiesGainLossByTypeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingActivityGainsAndLossesLineItems" xlink:label="loc_us-gaapTradingActivityGainsAndLossesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTradingActivitiesGainLossByTypeTable" xlink:to="loc_us-gaapTradingActivityGainsAndLossesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingActivityByTypeAxis" xlink:label="loc_us-gaapTradingActivityByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTradingActivitiesGainLossByTypeTable" xlink:to="loc_us-gaapTradingActivityByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingActivityByTypeDomain" xlink:label="loc_us-gaapTradingActivityByTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTradingActivityByTypeAxis" xlink:to="loc_us-gaapTradingActivityByTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableIncomeInterestRateMember" xlink:label="loc_us-gaapVariableIncomeInterestRateMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTradingActivityByTypeDomain" xlink:to="loc_us-gaapVariableIncomeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTradingActivityGainsAndLossesLineItems" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTradingActivityGainsAndLossesLineItems" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTradingActivityGainsAndLossesLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTradingActivityGainsAndLossesLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaapPrepaidTaxes" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTradingActivityGainsAndLossesLineItems" xlink:to="loc_us-gaapPrepaidTaxes" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTradingActivityGainsAndLossesLineItems" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_OtherPayablesRelatedPartyCurrent" xlink:label="loc_AATPOtherPayablesRelatedPartyCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTradingActivityGainsAndLossesLineItems" xlink:to="loc_AATPOtherPayablesRelatedPartyCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTradingActivityGainsAndLossesLineItems" xlink:to="loc_us-gaapLiabilitiesCurrent_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTradingActivityGainsAndLossesLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTradingActivityGainsAndLossesLineItems" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTradingActivityGainsAndLossesLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTradingActivityGainsAndLossesLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/VariableInterestEntityVieDetailsNarrative" xlink:title="00000052 - Disclosure - VARIABLE INTEREST ENTITY (&#8220;VIE&#8221;) (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SubsidiaryCompanyThreeMember" xlink:label="loc_AATPSubsidiaryCompanyThreeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_AATPSubsidiaryCompanyThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative" xlink:title="00000053 - Disclosure - CASH AND CASH EQUIVALENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TimeDeposits" xlink:label="loc_us-gaapTimeDeposits" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTimeDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits" xlink:label="loc_us-gaapPercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TimeDepositLiabilityUninsured" xlink:label="loc_us-gaapTimeDepositLiabilityUninsured" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTimeDepositLiabilityUninsured" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfAccountsReceivables-RelatedPartyDetails" xlink:title="00000054 - Disclosure - SCHEDULE OF ACCOUNTS RECEIVABLES - RELATED PARTY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaapReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaapAccountsReceivableGrossCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapAccountsReceivableGrossCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfInventoriesDetails" xlink:title="00000055 - Disclosure - SCHEDULE OF INVENTORIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/InventoriesDetailsNarrative" xlink:title="00000056 - Disclosure - INVENTORIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_InventriesWriteDown" xlink:label="loc_AATPInventriesWriteDown" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_AATPInventriesWriteDown" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_InventoryWriteOff" xlink:label="loc_AATPInventoryWriteOff" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_AATPInventoryWriteOff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfPrepaidExpensesAndDepositsDetails" xlink:title="00000057 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND DEPOSITS (Details)">
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DisclosurePrepaymentsAndDepositsAbstract" xlink:label="loc_AATPDisclosurePrepaymentsAndDepositsAbstract" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ReceivablesFromSalesDistributors" xlink:label="loc_AATPReceivablesFromSalesDistributors" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AATPDisclosurePrepaymentsAndDepositsAbstract" xlink:to="loc_AATPReceivablesFromSalesDistributors" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DepositsToSupplier" xlink:label="loc_AATPDepositsToSupplier" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AATPDisclosurePrepaymentsAndDepositsAbstract" xlink:to="loc_AATPDepositsToSupplier" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PrepaidExpensesGross" xlink:label="loc_AATPPrepaidExpensesGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AATPDisclosurePrepaymentsAndDepositsAbstract" xlink:to="loc_AATPPrepaidExpensesGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AATPDisclosurePrepaymentsAndDepositsAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AATPDisclosurePrepaymentsAndDepositsAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfChangesInAllowanceForDoubtfulAccountsDetails" xlink:title="00000058 - Disclosure - SCHEDULE OF CHANGES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details)">
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DisclosurePrepaymentsAndDepositsAbstract" xlink:label="loc_AATPDisclosurePrepaymentsAndDepositsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AATPDisclosurePrepaymentsAndDepositsAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AATPDisclosurePrepaymentsAndDepositsAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableWriteOffs" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AATPDisclosurePrepaymentsAndDepositsAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_AllowanceForDoubtfulAccountsReceivableExchangeRateEffect" xlink:label="loc_AATPAllowanceForDoubtfulAccountsReceivableExchangeRateEffect" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AATPDisclosurePrepaymentsAndDepositsAbstract" xlink:to="loc_AATPAllowanceForDoubtfulAccountsReceivableExchangeRateEffect" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AATPDisclosurePrepaymentsAndDepositsAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails" xlink:title="00000059 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ComputerAndOfficeEquipmentMember" xlink:label="loc_AATPComputerAndOfficeEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_AATPComputerAndOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_VehicleMember" xlink:label="loc_AATPVehicleMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_AATPVehicleMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="00000060 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfIntangibleAssetsNetDetails" xlink:title="00000061 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="loc_us-gaapCapitalizedComputerSoftwareGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapCapitalizedComputerSoftwareGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/IntangibleAssetsNetDetailsNarrative" xlink:title="00000062 - Disclosure - INTANGIBLE ASSETS, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails" xlink:title="00000063 - Disclosure - SCHEDULE OF INVESTMENT IN MARKETABLE SECURITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DisclosureInvestmentInMarketableSecuritiesAbstract" xlink:label="loc_AATPDisclosureInvestmentInMarketableSecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtCost" xlink:label="loc_us-gaapInvestmentOwnedAtCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AATPDisclosureInvestmentInMarketableSecuritiesAbstract" xlink:to="loc_us-gaapInvestmentOwnedAtCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_TransferFromNonmarketableSecurity" xlink:label="loc_AATPTransferFromNonmarketableSecurity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AATPDisclosureInvestmentInMarketableSecuritiesAbstract" xlink:to="loc_AATPTransferFromNonmarketableSecurity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_InvestmentsIncomeDividend" xlink:label="loc_AATPInvestmentsIncomeDividend" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AATPDisclosureInvestmentInMarketableSecuritiesAbstract" xlink:to="loc_AATPInvestmentsIncomeDividend" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_MarketableSecuritiesUnrealizedHoldingLoss" xlink:label="loc_AATPMarketableSecuritiesUnrealizedHoldingLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AATPDisclosureInvestmentInMarketableSecuritiesAbstract" xlink:to="loc_AATPMarketableSecuritiesUnrealizedHoldingLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ExchangeRateEffectOnInvestmentInMarketableSecurites" xlink:label="loc_AATPExchangeRateEffectOnInvestmentInMarketableSecurites" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AATPDisclosureInvestmentInMarketableSecuritiesAbstract" xlink:to="loc_AATPExchangeRateEffectOnInvestmentInMarketableSecurites" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="loc_us-gaapMarketableSecuritiesNoncurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AATPDisclosureInvestmentInMarketableSecuritiesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative" xlink:title="00000064 - Disclosure - INVESTMENT IN MARKETABLE SECURITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DisclosureInvestmentInMarketableSecuritiesAbstract" xlink:label="loc_AATPDisclosureInvestmentInMarketableSecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AATPDisclosureInvestmentInMarketableSecuritiesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_GreenproCapitalCorpMember" xlink:label="loc_AATPGreenproCapitalCorpMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_AATPGreenproCapitalCorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DSwissIncMember" xlink:label="loc_AATPDSwissIncMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_AATPDSwissIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_SEATechVenturesCorpMember" xlink:label="loc_AATPSEATechVenturesCorpMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_AATPSEATechVenturesCorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PhoenixPlusCorpMember" xlink:label="loc_AATPPhoenixPlusCorpMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_AATPPhoenixPlusCorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaapInvestmentOwnedBalanceShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentOwnedBalanceShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtCost" xlink:label="loc_us-gaapInvestmentOwnedAtCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentOwnedAtCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfInvestmentInNonMarketableSecuritiesDetails" xlink:title="00000065 - Disclosure - SCHEDULE OF INVESTMENT IN NON MARKETABLE SECURITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DisclosureInvestmentInNonmarketableSecuritiesAbstract" xlink:label="loc_AATPDisclosureInvestmentInNonmarketableSecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AATPDisclosureInvestmentInNonmarketableSecuritiesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PhoenixPlusCorpMember" xlink:label="loc_AATPPhoenixPlusCorpMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_AATPPhoenixPlusCorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtCost" xlink:label="loc_us-gaapInvestmentOwnedAtCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentOwnedAtCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_TransferToInvestmentInMarketableSecurities" xlink:label="loc_AATPTransferToInvestmentInMarketableSecurities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AATPTransferToInvestmentInMarketableSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_InvestmentInNonMarketableSecuritiesNoncurrent" xlink:label="loc_AATPInvestmentInNonMarketableSecuritiesNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AATPInvestmentInNonMarketableSecuritiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative" xlink:title="00000066 - Disclosure - INVESTMENT IN NON-MARKETABLE SECURITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DisclosureInvestmentInNonmarketableSecuritiesAbstract" xlink:label="loc_AATPDisclosureInvestmentInNonmarketableSecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AATPDisclosureInvestmentInNonmarketableSecuritiesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_PhoenixPlusCorpMember" xlink:label="loc_AATPPhoenixPlusCorpMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_AATPPhoenixPlusCorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaapInvestmentOwnedBalanceShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentOwnedBalanceShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtCost" xlink:label="loc_us-gaapInvestmentOwnedAtCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentOwnedAtCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfCustomerDepositsDetails" xlink:title="00000067 - Disclosure -  SCHEDULE OF CUSTOMER DEPOSITS (Details)">
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DisclosureCustomerDepositsAbstract" xlink:label="loc_AATPDisclosureCustomerDepositsAbstract" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_CustomerDeposits" xlink:label="loc_AATPCustomerDeposits" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AATPDisclosureCustomerDepositsAbstract" xlink:to="loc_AATPCustomerDeposits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_UnexpiredProductCoupons" xlink:label="loc_AATPUnexpiredProductCoupons" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AATPDisclosureCustomerDepositsAbstract" xlink:to="loc_AATPUnexpiredProductCoupons" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositLiabilityCurrent" xlink:label="loc_us-gaapDepositLiabilityCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AATPDisclosureCustomerDepositsAbstract" xlink:to="loc_us-gaapDepositLiabilityCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails" xlink:title="00000068 - Disclosure - SCHEDULE OF OTHER PAYABLES AND ACCRUED LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_AccruedPromotionExpensesCurrent" xlink:label="loc_AATPAccruedPromotionExpensesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_AATPAccruedPromotionExpensesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="loc_us-gaapAccruedPayrollTaxesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedPayrollTaxesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalesCommissionCurrent" xlink:label="loc_us-gaapAccruedSalesCommissionCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedSalesCommissionCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_AccruedTaxPenaltyCurrent" xlink:label="loc_AATPAccruedTaxPenaltyCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_AATPAccruedTaxPenaltyCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_OtherAccountPayableAndAccruedLiabilities" xlink:label="loc_AATPOtherAccountPayableAndAccruedLiabilities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_AATPOtherAccountPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesDetailsNarrative" xlink:title="00000069 - Disclosure - OTHER PAYABLES AND ACCRUED LIABILITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_CommissionPaymentsDescriptions" xlink:label="loc_AATPCommissionPaymentsDescriptions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AATPCommissionPaymentsDescriptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommissionsPayableToBrokerDealersAndClearingOrganizations" xlink:label="loc_us-gaapCommissionsPayableToBrokerDealersAndClearingOrganizations" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommissionsPayableToBrokerDealersAndClearingOrganizations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetGross" xlink:label="loc_us-gaapContractWithCustomerAssetGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapContractWithCustomerAssetGross" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails" xlink:title="00000070 - Disclosure - SCHEDULE OF RELATED PARTIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_TH3TechnologySdnBhdMember" xlink:label="loc_AATPTH3TechnologySdnBhdMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPTH3TechnologySdnBhdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DSYBeautySdnBhdMember" xlink:label="loc_AATPDSYBeautySdnBhdMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPDSYBeautySdnBhdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_AgapeATPAsiaLimitedMember" xlink:label="loc_AATPAgapeATPAsiaLimitedMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPAgapeATPAsiaLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_HostastaySdnBhdMember" xlink:label="loc_AATPHostastaySdnBhdMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPHostastaySdnBhdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_CTANutriceuticalsSdnBhdMember" xlink:label="loc_AATPCTANutriceuticalsSdnBhdMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPCTANutriceuticalsSdnBhdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_CTANutriceuticalsAsiaSdnBhdOneMember" xlink:label="loc_AATPCTANutriceuticalsAsiaSdnBhdOneMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPCTANutriceuticalsAsiaSdnBhdOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DSYBeautySdnBhdOneMember" xlink:label="loc_AATPDSYBeautySdnBhdOneMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPDSYBeautySdnBhdOneMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_HowKokChoongMember" xlink:label="loc_AATPHowKokChoongMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPHowKokChoongMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DSYWellnessandLongevityCenterSdnBhdTwoMember" xlink:label="loc_AATPDSYWellnessandLongevityCenterSdnBhdTwoMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPDSYWellnessandLongevityCenterSdnBhdTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_HostastaySdnBhdHostastayMember" xlink:label="loc_AATPHostastaySdnBhdHostastayMember" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPHostastaySdnBhdHostastayMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_CTANutriceuticalsAsiaSdnBhdMember" xlink:label="loc_AATPCTANutriceuticalsAsiaSdnBhdMember" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPCTANutriceuticalsAsiaSdnBhdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DSYWellnessAndLongevityCenterSdnBhdMember" xlink:label="loc_AATPDSYWellnessAndLongevityCenterSdnBhdMember" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPDSYWellnessAndLongevityCenterSdnBhdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_RedboyPictureSdnBhdMember" xlink:label="loc_AATPRedboyPictureSdnBhdMember" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPRedboyPictureSdnBhdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DSYWellnessAndLongevityCenterSdnBhdThreeMember" xlink:label="loc_AATPDSYWellnessAndLongevityCenterSdnBhdThreeMember" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPDSYWellnessAndLongevityCenterSdnBhdThreeMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_RelatedPartiesRelationshipsDescription" xlink:label="loc_AATPRelatedPartiesRelationshipsDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_AATPRelatedPartiesRelationshipsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaapDueFromRelatedParties" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDueFromRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_RelatedPartiesNatureDescription" xlink:label="loc_AATPRelatedPartiesNatureDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_AATPRelatedPartiesNatureDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrentAndNoncurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_RelatedPartyOtherIncome" xlink:label="loc_AATPRelatedPartyOtherIncome" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_AATPRelatedPartyOtherIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_RelatedPartyTransactionOtherPurchasesFromRelatedParty" xlink:label="loc_AATPRelatedPartyTransactionOtherPurchasesFromRelatedParty" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_AATPRelatedPartyTransactionOtherPurchasesFromRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="loc_us-gaapSalesCommissionsAndFees" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSalesCommissionsAndFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_RelatedPartyOtherExpenses" xlink:label="loc_AATPRelatedPartyOtherExpenses" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_AATPRelatedPartyOtherExpenses" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000071 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ShareForfeitureAgreementsMember" xlink:label="loc_AATPShareForfeitureAgreementsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AATPShareForfeitureAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_HowKokChoongTalentLimitedMember" xlink:label="loc_AATPHowKokChoongTalentLimitedMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPHowKokChoongTalentLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_HKCHoldingsSdnBhdMember" xlink:label="loc_AATPHKCHoldingsSdnBhdMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AATPHKCHoldingsSdnBhdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ShareholdersMember" xlink:label="loc_AATPShareholdersMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_AATPShareholdersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_ReductionInCommonStockOutstanding" xlink:label="loc_AATPReductionInCommonStockOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_AATPReductionInCommonStockOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfNonControllingInterestDetails" xlink:title="00000072 - Disclosure - SCHEDULE OF NON CONTROLLING INTEREST (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="loc_us-gaapNoncontrollingInterestAbstract" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_NonControllingInterestPaidinCapital" xlink:label="loc_AATPNonControllingInterestPaidinCapital" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncontrollingInterestAbstract" xlink:to="loc_AATPNonControllingInterestPaidinCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_NonControllingInterestAccumulatedDeficit" xlink:label="loc_AATPNonControllingInterestAccumulatedDeficit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncontrollingInterestAbstract" xlink:to="loc_AATPNonControllingInterestAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_NonControllingInterestAccumulatedOtherComprehensiveIncome" xlink:label="loc_AATPNonControllingInterestAccumulatedOtherComprehensiveIncome" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncontrollingInterestAbstract" xlink:to="loc_AATPNonControllingInterestAccumulatedOtherComprehensiveIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_NonControllingInterestNonControllingInterestGross" xlink:label="loc_AATPNonControllingInterestNonControllingInterestGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncontrollingInterestAbstract" xlink:to="loc_AATPNonControllingInterestNonControllingInterestGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_NonControllingInterestAsl" xlink:label="loc_AATPNonControllingInterestAsl" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncontrollingInterestAbstract" xlink:to="loc_AATPNonControllingInterestAsl" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncontrollingInterestAbstract" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails" xlink:title="00000073 - Disclosure - SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAX (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MY" xlink:label="loc_countryMY" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryMY" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_HK" xlink:label="loc_countryHK" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryHK" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails" xlink:title="00000074 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAX (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentForeignTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentForeignTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" xlink:title="00000075 - Disclosure - SCHEDULE OF EFFECTIVE INCOME TAX RATE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfEffectiveIncomeTaxRateDetailsParenthetical" xlink:title="00000076 - Disclosure -  SCHEDULE OF EFFECTIVE INCOME TAX RATE (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_AATPLBASLSEAAndWATPMember" xlink:label="loc_AATPAATPLBASLSEAAndWATPMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_AATPAATPLBASLSEAAndWATPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_AATPHKMember" xlink:label="loc_AATPAATPHKMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_AATPAATPHKMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_AATPLBASLSEAWATPAndDSYMember" xlink:label="loc_AATPAATPLBASLSEAWATPAndDSYMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_AATPAATPLBASLSEAWATPAndDSYMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:title="00000077 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MY" xlink:label="loc_countryMY" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryMY" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsForeign" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DeferredTaxLiabilitiesDepreciation" xlink:label="loc_AATPDeferredTaxLiabilitiesDepreciation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AATPDeferredTaxLiabilitiesDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000078 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_srtStatementGeographicalAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_LabuanMember" xlink:label="loc_AATPLabuanMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_AATPLabuanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MY" xlink:label="loc_countryMY" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryMY" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_HK" xlink:label="loc_countryHK" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryHK" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_srtStatementScenarioAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_TwoThousandTwentyEightMember" xlink:label="loc_AATPTwoThousandTwentyEightMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_AATPTwoThousandTwentyEightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_TwoThousandTwentyNineMember" xlink:label="loc_AATPTwoThousandTwentyNineMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_AATPTwoThousandTwentyNineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_TwoThousandThirtyMember" xlink:label="loc_AATPTwoThousandThirtyMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_AATPTwoThousandThirtyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_TaxRateDescription" xlink:label="loc_AATPTaxRateDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_AATPTaxRateDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DeferredTaxAssetsOperatingLossCarryforwardsReducedAmount" xlink:label="loc_AATPDeferredTaxAssetsOperatingLossCarryforwardsReducedAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_AATPDeferredTaxAssetsOperatingLossCarryforwardsReducedAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaapIncomeTaxExaminationDescription" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockSplit" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative" xlink:title="00000079 - Disclosure - CONCENTRATIONS OF RISKS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtMajorCustomersAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_NoCustomerMember" xlink:label="loc_AATPNoCustomerMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_AATPNoCustomerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_FiveIndividualCustomersMember" xlink:label="loc_AATPFiveIndividualCustomersMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_AATPFiveIndividualCustomersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_VendorOneMember" xlink:label="loc_AATPVendorOneMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_AATPVendorOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_VendorTwoMember" xlink:label="loc_AATPVendorTwoMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_AATPVendorTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_VendorThreeMember" xlink:label="loc_AATPVendorThreeMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_AATPVendorThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_VendorMember" xlink:label="loc_AATPVendorMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_AATPVendorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_OneVendorMember" xlink:label="loc_AATPOneVendorMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_AATPOneVendorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_OneSalesDistributorMember" xlink:label="loc_AATPOneSalesDistributorMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_AATPOneSalesDistributorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaapRevenueFromContractWithCustomerMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapRevenueFromContractWithCustomerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsTotalMember" xlink:label="loc_us-gaapCostOfGoodsTotalMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapCostOfGoodsTotalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember" xlink:label="loc_us-gaapAccountsPayableMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaapSupplierConcentrationRiskMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapSupplierConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_deiLegalEntityAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DSwissIncMember" xlink:label="loc_AATPDSwissIncMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_AATPDSwissIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DSwissIncMember" xlink:label="loc_AATPDSwissIncMember_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_AATPDSwissIncMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DividendShareForCommonStock" xlink:label="loc_AATPDividendShareForCommonStock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_AATPDividendShareForCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Deposits" xlink:label="loc_us-gaapDeposits" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_DepositForInsurance" xlink:label="loc_AATPDepositForInsurance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_AATPDepositForInsurance" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/ScheduleOfLeaseCommitmentsDetails" xlink:title="00000080 - Disclosure - SCHEDULE OF LEASE COMMITMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_LesseeOperatingLeaseLiabilityPaymentsDueAfterNextTwelveMonths" xlink:label="loc_AATPLesseeOperatingLeaseLiabilityPaymentsDueAfterNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_AATPLesseeOperatingLeaseLiabilityPaymentsDueAfterNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000081 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaapRestructuringCostAndReserveLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapRestructuringCostAndReserveLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_AgapeSuperiorLivingMember" xlink:label="loc_AATPAgapeSuperiorLivingMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_AATPAgapeSuperiorLivingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_TrainingCenterMember" xlink:label="loc_AATPTrainingCenterMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_AATPTrainingCenterMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_LeaseExpirationTerm" xlink:label="loc_AATPLeaseExpirationTerm" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_AATPLeaseExpirationTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aatp-20221231.xsd#AATP_IncreaseDecreaseInROUAssetsAndLiabilities" xlink:label="loc_AATPIncreaseDecreaseInROUAssetsAndLiabilities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_AATPIncreaseDecreaseInROUAssetsAndLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992547569104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 23, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">333-220144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AGAPE
ATP CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001713210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">36-4838886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1705
&#8211; 1708, Level 17, Tower 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Faber Towers<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Jalan Desa Bahagia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Kuala Lumpur<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">MY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">58100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(60)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">192230099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 293,809,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,452,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">5395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Friedman LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">New
York, New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992546488960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents (Included $1,609 and $17,493 in the consolidated VIE that can be used only to settle obligations of the consolidated VIE as of December 31, 2022 and 2021, respectively.)</a></td>
<td class="nump">$ 1,438,430<span></span>
</td>
<td class="nump">$ 2,597,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">2,826<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Amount due from related parties</a></td>
<td class="nump">10,534<span></span>
</td>
<td class="nump">7,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">46,277<span></span>
</td>
<td class="nump">375,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid taxes (Included $1,741 and $1,357 in the consolidated VIE that can be used only to settle obligations of the consolidated VIE as of December 31, 2022 and 2021, respectively.)</a></td>
<td class="nump">339,367<span></span>
</td>
<td class="nump">636,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepayments and deposits</a></td>
<td class="nump">191,100<span></span>
</td>
<td class="nump">295,517<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">2,028,534<span></span>
</td>
<td class="nump">3,912,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>OTHER ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">142,149<span></span>
</td>
<td class="nump">215,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">24,044<span></span>
</td>
<td class="nump">3,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating right-of-use assets</a></td>
<td class="nump">81,133<span></span>
</td>
<td class="nump">237,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Investment in marketable securities</a></td>
<td class="nump">16,687<span></span>
</td>
<td class="nump">89,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_InvestmentInNonMarketableSecuritiesNoncurrent', window );">Investment in non-marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred offering costs</a></td>
<td class="nump">499,202<span></span>
</td>
<td class="nump">264,735<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total other assets</a></td>
<td class="nump">763,215<span></span>
</td>
<td class="nump">812,413<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">2,791,749<span></span>
</td>
<td class="nump">4,724,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payable</a></td>
<td class="nump">28,833<span></span>
</td>
<td class="nump">13,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Accounts payable &#8211; related parties</a></td>
<td class="nump">25,611<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Customer deposits</a></td>
<td class="nump">363,018<span></span>
</td>
<td class="nump">279,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">82,708<span></span>
</td>
<td class="nump">157,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Other payables and accrued liabilities ($1,090 and $1,548 are included in the consolidated VIE that are without recourse to the credit of Agape ATP Corporation as of December 31, 2022 and 2021, respectively.)</a></td>
<td class="nump">713,277<span></span>
</td>
<td class="nump">858,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other payable &#8211; related parties</a></td>
<td class="nump">4,880<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income tax payable</a></td>
<td class="nump">10,968<span></span>
</td>
<td class="nump">3,988<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">1,229,295<span></span>
</td>
<td class="nump">1,312,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NON-CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">83,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">15,574<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total Non-current Liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">99,058<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">1,229,295<span></span>
</td>
<td class="nump">1,411,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 200,000,000 shares authorized; None issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, par value $0.0001; 1,000,000,000 shares authorized, 75,452,012 and 290,460,047 shares issued and outstanding as of December 31, 2022 and 2021, respectively.</a></td>
<td class="nump">7,545<span></span>
</td>
<td class="nump">29,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">6,470,716<span></span>
</td>
<td class="nump">6,449,215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(4,945,586)<span></span>
</td>
<td class="num">(3,258,687)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">9,266<span></span>
</td>
<td class="nump">93,398<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL AGAPE CORPORATION STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">1,541,941<span></span>
</td>
<td class="nump">3,312,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">NON-CONTROLLING INTERESTS</a></td>
<td class="nump">20,513<span></span>
</td>
<td class="num">(336)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">TOTAL EQUITY</a></td>
<td class="nump">1,562,454<span></span>
</td>
<td class="nump">3,312,636<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 2,791,749<span></span>
</td>
<td class="nump">$ 4,724,535<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_InvestmentInNonMarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in non-marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_InvestmentInNonMarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992547470368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_VariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents', window );">VIE consolidated amount of cash and cash equivalents</a></td>
<td class="nump">$ 1,609<span></span>
</td>
<td class="nump">$ 17,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_VariableInterestEntityConsolidatedAmountOfPrepaidTaxes', window );">VIE consolidated amount of prepaid taxes</a></td>
<td class="nump">1,741<span></span>
</td>
<td class="nump">1,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_VariableInterestEntityConsolidatedAmountOfOtherPayablesAndAccruedLiabilities', window );">VIE consolidated amount of other payables and accrued liabilities</a></td>
<td class="nump">$ 1,090<span></span>
</td>
<td class="nump">$ 1,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">75,452,012<span></span>
</td>
<td class="nump">290,460,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">75,452,012<span></span>
</td>
<td class="nump">290,460,047<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_VariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>VIE consolidated amount of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_VariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_VariableInterestEntityConsolidatedAmountOfOtherPayablesAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>VIE consolidated amount of other payables and accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_VariableInterestEntityConsolidatedAmountOfOtherPayablesAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_VariableInterestEntityConsolidatedAmountOfPrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>VIE consolidated amount of Prepaid taxes .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_VariableInterestEntityConsolidatedAmountOfPrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992538285696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">REVENUE</a></td>
<td class="nump">$ 1,856,564<span></span>
</td>
<td class="nump">$ 1,016,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">COST OF REVENUE</a></td>
<td class="num">(666,042)<span></span>
</td>
<td class="num">(297,333)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">1,190,522<span></span>
</td>
<td class="nump">719,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">SELLING</a></td>
<td class="num">(361,414)<span></span>
</td>
<td class="num">(394,682)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesCommissionsAndFees', window );">COMMISSION</a></td>
<td class="num">(405,351)<span></span>
</td>
<td class="num">(316,267)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">GENERAL AND ADMINISTRATIVE</a></td>
<td class="num">(1,957,023)<span></span>
</td>
<td class="num">(1,745,734)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">PROVISION FOR DOUBTFUL ACCOUNTS</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(121,514)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">TOTAL OPERATING EXPENSES</a></td>
<td class="num">(2,723,788)<span></span>
</td>
<td class="num">(2,578,197)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS</a></td>
<td class="num">(1,533,266)<span></span>
</td>
<td class="num">(1,858,568)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSES)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expenses, net</a></td>
<td class="num">(79,539)<span></span>
</td>
<td class="num">(68,323)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">16,190<span></span>
</td>
<td class="nump">25,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized holding loss on marketable securities</a></td>
<td class="num">(73,519)<span></span>
</td>
<td class="num">(505,231)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_PreferredStockDividendIncomeStatementImpact', window );">Dividend income from marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">18,939<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">TOTAL OTHER EXPENSES, NET</a></td>
<td class="num">(136,868)<span></span>
</td>
<td class="num">(529,045)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS BEFORE INCOME TAXES</a></td>
<td class="num">(1,670,134)<span></span>
</td>
<td class="num">(2,387,613)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">BENEFIT OF (PROVISION FOR) INCOME TAXES</a></td>
<td class="nump">4,055<span></span>
</td>
<td class="num">(137,067)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">NET LOSS</a></td>
<td class="num">(1,666,079)<span></span>
</td>
<td class="num">(2,524,680)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">NET (INCOME) LOSS ATTRIBUTABLE TO NON-CONTROLLING INTERESTS</a></td>
<td class="num">(20,820)<span></span>
</td>
<td class="nump">436<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS ATTRIBUTABLE TO AGAPE ATP CORPORATION</a></td>
<td class="num">(1,686,899)<span></span>
</td>
<td class="num">(2,524,244)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">NET LOSS</a></td>
<td class="num">(1,666,079)<span></span>
</td>
<td class="num">(2,524,680)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>OTHER COMPREHENSIVE LOSS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(84,132)<span></span>
</td>
<td class="num">(87,615)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">TOTAL COMPREHENSIVE LOSS</a></td>
<td class="num">(1,750,211)<span></span>
</td>
<td class="num">(2,612,295)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Less: Comprehensive income (loss) attributable to non-controlling interests</a></td>
<td class="nump">20,849<span></span>
</td>
<td class="num">(433)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">COMPREHENSIVE LOSS ATTRIBUTABLE TO AGAPE ATP CORPORATION</a></td>
<td class="num">$ (1,771,060)<span></span>
</td>
<td class="num">$ (2,611,862)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted</a></td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract', window );"><strong>WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic and diluted</a></td>
<td class="nump">87,822,337<span></span>
</td>
<td class="nump">376,216,452<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_PreferredStockDividendIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_PreferredStockDividendIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesCommissionsAndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesCommissionsAndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized in the period that are directly related to the selling and distribution of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992538447248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Noncontrolling Interest [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 37,645<span></span>
</td>
<td class="nump">$ 6,440,616<span></span>
</td>
<td class="num">$ (734,443)<span></span>
</td>
<td class="nump">$ 181,016<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,924,834<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, Outstanding, Beginning Balance at Dec. 31, 2020</a></td>
<td class="nump">376,452,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Forfeiture of common stock</a></td>
<td class="num">$ (8,599)<span></span>
</td>
<td class="nump">8,599<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited</a></td>
<td class="num">(85,992,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_ContributionsFromNoncontrollingInterestShareholders', window );">Contributions from non-controlling interest shareholders</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,524,244)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(436)<span></span>
</td>
<td class="num">(2,524,680)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 29,046<span></span>
</td>
<td class="nump">6,449,215<span></span>
</td>
<td class="num">(3,258,687)<span></span>
</td>
<td class="nump">93,398<span></span>
</td>
<td class="num">(336)<span></span>
</td>
<td class="nump">3,312,636<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, Outstanding, Ending Balance at Dec. 31, 2021</a></td>
<td class="nump">290,460,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Forfeiture of common stock</a></td>
<td class="num">$ (21,501)<span></span>
</td>
<td class="nump">21,501<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited</a></td>
<td class="num">(218,008,035)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,686,899)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">20,820<span></span>
</td>
<td class="num">(1,666,079)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(84,132)<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="num">(84,103)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 7,545<span></span>
</td>
<td class="nump">$ 6,470,716<span></span>
</td>
<td class="num">$ (4,945,586)<span></span>
</td>
<td class="nump">$ 9,266<span></span>
</td>
<td class="nump">$ 20,513<span></span>
</td>
<td class="nump">$ 1,562,454<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, Outstanding, Ending Balance at Dec. 31, 2022</a></td>
<td class="nump">72,452,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_ContributionsFromNoncontrollingInterestShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contributions from non controlling interest shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_ContributionsFromNoncontrollingInterestShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph c(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992546454848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (1,666,079)<span></span>
</td>
<td class="num">$ (2,524,680)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">71,754<span></span>
</td>
<td class="nump">75,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization</a></td>
<td class="nump">2,122<span></span>
</td>
<td class="nump">1,961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating right-of-use assets</a></td>
<td class="nump">144,064<span></span>
</td>
<td class="nump">139,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized holding loss on marketable securities</a></td>
<td class="nump">73,519<span></span>
</td>
<td class="nump">505,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_PreferredStockDividendIncomeStatementImpact', window );">Dividend income from marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(18,939)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax (benefit) expense</a></td>
<td class="num">(14,751)<span></span>
</td>
<td class="nump">10,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="nump">5,307<span></span>
</td>
<td class="nump">36,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for doubtful accounts</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">121,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivables</a></td>
<td class="num">(2,824)<span></span>
</td>
<td class="nump">167,566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent', window );">Amount due from related parties</a></td>
<td class="num">(3,786)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">343,483<span></span>
</td>
<td class="nump">192,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidTaxes', window );">Prepaid taxes</a></td>
<td class="nump">263,404<span></span>
</td>
<td class="nump">430,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Prepayments and deposits</a></td>
<td class="nump">89,113<span></span>
</td>
<td class="num">(128,363)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">15,825<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Accounts payable &#8211; related parties</a></td>
<td class="nump">25,597<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Customer deposits</a></td>
<td class="nump">94,877<span></span>
</td>
<td class="nump">52,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(145,197)<span></span>
</td>
<td class="num">(138,143)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Other payables and accrued liabilities</a></td>
<td class="num">(119,963)<span></span>
</td>
<td class="nump">226,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent', window );">Other payables &#8211; related parties</a></td>
<td class="nump">4,878<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax payables</a></td>
<td class="nump">6,974<span></span>
</td>
<td class="nump">3,988<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(811,683)<span></span>
</td>
<td class="num">(845,842)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMachineryAndEquipment', window );">Purchase of equipment</a></td>
<td class="num">(9,433)<span></span>
</td>
<td class="num">(3,959)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of intangible assets</a></td>
<td class="num">(22,686)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(32,119)<span></span>
</td>
<td class="num">(3,959)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Deferred offering costs</a></td>
<td class="num">(234,466)<span></span>
</td>
<td class="num">(15,210)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt', window );">Advances to related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(3,851)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(234,466)<span></span>
</td>
<td class="num">(19,061)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(81,150)<span></span>
</td>
<td class="num">(50,890)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(1,159,418)<span></span>
</td>
<td class="num">(919,752)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH AND CASH EQUIVALENTS, beginning of year</a></td>
<td class="nump">2,597,848<span></span>
</td>
<td class="nump">3,517,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH AND CASH EQUIVALENTS, end of year</a></td>
<td class="nump">1,438,430<span></span>
</td>
<td class="nump">2,597,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL CASH FLOWS INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="nump">78,511<span></span>
</td>
<td class="nump">326,838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTAL NON-CASH FLOWS INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_ChangesInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseModifications', window );">Changes in right-of-use assets and lease liabilities due to lease modifications</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_ChangesInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseModifications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in right of use asset and lease liabilities due to lease modifications.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_ChangesInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseModifications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_PreferredStockDividendIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_PreferredStockDividendIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in related party receivables classified as other, due within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in related party payables classified as other, due within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992639639696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND BUSINESS BACKGROUND<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">ORGANIZATION AND BUSINESS BACKGROUND</a></td>
<td class="text"><p id="xdx_803_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zR6JjLOESEf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
<span id="xdx_82D_ztREWQUryuRe">ORGANIZATION AND BUSINESS BACKGROUND</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
ATP Corporation, a Nevada corporation (&#8220;the Company&#8221;) was incorporated under the laws of the State of Nevada on June 1, 2016.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
ATP Corporation operates through its subsidiaries, namely, Agape ATP Corporation (&#8220;AATP LB&#8221;), a company incorporated in Labuan,
Malaysia, and Agape Superior Living Sdn. Bhd. (&#8220;ASL&#8221;), a company incorporated in Malaysia. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
ATP Corporation, incorporated in Labuan, Malaysia, is an investment holding company with <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AgapeATPInternationalHoldingLimitedMember_zc7eTvCZ2HD5" title="Ownership interest percentage">100</span>% equity interest in Agape ATP International
Holding Limited (&#8220;AATP HK&#8221;), a company incorporated in Hong Kong.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 8, 2020, the Company entered into a Share Exchange Agreement with Mr. How Kok Choong, CEO and director of the Company to acquire
<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20200507__20200508__us-gaap--TypeOfArrangementAxis__custom--ShareExchangeAgreementMember__srt--TitleOfIndividualAxis__custom--MrHowKokChoongMember_z802G6v5C9f9" title="Stock issued during period acquisitions, shares">9,590,596</span> ordinary shares, no par value, equivalent to approximately <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20200508__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zfnUebdMNK4j" title="Ownership interest percentage">99.99</span>% of the equity interest in Agape Superior Living Sdn. Bhd.,
a network marketing entity incorporated in Malaysia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
Superior Living Sdn. Bhd. is a limited company incorporated on August 8, 2003, under the laws of Malaysia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 11, 2020, the Company incorporated Wellness ATP International Holdings Sdn, Bhd. (&#8220;WATP&#8221;), a wholly owned subsidiary
under the laws of Malaysia, to pursue the business of promoting wellness and wellbeing lifestyle of the community by providing services
that includes online editorials, programs, events and campaigns on how to achieve positive wellness and lifestyle.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
November 11, 2021, Agape ATP Corporation (Labuan) formed a joint-venture entity, DSY Wellness International Sdn. Bhd. (&#8220;DSY Wellness&#8221;)
with an independent third party which Agape ATP Corporation (Labuan) owns <span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20211111__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zqShoCpWyng9" title="Ownership interest percentage">60</span>% of the equity interest, to pursue the business of providing
complementary health therapies</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and its subsidiaries are principally engaged in the Health and Wellness Industry. The principal activity of the Company is to
supply high-quality health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation,
anti-aging and products designed to improve the overall health system of the human body and various wellness programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements reflect the activities of the Company, AATP LB, AATP HK, WATP, ASL and its variable interest
entity (&#8220;VIE&#8221;), Agape S.E.A. Sdn. Bhd. (&#8220;SEA&#8221;) (See Note 3), and DSY Wellness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_z6jBKz43mij3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details
of the Company&#8217;s subsidiaries:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_z4U5U8Q2bO8b" style="display: none">SCHEDULE OF SUBSIDIARIES AND ASSOCIATES</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Subsidiary company name</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Place and date of incorporation</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Particulars of issued capital</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Principal activities</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Proportional of ownership interest and voting power held</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 4%; vertical-align: top">1.</td>
    <td id="xdx_98F_ecustom--NameOftheCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_z2wgyn1Dpdoi" style="vertical-align: top; width: 16%; text-align: center" title="Subsidiary company name">Agape ATP Corporation</td><td style="width: 2%">&#160;</td>
    <td id="xdx_98A_ecustom--PlaceAndDateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_zOH5MKL1PLkj" style="vertical-align: top; width: 16%; text-align: center" title="Place and date of incorporation">Labuan, <br/> March 6, 2017</td><td style="width: 2%">&#160;</td>
    <td id="xdx_98C_ecustom--ParticularsOfIssuedCapital_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_zU2TJAdQCsg1" style="vertical-align: top; width: 20%; text-align: center" title="Particulars of issued capital">100 shares of ordinary share of US$1 each</td><td style="width: 2%">&#160;</td>
    <td id="xdx_984_ecustom--PrincipalActivities_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_z0yc20sqe4e5" style="vertical-align: top; width: 18%; text-align: center" title="Principal activities">Investment holding</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_zlXDpPQbfo4c" style="width: 16%; text-align: right" title="Proportional of ownership interest and voting power held">100</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">2.</td>
    <td id="xdx_988_ecustom--NameOftheCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_zwISC4Dfxule" style="vertical-align: top; text-align: center" title="Subsidiary company name">Agape ATP International Holding Limited</td><td>&#160;</td>
    <td id="xdx_980_ecustom--PlaceAndDateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_zKZuiXDJIJO9" style="vertical-align: top; text-align: center" title="Place and date of incorporation">Hong Kong,<br/> June 1, 2017</td><td>&#160;</td>
    <td id="xdx_987_ecustom--ParticularsOfIssuedCapital_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_z1C2yO2Krxjf" style="vertical-align: top; text-align: center" title="Particulars of issued capital">1,000,000 shares of ordinary share of HK$1 each</td><td>&#160;</td>
    <td id="xdx_98A_ecustom--PrincipalActivities_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_ztkuR8UgE2Ga" style="vertical-align: top; text-align: center" title="Principal activities">Wholesaling of health and wellness products; and health solution advisory services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_zhrHuElxQgUb" style="text-align: right" title="Proportional of ownership interest and voting power held">100</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">3.</td>
    <td id="xdx_986_ecustom--NameOftheCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zWPZEeulGIaj" style="vertical-align: top; text-align: center" title="Subsidiary company name">Agape Superior Living Sdn. Bhd.</td><td>&#160;</td>
    <td id="xdx_989_ecustom--PlaceAndDateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_z2vG4JESWMse" style="vertical-align: top; text-align: center" title="Place and date of incorporation">Malaysia, <br/> August 8, 2003</td><td>&#160;</td>
    <td id="xdx_98F_ecustom--ParticularsOfIssuedCapital_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zlxQ0wCJyced" style="vertical-align: top; text-align: center" title="Particulars of issued capital">9,590,598 shares of ordinary share of RM1 each</td><td>&#160;</td>
    <td id="xdx_98F_ecustom--PrincipalActivities_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zaWmlnQpMVlk" style="vertical-align: top; text-align: center" title="Principal activities">Health and wellness products and health solution advisory services via network marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zRDu6wC8Y65g" style="text-align: right" title="Proportional of ownership interest and voting power held">99.99</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">4.</td>
    <td id="xdx_983_ecustom--NameOftheCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_zCQSxQOdMDV6" style="vertical-align: top; text-align: center" title="Subsidiary company name">Agape S.E.A. Sdn. Bhd.</td><td>&#160;</td>
    <td id="xdx_989_ecustom--PlaceAndDateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_zJkdhPBAnCx6" style="vertical-align: top; text-align: center" title="Place and date of incorporation">Malaysia, <br/> March 4, 2004</td><td>&#160;</td>
    <td id="xdx_981_ecustom--ParticularsOfIssuedCapital_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_zQVikuygSc68" style="vertical-align: top; text-align: center" title="Particulars of issued capital">2 shares of ordinary share of RM1 each</td><td>&#160;</td>
    <td id="xdx_98B_ecustom--PrincipalActivities_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_zx9nzdHshE9" style="vertical-align: top; text-align: center" title="Principal activities">VIE of Agape Superior Living Sdn. Bhd.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VIE</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">5.</td>
    <td id="xdx_988_ecustom--NameOftheCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_zVyxdcbNtEw4" style="vertical-align: top; text-align: center" title="Subsidiary company name">Wellness ATP International Holdings Sdn, Bhd</td><td>&#160;</td>
    <td id="xdx_98A_ecustom--PlaceAndDateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_zQzORBPslp6b" style="vertical-align: top; text-align: center" title="Place and date of incorporation">Malaysia, <br/> September 11, 2020</td><td>&#160;</td>
    <td id="xdx_98F_ecustom--ParticularsOfIssuedCapital_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_zzCN2vTm0Nrj" style="vertical-align: top; text-align: center" title="Particulars of issued capital">100 shares of ordinary share of RM1 each</td><td>&#160;</td>
    <td id="xdx_980_ecustom--PrincipalActivities_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_z4w9BFgkjcaf" style="vertical-align: top; text-align: center" title="Principal activities">The promotion of wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_zrwhNipqlX5h" style="text-align: right" title="Proportional of ownership interest and voting power held">100</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">6.</td>
    <td id="xdx_981_ecustom--NameOftheCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zPNDKJMYKVCf" style="vertical-align: top; text-align: center" title="Subsidiary company name">DSY Wellness International Sdn Bhd.</td><td>&#160;</td>
    <td id="xdx_987_ecustom--PlaceAndDateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zkpqjGWY6Im9" style="vertical-align: top; text-align: center" title="Place and date of incorporation">Malaysia, <br/> November 11, 2021</td><td>&#160;</td>
    <td id="xdx_989_ecustom--ParticularsOfIssuedCapital_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zSsNZhMC3uab" style="vertical-align: top; text-align: center" title="Particulars of issued capital">1,000 shares of ordinary share of RM1 each</td><td>&#160;</td>
    <td id="xdx_982_ecustom--PrincipalActivities_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_z5jZwgR6At6a" style="vertical-align: top; text-align: center" title="Principal activities">Provision of complementary health therapies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zWZ4bln97jE8" style="text-align: right" title="Proportional of ownership interest and voting power held">60</td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A0_zodYUjrS2ead" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
ORGANIZATION AND BUSINESS BACKGROUND (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
ATP Corporation is a company that provides health and wellness products and health solution advisory services to our clients. The Company
primarily focus its efforts on attracting customers in Malaysia. Its advisory services center on the &#8220;ATP Zeta Health Program&#8221;,
which is a health program designed to effectively prevent diseases caused by polluted environments, unhealthy dietary intake and unhealthy
lifestyles, and promotion of health. The program aims to promote improved health and longevity in our clients through a combination of
modern medicine, proper nutrition and advice from skilled nutritionists and/or dieticians.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to strengthen the Company&#8217;s supply chain, on May 8, 2020, the Company has successfully acquired approximately <span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20200508__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zWwMZGl7fYI9" title="Ownership interest percentage">99.99</span>% of ASL,
with the goal of securing an established network marketing sales channel that has been established in Malaysia for the past 15 years.
ASL has been offering the Company&#8217;s ATP Zeta Health Program as part of its product lineup. As such, the acquisition creates synergy
in the Company&#8217;s operation by boosting the Company&#8217;s retail and marketing capabilities. The newly acquired subsidiary allows
the Company to fulfill its mission of &#8220;helping people to create health and wealth&#8221; by providing a financially rewarding business
opportunity to distributors and quality products to distributors and customers who seek a healthy lifestyle.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Via
ASL, the Company offers three series of programs which consist of different services and products: ATP Zeta Health Program, &#201;NERG&#201;TIQUE
and BEAUNIQUE.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ATP Zeta Health Program is a health program designed to promote health and general wellbeing designed to prevent health diseases caused
by polluted environments, unhealthy dietary intake and unhealthy lifestyles. The program aims to promote improved health and longevity
through a combination of modern health supplements, proper nutrition and advice from skilled dieticians as well as trained members and
distributors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
&#201;NERG&#201;TIQUE series aims to provide a total dermal solution for a healthy skin beginning from the cellular level. The series
is comprised of the Energy Mask series, Hyaluronic Acid Serum and Mousse Facial Cleanser.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
BEAUNIQUE product series focuses on the research of our diet&#8217;s impact on modifying gene expressions in order to address genetic
variations and deliver a nutrigenomic solution for every individual.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company deems creating public awareness on wellness and wellbeing lifestyle as essential to enhance the provision of its health solution
advisory services; and therefore, incorporated WATP. Upon its establishment, WATP started collaborating with ASL to carry out various
wellness programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">To
further its reach in the Health and Wellness Industry, on November 11, 2021, Agape ATP Corporation (Labuan) formed a joint-venture entity,
DSY Wellness International Sdn. Bhd. (&#8220;DSY Wellness&#8221;) with an independent third party which Agape ATP Corporation (Labuan)
owns <span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20211111__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zwAGvqoA2HP9" title="Ownership interest percentage">60</span>% of the equity interest, to pursue the business of providing complementary health therapies</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992629481008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_z6WrXQERQkr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span id="xdx_823_zkfU5HXXyal3">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zNyP0JyAjBg1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86B_zswr0mP2xvua">Basis
of presentation</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#8220;U.S. GAAP&#8221;) for information pursuant to the rules and regulations of the Securities Exchange Commission
(&#8220;SEC&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the financial statements of the Company, its subsidiaries and its VIE over which the Company
exercises control and, where applicable, entities for which the Company has a controlling financial interest or is the primary beneficiary.
All transactions and balances among the Company, its subsidiaries and its VIE have been eliminated upon consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_zjSzSQwxiDdi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86B_zL3GCcj9fsy3">Principles
of consolidation</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries
are those entities in which the Company, directly or indirectly, controls more than one half of the voting power; or has the power to
govern the financial and operating policies, to appoint or remove the majority of the members of the board of directors, or to cast a
majority of votes at the meeting of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
VIE is an entity that has either a total equity investment that is insufficient to permit the entity to finance its activities without
additional subordinated financial support, or whose equity investors lack the characteristics of a controlling financial interest, such
as through voting rights, right to receive the expected residual returns of the entity or obligation to absorb the expected losses of
the entity. The variable interest holder, if any, that has a controlling financial interest in a VIE is deemed to be the primary beneficiary
and must consolidate the VIE. As of and for the year ended December 31, 2022, SEA, the only VIE of the Company has no significant operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--UseOfEstimates_zkjAIul2wCT" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86C_zVJBrVh7U4Aj">Use
of estimates</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of
the consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant
accounting estimates reflected in the Company&#8217;s consolidated financial statements include allowance for inventories
obsolescence, impairment of long-lived assets, allowance for deferred tax assets. Actual results could differ from
these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6f6d91OK2Rc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86B_zsTXHABZLZv4">Cash
and cash equivalents</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents represent cash on hand, time deposits placed with banks or other financial institutions and all highly liquid investments
with an original maturity of three months or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z3H4czMnpm65" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zzkCSgBX4RR5">Accounts
receivable</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable are recorded at the invoiced amount less an allowance for any uncollectible accounts and do not bear interest, which are due
on credit term. Management reviews the adequacy of the allowance for doubtful accounts on an ongoing basis,
using historical collection trends and aging of receivables. Management also periodically evaluates individual customer&#8217;s financial
condition, credit history, and the current economic conditions to make adjustments in the allowance when it is considered necessary.
Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery
is considered remote. The Company&#8217;s management continues to evaluate the reasonableness of the valuation allowance policy and update
it if necessary. As of December 31, 2022 and 2021, <span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_pp0p0_doxL_c20221231_zhiOqmrcPqr8" title="Accounts receivable, allowance for credit loss::XDX::-"><span id="xdx_901_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_pp0p0_doxL_c20221231_zIRpLQV9Lc8j" title="Accounts receivable, allowance for credit loss::XDX::-"><span id="xdx_90B_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_pp0p0_doxL_c20211231_zjYfB6tYQihl" title="Accounts receivable, allowance for credit loss::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0585"><span style="-sec-ix-hidden: xdx2ixbrl0587"><span style="-sec-ix-hidden: xdx2ixbrl0589">no</span></span></span></span></span></span> allowance of doubtful accounts was recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--InventoryPolicyTextBlock_zroHu3uZnh9c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86E_zb5B0Zq2D3Jc">Inventories</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
consist of finished goods and are stated at the lower of cost or net realizable value using the first-in first-out method. Management
reviews inventory on hand for estimated obsolescence or unmarketable items, as compared to future demand requirements and the shelf life
of the various products. Based on the review, the Company records inventory write-downs, when necessary, when costs exceed expected net
realizable value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2022 and 2021, the Company recognized $<span id="xdx_90F_ecustom--InventriesWriteDown_pp0p0_c20220101__20221231_zkXsJJfxpgR3" title="Inventories write-down">5,307</span> and $<span id="xdx_902_ecustom--InventriesWriteDown_pp0p0_c20210101__20211231_zViMsjV0vVu5" title="Inventories write-down">36,241</span> inventory write-down; and $<span id="xdx_902_ecustom--InventoryWriteOff_c20220101__20221231_z1Nv38Qn2qsf" title="Inventories write off">142,466</span> and $<span id="xdx_905_ecustom--InventoryWriteOff_dxL_c20210101__20211231_zGY4zxAPf0Q1" title="Inventories write off::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0599">0</span></span> inventory
write-off, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_ecustom--PrepaidTaxesPolicyTextBlock_z8UDeXO0uIVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_865_zJcRJJhWLRv">Prepaid
taxes</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Prepaid
taxes include prepaid income taxes that will either be refunded or utilized to offset future income tax</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_ecustom--PrepaymentsAndDepositsPolicyTextBlock_zvFkVXX4W746" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_z2uvTEKsIbGb">Prepayments
and deposits</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepayments
and deposits are mainly cash deposited or advanced to suppliers for future inventory purchases or service providers for future
services. This amount is refundable and bears no interest. For any prepayments and deposits determined by management that such
advances will not be in receipts of inventories, services, or refundable, the Company will recognize an allowance account to reserve
such balances. Management reviews its prepayments and deposits on a regular basis to determine if the allowance is adequate, and
adjusts the allowance when necessary. Delinquent account balances are written-off against allowance for doubtful accounts after
management has determined that the likelihood of collection is not probable. The Company&#8217;s management continues to evaluate
the reasonableness of the allowance policy and update it if necessary. For the years ended December 31, 2022 and 2021, the Company
wrote-off allowance for doubtful accounts of $<span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_c20220101__20221231_zW6bV9v1bfo2" title="Wrote-off allowance for doubtful accounts">120,372</span>
and $<span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_dxL_c20210101__20211231_zFMULrNMoPne" title="Wrote-off allowance for doubtful accounts::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0607">0</span></span>,
respectively. As of December 31, 2022 and 2021, there was $<span id="xdx_907_ecustom--AllowanceForDoubtfulAccountsReceivablesCurrent_iI_pp0p0_do_c20221231_zGvdFOudWL7c" title="Allowance for doubtful accounts">0</span>
and $<span id="xdx_905_ecustom--AllowanceForDoubtfulAccountsReceivablesCurrent_iI_pp0p0_do_c20211231_zv10kvuHJ4n3" title="Allowance for doubtful accounts">121,514</span>
allowance for the doubtful accounts recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zgg3hTGkHmZf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_zpVTMf0SNNfe">Property
and equipment, net</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated
useful lives of the assets with no residual value. The estimated useful lives are as follows:</span></p>

<p id="xdx_892_ecustom--ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_zxSyuQKO7vsa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zOyq8RivGFR9" style="display: none">SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful
    Life</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    and office equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zRaLyCBNVncf" title="Estimated Useful Life of Property and Equipment">5</span>-<span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zKSowKihepnf" title="Estimated Useful Life of Property and Equipment">7</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    &amp; fixtures</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zbVjqFcoASWf" title="Estimated Useful Life of Property and Equipment">6</span>-<span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_z0vZeH6V7xCf" title="Estimated Useful Life of Property and Equipment">7</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_ziqFH0okZyU7" title="Property and equipment, useful lives">Lease
    Term</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vehicle</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zP2bWwILT46e" title="Property and equipment, estimated useful life">5</span>
    years</span></td></tr>
  </table>
<p id="xdx_8A4_zbgOBOvXHTH4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cost and related accumulated depreciation of assets sold or otherwise retired are eliminated from the accounts and any gain or loss is
included in the consolidated statements of income and comprehensive income. Expenditures for maintenance and repairs are charged to earnings
as incurred, while additions, renewals and betterments, which are expected to extend the useful life of assets, are capitalized. The
Company also re-evaluates the periods of depreciation to determine whether subsequent events and circumstances warrant revised estimates
of useful lives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zBv5uUAm31Fa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zDVA3pZbA5M9">Intangible
assets, net</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_ecustom--ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock_zaVytQwRId14" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets, net, are stated at cost, less accumulated amortization. Amortization expense is recognized on the straight-line basis over the
estimated useful lives of the assets as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zDzRO3Dcan" style="display: none">SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 80%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Classification</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful
    Life</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    software</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zRsBzurNO1nc" title="Estimated useful lives of intangible assets">5</span>
    years</span></td></tr>
  </table>
<p id="xdx_8A4_zLUo8k4t2rki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zTvfaNfOGHP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_zuAN8gurejM7">Impairment
for long-lived assets</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived
assets, including property and equipment, and intangible assets with finite lives are reviewed for impairment whenever events or changes
in circumstances (such as a significant adverse change to market conditions that will impact the future use of the assets) indicate that
the carrying value of an asset may not be recoverable. The Company assesses the recoverability of the assets based on the undiscounted
future cash flows the assets are expected to generate and recognize an impairment loss when estimated undiscounted future cash flows
expected to result from the use of the asset plus net proceeds expected from disposition of the asset, if any, are less than the carrying
value of the asset. If an impairment is identified, the Company would reduce the carrying amount of the asset to its estimated fair value
based on a discounted cash flows approach or, when available and appropriate, to comparable market values. As of December 31, 2022 and
2021, <span id="xdx_90D_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20220101__20221231_zRooauhLHRQ6" title="Impairment of long-lived assets"><span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20210101__20211231_zlATP8y30Bn4" title="Impairment of long-lived assets">no</span></span> impairment of long-lived assets was recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--DeferredChargesPolicyTextBlock_zMw2aKdMtLE7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_zx7gkumGIB5b">Deferred
offering costs</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
offering costs represents costs associated with the Company&#8217;s current offering which will be netted against the proceeds from the
Company&#8217;s current offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--MarketableSecuritiesPolicy_z8aS297zZ9zi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zLchEfqtIIXg">Investment
in marketable equity securities</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company follows the provisions of ASU 2016-01, <i>Financial Instruments &#8211; Overall (Subtopic 825-10): Recognition and Measurement
of Financial Assets and Financial Liabilities</i>. Investments in marketable equity securities (non-current) are reported at fair value
with changes in fair value recognized in the Company&#8217;s consolidated statements of operations and comprehensive income (loss) in
the caption of &#8220;unrealized holding gain loss on marketable securities&#8221; in each reporting period</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_ecustom--NonMarketableSecuritiesPolicyTextBlock_zYzL1EUXi7gk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_zhnw5Q0KKIYd">Investment
in non-marketable equity securities</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the provisions of ASU 2016-01, <i>Financial Instruments &#8211; Overall (Subtopic 825-10): Recognition and Measurement
of Financial Assets and Financial Liabilities</i>. Due to the Company&#8217;s non-marketable equity securities (non-current) does not
qualify for the practical expedient to estimate fair value in accordance with ASC 820-10-35-59, the Company has selected to record its
investments in non-marketable equity securities (non-current) at cost minus impairment, if any, plus or minus changes resulting from
observable price changes in orderly transactions for the identical or a similar investment of the same issue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
each reporting period, the Company will make a qualitative assessment considering impairment indicators to evaluate whether the investment
is impaired. The qualitative assessment indicators include, but are not limited to: (1) A significant deterioration in the earnings performance,
credit rating, asset quality, or business prospects of the investee; (ii) A significant adverse change in the regulatory, economic, or
technological environment of the investee; (iii) A significant adverse change in the general market condition of either the geographical
area or the industry in which the investee operates; (iv) A bona fide offer to purchase, an offer by the investee to sell, or a completed
auction process for the same or similar investment for an amount less than the carrying amount of that investment; and (v) Factors that
raise significant concerns about the investee&#8217;s ability to continue as a going concern, such as negative cash flows from operations,
working capital deficiencies, or noncompliance with statutory capital requirements or debt covenants. If the qualitative assessment indicators
indicated that the non-marketable equity securities (non-current) is deemed to be impaired, the Company would recognize the impairment
loss equal to the difference between the fair value of the investment and its carrying amount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z3SZaMEFApKc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_869_zgCWme2SuQRb">Customer
deposits</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
deposits represent amounts advanced by customers on product orders and unapplied unexpired coupons. Customer deposits are reduced
when the related sale is recognized in accordance with the Company&#8217;s revenue recognition policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zl9XzPhLY6W4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_zL1ebv1bxSTe">Revenue
recognition</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers (ASC Topic 606). The core
principle underlying the revenue recognition of this ASU allows the Company to recognize - revenue that represents the transfer of goods
and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange.
This will require the Company to identify contractual performance obligations and determine whether revenue should be recognized at a
point in time or over time, based on when control of goods and services transfers to a customer. The Company&#8217;s revenue streams
are recognized at a point in time for the Company&#8217;s sale of health and wellness products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ASU requires the use of a new five-step model to recognize revenue from customer contracts. The five-step model requires that the Company
(i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction
price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate
the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies
the performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for a contract with a customer when the contract is committed in writing, the rights of the parties, including payment
terms, are identified, the contract has commercial substance and consideration is probable of substantially collection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sales
of Health and Wellness products</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
<i>Performance obligations satisfied at a point in time</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company derives its revenues from sales contracts with its customers with revenues being recognized when control of the health and wellness
products are transferred to its customer at the Company&#8217;s office or shipment of the goods. The revenue is recorded net of estimated
discounts and return allowances. Products are given 60 days for returns or exchanges from the date of purchase. Historically, there were
insignificant sales returns.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the Company&#8217;s network marketing business, the Company issues
product coupons to members and distributors when these customers made purchases above certain thresholds set by the Company. Depending
on the type of product coupons issued, the coupons carry varying values and can be used by the customers for reduction in the transaction
price of product purchases within the coupon validity period. The value of the product coupons issued is recorded as a reduction of the
Company&#8217;s revenue account upon issuance; the corresponding amount credited to the customer deposits account. Amounts in customer
deposits will be reversed when the coupons are used. The Company&#8217;s coupons have a validity period of between six and twelve months.
If the Company&#8217;s customers did not utilize the coupons after the validity period, the Company would recognize the forfeiture of
the originated sales value of the coupons as net revenues. For the years ended December 31, 2022 and 2021, the Company
recognized $<span id="xdx_905_ecustom--ForfeitedCouponIncome_pp0p0_c20220101__20221231_z1fGausFuaig" title="Value of coupons">7,543</span> and $<span id="xdx_90A_ecustom--ForfeitedCouponIncome_pp0p0_c20210101__20211231_zH33eqi84eae" title="Value of coupons">15,209</span> as forfeited coupon income, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company had contracts for the sales of health and wellness products amounting to $<span id="xdx_909_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20220101__20221231__srt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_zQlULzaPfKO" title="Cost of revenue">17,912</span> which it is expected
to fulfill within 12 months from December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sales of products for the provision of complementary
health therapies</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Products for the provision of complementary health
therapies are predominantly Chinese herbs in different forms, processed or otherwise, for prescriptions for treating non-communicable
diseases.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Provision
of Health and Wellness services</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
<i>Performance obligations satisfied at a point in time</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company carries out its Wellness program, where the Company&#8217;s products are bundled with health screening test and a health camp
program. The health screening test and the health camp programs are considered as separate performance obligations. The promises to deliver
the health screening test report and the attendance at the health camp are separately identifiable, which are evidenced by the fact that
the Company provides separate services of delivering the health screening test report and allowing admission of the customers to attend
the health camp. The Company derives its revenues from sales contracts with its customers with revenues being recognized when the test
reports are completed and delivered to its customers during the consultation section in person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also separately derives its revenues from sales contracts with its customers with revenues being recognized when the health
camp program is completed in the final day of the health camp. For the years ended December 31, 2022 and 2021, revenues from
providing health and wellness services are $<span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220101__20221231__srt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_zC5UZ5MD7tQ" title="Revenues">145,510</span>
and $<span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210101__20211231__srt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_zOxTFwz9GRPe" title="Revenues">7,543</span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--DisaggregationOfRevenueTableTextBlock_zL1STfYdysn6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disaggregated
information of revenues by products and services are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zSBL4CN1dXei" style="display: none">SCHEDULE OF DIS-AGGREGATED INFORMATION OF REVENUES</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_z21abgegsA4l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20211231_z7xtVmlVkoNi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--SurvivorSelectMember_z5LWKevPxJmd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Survivor Select</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">122,470</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">83,904</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--EnergizedMineralConcentrateMember_zr0zkyHoLKi8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Energized Mineral Concentrate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0666">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,047</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--IonizedCalMagMember_zcbfX7scUGK5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Ionized Cal-Mag</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">148,219</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,527</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--OmegaBlendMember_zslpoCg1cIPh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Omega Blend</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">272,332</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222,718</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--BetaMaxxMember_zFBHCEibRUgg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>BetaMaxx</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">137,447</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208,043</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--VegeFruitFiberMember_zKD0P0DckIMb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Vege Fruit Fiber</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0678">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65,757</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--IronMember_zqKvQRKr7jQc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Iron</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,697</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,114</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--YoungFormulaMember_zwDXHSYIX4Rj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Young Formula</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,403</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,425</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--OrganicYouthCarCleansingBarMember_zhkQlF7fn2S8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Organic Youth Care Cleansing Bar</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0687">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,137</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--ATPRMITOPlusMember_z3Dq7VueuIXa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">ATPR Mito+</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">271,493</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">183,800</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--LipomaskMember_zHMa8egFj19d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Lipomask</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0693">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,331</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--EnergetiqueMember_zIfNeHxtjAlg" style="vertical-align: bottom; background-color: White">
    <td>Energetique</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,089</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,574</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--TrimPlusMember_zkwcgP3YRps5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Trim+</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88,613</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,042</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--ProductHealthTherapiesMember_zCHcL6QqgpEh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Others &#8211; Products for the provision of complementary health therapies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">569,823</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0703">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--OthersMember_zDHxgz4Dsps5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,468</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0706">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zrDljTyzVArc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total revenues &#8211; products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,711,054</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,009,419</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_z2YRBKYgeNg4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Health and Wellness services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">145,510</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,543</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--Revenues_zUKQbvvSwePf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total revenues &#8211; products and services</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,856,564</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,016,962</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zE1GaDUQw54k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--CostOfSalesPolicyTextBlock_z6hmnXy5OW45" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zskQLX6oS36d">Cost
of revenue</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Cost
of revenue comprised freight-in, the purchase cost of manufactured goods for sale to customers </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
products for the provision of complementary health therapies. <span style="background-color: white">Cost of revenue amounted to $<span id="xdx_90A_eus-gaap--CostOfGoodsAndServicesSold_c20220101__20221231_zJWOrBaL3rZb" title="Cost of revenue">666,042</span>
(including inventory write-downs of $<span id="xdx_903_ecustom--InventriesWriteDown_pp0p0_c20220101__20221231_zRagiINTU2v3" title="Inventories write-down">5,307</span> and inventory written-off of $<span id="xdx_90A_ecustom--InventoryWriteOff_c20220101__20221231_zfIQAT5Y3WE9" title="Inventories write off">142,466</span>) and $<span id="xdx_901_eus-gaap--CostOfGoodsAndServicesSold_c20210101__20211231_zy3tBqIOa1G8" title="Cost of revenue">297,333</span> (including inventory write-downs of $<span id="xdx_906_ecustom--InventriesWriteDown_pp0p0_c20210101__20211231_zB1oBXGY34X2" title="Inventories write-down">36,241</span>)
for the years ended December 31, 2022 and 2021, respectively</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_ecustom--ShippingAndHandlingPolicyTextBlock_zvpO8NKxWZUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_865_z0aGmeBeTpgc">Shipping
and handling</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shipping
and handling charges amounted to $<span id="xdx_90C_eus-gaap--SellingExpense_pp0p0_c20220101__20221231__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_z6kvkMl8C7zf" title="Selling expenses">16,585</span> and $<span id="xdx_906_eus-gaap--SellingExpense_pp0p0_c20210101__20211231__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zlMEsfQKQ5A9" title="Selling expenses">11,054</span> for the years ended December 31, 2022 and 2021, respectively. Shipping and handling
charges are expensed as incurred and included in selling expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--AdvertisingCostsPolicyTextBlock_zPT6muVeN732" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_z7Es73GdWP47">Advertising
costs</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising
costs amounted to $<span id="xdx_90F_eus-gaap--AdvertisingExpense_pp0p0_c20220101__20221231_zYDnt2NU8M2f" title="Advertising costs">4,688</span> and $<span id="xdx_90A_eus-gaap--AdvertisingExpense_pp0p0_c20210101__20211231_zuP4dGeRsy0c" title="Advertising costs">20,218</span> for the years ended December 31, 2022 and 2021, respectively. Advertising costs are expensed as
incurred and included in selling expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--CommissionsExpensePolicyPolicyTextBlock_z9Mv3yTzzq3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86C_zZMSQOUlDMA2">Commission
expenses</span> </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
expenses are the Company&#8217;s most significant expenses. As with all companies in the network marketing industry, the Company&#8217;s
sales channel is external to the Company. The Company&#8217;s &#8220;external sales force&#8221; is stratified into two levels based
on priority recruitment. First, there are sales distributors. Second, all members recruited by a sales distributor, directly or indirectly,
are referred to as &#8220;sales network members&#8221;. The Company pays commission to every sales distributor based on purchases made
by its sales network members which includes the independent direct sales members. Top performing distributors with their own physical
stores may also become stockists of the Company, whereby they enjoy benefits such as maintaining a certain amount of the Company&#8217;s
inventory on their store premises. The stockists shall account to the Company for all products sales from their store premises as monitored
through the Company&#8217;s centralized stock tracking system. The Company pays a separate commission to stockists based on revenue generated
from the stockists&#8217; physical stores. Commission expenses amounted to $<span id="xdx_90B_eus-gaap--SalesCommissionsAndFees_pp0p0_c20220101__20221231_zX3h03VVO6v1" title="Commission expenses">405,351</span> and $<span id="xdx_903_eus-gaap--SalesCommissionsAndFees_pp0p0_c20210101__20211231_zp2dghig06Jl" title="Commission expenses">316,267</span> for the years ended December 31, 2022
and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_ecustom--DefinedContributionPlanPolicyTextBlock_zzTqGCuRJEU3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration: underline"><span id="xdx_862_z5HFBg68sykk">Defined
contribution plan</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
full-time employees of the Company are entitled to the government mandated defined contribution plan. The Company is required to accrue
and pay for these benefits based on certain percentages of the employees&#8217; respective salaries, subject to certain ceilings, in
accordance with the relevant government regulations, and make cash contributions to the government mandated defined contribution plan</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Total expenses for the plans were $<span id="xdx_906_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pp0p0_c20220101__20221231_zVicH7EgFDLa" title="Defined contribution plan expense">133,489</span> and $<span id="xdx_909_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pp0p0_c20210101__20211231_zfGWX5OFpjta" title="Defined contribution plan expense">99,488</span> for the years ended December 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
related contribution plans include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Social
    Security Organization (&#8220;SOSCO&#8221;) &#8211; <span id="xdx_90A_ecustom--SalaryPercentage_pid_dp_c20220101__20221231__dei--LegalEntityAxis__custom--SocialSecurityOrganizationMember_zBxcFz5qfd16" title="Salary percentage">1.75</span>% based on employee&#8217;s monthly salary capped of RM <span id="xdx_90E_ecustom--MonthlySalary_uRM_c20220101__20221231__dei--LegalEntityAxis__custom--SocialSecurityOrganizationMember_zF3FRUewo47b" title="Monthly salary">5,000</span>;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employees
    Provident Fund (&#8220;EPF&#8221;) &#8211;based on employee&#8217;s monthly salary, <span id="xdx_90D_ecustom--SalaryPercentage_pid_dp_c20220101__20221231__dei--LegalEntityAxis__custom--EmployeesProvidentFundMember__srt--RangeAxis__srt--MinimumMember_zQriZXqhOcEf" title="Salary percentage">13</span>% for employee earning RM<span id="xdx_90E_ecustom--MonthlySalary_uRM_c20220101__20221231__dei--LegalEntityAxis__custom--EmployeesProvidentFundMember__srt--RangeAxis__srt--MinimumMember_zhjGzhzfJlAc" title="Monthly salary">5,000</span> and below; and
    <span id="xdx_90E_ecustom--SalaryPercentage_pid_dp_c20220101__20221231__dei--LegalEntityAxis__custom--EmployeesProvidentFundMember__srt--RangeAxis__srt--MinimumMember__srt--RangeAxis__srt--MaximumMember_z2esrfOwXpSb" title="Salary percentage">12</span>% for employee earning RM<span id="xdx_906_ecustom--MonthlySalary_uRM_c20220101__20221231__dei--LegalEntityAxis__custom--EmployeesProvidentFundMember__srt--RangeAxis__srt--MaximumMember_zWZBWgz0MTwk" title="Monthly salary">5,001</span> and above.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment
    Insurance System (&#8220;EIS&#8221;) &#8211; <span id="xdx_90C_ecustom--SalaryPercentage_pid_dp_c20220101__20221231__dei--LegalEntityAxis__custom--EmploymentInsuranceSystemMember_zRHbOFUNH1f1" title="Salary percentage">0.2</span>% based on employee&#8217;s monthly salary capped of RM <span id="xdx_90E_ecustom--MonthlySalary_uRM_c20220101__20221231__dei--LegalEntityAxis__custom--EmploymentInsuranceSystemMember_ztc1arIXPmgb" title="Monthly salary">5,000</span>;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
    Resource Development Fund (&#8220;HRDF&#8221;) &#8211; <span id="xdx_907_ecustom--SalaryPercentage_pid_dp_c20220101__20221231__dei--LegalEntityAxis__custom--HumanResourceDevelopmentFundMember_zZfEeTcMmTd6" title="Salary percentage">1</span>% based on employee&#8217;s monthly salary</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zZdZiC8AkEH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_zCkcAvFtpGea">Income
taxes</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes in accordance with U.S. GAAP for income taxes. The charge for taxation is based on the results for
the fiscal year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted
or substantively enacted by the balance sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
taxes is accounted for using the asset and liability method in respect of temporary differences arising from differences between the
carrying amount of assets and liabilities in the consolidated financial statements and the corresponding tax basis used in the computation
of assessable tax profit. In principle, deferred tax liabilities are recognized for all taxable temporary differences. Deferred tax assets
are recognized to the extent that it is probable that taxable profit will be available against which deductible temporary differences
can be utilized. Deferred tax is calculated using tax rates that are expected to apply to the period when the asset is realized or the
liability is settled. Deferred tax is charged or credited in the income statement, except when it is related to items credited or charged
directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets are reduced by a valuation allowance
when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.
Current income taxes are provided for in accordance with the laws of the relevant taxing authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
uncertain tax position is recognized as a benefit only if it is &#8220;more likely than not&#8221; that the tax position would be sustained
in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that
is <span id="xdx_90F_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20220101__20221231_zridEaAy3q5d" title="Income tax description">greater than 50%</span> likely of being realized on examination. For tax positions not meeting the &#8220;more likely than not&#8221; test,
no tax benefit is recorded. $<span id="xdx_905_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_pp0p0_c20220101__20221231_zPKdG0hn2bma" title="Income tax examination, penalties and interest expense">0</span> and $<span id="xdx_904_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_pp0p0_c20210101__20211231_zSFYTL7JYgi1" title="Income tax examination, penalties and interest expense">395</span> penalties and interest incurred related to underpayment of income tax for the years ended December
31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company conducts much of its business activities in Hong Kong and Malaysia and is subject to tax in each of their jurisdictions. As a
result of its business activities, the Company will file separate tax returns that are subject to examination by the foreign tax authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zAIQ7gf36Ghj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_868_zwYFtkBQLvFa">Comprehensive
income (loss)</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
income (loss) consists of two components, net income (loss) and other comprehensive income (loss). Net income (loss) refers to revenue,
expenses, gains and losses that under GAAP are recorded as an element of stockholders&#8217; equity but are excluded from net income.
Other comprehensive income (loss) consists of a foreign currency translation adjustment resulting from the Company not using the U.S.
dollar as its functional currencies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_ecustom--NoncontrollingInterestPolicyTextBlock_zUmxJoS2Nq6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_z3pSSXQCI64h">Non-controlling
interest</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--MinorityInterestDescription_c20220101__20221231_z3bBup5MmeXk" title="Noncontrolling interest, description">Non-controlling
interest consists of 40% of the equity interests of DSY Wellness held by an individual and approximately 0.01% (2 ordinary shares out
of 9,590,598 shares) of the equity interests of ASL held by two individuals</span>. The non-controlling interests are presented in the consolidated
balance sheets, separately from equity attributable to the shareholders of the Company. Non-controlling interests in the results of the
Company are presented on the face of the consolidated statements of operations as an allocation of the total income or loss for the periods
between non-controlling interest holders and the shareholders of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zYeCXifgtjIc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_z17u0oqw1S65">Earnings
(loss) per share</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company computes earnings (loss) per share (&#8220;EPS&#8221;) in accordance with ASC 260, &#8220;Earnings per Share&#8221;. ASC 260
requires companies to present basic and diluted EPS. Basic EPS is measured as net income divided by the weighted average ordinary share
outstanding for the period. Diluted EPS presents the dilutive effect on a per share basis of the potential ordinary shares (e.g., convertible
securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later.
Potential ordinary shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are
excluded from the calculation of diluted EPS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. For the
years ended December 31, 2022 and 2021, there were <span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20220101__20221231_zZU9VYbmnxme" title="Potentially dilutive securities outstanding"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20210101__20211231_zTFE6S4QfcGg" title="Potentially dilutive securities outstanding">no</span></span> dilutive shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zpmvue0RnR04" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86F_zeX8FIyxsbb9">Foreign
currencies translation and transaction</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing
at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated
into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded
in the consolidated statements of operations and comprehensive income (loss).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reporting currency of the Company is United States Dollars (&#8220;US$&#8221;) and the accompanying financial statements have been expressed
in US$. The Company&#8217;s subsidiary in Labuan maintains its books and record in United States Dollars (&#8220;US$&#8221;) albeit its
functional currency being the primary currency of the economic environment in which the entity operates, which is the Malaysian Ringgit
(&#8220;MYR&#8221; or &#8220;RM&#8221;). The Company&#8217;s subsidiary in Hong Kong maintains its books and record in Hong Kong Dollars
(&#8220;HK$&#8221;), similar to its functional currency. The Company&#8217;s subsidiary and VIE in Malaysia conducts its businesses and
maintains its books and record in the local currency, Malaysian Ringgit (&#8220;MYR&#8221; or &#8220;RM&#8221;), as its functional currency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into
US$, in accordance with ASC Topic 830-30, &#8220;<i>Translation of Financial Statement&#8221;</i>, using the exchange rate on the balance
sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation
of financial statements of foreign subsidiary are recorded as a separate component of accumulated other comprehensive income within the
statements of stockholders&#8217; equity. Cash flows are also translated at average translation rates for the periods, therefore, amounts
reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance
sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_zTYA4P9FOinb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Translation
of foreign currencies into US$1 have been made at the following exchange rates for the respective periods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zdv4I7CXhGol" style="display: none">SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zgy5lSiaUnqg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20211231_zsVB6e9RZDpg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hus-gaap--VariableRateAxis__custom--PeriodEndMYRMember_zFRhCxqqi3Eh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Period-end MYR : US$1 exchange rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">4.41</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">4.18</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hus-gaap--VariableRateAxis__custom--PeriodEndHKDMember_zLYf4zb3Voe5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Period-end HKD : US$1 exchange rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.80</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hus-gaap--VariableRateAxis__custom--PeriodEndHKDMember_ziM6JpnK0o6" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign currency exchange
    rate, translation</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.80</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20220101__20221231_zu9ykfzTy0w3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20210101__20211231_zaKDMyylVgMj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_405_ecustom--ForeignCurrencyExchangeRateAverage_hus-gaap--VariableRateAxis__custom--PeriodAverageMYRMember_zqsIpHu1yyE" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Period-average MYR : US$1 exchange rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">4.41</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">4.14</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ForeignCurrencyExchangeRateAverage_hus-gaap--VariableRateAxis__custom--PeriodAverageHKDMember_zecoVeo3Tg3a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Period-average HKD : US$1 exchange rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.83</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.77</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ForeignCurrencyExchangeRateAverage_hus-gaap--VariableRateAxis__custom--PeriodAverageHKDMember_zCDRKLJohb0b" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign currency exchange
    rate period average</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.83</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.77</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zR6kyPJj6KLc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_ecustom--RelatedPartiesPolicyTextBlock_zI7d5N4JYGed" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zRTbziKHfAwb">Related
parties</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parties,
which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control
the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also
considered to be related if they are subject to common control or common significant influence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zE82vognobm5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_864_zepRYIYYprik">Fair
value of financial instruments</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting standard regarding fair value of financial instruments and related fair value measurements defines financial instruments and
requires disclosure of the fair value of financial instruments held by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting standards define fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance
disclosure requirements for fair value measures. The three levels are defined as follow:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that
    are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 inputs to the valuation methodology are unobservable and significant to the fair value.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments included in current assets and current liabilities are reported in the consolidated balance sheets at face value or cost,
which approximate fair value because of the short period of time between the origination of such instruments and their expected realization
and their current market rates of interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--LesseeLeasesPolicyTextBlock_z3UFyt6sece6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_zibQIkWeu1wg">Leases</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted ASU 2016-02, &#8220;Leases&#8221; (Topic 842), and elected the practical expedients that does not require the Company
to reassess: (1) whether any expired or existing contracts are, or contain, leases, (2) lease classification for any expired or existing
leases and (3) initial direct costs for any expired or existing leases. For lease terms of twelve months or fewer, a lessee is permitted
to make an accounting policy election not to recognize lease assets and liabilities. The Company also adopts the practical expedient
that allows lessees to treat the lease and non-lease components of a lease as a single lease component. Some of the Company&#8217;s leases
include one or more options to renew, which is typically at the Company&#8217;s sole discretion. The Company regularly evaluates the
renewal options, and, when it is reasonably certain of exercise, it will include the renewal period in its lease term. New lease modifications
result in re-measurement of the right of use (&#8220;ROU&#8221;) assets and lease liabilities. Operating ROU assets and lease liabilities
are recognized at the commencement date, based on the present value of lease payments over the lease term. Since the implicit rate for
the Company&#8217;s leases is not readily determinable, the Company use its incremental borrowing rate based on the information available
at the commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that
the Company would have to pay to borrow, on a collateralized basis, an amount equal to the lease payments, in a similar economic environment
and over a similar term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
terms used to calculate the present value of lease payments generally do not include any options to extend, renew, or terminate the lease,
as the Company does not have reasonable certainty at lease inception that these options will be exercised. The Company generally considers
the economic life of its operating lease ROU assets to be comparable to the useful life of similar owned assets. The Company has elected
the short-term lease exception, therefore operating lease ROU assets and liabilities do not include leases with a lease term of twelve
months or less. Its leases generally do not provide a residual guarantee. The operating lease ROU asset also excludes lease incentives.
Lease expense is recognized on a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews the impairment of its ROU assets consistent with the approach applied for its other long-lived assets. The Company reviews
the recoverability of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the
asset may not be recoverable. The assessment of possible impairment is based on its ability to recover the carrying value of the asset
from the expected undiscounted future pre-tax cash flows of the related operations. The Company has elected to include the carrying amount
of operating lease liabilities in any tested asset group and includes the associated operating lease payments in the undiscounted future
pre-tax cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zOEqo9L2pkTk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86C_zkQqYFp7vst4">Recent
accounting pronouncements</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has reviewed all recently issued, but not yet effective, considers the applicability and impact of all accounting standards updates
(&#8220;ASUs&#8221;). Management periodically reviews new accounting standards that are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2019, the FASB issued ASU No. 2019-10, which to update the effective date of ASU No. 2016-13 for private companies, not-for-profit
organizations and certain smaller reporting companies applying for credit losses, leases, and hedging standard. The new effective date
for these preparers is for fiscal years beginning after December 15, 2022. ASU 2019-05 is effective for the Company for annual and interim
reporting periods beginning January 1, 2023 as the Company is qualified as a smaller reporting company. The Company is currently evaluating
the impact ASUs 2016-13 and 2019-05 may have on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for the above-mentioned pronouncements, there are no new recent issued accounting standards that will have a material impact on the consolidated
financial position, statements of operations and cash flows.</span></p>

<p id="xdx_85D_zpd7CU8LeYd4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992544288032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>VARIABLE INTEREST ENTITY (&#8220;VIE&#8221;)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">VARIABLE INTEREST ENTITY (&#8220;VIE&#8221;)</a></td>
<td class="text"><p id="xdx_802_eus-gaap--VariableInterestEntityDisclosureTextBlock_zFRxQR1FO7hi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
<span id="xdx_824_zj2d1J3GbxTf">VARIABLE INTEREST ENTITY (&#8220;VIE&#8221;)</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEA
is a trading company incorporated on March 4, 2004, under the laws of Malaysia. SEA provided majority of ASL&#8217;s purchases. Its equity
at risk was insufficient to finance its activities and <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_zBAHgxlBLbg4" title="Ownership interest percentage">100</span>% of its business is transacted with ASL. Therefore, it was considered to be
a VIE and ASL is the primary beneficiary since it has both of the following characteristics:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
    power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
    obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the
    VIE that could potentially be significant to the VIE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
the accounts of SEA is consolidated in the accompanying financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
VARIABLE INTEREST ENTITY (&#8220;VIE&#8221;) (CONT&#8217;D)</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfVariableInterestEntitiesTextBlock_zNdRAR4wzbY5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amount of the VIE&#8217;s assets and liabilities were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zQFexFWDKz4c" style="display: none">SCHEDULE OF VARIABLE INTEREST ENTITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_49A_20221231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_z5lVlw6Fn3tc" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_493_20211231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zI4DBiW68nWg" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsCurrent_iI_zUmQYchAUCB5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Current assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">3,350</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">18,850</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesCurrent_iNI_di_zZSjd8BHuSs8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(43,512</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(51,272</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--StockholdersEquity_iI_z24RgFPig1Bj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deficit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(40,162</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(32,422</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20221231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zIZ5onYFsdw1" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20211231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zEYYv5IBQbTb" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_ztcWNesxOZqa" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,609</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">17,493</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidTaxes_iI_z00YJcaIpYid" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Prepaid taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,741</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,357</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsCurrent_iI_zUgacGYqQEni" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,350</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,850</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iI_zSSpL7fZ4Wy3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts payable &#8211; intercompany</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">42,422</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">49,724</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--OtherPayablesRelatedPartyCurrent_iI_zCiPzH9XUjbi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other payables and accrued liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,090</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,548</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesCurrent_iI_zRheyKpvRmF7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">43,512</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">51,272</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockholdersEquity_iI_zKO7drUZdXNc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deficit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(40,162</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(32,422</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
summarized operating results of the VIE&#8217;s are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_49D_20220101__20221231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zxKoIUlQxhh4" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_495_20210101__20211231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_z0QiRSbSOepl" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_z2Fz4S6CfAZ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 2.5pt">Operating revenues</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0857">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0858">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--GrossProfit_zkzi7RwfRXOj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Gross profit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0860">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0861">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingIncomeLoss_ztX6z0oXxJq4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Loss from operations</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9,432</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(21,966</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLoss_zV42ojDKQhxc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9,432</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(27,966</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8AA_zHMnheaZyNnd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992544565136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH AND CASH EQUIVALENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">CASH AND CASH EQUIVALENTS</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--CashAndCashEquivalentsDisclosureTextBlock_zujFwGP2qic1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
<span id="xdx_821_z5dqFc3yMcj7">CASH AND CASH EQUIVALENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
of December 31, 2022 and 2021 the Company had $<span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20221231_zoEHWX9rirq" title="Cash and cash equivalents">1,438,430</span> and $<span id="xdx_90F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20211231_zVjM6SiekJTc" title="Cash and cash equivalents">2,597,848</span>, respectively, of cash and cash equivalents, which consisted of
$<span id="xdx_90B_eus-gaap--Cash_iI_pp0p0_c20221231_z71GEdb78pQ8" title="Cash in bank">513,152</span> and $<span id="xdx_904_eus-gaap--Cash_iI_pp0p0_c20211231_zDOvVNzzIluj" title="Cash in bank">554,864</span>, respectively, of cash in banks and </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90A_eus-gaap--TimeDeposits_iI_pp0p0_c20221231_zW7yV59dKgF2" title="Time deposits">914,811</span>
<span style="background-color: white">and $</span><span id="xdx_90B_eus-gaap--TimeDeposits_iI_pp0p0_c20211231_zYIsVeV1EV43" title="Time deposits">1,975,347</span><span style="background-color: white">, respectively, of time deposits placed
with banks or other financial institutions and are all highly liquid investments with an original maturity of three months or less. The
effective interest rate for the time deposits ranges between <span id="xdx_90E_eus-gaap--PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits_iI_pid_dp_uPure_c20221231__srt--RangeAxis__srt--MinimumMember_zR1NmRU1EC6l" title="Percentage of Interest rate for time deposits">1.10</span>% to <span id="xdx_902_eus-gaap--PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits_iI_pid_dp_uPure_c20221231__srt--RangeAxis__srt--MaximumMember_zMZ80BAaKbdj" title="Percentage of Interest rate for time deposits">1.88</span>% per annum. As of December 31, 2022 and 2021, $<span id="xdx_90D_eus-gaap--TimeDepositLiabilityUninsured_iI_c20221231_zJ1saXAIpPp3" title="Time deposit uninsured">231,187</span> and
$<span id="xdx_90C_eus-gaap--TimeDepositLiabilityUninsured_iI_c20211231_zbUkhuYIUSC4" title="Time deposit uninsured">295,761</span> of these balances are not covered by deposit insurance, respectively.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992544307632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS RECEIVABLE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">ACCOUNTS RECEIVABLE</a></td>
<td class="text"><p id="xdx_800_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_z5Q2QJxfsYv4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>5.
<span id="xdx_82E_zelRnHFzaVRk">ACCOUNTS RECEIVABLE </span></b></span></p>

<p id="xdx_898_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zovZssHaUBh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span id="xdx_8B8_z2Lb6cEO3jPb" style="display: none">SCHEDULE OF ACCOUNTS RECEIVABLES - RELATED PARTY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_498_20221231_zhuxswMdXScl" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_49A_20211231_z4sPQYFIQRLk" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccountsReceivableGrossCurrent_iI_pp0p0_maARAARzRRC_zWvEKK9iCda2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Accounts receivable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,826</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0896">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_pp0p0_msARAARzRRC_zGbqLTZYDSq7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0898">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0899">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsReceivableNetCurrent_iTI_pp0p0_mtARAARzRRC_zbtUjgGqE52" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,826</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0902">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zGmGdYx9q2ai" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI https://asc.fasb.org/subtopic&amp;trid=2196772<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992544262400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><p id="xdx_808_eus-gaap--InventoryDisclosureTextBlock_zr9utPAPg9zl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
<span id="xdx_82B_z3iOu7BmGgsd">INVENTORIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zotCKPgQXxv4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zU8B3QydgPDg" style="display: none">SCHEDULE OF INVENTORIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td id="xdx_49A_20221231_zBaRxb2sOesg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td id="xdx_49E_20211231_zRW16l6SN7Ne" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; width: 64%; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; width: 2%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 14%; font-weight: bold; text-align: center">2022</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 2%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 14%; font-weight: bold; text-align: center">2021</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InventoryFinishedGoods_iI_zyTB0EwcnZd5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Finished goods</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">46,277</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">375,535</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zEjWgesrU6ha" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2022 and 2021, the Company recognized $<span id="xdx_907_ecustom--InventriesWriteDown_c20220101__20221231_z7U9hW7hyrbl" title="Inventory write-down">5,307</span> and $<span id="xdx_90A_ecustom--InventriesWriteDown_c20210101__20211231_zViZNDF5OAfg" title="Inventory write-down">36,241</span> inventory write-down; and $<span id="xdx_907_ecustom--InventoryWriteOff_pp0p0_c20220101__20221231_zsc1Be2WkdCl" title="Inventory write-off">142,466</span> and $<span id="xdx_907_ecustom--InventoryWriteOff_pp0p0_dxL_c20210101__20211231_zarA66562s99" title="Inventory write- off::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0917">0</span></span> inventory
write-off, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992544511088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAYMENTS AND DEPOSITS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_DisclosurePrepaymentsAndDepositsAbstract', window );"><strong>Prepayments And Deposits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_PrepaymentsAndDepositsTextBlock', window );">PREPAYMENTS AND DEPOSITS</a></td>
<td class="text"><p id="xdx_80E_ecustom--PrepaymentsAndDepositsTextBlock_zL7cdHSwwqG2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>7.
<span id="xdx_82B_zwdyY1bfdqs3">PREPAYMENTS AND DEPOSITS</span></b></span></p>

<p id="xdx_89F_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zjdtaEGFgsBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_z5pL7RUdAnWe" style="display: none">SCHEDULE OF PREPAID EXPENSES AND DEPOSITS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_49F_20221231_zR4XRYcqQTfj" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_498_20211231_znAMLzPN5TLh" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ReceivablesFromSalesDistributors_iI_maCzFPV_zCUi5vUgbfJh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Receivables from sales distributors</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">43,596</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">115,379</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DepositsToSupplier_iI_maCzFPV_zi1WAsQlc8J2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Deposits to suppliers</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">147,504</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">301,233</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--PrepaidExpensesGross_iTI_maCzxAt_mtCzFPV_zx851PNPzPR4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">191,100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">416,612</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iNI_di_msCzxAt_ztK47EHkLdij" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Provision for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0932">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(121,095</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtCzxAt_zh5aznB2iZWf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">191,100</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">295,517</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_z4IuqImDPMVa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zRnLg89Y2iH2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Movements
of allowance for doubtful accounts are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zIuXxCkXFkB3" style="display: none">SCHEDULE OF CHANGES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_499_20220101__20221231_zIMzlTah3pX8" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_494_20210101__20211231_zjYgUiIl1ba1" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_z8IiVjZTcvd4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Beginning balance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">121,095</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0941">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_zjRhyxAeJhv8" style="vertical-align: bottom; background-color: White">
    <td>Addition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0943">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121,514</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_di_zhkfGqoOLAC9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Write off</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(120,372</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0947">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AllowanceForDoubtfulAccountsReceivableExchangeRateEffect_zkAodHvfNy97" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange rate effect</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(723</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(419</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_zXdLcLP2wUDh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0952">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">121,095</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zSoJ7RFXnWj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_DisclosurePrepaymentsAndDepositsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_DisclosurePrepaymentsAndDepositsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_PrepaymentsAndDepositsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayments and Deposits [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_PrepaymentsAndDepositsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992544368032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><p id="xdx_802_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zrLPbDAFgTHk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
<span id="xdx_820_ztxby9rdsA99">PROPERTY AND EQUIPMENT, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--PropertyPlantAndEquipmentTextBlock_zmRWPBeyI347" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment, net consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B0_zJYY8Y96jaqi" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT, NET</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_490_20221231_zmnDw4egigNj" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_494_20211231_zGSBwYf9jRr2" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerAndOfficeEquipmentMember_zJTZVLonUMl7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Computer and office equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">87,428</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">82,298</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zT3bDv62yQu" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture &amp; fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">115,789</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122,185</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z7Y6kVTFQ22b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">191,965</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">202,570</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--VehicleMember_zP6q3kqDHDz3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Vehicle</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">93,535</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">98,702</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENz5ZB_zuXLsaldfBp1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">488,717</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">505,755</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENz5ZB_zNaotftUy1eb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(346,568</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(289,956</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz5ZB_zrGBUIeqXFsg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">142,149</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">215,799</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zD5zv4BXkAT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense for the years ended December 31, 2022 and 2021 amounted to $<span id="xdx_90F_eus-gaap--Depreciation_pp0p0_c20220101__20221231_zM1cQJCYtDqb" title="Depreciation">71,754</span> and $<span id="xdx_905_eus-gaap--Depreciation_pp0p0_c20210101__20211231_zo7fj0jzidFd" title="Depreciation">75,797</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992544288032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS, NET</a></td>
<td class="text"><p id="xdx_804_eus-gaap--IntangibleAssetsDisclosureTextBlock_zOgdM8JyWVQ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
<span id="xdx_824_zz8jNBrDFqp3">INTANGIBLE ASSETS, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zm6UnzTggnt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets, net, consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B7_zKqIDuKePe73" style="display: none">SCHEDULE OF INTANGIBLE ASSETS, NET</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_493_20221231_zd7VedRq0D5k" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_493_20211231_zZxbckCQ0w9a" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CapitalizedComputerSoftwareGross_iI_maCzFod_zrusbEBApco5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Computer software</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">55,348</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">34,453</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msCzFod_z66goRzTWTG3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(31,304</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(30,793</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtCzFod_z4FectFsIhM8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">24,044</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,660</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zB0qHIgrTsH7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
expense for the years ended December 31, 2022 and 2021 amounted to $<span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20220101__20221231_zIgF3JYdbu8e" title="Amortization expense">2,122</span> and $<span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20210101__20211231_zqKFeWR6wLd" title="Amortization expense">1,961</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992544409696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN MARKETABLE SECURITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_DisclosureInvestmentInMarketableSecuritiesAbstract', window );"><strong>Investment In Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_InvestmentInMarketableSecuritiesTextBlock', window );">INVESTMENT IN MARKETABLE SECURITIES</a></td>
<td class="text"><p id="xdx_807_ecustom--InvestmentInMarketableSecuritiesTextBlock_z0A1AgtbWSb9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
<span id="xdx_825_zQvuOqi8GWOf">INVESTMENT IN MARKETABLE SECURITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    May 17, 2018, the Company purchased <span id="xdx_90F_eus-gaap--InvestmentOwnedBalanceShares_iI_c20180517__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zm3gQDiLDcnd" title="Investment owned, balance, shares">83,333</span> shares of common stock in Greenpro Capital Corp. for $<span id="xdx_901_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20180517__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zPpH4oOHXtm5" title="Investment owned, balance, value">500,000</span> at a purchase price of $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20180517__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zaXyI8H7SnVi" title="Shares issued, price per share">6</span>
    per share.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    July 30, 2018, the Company disposed <span id="xdx_909_eus-gaap--InvestmentOwnedBalanceShares_iI_c20180730__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zvuOhS2JZVSl" title="Investment owned, balance, shares">20</span> shares of common stock in Greenpro Capital Corp. for $<span id="xdx_90A_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20180730__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zdZKwuzNtYd8" title="Investment owned, balance, value">125</span> at a purchase price of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20180730__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zgN0fw7pBxag" title="Shares issued, price per share">6.2613</span> per
    share.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    October 16, 2018, the Company purchased <span id="xdx_90C_eus-gaap--InvestmentOwnedBalanceShares_iI_c20181016__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zDqIWuJmaEa3" title="Investment owned, balance, shares">33,333</span> shares of common stock in Greenpro Capital Corp. for $<span id="xdx_902_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20181016__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zPi6lcUs4Eil" title="Investment owned, balance, value">1,000</span> at a purchase price of
    $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20181016__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zXS2rwZJaCV1" title="Shares issued, price per share">0.03</span> per share.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    July 19, 2022, Greenpro Capital Corp. filed a certificate of change with the Secretary of State of Nevada to effect a reverse split
    of <span id="xdx_907_eus-gaap--StockholdersEquityReverseStockSplit_c20220718__20220719_zwSn4r44Kra3" title="Stockholders equity reverse stock split">the
    company&#8217;s common stock at the ratio of 10-for-1 effective July 28, 2022. Under the reverse stock split, each 10 pre-split
    share of common stock outstanding will automatically combine into 1 new share of common stock of the company. As at July 28, 2022,
    the Company has an investment of <span id="xdx_90B_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20221231__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zTMsWNH24c05" title="Investment owned, balance shares">116,646</span>
    common stock of Greenpro Capital Corp. The Company&#8217;s investment of <span id="xdx_908_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20221231__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zQRIGxFVY9ee" title="Investment owned, balance shares">116,646</span>
    common stock of Greenpro Capital Corp. was reduced to <span id="xdx_90D_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220719__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zCB09Nfj7Ke8" title="Investment owned, balance shares">11,665</span>
    subsequent to the reverse stock split.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    November 3, 2020, the Company received dividend of <span id="xdx_904_eus-gaap--InvestmentOwnedBalanceShares_iI_c20201103__dei--LegalEntityAxis__custom--DSwissIncMember_zMIsUacusxo1" title="Investment owned, balance shares">6,667</span> shares of common stock in DSwiss, Inc. for $<span id="xdx_900_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20201103__dei--LegalEntityAxis__custom--DSwissIncMember_zi5CkLRH6nM" title="Investment amount">76,671</span> at fair value of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20201103__dei--LegalEntityAxis__custom--DSwissIncMember_zK1owfLgr3l9" title="Shares issued, price per share">11.50</span>
    per share from Greenpro Capital Corporation as result of its Spin-off of DSwiss, Inc.&#8217;s shares</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    December 9, 2020, the Company received dividend of <span id="xdx_90B_eus-gaap--InvestmentOwnedBalanceShares_iI_c20201209__dei--LegalEntityAxis__custom--DSwissIncMember_zdoG7Jk99tql" title="Investment owned, balance shares">16,663</span> shares of common stock in DSwiss, Inc. for $<span id="xdx_902_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20201209__dei--LegalEntityAxis__custom--DSwissIncMember_zFaH5SRmUoFg" title="Investment owned, balance, value">83,315</span> at fair value of $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_c20201209__dei--LegalEntityAxis__custom--DSwissIncMember_zDAfYwC4oh0h" title="Shares issued, price per share">5</span>
    per share from Greenpro Capital Corporation as result of its Spin-off of DSwiss, Inc.&#8217;s shares.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    September 27, 2021, the Company received dividend of <span id="xdx_906_eus-gaap--InvestmentOwnedBalanceShares_iI_c20210927__dei--LegalEntityAxis__custom--SEATechVenturesCorpMember_zlPcAJsUNjok" title="Investment in securities, shares">11,665</span> shares of common stock in SEATech Ventures Corp. for $<span id="xdx_903_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20210927__dei--LegalEntityAxis__custom--SEATechVenturesCorpMember_z2f9vVLdWhfj" title="Investment amount">18,874</span> at fair
    value of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20210927__dei--LegalEntityAxis__custom--SEATechVenturesCorpMember_zYfgGzL5GgNd" title="Purchased price per shares">1.62</span> per share from Greenpro Capital Corp as a dividend income since Greenpro Capital Corp previously owned these shares.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    April 3, 2019, the Company purchased a <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20190403__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PhoenixPlusCorpMember_zEurJrkWfvL3" title="Equity interest percentage">5</span>%
    of stock or <span id="xdx_904_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20190403__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PhoenixPlusCorpMember_zsZQVTglfUF9" title="Shares purchased during period">15,000,000</span>
    shares of common stock in Phoenix Plus Corp. (a non-marketable security) for $<span id="xdx_909_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20190403__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PhoenixPlusCorpMember_zOek7wSfajpe" title="Investment amount">1,500</span>
    at purchase price of $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20190403__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PhoenixPlusCorpMember_z97OVMGsYqx8" title="Shares issued price per share">0.0001</span>
    per share. Phoenix Plus Corp. obtained approval for Depository Trust Company eligibility on April 26, 2022. Since the commencement of trading of common stock of Phoenix Plus Corp. on May 18, 2022, to March 9, 2023,
    there were only <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210518__20230309__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zyLc59iB1OHd" title="Stock issued during peirod shares new issues">200</span> shares of common stock of the company traded. The Company deems there is an absence of a readily determinable
    fair value of the common stock of Phoenix Plus Corp. and has continued to value its investment in the company Phoenix Plus
    Corp. at cost.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
INVESTMENT IN MARKETABLE SECURITIES (CONT&#8217;D)</b></span></p>

<p id="xdx_895_eus-gaap--MarketableSecuritiesTextBlock_zuGzrtr9rAUc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;<span id="xdx_8B0_zN99PDRxKP02" style="display: none">SCHEDULE OF INVESTMENT IN MARKETABLE SECURITIES</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20221231_z4RIpzJXVA29" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20211231_z8xbbM4gX3Kf" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_maMSNzd9C_zzkch15ow0Z2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Cost of investment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">89,001</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">577,035</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--TransferFromNonmarketableSecurity_iNI_pp0p0_di_msMSNzd9C_z4pyxkB70cWa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Transfer from non-marketable security</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1063">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--InvestmentsIncomeDividend_iNI_pp0p0_di_msMSNzd9C_z4XWyTJDvR08" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend income from Greenpro Capital Corp.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1065">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,939</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--MarketableSecuritiesUnrealizedHoldingLoss_iNI_pp0p0_di_msMSNzd9C_z67Y6b3K59S7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Unrealized holding loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(73,519</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(505,231</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--ExchangeRateEffectOnInvestmentInMarketableSecurites_iI_pp0p0_maMSNzd9C_zA1iT4Zoqkrc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange rate effect</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(295</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,742</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--MarketableSecuritiesNoncurrent_iTI_pp0p0_mtMSNzd9C_zQpdBZmA4Cng" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Investment in marketable securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">16,687</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">89,001</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zJcQxpLuKbL1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_DisclosureInvestmentInMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_DisclosureInvestmentInMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_InvestmentInMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment In Marketable Securities [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_InvestmentInMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992544547168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN NON-MARKETABLE SECURITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_DisclosureInvestmentInNonmarketableSecuritiesAbstract', window );"><strong>Investment In Non-marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_InvestmentInNonMarketableSecuritiesTextBlock', window );">INVESTMENT IN NON-MARKETABLE SECURITIES</a></td>
<td class="text"><p id="xdx_80E_ecustom--InvestmentInNonMarketableSecuritiesTextBlock_zkjqdsvXMPd4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.
<span id="xdx_823_zaEyLiz194h2">INVESTMENT IN NON-MARKETABLE SECURITIES</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 3, 2019, the Company purchased a <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20190403__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PhoenixPlusCorpMember_zPQsOu2Iphhc" title="Equity interest percentage">5</span>% of stock or <span id="xdx_903_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20190403__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PhoenixPlusCorpMember_zG44J5ACcI84" title="Shares purchased during period">15,000,000</span> shares of common stock in Phoenix Plus Corp. for $<span id="xdx_909_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20190403__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PhoenixPlusCorpMember_zyyjs0mRv6ef" title="Investment amount">1,500</span> at purchase
price of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20190403__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PhoenixPlusCorpMember_zzAKlWVf0qhc" title="Shares issued price per share">0.0001</span> per share. Phoenix Plus Corp. attained its effective date with the Securities Exchange Commission for listing on OTC (Pink Sheet),
U.S. on March 12, 2021, and obtained approval for Depository trust Company (&#8220;DTC&#8221;)
eligibility on April 26, 2022. Accordingly, stocks of Phoenix Plus Corp. can be traded on OTC. As such the investment in Phoenix Plus Corp. was transferred to marketable securities.</span></p>

<p id="xdx_89E_ecustom--NonMarketableSecuritiesTableTextBlock_zBFVNM9h6jw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zsjdkcg96i46" style="display: none">SCHEDULE OF INVESTMENT IN NON MARKETABLE SECURITIES</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Phoenix Plus Corporation</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20221231__dei--LegalEntityAxis__custom--PhoenixPlusCorpMember_zXXHcTFvwT4a" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20211231__dei--LegalEntityAxis__custom--PhoenixPlusCorpMember_zdReaiw7n5o9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Phoenix Plus Corporation</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InvestmentOwnedAtCost_iI_maIINMSz0ls_zigDTIRmqOR9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Cost of investment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--TransferToInvestmentInMarketableSecurities_iNI_di_msIINMSz0ls_zpVXZpw00J8a" style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left; padding-bottom: 1.5pt">Less: Transfer to investment in marketable securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1093">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--InvestmentInNonMarketableSecuritiesNoncurrent_iTI_mtIINMSz0ls_z1Uxjbfm9Z17" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Investment in non-marketable securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1095">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_z76k0VA2FEzk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_DisclosureInvestmentInNonmarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_DisclosureInvestmentInNonmarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_InvestmentInNonMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment In Non Marketable Securities [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_InvestmentInNonMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992544327008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CUSTOMER DEPOSITS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_DisclosureCustomerDepositsAbstract', window );"><strong>Customer Deposits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_CustomerDepositsTextBlock', window );">CUSTOMER DEPOSITS</a></td>
<td class="text"><p id="xdx_809_ecustom--CustomerDepositsTextBlock_zBHnnqeVa9Ch" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>12. <span id="xdx_826_zQES4THSnK8l">CUSTOMER DEPOSITS</span></b></p>

<p id="xdx_89D_ecustom--CustomerDepositsTableTextBlock_zHhQaYUa9k5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF CUSTOMER DEPOSITS</span></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221231_zow2nIkKZI36" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20211231_zTv7W3RRpuqb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--CustomerDeposits_iI_zwD3eV7Y1YXi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Customer deposits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">289,487</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">273,581</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--UnexpiredProductCoupons_iI_zpZlYuDLeHh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Unexpired product coupons</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">73,531</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,108</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DepositLiabilityCurrent_iI_zI1umsyIVJ32" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">363,018</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">279,689</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A5_zFeI1mPtS7X2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Customer deposits represent amounts advanced by customers
on product orders and unexpired product coupons issued to the Company&#8217;s members and distributors of its network marketing business.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_CustomerDepositsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Customer Deposits [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_CustomerDepositsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_DisclosureCustomerDepositsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_DisclosureCustomerDepositsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992544368032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER PAYABLES AND ACCRUED LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">OTHER PAYABLES AND ACCRUED LIABILITIES</a></td>
<td class="text"><p id="xdx_806_eus-gaap--OtherLiabilitiesDisclosureTextBlock_zgP6LWKYW1vf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.
<span id="xdx_820_zPzlrUUAodIl">OTHER PAYABLES AND ACCRUED LIABILITIES</span></b></span></p>

<p id="xdx_899_ecustom--ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock_z0fAGKnF5AM" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zeSWMrAQEuWa" style="display: none">SCHEDULE OF OTHER PAYABLES AND ACCRUED LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_49C_20221231_zQIWaMMhHL12" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_49C_20211231_z45F1OSPJsFf" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maOAPAAz1Ku_zI8xwdf6tNn" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Professional fees</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">324,629</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">436,541</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--AccruedPromotionExpensesCurrent_iI_pp0p0_maOAPAAz1Ku_zK1vqfScw7Ti" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Promotion expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,583</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,024</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_maOAPAAz1Ku_zTU3Vl05AfI1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Payroll</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,164</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,669</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccruedSalesCommissionCurrent_iI_pp0p0_maOAPAAz1Ku_zBf7jn2I9sS" style="vertical-align: bottom; background-color: White">
    <td>Amounts held in eWallets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">216,049</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">223,781</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--AccruedTaxPenaltyCurrent_iI_pp0p0_maOAPAAz1Ku_zCTg4hKcqDfa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax penalty</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iI_pp0p0_maOAPAAz1Ku_zXbRWJ730LGf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">37,852</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">64,340</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--OtherAccountPayableAndAccruedLiabilities_iTI_pp0p0_mtOAPAAz1Ku_zooHneFb6om8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">713,277</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">858,355</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zRI6cdAor1X9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company requires all members and distributors of its network marketing business to maintain an electronic wallet (eWallet) account with
the Company. <span id="xdx_90D_ecustom--CommissionPaymentsDescriptions_c20220101__20221231_zMUgKigPDTa4" title="Commission payments descriptions">The eWallet is primarily for the crediting of any commission payment that falls below RM<span id="xdx_909_eus-gaap--CommissionsPayableToBrokerDealersAndClearingOrganizations_iI_uRM_c20221231_zv5mLNWiWRxk" title="Comission payable">100</span> (or $22.70).</span> Commission payment
exceeding the RM<span id="xdx_90F_eus-gaap--ContractWithCustomerAssetGross_iI_uRM_c20221231_zk9aTMMaZ3w4" title="Comission payable, threshold">100</span> threshold shall only be credited into the member&#8217;s or distributor&#8217;s eWallet upon request. The eWallet
functionality allows the members to place new product orders utilizing eWallet available balance and/or request commission payout via
multiple payment methods provided that each of the withdrawal amount exceeds RM<span id="xdx_904_eus-gaap--ContractWithCustomerAssetGross_iI_uRM_c20221231__srt--RangeAxis__srt--MaximumMember_zWQ98f2Fse27" title="Comission payable, threshold">100</span>. Amounts held in eWallets are reflected on the balance
sheet as a current liability.</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992538433216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY BALANCES AND TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY BALANCES AND TRANSACTIONS</a></td>
<td class="text"><p id="xdx_803_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zaYfTMIgUOEj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.
<span id="xdx_826_zBglaasqwYCi">RELATED PARTY BALANCES AND TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related
party balances</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount
due from related parties</b></span></p>

<p id="xdx_897_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zl0oYWLAAj4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_z727ztZuIZn6" style="display: none">SCHEDULE OF RELATED PARTIES</span></span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center">Name of Related</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Party</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Relationship</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nature</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 22%; text-align: left">TH3 Technology Sdn Bhd (&#8220;TH3&#8221;)</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 22%; text-align: center"><span id="xdx_904_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_ziLC6cF8O0Hb" title="Relationship"><span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_zzSz5d5bIqm9" title="Relationship">Mr. How Kok Choong, the CEO and director of the Company is also a director of TH3</span></span></td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center">Prepayment of IT expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_zZAUIMTT8fOj" style="width: 14%; text-align: right" title="Due from related parties">1,273</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_zukwEs1YngT4" style="width: 14%; text-align: right" title="Due from related parties"><span style="-sec-ix-hidden: xdx2ixbrl1154">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">DSY Beauty Sdn Bhd (&#8220;DSY Beauty&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_903_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_z0694WTKbtY1" title="Relationship"><span id="xdx_901_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zeZmlYSi7375" title="Relationship">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</span></span></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Deposits for products</p>
                                                        <p style="margin-top: 0; margin-bottom: 0">purchases</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zwDZUnOh83dc" style="text-align: right" title="Due from related parties">9,261</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zByqRivjGxmc" style="text-align: right" title="Due from related parties"><span style="-sec-ix-hidden: xdx2ixbrl1162">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Agape ATP (Asia) Limited (&#8220;AATP Asia&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_900_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zHWmYpA622q9" title="Relationship"><span id="xdx_902_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zP3giNs1HF4d" title="Relationship">Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of AATP Asia</span></span></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90B_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zvM7Hh1mF5pj" title="Nature"><span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zJUFhY5rF4V1" title="Nature">Expenses paid for AATP Asia</span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zybPyNfOgw56" style="text-align: right" title="Due from related parties"><span style="-sec-ix-hidden: xdx2ixbrl1172">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_ziSokE5HMXP7" style="text-align: right" title="Due from related parties">2,214</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">Hostastay Sdn. Bhd. <br/>&#8220;Hostastay&#8221;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_904_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_z9WLCOVt2aPa" title="Relationship"><span id="xdx_90F_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_z3VsvnIpOAm2" title="Relationship">Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021</span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_903_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zdj7boQy7Z08" title="Nature"><span id="xdx_906_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zUYOiG4dFOU3" title="Nature">Sublease rent due from Hostastay</span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zpXdWXaREyb2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Due from related parties"><span style="-sec-ix-hidden: xdx2ixbrl1184">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zXiuGQBFncKe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Due from related parties">4,790</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20221231_zF4oFTU7cPKd" style="border-bottom: Black 2.5pt double; text-align: right" title="Due from related parties">10,534</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20211231_z5LEII8mzdAe" style="border-bottom: Black 2.5pt double; text-align: right" title="Due from related parties">7,004</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accounts
payable &#8211; related parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center">Name of Related</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Party</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Relationship</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nature</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="text-align: center; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 22%; text-align: left">CTA Nutriceuticals (Asia) Sdn Bhd (&#8220;CTA&#8221;)</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 22%; text-align: center"><span id="xdx_906_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zerXYsBJD1ta" title="Relationship"><span id="xdx_90E_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zqorjRRHLqeh" title="Relationship">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd</span></span></td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center"><span id="xdx_900_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zIWoggCpvyz9" title="Nature"><span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zHhxRv48SPpb" title="Nature">Purchases of products for the provision of complementary health therapies</span></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zPFD76jbZAm2" style="width: 14%; text-align: right" title="Accounts payable, related parties, current">25,387</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zNdbULlh8yt8" style="width: 14%; text-align: right" title="Accounts payable, related parties, current"><span style="-sec-ix-hidden: xdx2ixbrl1202">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">DSY Beauty Sdn Bhd (&#8220;DSY Beauty&#8221;)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_908_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zM1z2HcEGkuj" title="Relationship"><span id="xdx_906_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_z8IOZfRRQTP2" title="Relationship">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_904_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zc7oweQDOY3f" title="Nature">Purchases of beauty products</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zfU3NUY42Nfb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accounts payable, related parties, current">224</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zV5eQ932Q825" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accounts payable, related parties, current"><span style="-sec-ix-hidden: xdx2ixbrl1212">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20221231_zGBB1JB6CVq4" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts payable, related parties, current">25,611</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20211231_zZAdIF7v7Zaa" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts payable, related parties, current"><span style="-sec-ix-hidden: xdx2ixbrl1216">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.
RELATED PARTY BALANCES AND TRANSACTIONS (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related
party balances</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other payable - related parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Name of Related</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">As of December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Party</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Relationship</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nature</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="text-align: center; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 22%; text-align: left">CTA Nutriceuticals (Asia) Sdn Bhd (&#8220;CTA&#8221;)</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 22%; text-align: center"><span id="xdx_906_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdOneMember_zRZjLu2pyuSk" title="Relationship"><span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdOneMember_zC9td5yiQjm1" title="Relationship">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd</span></span></td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center"><span id="xdx_901_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdOneMember_zz6M3NDzdZ5d" title="Nature"><span id="xdx_90A_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdOneMember_zzwxLVUhJ7Gj" title="Nature">Purchase of products for general use</span></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdOneMember_z4MvZfHbEqh5" style="width: 14%; text-align: right" title="Due to related parties">2,149</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdOneMember_zEE4fagrL1fd" style="width: 14%; text-align: right" title="Due to related parties"><span style="-sec-ix-hidden: xdx2ixbrl1228">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">DSY Beauty Sdn Bhd (&#8220;DSY Beauty&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_900_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_zjX7ki6BoTY1" title="Relationship"><span id="xdx_903_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_zztblYDJrAed" title="Relationship">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</span></span></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_901_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_z0iOuRmJMVBf" title="Nature"><span id="xdx_904_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_zHVZ5TNJC34l" title="Nature">Purchase of products for general use</span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_z8Wmhm3hUI43" style="text-align: right" title="Due to related parties">2,147</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_zah7ZUjUINIk" style="text-align: right" title="Due to related parties"><span style="-sec-ix-hidden: xdx2ixbrl1240">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">Mr. How Kok Choong</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_901_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zzfHYp7VfMm6" title="Relationship"><span id="xdx_90C_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zXbRwDLsk895" title="Relationship">Mr. How Kok Choong, the CEO and director of the Company</span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_909_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_z6dwnfOeuOqg" title="Nature"><span id="xdx_907_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zGwXo2mC8cKd" title="Nature">Commission expense</span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zH4Rwm5s39Og" style="border-bottom: Black 1.5pt solid; text-align: right" title="Due to related parties">584</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zjnTizCPpH8g" style="border-bottom: Black 1.5pt solid; text-align: right" title="Due to related parties"><span style="-sec-ix-hidden: xdx2ixbrl1252">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pdp0_c20221231_zJbx1u9mu5C9" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to related parties">4,880</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pdp0_c20211231_zS1BhyQ3Bi9i" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to related parties"><span style="-sec-ix-hidden: xdx2ixbrl1256">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related
party transactions </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Purchases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Name of Related</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Party</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Relationship</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nature</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 22%; text-align: left">CTA Nutriceuticals (Asia) Sdn Bhd (&#8220;CTA&#8221;)</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 22%; text-align: center"><span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zG9btHnwadC2" title="Relationship"><span id="xdx_908_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zauLz8fCZTk7" title="Relationship">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd</span></span></td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center"><span id="xdx_90A_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zwQlhwdt3st7" title="Nature"><span id="xdx_90C_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zUTGwGNmJzUi" title="Nature">Purchases of products for the provision of complementary health therapies</span></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zEDJpcz6QUD3" style="width: 14%; text-align: right" title="Purchases">198,376</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zjNU7dGm447l" style="width: 14%; text-align: right" title="Purchases"><span style="-sec-ix-hidden: xdx2ixbrl1268">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">DSY Beauty Sdn Bhd (&#8220;DSY Beauty&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_908_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zIGdx9Bw1blh" title="Relationship"><span id="xdx_90C_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zPFuB2i5T166" title="Relationship">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</span></span></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90B_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zPv0pPRzwuc6" title="Nature"><span id="xdx_908_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zYrKqkNdAo55" title="Nature">Purchases of beauty products</span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zugqbvRWvu3l" style="text-align: right" title="Purchases">3,975</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zu6p5YJuNohk" style="text-align: right" title="Purchases">718</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">DSY Wellness &amp; Longevity Center Sdn Bhd (&#8220;DSYWLC&#8221;)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_906_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zbVboKp0GiI5" title="Relationship"><span id="xdx_903_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_ziSDJiKeBjU6" title="Relationship">Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC</span></span>.</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_900_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zUuiIpm9PQeb" title="Nature"><span id="xdx_900_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zZRPuzBVaJBf" title="Nature">Purchases of products for the provision of complementary health therapies</span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zjB80Z6q022f" style="border-bottom: Black 1.5pt solid; text-align: right" title="Purchases">124</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zUPPsxbNbbu7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Purchases"><span style="-sec-ix-hidden: xdx2ixbrl1292">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220101__20221231_zIZqZ8Ed99Nd" style="border-bottom: Black 2.5pt double; text-align: right" title="Purchases">202,475</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210101__20211231_zx3eXt89sgO2" style="border-bottom: Black 2.5pt double; text-align: right" title="Purchases">718</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.
RELATED PARTY BALANCES AND TRANSACTIONS (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related
party transactions</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
income</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Name
    of Related</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the years ended December 31,</span></td>
    <td>&#160;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Party</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Relationship</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Nature</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td>
    <td>&#160;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td>&#160;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 26%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Hostastay
    Sdn. Bhd.</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_900_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zqcHbYBaJJmd" style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_z2EvLexgEEyc">Mr.
    How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director
    of Hostastay as of April 21, 2021</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 14%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_900_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_z1nEmOAMZg66" style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zAKIFOJ42Gng">Sublease
    rental income due from Hostastay</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--RelatedPartyOtherIncome_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_z6RcmQ3ozwGh" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Other income"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1302">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_ecustom--RelatedPartyOtherIncome_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_z7nXSW3qZRa4" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Other income"><span style="font-family: Times New Roman, Times, Serif">4,345</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_ecustom--RelatedPartyOtherIncome_pp0p0_c20220101__20221231_zuRLWr8prJsl" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Other income"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1306">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_ecustom--RelatedPartyOtherIncome_pp0p0_c20210101__20211231_z1H0garr44X9" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Other income"><span style="font-family: Times New Roman, Times, Serif">4,345</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
purchases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Name of Related</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Party</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Relationship</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nature</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 22%; text-align: left">CTA Nutriceuticals (Asia) Sdn Bhd (&#8220;CTA&#8221;)</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 22%; text-align: center"><span id="xdx_901_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdMember_zQpS1MGX9God" title="Relationship"><span id="xdx_904_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdMember_zQ7tlyF1WxH8" title="Relationship">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd</span></span></td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center"><span id="xdx_90A_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdMember_zOB0wRP6Zbwk" title="Nature"><span id="xdx_904_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdMember_zKuywerER7I5" title="Nature">Purchases of products for the provision of complementary health therapies</span></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdMember_zHyk1uIlG5X7" style="width: 14%; text-align: right" title="Other purchases">5,431</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdMember_zOJhGebFBwke" style="width: 14%; text-align: right" title="Other purchases"><span style="-sec-ix-hidden: xdx2ixbrl1320">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">DSY Beauty Sdn Bhd (&#8220;DSY Beauty&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zzmSc7AiZDU9" title="Relationship"><span id="xdx_90D_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zZszxc9zLCci" title="Relationship">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</span></span></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_z0Wk8Ark1EC9" title="Nature"><span id="xdx_90C_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zhWXpNnpqXsj" title="Nature">Purchases of beauty products</span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_z2yPLa3DzNw9" style="text-align: right" title="Other purchases">6,888</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zXmRjMkWYmi7" style="text-align: right" title="Other purchases"><span style="-sec-ix-hidden: xdx2ixbrl1332">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">DSY Wellness &amp; Longevity Center Sdn Bhd (&#8220;DSYWLC&#8221;)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_908_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z5Y8L65Fxfw5" title="Relationship"><span id="xdx_90E_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zCZxtEuEhEu8" title="Relationship">Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.</span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_901_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdMember_z9Arjnl5Pz17" title="Nature"><span id="xdx_903_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdMember_z6pp5SD6xYf5" title="Nature">Purchases of products for the provision of complementary health therapies</span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdMember_zhkqEQynYhXg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other purchases">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdMember_z9pDuZhyXAAd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other purchases"><span style="-sec-ix-hidden: xdx2ixbrl1344">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20220101__20221231_z76MRFD0m2B9" style="border-bottom: Black 2.5pt double; text-align: right" title="Other purchases">12,323</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20210101__20211231_zkBH9qsQYILf" style="border-bottom: Black 2.5pt double; text-align: right" title="Other purchases"><span style="-sec-ix-hidden: xdx2ixbrl1348">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.
RELATED PARTY BALANCES AND TRANSACTIONS (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related
party transactions</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
expense</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Name of Related</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Party</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Relationship</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nature</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 22%; text-align: left; padding-bottom: 1.5pt">Mr. How Kok Choong</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; width: 22%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_90C_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zu0Whq1PIPL8" title="Relationship"><span id="xdx_903_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_ziKt3iMOZKOf" title="Relationship">Mr. How Kok Choong, the CEO and director of the Company</span></span></td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_900_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zwKUCUPMtWLb" title="Nature"><span id="xdx_904_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_z8acQHVXjMAf" title="Nature">Commission expense</span></span></td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--SalesCommissionsAndFees_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zDVS0V5gpANk" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Commission expense">16,590</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--SalesCommissionsAndFees_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_znsRavhRLPGj" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Commission expense">12,758</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--SalesCommissionsAndFees_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zLYgWsHkbrUl" style="border-bottom: Black 2.5pt double; text-align: right" title="Commission expense">16,590</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--SalesCommissionsAndFees_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zoRsvIlllO4i" style="border-bottom: Black 2.5pt double; text-align: right" title="Commission expense">12,758</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Name of Related</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Party</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Relationship</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nature</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 22%; text-align: left">TH3 Technology Sdn Bhd (&#8220;TH3&#8221;)</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 22%; text-align: center"><span id="xdx_90E_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_z4iv32kYvk1l" title="Relationship"><span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_z0xuXefakGMb" title="Relationship">Mr. How Kok Choong, the CEO and director of the Company is also a director of TH3</span></span></td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center"><span id="xdx_90E_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_zQ6QjExXo1U7" title="Nature"><span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_zXGYWHCDNtCh" title="Nature">IT support services fee</span></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--RelatedPartyOtherExpenses_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_z8z2j3a0nVPd" style="width: 14%; text-align: right" title="Other expenses">56,450</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--RelatedPartyOtherExpenses_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_zABwXOfX473k" style="width: 14%; text-align: right" title="Other expenses"><span style="-sec-ix-hidden: xdx2ixbrl1376">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">Redboy Picture Sdn Bhd (&#8220;Redboy&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_908_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RedboyPictureSdnBhdMember_zTlZ7u9rRIy7" title="Relationship"><span id="xdx_907_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RedboyPictureSdnBhdMember_zi3zgmDv7iKd" title="Relationship">Mr. How Kok Choong, the CEO and director of the Company is also the director of Redboy</span></span></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90B_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RedboyPictureSdnBhdMember_z5yIEWjsXqtd" title="Nature"><span id="xdx_906_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RedboyPictureSdnBhdMember_zBJEOcGeyzn" title="Nature">Sponsorship fee</span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--RelatedPartyOtherExpenses_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RedboyPictureSdnBhdMember_zQ3qYXMAmiBj" style="text-align: right" title="Other expenses">22,686</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--RelatedPartyOtherExpenses_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RedboyPictureSdnBhdMember_z09R8ZOGeew9" style="text-align: right" title="Other expenses">718</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">DSY Wellness &amp; Longevity Center Sdn Bhd (&#8220;DSYWLC&#8221;)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_90C_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zcFhJLetkZFb" title="Relationship"><span id="xdx_901_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zK7nMlKX00y3" title="Relationship">Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.</span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_z7juN7qEQtMg" title="Nature"><span id="xdx_90C_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_z82d28JtijVi" title="Nature">Office rental expenses</span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--RelatedPartyOtherExpenses_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zW53VjqvfB7a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other expenses">21,779</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--RelatedPartyOtherExpenses_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zHVhurNTFL4a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other expenses"><span style="-sec-ix-hidden: xdx2ixbrl1400">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--RelatedPartyOtherExpenses_c20220101__20221231_zVoXaAlg39Lf" style="border-bottom: Black 2.5pt double; text-align: right" title="Other expenses">100,915</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--RelatedPartyOtherExpenses_c20210101__20211231_zLvySw9yI4bi" style="border-bottom: Black 2.5pt double; text-align: right" title="Other expenses">718</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zI0eiSIdihIi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992544504992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zrxrGEATJSG7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15.
<span id="xdx_828_z7H1JaGpStBb">STOCKHOLDERS&#8217; EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Preferred
stock</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 and 2021, there were <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_zty6O6HQbxW1" title="Preferred stock, shares authorized"><span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231_z9ul9eaResr2" title="Preferred stock, shares authorized">200,000,000</span></span> preferred stocks authorized but <span id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_dn_c20221231_zdiZyFzKB8yf" title="Preferred stock, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20221231_zdVAv5pFAaTd" title="Preferred stock, shares outstanding"><span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_dn_c20221231_z4GT5rfxaZz" title="Preferred stock, shares issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20211231_zW5jdvfloTRd" title="Preferred stock, shares outstanding">none</span></span></span></span> were issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Common
stock</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 and 2021, there were <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zNbnPSp1kgW9" title="Common stock, shares authorized"><span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zSTJp5umnSw" title="Common stock, shares authorized">1,000,000,000</span></span> common stocks authorized, <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20221231_zQBtTzjRuTH3" title="Common stock, shares issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_z5pPYvDUOk1a" title="Common stock, shares outstanding">75,452,012</span></span> and <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_c20211231_zMHzMgcbEL9d" title="Common stock, shares issued"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_zYAyTYa7hJok" title="Common stock, shares outstanding">290,460,047</span></span> shares issued and outstanding,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2021, there were share forfeiture agreements (the &#8220;<b>Share Forfeiture Agreements</b>&#8221;) between the Company and
(i) HKC Talent Limited; (ii) various shareholders of the Company (the &#8220;<b>Forfeiting Shareholders</b>&#8221;), pursuant to which:
(i) HKC Talent Limited had agreed to forfeiture of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ShareForfeitureAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongTalentLimitedMember_zm04t01nvDPl" title="Share- based payment arrangement, forfeited">41,750,000</span> shares of common stock of the Company, and (ii) the Forfeiting Shareholders
had agreed to forfeiture, in aggregate, <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ShareForfeitureAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongTalentLimitedMember__srt--TitleOfIndividualAxis__custom--ShareholdersMember_zN9m5lnyt6ih" title="Share- based payment arrangement, forfeited">44,242,000</span> shares of common stock of the Company. Included in (ii) is <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ShareForfeitureAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HKCHoldingsSdnBhdMember_zko4kprwOe7g" title="Share- based payment arrangement, forfeited">11,242,000</span> shares forfeited
from HKC Holdings Sdn. Bhd, a company in which <span style="background-color: white">Mr. How Kok Choong, </span>the CEO and director
of the Company, is a shareholder. As a result, the outstanding shares was reduced by <span id="xdx_90C_ecustom--ReductionInCommonStockOutstanding_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ShareForfeitureAgreementsMember_zHPpq9P03LB2" title="Reduction in outstanding shares">85,992,000</span> shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
share forfeiture agreement (the &#8220;Share Forfeiture Agreement&#8221;) dated January 20, 2022, between the Company and Mr. How Kok
Choong, the CEO and director of the Company, pursuant to which Mr. How Kok Choong agreed to forfeit <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--ShareForfeitureAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongTalentLimitedMember_zY1VZhyWHbJl" title="Number of shares forfeited">215,008,035</span> shares of common stock
of the Company. As a result, the outstanding shares was reduced by <span id="xdx_903_ecustom--ReductionInCommonStockOutstanding_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--ShareForfeitureAgreementsMember_zBgiQdmVV7u2" title="Reduction in outstanding shares">215,008,035</span> shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_do_c20220101__20221231_z6TOREpaB1j8" title="Potentially dilutive securities outstanding"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_do_c20210101__20211231_zzmSUykSSlS9" title="Potentially dilutive securities outstanding">no</span></span> stock options, warrants or other potentially dilutive securities outstanding as of December 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992544565136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NON-CONTROLLING INTEREST<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">NON-CONTROLLING INTEREST</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--MinorityInterestDisclosureTextBlock_zRMcY1MqRNO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16.
<span id="xdx_820_zLo6yEndAVUb">NON-CONTROLLING INTEREST</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_ecustom--ScheduleOfNonControllingInterestTableTextBlock_zItFSSqNjvNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s non-controlling interest consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zWLqh61alVOc" style="display: none">SCHEDULE OF NON CONTROLLING INTEREST</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_496_20221231_z8n1xYUN2KRc" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_497_20211231_zLxvsRVAtnza" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">DSY Wellness:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--NonControllingInterestPaidinCapital_iI_maNCINCzwzX_maNCINCzgCA_ztnQP5spxhD7" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Paid-in capital</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">97</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">97</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--NonControllingInterestAccumulatedDeficit_iI_maNCINCzwzX_maNCINCzgCA_zdhlZiZBS117" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accumulated surplus (deficit)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,384</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(436</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--NonControllingInterestAccumulatedOtherComprehensiveIncome_iI_maNCINCzwzX_maNCINCzgCA_zamMSBSCAIV8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated other comprehensive income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">32</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--NonControllingInterestNonControllingInterestGross_iTI_mtNCINCzgCA_zFjLER4eaPU1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Non Controlling interest Gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,513</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(336</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--NonControllingInterestAsl_iI_maMIzbTf_zhASwFT68lgk" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">ASL</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1464">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1465">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--MinorityInterest_iI_zHlazE5YlbS3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">20,513</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(336</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8AC_ztCYbvXrAQb5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992544314992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_804_eus-gaap--IncomeTaxDisclosureTextBlock_znvIM9XybCJa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17.
<span id="xdx_829_zeAaJlP7VpZe">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zbYrNSfpqOqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
United States and foreign components of loss before income taxes were comprised of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BC_zbw9RcdCJECe" style="display: none">SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAX</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20220101__20221231_zILNGugjEUVd" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20210101__20211231_zJModJ8xjfzb" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax jurisdictions from:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_zEfm59KnFAFd" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Local &#8211; United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(736,946</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(706,659</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_hsrt--StatementGeographicalAxis__country--MY_zKjnqwH7pae9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign &#8211; Malaysia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(864,794</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,064,314</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_hsrt--StatementGeographicalAxis__country--HK_zEcVHq1RW1wl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign &#8211; Hong Kong</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(68,394</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(616,640</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_hsrt--StatementGeographicalAxis__country--HK_zQZ4XU7Pz09d" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign, Tax jurisdictions</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(68,394</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(616,640</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ze9d2YDOMzhe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Loss before income tax</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,670,134</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,387,613</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A5_zuOOqa94XT0b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zvnkRDjToTH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
benefit of (provision for) income taxes consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zd1FtMJnpQK1" style="display: none">SCHEDULE OF PROVISION FOR INCOME TAX</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20220101__20221231_zyjO9HHS05l5" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20210101__20211231_zaZTlg3JC3n7" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zMK5QD2RIBb5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Current:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_iN_di_maITEBzQW2_z60POG4Cj7X3" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%">- Local</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1494">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(22,205</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--CurrentForeignTaxExpenseBenefit_iN_di_maITEBzQW2_zx6jaeMCGMG5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>- Foreign</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,962</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(104,735</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zf5oiH7PaL34" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Deferred:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_iN_di_maITEBzQW2_zYXpTW31pcRa" style="vertical-align: bottom; background-color: White">
    <td>- Local</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1503">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1504">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_iN_di_maITEBzQW2_zyDwuD45MHn9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">- Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">15,017</p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,127</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_iNT_pp0p0_di_mtITEBzQW2_zJnYG9RGYQ28" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Benefit of (Provision for) income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,055</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(137,067</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8AD_zLpr1cFDX1Z3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
effective tax rate in the periods presented is the result of the mix of income earned in various tax jurisdictions that apply a broad
range of income tax rates. The Company and its subsidiary that operate in various countries: United States, Malaysia (including Labuan)
and Hong Kong that are subject to taxes in the jurisdictions in which they operate, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>United
States of America</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
ATP Corporation was incorporated in the State of Nevada and is subject to the tax laws of the United States of America with a corporate
tax rate of <span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zgJNy2t1B1ze" title="Tax percentage">21</span>% on its taxable income. Agape ATP Corporation also subject to controlled foreign corporations Subpart F income (&#8220;Subpart
F&#8221;) tax, which is a tax primarily on passive income from controlled foreign corporations with a tax rate of <span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zz8ClLj2ufX1" title="Tax percentage">35</span>%. <span id="xdx_902_ecustom--TaxRateDescription_c20220101__20221231_ze4PeMh6BJud" title="Tax rate description">In addition, the
Tax Cuts and Jobs Act imposed a global intangible low-taxed income (&#8220;GILTI&#8221;) tax, which is a tax on certain off-shore earnings
at an effective rate of 10.5% for tax years (50% deduction of the current enacted tax rate of 21%) with a partial offset for 80% foreign
tax credits. If the foreign tax rate is 13.125% or higher, there will be no U.S. corporate tax after the 80% foreign tax credits are
applied.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2022 and 2021, the Company&#8217;s foreign subsidiaries did not generate any income that were subject to Subpart F
tax and GILTI tax.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17.
INCOME TAXES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 and 2021, the operations in the United States of America incurred approximately $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20221231__srt--StatementGeographicalAxis__country--US_zkoq4MMBUwha" title="Operating loss">1,357,000</span> and $<span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__srt--StatementGeographicalAxis__country--US_zWOT89Pcrepf" title="Operating loss">620,000</span>, respectively,
of cumulative net operating losses (&#8220;NOL&#8221;) which can be carried forward to offset future taxable income or Subpart F and
GILTI taxes. These balances can be carried forward indefinitely. The deferred tax valuation allowance as of December 31, 2022 and 2021
were approximately $<span id="xdx_901_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pp0p0_c20221231__srt--StatementGeographicalAxis__country--US_zRO6KfP9duZ3" title="Deferred tax valuation allowance">285,000</span> and $<span id="xdx_90F_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pp0p0_c20211231__srt--StatementGeographicalAxis__country--US_zEoT3y5h8boh" title="Deferred tax valuation allowance">130,000</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2021, the Company re-visited its fiscal 2020 U.S. income taxes and determined its stock dividend from Greenpro
Capital Corp as a result of its Spin-off of DSwiss Inc.&#8217;s shares in 2020 were subject to Subpart F and GILTI taxes. As a result,
the Company incurred additional income taxes expenses of $<span id="xdx_909_eus-gaap--IncomeTaxExpenseBenefit_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zcsImL44TVba" title="Income tax expense benefit">22,205</span>, including interest and penalty of $<span id="xdx_902_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_c20210101__20211231_zmMMvEdraQ5g" title="Income tax  examination penalties and interest expense">395</span>, for the year ended December
31, 2021, after utilizing its estimated cumulative net operating losses (&#8220;NOL&#8221;) of $<span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_iI_c20201231_zE6NfjrRcXk1" title="Cumulative net operating loss">312,608</span> as of December 31, 2020. As a
result, the Company&#8217;s deferred tax assets of estimated NOL of $<span id="xdx_90C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20211231_zsP4YJOKxmHl" title="Deferred tax assets operating loss carryforwards">65,648</span> were fully utilized and reduced to $<span id="xdx_900_ecustom--DeferredTaxAssetsOperatingLossCarryforwardsReducedAmount_iI_c20211231_ztjakd3u7C47" title="Deferred tax assets operating loss carryforwards reduced amount">0</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Malaysia</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
to the Labuan Business Activity Tax Act (LBATA) 1990 which was gazetted and came into operation on January 1, 2019 mandate companies
incorporated in Labuan to satisfy the &#8220;substantial activity requirements&#8221; to qualify for the preferential tax rate of <span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20181228__20190102__srt--StatementGeographicalAxis__custom--LabuanMember_zIRsUgxuLdag" title="Effective tax rate">3</span>%
on net audited profit. Subsequently, on April 29, 2020, a circular setting out revisions to the &#8220;substantial activity requirements&#8221;
was issued. As Agape ATP Corporation did not maintain a permanent establishment in Labuan, and therefore did not satisfy the said requirements,
the company was subjected to tax at <span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20181228__20190102__srt--StatementGeographicalAxis__custom--LabuanMember_zk0ogbKW0V3l" title="Taxp percentage">24</span>% on its net audited profit. On June 11, 2021, Agape ATP Corporation made an irrevocable election
to be taxed under the Malaysian Income Tax Act 1967 as the elected tax regime is more tax efficient to the entity compare to LBATA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
Superior Living Sdn Bhd, Agape S.E.A Sdn Bhd and Wellness ATP International Holdings Sdn Bhd. are governed by the income taxes laws of
Malaysia and the income taxes provision in respect of operations in Malaysia is calculated at the applicable tax rates on the taxable
income for the periods based on existing legislation, interpretations and practices in respect thereof. Under the Income Tax Act of Malaysia,
enterprises that incorporated in Malaysia are usually subject to a unified 24% enterprise income taxes rate while preferential tax rates,
tax holidays and even tax exemption may be granted on case-by-case basis. <span id="xdx_90D_eus-gaap--IncomeTaxExaminationDescription_c20220101__20221231__srt--StatementGeographicalAxis__country--MY_zNZZZmJheaGc" title="Income tax examination, description">The tax rate for small and medium sized companies (generally
companies incorporated in Malaysia with paid-in capital of RM <span id="xdx_903_eus-gaap--AdditionalPaidInCapitalCommonStock_iI_uRM_c20221231__srt--StatementGeographicalAxis__country--MY_zbKPsZfgFsXl" title="Paid in capital">2,500,000</span> or less) is <span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231__srt--StatementGeographicalAxis__country--MY_zZ62Snk1qEg1" title="Tax percentage">17</span>% for the first RM <span id="xdx_905_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockSplit_uRM_c20220101__20221231__srt--StatementGeographicalAxis__country--MY_zBNTbf6oiRb1" title="Additional paid in capital stock split">600,000</span> (or approximately $<span id="xdx_903_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockSplit_c20220101__20221231__srt--StatementGeographicalAxis__country--MY_zygUhR4xo3nh" title="Additional paid in capital stock split">150,000</span>)
for the year ended December 31, 2022 and 2021, with the remaining balance being taxed at the 24% rate.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022 and 2021, the operations in the Malaysia incurred approximately $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20221231__srt--StatementGeographicalAxis__country--MY_zDl4zfqro5ll" title="Operating loss carryforwards">1,723,000</span> and $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__srt--StatementGeographicalAxis__country--MY_zmekVsOtcVJ2" title="Operating loss carryforwards">946,000</span>, respectively, of cumulative
net operating losses (&#8220;NOL&#8221;) which can be carried forward to offset future taxable income. Approximately $<span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_c20221231__srt--StatementScenarioAxis__custom--TwoThousandTwentyEightMember_zShKKzS5sOMj" title="Net operating loss carryforward">790,000</span>, $<span id="xdx_907_eus-gaap--OperatingLossCarryforwards_iI_c20221231__srt--StatementScenarioAxis__custom--TwoThousandTwentyNineMember_z4R1I2LYn4i7" title="Operating loss carryforwards">897,000</span>
and $<span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_c20221231__srt--StatementScenarioAxis__custom--TwoThousandThirtyMember_zYdQzWPGiCtf" title="Operating loss carryforwards">36,000</span> of the net operating loss carry forwards will expire in 2028, 2029 and 2030, respectively, if unutilized. The deferred tax
valuation allowance as of December 31, 2022 and 2021 were approximately $<span id="xdx_904_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pp0p0_c20221231__srt--StatementGeographicalAxis__country--MY_zkNcrZV4Sqqd" title="Deferred tax valuation allowance">408,000</span> and $<span id="xdx_907_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pp0p0_c20211231__srt--StatementGeographicalAxis__country--MY_zIIliFXylte7" title="Deferred tax valuation allowance">217,000</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Hong
Kong</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agape
ATP International Holding (HK) Limited is subject to Hong Kong Profits Tax, which is charged at the statutory income rate of <span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231__srt--StatementGeographicalAxis__country--HK_z0iE2ahYAfTl" title="Tax percentage">16.5</span>% on
its assessable income derived from Hong Kong. Business income derived or business expenses incurred outside the Special Administrative
Region is not subject to Hong Kong Profits Tax or deduction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17.
INCOME TAXES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zs7koufBlsPe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table reconciles the local (United States) statutory rates to the Company&#8217;s effective tax rate for the periods indicated
below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_ztzQ54IozAzh" style="display: none">SCHEDULE OF EFFECTIVE INCOME TAX RATE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20220101__20221231_zHCxR3XC3b55" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20210101__20211231_zgGgyOd8ejc8" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_zYddPEdno3Oc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">U.S. statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">21.0</td><td style="width: 3%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">21.0</td><td style="width: 3%; text-align: left">%</td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_z5DvnDY0tKVa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22.9</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17.0</td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_dp_uPure_zQNCTYXfjhb5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Differential tax rate in Malaysia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.0</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_uPure_zsrG7A1gpjp3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Permanent difference</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">1.2</p></td><td style="padding-bottom: 1.5pt; text-align: left">%<span id="xdx_F27_zatEtQtRgLT8" style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12.7</td><td style="padding-bottom: 1.5pt; text-align: left">)%<span id="xdx_F2B_zOwAJzLC1RXf" style="font-family: Times New Roman, Times, Serif">(2)</span></td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_uPure_zXyJa4KL4mx9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Effective tax rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.3</td><td style="padding-bottom: 2.5pt; text-align: left">%&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5.7</td><td style="padding-bottom: 2.5pt; text-align: left">)%&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    amount comprised:</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F03_zytERM4xm703" style="display: none; font-family: Times New Roman, Times, Serif">(1)</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zOWyPY8rPQ44" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    amount comprised:  (1.0)% being expenses
    incurred in AATP LB, ASL, SEA and WATP that are not deductible in the Malaysia tax return.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTQ0hFRFVMRSBPRiBFRkZFQ1RJVkUgSU5DT01FIFRBWCBSQVRFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dp_uPure_c20220101__20221231__srt--ConsolidatedEntitiesAxis__custom--AATPLBASLSEAAndWATPMember_zi6DGrGLC2ag" title="Tax percentage">1.2</span>%
    being expenses incurred in AATP LB, ASL, SEA and WATP that are not deductible in the Malaysia tax return.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    amount comprised:</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F05_z2wAecmBq731" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zWKUhUXw4cdk" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    amount comprised: 6.2% being income derived in AATP HK that were not taxable in the Malaysia tax returns; and 6.7% being expenses
    incurred in AATP LB, ASL, SEA, WATP, and DSY Wellness that are not deductible in the Malaysia tax return.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTQ0hFRFVMRSBPRiBFRkZFQ1RJVkUgSU5DT01FIFRBWCBSQVRFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dp_uPure_c20210101__20211231__srt--ConsolidatedEntitiesAxis__custom--AATPHKMember_z6xpV1RMQVUj" title="Tax percentage">6.2</span>%
    being income derived in AATP HK that were not taxable in the Malaysia tax returns; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTQ0hFRFVMRSBPRiBFRkZFQ1RJVkUgSU5DT01FIFRBWCBSQVRFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dp_uPure_c20210101__20211231__srt--ConsolidatedEntitiesAxis__custom--AATPLBASLSEAWATPAndDSYMember_zbGeGh7tMbTi" title="Tax percentage">6.5</span>%
    being expenses incurred in AATP LB, ASL, SEA, WATP, and DSY Wellness that are not deductible in the Malaysia tax return.</span></td></tr>
  </table>
<p id="xdx_8AA_zNnq9UE82us8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zfEpPIcQn1Lf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the significant components of the aggregate deferred tax assets of the Company as of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zWpLBFPc1Dkb" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_49A_20221231_zn52KdWrhKTj" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_490_20211231_z0VTgYqVbouf" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_hsrt--StatementGeographicalAxis__country--US_zVEaoySimCW6" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Net operating loss carry forwards in U.S.</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">284,959</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">153,061</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_hsrt--StatementGeographicalAxis__country--MY_zKdi2QR162R4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net operating loss carry forwards in Malaysia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">408,226</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">227,106</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_hsrt--StatementGeographicalAxis__country--MY_z1c62vy6Wc2h" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net operating loss carry forwards in Malaysia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">408,226</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">227,106</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_c20221231_zoFkfth0N4jk" style="text-align: right" title="Less: valuation allowance">(693,185</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_c20211231_zHah2jn5TAA3" style="text-align: right" title="Less: valuation allowance">(380,167</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DeferredTaxLiabilitiesDepreciation_iI_zz9ivyR9T0h9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1606">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15,574</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iNI_di_zrvCGHXA3RVl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Deferred tax liabilities, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1609">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(15,574</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8AD_zUlQheZGTDob" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Uncertain
tax positions</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company evaluates each uncertain tax position (including the potential application of interest and penalties) based on the technical
merits, and measure the unrecognized benefits associated with the tax positions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
As of December 31, 2022 and 2021, the Company did not have any significant unrecognized uncertain tax positions. The Company did not
incur interest and penalties tax for the years ended December 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992544368032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONCENTRATIONS OF RISKS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">CONCENTRATIONS OF RISKS</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--ConcentrationRiskDisclosureTextBlock_zROLBkIHSamd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>18.
<span id="xdx_821_zlvbAJHpNgn5">CONCENTRATIONS OF RISKS</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Major customers</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2022 and 2021, no customer accounted for <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--NoCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWKJc4bsj6Uc" title="Concentrations of risk percentage"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--NoCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zAONw3R7qX0b" title="Concentrations of risk percentage">10.0</span></span>% or more of the Company&#8217;s total revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, five individual customers accounted for approximately <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--FiveIndividualCustomersMember_zBwk0nuBy2zc" title="Concentrations of risk percentage">72.0</span>% of the Company&#8217;s balance of accounts receivable.
There was no accounts receivable balance as of December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Major vendors</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2022, three vendors accounted for approximately <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zfuoGkoRdPA3" title="Concentrations of risk percentage">53.3</span>%, <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zoZqGJPNUz78" title="Concentrations of risk percentage">22.1</span>% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zDnV58Jej51h" title="Concentrations of risk percentage">21.3</span>% of the Company&#8217;s total purchases.
For the year ended December 31, 2021, two vendors accounted for approximately <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zQPkwlZce1Z9" title="Concentrations of risk percentage">47.3</span>% and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_ziDzEcL0CCl2" title="Concentrations of risk percentage">45.2</span>% of the Company&#8217;s total purchases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Via a dividend distribution, the Company acquired <span id="xdx_90E_ecustom--DividendShareForCommonStock_pid_c20210101__20211231__dei--LegalEntityAxis__custom--DSwissIncMember_zca4wE7CywH" title="Dividend share for common stock">23,330</span> shares of common stock of DSwiss, Inc., represents approximately <span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20211231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DSwissIncMember_zleAnAUhNaJ2" title="Equity method investment ownership percentage">0.01</span>% ownership,
that the Company accounted for as investment in marketable securities (See Note 11). DSwiss, Inc.&#8217;s wholly owned subsidiary is
the vendor that accounted for the Company&#8217;s total purchases of approximately <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__srt--MajorCustomersAxis__custom--VendorOneMember__dei--LegalEntityAxis__custom--DSwissIncMember_zusE8A7Yki5d" title="Concentration risk percentage">22.1</span>% and <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__srt--MajorCustomersAxis__custom--VendorOneMember__dei--LegalEntityAxis__custom--DSwissIncMember_z5Lx7iFKKLlh" title="Concentration risk percentage">47.3</span>% for the years ended December 31, 2022
and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, three vendors accounted for approximately <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zBdUEcqmBp4i">46.6</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
<span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zsDL8yJK0zxh">25.8</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_z7gJ9lvHSQf2">23.9</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the Company&#8217;s total balance of accounts payable, respectively. CTA Nutriceuticals (Asia) Sdn Bhd, a related company, accounted
for approximately <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zk63rwWeuecd">47</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the Company&#8217;s total balance of accounts payable. As of December 31, 2021, one vendor accounted for <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__srt--MajorCustomersAxis__custom--OneVendorMember_zhnOu5e2jfLl">100</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the total balance of accounts payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Commission Expenses to Sales Distributors and Stockists</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2022, one sales distributor accounted for approximately <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__srt--MajorCustomersAxis__custom--OneSalesDistributorMember_zJL3nnPr6syj" title="Concentrations of risk percentage">10.3</span>%
of the Company&#8217;s total commission expense. For the year ended December 2021, one sales distributor accounted for approximately <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__srt--MajorCustomersAxis__custom--OneSalesDistributorMember_zhaCbealWL3l" title="Concentrations of risk percentage">17.9</span>%
of the Company&#8217;s total commission expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Credit risk</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. As of December
31, 2022 and 2021, $<span id="xdx_901_eus-gaap--Deposits_iI_pp0p0_c20221231_z6mGVwNczc65" title="Deposits">513,152</span> and $<span id="xdx_90F_eus-gaap--Deposits_iI_pp0p0_c20211231_z7vQs6ijMMzl" title="Deposits">554,864</span> were deposited with financial institutions, respectively, $<span id="xdx_908_ecustom--DepositForInsurance_iI_pp0p0_c20221231_zeLPRNuQv3p" title="Deposit for insurance">231,187</span> and $<span id="xdx_900_ecustom--DepositForInsurance_iI_pp0p0_c20211231_zrvdO8zk80Ag" title="Deposit for insurance">295,761</span> of these balances
are not covered by deposit insurance. While management believes that these financial institutions are of high credit quality, it also
continually monitors their credit worthiness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that are potentially subject to credit risk consist principally of accounts receivable. The Company believes the concentration
of credit risk in its account receivable is substantially mitigated by its ongoing credit evaluation process and relatively short collection
terms. The Company does not generally require collateral from customers. The Company evaluates the need for an allowance for doubtful
accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information. Historically,
the Company did not have any bad debt on its account receivable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Exchange rate risk</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company cannot guarantee that the current exchange rate will remain steady; therefore, there is a possibility that the Company could
post the same amount of profit for two comparable periods and because of the fluctuating exchange rate actually post higher or lower
profit depending on exchange rate of RM and HK$ converted to US$ on that date. The exchange rate could fluctuate depending on changes
in political and economic environments without notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992544347424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z69LD8AdR3ud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>19.
<span id="xdx_822_zheUq6pXeslf">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Lease
commitments</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 1, 2020, the Company adopted ASC 842 for ASL&#8217;s office space lease and sales and training center as the lease commencement
date upon the acquisition of ASL. The Company recognized lease liabilities of approximately $<span id="xdx_905_eus-gaap--OperatingLeaseLiability_iI_c20200401__us-gaap--BusinessAcquisitionAxis__custom--AgapeSuperiorLivingMember_zHEG7ffirE7f" title="Operating lease liability">490,000</span>, with a corresponding right-of-use
(&#8220;ROU&#8221;) asset in the same amount based on the present value of the future minimum rental payments of the lease, using an
effective interest rate of <span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20200401__us-gaap--BusinessAcquisitionAxis__custom--AgapeSuperiorLivingMember_zsfc97PkyXX" title="Operating lease effective interest rate">5.5</span>%, which was determined using the Company&#8217;s estimated incremental borrowing rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 31, 2021, the Company entered into two separate two-year leases extension with the modified lease expiring <span id="xdx_902_ecustom--LeaseExpirationTerm_dd_c20210530__20210531_z5HRcpGjQYe4" title="Lease expiration term">May 31, 2023</span> for its office
space and expiring <span id="xdx_906_ecustom--LeaseExpirationTerm_dd_c20210530__20210531__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--TrainingCenterMember_zgWo3XXLKBk4" title="Lease expiration term">August 31, 2023</span> for its training center. The lease modification required the Company to re-measure the ROU assets
and lease liabilities based on the modified leases. The Company recognized a reduction of $<span id="xdx_907_ecustom--IncreaseDecreaseInROUAssetsAndLiabilities_iI_c20210531_zMm1KiV1UOf5" title="Reduction in ROU assets and liabilities">3,250</span> in ROU assets and lease liabilities
upon lease modifications based on the present value of the future minimum rental payments of the lease, using an effective interest rate
of <span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20210531__us-gaap--BusinessAcquisitionAxis__custom--AgapeSuperiorLivingMember_zZFVSgvwkURl" title="Operating lease effective interest rate">5.5</span>%, which was determined using the Company&#8217;s estimated incremental borrowing rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 1, 2021, the Company entered into a <span id="xdx_90B_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dxL_c20211001_zwO49qHuz3n7" title="Operating lease term::XDX::P2Y"><span style="-sec-ix-hidden: xdx2ixbrl1669">two-years</span></span>
lease for an apartment to serve as staff accommodation. The Company recognized lease liabilities of approximately $<span id="xdx_908_eus-gaap--OperatingLeaseLiability_iI_c20211001_zQfxh8uQLN0i" title="Operating lease liability"><span id="xdx_905_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20211001_zoOOaZ2efkBe" title="Operating right-of-use assets">9,777</span></span>, with a corresponding
right-of-use (&#8220;ROU&#8221;) asset in the same amount based on the present value of the future minimum rental payments of the lease,
using an effective interest rate of <span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20211001_zi8zLBxgsmve" title="Operating lease effective interest rate">5.5</span>%, which was determined using the Company&#8217;s estimated incremental borrowing rate.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">On November 1, 2021, the Company entered into a <span id="xdx_90A_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dxL_c20211101_zJeDmQwI3MWk" title="Lease term::XDX::P2Y"><span style="-sec-ix-hidden: xdx2ixbrl1677">two-years</span></span> lease for a branch
office and operating centre. The Company recognized lease liabilities of approximately $<span id="xdx_907_eus-gaap--OperatingLeaseLiability_iI_c20211101_zpBUZLZW2Lbh" title="Operating lease liability"><span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20211101_zgVkR9kWAfa4" title="Operating right-of-use assets">10,864</span></span>, with a corresponding right-of-use (&#8220;ROU&#8221;)
asset in the same amount based on the present value of the future minimum rental payments of the lease, using an effective interest rate
of <span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20211101_zUAmwGr4yWbi" title="Operating lease effective interest rate">5.5</span>%, which was determined using the Company&#8217;s estimated incremental borrowing rate.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
of December 31, 2022, the weighted remaining term of the lease is approximately <span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231__us-gaap--BusinessAcquisitionAxis__custom--AgapeSuperiorLivingMember_zXR7UdCxOVR9" title="Operating lease, weighted average remaining lease term">0.54</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z19xei46SuY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
five-year maturity of the Company&#8217;s operating lease liabilities is as follow:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B8_zPzwct6CWzei" style="display: none">SCHEDULE OF LEASE COMMITMENTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_498_20221231_zelUUryFsmN9" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Twelve Months Ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating lease liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzA1T_znNAabTgceb9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">84,146</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterNextTwelveMonths_iI_pp0p0_maLOLLPzA1T_zVWVdRWGvhwa" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1691">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzA1T_zr1jivH6QUx5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84,146</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zxPaMYfFvuCg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,439</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zbhS2P8SMYie" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">82,707</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zKoWpdy9tLcj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also leased one office and operation center, and one shophouse with an expiring term of twelve months or less, which were classified
as operation leases. Since the lease terms for these leases were twelve months or less, a lessee is permitted to elect not to recognize
lease assets and liabilities. The Company has elected not to recognize lease assets and liabilities on these leases. As of December 31,
2022, the Company&#8217;s commitment for minimum lease payment under these operating leases within the next twelve months were $<span id="xdx_906_eus-gaap--OperatingLeasePayments_c20220101__20221231_zGIFHSAk5Ky1" title="Operating lease payments">567</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent
expense for the years ended December 31, 2022 and 2021 was $<span id="xdx_90C_eus-gaap--OperatingLeaseExpense_pp0p0_c20220101__20221231_zcxO7WDxBHfd" title="Operating lease, expense">190,547</span> and $<span id="xdx_900_eus-gaap--OperatingLeaseExpense_pp0p0_c20210101__20211231_z7CK0VXCjhHg" title="Operating lease, expense">179,562</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Contingencies</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Company is party to certain legal proceedings, as well as certain asserted and un-asserted claims. Amounts accrued,
as well as the total amount of reasonably possible losses with respect to such matters, individually and in the aggregate, are not deemed
to be material to the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COVID-19</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malaysia,
where the operations of the Company predominantly reside, officially transitioned to the endemic phase of COVID-19 effective April 1,
2022. Restrictions on businesses and people are minimal. Meanwhile, the government continues to encourage inoculation for those between
the ages of 5 and 11 years and its adolescent group which comprised those between the ages 12 and 17. Adults who have been fully vaccinated,
i.e. received two doses of the COVID-19 vaccine are encouraged to take booster shots.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantially
all of our revenues are concentrated in Malaysia. Consequently, our results of operations will likely be adversely, and may be materially,
affected, to the extent that the COVID-19 or any other epidemic harms the Malaysia and global economy in general. Any potential impact
to our results will depend on, to a large extent, future developments and new information that may emerge regarding the duration and
severity of the COVID-19 and the actions taken by government authorities and other entities to contain the COVID-19 or treat its impact,
almost all of which are beyond our control. Potential impacts include, but are not limited to, the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">temporary
    closure of offices, travel restrictions, disruption or suspension of supplies, our customers may be negatively impacted financially
    resulting in which the demand for our products may be adversely affected</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">we
    may have to provide significant sales incentives to our customers during the outbreak, which may in turn materially adversely affect
    our financial condition and operating results</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    disruption of our supply chain, logistics providers or customers could adversely impact our business and results of operations, including
    causing us or our suppliers to cease manufacturing for a period of time or materially delay delivery to our customers, which may
    also lead to loss of our customers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the uncertainty surrounding the COVID-19 outbreak, the financial impact related to the outbreak of and response to the COVID-19 cannot
be reasonably estimated at this time. There is no guarantee that the Company&#8217;s total revenues will grow or remain at similar levels
year over year in 2023 and beyond.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992544368032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zyuucV8ANjb8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>20.
<span id="xdx_824_zM4zIO21U53c">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman PS Std,serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated subsequent events through the date of issuance of this consolidated financial statements,
and does not identify any events with material financial impact on the Company&#8217;s consolidated financial statements.</span></p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992541614032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><p id="xdx_844_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zNyP0JyAjBg1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86B_zswr0mP2xvua">Basis
of presentation</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#8220;U.S. GAAP&#8221;) for information pursuant to the rules and regulations of the Securities Exchange Commission
(&#8220;SEC&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the financial statements of the Company, its subsidiaries and its VIE over which the Company
exercises control and, where applicable, entities for which the Company has a controlling financial interest or is the primary beneficiary.
All transactions and balances among the Company, its subsidiaries and its VIE have been eliminated upon consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_zjSzSQwxiDdi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86B_zL3GCcj9fsy3">Principles
of consolidation</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries
are those entities in which the Company, directly or indirectly, controls more than one half of the voting power; or has the power to
govern the financial and operating policies, to appoint or remove the majority of the members of the board of directors, or to cast a
majority of votes at the meeting of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
VIE is an entity that has either a total equity investment that is insufficient to permit the entity to finance its activities without
additional subordinated financial support, or whose equity investors lack the characteristics of a controlling financial interest, such
as through voting rights, right to receive the expected residual returns of the entity or obligation to absorb the expected losses of
the entity. The variable interest holder, if any, that has a controlling financial interest in a VIE is deemed to be the primary beneficiary
and must consolidate the VIE. As of and for the year ended December 31, 2022, SEA, the only VIE of the Company has no significant operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p id="xdx_847_eus-gaap--UseOfEstimates_zkjAIul2wCT" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86C_zVJBrVh7U4Aj">Use
of estimates</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of
the consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant
accounting estimates reflected in the Company&#8217;s consolidated financial statements include allowance for inventories
obsolescence, impairment of long-lived assets, allowance for deferred tax assets. Actual results could differ from
these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6f6d91OK2Rc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86B_zsTXHABZLZv4">Cash
and cash equivalents</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents represent cash on hand, time deposits placed with banks or other financial institutions and all highly liquid investments
with an original maturity of three months or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts receivable</a></td>
<td class="text"><p id="xdx_847_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z3H4czMnpm65" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zzkCSgBX4RR5">Accounts
receivable</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable are recorded at the invoiced amount less an allowance for any uncollectible accounts and do not bear interest, which are due
on credit term. Management reviews the adequacy of the allowance for doubtful accounts on an ongoing basis,
using historical collection trends and aging of receivables. Management also periodically evaluates individual customer&#8217;s financial
condition, credit history, and the current economic conditions to make adjustments in the allowance when it is considered necessary.
Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery
is considered remote. The Company&#8217;s management continues to evaluate the reasonableness of the valuation allowance policy and update
it if necessary. As of December 31, 2022 and 2021, <span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_pp0p0_doxL_c20221231_zhiOqmrcPqr8" title="Accounts receivable, allowance for credit loss::XDX::-"><span id="xdx_901_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_pp0p0_doxL_c20221231_zIRpLQV9Lc8j" title="Accounts receivable, allowance for credit loss::XDX::-"><span id="xdx_90B_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_pp0p0_doxL_c20211231_zjYfB6tYQihl" title="Accounts receivable, allowance for credit loss::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0585"><span style="-sec-ix-hidden: xdx2ixbrl0587"><span style="-sec-ix-hidden: xdx2ixbrl0589">no</span></span></span></span></span></span> allowance of doubtful accounts was recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p id="xdx_844_eus-gaap--InventoryPolicyTextBlock_zroHu3uZnh9c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86E_zb5B0Zq2D3Jc">Inventories</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
consist of finished goods and are stated at the lower of cost or net realizable value using the first-in first-out method. Management
reviews inventory on hand for estimated obsolescence or unmarketable items, as compared to future demand requirements and the shelf life
of the various products. Based on the review, the Company records inventory write-downs, when necessary, when costs exceed expected net
realizable value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2022 and 2021, the Company recognized $<span id="xdx_90F_ecustom--InventriesWriteDown_pp0p0_c20220101__20221231_zkXsJJfxpgR3" title="Inventories write-down">5,307</span> and $<span id="xdx_902_ecustom--InventriesWriteDown_pp0p0_c20210101__20211231_zViMsjV0vVu5" title="Inventories write-down">36,241</span> inventory write-down; and $<span id="xdx_902_ecustom--InventoryWriteOff_c20220101__20221231_z1Nv38Qn2qsf" title="Inventories write off">142,466</span> and $<span id="xdx_905_ecustom--InventoryWriteOff_dxL_c20210101__20211231_zGY4zxAPf0Q1" title="Inventories write off::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0599">0</span></span> inventory
write-off, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_PrepaidTaxesPolicyTextBlock', window );">Prepaid taxes</a></td>
<td class="text"><p id="xdx_84E_ecustom--PrepaidTaxesPolicyTextBlock_z8UDeXO0uIVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_865_zJcRJJhWLRv">Prepaid
taxes</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Prepaid
taxes include prepaid income taxes that will either be refunded or utilized to offset future income tax</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_PrepaymentsAndDepositsPolicyTextBlock', window );">Prepayments and deposits</a></td>
<td class="text"><p id="xdx_841_ecustom--PrepaymentsAndDepositsPolicyTextBlock_zvFkVXX4W746" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_z2uvTEKsIbGb">Prepayments
and deposits</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepayments
and deposits are mainly cash deposited or advanced to suppliers for future inventory purchases or service providers for future
services. This amount is refundable and bears no interest. For any prepayments and deposits determined by management that such
advances will not be in receipts of inventories, services, or refundable, the Company will recognize an allowance account to reserve
such balances. Management reviews its prepayments and deposits on a regular basis to determine if the allowance is adequate, and
adjusts the allowance when necessary. Delinquent account balances are written-off against allowance for doubtful accounts after
management has determined that the likelihood of collection is not probable. The Company&#8217;s management continues to evaluate
the reasonableness of the allowance policy and update it if necessary. For the years ended December 31, 2022 and 2021, the Company
wrote-off allowance for doubtful accounts of $<span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_c20220101__20221231_zW6bV9v1bfo2" title="Wrote-off allowance for doubtful accounts">120,372</span>
and $<span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_dxL_c20210101__20211231_zFMULrNMoPne" title="Wrote-off allowance for doubtful accounts::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0607">0</span></span>,
respectively. As of December 31, 2022 and 2021, there was $<span id="xdx_907_ecustom--AllowanceForDoubtfulAccountsReceivablesCurrent_iI_pp0p0_do_c20221231_zGvdFOudWL7c" title="Allowance for doubtful accounts">0</span>
and $<span id="xdx_905_ecustom--AllowanceForDoubtfulAccountsReceivablesCurrent_iI_pp0p0_do_c20211231_zv10kvuHJ4n3" title="Allowance for doubtful accounts">121,514</span>
allowance for the doubtful accounts recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment, net</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zgg3hTGkHmZf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_zpVTMf0SNNfe">Property
and equipment, net</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated
useful lives of the assets with no residual value. The estimated useful lives are as follows:</span></p>

<p id="xdx_892_ecustom--ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_zxSyuQKO7vsa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zOyq8RivGFR9" style="display: none">SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful
    Life</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    and office equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zRaLyCBNVncf" title="Estimated Useful Life of Property and Equipment">5</span>-<span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zKSowKihepnf" title="Estimated Useful Life of Property and Equipment">7</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    &amp; fixtures</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zbVjqFcoASWf" title="Estimated Useful Life of Property and Equipment">6</span>-<span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_z0vZeH6V7xCf" title="Estimated Useful Life of Property and Equipment">7</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_ziqFH0okZyU7" title="Property and equipment, useful lives">Lease
    Term</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vehicle</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zP2bWwILT46e" title="Property and equipment, estimated useful life">5</span>
    years</span></td></tr>
  </table>
<p id="xdx_8A4_zbgOBOvXHTH4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cost and related accumulated depreciation of assets sold or otherwise retired are eliminated from the accounts and any gain or loss is
included in the consolidated statements of income and comprehensive income. Expenditures for maintenance and repairs are charged to earnings
as incurred, while additions, renewals and betterments, which are expected to extend the useful life of assets, are capitalized. The
Company also re-evaluates the periods of depreciation to determine whether subsequent events and circumstances warrant revised estimates
of useful lives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible assets, net</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zBv5uUAm31Fa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zDVA3pZbA5M9">Intangible
assets, net</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_ecustom--ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock_zaVytQwRId14" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets, net, are stated at cost, less accumulated amortization. Amortization expense is recognized on the straight-line basis over the
estimated useful lives of the assets as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zDzRO3Dcan" style="display: none">SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 80%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Classification</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful
    Life</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    software</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zRsBzurNO1nc" title="Estimated useful lives of intangible assets">5</span>
    years</span></td></tr>
  </table>
<p id="xdx_8A4_zLUo8k4t2rki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment for long-lived assets</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zTvfaNfOGHP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_zuAN8gurejM7">Impairment
for long-lived assets</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived
assets, including property and equipment, and intangible assets with finite lives are reviewed for impairment whenever events or changes
in circumstances (such as a significant adverse change to market conditions that will impact the future use of the assets) indicate that
the carrying value of an asset may not be recoverable. The Company assesses the recoverability of the assets based on the undiscounted
future cash flows the assets are expected to generate and recognize an impairment loss when estimated undiscounted future cash flows
expected to result from the use of the asset plus net proceeds expected from disposition of the asset, if any, are less than the carrying
value of the asset. If an impairment is identified, the Company would reduce the carrying amount of the asset to its estimated fair value
based on a discounted cash flows approach or, when available and appropriate, to comparable market values. As of December 31, 2022 and
2021, <span id="xdx_90D_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20220101__20221231_zRooauhLHRQ6" title="Impairment of long-lived assets"><span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20210101__20211231_zlATP8y30Bn4" title="Impairment of long-lived assets">no</span></span> impairment of long-lived assets was recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred offering costs</a></td>
<td class="text"><p id="xdx_842_eus-gaap--DeferredChargesPolicyTextBlock_zMw2aKdMtLE7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_zx7gkumGIB5b">Deferred
offering costs</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
offering costs represents costs associated with the Company&#8217;s current offering which will be netted against the proceeds from the
Company&#8217;s current offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investment in marketable equity securities</a></td>
<td class="text"><p id="xdx_848_eus-gaap--MarketableSecuritiesPolicy_z8aS297zZ9zi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zLchEfqtIIXg">Investment
in marketable equity securities</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company follows the provisions of ASU 2016-01, <i>Financial Instruments &#8211; Overall (Subtopic 825-10): Recognition and Measurement
of Financial Assets and Financial Liabilities</i>. Investments in marketable equity securities (non-current) are reported at fair value
with changes in fair value recognized in the Company&#8217;s consolidated statements of operations and comprehensive income (loss) in
the caption of &#8220;unrealized holding gain loss on marketable securities&#8221; in each reporting period</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_NonMarketableSecuritiesPolicyTextBlock', window );">Investment in non-marketable equity securities</a></td>
<td class="text"><p id="xdx_84F_ecustom--NonMarketableSecuritiesPolicyTextBlock_zYzL1EUXi7gk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_zhnw5Q0KKIYd">Investment
in non-marketable equity securities</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the provisions of ASU 2016-01, <i>Financial Instruments &#8211; Overall (Subtopic 825-10): Recognition and Measurement
of Financial Assets and Financial Liabilities</i>. Due to the Company&#8217;s non-marketable equity securities (non-current) does not
qualify for the practical expedient to estimate fair value in accordance with ASC 820-10-35-59, the Company has selected to record its
investments in non-marketable equity securities (non-current) at cost minus impairment, if any, plus or minus changes resulting from
observable price changes in orderly transactions for the identical or a similar investment of the same issue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
each reporting period, the Company will make a qualitative assessment considering impairment indicators to evaluate whether the investment
is impaired. The qualitative assessment indicators include, but are not limited to: (1) A significant deterioration in the earnings performance,
credit rating, asset quality, or business prospects of the investee; (ii) A significant adverse change in the regulatory, economic, or
technological environment of the investee; (iii) A significant adverse change in the general market condition of either the geographical
area or the industry in which the investee operates; (iv) A bona fide offer to purchase, an offer by the investee to sell, or a completed
auction process for the same or similar investment for an amount less than the carrying amount of that investment; and (v) Factors that
raise significant concerns about the investee&#8217;s ability to continue as a going concern, such as negative cash flows from operations,
working capital deficiencies, or noncompliance with statutory capital requirements or debt covenants. If the qualitative assessment indicators
indicated that the non-marketable equity securities (non-current) is deemed to be impaired, the Company would recognize the impairment
loss equal to the difference between the fair value of the investment and its carrying amount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Customer deposits</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z3SZaMEFApKc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_869_zgCWme2SuQRb">Customer
deposits</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
deposits represent amounts advanced by customers on product orders and unapplied unexpired coupons. Customer deposits are reduced
when the related sale is recognized in accordance with the Company&#8217;s revenue recognition policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zl9XzPhLY6W4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_zL1ebv1bxSTe">Revenue
recognition</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers (ASC Topic 606). The core
principle underlying the revenue recognition of this ASU allows the Company to recognize - revenue that represents the transfer of goods
and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange.
This will require the Company to identify contractual performance obligations and determine whether revenue should be recognized at a
point in time or over time, based on when control of goods and services transfers to a customer. The Company&#8217;s revenue streams
are recognized at a point in time for the Company&#8217;s sale of health and wellness products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ASU requires the use of a new five-step model to recognize revenue from customer contracts. The five-step model requires that the Company
(i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction
price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate
the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies
the performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for a contract with a customer when the contract is committed in writing, the rights of the parties, including payment
terms, are identified, the contract has commercial substance and consideration is probable of substantially collection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sales
of Health and Wellness products</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
<i>Performance obligations satisfied at a point in time</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company derives its revenues from sales contracts with its customers with revenues being recognized when control of the health and wellness
products are transferred to its customer at the Company&#8217;s office or shipment of the goods. The revenue is recorded net of estimated
discounts and return allowances. Products are given 60 days for returns or exchanges from the date of purchase. Historically, there were
insignificant sales returns.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the Company&#8217;s network marketing business, the Company issues
product coupons to members and distributors when these customers made purchases above certain thresholds set by the Company. Depending
on the type of product coupons issued, the coupons carry varying values and can be used by the customers for reduction in the transaction
price of product purchases within the coupon validity period. The value of the product coupons issued is recorded as a reduction of the
Company&#8217;s revenue account upon issuance; the corresponding amount credited to the customer deposits account. Amounts in customer
deposits will be reversed when the coupons are used. The Company&#8217;s coupons have a validity period of between six and twelve months.
If the Company&#8217;s customers did not utilize the coupons after the validity period, the Company would recognize the forfeiture of
the originated sales value of the coupons as net revenues. For the years ended December 31, 2022 and 2021, the Company
recognized $<span id="xdx_905_ecustom--ForfeitedCouponIncome_pp0p0_c20220101__20221231_z1fGausFuaig" title="Value of coupons">7,543</span> and $<span id="xdx_90A_ecustom--ForfeitedCouponIncome_pp0p0_c20210101__20211231_zH33eqi84eae" title="Value of coupons">15,209</span> as forfeited coupon income, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company had contracts for the sales of health and wellness products amounting to $<span id="xdx_909_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20220101__20221231__srt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_zQlULzaPfKO" title="Cost of revenue">17,912</span> which it is expected
to fulfill within 12 months from December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sales of products for the provision of complementary
health therapies</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Products for the provision of complementary health
therapies are predominantly Chinese herbs in different forms, processed or otherwise, for prescriptions for treating non-communicable
diseases.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Provision
of Health and Wellness services</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
<i>Performance obligations satisfied at a point in time</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company carries out its Wellness program, where the Company&#8217;s products are bundled with health screening test and a health camp
program. The health screening test and the health camp programs are considered as separate performance obligations. The promises to deliver
the health screening test report and the attendance at the health camp are separately identifiable, which are evidenced by the fact that
the Company provides separate services of delivering the health screening test report and allowing admission of the customers to attend
the health camp. The Company derives its revenues from sales contracts with its customers with revenues being recognized when the test
reports are completed and delivered to its customers during the consultation section in person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also separately derives its revenues from sales contracts with its customers with revenues being recognized when the health
camp program is completed in the final day of the health camp. For the years ended December 31, 2022 and 2021, revenues from
providing health and wellness services are $<span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220101__20221231__srt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_zC5UZ5MD7tQ" title="Revenues">145,510</span>
and $<span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210101__20211231__srt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_zOxTFwz9GRPe" title="Revenues">7,543</span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--DisaggregationOfRevenueTableTextBlock_zL1STfYdysn6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disaggregated
information of revenues by products and services are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zSBL4CN1dXei" style="display: none">SCHEDULE OF DIS-AGGREGATED INFORMATION OF REVENUES</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_z21abgegsA4l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20211231_z7xtVmlVkoNi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--SurvivorSelectMember_z5LWKevPxJmd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Survivor Select</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">122,470</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">83,904</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--EnergizedMineralConcentrateMember_zr0zkyHoLKi8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Energized Mineral Concentrate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0666">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,047</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--IonizedCalMagMember_zcbfX7scUGK5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Ionized Cal-Mag</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">148,219</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,527</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--OmegaBlendMember_zslpoCg1cIPh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Omega Blend</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">272,332</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222,718</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--BetaMaxxMember_zFBHCEibRUgg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>BetaMaxx</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">137,447</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208,043</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--VegeFruitFiberMember_zKD0P0DckIMb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Vege Fruit Fiber</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0678">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65,757</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--IronMember_zqKvQRKr7jQc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Iron</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,697</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,114</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--YoungFormulaMember_zwDXHSYIX4Rj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Young Formula</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,403</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,425</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--OrganicYouthCarCleansingBarMember_zhkQlF7fn2S8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Organic Youth Care Cleansing Bar</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0687">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,137</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--ATPRMITOPlusMember_z3Dq7VueuIXa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">ATPR Mito+</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">271,493</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">183,800</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--LipomaskMember_zHMa8egFj19d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Lipomask</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0693">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,331</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--EnergetiqueMember_zIfNeHxtjAlg" style="vertical-align: bottom; background-color: White">
    <td>Energetique</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,089</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,574</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--TrimPlusMember_zkwcgP3YRps5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Trim+</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88,613</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,042</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--ProductHealthTherapiesMember_zCHcL6QqgpEh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Others &#8211; Products for the provision of complementary health therapies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">569,823</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0703">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--OthersMember_zDHxgz4Dsps5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,468</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0706">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zrDljTyzVArc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total revenues &#8211; products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,711,054</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,009,419</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_z2YRBKYgeNg4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Health and Wellness services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">145,510</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,543</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--Revenues_zUKQbvvSwePf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total revenues &#8211; products and services</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,856,564</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,016,962</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zE1GaDUQw54k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of revenue</a></td>
<td class="text"><p id="xdx_843_eus-gaap--CostOfSalesPolicyTextBlock_z6hmnXy5OW45" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zskQLX6oS36d">Cost
of revenue</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Cost
of revenue comprised freight-in, the purchase cost of manufactured goods for sale to customers </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
products for the provision of complementary health therapies. <span style="background-color: white">Cost of revenue amounted to $<span id="xdx_90A_eus-gaap--CostOfGoodsAndServicesSold_c20220101__20221231_zJWOrBaL3rZb" title="Cost of revenue">666,042</span>
(including inventory write-downs of $<span id="xdx_903_ecustom--InventriesWriteDown_pp0p0_c20220101__20221231_zRagiINTU2v3" title="Inventories write-down">5,307</span> and inventory written-off of $<span id="xdx_90A_ecustom--InventoryWriteOff_c20220101__20221231_zfIQAT5Y3WE9" title="Inventories write off">142,466</span>) and $<span id="xdx_901_eus-gaap--CostOfGoodsAndServicesSold_c20210101__20211231_zy3tBqIOa1G8" title="Cost of revenue">297,333</span> (including inventory write-downs of $<span id="xdx_906_ecustom--InventriesWriteDown_pp0p0_c20210101__20211231_zB1oBXGY34X2" title="Inventories write-down">36,241</span>)
for the years ended December 31, 2022 and 2021, respectively</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_ShippingAndHandlingPolicyTextBlock', window );">Shipping and handling</a></td>
<td class="text"><p id="xdx_845_ecustom--ShippingAndHandlingPolicyTextBlock_zvpO8NKxWZUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_865_z0aGmeBeTpgc">Shipping
and handling</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shipping
and handling charges amounted to $<span id="xdx_90C_eus-gaap--SellingExpense_pp0p0_c20220101__20221231__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_z6kvkMl8C7zf" title="Selling expenses">16,585</span> and $<span id="xdx_906_eus-gaap--SellingExpense_pp0p0_c20210101__20211231__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zlMEsfQKQ5A9" title="Selling expenses">11,054</span> for the years ended December 31, 2022 and 2021, respectively. Shipping and handling
charges are expensed as incurred and included in selling expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising costs</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--AdvertisingCostsPolicyTextBlock_zPT6muVeN732" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_z7Es73GdWP47">Advertising
costs</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising
costs amounted to $<span id="xdx_90F_eus-gaap--AdvertisingExpense_pp0p0_c20220101__20221231_zYDnt2NU8M2f" title="Advertising costs">4,688</span> and $<span id="xdx_90A_eus-gaap--AdvertisingExpense_pp0p0_c20210101__20211231_zuP4dGeRsy0c" title="Advertising costs">20,218</span> for the years ended December 31, 2022 and 2021, respectively. Advertising costs are expensed as
incurred and included in selling expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommissionsExpensePolicyPolicyTextBlock', window );">Commission expenses</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--CommissionsExpensePolicyPolicyTextBlock_z9Mv3yTzzq3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86C_zZMSQOUlDMA2">Commission
expenses</span> </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
expenses are the Company&#8217;s most significant expenses. As with all companies in the network marketing industry, the Company&#8217;s
sales channel is external to the Company. The Company&#8217;s &#8220;external sales force&#8221; is stratified into two levels based
on priority recruitment. First, there are sales distributors. Second, all members recruited by a sales distributor, directly or indirectly,
are referred to as &#8220;sales network members&#8221;. The Company pays commission to every sales distributor based on purchases made
by its sales network members which includes the independent direct sales members. Top performing distributors with their own physical
stores may also become stockists of the Company, whereby they enjoy benefits such as maintaining a certain amount of the Company&#8217;s
inventory on their store premises. The stockists shall account to the Company for all products sales from their store premises as monitored
through the Company&#8217;s centralized stock tracking system. The Company pays a separate commission to stockists based on revenue generated
from the stockists&#8217; physical stores. Commission expenses amounted to $<span id="xdx_90B_eus-gaap--SalesCommissionsAndFees_pp0p0_c20220101__20221231_zX3h03VVO6v1" title="Commission expenses">405,351</span> and $<span id="xdx_903_eus-gaap--SalesCommissionsAndFees_pp0p0_c20210101__20211231_zp2dghig06Jl" title="Commission expenses">316,267</span> for the years ended December 31, 2022
and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_DefinedContributionPlanPolicyTextBlock', window );">Defined contribution plan</a></td>
<td class="text"><p id="xdx_84A_ecustom--DefinedContributionPlanPolicyTextBlock_zzTqGCuRJEU3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration: underline"><span id="xdx_862_z5HFBg68sykk">Defined
contribution plan</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
full-time employees of the Company are entitled to the government mandated defined contribution plan. The Company is required to accrue
and pay for these benefits based on certain percentages of the employees&#8217; respective salaries, subject to certain ceilings, in
accordance with the relevant government regulations, and make cash contributions to the government mandated defined contribution plan</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Total expenses for the plans were $<span id="xdx_906_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pp0p0_c20220101__20221231_zVicH7EgFDLa" title="Defined contribution plan expense">133,489</span> and $<span id="xdx_909_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pp0p0_c20210101__20211231_zfGWX5OFpjta" title="Defined contribution plan expense">99,488</span> for the years ended December 31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
related contribution plans include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Social
    Security Organization (&#8220;SOSCO&#8221;) &#8211; <span id="xdx_90A_ecustom--SalaryPercentage_pid_dp_c20220101__20221231__dei--LegalEntityAxis__custom--SocialSecurityOrganizationMember_zBxcFz5qfd16" title="Salary percentage">1.75</span>% based on employee&#8217;s monthly salary capped of RM <span id="xdx_90E_ecustom--MonthlySalary_uRM_c20220101__20221231__dei--LegalEntityAxis__custom--SocialSecurityOrganizationMember_zF3FRUewo47b" title="Monthly salary">5,000</span>;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employees
    Provident Fund (&#8220;EPF&#8221;) &#8211;based on employee&#8217;s monthly salary, <span id="xdx_90D_ecustom--SalaryPercentage_pid_dp_c20220101__20221231__dei--LegalEntityAxis__custom--EmployeesProvidentFundMember__srt--RangeAxis__srt--MinimumMember_zQriZXqhOcEf" title="Salary percentage">13</span>% for employee earning RM<span id="xdx_90E_ecustom--MonthlySalary_uRM_c20220101__20221231__dei--LegalEntityAxis__custom--EmployeesProvidentFundMember__srt--RangeAxis__srt--MinimumMember_zhjGzhzfJlAc" title="Monthly salary">5,000</span> and below; and
    <span id="xdx_90E_ecustom--SalaryPercentage_pid_dp_c20220101__20221231__dei--LegalEntityAxis__custom--EmployeesProvidentFundMember__srt--RangeAxis__srt--MinimumMember__srt--RangeAxis__srt--MaximumMember_z2esrfOwXpSb" title="Salary percentage">12</span>% for employee earning RM<span id="xdx_906_ecustom--MonthlySalary_uRM_c20220101__20221231__dei--LegalEntityAxis__custom--EmployeesProvidentFundMember__srt--RangeAxis__srt--MaximumMember_zWZBWgz0MTwk" title="Monthly salary">5,001</span> and above.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment
    Insurance System (&#8220;EIS&#8221;) &#8211; <span id="xdx_90C_ecustom--SalaryPercentage_pid_dp_c20220101__20221231__dei--LegalEntityAxis__custom--EmploymentInsuranceSystemMember_zRHbOFUNH1f1" title="Salary percentage">0.2</span>% based on employee&#8217;s monthly salary capped of RM <span id="xdx_90E_ecustom--MonthlySalary_uRM_c20220101__20221231__dei--LegalEntityAxis__custom--EmploymentInsuranceSystemMember_ztc1arIXPmgb" title="Monthly salary">5,000</span>;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
    Resource Development Fund (&#8220;HRDF&#8221;) &#8211; <span id="xdx_907_ecustom--SalaryPercentage_pid_dp_c20220101__20221231__dei--LegalEntityAxis__custom--HumanResourceDevelopmentFundMember_zZfEeTcMmTd6" title="Salary percentage">1</span>% based on employee&#8217;s monthly salary</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zZdZiC8AkEH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_zCkcAvFtpGea">Income
taxes</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes in accordance with U.S. GAAP for income taxes. The charge for taxation is based on the results for
the fiscal year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted
or substantively enacted by the balance sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
taxes is accounted for using the asset and liability method in respect of temporary differences arising from differences between the
carrying amount of assets and liabilities in the consolidated financial statements and the corresponding tax basis used in the computation
of assessable tax profit. In principle, deferred tax liabilities are recognized for all taxable temporary differences. Deferred tax assets
are recognized to the extent that it is probable that taxable profit will be available against which deductible temporary differences
can be utilized. Deferred tax is calculated using tax rates that are expected to apply to the period when the asset is realized or the
liability is settled. Deferred tax is charged or credited in the income statement, except when it is related to items credited or charged
directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets are reduced by a valuation allowance
when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.
Current income taxes are provided for in accordance with the laws of the relevant taxing authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
uncertain tax position is recognized as a benefit only if it is &#8220;more likely than not&#8221; that the tax position would be sustained
in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that
is <span id="xdx_90F_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20220101__20221231_zridEaAy3q5d" title="Income tax description">greater than 50%</span> likely of being realized on examination. For tax positions not meeting the &#8220;more likely than not&#8221; test,
no tax benefit is recorded. $<span id="xdx_905_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_pp0p0_c20220101__20221231_zPKdG0hn2bma" title="Income tax examination, penalties and interest expense">0</span> and $<span id="xdx_904_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_pp0p0_c20210101__20211231_zSFYTL7JYgi1" title="Income tax examination, penalties and interest expense">395</span> penalties and interest incurred related to underpayment of income tax for the years ended December
31, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company conducts much of its business activities in Hong Kong and Malaysia and is subject to tax in each of their jurisdictions. As a
result of its business activities, the Company will file separate tax returns that are subject to examination by the foreign tax authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive income (loss)</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zAIQ7gf36Ghj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_868_zwYFtkBQLvFa">Comprehensive
income (loss)</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
income (loss) consists of two components, net income (loss) and other comprehensive income (loss). Net income (loss) refers to revenue,
expenses, gains and losses that under GAAP are recorded as an element of stockholders&#8217; equity but are excluded from net income.
Other comprehensive income (loss) consists of a foreign currency translation adjustment resulting from the Company not using the U.S.
dollar as its functional currencies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_NoncontrollingInterestPolicyTextBlock', window );">Non-controlling interest</a></td>
<td class="text"><p id="xdx_848_ecustom--NoncontrollingInterestPolicyTextBlock_zUmxJoS2Nq6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_z3pSSXQCI64h">Non-controlling
interest</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--MinorityInterestDescription_c20220101__20221231_z3bBup5MmeXk" title="Noncontrolling interest, description">Non-controlling
interest consists of 40% of the equity interests of DSY Wellness held by an individual and approximately 0.01% (2 ordinary shares out
of 9,590,598 shares) of the equity interests of ASL held by two individuals</span>. The non-controlling interests are presented in the consolidated
balance sheets, separately from equity attributable to the shareholders of the Company. Non-controlling interests in the results of the
Company are presented on the face of the consolidated statements of operations as an allocation of the total income or loss for the periods
between non-controlling interest holders and the shareholders of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (loss) per share</a></td>
<td class="text"><p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zYeCXifgtjIc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_z17u0oqw1S65">Earnings
(loss) per share</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company computes earnings (loss) per share (&#8220;EPS&#8221;) in accordance with ASC 260, &#8220;Earnings per Share&#8221;. ASC 260
requires companies to present basic and diluted EPS. Basic EPS is measured as net income divided by the weighted average ordinary share
outstanding for the period. Diluted EPS presents the dilutive effect on a per share basis of the potential ordinary shares (e.g., convertible
securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later.
Potential ordinary shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are
excluded from the calculation of diluted EPS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. For the
years ended December 31, 2022 and 2021, there were <span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20220101__20221231_zZU9VYbmnxme" title="Potentially dilutive securities outstanding"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20210101__20211231_zTFE6S4QfcGg" title="Potentially dilutive securities outstanding">no</span></span> dilutive shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currencies translation and transaction</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zpmvue0RnR04" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86F_zeX8FIyxsbb9">Foreign
currencies translation and transaction</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing
at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated
into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded
in the consolidated statements of operations and comprehensive income (loss).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reporting currency of the Company is United States Dollars (&#8220;US$&#8221;) and the accompanying financial statements have been expressed
in US$. The Company&#8217;s subsidiary in Labuan maintains its books and record in United States Dollars (&#8220;US$&#8221;) albeit its
functional currency being the primary currency of the economic environment in which the entity operates, which is the Malaysian Ringgit
(&#8220;MYR&#8221; or &#8220;RM&#8221;). The Company&#8217;s subsidiary in Hong Kong maintains its books and record in Hong Kong Dollars
(&#8220;HK$&#8221;), similar to its functional currency. The Company&#8217;s subsidiary and VIE in Malaysia conducts its businesses and
maintains its books and record in the local currency, Malaysian Ringgit (&#8220;MYR&#8221; or &#8220;RM&#8221;), as its functional currency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into
US$, in accordance with ASC Topic 830-30, &#8220;<i>Translation of Financial Statement&#8221;</i>, using the exchange rate on the balance
sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation
of financial statements of foreign subsidiary are recorded as a separate component of accumulated other comprehensive income within the
statements of stockholders&#8217; equity. Cash flows are also translated at average translation rates for the periods, therefore, amounts
reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance
sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_zTYA4P9FOinb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Translation
of foreign currencies into US$1 have been made at the following exchange rates for the respective periods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zdv4I7CXhGol" style="display: none">SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zgy5lSiaUnqg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20211231_zsVB6e9RZDpg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hus-gaap--VariableRateAxis__custom--PeriodEndMYRMember_zFRhCxqqi3Eh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Period-end MYR : US$1 exchange rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">4.41</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">4.18</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hus-gaap--VariableRateAxis__custom--PeriodEndHKDMember_zLYf4zb3Voe5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Period-end HKD : US$1 exchange rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.80</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hus-gaap--VariableRateAxis__custom--PeriodEndHKDMember_ziM6JpnK0o6" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign currency exchange
    rate, translation</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.80</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20220101__20221231_zu9ykfzTy0w3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20210101__20211231_zaKDMyylVgMj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_405_ecustom--ForeignCurrencyExchangeRateAverage_hus-gaap--VariableRateAxis__custom--PeriodAverageMYRMember_zqsIpHu1yyE" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Period-average MYR : US$1 exchange rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">4.41</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">4.14</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ForeignCurrencyExchangeRateAverage_hus-gaap--VariableRateAxis__custom--PeriodAverageHKDMember_zecoVeo3Tg3a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Period-average HKD : US$1 exchange rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.83</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.77</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ForeignCurrencyExchangeRateAverage_hus-gaap--VariableRateAxis__custom--PeriodAverageHKDMember_zCDRKLJohb0b" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign currency exchange
    rate period average</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.83</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.77</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zR6kyPJj6KLc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartiesPolicyTextBlock', window );">Related parties</a></td>
<td class="text"><p id="xdx_840_ecustom--RelatedPartiesPolicyTextBlock_zI7d5N4JYGed" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zRTbziKHfAwb">Related
parties</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parties,
which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control
the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also
considered to be related if they are subject to common control or common significant influence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments</a></td>
<td class="text"><p id="xdx_844_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zE82vognobm5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_864_zepRYIYYprik">Fair
value of financial instruments</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting standard regarding fair value of financial instruments and related fair value measurements defines financial instruments and
requires disclosure of the fair value of financial instruments held by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting standards define fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance
disclosure requirements for fair value measures. The three levels are defined as follow:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that
    are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 inputs to the valuation methodology are unobservable and significant to the fair value.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments included in current assets and current liabilities are reported in the consolidated balance sheets at face value or cost,
which approximate fair value because of the short period of time between the origination of such instruments and their expected realization
and their current market rates of interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--LesseeLeasesPolicyTextBlock_z3UFyt6sece6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_zibQIkWeu1wg">Leases</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted ASU 2016-02, &#8220;Leases&#8221; (Topic 842), and elected the practical expedients that does not require the Company
to reassess: (1) whether any expired or existing contracts are, or contain, leases, (2) lease classification for any expired or existing
leases and (3) initial direct costs for any expired or existing leases. For lease terms of twelve months or fewer, a lessee is permitted
to make an accounting policy election not to recognize lease assets and liabilities. The Company also adopts the practical expedient
that allows lessees to treat the lease and non-lease components of a lease as a single lease component. Some of the Company&#8217;s leases
include one or more options to renew, which is typically at the Company&#8217;s sole discretion. The Company regularly evaluates the
renewal options, and, when it is reasonably certain of exercise, it will include the renewal period in its lease term. New lease modifications
result in re-measurement of the right of use (&#8220;ROU&#8221;) assets and lease liabilities. Operating ROU assets and lease liabilities
are recognized at the commencement date, based on the present value of lease payments over the lease term. Since the implicit rate for
the Company&#8217;s leases is not readily determinable, the Company use its incremental borrowing rate based on the information available
at the commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that
the Company would have to pay to borrow, on a collateralized basis, an amount equal to the lease payments, in a similar economic environment
and over a similar term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
terms used to calculate the present value of lease payments generally do not include any options to extend, renew, or terminate the lease,
as the Company does not have reasonable certainty at lease inception that these options will be exercised. The Company generally considers
the economic life of its operating lease ROU assets to be comparable to the useful life of similar owned assets. The Company has elected
the short-term lease exception, therefore operating lease ROU assets and liabilities do not include leases with a lease term of twelve
months or less. Its leases generally do not provide a residual guarantee. The operating lease ROU asset also excludes lease incentives.
Lease expense is recognized on a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews the impairment of its ROU assets consistent with the approach applied for its other long-lived assets. The Company reviews
the recoverability of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the
asset may not be recoverable. The assessment of possible impairment is based on its ability to recover the carrying value of the asset
from the expected undiscounted future pre-tax cash flows of the related operations. The Company has elected to include the carrying amount
of operating lease liabilities in any tested asset group and includes the associated operating lease payments in the undiscounted future
pre-tax cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zOEqo9L2pkTk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86C_zkQqYFp7vst4">Recent
accounting pronouncements</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has reviewed all recently issued, but not yet effective, considers the applicability and impact of all accounting standards updates
(&#8220;ASUs&#8221;). Management periodically reviews new accounting standards that are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2019, the FASB issued ASU No. 2019-10, which to update the effective date of ASU No. 2016-13 for private companies, not-for-profit
organizations and certain smaller reporting companies applying for credit losses, leases, and hedging standard. The new effective date
for these preparers is for fiscal years beginning after December 15, 2022. ASU 2019-05 is effective for the Company for annual and interim
reporting periods beginning January 1, 2023 as the Company is qualified as a smaller reporting company. The Company is currently evaluating
the impact ASUs 2016-13 and 2019-05 may have on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for the above-mentioned pronouncements, there are no new recent issued accounting standards that will have a material impact on the consolidated
financial position, statements of operations and cash flows.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_DefinedContributionPlanPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_DefinedContributionPlanPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_NonMarketableSecuritiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Marketable Securities [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_NonMarketableSecuritiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_NoncontrollingInterestPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_NoncontrollingInterestPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_PrepaidTaxesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Taxes [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_PrepaidTaxesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_PrepaymentsAndDepositsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayments And Deposits [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_PrepaymentsAndDepositsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_RelatedPartiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Parties [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_RelatedPartiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_ShippingAndHandlingPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shipping and Handling [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_ShippingAndHandlingPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommissionsExpensePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commissions incurred in relation to revenue generating activities or operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommissionsExpensePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI https://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992544409696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND BUSINESS BACKGROUND (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock', window );">SCHEDULE OF SUBSIDIARIES AND ASSOCIATES</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_z6jBKz43mij3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details
of the Company&#8217;s subsidiaries:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_z4U5U8Q2bO8b" style="display: none">SCHEDULE OF SUBSIDIARIES AND ASSOCIATES</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Subsidiary company name</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Place and date of incorporation</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Particulars of issued capital</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Principal activities</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Proportional of ownership interest and voting power held</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 4%; vertical-align: top">1.</td>
    <td id="xdx_98F_ecustom--NameOftheCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_z2wgyn1Dpdoi" style="vertical-align: top; width: 16%; text-align: center" title="Subsidiary company name">Agape ATP Corporation</td><td style="width: 2%">&#160;</td>
    <td id="xdx_98A_ecustom--PlaceAndDateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_zOH5MKL1PLkj" style="vertical-align: top; width: 16%; text-align: center" title="Place and date of incorporation">Labuan, <br/> March 6, 2017</td><td style="width: 2%">&#160;</td>
    <td id="xdx_98C_ecustom--ParticularsOfIssuedCapital_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_zU2TJAdQCsg1" style="vertical-align: top; width: 20%; text-align: center" title="Particulars of issued capital">100 shares of ordinary share of US$1 each</td><td style="width: 2%">&#160;</td>
    <td id="xdx_984_ecustom--PrincipalActivities_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_z0yc20sqe4e5" style="vertical-align: top; width: 18%; text-align: center" title="Principal activities">Investment holding</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_zlXDpPQbfo4c" style="width: 16%; text-align: right" title="Proportional of ownership interest and voting power held">100</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">2.</td>
    <td id="xdx_988_ecustom--NameOftheCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_zwISC4Dfxule" style="vertical-align: top; text-align: center" title="Subsidiary company name">Agape ATP International Holding Limited</td><td>&#160;</td>
    <td id="xdx_980_ecustom--PlaceAndDateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_zKZuiXDJIJO9" style="vertical-align: top; text-align: center" title="Place and date of incorporation">Hong Kong,<br/> June 1, 2017</td><td>&#160;</td>
    <td id="xdx_987_ecustom--ParticularsOfIssuedCapital_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_z1C2yO2Krxjf" style="vertical-align: top; text-align: center" title="Particulars of issued capital">1,000,000 shares of ordinary share of HK$1 each</td><td>&#160;</td>
    <td id="xdx_98A_ecustom--PrincipalActivities_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_ztkuR8UgE2Ga" style="vertical-align: top; text-align: center" title="Principal activities">Wholesaling of health and wellness products; and health solution advisory services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_zhrHuElxQgUb" style="text-align: right" title="Proportional of ownership interest and voting power held">100</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">3.</td>
    <td id="xdx_986_ecustom--NameOftheCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zWPZEeulGIaj" style="vertical-align: top; text-align: center" title="Subsidiary company name">Agape Superior Living Sdn. Bhd.</td><td>&#160;</td>
    <td id="xdx_989_ecustom--PlaceAndDateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_z2vG4JESWMse" style="vertical-align: top; text-align: center" title="Place and date of incorporation">Malaysia, <br/> August 8, 2003</td><td>&#160;</td>
    <td id="xdx_98F_ecustom--ParticularsOfIssuedCapital_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zlxQ0wCJyced" style="vertical-align: top; text-align: center" title="Particulars of issued capital">9,590,598 shares of ordinary share of RM1 each</td><td>&#160;</td>
    <td id="xdx_98F_ecustom--PrincipalActivities_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zaWmlnQpMVlk" style="vertical-align: top; text-align: center" title="Principal activities">Health and wellness products and health solution advisory services via network marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zRDu6wC8Y65g" style="text-align: right" title="Proportional of ownership interest and voting power held">99.99</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">4.</td>
    <td id="xdx_983_ecustom--NameOftheCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_zCQSxQOdMDV6" style="vertical-align: top; text-align: center" title="Subsidiary company name">Agape S.E.A. Sdn. Bhd.</td><td>&#160;</td>
    <td id="xdx_989_ecustom--PlaceAndDateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_zJkdhPBAnCx6" style="vertical-align: top; text-align: center" title="Place and date of incorporation">Malaysia, <br/> March 4, 2004</td><td>&#160;</td>
    <td id="xdx_981_ecustom--ParticularsOfIssuedCapital_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_zQVikuygSc68" style="vertical-align: top; text-align: center" title="Particulars of issued capital">2 shares of ordinary share of RM1 each</td><td>&#160;</td>
    <td id="xdx_98B_ecustom--PrincipalActivities_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_zx9nzdHshE9" style="vertical-align: top; text-align: center" title="Principal activities">VIE of Agape Superior Living Sdn. Bhd.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VIE</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">5.</td>
    <td id="xdx_988_ecustom--NameOftheCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_zVyxdcbNtEw4" style="vertical-align: top; text-align: center" title="Subsidiary company name">Wellness ATP International Holdings Sdn, Bhd</td><td>&#160;</td>
    <td id="xdx_98A_ecustom--PlaceAndDateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_zQzORBPslp6b" style="vertical-align: top; text-align: center" title="Place and date of incorporation">Malaysia, <br/> September 11, 2020</td><td>&#160;</td>
    <td id="xdx_98F_ecustom--ParticularsOfIssuedCapital_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_zzCN2vTm0Nrj" style="vertical-align: top; text-align: center" title="Particulars of issued capital">100 shares of ordinary share of RM1 each</td><td>&#160;</td>
    <td id="xdx_980_ecustom--PrincipalActivities_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_z4w9BFgkjcaf" style="vertical-align: top; text-align: center" title="Principal activities">The promotion of wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_zrwhNipqlX5h" style="text-align: right" title="Proportional of ownership interest and voting power held">100</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">6.</td>
    <td id="xdx_981_ecustom--NameOftheCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zPNDKJMYKVCf" style="vertical-align: top; text-align: center" title="Subsidiary company name">DSY Wellness International Sdn Bhd.</td><td>&#160;</td>
    <td id="xdx_987_ecustom--PlaceAndDateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zkpqjGWY6Im9" style="vertical-align: top; text-align: center" title="Place and date of incorporation">Malaysia, <br/> November 11, 2021</td><td>&#160;</td>
    <td id="xdx_989_ecustom--ParticularsOfIssuedCapital_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zSsNZhMC3uab" style="vertical-align: top; text-align: center" title="Particulars of issued capital">1,000 shares of ordinary share of RM1 each</td><td>&#160;</td>
    <td id="xdx_982_ecustom--PrincipalActivities_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_z5jZwgR6At6a" style="vertical-align: top; text-align: center" title="Principal activities">Provision of complementary health therapies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zWZ4bln97jE8" style="text-align: right" title="Proportional of ownership interest and voting power held">60</td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the key aspects of a subsidiary (partnership, corporation, or other entity) of the limited liability company or limited partnership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992545661792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock', window );">SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_892_ecustom--ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_zxSyuQKO7vsa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zOyq8RivGFR9" style="display: none">SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful
    Life</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    and office equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zRaLyCBNVncf" title="Estimated Useful Life of Property and Equipment">5</span>-<span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zKSowKihepnf" title="Estimated Useful Life of Property and Equipment">7</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    &amp; fixtures</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zbVjqFcoASWf" title="Estimated Useful Life of Property and Equipment">6</span>-<span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_z0vZeH6V7xCf" title="Estimated Useful Life of Property and Equipment">7</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_ziqFH0okZyU7" title="Property and equipment, useful lives">Lease
    Term</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vehicle</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zP2bWwILT46e" title="Property and equipment, estimated useful life">5</span>
    years</span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock', window );">SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET</a></td>
<td class="text"><p id="xdx_89B_ecustom--ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock_zaVytQwRId14" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets, net, are stated at cost, less accumulated amortization. Amortization expense is recognized on the straight-line basis over the
estimated useful lives of the assets as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zDzRO3Dcan" style="display: none">SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 80%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Classification</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful
    Life</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    software</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zRsBzurNO1nc" title="Estimated useful lives of intangible assets">5</span>
    years</span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">SCHEDULE OF DIS-AGGREGATED INFORMATION OF REVENUES</a></td>
<td class="text"><p id="xdx_899_eus-gaap--DisaggregationOfRevenueTableTextBlock_zL1STfYdysn6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disaggregated
information of revenues by products and services are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zSBL4CN1dXei" style="display: none">SCHEDULE OF DIS-AGGREGATED INFORMATION OF REVENUES</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_z21abgegsA4l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20211231_z7xtVmlVkoNi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--SurvivorSelectMember_z5LWKevPxJmd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Survivor Select</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">122,470</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">83,904</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--EnergizedMineralConcentrateMember_zr0zkyHoLKi8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Energized Mineral Concentrate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0666">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,047</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--IonizedCalMagMember_zcbfX7scUGK5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Ionized Cal-Mag</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">148,219</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,527</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--OmegaBlendMember_zslpoCg1cIPh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Omega Blend</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">272,332</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222,718</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--BetaMaxxMember_zFBHCEibRUgg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>BetaMaxx</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">137,447</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208,043</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--VegeFruitFiberMember_zKD0P0DckIMb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Vege Fruit Fiber</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0678">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65,757</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--IronMember_zqKvQRKr7jQc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Iron</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,697</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,114</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--YoungFormulaMember_zwDXHSYIX4Rj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Young Formula</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,403</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,425</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--OrganicYouthCarCleansingBarMember_zhkQlF7fn2S8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Organic Youth Care Cleansing Bar</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0687">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,137</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--ATPRMITOPlusMember_z3Dq7VueuIXa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">ATPR Mito+</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">271,493</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">183,800</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--LipomaskMember_zHMa8egFj19d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Lipomask</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0693">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,331</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--EnergetiqueMember_zIfNeHxtjAlg" style="vertical-align: bottom; background-color: White">
    <td>Energetique</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,089</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,574</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--TrimPlusMember_zkwcgP3YRps5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Trim+</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88,613</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,042</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--ProductHealthTherapiesMember_zCHcL6QqgpEh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Others &#8211; Products for the provision of complementary health therapies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">569,823</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0703">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--OthersMember_zDHxgz4Dsps5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,468</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0706">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zrDljTyzVArc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total revenues &#8211; products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,711,054</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,009,419</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_z2YRBKYgeNg4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Health and Wellness services</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">145,510</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,543</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--Revenues_zUKQbvvSwePf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total revenues &#8211; products and services</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,856,564</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,016,962</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock', window );">SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_zTYA4P9FOinb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Translation
of foreign currencies into US$1 have been made at the following exchange rates for the respective periods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zdv4I7CXhGol" style="display: none">SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zgy5lSiaUnqg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20211231_zsVB6e9RZDpg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hus-gaap--VariableRateAxis__custom--PeriodEndMYRMember_zFRhCxqqi3Eh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Period-end MYR : US$1 exchange rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">4.41</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">4.18</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hus-gaap--VariableRateAxis__custom--PeriodEndHKDMember_zLYf4zb3Voe5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Period-end HKD : US$1 exchange rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.80</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hus-gaap--VariableRateAxis__custom--PeriodEndHKDMember_ziM6JpnK0o6" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign currency exchange
    rate, translation</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.80</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20220101__20221231_zu9ykfzTy0w3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20210101__20211231_zaKDMyylVgMj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_405_ecustom--ForeignCurrencyExchangeRateAverage_hus-gaap--VariableRateAxis__custom--PeriodAverageMYRMember_zqsIpHu1yyE" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Period-average MYR : US$1 exchange rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">4.41</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">4.14</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ForeignCurrencyExchangeRateAverage_hus-gaap--VariableRateAxis__custom--PeriodAverageHKDMember_zecoVeo3Tg3a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Period-average HKD : US$1 exchange rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.83</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.77</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ForeignCurrencyExchangeRateAverage_hus-gaap--VariableRateAxis__custom--PeriodAverageHKDMember_zCDRKLJohb0b" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign currency exchange
    rate period average</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.83</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.77</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Estimated Useful Lives of Intangible Assets Net [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Estimated Useful Lives Of Property And Equipment [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992544407216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>VARIABLE INTEREST ENTITY (&#8220;VIE&#8221;) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock', window );">SCHEDULE OF VARIABLE INTEREST ENTITY</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfVariableInterestEntitiesTextBlock_zNdRAR4wzbY5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amount of the VIE&#8217;s assets and liabilities were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zQFexFWDKz4c" style="display: none">SCHEDULE OF VARIABLE INTEREST ENTITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_49A_20221231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_z5lVlw6Fn3tc" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_493_20211231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zI4DBiW68nWg" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsCurrent_iI_zUmQYchAUCB5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Current assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">3,350</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">18,850</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesCurrent_iNI_di_zZSjd8BHuSs8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(43,512</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(51,272</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--StockholdersEquity_iI_z24RgFPig1Bj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deficit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(40,162</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(32,422</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20221231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zIZ5onYFsdw1" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20211231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zEYYv5IBQbTb" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_ztcWNesxOZqa" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,609</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">17,493</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidTaxes_iI_z00YJcaIpYid" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Prepaid taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,741</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,357</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsCurrent_iI_zUgacGYqQEni" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,350</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,850</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iI_zSSpL7fZ4Wy3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts payable &#8211; intercompany</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">42,422</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">49,724</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--OtherPayablesRelatedPartyCurrent_iI_zCiPzH9XUjbi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other payables and accrued liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,090</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,548</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesCurrent_iI_zRheyKpvRmF7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">43,512</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">51,272</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockholdersEquity_iI_zKO7drUZdXNc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deficit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(40,162</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(32,422</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
summarized operating results of the VIE&#8217;s are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_49D_20220101__20221231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zxKoIUlQxhh4" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_495_20210101__20211231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_z0QiRSbSOepl" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_z2Fz4S6CfAZ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 2.5pt">Operating revenues</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0857">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0858">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--GrossProfit_zkzi7RwfRXOj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Gross profit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0860">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0861">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingIncomeLoss_ztX6z0oXxJq4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Loss from operations</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9,432</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(21,966</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLoss_zV42ojDKQhxc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9,432</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(27,966</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5747-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6228884-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfVariableInterestEntitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992544327008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS RECEIVABLE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">SCHEDULE OF ACCOUNTS RECEIVABLES - RELATED PARTY</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zovZssHaUBh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span id="xdx_8B8_z2Lb6cEO3jPb" style="display: none">SCHEDULE OF ACCOUNTS RECEIVABLES - RELATED PARTY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_498_20221231_zhuxswMdXScl" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_49A_20211231_z4sPQYFIQRLk" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccountsReceivableGrossCurrent_iI_pp0p0_maARAARzRRC_zWvEKK9iCda2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Accounts receivable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,826</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0896">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_pp0p0_msARAARzRRC_zGbqLTZYDSq7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0898">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0899">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsReceivableNetCurrent_iTI_pp0p0_mtARAARzRRC_zbtUjgGqE52" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,826</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0902">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992544288032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">SCHEDULE OF INVENTORIES</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zotCKPgQXxv4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zU8B3QydgPDg" style="display: none">SCHEDULE OF INVENTORIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td id="xdx_49A_20221231_zBaRxb2sOesg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td id="xdx_49E_20211231_zRW16l6SN7Ne" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; width: 64%; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; width: 2%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 14%; font-weight: bold; text-align: center">2022</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; width: 2%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 14%; font-weight: bold; text-align: center">2021</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InventoryFinishedGoods_iI_zyTB0EwcnZd5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Finished goods</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">46,277</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">375,535</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992546446496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAYMENTS AND DEPOSITS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_DisclosurePrepaymentsAndDepositsAbstract', window );"><strong>Prepayments And Deposits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">SCHEDULE OF PREPAID EXPENSES AND DEPOSITS</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zjdtaEGFgsBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_z5pL7RUdAnWe" style="display: none">SCHEDULE OF PREPAID EXPENSES AND DEPOSITS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_49F_20221231_zR4XRYcqQTfj" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_498_20211231_znAMLzPN5TLh" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ReceivablesFromSalesDistributors_iI_maCzFPV_zCUi5vUgbfJh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Receivables from sales distributors</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">43,596</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">115,379</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DepositsToSupplier_iI_maCzFPV_zi1WAsQlc8J2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Deposits to suppliers</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">147,504</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">301,233</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--PrepaidExpensesGross_iTI_maCzxAt_mtCzFPV_zx851PNPzPR4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">191,100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">416,612</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iNI_di_msCzxAt_ztK47EHkLdij" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Provision for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0932">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(121,095</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtCzxAt_zh5aznB2iZWf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">191,100</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">295,517</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">SCHEDULE OF CHANGES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zRnLg89Y2iH2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Movements
of allowance for doubtful accounts are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zIuXxCkXFkB3" style="display: none">SCHEDULE OF CHANGES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_499_20220101__20221231_zIMzlTah3pX8" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_494_20210101__20211231_zjYgUiIl1ba1" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_z8IiVjZTcvd4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Beginning balance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">121,095</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0941">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_zjRhyxAeJhv8" style="vertical-align: bottom; background-color: White">
    <td>Addition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0943">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121,514</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_di_zhkfGqoOLAC9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Write off</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(120,372</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0947">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AllowanceForDoubtfulAccountsReceivableExchangeRateEffect_zkAodHvfNy97" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange rate effect</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(723</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(419</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_zXdLcLP2wUDh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0952">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">121,095</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_DisclosurePrepaymentsAndDepositsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_DisclosurePrepaymentsAndDepositsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992544565136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">SCHEDULE OF PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--PropertyPlantAndEquipmentTextBlock_zmRWPBeyI347" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment, net consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B0_zJYY8Y96jaqi" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT, NET</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_490_20221231_zmnDw4egigNj" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_494_20211231_zGSBwYf9jRr2" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerAndOfficeEquipmentMember_zJTZVLonUMl7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Computer and office equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">87,428</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">82,298</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zT3bDv62yQu" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture &amp; fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">115,789</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122,185</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z7Y6kVTFQ22b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">191,965</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">202,570</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--VehicleMember_zP6q3kqDHDz3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Vehicle</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">93,535</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">98,702</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENz5ZB_zuXLsaldfBp1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">488,717</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">505,755</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENz5ZB_zNaotftUy1eb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(346,568</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(289,956</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz5ZB_zrGBUIeqXFsg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">142,149</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">215,799</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992541399120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">SCHEDULE OF INTANGIBLE ASSETS, NET</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zm6UnzTggnt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets, net, consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B7_zKqIDuKePe73" style="display: none">SCHEDULE OF INTANGIBLE ASSETS, NET</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_493_20221231_zd7VedRq0D5k" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_493_20211231_zZxbckCQ0w9a" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CapitalizedComputerSoftwareGross_iI_maCzFod_zrusbEBApco5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Computer software</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">55,348</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">34,453</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msCzFod_z66goRzTWTG3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(31,304</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(30,793</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtCzFod_z4FectFsIhM8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">24,044</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,660</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992541597744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN MARKETABLE SECURITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_DisclosureInvestmentInMarketableSecuritiesAbstract', window );"><strong>Investment In Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">SCHEDULE OF INVESTMENT IN MARKETABLE SECURITIES</a></td>
<td class="text"><p id="xdx_895_eus-gaap--MarketableSecuritiesTextBlock_zuGzrtr9rAUc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;<span id="xdx_8B0_zN99PDRxKP02" style="display: none">SCHEDULE OF INVESTMENT IN MARKETABLE SECURITIES</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20221231_z4RIpzJXVA29" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20211231_z8xbbM4gX3Kf" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_maMSNzd9C_zzkch15ow0Z2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Cost of investment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">89,001</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">577,035</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--TransferFromNonmarketableSecurity_iNI_pp0p0_di_msMSNzd9C_z4pyxkB70cWa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Transfer from non-marketable security</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1063">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--InvestmentsIncomeDividend_iNI_pp0p0_di_msMSNzd9C_z4XWyTJDvR08" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend income from Greenpro Capital Corp.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1065">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,939</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--MarketableSecuritiesUnrealizedHoldingLoss_iNI_pp0p0_di_msMSNzd9C_z67Y6b3K59S7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Unrealized holding loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(73,519</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(505,231</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--ExchangeRateEffectOnInvestmentInMarketableSecurites_iI_pp0p0_maMSNzd9C_zA1iT4Zoqkrc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange rate effect</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(295</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,742</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--MarketableSecuritiesNoncurrent_iTI_pp0p0_mtMSNzd9C_zQpdBZmA4Cng" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Investment in marketable securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">16,687</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">89,001</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_DisclosureInvestmentInMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_DisclosureInvestmentInMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992544432128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN NON-MARKETABLE SECURITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_DisclosureInvestmentInNonmarketableSecuritiesAbstract', window );"><strong>Investment In Non-marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_NonMarketableSecuritiesTableTextBlock', window );">SCHEDULE OF INVESTMENT IN NON MARKETABLE SECURITIES</a></td>
<td class="text"><p id="xdx_89E_ecustom--NonMarketableSecuritiesTableTextBlock_zBFVNM9h6jw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zsjdkcg96i46" style="display: none">SCHEDULE OF INVESTMENT IN NON MARKETABLE SECURITIES</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Phoenix Plus Corporation</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20221231__dei--LegalEntityAxis__custom--PhoenixPlusCorpMember_zXXHcTFvwT4a" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20211231__dei--LegalEntityAxis__custom--PhoenixPlusCorpMember_zdReaiw7n5o9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Phoenix Plus Corporation</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InvestmentOwnedAtCost_iI_maIINMSz0ls_zigDTIRmqOR9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Cost of investment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--TransferToInvestmentInMarketableSecurities_iNI_di_msIINMSz0ls_zpVXZpw00J8a" style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left; padding-bottom: 1.5pt">Less: Transfer to investment in marketable securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1093">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--InvestmentInNonMarketableSecuritiesNoncurrent_iTI_mtIINMSz0ls_z1Uxjbfm9Z17" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Investment in non-marketable securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1095">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_DisclosureInvestmentInNonmarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_DisclosureInvestmentInNonmarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_NonMarketableSecuritiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Marketable Securities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_NonMarketableSecuritiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992544452416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CUSTOMER DEPOSITS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_DisclosureCustomerDepositsAbstract', window );"><strong>Customer Deposits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_CustomerDepositsTableTextBlock', window );">SCHEDULE OF CUSTOMER DEPOSITS</a></td>
<td class="text"><p id="xdx_89D_ecustom--CustomerDepositsTableTextBlock_zHhQaYUa9k5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF CUSTOMER DEPOSITS</span></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221231_zow2nIkKZI36" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20211231_zTv7W3RRpuqb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--CustomerDeposits_iI_zwD3eV7Y1YXi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Customer deposits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">289,487</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">273,581</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--UnexpiredProductCoupons_iI_zpZlYuDLeHh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Unexpired product coupons</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">73,531</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,108</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DepositLiabilityCurrent_iI_zI1umsyIVJ32" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">363,018</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">279,689</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_CustomerDepositsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_CustomerDepositsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_DisclosureCustomerDepositsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_DisclosureCustomerDepositsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992544419920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER PAYABLES AND ACCRUED LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock', window );">SCHEDULE OF OTHER PAYABLES AND ACCRUED LIABILITIES</a></td>
<td class="text"><p id="xdx_899_ecustom--ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock_z0fAGKnF5AM" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zeSWMrAQEuWa" style="display: none">SCHEDULE OF OTHER PAYABLES AND ACCRUED LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_49C_20221231_zQIWaMMhHL12" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_49C_20211231_z45F1OSPJsFf" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maOAPAAz1Ku_zI8xwdf6tNn" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Professional fees</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">324,629</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">436,541</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--AccruedPromotionExpensesCurrent_iI_pp0p0_maOAPAAz1Ku_zK1vqfScw7Ti" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Promotion expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,583</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,024</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_maOAPAAz1Ku_zTU3Vl05AfI1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Payroll</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,164</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,669</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccruedSalesCommissionCurrent_iI_pp0p0_maOAPAAz1Ku_zBf7jn2I9sS" style="vertical-align: bottom; background-color: White">
    <td>Amounts held in eWallets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">216,049</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">223,781</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--AccruedTaxPenaltyCurrent_iI_pp0p0_maOAPAAz1Ku_zCTg4hKcqDfa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax penalty</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iI_pp0p0_maOAPAAz1Ku_zXbRWJ730LGf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">37,852</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">64,340</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--OtherAccountPayableAndAccruedLiabilities_iTI_pp0p0_mtOAPAAz1Ku_zooHneFb6om8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">713,277</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">858,355</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Other Payables And Accrued Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992544535296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY BALANCES AND TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">SCHEDULE OF RELATED PARTIES</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zl0oYWLAAj4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_z727ztZuIZn6" style="display: none">SCHEDULE OF RELATED PARTIES</span></span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center">Name of Related</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Party</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Relationship</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nature</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: left">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 22%; text-align: left">TH3 Technology Sdn Bhd (&#8220;TH3&#8221;)</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 22%; text-align: center"><span id="xdx_904_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_ziLC6cF8O0Hb" title="Relationship"><span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_zzSz5d5bIqm9" title="Relationship">Mr. How Kok Choong, the CEO and director of the Company is also a director of TH3</span></span></td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center">Prepayment of IT expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_zZAUIMTT8fOj" style="width: 14%; text-align: right" title="Due from related parties">1,273</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_zukwEs1YngT4" style="width: 14%; text-align: right" title="Due from related parties"><span style="-sec-ix-hidden: xdx2ixbrl1154">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">DSY Beauty Sdn Bhd (&#8220;DSY Beauty&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_903_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_z0694WTKbtY1" title="Relationship"><span id="xdx_901_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zeZmlYSi7375" title="Relationship">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</span></span></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Deposits for products</p>
                                                        <p style="margin-top: 0; margin-bottom: 0">purchases</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zwDZUnOh83dc" style="text-align: right" title="Due from related parties">9,261</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zByqRivjGxmc" style="text-align: right" title="Due from related parties"><span style="-sec-ix-hidden: xdx2ixbrl1162">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Agape ATP (Asia) Limited (&#8220;AATP Asia&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_900_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zHWmYpA622q9" title="Relationship"><span id="xdx_902_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zP3giNs1HF4d" title="Relationship">Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of AATP Asia</span></span></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90B_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zvM7Hh1mF5pj" title="Nature"><span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zJUFhY5rF4V1" title="Nature">Expenses paid for AATP Asia</span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zybPyNfOgw56" style="text-align: right" title="Due from related parties"><span style="-sec-ix-hidden: xdx2ixbrl1172">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_ziSokE5HMXP7" style="text-align: right" title="Due from related parties">2,214</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">Hostastay Sdn. Bhd. <br/>&#8220;Hostastay&#8221;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_904_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_z9WLCOVt2aPa" title="Relationship"><span id="xdx_90F_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_z3VsvnIpOAm2" title="Relationship">Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021</span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_903_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zdj7boQy7Z08" title="Nature"><span id="xdx_906_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zUYOiG4dFOU3" title="Nature">Sublease rent due from Hostastay</span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zpXdWXaREyb2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Due from related parties"><span style="-sec-ix-hidden: xdx2ixbrl1184">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zXiuGQBFncKe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Due from related parties">4,790</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20221231_zF4oFTU7cPKd" style="border-bottom: Black 2.5pt double; text-align: right" title="Due from related parties">10,534</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20211231_z5LEII8mzdAe" style="border-bottom: Black 2.5pt double; text-align: right" title="Due from related parties">7,004</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accounts
payable &#8211; related parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center">Name of Related</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Party</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Relationship</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nature</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="text-align: center; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 22%; text-align: left">CTA Nutriceuticals (Asia) Sdn Bhd (&#8220;CTA&#8221;)</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 22%; text-align: center"><span id="xdx_906_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zerXYsBJD1ta" title="Relationship"><span id="xdx_90E_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zqorjRRHLqeh" title="Relationship">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd</span></span></td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center"><span id="xdx_900_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zIWoggCpvyz9" title="Nature"><span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zHhxRv48SPpb" title="Nature">Purchases of products for the provision of complementary health therapies</span></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zPFD76jbZAm2" style="width: 14%; text-align: right" title="Accounts payable, related parties, current">25,387</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zNdbULlh8yt8" style="width: 14%; text-align: right" title="Accounts payable, related parties, current"><span style="-sec-ix-hidden: xdx2ixbrl1202">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">DSY Beauty Sdn Bhd (&#8220;DSY Beauty&#8221;)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_908_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zM1z2HcEGkuj" title="Relationship"><span id="xdx_906_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_z8IOZfRRQTP2" title="Relationship">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_904_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zc7oweQDOY3f" title="Nature">Purchases of beauty products</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zfU3NUY42Nfb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accounts payable, related parties, current">224</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zV5eQ932Q825" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accounts payable, related parties, current"><span style="-sec-ix-hidden: xdx2ixbrl1212">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20221231_zGBB1JB6CVq4" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts payable, related parties, current">25,611</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20211231_zZAdIF7v7Zaa" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts payable, related parties, current"><span style="-sec-ix-hidden: xdx2ixbrl1216">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.
RELATED PARTY BALANCES AND TRANSACTIONS (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related
party balances</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other payable - related parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Name of Related</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">As of December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Party</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Relationship</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nature</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="text-align: center; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 22%; text-align: left">CTA Nutriceuticals (Asia) Sdn Bhd (&#8220;CTA&#8221;)</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 22%; text-align: center"><span id="xdx_906_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdOneMember_zRZjLu2pyuSk" title="Relationship"><span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdOneMember_zC9td5yiQjm1" title="Relationship">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd</span></span></td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center"><span id="xdx_901_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdOneMember_zz6M3NDzdZ5d" title="Nature"><span id="xdx_90A_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdOneMember_zzwxLVUhJ7Gj" title="Nature">Purchase of products for general use</span></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdOneMember_z4MvZfHbEqh5" style="width: 14%; text-align: right" title="Due to related parties">2,149</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdOneMember_zEE4fagrL1fd" style="width: 14%; text-align: right" title="Due to related parties"><span style="-sec-ix-hidden: xdx2ixbrl1228">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">DSY Beauty Sdn Bhd (&#8220;DSY Beauty&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_900_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_zjX7ki6BoTY1" title="Relationship"><span id="xdx_903_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_zztblYDJrAed" title="Relationship">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</span></span></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_901_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_z0iOuRmJMVBf" title="Nature"><span id="xdx_904_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_zHVZ5TNJC34l" title="Nature">Purchase of products for general use</span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_z8Wmhm3hUI43" style="text-align: right" title="Due to related parties">2,147</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_zah7ZUjUINIk" style="text-align: right" title="Due to related parties"><span style="-sec-ix-hidden: xdx2ixbrl1240">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">Mr. How Kok Choong</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_901_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zzfHYp7VfMm6" title="Relationship"><span id="xdx_90C_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zXbRwDLsk895" title="Relationship">Mr. How Kok Choong, the CEO and director of the Company</span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_909_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_z6dwnfOeuOqg" title="Nature"><span id="xdx_907_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zGwXo2mC8cKd" title="Nature">Commission expense</span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zH4Rwm5s39Og" style="border-bottom: Black 1.5pt solid; text-align: right" title="Due to related parties">584</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zjnTizCPpH8g" style="border-bottom: Black 1.5pt solid; text-align: right" title="Due to related parties"><span style="-sec-ix-hidden: xdx2ixbrl1252">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pdp0_c20221231_zJbx1u9mu5C9" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to related parties">4,880</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pdp0_c20211231_zS1BhyQ3Bi9i" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to related parties"><span style="-sec-ix-hidden: xdx2ixbrl1256">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related
party transactions </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Purchases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Name of Related</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Party</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Relationship</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nature</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 22%; text-align: left">CTA Nutriceuticals (Asia) Sdn Bhd (&#8220;CTA&#8221;)</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 22%; text-align: center"><span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zG9btHnwadC2" title="Relationship"><span id="xdx_908_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zauLz8fCZTk7" title="Relationship">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd</span></span></td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center"><span id="xdx_90A_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zwQlhwdt3st7" title="Nature"><span id="xdx_90C_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zUTGwGNmJzUi" title="Nature">Purchases of products for the provision of complementary health therapies</span></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zEDJpcz6QUD3" style="width: 14%; text-align: right" title="Purchases">198,376</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zjNU7dGm447l" style="width: 14%; text-align: right" title="Purchases"><span style="-sec-ix-hidden: xdx2ixbrl1268">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">DSY Beauty Sdn Bhd (&#8220;DSY Beauty&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_908_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zIGdx9Bw1blh" title="Relationship"><span id="xdx_90C_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zPFuB2i5T166" title="Relationship">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</span></span></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90B_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zPv0pPRzwuc6" title="Nature"><span id="xdx_908_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zYrKqkNdAo55" title="Nature">Purchases of beauty products</span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zugqbvRWvu3l" style="text-align: right" title="Purchases">3,975</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zu6p5YJuNohk" style="text-align: right" title="Purchases">718</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">DSY Wellness &amp; Longevity Center Sdn Bhd (&#8220;DSYWLC&#8221;)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_906_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zbVboKp0GiI5" title="Relationship"><span id="xdx_903_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_ziSDJiKeBjU6" title="Relationship">Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC</span></span>.</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_900_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zUuiIpm9PQeb" title="Nature"><span id="xdx_900_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zZRPuzBVaJBf" title="Nature">Purchases of products for the provision of complementary health therapies</span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zjB80Z6q022f" style="border-bottom: Black 1.5pt solid; text-align: right" title="Purchases">124</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zUPPsxbNbbu7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Purchases"><span style="-sec-ix-hidden: xdx2ixbrl1292">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220101__20221231_zIZqZ8Ed99Nd" style="border-bottom: Black 2.5pt double; text-align: right" title="Purchases">202,475</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210101__20211231_zx3eXt89sgO2" style="border-bottom: Black 2.5pt double; text-align: right" title="Purchases">718</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.
RELATED PARTY BALANCES AND TRANSACTIONS (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related
party transactions</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
income</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Name
    of Related</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the years ended December 31,</span></td>
    <td>&#160;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Party</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Relationship</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Nature</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td>
    <td>&#160;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td>&#160;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 26%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Hostastay
    Sdn. Bhd.</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 20%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_900_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zqcHbYBaJJmd" style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_z2EvLexgEEyc">Mr.
    How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director
    of Hostastay as of April 21, 2021</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 14%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_900_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_z1nEmOAMZg66" style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zAKIFOJ42Gng">Sublease
    rental income due from Hostastay</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_ecustom--RelatedPartyOtherIncome_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_z6RcmQ3ozwGh" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Other income"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1302">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_ecustom--RelatedPartyOtherIncome_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_z7nXSW3qZRa4" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Other income"><span style="font-family: Times New Roman, Times, Serif">4,345</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_ecustom--RelatedPartyOtherIncome_pp0p0_c20220101__20221231_zuRLWr8prJsl" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Other income"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1306">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_ecustom--RelatedPartyOtherIncome_pp0p0_c20210101__20211231_z1H0garr44X9" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Other income"><span style="font-family: Times New Roman, Times, Serif">4,345</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
purchases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Name of Related</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Party</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Relationship</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nature</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 22%; text-align: left">CTA Nutriceuticals (Asia) Sdn Bhd (&#8220;CTA&#8221;)</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 22%; text-align: center"><span id="xdx_901_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdMember_zQpS1MGX9God" title="Relationship"><span id="xdx_904_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdMember_zQ7tlyF1WxH8" title="Relationship">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd</span></span></td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center"><span id="xdx_90A_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdMember_zOB0wRP6Zbwk" title="Nature"><span id="xdx_904_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdMember_zKuywerER7I5" title="Nature">Purchases of products for the provision of complementary health therapies</span></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdMember_zHyk1uIlG5X7" style="width: 14%; text-align: right" title="Other purchases">5,431</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdMember_zOJhGebFBwke" style="width: 14%; text-align: right" title="Other purchases"><span style="-sec-ix-hidden: xdx2ixbrl1320">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">DSY Beauty Sdn Bhd (&#8220;DSY Beauty&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zzmSc7AiZDU9" title="Relationship"><span id="xdx_90D_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zZszxc9zLCci" title="Relationship">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</span></span></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_z0Wk8Ark1EC9" title="Nature"><span id="xdx_90C_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zhWXpNnpqXsj" title="Nature">Purchases of beauty products</span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_z2yPLa3DzNw9" style="text-align: right" title="Other purchases">6,888</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zXmRjMkWYmi7" style="text-align: right" title="Other purchases"><span style="-sec-ix-hidden: xdx2ixbrl1332">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">DSY Wellness &amp; Longevity Center Sdn Bhd (&#8220;DSYWLC&#8221;)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_908_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z5Y8L65Fxfw5" title="Relationship"><span id="xdx_90E_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zCZxtEuEhEu8" title="Relationship">Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.</span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_901_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdMember_z9Arjnl5Pz17" title="Nature"><span id="xdx_903_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdMember_z6pp5SD6xYf5" title="Nature">Purchases of products for the provision of complementary health therapies</span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdMember_zhkqEQynYhXg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other purchases">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdMember_z9pDuZhyXAAd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other purchases"><span style="-sec-ix-hidden: xdx2ixbrl1344">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20220101__20221231_z76MRFD0m2B9" style="border-bottom: Black 2.5pt double; text-align: right" title="Other purchases">12,323</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20210101__20211231_zkBH9qsQYILf" style="border-bottom: Black 2.5pt double; text-align: right" title="Other purchases"><span style="-sec-ix-hidden: xdx2ixbrl1348">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AGAPE
ATP CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Currency
expressed in United States Dollars (&#8220;US$&#8221;), except for number of shares)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.
RELATED PARTY BALANCES AND TRANSACTIONS (CONT&#8217;D)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Related
party transactions</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
expense</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Name of Related</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Party</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Relationship</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nature</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 22%; text-align: left; padding-bottom: 1.5pt">Mr. How Kok Choong</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; width: 22%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_90C_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zu0Whq1PIPL8" title="Relationship"><span id="xdx_903_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_ziKt3iMOZKOf" title="Relationship">Mr. How Kok Choong, the CEO and director of the Company</span></span></td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center; padding-bottom: 1.5pt"><span id="xdx_900_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zwKUCUPMtWLb" title="Nature"><span id="xdx_904_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_z8acQHVXjMAf" title="Nature">Commission expense</span></span></td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--SalesCommissionsAndFees_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zDVS0V5gpANk" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Commission expense">16,590</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--SalesCommissionsAndFees_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_znsRavhRLPGj" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Commission expense">12,758</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--SalesCommissionsAndFees_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zLYgWsHkbrUl" style="border-bottom: Black 2.5pt double; text-align: right" title="Commission expense">16,590</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--SalesCommissionsAndFees_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zoRsvIlllO4i" style="border-bottom: Black 2.5pt double; text-align: right" title="Commission expense">12,758</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Name of Related</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Party</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Relationship</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Nature</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 22%; text-align: left">TH3 Technology Sdn Bhd (&#8220;TH3&#8221;)</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 22%; text-align: center"><span id="xdx_90E_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_z4iv32kYvk1l" title="Relationship"><span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_z0xuXefakGMb" title="Relationship">Mr. How Kok Choong, the CEO and director of the Company is also a director of TH3</span></span></td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 16%; text-align: center"><span id="xdx_90E_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_zQ6QjExXo1U7" title="Nature"><span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_zXGYWHCDNtCh" title="Nature">IT support services fee</span></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--RelatedPartyOtherExpenses_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_z8z2j3a0nVPd" style="width: 14%; text-align: right" title="Other expenses">56,450</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--RelatedPartyOtherExpenses_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_zABwXOfX473k" style="width: 14%; text-align: right" title="Other expenses"><span style="-sec-ix-hidden: xdx2ixbrl1376">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">Redboy Picture Sdn Bhd (&#8220;Redboy&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_908_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RedboyPictureSdnBhdMember_zTlZ7u9rRIy7" title="Relationship"><span id="xdx_907_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RedboyPictureSdnBhdMember_zi3zgmDv7iKd" title="Relationship">Mr. How Kok Choong, the CEO and director of the Company is also the director of Redboy</span></span></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90B_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RedboyPictureSdnBhdMember_z5yIEWjsXqtd" title="Nature"><span id="xdx_906_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RedboyPictureSdnBhdMember_zBJEOcGeyzn" title="Nature">Sponsorship fee</span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--RelatedPartyOtherExpenses_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RedboyPictureSdnBhdMember_zQ3qYXMAmiBj" style="text-align: right" title="Other expenses">22,686</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--RelatedPartyOtherExpenses_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RedboyPictureSdnBhdMember_z09R8ZOGeew9" style="text-align: right" title="Other expenses">718</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">DSY Wellness &amp; Longevity Center Sdn Bhd (&#8220;DSYWLC&#8221;)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_90C_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zcFhJLetkZFb" title="Relationship"><span id="xdx_901_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zK7nMlKX00y3" title="Relationship">Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.</span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"><span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_z7juN7qEQtMg" title="Nature"><span id="xdx_90C_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_z82d28JtijVi" title="Nature">Office rental expenses</span></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--RelatedPartyOtherExpenses_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zW53VjqvfB7a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other expenses">21,779</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--RelatedPartyOtherExpenses_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zHVhurNTFL4a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other expenses"><span style="-sec-ix-hidden: xdx2ixbrl1400">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--RelatedPartyOtherExpenses_c20220101__20221231_zVoXaAlg39Lf" style="border-bottom: Black 2.5pt double; text-align: right" title="Other expenses">100,915</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--RelatedPartyOtherExpenses_c20210101__20211231_zLvySw9yI4bi" style="border-bottom: Black 2.5pt double; text-align: right" title="Other expenses">718</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992541308432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NON-CONTROLLING INTEREST (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_ScheduleOfNonControllingInterestTableTextBlock', window );">SCHEDULE OF NON CONTROLLING INTEREST</a></td>
<td class="text"><p id="xdx_89E_ecustom--ScheduleOfNonControllingInterestTableTextBlock_zItFSSqNjvNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s non-controlling interest consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zWLqh61alVOc" style="display: none">SCHEDULE OF NON CONTROLLING INTEREST</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_496_20221231_z8n1xYUN2KRc" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_497_20211231_zLxvsRVAtnza" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">DSY Wellness:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--NonControllingInterestPaidinCapital_iI_maNCINCzwzX_maNCINCzgCA_ztnQP5spxhD7" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Paid-in capital</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">97</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">97</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--NonControllingInterestAccumulatedDeficit_iI_maNCINCzwzX_maNCINCzgCA_zdhlZiZBS117" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accumulated surplus (deficit)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,384</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(436</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--NonControllingInterestAccumulatedOtherComprehensiveIncome_iI_maNCINCzwzX_maNCINCzgCA_zamMSBSCAIV8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated other comprehensive income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">32</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--NonControllingInterestNonControllingInterestGross_iTI_mtNCINCzgCA_zFjLER4eaPU1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Non Controlling interest Gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,513</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(336</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--NonControllingInterestAsl_iI_maMIzbTf_zhASwFT68lgk" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">ASL</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1464">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1465">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--MinorityInterest_iI_zHlazE5YlbS3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">20,513</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(336</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_ScheduleOfNonControllingInterestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Non Controlling Interest [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_ScheduleOfNonControllingInterestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992547739904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAX</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zbYrNSfpqOqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
United States and foreign components of loss before income taxes were comprised of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BC_zbw9RcdCJECe" style="display: none">SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAX</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20220101__20221231_zILNGugjEUVd" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20210101__20211231_zJModJ8xjfzb" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax jurisdictions from:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_zEfm59KnFAFd" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Local &#8211; United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(736,946</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(706,659</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_hsrt--StatementGeographicalAxis__country--MY_zKjnqwH7pae9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign &#8211; Malaysia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(864,794</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,064,314</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_hsrt--StatementGeographicalAxis__country--HK_zEcVHq1RW1wl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign &#8211; Hong Kong</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(68,394</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(616,640</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_hsrt--StatementGeographicalAxis__country--HK_zQZ4XU7Pz09d" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign, Tax jurisdictions</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(68,394</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(616,640</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ze9d2YDOMzhe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Loss before income tax</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,670,134</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,387,613</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">SCHEDULE OF PROVISION FOR INCOME TAX</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zvnkRDjToTH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
benefit of (provision for) income taxes consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zd1FtMJnpQK1" style="display: none">SCHEDULE OF PROVISION FOR INCOME TAX</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20220101__20221231_zyjO9HHS05l5" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20210101__20211231_zaZTlg3JC3n7" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zMK5QD2RIBb5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Current:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_iN_di_maITEBzQW2_z60POG4Cj7X3" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%">- Local</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1494">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(22,205</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--CurrentForeignTaxExpenseBenefit_iN_di_maITEBzQW2_zx6jaeMCGMG5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>- Foreign</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,962</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(104,735</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zf5oiH7PaL34" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Deferred:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_iN_di_maITEBzQW2_zYXpTW31pcRa" style="vertical-align: bottom; background-color: White">
    <td>- Local</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1503">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1504">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_iN_di_maITEBzQW2_zyDwuD45MHn9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">- Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">15,017</p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,127</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_iNT_pp0p0_di_mtITEBzQW2_zJnYG9RGYQ28" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Benefit of (Provision for) income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,055</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(137,067</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">SCHEDULE OF EFFECTIVE INCOME TAX RATE</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zs7koufBlsPe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table reconciles the local (United States) statutory rates to the Company&#8217;s effective tax rate for the periods indicated
below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_ztzQ54IozAzh" style="display: none">SCHEDULE OF EFFECTIVE INCOME TAX RATE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20220101__20221231_zHCxR3XC3b55" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20210101__20211231_zgGgyOd8ejc8" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_zYddPEdno3Oc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">U.S. statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">21.0</td><td style="width: 3%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">21.0</td><td style="width: 3%; text-align: left">%</td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_z5DvnDY0tKVa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22.9</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17.0</td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_dp_uPure_zQNCTYXfjhb5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Differential tax rate in Malaysia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.0</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_uPure_zsrG7A1gpjp3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Permanent difference</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">1.2</p></td><td style="padding-bottom: 1.5pt; text-align: left">%<span id="xdx_F27_zatEtQtRgLT8" style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12.7</td><td style="padding-bottom: 1.5pt; text-align: left">)%<span id="xdx_F2B_zOwAJzLC1RXf" style="font-family: Times New Roman, Times, Serif">(2)</span></td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_uPure_zXyJa4KL4mx9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Effective tax rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.3</td><td style="padding-bottom: 2.5pt; text-align: left">%&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5.7</td><td style="padding-bottom: 2.5pt; text-align: left">)%&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    amount comprised:</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F03_zytERM4xm703" style="display: none; font-family: Times New Roman, Times, Serif">(1)</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zOWyPY8rPQ44" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    amount comprised:  (1.0)% being expenses
    incurred in AATP LB, ASL, SEA and WATP that are not deductible in the Malaysia tax return.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTQ0hFRFVMRSBPRiBFRkZFQ1RJVkUgSU5DT01FIFRBWCBSQVRFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dp_uPure_c20220101__20221231__srt--ConsolidatedEntitiesAxis__custom--AATPLBASLSEAAndWATPMember_zi6DGrGLC2ag" title="Tax percentage">1.2</span>%
    being expenses incurred in AATP LB, ASL, SEA and WATP that are not deductible in the Malaysia tax return.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    amount comprised:</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F05_z2wAecmBq731" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zWKUhUXw4cdk" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    amount comprised: 6.2% being income derived in AATP HK that were not taxable in the Malaysia tax returns; and 6.7% being expenses
    incurred in AATP LB, ASL, SEA, WATP, and DSY Wellness that are not deductible in the Malaysia tax return.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTQ0hFRFVMRSBPRiBFRkZFQ1RJVkUgSU5DT01FIFRBWCBSQVRFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dp_uPure_c20210101__20211231__srt--ConsolidatedEntitiesAxis__custom--AATPHKMember_z6xpV1RMQVUj" title="Tax percentage">6.2</span>%
    being income derived in AATP HK that were not taxable in the Malaysia tax returns; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTQ0hFRFVMRSBPRiBFRkZFQ1RJVkUgSU5DT01FIFRBWCBSQVRFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dp_uPure_c20210101__20211231__srt--ConsolidatedEntitiesAxis__custom--AATPLBASLSEAWATPAndDSYMember_zbGeGh7tMbTi" title="Tax percentage">6.5</span>%
    being expenses incurred in AATP LB, ASL, SEA, WATP, and DSY Wellness that are not deductible in the Malaysia tax return.</span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">SCHEDULE OF DEFERRED TAX ASSETS</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zfEpPIcQn1Lf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the significant components of the aggregate deferred tax assets of the Company as of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zWpLBFPc1Dkb" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_49A_20221231_zn52KdWrhKTj" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_490_20211231_z0VTgYqVbouf" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_hsrt--StatementGeographicalAxis__country--US_zVEaoySimCW6" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Net operating loss carry forwards in U.S.</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">284,959</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">153,061</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_hsrt--StatementGeographicalAxis__country--MY_zKdi2QR162R4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net operating loss carry forwards in Malaysia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">408,226</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">227,106</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_hsrt--StatementGeographicalAxis__country--MY_z1c62vy6Wc2h" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net operating loss carry forwards in Malaysia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">408,226</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">227,106</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_c20221231_zoFkfth0N4jk" style="text-align: right" title="Less: valuation allowance">(693,185</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_c20211231_zHah2jn5TAA3" style="text-align: right" title="Less: valuation allowance">(380,167</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DeferredTaxLiabilitiesDepreciation_iI_zz9ivyR9T0h9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1606">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15,574</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iNI_di_zrvCGHXA3RVl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Deferred tax liabilities, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1609">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(15,574</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992544445248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">SCHEDULE OF LEASE COMMITMENTS</a></td>
<td class="text"><p id="xdx_894_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z19xei46SuY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
five-year maturity of the Company&#8217;s operating lease liabilities is as follow:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B8_zPzwct6CWzei" style="display: none">SCHEDULE OF LEASE COMMITMENTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_498_20221231_zelUUryFsmN9" style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Twelve Months Ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating lease liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzA1T_znNAabTgceb9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">84,146</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterNextTwelveMonths_iI_pp0p0_maLOLLPzA1T_zVWVdRWGvhwa" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1691">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzA1T_zr1jivH6QUx5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84,146</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zxPaMYfFvuCg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,439</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zbhS2P8SMYie" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">82,707</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992546385152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF SUBSIDIARIES AND ASSOCIATES (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 11, 2021</div></th>
<th class="th"><div>May 08, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_SubsidiaryCompanyMember', window );">Subsidiary Company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_NameOftheCompany', window );">Subsidiary company name</a></td>
<td class="text">Agape ATP Corporation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_PlaceAndDateOfIncorporation', window );">Place and date of incorporation</a></td>
<td class="text">Labuan,  March 6, 2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_ParticularsOfIssuedCapital', window );">Particulars of issued capital</a></td>
<td class="text">100 shares of ordinary share of US$1 each<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_PrincipalActivities', window );">Principal activities</a></td>
<td class="text">Investment holding<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Proportional of ownership interest and voting power held</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_SubsidiaryCompanyOneMember', window );">Subsidiary Company One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_NameOftheCompany', window );">Subsidiary company name</a></td>
<td class="text">Agape ATP International Holding Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_PlaceAndDateOfIncorporation', window );">Place and date of incorporation</a></td>
<td class="text">Hong Kong, June 1, 2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_ParticularsOfIssuedCapital', window );">Particulars of issued capital</a></td>
<td class="text">1,000,000 shares of ordinary share of HK$1 each<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_PrincipalActivities', window );">Principal activities</a></td>
<td class="text">Wholesaling of health and wellness products; and health solution advisory services<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Proportional of ownership interest and voting power held</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_SubsidiaryCompanyTwoMember', window );">Subsidiary Company Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_NameOftheCompany', window );">Subsidiary company name</a></td>
<td class="text">Agape Superior Living Sdn. Bhd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_PlaceAndDateOfIncorporation', window );">Place and date of incorporation</a></td>
<td class="text">Malaysia,  August 8, 2003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_ParticularsOfIssuedCapital', window );">Particulars of issued capital</a></td>
<td class="text">9,590,598 shares of ordinary share of RM1 each<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_PrincipalActivities', window );">Principal activities</a></td>
<td class="text">Health and wellness products and health solution advisory services via network marketing<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Proportional of ownership interest and voting power held</a></td>
<td class="nump">99.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.99%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_SubsidiaryCompanyThreeMember', window );">Subsidiary Company Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_NameOftheCompany', window );">Subsidiary company name</a></td>
<td class="text">Agape S.E.A. Sdn. Bhd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_PlaceAndDateOfIncorporation', window );">Place and date of incorporation</a></td>
<td class="text">Malaysia,  March 4, 2004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_ParticularsOfIssuedCapital', window );">Particulars of issued capital</a></td>
<td class="text">2 shares of ordinary share of RM1 each<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_PrincipalActivities', window );">Principal activities</a></td>
<td class="text">VIE of Agape Superior Living Sdn. Bhd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Proportional of ownership interest and voting power held</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_SubsidiaryCompanyFourMember', window );">Subsidiary Company Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_NameOftheCompany', window );">Subsidiary company name</a></td>
<td class="text">Wellness ATP International Holdings Sdn, Bhd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_PlaceAndDateOfIncorporation', window );">Place and date of incorporation</a></td>
<td class="text">Malaysia,  September 11, 2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_ParticularsOfIssuedCapital', window );">Particulars of issued capital</a></td>
<td class="text">100 shares of ordinary share of RM1 each<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_PrincipalActivities', window );">Principal activities</a></td>
<td class="text">The promotion of wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Proportional of ownership interest and voting power held</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_SubsidiaryCompanyFiveMember', window );">Subsidiary Company Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_NameOftheCompany', window );">Subsidiary company name</a></td>
<td class="text">DSY Wellness International Sdn Bhd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_PlaceAndDateOfIncorporation', window );">Place and date of incorporation</a></td>
<td class="text">Malaysia,  November 11, 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_ParticularsOfIssuedCapital', window );">Particulars of issued capital</a></td>
<td class="text">1,000 shares of ordinary share of RM1 each<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_PrincipalActivities', window );">Principal activities</a></td>
<td class="text">Provision of complementary health therapies<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Proportional of ownership interest and voting power held</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_NameOftheCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the company name.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_NameOftheCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_ParticularsOfIssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Particulars of issued capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_ParticularsOfIssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_PlaceAndDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Place and date of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_PlaceAndDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_PrincipalActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Principal activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_PrincipalActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_SubsidiaryCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_SubsidiaryCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_SubsidiaryCompanyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_SubsidiaryCompanyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_SubsidiaryCompanyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_SubsidiaryCompanyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_SubsidiaryCompanyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_SubsidiaryCompanyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_SubsidiaryCompanyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_SubsidiaryCompanyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_SubsidiaryCompanyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_SubsidiaryCompanyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992538286512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION AND BUSINESS BACKGROUND (Details Narrative) - shares<br></strong></div></th>
<th class="th"><div>May 08, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 11, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=AATP_ShareExchangeAgreementMember', window );">Share Exchange Agreement [Member] | Mr.How Kok Choong [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period acquisitions, shares</a></td>
<td class="nump">9,590,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_AgapeATPInternationalHoldingLimitedMember', window );">Agape ATP International Holding Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_SubsidiaryCompanyTwoMember', window );">Subsidiary Company Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest percentage</a></td>
<td class="nump">99.99%<span></span>
</td>
<td class="nump">99.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_SubsidiaryCompanyFiveMember', window );">Subsidiary Company Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=AATP_ShareExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=AATP_ShareExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=AATP_MrHowKokChoongMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=AATP_MrHowKokChoongMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_AgapeATPInternationalHoldingLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_AgapeATPInternationalHoldingLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_SubsidiaryCompanyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_SubsidiaryCompanyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_SubsidiaryCompanyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_SubsidiaryCompanyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992538287792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property and equipment, useful lives</a></td>
<td class="text">Lease
    Term<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905813&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992545613504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer Software, Intangible Asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives of intangible assets</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992538380192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF DIS-AGGREGATED INFORMATION OF REVENUES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues &#8211; products and services</a></td>
<td class="nump">$ 1,856,564<span></span>
</td>
<td class="nump">$ 1,016,962<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=AATP_SurvivorSelectMember', window );">Survivor Select [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues &#8211; products and services</a></td>
<td class="nump">122,470<span></span>
</td>
<td class="nump">83,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=AATP_EnergizedMineralConcentrateMember', window );">Energized Mineral Concentrate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues &#8211; products and services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">52,047<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=AATP_IonizedCalMagMember', window );">Ionized Cal Mag [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues &#8211; products and services</a></td>
<td class="nump">148,219<span></span>
</td>
<td class="nump">39,527<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=AATP_OmegaBlendMember', window );">Omega Blend [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues &#8211; products and services</a></td>
<td class="nump">272,332<span></span>
</td>
<td class="nump">222,718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=AATP_BetaMaxxMember', window );">Beta Maxx [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues &#8211; products and services</a></td>
<td class="nump">137,447<span></span>
</td>
<td class="nump">208,043<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=AATP_VegeFruitFiberMember', window );">Vege Fruit Fiber [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues &#8211; products and services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">65,757<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=AATP_IronMember', window );">Iron [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues &#8211; products and services</a></td>
<td class="nump">16,697<span></span>
</td>
<td class="nump">28,114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=AATP_YoungFormulaMember', window );">Young Formula [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues &#8211; products and services</a></td>
<td class="nump">31,403<span></span>
</td>
<td class="nump">52,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=AATP_OrganicYouthCarCleansingBarMember', window );">Organic Youth Car Cleansing Bar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues &#8211; products and services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,137<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=AATP_ATPRMITOPlusMember', window );">A T P R M I T O Plus [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues &#8211; products and services</a></td>
<td class="nump">271,493<span></span>
</td>
<td class="nump">183,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=AATP_LipomaskMember', window );">Lipomask [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues &#8211; products and services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">15,331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=AATP_EnergetiqueMember', window );">Energetique [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues &#8211; products and services</a></td>
<td class="nump">49,089<span></span>
</td>
<td class="nump">25,574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=AATP_TrimPlusMember', window );">Trim Plus [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues &#8211; products and services</a></td>
<td class="nump">88,613<span></span>
</td>
<td class="nump">27,042<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=AATP_ProductHealthTherapiesMember', window );">Product Health Therapies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues &#8211; products and services</a></td>
<td class="nump">569,823<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=AATP_OthersMember', window );">Others [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues &#8211; products and services</a></td>
<td class="nump">3,468<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues &#8211; products and services</a></td>
<td class="nump">1,711,054<span></span>
</td>
<td class="nump">1,009,419<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=AATP_HealthAndWellnessServicesMember', window );">Health and Wellness Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues &#8211; products and services</a></td>
<td class="nump">$ 145,510<span></span>
</td>
<td class="nump">$ 7,543<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=AATP_SurvivorSelectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=AATP_SurvivorSelectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=AATP_EnergizedMineralConcentrateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=AATP_EnergizedMineralConcentrateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=AATP_IonizedCalMagMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=AATP_IonizedCalMagMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=AATP_OmegaBlendMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=AATP_OmegaBlendMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=AATP_BetaMaxxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=AATP_BetaMaxxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=AATP_VegeFruitFiberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=AATP_VegeFruitFiberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=AATP_IronMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=AATP_IronMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=AATP_YoungFormulaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=AATP_YoungFormulaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=AATP_OrganicYouthCarCleansingBarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=AATP_OrganicYouthCarCleansingBarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=AATP_ATPRMITOPlusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=AATP_ATPRMITOPlusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=AATP_LipomaskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=AATP_LipomaskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=AATP_EnergetiqueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=AATP_EnergetiqueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=AATP_TrimPlusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=AATP_TrimPlusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=AATP_ProductHealthTherapiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=AATP_ProductHealthTherapiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=AATP_OthersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=AATP_OthersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=AATP_HealthAndWellnessServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=AATP_HealthAndWellnessServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992541414016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=AATP_PeriodEndMYRMember', window );">Period End M Y R [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency exchange rate, translation</a></td>
<td class="nump">4.41<span></span>
</td>
<td class="nump">4.18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=AATP_PeriodEndHKDMember', window );">Period End H K D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency exchange rate, translation</a></td>
<td class="nump">7.80<span></span>
</td>
<td class="nump">7.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=AATP_PeriodAverageMYRMember', window );">Period Average M Y R [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_ForeignCurrencyExchangeRateAverage', window );">Foreign currency exchange rate period average</a></td>
<td class="nump">4.41<span></span>
</td>
<td class="nump">4.14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=AATP_PeriodAverageHKDMember', window );">Period-average HKD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_ForeignCurrencyExchangeRateAverage', window );">Foreign currency exchange rate period average</a></td>
<td class="nump">7.83<span></span>
</td>
<td class="nump">7.77<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_ForeignCurrencyExchangeRateAverage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign currency exchange rate period average.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_ForeignCurrencyExchangeRateAverage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32618-110901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=AATP_PeriodEndMYRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=AATP_PeriodEndMYRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=AATP_PeriodEndHKDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=AATP_PeriodEndHKDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=AATP_PeriodAverageMYRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=AATP_PeriodAverageMYRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=AATP_PeriodAverageHKDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=AATP_PeriodAverageHKDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992541514576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>MYR (RM) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, allowance for credit loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_InventriesWriteDown', window );">Inventories write-down</a></td>
<td class="nump">5,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_InventoryWriteOff', window );">Inventories write off</a></td>
<td class="nump">142,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Wrote-off allowance for doubtful accounts</a></td>
<td class="nump">120,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_AllowanceForDoubtfulAccountsReceivablesCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_ForfeitedCouponIncome', window );">Value of coupons</a></td>
<td class="nump">7,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="nump">666,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,856,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,016,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Selling expenses</a></td>
<td class="nump">361,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">394,682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising costs</a></td>
<td class="nump">4,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesCommissionsAndFees', window );">Commission expenses</a></td>
<td class="nump">405,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined contribution plan expense</a></td>
<td class="nump">$ 133,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement', window );">Income tax description</a></td>
<td class="text">greater than 50%<span></span>
</td>
<td class="text">greater than 50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Income tax examination, penalties and interest expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDescription', window );">Noncontrolling interest, description</a></td>
<td class="text">Non-controlling
interest consists of 40% of the equity interests of DSY Wellness held by an individual and approximately 0.01% (2 ordinary shares out
of 9,590,598 shares) of the equity interests of ASL held by two individuals<span></span>
</td>
<td class="text">Non-controlling
interest consists of 40% of the equity interests of DSY Wellness held by an individual and approximately 0.01% (2 ordinary shares out
of 9,590,598 shares) of the equity interests of ASL held by two individuals<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities outstanding | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AATP_SocialSecurityOrganizationMember', window );">Social Security Organization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_SalaryPercentage', window );">Salary percentage</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_MonthlySalary', window );">Monthly salary | RM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">RM 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AATP_EmployeesProvidentFundMember', window );">Employees Provident Fund [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_SalaryPercentage', window );">Salary percentage</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_MonthlySalary', window );">Monthly salary | RM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">RM 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AATP_EmployeesProvidentFundMember', window );">Employees Provident Fund [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_SalaryPercentage', window );">Salary percentage</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_MonthlySalary', window );">Monthly salary | RM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">RM 5,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AATP_EmploymentInsuranceSystemMember', window );">Employment Insurance System [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_SalaryPercentage', window );">Salary percentage</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_MonthlySalary', window );">Monthly salary | RM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">RM 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AATP_HumanResourceDevelopmentFundMember', window );">Human Resource Development Fund [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_SalaryPercentage', window );">Salary percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=AATP_HealthAndWellnessServicesMember', window );">Health and Wellness Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="nump">$ 17,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">145,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,543<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember', window );">Shipping and Handling [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Selling expenses</a></td>
<td class="nump">$ 16,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,054<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_AllowanceForDoubtfulAccountsReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowance for doubtful accounts,</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_AllowanceForDoubtfulAccountsReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_ForfeitedCouponIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Forfeited coupon income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_ForfeitedCouponIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_InventoryWriteOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory write off.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_InventoryWriteOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_InventriesWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventries write down.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_InventriesWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_MonthlySalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monthly salary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_MonthlySalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_SalaryPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Salary percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_SalaryPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 15<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121825205&amp;loc=d3e27249-109313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of noncontrolling interest which might include background information, terms of the ownership arrangement, and type and terms of equity interest owned by the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesCommissionsAndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesCommissionsAndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized in the period that are directly related to the selling and distribution of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=AATP_SocialSecurityOrganizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=AATP_SocialSecurityOrganizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=AATP_EmployeesProvidentFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=AATP_EmployeesProvidentFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=AATP_EmploymentInsuranceSystemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=AATP_EmploymentInsuranceSystemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=AATP_HumanResourceDevelopmentFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=AATP_HumanResourceDevelopmentFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=AATP_HealthAndWellnessServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=AATP_HealthAndWellnessServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992546275200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF VARIABLE INTEREST ENTITY (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingActivityGainsAndLossesLineItems', window );"><strong>Trading Activity, Gains and Losses, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">$ 2,028,534<span></span>
</td>
<td class="nump">$ 3,912,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="num">(1,229,295)<span></span>
</td>
<td class="num">(1,312,841)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Net deficit</a></td>
<td class="nump">1,541,941<span></span>
</td>
<td class="nump">3,312,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">1,438,430<span></span>
</td>
<td class="nump">2,597,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid taxes</a></td>
<td class="nump">339,367<span></span>
</td>
<td class="nump">636,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,229,295<span></span>
</td>
<td class="nump">1,312,841<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Operating revenues</a></td>
<td class="nump">1,856,564<span></span>
</td>
<td class="nump">1,016,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">1,190,522<span></span>
</td>
<td class="nump">719,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(1,533,266)<span></span>
</td>
<td class="num">(1,858,568)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,686,899)<span></span>
</td>
<td class="num">(2,524,244)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingActivityByTypeAxis=us-gaap_VariableIncomeInterestRateMember', window );">Variable Income Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingActivityGainsAndLossesLineItems', window );"><strong>Trading Activity, Gains and Losses, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">3,350<span></span>
</td>
<td class="nump">18,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="num">(43,512)<span></span>
</td>
<td class="num">(51,272)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Net deficit</a></td>
<td class="num">(40,162)<span></span>
</td>
<td class="num">(32,422)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">1,609<span></span>
</td>
<td class="nump">17,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid taxes</a></td>
<td class="nump">1,741<span></span>
</td>
<td class="nump">1,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable &#8211; intercompany</a></td>
<td class="nump">42,422<span></span>
</td>
<td class="nump">49,724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_OtherPayablesRelatedPartyCurrent', window );">Other payables and accrued liabilities</a></td>
<td class="nump">1,090<span></span>
</td>
<td class="nump">1,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">43,512<span></span>
</td>
<td class="nump">51,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Operating revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(9,432)<span></span>
</td>
<td class="num">(21,966)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,432)<span></span>
</td>
<td class="num">$ (27,966)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_OtherPayablesRelatedPartyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other payables - related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_OtherPayablesRelatedPartyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingActivityGainsAndLossesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingActivityGainsAndLossesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingActivityByTypeAxis=us-gaap_VariableIncomeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingActivityByTypeAxis=us-gaap_VariableIncomeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992541399120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>VARIABLE INTEREST ENTITY (&#8220;VIE&#8221;) (Details Narrative)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_SubsidiaryCompanyThreeMember', window );">Subsidiary Company Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_SubsidiaryCompanyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_SubsidiaryCompanyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992547828912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CASH AND CASH EQUIVALENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,438,430<span></span>
</td>
<td class="nump">$ 2,597,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash in bank</a></td>
<td class="nump">513,152<span></span>
</td>
<td class="nump">554,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TimeDeposits', window );">Time deposits</a></td>
<td class="nump">914,811<span></span>
</td>
<td class="nump">1,975,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TimeDepositLiabilityUninsured', window );">Time deposit uninsured</a></td>
<td class="nump">$ 231,187<span></span>
</td>
<td class="nump">$ 295,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits', window );">Percentage of Interest rate for time deposits</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits', window );">Percentage of Interest rate for time deposits</a></td>
<td class="nump">1.88%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of interest-bearing domestic time deposit liabilities to total deposit liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimeDepositLiabilityUninsured">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of uninsured time deposit liability. Excludes uninsured time deposit liability in excess of Federal Deposit Insurance Corporation (FDIC) insurance limit or similar state deposit insurance regime in United States of America (US).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1406<br> -Paragraph (f)<br> -Subparagraph (2)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimeDepositLiabilityUninsured</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimeDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of time deposit liabilities, including certificates of deposit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116652737&amp;loc=d3e64164-112818<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.12)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimeDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992541612976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ACCOUNTS RECEIVABLES - RELATED PARTY (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 2,826<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Total</a></td>
<td class="nump">$ 2,826<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992629484528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF INVENTORIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">$ 46,277<span></span>
</td>
<td class="nump">$ 375,535<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992542674080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_InventriesWriteDown', window );">Inventory write-down</a></td>
<td class="nump">$ 5,307<span></span>
</td>
<td class="nump">$ 36,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_InventoryWriteOff', window );">Inventory write- off</a></td>
<td class="nump">$ 142,466<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_InventoryWriteOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory write off.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_InventoryWriteOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_InventriesWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventries write down.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_InventriesWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992538320800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PREPAID EXPENSES AND DEPOSITS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_DisclosurePrepaymentsAndDepositsAbstract', window );"><strong>Prepayments And Deposits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_ReceivablesFromSalesDistributors', window );">Receivables from sales distributors</a></td>
<td class="nump">$ 43,596<span></span>
</td>
<td class="nump">$ 115,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_DepositsToSupplier', window );">Deposits to suppliers</a></td>
<td class="nump">147,504<span></span>
</td>
<td class="nump">301,233<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_PrepaidExpensesGross', window );">Subtotal</a></td>
<td class="nump">191,100<span></span>
</td>
<td class="nump">416,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables', window );">Less: Provision for doubtful accounts</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(121,095)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 191,100<span></span>
</td>
<td class="nump">$ 295,517<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_DepositsToSupplier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deposits to supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_DepositsToSupplier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_DisclosurePrepaymentsAndDepositsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_DisclosurePrepaymentsAndDepositsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_PrepaidExpensesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_PrepaidExpensesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_ReceivablesFromSalesDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables from sales distributors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_ReceivablesFromSalesDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992541852160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF CHANGES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_DisclosurePrepaymentsAndDepositsAbstract', window );"><strong>Prepayments And Deposits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Beginning balance</a></td>
<td class="nump">$ 121,095<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease', window );">Addition</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">121,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Write off</a></td>
<td class="num">(120,372)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_AllowanceForDoubtfulAccountsReceivableExchangeRateEffect', window );">Exchange rate effect</a></td>
<td class="num">(723)<span></span>
</td>
<td class="num">(419)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 121,095<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_AllowanceForDoubtfulAccountsReceivableExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowance for doubtful accounts receivable exchange rate effect.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_AllowanceForDoubtfulAccountsReceivableExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_DisclosurePrepaymentsAndDepositsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_DisclosurePrepaymentsAndDepositsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992543648592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 488,717<span></span>
</td>
<td class="nump">$ 505,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(346,568)<span></span>
</td>
<td class="num">(289,956)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total</a></td>
<td class="nump">142,149<span></span>
</td>
<td class="nump">215,799<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=AATP_ComputerAndOfficeEquipmentMember', window );">Computer And Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">87,428<span></span>
</td>
<td class="nump">82,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">115,789<span></span>
</td>
<td class="nump">122,185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">191,965<span></span>
</td>
<td class="nump">202,570<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=AATP_VehicleMember', window );">Vehicle [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 93,535<span></span>
</td>
<td class="nump">$ 98,702<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=AATP_ComputerAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=AATP_ComputerAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=AATP_VehicleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=AATP_VehicleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992629455072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 71,754<span></span>
</td>
<td class="nump">$ 75,797<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992545462848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF INTANGIBLE ASSETS, NET (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareGross', window );">Computer software</a></td>
<td class="nump">$ 55,348<span></span>
</td>
<td class="nump">$ 34,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: accumulated amortization</a></td>
<td class="num">(31,304)<span></span>
</td>
<td class="num">(30,793)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 24,044<span></span>
</td>
<td class="nump">$ 3,660<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992544256912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, NET (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 2,122<span></span>
</td>
<td class="nump">$ 1,961<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992541288464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF INVESTMENT IN MARKETABLE SECURITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_DisclosureInvestmentInMarketableSecuritiesAbstract', window );"><strong>Investment In Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Cost of investment</a></td>
<td class="nump">$ 89,001<span></span>
</td>
<td class="nump">$ 577,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_TransferFromNonmarketableSecurity', window );">Transfer from non-marketable security</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_InvestmentsIncomeDividend', window );">Dividend income from Greenpro Capital Corp.</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">18,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_MarketableSecuritiesUnrealizedHoldingLoss', window );">Unrealized holding loss</a></td>
<td class="num">(73,519)<span></span>
</td>
<td class="num">(505,231)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_ExchangeRateEffectOnInvestmentInMarketableSecurites', window );">Exchange rate effect</a></td>
<td class="num">(295)<span></span>
</td>
<td class="num">(1,742)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Investment in marketable securities</a></td>
<td class="nump">$ 16,687<span></span>
</td>
<td class="nump">$ 89,001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_DisclosureInvestmentInMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_DisclosureInvestmentInMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_ExchangeRateEffectOnInvestmentInMarketableSecurites">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange rate effect.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_ExchangeRateEffectOnInvestmentInMarketableSecurites</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_InvestmentsIncomeDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividend income .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_InvestmentsIncomeDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_MarketableSecuritiesUnrealizedHoldingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrealized holding (loss) gain.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_MarketableSecuritiesUnrealizedHoldingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_TransferFromNonmarketableSecurity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transfer from non marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_TransferFromNonmarketableSecurity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of the investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992541073392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN MARKETABLE SECURITIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">22 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 19, 2022</div></th>
<th class="th"><div>Mar. 09, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 27, 2021</div></th>
<th class="th"><div>Dec. 09, 2020</div></th>
<th class="th"><div>Nov. 03, 2020</div></th>
<th class="th"><div>Apr. 03, 2019</div></th>
<th class="th"><div>Oct. 16, 2018</div></th>
<th class="th"><div>Jul. 30, 2018</div></th>
<th class="th"><div>May 17, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,001<span></span>
</td>
<td class="nump">$ 577,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders equity reverse stock split</a></td>
<td class="text">the
    company&#8217;s common stock at the ratio of 10-for-1 effective July 28, 2022. Under the reverse stock split, each 10 pre-split
    share of common stock outstanding will automatically combine into 1 new share of common stock of the company. As at July 28, 2022,
    the Company has an investment of 116,646
    common stock of Greenpro Capital Corp. The Company&#8217;s investment of 116,646
    common stock of Greenpro Capital Corp. was reduced to 11,665
    subsequent to the reverse stock split.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during peirod shares new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_PhoenixPlusCorpMember', window );">Phoenix Plus Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_PhoenixPlusCorpMember', window );">Phoenix Plus Corporation [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares purchased during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AATP_GreenproCapitalCorpMember', window );">Greenpro Capital Corp. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares purchased during period</a></td>
<td class="nump">11,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,333<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">83,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="nump">$ 6.2613<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AATP_DSwissIncMember', window );">DSwiss Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares purchased during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,663<span></span>
</td>
<td class="nump">6,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,315<span></span>
</td>
<td class="nump">$ 76,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AATP_SEATechVenturesCorpMember', window );">SEATech Ventures Corp. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares purchased during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of the investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_PhoenixPlusCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_PhoenixPlusCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=AATP_GreenproCapitalCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=AATP_GreenproCapitalCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=AATP_DSwissIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=AATP_DSwissIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=AATP_SEATechVenturesCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=AATP_SEATechVenturesCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992547601952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF INVESTMENT IN NON MARKETABLE SECURITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Cost of investment</a></td>
<td class="nump">$ 89,001<span></span>
</td>
<td class="nump">$ 577,035<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_InvestmentInNonMarketableSecuritiesNoncurrent', window );">Investment in non-marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AATP_PhoenixPlusCorpMember', window );">Phoenix Plus Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Cost of investment</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_TransferToInvestmentInMarketableSecurities', window );">Less: Transfer to investment in marketable securities</a></td>
<td class="num">(1,500)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_InvestmentInNonMarketableSecuritiesNoncurrent', window );">Investment in non-marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_InvestmentInNonMarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in non-marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_InvestmentInNonMarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_TransferToInvestmentInMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transfer to investment in marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_TransferToInvestmentInMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of the investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=AATP_PhoenixPlusCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=AATP_PhoenixPlusCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992541516896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVESTMENT IN NON-MARKETABLE SECURITIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Apr. 03, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Investment amount</a></td>
<td class="nump">$ 89,001<span></span>
</td>
<td class="nump">$ 577,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_PhoenixPlusCorpMember', window );">Phoenix Plus Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_PhoenixPlusCorpMember', window );">Phoenix Plus Corporation [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares purchased during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of the investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_PhoenixPlusCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_PhoenixPlusCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992546299568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF CUSTOMER DEPOSITS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_DisclosureCustomerDepositsAbstract', window );"><strong>Customer Deposits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_CustomerDeposits', window );">Customer deposits</a></td>
<td class="nump">$ 289,487<span></span>
</td>
<td class="nump">$ 273,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_UnexpiredProductCoupons', window );">Unexpired product coupons</a></td>
<td class="nump">73,531<span></span>
</td>
<td class="nump">6,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositLiabilityCurrent', window );">Total</a></td>
<td class="nump">$ 363,018<span></span>
</td>
<td class="nump">$ 279,689<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_CustomerDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Customer deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_CustomerDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_DisclosureCustomerDepositsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_DisclosureCustomerDepositsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_UnexpiredProductCoupons">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unexpired product coupons.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_UnexpiredProductCoupons</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current portion, due within one year or one operating cycle, if longer, of deposits held other than customer deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992541831760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF OTHER PAYABLES AND ACCRUED LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">$ 324,629<span></span>
</td>
<td class="nump">$ 436,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_AccruedPromotionExpensesCurrent', window );">Promotion expenses</a></td>
<td class="nump">38,583<span></span>
</td>
<td class="nump">36,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedPayrollTaxesCurrent', window );">Payroll</a></td>
<td class="nump">21,164<span></span>
</td>
<td class="nump">22,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalesCommissionCurrent', window );">Amounts held in eWallets</a></td>
<td class="nump">216,049<span></span>
</td>
<td class="nump">223,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_AccruedTaxPenaltyCurrent', window );">Tax penalty</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Others</a></td>
<td class="nump">37,852<span></span>
</td>
<td class="nump">64,340<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_OtherAccountPayableAndAccruedLiabilities', window );">Total</a></td>
<td class="nump">$ 713,277<span></span>
</td>
<td class="nump">$ 858,355<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_AccruedPromotionExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued promotion expenses current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_AccruedPromotionExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_AccruedTaxPenaltyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued tax penalty, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_AccruedTaxPenaltyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_OtherAccountPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_OtherAccountPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedPayrollTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedPayrollTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalesCommissionCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalesCommissionCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992545983536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER PAYABLES AND ACCRUED LIABILITIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>MYR (RM)</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_CommissionPaymentsDescriptions', window );">Commission payments descriptions</a></td>
<td class="text">The eWallet is primarily for the crediting of any commission payment that falls below RM100 (or $22.70).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommissionsPayableToBrokerDealersAndClearingOrganizations', window );">Comission payable</a></td>
<td class="nump">RM 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetGross', window );">Comission payable, threshold</a></td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetGross', window );">Comission payable, threshold</a></td>
<td class="nump">RM 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_CommissionPaymentsDescriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission payments descriptions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_CommissionPaymentsDescriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommissionsPayableToBrokerDealersAndClearingOrganizations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount payable to broker-dealers or clearing organizations for executing or clearing trades or orders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41256-110953<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommissionsPayableToBrokerDealersAndClearingOrganizations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992538570656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RELATED PARTIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from related parties</a></td>
<td class="nump">$ 10,534<span></span>
</td>
<td class="nump">$ 7,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Accounts payable, related parties, current</a></td>
<td class="nump">25,611<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="nump">4,880<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Purchases</a></td>
<td class="nump">202,475<span></span>
</td>
<td class="nump">718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartyOtherIncome', window );">Other income</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartyTransactionOtherPurchasesFromRelatedParty', window );">Other purchases</a></td>
<td class="nump">12,323<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesCommissionsAndFees', window );">Commission expense</a></td>
<td class="nump">405,351<span></span>
</td>
<td class="nump">316,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartyOtherExpenses', window );">Other expenses</a></td>
<td class="nump">$ 100,915<span></span>
</td>
<td class="nump">$ 718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_TH3TechnologySdnBhdMember', window );">TH3 Technology Sdn Bhd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartiesRelationshipsDescription', window );">Relationship</a></td>
<td class="text">Mr. How Kok Choong, the CEO and director of the Company is also a director of TH3<span></span>
</td>
<td class="text">Mr. How Kok Choong, the CEO and director of the Company is also a director of TH3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from related parties</a></td>
<td class="nump">$ 1,273<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartiesNatureDescription', window );">Nature</a></td>
<td class="text">IT support services fee<span></span>
</td>
<td class="text">IT support services fee<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartyOtherExpenses', window );">Other expenses</a></td>
<td class="nump">$ 56,450<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_DSYBeautySdnBhdMember', window );">DSY Beauty Sdn Bhd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartiesRelationshipsDescription', window );">Relationship</a></td>
<td class="text">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd<span></span>
</td>
<td class="text">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from related parties</a></td>
<td class="nump">$ 9,261<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartiesNatureDescription', window );">Nature</a></td>
<td class="text">Purchases of beauty products<span></span>
</td>
<td class="text">Purchases of beauty products<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Accounts payable, related parties, current</a></td>
<td class="nump">$ 224<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Purchases</a></td>
<td class="nump">3,975<span></span>
</td>
<td class="nump">718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartyTransactionOtherPurchasesFromRelatedParty', window );">Other purchases</a></td>
<td class="nump">$ 6,888<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_AgapeATPAsiaLimitedMember', window );">Agape ATP (Asia) Limited ("AATP Asia") [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartiesRelationshipsDescription', window );">Relationship</a></td>
<td class="text">Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of AATP Asia<span></span>
</td>
<td class="text">Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of AATP Asia<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartiesNatureDescription', window );">Nature</a></td>
<td class="text">Expenses paid for AATP Asia<span></span>
</td>
<td class="text">Expenses paid for AATP Asia<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_HostastaySdnBhdMember', window );">Hostastay Sdn. Bhd. (&#147;Hostastay&#148;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartiesRelationshipsDescription', window );">Relationship</a></td>
<td class="text">Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021<span></span>
</td>
<td class="text">Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartiesNatureDescription', window );">Nature</a></td>
<td class="text">Sublease rent due from Hostastay<span></span>
</td>
<td class="text">Sublease rent due from Hostastay<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_CTANutriceuticalsSdnBhdMember', window );">CTA Nutriceuticals Sdn Bhd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartiesRelationshipsDescription', window );">Relationship</a></td>
<td class="text">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd<span></span>
</td>
<td class="text">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartiesNatureDescription', window );">Nature</a></td>
<td class="text">Purchases of products for the provision of complementary health therapies<span></span>
</td>
<td class="text">Purchases of products for the provision of complementary health therapies<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Accounts payable, related parties, current</a></td>
<td class="nump">$ 25,387<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Purchases</a></td>
<td class="nump">$ 198,376<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_CTANutriceuticalsAsiaSdnBhdOneMember', window );">CTA Nutriceuticals Asia Sdn Bhd One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartiesRelationshipsDescription', window );">Relationship</a></td>
<td class="text">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd<span></span>
</td>
<td class="text">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartiesNatureDescription', window );">Nature</a></td>
<td class="text">Purchase of products for general use<span></span>
</td>
<td class="text">Purchase of products for general use<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="nump">$ 2,149<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_DSYBeautySdnBhdOneMember', window );">DSY Beauty Sdn Bhd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartiesRelationshipsDescription', window );">Relationship</a></td>
<td class="text">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd<span></span>
</td>
<td class="text">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartiesNatureDescription', window );">Nature</a></td>
<td class="text">Purchase of products for general use<span></span>
</td>
<td class="text">Purchase of products for general use<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="nump">$ 2,147<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_HowKokChoongMember', window );">How Kok Choong [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartiesRelationshipsDescription', window );">Relationship</a></td>
<td class="text">Mr. How Kok Choong, the CEO and director of the Company<span></span>
</td>
<td class="text">Mr. How Kok Choong, the CEO and director of the Company<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartiesNatureDescription', window );">Nature</a></td>
<td class="text">Commission expense<span></span>
</td>
<td class="text">Commission expense<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="nump">$ 584<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesCommissionsAndFees', window );">Commission expense</a></td>
<td class="nump">16,590<span></span>
</td>
<td class="nump">12,758<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_HowKokChoongMember', window );">How Kok Choong [Member] | Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesCommissionsAndFees', window );">Commission expense</a></td>
<td class="nump">$ 16,590<span></span>
</td>
<td class="nump">$ 12,758<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_DSYWellnessandLongevityCenterSdnBhdTwoMember', window );">DSY Wellness and Longevity Center Sdn Bhd ("DSYWLC") [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartiesRelationshipsDescription', window );">Relationship</a></td>
<td class="text">Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC<span></span>
</td>
<td class="text">Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartiesNatureDescription', window );">Nature</a></td>
<td class="text">Purchases of products for the provision of complementary health therapies<span></span>
</td>
<td class="text">Purchases of products for the provision of complementary health therapies<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Purchases</a></td>
<td class="nump">$ 124<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_HostastaySdnBhdHostastayMember', window );">Hostastay Sdn. Bhd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartiesRelationshipsDescription', window );">Relationship</a></td>
<td class="text">Mr.
    How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director
    of Hostastay as of April 21, 2021<span></span>
</td>
<td class="text">Mr.
    How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director
    of Hostastay as of April 21, 2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartiesNatureDescription', window );">Nature</a></td>
<td class="text">Sublease
    rental income due from Hostastay<span></span>
</td>
<td class="text">Sublease
    rental income due from Hostastay<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartyOtherIncome', window );">Other income</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,345<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_CTANutriceuticalsAsiaSdnBhdMember', window );">CTA Nutriceuticals Asia Sdn Bhd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartiesRelationshipsDescription', window );">Relationship</a></td>
<td class="text">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd<span></span>
</td>
<td class="text">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartiesNatureDescription', window );">Nature</a></td>
<td class="text">Purchases of products for the provision of complementary health therapies<span></span>
</td>
<td class="text">Purchases of products for the provision of complementary health therapies<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartyTransactionOtherPurchasesFromRelatedParty', window );">Other purchases</a></td>
<td class="nump">$ 5,431<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_DSYWellnessAndLongevityCenterSdnBhdMember', window );">DSY Wellness &amp; Longevity Center Sdn Bhd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartiesNatureDescription', window );">Nature</a></td>
<td class="text">Purchases of products for the provision of complementary health therapies<span></span>
</td>
<td class="text">Purchases of products for the provision of complementary health therapies<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartyTransactionOtherPurchasesFromRelatedParty', window );">Other purchases</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_DSYWellnessAndLongevityCenterSdnBhdMember', window );">DSY Wellness &amp; Longevity Center Sdn Bhd [Member] | Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartiesRelationshipsDescription', window );">Relationship</a></td>
<td class="text">Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.<span></span>
</td>
<td class="text">Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_RedboyPictureSdnBhdMember', window );">Redboy Picture Sdn Bhd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartiesRelationshipsDescription', window );">Relationship</a></td>
<td class="text">Mr. How Kok Choong, the CEO and director of the Company is also the director of Redboy<span></span>
</td>
<td class="text">Mr. How Kok Choong, the CEO and director of the Company is also the director of Redboy<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartiesNatureDescription', window );">Nature</a></td>
<td class="text">Sponsorship fee<span></span>
</td>
<td class="text">Sponsorship fee<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartyOtherExpenses', window );">Other expenses</a></td>
<td class="nump">$ 22,686<span></span>
</td>
<td class="nump">$ 718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_DSYWellnessAndLongevityCenterSdnBhdThreeMember', window );">DSY Wellness and Longevity Center Sdn Bhd ("DSYWLC") [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartiesRelationshipsDescription', window );">Relationship</a></td>
<td class="text">Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.<span></span>
</td>
<td class="text">Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartiesNatureDescription', window );">Nature</a></td>
<td class="text">Office rental expenses<span></span>
</td>
<td class="text">Office rental expenses<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_RelatedPartyOtherExpenses', window );">Other expenses</a></td>
<td class="nump">$ 21,779<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_RelatedPartiesNatureDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related parties nature description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_RelatedPartiesNatureDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_RelatedPartiesRelationshipsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related parties relationships description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_RelatedPartiesRelationshipsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_RelatedPartyOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party other expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_RelatedPartyOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_RelatedPartyOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party other income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_RelatedPartyOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_RelatedPartyTransactionOtherPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party transaction other purchases from related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_RelatedPartyTransactionOtherPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesCommissionsAndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesCommissionsAndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_TH3TechnologySdnBhdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_TH3TechnologySdnBhdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_DSYBeautySdnBhdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_DSYBeautySdnBhdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_AgapeATPAsiaLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_AgapeATPAsiaLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_HostastaySdnBhdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_HostastaySdnBhdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_CTANutriceuticalsSdnBhdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_CTANutriceuticalsSdnBhdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_CTANutriceuticalsAsiaSdnBhdOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_CTANutriceuticalsAsiaSdnBhdOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_DSYBeautySdnBhdOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_DSYBeautySdnBhdOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_HowKokChoongMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_HowKokChoongMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_DSYWellnessandLongevityCenterSdnBhdTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_DSYWellnessandLongevityCenterSdnBhdTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_HostastaySdnBhdHostastayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_HostastaySdnBhdHostastayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_CTANutriceuticalsAsiaSdnBhdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_CTANutriceuticalsAsiaSdnBhdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_DSYWellnessAndLongevityCenterSdnBhdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_DSYWellnessAndLongevityCenterSdnBhdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_RedboyPictureSdnBhdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_RedboyPictureSdnBhdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_DSYWellnessAndLongevityCenterSdnBhdThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_DSYWellnessAndLongevityCenterSdnBhdThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992546475392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">75,452,012<span></span>
</td>
<td class="nump">290,460,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">75,452,012<span></span>
</td>
<td class="nump">290,460,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=AATP_ShareForfeitureAgreementsMember', window );">Share Forfeiture Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_ReductionInCommonStockOutstanding', window );">Reduction in outstanding shares</a></td>
<td class="nump">215,008,035<span></span>
</td>
<td class="nump">85,992,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=AATP_ShareForfeitureAgreementsMember', window );">Share Forfeiture Agreements [Member] | How Kok Choong Talent Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Number of shares forfeited</a></td>
<td class="nump">215,008,035<span></span>
</td>
<td class="nump">41,750,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=AATP_ShareForfeitureAgreementsMember', window );">Share Forfeiture Agreements [Member] | How Kok Choong Talent Limited [Member] | Shareholders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Number of shares forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,242,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=AATP_ShareForfeitureAgreementsMember', window );">Share Forfeiture Agreements [Member] | HKC Holdings Sdn Bhd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Number of shares forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,242,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_ReductionInCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in common stock outstanding during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_ReductionInCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=AATP_ShareForfeitureAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=AATP_ShareForfeitureAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_HowKokChoongTalentLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_HowKokChoongTalentLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=AATP_ShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=AATP_ShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_HKCHoldingsSdnBhdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AATP_HKCHoldingsSdnBhdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992546018336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF NON CONTROLLING INTEREST (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_NonControllingInterestPaidinCapital', window );">Paid-in capital</a></td>
<td class="nump">$ 97<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_NonControllingInterestAccumulatedDeficit', window );">Accumulated surplus (deficit)</a></td>
<td class="nump">20,384<span></span>
</td>
<td class="num">(436)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_NonControllingInterestAccumulatedOtherComprehensiveIncome', window );">Accumulated other comprehensive income</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_NonControllingInterestNonControllingInterestGross', window );">Non Controlling interest Gross</a></td>
<td class="nump">20,513<span></span>
</td>
<td class="num">(336)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_NonControllingInterestAsl', window );">ASL</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Total</a></td>
<td class="nump">$ 20,513<span></span>
</td>
<td class="num">$ (336)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_NonControllingInterestAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non controlling interest accumulated deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_NonControllingInterestAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_NonControllingInterestAccumulatedOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non controlling interest accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_NonControllingInterestAccumulatedOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_NonControllingInterestAsl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non controlling interest ASL.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_NonControllingInterestAsl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_NonControllingInterestNonControllingInterestGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Controlling interest non controlling interest gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_NonControllingInterestNonControllingInterestGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_NonControllingInterestPaidinCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non controlling interest paid in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_NonControllingInterestPaidinCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992538289728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAX (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Local &#8211; United States</a></td>
<td class="num">$ (736,946)<span></span>
</td>
<td class="num">$ (706,659)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">(1,670,134)<span></span>
</td>
<td class="num">(2,387,613)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MY', window );">MALAYSIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign, Tax jurisdictions</a></td>
<td class="num">(864,794)<span></span>
</td>
<td class="num">(1,064,314)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_HK', window );">HONG KONG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign, Tax jurisdictions</a></td>
<td class="num">$ (68,394)<span></span>
</td>
<td class="num">$ (616,640)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_HK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_HK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992546424176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF PROVISION FOR INCOME TAX (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">- Local</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (22,205)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">- Foreign</a></td>
<td class="num">(10,962)<span></span>
</td>
<td class="num">(104,735)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">- Local</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">- Foreign</a></td>
<td class="nump">15,017<span></span>
</td>
<td class="num">(10,127)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit of (Provision for) income taxes</a></td>
<td class="nump">$ 4,055<span></span>
</td>
<td class="num">$ (137,067)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992547539392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF EFFECTIVE INCOME TAX RATE (Details)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(22.90%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(17.00%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Differential tax rate in Malaysia</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Permanent difference</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(12.70%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5.70%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The
    amount comprised:  (1.0)% being expenses
    incurred in AATP LB, ASL, SEA and WATP that are not deductible in the Malaysia tax return.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The
    amount comprised: 6.2% being income derived in AATP HK that were not taxable in the Malaysia tax returns; and 6.7% being expenses
    incurred in AATP LB, ASL, SEA, WATP, and DSY Wellness that are not deductible in the Malaysia tax return.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992541348080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF EFFECTIVE INCOME TAX RATE (Details) (Parenthetical)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=AATP_AATPLBASLSEAAndWATPMember', window );">AATP LB, ASL, SEA and WATP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Tax percentage</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=AATP_AATPHKMember', window );">AATP HK [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Tax percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=AATP_AATPLBASLSEAWATPAndDSYMember', window );">AATP LB, ASL, SEA, WATP, and DSY [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Tax percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=AATP_AATPLBASLSEAAndWATPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=AATP_AATPLBASLSEAAndWATPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=AATP_AATPHKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=AATP_AATPHKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=AATP_AATPLBASLSEAWATPAndDSYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=AATP_AATPLBASLSEAWATPAndDSYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992538410608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF DEFERRED TAX ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">$ (693,185)<span></span>
</td>
<td class="num">$ (380,167)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_DeferredTaxLiabilitiesDepreciation', window );">Depreciation</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(15,574)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax liabilities, net</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(15,574)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Net operating loss carry forwards in Malaysia</a></td>
<td class="nump">284,959<span></span>
</td>
<td class="nump">153,061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(285,000)<span></span>
</td>
<td class="num">(130,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MY', window );">MALAYSIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Net operating loss carry forwards in Malaysia</a></td>
<td class="nump">408,226<span></span>
</td>
<td class="nump">227,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">$ (408,000)<span></span>
</td>
<td class="num">$ (217,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_DeferredTaxLiabilitiesDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities, depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_DeferredTaxLiabilitiesDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992538720752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2019</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>MYR (RM)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>MYR (RM)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_TaxRateDescription', window );">Tax rate description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In addition, the
Tax Cuts and Jobs Act imposed a global intangible low-taxed income (&#8220;GILTI&#8221;) tax, which is a tax on certain off-shore earnings
at an effective rate of 10.5% for tax years (50% deduction of the current enacted tax rate of 21%) with a partial offset for 80% foreign
tax credits. If the foreign tax rate is 13.125% or higher, there will be no U.S. corporate tax after the 80% foreign tax credits are
applied.<span></span>
</td>
<td class="text">In addition, the
Tax Cuts and Jobs Act imposed a global intangible low-taxed income (&#8220;GILTI&#8221;) tax, which is a tax on certain off-shore earnings
at an effective rate of 10.5% for tax years (50% deduction of the current enacted tax rate of 21%) with a partial offset for 80% foreign
tax credits. If the foreign tax rate is 13.125% or higher, there will be no U.S. corporate tax after the 80% foreign tax credits are
applied.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 312,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 693,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 380,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,055)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Income tax examination penalties and interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Deferred tax assets operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_DeferredTaxAssetsOperatingLossCarryforwardsReducedAmount', window );">Deferred tax assets operating loss carryforwards reduced amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="num">(5.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=AATP_TwoThousandTwentyEightMember', window );">2028 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 790,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=AATP_TwoThousandTwentyNineMember', window );">2029 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">897,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=AATP_TwoThousandThirtyMember', window );">2030 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,357,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 620,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=AATP_LabuanMember', window );">Labuan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax percentage</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MY', window );">MALAYSIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,723,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">946,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 408,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationDescription', window );">Income tax examination, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The tax rate for small and medium sized companies (generally
companies incorporated in Malaysia with paid-in capital of RM 2,500,000 or less) is 17% for the first RM 600,000 (or approximately $150,000)
for the year ended December 31, 2022 and 2021, with the remaining balance being taxed at the 24% rate.<span></span>
</td>
<td class="text">The tax rate for small and medium sized companies (generally
companies incorporated in Malaysia with paid-in capital of RM 2,500,000 or less) is 17% for the first RM 600,000 (or approximately $150,000)
for the year ended December 31, 2022 and 2021, with the remaining balance being taxed at the 24% rate.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Paid in capital | RM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">RM 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit', window );">Additional paid in capital stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">RM 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_HK', window );">HONG KONG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.50%<span></span>
</td>
<td class="nump">16.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_DeferredTaxAssetsOperatingLossCarryforwardsReducedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating loss carryforwards reduced amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_DeferredTaxAssetsOperatingLossCarryforwardsReducedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_TaxRateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax rate description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_TaxRateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=AATP_TwoThousandTwentyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=AATP_TwoThousandTwentyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=AATP_TwoThousandTwentyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=AATP_TwoThousandTwentyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=AATP_TwoThousandThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=AATP_TwoThousandThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=AATP_LabuanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=AATP_LabuanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_HK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_HK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992538127312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONCENTRATIONS OF RISKS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Deposits', window );">Deposits</a></td>
<td class="nump">$ 513,152<span></span>
</td>
<td class="nump">$ 554,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_DepositForInsurance', window );">Deposit for insurance</a></td>
<td class="nump">$ 231,187<span></span>
</td>
<td class="nump">$ 295,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_DSwissIncMember', window );">DSwiss Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Proportional of ownership interest and voting power held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AATP_DSwissIncMember', window );">DSwiss Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_DividendShareForCommonStock', window );">Dividend share for common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,330<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=AATP_NoCustomerMember', window );">No Customer [Member] | Revenue from Contract with Customer Benchmark [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations of risk percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=AATP_FiveIndividualCustomersMember', window );">Five Individual Customers [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations of risk percentage</a></td>
<td class="nump">72.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=AATP_VendorOneMember', window );">Vendor One [Member] | Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations of risk percentage</a></td>
<td class="nump">53.30%<span></span>
</td>
<td class="nump">47.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=AATP_VendorOneMember', window );">Vendor One [Member] | Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member] | DSwiss Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations of risk percentage</a></td>
<td class="nump">22.10%<span></span>
</td>
<td class="nump">47.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=AATP_VendorOneMember', window );">Vendor One [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations of risk percentage</a></td>
<td class="nump">46.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=AATP_VendorTwoMember', window );">Vendor Two [Member] | Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations of risk percentage</a></td>
<td class="nump">22.10%<span></span>
</td>
<td class="nump">45.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=AATP_VendorTwoMember', window );">Vendor Two [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations of risk percentage</a></td>
<td class="nump">25.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=AATP_VendorThreeMember', window );">Vendor Three [Member] | Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations of risk percentage</a></td>
<td class="nump">21.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=AATP_VendorThreeMember', window );">Vendor Three [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations of risk percentage</a></td>
<td class="nump">23.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=AATP_VendorMember', window );">Vendor [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations of risk percentage</a></td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=AATP_OneVendorMember', window );">One Vendor [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations of risk percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=AATP_OneSalesDistributorMember', window );">One Sales Distributor [Member] | Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentrations of risk percentage</a></td>
<td class="nump">10.30%<span></span>
</td>
<td class="nump">17.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_DepositForInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deposit for insurance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_DepositForInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_DividendShareForCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividend share for common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_DividendShareForCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Deposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.12)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Deposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_DSwissIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AATP_DSwissIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=AATP_DSwissIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=AATP_DSwissIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=AATP_NoCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=AATP_NoCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=AATP_FiveIndividualCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=AATP_FiveIndividualCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=AATP_VendorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=AATP_VendorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=AATP_VendorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=AATP_VendorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=AATP_VendorThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=AATP_VendorThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=AATP_VendorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=AATP_VendorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=AATP_OneVendorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=AATP_OneVendorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=AATP_OneSalesDistributorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=AATP_OneSalesDistributorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992546433200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF LEASE COMMITMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 01, 2021</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 84,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_LesseeOperatingLeaseLiabilityPaymentsDueAfterNextTwelveMonths', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">84,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest</a></td>
<td class="num">(1,439)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 82,707<span></span>
</td>
<td class="nump">$ 10,864<span></span>
</td>
<td class="nump">$ 9,777<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_LesseeOperatingLeaseLiabilityPaymentsDueAfterNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due after next twelve months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_LesseeOperatingLeaseLiabilityPaymentsDueAfterNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139992538598560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 01, 2021</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Apr. 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,864<span></span>
</td>
<td class="nump">$ 9,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_LeaseExpirationTerm', window );">Lease expiration term</a></td>
<td class="text">May 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_IncreaseDecreaseInROUAssetsAndLiabilities', window );">Reduction in ROU assets and liabilities</a></td>
<td class="nump">$ 3,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,133<span></span>
</td>
<td class="nump">$ 237,718<span></span>
</td>
<td class="nump">$ 10,864<span></span>
</td>
<td class="nump">$ 9,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,547<span></span>
</td>
<td class="nump">$ 179,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=AATP_TrainingCenterMember', window );">Training Center [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AATP_LeaseExpirationTerm', window );">Lease expiration term</a></td>
<td class="text">Aug. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=AATP_AgapeSuperiorLivingMember', window );">ASL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 490,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease effective interest rate</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_IncreaseDecreaseInROUAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in ROU assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_IncreaseDecreaseInROUAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AATP_LeaseExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease expiration term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AATP_LeaseExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AATP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=AATP_TrainingCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=AATP_TrainingCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=AATP_AgapeSuperiorLivingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=AATP_AgapeSuperiorLivingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:AATP="http://agapeatp.com/20221231"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="aatp-20221231.xsd" xlink:type="simple"/>
    <context id="From2022-01-01to2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-03-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
        </entity>
        <period>
            <instant>2023-03-23</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_AgapeATPInternationalHoldingLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:AgapeATPInternationalHoldingLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2020-05-072020-05-08_custom_ShareExchangeAgreementMember_custom_MrHowKokChoongMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AATP:MrHowKokChoongMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AATP:ShareExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-07</startDate>
            <endDate>2020-05-08</endDate>
        </period>
    </context>
    <context id="AsOf2020-05-08_custom_SubsidiaryCompanyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:SubsidiaryCompanyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-08</instant>
        </period>
    </context>
    <context id="AsOf2021-11-11_custom_SubsidiaryCompanyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:SubsidiaryCompanyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-11</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SubsidiaryCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:SubsidiaryCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SubsidiaryCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:SubsidiaryCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SubsidiaryCompanyOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:SubsidiaryCompanyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SubsidiaryCompanyOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:SubsidiaryCompanyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SubsidiaryCompanyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:SubsidiaryCompanyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SubsidiaryCompanyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:SubsidiaryCompanyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SubsidiaryCompanyThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:SubsidiaryCompanyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SubsidiaryCompanyFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:SubsidiaryCompanyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SubsidiaryCompanyFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:SubsidiaryCompanyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SubsidiaryCompanyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:SubsidiaryCompanyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SubsidiaryCompanyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:SubsidiaryCompanyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_HealthAndWellnessServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:HealthAndWellnessServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_HealthAndWellnessServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:HealthAndWellnessServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ShippingAndHandlingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_ShippingAndHandlingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SocialSecurityOrganizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:SocialSecurityOrganizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EmployeesProvidentFundMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:EmployeesProvidentFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EmployeesProvidentFundMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:EmployeesProvidentFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EmploymentInsuranceSystemMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:EmploymentInsuranceSystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_HumanResourceDevelopmentFundMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:HumanResourceDevelopmentFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_VehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SurvivorSelectMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:SurvivorSelectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_SurvivorSelectMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:SurvivorSelectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EnergizedMineralConcentrateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:EnergizedMineralConcentrateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_EnergizedMineralConcentrateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:EnergizedMineralConcentrateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_IonizedCalMagMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:IonizedCalMagMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_IonizedCalMagMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:IonizedCalMagMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_OmegaBlendMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:OmegaBlendMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_OmegaBlendMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:OmegaBlendMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_BetaMaxxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:BetaMaxxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_BetaMaxxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:BetaMaxxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_VegeFruitFiberMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:VegeFruitFiberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_VegeFruitFiberMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:VegeFruitFiberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_IronMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:IronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_IronMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:IronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_YoungFormulaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:YoungFormulaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_YoungFormulaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:YoungFormulaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_OrganicYouthCarCleansingBarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:OrganicYouthCarCleansingBarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_OrganicYouthCarCleansingBarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:OrganicYouthCarCleansingBarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ATPRMITOPlusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:ATPRMITOPlusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_ATPRMITOPlusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:ATPRMITOPlusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_LipomaskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:LipomaskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_LipomaskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:LipomaskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EnergetiqueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:EnergetiqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_EnergetiqueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:EnergetiqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_TrimPlusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:TrimPlusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_TrimPlusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:TrimPlusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ProductHealthTherapiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:ProductHealthTherapiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_ProductHealthTherapiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:ProductHealthTherapiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_OthersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:OthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_OthersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AATP:OthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PeriodEndMYRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">AATP:PeriodEndMYRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_PeriodEndMYRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">AATP:PeriodEndMYRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PeriodEndHKDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">AATP:PeriodEndHKDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_PeriodEndHKDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">AATP:PeriodEndHKDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PeriodAverageMYRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">AATP:PeriodAverageMYRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_PeriodAverageMYRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">AATP:PeriodAverageMYRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PeriodAverageHKDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">AATP:PeriodAverageHKDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_PeriodAverageHKDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">AATP:PeriodAverageHKDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SubsidiaryCompanyThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:SubsidiaryCompanyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_VariableIncomeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">us-gaap:VariableIncomeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_VariableIncomeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">us-gaap:VariableIncomeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_VariableIncomeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">us-gaap:VariableIncomeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_VariableIncomeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">us-gaap:VariableIncomeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ComputerAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">AATP:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ComputerAndOfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">AATP:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_VehicleMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">AATP:VehicleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_VehicleMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">AATP:VehicleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-05-17_custom_GreenproCapitalCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:GreenproCapitalCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-17</instant>
        </period>
    </context>
    <context id="AsOf2018-07-30_custom_GreenproCapitalCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:GreenproCapitalCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-30</instant>
        </period>
    </context>
    <context id="AsOf2018-10-16_custom_GreenproCapitalCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:GreenproCapitalCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-16</instant>
        </period>
    </context>
    <context id="From2022-07-182022-07-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
        </entity>
        <period>
            <startDate>2022-07-18</startDate>
            <endDate>2022-07-19</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_GreenproCapitalCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:GreenproCapitalCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-07-19_custom_GreenproCapitalCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:GreenproCapitalCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-19</instant>
        </period>
    </context>
    <context id="AsOf2020-11-03_custom_DSwissIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:DSwissIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-03</instant>
        </period>
    </context>
    <context id="AsOf2020-12-09_custom_DSwissIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:DSwissIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-09</instant>
        </period>
    </context>
    <context id="AsOf2021-09-27_custom_SEATechVenturesCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:SEATechVenturesCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-27</instant>
        </period>
    </context>
    <context id="AsOf2019-04-03_custom_PhoenixPlusCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:PhoenixPlusCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-03</instant>
        </period>
    </context>
    <context id="AsOf2019-04-03_us-gaap_CommonStockMember_custom_PhoenixPlusCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:PhoenixPlusCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-03</instant>
        </period>
    </context>
    <context id="From2021-05-182023-03-09_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-18</startDate>
            <endDate>2023-03-09</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PhoenixPlusCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:PhoenixPlusCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_PhoenixPlusCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:PhoenixPlusCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_TH3TechnologySdnBhdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:TH3TechnologySdnBhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_TH3TechnologySdnBhdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:TH3TechnologySdnBhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TH3TechnologySdnBhdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:TH3TechnologySdnBhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_TH3TechnologySdnBhdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:TH3TechnologySdnBhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_DSYBeautySdnBhdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYBeautySdnBhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_DSYBeautySdnBhdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYBeautySdnBhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_DSYBeautySdnBhdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYBeautySdnBhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_DSYBeautySdnBhdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYBeautySdnBhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_AgapeATPAsiaLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:AgapeATPAsiaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_AgapeATPAsiaLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:AgapeATPAsiaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_AgapeATPAsiaLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:AgapeATPAsiaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_AgapeATPAsiaLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:AgapeATPAsiaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_HostastaySdnBhdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HostastaySdnBhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_HostastaySdnBhdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HostastaySdnBhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_HostastaySdnBhdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HostastaySdnBhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_HostastaySdnBhdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HostastaySdnBhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CTANutriceuticalsSdnBhdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:CTANutriceuticalsSdnBhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_CTANutriceuticalsSdnBhdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:CTANutriceuticalsSdnBhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_CTANutriceuticalsSdnBhdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:CTANutriceuticalsSdnBhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CTANutriceuticalsSdnBhdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:CTANutriceuticalsSdnBhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CTANutriceuticalsAsiaSdnBhdOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:CTANutriceuticalsAsiaSdnBhdOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_CTANutriceuticalsAsiaSdnBhdOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:CTANutriceuticalsAsiaSdnBhdOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_CTANutriceuticalsAsiaSdnBhdOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:CTANutriceuticalsAsiaSdnBhdOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CTANutriceuticalsAsiaSdnBhdOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:CTANutriceuticalsAsiaSdnBhdOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_DSYBeautySdnBhdOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYBeautySdnBhdOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_DSYBeautySdnBhdOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYBeautySdnBhdOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_DSYBeautySdnBhdOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYBeautySdnBhdOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_DSYBeautySdnBhdOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYBeautySdnBhdOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_HowKokChoongMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HowKokChoongMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_HowKokChoongMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HowKokChoongMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_HowKokChoongMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HowKokChoongMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_HowKokChoongMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HowKokChoongMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_DSYWellnessandLongevityCenterSdnBhdTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYWellnessandLongevityCenterSdnBhdTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_DSYWellnessandLongevityCenterSdnBhdTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYWellnessandLongevityCenterSdnBhdTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_HostastaySdnBhdHostastayMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HostastaySdnBhdHostastayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_HostastaySdnBhdHostastayMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HostastaySdnBhdHostastayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CTANutriceuticalsAsiaSdnBhdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:CTANutriceuticalsAsiaSdnBhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_CTANutriceuticalsAsiaSdnBhdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:CTANutriceuticalsAsiaSdnBhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYWellnessAndLongevityCenterSdnBhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYWellnessAndLongevityCenterSdnBhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYWellnessAndLongevityCenterSdnBhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYWellnessAndLongevityCenterSdnBhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_HowKokChoongMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HowKokChoongMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_HowKokChoongMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HowKokChoongMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_RedboyPictureSdnBhdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:RedboyPictureSdnBhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_RedboyPictureSdnBhdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:RedboyPictureSdnBhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYWellnessAndLongevityCenterSdnBhdThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:DSYWellnessAndLongevityCenterSdnBhdThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_ShareForfeitureAgreementsMember_custom_HowKokChoongTalentLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HowKokChoongTalentLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AATP:ShareForfeitureAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_ShareForfeitureAgreementsMember_custom_HowKokChoongTalentLimitedMember_custom_ShareholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AATP:ShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HowKokChoongTalentLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AATP:ShareForfeitureAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_ShareForfeitureAgreementsMember_custom_HKCHoldingsSdnBhdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HKCHoldingsSdnBhdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AATP:ShareForfeitureAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_ShareForfeitureAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AATP:ShareForfeitureAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ShareForfeitureAgreementsMember_custom_HowKokChoongTalentLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AATP:HowKokChoongTalentLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AATP:ShareForfeitureAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ShareForfeitureAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AATP:ShareForfeitureAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_country_MY">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_country_MY">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_country_HK">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_country_HK">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2018-12-282019-01-02_custom_LabuanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">AATP:LabuanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-28</startDate>
            <endDate>2019-01-02</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_country_MY">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_country_MY">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TwoThousandTwentyEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">AATP:TwoThousandTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TwoThousandTwentyNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">AATP:TwoThousandTwentyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TwoThousandThirtyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">AATP:TwoThousandThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_AATPLBASLSEAAndWATPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">AATP:AATPLBASLSEAAndWATPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_AATPHKMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">AATP:AATPHKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_AATPLBASLSEAWATPAndDSYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">AATP:AATPLBASLSEAWATPAndDSYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_NoCustomerMember_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:NoCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_NoCustomerMember_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:NoCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_FiveIndividualCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:FiveIndividualCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_VendorOneMember_us-gaap_CostOfGoodsTotalMember_us-gaap_SupplierConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:VendorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_VendorTwoMember_us-gaap_CostOfGoodsTotalMember_us-gaap_SupplierConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:VendorTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_VendorThreeMember_us-gaap_CostOfGoodsTotalMember_us-gaap_SupplierConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:VendorThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_VendorOneMember_us-gaap_CostOfGoodsTotalMember_us-gaap_SupplierConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:VendorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_VendorTwoMember_us-gaap_CostOfGoodsTotalMember_us-gaap_SupplierConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:VendorTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_DSwissIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:DSwissIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_DSwissIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AATP:DSwissIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfGoodsTotalMember_custom_VendorOneMember_custom_DSwissIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:VendorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:DSwissIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfGoodsTotalMember_custom_VendorOneMember_custom_DSwissIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:VendorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AATP:DSwissIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_VendorOneMember_us-gaap_AccountsPayableMember_us-gaap_SupplierConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:VendorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_VendorTwoMember_us-gaap_AccountsPayableMember_us-gaap_SupplierConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:VendorTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_VendorThreeMember_us-gaap_AccountsPayableMember_us-gaap_SupplierConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:VendorThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_VendorMember_us-gaap_AccountsPayableMember_us-gaap_SupplierConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:VendorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_SupplierConcentrationRiskMember_us-gaap_AccountsPayableMember_custom_OneVendorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:OneVendorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfGoodsTotalMember_custom_OneSalesDistributorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:OneSalesDistributorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfGoodsTotalMember_custom_OneSalesDistributorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">AATP:OneSalesDistributorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-04-01_custom_AgapeSuperiorLivingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">AATP:AgapeSuperiorLivingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-01</instant>
        </period>
    </context>
    <context id="From2021-05-302021-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
        </entity>
        <period>
            <startDate>2021-05-30</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="From2021-05-302021-05-31_custom_TrainingCenterMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">AATP:TrainingCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-30</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="AsOf2021-05-31_custom_AgapeSuperiorLivingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">AATP:AgapeSuperiorLivingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="AsOf2021-10-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="AsOf2021-11-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_AgapeSuperiorLivingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001713210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">AATP:AgapeSuperiorLivingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="RM">
        <measure>iso4217:MYR</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-01-01to2022-12-31">0001713210</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-01-01to2022-12-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-01-01to2022-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCurrentReportingStatus contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0033">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-01-01to2022-12-31" id="xdx2ixbrl0034">Yes</dei:EntityInteractiveDataCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0059"
      unitRef="USD"
      xsi:nil="true"/>
    <AATP:InvestmentInNonMarketableSecuritiesNoncurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0095"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0117"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0133"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0144"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0147"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0150"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0159"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0160"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0236"
      unitRef="USD"
      xsi:nil="true"/>
    <AATP:PreferredStockDividendIncomeStatementImpact
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0257"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0312"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0320"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0321"
      unitRef="USD"
      xsi:nil="true"/>
    <AATP:ContributionsFromNoncontrollingInterestShareholders
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <AATP:ContributionsFromNoncontrollingInterestShareholders
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <AATP:ContributionsFromNoncontrollingInterestShareholders
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0326"
      unitRef="USD"
      xsi:nil="true"/>
    <AATP:ContributionsFromNoncontrollingInterestShareholders
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2021-01-012021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0349"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <AATP:PreferredStockDividendIncomeStatementImpact
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0406"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0428"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0431"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0443"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0458"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0469"
      unitRef="USD"
      xsi:nil="true"/>
    <AATP:ChangesInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseModifications
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0496"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0585"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0587"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0589"
      unitRef="USD"
      xsi:nil="true"/>
    <AATP:InventoryWriteOff
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0599"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0607"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_custom_EnergizedMineralConcentrateMember"
      id="xdx2ixbrl0666"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_custom_VegeFruitFiberMember"
      id="xdx2ixbrl0678"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_custom_OrganicYouthCarCleansingBarMember"
      id="xdx2ixbrl0687"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_custom_LipomaskMember"
      id="xdx2ixbrl0693"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-12-31_custom_ProductHealthTherapiesMember"
      id="xdx2ixbrl0703"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-12-31_custom_OthersMember"
      id="xdx2ixbrl0706"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31_us-gaap_VariableIncomeInterestRateMember"
      id="xdx2ixbrl0857"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-12-31_us-gaap_VariableIncomeInterestRateMember"
      id="xdx2ixbrl0858"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="From2022-01-012022-12-31_us-gaap_VariableIncomeInterestRateMember"
      id="xdx2ixbrl0860"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="From2021-01-012021-12-31_us-gaap_VariableIncomeInterestRateMember"
      id="xdx2ixbrl0861"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0896"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0898"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0899"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0902"
      unitRef="USD"
      xsi:nil="true"/>
    <AATP:InventoryWriteOff
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0917"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0932"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0941"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl0943"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0947"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0952"
      unitRef="USD"
      xsi:nil="true"/>
    <AATP:TransferFromNonmarketableSecurity
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1063"
      unitRef="USD"
      xsi:nil="true"/>
    <AATP:InvestmentsIncomeDividend
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1065"
      unitRef="USD"
      xsi:nil="true"/>
    <AATP:TransferToInvestmentInMarketableSecurities
      contextRef="AsOf2021-12-31_custom_PhoenixPlusCorpMember"
      id="xdx2ixbrl1093"
      unitRef="USD"
      xsi:nil="true"/>
    <AATP:InvestmentInNonMarketableSecuritiesNoncurrent
      contextRef="AsOf2022-12-31_custom_PhoenixPlusCorpMember"
      id="xdx2ixbrl1095"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DueFromRelatedParties
      contextRef="AsOf2021-12-31_custom_TH3TechnologySdnBhdMember"
      id="xdx2ixbrl1154"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DueFromRelatedParties
      contextRef="AsOf2021-12-31_custom_DSYBeautySdnBhdMember"
      id="xdx2ixbrl1162"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DueFromRelatedParties
      contextRef="AsOf2022-12-31_custom_AgapeATPAsiaLimitedMember"
      id="xdx2ixbrl1172"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DueFromRelatedParties
      contextRef="AsOf2022-12-31_custom_HostastaySdnBhdMember"
      id="xdx2ixbrl1184"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="AsOf2021-12-31_custom_CTANutriceuticalsSdnBhdMember"
      id="xdx2ixbrl1202"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="AsOf2021-12-31_custom_DSYBeautySdnBhdMember"
      id="xdx2ixbrl1212"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1216"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2021-12-31_custom_CTANutriceuticalsAsiaSdnBhdOneMember"
      id="xdx2ixbrl1228"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2021-12-31_custom_DSYBeautySdnBhdOneMember"
      id="xdx2ixbrl1240"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2021-12-31_custom_HowKokChoongMember"
      id="xdx2ixbrl1252"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1256"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2021-01-012021-12-31_custom_CTANutriceuticalsSdnBhdMember"
      id="xdx2ixbrl1268"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2021-01-012021-12-31_custom_DSYWellnessandLongevityCenterSdnBhdTwoMember"
      id="xdx2ixbrl1292"
      unitRef="USD"
      xsi:nil="true"/>
    <AATP:RelatedPartyOtherIncome
      contextRef="From2022-01-012022-12-31_custom_HostastaySdnBhdHostastayMember"
      id="xdx2ixbrl1302"
      unitRef="USD"
      xsi:nil="true"/>
    <AATP:RelatedPartyOtherIncome
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1306"
      unitRef="USD"
      xsi:nil="true"/>
    <AATP:RelatedPartyTransactionOtherPurchasesFromRelatedParty
      contextRef="From2021-01-012021-12-31_custom_CTANutriceuticalsAsiaSdnBhdMember"
      id="xdx2ixbrl1320"
      unitRef="USD"
      xsi:nil="true"/>
    <AATP:RelatedPartyTransactionOtherPurchasesFromRelatedParty
      contextRef="From2021-01-012021-12-31_custom_DSYBeautySdnBhdMember"
      id="xdx2ixbrl1332"
      unitRef="USD"
      xsi:nil="true"/>
    <AATP:RelatedPartyTransactionOtherPurchasesFromRelatedParty
      contextRef="From2021-01-012021-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdMember"
      id="xdx2ixbrl1344"
      unitRef="USD"
      xsi:nil="true"/>
    <AATP:RelatedPartyTransactionOtherPurchasesFromRelatedParty
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl1348"
      unitRef="USD"
      xsi:nil="true"/>
    <AATP:RelatedPartyOtherExpenses
      contextRef="From2021-01-012021-12-31_custom_TH3TechnologySdnBhdMember"
      id="xdx2ixbrl1376"
      unitRef="USD"
      xsi:nil="true"/>
    <AATP:RelatedPartyOtherExpenses
      contextRef="From2021-01-012021-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdThreeMember"
      id="xdx2ixbrl1400"
      unitRef="USD"
      xsi:nil="true"/>
    <AATP:NonControllingInterestAsl
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1464"
      unitRef="USD"
      xsi:nil="true"/>
    <AATP:NonControllingInterestAsl
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1465"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1494"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      id="xdx2ixbrl1503"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl1504"
      unitRef="USD"
      xsi:nil="true"/>
    <AATP:DeferredTaxLiabilitiesDepreciation
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1606"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1609"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2021-10-01" id="xdx2ixbrl1669">P2Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2021-11-01" id="xdx2ixbrl1677">P2Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <AATP:LesseeOperatingLeaseLiabilityPaymentsDueAfterNextTwelveMonths
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1691"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2022-01-01to2022-12-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2022-01-01to2022-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2022-01-01to2022-12-31">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-01-01to2022-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2022-01-01to2022-12-31">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2022-01-01to2022-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2022-01-01to2022-12-31">333-220144</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2022-01-01to2022-12-31">AGAPE ATP CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-01-01to2022-12-31">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-01-01to2022-12-31">36-4838886</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-01-01to2022-12-31">1705 &#x2013; 1708, Level 17, Tower 2</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-01-01to2022-12-31">Faber Towers</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="From2022-01-01to2022-12-31">Jalan Desa Bahagia</dei:EntityAddressAddressLine3>
    <dei:EntityAddressPostalZipCode contextRef="From2022-01-01to2022-12-31">58100</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="From2022-01-01to2022-12-31">Kuala Lumpur</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="From2022-01-01to2022-12-31">MY</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="From2022-01-01to2022-12-31">(60)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-01-01to2022-12-31">192230099</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-01-01to2022-12-31">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2022-01-01to2022-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2022-01-01to2022-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityFilerCategory contextRef="From2022-01-01to2022-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-01-01to2022-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityShellCompany contextRef="From2022-01-01to2022-12-31">false</dei:EntityShellCompany>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-01-01to2022-12-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityPublicFloat contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">293809710</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-03-23" decimals="INF" unitRef="Shares">75452012</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="From2022-01-01to2022-12-31">5395</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2022-01-01to2022-12-31">Friedman LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2022-01-01to2022-12-31">New York, New York</dei:AuditorLocation>
    <AATP:VariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1609</AATP:VariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents>
    <AATP:VariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">17493</AATP:VariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1438430</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2597848</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2826</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">10534</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">7004</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">46277</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">375535</us-gaap:InventoryNet>
    <AATP:VariableInterestEntityConsolidatedAmountOfPrepaidTaxes contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1741</AATP:VariableInterestEntityConsolidatedAmountOfPrepaidTaxes>
    <AATP:VariableInterestEntityConsolidatedAmountOfPrepaidTaxes contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1357</AATP:VariableInterestEntityConsolidatedAmountOfPrepaidTaxes>
    <us-gaap:PrepaidTaxes contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">339367</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">636218</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">191100</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">295517</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2028534</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">3912122</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">142149</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">215799</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">24044</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">3660</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">81133</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">237718</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">16687</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">89001</us-gaap:MarketableSecuritiesNoncurrent>
    <AATP:InvestmentInNonMarketableSecuritiesNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1500</AATP:InvestmentInNonMarketableSecuritiesNoncurrent>
    <us-gaap:DeferredCosts contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">499202</us-gaap:DeferredCosts>
    <us-gaap:DeferredCosts contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">264735</us-gaap:DeferredCosts>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">763215</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">812413</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2791749</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4724535</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">28833</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">13715</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">25611</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">363018</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">279689</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">82708</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">157094</us-gaap:OperatingLeaseLiabilityCurrent>
    <AATP:VariableInterestEntityConsolidatedAmountOfOtherPayablesAndAccruedLiabilities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1090</AATP:VariableInterestEntityConsolidatedAmountOfOtherPayablesAndAccruedLiabilities>
    <AATP:VariableInterestEntityConsolidatedAmountOfOtherPayablesAndAccruedLiabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1548</AATP:VariableInterestEntityConsolidatedAmountOfOtherPayablesAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">713277</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">858355</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:AccountsPayableOtherCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">4880</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">10968</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">3988</us-gaap:TaxesPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1229295</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1312841</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">83484</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">15574</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">99058</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1229295</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1411899</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">200000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">200000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">75452012</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">75452012</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">290460047</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">290460047</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">7545</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">29046</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">6470716</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">6449215</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">-4945586</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-3258687</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">9266</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">93398</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1541941</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">3312972</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">20513</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-336</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1562454</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">3312636</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2791749</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4724535</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">1856564</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1016962</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">666042</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">297333</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">1190522</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">719629</us-gaap:GrossProfit>
    <us-gaap:SellingExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">361414</us-gaap:SellingExpense>
    <us-gaap:SellingExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">394682</us-gaap:SellingExpense>
    <us-gaap:SalesCommissionsAndFees
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">405351</us-gaap:SalesCommissionsAndFees>
    <us-gaap:SalesCommissionsAndFees
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">316267</us-gaap:SalesCommissionsAndFees>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">1957023</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1745734</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">121514</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">2723788</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">2578197</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-1533266</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-1858568</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-79539</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-68323</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">16190</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">25570</us-gaap:InvestmentIncomeInterest>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-73519</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-505231</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <AATP:PreferredStockDividendIncomeStatementImpact
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-18939</AATP:PreferredStockDividendIncomeStatementImpact>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-136868</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-529045</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-1670134</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-2387613</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-4055</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">137067</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-1666079</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-2524680</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">20820</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-436</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-1686899</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-2524244</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-1666079</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-2524680</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-84132</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-87615</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-1750211</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-2612295</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">20849</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-433</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-1771060</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-2611862</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">87822337</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">376216452</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">376452047</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">37645</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">6440616</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-734443</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">181016</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">5924834</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">85992000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">-8599</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">8599</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <AATP:ContributionsFromNoncontrollingInterestShareholders
      contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">97</AATP:ContributionsFromNoncontrollingInterestShareholders>
    <AATP:ContributionsFromNoncontrollingInterestShareholders
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">97</AATP:ContributionsFromNoncontrollingInterestShareholders>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-2524244</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">-436</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-2524680</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">290460047</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">29046</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">6449215</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-3258687</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">93398</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">-336</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">3312636</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">218008035</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">-21501</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">21501</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-1686899</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">20820</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-1666079</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-84132</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">29</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-84103</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">72452012</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">7545</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">6470716</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-4945586</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">9266</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">20513</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1562454</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-1666079</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-2524680</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:Depreciation
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">71754</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">75797</us-gaap:Depreciation>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">2122</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1961</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">144064</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">139451</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-73519</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-505231</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <AATP:PreferredStockDividendIncomeStatementImpact
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-18939</AATP:PreferredStockDividendIncomeStatementImpact>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-14751</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">10127</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:InventoryWriteDown
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">5307</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">36241</us-gaap:InventoryWriteDown>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">121514</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">2824</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-167566</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">3786</us-gaap:IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-343483</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-192713</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidTaxes
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-263404</us-gaap:IncreaseDecreaseInPrepaidTaxes>
    <us-gaap:IncreaseDecreaseInPrepaidTaxes
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-430062</us-gaap:IncreaseDecreaseInPrepaidTaxes>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-89113</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">128363</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">15825</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">25597</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">94877</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">52981</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-145197</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-138143</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-119963</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">226651</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">4878</us-gaap:IncreaseDecreaseInDueToOtherRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">6974</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">3988</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-811683</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-845842</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">9433</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">3959</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">22686</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-32119</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-3959</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">234466</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">15210</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-3851</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-234466</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-19061</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-81150</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-50890</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-1159418</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-919752</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2597848</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">3517600</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1438430</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2597848</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">78511</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">326838</us-gaap:IncomeTaxesPaidNet>
    <AATP:ChangesInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseModifications
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">3250</AATP:ChangesInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseModifications>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_803_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zR6JjLOESEf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.
&lt;span id="xdx_82D_ztREWQUryuRe"&gt;ORGANIZATION AND BUSINESS BACKGROUND&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Agape
ATP Corporation, a Nevada corporation (&#x201c;the Company&#x201d;) was incorporated under the laws of the State of Nevada on June 1, 2016.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Agape
ATP Corporation operates through its subsidiaries, namely, Agape ATP Corporation (&#x201c;AATP LB&#x201d;), a company incorporated in Labuan,
Malaysia, and Agape Superior Living Sdn. Bhd. (&#x201c;ASL&#x201d;), a company incorporated in Malaysia. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Agape
ATP Corporation, incorporated in Labuan, Malaysia, is an investment holding company with &lt;span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AgapeATPInternationalHoldingLimitedMember_zc7eTvCZ2HD5" title="Ownership interest percentage"&gt;100&lt;/span&gt;% equity interest in Agape ATP International
Holding Limited (&#x201c;AATP HK&#x201d;), a company incorporated in Hong Kong.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 8, 2020, the Company entered into a Share Exchange Agreement with Mr. How Kok Choong, CEO and director of the Company to acquire
&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20200507__20200508__us-gaap--TypeOfArrangementAxis__custom--ShareExchangeAgreementMember__srt--TitleOfIndividualAxis__custom--MrHowKokChoongMember_z802G6v5C9f9" title="Stock issued during period acquisitions, shares"&gt;9,590,596&lt;/span&gt; ordinary shares, no par value, equivalent to approximately &lt;span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20200508__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zfnUebdMNK4j" title="Ownership interest percentage"&gt;99.99&lt;/span&gt;% of the equity interest in Agape Superior Living Sdn. Bhd.,
a network marketing entity incorporated in Malaysia.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Agape
Superior Living Sdn. Bhd. is a limited company incorporated on August 8, 2003, under the laws of Malaysia.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 11, 2020, the Company incorporated Wellness ATP International Holdings Sdn, Bhd. (&#x201c;WATP&#x201d;), a wholly owned subsidiary
under the laws of Malaysia, to pursue the business of promoting wellness and wellbeing lifestyle of the community by providing services
that includes online editorials, programs, events and campaigns on how to achieve positive wellness and lifestyle.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
November 11, 2021, Agape ATP Corporation (Labuan) formed a joint-venture entity, DSY Wellness International Sdn. Bhd. (&#x201c;DSY Wellness&#x201d;)
with an independent third party which Agape ATP Corporation (Labuan) owns &lt;span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20211111__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zqShoCpWyng9" title="Ownership interest percentage"&gt;60&lt;/span&gt;% of the equity interest, to pursue the business of providing
complementary health therapies&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company and its subsidiaries are principally engaged in the Health and Wellness Industry. The principal activity of the Company is to
supply high-quality health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation,
anti-aging and products designed to improve the overall health system of the human body and various wellness programs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements reflect the activities of the Company, AATP LB, AATP HK, WATP, ASL and its variable interest
entity (&#x201c;VIE&#x201d;), Agape S.E.A. Sdn. Bhd. (&#x201c;SEA&#x201d;) (See Note 3), and DSY Wellness.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_z6jBKz43mij3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Details
of the Company&#x2019;s subsidiaries:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_z4U5U8Q2bO8b" style="display: none"&gt;SCHEDULE OF SUBSIDIARIES AND ASSOCIATES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Subsidiary company name&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Place and date of incorporation&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Particulars of issued capital&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Principal activities&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Proportional of ownership interest and voting power held&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 4%; vertical-align: top"&gt;1.&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--NameOftheCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_z2wgyn1Dpdoi" style="vertical-align: top; width: 16%; text-align: center" title="Subsidiary company name"&gt;Agape ATP Corporation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--PlaceAndDateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_zOH5MKL1PLkj" style="vertical-align: top; width: 16%; text-align: center" title="Place and date of incorporation"&gt;Labuan, &lt;br/&gt; March 6, 2017&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ParticularsOfIssuedCapital_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_zU2TJAdQCsg1" style="vertical-align: top; width: 20%; text-align: center" title="Particulars of issued capital"&gt;100 shares of ordinary share of US$1 each&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--PrincipalActivities_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_z0yc20sqe4e5" style="vertical-align: top; width: 18%; text-align: center" title="Principal activities"&gt;Investment holding&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_zlXDpPQbfo4c" style="width: 16%; text-align: right" title="Proportional of ownership interest and voting power held"&gt;100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;2.&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--NameOftheCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_zwISC4Dfxule" style="vertical-align: top; text-align: center" title="Subsidiary company name"&gt;Agape ATP International Holding Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--PlaceAndDateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_zKZuiXDJIJO9" style="vertical-align: top; text-align: center" title="Place and date of incorporation"&gt;Hong Kong,&lt;br/&gt; June 1, 2017&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ParticularsOfIssuedCapital_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_z1C2yO2Krxjf" style="vertical-align: top; text-align: center" title="Particulars of issued capital"&gt;1,000,000 shares of ordinary share of HK$1 each&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--PrincipalActivities_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_ztkuR8UgE2Ga" style="vertical-align: top; text-align: center" title="Principal activities"&gt;Wholesaling of health and wellness products; and health solution advisory services&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_zhrHuElxQgUb" style="text-align: right" title="Proportional of ownership interest and voting power held"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;3.&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--NameOftheCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zWPZEeulGIaj" style="vertical-align: top; text-align: center" title="Subsidiary company name"&gt;Agape Superior Living Sdn. Bhd.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--PlaceAndDateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_z2vG4JESWMse" style="vertical-align: top; text-align: center" title="Place and date of incorporation"&gt;Malaysia, &lt;br/&gt; August 8, 2003&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ParticularsOfIssuedCapital_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zlxQ0wCJyced" style="vertical-align: top; text-align: center" title="Particulars of issued capital"&gt;9,590,598 shares of ordinary share of RM1 each&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--PrincipalActivities_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zaWmlnQpMVlk" style="vertical-align: top; text-align: center" title="Principal activities"&gt;Health and wellness products and health solution advisory services via network marketing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zRDu6wC8Y65g" style="text-align: right" title="Proportional of ownership interest and voting power held"&gt;99.99&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;4.&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--NameOftheCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_zCQSxQOdMDV6" style="vertical-align: top; text-align: center" title="Subsidiary company name"&gt;Agape S.E.A. Sdn. Bhd.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--PlaceAndDateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_zJkdhPBAnCx6" style="vertical-align: top; text-align: center" title="Place and date of incorporation"&gt;Malaysia, &lt;br/&gt; March 4, 2004&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ParticularsOfIssuedCapital_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_zQVikuygSc68" style="vertical-align: top; text-align: center" title="Particulars of issued capital"&gt;2 shares of ordinary share of RM1 each&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--PrincipalActivities_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_zx9nzdHshE9" style="vertical-align: top; text-align: center" title="Principal activities"&gt;VIE of Agape Superior Living Sdn. Bhd.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;VIE&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;5.&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--NameOftheCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_zVyxdcbNtEw4" style="vertical-align: top; text-align: center" title="Subsidiary company name"&gt;Wellness ATP International Holdings Sdn, Bhd&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--PlaceAndDateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_zQzORBPslp6b" style="vertical-align: top; text-align: center" title="Place and date of incorporation"&gt;Malaysia, &lt;br/&gt; September 11, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ParticularsOfIssuedCapital_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_zzCN2vTm0Nrj" style="vertical-align: top; text-align: center" title="Particulars of issued capital"&gt;100 shares of ordinary share of RM1 each&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--PrincipalActivities_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_z4w9BFgkjcaf" style="vertical-align: top; text-align: center" title="Principal activities"&gt;The promotion of wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_zrwhNipqlX5h" style="text-align: right" title="Proportional of ownership interest and voting power held"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;6.&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--NameOftheCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zPNDKJMYKVCf" style="vertical-align: top; text-align: center" title="Subsidiary company name"&gt;DSY Wellness International Sdn Bhd.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--PlaceAndDateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zkpqjGWY6Im9" style="vertical-align: top; text-align: center" title="Place and date of incorporation"&gt;Malaysia, &lt;br/&gt; November 11, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ParticularsOfIssuedCapital_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zSsNZhMC3uab" style="vertical-align: top; text-align: center" title="Particulars of issued capital"&gt;1,000 shares of ordinary share of RM1 each&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--PrincipalActivities_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_z5jZwgR6At6a" style="vertical-align: top; text-align: center" title="Principal activities"&gt;Provision of complementary health therapies&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zWZ4bln97jE8" style="text-align: right" title="Proportional of ownership interest and voting power held"&gt;60&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zodYUjrS2ead" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.
ORGANIZATION AND BUSINESS BACKGROUND (CONT&#x2019;D)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Business
Overview&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Agape
ATP Corporation is a company that provides health and wellness products and health solution advisory services to our clients. The Company
primarily focus its efforts on attracting customers in Malaysia. Its advisory services center on the &#x201c;ATP Zeta Health Program&#x201d;,
which is a health program designed to effectively prevent diseases caused by polluted environments, unhealthy dietary intake and unhealthy
lifestyles, and promotion of health. The program aims to promote improved health and longevity in our clients through a combination of
modern medicine, proper nutrition and advice from skilled nutritionists and/or dieticians.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
order to strengthen the Company&#x2019;s supply chain, on May 8, 2020, the Company has successfully acquired approximately &lt;span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20200508__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zWwMZGl7fYI9" title="Ownership interest percentage"&gt;99.99&lt;/span&gt;% of ASL,
with the goal of securing an established network marketing sales channel that has been established in Malaysia for the past 15 years.
ASL has been offering the Company&#x2019;s ATP Zeta Health Program as part of its product lineup. As such, the acquisition creates synergy
in the Company&#x2019;s operation by boosting the Company&#x2019;s retail and marketing capabilities. The newly acquired subsidiary allows
the Company to fulfill its mission of &#x201c;helping people to create health and wealth&#x201d; by providing a financially rewarding business
opportunity to distributors and quality products to distributors and customers who seek a healthy lifestyle.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Via
ASL, the Company offers three series of programs which consist of different services and products: ATP Zeta Health Program, &#xc9;NERG&#xc9;TIQUE
and BEAUNIQUE.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
ATP Zeta Health Program is a health program designed to promote health and general wellbeing designed to prevent health diseases caused
by polluted environments, unhealthy dietary intake and unhealthy lifestyles. The program aims to promote improved health and longevity
through a combination of modern health supplements, proper nutrition and advice from skilled dieticians as well as trained members and
distributors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
&#xc9;NERG&#xc9;TIQUE series aims to provide a total dermal solution for a healthy skin beginning from the cellular level. The series
is comprised of the Energy Mask series, Hyaluronic Acid Serum and Mousse Facial Cleanser.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
BEAUNIQUE product series focuses on the research of our diet&#x2019;s impact on modifying gene expressions in order to address genetic
variations and deliver a nutrigenomic solution for every individual.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company deems creating public awareness on wellness and wellbeing lifestyle as essential to enhance the provision of its health solution
advisory services; and therefore, incorporated WATP. Upon its establishment, WATP started collaborating with ASL to carry out various
wellness programs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;To
further its reach in the Health and Wellness Industry, on November 11, 2021, Agape ATP Corporation (Labuan) formed a joint-venture entity,
DSY Wellness International Sdn. Bhd. (&#x201c;DSY Wellness&#x201d;) with an independent third party which Agape ATP Corporation (Labuan)
owns &lt;span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20211111__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zwAGvqoA2HP9" title="Ownership interest percentage"&gt;60&lt;/span&gt;% of the equity interest, to pursue the business of providing complementary health therapies&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-31_custom_AgapeATPInternationalHoldingLimitedMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2020-05-072020-05-08_custom_ShareExchangeAgreementMember_custom_MrHowKokChoongMember"
      decimals="INF"
      unitRef="Shares">9590596</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2020-05-08_custom_SubsidiaryCompanyTwoMember"
      decimals="INF"
      unitRef="Pure">0.9999</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2021-11-11_custom_SubsidiaryCompanyFiveMember"
      decimals="INF"
      unitRef="Pure">0.60</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89B_eus-gaap--ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_z6jBKz43mij3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Details
of the Company&#x2019;s subsidiaries:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_z4U5U8Q2bO8b" style="display: none"&gt;SCHEDULE OF SUBSIDIARIES AND ASSOCIATES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Subsidiary company name&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Place and date of incorporation&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Particulars of issued capital&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Principal activities&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Proportional of ownership interest and voting power held&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 4%; vertical-align: top"&gt;1.&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--NameOftheCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_z2wgyn1Dpdoi" style="vertical-align: top; width: 16%; text-align: center" title="Subsidiary company name"&gt;Agape ATP Corporation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--PlaceAndDateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_zOH5MKL1PLkj" style="vertical-align: top; width: 16%; text-align: center" title="Place and date of incorporation"&gt;Labuan, &lt;br/&gt; March 6, 2017&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ParticularsOfIssuedCapital_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_zU2TJAdQCsg1" style="vertical-align: top; width: 20%; text-align: center" title="Particulars of issued capital"&gt;100 shares of ordinary share of US$1 each&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--PrincipalActivities_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_z0yc20sqe4e5" style="vertical-align: top; width: 18%; text-align: center" title="Principal activities"&gt;Investment holding&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyMember_zlXDpPQbfo4c" style="width: 16%; text-align: right" title="Proportional of ownership interest and voting power held"&gt;100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;2.&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--NameOftheCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_zwISC4Dfxule" style="vertical-align: top; text-align: center" title="Subsidiary company name"&gt;Agape ATP International Holding Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--PlaceAndDateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_zKZuiXDJIJO9" style="vertical-align: top; text-align: center" title="Place and date of incorporation"&gt;Hong Kong,&lt;br/&gt; June 1, 2017&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ParticularsOfIssuedCapital_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_z1C2yO2Krxjf" style="vertical-align: top; text-align: center" title="Particulars of issued capital"&gt;1,000,000 shares of ordinary share of HK$1 each&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--PrincipalActivities_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_ztkuR8UgE2Ga" style="vertical-align: top; text-align: center" title="Principal activities"&gt;Wholesaling of health and wellness products; and health solution advisory services&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyOneMember_zhrHuElxQgUb" style="text-align: right" title="Proportional of ownership interest and voting power held"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;3.&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--NameOftheCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zWPZEeulGIaj" style="vertical-align: top; text-align: center" title="Subsidiary company name"&gt;Agape Superior Living Sdn. Bhd.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--PlaceAndDateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_z2vG4JESWMse" style="vertical-align: top; text-align: center" title="Place and date of incorporation"&gt;Malaysia, &lt;br/&gt; August 8, 2003&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ParticularsOfIssuedCapital_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zlxQ0wCJyced" style="vertical-align: top; text-align: center" title="Particulars of issued capital"&gt;9,590,598 shares of ordinary share of RM1 each&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--PrincipalActivities_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zaWmlnQpMVlk" style="vertical-align: top; text-align: center" title="Principal activities"&gt;Health and wellness products and health solution advisory services via network marketing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyTwoMember_zRDu6wC8Y65g" style="text-align: right" title="Proportional of ownership interest and voting power held"&gt;99.99&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;4.&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--NameOftheCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_zCQSxQOdMDV6" style="vertical-align: top; text-align: center" title="Subsidiary company name"&gt;Agape S.E.A. Sdn. Bhd.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--PlaceAndDateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_zJkdhPBAnCx6" style="vertical-align: top; text-align: center" title="Place and date of incorporation"&gt;Malaysia, &lt;br/&gt; March 4, 2004&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ParticularsOfIssuedCapital_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_zQVikuygSc68" style="vertical-align: top; text-align: center" title="Particulars of issued capital"&gt;2 shares of ordinary share of RM1 each&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--PrincipalActivities_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_zx9nzdHshE9" style="vertical-align: top; text-align: center" title="Principal activities"&gt;VIE of Agape Superior Living Sdn. Bhd.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;VIE&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;5.&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--NameOftheCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_zVyxdcbNtEw4" style="vertical-align: top; text-align: center" title="Subsidiary company name"&gt;Wellness ATP International Holdings Sdn, Bhd&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--PlaceAndDateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_zQzORBPslp6b" style="vertical-align: top; text-align: center" title="Place and date of incorporation"&gt;Malaysia, &lt;br/&gt; September 11, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ParticularsOfIssuedCapital_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_zzCN2vTm0Nrj" style="vertical-align: top; text-align: center" title="Particulars of issued capital"&gt;100 shares of ordinary share of RM1 each&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--PrincipalActivities_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_z4w9BFgkjcaf" style="vertical-align: top; text-align: center" title="Principal activities"&gt;The promotion of wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFourMember_zrwhNipqlX5h" style="text-align: right" title="Proportional of ownership interest and voting power held"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;6.&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--NameOftheCompany_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zPNDKJMYKVCf" style="vertical-align: top; text-align: center" title="Subsidiary company name"&gt;DSY Wellness International Sdn Bhd.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--PlaceAndDateOfIncorporation_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zkpqjGWY6Im9" style="vertical-align: top; text-align: center" title="Place and date of incorporation"&gt;Malaysia, &lt;br/&gt; November 11, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ParticularsOfIssuedCapital_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zSsNZhMC3uab" style="vertical-align: top; text-align: center" title="Particulars of issued capital"&gt;1,000 shares of ordinary share of RM1 each&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--PrincipalActivities_c20220101__20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_z5jZwgR6At6a" style="vertical-align: top; text-align: center" title="Principal activities"&gt;Provision of complementary health therapies&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyFiveMember_zWZ4bln97jE8" style="text-align: right" title="Proportional of ownership interest and voting power held"&gt;60&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock>
    <AATP:NameOftheCompany contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyMember">Agape ATP Corporation</AATP:NameOftheCompany>
    <AATP:PlaceAndDateOfIncorporation contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyMember">Labuan,  March 6, 2017</AATP:PlaceAndDateOfIncorporation>
    <AATP:ParticularsOfIssuedCapital contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyMember">100 shares of ordinary share of US$1 each</AATP:ParticularsOfIssuedCapital>
    <AATP:PrincipalActivities contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyMember">Investment holding</AATP:PrincipalActivities>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-31_custom_SubsidiaryCompanyMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <AATP:NameOftheCompany contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyOneMember">Agape ATP International Holding Limited</AATP:NameOftheCompany>
    <AATP:PlaceAndDateOfIncorporation contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyOneMember">Hong Kong, June 1, 2017</AATP:PlaceAndDateOfIncorporation>
    <AATP:ParticularsOfIssuedCapital contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyOneMember">1,000,000 shares of ordinary share of HK$1 each</AATP:ParticularsOfIssuedCapital>
    <AATP:PrincipalActivities contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyOneMember">Wholesaling of health and wellness products; and health solution advisory services</AATP:PrincipalActivities>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-31_custom_SubsidiaryCompanyOneMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <AATP:NameOftheCompany contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyTwoMember">Agape Superior Living Sdn. Bhd.</AATP:NameOftheCompany>
    <AATP:PlaceAndDateOfIncorporation contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyTwoMember">Malaysia,  August 8, 2003</AATP:PlaceAndDateOfIncorporation>
    <AATP:ParticularsOfIssuedCapital contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyTwoMember">9,590,598 shares of ordinary share of RM1 each</AATP:ParticularsOfIssuedCapital>
    <AATP:PrincipalActivities contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyTwoMember">Health and wellness products and health solution advisory services via network marketing</AATP:PrincipalActivities>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-31_custom_SubsidiaryCompanyTwoMember"
      decimals="INF"
      unitRef="Pure">0.9999</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <AATP:NameOftheCompany contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyThreeMember">Agape S.E.A. Sdn. Bhd.</AATP:NameOftheCompany>
    <AATP:PlaceAndDateOfIncorporation contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyThreeMember">Malaysia,  March 4, 2004</AATP:PlaceAndDateOfIncorporation>
    <AATP:ParticularsOfIssuedCapital contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyThreeMember">2 shares of ordinary share of RM1 each</AATP:ParticularsOfIssuedCapital>
    <AATP:PrincipalActivities contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyThreeMember">VIE of Agape Superior Living Sdn. Bhd.</AATP:PrincipalActivities>
    <AATP:NameOftheCompany contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyFourMember">Wellness ATP International Holdings Sdn, Bhd</AATP:NameOftheCompany>
    <AATP:PlaceAndDateOfIncorporation contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyFourMember">Malaysia,  September 11, 2020</AATP:PlaceAndDateOfIncorporation>
    <AATP:ParticularsOfIssuedCapital contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyFourMember">100 shares of ordinary share of RM1 each</AATP:ParticularsOfIssuedCapital>
    <AATP:PrincipalActivities contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyFourMember">The promotion of wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns</AATP:PrincipalActivities>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-31_custom_SubsidiaryCompanyFourMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <AATP:NameOftheCompany contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyFiveMember">DSY Wellness International Sdn Bhd.</AATP:NameOftheCompany>
    <AATP:PlaceAndDateOfIncorporation contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyFiveMember">Malaysia,  November 11, 2021</AATP:PlaceAndDateOfIncorporation>
    <AATP:ParticularsOfIssuedCapital contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyFiveMember">1,000 shares of ordinary share of RM1 each</AATP:ParticularsOfIssuedCapital>
    <AATP:PrincipalActivities contextRef="From2022-01-012022-12-31_custom_SubsidiaryCompanyFiveMember">Provision of complementary health therapies</AATP:PrincipalActivities>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-31_custom_SubsidiaryCompanyFiveMember"
      decimals="INF"
      unitRef="Pure">0.60</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2020-05-08_custom_SubsidiaryCompanyTwoMember"
      decimals="INF"
      unitRef="Pure">0.9999</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2021-11-11_custom_SubsidiaryCompanyFiveMember"
      decimals="INF"
      unitRef="Pure">0.60</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_z6WrXQERQkr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
&lt;span id="xdx_823_zkfU5HXXyal3"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zNyP0JyAjBg1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zswr0mP2xvua"&gt;Basis
of presentation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#x201c;U.S. GAAP&#x201d;) for information pursuant to the rules and regulations of the Securities Exchange Commission
(&#x201c;SEC&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include the financial statements of the Company, its subsidiaries and its VIE over which the Company
exercises control and, where applicable, entities for which the Company has a controlling financial interest or is the primary beneficiary.
All transactions and balances among the Company, its subsidiaries and its VIE have been eliminated upon consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#x2019;D)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_zjSzSQwxiDdi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zL3GCcj9fsy3"&gt;Principles
of consolidation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsidiaries
are those entities in which the Company, directly or indirectly, controls more than one half of the voting power; or has the power to
govern the financial and operating policies, to appoint or remove the majority of the members of the board of directors, or to cast a
majority of votes at the meeting of directors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
VIE is an entity that has either a total equity investment that is insufficient to permit the entity to finance its activities without
additional subordinated financial support, or whose equity investors lack the characteristics of a controlling financial interest, such
as through voting rights, right to receive the expected residual returns of the entity or obligation to absorb the expected losses of
the entity. The variable interest holder, if any, that has a controlling financial interest in a VIE is deemed to be the primary beneficiary
and must consolidate the VIE. As of and for the year ended December 31, 2022, SEA, the only VIE of the Company has no significant operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--UseOfEstimates_zkjAIul2wCT" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zVJBrVh7U4Aj"&gt;Use
of estimates&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of
the consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant
accounting estimates reflected in the Company&#x2019;s consolidated financial statements include allowance for inventories
obsolescence, impairment of long-lived assets, allowance for deferred tax assets. Actual results could differ from
these estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6f6d91OK2Rc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zsTXHABZLZv4"&gt;Cash
and cash equivalents&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents represent cash on hand, time deposits placed with banks or other financial institutions and all highly liquid investments
with an original maturity of three months or less.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z3H4czMnpm65" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zzkCSgBX4RR5"&gt;Accounts
receivable&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
receivable are recorded at the invoiced amount less an allowance for any uncollectible accounts and do not bear interest, which are due
on credit term. Management reviews the adequacy of the allowance for doubtful accounts on an ongoing basis,
using historical collection trends and aging of receivables. Management also periodically evaluates individual customer&#x2019;s financial
condition, credit history, and the current economic conditions to make adjustments in the allowance when it is considered necessary.
Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery
is considered remote. The Company&#x2019;s management continues to evaluate the reasonableness of the valuation allowance policy and update
it if necessary. As of December 31, 2022 and 2021, &lt;span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_pp0p0_doxL_c20221231_zhiOqmrcPqr8" title="Accounts receivable, allowance for credit loss::XDX::-"&gt;&lt;span id="xdx_901_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_pp0p0_doxL_c20221231_zIRpLQV9Lc8j" title="Accounts receivable, allowance for credit loss::XDX::-"&gt;&lt;span id="xdx_90B_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_pp0p0_doxL_c20211231_zjYfB6tYQihl" title="Accounts receivable, allowance for credit loss::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0585"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0587"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0589"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; allowance of doubtful accounts was recorded.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#x2019;D)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--InventoryPolicyTextBlock_zroHu3uZnh9c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zb5B0Zq2D3Jc"&gt;Inventories&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories
consist of finished goods and are stated at the lower of cost or net realizable value using the first-in first-out method. Management
reviews inventory on hand for estimated obsolescence or unmarketable items, as compared to future demand requirements and the shelf life
of the various products. Based on the review, the Company records inventory write-downs, when necessary, when costs exceed expected net
realizable value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2022 and 2021, the Company recognized $&lt;span id="xdx_90F_ecustom--InventriesWriteDown_pp0p0_c20220101__20221231_zkXsJJfxpgR3" title="Inventories write-down"&gt;5,307&lt;/span&gt; and $&lt;span id="xdx_902_ecustom--InventriesWriteDown_pp0p0_c20210101__20211231_zViMsjV0vVu5" title="Inventories write-down"&gt;36,241&lt;/span&gt; inventory write-down; and $&lt;span id="xdx_902_ecustom--InventoryWriteOff_c20220101__20221231_z1Nv38Qn2qsf" title="Inventories write off"&gt;142,466&lt;/span&gt; and $&lt;span id="xdx_905_ecustom--InventoryWriteOff_dxL_c20210101__20211231_zGY4zxAPf0Q1" title="Inventories write off::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0599"&gt;0&lt;/span&gt;&lt;/span&gt; inventory
write-off, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--PrepaidTaxesPolicyTextBlock_z8UDeXO0uIVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_zJcRJJhWLRv"&gt;Prepaid
taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Prepaid
taxes include prepaid income taxes that will either be refunded or utilized to offset future income tax&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_ecustom--PrepaymentsAndDepositsPolicyTextBlock_zvFkVXX4W746" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_z2uvTEKsIbGb"&gt;Prepayments
and deposits&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepayments
and deposits are mainly cash deposited or advanced to suppliers for future inventory purchases or service providers for future
services. This amount is refundable and bears no interest. For any prepayments and deposits determined by management that such
advances will not be in receipts of inventories, services, or refundable, the Company will recognize an allowance account to reserve
such balances. Management reviews its prepayments and deposits on a regular basis to determine if the allowance is adequate, and
adjusts the allowance when necessary. Delinquent account balances are written-off against allowance for doubtful accounts after
management has determined that the likelihood of collection is not probable. The Company&#x2019;s management continues to evaluate
the reasonableness of the allowance policy and update it if necessary. For the years ended December 31, 2022 and 2021, the Company
wrote-off allowance for doubtful accounts of $&lt;span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_c20220101__20221231_zW6bV9v1bfo2" title="Wrote-off allowance for doubtful accounts"&gt;120,372&lt;/span&gt;
and $&lt;span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_dxL_c20210101__20211231_zFMULrNMoPne" title="Wrote-off allowance for doubtful accounts::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0607"&gt;0&lt;/span&gt;&lt;/span&gt;,
respectively. As of December 31, 2022 and 2021, there was $&lt;span id="xdx_907_ecustom--AllowanceForDoubtfulAccountsReceivablesCurrent_iI_pp0p0_do_c20221231_zGvdFOudWL7c" title="Allowance for doubtful accounts"&gt;0&lt;/span&gt;
and $&lt;span id="xdx_905_ecustom--AllowanceForDoubtfulAccountsReceivablesCurrent_iI_pp0p0_do_c20211231_zv10kvuHJ4n3" title="Allowance for doubtful accounts"&gt;121,514&lt;/span&gt;
allowance for the doubtful accounts recorded.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zgg3hTGkHmZf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zpVTMf0SNNfe"&gt;Property
and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated
useful lives of the assets with no residual value. The estimated useful lives are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_ecustom--ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_zxSyuQKO7vsa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zOyq8RivGFR9" style="display: none"&gt;SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Useful
    Life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer
    and office equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zRaLyCBNVncf" title="Estimated Useful Life of Property and Equipment"&gt;5&lt;/span&gt;-&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zKSowKihepnf" title="Estimated Useful Life of Property and Equipment"&gt;7&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture
    &amp;amp; fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zbVjqFcoASWf" title="Estimated Useful Life of Property and Equipment"&gt;6&lt;/span&gt;-&lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_z0vZeH6V7xCf" title="Estimated Useful Life of Property and Equipment"&gt;7&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
    improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_ziqFH0okZyU7" title="Property and equipment, useful lives"&gt;Lease
    Term&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Vehicle&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zP2bWwILT46e" title="Property and equipment, estimated useful life"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A4_zbgOBOvXHTH4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
cost and related accumulated depreciation of assets sold or otherwise retired are eliminated from the accounts and any gain or loss is
included in the consolidated statements of income and comprehensive income. Expenditures for maintenance and repairs are charged to earnings
as incurred, while additions, renewals and betterments, which are expected to extend the useful life of assets, are capitalized. The
Company also re-evaluates the periods of depreciation to determine whether subsequent events and circumstances warrant revised estimates
of useful lives.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#x2019;D)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zBv5uUAm31Fa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zDVA3pZbA5M9"&gt;Intangible
assets, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_ecustom--ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock_zaVytQwRId14" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets, net, are stated at cost, less accumulated amortization. Amortization expense is recognized on the straight-line basis over the
estimated useful lives of the assets as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zDzRO3Dcan" style="display: none"&gt;SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 80%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Classification&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Useful
    Life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer
    software&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zRsBzurNO1nc" title="Estimated useful lives of intangible assets"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A4_zLUo8k4t2rki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zTvfaNfOGHP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zuAN8gurejM7"&gt;Impairment
for long-lived assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-lived
assets, including property and equipment, and intangible assets with finite lives are reviewed for impairment whenever events or changes
in circumstances (such as a significant adverse change to market conditions that will impact the future use of the assets) indicate that
the carrying value of an asset may not be recoverable. The Company assesses the recoverability of the assets based on the undiscounted
future cash flows the assets are expected to generate and recognize an impairment loss when estimated undiscounted future cash flows
expected to result from the use of the asset plus net proceeds expected from disposition of the asset, if any, are less than the carrying
value of the asset. If an impairment is identified, the Company would reduce the carrying amount of the asset to its estimated fair value
based on a discounted cash flows approach or, when available and appropriate, to comparable market values. As of December 31, 2022 and
2021, &lt;span id="xdx_90D_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20220101__20221231_zRooauhLHRQ6" title="Impairment of long-lived assets"&gt;&lt;span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20210101__20211231_zlATP8y30Bn4" title="Impairment of long-lived assets"&gt;no&lt;/span&gt;&lt;/span&gt; impairment of long-lived assets was recognized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--DeferredChargesPolicyTextBlock_zMw2aKdMtLE7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zx7gkumGIB5b"&gt;Deferred
offering costs&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
offering costs represents costs associated with the Company&#x2019;s current offering which will be netted against the proceeds from the
Company&#x2019;s current offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--MarketableSecuritiesPolicy_z8aS297zZ9zi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zLchEfqtIIXg"&gt;Investment
in marketable equity securities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company follows the provisions of ASU 2016-01, &lt;i&gt;Financial Instruments &#x2013; Overall (Subtopic 825-10): Recognition and Measurement
of Financial Assets and Financial Liabilities&lt;/i&gt;. Investments in marketable equity securities (non-current) are reported at fair value
with changes in fair value recognized in the Company&#x2019;s consolidated statements of operations and comprehensive income (loss) in
the caption of &#x201c;unrealized holding gain loss on marketable securities&#x201d; in each reporting period&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--NonMarketableSecuritiesPolicyTextBlock_zYzL1EUXi7gk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_zhnw5Q0KKIYd"&gt;Investment
in non-marketable equity securities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows the provisions of ASU 2016-01, &lt;i&gt;Financial Instruments &#x2013; Overall (Subtopic 825-10): Recognition and Measurement
of Financial Assets and Financial Liabilities&lt;/i&gt;. Due to the Company&#x2019;s non-marketable equity securities (non-current) does not
qualify for the practical expedient to estimate fair value in accordance with ASC 820-10-35-59, the Company has selected to record its
investments in non-marketable equity securities (non-current) at cost minus impairment, if any, plus or minus changes resulting from
observable price changes in orderly transactions for the identical or a similar investment of the same issue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
each reporting period, the Company will make a qualitative assessment considering impairment indicators to evaluate whether the investment
is impaired. The qualitative assessment indicators include, but are not limited to: (1) A significant deterioration in the earnings performance,
credit rating, asset quality, or business prospects of the investee; (ii) A significant adverse change in the regulatory, economic, or
technological environment of the investee; (iii) A significant adverse change in the general market condition of either the geographical
area or the industry in which the investee operates; (iv) A bona fide offer to purchase, an offer by the investee to sell, or a completed
auction process for the same or similar investment for an amount less than the carrying amount of that investment; and (v) Factors that
raise significant concerns about the investee&#x2019;s ability to continue as a going concern, such as negative cash flows from operations,
working capital deficiencies, or noncompliance with statutory capital requirements or debt covenants. If the qualitative assessment indicators
indicated that the non-marketable equity securities (non-current) is deemed to be impaired, the Company would recognize the impairment
loss equal to the difference between the fair value of the investment and its carrying amount.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#x2019;D)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z3SZaMEFApKc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zgCWme2SuQRb"&gt;Customer
deposits&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Customer
deposits represent amounts advanced by customers on product orders and unapplied unexpired coupons. Customer deposits are reduced
when the related sale is recognized in accordance with the Company&#x2019;s revenue recognition policy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zl9XzPhLY6W4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zL1ebv1bxSTe"&gt;Revenue
recognition&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company adopted Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, Revenue from Contracts with Customers (ASC Topic 606). The core
principle underlying the revenue recognition of this ASU allows the Company to recognize - revenue that represents the transfer of goods
and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange.
This will require the Company to identify contractual performance obligations and determine whether revenue should be recognized at a
point in time or over time, based on when control of goods and services transfers to a customer. The Company&#x2019;s revenue streams
are recognized at a point in time for the Company&#x2019;s sale of health and wellness products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
ASU requires the use of a new five-step model to recognize revenue from customer contracts. The five-step model requires that the Company
(i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction
price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate
the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies
the performance obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for a contract with a customer when the contract is committed in writing, the rights of the parties, including payment
terms, are identified, the contract has commercial substance and consideration is probable of substantially collection.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Sales
of Health and Wellness products&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
&lt;i&gt;Performance obligations satisfied at a point in time&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company derives its revenues from sales contracts with its customers with revenues being recognized when control of the health and wellness
products are transferred to its customer at the Company&#x2019;s office or shipment of the goods. The revenue is recorded net of estimated
discounts and return allowances. Products are given 60 days for returns or exchanges from the date of purchase. Historically, there were
insignificant sales returns.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under the Company&#x2019;s network marketing business, the Company issues
product coupons to members and distributors when these customers made purchases above certain thresholds set by the Company. Depending
on the type of product coupons issued, the coupons carry varying values and can be used by the customers for reduction in the transaction
price of product purchases within the coupon validity period. The value of the product coupons issued is recorded as a reduction of the
Company&#x2019;s revenue account upon issuance; the corresponding amount credited to the customer deposits account. Amounts in customer
deposits will be reversed when the coupons are used. The Company&#x2019;s coupons have a validity period of between six and twelve months.
If the Company&#x2019;s customers did not utilize the coupons after the validity period, the Company would recognize the forfeiture of
the originated sales value of the coupons as net revenues. For the years ended December 31, 2022 and 2021, the Company
recognized $&lt;span id="xdx_905_ecustom--ForfeitedCouponIncome_pp0p0_c20220101__20221231_z1fGausFuaig" title="Value of coupons"&gt;7,543&lt;/span&gt; and $&lt;span id="xdx_90A_ecustom--ForfeitedCouponIncome_pp0p0_c20210101__20211231_zH33eqi84eae" title="Value of coupons"&gt;15,209&lt;/span&gt; as forfeited coupon income, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, the Company had contracts for the sales of health and wellness products amounting to $&lt;span id="xdx_909_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20220101__20221231__srt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_zQlULzaPfKO" title="Cost of revenue"&gt;17,912&lt;/span&gt; which it is expected
to fulfill within 12 months from December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Sales of products for the provision of complementary
health therapies&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Products for the provision of complementary health
therapies are predominantly Chinese herbs in different forms, processed or otherwise, for prescriptions for treating non-communicable
diseases.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#x2019;D)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Provision
of Health and Wellness services&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
&lt;i&gt;Performance obligations satisfied at a point in time&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company carries out its Wellness program, where the Company&#x2019;s products are bundled with health screening test and a health camp
program. The health screening test and the health camp programs are considered as separate performance obligations. The promises to deliver
the health screening test report and the attendance at the health camp are separately identifiable, which are evidenced by the fact that
the Company provides separate services of delivering the health screening test report and allowing admission of the customers to attend
the health camp. The Company derives its revenues from sales contracts with its customers with revenues being recognized when the test
reports are completed and delivered to its customers during the consultation section in person.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also separately derives its revenues from sales contracts with its customers with revenues being recognized when the health
camp program is completed in the final day of the health camp. For the years ended December 31, 2022 and 2021, revenues from
providing health and wellness services are $&lt;span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220101__20221231__srt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_zC5UZ5MD7tQ" title="Revenues"&gt;145,510&lt;/span&gt;
and $&lt;span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210101__20211231__srt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_zOxTFwz9GRPe" title="Revenues"&gt;7,543&lt;/span&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--DisaggregationOfRevenueTableTextBlock_zL1STfYdysn6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Disaggregated
information of revenues by products and services are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_zSBL4CN1dXei" style="display: none"&gt;SCHEDULE OF DIS-AGGREGATED INFORMATION OF REVENUES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220101__20221231_z21abgegsA4l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210101__20211231_z7xtVmlVkoNi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--SurvivorSelectMember_z5LWKevPxJmd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Survivor Select&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;122,470&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;83,904&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--EnergizedMineralConcentrateMember_zr0zkyHoLKi8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Energized Mineral Concentrate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0666"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,047&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--IonizedCalMagMember_zcbfX7scUGK5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Ionized Cal-Mag&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;148,219&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;39,527&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--OmegaBlendMember_zslpoCg1cIPh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Omega Blend&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;272,332&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;222,718&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--BetaMaxxMember_zFBHCEibRUgg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;BetaMaxx&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;137,447&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;208,043&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--VegeFruitFiberMember_zKD0P0DckIMb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Vege Fruit Fiber&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0678"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;65,757&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--IronMember_zqKvQRKr7jQc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Iron&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,697&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,114&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--YoungFormulaMember_zwDXHSYIX4Rj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Young Formula&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31,403&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,425&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--OrganicYouthCarCleansingBarMember_zhkQlF7fn2S8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Organic Youth Care Cleansing Bar&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0687"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--ATPRMITOPlusMember_z3Dq7VueuIXa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;ATPR Mito+&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;271,493&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;183,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--LipomaskMember_zHMa8egFj19d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Lipomask&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0693"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,331&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--EnergetiqueMember_zIfNeHxtjAlg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Energetique&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,089&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,574&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--TrimPlusMember_zkwcgP3YRps5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Trim+&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;88,613&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,042&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--ProductHealthTherapiesMember_zCHcL6QqgpEh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Others &#x2013; Products for the provision of complementary health therapies&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;569,823&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0703"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--OthersMember_zDHxgz4Dsps5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,468&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0706"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zrDljTyzVArc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total revenues &#x2013; products&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,711,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,009,419&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_z2YRBKYgeNg4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Health and Wellness services&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;145,510&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,543&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--Revenues_zUKQbvvSwePf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total revenues &#x2013; products and services&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,856,564&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,016,962&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zE1GaDUQw54k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#x2019;D)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--CostOfSalesPolicyTextBlock_z6hmnXy5OW45" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zskQLX6oS36d"&gt;Cost
of revenue&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Cost
of revenue comprised freight-in, the purchase cost of manufactured goods for sale to customers &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and
products for the provision of complementary health therapies. &lt;span style="background-color: white"&gt;Cost of revenue amounted to $&lt;span id="xdx_90A_eus-gaap--CostOfGoodsAndServicesSold_c20220101__20221231_zJWOrBaL3rZb" title="Cost of revenue"&gt;666,042&lt;/span&gt;
(including inventory write-downs of $&lt;span id="xdx_903_ecustom--InventriesWriteDown_pp0p0_c20220101__20221231_zRagiINTU2v3" title="Inventories write-down"&gt;5,307&lt;/span&gt; and inventory written-off of $&lt;span id="xdx_90A_ecustom--InventoryWriteOff_c20220101__20221231_zfIQAT5Y3WE9" title="Inventories write off"&gt;142,466&lt;/span&gt;) and $&lt;span id="xdx_901_eus-gaap--CostOfGoodsAndServicesSold_c20210101__20211231_zy3tBqIOa1G8" title="Cost of revenue"&gt;297,333&lt;/span&gt; (including inventory write-downs of $&lt;span id="xdx_906_ecustom--InventriesWriteDown_pp0p0_c20210101__20211231_zB1oBXGY34X2" title="Inventories write-down"&gt;36,241&lt;/span&gt;)
for the years ended December 31, 2022 and 2021, respectively&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--ShippingAndHandlingPolicyTextBlock_zvpO8NKxWZUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_z0aGmeBeTpgc"&gt;Shipping
and handling&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shipping
and handling charges amounted to $&lt;span id="xdx_90C_eus-gaap--SellingExpense_pp0p0_c20220101__20221231__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_z6kvkMl8C7zf" title="Selling expenses"&gt;16,585&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--SellingExpense_pp0p0_c20210101__20211231__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zlMEsfQKQ5A9" title="Selling expenses"&gt;11,054&lt;/span&gt; for the years ended December 31, 2022 and 2021, respectively. Shipping and handling
charges are expensed as incurred and included in selling expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--AdvertisingCostsPolicyTextBlock_zPT6muVeN732" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_z7Es73GdWP47"&gt;Advertising
costs&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Advertising
costs amounted to $&lt;span id="xdx_90F_eus-gaap--AdvertisingExpense_pp0p0_c20220101__20221231_zYDnt2NU8M2f" title="Advertising costs"&gt;4,688&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--AdvertisingExpense_pp0p0_c20210101__20211231_zuP4dGeRsy0c" title="Advertising costs"&gt;20,218&lt;/span&gt; for the years ended December 31, 2022 and 2021, respectively. Advertising costs are expensed as
incurred and included in selling expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--CommissionsExpensePolicyPolicyTextBlock_z9Mv3yTzzq3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zZMSQOUlDMA2"&gt;Commission
expenses&lt;/span&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Commission
expenses are the Company&#x2019;s most significant expenses. As with all companies in the network marketing industry, the Company&#x2019;s
sales channel is external to the Company. The Company&#x2019;s &#x201c;external sales force&#x201d; is stratified into two levels based
on priority recruitment. First, there are sales distributors. Second, all members recruited by a sales distributor, directly or indirectly,
are referred to as &#x201c;sales network members&#x201d;. The Company pays commission to every sales distributor based on purchases made
by its sales network members which includes the independent direct sales members. Top performing distributors with their own physical
stores may also become stockists of the Company, whereby they enjoy benefits such as maintaining a certain amount of the Company&#x2019;s
inventory on their store premises. The stockists shall account to the Company for all products sales from their store premises as monitored
through the Company&#x2019;s centralized stock tracking system. The Company pays a separate commission to stockists based on revenue generated
from the stockists&#x2019; physical stores. Commission expenses amounted to $&lt;span id="xdx_90B_eus-gaap--SalesCommissionsAndFees_pp0p0_c20220101__20221231_zX3h03VVO6v1" title="Commission expenses"&gt;405,351&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--SalesCommissionsAndFees_pp0p0_c20210101__20211231_zp2dghig06Jl" title="Commission expenses"&gt;316,267&lt;/span&gt; for the years ended December 31, 2022
and 2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_ecustom--DefinedContributionPlanPolicyTextBlock_zzTqGCuRJEU3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_z5HFBg68sykk"&gt;Defined
contribution plan&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
full-time employees of the Company are entitled to the government mandated defined contribution plan. The Company is required to accrue
and pay for these benefits based on certain percentages of the employees&#x2019; respective salaries, subject to certain ceilings, in
accordance with the relevant government regulations, and make cash contributions to the government mandated defined contribution plan&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
Total expenses for the plans were $&lt;span id="xdx_906_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pp0p0_c20220101__20221231_zVicH7EgFDLa" title="Defined contribution plan expense"&gt;133,489&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pp0p0_c20210101__20211231_zfGWX5OFpjta" title="Defined contribution plan expense"&gt;99,488&lt;/span&gt; for the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
related contribution plans include:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Social
    Security Organization (&#x201c;SOSCO&#x201d;) &#x2013; &lt;span id="xdx_90A_ecustom--SalaryPercentage_pid_dp_c20220101__20221231__dei--LegalEntityAxis__custom--SocialSecurityOrganizationMember_zBxcFz5qfd16" title="Salary percentage"&gt;1.75&lt;/span&gt;% based on employee&#x2019;s monthly salary capped of RM &lt;span id="xdx_90E_ecustom--MonthlySalary_uRM_c20220101__20221231__dei--LegalEntityAxis__custom--SocialSecurityOrganizationMember_zF3FRUewo47b" title="Monthly salary"&gt;5,000&lt;/span&gt;;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Employees
    Provident Fund (&#x201c;EPF&#x201d;) &#x2013;based on employee&#x2019;s monthly salary, &lt;span id="xdx_90D_ecustom--SalaryPercentage_pid_dp_c20220101__20221231__dei--LegalEntityAxis__custom--EmployeesProvidentFundMember__srt--RangeAxis__srt--MinimumMember_zQriZXqhOcEf" title="Salary percentage"&gt;13&lt;/span&gt;% for employee earning RM&lt;span id="xdx_90E_ecustom--MonthlySalary_uRM_c20220101__20221231__dei--LegalEntityAxis__custom--EmployeesProvidentFundMember__srt--RangeAxis__srt--MinimumMember_zhjGzhzfJlAc" title="Monthly salary"&gt;5,000&lt;/span&gt; and below; and
    &lt;span id="xdx_90E_ecustom--SalaryPercentage_pid_dp_c20220101__20221231__dei--LegalEntityAxis__custom--EmployeesProvidentFundMember__srt--RangeAxis__srt--MinimumMember__srt--RangeAxis__srt--MaximumMember_z2esrfOwXpSb" title="Salary percentage"&gt;12&lt;/span&gt;% for employee earning RM&lt;span id="xdx_906_ecustom--MonthlySalary_uRM_c20220101__20221231__dei--LegalEntityAxis__custom--EmployeesProvidentFundMember__srt--RangeAxis__srt--MaximumMember_zWZBWgz0MTwk" title="Monthly salary"&gt;5,001&lt;/span&gt; and above.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Employment
    Insurance System (&#x201c;EIS&#x201d;) &#x2013; &lt;span id="xdx_90C_ecustom--SalaryPercentage_pid_dp_c20220101__20221231__dei--LegalEntityAxis__custom--EmploymentInsuranceSystemMember_zRHbOFUNH1f1" title="Salary percentage"&gt;0.2&lt;/span&gt;% based on employee&#x2019;s monthly salary capped of RM &lt;span id="xdx_90E_ecustom--MonthlySalary_uRM_c20220101__20221231__dei--LegalEntityAxis__custom--EmploymentInsuranceSystemMember_ztc1arIXPmgb" title="Monthly salary"&gt;5,000&lt;/span&gt;;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Human
    Resource Development Fund (&#x201c;HRDF&#x201d;) &#x2013; &lt;span id="xdx_907_ecustom--SalaryPercentage_pid_dp_c20220101__20221231__dei--LegalEntityAxis__custom--HumanResourceDevelopmentFundMember_zZfEeTcMmTd6" title="Salary percentage"&gt;1&lt;/span&gt;% based on employee&#x2019;s monthly salary&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#x2019;D)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zZdZiC8AkEH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zCkcAvFtpGea"&gt;Income
taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes in accordance with U.S. GAAP for income taxes. The charge for taxation is based on the results for
the fiscal year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted
or substantively enacted by the balance sheet date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
taxes is accounted for using the asset and liability method in respect of temporary differences arising from differences between the
carrying amount of assets and liabilities in the consolidated financial statements and the corresponding tax basis used in the computation
of assessable tax profit. In principle, deferred tax liabilities are recognized for all taxable temporary differences. Deferred tax assets
are recognized to the extent that it is probable that taxable profit will be available against which deductible temporary differences
can be utilized. Deferred tax is calculated using tax rates that are expected to apply to the period when the asset is realized or the
liability is settled. Deferred tax is charged or credited in the income statement, except when it is related to items credited or charged
directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets are reduced by a valuation allowance
when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.
Current income taxes are provided for in accordance with the laws of the relevant taxing authorities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An
uncertain tax position is recognized as a benefit only if it is &#x201c;more likely than not&#x201d; that the tax position would be sustained
in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that
is &lt;span id="xdx_90F_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20220101__20221231_zridEaAy3q5d" title="Income tax description"&gt;greater than 50%&lt;/span&gt; likely of being realized on examination. For tax positions not meeting the &#x201c;more likely than not&#x201d; test,
no tax benefit is recorded. $&lt;span id="xdx_905_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_pp0p0_c20220101__20221231_zPKdG0hn2bma" title="Income tax examination, penalties and interest expense"&gt;0&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_pp0p0_c20210101__20211231_zSFYTL7JYgi1" title="Income tax examination, penalties and interest expense"&gt;395&lt;/span&gt; penalties and interest incurred related to underpayment of income tax for the years ended December
31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company conducts much of its business activities in Hong Kong and Malaysia and is subject to tax in each of their jurisdictions. As a
result of its business activities, the Company will file separate tax returns that are subject to examination by the foreign tax authorities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zAIQ7gf36Ghj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zwYFtkBQLvFa"&gt;Comprehensive
income (loss)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive
income (loss) consists of two components, net income (loss) and other comprehensive income (loss). Net income (loss) refers to revenue,
expenses, gains and losses that under GAAP are recorded as an element of stockholders&#x2019; equity but are excluded from net income.
Other comprehensive income (loss) consists of a foreign currency translation adjustment resulting from the Company not using the U.S.
dollar as its functional currencies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_ecustom--NoncontrollingInterestPolicyTextBlock_zUmxJoS2Nq6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_z3pSSXQCI64h"&gt;Non-controlling
interest&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--MinorityInterestDescription_c20220101__20221231_z3bBup5MmeXk" title="Noncontrolling interest, description"&gt;Non-controlling
interest consists of 40% of the equity interests of DSY Wellness held by an individual and approximately 0.01% (2 ordinary shares out
of 9,590,598 shares) of the equity interests of ASL held by two individuals&lt;/span&gt;. The non-controlling interests are presented in the consolidated
balance sheets, separately from equity attributable to the shareholders of the Company. Non-controlling interests in the results of the
Company are presented on the face of the consolidated statements of operations as an allocation of the total income or loss for the periods
between non-controlling interest holders and the shareholders of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#x2019;D)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zYeCXifgtjIc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_z17u0oqw1S65"&gt;Earnings
(loss) per share&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company computes earnings (loss) per share (&#x201c;EPS&#x201d;) in accordance with ASC 260, &#x201c;Earnings per Share&#x201d;. ASC 260
requires companies to present basic and diluted EPS. Basic EPS is measured as net income divided by the weighted average ordinary share
outstanding for the period. Diluted EPS presents the dilutive effect on a per share basis of the potential ordinary shares (e.g., convertible
securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later.
Potential ordinary shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are
excluded from the calculation of diluted EPS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;. For the
years ended December 31, 2022 and 2021, there were &lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20220101__20221231_zZU9VYbmnxme" title="Potentially dilutive securities outstanding"&gt;&lt;span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20210101__20211231_zTFE6S4QfcGg" title="Potentially dilutive securities outstanding"&gt;no&lt;/span&gt;&lt;/span&gt; dilutive shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zpmvue0RnR04" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zeX8FIyxsbb9"&gt;Foreign
currencies translation and transaction&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transactions
denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing
at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated
into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded
in the consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
reporting currency of the Company is United States Dollars (&#x201c;US$&#x201d;) and the accompanying financial statements have been expressed
in US$. The Company&#x2019;s subsidiary in Labuan maintains its books and record in United States Dollars (&#x201c;US$&#x201d;) albeit its
functional currency being the primary currency of the economic environment in which the entity operates, which is the Malaysian Ringgit
(&#x201c;MYR&#x201d; or &#x201c;RM&#x201d;). The Company&#x2019;s subsidiary in Hong Kong maintains its books and record in Hong Kong Dollars
(&#x201c;HK$&#x201d;), similar to its functional currency. The Company&#x2019;s subsidiary and VIE in Malaysia conducts its businesses and
maintains its books and record in the local currency, Malaysian Ringgit (&#x201c;MYR&#x201d; or &#x201c;RM&#x201d;), as its functional currency.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into
US$, in accordance with ASC Topic 830-30, &#x201c;&lt;i&gt;Translation of Financial Statement&#x201d;&lt;/i&gt;, using the exchange rate on the balance
sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation
of financial statements of foreign subsidiary are recorded as a separate component of accumulated other comprehensive income within the
statements of stockholders&#x2019; equity. Cash flows are also translated at average translation rates for the periods, therefore, amounts
reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance
sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_zTYA4P9FOinb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Translation
of foreign currencies into US$1 have been made at the following exchange rates for the respective periods:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zdv4I7CXhGol" style="display: none"&gt;SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_zgy5lSiaUnqg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20211231_zsVB6e9RZDpg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hus-gaap--VariableRateAxis__custom--PeriodEndMYRMember_zFRhCxqqi3Eh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Period-end MYR : US$1 exchange rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;4.41&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;4.18&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hus-gaap--VariableRateAxis__custom--PeriodEndHKDMember_zLYf4zb3Voe5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Period-end HKD : US$1 exchange rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hus-gaap--VariableRateAxis__custom--PeriodEndHKDMember_ziM6JpnK0o6" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Foreign currency exchange
    rate, translation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20220101__20221231_zu9ykfzTy0w3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210101__20211231_zaKDMyylVgMj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--ForeignCurrencyExchangeRateAverage_hus-gaap--VariableRateAxis__custom--PeriodAverageMYRMember_zqsIpHu1yyE" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Period-average MYR : US$1 exchange rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;4.41&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;4.14&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--ForeignCurrencyExchangeRateAverage_hus-gaap--VariableRateAxis__custom--PeriodAverageHKDMember_zecoVeo3Tg3a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Period-average HKD : US$1 exchange rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.83&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.77&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--ForeignCurrencyExchangeRateAverage_hus-gaap--VariableRateAxis__custom--PeriodAverageHKDMember_zCDRKLJohb0b" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Foreign currency exchange
    rate period average&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.83&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.77&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zR6kyPJj6KLc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#x2019;D)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_ecustom--RelatedPartiesPolicyTextBlock_zI7d5N4JYGed" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zRTbziKHfAwb"&gt;Related
parties&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Parties,
which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control
the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also
considered to be related if they are subject to common control or common significant influence.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zE82vognobm5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_zepRYIYYprik"&gt;Fair
value of financial instruments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accounting standard regarding fair value of financial instruments and related fair value measurements defines financial instruments and
requires disclosure of the fair value of financial instruments held by the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accounting standards define fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance
disclosure requirements for fair value measures. The three levels are defined as follow:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that
    are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3 inputs to the valuation methodology are unobservable and significant to the fair value.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments included in current assets and current liabilities are reported in the consolidated balance sheets at face value or cost,
which approximate fair value because of the short period of time between the origination of such instruments and their expected realization
and their current market rates of interest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--LesseeLeasesPolicyTextBlock_z3UFyt6sece6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zibQIkWeu1wg"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company adopted ASU 2016-02, &#x201c;Leases&#x201d; (Topic 842), and elected the practical expedients that does not require the Company
to reassess: (1) whether any expired or existing contracts are, or contain, leases, (2) lease classification for any expired or existing
leases and (3) initial direct costs for any expired or existing leases. For lease terms of twelve months or fewer, a lessee is permitted
to make an accounting policy election not to recognize lease assets and liabilities. The Company also adopts the practical expedient
that allows lessees to treat the lease and non-lease components of a lease as a single lease component. Some of the Company&#x2019;s leases
include one or more options to renew, which is typically at the Company&#x2019;s sole discretion. The Company regularly evaluates the
renewal options, and, when it is reasonably certain of exercise, it will include the renewal period in its lease term. New lease modifications
result in re-measurement of the right of use (&#x201c;ROU&#x201d;) assets and lease liabilities. Operating ROU assets and lease liabilities
are recognized at the commencement date, based on the present value of lease payments over the lease term. Since the implicit rate for
the Company&#x2019;s leases is not readily determinable, the Company use its incremental borrowing rate based on the information available
at the commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that
the Company would have to pay to borrow, on a collateralized basis, an amount equal to the lease payments, in a similar economic environment
and over a similar term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#x2019;D)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
terms used to calculate the present value of lease payments generally do not include any options to extend, renew, or terminate the lease,
as the Company does not have reasonable certainty at lease inception that these options will be exercised. The Company generally considers
the economic life of its operating lease ROU assets to be comparable to the useful life of similar owned assets. The Company has elected
the short-term lease exception, therefore operating lease ROU assets and liabilities do not include leases with a lease term of twelve
months or less. Its leases generally do not provide a residual guarantee. The operating lease ROU asset also excludes lease incentives.
Lease expense is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviews the impairment of its ROU assets consistent with the approach applied for its other long-lived assets. The Company reviews
the recoverability of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the
asset may not be recoverable. The assessment of possible impairment is based on its ability to recover the carrying value of the asset
from the expected undiscounted future pre-tax cash flows of the related operations. The Company has elected to include the carrying amount
of operating lease liabilities in any tested asset group and includes the associated operating lease payments in the undiscounted future
pre-tax cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zOEqo9L2pkTk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zkQqYFp7vst4"&gt;Recent
accounting pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has reviewed all recently issued, but not yet effective, considers the applicability and impact of all accounting standards updates
(&#x201c;ASUs&#x201d;). Management periodically reviews new accounting standards that are issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2019, the FASB issued ASU No. 2019-10, which to update the effective date of ASU No. 2016-13 for private companies, not-for-profit
organizations and certain smaller reporting companies applying for credit losses, leases, and hedging standard. The new effective date
for these preparers is for fiscal years beginning after December 15, 2022. ASU 2019-05 is effective for the Company for annual and interim
reporting periods beginning January 1, 2023 as the Company is qualified as a smaller reporting company. The Company is currently evaluating
the impact ASUs 2016-13 and 2019-05 may have on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Except
for the above-mentioned pronouncements, there are no new recent issued accounting standards that will have a material impact on the consolidated
financial position, statements of operations and cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_85D_zpd7CU8LeYd4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_844_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zNyP0JyAjBg1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zswr0mP2xvua"&gt;Basis
of presentation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#x201c;U.S. GAAP&#x201d;) for information pursuant to the rules and regulations of the Securities Exchange Commission
(&#x201c;SEC&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include the financial statements of the Company, its subsidiaries and its VIE over which the Company
exercises control and, where applicable, entities for which the Company has a controlling financial interest or is the primary beneficiary.
All transactions and balances among the Company, its subsidiaries and its VIE have been eliminated upon consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#x2019;D)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_zjSzSQwxiDdi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zL3GCcj9fsy3"&gt;Principles
of consolidation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsidiaries
are those entities in which the Company, directly or indirectly, controls more than one half of the voting power; or has the power to
govern the financial and operating policies, to appoint or remove the majority of the members of the board of directors, or to cast a
majority of votes at the meeting of directors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
VIE is an entity that has either a total equity investment that is insufficient to permit the entity to finance its activities without
additional subordinated financial support, or whose equity investors lack the characteristics of a controlling financial interest, such
as through voting rights, right to receive the expected residual returns of the entity or obligation to absorb the expected losses of
the entity. The variable interest holder, if any, that has a controlling financial interest in a VIE is deemed to be the primary beneficiary
and must consolidate the VIE. As of and for the year ended December 31, 2022, SEA, the only VIE of the Company has no significant operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_847_eus-gaap--UseOfEstimates_zkjAIul2wCT" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zVJBrVh7U4Aj"&gt;Use
of estimates&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of
the consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant
accounting estimates reflected in the Company&#x2019;s consolidated financial statements include allowance for inventories
obsolescence, impairment of long-lived assets, allowance for deferred tax assets. Actual results could differ from
these estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6f6d91OK2Rc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zsTXHABZLZv4"&gt;Cash
and cash equivalents&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents represent cash on hand, time deposits placed with banks or other financial institutions and all highly liquid investments
with an original maturity of three months or less.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_847_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z3H4czMnpm65" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zzkCSgBX4RR5"&gt;Accounts
receivable&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
receivable are recorded at the invoiced amount less an allowance for any uncollectible accounts and do not bear interest, which are due
on credit term. Management reviews the adequacy of the allowance for doubtful accounts on an ongoing basis,
using historical collection trends and aging of receivables. Management also periodically evaluates individual customer&#x2019;s financial
condition, credit history, and the current economic conditions to make adjustments in the allowance when it is considered necessary.
Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery
is considered remote. The Company&#x2019;s management continues to evaluate the reasonableness of the valuation allowance policy and update
it if necessary. As of December 31, 2022 and 2021, &lt;span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_pp0p0_doxL_c20221231_zhiOqmrcPqr8" title="Accounts receivable, allowance for credit loss::XDX::-"&gt;&lt;span id="xdx_901_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_pp0p0_doxL_c20221231_zIRpLQV9Lc8j" title="Accounts receivable, allowance for credit loss::XDX::-"&gt;&lt;span id="xdx_90B_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_pp0p0_doxL_c20211231_zjYfB6tYQihl" title="Accounts receivable, allowance for credit loss::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0585"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0587"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0589"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; allowance of doubtful accounts was recorded.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#x2019;D)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_844_eus-gaap--InventoryPolicyTextBlock_zroHu3uZnh9c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zb5B0Zq2D3Jc"&gt;Inventories&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories
consist of finished goods and are stated at the lower of cost or net realizable value using the first-in first-out method. Management
reviews inventory on hand for estimated obsolescence or unmarketable items, as compared to future demand requirements and the shelf life
of the various products. Based on the review, the Company records inventory write-downs, when necessary, when costs exceed expected net
realizable value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2022 and 2021, the Company recognized $&lt;span id="xdx_90F_ecustom--InventriesWriteDown_pp0p0_c20220101__20221231_zkXsJJfxpgR3" title="Inventories write-down"&gt;5,307&lt;/span&gt; and $&lt;span id="xdx_902_ecustom--InventriesWriteDown_pp0p0_c20210101__20211231_zViMsjV0vVu5" title="Inventories write-down"&gt;36,241&lt;/span&gt; inventory write-down; and $&lt;span id="xdx_902_ecustom--InventoryWriteOff_c20220101__20221231_z1Nv38Qn2qsf" title="Inventories write off"&gt;142,466&lt;/span&gt; and $&lt;span id="xdx_905_ecustom--InventoryWriteOff_dxL_c20210101__20211231_zGY4zxAPf0Q1" title="Inventories write off::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0599"&gt;0&lt;/span&gt;&lt;/span&gt; inventory
write-off, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <AATP:InventriesWriteDown
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">5307</AATP:InventriesWriteDown>
    <AATP:InventriesWriteDown
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">36241</AATP:InventriesWriteDown>
    <AATP:InventoryWriteOff
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">142466</AATP:InventoryWriteOff>
    <AATP:PrepaidTaxesPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84E_ecustom--PrepaidTaxesPolicyTextBlock_z8UDeXO0uIVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_zJcRJJhWLRv"&gt;Prepaid
taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Prepaid
taxes include prepaid income taxes that will either be refunded or utilized to offset future income tax&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</AATP:PrepaidTaxesPolicyTextBlock>
    <AATP:PrepaymentsAndDepositsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_841_ecustom--PrepaymentsAndDepositsPolicyTextBlock_zvFkVXX4W746" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_z2uvTEKsIbGb"&gt;Prepayments
and deposits&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepayments
and deposits are mainly cash deposited or advanced to suppliers for future inventory purchases or service providers for future
services. This amount is refundable and bears no interest. For any prepayments and deposits determined by management that such
advances will not be in receipts of inventories, services, or refundable, the Company will recognize an allowance account to reserve
such balances. Management reviews its prepayments and deposits on a regular basis to determine if the allowance is adequate, and
adjusts the allowance when necessary. Delinquent account balances are written-off against allowance for doubtful accounts after
management has determined that the likelihood of collection is not probable. The Company&#x2019;s management continues to evaluate
the reasonableness of the allowance policy and update it if necessary. For the years ended December 31, 2022 and 2021, the Company
wrote-off allowance for doubtful accounts of $&lt;span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_c20220101__20221231_zW6bV9v1bfo2" title="Wrote-off allowance for doubtful accounts"&gt;120,372&lt;/span&gt;
and $&lt;span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_dxL_c20210101__20211231_zFMULrNMoPne" title="Wrote-off allowance for doubtful accounts::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0607"&gt;0&lt;/span&gt;&lt;/span&gt;,
respectively. As of December 31, 2022 and 2021, there was $&lt;span id="xdx_907_ecustom--AllowanceForDoubtfulAccountsReceivablesCurrent_iI_pp0p0_do_c20221231_zGvdFOudWL7c" title="Allowance for doubtful accounts"&gt;0&lt;/span&gt;
and $&lt;span id="xdx_905_ecustom--AllowanceForDoubtfulAccountsReceivablesCurrent_iI_pp0p0_do_c20211231_zv10kvuHJ4n3" title="Allowance for doubtful accounts"&gt;121,514&lt;/span&gt;
allowance for the doubtful accounts recorded.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</AATP:PrepaymentsAndDepositsPolicyTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">120372</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <AATP:AllowanceForDoubtfulAccountsReceivablesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">0</AATP:AllowanceForDoubtfulAccountsReceivablesCurrent>
    <AATP:AllowanceForDoubtfulAccountsReceivablesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">121514</AATP:AllowanceForDoubtfulAccountsReceivablesCurrent>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zgg3hTGkHmZf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zpVTMf0SNNfe"&gt;Property
and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated
useful lives of the assets with no residual value. The estimated useful lives are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_ecustom--ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_zxSyuQKO7vsa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zOyq8RivGFR9" style="display: none"&gt;SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Useful
    Life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer
    and office equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zRaLyCBNVncf" title="Estimated Useful Life of Property and Equipment"&gt;5&lt;/span&gt;-&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zKSowKihepnf" title="Estimated Useful Life of Property and Equipment"&gt;7&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture
    &amp;amp; fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zbVjqFcoASWf" title="Estimated Useful Life of Property and Equipment"&gt;6&lt;/span&gt;-&lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_z0vZeH6V7xCf" title="Estimated Useful Life of Property and Equipment"&gt;7&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
    improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_ziqFH0okZyU7" title="Property and equipment, useful lives"&gt;Lease
    Term&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Vehicle&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zP2bWwILT46e" title="Property and equipment, estimated useful life"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A4_zbgOBOvXHTH4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
cost and related accumulated depreciation of assets sold or otherwise retired are eliminated from the accounts and any gain or loss is
included in the consolidated statements of income and comprehensive income. Expenditures for maintenance and repairs are charged to earnings
as incurred, while additions, renewals and betterments, which are expected to extend the useful life of assets, are capitalized. The
Company also re-evaluates the periods of depreciation to determine whether subsequent events and circumstances warrant revised estimates
of useful lives.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#x2019;D)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <AATP:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_892_ecustom--ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_zxSyuQKO7vsa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zOyq8RivGFR9" style="display: none"&gt;SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Useful
    Life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer
    and office equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zRaLyCBNVncf" title="Estimated Useful Life of Property and Equipment"&gt;5&lt;/span&gt;-&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zKSowKihepnf" title="Estimated Useful Life of Property and Equipment"&gt;7&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture
    &amp;amp; fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zbVjqFcoASWf" title="Estimated Useful Life of Property and Equipment"&gt;6&lt;/span&gt;-&lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_z0vZeH6V7xCf" title="Estimated Useful Life of Property and Equipment"&gt;7&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
    improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_ziqFH0okZyU7" title="Property and equipment, useful lives"&gt;Lease
    Term&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Vehicle&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zP2bWwILT46e" title="Property and equipment, estimated useful life"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</AATP:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MinimumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MaximumMember">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember">P6Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="From2022-01-012022-12-31_us-gaap_LeaseholdImprovementsMember">Lease
    Term</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-12-31_us-gaap_VehiclesMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84D_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zBv5uUAm31Fa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zDVA3pZbA5M9"&gt;Intangible
assets, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_ecustom--ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock_zaVytQwRId14" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets, net, are stated at cost, less accumulated amortization. Amortization expense is recognized on the straight-line basis over the
estimated useful lives of the assets as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zDzRO3Dcan" style="display: none"&gt;SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 80%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Classification&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Useful
    Life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer
    software&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zRsBzurNO1nc" title="Estimated useful lives of intangible assets"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A4_zLUo8k4t2rki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <AATP:ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89B_ecustom--ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock_zaVytQwRId14" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets, net, are stated at cost, less accumulated amortization. Amortization expense is recognized on the straight-line basis over the
estimated useful lives of the assets as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zDzRO3Dcan" style="display: none"&gt;SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 80%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Classification&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Useful
    Life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer
    software&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zRsBzurNO1nc" title="Estimated useful lives of intangible assets"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</AATP:ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2022-01-012022-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84D_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zTvfaNfOGHP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zuAN8gurejM7"&gt;Impairment
for long-lived assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-lived
assets, including property and equipment, and intangible assets with finite lives are reviewed for impairment whenever events or changes
in circumstances (such as a significant adverse change to market conditions that will impact the future use of the assets) indicate that
the carrying value of an asset may not be recoverable. The Company assesses the recoverability of the assets based on the undiscounted
future cash flows the assets are expected to generate and recognize an impairment loss when estimated undiscounted future cash flows
expected to result from the use of the asset plus net proceeds expected from disposition of the asset, if any, are less than the carrying
value of the asset. If an impairment is identified, the Company would reduce the carrying amount of the asset to its estimated fair value
based on a discounted cash flows approach or, when available and appropriate, to comparable market values. As of December 31, 2022 and
2021, &lt;span id="xdx_90D_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20220101__20221231_zRooauhLHRQ6" title="Impairment of long-lived assets"&gt;&lt;span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pp0p0_do_c20210101__20211231_zlATP8y30Bn4" title="Impairment of long-lived assets"&gt;no&lt;/span&gt;&lt;/span&gt; impairment of long-lived assets was recognized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_842_eus-gaap--DeferredChargesPolicyTextBlock_zMw2aKdMtLE7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zx7gkumGIB5b"&gt;Deferred
offering costs&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
offering costs represents costs associated with the Company&#x2019;s current offering which will be netted against the proceeds from the
Company&#x2019;s current offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_848_eus-gaap--MarketableSecuritiesPolicy_z8aS297zZ9zi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zLchEfqtIIXg"&gt;Investment
in marketable equity securities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company follows the provisions of ASU 2016-01, &lt;i&gt;Financial Instruments &#x2013; Overall (Subtopic 825-10): Recognition and Measurement
of Financial Assets and Financial Liabilities&lt;/i&gt;. Investments in marketable equity securities (non-current) are reported at fair value
with changes in fair value recognized in the Company&#x2019;s consolidated statements of operations and comprehensive income (loss) in
the caption of &#x201c;unrealized holding gain loss on marketable securities&#x201d; in each reporting period&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:MarketableSecuritiesPolicy>
    <AATP:NonMarketableSecuritiesPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84F_ecustom--NonMarketableSecuritiesPolicyTextBlock_zYzL1EUXi7gk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_zhnw5Q0KKIYd"&gt;Investment
in non-marketable equity securities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows the provisions of ASU 2016-01, &lt;i&gt;Financial Instruments &#x2013; Overall (Subtopic 825-10): Recognition and Measurement
of Financial Assets and Financial Liabilities&lt;/i&gt;. Due to the Company&#x2019;s non-marketable equity securities (non-current) does not
qualify for the practical expedient to estimate fair value in accordance with ASC 820-10-35-59, the Company has selected to record its
investments in non-marketable equity securities (non-current) at cost minus impairment, if any, plus or minus changes resulting from
observable price changes in orderly transactions for the identical or a similar investment of the same issue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
each reporting period, the Company will make a qualitative assessment considering impairment indicators to evaluate whether the investment
is impaired. The qualitative assessment indicators include, but are not limited to: (1) A significant deterioration in the earnings performance,
credit rating, asset quality, or business prospects of the investee; (ii) A significant adverse change in the regulatory, economic, or
technological environment of the investee; (iii) A significant adverse change in the general market condition of either the geographical
area or the industry in which the investee operates; (iv) A bona fide offer to purchase, an offer by the investee to sell, or a completed
auction process for the same or similar investment for an amount less than the carrying amount of that investment; and (v) Factors that
raise significant concerns about the investee&#x2019;s ability to continue as a going concern, such as negative cash flows from operations,
working capital deficiencies, or noncompliance with statutory capital requirements or debt covenants. If the qualitative assessment indicators
indicated that the non-marketable equity securities (non-current) is deemed to be impaired, the Company would recognize the impairment
loss equal to the difference between the fair value of the investment and its carrying amount.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#x2019;D)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</AATP:NonMarketableSecuritiesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84D_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z3SZaMEFApKc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zgCWme2SuQRb"&gt;Customer
deposits&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Customer
deposits represent amounts advanced by customers on product orders and unapplied unexpired coupons. Customer deposits are reduced
when the related sale is recognized in accordance with the Company&#x2019;s revenue recognition policy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zl9XzPhLY6W4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zL1ebv1bxSTe"&gt;Revenue
recognition&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company adopted Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, Revenue from Contracts with Customers (ASC Topic 606). The core
principle underlying the revenue recognition of this ASU allows the Company to recognize - revenue that represents the transfer of goods
and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange.
This will require the Company to identify contractual performance obligations and determine whether revenue should be recognized at a
point in time or over time, based on when control of goods and services transfers to a customer. The Company&#x2019;s revenue streams
are recognized at a point in time for the Company&#x2019;s sale of health and wellness products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
ASU requires the use of a new five-step model to recognize revenue from customer contracts. The five-step model requires that the Company
(i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction
price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate
the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies
the performance obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for a contract with a customer when the contract is committed in writing, the rights of the parties, including payment
terms, are identified, the contract has commercial substance and consideration is probable of substantially collection.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Sales
of Health and Wellness products&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
&lt;i&gt;Performance obligations satisfied at a point in time&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company derives its revenues from sales contracts with its customers with revenues being recognized when control of the health and wellness
products are transferred to its customer at the Company&#x2019;s office or shipment of the goods. The revenue is recorded net of estimated
discounts and return allowances. Products are given 60 days for returns or exchanges from the date of purchase. Historically, there were
insignificant sales returns.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under the Company&#x2019;s network marketing business, the Company issues
product coupons to members and distributors when these customers made purchases above certain thresholds set by the Company. Depending
on the type of product coupons issued, the coupons carry varying values and can be used by the customers for reduction in the transaction
price of product purchases within the coupon validity period. The value of the product coupons issued is recorded as a reduction of the
Company&#x2019;s revenue account upon issuance; the corresponding amount credited to the customer deposits account. Amounts in customer
deposits will be reversed when the coupons are used. The Company&#x2019;s coupons have a validity period of between six and twelve months.
If the Company&#x2019;s customers did not utilize the coupons after the validity period, the Company would recognize the forfeiture of
the originated sales value of the coupons as net revenues. For the years ended December 31, 2022 and 2021, the Company
recognized $&lt;span id="xdx_905_ecustom--ForfeitedCouponIncome_pp0p0_c20220101__20221231_z1fGausFuaig" title="Value of coupons"&gt;7,543&lt;/span&gt; and $&lt;span id="xdx_90A_ecustom--ForfeitedCouponIncome_pp0p0_c20210101__20211231_zH33eqi84eae" title="Value of coupons"&gt;15,209&lt;/span&gt; as forfeited coupon income, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, the Company had contracts for the sales of health and wellness products amounting to $&lt;span id="xdx_909_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20220101__20221231__srt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_zQlULzaPfKO" title="Cost of revenue"&gt;17,912&lt;/span&gt; which it is expected
to fulfill within 12 months from December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Sales of products for the provision of complementary
health therapies&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Products for the provision of complementary health
therapies are predominantly Chinese herbs in different forms, processed or otherwise, for prescriptions for treating non-communicable
diseases.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#x2019;D)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Provision
of Health and Wellness services&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
&lt;i&gt;Performance obligations satisfied at a point in time&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company carries out its Wellness program, where the Company&#x2019;s products are bundled with health screening test and a health camp
program. The health screening test and the health camp programs are considered as separate performance obligations. The promises to deliver
the health screening test report and the attendance at the health camp are separately identifiable, which are evidenced by the fact that
the Company provides separate services of delivering the health screening test report and allowing admission of the customers to attend
the health camp. The Company derives its revenues from sales contracts with its customers with revenues being recognized when the test
reports are completed and delivered to its customers during the consultation section in person.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also separately derives its revenues from sales contracts with its customers with revenues being recognized when the health
camp program is completed in the final day of the health camp. For the years ended December 31, 2022 and 2021, revenues from
providing health and wellness services are $&lt;span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220101__20221231__srt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_zC5UZ5MD7tQ" title="Revenues"&gt;145,510&lt;/span&gt;
and $&lt;span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210101__20211231__srt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_zOxTFwz9GRPe" title="Revenues"&gt;7,543&lt;/span&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--DisaggregationOfRevenueTableTextBlock_zL1STfYdysn6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Disaggregated
information of revenues by products and services are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_zSBL4CN1dXei" style="display: none"&gt;SCHEDULE OF DIS-AGGREGATED INFORMATION OF REVENUES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220101__20221231_z21abgegsA4l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210101__20211231_z7xtVmlVkoNi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--SurvivorSelectMember_z5LWKevPxJmd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Survivor Select&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;122,470&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;83,904&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--EnergizedMineralConcentrateMember_zr0zkyHoLKi8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Energized Mineral Concentrate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0666"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,047&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--IonizedCalMagMember_zcbfX7scUGK5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Ionized Cal-Mag&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;148,219&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;39,527&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--OmegaBlendMember_zslpoCg1cIPh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Omega Blend&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;272,332&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;222,718&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--BetaMaxxMember_zFBHCEibRUgg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;BetaMaxx&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;137,447&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;208,043&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--VegeFruitFiberMember_zKD0P0DckIMb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Vege Fruit Fiber&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0678"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;65,757&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--IronMember_zqKvQRKr7jQc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Iron&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,697&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,114&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--YoungFormulaMember_zwDXHSYIX4Rj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Young Formula&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31,403&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,425&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--OrganicYouthCarCleansingBarMember_zhkQlF7fn2S8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Organic Youth Care Cleansing Bar&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0687"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--ATPRMITOPlusMember_z3Dq7VueuIXa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;ATPR Mito+&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;271,493&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;183,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--LipomaskMember_zHMa8egFj19d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Lipomask&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0693"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,331&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--EnergetiqueMember_zIfNeHxtjAlg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Energetique&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,089&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,574&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--TrimPlusMember_zkwcgP3YRps5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Trim+&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;88,613&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,042&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--ProductHealthTherapiesMember_zCHcL6QqgpEh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Others &#x2013; Products for the provision of complementary health therapies&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;569,823&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0703"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--OthersMember_zDHxgz4Dsps5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,468&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0706"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zrDljTyzVArc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total revenues &#x2013; products&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,711,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,009,419&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_z2YRBKYgeNg4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Health and Wellness services&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;145,510&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,543&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--Revenues_zUKQbvvSwePf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total revenues &#x2013; products and services&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,856,564&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,016,962&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zE1GaDUQw54k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#x2019;D)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <AATP:ForfeitedCouponIncome
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">7543</AATP:ForfeitedCouponIncome>
    <AATP:ForfeitedCouponIncome
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">15209</AATP:ForfeitedCouponIncome>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2022-01-012022-12-31_custom_HealthAndWellnessServicesMember"
      decimals="0"
      unitRef="USD">17912</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31_custom_HealthAndWellnessServicesMember"
      decimals="0"
      unitRef="USD">145510</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-12-31_custom_HealthAndWellnessServicesMember"
      decimals="0"
      unitRef="USD">7543</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_899_eus-gaap--DisaggregationOfRevenueTableTextBlock_zL1STfYdysn6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Disaggregated
information of revenues by products and services are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_zSBL4CN1dXei" style="display: none"&gt;SCHEDULE OF DIS-AGGREGATED INFORMATION OF REVENUES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220101__20221231_z21abgegsA4l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210101__20211231_z7xtVmlVkoNi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--SurvivorSelectMember_z5LWKevPxJmd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Survivor Select&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;122,470&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;83,904&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--EnergizedMineralConcentrateMember_zr0zkyHoLKi8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Energized Mineral Concentrate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0666"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,047&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--IonizedCalMagMember_zcbfX7scUGK5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Ionized Cal-Mag&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;148,219&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;39,527&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--OmegaBlendMember_zslpoCg1cIPh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Omega Blend&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;272,332&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;222,718&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--BetaMaxxMember_zFBHCEibRUgg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;BetaMaxx&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;137,447&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;208,043&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--VegeFruitFiberMember_zKD0P0DckIMb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Vege Fruit Fiber&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0678"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;65,757&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--IronMember_zqKvQRKr7jQc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Iron&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,697&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,114&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--YoungFormulaMember_zwDXHSYIX4Rj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Young Formula&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31,403&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,425&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--OrganicYouthCarCleansingBarMember_zhkQlF7fn2S8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Organic Youth Care Cleansing Bar&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0687"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--ATPRMITOPlusMember_z3Dq7VueuIXa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;ATPR Mito+&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;271,493&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;183,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--LipomaskMember_zHMa8egFj19d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Lipomask&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0693"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,331&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--EnergetiqueMember_zIfNeHxtjAlg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Energetique&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,089&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,574&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--Revenues_pp0p0_hsrt--ProductOrServiceAxis__custom--TrimPlusMember_zkwcgP3YRps5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Trim+&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;88,613&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,042&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--ProductHealthTherapiesMember_zCHcL6QqgpEh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Others &#x2013; Products for the provision of complementary health therapies&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;569,823&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0703"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--OthersMember_zDHxgz4Dsps5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,468&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0706"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zrDljTyzVArc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total revenues &#x2013; products&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,711,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,009,419&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--HealthAndWellnessServicesMember_z2YRBKYgeNg4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Health and Wellness services&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;145,510&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,543&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--Revenues_zUKQbvvSwePf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total revenues &#x2013; products and services&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,856,564&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,016,962&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_custom_SurvivorSelectMember"
      decimals="0"
      unitRef="USD">122470</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-12-31_custom_SurvivorSelectMember"
      decimals="0"
      unitRef="USD">83904</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-12-31_custom_EnergizedMineralConcentrateMember"
      decimals="0"
      unitRef="USD">52047</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_custom_IonizedCalMagMember"
      decimals="0"
      unitRef="USD">148219</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-12-31_custom_IonizedCalMagMember"
      decimals="0"
      unitRef="USD">39527</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_custom_OmegaBlendMember"
      decimals="0"
      unitRef="USD">272332</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-12-31_custom_OmegaBlendMember"
      decimals="0"
      unitRef="USD">222718</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_custom_BetaMaxxMember"
      decimals="0"
      unitRef="USD">137447</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-12-31_custom_BetaMaxxMember"
      decimals="0"
      unitRef="USD">208043</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-12-31_custom_VegeFruitFiberMember"
      decimals="0"
      unitRef="USD">65757</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_custom_IronMember"
      decimals="0"
      unitRef="USD">16697</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-12-31_custom_IronMember"
      decimals="0"
      unitRef="USD">28114</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_custom_YoungFormulaMember"
      decimals="0"
      unitRef="USD">31403</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-12-31_custom_YoungFormulaMember"
      decimals="0"
      unitRef="USD">52425</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-12-31_custom_OrganicYouthCarCleansingBarMember"
      decimals="0"
      unitRef="USD">5137</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_custom_ATPRMITOPlusMember"
      decimals="0"
      unitRef="USD">271493</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-12-31_custom_ATPRMITOPlusMember"
      decimals="0"
      unitRef="USD">183800</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-12-31_custom_LipomaskMember"
      decimals="0"
      unitRef="USD">15331</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_custom_EnergetiqueMember"
      decimals="0"
      unitRef="USD">49089</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-12-31_custom_EnergetiqueMember"
      decimals="0"
      unitRef="USD">25574</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_custom_TrimPlusMember"
      decimals="0"
      unitRef="USD">88613</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-12-31_custom_TrimPlusMember"
      decimals="0"
      unitRef="USD">27042</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_custom_ProductHealthTherapiesMember"
      decimals="0"
      unitRef="USD">569823</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_custom_OthersMember"
      decimals="0"
      unitRef="USD">3468</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_us-gaap_ProductMember"
      decimals="0"
      unitRef="USD">1711054</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-12-31_us-gaap_ProductMember"
      decimals="0"
      unitRef="USD">1009419</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_custom_HealthAndWellnessServicesMember"
      decimals="0"
      unitRef="USD">145510</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-12-31_custom_HealthAndWellnessServicesMember"
      decimals="0"
      unitRef="USD">7543</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">1856564</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1016962</us-gaap:Revenues>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_843_eus-gaap--CostOfSalesPolicyTextBlock_z6hmnXy5OW45" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zskQLX6oS36d"&gt;Cost
of revenue&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Cost
of revenue comprised freight-in, the purchase cost of manufactured goods for sale to customers &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and
products for the provision of complementary health therapies. &lt;span style="background-color: white"&gt;Cost of revenue amounted to $&lt;span id="xdx_90A_eus-gaap--CostOfGoodsAndServicesSold_c20220101__20221231_zJWOrBaL3rZb" title="Cost of revenue"&gt;666,042&lt;/span&gt;
(including inventory write-downs of $&lt;span id="xdx_903_ecustom--InventriesWriteDown_pp0p0_c20220101__20221231_zRagiINTU2v3" title="Inventories write-down"&gt;5,307&lt;/span&gt; and inventory written-off of $&lt;span id="xdx_90A_ecustom--InventoryWriteOff_c20220101__20221231_zfIQAT5Y3WE9" title="Inventories write off"&gt;142,466&lt;/span&gt;) and $&lt;span id="xdx_901_eus-gaap--CostOfGoodsAndServicesSold_c20210101__20211231_zy3tBqIOa1G8" title="Cost of revenue"&gt;297,333&lt;/span&gt; (including inventory write-downs of $&lt;span id="xdx_906_ecustom--InventriesWriteDown_pp0p0_c20210101__20211231_zB1oBXGY34X2" title="Inventories write-down"&gt;36,241&lt;/span&gt;)
for the years ended December 31, 2022 and 2021, respectively&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">666042</us-gaap:CostOfGoodsAndServicesSold>
    <AATP:InventriesWriteDown
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">5307</AATP:InventriesWriteDown>
    <AATP:InventoryWriteOff
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">142466</AATP:InventoryWriteOff>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">297333</us-gaap:CostOfGoodsAndServicesSold>
    <AATP:InventriesWriteDown
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">36241</AATP:InventriesWriteDown>
    <AATP:ShippingAndHandlingPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_845_ecustom--ShippingAndHandlingPolicyTextBlock_zvpO8NKxWZUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_z0aGmeBeTpgc"&gt;Shipping
and handling&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shipping
and handling charges amounted to $&lt;span id="xdx_90C_eus-gaap--SellingExpense_pp0p0_c20220101__20221231__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_z6kvkMl8C7zf" title="Selling expenses"&gt;16,585&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--SellingExpense_pp0p0_c20210101__20211231__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zlMEsfQKQ5A9" title="Selling expenses"&gt;11,054&lt;/span&gt; for the years ended December 31, 2022 and 2021, respectively. Shipping and handling
charges are expensed as incurred and included in selling expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</AATP:ShippingAndHandlingPolicyTextBlock>
    <us-gaap:SellingExpense
      contextRef="From2022-01-012022-12-31_us-gaap_ShippingAndHandlingMember"
      decimals="0"
      unitRef="USD">16585</us-gaap:SellingExpense>
    <us-gaap:SellingExpense
      contextRef="From2021-01-012021-12-31_us-gaap_ShippingAndHandlingMember"
      decimals="0"
      unitRef="USD">11054</us-gaap:SellingExpense>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84B_eus-gaap--AdvertisingCostsPolicyTextBlock_zPT6muVeN732" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_z7Es73GdWP47"&gt;Advertising
costs&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Advertising
costs amounted to $&lt;span id="xdx_90F_eus-gaap--AdvertisingExpense_pp0p0_c20220101__20221231_zYDnt2NU8M2f" title="Advertising costs"&gt;4,688&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--AdvertisingExpense_pp0p0_c20210101__20211231_zuP4dGeRsy0c" title="Advertising costs"&gt;20,218&lt;/span&gt; for the years ended December 31, 2022 and 2021, respectively. Advertising costs are expensed as
incurred and included in selling expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">4688</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">20218</us-gaap:AdvertisingExpense>
    <us-gaap:CommissionsExpensePolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84F_eus-gaap--CommissionsExpensePolicyPolicyTextBlock_z9Mv3yTzzq3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zZMSQOUlDMA2"&gt;Commission
expenses&lt;/span&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Commission
expenses are the Company&#x2019;s most significant expenses. As with all companies in the network marketing industry, the Company&#x2019;s
sales channel is external to the Company. The Company&#x2019;s &#x201c;external sales force&#x201d; is stratified into two levels based
on priority recruitment. First, there are sales distributors. Second, all members recruited by a sales distributor, directly or indirectly,
are referred to as &#x201c;sales network members&#x201d;. The Company pays commission to every sales distributor based on purchases made
by its sales network members which includes the independent direct sales members. Top performing distributors with their own physical
stores may also become stockists of the Company, whereby they enjoy benefits such as maintaining a certain amount of the Company&#x2019;s
inventory on their store premises. The stockists shall account to the Company for all products sales from their store premises as monitored
through the Company&#x2019;s centralized stock tracking system. The Company pays a separate commission to stockists based on revenue generated
from the stockists&#x2019; physical stores. Commission expenses amounted to $&lt;span id="xdx_90B_eus-gaap--SalesCommissionsAndFees_pp0p0_c20220101__20221231_zX3h03VVO6v1" title="Commission expenses"&gt;405,351&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--SalesCommissionsAndFees_pp0p0_c20210101__20211231_zp2dghig06Jl" title="Commission expenses"&gt;316,267&lt;/span&gt; for the years ended December 31, 2022
and 2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommissionsExpensePolicyPolicyTextBlock>
    <us-gaap:SalesCommissionsAndFees
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">405351</us-gaap:SalesCommissionsAndFees>
    <us-gaap:SalesCommissionsAndFees
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">316267</us-gaap:SalesCommissionsAndFees>
    <AATP:DefinedContributionPlanPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84A_ecustom--DefinedContributionPlanPolicyTextBlock_zzTqGCuRJEU3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_z5HFBg68sykk"&gt;Defined
contribution plan&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
full-time employees of the Company are entitled to the government mandated defined contribution plan. The Company is required to accrue
and pay for these benefits based on certain percentages of the employees&#x2019; respective salaries, subject to certain ceilings, in
accordance with the relevant government regulations, and make cash contributions to the government mandated defined contribution plan&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
Total expenses for the plans were $&lt;span id="xdx_906_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pp0p0_c20220101__20221231_zVicH7EgFDLa" title="Defined contribution plan expense"&gt;133,489&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pp0p0_c20210101__20211231_zfGWX5OFpjta" title="Defined contribution plan expense"&gt;99,488&lt;/span&gt; for the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
related contribution plans include:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Social
    Security Organization (&#x201c;SOSCO&#x201d;) &#x2013; &lt;span id="xdx_90A_ecustom--SalaryPercentage_pid_dp_c20220101__20221231__dei--LegalEntityAxis__custom--SocialSecurityOrganizationMember_zBxcFz5qfd16" title="Salary percentage"&gt;1.75&lt;/span&gt;% based on employee&#x2019;s monthly salary capped of RM &lt;span id="xdx_90E_ecustom--MonthlySalary_uRM_c20220101__20221231__dei--LegalEntityAxis__custom--SocialSecurityOrganizationMember_zF3FRUewo47b" title="Monthly salary"&gt;5,000&lt;/span&gt;;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Employees
    Provident Fund (&#x201c;EPF&#x201d;) &#x2013;based on employee&#x2019;s monthly salary, &lt;span id="xdx_90D_ecustom--SalaryPercentage_pid_dp_c20220101__20221231__dei--LegalEntityAxis__custom--EmployeesProvidentFundMember__srt--RangeAxis__srt--MinimumMember_zQriZXqhOcEf" title="Salary percentage"&gt;13&lt;/span&gt;% for employee earning RM&lt;span id="xdx_90E_ecustom--MonthlySalary_uRM_c20220101__20221231__dei--LegalEntityAxis__custom--EmployeesProvidentFundMember__srt--RangeAxis__srt--MinimumMember_zhjGzhzfJlAc" title="Monthly salary"&gt;5,000&lt;/span&gt; and below; and
    &lt;span id="xdx_90E_ecustom--SalaryPercentage_pid_dp_c20220101__20221231__dei--LegalEntityAxis__custom--EmployeesProvidentFundMember__srt--RangeAxis__srt--MinimumMember__srt--RangeAxis__srt--MaximumMember_z2esrfOwXpSb" title="Salary percentage"&gt;12&lt;/span&gt;% for employee earning RM&lt;span id="xdx_906_ecustom--MonthlySalary_uRM_c20220101__20221231__dei--LegalEntityAxis__custom--EmployeesProvidentFundMember__srt--RangeAxis__srt--MaximumMember_zWZBWgz0MTwk" title="Monthly salary"&gt;5,001&lt;/span&gt; and above.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Employment
    Insurance System (&#x201c;EIS&#x201d;) &#x2013; &lt;span id="xdx_90C_ecustom--SalaryPercentage_pid_dp_c20220101__20221231__dei--LegalEntityAxis__custom--EmploymentInsuranceSystemMember_zRHbOFUNH1f1" title="Salary percentage"&gt;0.2&lt;/span&gt;% based on employee&#x2019;s monthly salary capped of RM &lt;span id="xdx_90E_ecustom--MonthlySalary_uRM_c20220101__20221231__dei--LegalEntityAxis__custom--EmploymentInsuranceSystemMember_ztc1arIXPmgb" title="Monthly salary"&gt;5,000&lt;/span&gt;;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Human
    Resource Development Fund (&#x201c;HRDF&#x201d;) &#x2013; &lt;span id="xdx_907_ecustom--SalaryPercentage_pid_dp_c20220101__20221231__dei--LegalEntityAxis__custom--HumanResourceDevelopmentFundMember_zZfEeTcMmTd6" title="Salary percentage"&gt;1&lt;/span&gt;% based on employee&#x2019;s monthly salary&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#x2019;D)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</AATP:DefinedContributionPlanPolicyTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">133489</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">99488</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <AATP:SalaryPercentage
      contextRef="From2022-01-012022-12-31_custom_SocialSecurityOrganizationMember"
      decimals="INF"
      unitRef="Pure">0.0175</AATP:SalaryPercentage>
    <AATP:MonthlySalary
      contextRef="From2022-01-012022-12-31_custom_SocialSecurityOrganizationMember"
      decimals="0"
      unitRef="RM">5000</AATP:MonthlySalary>
    <AATP:SalaryPercentage
      contextRef="From2022-01-012022-12-31_custom_EmployeesProvidentFundMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.13</AATP:SalaryPercentage>
    <AATP:MonthlySalary
      contextRef="From2022-01-012022-12-31_custom_EmployeesProvidentFundMember_srt_MinimumMember"
      decimals="0"
      unitRef="RM">5000</AATP:MonthlySalary>
    <AATP:SalaryPercentage
      contextRef="From2022-01-012022-12-31_custom_EmployeesProvidentFundMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.12</AATP:SalaryPercentage>
    <AATP:MonthlySalary
      contextRef="From2022-01-012022-12-31_custom_EmployeesProvidentFundMember_srt_MaximumMember"
      decimals="0"
      unitRef="RM">5001</AATP:MonthlySalary>
    <AATP:SalaryPercentage
      contextRef="From2022-01-012022-12-31_custom_EmploymentInsuranceSystemMember"
      decimals="INF"
      unitRef="Pure">0.002</AATP:SalaryPercentage>
    <AATP:MonthlySalary
      contextRef="From2022-01-012022-12-31_custom_EmploymentInsuranceSystemMember"
      decimals="0"
      unitRef="RM">5000</AATP:MonthlySalary>
    <AATP:SalaryPercentage
      contextRef="From2022-01-012022-12-31_custom_HumanResourceDevelopmentFundMember"
      decimals="INF"
      unitRef="Pure">0.01</AATP:SalaryPercentage>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zZdZiC8AkEH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zCkcAvFtpGea"&gt;Income
taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes in accordance with U.S. GAAP for income taxes. The charge for taxation is based on the results for
the fiscal year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted
or substantively enacted by the balance sheet date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
taxes is accounted for using the asset and liability method in respect of temporary differences arising from differences between the
carrying amount of assets and liabilities in the consolidated financial statements and the corresponding tax basis used in the computation
of assessable tax profit. In principle, deferred tax liabilities are recognized for all taxable temporary differences. Deferred tax assets
are recognized to the extent that it is probable that taxable profit will be available against which deductible temporary differences
can be utilized. Deferred tax is calculated using tax rates that are expected to apply to the period when the asset is realized or the
liability is settled. Deferred tax is charged or credited in the income statement, except when it is related to items credited or charged
directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets are reduced by a valuation allowance
when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.
Current income taxes are provided for in accordance with the laws of the relevant taxing authorities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An
uncertain tax position is recognized as a benefit only if it is &#x201c;more likely than not&#x201d; that the tax position would be sustained
in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that
is &lt;span id="xdx_90F_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20220101__20221231_zridEaAy3q5d" title="Income tax description"&gt;greater than 50%&lt;/span&gt; likely of being realized on examination. For tax positions not meeting the &#x201c;more likely than not&#x201d; test,
no tax benefit is recorded. $&lt;span id="xdx_905_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_pp0p0_c20220101__20221231_zPKdG0hn2bma" title="Income tax examination, penalties and interest expense"&gt;0&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_pp0p0_c20210101__20211231_zSFYTL7JYgi1" title="Income tax examination, penalties and interest expense"&gt;395&lt;/span&gt; penalties and interest incurred related to underpayment of income tax for the years ended December
31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company conducts much of its business activities in Hong Kong and Malaysia and is subject to tax in each of their jurisdictions. As a
result of its business activities, the Company will file separate tax returns that are subject to examination by the foreign tax authorities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement contextRef="From2022-01-01to2022-12-31">greater than 50%</us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">395</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_841_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zAIQ7gf36Ghj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zwYFtkBQLvFa"&gt;Comprehensive
income (loss)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive
income (loss) consists of two components, net income (loss) and other comprehensive income (loss). Net income (loss) refers to revenue,
expenses, gains and losses that under GAAP are recorded as an element of stockholders&#x2019; equity but are excluded from net income.
Other comprehensive income (loss) consists of a foreign currency translation adjustment resulting from the Company not using the U.S.
dollar as its functional currencies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <AATP:NoncontrollingInterestPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_848_ecustom--NoncontrollingInterestPolicyTextBlock_zUmxJoS2Nq6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_z3pSSXQCI64h"&gt;Non-controlling
interest&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--MinorityInterestDescription_c20220101__20221231_z3bBup5MmeXk" title="Noncontrolling interest, description"&gt;Non-controlling
interest consists of 40% of the equity interests of DSY Wellness held by an individual and approximately 0.01% (2 ordinary shares out
of 9,590,598 shares) of the equity interests of ASL held by two individuals&lt;/span&gt;. The non-controlling interests are presented in the consolidated
balance sheets, separately from equity attributable to the shareholders of the Company. Non-controlling interests in the results of the
Company are presented on the face of the consolidated statements of operations as an allocation of the total income or loss for the periods
between non-controlling interest holders and the shareholders of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#x2019;D)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</AATP:NoncontrollingInterestPolicyTextBlock>
    <us-gaap:MinorityInterestDescription contextRef="From2022-01-01to2022-12-31">Non-controlling
interest consists of 40% of the equity interests of DSY Wellness held by an individual and approximately 0.01% (2 ordinary shares out
of 9,590,598 shares) of the equity interests of ASL held by two individuals</us-gaap:MinorityInterestDescription>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zYeCXifgtjIc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_z17u0oqw1S65"&gt;Earnings
(loss) per share&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company computes earnings (loss) per share (&#x201c;EPS&#x201d;) in accordance with ASC 260, &#x201c;Earnings per Share&#x201d;. ASC 260
requires companies to present basic and diluted EPS. Basic EPS is measured as net income divided by the weighted average ordinary share
outstanding for the period. Diluted EPS presents the dilutive effect on a per share basis of the potential ordinary shares (e.g., convertible
securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later.
Potential ordinary shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are
excluded from the calculation of diluted EPS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;. For the
years ended December 31, 2022 and 2021, there were &lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20220101__20221231_zZU9VYbmnxme" title="Potentially dilutive securities outstanding"&gt;&lt;span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_do_c20210101__20211231_zTFE6S4QfcGg" title="Potentially dilutive securities outstanding"&gt;no&lt;/span&gt;&lt;/span&gt; dilutive shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zpmvue0RnR04" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zeX8FIyxsbb9"&gt;Foreign
currencies translation and transaction&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transactions
denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing
at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated
into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded
in the consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
reporting currency of the Company is United States Dollars (&#x201c;US$&#x201d;) and the accompanying financial statements have been expressed
in US$. The Company&#x2019;s subsidiary in Labuan maintains its books and record in United States Dollars (&#x201c;US$&#x201d;) albeit its
functional currency being the primary currency of the economic environment in which the entity operates, which is the Malaysian Ringgit
(&#x201c;MYR&#x201d; or &#x201c;RM&#x201d;). The Company&#x2019;s subsidiary in Hong Kong maintains its books and record in Hong Kong Dollars
(&#x201c;HK$&#x201d;), similar to its functional currency. The Company&#x2019;s subsidiary and VIE in Malaysia conducts its businesses and
maintains its books and record in the local currency, Malaysian Ringgit (&#x201c;MYR&#x201d; or &#x201c;RM&#x201d;), as its functional currency.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into
US$, in accordance with ASC Topic 830-30, &#x201c;&lt;i&gt;Translation of Financial Statement&#x201d;&lt;/i&gt;, using the exchange rate on the balance
sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation
of financial statements of foreign subsidiary are recorded as a separate component of accumulated other comprehensive income within the
statements of stockholders&#x2019; equity. Cash flows are also translated at average translation rates for the periods, therefore, amounts
reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance
sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_zTYA4P9FOinb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Translation
of foreign currencies into US$1 have been made at the following exchange rates for the respective periods:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zdv4I7CXhGol" style="display: none"&gt;SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_zgy5lSiaUnqg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20211231_zsVB6e9RZDpg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hus-gaap--VariableRateAxis__custom--PeriodEndMYRMember_zFRhCxqqi3Eh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Period-end MYR : US$1 exchange rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;4.41&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;4.18&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hus-gaap--VariableRateAxis__custom--PeriodEndHKDMember_zLYf4zb3Voe5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Period-end HKD : US$1 exchange rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hus-gaap--VariableRateAxis__custom--PeriodEndHKDMember_ziM6JpnK0o6" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Foreign currency exchange
    rate, translation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20220101__20221231_zu9ykfzTy0w3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210101__20211231_zaKDMyylVgMj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--ForeignCurrencyExchangeRateAverage_hus-gaap--VariableRateAxis__custom--PeriodAverageMYRMember_zqsIpHu1yyE" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Period-average MYR : US$1 exchange rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;4.41&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;4.14&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--ForeignCurrencyExchangeRateAverage_hus-gaap--VariableRateAxis__custom--PeriodAverageHKDMember_zecoVeo3Tg3a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Period-average HKD : US$1 exchange rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.83&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.77&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--ForeignCurrencyExchangeRateAverage_hus-gaap--VariableRateAxis__custom--PeriodAverageHKDMember_zCDRKLJohb0b" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Foreign currency exchange
    rate period average&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.83&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.77&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zR6kyPJj6KLc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#x2019;D)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_899_eus-gaap--ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_zTYA4P9FOinb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Translation
of foreign currencies into US$1 have been made at the following exchange rates for the respective periods:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zdv4I7CXhGol" style="display: none"&gt;SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_zgy5lSiaUnqg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20211231_zsVB6e9RZDpg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hus-gaap--VariableRateAxis__custom--PeriodEndMYRMember_zFRhCxqqi3Eh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Period-end MYR : US$1 exchange rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;4.41&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;4.18&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hus-gaap--VariableRateAxis__custom--PeriodEndHKDMember_zLYf4zb3Voe5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Period-end HKD : US$1 exchange rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ForeignCurrencyExchangeRateTranslation1_iI_hus-gaap--VariableRateAxis__custom--PeriodEndHKDMember_ziM6JpnK0o6" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Foreign currency exchange
    rate, translation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20220101__20221231_zu9ykfzTy0w3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210101__20211231_zaKDMyylVgMj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--ForeignCurrencyExchangeRateAverage_hus-gaap--VariableRateAxis__custom--PeriodAverageMYRMember_zqsIpHu1yyE" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Period-average MYR : US$1 exchange rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;4.41&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;4.14&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--ForeignCurrencyExchangeRateAverage_hus-gaap--VariableRateAxis__custom--PeriodAverageHKDMember_zecoVeo3Tg3a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Period-average HKD : US$1 exchange rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.83&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.77&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--ForeignCurrencyExchangeRateAverage_hus-gaap--VariableRateAxis__custom--PeriodAverageHKDMember_zCDRKLJohb0b" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Foreign currency exchange
    rate period average&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.83&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.77&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="AsOf2022-12-31_custom_PeriodEndMYRMember"
      decimals="INF"
      unitRef="Pure">4.41</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="AsOf2021-12-31_custom_PeriodEndMYRMember"
      decimals="INF"
      unitRef="Pure">4.18</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="AsOf2022-12-31_custom_PeriodEndHKDMember"
      decimals="INF"
      unitRef="Pure">7.80</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="AsOf2021-12-31_custom_PeriodEndHKDMember"
      decimals="INF"
      unitRef="Pure">7.80</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="AsOf2022-12-31_custom_PeriodEndHKDMember"
      decimals="INF"
      unitRef="Pure">7.80</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="AsOf2021-12-31_custom_PeriodEndHKDMember"
      decimals="INF"
      unitRef="Pure">7.80</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <AATP:ForeignCurrencyExchangeRateAverage
      contextRef="From2022-01-012022-12-31_custom_PeriodAverageMYRMember"
      decimals="INF"
      unitRef="Pure">4.41</AATP:ForeignCurrencyExchangeRateAverage>
    <AATP:ForeignCurrencyExchangeRateAverage
      contextRef="From2021-01-012021-12-31_custom_PeriodAverageMYRMember"
      decimals="INF"
      unitRef="Pure">4.14</AATP:ForeignCurrencyExchangeRateAverage>
    <AATP:ForeignCurrencyExchangeRateAverage
      contextRef="From2022-01-012022-12-31_custom_PeriodAverageHKDMember"
      decimals="INF"
      unitRef="Pure">7.83</AATP:ForeignCurrencyExchangeRateAverage>
    <AATP:ForeignCurrencyExchangeRateAverage
      contextRef="From2021-01-012021-12-31_custom_PeriodAverageHKDMember"
      decimals="INF"
      unitRef="Pure">7.77</AATP:ForeignCurrencyExchangeRateAverage>
    <AATP:ForeignCurrencyExchangeRateAverage
      contextRef="From2022-01-012022-12-31_custom_PeriodAverageHKDMember"
      decimals="INF"
      unitRef="Pure">7.83</AATP:ForeignCurrencyExchangeRateAverage>
    <AATP:ForeignCurrencyExchangeRateAverage
      contextRef="From2021-01-012021-12-31_custom_PeriodAverageHKDMember"
      decimals="INF"
      unitRef="Pure">7.77</AATP:ForeignCurrencyExchangeRateAverage>
    <AATP:RelatedPartiesPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_840_ecustom--RelatedPartiesPolicyTextBlock_zI7d5N4JYGed" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zRTbziKHfAwb"&gt;Related
parties&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Parties,
which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control
the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also
considered to be related if they are subject to common control or common significant influence.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</AATP:RelatedPartiesPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_844_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zE82vognobm5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_zepRYIYYprik"&gt;Fair
value of financial instruments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accounting standard regarding fair value of financial instruments and related fair value measurements defines financial instruments and
requires disclosure of the fair value of financial instruments held by the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accounting standards define fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance
disclosure requirements for fair value measures. The three levels are defined as follow:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that
    are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3 inputs to the valuation methodology are unobservable and significant to the fair value.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments included in current assets and current liabilities are reported in the consolidated balance sheets at face value or cost,
which approximate fair value because of the short period of time between the origination of such instruments and their expected realization
and their current market rates of interest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84F_eus-gaap--LesseeLeasesPolicyTextBlock_z3UFyt6sece6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zibQIkWeu1wg"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company adopted ASU 2016-02, &#x201c;Leases&#x201d; (Topic 842), and elected the practical expedients that does not require the Company
to reassess: (1) whether any expired or existing contracts are, or contain, leases, (2) lease classification for any expired or existing
leases and (3) initial direct costs for any expired or existing leases. For lease terms of twelve months or fewer, a lessee is permitted
to make an accounting policy election not to recognize lease assets and liabilities. The Company also adopts the practical expedient
that allows lessees to treat the lease and non-lease components of a lease as a single lease component. Some of the Company&#x2019;s leases
include one or more options to renew, which is typically at the Company&#x2019;s sole discretion. The Company regularly evaluates the
renewal options, and, when it is reasonably certain of exercise, it will include the renewal period in its lease term. New lease modifications
result in re-measurement of the right of use (&#x201c;ROU&#x201d;) assets and lease liabilities. Operating ROU assets and lease liabilities
are recognized at the commencement date, based on the present value of lease payments over the lease term. Since the implicit rate for
the Company&#x2019;s leases is not readily determinable, the Company use its incremental borrowing rate based on the information available
at the commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that
the Company would have to pay to borrow, on a collateralized basis, an amount equal to the lease payments, in a similar economic environment
and over a similar term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT&#x2019;D)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
terms used to calculate the present value of lease payments generally do not include any options to extend, renew, or terminate the lease,
as the Company does not have reasonable certainty at lease inception that these options will be exercised. The Company generally considers
the economic life of its operating lease ROU assets to be comparable to the useful life of similar owned assets. The Company has elected
the short-term lease exception, therefore operating lease ROU assets and liabilities do not include leases with a lease term of twelve
months or less. Its leases generally do not provide a residual guarantee. The operating lease ROU asset also excludes lease incentives.
Lease expense is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviews the impairment of its ROU assets consistent with the approach applied for its other long-lived assets. The Company reviews
the recoverability of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the
asset may not be recoverable. The assessment of possible impairment is based on its ability to recover the carrying value of the asset
from the expected undiscounted future pre-tax cash flows of the related operations. The Company has elected to include the carrying amount
of operating lease liabilities in any tested asset group and includes the associated operating lease payments in the undiscounted future
pre-tax cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zOEqo9L2pkTk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zkQqYFp7vst4"&gt;Recent
accounting pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has reviewed all recently issued, but not yet effective, considers the applicability and impact of all accounting standards updates
(&#x201c;ASUs&#x201d;). Management periodically reviews new accounting standards that are issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2019, the FASB issued ASU No. 2019-10, which to update the effective date of ASU No. 2016-13 for private companies, not-for-profit
organizations and certain smaller reporting companies applying for credit losses, leases, and hedging standard. The new effective date
for these preparers is for fiscal years beginning after December 15, 2022. ASU 2019-05 is effective for the Company for annual and interim
reporting periods beginning January 1, 2023 as the Company is qualified as a smaller reporting company. The Company is currently evaluating
the impact ASUs 2016-13 and 2019-05 may have on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Except
for the above-mentioned pronouncements, there are no new recent issued accounting standards that will have a material impact on the consolidated
financial position, statements of operations and cash flows.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:VariableInterestEntityDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_802_eus-gaap--VariableInterestEntityDisclosureTextBlock_zFRxQR1FO7hi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.
&lt;span id="xdx_824_zj2d1J3GbxTf"&gt;VARIABLE INTEREST ENTITY (&#x201c;VIE&#x201d;)&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SEA
is a trading company incorporated on March 4, 2004, under the laws of Malaysia. SEA provided majority of ASL&#x2019;s purchases. Its equity
at risk was insufficient to finance its activities and &lt;span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SubsidiaryCompanyThreeMember_zBAHgxlBLbg4" title="Ownership interest percentage"&gt;100&lt;/span&gt;% of its business is transacted with ASL. Therefore, it was considered to be
a VIE and ASL is the primary beneficiary since it has both of the following characteristics:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
    power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
    obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the
    VIE that could potentially be significant to the VIE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accordingly,
the accounts of SEA is consolidated in the accompanying financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.
VARIABLE INTEREST ENTITY (&#x201c;VIE&#x201d;) (CONT&#x2019;D)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfVariableInterestEntitiesTextBlock_zNdRAR4wzbY5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amount of the VIE&#x2019;s assets and liabilities were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zQFexFWDKz4c" style="display: none"&gt;SCHEDULE OF VARIABLE INTEREST ENTITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20221231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_z5lVlw6Fn3tc" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20211231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zI4DBiW68nWg" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AssetsCurrent_iI_zUmQYchAUCB5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Current assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;3,350&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;18,850&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LiabilitiesCurrent_iNI_di_zZSjd8BHuSs8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(43,512&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(51,272&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--StockholdersEquity_iI_z24RgFPig1Bj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deficit&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(40,162&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(32,422&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20221231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zIZ5onYFsdw1" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20211231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zEYYv5IBQbTb" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_ztcWNesxOZqa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,609&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;17,493&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PrepaidTaxes_iI_z00YJcaIpYid" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Prepaid taxes&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,741&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,357&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AssetsCurrent_iI_zUgacGYqQEni" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,350&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,850&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Current liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iI_zSSpL7fZ4Wy3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accounts payable &#x2013; intercompany&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;42,422&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;49,724&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--OtherPayablesRelatedPartyCurrent_iI_zCiPzH9XUjbi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other payables and accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,090&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,548&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LiabilitiesCurrent_iI_zRheyKpvRmF7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;43,512&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;51,272&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--StockholdersEquity_iI_zKO7drUZdXNc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deficit&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(40,162&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(32,422&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
summarized operating results of the VIE&#x2019;s are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20220101__20221231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zxKoIUlQxhh4" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20210101__20211231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_z0QiRSbSOepl" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_z2Fz4S6CfAZ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 2.5pt"&gt;Operating revenues&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0857"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0858"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--GrossProfit_zkzi7RwfRXOj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Gross profit&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0860"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0861"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingIncomeLoss_ztX6z0oXxJq4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Loss from operations&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(9,432&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(21,966&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--NetIncomeLoss_zV42ojDKQhxc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(9,432&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(27,966&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zHMnheaZyNnd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-31_custom_SubsidiaryCompanyThreeMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_892_eus-gaap--ScheduleOfVariableInterestEntitiesTextBlock_zNdRAR4wzbY5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amount of the VIE&#x2019;s assets and liabilities were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zQFexFWDKz4c" style="display: none"&gt;SCHEDULE OF VARIABLE INTEREST ENTITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20221231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_z5lVlw6Fn3tc" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20211231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zI4DBiW68nWg" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AssetsCurrent_iI_zUmQYchAUCB5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Current assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;3,350&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;18,850&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LiabilitiesCurrent_iNI_di_zZSjd8BHuSs8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(43,512&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(51,272&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--StockholdersEquity_iI_z24RgFPig1Bj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deficit&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(40,162&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(32,422&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20221231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zIZ5onYFsdw1" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20211231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zEYYv5IBQbTb" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_ztcWNesxOZqa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,609&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;17,493&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PrepaidTaxes_iI_z00YJcaIpYid" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Prepaid taxes&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,741&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,357&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AssetsCurrent_iI_zUgacGYqQEni" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,350&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,850&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Current liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iI_zSSpL7fZ4Wy3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accounts payable &#x2013; intercompany&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;42,422&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;49,724&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--OtherPayablesRelatedPartyCurrent_iI_zCiPzH9XUjbi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other payables and accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,090&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,548&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LiabilitiesCurrent_iI_zRheyKpvRmF7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;43,512&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;51,272&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--StockholdersEquity_iI_zKO7drUZdXNc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deficit&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(40,162&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(32,422&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
summarized operating results of the VIE&#x2019;s are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20220101__20221231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_zxKoIUlQxhh4" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20210101__20211231__us-gaap--TradingActivityByTypeAxis__us-gaap--VariableIncomeInterestRateMember_z0QiRSbSOepl" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_z2Fz4S6CfAZ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 2.5pt"&gt;Operating revenues&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0857"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0858"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--GrossProfit_zkzi7RwfRXOj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Gross profit&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0860"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0861"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingIncomeLoss_ztX6z0oXxJq4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Loss from operations&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(9,432&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(21,966&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--NetIncomeLoss_zV42ojDKQhxc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(9,432&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(27,966&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2022-12-31_us-gaap_VariableIncomeInterestRateMember"
      decimals="0"
      unitRef="USD">3350</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2021-12-31_us-gaap_VariableIncomeInterestRateMember"
      decimals="0"
      unitRef="USD">18850</us-gaap:AssetsCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2022-12-31_us-gaap_VariableIncomeInterestRateMember"
      decimals="0"
      unitRef="USD">43512</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2021-12-31_us-gaap_VariableIncomeInterestRateMember"
      decimals="0"
      unitRef="USD">51272</us-gaap:LiabilitiesCurrent>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_VariableIncomeInterestRateMember"
      decimals="0"
      unitRef="USD">-40162</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_VariableIncomeInterestRateMember"
      decimals="0"
      unitRef="USD">-32422</us-gaap:StockholdersEquity>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2022-12-31_us-gaap_VariableIncomeInterestRateMember"
      decimals="0"
      unitRef="USD">1609</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2021-12-31_us-gaap_VariableIncomeInterestRateMember"
      decimals="0"
      unitRef="USD">17493</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidTaxes
      contextRef="AsOf2022-12-31_us-gaap_VariableIncomeInterestRateMember"
      decimals="0"
      unitRef="USD">1741</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes
      contextRef="AsOf2021-12-31_us-gaap_VariableIncomeInterestRateMember"
      decimals="0"
      unitRef="USD">1357</us-gaap:PrepaidTaxes>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2022-12-31_us-gaap_VariableIncomeInterestRateMember"
      decimals="0"
      unitRef="USD">3350</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2021-12-31_us-gaap_VariableIncomeInterestRateMember"
      decimals="0"
      unitRef="USD">18850</us-gaap:AssetsCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31_us-gaap_VariableIncomeInterestRateMember"
      decimals="0"
      unitRef="USD">42422</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="AsOf2021-12-31_us-gaap_VariableIncomeInterestRateMember"
      decimals="0"
      unitRef="USD">49724</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <AATP:OtherPayablesRelatedPartyCurrent
      contextRef="AsOf2022-12-31_us-gaap_VariableIncomeInterestRateMember"
      decimals="0"
      unitRef="USD">1090</AATP:OtherPayablesRelatedPartyCurrent>
    <AATP:OtherPayablesRelatedPartyCurrent
      contextRef="AsOf2021-12-31_us-gaap_VariableIncomeInterestRateMember"
      decimals="0"
      unitRef="USD">1548</AATP:OtherPayablesRelatedPartyCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2022-12-31_us-gaap_VariableIncomeInterestRateMember"
      decimals="0"
      unitRef="USD">43512</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2021-12-31_us-gaap_VariableIncomeInterestRateMember"
      decimals="0"
      unitRef="USD">51272</us-gaap:LiabilitiesCurrent>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_VariableIncomeInterestRateMember"
      decimals="0"
      unitRef="USD">-40162</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_VariableIncomeInterestRateMember"
      decimals="0"
      unitRef="USD">-32422</us-gaap:StockholdersEquity>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_VariableIncomeInterestRateMember"
      decimals="0"
      unitRef="USD">-9432</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_VariableIncomeInterestRateMember"
      decimals="0"
      unitRef="USD">-21966</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_VariableIncomeInterestRateMember"
      decimals="0"
      unitRef="USD">-9432</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31_us-gaap_VariableIncomeInterestRateMember"
      decimals="0"
      unitRef="USD">-27966</us-gaap:NetIncomeLoss>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80C_eus-gaap--CashAndCashEquivalentsDisclosureTextBlock_zujFwGP2qic1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;4.
&lt;span id="xdx_821_z5dqFc3yMcj7"&gt;CASH AND CASH EQUIVALENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;As
of December 31, 2022 and 2021 the Company had $&lt;span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20221231_zoEHWX9rirq" title="Cash and cash equivalents"&gt;1,438,430&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20211231_zVjM6SiekJTc" title="Cash and cash equivalents"&gt;2,597,848&lt;/span&gt;, respectively, of cash and cash equivalents, which consisted of
$&lt;span id="xdx_90B_eus-gaap--Cash_iI_pp0p0_c20221231_z71GEdb78pQ8" title="Cash in bank"&gt;513,152&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--Cash_iI_pp0p0_c20211231_zDOvVNzzIluj" title="Cash in bank"&gt;554,864&lt;/span&gt;, respectively, of cash in banks and &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_90A_eus-gaap--TimeDeposits_iI_pp0p0_c20221231_zW7yV59dKgF2" title="Time deposits"&gt;914,811&lt;/span&gt;
&lt;span style="background-color: white"&gt;and $&lt;/span&gt;&lt;span id="xdx_90B_eus-gaap--TimeDeposits_iI_pp0p0_c20211231_zYIsVeV1EV43" title="Time deposits"&gt;1,975,347&lt;/span&gt;&lt;span style="background-color: white"&gt;, respectively, of time deposits placed
with banks or other financial institutions and are all highly liquid investments with an original maturity of three months or less. The
effective interest rate for the time deposits ranges between &lt;span id="xdx_90E_eus-gaap--PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits_iI_pid_dp_uPure_c20221231__srt--RangeAxis__srt--MinimumMember_zR1NmRU1EC6l" title="Percentage of Interest rate for time deposits"&gt;1.10&lt;/span&gt;% to &lt;span id="xdx_902_eus-gaap--PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits_iI_pid_dp_uPure_c20221231__srt--RangeAxis__srt--MaximumMember_zMZ80BAaKbdj" title="Percentage of Interest rate for time deposits"&gt;1.88&lt;/span&gt;% per annum. As of December 31, 2022 and 2021, $&lt;span id="xdx_90D_eus-gaap--TimeDepositLiabilityUninsured_iI_c20221231_zJ1saXAIpPp3" title="Time deposit uninsured"&gt;231,187&lt;/span&gt; and
$&lt;span id="xdx_90C_eus-gaap--TimeDepositLiabilityUninsured_iI_c20211231_zbUkhuYIUSC4" title="Time deposit uninsured"&gt;295,761&lt;/span&gt; of these balances are not covered by deposit insurance, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1438430</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2597848</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:Cash contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">513152</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">554864</us-gaap:Cash>
    <us-gaap:TimeDeposits contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">914811</us-gaap:TimeDeposits>
    <us-gaap:TimeDeposits contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1975347</us-gaap:TimeDeposits>
    <us-gaap:PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits
      contextRef="AsOf2022-12-31_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.0110</us-gaap:PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits>
    <us-gaap:PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits
      contextRef="AsOf2022-12-31_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.0188</us-gaap:PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits>
    <us-gaap:TimeDepositLiabilityUninsured contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">231187</us-gaap:TimeDepositLiabilityUninsured>
    <us-gaap:TimeDepositLiabilityUninsured contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">295761</us-gaap:TimeDepositLiabilityUninsured>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_800_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_z5Q2QJxfsYv4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;5.
&lt;span id="xdx_82E_zelRnHFzaVRk"&gt;ACCOUNTS RECEIVABLE &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zovZssHaUBh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_8B8_z2Lb6cEO3jPb" style="display: none"&gt;SCHEDULE OF ACCOUNTS RECEIVABLES - RELATED PARTY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20221231_zhuxswMdXScl" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20211231_z4sPQYFIQRLk" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AccountsReceivableGrossCurrent_iI_pp0p0_maARAARzRRC_zWvEKK9iCda2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;2,826&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0896"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_pp0p0_msARAARzRRC_zGbqLTZYDSq7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0898"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0899"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccountsReceivableNetCurrent_iTI_pp0p0_mtARAARzRRC_zbtUjgGqE52" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,826&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0902"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zGmGdYx9q2ai" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_898_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zovZssHaUBh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_8B8_z2Lb6cEO3jPb" style="display: none"&gt;SCHEDULE OF ACCOUNTS RECEIVABLES - RELATED PARTY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20221231_zhuxswMdXScl" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20211231_z4sPQYFIQRLk" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AccountsReceivableGrossCurrent_iI_pp0p0_maARAARzRRC_zWvEKK9iCda2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;2,826&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0896"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_pp0p0_msARAARzRRC_zGbqLTZYDSq7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0898"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0899"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccountsReceivableNetCurrent_iTI_pp0p0_mtARAARzRRC_zbtUjgGqE52" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,826&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0902"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2826</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2826</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_808_eus-gaap--InventoryDisclosureTextBlock_zr9utPAPg9zl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;6.
&lt;span id="xdx_82B_z3iOu7BmGgsd"&gt;INVENTORIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zotCKPgQXxv4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories
consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zU8B3QydgPDg" style="display: none"&gt;SCHEDULE OF INVENTORIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20221231_zBaRxb2sOesg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20211231_zRW16l6SN7Ne" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; width: 64%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 2%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 2%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--InventoryFinishedGoods_iI_zyTB0EwcnZd5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;46,277&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;375,535&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zEjWgesrU6ha" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2022 and 2021, the Company recognized $&lt;span id="xdx_907_ecustom--InventriesWriteDown_c20220101__20221231_z7U9hW7hyrbl" title="Inventory write-down"&gt;5,307&lt;/span&gt; and $&lt;span id="xdx_90A_ecustom--InventriesWriteDown_c20210101__20211231_zViZNDF5OAfg" title="Inventory write-down"&gt;36,241&lt;/span&gt; inventory write-down; and $&lt;span id="xdx_907_ecustom--InventoryWriteOff_pp0p0_c20220101__20221231_zsc1Be2WkdCl" title="Inventory write-off"&gt;142,466&lt;/span&gt; and $&lt;span id="xdx_907_ecustom--InventoryWriteOff_pp0p0_dxL_c20210101__20211231_zarA66562s99" title="Inventory write- off::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0917"&gt;0&lt;/span&gt;&lt;/span&gt; inventory
write-off, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89B_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zotCKPgQXxv4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories
consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zU8B3QydgPDg" style="display: none"&gt;SCHEDULE OF INVENTORIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20221231_zBaRxb2sOesg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20211231_zRW16l6SN7Ne" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; width: 64%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 2%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 2%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--InventoryFinishedGoods_iI_zyTB0EwcnZd5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;46,277&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;375,535&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">46277</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">375535</us-gaap:InventoryFinishedGoods>
    <AATP:InventriesWriteDown
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">5307</AATP:InventriesWriteDown>
    <AATP:InventriesWriteDown
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">36241</AATP:InventriesWriteDown>
    <AATP:InventoryWriteOff
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">142466</AATP:InventoryWriteOff>
    <AATP:PrepaymentsAndDepositsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80E_ecustom--PrepaymentsAndDepositsTextBlock_zL7cdHSwwqG2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;7.
&lt;span id="xdx_82B_zwdyY1bfdqs3"&gt;PREPAYMENTS AND DEPOSITS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zjdtaEGFgsBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_z5pL7RUdAnWe" style="display: none"&gt;SCHEDULE OF PREPAID EXPENSES AND DEPOSITS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20221231_zR4XRYcqQTfj" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20211231_znAMLzPN5TLh" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--ReceivablesFromSalesDistributors_iI_maCzFPV_zCUi5vUgbfJh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Receivables from sales distributors&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;43,596&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;115,379&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DepositsToSupplier_iI_maCzFPV_zi1WAsQlc8J2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Deposits to suppliers&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;147,504&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;301,233&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--PrepaidExpensesGross_iTI_maCzxAt_mtCzFPV_zx851PNPzPR4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Subtotal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;191,100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;416,612&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iNI_di_msCzxAt_ztK47EHkLdij" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Provision for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0932"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(121,095&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtCzxAt_zh5aznB2iZWf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;191,100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;295,517&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_z4IuqImDPMVa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zRnLg89Y2iH2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Movements
of allowance for doubtful accounts are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zIuXxCkXFkB3" style="display: none"&gt;SCHEDULE OF CHANGES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20220101__20221231_zIMzlTah3pX8" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20210101__20211231_zjYgUiIl1ba1" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_z8IiVjZTcvd4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Beginning balance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;121,095&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0941"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_zjRhyxAeJhv8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Addition&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0943"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;121,514&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_di_zhkfGqoOLAC9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Write off&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(120,372&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0947"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--AllowanceForDoubtfulAccountsReceivableExchangeRateEffect_zkAodHvfNy97" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exchange rate effect&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(723&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(419&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_zXdLcLP2wUDh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0952"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;121,095&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zSoJ7RFXnWj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</AATP:PrepaymentsAndDepositsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89F_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zjdtaEGFgsBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_z5pL7RUdAnWe" style="display: none"&gt;SCHEDULE OF PREPAID EXPENSES AND DEPOSITS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20221231_zR4XRYcqQTfj" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20211231_znAMLzPN5TLh" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--ReceivablesFromSalesDistributors_iI_maCzFPV_zCUi5vUgbfJh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Receivables from sales distributors&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;43,596&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;115,379&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DepositsToSupplier_iI_maCzFPV_zi1WAsQlc8J2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Deposits to suppliers&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;147,504&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;301,233&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--PrepaidExpensesGross_iTI_maCzxAt_mtCzFPV_zx851PNPzPR4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Subtotal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;191,100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;416,612&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_iNI_di_msCzxAt_ztK47EHkLdij" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Provision for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0932"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(121,095&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtCzxAt_zh5aznB2iZWf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;191,100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;295,517&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <AATP:ReceivablesFromSalesDistributors contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">43596</AATP:ReceivablesFromSalesDistributors>
    <AATP:ReceivablesFromSalesDistributors contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">115379</AATP:ReceivablesFromSalesDistributors>
    <AATP:DepositsToSupplier contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">147504</AATP:DepositsToSupplier>
    <AATP:DepositsToSupplier contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">301233</AATP:DepositsToSupplier>
    <AATP:PrepaidExpensesGross contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">191100</AATP:PrepaidExpensesGross>
    <AATP:PrepaidExpensesGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">416612</AATP:PrepaidExpensesGross>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">121095</us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">191100</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">295517</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89D_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zRnLg89Y2iH2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Movements
of allowance for doubtful accounts are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zIuXxCkXFkB3" style="display: none"&gt;SCHEDULE OF CHANGES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20220101__20221231_zIMzlTah3pX8" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20210101__20211231_zjYgUiIl1ba1" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_z8IiVjZTcvd4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Beginning balance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;121,095&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0941"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_zjRhyxAeJhv8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Addition&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0943"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;121,514&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_di_zhkfGqoOLAC9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Write off&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(120,372&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0947"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--AllowanceForDoubtfulAccountsReceivableExchangeRateEffect_zkAodHvfNy97" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exchange rate effect&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(723&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(419&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_zXdLcLP2wUDh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0952"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;121,095&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">121095</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">121514</us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">120372</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <AATP:AllowanceForDoubtfulAccountsReceivableExchangeRateEffect
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-723</AATP:AllowanceForDoubtfulAccountsReceivableExchangeRateEffect>
    <AATP:AllowanceForDoubtfulAccountsReceivableExchangeRateEffect
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-419</AATP:AllowanceForDoubtfulAccountsReceivableExchangeRateEffect>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">121095</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_802_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zrLPbDAFgTHk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;8.
&lt;span id="xdx_820_ztxby9rdsA99"&gt;PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--PropertyPlantAndEquipmentTextBlock_zmRWPBeyI347" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment, net consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B0_zJYY8Y96jaqi" style="display: none"&gt;SCHEDULE OF PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20221231_zmnDw4egigNj" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20211231_zGSBwYf9jRr2" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerAndOfficeEquipmentMember_zJTZVLonUMl7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Computer and office equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;87,428&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;82,298&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zT3bDv62yQu" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Furniture &amp;amp; fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;115,789&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122,185&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z7Y6kVTFQ22b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;191,965&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;202,570&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--VehicleMember_zP6q3kqDHDz3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Vehicle&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;93,535&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;98,702&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENz5ZB_zuXLsaldfBp1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Subtotal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;488,717&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;505,755&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENz5ZB_zNaotftUy1eb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(346,568&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(289,956&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz5ZB_zrGBUIeqXFsg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;142,149&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;215,799&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zD5zv4BXkAT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
expense for the years ended December 31, 2022 and 2021 amounted to $&lt;span id="xdx_90F_eus-gaap--Depreciation_pp0p0_c20220101__20221231_zM1cQJCYtDqb" title="Depreciation"&gt;71,754&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--Depreciation_pp0p0_c20210101__20211231_zo7fj0jzidFd" title="Depreciation"&gt;75,797&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89D_eus-gaap--PropertyPlantAndEquipmentTextBlock_zmRWPBeyI347" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment, net consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B0_zJYY8Y96jaqi" style="display: none"&gt;SCHEDULE OF PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20221231_zmnDw4egigNj" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20211231_zGSBwYf9jRr2" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerAndOfficeEquipmentMember_zJTZVLonUMl7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Computer and office equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;87,428&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;82,298&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zT3bDv62yQu" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Furniture &amp;amp; fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;115,789&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122,185&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z7Y6kVTFQ22b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;191,965&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;202,570&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--VehicleMember_zP6q3kqDHDz3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Vehicle&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;93,535&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;98,702&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENz5ZB_zuXLsaldfBp1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Subtotal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;488,717&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;505,755&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENz5ZB_zNaotftUy1eb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(346,568&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(289,956&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz5ZB_zrGBUIeqXFsg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;142,149&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;215,799&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_custom_ComputerAndOfficeEquipmentMember"
      decimals="0"
      unitRef="USD">87428</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_custom_ComputerAndOfficeEquipmentMember"
      decimals="0"
      unitRef="USD">82298</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      unitRef="USD">115789</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      unitRef="USD">122185</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">191965</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">202570</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_custom_VehicleMember"
      decimals="0"
      unitRef="USD">93535</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_custom_VehicleMember"
      decimals="0"
      unitRef="USD">98702</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">488717</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">505755</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">346568</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">289956</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">142149</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">215799</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">71754</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">75797</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_804_eus-gaap--IntangibleAssetsDisclosureTextBlock_zOgdM8JyWVQ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;9.
&lt;span id="xdx_824_zz8jNBrDFqp3"&gt;INTANGIBLE ASSETS, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zm6UnzTggnt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets, net, consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B7_zKqIDuKePe73" style="display: none"&gt;SCHEDULE OF INTANGIBLE ASSETS, NET&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20221231_zd7VedRq0D5k" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20211231_zZxbckCQ0w9a" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CapitalizedComputerSoftwareGross_iI_maCzFod_zrusbEBApco5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Computer software&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;55,348&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;34,453&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msCzFod_z66goRzTWTG3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(31,304&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(30,793&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtCzFod_z4FectFsIhM8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;24,044&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,660&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zB0qHIgrTsH7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
expense for the years ended December 31, 2022 and 2021 amounted to $&lt;span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20220101__20221231_zIgF3JYdbu8e" title="Amortization expense"&gt;2,122&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20210101__20211231_zqKFeWR6wLd" title="Amortization expense"&gt;1,961&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_890_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zm6UnzTggnt1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets, net, consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B7_zKqIDuKePe73" style="display: none"&gt;SCHEDULE OF INTANGIBLE ASSETS, NET&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20221231_zd7VedRq0D5k" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20211231_zZxbckCQ0w9a" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CapitalizedComputerSoftwareGross_iI_maCzFod_zrusbEBApco5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Computer software&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;55,348&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;34,453&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msCzFod_z66goRzTWTG3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(31,304&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(30,793&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtCzFod_z4FectFsIhM8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;24,044&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,660&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:CapitalizedComputerSoftwareGross contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">55348</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">34453</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">31304</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">30793</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">24044</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">3660</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">2122</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1961</us-gaap:AmortizationOfIntangibleAssets>
    <AATP:InvestmentInMarketableSecuritiesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_807_ecustom--InvestmentInMarketableSecuritiesTextBlock_z0A1AgtbWSb9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;10.
&lt;span id="xdx_825_zQvuOqi8GWOf"&gt;INVESTMENT IN MARKETABLE SECURITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(i)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    May 17, 2018, the Company purchased &lt;span id="xdx_90F_eus-gaap--InvestmentOwnedBalanceShares_iI_c20180517__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zm3gQDiLDcnd" title="Investment owned, balance, shares"&gt;83,333&lt;/span&gt; shares of common stock in Greenpro Capital Corp. for $&lt;span id="xdx_901_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20180517__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zPpH4oOHXtm5" title="Investment owned, balance, value"&gt;500,000&lt;/span&gt; at a purchase price of $&lt;span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20180517__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zaXyI8H7SnVi" title="Shares issued, price per share"&gt;6&lt;/span&gt;
    per share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(ii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    July 30, 2018, the Company disposed &lt;span id="xdx_909_eus-gaap--InvestmentOwnedBalanceShares_iI_c20180730__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zvuOhS2JZVSl" title="Investment owned, balance, shares"&gt;20&lt;/span&gt; shares of common stock in Greenpro Capital Corp. for $&lt;span id="xdx_90A_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20180730__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zdZKwuzNtYd8" title="Investment owned, balance, value"&gt;125&lt;/span&gt; at a purchase price of $&lt;span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20180730__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zgN0fw7pBxag" title="Shares issued, price per share"&gt;6.2613&lt;/span&gt; per
    share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(iii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    October 16, 2018, the Company purchased &lt;span id="xdx_90C_eus-gaap--InvestmentOwnedBalanceShares_iI_c20181016__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zDqIWuJmaEa3" title="Investment owned, balance, shares"&gt;33,333&lt;/span&gt; shares of common stock in Greenpro Capital Corp. for $&lt;span id="xdx_902_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20181016__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zPi6lcUs4Eil" title="Investment owned, balance, value"&gt;1,000&lt;/span&gt; at a purchase price of
    $&lt;span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20181016__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zXS2rwZJaCV1" title="Shares issued, price per share"&gt;0.03&lt;/span&gt; per share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(iv)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    July 19, 2022, Greenpro Capital Corp. filed a certificate of change with the Secretary of State of Nevada to effect a reverse split
    of &lt;span id="xdx_907_eus-gaap--StockholdersEquityReverseStockSplit_c20220718__20220719_zwSn4r44Kra3" title="Stockholders equity reverse stock split"&gt;the
    company&#x2019;s common stock at the ratio of 10-for-1 effective July 28, 2022. Under the reverse stock split, each 10 pre-split
    share of common stock outstanding will automatically combine into 1 new share of common stock of the company. As at July 28, 2022,
    the Company has an investment of &lt;span id="xdx_90B_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20221231__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zTMsWNH24c05" title="Investment owned, balance shares"&gt;116,646&lt;/span&gt;
    common stock of Greenpro Capital Corp. The Company&#x2019;s investment of &lt;span id="xdx_908_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20221231__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zQRIGxFVY9ee" title="Investment owned, balance shares"&gt;116,646&lt;/span&gt;
    common stock of Greenpro Capital Corp. was reduced to &lt;span id="xdx_90D_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220719__dei--LegalEntityAxis__custom--GreenproCapitalCorpMember_zCB09Nfj7Ke8" title="Investment owned, balance shares"&gt;11,665&lt;/span&gt;
    subsequent to the reverse stock split.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(v)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    November 3, 2020, the Company received dividend of &lt;span id="xdx_904_eus-gaap--InvestmentOwnedBalanceShares_iI_c20201103__dei--LegalEntityAxis__custom--DSwissIncMember_zMIsUacusxo1" title="Investment owned, balance shares"&gt;6,667&lt;/span&gt; shares of common stock in DSwiss, Inc. for $&lt;span id="xdx_900_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20201103__dei--LegalEntityAxis__custom--DSwissIncMember_zi5CkLRH6nM" title="Investment amount"&gt;76,671&lt;/span&gt; at fair value of $&lt;span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20201103__dei--LegalEntityAxis__custom--DSwissIncMember_zK1owfLgr3l9" title="Shares issued, price per share"&gt;11.50&lt;/span&gt;
    per share from Greenpro Capital Corporation as result of its Spin-off of DSwiss, Inc.&#x2019;s shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(vi)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    December 9, 2020, the Company received dividend of &lt;span id="xdx_90B_eus-gaap--InvestmentOwnedBalanceShares_iI_c20201209__dei--LegalEntityAxis__custom--DSwissIncMember_zdoG7Jk99tql" title="Investment owned, balance shares"&gt;16,663&lt;/span&gt; shares of common stock in DSwiss, Inc. for $&lt;span id="xdx_902_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20201209__dei--LegalEntityAxis__custom--DSwissIncMember_zFaH5SRmUoFg" title="Investment owned, balance, value"&gt;83,315&lt;/span&gt; at fair value of $&lt;span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_c20201209__dei--LegalEntityAxis__custom--DSwissIncMember_zDAfYwC4oh0h" title="Shares issued, price per share"&gt;5&lt;/span&gt;
    per share from Greenpro Capital Corporation as result of its Spin-off of DSwiss, Inc.&#x2019;s shares.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(vii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    September 27, 2021, the Company received dividend of &lt;span id="xdx_906_eus-gaap--InvestmentOwnedBalanceShares_iI_c20210927__dei--LegalEntityAxis__custom--SEATechVenturesCorpMember_zlPcAJsUNjok" title="Investment in securities, shares"&gt;11,665&lt;/span&gt; shares of common stock in SEATech Ventures Corp. for $&lt;span id="xdx_903_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20210927__dei--LegalEntityAxis__custom--SEATechVenturesCorpMember_z2f9vVLdWhfj" title="Investment amount"&gt;18,874&lt;/span&gt; at fair
    value of $&lt;span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20210927__dei--LegalEntityAxis__custom--SEATechVenturesCorpMember_zYfgGzL5GgNd" title="Purchased price per shares"&gt;1.62&lt;/span&gt; per share from Greenpro Capital Corp as a dividend income since Greenpro Capital Corp previously owned these shares.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(viii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    April 3, 2019, the Company purchased a &lt;span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20190403__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PhoenixPlusCorpMember_zEurJrkWfvL3" title="Equity interest percentage"&gt;5&lt;/span&gt;%
    of stock or &lt;span id="xdx_904_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20190403__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PhoenixPlusCorpMember_zsZQVTglfUF9" title="Shares purchased during period"&gt;15,000,000&lt;/span&gt;
    shares of common stock in Phoenix Plus Corp. (a non-marketable security) for $&lt;span id="xdx_909_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20190403__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PhoenixPlusCorpMember_zOek7wSfajpe" title="Investment amount"&gt;1,500&lt;/span&gt;
    at purchase price of $&lt;span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20190403__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PhoenixPlusCorpMember_z97OVMGsYqx8" title="Shares issued price per share"&gt;0.0001&lt;/span&gt;
    per share. Phoenix Plus Corp. obtained approval for Depository Trust Company eligibility on April 26, 2022. Since the commencement of trading of common stock of Phoenix Plus Corp. on May 18, 2022, to March 9, 2023,
    there were only &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210518__20230309__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zyLc59iB1OHd" title="Stock issued during peirod shares new issues"&gt;200&lt;/span&gt; shares of common stock of the company traded. The Company deems there is an absence of a readily determinable
    fair value of the common stock of Phoenix Plus Corp. and has continued to value its investment in the company Phoenix Plus
    Corp. at cost.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;10.
INVESTMENT IN MARKETABLE SECURITIES (CONT&#x2019;D)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--MarketableSecuritiesTextBlock_zuGzrtr9rAUc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8B0_zN99PDRxKP02" style="display: none"&gt;SCHEDULE OF INVESTMENT IN MARKETABLE SECURITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20221231_z4RIpzJXVA29" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20211231_z8xbbM4gX3Kf" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_maMSNzd9C_zzkch15ow0Z2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Cost of investment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;89,001&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;577,035&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--TransferFromNonmarketableSecurity_iNI_pp0p0_di_msMSNzd9C_z4pyxkB70cWa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Transfer from non-marketable security&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1063"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--InvestmentsIncomeDividend_iNI_pp0p0_di_msMSNzd9C_z4XWyTJDvR08" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend income from Greenpro Capital Corp.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1065"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,939&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--MarketableSecuritiesUnrealizedHoldingLoss_iNI_pp0p0_di_msMSNzd9C_z67Y6b3K59S7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Unrealized holding loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(73,519&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(505,231&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--ExchangeRateEffectOnInvestmentInMarketableSecurites_iI_pp0p0_maMSNzd9C_zA1iT4Zoqkrc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exchange rate effect&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(295&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,742&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--MarketableSecuritiesNoncurrent_iTI_pp0p0_mtMSNzd9C_zQpdBZmA4Cng" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Investment in marketable securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;16,687&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;89,001&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zJcQxpLuKbL1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</AATP:InvestmentInMarketableSecuritiesTextBlock>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2018-05-17_custom_GreenproCapitalCorpMember"
      decimals="INF"
      unitRef="Shares">83333</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="AsOf2018-05-17_custom_GreenproCapitalCorpMember"
      decimals="0"
      unitRef="USD">500000</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2018-05-17_custom_GreenproCapitalCorpMember"
      decimals="INF"
      unitRef="USDPShares">6</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2018-07-30_custom_GreenproCapitalCorpMember"
      decimals="INF"
      unitRef="Shares">20</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="AsOf2018-07-30_custom_GreenproCapitalCorpMember"
      decimals="0"
      unitRef="USD">125</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2018-07-30_custom_GreenproCapitalCorpMember"
      decimals="INF"
      unitRef="USDPShares">6.2613</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2018-10-16_custom_GreenproCapitalCorpMember"
      decimals="INF"
      unitRef="Shares">33333</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="AsOf2018-10-16_custom_GreenproCapitalCorpMember"
      decimals="0"
      unitRef="USD">1000</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2018-10-16_custom_GreenproCapitalCorpMember"
      decimals="INF"
      unitRef="USDPShares">0.03</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2022-07-182022-07-19">the
    company&#x2019;s common stock at the ratio of 10-for-1 effective July 28, 2022. Under the reverse stock split, each 10 pre-split
    share of common stock outstanding will automatically combine into 1 new share of common stock of the company. As at July 28, 2022,
    the Company has an investment of 116,646
    common stock of Greenpro Capital Corp. The Company&#x2019;s investment of 116,646
    common stock of Greenpro Capital Corp. was reduced to 11,665
    subsequent to the reverse stock split.</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2022-12-31_custom_GreenproCapitalCorpMember"
      decimals="INF"
      unitRef="Shares">116646</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2022-12-31_custom_GreenproCapitalCorpMember"
      decimals="INF"
      unitRef="Shares">116646</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2022-07-19_custom_GreenproCapitalCorpMember"
      decimals="INF"
      unitRef="Shares">11665</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2020-11-03_custom_DSwissIncMember"
      decimals="INF"
      unitRef="Shares">6667</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="AsOf2020-11-03_custom_DSwissIncMember"
      decimals="0"
      unitRef="USD">76671</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2020-11-03_custom_DSwissIncMember"
      decimals="INF"
      unitRef="USDPShares">11.50</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2020-12-09_custom_DSwissIncMember"
      decimals="INF"
      unitRef="Shares">16663</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="AsOf2020-12-09_custom_DSwissIncMember"
      decimals="0"
      unitRef="USD">83315</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2020-12-09_custom_DSwissIncMember"
      decimals="INF"
      unitRef="USDPShares">5</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2021-09-27_custom_SEATechVenturesCorpMember"
      decimals="INF"
      unitRef="Shares">11665</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="AsOf2021-09-27_custom_SEATechVenturesCorpMember"
      decimals="0"
      unitRef="USD">18874</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2021-09-27_custom_SEATechVenturesCorpMember"
      decimals="INF"
      unitRef="USDPShares">1.62</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2019-04-03_custom_PhoenixPlusCorpMember"
      decimals="INF"
      unitRef="Pure">0.05</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2019-04-03_us-gaap_CommonStockMember_custom_PhoenixPlusCorpMember"
      decimals="INF"
      unitRef="Shares">15000000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="AsOf2019-04-03_custom_PhoenixPlusCorpMember"
      decimals="0"
      unitRef="USD">1500</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2019-04-03_custom_PhoenixPlusCorpMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-05-182023-03-09_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">200</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_895_eus-gaap--MarketableSecuritiesTextBlock_zuGzrtr9rAUc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8B0_zN99PDRxKP02" style="display: none"&gt;SCHEDULE OF INVESTMENT IN MARKETABLE SECURITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20221231_z4RIpzJXVA29" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20211231_z8xbbM4gX3Kf" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_maMSNzd9C_zzkch15ow0Z2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Cost of investment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;89,001&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;577,035&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--TransferFromNonmarketableSecurity_iNI_pp0p0_di_msMSNzd9C_z4pyxkB70cWa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Transfer from non-marketable security&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1063"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--InvestmentsIncomeDividend_iNI_pp0p0_di_msMSNzd9C_z4XWyTJDvR08" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend income from Greenpro Capital Corp.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1065"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,939&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--MarketableSecuritiesUnrealizedHoldingLoss_iNI_pp0p0_di_msMSNzd9C_z67Y6b3K59S7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Unrealized holding loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(73,519&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(505,231&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--ExchangeRateEffectOnInvestmentInMarketableSecurites_iI_pp0p0_maMSNzd9C_zA1iT4Zoqkrc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exchange rate effect&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(295&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,742&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--MarketableSecuritiesNoncurrent_iTI_pp0p0_mtMSNzd9C_zQpdBZmA4Cng" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Investment in marketable securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;16,687&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;89,001&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:InvestmentOwnedAtCost contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">89001</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:InvestmentOwnedAtCost contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">577035</us-gaap:InvestmentOwnedAtCost>
    <AATP:TransferFromNonmarketableSecurity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">-1500</AATP:TransferFromNonmarketableSecurity>
    <AATP:InvestmentsIncomeDividend contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-18939</AATP:InvestmentsIncomeDividend>
    <AATP:MarketableSecuritiesUnrealizedHoldingLoss contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">73519</AATP:MarketableSecuritiesUnrealizedHoldingLoss>
    <AATP:MarketableSecuritiesUnrealizedHoldingLoss contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">505231</AATP:MarketableSecuritiesUnrealizedHoldingLoss>
    <AATP:ExchangeRateEffectOnInvestmentInMarketableSecurites contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">-295</AATP:ExchangeRateEffectOnInvestmentInMarketableSecurites>
    <AATP:ExchangeRateEffectOnInvestmentInMarketableSecurites contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-1742</AATP:ExchangeRateEffectOnInvestmentInMarketableSecurites>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">16687</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">89001</us-gaap:MarketableSecuritiesNoncurrent>
    <AATP:InvestmentInNonMarketableSecuritiesTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80E_ecustom--InvestmentInNonMarketableSecuritiesTextBlock_zkjqdsvXMPd4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;11.
&lt;span id="xdx_823_zaEyLiz194h2"&gt;INVESTMENT IN NON-MARKETABLE SECURITIES&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 3, 2019, the Company purchased a &lt;span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20190403__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PhoenixPlusCorpMember_zPQsOu2Iphhc" title="Equity interest percentage"&gt;5&lt;/span&gt;% of stock or &lt;span id="xdx_903_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20190403__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PhoenixPlusCorpMember_zG44J5ACcI84" title="Shares purchased during period"&gt;15,000,000&lt;/span&gt; shares of common stock in Phoenix Plus Corp. for $&lt;span id="xdx_909_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20190403__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PhoenixPlusCorpMember_zyyjs0mRv6ef" title="Investment amount"&gt;1,500&lt;/span&gt; at purchase
price of $&lt;span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20190403__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PhoenixPlusCorpMember_zzAKlWVf0qhc" title="Shares issued price per share"&gt;0.0001&lt;/span&gt; per share. Phoenix Plus Corp. attained its effective date with the Securities Exchange Commission for listing on OTC (Pink Sheet),
U.S. on March 12, 2021, and obtained approval for Depository trust Company (&#x201c;DTC&#x201d;)
eligibility on April 26, 2022. Accordingly, stocks of Phoenix Plus Corp. can be traded on OTC. As such the investment in Phoenix Plus Corp. was transferred to marketable securities.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_ecustom--NonMarketableSecuritiesTableTextBlock_zBFVNM9h6jw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zsjdkcg96i46" style="display: none"&gt;SCHEDULE OF INVESTMENT IN NON MARKETABLE SECURITIES&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;Phoenix Plus Corporation&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20221231__dei--LegalEntityAxis__custom--PhoenixPlusCorpMember_zXXHcTFvwT4a" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20211231__dei--LegalEntityAxis__custom--PhoenixPlusCorpMember_zdReaiw7n5o9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;Phoenix Plus Corporation&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InvestmentOwnedAtCost_iI_maIINMSz0ls_zigDTIRmqOR9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Cost of investment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--TransferToInvestmentInMarketableSecurities_iNI_di_msIINMSz0ls_zpVXZpw00J8a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-style: italic; text-align: left; padding-bottom: 1.5pt"&gt;Less: Transfer to investment in marketable securities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1093"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--InvestmentInNonMarketableSecuritiesNoncurrent_iTI_mtIINMSz0ls_z1Uxjbfm9Z17" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Investment in non-marketable securities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1095"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_z76k0VA2FEzk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

</AATP:InvestmentInNonMarketableSecuritiesTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2019-04-03_custom_PhoenixPlusCorpMember"
      decimals="INF"
      unitRef="Pure">0.05</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2019-04-03_us-gaap_CommonStockMember_custom_PhoenixPlusCorpMember"
      decimals="INF"
      unitRef="Shares">15000000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="AsOf2019-04-03_custom_PhoenixPlusCorpMember"
      decimals="0"
      unitRef="USD">1500</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2019-04-03_custom_PhoenixPlusCorpMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:SharesIssuedPricePerShare>
    <AATP:NonMarketableSecuritiesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89E_ecustom--NonMarketableSecuritiesTableTextBlock_zBFVNM9h6jw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zsjdkcg96i46" style="display: none"&gt;SCHEDULE OF INVESTMENT IN NON MARKETABLE SECURITIES&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;Phoenix Plus Corporation&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20221231__dei--LegalEntityAxis__custom--PhoenixPlusCorpMember_zXXHcTFvwT4a" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20211231__dei--LegalEntityAxis__custom--PhoenixPlusCorpMember_zdReaiw7n5o9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;Phoenix Plus Corporation&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InvestmentOwnedAtCost_iI_maIINMSz0ls_zigDTIRmqOR9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Cost of investment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--TransferToInvestmentInMarketableSecurities_iNI_di_msIINMSz0ls_zpVXZpw00J8a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-style: italic; text-align: left; padding-bottom: 1.5pt"&gt;Less: Transfer to investment in marketable securities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1093"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--InvestmentInNonMarketableSecuritiesNoncurrent_iTI_mtIINMSz0ls_z1Uxjbfm9Z17" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Investment in non-marketable securities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1095"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</AATP:NonMarketableSecuritiesTableTextBlock>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="AsOf2022-12-31_custom_PhoenixPlusCorpMember"
      decimals="0"
      unitRef="USD">1500</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="AsOf2021-12-31_custom_PhoenixPlusCorpMember"
      decimals="0"
      unitRef="USD">1500</us-gaap:InvestmentOwnedAtCost>
    <AATP:TransferToInvestmentInMarketableSecurities
      contextRef="AsOf2022-12-31_custom_PhoenixPlusCorpMember"
      decimals="0"
      unitRef="USD">1500</AATP:TransferToInvestmentInMarketableSecurities>
    <AATP:InvestmentInNonMarketableSecuritiesNoncurrent
      contextRef="AsOf2021-12-31_custom_PhoenixPlusCorpMember"
      decimals="0"
      unitRef="USD">1500</AATP:InvestmentInNonMarketableSecuritiesNoncurrent>
    <AATP:CustomerDepositsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_809_ecustom--CustomerDepositsTextBlock_zBHnnqeVa9Ch" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;12. &lt;span id="xdx_826_zQES4THSnK8l"&gt;CUSTOMER DEPOSITS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_89D_ecustom--CustomerDepositsTableTextBlock_zHhQaYUa9k5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF CUSTOMER DEPOSITS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221231_zow2nIkKZI36" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20211231_zTv7W3RRpuqb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--CustomerDeposits_iI_zwD3eV7Y1YXi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Customer deposits&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;289,487&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;273,581&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--UnexpiredProductCoupons_iI_zpZlYuDLeHh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Unexpired product coupons&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;73,531&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,108&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DepositLiabilityCurrent_iI_zI1umsyIVJ32" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;363,018&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;279,689&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A5_zFeI1mPtS7X2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Customer deposits represent amounts advanced by customers
on product orders and unexpired product coupons issued to the Company&#x2019;s members and distributors of its network marketing business.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</AATP:CustomerDepositsTextBlock>
    <AATP:CustomerDepositsTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89D_ecustom--CustomerDepositsTableTextBlock_zHhQaYUa9k5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF CUSTOMER DEPOSITS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221231_zow2nIkKZI36" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20211231_zTv7W3RRpuqb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--CustomerDeposits_iI_zwD3eV7Y1YXi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Customer deposits&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;289,487&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;273,581&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--UnexpiredProductCoupons_iI_zpZlYuDLeHh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Unexpired product coupons&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;73,531&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,108&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DepositLiabilityCurrent_iI_zI1umsyIVJ32" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;363,018&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;279,689&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</AATP:CustomerDepositsTableTextBlock>
    <AATP:CustomerDeposits contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">289487</AATP:CustomerDeposits>
    <AATP:CustomerDeposits contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">273581</AATP:CustomerDeposits>
    <AATP:UnexpiredProductCoupons contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">73531</AATP:UnexpiredProductCoupons>
    <AATP:UnexpiredProductCoupons contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">6108</AATP:UnexpiredProductCoupons>
    <us-gaap:DepositLiabilityCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">363018</us-gaap:DepositLiabilityCurrent>
    <us-gaap:DepositLiabilityCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">279689</us-gaap:DepositLiabilityCurrent>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_806_eus-gaap--OtherLiabilitiesDisclosureTextBlock_zgP6LWKYW1vf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;13.
&lt;span id="xdx_820_zPzlrUUAodIl"&gt;OTHER PAYABLES AND ACCRUED LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_ecustom--ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock_z0fAGKnF5AM" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_zeSWMrAQEuWa" style="display: none"&gt;SCHEDULE OF OTHER PAYABLES AND ACCRUED LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20221231_zQIWaMMhHL12" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20211231_z45F1OSPJsFf" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maOAPAAz1Ku_zI8xwdf6tNn" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;324,629&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;436,541&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--AccruedPromotionExpensesCurrent_iI_pp0p0_maOAPAAz1Ku_zK1vqfScw7Ti" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Promotion expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,583&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36,024&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_maOAPAAz1Ku_zTU3Vl05AfI1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Payroll&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,164&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,669&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccruedSalesCommissionCurrent_iI_pp0p0_maOAPAAz1Ku_zBf7jn2I9sS" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Amounts held in eWallets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;216,049&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;223,781&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--AccruedTaxPenaltyCurrent_iI_pp0p0_maOAPAAz1Ku_zCTg4hKcqDfa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Tax penalty&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iI_pp0p0_maOAPAAz1Ku_zXbRWJ730LGf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;37,852&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;64,340&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--OtherAccountPayableAndAccruedLiabilities_iTI_pp0p0_mtOAPAAz1Ku_zooHneFb6om8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;713,277&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;858,355&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zRI6cdAor1X9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company requires all members and distributors of its network marketing business to maintain an electronic wallet (eWallet) account with
the Company. &lt;span id="xdx_90D_ecustom--CommissionPaymentsDescriptions_c20220101__20221231_zMUgKigPDTa4" title="Commission payments descriptions"&gt;The eWallet is primarily for the crediting of any commission payment that falls below RM&lt;span id="xdx_909_eus-gaap--CommissionsPayableToBrokerDealersAndClearingOrganizations_iI_uRM_c20221231_zv5mLNWiWRxk" title="Comission payable"&gt;100&lt;/span&gt; (or $22.70).&lt;/span&gt; Commission payment
exceeding the RM&lt;span id="xdx_90F_eus-gaap--ContractWithCustomerAssetGross_iI_uRM_c20221231_zk9aTMMaZ3w4" title="Comission payable, threshold"&gt;100&lt;/span&gt; threshold shall only be credited into the member&#x2019;s or distributor&#x2019;s eWallet upon request. The eWallet
functionality allows the members to place new product orders utilizing eWallet available balance and/or request commission payout via
multiple payment methods provided that each of the withdrawal amount exceeds RM&lt;span id="xdx_904_eus-gaap--ContractWithCustomerAssetGross_iI_uRM_c20221231__srt--RangeAxis__srt--MaximumMember_zWQ98f2Fse27" title="Comission payable, threshold"&gt;100&lt;/span&gt;. Amounts held in eWallets are reflected on the balance
sheet as a current liability.&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <AATP:ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_899_ecustom--ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock_z0fAGKnF5AM" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_zeSWMrAQEuWa" style="display: none"&gt;SCHEDULE OF OTHER PAYABLES AND ACCRUED LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20221231_zQIWaMMhHL12" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20211231_z45F1OSPJsFf" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maOAPAAz1Ku_zI8xwdf6tNn" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;324,629&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;436,541&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--AccruedPromotionExpensesCurrent_iI_pp0p0_maOAPAAz1Ku_zK1vqfScw7Ti" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Promotion expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,583&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36,024&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_maOAPAAz1Ku_zTU3Vl05AfI1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Payroll&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,164&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,669&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccruedSalesCommissionCurrent_iI_pp0p0_maOAPAAz1Ku_zBf7jn2I9sS" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Amounts held in eWallets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;216,049&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;223,781&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--AccruedTaxPenaltyCurrent_iI_pp0p0_maOAPAAz1Ku_zCTg4hKcqDfa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Tax penalty&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iI_pp0p0_maOAPAAz1Ku_zXbRWJ730LGf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;37,852&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;64,340&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--OtherAccountPayableAndAccruedLiabilities_iTI_pp0p0_mtOAPAAz1Ku_zooHneFb6om8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;713,277&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;858,355&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</AATP:ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">324629</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">436541</us-gaap:AccruedProfessionalFeesCurrent>
    <AATP:AccruedPromotionExpensesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">38583</AATP:AccruedPromotionExpensesCurrent>
    <AATP:AccruedPromotionExpensesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">36024</AATP:AccruedPromotionExpensesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">21164</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">22669</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedSalesCommissionCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">216049</us-gaap:AccruedSalesCommissionCurrent>
    <us-gaap:AccruedSalesCommissionCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">223781</us-gaap:AccruedSalesCommissionCurrent>
    <AATP:AccruedTaxPenaltyCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">75000</AATP:AccruedTaxPenaltyCurrent>
    <AATP:AccruedTaxPenaltyCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">75000</AATP:AccruedTaxPenaltyCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">37852</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">64340</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <AATP:OtherAccountPayableAndAccruedLiabilities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">713277</AATP:OtherAccountPayableAndAccruedLiabilities>
    <AATP:OtherAccountPayableAndAccruedLiabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">858355</AATP:OtherAccountPayableAndAccruedLiabilities>
    <AATP:CommissionPaymentsDescriptions contextRef="From2022-01-01to2022-12-31">The eWallet is primarily for the crediting of any commission payment that falls below RM100 (or $22.70).</AATP:CommissionPaymentsDescriptions>
    <us-gaap:CommissionsPayableToBrokerDealersAndClearingOrganizations contextRef="AsOf2022-12-31" decimals="0" unitRef="RM">100</us-gaap:CommissionsPayableToBrokerDealersAndClearingOrganizations>
    <us-gaap:ContractWithCustomerAssetGross contextRef="AsOf2022-12-31" decimals="0" unitRef="RM">100</us-gaap:ContractWithCustomerAssetGross>
    <us-gaap:ContractWithCustomerAssetGross
      contextRef="AsOf2022-12-31_srt_MaximumMember"
      decimals="0"
      unitRef="RM">100</us-gaap:ContractWithCustomerAssetGross>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_803_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zaYfTMIgUOEj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;14.
&lt;span id="xdx_826_zBglaasqwYCi"&gt;RELATED PARTY BALANCES AND TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Related
party balances&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amount
due from related parties&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zl0oYWLAAj4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_z727ztZuIZn6" style="display: none"&gt;SCHEDULE OF RELATED PARTIES&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Name of Related&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Party&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Relationship&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Nature&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 22%; text-align: left"&gt;TH3 Technology Sdn Bhd (&#x201c;TH3&#x201d;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 22%; text-align: center"&gt;&lt;span id="xdx_904_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_ziLC6cF8O0Hb" title="Relationship"&gt;&lt;span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_zzSz5d5bIqm9" title="Relationship"&gt;Mr. How Kok Choong, the CEO and director of the Company is also a director of TH3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 16%; text-align: center"&gt;Prepayment of IT expenses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_zZAUIMTT8fOj" style="width: 14%; text-align: right" title="Due from related parties"&gt;1,273&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_zukwEs1YngT4" style="width: 14%; text-align: right" title="Due from related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1154"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;DSY Beauty Sdn Bhd (&#x201c;DSY Beauty&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_903_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_z0694WTKbtY1" title="Relationship"&gt;&lt;span id="xdx_901_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zeZmlYSi7375" title="Relationship"&gt;The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Deposits for products&lt;/p&gt;
                                                        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;purchases&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zwDZUnOh83dc" style="text-align: right" title="Due from related parties"&gt;9,261&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zByqRivjGxmc" style="text-align: right" title="Due from related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1162"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Agape ATP (Asia) Limited (&#x201c;AATP Asia&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_900_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zHWmYpA622q9" title="Relationship"&gt;&lt;span id="xdx_902_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zP3giNs1HF4d" title="Relationship"&gt;Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of AATP Asia&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_90B_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zvM7Hh1mF5pj" title="Nature"&gt;&lt;span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zJUFhY5rF4V1" title="Nature"&gt;Expenses paid for AATP Asia&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zybPyNfOgw56" style="text-align: right" title="Due from related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1172"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_ziSokE5HMXP7" style="text-align: right" title="Due from related parties"&gt;2,214&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt"&gt;Hostastay Sdn. Bhd. &lt;br/&gt;&#x201c;Hostastay&#x201d;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_904_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_z9WLCOVt2aPa" title="Relationship"&gt;&lt;span id="xdx_90F_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_z3VsvnIpOAm2" title="Relationship"&gt;Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_903_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zdj7boQy7Z08" title="Nature"&gt;&lt;span id="xdx_906_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zUYOiG4dFOU3" title="Nature"&gt;Sublease rent due from Hostastay&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zpXdWXaREyb2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Due from related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1184"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zXiuGQBFncKe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Due from related parties"&gt;4,790&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20221231_zF4oFTU7cPKd" style="border-bottom: Black 2.5pt double; text-align: right" title="Due from related parties"&gt;10,534&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20211231_z5LEII8mzdAe" style="border-bottom: Black 2.5pt double; text-align: right" title="Due from related parties"&gt;7,004&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Accounts
payable &#x2013; related parties&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Name of Related&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Party&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Relationship&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Nature&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 22%; text-align: left"&gt;CTA Nutriceuticals (Asia) Sdn Bhd (&#x201c;CTA&#x201d;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 22%; text-align: center"&gt;&lt;span id="xdx_906_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zerXYsBJD1ta" title="Relationship"&gt;&lt;span id="xdx_90E_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zqorjRRHLqeh" title="Relationship"&gt;The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 16%; text-align: center"&gt;&lt;span id="xdx_900_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zIWoggCpvyz9" title="Nature"&gt;&lt;span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zHhxRv48SPpb" title="Nature"&gt;Purchases of products for the provision of complementary health therapies&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zPFD76jbZAm2" style="width: 14%; text-align: right" title="Accounts payable, related parties, current"&gt;25,387&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zNdbULlh8yt8" style="width: 14%; text-align: right" title="Accounts payable, related parties, current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1202"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt"&gt;DSY Beauty Sdn Bhd (&#x201c;DSY Beauty&#x201d;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_908_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zM1z2HcEGkuj" title="Relationship"&gt;&lt;span id="xdx_906_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_z8IOZfRRQTP2" title="Relationship"&gt;The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_904_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zc7oweQDOY3f" title="Nature"&gt;Purchases of beauty products&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zfU3NUY42Nfb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accounts payable, related parties, current"&gt;224&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zV5eQ932Q825" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accounts payable, related parties, current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1212"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20221231_zGBB1JB6CVq4" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts payable, related parties, current"&gt;25,611&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20211231_zZAdIF7v7Zaa" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts payable, related parties, current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1216"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;14.
RELATED PARTY BALANCES AND TRANSACTIONS (CONT&#x2019;D)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Related
party balances&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Other payable - related parties&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Name of Related&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Party&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Relationship&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Nature&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 22%; text-align: left"&gt;CTA Nutriceuticals (Asia) Sdn Bhd (&#x201c;CTA&#x201d;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 22%; text-align: center"&gt;&lt;span id="xdx_906_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdOneMember_zRZjLu2pyuSk" title="Relationship"&gt;&lt;span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdOneMember_zC9td5yiQjm1" title="Relationship"&gt;The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 16%; text-align: center"&gt;&lt;span id="xdx_901_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdOneMember_zz6M3NDzdZ5d" title="Nature"&gt;&lt;span id="xdx_90A_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdOneMember_zzwxLVUhJ7Gj" title="Nature"&gt;Purchase of products for general use&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdOneMember_z4MvZfHbEqh5" style="width: 14%; text-align: right" title="Due to related parties"&gt;2,149&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdOneMember_zEE4fagrL1fd" style="width: 14%; text-align: right" title="Due to related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1228"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;DSY Beauty Sdn Bhd (&#x201c;DSY Beauty&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_900_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_zjX7ki6BoTY1" title="Relationship"&gt;&lt;span id="xdx_903_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_zztblYDJrAed" title="Relationship"&gt;The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_901_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_z0iOuRmJMVBf" title="Nature"&gt;&lt;span id="xdx_904_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_zHVZ5TNJC34l" title="Nature"&gt;Purchase of products for general use&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_z8Wmhm3hUI43" style="text-align: right" title="Due to related parties"&gt;2,147&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_zah7ZUjUINIk" style="text-align: right" title="Due to related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1240"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt"&gt;Mr. How Kok Choong&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_901_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zzfHYp7VfMm6" title="Relationship"&gt;&lt;span id="xdx_90C_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zXbRwDLsk895" title="Relationship"&gt;Mr. How Kok Choong, the CEO and director of the Company&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_909_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_z6dwnfOeuOqg" title="Nature"&gt;&lt;span id="xdx_907_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zGwXo2mC8cKd" title="Nature"&gt;Commission expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zH4Rwm5s39Og" style="border-bottom: Black 1.5pt solid; text-align: right" title="Due to related parties"&gt;584&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zjnTizCPpH8g" style="border-bottom: Black 1.5pt solid; text-align: right" title="Due to related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1252"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pdp0_c20221231_zJbx1u9mu5C9" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to related parties"&gt;4,880&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pdp0_c20211231_zS1BhyQ3Bi9i" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1256"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Related
party transactions &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Purchases&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Name of Related&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;For the years ended December 31,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Party&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Relationship&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Nature&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 22%; text-align: left"&gt;CTA Nutriceuticals (Asia) Sdn Bhd (&#x201c;CTA&#x201d;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 22%; text-align: center"&gt;&lt;span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zG9btHnwadC2" title="Relationship"&gt;&lt;span id="xdx_908_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zauLz8fCZTk7" title="Relationship"&gt;The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 16%; text-align: center"&gt;&lt;span id="xdx_90A_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zwQlhwdt3st7" title="Nature"&gt;&lt;span id="xdx_90C_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zUTGwGNmJzUi" title="Nature"&gt;Purchases of products for the provision of complementary health therapies&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zEDJpcz6QUD3" style="width: 14%; text-align: right" title="Purchases"&gt;198,376&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zjNU7dGm447l" style="width: 14%; text-align: right" title="Purchases"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1268"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;DSY Beauty Sdn Bhd (&#x201c;DSY Beauty&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_908_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zIGdx9Bw1blh" title="Relationship"&gt;&lt;span id="xdx_90C_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zPFuB2i5T166" title="Relationship"&gt;The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_90B_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zPv0pPRzwuc6" title="Nature"&gt;&lt;span id="xdx_908_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zYrKqkNdAo55" title="Nature"&gt;Purchases of beauty products&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zugqbvRWvu3l" style="text-align: right" title="Purchases"&gt;3,975&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zu6p5YJuNohk" style="text-align: right" title="Purchases"&gt;718&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt"&gt;DSY Wellness &amp;amp; Longevity Center Sdn Bhd (&#x201c;DSYWLC&#x201d;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_906_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zbVboKp0GiI5" title="Relationship"&gt;&lt;span id="xdx_903_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_ziSDJiKeBjU6" title="Relationship"&gt;Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC&lt;/span&gt;&lt;/span&gt;.&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_900_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zUuiIpm9PQeb" title="Nature"&gt;&lt;span id="xdx_900_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zZRPuzBVaJBf" title="Nature"&gt;Purchases of products for the provision of complementary health therapies&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zjB80Z6q022f" style="border-bottom: Black 1.5pt solid; text-align: right" title="Purchases"&gt;124&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zUPPsxbNbbu7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Purchases"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1292"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220101__20221231_zIZqZ8Ed99Nd" style="border-bottom: Black 2.5pt double; text-align: right" title="Purchases"&gt;202,475&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210101__20211231_zx3eXt89sgO2" style="border-bottom: Black 2.5pt double; text-align: right" title="Purchases"&gt;718&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;14.
RELATED PARTY BALANCES AND TRANSACTIONS (CONT&#x2019;D)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Related
party transactions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Other
income&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Name
    of Related&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the years ended December 31,&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Party&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Relationship&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Nature&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 26%; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Hostastay
    Sdn. Bhd.&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 20%; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_900_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zqcHbYBaJJmd" style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_z2EvLexgEEyc"&gt;Mr.
    How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director
    of Hostastay as of April 21, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 14%; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_900_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_z1nEmOAMZg66" style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zAKIFOJ42Gng"&gt;Sublease
    rental income due from Hostastay&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--RelatedPartyOtherIncome_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_z6RcmQ3ozwGh" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Other income"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1302"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--RelatedPartyOtherIncome_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_z7nXSW3qZRa4" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Other income"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,345&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--RelatedPartyOtherIncome_pp0p0_c20220101__20221231_zuRLWr8prJsl" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Other income"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1306"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--RelatedPartyOtherIncome_pp0p0_c20210101__20211231_z1H0garr44X9" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Other income"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,345&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Other
purchases&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Name of Related&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;For the years ended December 31,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Party&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Relationship&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Nature&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 22%; text-align: left"&gt;CTA Nutriceuticals (Asia) Sdn Bhd (&#x201c;CTA&#x201d;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 22%; text-align: center"&gt;&lt;span id="xdx_901_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdMember_zQpS1MGX9God" title="Relationship"&gt;&lt;span id="xdx_904_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdMember_zQ7tlyF1WxH8" title="Relationship"&gt;The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 16%; text-align: center"&gt;&lt;span id="xdx_90A_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdMember_zOB0wRP6Zbwk" title="Nature"&gt;&lt;span id="xdx_904_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdMember_zKuywerER7I5" title="Nature"&gt;Purchases of products for the provision of complementary health therapies&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdMember_zHyk1uIlG5X7" style="width: 14%; text-align: right" title="Other purchases"&gt;5,431&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdMember_zOJhGebFBwke" style="width: 14%; text-align: right" title="Other purchases"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1320"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;DSY Beauty Sdn Bhd (&#x201c;DSY Beauty&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zzmSc7AiZDU9" title="Relationship"&gt;&lt;span id="xdx_90D_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zZszxc9zLCci" title="Relationship"&gt;The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_z0Wk8Ark1EC9" title="Nature"&gt;&lt;span id="xdx_90C_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zhWXpNnpqXsj" title="Nature"&gt;Purchases of beauty products&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_z2yPLa3DzNw9" style="text-align: right" title="Other purchases"&gt;6,888&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zXmRjMkWYmi7" style="text-align: right" title="Other purchases"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1332"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt"&gt;DSY Wellness &amp;amp; Longevity Center Sdn Bhd (&#x201c;DSYWLC&#x201d;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_908_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z5Y8L65Fxfw5" title="Relationship"&gt;&lt;span id="xdx_90E_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zCZxtEuEhEu8" title="Relationship"&gt;Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_901_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdMember_z9Arjnl5Pz17" title="Nature"&gt;&lt;span id="xdx_903_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdMember_z6pp5SD6xYf5" title="Nature"&gt;Purchases of products for the provision of complementary health therapies&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdMember_zhkqEQynYhXg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other purchases"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdMember_z9pDuZhyXAAd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other purchases"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1344"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20220101__20221231_z76MRFD0m2B9" style="border-bottom: Black 2.5pt double; text-align: right" title="Other purchases"&gt;12,323&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20210101__20211231_zkBH9qsQYILf" style="border-bottom: Black 2.5pt double; text-align: right" title="Other purchases"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1348"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;14.
RELATED PARTY BALANCES AND TRANSACTIONS (CONT&#x2019;D)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Related
party transactions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Commission
expense&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Name of Related&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;For the years ended December 31,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Party&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Relationship&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Nature&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 22%; text-align: left; padding-bottom: 1.5pt"&gt;Mr. How Kok Choong&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 22%; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_90C_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zu0Whq1PIPL8" title="Relationship"&gt;&lt;span id="xdx_903_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_ziKt3iMOZKOf" title="Relationship"&gt;Mr. How Kok Choong, the CEO and director of the Company&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 16%; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_900_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zwKUCUPMtWLb" title="Nature"&gt;&lt;span id="xdx_904_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_z8acQHVXjMAf" title="Nature"&gt;Commission expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SalesCommissionsAndFees_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zDVS0V5gpANk" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Commission expense"&gt;16,590&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SalesCommissionsAndFees_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_znsRavhRLPGj" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Commission expense"&gt;12,758&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SalesCommissionsAndFees_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zLYgWsHkbrUl" style="border-bottom: Black 2.5pt double; text-align: right" title="Commission expense"&gt;16,590&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SalesCommissionsAndFees_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zoRsvIlllO4i" style="border-bottom: Black 2.5pt double; text-align: right" title="Commission expense"&gt;12,758&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Other
expenses&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Name of Related&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;For the years ended December 31,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Party&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Relationship&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Nature&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 22%; text-align: left"&gt;TH3 Technology Sdn Bhd (&#x201c;TH3&#x201d;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 22%; text-align: center"&gt;&lt;span id="xdx_90E_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_z4iv32kYvk1l" title="Relationship"&gt;&lt;span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_z0xuXefakGMb" title="Relationship"&gt;Mr. How Kok Choong, the CEO and director of the Company is also a director of TH3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 16%; text-align: center"&gt;&lt;span id="xdx_90E_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_zQ6QjExXo1U7" title="Nature"&gt;&lt;span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_zXGYWHCDNtCh" title="Nature"&gt;IT support services fee&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--RelatedPartyOtherExpenses_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_z8z2j3a0nVPd" style="width: 14%; text-align: right" title="Other expenses"&gt;56,450&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--RelatedPartyOtherExpenses_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_zABwXOfX473k" style="width: 14%; text-align: right" title="Other expenses"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1376"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Redboy Picture Sdn Bhd (&#x201c;Redboy&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_908_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RedboyPictureSdnBhdMember_zTlZ7u9rRIy7" title="Relationship"&gt;&lt;span id="xdx_907_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RedboyPictureSdnBhdMember_zi3zgmDv7iKd" title="Relationship"&gt;Mr. How Kok Choong, the CEO and director of the Company is also the director of Redboy&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_90B_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RedboyPictureSdnBhdMember_z5yIEWjsXqtd" title="Nature"&gt;&lt;span id="xdx_906_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RedboyPictureSdnBhdMember_zBJEOcGeyzn" title="Nature"&gt;Sponsorship fee&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--RelatedPartyOtherExpenses_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RedboyPictureSdnBhdMember_zQ3qYXMAmiBj" style="text-align: right" title="Other expenses"&gt;22,686&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--RelatedPartyOtherExpenses_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RedboyPictureSdnBhdMember_z09R8ZOGeew9" style="text-align: right" title="Other expenses"&gt;718&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt"&gt;DSY Wellness &amp;amp; Longevity Center Sdn Bhd (&#x201c;DSYWLC&#x201d;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_90C_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zcFhJLetkZFb" title="Relationship"&gt;&lt;span id="xdx_901_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zK7nMlKX00y3" title="Relationship"&gt;Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_z7juN7qEQtMg" title="Nature"&gt;&lt;span id="xdx_90C_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_z82d28JtijVi" title="Nature"&gt;Office rental expenses&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--RelatedPartyOtherExpenses_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zW53VjqvfB7a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other expenses"&gt;21,779&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--RelatedPartyOtherExpenses_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zHVhurNTFL4a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other expenses"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1400"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--RelatedPartyOtherExpenses_c20220101__20221231_zVoXaAlg39Lf" style="border-bottom: Black 2.5pt double; text-align: right" title="Other expenses"&gt;100,915&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--RelatedPartyOtherExpenses_c20210101__20211231_zLvySw9yI4bi" style="border-bottom: Black 2.5pt double; text-align: right" title="Other expenses"&gt;718&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zI0eiSIdihIi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_897_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zl0oYWLAAj4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_z727ztZuIZn6" style="display: none"&gt;SCHEDULE OF RELATED PARTIES&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Name of Related&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Party&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Relationship&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Nature&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 22%; text-align: left"&gt;TH3 Technology Sdn Bhd (&#x201c;TH3&#x201d;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 22%; text-align: center"&gt;&lt;span id="xdx_904_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_ziLC6cF8O0Hb" title="Relationship"&gt;&lt;span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_zzSz5d5bIqm9" title="Relationship"&gt;Mr. How Kok Choong, the CEO and director of the Company is also a director of TH3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 16%; text-align: center"&gt;Prepayment of IT expenses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_zZAUIMTT8fOj" style="width: 14%; text-align: right" title="Due from related parties"&gt;1,273&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_zukwEs1YngT4" style="width: 14%; text-align: right" title="Due from related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1154"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;DSY Beauty Sdn Bhd (&#x201c;DSY Beauty&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_903_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_z0694WTKbtY1" title="Relationship"&gt;&lt;span id="xdx_901_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zeZmlYSi7375" title="Relationship"&gt;The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Deposits for products&lt;/p&gt;
                                                        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;purchases&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zwDZUnOh83dc" style="text-align: right" title="Due from related parties"&gt;9,261&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zByqRivjGxmc" style="text-align: right" title="Due from related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1162"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Agape ATP (Asia) Limited (&#x201c;AATP Asia&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_900_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zHWmYpA622q9" title="Relationship"&gt;&lt;span id="xdx_902_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zP3giNs1HF4d" title="Relationship"&gt;Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of AATP Asia&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_90B_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zvM7Hh1mF5pj" title="Nature"&gt;&lt;span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zJUFhY5rF4V1" title="Nature"&gt;Expenses paid for AATP Asia&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_zybPyNfOgw56" style="text-align: right" title="Due from related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1172"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AgapeATPAsiaLimitedMember_ziSokE5HMXP7" style="text-align: right" title="Due from related parties"&gt;2,214&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt"&gt;Hostastay Sdn. Bhd. &lt;br/&gt;&#x201c;Hostastay&#x201d;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_904_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_z9WLCOVt2aPa" title="Relationship"&gt;&lt;span id="xdx_90F_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_z3VsvnIpOAm2" title="Relationship"&gt;Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_903_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zdj7boQy7Z08" title="Nature"&gt;&lt;span id="xdx_906_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zUYOiG4dFOU3" title="Nature"&gt;Sublease rent due from Hostastay&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zpXdWXaREyb2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Due from related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1184"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdMember_zXiuGQBFncKe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Due from related parties"&gt;4,790&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20221231_zF4oFTU7cPKd" style="border-bottom: Black 2.5pt double; text-align: right" title="Due from related parties"&gt;10,534&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--DueFromRelatedParties_iI_pp0p0_c20211231_z5LEII8mzdAe" style="border-bottom: Black 2.5pt double; text-align: right" title="Due from related parties"&gt;7,004&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Accounts
payable &#x2013; related parties&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Name of Related&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Party&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Relationship&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Nature&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 22%; text-align: left"&gt;CTA Nutriceuticals (Asia) Sdn Bhd (&#x201c;CTA&#x201d;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 22%; text-align: center"&gt;&lt;span id="xdx_906_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zerXYsBJD1ta" title="Relationship"&gt;&lt;span id="xdx_90E_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zqorjRRHLqeh" title="Relationship"&gt;The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 16%; text-align: center"&gt;&lt;span id="xdx_900_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zIWoggCpvyz9" title="Nature"&gt;&lt;span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zHhxRv48SPpb" title="Nature"&gt;Purchases of products for the provision of complementary health therapies&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zPFD76jbZAm2" style="width: 14%; text-align: right" title="Accounts payable, related parties, current"&gt;25,387&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zNdbULlh8yt8" style="width: 14%; text-align: right" title="Accounts payable, related parties, current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1202"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt"&gt;DSY Beauty Sdn Bhd (&#x201c;DSY Beauty&#x201d;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_908_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zM1z2HcEGkuj" title="Relationship"&gt;&lt;span id="xdx_906_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_z8IOZfRRQTP2" title="Relationship"&gt;The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_904_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zc7oweQDOY3f" title="Nature"&gt;Purchases of beauty products&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zfU3NUY42Nfb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accounts payable, related parties, current"&gt;224&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zV5eQ932Q825" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accounts payable, related parties, current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1212"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20221231_zGBB1JB6CVq4" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts payable, related parties, current"&gt;25,611&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20211231_zZAdIF7v7Zaa" style="border-bottom: Black 2.5pt double; text-align: right" title="Accounts payable, related parties, current"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1216"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;14.
RELATED PARTY BALANCES AND TRANSACTIONS (CONT&#x2019;D)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Related
party balances&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Other payable - related parties&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Name of Related&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Party&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Relationship&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Nature&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 22%; text-align: left"&gt;CTA Nutriceuticals (Asia) Sdn Bhd (&#x201c;CTA&#x201d;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 22%; text-align: center"&gt;&lt;span id="xdx_906_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdOneMember_zRZjLu2pyuSk" title="Relationship"&gt;&lt;span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdOneMember_zC9td5yiQjm1" title="Relationship"&gt;The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 16%; text-align: center"&gt;&lt;span id="xdx_901_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdOneMember_zz6M3NDzdZ5d" title="Nature"&gt;&lt;span id="xdx_90A_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdOneMember_zzwxLVUhJ7Gj" title="Nature"&gt;Purchase of products for general use&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdOneMember_z4MvZfHbEqh5" style="width: 14%; text-align: right" title="Due to related parties"&gt;2,149&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdOneMember_zEE4fagrL1fd" style="width: 14%; text-align: right" title="Due to related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1228"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;DSY Beauty Sdn Bhd (&#x201c;DSY Beauty&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_900_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_zjX7ki6BoTY1" title="Relationship"&gt;&lt;span id="xdx_903_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_zztblYDJrAed" title="Relationship"&gt;The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_901_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_z0iOuRmJMVBf" title="Nature"&gt;&lt;span id="xdx_904_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_zHVZ5TNJC34l" title="Nature"&gt;Purchase of products for general use&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_z8Wmhm3hUI43" style="text-align: right" title="Due to related parties"&gt;2,147&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdOneMember_zah7ZUjUINIk" style="text-align: right" title="Due to related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1240"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt"&gt;Mr. How Kok Choong&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_901_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zzfHYp7VfMm6" title="Relationship"&gt;&lt;span id="xdx_90C_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zXbRwDLsk895" title="Relationship"&gt;Mr. How Kok Choong, the CEO and director of the Company&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_909_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_z6dwnfOeuOqg" title="Nature"&gt;&lt;span id="xdx_907_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zGwXo2mC8cKd" title="Nature"&gt;Commission expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zH4Rwm5s39Og" style="border-bottom: Black 1.5pt solid; text-align: right" title="Due to related parties"&gt;584&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zjnTizCPpH8g" style="border-bottom: Black 1.5pt solid; text-align: right" title="Due to related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1252"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pdp0_c20221231_zJbx1u9mu5C9" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to related parties"&gt;4,880&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pdp0_c20211231_zS1BhyQ3Bi9i" style="border-bottom: Black 2.5pt double; text-align: right" title="Due to related parties"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1256"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Related
party transactions &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Purchases&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Name of Related&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;For the years ended December 31,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Party&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Relationship&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Nature&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 22%; text-align: left"&gt;CTA Nutriceuticals (Asia) Sdn Bhd (&#x201c;CTA&#x201d;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 22%; text-align: center"&gt;&lt;span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zG9btHnwadC2" title="Relationship"&gt;&lt;span id="xdx_908_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zauLz8fCZTk7" title="Relationship"&gt;The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 16%; text-align: center"&gt;&lt;span id="xdx_90A_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zwQlhwdt3st7" title="Nature"&gt;&lt;span id="xdx_90C_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zUTGwGNmJzUi" title="Nature"&gt;Purchases of products for the provision of complementary health therapies&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zEDJpcz6QUD3" style="width: 14%; text-align: right" title="Purchases"&gt;198,376&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsSdnBhdMember_zjNU7dGm447l" style="width: 14%; text-align: right" title="Purchases"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1268"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;DSY Beauty Sdn Bhd (&#x201c;DSY Beauty&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_908_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zIGdx9Bw1blh" title="Relationship"&gt;&lt;span id="xdx_90C_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zPFuB2i5T166" title="Relationship"&gt;The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_90B_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zPv0pPRzwuc6" title="Nature"&gt;&lt;span id="xdx_908_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zYrKqkNdAo55" title="Nature"&gt;Purchases of beauty products&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zugqbvRWvu3l" style="text-align: right" title="Purchases"&gt;3,975&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zu6p5YJuNohk" style="text-align: right" title="Purchases"&gt;718&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt"&gt;DSY Wellness &amp;amp; Longevity Center Sdn Bhd (&#x201c;DSYWLC&#x201d;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_906_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zbVboKp0GiI5" title="Relationship"&gt;&lt;span id="xdx_903_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_ziSDJiKeBjU6" title="Relationship"&gt;Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC&lt;/span&gt;&lt;/span&gt;.&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_900_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zUuiIpm9PQeb" title="Nature"&gt;&lt;span id="xdx_900_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zZRPuzBVaJBf" title="Nature"&gt;Purchases of products for the provision of complementary health therapies&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zjB80Z6q022f" style="border-bottom: Black 1.5pt solid; text-align: right" title="Purchases"&gt;124&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessandLongevityCenterSdnBhdTwoMember_zUPPsxbNbbu7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Purchases"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1292"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20220101__20221231_zIZqZ8Ed99Nd" style="border-bottom: Black 2.5pt double; text-align: right" title="Purchases"&gt;202,475&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_pp0p0_c20210101__20211231_zx3eXt89sgO2" style="border-bottom: Black 2.5pt double; text-align: right" title="Purchases"&gt;718&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;14.
RELATED PARTY BALANCES AND TRANSACTIONS (CONT&#x2019;D)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Related
party transactions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Other
income&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Name
    of Related&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the years ended December 31,&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Party&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Relationship&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Nature&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 26%; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Hostastay
    Sdn. Bhd.&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 20%; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_900_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zqcHbYBaJJmd" style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_z2EvLexgEEyc"&gt;Mr.
    How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director
    of Hostastay as of April 21, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 14%; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_900_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_z1nEmOAMZg66" style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_zAKIFOJ42Gng"&gt;Sublease
    rental income due from Hostastay&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--RelatedPartyOtherIncome_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_z6RcmQ3ozwGh" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Other income"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1302"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--RelatedPartyOtherIncome_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HostastaySdnBhdHostastayMember_z7nXSW3qZRa4" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Other income"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,345&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--RelatedPartyOtherIncome_pp0p0_c20220101__20221231_zuRLWr8prJsl" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Other income"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1306"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--RelatedPartyOtherIncome_pp0p0_c20210101__20211231_z1H0garr44X9" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Other income"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,345&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Other
purchases&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Name of Related&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;For the years ended December 31,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Party&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Relationship&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Nature&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 22%; text-align: left"&gt;CTA Nutriceuticals (Asia) Sdn Bhd (&#x201c;CTA&#x201d;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 22%; text-align: center"&gt;&lt;span id="xdx_901_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdMember_zQpS1MGX9God" title="Relationship"&gt;&lt;span id="xdx_904_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdMember_zQ7tlyF1WxH8" title="Relationship"&gt;The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 16%; text-align: center"&gt;&lt;span id="xdx_90A_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdMember_zOB0wRP6Zbwk" title="Nature"&gt;&lt;span id="xdx_904_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdMember_zKuywerER7I5" title="Nature"&gt;Purchases of products for the provision of complementary health therapies&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdMember_zHyk1uIlG5X7" style="width: 14%; text-align: right" title="Other purchases"&gt;5,431&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CTANutriceuticalsAsiaSdnBhdMember_zOJhGebFBwke" style="width: 14%; text-align: right" title="Other purchases"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1320"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;DSY Beauty Sdn Bhd (&#x201c;DSY Beauty&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zzmSc7AiZDU9" title="Relationship"&gt;&lt;span id="xdx_90D_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zZszxc9zLCci" title="Relationship"&gt;The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_z0Wk8Ark1EC9" title="Nature"&gt;&lt;span id="xdx_90C_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zhWXpNnpqXsj" title="Nature"&gt;Purchases of beauty products&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_z2yPLa3DzNw9" style="text-align: right" title="Other purchases"&gt;6,888&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYBeautySdnBhdMember_zXmRjMkWYmi7" style="text-align: right" title="Other purchases"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1332"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt"&gt;DSY Wellness &amp;amp; Longevity Center Sdn Bhd (&#x201c;DSYWLC&#x201d;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_908_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z5Y8L65Fxfw5" title="Relationship"&gt;&lt;span id="xdx_90E_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zCZxtEuEhEu8" title="Relationship"&gt;Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_901_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdMember_z9Arjnl5Pz17" title="Nature"&gt;&lt;span id="xdx_903_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdMember_z6pp5SD6xYf5" title="Nature"&gt;Purchases of products for the provision of complementary health therapies&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdMember_zhkqEQynYhXg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other purchases"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdMember_z9pDuZhyXAAd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other purchases"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1344"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20220101__20221231_z76MRFD0m2B9" style="border-bottom: Black 2.5pt double; text-align: right" title="Other purchases"&gt;12,323&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--RelatedPartyTransactionOtherPurchasesFromRelatedParty_pp0p0_c20210101__20211231_zkBH9qsQYILf" style="border-bottom: Black 2.5pt double; text-align: right" title="Other purchases"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1348"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;14.
RELATED PARTY BALANCES AND TRANSACTIONS (CONT&#x2019;D)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Related
party transactions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Commission
expense&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Name of Related&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;For the years ended December 31,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Party&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Relationship&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Nature&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 22%; text-align: left; padding-bottom: 1.5pt"&gt;Mr. How Kok Choong&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 22%; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_90C_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zu0Whq1PIPL8" title="Relationship"&gt;&lt;span id="xdx_903_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_ziKt3iMOZKOf" title="Relationship"&gt;Mr. How Kok Choong, the CEO and director of the Company&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 16%; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_900_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zwKUCUPMtWLb" title="Nature"&gt;&lt;span id="xdx_904_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_z8acQHVXjMAf" title="Nature"&gt;Commission expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SalesCommissionsAndFees_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_zDVS0V5gpANk" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Commission expense"&gt;16,590&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SalesCommissionsAndFees_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember_znsRavhRLPGj" style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right" title="Commission expense"&gt;12,758&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SalesCommissionsAndFees_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zLYgWsHkbrUl" style="border-bottom: Black 2.5pt double; text-align: right" title="Commission expense"&gt;16,590&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SalesCommissionsAndFees_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zoRsvIlllO4i" style="border-bottom: Black 2.5pt double; text-align: right" title="Commission expense"&gt;12,758&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Other
expenses&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Name of Related&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;For the years ended December 31,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Party&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Relationship&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Nature&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 22%; text-align: left"&gt;TH3 Technology Sdn Bhd (&#x201c;TH3&#x201d;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 22%; text-align: center"&gt;&lt;span id="xdx_90E_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_z4iv32kYvk1l" title="Relationship"&gt;&lt;span id="xdx_909_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_z0xuXefakGMb" title="Relationship"&gt;Mr. How Kok Choong, the CEO and director of the Company is also a director of TH3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 16%; text-align: center"&gt;&lt;span id="xdx_90E_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_zQ6QjExXo1U7" title="Nature"&gt;&lt;span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_zXGYWHCDNtCh" title="Nature"&gt;IT support services fee&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--RelatedPartyOtherExpenses_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_z8z2j3a0nVPd" style="width: 14%; text-align: right" title="Other expenses"&gt;56,450&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--RelatedPartyOtherExpenses_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TH3TechnologySdnBhdMember_zABwXOfX473k" style="width: 14%; text-align: right" title="Other expenses"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1376"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Redboy Picture Sdn Bhd (&#x201c;Redboy&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_908_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RedboyPictureSdnBhdMember_zTlZ7u9rRIy7" title="Relationship"&gt;&lt;span id="xdx_907_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RedboyPictureSdnBhdMember_zi3zgmDv7iKd" title="Relationship"&gt;Mr. How Kok Choong, the CEO and director of the Company is also the director of Redboy&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;&lt;span id="xdx_90B_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RedboyPictureSdnBhdMember_z5yIEWjsXqtd" title="Nature"&gt;&lt;span id="xdx_906_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RedboyPictureSdnBhdMember_zBJEOcGeyzn" title="Nature"&gt;Sponsorship fee&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--RelatedPartyOtherExpenses_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RedboyPictureSdnBhdMember_zQ3qYXMAmiBj" style="text-align: right" title="Other expenses"&gt;22,686&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--RelatedPartyOtherExpenses_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RedboyPictureSdnBhdMember_z09R8ZOGeew9" style="text-align: right" title="Other expenses"&gt;718&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt"&gt;DSY Wellness &amp;amp; Longevity Center Sdn Bhd (&#x201c;DSYWLC&#x201d;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_90C_ecustom--RelatedPartiesRelationshipsDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zcFhJLetkZFb" title="Relationship"&gt;&lt;span id="xdx_901_ecustom--RelatedPartiesRelationshipsDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zK7nMlKX00y3" title="Relationship"&gt;Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_905_ecustom--RelatedPartiesNatureDescription_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_z7juN7qEQtMg" title="Nature"&gt;&lt;span id="xdx_90C_ecustom--RelatedPartiesNatureDescription_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_z82d28JtijVi" title="Nature"&gt;Office rental expenses&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--RelatedPartyOtherExpenses_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zW53VjqvfB7a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other expenses"&gt;21,779&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--RelatedPartyOtherExpenses_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DSYWellnessAndLongevityCenterSdnBhdThreeMember_zHVhurNTFL4a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Other expenses"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1400"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; vertical-align: top"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--RelatedPartyOtherExpenses_c20220101__20221231_zVoXaAlg39Lf" style="border-bottom: Black 2.5pt double; text-align: right" title="Other expenses"&gt;100,915&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--RelatedPartyOtherExpenses_c20210101__20211231_zLvySw9yI4bi" style="border-bottom: Black 2.5pt double; text-align: right" title="Other expenses"&gt;718&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2022-01-012022-12-31_custom_TH3TechnologySdnBhdMember">Mr. How Kok Choong, the CEO and director of the Company is also a director of TH3</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2021-01-012021-12-31_custom_TH3TechnologySdnBhdMember">Mr. How Kok Choong, the CEO and director of the Company is also a director of TH3</AATP:RelatedPartiesRelationshipsDescription>
    <us-gaap:DueFromRelatedParties
      contextRef="AsOf2022-12-31_custom_TH3TechnologySdnBhdMember"
      decimals="0"
      unitRef="USD">1273</us-gaap:DueFromRelatedParties>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2022-01-012022-12-31_custom_DSYBeautySdnBhdMember">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2021-01-012021-12-31_custom_DSYBeautySdnBhdMember">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</AATP:RelatedPartiesRelationshipsDescription>
    <us-gaap:DueFromRelatedParties
      contextRef="AsOf2022-12-31_custom_DSYBeautySdnBhdMember"
      decimals="0"
      unitRef="USD">9261</us-gaap:DueFromRelatedParties>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2022-01-012022-12-31_custom_AgapeATPAsiaLimitedMember">Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of AATP Asia</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2021-01-012021-12-31_custom_AgapeATPAsiaLimitedMember">Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of AATP Asia</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2022-01-012022-12-31_custom_AgapeATPAsiaLimitedMember">Expenses paid for AATP Asia</AATP:RelatedPartiesNatureDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2021-01-012021-12-31_custom_AgapeATPAsiaLimitedMember">Expenses paid for AATP Asia</AATP:RelatedPartiesNatureDescription>
    <us-gaap:DueFromRelatedParties
      contextRef="AsOf2021-12-31_custom_AgapeATPAsiaLimitedMember"
      decimals="0"
      unitRef="USD">2214</us-gaap:DueFromRelatedParties>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2022-01-012022-12-31_custom_HostastaySdnBhdMember">Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2021-01-012021-12-31_custom_HostastaySdnBhdMember">Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director of Hostastay as of April 21, 2021</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2022-01-012022-12-31_custom_HostastaySdnBhdMember">Sublease rent due from Hostastay</AATP:RelatedPartiesNatureDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2021-01-012021-12-31_custom_HostastaySdnBhdMember">Sublease rent due from Hostastay</AATP:RelatedPartiesNatureDescription>
    <us-gaap:DueFromRelatedParties
      contextRef="AsOf2021-12-31_custom_HostastaySdnBhdMember"
      decimals="0"
      unitRef="USD">4790</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">10534</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">7004</us-gaap:DueFromRelatedParties>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2022-01-012022-12-31_custom_CTANutriceuticalsSdnBhdMember">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2021-01-012021-12-31_custom_CTANutriceuticalsSdnBhdMember">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2022-01-012022-12-31_custom_CTANutriceuticalsSdnBhdMember">Purchases of products for the provision of complementary health therapies</AATP:RelatedPartiesNatureDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2021-01-012021-12-31_custom_CTANutriceuticalsSdnBhdMember">Purchases of products for the provision of complementary health therapies</AATP:RelatedPartiesNatureDescription>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="AsOf2022-12-31_custom_CTANutriceuticalsSdnBhdMember"
      decimals="0"
      unitRef="USD">25387</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2022-01-012022-12-31_custom_DSYBeautySdnBhdMember">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2021-01-012021-12-31_custom_DSYBeautySdnBhdMember">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2021-01-012021-12-31_custom_DSYBeautySdnBhdMember">Purchases of beauty products</AATP:RelatedPartiesNatureDescription>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="AsOf2022-12-31_custom_DSYBeautySdnBhdMember"
      decimals="0"
      unitRef="USD">224</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">25611</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2022-01-012022-12-31_custom_CTANutriceuticalsAsiaSdnBhdOneMember">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2021-01-012021-12-31_custom_CTANutriceuticalsAsiaSdnBhdOneMember">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2022-01-012022-12-31_custom_CTANutriceuticalsAsiaSdnBhdOneMember">Purchase of products for general use</AATP:RelatedPartiesNatureDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2021-01-012021-12-31_custom_CTANutriceuticalsAsiaSdnBhdOneMember">Purchase of products for general use</AATP:RelatedPartiesNatureDescription>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2022-12-31_custom_CTANutriceuticalsAsiaSdnBhdOneMember"
      decimals="0"
      unitRef="USD">2149</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2022-01-012022-12-31_custom_DSYBeautySdnBhdOneMember">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2021-01-012021-12-31_custom_DSYBeautySdnBhdOneMember">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2022-01-012022-12-31_custom_DSYBeautySdnBhdOneMember">Purchase of products for general use</AATP:RelatedPartiesNatureDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2021-01-012021-12-31_custom_DSYBeautySdnBhdOneMember">Purchase of products for general use</AATP:RelatedPartiesNatureDescription>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2022-12-31_custom_DSYBeautySdnBhdOneMember"
      decimals="0"
      unitRef="USD">2147</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2022-01-012022-12-31_custom_HowKokChoongMember">Mr. How Kok Choong, the CEO and director of the Company</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2021-01-012021-12-31_custom_HowKokChoongMember">Mr. How Kok Choong, the CEO and director of the Company</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2022-01-012022-12-31_custom_HowKokChoongMember">Commission expense</AATP:RelatedPartiesNatureDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2021-01-012021-12-31_custom_HowKokChoongMember">Commission expense</AATP:RelatedPartiesNatureDescription>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2022-12-31_custom_HowKokChoongMember"
      decimals="0"
      unitRef="USD">584</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">4880</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2022-01-012022-12-31_custom_CTANutriceuticalsSdnBhdMember">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2021-01-012021-12-31_custom_CTANutriceuticalsSdnBhdMember">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2022-01-012022-12-31_custom_CTANutriceuticalsSdnBhdMember">Purchases of products for the provision of complementary health therapies</AATP:RelatedPartiesNatureDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2021-01-012021-12-31_custom_CTANutriceuticalsSdnBhdMember">Purchases of products for the provision of complementary health therapies</AATP:RelatedPartiesNatureDescription>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2022-01-012022-12-31_custom_CTANutriceuticalsSdnBhdMember"
      decimals="0"
      unitRef="USD">198376</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2022-01-012022-12-31_custom_DSYBeautySdnBhdMember">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2021-01-012021-12-31_custom_DSYBeautySdnBhdMember">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2022-01-012022-12-31_custom_DSYBeautySdnBhdMember">Purchases of beauty products</AATP:RelatedPartiesNatureDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2021-01-012021-12-31_custom_DSYBeautySdnBhdMember">Purchases of beauty products</AATP:RelatedPartiesNatureDescription>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2022-01-012022-12-31_custom_DSYBeautySdnBhdMember"
      decimals="0"
      unitRef="USD">3975</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2021-01-012021-12-31_custom_DSYBeautySdnBhdMember"
      decimals="0"
      unitRef="USD">718</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2022-01-012022-12-31_custom_DSYWellnessandLongevityCenterSdnBhdTwoMember">Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2021-01-012021-12-31_custom_DSYWellnessandLongevityCenterSdnBhdTwoMember">Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2022-01-012022-12-31_custom_DSYWellnessandLongevityCenterSdnBhdTwoMember">Purchases of products for the provision of complementary health therapies</AATP:RelatedPartiesNatureDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2021-01-012021-12-31_custom_DSYWellnessandLongevityCenterSdnBhdTwoMember">Purchases of products for the provision of complementary health therapies</AATP:RelatedPartiesNatureDescription>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2022-01-012022-12-31_custom_DSYWellnessandLongevityCenterSdnBhdTwoMember"
      decimals="0"
      unitRef="USD">124</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">202475</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">718</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2021-01-012021-12-31_custom_HostastaySdnBhdHostastayMember">Mr.
    How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director
    of Hostastay as of April 21, 2021</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2022-01-012022-12-31_custom_HostastaySdnBhdHostastayMember">Mr.
    How Kok Choong, the CEO and director of the Company is also the director of Hostastay. Mr. How Kok Choong ceased to be the director
    of Hostastay as of April 21, 2021</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2021-01-012021-12-31_custom_HostastaySdnBhdHostastayMember">Sublease
    rental income due from Hostastay</AATP:RelatedPartiesNatureDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2022-01-012022-12-31_custom_HostastaySdnBhdHostastayMember">Sublease
    rental income due from Hostastay</AATP:RelatedPartiesNatureDescription>
    <AATP:RelatedPartyOtherIncome
      contextRef="From2021-01-012021-12-31_custom_HostastaySdnBhdHostastayMember"
      decimals="0"
      unitRef="USD">4345</AATP:RelatedPartyOtherIncome>
    <AATP:RelatedPartyOtherIncome
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">4345</AATP:RelatedPartyOtherIncome>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2022-01-012022-12-31_custom_CTANutriceuticalsAsiaSdnBhdMember">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2021-01-012021-12-31_custom_CTANutriceuticalsAsiaSdnBhdMember">The directors and shareholders of CTA are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY International Wellness Sdn Bhd</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2022-01-012022-12-31_custom_CTANutriceuticalsAsiaSdnBhdMember">Purchases of products for the provision of complementary health therapies</AATP:RelatedPartiesNatureDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2021-01-012021-12-31_custom_CTANutriceuticalsAsiaSdnBhdMember">Purchases of products for the provision of complementary health therapies</AATP:RelatedPartiesNatureDescription>
    <AATP:RelatedPartyTransactionOtherPurchasesFromRelatedParty
      contextRef="From2022-01-012022-12-31_custom_CTANutriceuticalsAsiaSdnBhdMember"
      decimals="0"
      unitRef="USD">5431</AATP:RelatedPartyTransactionOtherPurchasesFromRelatedParty>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2022-01-012022-12-31_custom_DSYBeautySdnBhdMember">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2021-01-012021-12-31_custom_DSYBeautySdnBhdMember">The directors and shareholders of DSY Beauty are related parties to Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2022-01-012022-12-31_custom_DSYBeautySdnBhdMember">Purchases of beauty products</AATP:RelatedPartiesNatureDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2021-01-012021-12-31_custom_DSYBeautySdnBhdMember">Purchases of beauty products</AATP:RelatedPartiesNatureDescription>
    <AATP:RelatedPartyTransactionOtherPurchasesFromRelatedParty
      contextRef="From2022-01-012022-12-31_custom_DSYBeautySdnBhdMember"
      decimals="0"
      unitRef="USD">6888</AATP:RelatedPartyTransactionOtherPurchasesFromRelatedParty>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2022-01-012022-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdMember_srt_ChiefExecutiveOfficerMember">Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2021-01-012021-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdMember_srt_ChiefExecutiveOfficerMember">Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2022-01-012022-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdMember">Purchases of products for the provision of complementary health therapies</AATP:RelatedPartiesNatureDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2021-01-012021-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdMember">Purchases of products for the provision of complementary health therapies</AATP:RelatedPartiesNatureDescription>
    <AATP:RelatedPartyTransactionOtherPurchasesFromRelatedParty
      contextRef="From2022-01-012022-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdMember"
      decimals="0"
      unitRef="USD">4</AATP:RelatedPartyTransactionOtherPurchasesFromRelatedParty>
    <AATP:RelatedPartyTransactionOtherPurchasesFromRelatedParty
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">12323</AATP:RelatedPartyTransactionOtherPurchasesFromRelatedParty>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2022-01-012022-12-31_custom_HowKokChoongMember">Mr. How Kok Choong, the CEO and director of the Company</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2021-01-012021-12-31_custom_HowKokChoongMember">Mr. How Kok Choong, the CEO and director of the Company</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2022-01-012022-12-31_custom_HowKokChoongMember">Commission expense</AATP:RelatedPartiesNatureDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2021-01-012021-12-31_custom_HowKokChoongMember">Commission expense</AATP:RelatedPartiesNatureDescription>
    <us-gaap:SalesCommissionsAndFees
      contextRef="From2022-01-012022-12-31_custom_HowKokChoongMember"
      decimals="0"
      unitRef="USD">16590</us-gaap:SalesCommissionsAndFees>
    <us-gaap:SalesCommissionsAndFees
      contextRef="From2021-01-012021-12-31_custom_HowKokChoongMember"
      decimals="0"
      unitRef="USD">12758</us-gaap:SalesCommissionsAndFees>
    <us-gaap:SalesCommissionsAndFees
      contextRef="From2022-01-012022-12-31_custom_HowKokChoongMember_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      unitRef="USD">16590</us-gaap:SalesCommissionsAndFees>
    <us-gaap:SalesCommissionsAndFees
      contextRef="From2021-01-012021-12-31_custom_HowKokChoongMember_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      unitRef="USD">12758</us-gaap:SalesCommissionsAndFees>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2022-01-012022-12-31_custom_TH3TechnologySdnBhdMember">Mr. How Kok Choong, the CEO and director of the Company is also a director of TH3</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2021-01-012021-12-31_custom_TH3TechnologySdnBhdMember">Mr. How Kok Choong, the CEO and director of the Company is also a director of TH3</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2022-01-012022-12-31_custom_TH3TechnologySdnBhdMember">IT support services fee</AATP:RelatedPartiesNatureDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2021-01-012021-12-31_custom_TH3TechnologySdnBhdMember">IT support services fee</AATP:RelatedPartiesNatureDescription>
    <AATP:RelatedPartyOtherExpenses
      contextRef="From2022-01-012022-12-31_custom_TH3TechnologySdnBhdMember"
      decimals="0"
      unitRef="USD">56450</AATP:RelatedPartyOtherExpenses>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2022-01-012022-12-31_custom_RedboyPictureSdnBhdMember">Mr. How Kok Choong, the CEO and director of the Company is also the director of Redboy</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2021-01-012021-12-31_custom_RedboyPictureSdnBhdMember">Mr. How Kok Choong, the CEO and director of the Company is also the director of Redboy</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2022-01-012022-12-31_custom_RedboyPictureSdnBhdMember">Sponsorship fee</AATP:RelatedPartiesNatureDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2021-01-012021-12-31_custom_RedboyPictureSdnBhdMember">Sponsorship fee</AATP:RelatedPartiesNatureDescription>
    <AATP:RelatedPartyOtherExpenses
      contextRef="From2022-01-012022-12-31_custom_RedboyPictureSdnBhdMember"
      decimals="0"
      unitRef="USD">22686</AATP:RelatedPartyOtherExpenses>
    <AATP:RelatedPartyOtherExpenses
      contextRef="From2021-01-012021-12-31_custom_RedboyPictureSdnBhdMember"
      decimals="0"
      unitRef="USD">718</AATP:RelatedPartyOtherExpenses>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2022-01-012022-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdThreeMember">Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesRelationshipsDescription contextRef="From2021-01-012021-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdThreeMember">Mr. Yap Foo Ching (Steve Yap), a director of DSY Wellness International Sdn Bhd is also a director of DSYWLC.</AATP:RelatedPartiesRelationshipsDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2022-01-012022-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdThreeMember">Office rental expenses</AATP:RelatedPartiesNatureDescription>
    <AATP:RelatedPartiesNatureDescription contextRef="From2021-01-012021-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdThreeMember">Office rental expenses</AATP:RelatedPartiesNatureDescription>
    <AATP:RelatedPartyOtherExpenses
      contextRef="From2022-01-012022-12-31_custom_DSYWellnessAndLongevityCenterSdnBhdThreeMember"
      decimals="0"
      unitRef="USD">21779</AATP:RelatedPartyOtherExpenses>
    <AATP:RelatedPartyOtherExpenses
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">100915</AATP:RelatedPartyOtherExpenses>
    <AATP:RelatedPartyOtherExpenses
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">718</AATP:RelatedPartyOtherExpenses>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80D_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zrxrGEATJSG7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;15.
&lt;span id="xdx_828_z7H1JaGpStBb"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Preferred
stock&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022 and 2021, there were &lt;span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_zty6O6HQbxW1" title="Preferred stock, shares authorized"&gt;&lt;span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231_z9ul9eaResr2" title="Preferred stock, shares authorized"&gt;200,000,000&lt;/span&gt;&lt;/span&gt; preferred stocks authorized but &lt;span id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_dn_c20221231_zdiZyFzKB8yf" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20221231_zdVAv5pFAaTd" title="Preferred stock, shares outstanding"&gt;&lt;span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_dn_c20221231_z4GT5rfxaZz" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20211231_zW5jdvfloTRd" title="Preferred stock, shares outstanding"&gt;none&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; were issued and outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Common
stock&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022 and 2021, there were &lt;span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zNbnPSp1kgW9" title="Common stock, shares authorized"&gt;&lt;span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zSTJp5umnSw" title="Common stock, shares authorized"&gt;1,000,000,000&lt;/span&gt;&lt;/span&gt; common stocks authorized, &lt;span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20221231_zQBtTzjRuTH3" title="Common stock, shares issued"&gt;&lt;span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_z5pPYvDUOk1a" title="Common stock, shares outstanding"&gt;75,452,012&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_c20211231_zMHzMgcbEL9d" title="Common stock, shares issued"&gt;&lt;span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_zYAyTYa7hJok" title="Common stock, shares outstanding"&gt;290,460,047&lt;/span&gt;&lt;/span&gt; shares issued and outstanding,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2021, there were share forfeiture agreements (the &#x201c;&lt;b&gt;Share Forfeiture Agreements&lt;/b&gt;&#x201d;) between the Company and
(i) HKC Talent Limited; (ii) various shareholders of the Company (the &#x201c;&lt;b&gt;Forfeiting Shareholders&lt;/b&gt;&#x201d;), pursuant to which:
(i) HKC Talent Limited had agreed to forfeiture of &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ShareForfeitureAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongTalentLimitedMember_zm04t01nvDPl" title="Share- based payment arrangement, forfeited"&gt;41,750,000&lt;/span&gt; shares of common stock of the Company, and (ii) the Forfeiting Shareholders
had agreed to forfeiture, in aggregate, &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ShareForfeitureAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongTalentLimitedMember__srt--TitleOfIndividualAxis__custom--ShareholdersMember_zN9m5lnyt6ih" title="Share- based payment arrangement, forfeited"&gt;44,242,000&lt;/span&gt; shares of common stock of the Company. Included in (ii) is &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ShareForfeitureAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HKCHoldingsSdnBhdMember_zko4kprwOe7g" title="Share- based payment arrangement, forfeited"&gt;11,242,000&lt;/span&gt; shares forfeited
from HKC Holdings Sdn. Bhd, a company in which &lt;span style="background-color: white"&gt;Mr. How Kok Choong, &lt;/span&gt;the CEO and director
of the Company, is a shareholder. As a result, the outstanding shares was reduced by &lt;span id="xdx_90C_ecustom--ReductionInCommonStockOutstanding_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ShareForfeitureAgreementsMember_zHPpq9P03LB2" title="Reduction in outstanding shares"&gt;85,992,000&lt;/span&gt; shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
share forfeiture agreement (the &#x201c;Share Forfeiture Agreement&#x201d;) dated January 20, 2022, between the Company and Mr. How Kok
Choong, the CEO and director of the Company, pursuant to which Mr. How Kok Choong agreed to forfeit &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--ShareForfeitureAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowKokChoongTalentLimitedMember_zY1VZhyWHbJl" title="Number of shares forfeited"&gt;215,008,035&lt;/span&gt; shares of common stock
of the Company. As a result, the outstanding shares was reduced by &lt;span id="xdx_903_ecustom--ReductionInCommonStockOutstanding_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--ShareForfeitureAgreementsMember_zBgiQdmVV7u2" title="Reduction in outstanding shares"&gt;215,008,035&lt;/span&gt; shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were &lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_do_c20220101__20221231_z6TOREpaB1j8" title="Potentially dilutive securities outstanding"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_do_c20210101__20211231_zzmSUykSSlS9" title="Potentially dilutive securities outstanding"&gt;no&lt;/span&gt;&lt;/span&gt; stock options, warrants or other potentially dilutive securities outstanding as of December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">200000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">200000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">75452012</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">75452012</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">290460047</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">290460047</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="From2021-01-012021-12-31_custom_ShareForfeitureAgreementsMember_custom_HowKokChoongTalentLimitedMember"
      decimals="INF"
      unitRef="Shares">41750000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="From2021-01-012021-12-31_custom_ShareForfeitureAgreementsMember_custom_HowKokChoongTalentLimitedMember_custom_ShareholdersMember"
      decimals="INF"
      unitRef="Shares">44242000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="From2021-01-012021-12-31_custom_ShareForfeitureAgreementsMember_custom_HKCHoldingsSdnBhdMember"
      decimals="INF"
      unitRef="Shares">11242000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <AATP:ReductionInCommonStockOutstanding
      contextRef="From2021-01-012021-12-31_custom_ShareForfeitureAgreementsMember"
      decimals="INF"
      unitRef="Shares">85992000</AATP:ReductionInCommonStockOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="From2022-01-012022-12-31_custom_ShareForfeitureAgreementsMember_custom_HowKokChoongTalentLimitedMember"
      decimals="INF"
      unitRef="Shares">215008035</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <AATP:ReductionInCommonStockOutstanding
      contextRef="From2022-01-012022-12-31_custom_ShareForfeitureAgreementsMember"
      decimals="INF"
      unitRef="Shares">215008035</AATP:ReductionInCommonStockOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:MinorityInterestDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80A_eus-gaap--MinorityInterestDisclosureTextBlock_zRMcY1MqRNO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;16.
&lt;span id="xdx_820_zLo6yEndAVUb"&gt;NON-CONTROLLING INTEREST&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_ecustom--ScheduleOfNonControllingInterestTableTextBlock_zItFSSqNjvNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s non-controlling interest consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zWLqh61alVOc" style="display: none"&gt;SCHEDULE OF NON CONTROLLING INTEREST&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_496_20221231_z8n1xYUN2KRc" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20211231_zLxvsRVAtnza" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;DSY Wellness:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--NonControllingInterestPaidinCapital_iI_maNCINCzwzX_maNCINCzgCA_ztnQP5spxhD7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Paid-in capital&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;97&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;97&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--NonControllingInterestAccumulatedDeficit_iI_maNCINCzwzX_maNCINCzgCA_zdhlZiZBS117" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accumulated surplus (deficit)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,384&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(436&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--NonControllingInterestAccumulatedOtherComprehensiveIncome_iI_maNCINCzwzX_maNCINCzgCA_zamMSBSCAIV8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accumulated other comprehensive income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;32&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--NonControllingInterestNonControllingInterestGross_iTI_mtNCINCzgCA_zFjLER4eaPU1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non Controlling interest Gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,513&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(336&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--NonControllingInterestAsl_iI_maMIzbTf_zhASwFT68lgk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;ASL&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1464"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1465"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--MinorityInterest_iI_zHlazE5YlbS3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;20,513&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(336&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_ztCYbvXrAQb5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:MinorityInterestDisclosureTextBlock>
    <AATP:ScheduleOfNonControllingInterestTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89E_ecustom--ScheduleOfNonControllingInterestTableTextBlock_zItFSSqNjvNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s non-controlling interest consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zWLqh61alVOc" style="display: none"&gt;SCHEDULE OF NON CONTROLLING INTEREST&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_496_20221231_z8n1xYUN2KRc" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20211231_zLxvsRVAtnza" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;DSY Wellness:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--NonControllingInterestPaidinCapital_iI_maNCINCzwzX_maNCINCzgCA_ztnQP5spxhD7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Paid-in capital&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;97&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;97&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--NonControllingInterestAccumulatedDeficit_iI_maNCINCzwzX_maNCINCzgCA_zdhlZiZBS117" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accumulated surplus (deficit)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,384&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(436&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--NonControllingInterestAccumulatedOtherComprehensiveIncome_iI_maNCINCzwzX_maNCINCzgCA_zamMSBSCAIV8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accumulated other comprehensive income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;32&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--NonControllingInterestNonControllingInterestGross_iTI_mtNCINCzgCA_zFjLER4eaPU1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non Controlling interest Gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,513&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(336&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--NonControllingInterestAsl_iI_maMIzbTf_zhASwFT68lgk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;ASL&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1464"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1465"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--MinorityInterest_iI_zHlazE5YlbS3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;20,513&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(336&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</AATP:ScheduleOfNonControllingInterestTableTextBlock>
    <AATP:NonControllingInterestPaidinCapital contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">97</AATP:NonControllingInterestPaidinCapital>
    <AATP:NonControllingInterestPaidinCapital contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">97</AATP:NonControllingInterestPaidinCapital>
    <AATP:NonControllingInterestAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">20384</AATP:NonControllingInterestAccumulatedDeficit>
    <AATP:NonControllingInterestAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-436</AATP:NonControllingInterestAccumulatedDeficit>
    <AATP:NonControllingInterestAccumulatedOtherComprehensiveIncome contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">32</AATP:NonControllingInterestAccumulatedOtherComprehensiveIncome>
    <AATP:NonControllingInterestAccumulatedOtherComprehensiveIncome contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">3</AATP:NonControllingInterestAccumulatedOtherComprehensiveIncome>
    <AATP:NonControllingInterestNonControllingInterestGross contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">20513</AATP:NonControllingInterestNonControllingInterestGross>
    <AATP:NonControllingInterestNonControllingInterestGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-336</AATP:NonControllingInterestNonControllingInterestGross>
    <us-gaap:MinorityInterest contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">20513</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-336</us-gaap:MinorityInterest>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_804_eus-gaap--IncomeTaxDisclosureTextBlock_znvIM9XybCJa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;17.
&lt;span id="xdx_829_zeAaJlP7VpZe"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zbYrNSfpqOqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
United States and foreign components of loss before income taxes were comprised of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BC_zbw9RcdCJECe" style="display: none"&gt;SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAX&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20220101__20221231_zILNGugjEUVd" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20210101__20211231_zJModJ8xjfzb" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Tax jurisdictions from:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_zEfm59KnFAFd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Local &#x2013; United States&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(736,946&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(706,659&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_hsrt--StatementGeographicalAxis__country--MY_zKjnqwH7pae9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Foreign &#x2013; Malaysia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(864,794&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,064,314&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_hsrt--StatementGeographicalAxis__country--HK_zEcVHq1RW1wl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Foreign &#x2013; Hong Kong&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(68,394&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(616,640&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_hsrt--StatementGeographicalAxis__country--HK_zQZ4XU7Pz09d" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Foreign, Tax jurisdictions&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(68,394&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(616,640&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ze9d2YDOMzhe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Loss before income tax&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1,670,134&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,387,613&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zuOOqa94XT0b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zvnkRDjToTH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
benefit of (provision for) income taxes consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zd1FtMJnpQK1" style="display: none"&gt;SCHEDULE OF PROVISION FOR INCOME TAX&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20220101__20221231_zyjO9HHS05l5" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20210101__20211231_zaZTlg3JC3n7" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zMK5QD2RIBb5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Current:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_iN_di_maITEBzQW2_z60POG4Cj7X3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%"&gt;- Local&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1494"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(22,205&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--CurrentForeignTaxExpenseBenefit_iN_di_maITEBzQW2_zx6jaeMCGMG5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;- Foreign&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,962&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(104,735&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zf5oiH7PaL34" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Deferred:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_iN_di_maITEBzQW2_zYXpTW31pcRa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;- Local&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1503"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1504"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_iN_di_maITEBzQW2_zyDwuD45MHn9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;- Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;15,017&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(10,127&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_iNT_pp0p0_di_mtITEBzQW2_zJnYG9RGYQ28" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Benefit of (Provision for) income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,055&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(137,067&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zLpr1cFDX1Z3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
effective tax rate in the periods presented is the result of the mix of income earned in various tax jurisdictions that apply a broad
range of income tax rates. The Company and its subsidiary that operate in various countries: United States, Malaysia (including Labuan)
and Hong Kong that are subject to taxes in the jurisdictions in which they operate, are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;United
States of America&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Agape
ATP Corporation was incorporated in the State of Nevada and is subject to the tax laws of the United States of America with a corporate
tax rate of &lt;span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zgJNy2t1B1ze" title="Tax percentage"&gt;21&lt;/span&gt;% on its taxable income. Agape ATP Corporation also subject to controlled foreign corporations Subpart F income (&#x201c;Subpart
F&#x201d;) tax, which is a tax primarily on passive income from controlled foreign corporations with a tax rate of &lt;span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zz8ClLj2ufX1" title="Tax percentage"&gt;35&lt;/span&gt;%. &lt;span id="xdx_902_ecustom--TaxRateDescription_c20220101__20221231_ze4PeMh6BJud" title="Tax rate description"&gt;In addition, the
Tax Cuts and Jobs Act imposed a global intangible low-taxed income (&#x201c;GILTI&#x201d;) tax, which is a tax on certain off-shore earnings
at an effective rate of 10.5% for tax years (50% deduction of the current enacted tax rate of 21%) with a partial offset for 80% foreign
tax credits. If the foreign tax rate is 13.125% or higher, there will be no U.S. corporate tax after the 80% foreign tax credits are
applied.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the year ended December 31, 2022 and 2021, the Company&#x2019;s foreign subsidiaries did not generate any income that were subject to Subpart F
tax and GILTI tax.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;17.
INCOME TAXES (CONT&#x2019;D)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022 and 2021, the operations in the United States of America incurred approximately $&lt;span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20221231__srt--StatementGeographicalAxis__country--US_zkoq4MMBUwha" title="Operating loss"&gt;1,357,000&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__srt--StatementGeographicalAxis__country--US_zWOT89Pcrepf" title="Operating loss"&gt;620,000&lt;/span&gt;, respectively,
of cumulative net operating losses (&#x201c;NOL&#x201d;) which can be carried forward to offset future taxable income or Subpart F and
GILTI taxes. These balances can be carried forward indefinitely. The deferred tax valuation allowance as of December 31, 2022 and 2021
were approximately $&lt;span id="xdx_901_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pp0p0_c20221231__srt--StatementGeographicalAxis__country--US_zRO6KfP9duZ3" title="Deferred tax valuation allowance"&gt;285,000&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pp0p0_c20211231__srt--StatementGeographicalAxis__country--US_zEoT3y5h8boh" title="Deferred tax valuation allowance"&gt;130,000&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the year ended December 31, 2021, the Company re-visited its fiscal 2020 U.S. income taxes and determined its stock dividend from Greenpro
Capital Corp as a result of its Spin-off of DSwiss Inc.&#x2019;s shares in 2020 were subject to Subpart F and GILTI taxes. As a result,
the Company incurred additional income taxes expenses of $&lt;span id="xdx_909_eus-gaap--IncomeTaxExpenseBenefit_c20210101__20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zcsImL44TVba" title="Income tax expense benefit"&gt;22,205&lt;/span&gt;, including interest and penalty of $&lt;span id="xdx_902_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestExpense_c20210101__20211231_zmMMvEdraQ5g" title="Income tax  examination penalties and interest expense"&gt;395&lt;/span&gt;, for the year ended December
31, 2021, after utilizing its estimated cumulative net operating losses (&#x201c;NOL&#x201d;) of $&lt;span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_iI_c20201231_zE6NfjrRcXk1" title="Cumulative net operating loss"&gt;312,608&lt;/span&gt; as of December 31, 2020. As a
result, the Company&#x2019;s deferred tax assets of estimated NOL of $&lt;span id="xdx_90C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20211231_zsP4YJOKxmHl" title="Deferred tax assets operating loss carryforwards"&gt;65,648&lt;/span&gt; were fully utilized and reduced to $&lt;span id="xdx_900_ecustom--DeferredTaxAssetsOperatingLossCarryforwardsReducedAmount_iI_c20211231_ztjakd3u7C47" title="Deferred tax assets operating loss carryforwards reduced amount"&gt;0&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Malaysia&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Changes
to the Labuan Business Activity Tax Act (LBATA) 1990 which was gazetted and came into operation on January 1, 2019 mandate companies
incorporated in Labuan to satisfy the &#x201c;substantial activity requirements&#x201d; to qualify for the preferential tax rate of &lt;span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20181228__20190102__srt--StatementGeographicalAxis__custom--LabuanMember_zIRsUgxuLdag" title="Effective tax rate"&gt;3&lt;/span&gt;%
on net audited profit. Subsequently, on April 29, 2020, a circular setting out revisions to the &#x201c;substantial activity requirements&#x201d;
was issued. As Agape ATP Corporation did not maintain a permanent establishment in Labuan, and therefore did not satisfy the said requirements,
the company was subjected to tax at &lt;span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20181228__20190102__srt--StatementGeographicalAxis__custom--LabuanMember_zk0ogbKW0V3l" title="Taxp percentage"&gt;24&lt;/span&gt;% on its net audited profit. On June 11, 2021, Agape ATP Corporation made an irrevocable election
to be taxed under the Malaysian Income Tax Act 1967 as the elected tax regime is more tax efficient to the entity compare to LBATA.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Agape
Superior Living Sdn Bhd, Agape S.E.A Sdn Bhd and Wellness ATP International Holdings Sdn Bhd. are governed by the income taxes laws of
Malaysia and the income taxes provision in respect of operations in Malaysia is calculated at the applicable tax rates on the taxable
income for the periods based on existing legislation, interpretations and practices in respect thereof. Under the Income Tax Act of Malaysia,
enterprises that incorporated in Malaysia are usually subject to a unified 24% enterprise income taxes rate while preferential tax rates,
tax holidays and even tax exemption may be granted on case-by-case basis. &lt;span id="xdx_90D_eus-gaap--IncomeTaxExaminationDescription_c20220101__20221231__srt--StatementGeographicalAxis__country--MY_zNZZZmJheaGc" title="Income tax examination, description"&gt;The tax rate for small and medium sized companies (generally
companies incorporated in Malaysia with paid-in capital of RM &lt;span id="xdx_903_eus-gaap--AdditionalPaidInCapitalCommonStock_iI_uRM_c20221231__srt--StatementGeographicalAxis__country--MY_zbKPsZfgFsXl" title="Paid in capital"&gt;2,500,000&lt;/span&gt; or less) is &lt;span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231__srt--StatementGeographicalAxis__country--MY_zZ62Snk1qEg1" title="Tax percentage"&gt;17&lt;/span&gt;% for the first RM &lt;span id="xdx_905_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockSplit_uRM_c20220101__20221231__srt--StatementGeographicalAxis__country--MY_zBNTbf6oiRb1" title="Additional paid in capital stock split"&gt;600,000&lt;/span&gt; (or approximately $&lt;span id="xdx_903_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockSplit_c20220101__20221231__srt--StatementGeographicalAxis__country--MY_zygUhR4xo3nh" title="Additional paid in capital stock split"&gt;150,000&lt;/span&gt;)
for the year ended December 31, 2022 and 2021, with the remaining balance being taxed at the 24% rate.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022 and 2021, the operations in the Malaysia incurred approximately $&lt;span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20221231__srt--StatementGeographicalAxis__country--MY_zDl4zfqro5ll" title="Operating loss carryforwards"&gt;1,723,000&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20211231__srt--StatementGeographicalAxis__country--MY_zmekVsOtcVJ2" title="Operating loss carryforwards"&gt;946,000&lt;/span&gt;, respectively, of cumulative
net operating losses (&#x201c;NOL&#x201d;) which can be carried forward to offset future taxable income. Approximately $&lt;span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_c20221231__srt--StatementScenarioAxis__custom--TwoThousandTwentyEightMember_zShKKzS5sOMj" title="Net operating loss carryforward"&gt;790,000&lt;/span&gt;, $&lt;span id="xdx_907_eus-gaap--OperatingLossCarryforwards_iI_c20221231__srt--StatementScenarioAxis__custom--TwoThousandTwentyNineMember_z4R1I2LYn4i7" title="Operating loss carryforwards"&gt;897,000&lt;/span&gt;
and $&lt;span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_c20221231__srt--StatementScenarioAxis__custom--TwoThousandThirtyMember_zYdQzWPGiCtf" title="Operating loss carryforwards"&gt;36,000&lt;/span&gt; of the net operating loss carry forwards will expire in 2028, 2029 and 2030, respectively, if unutilized. The deferred tax
valuation allowance as of December 31, 2022 and 2021 were approximately $&lt;span id="xdx_904_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pp0p0_c20221231__srt--StatementGeographicalAxis__country--MY_zkNcrZV4Sqqd" title="Deferred tax valuation allowance"&gt;408,000&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_pp0p0_c20211231__srt--StatementGeographicalAxis__country--MY_zIIliFXylte7" title="Deferred tax valuation allowance"&gt;217,000&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Hong
Kong&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Agape
ATP International Holding (HK) Limited is subject to Hong Kong Profits Tax, which is charged at the statutory income rate of &lt;span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231__srt--StatementGeographicalAxis__country--HK_z0iE2ahYAfTl" title="Tax percentage"&gt;16.5&lt;/span&gt;% on
its assessable income derived from Hong Kong. Business income derived or business expenses incurred outside the Special Administrative
Region is not subject to Hong Kong Profits Tax or deduction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;17.
INCOME TAXES (CONT&#x2019;D)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zs7koufBlsPe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table reconciles the local (United States) statutory rates to the Company&#x2019;s effective tax rate for the periods indicated
below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_ztzQ54IozAzh" style="display: none"&gt;SCHEDULE OF EFFECTIVE INCOME TAX RATE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20220101__20221231_zHCxR3XC3b55" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20210101__20211231_zgGgyOd8ejc8" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_zYddPEdno3Oc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;U.S. statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 3%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 3%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_z5DvnDY0tKVa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(22.9&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(17.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_dp_uPure_zQNCTYXfjhb5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Differential tax rate in Malaysia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_uPure_zsrG7A1gpjp3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Permanent difference&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;1.2&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;span id="xdx_F27_zatEtQtRgLT8" style="font-family: Times New Roman, Times, Serif"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(12.7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;span id="xdx_F2B_zOwAJzLC1RXf" style="font-family: Times New Roman, Times, Serif"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_uPure_zXyJa4KL4mx9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Effective tax rate&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.3&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(5.7&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)%&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    amount comprised:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F03_zytERM4xm703" style="display: none; font-family: Times New Roman, Times, Serif"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F15_zOWyPY8rPQ44" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    amount comprised:  (1.0)% being expenses
    incurred in AATP LB, ASL, SEA and WATP that are not deductible in the Malaysia tax return.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTQ0hFRFVMRSBPRiBFRkZFQ1RJVkUgSU5DT01FIFRBWCBSQVRFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dp_uPure_c20220101__20221231__srt--ConsolidatedEntitiesAxis__custom--AATPLBASLSEAAndWATPMember_zi6DGrGLC2ag" title="Tax percentage"&gt;1.2&lt;/span&gt;%
    being expenses incurred in AATP LB, ASL, SEA and WATP that are not deductible in the Malaysia tax return.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    amount comprised:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F05_z2wAecmBq731" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1B_zWKUhUXw4cdk" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    amount comprised: 6.2% being income derived in AATP HK that were not taxable in the Malaysia tax returns; and 6.7% being expenses
    incurred in AATP LB, ASL, SEA, WATP, and DSY Wellness that are not deductible in the Malaysia tax return.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTQ0hFRFVMRSBPRiBFRkZFQ1RJVkUgSU5DT01FIFRBWCBSQVRFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dp_uPure_c20210101__20211231__srt--ConsolidatedEntitiesAxis__custom--AATPHKMember_z6xpV1RMQVUj" title="Tax percentage"&gt;6.2&lt;/span&gt;%
    being income derived in AATP HK that were not taxable in the Malaysia tax returns; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTQ0hFRFVMRSBPRiBFRkZFQ1RJVkUgSU5DT01FIFRBWCBSQVRFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dp_uPure_c20210101__20211231__srt--ConsolidatedEntitiesAxis__custom--AATPLBASLSEAWATPAndDSYMember_zbGeGh7tMbTi" title="Tax percentage"&gt;6.5&lt;/span&gt;%
    being expenses incurred in AATP LB, ASL, SEA, WATP, and DSY Wellness that are not deductible in the Malaysia tax return.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AA_zNnq9UE82us8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zfEpPIcQn1Lf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth the significant components of the aggregate deferred tax assets of the Company as of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zWpLBFPc1Dkb" style="display: none"&gt;SCHEDULE OF DEFERRED TAX ASSETS&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20221231_zn52KdWrhKTj" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20211231_z0VTgYqVbouf" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_hsrt--StatementGeographicalAxis__country--US_zVEaoySimCW6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Net operating loss carry forwards in U.S.&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;284,959&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;153,061&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_hsrt--StatementGeographicalAxis__country--MY_zKdi2QR162R4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net operating loss carry forwards in Malaysia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;408,226&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;227,106&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_hsrt--StatementGeographicalAxis__country--MY_z1c62vy6Wc2h" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net operating loss carry forwards in Malaysia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;408,226&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;227,106&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_c20221231_zoFkfth0N4jk" style="text-align: right" title="Less: valuation allowance"&gt;(693,185&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_c20211231_zHah2jn5TAA3" style="text-align: right" title="Less: valuation allowance"&gt;(380,167&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DeferredTaxLiabilitiesDepreciation_iI_zz9ivyR9T0h9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1606"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(15,574&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iNI_di_zrvCGHXA3RVl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Deferred tax liabilities, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1609"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(15,574&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zUlQheZGTDob" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Uncertain
tax positions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company evaluates each uncertain tax position (including the potential application of interest and penalties) based on the technical
merits, and measure the unrecognized benefits associated with the tax positions&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
As of December 31, 2022 and 2021, the Company did not have any significant unrecognized uncertain tax positions. The Company did not
incur interest and penalties tax for the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_891_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zbYrNSfpqOqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
United States and foreign components of loss before income taxes were comprised of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BC_zbw9RcdCJECe" style="display: none"&gt;SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAX&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20220101__20221231_zILNGugjEUVd" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20210101__20211231_zJModJ8xjfzb" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Tax jurisdictions from:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_zEfm59KnFAFd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Local &#x2013; United States&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(736,946&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(706,659&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_hsrt--StatementGeographicalAxis__country--MY_zKjnqwH7pae9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Foreign &#x2013; Malaysia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(864,794&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,064,314&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_hsrt--StatementGeographicalAxis__country--HK_zEcVHq1RW1wl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Foreign &#x2013; Hong Kong&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(68,394&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(616,640&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_hsrt--StatementGeographicalAxis__country--HK_zQZ4XU7Pz09d" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Foreign, Tax jurisdictions&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(68,394&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(616,640&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ze9d2YDOMzhe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Loss before income tax&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1,670,134&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,387,613&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-736946</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-706659</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2022-01-012022-12-31_country_MY"
      decimals="0"
      unitRef="USD">-864794</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2021-01-012021-12-31_country_MY"
      decimals="0"
      unitRef="USD">-1064314</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2022-01-012022-12-31_country_HK"
      decimals="0"
      unitRef="USD">-68394</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2021-01-012021-12-31_country_HK"
      decimals="0"
      unitRef="USD">-616640</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2022-01-012022-12-31_country_HK"
      decimals="0"
      unitRef="USD">-68394</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2021-01-012021-12-31_country_HK"
      decimals="0"
      unitRef="USD">-616640</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-1670134</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-2387613</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89B_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zvnkRDjToTH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
benefit of (provision for) income taxes consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zd1FtMJnpQK1" style="display: none"&gt;SCHEDULE OF PROVISION FOR INCOME TAX&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20220101__20221231_zyjO9HHS05l5" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20210101__20211231_zaZTlg3JC3n7" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zMK5QD2RIBb5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Current:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_iN_di_maITEBzQW2_z60POG4Cj7X3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%"&gt;- Local&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1494"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(22,205&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--CurrentForeignTaxExpenseBenefit_iN_di_maITEBzQW2_zx6jaeMCGMG5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;- Foreign&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,962&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(104,735&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zf5oiH7PaL34" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Deferred:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_iN_di_maITEBzQW2_zYXpTW31pcRa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;- Local&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1503"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1504"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_iN_di_maITEBzQW2_zyDwuD45MHn9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;- Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;15,017&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(10,127&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_iNT_pp0p0_di_mtITEBzQW2_zJnYG9RGYQ28" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Benefit of (Provision for) income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,055&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(137,067&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">22205</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">10962</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">104735</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-15017</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">10127</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">-4055</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">137067</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-012022-12-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="INF"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-012022-12-31_us-gaap_ForeignCountryMember"
      decimals="INF"
      unitRef="Pure">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <AATP:TaxRateDescription contextRef="From2022-01-01to2022-12-31">In addition, the
Tax Cuts and Jobs Act imposed a global intangible low-taxed income (&#x201c;GILTI&#x201d;) tax, which is a tax on certain off-shore earnings
at an effective rate of 10.5% for tax years (50% deduction of the current enacted tax rate of 21%) with a partial offset for 80% foreign
tax credits. If the foreign tax rate is 13.125% or higher, there will be no U.S. corporate tax after the 80% foreign tax credits are
applied.</AATP:TaxRateDescription>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_country_US"
      decimals="0"
      unitRef="USD">1357000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2021-12-31_country_US"
      decimals="0"
      unitRef="USD">620000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2022-12-31_country_US"
      decimals="0"
      unitRef="USD">285000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2021-12-31_country_US"
      decimals="0"
      unitRef="USD">130000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31_us-gaap_DomesticCountryMember"
      decimals="0"
      unitRef="USD">22205</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">395</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">312608</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">65648</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <AATP:DeferredTaxAssetsOperatingLossCarryforwardsReducedAmount contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">0</AATP:DeferredTaxAssetsOperatingLossCarryforwardsReducedAmount>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2018-12-282019-01-02_custom_LabuanMember"
      decimals="INF"
      unitRef="Pure">0.03</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2018-12-282019-01-02_custom_LabuanMember"
      decimals="INF"
      unitRef="Pure">0.24</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxExaminationDescription contextRef="From2022-01-012022-12-31_country_MY">The tax rate for small and medium sized companies (generally
companies incorporated in Malaysia with paid-in capital of RM 2,500,000 or less) is 17% for the first RM 600,000 (or approximately $150,000)
for the year ended December 31, 2022 and 2021, with the remaining balance being taxed at the 24% rate.</us-gaap:IncomeTaxExaminationDescription>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2022-12-31_country_MY"
      decimals="0"
      unitRef="RM">2500000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-012022-12-31_country_MY"
      decimals="INF"
      unitRef="Pure">0.17</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="From2022-01-012022-12-31_country_MY"
      decimals="0"
      unitRef="RM">600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="From2022-01-012022-12-31_country_MY"
      decimals="0"
      unitRef="USD">150000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_country_MY"
      decimals="0"
      unitRef="USD">1723000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2021-12-31_country_MY"
      decimals="0"
      unitRef="USD">946000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_custom_TwoThousandTwentyEightMember"
      decimals="0"
      unitRef="USD">790000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_custom_TwoThousandTwentyNineMember"
      decimals="0"
      unitRef="USD">897000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_custom_TwoThousandThirtyMember"
      decimals="0"
      unitRef="USD">36000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2022-12-31_country_MY"
      decimals="0"
      unitRef="USD">408000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2021-12-31_country_MY"
      decimals="0"
      unitRef="USD">217000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-012022-12-31_country_HK"
      decimals="INF"
      unitRef="Pure">0.165</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zs7koufBlsPe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table reconciles the local (United States) statutory rates to the Company&#x2019;s effective tax rate for the periods indicated
below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_ztzQ54IozAzh" style="display: none"&gt;SCHEDULE OF EFFECTIVE INCOME TAX RATE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20220101__20221231_zHCxR3XC3b55" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20210101__20211231_zgGgyOd8ejc8" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_zYddPEdno3Oc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;U.S. statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 3%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 3%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_z5DvnDY0tKVa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(22.9&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(17.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_dp_uPure_zQNCTYXfjhb5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Differential tax rate in Malaysia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_uPure_zsrG7A1gpjp3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Permanent difference&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;1.2&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;span id="xdx_F27_zatEtQtRgLT8" style="font-family: Times New Roman, Times, Serif"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(12.7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;span id="xdx_F2B_zOwAJzLC1RXf" style="font-family: Times New Roman, Times, Serif"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_uPure_zXyJa4KL4mx9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Effective tax rate&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.3&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(5.7&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)%&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    amount comprised:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F03_zytERM4xm703" style="display: none; font-family: Times New Roman, Times, Serif"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F15_zOWyPY8rPQ44" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    amount comprised:  (1.0)% being expenses
    incurred in AATP LB, ASL, SEA and WATP that are not deductible in the Malaysia tax return.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTQ0hFRFVMRSBPRiBFRkZFQ1RJVkUgSU5DT01FIFRBWCBSQVRFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dp_uPure_c20220101__20221231__srt--ConsolidatedEntitiesAxis__custom--AATPLBASLSEAAndWATPMember_zi6DGrGLC2ag" title="Tax percentage"&gt;1.2&lt;/span&gt;%
    being expenses incurred in AATP LB, ASL, SEA and WATP that are not deductible in the Malaysia tax return.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    amount comprised:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F05_z2wAecmBq731" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1B_zWKUhUXw4cdk" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    amount comprised: 6.2% being income derived in AATP HK that were not taxable in the Malaysia tax returns; and 6.7% being expenses
    incurred in AATP LB, ASL, SEA, WATP, and DSY Wellness that are not deductible in the Malaysia tax return.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTQ0hFRFVMRSBPRiBFRkZFQ1RJVkUgSU5DT01FIFRBWCBSQVRFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dp_uPure_c20210101__20211231__srt--ConsolidatedEntitiesAxis__custom--AATPHKMember_z6xpV1RMQVUj" title="Tax percentage"&gt;6.2&lt;/span&gt;%
    being income derived in AATP HK that were not taxable in the Malaysia tax returns; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTQ0hFRFVMRSBPRiBFRkZFQ1RJVkUgSU5DT01FIFRBWCBSQVRFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dp_uPure_c20210101__20211231__srt--ConsolidatedEntitiesAxis__custom--AATPLBASLSEAWATPAndDSYMember_zbGeGh7tMbTi" title="Tax percentage"&gt;6.5&lt;/span&gt;%
    being expenses incurred in AATP LB, ASL, SEA, WATP, and DSY Wellness that are not deductible in the Malaysia tax return.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">-0.229</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">-0.170</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.030</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      id="Fact001577"
      unitRef="Pure">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      id="Fact001578"
      unitRef="Pure">-0.127</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-01-01to2022-12-31"
      decimals="INF"
      unitRef="Pure">0.003</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">-0.057</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="From2022-01-012022-12-31_custom_AATPLBASLSEAAndWATPMember"
      decimals="INF"
      unitRef="Pure">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="From2021-01-012021-12-31_custom_AATPHKMember"
      decimals="INF"
      unitRef="Pure">0.062</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="From2021-01-012021-12-31_custom_AATPLBASLSEAWATPAndDSYMember"
      decimals="INF"
      unitRef="Pure">0.065</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zfEpPIcQn1Lf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth the significant components of the aggregate deferred tax assets of the Company as of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zWpLBFPc1Dkb" style="display: none"&gt;SCHEDULE OF DEFERRED TAX ASSETS&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20221231_zn52KdWrhKTj" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20211231_z0VTgYqVbouf" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_hsrt--StatementGeographicalAxis__country--US_zVEaoySimCW6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Net operating loss carry forwards in U.S.&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;284,959&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;153,061&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_hsrt--StatementGeographicalAxis__country--MY_zKdi2QR162R4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net operating loss carry forwards in Malaysia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;408,226&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;227,106&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_hsrt--StatementGeographicalAxis__country--MY_z1c62vy6Wc2h" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net operating loss carry forwards in Malaysia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;408,226&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;227,106&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_c20221231_zoFkfth0N4jk" style="text-align: right" title="Less: valuation allowance"&gt;(693,185&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_c20211231_zHah2jn5TAA3" style="text-align: right" title="Less: valuation allowance"&gt;(380,167&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DeferredTaxLiabilitiesDepreciation_iI_zz9ivyR9T0h9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1606"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(15,574&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iNI_di_zrvCGHXA3RVl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Deferred tax liabilities, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1609"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(15,574&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="AsOf2022-12-31_country_US"
      decimals="0"
      unitRef="USD">284959</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="AsOf2021-12-31_country_US"
      decimals="0"
      unitRef="USD">153061</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="AsOf2022-12-31_country_MY"
      decimals="0"
      unitRef="USD">408226</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="AsOf2021-12-31_country_MY"
      decimals="0"
      unitRef="USD">227106</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="AsOf2022-12-31_country_MY"
      decimals="0"
      unitRef="USD">408226</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="AsOf2021-12-31_country_MY"
      decimals="0"
      unitRef="USD">227106</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">693185</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">380167</us-gaap:DeferredTaxAssetsValuationAllowance>
    <AATP:DeferredTaxLiabilitiesDepreciation contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-15574</AATP:DeferredTaxLiabilitiesDepreciation>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">15574</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80B_eus-gaap--ConcentrationRiskDisclosureTextBlock_zROLBkIHSamd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;18.
&lt;span id="xdx_821_zlvbAJHpNgn5"&gt;CONCENTRATIONS OF RISKS&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)
Major customers&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2022 and 2021, no customer accounted for &lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--NoCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWKJc4bsj6Uc" title="Concentrations of risk percentage"&gt;&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--NoCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zAONw3R7qX0b" title="Concentrations of risk percentage"&gt;10.0&lt;/span&gt;&lt;/span&gt;% or more of the Company&#x2019;s total revenues.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, five individual customers accounted for approximately &lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--FiveIndividualCustomersMember_zBwk0nuBy2zc" title="Concentrations of risk percentage"&gt;72.0&lt;/span&gt;% of the Company&#x2019;s balance of accounts receivable.
There was no accounts receivable balance as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)
Major vendors&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the year ended December 31, 2022, three vendors accounted for approximately &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zfuoGkoRdPA3" title="Concentrations of risk percentage"&gt;53.3&lt;/span&gt;%, &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zoZqGJPNUz78" title="Concentrations of risk percentage"&gt;22.1&lt;/span&gt;% and &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zDnV58Jej51h" title="Concentrations of risk percentage"&gt;21.3&lt;/span&gt;% of the Company&#x2019;s total purchases.
For the year ended December 31, 2021, two vendors accounted for approximately &lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zQPkwlZce1Z9" title="Concentrations of risk percentage"&gt;47.3&lt;/span&gt;% and &lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_ziDzEcL0CCl2" title="Concentrations of risk percentage"&gt;45.2&lt;/span&gt;% of the Company&#x2019;s total purchases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Via a dividend distribution, the Company acquired &lt;span id="xdx_90E_ecustom--DividendShareForCommonStock_pid_c20210101__20211231__dei--LegalEntityAxis__custom--DSwissIncMember_zca4wE7CywH" title="Dividend share for common stock"&gt;23,330&lt;/span&gt; shares of common stock of DSwiss, Inc., represents approximately &lt;span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20211231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DSwissIncMember_zleAnAUhNaJ2" title="Equity method investment ownership percentage"&gt;0.01&lt;/span&gt;% ownership,
that the Company accounted for as investment in marketable securities (See Note 11). DSwiss, Inc.&#x2019;s wholly owned subsidiary is
the vendor that accounted for the Company&#x2019;s total purchases of approximately &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__srt--MajorCustomersAxis__custom--VendorOneMember__dei--LegalEntityAxis__custom--DSwissIncMember_zusE8A7Yki5d" title="Concentration risk percentage"&gt;22.1&lt;/span&gt;% and &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__srt--MajorCustomersAxis__custom--VendorOneMember__dei--LegalEntityAxis__custom--DSwissIncMember_z5Lx7iFKKLlh" title="Concentration risk percentage"&gt;47.3&lt;/span&gt;% for the years ended December 31, 2022
and 2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, three vendors accounted for approximately &lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zBdUEcqmBp4i"&gt;46.6&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%,
&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zsDL8yJK0zxh"&gt;25.8&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
and &lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_z7gJ9lvHSQf2"&gt;23.9&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the Company&#x2019;s total balance of accounts payable, respectively. CTA Nutriceuticals (Asia) Sdn Bhd, a related company, accounted
for approximately &lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--VendorMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zk63rwWeuecd"&gt;47&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the Company&#x2019;s total balance of accounts payable. As of December 31, 2021, one vendor accounted for &lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__srt--MajorCustomersAxis__custom--OneVendorMember_zhnOu5e2jfLl"&gt;100&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the total balance of accounts payable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(c)
Commission Expenses to Sales Distributors and Stockists&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the year ended December 31, 2022, one sales distributor accounted for approximately &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__srt--MajorCustomersAxis__custom--OneSalesDistributorMember_zJL3nnPr6syj" title="Concentrations of risk percentage"&gt;10.3&lt;/span&gt;%
of the Company&#x2019;s total commission expense. For the year ended December 2021, one sales distributor accounted for approximately &lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__srt--MajorCustomersAxis__custom--OneSalesDistributorMember_zhaCbealWL3l" title="Concentrations of risk percentage"&gt;17.9&lt;/span&gt;%
of the Company&#x2019;s total commission expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(d)
Credit risk&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. As of December
31, 2022 and 2021, $&lt;span id="xdx_901_eus-gaap--Deposits_iI_pp0p0_c20221231_z6mGVwNczc65" title="Deposits"&gt;513,152&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--Deposits_iI_pp0p0_c20211231_z7vQs6ijMMzl" title="Deposits"&gt;554,864&lt;/span&gt; were deposited with financial institutions, respectively, $&lt;span id="xdx_908_ecustom--DepositForInsurance_iI_pp0p0_c20221231_zeLPRNuQv3p" title="Deposit for insurance"&gt;231,187&lt;/span&gt; and $&lt;span id="xdx_900_ecustom--DepositForInsurance_iI_pp0p0_c20211231_zrvdO8zk80Ag" title="Deposit for insurance"&gt;295,761&lt;/span&gt; of these balances
are not covered by deposit insurance. While management believes that these financial institutions are of high credit quality, it also
continually monitors their credit worthiness.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that are potentially subject to credit risk consist principally of accounts receivable. The Company believes the concentration
of credit risk in its account receivable is substantially mitigated by its ongoing credit evaluation process and relatively short collection
terms. The Company does not generally require collateral from customers. The Company evaluates the need for an allowance for doubtful
accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information. Historically,
the Company did not have any bad debt on its account receivable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(e)
Exchange rate risk&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company cannot guarantee that the current exchange rate will remain steady; therefore, there is a possibility that the Company could
post the same amount of profit for two comparable periods and because of the fluctuating exchange rate actually post higher or lower
profit depending on exchange rate of RM and HK$ converted to US$ on that date. The exchange rate could fluctuate depending on changes
in political and economic environments without notice.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;AGAPE
ATP CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Currency
expressed in United States Dollars (&#x201c;US$&#x201d;), except for number of shares)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_custom_NoCustomerMember_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.100</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-01-012021-12-31_custom_NoCustomerMember_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.100</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_FiveIndividualCustomersMember"
      decimals="INF"
      unitRef="Pure">0.720</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_custom_VendorOneMember_us-gaap_CostOfGoodsTotalMember_us-gaap_SupplierConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.533</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_custom_VendorTwoMember_us-gaap_CostOfGoodsTotalMember_us-gaap_SupplierConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.221</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_custom_VendorThreeMember_us-gaap_CostOfGoodsTotalMember_us-gaap_SupplierConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.213</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-01-012021-12-31_custom_VendorOneMember_us-gaap_CostOfGoodsTotalMember_us-gaap_SupplierConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.473</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-01-012021-12-31_custom_VendorTwoMember_us-gaap_CostOfGoodsTotalMember_us-gaap_SupplierConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.452</us-gaap:ConcentrationRiskPercentage1>
    <AATP:DividendShareForCommonStock
      contextRef="From2021-01-012021-12-31_custom_DSwissIncMember"
      decimals="INF"
      unitRef="Shares">23330</AATP:DividendShareForCommonStock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2021-12-31_custom_DSwissIncMember"
      decimals="INF"
      unitRef="Pure">0.0001</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfGoodsTotalMember_custom_VendorOneMember_custom_DSwissIncMember"
      decimals="INF"
      unitRef="Pure">0.221</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-01-012021-12-31_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfGoodsTotalMember_custom_VendorOneMember_custom_DSwissIncMember"
      decimals="INF"
      unitRef="Pure">0.473</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_custom_VendorOneMember_us-gaap_AccountsPayableMember_us-gaap_SupplierConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.466</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_custom_VendorTwoMember_us-gaap_AccountsPayableMember_us-gaap_SupplierConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.258</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_custom_VendorThreeMember_us-gaap_AccountsPayableMember_us-gaap_SupplierConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.239</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_custom_VendorMember_us-gaap_AccountsPayableMember_us-gaap_SupplierConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.47</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_us-gaap_SupplierConcentrationRiskMember_us-gaap_AccountsPayableMember_custom_OneVendorMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfGoodsTotalMember_custom_OneSalesDistributorMember"
      decimals="INF"
      unitRef="Pure">0.103</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-01-012021-12-31_us-gaap_SupplierConcentrationRiskMember_us-gaap_CostOfGoodsTotalMember_custom_OneSalesDistributorMember"
      decimals="INF"
      unitRef="Pure">0.179</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:Deposits contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">513152</us-gaap:Deposits>
    <us-gaap:Deposits contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">554864</us-gaap:Deposits>
    <AATP:DepositForInsurance contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">231187</AATP:DepositForInsurance>
    <AATP:DepositForInsurance contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">295761</AATP:DepositForInsurance>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_80C_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z69LD8AdR3ud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;19.
&lt;span id="xdx_822_zheUq6pXeslf"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Lease
commitments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 1, 2020, the Company adopted ASC 842 for ASL&#x2019;s office space lease and sales and training center as the lease commencement
date upon the acquisition of ASL. The Company recognized lease liabilities of approximately $&lt;span id="xdx_905_eus-gaap--OperatingLeaseLiability_iI_c20200401__us-gaap--BusinessAcquisitionAxis__custom--AgapeSuperiorLivingMember_zHEG7ffirE7f" title="Operating lease liability"&gt;490,000&lt;/span&gt;, with a corresponding right-of-use
(&#x201c;ROU&#x201d;) asset in the same amount based on the present value of the future minimum rental payments of the lease, using an
effective interest rate of &lt;span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20200401__us-gaap--BusinessAcquisitionAxis__custom--AgapeSuperiorLivingMember_zsfc97PkyXX" title="Operating lease effective interest rate"&gt;5.5&lt;/span&gt;%, which was determined using the Company&#x2019;s estimated incremental borrowing rate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 31, 2021, the Company entered into two separate two-year leases extension with the modified lease expiring &lt;span id="xdx_902_ecustom--LeaseExpirationTerm_dd_c20210530__20210531_z5HRcpGjQYe4" title="Lease expiration term"&gt;May 31, 2023&lt;/span&gt; for its office
space and expiring &lt;span id="xdx_906_ecustom--LeaseExpirationTerm_dd_c20210530__20210531__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--TrainingCenterMember_zgWo3XXLKBk4" title="Lease expiration term"&gt;August 31, 2023&lt;/span&gt; for its training center. The lease modification required the Company to re-measure the ROU assets
and lease liabilities based on the modified leases. The Company recognized a reduction of $&lt;span id="xdx_907_ecustom--IncreaseDecreaseInROUAssetsAndLiabilities_iI_c20210531_zMm1KiV1UOf5" title="Reduction in ROU assets and liabilities"&gt;3,250&lt;/span&gt; in ROU assets and lease liabilities
upon lease modifications based on the present value of the future minimum rental payments of the lease, using an effective interest rate
of &lt;span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20210531__us-gaap--BusinessAcquisitionAxis__custom--AgapeSuperiorLivingMember_zZFVSgvwkURl" title="Operating lease effective interest rate"&gt;5.5&lt;/span&gt;%, which was determined using the Company&#x2019;s estimated incremental borrowing rate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On October 1, 2021, the Company entered into a &lt;span id="xdx_90B_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dxL_c20211001_zwO49qHuz3n7" title="Operating lease term::XDX::P2Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1669"&gt;two-years&lt;/span&gt;&lt;/span&gt;
lease for an apartment to serve as staff accommodation. The Company recognized lease liabilities of approximately $&lt;span id="xdx_908_eus-gaap--OperatingLeaseLiability_iI_c20211001_zQfxh8uQLN0i" title="Operating lease liability"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20211001_zoOOaZ2efkBe" title="Operating right-of-use assets"&gt;9,777&lt;/span&gt;&lt;/span&gt;, with a corresponding
right-of-use (&#x201c;ROU&#x201d;) asset in the same amount based on the present value of the future minimum rental payments of the lease,
using an effective interest rate of &lt;span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20211001_zi8zLBxgsmve" title="Operating lease effective interest rate"&gt;5.5&lt;/span&gt;%, which was determined using the Company&#x2019;s estimated incremental borrowing rate.&lt;/p&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;On November 1, 2021, the Company entered into a &lt;span id="xdx_90A_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dxL_c20211101_zJeDmQwI3MWk" title="Lease term::XDX::P2Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1677"&gt;two-years&lt;/span&gt;&lt;/span&gt; lease for a branch
office and operating centre. The Company recognized lease liabilities of approximately $&lt;span id="xdx_907_eus-gaap--OperatingLeaseLiability_iI_c20211101_zpBUZLZW2Lbh" title="Operating lease liability"&gt;&lt;span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20211101_zgVkR9kWAfa4" title="Operating right-of-use assets"&gt;10,864&lt;/span&gt;&lt;/span&gt;, with a corresponding right-of-use (&#x201c;ROU&#x201d;)
asset in the same amount based on the present value of the future minimum rental payments of the lease, using an effective interest rate
of &lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20211101_zUAmwGr4yWbi" title="Operating lease effective interest rate"&gt;5.5&lt;/span&gt;%, which was determined using the Company&#x2019;s estimated incremental borrowing rate.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;As
of December 31, 2022, the weighted remaining term of the lease is approximately &lt;span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231__us-gaap--BusinessAcquisitionAxis__custom--AgapeSuperiorLivingMember_zXR7UdCxOVR9" title="Operating lease, weighted average remaining lease term"&gt;0.54&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z19xei46SuY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
five-year maturity of the Company&#x2019;s operating lease liabilities is as follow:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B8_zPzwct6CWzei" style="display: none"&gt;SCHEDULE OF LEASE COMMITMENTS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20221231_zelUUryFsmN9" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Twelve Months Ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzA1T_znNAabTgceb9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;84,146&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterNextTwelveMonths_iI_pp0p0_maLOLLPzA1T_zVWVdRWGvhwa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1691"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzA1T_zr1jivH6QUx5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;84,146&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zxPaMYfFvuCg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,439&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zbhS2P8SMYie" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;82,707&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zKoWpdy9tLcj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also leased one office and operation center, and one shophouse with an expiring term of twelve months or less, which were classified
as operation leases. Since the lease terms for these leases were twelve months or less, a lessee is permitted to elect not to recognize
lease assets and liabilities. The Company has elected not to recognize lease assets and liabilities on these leases. As of December 31,
2022, the Company&#x2019;s commitment for minimum lease payment under these operating leases within the next twelve months were $&lt;span id="xdx_906_eus-gaap--OperatingLeasePayments_c20220101__20221231_zGIFHSAk5Ky1" title="Operating lease payments"&gt;567&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rent
expense for the years ended December 31, 2022 and 2021 was $&lt;span id="xdx_90C_eus-gaap--OperatingLeaseExpense_pp0p0_c20220101__20221231_zcxO7WDxBHfd" title="Operating lease, expense"&gt;190,547&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--OperatingLeaseExpense_pp0p0_c20210101__20211231_z7CK0VXCjhHg" title="Operating lease, expense"&gt;179,562&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Contingencies&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Legal&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, the Company is party to certain legal proceedings, as well as certain asserted and un-asserted claims. Amounts accrued,
as well as the total amount of reasonably possible losses with respect to such matters, individually and in the aggregate, are not deemed
to be material to the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;COVID-19&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Malaysia,
where the operations of the Company predominantly reside, officially transitioned to the endemic phase of COVID-19 effective April 1,
2022. Restrictions on businesses and people are minimal. Meanwhile, the government continues to encourage inoculation for those between
the ages of 5 and 11 years and its adolescent group which comprised those between the ages 12 and 17. Adults who have been fully vaccinated,
i.e. received two doses of the COVID-19 vaccine are encouraged to take booster shots.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Substantially
all of our revenues are concentrated in Malaysia. Consequently, our results of operations will likely be adversely, and may be materially,
affected, to the extent that the COVID-19 or any other epidemic harms the Malaysia and global economy in general. Any potential impact
to our results will depend on, to a large extent, future developments and new information that may emerge regarding the duration and
severity of the COVID-19 and the actions taken by government authorities and other entities to contain the COVID-19 or treat its impact,
almost all of which are beyond our control. Potential impacts include, but are not limited to, the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;temporary
    closure of offices, travel restrictions, disruption or suspension of supplies, our customers may be negatively impacted financially
    resulting in which the demand for our products may be adversely affected&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;we
    may have to provide significant sales incentives to our customers during the outbreak, which may in turn materially adversely affect
    our financial condition and operating results&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;any
    disruption of our supply chain, logistics providers or customers could adversely impact our business and results of operations, including
    causing us or our suppliers to cease manufacturing for a period of time or materially delay delivery to our customers, which may
    also lead to loss of our customers.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Because
of the uncertainty surrounding the COVID-19 outbreak, the financial impact related to the outbreak of and response to the COVID-19 cannot
be reasonably estimated at this time. There is no guarantee that the Company&#x2019;s total revenues will grow or remain at similar levels
year over year in 2023 and beyond.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2020-04-01_custom_AgapeSuperiorLivingMember"
      decimals="0"
      unitRef="USD">490000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2020-04-01_custom_AgapeSuperiorLivingMember"
      decimals="INF"
      unitRef="Pure">0.055</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <AATP:LeaseExpirationTerm contextRef="From2021-05-302021-05-31">2023-05-31</AATP:LeaseExpirationTerm>
    <AATP:LeaseExpirationTerm contextRef="From2021-05-302021-05-31_custom_TrainingCenterMember">2023-08-31</AATP:LeaseExpirationTerm>
    <AATP:IncreaseDecreaseInROUAssetsAndLiabilities contextRef="AsOf2021-05-31" decimals="0" unitRef="USD">3250</AATP:IncreaseDecreaseInROUAssetsAndLiabilities>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2021-05-31_custom_AgapeSuperiorLivingMember"
      decimals="INF"
      unitRef="Pure">0.055</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2021-10-01" decimals="0" unitRef="USD">9777</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-10-01" decimals="0" unitRef="USD">9777</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2021-10-01" decimals="INF" unitRef="Pure">0.055</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2021-11-01" decimals="0" unitRef="USD">10864</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-11-01" decimals="0" unitRef="USD">10864</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2021-11-01" decimals="INF" unitRef="Pure">0.055</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-12-31_custom_AgapeSuperiorLivingMember">P0Y6M14D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_894_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z19xei46SuY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
five-year maturity of the Company&#x2019;s operating lease liabilities is as follow:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B8_zPzwct6CWzei" style="display: none"&gt;SCHEDULE OF LEASE COMMITMENTS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20221231_zelUUryFsmN9" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Twelve Months Ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzA1T_znNAabTgceb9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;84,146&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterNextTwelveMonths_iI_pp0p0_maLOLLPzA1T_zVWVdRWGvhwa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1691"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzA1T_zr1jivH6QUx5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;84,146&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zxPaMYfFvuCg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,439&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zbhS2P8SMYie" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;82,707&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">84146</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">84146</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1439</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">82707</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">567</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">190547</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">179562</us-gaap:OperatingLeaseExpense>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zyuucV8ANjb8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;20.
&lt;span id="xdx_824_zM4zIO21U53c"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman PS Std,serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has evaluated subsequent events through the date of issuance of this consolidated financial statements,
and does not identify any events with material financial impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;
</us-gaap:SubsequentEventsTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact001577"
          xlink:label="Fact001577"
          xlink:type="locator"/>
        <link:footnote id="Footnote001582" xlink:label="Footnote001582" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
    amount comprised:  (1.0)% being expenses
    incurred in AATP LB, ASL, SEA and WATP that are not deductible in the Malaysia tax return.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001577"
          xlink:to="Footnote001582"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001578"
          xlink:label="Fact001578"
          xlink:type="locator"/>
        <link:footnote id="Footnote001585" xlink:label="Footnote001585" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
    amount comprised: 6.2% being income derived in AATP HK that were not taxable in the Malaysia tax returns; and 6.7% being expenses
    incurred in AATP LB, ASL, SEA, WATP, and DSY Wellness that are not deductible in the Malaysia tax return.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001578"
          xlink:to="Footnote001585"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>114
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" #E7G]6.3 ")T8'  "5+P  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;+6:77.;.!B%[_,K-&YGIYV)8Q"V8[>)9QP<=]WFPQ.G[61W]D(!Q68*R"M$
MG/S[%1\VH2M>PXQ\TP#F/:"G$CH'=+9A_%>THE2@E\ /H_/62HCUITXG<E8T
M(-$)6]-0_O+$>$"$W.7+3K3FE+AI4>!WL&'T.P'QPM;H+#TVYZ,S%@O?"^F<
MHR@. L)?+ZC/-N<ML[4]<.<M5R(YT!F=K<F2+JCXOIYSN=?9J;A>0,/(8R'B
M].F\-38_3:Q!4I">\<.CF^C--DJ:\LC8KV1GYIZWC.2.J$\=D4@0^>>9VM3W
M$R5Y'__FHJW=-9/"M]M;]6G:>-F81Q)1F_D_/5>LSEN#%G+I$XE]<<<V?]*\
M0;U$SV%^E/Z+-MFYW6X+.7$D6) 7RSL(O##[2UYR$&\*+%Q1@/,"_%N!674%
M*R^PZA9T\X)N2B9K2LIA0@09G7&V03PY6ZHE&RG,M%HVWPN3__>%X/)73]:)
MD<V>*4=M]'TQ01_>?SSK""F:_-1Q<H&+3 !7")@87;-0K")T&;K4+0MTY-WL
M;@EO;^D"@XH3ZIP@RSQ&V,!8<4,V7'Y-^ G"5EIN*<HG</G7.)17-U17+[7&
MV@&V4CT+!/SW^#$27';R?U2$,X6N6B$9^9^B-7'H>4L.[8CR9]H:_?'.[!N?
M571TBDTTB97(=7?DNI#Z:,*<6#YA!+I_75,5-KC<--K?5'S JJ9\-(F5^/1V
M?'I@ \<2CIL"FOIDJ0($US\1/U)QM<&RIH0TB94(]7>$^O5ZT#@,8^*C.[IF
M7*A(P3J"QTI08%534)K$2J!.=Z!.:PXU3N24GL[(U;!@K<IN!98UI:5)K$1K
ML*,UJ$=K3KG'W&3B0W+R53ZC]BAMI[K*N0ZL;PI-DU@)VG ';5@/VM2+'#D6
M<W93>3A2@8/5I@\J6&!-4UB:Q$JP3*.P948C7 ^4\&I8>\2J.A=<UA28+K4R
ML3=&U@0;:<><_PX,&IE[Y-IM$[<M4XD-K&R,39-:&1LNL&&PG9>A\,2KI.93
M=!,'CY0K8<$BEF6U,3;,;E?)"RQNS$N36IE78>=-T/-N>=W1I9<X>MGA;DB@
M[F"PT/C+>'YY-+Z?(_OV;GY[-[Z?W=XH\6EU]+K4RO@*3V_"KCS'9\N1RN4H
MG<G,^(*^T5<E0%C*, SSU+2P:2BI:?7YNM3*U JG;\)6/:=V3U[0S)7HO"?/
M(:E+ X8L+&GUV]V!-1@,^DIZ6C. +K4RO2(%F+!]S^G-0H=QZ6E3<,=H(>3$
M@!A'-HME9Y1]DKGJ<0RKW_Q0 M2:#72IE0$6Z<"$+7T.<.RZ4CTZWFZ@*WD>
MN@W5U&!)\]3H'?WQ;H!-\S.2.X-C=$6?J2^WC]$]VU".U)9%:XK0I5;F6N0(
M$[;_(-?[#5-RA26G1#X.,H JIVC#Y8WY'2)1F$6D,.$4 /-;<:KNF;#H5^*3
M$$UH1- %69&E1Y0<M68-76KE]ZU%V,!P/OB=HYWLL;0;A2J">^2^Q1(ANHJ#
M=:R:F6RXO"D[76IE=D7LP'!.^!^[;#918H.5KI69%BYJ#.L080,780/7"AL[
M6',6">D"__+6E;/O'L7>P#24_@^N:\SM$*$#%Z$#PUDA'9!C3DDU)EC@0]]0
M?=NQX;+&E Z1+7"1+3 <"*Y8^F)IQ4(HRNX1,8<86X8Q'"IQ:0T5NM3*N(I0
M@>$$<.\)F?G9$S+QA\>/:$&=F,M^IF0&*]DL"%AXM!#,^76,WALG231#:\+1
M,_'5K\YAQ<8D#Q$P<!$P<*V \9/Z?OM7*"=-"9-$LANZ:!9%<44_W!,K5.[/
MAHL:8SM$K,!%K,"U8L4/YLLID_#L)932ME[L4:J I34KZ%(KPRJR JZ5%;9O
M.;.O,UZX3'.L^JWP'L4'JDP(<%5C:H=("+A("+A60IB%@O)LB4GR/IAL,2JI
MP8I5U+3F 5UJY14+11ZP:N6!=#@BFPBZ9&I'NT?GAH5MXCA4RD@1-Q-4KEG0
MF@ATJ97I%8G JI4(%@'Q?7011_+G2#D^]^A4?76&RQK#.D0BL(I$8-5*!)<!
MY<OD:?9%*HB5M+G!FH3J/@<+5GY^ANL:8SM$(+#>+"JJ]15BL9*6 X0%RU3#
MTKN*Z!"YP"IR@57KF\,\?O0]!TU]1I0/?EBE\3(LK5$A5^NE:LE:SN<1'EH#
M8WB:?/UX5N$I<H!5Z^-"9N)1;N(7*R)O"]W&0B;TT)5#4XE,IXNW<[7^FT:>
M]KH];)AXU\8<QR'\OE7X?0OVYN/8]03C<C[C 9I-E&1@A9XU["D1:/7WNM3*
MF I_;\&N?(NIZ@/IGO(I]Z@;D!!=7<V5K+3:>UUJ95:%O;=@,[YEE;S#2+Y/
M*7G!$C=T<_3 N!R\<@LE6TIJ6NV]+K6,6N?-.N;$$*3KP2/D)*]4LR7-NZ.[
M->?C=*5UIS@]6[!^31(_$2&?/LE2X^14/C%XM@8\VQ%LG:Z*?F1"L"#=7%'B
M4IZ<(']_8DQL=Y(+[%;BC_X#4$L#!!0    ( .5>?U9VT8?T3@@  'PD   8
M    >&PO=V]R:W-H965T<R]S:&5E=#(N>&ULS5IM<^(X$OXK*G9J:ZZ*!.O%
M;Y.7*H:P.]3E( ?,7MU'QXC@&F.QMD@F]^NO91P,EJS 7C[<AYD8:+6[6]W]
M/"W[^D7D/XH5YQ+]7*=9<=-92;GYTNL5\8JOH^)2;'@&ORQ%OHXD?,R?>L4F
MY]&B7+1.>\1QO-XZ2K+.[77YW4-^>RVV,DTR_I"C8KM>1_GK5YZ*EYL.[KQ]
M,4V>5E)]T;N]WD1/?,;E]\U##I]Z>RV+9,VS(A$9ROGRIM/'7P:,J 6EQ!\)
M?RD.KI%RY5&('^K#:''3<91%/.6Q5"HB^//,!SQ-E2:PX\]*:6=_3[7P\/I-
M^V^E\^#,8U3P@4C_E2SDZJ83=-""+Z-M*J?BY1NO''*5OEBD1?D_>JEDG0Z*
MMX44ZVHQ6+!.LMW?Z&<5B(,%F+4L(-4"<NH"6BV@I:,[RTJW[B(9W5[GX@7E
M2AJTJ8LR-N5J\";)U#;.9 Z_)K!.W@Y$5H@T6422+]#7*(VRF*.94E>@"_1]
M=H<^?_K;=4_"K=2"7ERI_;I32UK4WO'X$E'<1<0AQ+!\</IR?+R\!P[NO21[
M+TFIC[9Y^7TZ'8[GJ#^;#><SDSN[]<R\7M72EV(3Q?RF \52\/R9=VY__05[
MSI7)N0]2=N0JW;M*;=IO!U&Q0E&V0+&ZX']ND^<HY1ELY^=1%J?;!>SS)]SU
MG+"4^H3]+@LI2C(D5QS%A^GPQV@(7T825&7HD:-M 5^*+'U%4J""2YER)![3
MY"E2%5D@L33KB,J?8$_Y^I'G^[0H[Z\VN O]H-CPLJ#3UTMCNNV<=DNG56MZ
MOL6,!HPZU[WGP]#K<L0-_8 %>[FCJ+)]5)DUJOTX%EL5Q!R\@(@^IMQDY4Z)
M=WCW@'@-$ZUW,F<'LB2&NW?!M;NP5AZ@Q9:C92[6X$E:[M FRF7""Y,[KN8.
M=ES*&O[H4K[C,'.\O;VQGM784?8,.2OR%L,\[9;,([[?,$R7HK[K4M=LFK\W
MS;>:]I#S390LD(Q^\D91^0Q71=6EKO]_7U.^'A\:4J\91EW,HQ[!+145[,,8
MO!_&UW79F931"[X112*-VQWH>1AB[#1K7Q<CH>MBWVQHN#<TM!HZ%S)*T6";
MYV KZA>P248C0_WN#@GT<M'E:(@)5C!I,A,[-9([5I";S+\-IQ:(JY9_$,9]
ME+9C9P]H"WXG?8#)YO*US!V%<AN52EV4<6GT'>LIQ AF86-S#'($NWX8MFQ.
M34"P%?2AH<DH>TH -Z!T50JUFTIT$YC#FFED$*.>Y[386;,';*</$X@JM)[L
M">6* %^(Y06TJ,IFH[E4LR/ F-*FN;H8H;[?UD5P#<S8CLP**0JI-E_U6QA%
M?G"IX!F::;S-DS9HPSI48\\+FKW/(!:$CH-;K*ZQ&-O!^-CJ3&07IUMNU7P2
M?ZA\,\"[Z[1E4(W<V [==WS)H5<"JBWA0F52+(J6W#'@>!A"VVSN@BY'/.:W
M(3FNH1S;L7S7VP4@;&Y+<1T!?8]"7VB:J<L%F#!,6\RLH1+;L7(^F??O;9W=
M@'Q^B'V]O>F"S">LE1/A&B1Q>-*$=3_J?QW=C^:CH=E2*]:>C4$?I.UXIJP!
MEU@QKAX*@,BT3025BN.1(-#:HT$,4Q^W; NI89+88;)I(OKUEX!@?'4*^R<&
M+'0]C)NF6RTX?YXA!T.]'5,'Y?$(E*Z-.Q(33E+G '@J-PRPZX=>T(+\I$94
M<BJBICP"*$V3Z#%)6]L[,> I\1W-7%T,>(H3MLQ=I,938L?32=D,JW394?,H
MCO,MY,J!Y>@SS#A.Z+R-.RX+4)1S +-J&K+./DKR)9$KL95JH!;;'.("\T^Y
M J CD6JXZ3]%&X[Z\P<T$/E&Y-'NW.\#!A^BH[J/J3Y &N0"-Z!N6UG6\$_L
M\'\4Y+-J4L=L%@3-0<A^][]0DC7XD_?F]A@J4LW&UJ:HXSEVH-::;A@&^#!H
M88RD!GUR"NB_#73W[Y2CCNDPJH4P6#:--0A23 +6PA5)C?XDL$+K>#*^.!%>
MB95'G'V,^4':COVN*06Q#][G-LZ_0 :,O)CH$WI 6=#266E-%ZB=+NR)L:J.
M=YRQJSK#&6H@%J[KMSE3$PMJ)Q:[(AK#X!*?5DAV?>=XI-.2,'3<EK9 :S9!
M[6QB1[+?*3"JLP1S.S ),HR#MI,$>G"^3ZWM8#:?#/[^;7)_-YS.2N3PK]#P
MG]]'\W\;#;:2DW,[PD=I.W:]YB;4SDT>\K<2 N(7_^BB3\ZE ].X0DST'*5;
M?@4<P.DZNW^H6 '3  ZS!:J1)__ABRN5L<!2BD+Q&449@((4$BZ@S1C#][\?
MUE>1^^!3?UIS#6KG&@.Q7@-OFNTBMH_46^RN$'Z+ESEF7>2[7>:2KH,KEA4Z
M7>:!-//?I,T!/9>K&3? \'3!95JUZ5)@)?-::JVF,]1.9_H+X*+ .J'5E6?^
MP&KC:)- ZS/:JO,5C_F.CYM/@(R"+"1M\QZMN0VU<QN8][;K[8Y&+O@RB1/C
M&2/5R<H%"YGK!IJI!DE*0"YH.5:G-:^A]E.-0UMW1S# '2'[5^HE@>=RE@ N
M:31?/\8(B:>9;I"B0"!;[*YY"7WG@<#N-.;W_L,0#2;3A\FT/Q]-QNC,QJRS
M#.PR'++F?&T0I$ L0[_E@0&K"0FS$Y*26$[&\^GD_GXT_AV-QO/A=#@SGS$Q
MPT&&X^+F089![(+2ED)D-=U@[]"-,N;MT62&\WW7(\QM'IL;!%4TO583:_[
MSN0/J#^^.S,IJEL</;XV'N09!,T'>;V#5T/4>SG_B/*G)"N 4B]AI7/I@XI\
M]ZK+[H,4F_)MD4<AI5B7ERL>+7BN!.#WI1#R[8-Z 67_PM'M?P%02P,$%
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M^A?F<YW,;QTY!Y/!:1><WMZ[%BN6/U6OH!2H.CZJWV'8W=V]YC*H7NYHW?^
M+X;URRJ-F_K=F9LPAUI:0 <LP*7UW@-)>?TZ2OVAY.OJC8Y'7I9\55TN61BS
M7!C ]PO.R]</X@&[EX+Z_P-02P,$%     @ Y5Y_5G[Q3MR,"@  [AL  !@
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M,]@W@KD M802(F\9L0@DB=1U#14R_ 0ICBCG[0!3Y\G4L1N-B-,W*8$"H,[
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M?5Q:8-1:63-G^W]NOY*) /!'#+^EM82>)2A R]\V6!L'6I _ZE1. I?&V2#
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MO(,E!_V!.(M$Q614S!(NOOR'L*5Z8B(Y^CIUG.*)7XRNHZ8[ 'L-K,4S,,!
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M=',O<VAE970Q,BYX;6R%5,ENVS 0O?LK!FK0DV&MM@/7%N M2(!LB)OT4/1
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M(Q_\*.A&@P%X<*H4;LLD)8K,M@()"=\R5?NEV6VZS;0VV;_PNE7=$9%1)J'
MC89ZO6'? 5';OUXH7EG+K;G2!K;37'=,%"9 GV\X5\>%N:#IP?%?4$L#!!0
M   ( .5>?U8R$&<*R0,  )L'   9    >&PO=V]R:W-H965T<R]S:&5E=#$S
M+GAM;)55T6[J.!!]SU>,<JNK5J(E"5!*"T@!TELD2A"![>ZC20:(;A+GVJ:T
M?[]CA[)4*I7V);'',\?GS-CC[IZ+WW*+J. MSPK9L[=*E??UNHRWF#-YPTLL
M:&7-1<X43<6F+DN!+#%!>5;W'.>VGK.TL/M=8YN)?I?O5)86.!,@=WG.Q/L
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MUO6L"4IY#S/!7U/3,ZAE0<+)>[W+Z/K'?*<K?PV7KN?6G$X+KJR% ;HX0EV
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ML5)9W[9E&&-*9)MGR/3-EHN4*+T5.UMF DE4@-+$]ASGPDX)9=9H4)PMQ&C
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MV^^V@S!V -?M?GP-7],H=/4) ZR0E2 -2]^92"C'ZG,W,JATBT9^GU.JE#3
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MK-_LDT-XP^MPA1[YE;V'WH*Q;&Z"7%#H#<9 L@BBF".<,*[DT/TLS4FVA%@
M200#LD6A%IYPFI,EPIA4/<, Z <$5(&:OP3;=#I-?!X9?1]-2TDA'XOW,%1)
M&>#*ZW6$EDLL"*<+ED24ES9ZX(<#CXPNF=;T'<GADC'4-,[F<.!+>D=5YZ'Y
MD2**W5M$SHP* <-,4IYI>Y.D$K=/<R9B*0 +!>2<146(C;S@X8(H;8]-IVVC
MIMZ<Y!2\8 ('GHC)(5S'::QD6^OKJ3$UM#>GJ#[!$KIII4<3JV5AL'903N)(
MJ_,P=@2.Z=BN<<6$)/C3[JHK ]3W(N8F3;7&+M804C1KI#PYI4]/!:+#P<MY
MG(!38J<-?C%-U'2,"PS+*C4?9AV!:W:.+2-@$EV,@6J9K::++QW3LESPPE E
MM<!<7Q)D!<I5MGWR<9SM*X%[@0>C0O(XI(6,0[36.G@^3A:D_(PL47SWE1[;
M65$ERUK 294(2%^EAPHNY3OLN(OU/@='0XR+A"K$P%T2+"A)Y$)1<9+'&C:<
MEMGL=KX3W-@RS+1<NK*/X[BHY#H*4>^V;2N]P?O%FPP,E9:]\<UD?..I&@2C
M<8!5(QACY\@?7P_[NII<#D=8LH;>-?@!=KP9C (?#GH%Q^@/EP;B,=8[E4MQ
M!K>9QB)?HMH"^BQ)"!IF;=);_^7:EB;B>$ASJ5V8%3J<40%M3W$(GU,X#U#:
M0&=0YZ1_^%0=':L(@'7"'?U,M;]-M4>9-J<9)E$"!8YA-)FV>_R=)=&S*BN%
M.ZCNCF+R3TL7/M-8:.!:;6N@U=U,6=?L=BV=L=MA+3=WVQ4$/ KBRQ4^+JE*
M0ZH.$C]T2.^C>MC'7;/9:7]GD;^S?#3-XTX+.G;7V.+TBJ3Y"5QCE-.[&.E[
M5+'>98&WU[VM7>@^)=]]9"@7W:/#[>T2:CFFBS9YJ:SRXU31+;C1E=2(,S0<
MU8AC;"..\<6(4VVDC:W3@?$_.!T8GWXZ,-3I *.FM-2N8X+"=87Q3;=515C5
ML[)S_A/<_T5P;YENT_X1H+V-&XON2LUO"-CK>_3V)J[;CMETFC_6T6@+U!]V
MHL9J)_IU\.;K;I[1D6VS=6R5'NVTN@\.WNY?@>OZ6^+7T?4__6XZ#$ 4><ZX
M!/4Q.E9GX!E5)FJU3;>E#Q7&#8VF; F3.-2B?RQA.;S7[XB;-*O5_1P-B+"I
M;*@D=!RSW6U_B]O..HQG,[0TK"I_]:D:]P:=SO$FWEB6>6Q_*_O(7?<NC8T[
MLY3RN;X9%* _;);79U5O=?GHE7=N#^3ES>4;PN<Q8E!"9SC5JG=:->#E;6#9
MD"S7-W!3)B5+]2NB.59618#C,\;DNJ$6J*YDS_\"4$L#!!0    ( .5>?U;#
M\H5R(0,  $$'   9    >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;)U5VV[;
M.!!]]U<,5*#8!03K8BEV$MN X[A(MALD&Z=;%$4?:&EL"9%(E:2JYN]W2-F*
M@]H&N@^29L@SAV<XXG#<"/FL,D0-/\N"JXF3:5U=>)Y*,BR9ZHL*.<VLA2R9
M)E=N/%5)9*D-*@LO]/TSKV0Y=Z9C._8@IV-1ZR+G^"!!U67)Y,L5%J*9.(&S
M&WC,-YDV ]YT7+$-+E%_JAXD>5['DN8E<I4+#A+7$V<67%Q%!F\!_^;8J#T;
M3"8K(9Z-<YM.'-\(P@(3;1@8?7[@'(O"$)&,[UM.IUO2!.[;._8/-G?*9<44
MSD7Q.4]U-G%&#J2X9G6A'T5S@]M\8L.7B$+9-S0M-J05DUII46Z#R2]SWG[9
MS^T^[ 6,_",!X38@M+K;A:S*:Z;9="Q% ]*@B<T8-E4;3>)R;HJRU))F<XK3
MT^73_?SCS?W?UXO'Y?MWHS 87L+BGT^W3U_&GB9^@_*2+==5RQ4>X0I"N!-<
M9PH6/,7T+8%'PCIUX4[=57B2\1J3/@P"%T(_#$_P#;IL!Y9O<(1O\;W.]0M\
MG:V4EO1#?#N49$L1':8PA^1"52S!B4.G0*'\@<[T_;O@S+\\(3#J!$:GV'^S
M'">Y#BL-XG[O^"+P0&<"I<2T1W]>\@PSU1-KH#)@N4+9E0(83XU!KLY0(C3F
M18W ]=L'N. (<U&6@O\?JF!'9,F&L1O%H>O3#Q:>^VYT1L/1$&YYKZ/[A4%E
MC-[4M=:8ZYI,MI&(U$ZT@C\(!R;ST+^$I05^> 7.7H';T9QO6E@FBA2E@BAP
MAW&K+8K<, JM&02=>2?[<$.E_RB>89X)P3<NC&+W_+R=GO6.RWNC[K@X"P@N
M_X24:4SA+\9K:JJT#^VVNK!"W2!RLR>F$!7C+W:O]Z3U=M(L9G%OY]-<4L<4
M$JA:>[$N5+54-2.!6D"3Y4EV(,LVC=1 MKE!&,24\\CU!_$;^\G4JF=KQ04<
M.CO>7ELK46YL\U:0B)KKML-UH]W],&O;XBN\O5SNF-SD7$&!:PKU^\/8 =DV
M[-;1HK)-<B4TM5QK9G3'H30 FE\+H7>.6:"[-:?_ 5!+ P04    " #E7G]6
M+N$QNDH#  #*!@  &0   'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6R555UO
MVDH0??>O&+E1E4@AQC;Y* $D!TB*1 !AIU5U=1\6,V"K]JZ[NP[)O^^L#91*
M!*DO]NY\G#UGQCON;(3\J1)$#6]YQE773K0NVHZCX@1SIJY$@9P\*R%SIFDK
MUXXJ)+)EE91GCM=LWC@Y2[G=ZU2VF>QU1*FSE.-,@BKSG,GW!\S$IFN[]LXP
M3]>)-@:GURG8&D/4+\5,TL[9HRS3'+E*!0>)JZX=N.V'EHFO KZEN%$':S!*
M%D+\-)O1LFLW#2',,-8&@='K%?N890:(:/S:8MK[(TWBX7J'_EAI)RT+IK O
MLN_I4B==^\Z&):Y8F>FYV'S%K9YK@Q>+3%5/V-2Q_K4-<:FTR+?)Q"!/>?UF
M;]LZ'"3<-3](\+8)7L6[/JAB.6":]3I2;$"::$(SBTIJE4WD4FZ:$FI)WI3R
M=&\RG33ZTTDTGX['H\D3C";1<#X,HXZC"=W$./$6Z:%&\CY <CUX%EPG"H9\
MB<N_ 1RBM>?F[;@]>"<1!QA?@>]>@M?TO!-X_EZK7^'Y'VD5/":&4F3D6<.(
M:Y2H-/P7+)26]'W\?TQUC=DZCFGN3%L5+,:N39="H7Q%N_?YDWO3O#_!N+5G
MW#J%_D_=.8ETG*=[<V5]= 1$"5I]D1>,OW_^=.>YM_<*N."-PQ*FNQ*24:5*
M*Q KT G"B@+$AD+:$/:_#@<OXR%,'X$.@V.'64&520W'?('2--TR33>==ZU!
M^ .^T[WEJ%3;FK%TV4@YQ*Q(-<O@#+[<5@\KB.,R+S.F<4E#1A99J>"<;F@:
MI_J"H"[]NQ:<M_P;N/@K5A!C21)RJDQBYLTKDC+:(_@>^!9]-] _IOI)"J4,
M\+7KP[E? X=C:$##BD1-;NL]V_HA> IF0RN(9E2(^6PZ#Z(1%64RC8:A%4U-
M=<+I>#0(HN$ 'D>38-(?!6,((S(\#R=1".?]4DKD\;N%;Z:5BA10.5YX:K2$
MFB0I&!!5)DF^:9W7O'\)SZJ5>W]Q"?@68Z&I1Q)X6=6;:J\21F 7<.RK=0[F
M2XYR74U1114KN:Y'S=ZZ']1!/9_^A-=3_IG)=<H59+BBU.;5+<U%64_.>J-%
M44VKA= T^ZIE0C\;E": _"LA]&YC#MC_OGJ_ 5!+ P04    " #E7G]6S+Z^
M]F<+   )'0  &0   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6S565MSFT@6
M?N=7=&GB*:D*84!W)W&5;,D3SSBVRU(RN[6U#RUH23U!H*'!LN?7[W>Z :%$
M=F9F7W8?; 3T.7W.=^[-NUV2?E%K(3+VM(EB];ZQSK+MV>FI"M9BPY63;$6,
M-\LDW? ,M^GJ5&U3P4--M(E.?=?MGVZXC!OG[_2S^_3\79)GD8S%?<I4OMGP
M]/E"1,GN?<-KE \>Y&J=T8/3\W=;OA(SD7W:WJ>X.ZVXA'(C8B63F*5B^;XQ
M]LXNNK1>+_@LQ4[5?C/29)$D7^CF.GS?<$D@$8D@(PX<ET=Q*:*(&$&,WPN>
MC6I+(JS_+KE?:=VARX(K<9E$O\HP6[]O#!LL%$N>1]E#LOL@"GUZQ"]((J7_
MLYU9V^DT6)"K+-D4Q)!@(V-SY4\%#C6"H?L"@5\0^%INLY&6<L(S?OXN378L
MI=7@1C^TJIH:PLF8C#++4KR5H,O.KV\O[SY.V7S\C^GLW6D&CO3\-"BH+PRU
M_P*UY[./29RM%9O&H0@/&9Q"E$H>OY3GPG^5XT0$#NMX-O-=WW^%7Z?2KZ/Y
M=5[2+PZ2C6!S_L0F4@51HO)4L'^-%RI+X1'_/J:SX=@]SI&BY$QM>2#>-Q &
M2J2/HG'^XP]>WWW[BKS=2M[N:]R_:X]7J8_+Y@T<J\Z6S=?"^A3+3(1LEO%,
M*,;CD"' X<(Q U[;)!9QIEBR9 !,L86@ETP:+#/^!)*=P!-:FTH%1EB:K068
M1 AS&:_.V.SRPW3RZ6;*[JX8-K^_NYW>SF=T9X0Y;=[<S68M=C&]NGN8LKV$
M%L)-,WL6/%5,D&<Q^(78+$1*OF&1;Y"#>!;9];<<(H121[EBRS39G%DW2< C
M]N,/0]_SWK)#9=^PYJ#3MT?=/FOI&[=O]WLCUJ*--00EW4<>\6<E.6L.^UU[
M,.J"H.G9+FXZ7O<(P8<D7K%?Z%^S/[0[AJ#O@7_7W2^WV;=B'UU_<Q1\DMFS
M^P/7]CI=HX)O=X8#N^]U<$O678A8+&5&5FENT^11ZAP*/JU#(P;86JKLN_:[
M?[C[?#V[OKMEL-7?--5EGJ;PJC.KS8QUWK"VEMVW?;<';=NLA+/IN?:H[VNT
M70#?H=<3L13@$.X9M%F[1N3U;-<;:%K/'X#@H@;"_2L@O&%=V^WU-*R= :P[
M*% 4RZ7014.CGL)Y0*C5W8I4)J%B.LABPD\J_0+W* <EFAOY1#^+W0!13"MC
M]LA!GBO-]M -LC7/&-]NHV?&V2)->&BE/%Z)&IM2%N60D.P2(<CC9QW"$C&K
M\H62H42!-<Q0ODO)RVV#)(^S5 IU=A@9=LWAL5F4AW $=L,7.8];%FVP]V\C
M*/P2^_T&E%B6%' 6$!WJA8>[M0S6].JYE,G6#+@JO*X2QRH"%3J/-T ZX&R\
MXEMAC>?WT#?=)J F6^ZXTJB8)P9;VEO3$_FM>.0A-]BH U'7!LB([U1IK<,L
M4=M\)[,US%'M8U7N@$6^Q^">U^@OPE"25#8QTXGI,L],:OTY62@VQLX2J96R
M)6>K*%G A66<P;QR$0EDVEV;$ Q+0S<IJ_CNVY^N;^;7^K?WMD52VP664(EK
M+0!%(-(,+1@D6K;5FA(&N1OLIRPR5,SVSEQ*[KE.[X3B0?,P$=SLN2=H:L+<
M]$P%,H$)7<0W2B8$/-3_I%4BM.5I)J$5A%#H)XGUT#TI*XN&+4 $PTT==ETF
M'!.]^PA3S.LXG@_10+Y&4R52#2E4VLDH0CYD<<(^.3-G;Q%-SI>9,-FHMBFK
M;4KN9E%P21$ZE#>L,G4=R5RZ ='6H^RE)2AC36?[P5M5[5'%'&**A3*$@!E;
M(?UHV2@ZR]BEJ-&5L^:+LWQ!P+$K#1#MJ"U.DCML_-/X?FH<_^[A_NYA/*<L
M?'LWG\ZL^1T>WL[N;JXGX_ETPJZN;\>WE]?C&S:;X\%'76^;)N\&SY9XHG2E
M3)@<.OL$ :C-7[C<I]F;TN%L)IX"L376C',-#\RNU@!3M=@WS443(LT+A"8M
M-E865G\/6),0RDSQ:C "25(HI"R9)D\2C;E MGS#/+O30_9V7=;W77WUASU]
M]3KF_D]8_-#02.=M*ALZM<!_EN@@X=Y8YQH'/*@CI%(HX(-HTPL"M._!%WC$
MHPP%M5CH3=A/J1 Q1+<N^59F8$<9C;(@KU4/(IYM9=Q&*-']9+:3Z 70S3J5
M]QD3$&!:H!?=ZM"EJ&Z,]YO95EW?/;A%,M,IJJ8C? @#F;'(&U:4[LX(?YYO
M]]TAZ_?0NPR9NR\EEVLJ8,HJLJXI)^PB5T!)Z;0(>+)GW1-1CFS>7(SG8WC6
M:.06B8[R_(K_(3(R!&D3\ U5-+"L/(>2X,\\SJGP:5MZ(\Q)<4@1&&CU$)S6
MU]6BD :,%+BHY;.6L8@""FND9YW2>"EF*G[/92HVU" 7,4+DO^<\DB!?%@T1
M0@WMBC#$]7S987ZW*&>S7/<1*;L!:]3460A<UJ%M7K.9,W7&Y4.M]J\87@UH
MR ?7Z#O2F!=6^I!$5*U5N=[1M765/ K=="R,8@>V+&J?55F*MOAFU;Y]E#2%
MJRVY%_0X#-F*!](W0B3((XTPLATQU#DWX%3EJNZ%[%5487IA%9M6^!4=%DW<
M(:T53VA4":5(K*2*N"FUDD  UEDA"JFPI<%.!B8T2HEU 4F6#A)+6%2)VF@X
M-CJ56MB6,'PEN;I.VE\[SAXTP)PK6!])J!9]G.6Q7*+0P-PG;,_N$%SM%/#Q
MZ 6'4;:N">LDDB&VT^J)1V&JFG@2FZUV_0U_IK*X0JN8&;0"P-9>/+?I2AC*
MHENL/)%P5AM(K7EN4!_S#5/R#Y!7T<*:IH9!-6O_\$4D=!.PY3)L2Q+ )#>@
M^O"1^7;/-3D8'7J__-DSU[];(O8^]W))&/@=O0>&/7T=C,R>PY$I%1WSN.L.
M3<7PS&/J<RW=Y^X;SZ/QQIH??FDA?C>R& )J+K!OEC%]+"FCSP]ZMP#Y>[4/
M$J2:+,^2M&H6JCZM[_3^[_L FJ>JX1)N2+D@%9@_ SB_F9TB/=0U#R1JU6 Q
M::,H(U^W8D=FM:]3B8PQCI#78CR&'(<3[O3J:GHYO_Y</XA@0'GZ5T9<W1,<
M"@R7<EQV4ERLSSS*3;GBA 6/ T$3L#-BK1.,GP,L:IU8$[D\4CSJL6:8=C3/
M>W0<G YLT&@8.C#U')\11QJA?6>@V?LM:_HM3*[3H94]O<@B"K(5W]"0N#_@
M.7OY#79P7/!?"#)MV2%8551"[C$Y[LT%*MOLQF:SZ=B4,WI:#9+4,Q>3!SG'
MUT&NY159GL8.AGZH9T&?ET1]Z0WK.WXI:!%EJ : 8R_EAU]J73K)5!2H5P12
M;[4Z?6?PUT"P-0*V)I[,_KDO[W\+$PNZZ?^]H\&&@4P/+-G:9!O,+:A/ 2_P
MV9_XZ8*]6J5B1=X1%J<N9L)2FDNQJ#IYH">'T3297DT?'I"**(K&L]ET/K/&
MFO"%R)E\N\V9=2O*XPM=]^DP+.!IJINL'4]U2)L^'*WHL&N/>B-*^CVD_+[W
MYZ@K**D"^'X?+>W ]MS^?TE] RN>L<=CP=X?=6QOV*.SK<[0M3TZ;3I4/Y)\
M(2.TWP(83 22=2 -FS9"K6?W!MU72&P60_3B;*U<C31?'!#H?F*;*&E**7E*
M:4=AY*4NGZ-"Y24)JY/43X9T<DVR(D\535YY;J [,Z$RTY()U$R2KK5OZ'3S
M)X)U#*+(HNDN4W;1C7!]2D\K\IBJ!'R5.I/B6%.1AR0$"I[IKJ,\SMDKYASQ
MMU=&^FIJ7_-',['7 ^1 B..X?'4:5[ S\?\"%II^^9WJ<BCS__YYP+%/(*>U
MSU.P\TI_A"N.(<V7JNII]9UO;#YO[9>;CX0?T3))F#<22Y"ZSJ#78*GY\&9N
MLF2K/W8MDBQ+-OKG6G D>5J ]\L$#EO<T ;5U\_S_P!02P,$%     @ Y5Y_
M5F8>,#HN!@  2 X  !D   !X;"]W;W)K<VAE971S+W-H965T,C0N>&ULI5=;
M;^.V$G[7KQBXVR(!#-N2XR3=7 #'R7:#-A?$WIZ'H@^T-+;8E4@M2=GQOS\?
M*=NQMTFP!^?%IBC.-]]<-3Q?:O/5YLR.GLM"V8M6[ESUL=NU:<ZEL!U=L<*;
MF3:E<'@T\ZZM#(LL")5%-^GUCKNED*IU>1[V'LWEN:Y=(14_&K)U60JSNN)"
M+R]:<6NS\23GN?,;W<OS2LQYS.Y+]6CPU-VB9+)D9:569'AVT1K&'Z^._/EP
MX$_)2[NS)F_)5.NO_N$VNVCU/"$N.'4>0>!OP2,N"@\$&M_6F*VM2B^XN]Z@
M?PJVPY:IL#S2Q7]DYO*+UFF+,IZ)NG!/>OF9U_8,/%ZJ"QM^:=F<[0]:E-;6
MZ7(M# :E5,V_>%[[84?@M/>&0+(62 +O1E%@>2V<N#PW>DG&GP::7P13@S3(
M2>6#,G8&;R7DW.7HX7YT<S]Y&DYN'^[']/")GF['OX_/NP[@_D@W70-=-4#)
M&T!Q0G=:N=S2C<HXVP?H@M666K*A=I6\BWC-:8?Z<9N27I*\@]??FMH/>/TW
M\)ZD_6I)J(R^J)2-0\8ZR9;^&DZM,TB/OU^SNL$\>AW3E\Q'6XF4+UJH"<MF
MP:W+7WZ*CWMG[S ^VC(^>@_]?PG.NT"OTXQ/.]$;&NA '$9WXA]MUCG(QA*J
M('(YTXH%GMA'F1 C+J=LMG$*_L4"CTIOA5%\J:Z5@P3Z",6]3H^&-M*S?P.T
M:88R):DRN9!9+8H=!OLHHJJ,?I:H3"Y6=)( \V"ZH;T /_T=Z;<XM\GEAGDK
M\YZ:0;_3IR3IQ)3$6!V=^)]!)Z$_I2!!@31@L$!.R6GM6X_'9QKILA)J!?1O
MM30 3_KM?K]'\$7<( :P-]WRXQR/CCO']',[2@:=4_HY"A'I=W[%$L@[5'[Y
MZ32)3\XL.>W@YZDH! J#<&B-;JD2*S$MN(W^:RL.';18=6@T&=)]#0-3AH6I
M*"P=#*T4AS3.%%WE61N^,%P(3S!MM+5?.$>O<#[Y/^AUX#5ZQ6OXU6KCLW_E
M8.]%XP]H.$@/(Q KI0W?HYMG?!8M>W(T%@46UYN(A_# YV.GTZ_8_-$D]%1M
M@,I>H-X--.JH3_$)0GN0@1V22CHR:'/T22J8(D41206L&I]1\'"Y<%1IAP>\
M H"MI_\@JGOY"8.LG"LY0UR50_3@$H7^Z#,Y>#G=T8.W%F2I,N!D)"#] 6'S
M[T,2O=(@/M @[K?C04*#P5'[]/@(:1JWX],32GX=M$^.X_?,$(9?-T6_11!
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M6^XH%B@,O 1YSHG;E@ZA0M$@>QJHN/I!<1B9@LQ1;V/?T#:DV[3^#9&Y0'>
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M$N@,8GC;:UQLMWS'AQ!V(-T0V+'8!(@+2!XZ!#:1@OJSD@.WBKYIKU_<C*@
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M3F!=LGAJCRM-%]>F3LG(VJMT"G()32O4EID-,9D,F'X)<B?*/9',& X[G57
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MVD*"F+>!Z7ES_JB@JTTG8#JC5, 6L61I#O< I-'!87@XZ(M(O(B+:+'(T;4
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M /+4.?>MM:S-JB)\U;[#K<$1GVIAM-@D1L2SW1ICJZ'9ITPE<)(3"0T.V!G
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MFR*AJ3?M-J-AB-(XT'TJA-X9)D W7H,_4$L#!!0    ( .5>?U:%09@\80(
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MB>I\XFK*9/S==(=ZV:,&KZ#Z =R*6A<*%G6&V=\ +E$\\ SV/"^#DXC7F%[
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MDYZQKPR>*&[EP1Q,)FO.G\TBB$>68P+"#"-E&(@>7G"*66:(=!B_=YQ6X](
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ML@'D7TII=H8]8/\#:/T%4$L#!!0    ( .5>?U9P)P?.U 4  ",/   9
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MOSH"?BXWW'4$LH6@ 56=#DU8G.+D!?UU1^(%X7^WL0;%]%7B@TCQDESVU&5
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M76MX\8)'L2!9FK_RL&!2LCC_J,ZI@'"]@?K^F3'YNJ KJ%ZS&?T+4$L#!!0
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MLGU8PEY)X0[8- HV#?U,7<\Y"8C<0Z ^C5.<O*"'+=46F=;P7#IEFGDEF1V
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MU_CJQO>,0;'CGL):[HR1">6!\^]F,HIZCF<800*A,A!$_SS"+22)0=(\?FQ
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M'PZB;&#+B>)9T30^<*5;T&(8ZZ8?A-F@KR\Y5]N)<5#]C=#_!5!+ P04
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MY]3G,"N#[NBWU3\1',EU?JNAO!NQ4%%HH,HBW9+4X_:=0T;1?%-H=4TKE^Y
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M"0X)STY0OR\9DR]?L@#E6WK3_P-02P,$%     @ Y5Y_5FPA"+8F!0  [!4
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M1KMLQUD;:%&[B; 4VLP7MRS-%P"D33#GA1!Z&]@"_3<E_0U02P,$%     @
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M.8VRN(V<K_$&WYQ#AE_4GI<">31$0\B8(%)4E:I@:E8SZ;-\)3(<0-]0AU4
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M0C<^7K3&8B)9EG>71R95K\J'L?J: *X#U/N(,;F?Z 3E]XG[%U!+ P04
M" #E7G]6J4(>]K\#  #4$   &0   'AL+W=O<FMS:&5E=',O<VAE970U.2YX
M;6RU6&UOXC@0_BM6[G3:E;I-G)"W'B!U@6HK]84K[9Y.I_M@PE"B3>*L[4#W
MWY\=:" 0K&45OA [F7G\S/BQ/::[HNP;7P (])8F&>\9"R'R*]/DT0)2PB]I
M#IG\,J<L)4)VV:O)<P9D5CJEB6E;EF>F),Z,?K=\-V;]+BU$$F<P9H@7:4K8
MC\^0T%7/P,;[BZ?X=2'4"[/?S<DK3$"\Y&,F>V:%,HM3R'A,,\1@WC.N\=4
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ME8;@EU=Z<*"]P._8^PNGP<JVPZ!9H&%%*]32NBE8%HN"03DO-_&;:G.M,K6
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MRD!^GU,JWCOJ8EO]D='_'U!+ P04    " #E7G]6G,_.]FL"  "K!0  &0
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M0=D O%]):?:&3=#LY_@/4$L#!!0    ( .5>?U:EKL:)CP(  %8&   9
M>&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;*U574_;,!3]*U8V32 !^2ZL2R.5
MMD EQA IV\.T!S>Y;2V<.+.=ANW7SW9"5"!%/.RE\;7O.?><F_HFJAE_$!L
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M!+Z1W.H.=[J'X8N,8TS/(0K.(.R$X0%!HW^'!R_(B=HV1HXO.L)W+4164<:
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M2T?B6?%L%1U!L[SRKZF0[TC>C.1+#TP%R/F04O'248])]=_!_0-02P,$%
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MRG/.\@HS[PB:9#77D@I9P67-0!;EP-0$^7Y%J7CNJ#*N+//M?U!+ P04
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M*+T,"%:=2!NH[Q=,_43+;_0"Q0'T^"=02P,$%     @ Y5Y_5L2MMX#4 @
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MIL+SXF8K.I)E^>6P8%)=-7DS5C\#P'6 FE\Q)@\=?=^4OQ?A7U!+ P04
M" #E7G]698_T4?H"  "="   &0   'AL+W=O<FMS:&5E=',O<VAE970W,RYX
M;6RM5FMOFS 4_2L6FZI6:LLSAK9)I+RZ5LM+I=GCHPLW"2O@S'8>^_>S@; D
M)=DF]0OXFGN.S['A7NIKRE[Y'$"@31*GO*'-A5C<ZCH/YI 0?DT7D,HG4\H2
M(F3(9CI?,"!A!DIBW3(,K"<D2K5F/9L;LV:=+D4<I3!FB"^3A+!?;8CINJ&9
MVG;B*9K-A9K0F_4%F8$/8K(8,QGI)4L8)9#RB*:(P;2AM<S;CJ?RLX0O$:SY
MSA@I)R^4OJK@,6QHAA($,01",1!Y6T$'XE@121D_"TZM7%(!=\=;]OO,N_3R
M0CAT:/PU"L6\H7D:"F%*EK%XHNL'*/S4%%] 8YY=T3K/=65RL.2")@58*DBB
M-+^33;$/.P 3'P%8!< Z!#A' '8!L#.CN;+,5I<(TJPSND9,94LV-<CV)D-+
M-U&J3M$73#Z-)$XT_<Y#KSOI]]#H'G5&@_%HV!L^^RIZ',JXIY_W1[Y_@=J]
M^]%3KYA$SZUOZ+P+@D0QOT!7:.)WT?G'B[HNI"1%K ?%\NU\>>O(\J:%!C05
M<XYZ:0CA/H$NO92&K*VAMG62L0O!-;+-2V09EE4AJ//O</.$'+O<7SOC<X[P
M]6E 8G3VP;-,\PY-TDA B'Q!!/"JW<K):AF9^@!7S2O7QC<.KNNK71-5>0;&
MM9LR;T^M4ZIU_J*6<_0"LC@ BM* )H $V50)S7GPK@ 3NX9I.P=**Q(MVW.Q
M:5=+K952:R>E#EK]UG?_L54E[B12U<5;OB !-#19^#BP%6C-LP\F-NZJWI=W
M(MLSB4N3^*1)6:ED'4HOT3/9H!]+%O$PRLI?Y<N#WVZUAQWWYO!(*O), SNV
MZ50?B5NJ=4^J?1@-/Z'/\E(E[B3T?\_DG<CV7'JE2^\=S\1[^Z%BSWYS)%5I
M)L:.<7 B^DZE3X#-L@;(44"7J<AK9#E;]MA6UEH.YMNR]^:M\@]-WK@'A,VB
ME*,8II+2N':E*I8WPSP0=)'UDQ<J9'?*AG/Y_P!,)<CG4TK%-E +E'\DS=]0
M2P,$%     @ Y5Y_5N'6,V[J @  4PD  !D   !X;"]W;W)K<VAE971S+W-H
M965T-S0N>&ULK59K;]HP%/TK5C9-K32:%TF 0:3RJ(K4%@1KMZ]N<@-1$YO9
M!KI_/]N!C$=@6]<OQ';N.?<<<YWK]IJR%SX'$.@USPCO&',A%BW3Y-$<<LRO
MZ *(?)-0EF,AIVQF\@4#'&M0GIF.9?EFCE-BA&V]-F9AFRY%EA(8,\27>8[9
MSRYD=-TQ;&.[,$EG<Z$6S+"]P#.8@GA<C)F<F25+G.9 >$H)8I!TC&N[U6NJ
M>!WPE,*:[XR1<O),Z8N:#...82E!D$$D% .6CQ7T(,L4D93Q8\-IE"D5<'>\
M9;_1WJ679\RA1[-O:2SF':-AH!@2O,S$A*YO8>/'4WP1S;C^1>LBU@L,%"VY
MH/D&+!7D*2F>^'6S#SL VS\!<#8 YQ!0/P%P-P!7&RV4:5M]+'#89G2-F(J6
M;&J@]T:CI9N4J']Q*IA\FTJ<"*>]VT'_\6Z 1C=H/!D]#:?#T0.Z&4W0\*$W
MNA^@K]??T44?!$XS?HEJZ'':1Q<?+]NFD-D5AQEM,G6+3,Z)3+:#[BD1<XX&
M)(9XG\"4LDOMSE9[USG+V(?H"KGV9^18CE,AJ/?W</N,'+?<2E?SN2?X>DO&
M@(A6U=84R'HU4IW4%E_@"#J&/(H<V J,\-,'V[>^5-EZ)[(]D_729/T<>UA#
M=S3"697'L\!J6:C*7L'C:1[U$5J%-<=Q+*]MKBJ$>Z5P[P_"Y;&7AYI422^@
M_FY*VVKZ3IFR4%895@_<$]+\4II_MG#ZD( LG;BR<OSWK)QW(MMS&90N@[=6
MSEG@/U3.__/L.6N4SAIO+ZW&4<W8GF4'!Y5U'"4KRW:"ZL)JEL*:9X5U@4"2
M"D03=#%F=)7JWBM;_R5*241S0 *_ J^2W3PZA'7+\PY4'P?5;#>P_$/9YDY_
MRH'-=-OF**)+(HK/?;E:W@RN=4,\6._*&T/1X'_3%->->\QF*>$H@T126E>!
M5,6*%EY,!%WH+OA,A>RI>CB7MQY@*D"^3R@5VXE*4-ZCPE]02P,$%     @
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M;8"9GPJA7SKV%5&\&MM_ %!+ P04    " #E7G]6&JM[ZRP+  #6;   &0
M 'AL+W=O<FMS:&5E=',O<VAE970W."YX;6SMG>]SFS@:Q]_GK]!XMSOI3&J#
MP+_:)#/9(+3I)6VG2>]N9^=>$%N.F6+P 6Z2F_OC3P)B+)LH9N>;-S?;%ZDQ
MTN<1/ ]ZQ-=('-\GZ?=L+D1.'A91G)UTYGF^?-_K99.Y6 19-UF*6.Z9)>DB
MR.5F>M?+EJD(ID6E1=2CEC7H+8(P[IP>%]]]24^/DU4>A;'XDI)LM5@$Z>.O
M(DKN3SIVY^F+K^'=/%=?]$Z/E\&=N!;YM^675&[UUI1IN!!Q%B8Q2<7LI'-F
MO^?N6%4H2OP]%/?9QF>B#N4V2;ZKC8OI2<=2+1*1F.0*$<C_?HAS$46*)-OQ
M[PK:6=M4%3<_/]']XN#EP=P&F3A/HG^$TWQ^TAEUR%3,@E64?TWN?Q/5 ?45
M;Y)$6?&7W)=E!VZ'3%99GBRJRK(%BS N_P\>JA.Q4<%^K@*M*M"M"B/KF0I.
M5<'9MX);57"W*E#Z3(5^5:&_7<%YIL*@JC#8U\*PJC LG%6>W<(U7I 'I\=I
M<D]255K2U(?"OT5MZ9$P5J%XG:=R;RCKY:<7G\X_7S%R<_9/=DT./9$'8921
M3T&:!BI&WA[W<FE%E>U-*N)Y2:3/$&U*KI(XGV>$Q5,QU0$]V;QU&^E3&W^E
M1N+'(.X2BQX1:MGCI@:9JWMBTB6.K:I32KY=>^3PYZ;C\MI@KG[_2@Z_7C5Q
MV/X<V] <']0<OC_':FZ.YC1G'5A.P76>X7Y>"A5"\1VY3+*,G,N(>I0]YWV0
M3C/RQZ4L32YRL<C^U=#D7TNTVXQ6O?/[;!E,Q$E'=K^92'^(SNDO/]D#ZT-3
M="!A'A+&D# ?">,@F!8Y[CIR7!/]]"9X(#)X)B+.93)L"@]C_;;A4<+&!4PE
M[A^G5I?:Q[T?FV[?IQ#;IY"/;#L'P30W]==NZK_H)GF%"YGXLTD:+M7(HLE9
M1DI;9YF;="&'-M-IJ%IR1/*Y.%!M/%_E&0GB*?F8W&;D;)*3<+%,,C$E ;F+
MDML@(J&,M/@NO(T$D4.S=WGP(/>&\219"'+XRT\C2JT/_.+RYJ+X;']X2V21
M(W(_#R=S$DJZVB9R8#41J4R@,4EFLW?9/$D%$4$:RTXP.PARV0@B9C-1#+[*
M4Y?,B&UU^V^([!D+QJ,LGY'#OO5&GM;IJARNR5+R8.1H($WE-4%$+,=OLH'Y
MDP/D?FJ_>2M'#OE<MF49I'DHCTHV(I-C684>684).2Z+#U2U22KD:<JZY*)$
M5_MJI#PHV^G:5#9-5I_+\9Q(BU,J#^D^C")R*TB<D&_=ZRZ9).DR*6JIZL$L
M%VD!W3!*-HR2(!4'P7(9A6+:;>IB__+Q_[V/&;)3\)$P#H)I7>I@W:4.C+%=
MCYDB-6::;(Z9FKI6(ZUMUXJ$>4@80\)\)(R7L/Y&QG=L.K!&ZYROA<%P'09#
M8QAX8B9D-U!>_3^":!64=^V1[+B">-(X)#(2VX;"<.>P!F/''O6W!D5(FVS7
MIC.R[,%P:_B$M,E!,,W)H[631R_DL2+U*!>+AZ6(,R'[VUC,PKS)O4966_>6
ML,'&J7[G6OUM[R)-LEV3MC.T=KR+M,E!,,V[X[5WQ_M[-UB$<7D)2S\'41Z*
M<K BAR0RUV;Y4P T.=YHIJWCQSO7F+7E=*0Y-MYQNC/>BC(?:9"#8)K';:M6
MTJS]N^T@D^.RC"0M,[K91%M_0VD>E,8JVF9T#/H#=[05'U"C'$73(V1#:[6A
M$4)2=7^@[F(6R2IN3 QFBZT#!DGSH#16T0R]EP\UR%$T/5AH'2S4&"QL?1OY
M=,?6Z'\CI+7_2YJZ3#8T+,MRMM+$GN78"X=XV.\.K3>-XC?TN#B*IKNREL)M
MHUYZ2BTZ(G]<B<6M2!OU;G/]UEZ$*MY0&H/2?"B-HVAZE-2RM^V^WB\F-E03
MA](\*(U!:3Z4QE$T/8)J1=XV:Z-M]2,SKG70]'<2]'!LR7_;R0-IE4%I/I3&
M430]'&HUT3;+B3+MC,UI!RH@0FD>E,:@-!]*XRB:'B6UV&@/7S'M0'5'*,V#
MTAB4YD-I'$73(ZA6,FVSE-DZ[4#53'M76QR-APUI!RIH0FD^E,91-#T<:NG3
M-FN?U'(L<]J!BII0F@>E,2C-A](XBJ8_TE>KI=1ZO;1#H3(IE.9!:0Q*\Z$T
MCJ+I$52KJ=2LIK9-.V9<ZZ"Q=W_=&.QF':A1!J7Y4!I'T?1HJ.52:M82OWVZ
MN&$>N;XYNV'7C>Z'*J50F@>E,2C-A](XBJ9'2:W$TE=\*IE"55HHS8/2&)3F
M0VD<1=,CJ%9IJ5'#:Y]UH,)L1=,?I.@WW.U S;**ICT11'>E/1]JE:-HNJ=K
M-96:U=0_\QB6&=G:V[N**AWU&YP-550KFAYC3<Z&:J4HFN[L6BNE9JWT,KA=
M!;'QMM5,:.U;J%H*I3$HS8?2.(JFQTFMEM)75$LI5"V%TCPHC4%I/I3&430]
M@FJUE)K5TI>G-U6 K8E$KM[]GIO-M'8_5!V%TGPHC:-HNOMK=92:U=']'NNI
M('H(;#]><VXVU3H$H-(GE.9#:1Q%TR?&UM*G8WY0].KL\NSWZXNS)L>;J[9-
M$5":!Z4Q*,V'TCB*I@=(K6PZ]NL-,ARHS FE>5 :@])\*(VC:'H$U6JH8U9#
M7QYDF &MPX0VY"M[:WJ'MU<I!FV9#Z5Q%$UWZ\::"N8'2=N*3V9<:R<[.W*$
M/:3.KAX!-<LJVJ8>,79W?VKQH58YBJ9[NI89';/,^&?$)S.RM;=W-3_7&C4X
M&ZHT.KL")[5W]4T?:I6C:+JS:Z71>6E.>]-LL:.75E8P4UO[^X7E'N;U'4LQ
MWSQ;R& LYK$MQ#1<+4@6_D?&JSR291"K*6Z'=R*6W544/1[47ZH9]]54<C4!
MCEP%4?"8A4$YL7T9A--W\MM)L SS8GH[^7I%Z%'?LHYD#*AYZI'(LK?%W/5A
M-:5>S6T/TRQ710=5P4.Y(U@NT^0A7$A3T2/YV>X7N]X>/%52\_")4&L4$4],
M"MVO7E!''9=:H.>H;)@JGPJUM)?J?&]EH^4U2&Z%VBJ7$@CRHA!UWQ2GJ'%E
M@[].\6N?8@:])GPHC:-H>B]32]R.6>+^(CU/-CS_7^G-QFX%JG-#:1Z4QJ T
MOZ+9=#-WJ5]KMI,71]G5 Z'6L!WS^@)GU?HI,@:66S&1Y<GD.\F64?,T=#.X
M=6CLSOFW^PT3!JIRVHD=-)Q7!FV>#Z5Q%$WW>:TZ.V;5^;?/GSCYF_S3Z%;H
M [E0F@>E,2C-A](XBJ9'2"U,.^-7%)V@C_1":1Z4QJ T'TKC*)J^;%^M:[MF
M77N/A?N@ZG9%VYJ%; ^V5S+9LQR#MLZ'TCB*IKNV5J1=\[.VU[FZ)U$C]LMD
M(L<)'U=IF$W#<NTRTT,39FYKCT/5:"B-06D^E,91-#UZ:C7:I:^76ERH4 VE
M>5 :@])\*(VC:'H$U<*W:Q:^]T@M4*F[HKVT*NP^I1BT93Z4QE$TW:T;*_V:
M56Z_6CI2N?=LE<^3-,P?S?D$JG%#:1Z4QJ T'TKC*)H>-K5>[O9?,9] 57,H
MS8/2&)3F0VD<1=,CJ-9"7;,6ND<^@:J@%4W/%,[.C<H^I1BT93Z4QE$TW:VU
MLNF^L')JLA!9'D[:)!2HI FE>5 :@])\*(VC:'K<U.JH.WK%A )53Z$T#TIC
M4)H/I7$438^@6CUU6RSX^N)ROF98ZY"!RJ50&G-WUYREE%K;R\!"C7(4K8R%
MWL;;E18BO2M>G)61B5J2LWR)T?K;]<NYSHI74FU]?VZ_9^4KMFI,^<:OJR"]
M"^.,1&(FD59W*,]76KY$J]S(DV7Q#J?;),^31?%Q+H*I2%4!N7^6)/G3AC*P
M?I79Z?\ 4$L#!!0    ( .5>?U;KSZ]3<P8  +(P   9    >&PO=V]R:W-H
M965T<R]S:&5E=#<Y+GAM;,6;76_;-A2&_PKA#4,+;+%(RE]98B!QVBW8F@1Q
MVUT4NU!D)A8BB1I)VRVP'S]*ED53E;E(.&YO&ELF7YZ7.D=Z1*IG&RZ>Y9(Q
MA3XG<2K/>TNELM-^7X9+E@3RA&<LU;\\<I$$2G\53WV9"18LBDY)W">>-^PG
M093VIF?%L3LQ/>,K%4<INQ-(KI(D$%\N6<PWYSW<VQVXCYZ6*C_0GYYEP1.;
M,_4ANQ/Z6[]2640)2V7$4R38XWGO I_._%'>H6CQ,6(;N?<9Y58>.'_.OUPO
MSGM>'A&+6:ARB4#_6;,9B^-<2<?Q3RG:J\;,.^Y_WJF_+<QK,P^!9#,>_Q4M
MU/*\-^ZA!7L,5K&ZYYO?66EHD.N%/);%OVA3MO5Z*%Q)Q9.RLXX@B=+MW^!S
M.1%['?#P0 =2=B#U#OZ!#K3L0 NCV\@*6U>!"J9G@F^0R%MKM?Q#,3=%;^TF
M2O/3.%="_QKI?FHZN[V9O;EY?W_Q_OKV9HYNWZ+[Z_D?<_3JBJD@BB6Z"80(
M\JE^C7Y!'^97Z-6/K\_Z2@^="_3#<IC+[3#DP#"8H'<\54N)WJ0+MK %^CKF
M*G"R"_R2.!6O6'B"*/X9$8^0AH!F+^^.'>'0:AYIH4</S2-/0Y:J?*IT<MY'
M\AE]^E.W0=>*)?+OIAG;"OK-@GGYGLHL"-EY3]>G9&+->M.??L!#[]<FMT!B
MEG>_\NZ[U/5<9EQ&2C:9W/8<%#WS2\IZ.L 4#_096^^'W]!LX(^'?M7,"FQ0
M!39X26!(7^U0E,J5"/1):HIR\-7PA&(\'M6B;&@V&8R&N#G*817ET!WE?!-)
MB:Y3G9&?WK'D@8G&?'&JM,T7(#'+\*@R/(*NE1&D=R QR_NX\CYVGNP[P3,N
M<N-!C/@CXIN4";F,,IV@BNGQ% K2!5IS%:5/*.,;)M"2Q8NF27&.U'92MF+8
MVTMN[\3SO /)/:G\3D"2VZG2U@N0F&48>^:.ZD&G=ZD(9!]*S?:_1Q38?<JC
M=;1@.HGE,A"LN/B&/$GT7&B:"9\;_3L56_O?J@VMRSFE7G,F8V*,$:>Q&XYF
M!9'IFMSE,OH7W;,U2U?:J. )TB=?G_E0:8Q32]/\DJ7A4G/R\W['ZM>FC''4
MBCO,UK,%I&9/JN$F# Y.&)2<H-1L_X:=L!N>+/\ROR6(? XR)O+#^DFJ<0:V
MFA/K8HUKM/(_C>QX#5)A-U.]U8\"^G*^R(M\I>]ANR26^YE]$89\E2JI:R-D
MT3IXB!E(XCM#:WWB@=3LB334AX?@B0^*@%!JMG\#@=C)61T3?]20TZ/ZTX1[
MY*[.#.)A-^-]U#<_?=.[3>VDYYKMM,O?.%_( O+F>N0H9,TWA_DJR^*H0XV
M4B&4FCV3!A[Q!+Q&0$D22LU>XC H29RHUJU&2LT:R@\HK55)<SM_1)MO$<0
M('$#X#?+?]WLI<\7[I#;I@64FCW!!D0)@2X+ LJ,4&JV?\.,Q,ED'<N"-J4[
M(75L:FYWN"P,Z1$WZ367185*=\&7.B=UO0>X VE]LH'4[&DSP$D&X,D.RHE0
M:K9_PXG$O3S8+=F'C4D\'-:3_1@,2 P#$C<#EB7Q?L._ RFY8VN=)<=@3F*8
MDXS!JP24%*'4;/^&%(E[G;%;E4Q>>$MH;.?O[6+8>T:&[ZB;[YKS_QBW!'<@
MK7>;CK'"2 U@4@R^V0;*?U!JMG_#?]2]$-DIV4O->K(/QK5D=X_=U=O>/JJ;
M[78EL13L>SP^NZ-KG2?'6%NDACBI#UXGH.@(I6;[-^A(W6N5W>IDT%@GN/[X
M[!Z[JS>#A=2-A8?JY"@W#]!U1R@U>^(,<U+PW6<*2HI0:K9_0XK4O3K9K2@:
MMX<)G=2+XA@42 T%4C<%ED5Q['( 76*$4K-?W3$(ZH/O5ON@+ FE9OLW+.F[
M%RL[E4.I:6]#^/77A=PC=W5F*-%W4V*^T/1M"L(=2.N$. : ^@9 ?? -:1\4
M&J'4;/][+_,=84/:_WJON?X0[1ZVJRW#@KZ;!?-JF <QD^@JDDI$#RME%\8W
M>L!PA]DZ5XX!H;Z!4!]\#]L'94DH-=N_84G_"'O8I6:-I;!7?\ XT&XTJ:TZ
M]??>_DZ8>"I>BI>HN,QOWZ>NCE8OWE\4KYO7CE_BT]GV]7DCLWV;_UT@GB)M
M,&:/6M([&>FT$]L7Y+=?%,^*=\P?N%(\*3XN6;!@(F^@?W_D7.V^Y -4_TUA
M^A]02P,$%     @ Y5Y_5@7V8\3P @  7PH  !D   !X;"]W;W)K<VAE971S
M+W-H965T.# N>&ULK99=;]HP%(;_BI5-4RNMY).D91"I)52M5%I4VNUBVH4)
M![#JQ)EMH/WWLY,T@Q*R=N(FL9/SOL?GB>VXNV;\22P )'I.:"IZQD+*K&.:
M(EY @D6+99"J-S/&$RQ5E\]-D7' TUR44-.Q+-],,$F-L)L_&_&PRY:2DA1&
M'(EEDF#^<@&4K7N&;;P^N"?SA=0/S+";X3F,03YF(ZYZ9N4R)0FD@K 4<9CU
MC'.[$P4Z/@_X3F M-MI(5S)A[$EWKJ<]P](# @JQU Y8W5;0!TJUD1K&[]+3
MJ%)JX6;[U?TRKUW5,L$"^HS^(%.YZ!FG!IK"#"^IO&?K*RCK:6N_F%&17]&Z
MB&T[!HJ70K*D%*L1)"0M[OBYY+ AL+T] J<4..\5N*7 ?:_ *P5>3J8H)><0
M88G#+F=KQ'6T<M.-'&:N5N635'_VL>3J+5$Z&8[[5X/H\6: [B[1S>!\/$#]
MN^'P^F$XN'T8HZ,()"94'*,3]#B.T-'GXZXI55HM-N,RQ461PMF3(H*XA5S[
M*W(LQZF1]YOEMVS50E8AMVOD4;/\+I;[Y*9B50%S*F!.[N?N\>NS)"%237PI
M$$ZGJ,]22=(YI#$!@2(B8LK$D@/Z>3X1DJMY_:L.69'$JT^BUWI'9#B&GJ$6
MLP"^ B/\\LGVK6]U  ]I%AW(; NN6\%UF]Q#]8W<.EJ%JIVK]$:V"D\]V_.[
MYFH30Z/W1S$<R&P+@U=A\!HQ/"Q ;>$S";P.1J.V?F2H;M;\A\]^7 <RV\+5
MKG"UFW$QB2FBH+9_E.&7?&W6@2M<_'_,HL9<'\5R(+,M+'Z%Q6_$<@-"=!!)
MU30"(>N ^#M 3FS//7L#I#'+1X$<R&P+2% !"1J!C+1E*M$*TR4@-BNG#"5X
M0BB1:O^N@Q3L[CU.8 5O(.U&V=:I[VU'1;M19T'PUZJHRMSXF^NCUQ#S.4F%
M&NU,R:Q6H/2\.,X4'<FR_ <_85(=%_+F0IT @>L ]7[&F'SMZ#-#=:8,_P!0
M2P,$%     @ Y5Y_5LG#:,1R!0  AB@  !D   !X;"]W;W)K<VAE971S+W-H
M965T.#$N>&ULM9IK;^(X%(;_BL6N5C/2E,0!$N@"4DLN6ZG0JK2['T;[P24&
MHLF%=0R4?[_.A4 @N&3W3#^47/P^/LE[<)R#^]N(_8B7E'+T$?AA/&@L.5_=
M*DH\6]* Q,UH14-Q9AZQ@'"QRQ9*O&*4N*DH\!5-574E(%[8&/;38\]LV(_6
MW/="^LQ0O X"PG;WU(^V@P9N[ ^\>(LE3PXHP_Z*+.B4\K?5,Q-[2D%QO8"&
ML1>%B-'YH'&';QW<2P1IBS\]NHV/ME%R*>]1]"/9>7 '#36)B/ITQA,$$1\;
M.J*^GY!$'/_DT$;19R(\WM[3[?3BQ<6\DYB.(O\OS^7+0:/;0"Z=D[7/7Z+M
M'S2_H$["FT5^G/Y'VZRMKC;0;!WS*,C%(H+ "[-/\I'?B".!X%0+M%R@G0J,
M"X)6+FB="MH7!.U<T+Y6T,D%G6L%>B[0KQ48N<!(S<KN;FJ-23@9]EFT12QI
M+6C)1NIOJA:.>&&2BE/.Q%E/Z/AP]#0>/[R.K<GK%-U-3#1ZFKP^3!QK,GJP
MINB+23GQ_!A-"&,D29JOZ :]34WTY=>O?86+ !*,,LL[&V6=:1<ZPQH:1R%?
MQL@*7>J6 8J(O A?VX=_KTF)8[)#+?P-::J&J^*1JTTZ:^[E6H7<O%Y>U;LE
MET^B31.IE^6V7/XTXU*Y(Y??K5@A5R5.M(I$:J6\U@7>"XTY6\_XFGGA HVB
MF",2ND@<IFQ#T?='T1X]<!K$?U<$>Y_!V]7P9#R^C5=D1@<-,>"FQ,;PMU^P
MKOY>Y3HDS(2$69 P&Q+F ,%*N=,N<J<MHP^?5C09743>^%0\5I#OD7?/]_BN
M*E.DJ+J9DL$Z*2QY:F^&7<U0C;ZR.4X!R"ZM\RZQVM7;Y2[M\U8]PSB)RP&*
MJ^19I_"L4\LS.I_3=%J!O)!3T1]'XCRM<E *KNL@),R$A%D9#*M''JI-M=,Y
M<?JZ9@Y0:"6O]<)K7>KU8^;PQ\I++!<32&%P4.6L'+-_6">/G%:5EU)Y72\A
M818DS(:$.4"P4EX815X84D-?J+O.WBB\$+T\O2$2QY3'Z8-_/X9[-*[*%.-L
M?&MI';6<\R-I[W7S 1)F0<)L2)@#!"OE0[?(A^X5X\2EP4&JK3OL0\),2)@E
MOT4:VE'"JKX2]G\5.D#AERSO%9;WKIP&L.2E_R::WZQ%#F0#05462'%ULR"#
MZ<?3-XQ;K9/I6^]LK-%:AH&[Y6;6>;.JB=EYJXJ)&=!%EAS!ZN&57JTU-5N1
M74##:CODJ+I^Y+1C0SKZZ6P:M$L+E&:#TAPH6CD/CDH[N$X>?$MF<#2,*^?D
M<E3M/,#GWZ6>VFF?I4)%.Z/7T;63KR9H=#8HS8&BE4W6#B9K4I-?&?'"M.1"
MD_<N]'U,@W?**HLL<E1MDR%I)BC- J79H#0'BE9.F$.=#O_40AT&K=2!TDQ0
MF@5*LT%I#A2MG$.'>AV6%^RN+@A\PKE;+YKRDH <4#M!0"MYH#0;E.9 T<H)
M<B@.8GEU\&[Z*'\2@=8 06DF*,T"I=F@- >*5DZ20U41ZS_U20191QN!TDQ0
MF@5*LT%I#A2MG$.'"B26ER!K_70D9]7.&-#R)"C- J79H#0'G]=^VSU5_!4O
M?>5<.%0?L;Q$]C]^DLK)G_T*,Y)'4-MST,(C*,T&I3F?W]^RYX?R([ZV_IC7
M.+;IXB/J(K(19Q84,1KD;\B^M#PM[ZCVX" /6T=!MA &MY%+=E6E.1,T( N4
M9H/2'"A:ED/*T6JH@+)%NM M1K-H'?)L95%QM%A,=Y<N(3LY/L*W9K8D[H#)
M5NB-"5MX82PR:BZ0:M,0@QG+%KUE.SQ:I6NNWB/.HR#=7%+B4I8T$.?G4<3W
M.TD'Q=+#X;]02P,$%     @ Y5Y_5JM+T*M" P  [!,   T   !X;"]S='EL
M97,N>&ULW5AM3]LP$/XKD1G3D";2-B,THZVT54*:-"8T^+!OR&V<UI)C9X[+
M6G[]?'::ON!#C ];62H:WSV^YQ[[+L0PJ,U*L)LY8R9:ED+60S(WIOH8Q_5T
MSDI:GZJ*28L42I?46%//XKK2C.8U!)4B[G4Z:5Q2+LEH(!?E96GJ:*H6T@Q)
MVKHB?_N2#TDW_4 B3S=6.1N2NW=O?RZ4N7@3^?O1^Z.CSMW)Q;[_G0-.2!PD
M/7L&Z6G'7BBS0S'Z]'GT3Y%CU.>[U&[ZL27R@<=86#\09K-L(L' @K/P<KY?
M(35H@:TBQ$VU1X-"R4W1$^(=-B\M671/Q9",J> 3S2&JH"47*^_N@6.JA-*1
ML=UFA73!4S]XN.LM:,2&I^12:9?;9_#?DV;Z'K"V0" 7HA78(]XQ&E34&*;E
MI37<9.=\!$7-^'95684S35?=WAG9!+B;33)1.F>Z3=,E:]=H(%@!<C2?S>%N
M5!4#:(PJ[2#G=*8D=1K6$<W TDZ9$#?PE/XH=KB7Q59%.U!/V0ZMH&;H:;P!
M_-MLGGN;-GD1;U3Q>V4^+^QRI+.A4]BU9@5?.GM9M (P]B[.3JM*K#X)/I,E
M\XM_=L+1@*[CHKG2_,%F@U:96@?3)+IGVO#IMN>7IM4M6YIU.RT+7'/O%6K^
MN_L\8Y)I*K9%V]X_Y%U^L>+FM?8O-+M?*_N*@R*3\\/7V+S*#UUD^AI$OHIR
M]P]?9)(=OL;F4'=P(N/FD+%UDMDYQ[3>",Z+0_(-SJ5BDS2:++@P7#;6G.<Y
MDX^.,Y;>T(G]4V:'W\[/64$7PMRVX)!LQE<LYXLR:V==PT8TLS;CK["\;MH>
M5FTN+G.V9/FX,?5LXH:1'=BLS04!^\BEN\((%N.Q, (8E@=3@,7X*"S/_[2>
M/KH>CV':^D&DC\;TT1@?%4+&[H/E"<=D]@JO-,N2)$VQ'1V/@PK&V+ZE*?R$
MV3!M$('E@4Q_MM=XM?$.>;H/L)H^U2'82O%.Q%:*[S4@X7V#B"P+5QO+ Q%8
M%;#>@?SA/-!3X9@D@:IBVK G&$>R#$.@%\,]FJ;([J3P"=<'>TJ2),O""&!A
M!4F"(? TX@BF #1@2)*X]^#>^RA>OZ?BS?_W1K\!4$L#!!0    ( .5>?U:7
MBKL<P    !,"   +    7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E
M\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!
M2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/
M06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3
MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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MZCV,GX<RW'J^UGC][Z1ZO)Q;;I>_+K]V3F["%>?ZOF)X_@M02P,$%     @
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( .5>?U9!NKKY[P   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( .5>
M?U:97)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ Y5Y_5CDP B=&!P  E2\  !@
M ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( .5>
M?U9VT8?T3@@  'PD   8              " @8H/  !X;"]W;W)K<VAE971S
M+W-H965T,BYX;6Q02P$"% ,4    " #E7G]6U(?E*&\#   Y#   &
M        @($.&   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%
M  @ Y5Y_5GV.<G;F!@  3AL  !@              ("!LQL  'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( .5>?U:FJ%JMG@4  .\>   8
M              " @<\B  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"
M% ,4    " #E7G]6_GE*Z>D'   @)   &               @(&C*   >&PO
M=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ Y5Y_5G[Q3MR,"@
M[AL  !@              ("!PC   'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;%!+ 0(4 Q0    ( .5>?U868P!;FRD   ."   8              " @80[
M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #E7G]6>F5^
M]C8%  "T"P  &               @(%590  >&PO=V]R:W-H965T<R]S:&5E
M=#DN>&UL4$L! A0#%     @ Y5Y_5MRD7H!T P  [P8  !D
M ("!P6H  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " #E
M7G]6?_U!+F@"  !;!0  &0              @(%L;@  >&PO=V]R:W-H965T
M<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( .5>?U8%(ENFCP(  (\%   9
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M970Q-BYX;6Q02P$"% ,4    " #E7G]64FXP#[\"  !J!@  &0
M    @(&&@P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (
M .5>?U86[$'HP@(  !T&   9              " @7R&  !X;"]W;W)K<VAE
M971S+W-H965T,3@N>&UL4$L! A0#%     @ Y5Y_5O\GYY/= P  OP<  !D
M             ("!=8D  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"
M% ,4    " #E7G]6<UF%LF &  ">'0  &0              @(&)C0  >&PO
M=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( .5>?U;#\H5R(0,
M $$'   9              " @2"4  !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&UL4$L! A0#%     @ Y5Y_5B[A,;I* P  R@8  !D              ("!
M>)<  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #E7G]6
MS+Z^]F<+   )'0  &0              @('YF@  >&PO=V]R:W-H965T<R]S
M:&5E=#(S+GAM;%!+ 0(4 Q0    ( .5>?U9F'C Z+@8  $@.   9
M      " @9>F  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%
M  @ Y5Y_5D\D8!Y'"0  .14  !D              ("!_*P  'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " #E7G]6P*"!G'T"  "0!0
M&0              @(%ZM@  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+
M 0(4 Q0    ( .5>?U;2(5V5_2L  $J4   9              " @2ZY  !X
M;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ Y5Y_5CP47FH_
M!   G@D  !D              ("!8N4  'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6Q02P$"% ,4    " #E7G]6CNTF3R4&  !I#@  &0
M@('8Z0  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( .5>
M?U8]#2)NIP,  #$(   9              " @33P  !X;"]W;W)K<VAE971S
M+W-H965T,S N>&UL4$L! A0#%     @ Y5Y_5@0E0_AN @  :@4  !D
M         ("!$O0  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
M    " #E7G]6A4&8/&$"   U!0  &0              @(&W]@  >&PO=V]R
M:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( .5>?U:&<IKS;P,  +H'
M   9              " @4_Y  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL
M4$L! A0#%     @ Y5Y_5HILR>T1 P  4 8  !D              ("!]?P
M 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #E7G]6ODF=
M2K,"  "Y!0  &0              @($]  $ >&PO=V]R:W-H965T<R]S:&5E
M=#,U+GAM;%!+ 0(4 Q0    ( .5>?U:XC#UZZ0(  $$&   9
M  " @2<# 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @
MY5Y_5LD -TB9 @  #P8  !D              ("!1P8! 'AL+W=O<FMS:&5E
M=',O<VAE970S-RYX;6Q02P$"% ,4    " #E7G]67+WKPVP"  !9!0  &0
M            @($7"0$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4
M Q0    ( .5>?U9+TAG_W (   P&   9              " @;H+ 0!X;"]W
M;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ Y5Y_5BLRWQU:!@
MF1P  !D              ("!S0X! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX
M;6Q02P$"% ,4    " #E7G]6+4Z9F]D"   ,!@  &0              @(%>
M%0$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( .5>?U9P
M)P?.U 4  ",/   9              " @6X8 0!X;"]W;W)K<VAE971S+W-H
M965T-#(N>&UL4$L! A0#%     @ Y5Y_5A0\BLO7 @  "08  !D
M     ("!>1X! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .5>?U8L\LBZ\P8  .(T   9              "
M@>PR 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ Y5Y_
M5N<T>$5D P  U@X  !D              ("!%CH! 'AL+W=O<FMS:&5E=',O
M<VAE970T.2YX;6Q02P$"% ,4    " #E7G]6!5O05)D(  "Q-P  &0
M        @(&Q/0$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0
M   ( .5>?U9L(0BV)@4  .P5   9              " @8%& 0!X;"]W;W)K
M<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ Y5Y_5L2J>E,< @  , 0
M !D              ("!WDL! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q0
M2P$"% ,4    " #E7G]6I+A!0>P"  "6"0  &0              @($Q3@$
M>&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( .5>?U8I!%NR
M;P(  ,X&   9              " @511 0!X;"]W;W)K<VAE971S+W-H965T
M-30N>&UL4$L! A0#%     @ Y5Y_5M2(M!(I @  \@0  !D
M ("!^E,! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " #E
M7G]6""CWZG0"  !?!@  &0              @(%:5@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( .5>?U8;:#E0SP(  +\'   9
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M970V,2YX;6Q02P$"% ,4    " #E7G]6LWE7X7,"  "X!0  &0
M    @(&,: $ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    (
M .5>?U;']#ZS$0,  , (   9              " @39K 0!X;"]W;W)K<VAE
M971S+W-H965T-C,N>&UL4$L! A0#%     @ Y5Y_5N/&A**7"   @5<  !D
M             ("!?FX! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"
M% ,4    " #E7G]6PN&;6+X"  !'"   &0              @(%,=P$ >&PO
M=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( .5>?U;?DD:A'P,
M /(+   9              " @4%Z 0!X;"]W;W)K<VAE971S+W-H965T-C8N
M>&UL4$L! A0#%     @ Y5Y_5E"/:'YC @  *P8  !D              ("!
MEWT! 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    " #E7G]6
M?!@S!0<#  "^"   &0              @($Q@ $ >&PO=V]R:W-H965T<R]S
M:&5E=#8X+GAM;%!+ 0(4 Q0    ( .5>?U9VC!:PM (  *H&   9
M      " @6^# 0!X;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%
M  @ Y5Y_5HV3N>Y "P  4&$  !D              ("!6H8! 'AL+W=O<FMS
M:&5E=',O<VAE970W,"YX;6Q02P$"% ,4    " #E7G]67V07;G<$  ",%@
M&0              @('1D0$ >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+
M 0(4 Q0    ( .5>?U;$K;> U (  &H(   9              " @7^6 0!X
M;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @ Y5Y_5F6/]%'Z
M @  G0@  !D              ("!BID! 'AL+W=O<FMS:&5E=',O<VAE970W
M,RYX;6Q02P$"% ,4    " #E7G]6X=8S;NH"  !3"0  &0
M@(&[G $ >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    ( .5>
M?U;DM=MRTP,  )0+   9              " @=R? 0!X;"]W;W)K<VAE971S
M+W-H965T-S4N>&UL4$L! A0#%     @ Y5Y_5@G?W1#" @  4PD  !D
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M=#@P+GAM;%!+ 0(4 Q0    ( .5>?U;)PVC$<@4  (8H   9
M  " @5R_ 0!X;"]W;W)K<VAE971S+W-H965T.#$N>&UL4$L! A0#%     @
MY5Y_5JM+T*M" P  [!,   T              ( !!<4! 'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    " #E7G]6EXJ[',     3 @  "P              @ %R
MR $ 7W)E;',O+G)E;'-02P$"% ,4    " #E7G]6"H.LG4X&  "<-0  #P
M            @ %;R0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ Y5Y_
M5JN<,4MN @  VB\  !H              ( !UL\! 'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ Y5Y_5D3DWU@> @  ERX  !,
M         ( !?-(! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %D 60!F
)&   R]0!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>231</ContextCount>
  <ElementCount>339</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>105</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/OrganizationAndBusinessBackground</Role>
      <ShortName>ORGANIZATION AND BUSINESS BACKGROUND</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - VARIABLE INTEREST ENTITY (???VIE???)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/VariableInterestEntityVie</Role>
      <ShortName>VARIABLE INTEREST ENTITY (???VIE???)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - CASH AND CASH EQUIVALENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/CashAndCashEquivalents</Role>
      <ShortName>CASH AND CASH EQUIVALENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - ACCOUNTS RECEIVABLE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/AccountsReceivable</Role>
      <ShortName>ACCOUNTS RECEIVABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/Inventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - PREPAYMENTS AND DEPOSITS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/PrepaymentsAndDeposits</Role>
      <ShortName>PREPAYMENTS AND DEPOSITS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - PROPERTY AND EQUIPMENT, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - INTANGIBLE ASSETS, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/IntangibleAssetsNet</Role>
      <ShortName>INTANGIBLE ASSETS, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - INVESTMENT IN MARKETABLE SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/InvestmentInMarketableSecurities</Role>
      <ShortName>INVESTMENT IN MARKETABLE SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - INVESTMENT IN NON-MARKETABLE SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/InvestmentInNon-marketableSecurities</Role>
      <ShortName>INVESTMENT IN NON-MARKETABLE SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - CUSTOMER DEPOSITS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/CustomerDeposits</Role>
      <ShortName>CUSTOMER DEPOSITS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - OTHER PAYABLES AND ACCRUED LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/OtherPayablesAndAccruedLiabilities</Role>
      <ShortName>OTHER PAYABLES AND ACCRUED LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/RelatedPartyBalancesAndTransactions</Role>
      <ShortName>RELATED PARTY BALANCES AND TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - NON-CONTROLLING INTEREST</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/Non-controllingInterest</Role>
      <ShortName>NON-CONTROLLING INTEREST</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - CONCENTRATIONS OF RISKS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/ConcentrationsOfRisks</Role>
      <ShortName>CONCENTRATIONS OF RISKS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/OrganizationAndBusinessBackgroundTables</Role>
      <ShortName>ORGANIZATION AND BUSINESS BACKGROUND (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agapeatp.com/role/OrganizationAndBusinessBackground</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agapeatp.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - VARIABLE INTEREST ENTITY (???VIE???) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/VariableInterestEntityVieTables</Role>
      <ShortName>VARIABLE INTEREST ENTITY (???VIE???) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agapeatp.com/role/VariableInterestEntityVie</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - ACCOUNTS RECEIVABLE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/AccountsReceivableTables</Role>
      <ShortName>ACCOUNTS RECEIVABLE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agapeatp.com/role/AccountsReceivable</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/InventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agapeatp.com/role/Inventories</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - PREPAYMENTS AND DEPOSITS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/PrepaymentsAndDepositsTables</Role>
      <ShortName>PREPAYMENTS AND DEPOSITS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agapeatp.com/role/PrepaymentsAndDeposits</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agapeatp.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - INTANGIBLE ASSETS, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/IntangibleAssetsNetTables</Role>
      <ShortName>INTANGIBLE ASSETS, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agapeatp.com/role/IntangibleAssetsNet</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - INVESTMENT IN MARKETABLE SECURITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/InvestmentInMarketableSecuritiesTables</Role>
      <ShortName>INVESTMENT IN MARKETABLE SECURITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agapeatp.com/role/InvestmentInMarketableSecurities</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - INVESTMENT IN NON-MARKETABLE SECURITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesTables</Role>
      <ShortName>INVESTMENT IN NON-MARKETABLE SECURITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agapeatp.com/role/InvestmentInNon-marketableSecurities</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - CUSTOMER DEPOSITS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/CustomerDepositsTables</Role>
      <ShortName>CUSTOMER DEPOSITS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agapeatp.com/role/CustomerDeposits</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - OTHER PAYABLES AND ACCRUED LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesTables</Role>
      <ShortName>OTHER PAYABLES AND ACCRUED LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agapeatp.com/role/OtherPayablesAndAccruedLiabilities</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/RelatedPartyBalancesAndTransactionsTables</Role>
      <ShortName>RELATED PARTY BALANCES AND TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agapeatp.com/role/RelatedPartyBalancesAndTransactions</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - NON-CONTROLLING INTEREST (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/Non-controllingInterestTables</Role>
      <ShortName>NON-CONTROLLING INTEREST (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agapeatp.com/role/Non-controllingInterest</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agapeatp.com/role/IncomeTaxes</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agapeatp.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - SCHEDULE OF SUBSIDIARIES AND ASSOCIATES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails</Role>
      <ShortName>SCHEDULE OF SUBSIDIARIES AND ASSOCIATES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative</Role>
      <ShortName>ORGANIZATION AND BUSINESS BACKGROUND (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agapeatp.com/role/OrganizationAndBusinessBackgroundTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails</Role>
      <ShortName>SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetDetails</Role>
      <ShortName>SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - SCHEDULE OF DIS-AGGREGATED INFORMATION OF REVENUES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails</Role>
      <ShortName>SCHEDULE OF DIS-AGGREGATED INFORMATION OF REVENUES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails</Role>
      <ShortName>SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - SCHEDULE OF VARIABLE INTEREST ENTITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails</Role>
      <ShortName>SCHEDULE OF VARIABLE INTEREST ENTITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - VARIABLE INTEREST ENTITY (???VIE???) (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/VariableInterestEntityVieDetailsNarrative</Role>
      <ShortName>VARIABLE INTEREST ENTITY (???VIE???) (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agapeatp.com/role/VariableInterestEntityVieTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - CASH AND CASH EQUIVALENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative</Role>
      <ShortName>CASH AND CASH EQUIVALENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agapeatp.com/role/CashAndCashEquivalents</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - SCHEDULE OF ACCOUNTS RECEIVABLES - RELATED PARTY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/ScheduleOfAccountsReceivables-RelatedPartyDetails</Role>
      <ShortName>SCHEDULE OF ACCOUNTS RECEIVABLES - RELATED PARTY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - SCHEDULE OF INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/ScheduleOfInventoriesDetails</Role>
      <ShortName>SCHEDULE OF INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - INVENTORIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/InventoriesDetailsNarrative</Role>
      <ShortName>INVENTORIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agapeatp.com/role/InventoriesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND DEPOSITS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/ScheduleOfPrepaidExpensesAndDepositsDetails</Role>
      <ShortName>SCHEDULE OF PREPAID EXPENSES AND DEPOSITS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - SCHEDULE OF CHANGES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/ScheduleOfChangesInAllowanceForDoubtfulAccountsDetails</Role>
      <ShortName>SCHEDULE OF CHANGES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/PropertyAndEquipmentNetDetailsNarrative</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agapeatp.com/role/PropertyAndEquipmentNetTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS, NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/ScheduleOfIntangibleAssetsNetDetails</Role>
      <ShortName>SCHEDULE OF INTANGIBLE ASSETS, NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - INTANGIBLE ASSETS, NET (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/IntangibleAssetsNetDetailsNarrative</Role>
      <ShortName>INTANGIBLE ASSETS, NET (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agapeatp.com/role/IntangibleAssetsNetTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - SCHEDULE OF INVESTMENT IN MARKETABLE SECURITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails</Role>
      <ShortName>SCHEDULE OF INVESTMENT IN MARKETABLE SECURITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>00000064 - Disclosure - INVESTMENT IN MARKETABLE SECURITIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative</Role>
      <ShortName>INVESTMENT IN MARKETABLE SECURITIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agapeatp.com/role/InvestmentInMarketableSecuritiesTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>00000065 - Disclosure - SCHEDULE OF INVESTMENT IN NON MARKETABLE SECURITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/ScheduleOfInvestmentInNonMarketableSecuritiesDetails</Role>
      <ShortName>SCHEDULE OF INVESTMENT IN NON MARKETABLE SECURITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>00000066 - Disclosure - INVESTMENT IN NON-MARKETABLE SECURITIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative</Role>
      <ShortName>INVESTMENT IN NON-MARKETABLE SECURITIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>00000067 - Disclosure -  SCHEDULE OF CUSTOMER DEPOSITS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/ScheduleOfCustomerDepositsDetails</Role>
      <ShortName>SCHEDULE OF CUSTOMER DEPOSITS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>00000068 - Disclosure - SCHEDULE OF OTHER PAYABLES AND ACCRUED LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF OTHER PAYABLES AND ACCRUED LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>00000069 - Disclosure - OTHER PAYABLES AND ACCRUED LIABILITIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesDetailsNarrative</Role>
      <ShortName>OTHER PAYABLES AND ACCRUED LIABILITIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>00000070 - Disclosure - SCHEDULE OF RELATED PARTIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails</Role>
      <ShortName>SCHEDULE OF RELATED PARTIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>00000071 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agapeatp.com/role/StockholdersEquity</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>00000072 - Disclosure - SCHEDULE OF NON CONTROLLING INTEREST (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/ScheduleOfNonControllingInterestDetails</Role>
      <ShortName>SCHEDULE OF NON CONTROLLING INTEREST (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>00000073 - Disclosure - SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAX (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails</Role>
      <ShortName>SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAX (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>00000074 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAX (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails</Role>
      <ShortName>SCHEDULE OF PROVISION FOR INCOME TAX (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>00000075 - Disclosure - SCHEDULE OF EFFECTIVE INCOME TAX RATE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/ScheduleOfEffectiveIncomeTaxRateDetails</Role>
      <ShortName>SCHEDULE OF EFFECTIVE INCOME TAX RATE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>00000076 - Disclosure -  SCHEDULE OF EFFECTIVE INCOME TAX RATE (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/ScheduleOfEffectiveIncomeTaxRateDetailsParenthetical</Role>
      <ShortName>SCHEDULE OF EFFECTIVE INCOME TAX RATE (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>00000077 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/ScheduleOfDeferredTaxAssetsDetails</Role>
      <ShortName>SCHEDULE OF DEFERRED TAX ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>00000078 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agapeatp.com/role/IncomeTaxesTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>00000079 - Disclosure - CONCENTRATIONS OF RISKS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative</Role>
      <ShortName>CONCENTRATIONS OF RISKS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agapeatp.com/role/ConcentrationsOfRisks</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>00000080 - Disclosure - SCHEDULE OF LEASE COMMITMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/ScheduleOfLeaseCommitmentsDetails</Role>
      <ShortName>SCHEDULE OF LEASE COMMITMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>00000081 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agapeatp.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept AccountsPayableRelatedPartiesCurrent in us-gaap/2022 used in 8 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 29, 102, 103, 104, 10234, 13347, 13353, 13359</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueFromRelatedParties in us-gaap/2022 used in 10 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 98, 99, 100, 101, 13288, 13295, 13302, 13308, 13313, 13314</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesCurrentAndNoncurrent in us-gaap/2022 used in 8 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 105, 106, 107, 108, 13420, 13426, 13432, 13438</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueFromRelatedPartiesCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 10154, 10155</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept PropertyPlantAndEquipmentEstimatedUsefulLives in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 11489</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:LesseeOperatingLeaseTermOfContract -  form10-k.htm 126, 127</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="form10-k.htm">form10-k.htm</File>
    <File>aatp-20221231.xsd</File>
    <File>aatp-20221231_cal.xml</File>
    <File>aatp-20221231_def.xml</File>
    <File>aatp-20221231_lab.xml</File>
    <File>aatp-20221231_pre.xml</File>
    <File>ex31-1.htm</File>
    <File>ex32-1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-k_001.jpg</File>
    <File>form10-k_002.jpg</File>
    <File>form10-k_003.jpg</File>
    <File>form10-k_004.jpg</File>
    <File>form10-k_005.jpg</File>
    <File>form10-k_006.jpg</File>
    <File>form10-k_007.jpg</File>
    <File>form10-k_008.jpg</File>
    <File>form10-k_009.jpg</File>
    <File>form10-k_010.jpg</File>
    <File>form10-k_011.jpg</File>
    <File>form10-k_012.jpg</File>
    <File>form10-k_013.jpg</File>
    <File>form10-k_014.jpg</File>
    <File>form10-k_015.jpg</File>
    <File>form10-k_016.jpg</File>
    <File>form10-k_017.jpg</File>
    <File>form10-k_018.jpg</File>
    <File>form10-k_019.jpg</File>
    <File>form10-k_020.jpg</File>
    <File>form10-k_021.jpg</File>
    <File>form10-k_022.jpg</File>
    <File>form10-k_023.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="689">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="35">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>120
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form10-k.htm": {
   "axisCustom": 0,
   "axisStandard": 21,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 689,
    "http://xbrl.sec.gov/dei/2022": 35
   },
   "contextCount": 231,
   "dts": {
    "calculationLink": {
     "local": [
      "aatp-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "aatp-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "aatp-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "aatp-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "aatp-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 576,
   "entityCount": 1,
   "hidden": {
    "http://agapeatp.com/20221231": 26,
    "http://fasb.org/us-gaap/2022": 76,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 107
   },
   "keyCustom": 70,
   "keyStandard": 269,
   "memberCustom": 74,
   "memberStandard": 29,
   "nsprefix": "AATP",
   "nsuri": "http://agapeatp.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://agapeatp.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - CASH AND CASH EQUIVALENTS",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://agapeatp.com/role/CashAndCashEquivalents",
     "shortName": "CASH AND CASH EQUIVALENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - ACCOUNTS RECEIVABLE",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://agapeatp.com/role/AccountsReceivable",
     "shortName": "ACCOUNTS RECEIVABLE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - INVENTORIES",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://agapeatp.com/role/Inventories",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "AATP:PrepaymentsAndDepositsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - PREPAYMENTS AND DEPOSITS",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://agapeatp.com/role/PrepaymentsAndDeposits",
     "shortName": "PREPAYMENTS AND DEPOSITS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "AATP:PrepaymentsAndDepositsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - PROPERTY AND EQUIPMENT, NET",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://agapeatp.com/role/PropertyAndEquipmentNet",
     "shortName": "PROPERTY AND EQUIPMENT, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - INTANGIBLE ASSETS, NET",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://agapeatp.com/role/IntangibleAssetsNet",
     "shortName": "INTANGIBLE ASSETS, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "AATP:InvestmentInMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - INVESTMENT IN MARKETABLE SECURITIES",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://agapeatp.com/role/InvestmentInMarketableSecurities",
     "shortName": "INVESTMENT IN MARKETABLE SECURITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "AATP:InvestmentInMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "AATP:InvestmentInNonMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - INVESTMENT IN NON-MARKETABLE SECURITIES",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://agapeatp.com/role/InvestmentInNon-marketableSecurities",
     "shortName": "INVESTMENT IN NON-MARKETABLE SECURITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "AATP:InvestmentInNonMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "AATP:CustomerDepositsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - CUSTOMER DEPOSITS",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://agapeatp.com/role/CustomerDeposits",
     "shortName": "CUSTOMER DEPOSITS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "AATP:CustomerDepositsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - OTHER PAYABLES AND ACCRUED LIABILITIES",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://agapeatp.com/role/OtherPayablesAndAccruedLiabilities",
     "shortName": "OTHER PAYABLES AND ACCRUED LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://agapeatp.com/role/BalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DueFromRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://agapeatp.com/role/RelatedPartyBalancesAndTransactions",
     "shortName": "RELATED PARTY BALANCES AND TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://agapeatp.com/role/StockholdersEquity",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - NON-CONTROLLING INTEREST",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://agapeatp.com/role/Non-controllingInterest",
     "shortName": "NON-CONTROLLING INTEREST",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - INCOME TAXES",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://agapeatp.com/role/IncomeTaxes",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - CONCENTRATIONS OF RISKS",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://agapeatp.com/role/ConcentrationsOfRisks",
     "shortName": "CONCENTRATIONS OF RISKS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://agapeatp.com/role/CommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - SUBSEQUENT EVENTS",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://agapeatp.com/role/SubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "27",
     "role": "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://agapeatp.com/role/OrganizationAndBusinessBackgroundTables",
     "shortName": "ORGANIZATION AND BUSINESS BACKGROUND (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "AATP:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "AATP:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "AATP:VariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://agapeatp.com/role/BalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "AATP:VariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - VARIABLE INTEREST ENTITY (\u201cVIE\u201d) (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://agapeatp.com/role/VariableInterestEntityVieTables",
     "shortName": "VARIABLE INTEREST ENTITY (\u201cVIE\u201d) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - ACCOUNTS RECEIVABLE (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://agapeatp.com/role/AccountsReceivableTables",
     "shortName": "ACCOUNTS RECEIVABLE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - INVENTORIES (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://agapeatp.com/role/InventoriesTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "AATP:PrepaymentsAndDepositsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - PREPAYMENTS AND DEPOSITS (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://agapeatp.com/role/PrepaymentsAndDepositsTables",
     "shortName": "PREPAYMENTS AND DEPOSITS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "AATP:PrepaymentsAndDepositsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://agapeatp.com/role/PropertyAndEquipmentNetTables",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - INTANGIBLE ASSETS, NET (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://agapeatp.com/role/IntangibleAssetsNetTables",
     "shortName": "INTANGIBLE ASSETS, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "AATP:InvestmentInMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - INVESTMENT IN MARKETABLE SECURITIES (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://agapeatp.com/role/InvestmentInMarketableSecuritiesTables",
     "shortName": "INVESTMENT IN MARKETABLE SECURITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "AATP:InvestmentInMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "AATP:InvestmentInNonMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "AATP:NonMarketableSecuritiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - INVESTMENT IN NON-MARKETABLE SECURITIES (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesTables",
     "shortName": "INVESTMENT IN NON-MARKETABLE SECURITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "AATP:InvestmentInNonMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "AATP:NonMarketableSecuritiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "AATP:CustomerDepositsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "AATP:CustomerDepositsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - CUSTOMER DEPOSITS (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://agapeatp.com/role/CustomerDepositsTables",
     "shortName": "CUSTOMER DEPOSITS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "AATP:CustomerDepositsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "AATP:CustomerDepositsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "AATP:ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - OTHER PAYABLES AND ACCRUED LIABILITIES (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesTables",
     "shortName": "OTHER PAYABLES AND ACCRUED LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "AATP:ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://agapeatp.com/role/RelatedPartyBalancesAndTransactionsTables",
     "shortName": "RELATED PARTY BALANCES AND TRANSACTIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:MinorityInterestDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "AATP:ScheduleOfNonControllingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - NON-CONTROLLING INTEREST (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://agapeatp.com/role/Non-controllingInterestTables",
     "shortName": "NON-CONTROLLING INTEREST (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:MinorityInterestDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "AATP:ScheduleOfNonControllingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - INCOME TAXES (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://agapeatp.com/role/IncomeTaxesTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "menuCat": "Tables",
     "order": "43",
     "role": "http://agapeatp.com/role/CommitmentsAndContingenciesTables",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_custom_SubsidiaryCompanyMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "AATP:NameOftheCompany",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - SCHEDULE OF SUBSIDIARIES AND ASSOCIATES (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails",
     "shortName": "SCHEDULE OF SUBSIDIARIES AND ASSOCIATES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_custom_SubsidiaryCompanyMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "AATP:NameOftheCompany",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-05-072020-05-08_custom_ShareExchangeAgreementMember_custom_MrHowKokChoongMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesAcquisitions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND (Details Narrative)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative",
     "shortName": "ORGANIZATION AND BUSINESS BACKGROUND (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-05-072020-05-08_custom_ShareExchangeAgreementMember_custom_MrHowKokChoongMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesAcquisitions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "AATP:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MinimumMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
     "shortName": "SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "AATP:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember_srt_MinimumMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "AATP:ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetDetails",
     "shortName": "SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "AATP:ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - SCHEDULE OF DIS-AGGREGATED INFORMATION OF REVENUES (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails",
     "shortName": "SCHEDULE OF DIS-AGGREGATED INFORMATION OF REVENUES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31_custom_PeriodEndMYRMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ForeignCurrencyExchangeRateTranslation1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000049 - Disclosure - SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://agapeatp.com/role/ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails",
     "shortName": "SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31_custom_PeriodEndMYRMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ForeignCurrencyExchangeRateTranslation1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:InventoryPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "AATP:InventriesWriteDown",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000050 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "AATP:PrepaymentsAndDepositsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "AATP:AllowanceForDoubtfulAccountsReceivablesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000051 - Disclosure - SCHEDULE OF VARIABLE INTEREST ENTITY (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails",
     "shortName": "SCHEDULE OF VARIABLE INTEREST ENTITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_VariableIncomeInterestRateMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31_custom_SubsidiaryCompanyThreeMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000052 - Disclosure - VARIABLE INTEREST ENTITY (\u201cVIE\u201d) (Details Narrative)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://agapeatp.com/role/VariableInterestEntityVieDetailsNarrative",
     "shortName": "VARIABLE INTEREST ENTITY (\u201cVIE\u201d) (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000053 - Disclosure - CASH AND CASH EQUIVALENTS (Details Narrative)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative",
     "shortName": "CASH AND CASH EQUIVALENTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000054 - Disclosure - SCHEDULE OF ACCOUNTS RECEIVABLES - RELATED PARTY (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://agapeatp.com/role/ScheduleOfAccountsReceivables-RelatedPartyDetails",
     "shortName": "SCHEDULE OF ACCOUNTS RECEIVABLES - RELATED PARTY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000055 - Disclosure - SCHEDULE OF INVENTORIES (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://agapeatp.com/role/ScheduleOfInventoriesDetails",
     "shortName": "SCHEDULE OF INVENTORIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:InventoryPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "AATP:InventriesWriteDown",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000056 - Disclosure - INVENTORIES (Details Narrative)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://agapeatp.com/role/InventoriesDetailsNarrative",
     "shortName": "INVENTORIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "AATP:PrepaymentsAndDepositsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "AATP:ReceivablesFromSalesDistributors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000057 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND DEPOSITS (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://agapeatp.com/role/ScheduleOfPrepaidExpensesAndDepositsDetails",
     "shortName": "SCHEDULE OF PREPAID EXPENSES AND DEPOSITS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "AATP:PrepaymentsAndDepositsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "AATP:ReceivablesFromSalesDistributors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "AATP:PrepaymentsAndDepositsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000058 - Disclosure - SCHEDULE OF CHANGES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://agapeatp.com/role/ScheduleOfChangesInAllowanceForDoubtfulAccountsDetails",
     "shortName": "SCHEDULE OF CHANGES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "AATP:PrepaymentsAndDepositsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000059 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails",
     "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://agapeatp.com/role/StatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSoldAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000060 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://agapeatp.com/role/PropertyAndEquipmentNetDetailsNarrative",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalizedComputerSoftwareGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000061 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS, NET (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://agapeatp.com/role/ScheduleOfIntangibleAssetsNetDetails",
     "shortName": "SCHEDULE OF INTANGIBLE ASSETS, NET (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalizedComputerSoftwareGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000062 - Disclosure - INTANGIBLE ASSETS, NET (Details Narrative)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://agapeatp.com/role/IntangibleAssetsNetDetailsNarrative",
     "shortName": "INTANGIBLE ASSETS, NET (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "AATP:InvestmentInMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentOwnedAtCost",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000063 - Disclosure - SCHEDULE OF INVESTMENT IN MARKETABLE SECURITIES (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails",
     "shortName": "SCHEDULE OF INVESTMENT IN MARKETABLE SECURITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "AATP:InvestmentInMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "lang": null,
      "name": "AATP:TransferFromNonmarketableSecurity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "AATP:InvestmentInMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentOwnedAtCost",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000064 - Disclosure - INVESTMENT IN MARKETABLE SECURITIES (Details Narrative)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative",
     "shortName": "INVESTMENT IN MARKETABLE SECURITIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "AATP:InvestmentInMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-07-182022-07-19",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "AATP:InvestmentInMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentOwnedAtCost",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000065 - Disclosure - SCHEDULE OF INVESTMENT IN NON MARKETABLE SECURITIES (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://agapeatp.com/role/ScheduleOfInvestmentInNonMarketableSecuritiesDetails",
     "shortName": "SCHEDULE OF INVESTMENT IN NON MARKETABLE SECURITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "AATP:NonMarketableSecuritiesTableTextBlock",
       "AATP:InvestmentInNonMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31_custom_PhoenixPlusCorpMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:InvestmentOwnedAtCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "AATP:InvestmentInMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentOwnedAtCost",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000066 - Disclosure - INVESTMENT IN NON-MARKETABLE SECURITIES (Details Narrative)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative",
     "shortName": "INVESTMENT IN NON-MARKETABLE SECURITIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "AATP:CustomerDepositsTableTextBlock",
       "AATP:CustomerDepositsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "AATP:CustomerDeposits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000067 - Disclosure -  SCHEDULE OF CUSTOMER DEPOSITS (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://agapeatp.com/role/ScheduleOfCustomerDepositsDetails",
     "shortName": "SCHEDULE OF CUSTOMER DEPOSITS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "AATP:CustomerDepositsTableTextBlock",
       "AATP:CustomerDepositsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "AATP:CustomerDeposits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "AATP:ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000068 - Disclosure - SCHEDULE OF OTHER PAYABLES AND ACCRUED LIABILITIES (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails",
     "shortName": "SCHEDULE OF OTHER PAYABLES AND ACCRUED LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "AATP:ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "AATP:CommissionPaymentsDescriptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000069 - Disclosure - OTHER PAYABLES AND ACCRUED LIABILITIES (Details Narrative)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesDetailsNarrative",
     "shortName": "OTHER PAYABLES AND ACCRUED LIABILITIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "AATP:CommissionPaymentsDescriptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - ORGANIZATION AND BUSINESS BACKGROUND",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://agapeatp.com/role/OrganizationAndBusinessBackground",
     "shortName": "ORGANIZATION AND BUSINESS BACKGROUND",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000070 - Disclosure - SCHEDULE OF RELATED PARTIES (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails",
     "shortName": "SCHEDULE OF RELATED PARTIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000071 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://agapeatp.com/role/StockholdersEquityDetailsNarrative",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_custom_ShareForfeitureAgreementsMember",
      "decimals": "INF",
      "lang": null,
      "name": "AATP:ReductionInCommonStockOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "AATP:ScheduleOfNonControllingInterestTableTextBlock",
       "us-gaap:MinorityInterestDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "AATP:NonControllingInterestPaidinCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000072 - Disclosure - SCHEDULE OF NON CONTROLLING INTEREST (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://agapeatp.com/role/ScheduleOfNonControllingInterestDetails",
     "shortName": "SCHEDULE OF NON CONTROLLING INTEREST (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "AATP:ScheduleOfNonControllingInterestTableTextBlock",
       "us-gaap:MinorityInterestDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "AATP:NonControllingInterestPaidinCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000073 - Disclosure - SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAX (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://agapeatp.com/role/ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails",
     "shortName": "SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAX (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000074 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAX (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails",
     "shortName": "SCHEDULE OF PROVISION FOR INCOME TAX (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000075 - Disclosure - SCHEDULE OF EFFECTIVE INCOME TAX RATE (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://agapeatp.com/role/ScheduleOfEffectiveIncomeTaxRateDetails",
     "shortName": "SCHEDULE OF EFFECTIVE INCOME TAX RATE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_custom_AATPLBASLSEAAndWATPMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000076 - Disclosure -  SCHEDULE OF EFFECTIVE INCOME TAX RATE (Details) (Parenthetical)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://agapeatp.com/role/ScheduleOfEffectiveIncomeTaxRateDetailsParenthetical",
     "shortName": "SCHEDULE OF EFFECTIVE INCOME TAX RATE (Details) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-012022-12-31_custom_AATPLBASLSEAAndWATPMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000077 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://agapeatp.com/role/ScheduleOfDeferredTaxAssetsDetails",
     "shortName": "SCHEDULE OF DEFERRED TAX ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "lang": null,
      "name": "AATP:DeferredTaxLiabilitiesDepreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000078 - Disclosure - INCOME TAXES (Details Narrative)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://agapeatp.com/role/IncomeTaxesDetailsNarrative",
     "shortName": "INCOME TAXES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Deposits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000079 - Disclosure - CONCENTRATIONS OF RISKS (Details Narrative)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative",
     "shortName": "CONCENTRATIONS OF RISKS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Deposits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://agapeatp.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000080 - Disclosure - SCHEDULE OF LEASE COMMITMENTS (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://agapeatp.com/role/ScheduleOfLeaseCommitmentsDetails",
     "shortName": "SCHEDULE OF LEASE COMMITMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiability",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000081 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2021-11-01",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - VARIABLE INTEREST ENTITY (\u201cVIE\u201d)",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://agapeatp.com/role/VariableInterestEntityVie",
     "shortName": "VARIABLE INTEREST ENTITY (\u201cVIE\u201d)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 105,
   "tag": {
    "AATP_AATPHKMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AATP HK [Member]",
        "label": "AATP HK [Member]"
       }
      }
     },
     "localname": "AATPHKMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfEffectiveIncomeTaxRateDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_AATPLBASLSEAAndWATPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AATP LB, ASL, SEA and WATP [Member]",
        "label": "AATP LB, ASL, SEA and WATP [Member]"
       }
      }
     },
     "localname": "AATPLBASLSEAAndWATPMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfEffectiveIncomeTaxRateDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_AATPLBASLSEAWATPAndDSYMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AATP LB, ASL, SEA, WATP, and DSY [Member]",
        "label": "AATP LB, ASL, SEA, WATP, and DSY [Member]"
       }
      }
     },
     "localname": "AATPLBASLSEAWATPAndDSYMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfEffectiveIncomeTaxRateDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_ATPRMITOPlusMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "A T P R M I T O Plus [Member]"
       }
      }
     },
     "localname": "ATPRMITOPlusMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_AccruedPromotionExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "AATP_OtherAccountPayableAndAccruedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued promotion expenses current.",
        "label": "Promotion expenses"
       }
      }
     },
     "localname": "AccruedPromotionExpensesCurrent",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_AccruedTaxPenaltyCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "AATP_OtherAccountPayableAndAccruedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued tax penalty, current.",
        "label": "Tax penalty"
       }
      }
     },
     "localname": "AccruedTaxPenaltyCurrent",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_AgapeATPAsiaLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agape ATP (Asia) Limited (\"AATP Asia\") [Member]",
        "label": "Agape ATP (Asia) Limited (\"AATP Asia\") [Member]"
       }
      }
     },
     "localname": "AgapeATPAsiaLimitedMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_AgapeATPInternationalHoldingLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agape ATP International Holding Limited [Member]",
        "label": "Agape ATP International Holding Limited [Member]"
       }
      }
     },
     "localname": "AgapeATPInternationalHoldingLimitedMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_AgapeSuperiorLivingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ASL [Member]",
        "label": "ASL [Member]"
       }
      }
     },
     "localname": "AgapeSuperiorLivingMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_AllowanceForDoubtfulAccountsReceivableExchangeRateEffect": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance for doubtful accounts receivable exchange rate effect.",
        "label": "Exchange rate effect"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableExchangeRateEffect",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfChangesInAllowanceForDoubtfulAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_AllowanceForDoubtfulAccountsReceivablesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance for doubtful accounts,",
        "label": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivablesCurrent",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_BetaMaxxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Beta Maxx [Member]"
       }
      }
     },
     "localname": "BetaMaxxMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_CTANutriceuticalsAsiaSdnBhdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CTA Nutriceuticals Asia Sdn Bhd [Member]",
        "label": "CTA Nutriceuticals Asia Sdn Bhd [Member]"
       }
      }
     },
     "localname": "CTANutriceuticalsAsiaSdnBhdMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_CTANutriceuticalsAsiaSdnBhdOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CTA Nutriceuticals Asia Sdn Bhd One [Member]",
        "label": "CTA Nutriceuticals Asia Sdn Bhd One [Member]"
       }
      }
     },
     "localname": "CTANutriceuticalsAsiaSdnBhdOneMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_CTANutriceuticalsSdnBhdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CTA Nutriceuticals Sdn Bhd [Member]",
        "label": "CTA Nutriceuticals Sdn Bhd [Member]"
       }
      }
     },
     "localname": "CTANutriceuticalsSdnBhdMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_ChangesInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseModifications": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes in right of use asset and lease liabilities due to lease modifications.",
        "label": "Changes in right-of-use assets and lease liabilities due to lease modifications"
       }
      }
     },
     "localname": "ChangesInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseModifications",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_CommissionPaymentsDescriptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission payments descriptions.",
        "label": "Commission payments descriptions"
       }
      }
     },
     "localname": "CommissionPaymentsDescriptions",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "AATP_ComputerAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer And Office Equipment [Member]"
       }
      }
     },
     "localname": "ComputerAndOfficeEquipmentMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_ContributionsFromNoncontrollingInterestShareholders": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contributions from non controlling interest shareholders.",
        "label": "Contributions from non-controlling interest shareholders"
       }
      }
     },
     "localname": "ContributionsFromNoncontrollingInterestShareholders",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_CustomerDeposits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer deposits.",
        "label": "CustomerDeposits",
        "verboseLabel": "Customer deposits"
       }
      }
     },
     "localname": "CustomerDeposits",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfCustomerDepositsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_CustomerDepositsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF CUSTOMER DEPOSITS"
       }
      }
     },
     "localname": "CustomerDepositsTableTextBlock",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/CustomerDepositsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "AATP_CustomerDepositsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer Deposits [Text Block]",
        "label": "CUSTOMER DEPOSITS"
       }
      }
     },
     "localname": "CustomerDepositsTextBlock",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/CustomerDeposits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "AATP_DSYBeautySdnBhdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DSY Beauty Sdn Bhd [Member]",
        "label": "DSY Beauty Sdn Bhd [Member]"
       }
      }
     },
     "localname": "DSYBeautySdnBhdMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_DSYBeautySdnBhdOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DSY Beauty Sdn Bhd [Member]",
        "label": "DSY Beauty Sdn Bhd [Member] [Default Label]",
        "verboseLabel": "DSY Beauty Sdn Bhd [Member]"
       }
      }
     },
     "localname": "DSYBeautySdnBhdOneMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_DSYWellnessAndLongevityCenterSdnBhdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DSY Wellness &amp; Longevity Center Sdn Bhd [Member].",
        "label": "DSY Wellness &amp; Longevity Center Sdn Bhd [Member]"
       }
      }
     },
     "localname": "DSYWellnessAndLongevityCenterSdnBhdMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_DSYWellnessAndLongevityCenterSdnBhdThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DSY Wellness and Longevity Center Sdn Bhd (\"DSYWLC\") [Member]",
        "label": "DSY Wellness and Longevity Center Sdn Bhd (\"DSYWLC\") [Member] [Default Label]",
        "verboseLabel": "DSY Wellness and Longevity Center Sdn Bhd (\"DSYWLC\") [Member]"
       }
      }
     },
     "localname": "DSYWellnessAndLongevityCenterSdnBhdThreeMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_DSYWellnessandLongevityCenterSdnBhdTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DSY Wellness and Longevity Center Sdn Bhd (\"DSYWLC\") [Member]",
        "label": "DSY Wellness and Longevity Center Sdn Bhd (\"DSYWLC\") [Member]"
       }
      }
     },
     "localname": "DSYWellnessandLongevityCenterSdnBhdTwoMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_DSwissIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DSwiss Inc. [Member]",
        "label": "DSwiss Inc. [Member]"
       }
      }
     },
     "localname": "DSwissIncMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative",
      "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_DeferredTaxAssetsOperatingLossCarryforwardsReducedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets operating loss carryforwards reduced amount.",
        "label": "Deferred tax assets operating loss carryforwards reduced amount"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsReducedAmount",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_DeferredTaxLiabilitiesDepreciation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities, depreciation.",
        "label": "DeferredTaxLiabilitiesDepreciation",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDepreciation",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_DefinedContributionPlanPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan [Policy Text Block]",
        "label": "Defined contribution plan"
       }
      }
     },
     "localname": "DefinedContributionPlanPolicyTextBlock",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "AATP_DepositForInsurance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deposit for insurance.",
        "label": "Deposit for insurance"
       }
      }
     },
     "localname": "DepositForInsurance",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_DepositsToSupplier": {
     "auth_ref": [],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfPrepaidExpensesAndDepositsDetails": {
       "order": 2.0,
       "parentTag": "AATP_PrepaidExpensesGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deposits to supplier.",
        "label": "Deposits to suppliers"
       }
      }
     },
     "localname": "DepositsToSupplier",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfPrepaidExpensesAndDepositsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_DisclosureCustomerDepositsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Deposits",
        "verboseLabel": "Schedule Of Customer Deposits"
       }
      }
     },
     "localname": "DisclosureCustomerDepositsAbstract",
     "nsuri": "http://agapeatp.com/20221231",
     "xbrltype": "stringItemType"
    },
    "AATP_DisclosureInvestmentInMarketableSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment In Marketable Securities",
        "verboseLabel": "Schedule Of Investment In Marketable Securities"
       }
      }
     },
     "localname": "DisclosureInvestmentInMarketableSecuritiesAbstract",
     "nsuri": "http://agapeatp.com/20221231",
     "xbrltype": "stringItemType"
    },
    "AATP_DisclosureInvestmentInNonmarketableSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment In Non-marketable Securities"
       }
      }
     },
     "localname": "DisclosureInvestmentInNonmarketableSecuritiesAbstract",
     "nsuri": "http://agapeatp.com/20221231",
     "xbrltype": "stringItemType"
    },
    "AATP_DisclosurePrepaymentsAndDepositsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayments And Deposits",
        "terseLabel": "Schedule Of Changes In Allowance For Doubtful Accounts",
        "verboseLabel": "Schedule Of Prepaid Expenses And Deposits"
       }
      }
     },
     "localname": "DisclosurePrepaymentsAndDepositsAbstract",
     "nsuri": "http://agapeatp.com/20221231",
     "xbrltype": "stringItemType"
    },
    "AATP_DividendShareForCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividend share for common stock.",
        "label": "Dividend share for common stock"
       }
      }
     },
     "localname": "DividendShareForCommonStock",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "AATP_EmployeesProvidentFundMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees Provident Fund [Member]",
        "label": "Employees Provident Fund [Member]"
       }
      }
     },
     "localname": "EmployeesProvidentFundMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_EmploymentInsuranceSystemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employment Insurance System [Member]",
        "label": "Employment Insurance System [Member]"
       }
      }
     },
     "localname": "EmploymentInsuranceSystemMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_EnergetiqueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Energetique [Member]",
        "label": "Energetique [Member]"
       }
      }
     },
     "localname": "EnergetiqueMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_EnergizedMineralConcentrateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Energized Mineral Concentrate [Member]"
       }
      }
     },
     "localname": "EnergizedMineralConcentrateMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_ExchangeRateEffectOnInvestmentInMarketableSecurites": {
     "auth_ref": [],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_MarketableSecuritiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange rate effect.",
        "label": "Exchange rate effect [Default Label]",
        "verboseLabel": "Exchange rate effect"
       }
      }
     },
     "localname": "ExchangeRateEffectOnInvestmentInMarketableSecurites",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_FiveIndividualCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Individual Customers [Member]",
        "label": "Five Individual Customers [Member]"
       }
      }
     },
     "localname": "FiveIndividualCustomersMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_ForeignCurrencyExchangeRateAverage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign currency exchange rate period average.",
        "label": "Foreign currency exchange rate period average"
       }
      }
     },
     "localname": "ForeignCurrencyExchangeRateAverage",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "AATP_ForfeitedCouponIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forfeited coupon income.",
        "label": "Value of coupons"
       }
      }
     },
     "localname": "ForfeitedCouponIncome",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_GreenproCapitalCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Greenpro Capital Corp. [Member]",
        "label": "Greenpro Capital Corp. [Member]"
       }
      }
     },
     "localname": "GreenproCapitalCorpMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_HKCHoldingsSdnBhdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HKC Holdings Sdn Bhd [Member]",
        "label": "HKC Holdings Sdn Bhd [Member]"
       }
      }
     },
     "localname": "HKCHoldingsSdnBhdMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_HealthAndWellnessServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health and Wellness Services [Member]",
        "label": "Health and Wellness Services [Member]"
       }
      }
     },
     "localname": "HealthAndWellnessServicesMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails",
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_HostastaySdnBhdHostastayMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hostastay Sdn. Bhd. (\u201cHostastay\u201d) [Member]",
        "label": "Hostastay Sdn. Bhd. [Member]"
       }
      }
     },
     "localname": "HostastaySdnBhdHostastayMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_HostastaySdnBhdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hostastay Sdn. Bhd. (\u201cHostastay\u201d) [Member]",
        "label": "Hostastay Sdn. Bhd. (\u0093Hostastay\u0094) [Member]"
       }
      }
     },
     "localname": "HostastaySdnBhdMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_HowKokChoongMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "How Kok Choong [Member]",
        "label": "How Kok Choong [Member]"
       }
      }
     },
     "localname": "HowKokChoongMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_HowKokChoongTalentLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "How Kok Choong Talent Limited [Member]",
        "label": "How Kok Choong Talent Limited [Member]"
       }
      }
     },
     "localname": "HowKokChoongTalentLimitedMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_HumanResourceDevelopmentFundMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Human Resource Development Fund [Member]",
        "label": "Human Resource Development Fund [Member]"
       }
      }
     },
     "localname": "HumanResourceDevelopmentFundMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_IncreaseDecreaseInROUAssetsAndLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in ROU assets and liabilities.",
        "label": "Reduction in ROU assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInROUAssetsAndLiabilities",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_InventoryWriteOff": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory write off.",
        "label": "Inventories write off",
        "verboseLabel": "Inventory write- off"
       }
      }
     },
     "localname": "InventoryWriteOff",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/InventoriesDetailsNarrative",
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_InventriesWriteDown": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventries write down.",
        "label": "Inventories write-down",
        "verboseLabel": "Inventory write-down"
       }
      }
     },
     "localname": "InventriesWriteDown",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/InventoriesDetailsNarrative",
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_InvestmentInMarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment In Marketable Securities [Text Block]",
        "label": "INVESTMENT IN MARKETABLE SECURITIES"
       }
      }
     },
     "localname": "InvestmentInMarketableSecuritiesTextBlock",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/InvestmentInMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "AATP_InvestmentInNonMarketableSecuritiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://agapeatp.com/role/ScheduleOfInvestmentInNonMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in non-marketable securities.",
        "label": "Investment in non-marketable securities",
        "totalLabel": "Investment in non-marketable securities"
       }
      }
     },
     "localname": "InvestmentInNonMarketableSecuritiesNoncurrent",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets",
      "http://agapeatp.com/role/ScheduleOfInvestmentInNonMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_InvestmentInNonMarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment In Non Marketable Securities [Text Block]",
        "label": "INVESTMENT IN NON-MARKETABLE SECURITIES"
       }
      }
     },
     "localname": "InvestmentInNonMarketableSecuritiesTextBlock",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/InvestmentInNon-marketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "AATP_InvestmentsIncomeDividend": {
     "auth_ref": [],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_MarketableSecuritiesNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividend income .",
        "label": "Dividend income",
        "negatedLabel": "Dividend income from Greenpro Capital Corp."
       }
      }
     },
     "localname": "InvestmentsIncomeDividend",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_IonizedCalMagMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ionized Cal Mag [Member]"
       }
      }
     },
     "localname": "IonizedCalMagMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_IronMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Iron [Member]"
       }
      }
     },
     "localname": "IronMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_LabuanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Labuan [Member]",
        "label": "Labuan [Member]"
       }
      }
     },
     "localname": "LabuanMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_LeaseExpirationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease expiration term.",
        "label": "Lease expiration term"
       }
      }
     },
     "localname": "LeaseExpirationTerm",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "AATP_LesseeOperatingLeaseLiabilityPaymentsDueAfterNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfLeaseCommitmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments due after next twelve months.",
        "label": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterNextTwelveMonths",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_LipomaskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lipomask [Member]",
        "label": "Lipomask [Member]"
       }
      }
     },
     "localname": "LipomaskMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_MarketableSecuritiesUnrealizedHoldingLoss": {
     "auth_ref": [],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_MarketableSecuritiesNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized holding (loss) gain.",
        "label": "MarketableSecuritiesUnrealizedHoldingLoss",
        "negatedLabel": "Unrealized holding loss"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedHoldingLoss",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_MonthlySalary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monthly salary.",
        "label": "Monthly salary"
       }
      }
     },
     "localname": "MonthlySalary",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_MrHowKokChoongMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mr.How Kok Choong [Member]",
        "label": "Mr.How Kok Choong [Member]"
       }
      }
     },
     "localname": "MrHowKokChoongMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_NameOftheCompany": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the company name.",
        "label": "Subsidiary company name"
       }
      }
     },
     "localname": "NameOftheCompany",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "AATP_NoCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No Customer [Member].",
        "label": "No Customer [Member]"
       }
      }
     },
     "localname": "NoCustomerMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_NonControllingInterestAccumulatedDeficit": {
     "auth_ref": [],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfNonControllingInterestDetails": {
       "order": 2.0,
       "parentTag": "AATP_NonControllingInterestNonControllingInterestGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non controlling interest accumulated deficit.",
        "label": "Accumulated surplus (deficit)"
       }
      }
     },
     "localname": "NonControllingInterestAccumulatedDeficit",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfNonControllingInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_NonControllingInterestAccumulatedOtherComprehensiveIncome": {
     "auth_ref": [],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfNonControllingInterestDetails": {
       "order": 3.0,
       "parentTag": "AATP_NonControllingInterestNonControllingInterestGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non controlling interest accumulated other comprehensive income.",
        "label": "NonControllingInterestAccumulatedOtherComprehensiveIncome",
        "verboseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "NonControllingInterestAccumulatedOtherComprehensiveIncome",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfNonControllingInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_NonControllingInterestAsl": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non controlling interest ASL.",
        "label": "ASL"
       }
      }
     },
     "localname": "NonControllingInterestAsl",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfNonControllingInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_NonControllingInterestNonControllingInterestGross": {
     "auth_ref": [],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfNonControllingInterestDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Controlling interest non controlling interest gross",
        "label": "NonControllingInterestNonControllingInterestGross",
        "totalLabel": "Non Controlling interest Gross"
       }
      }
     },
     "localname": "NonControllingInterestNonControllingInterestGross",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfNonControllingInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_NonControllingInterestPaidinCapital": {
     "auth_ref": [],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfNonControllingInterestDetails": {
       "order": 1.0,
       "parentTag": "AATP_NonControllingInterestNonControllingInterestGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non controlling interest paid in capital.",
        "label": "Paid-in capital"
       }
      }
     },
     "localname": "NonControllingInterestPaidinCapital",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfNonControllingInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_NonMarketableSecuritiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Marketable Securities [Policy Text Block]",
        "label": "Investment in non-marketable equity securities"
       }
      }
     },
     "localname": "NonMarketableSecuritiesPolicyTextBlock",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "AATP_NonMarketableSecuritiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Marketable Securities [Table Text Block]",
        "label": "SCHEDULE OF INVESTMENT IN NON MARKETABLE SECURITIES"
       }
      }
     },
     "localname": "NonMarketableSecuritiesTableTextBlock",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "AATP_NoncontrollingInterestPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest [Policy Text Block]",
        "label": "Non-controlling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestPolicyTextBlock",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "AATP_OmegaBlendMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Omega Blend [Member]"
       }
      }
     },
     "localname": "OmegaBlendMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_OneSalesDistributorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Sales Distributor [Member]",
        "label": "One Sales Distributor [Member]"
       }
      }
     },
     "localname": "OneSalesDistributorMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_OneVendorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Vendor [Member]",
        "label": "One Vendor [Member]"
       }
      }
     },
     "localname": "OneVendorMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_OrganicYouthCarCleansingBarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organic Youth Car Cleansing Bar [Member]"
       }
      }
     },
     "localname": "OrganicYouthCarCleansingBarMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_OtherAccountPayableAndAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.",
        "label": "OtherAccountPayableAndAccruedLiabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OtherAccountPayableAndAccruedLiabilities",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_OtherPayablesRelatedPartyCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other payables - related party.",
        "label": "OtherPayablesRelatedPartyCurrent",
        "verboseLabel": "Other payables and accrued liabilities"
       }
      }
     },
     "localname": "OtherPayablesRelatedPartyCurrent",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_OthersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Others [Member]"
       }
      }
     },
     "localname": "OthersMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_ParticularsOfIssuedCapital": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Particulars of issued capital.",
        "label": "Particulars of issued capital"
       }
      }
     },
     "localname": "ParticularsOfIssuedCapital",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "AATP_PeriodAverageHKDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period-average HKD [Member]",
        "label": "Period-average HKD [Member]"
       }
      }
     },
     "localname": "PeriodAverageHKDMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_PeriodAverageMYRMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period Average M Y R [Member]"
       }
      }
     },
     "localname": "PeriodAverageMYRMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_PeriodEndHKDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period End H K D [Member]"
       }
      }
     },
     "localname": "PeriodEndHKDMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_PeriodEndMYRMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period End M Y R [Member]"
       }
      }
     },
     "localname": "PeriodEndMYRMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_PhoenixPlusCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phoenix Plus Corporation [Member]",
        "label": "Phoenix Plus Corporation [Member]"
       }
      }
     },
     "localname": "PhoenixPlusCorpMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative",
      "http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative",
      "http://agapeatp.com/role/ScheduleOfInvestmentInNonMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_PlaceAndDateOfIncorporation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Place and date of incorporation.",
        "label": "Place and date of incorporation"
       }
      }
     },
     "localname": "PlaceAndDateOfIncorporation",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "AATP_PreferredStockDividendIncomeStatementImpact": {
     "auth_ref": [],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.",
        "label": "Dividend income from marketable securities",
        "negatedLabel": "Dividend income from marketable securities"
       }
      }
     },
     "localname": "PreferredStockDividendIncomeStatementImpact",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows",
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_PrepaidExpensesGross": {
     "auth_ref": [],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfPrepaidExpensesAndDepositsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expenses gross.",
        "label": "Prepaid expenses gross",
        "totalLabel": "Subtotal"
       }
      }
     },
     "localname": "PrepaidExpensesGross",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfPrepaidExpensesAndDepositsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_PrepaidTaxesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Taxes [Policy Text Block]",
        "label": "Prepaid taxes"
       }
      }
     },
     "localname": "PrepaidTaxesPolicyTextBlock",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "AATP_PrepaymentsAndDepositsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayments And Deposits [Policy Text Block]",
        "label": "PrepaymentsAndDepositsPolicyTextBlock",
        "verboseLabel": "Prepayments and deposits"
       }
      }
     },
     "localname": "PrepaymentsAndDepositsPolicyTextBlock",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "AATP_PrepaymentsAndDepositsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayments and Deposits [Text Block]",
        "label": "PREPAYMENTS AND DEPOSITS"
       }
      }
     },
     "localname": "PrepaymentsAndDepositsTextBlock",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/PrepaymentsAndDeposits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "AATP_PrincipalActivities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Principal activities.",
        "label": "Principal activities"
       }
      }
     },
     "localname": "PrincipalActivities",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "AATP_ProductHealthTherapiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Health Therapies [Member]"
       }
      }
     },
     "localname": "ProductHealthTherapiesMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_ReceivablesFromSalesDistributors": {
     "auth_ref": [],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfPrepaidExpensesAndDepositsDetails": {
       "order": 1.0,
       "parentTag": "AATP_PrepaidExpensesGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivables from sales distributors.",
        "label": "Receivables from sales distributors"
       }
      }
     },
     "localname": "ReceivablesFromSalesDistributors",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfPrepaidExpensesAndDepositsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_RedboyPictureSdnBhdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redboy Picture Sdn Bhd [Member]",
        "label": "Redboy Picture Sdn Bhd [Member]"
       }
      }
     },
     "localname": "RedboyPictureSdnBhdMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_ReductionInCommonStockOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in common stock outstanding during period.",
        "label": "Reduction in outstanding shares"
       }
      }
     },
     "localname": "ReductionInCommonStockOutstanding",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "AATP_RelatedPartiesNatureDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties nature description.",
        "label": "Nature"
       }
      }
     },
     "localname": "RelatedPartiesNatureDescription",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "AATP_RelatedPartiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Parties [Policy Text Block]",
        "label": "Related parties"
       }
      }
     },
     "localname": "RelatedPartiesPolicyTextBlock",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "AATP_RelatedPartiesRelationshipsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties relationships description.",
        "label": "Relationship"
       }
      }
     },
     "localname": "RelatedPartiesRelationshipsDescription",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "AATP_RelatedPartyOtherExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party other expenses.",
        "label": "Other expenses"
       }
      }
     },
     "localname": "RelatedPartyOtherExpenses",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_RelatedPartyOtherIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party other income.",
        "label": "Other income"
       }
      }
     },
     "localname": "RelatedPartyOtherIncome",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_RelatedPartyTransactionOtherPurchasesFromRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party transaction other purchases from related party.",
        "label": "Other purchases"
       }
      }
     },
     "localname": "RelatedPartyTransactionOtherPurchasesFromRelatedParty",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_SEATechVenturesCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SEATech Ventures Corp. [Member]",
        "label": "SEATech Ventures Corp. [Member]"
       }
      }
     },
     "localname": "SEATechVenturesCorpMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_SalaryPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Salary percentage.",
        "label": "Salary percentage"
       }
      }
     },
     "localname": "SalaryPercentage",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "AATP_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Estimated Useful Lives of Intangible Assets Net [Table Text Block]",
        "label": "SCHEDULE OF ESTIMATED USEFUL LIVES OF INTANGIBLE ASSETS, NET"
       }
      }
     },
     "localname": "ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetTableTextBlock",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "AATP_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Estimated Useful Lives Of Property And Equipment [Table Text Block]",
        "label": "SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "AATP_ScheduleOfNonControllingInterestTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Non Controlling Interest [Table Text Block]",
        "label": "SCHEDULE OF NON CONTROLLING INTEREST"
       }
      }
     },
     "localname": "ScheduleOfNonControllingInterestTableTextBlock",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/Non-controllingInterestTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "AATP_ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Other Payables And Accrued Liabilities [Table Text Block]",
        "label": "SCHEDULE OF OTHER PAYABLES AND ACCRUED LIABILITIES"
       }
      }
     },
     "localname": "ScheduleOfOtherPayablesAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "AATP_ShareExchangeAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Exchange Agreement [Member]",
        "label": "Share Exchange Agreement [Member]"
       }
      }
     },
     "localname": "ShareExchangeAgreementMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_ShareForfeitureAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Forfeiture Agreements [Member]",
        "label": "Share Forfeiture Agreements [Member]"
       }
      }
     },
     "localname": "ShareForfeitureAgreementsMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_ShareholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholders [Member]",
        "label": "Shareholders [Member]"
       }
      }
     },
     "localname": "ShareholdersMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_ShippingAndHandlingPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shipping and Handling [Policy Text Block]",
        "label": "Shipping and handling"
       }
      }
     },
     "localname": "ShippingAndHandlingPolicyTextBlock",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "AATP_SocialSecurityOrganizationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Social Security Organization [Member]",
        "label": "Social Security Organization [Member]"
       }
      }
     },
     "localname": "SocialSecurityOrganizationMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_SubsidiaryCompanyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary Company Five [Member]",
        "label": "Subsidiary Company Five [Member]"
       }
      }
     },
     "localname": "SubsidiaryCompanyFiveMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative",
      "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_SubsidiaryCompanyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary Company Four [Member]",
        "label": "Subsidiary Company Four [Member]"
       }
      }
     },
     "localname": "SubsidiaryCompanyFourMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_SubsidiaryCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary Company [Member]",
        "label": "Subsidiary Company [Member]"
       }
      }
     },
     "localname": "SubsidiaryCompanyMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_SubsidiaryCompanyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary Company One [Member]",
        "label": "Subsidiary Company One [Member]"
       }
      }
     },
     "localname": "SubsidiaryCompanyOneMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_SubsidiaryCompanyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary Company Three [Member]",
        "label": "Subsidiary Company Three [Member]"
       }
      }
     },
     "localname": "SubsidiaryCompanyThreeMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails",
      "http://agapeatp.com/role/VariableInterestEntityVieDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_SubsidiaryCompanyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary Company Two [Member]",
        "label": "Subsidiary Company Two [Member]"
       }
      }
     },
     "localname": "SubsidiaryCompanyTwoMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative",
      "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_SurvivorSelectMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Survivor Select [Member]"
       }
      }
     },
     "localname": "SurvivorSelectMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_TH3TechnologySdnBhdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TH3 Technology Sdn Bhd [Member]",
        "label": "TH3 Technology Sdn Bhd [Member]"
       }
      }
     },
     "localname": "TH3TechnologySdnBhdMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_TaxRateDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax rate description.",
        "label": "Tax rate description"
       }
      }
     },
     "localname": "TaxRateDescription",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "AATP_TrainingCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Training Center [Member]",
        "label": "Training Center [Member]"
       }
      }
     },
     "localname": "TrainingCenterMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_TransferFromNonmarketableSecurity": {
     "auth_ref": [],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_MarketableSecuritiesNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfer from non marketable security.",
        "label": "TransferFromNonmarketableSecurity",
        "negatedLabel": "Transfer from non-marketable security"
       }
      }
     },
     "localname": "TransferFromNonmarketableSecurity",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_TransferToInvestmentInMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfInvestmentInNonMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "AATP_InvestmentInNonMarketableSecuritiesNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfer to investment in marketable securities.",
        "label": "TransferToInvestmentInMarketableSecurities",
        "negatedLabel": "Less: Transfer to investment in marketable securities"
       }
      }
     },
     "localname": "TransferToInvestmentInMarketableSecurities",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfInvestmentInNonMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_TrimPlusMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trim Plus [Member]"
       }
      }
     },
     "localname": "TrimPlusMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_TwoThousandThirtyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2030 [Member]",
        "label": "2030 [Member]"
       }
      }
     },
     "localname": "TwoThousandThirtyMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_TwoThousandTwentyEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2028 [Member]",
        "label": "2028 [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyEightMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_TwoThousandTwentyNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2029 [Member]",
        "label": "2029 [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyNineMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_UnexpiredProductCoupons": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unexpired product coupons.",
        "label": "Unexpired product coupons"
       }
      }
     },
     "localname": "UnexpiredProductCoupons",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfCustomerDepositsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_VariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "VIE consolidated amount of cash and cash equivalents.",
        "label": "VIE consolidated amount of cash and cash equivalents"
       }
      }
     },
     "localname": "VariableInterestEntityConsolidatedAmountOfCashAndCashEquivalents",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_VariableInterestEntityConsolidatedAmountOfOtherPayablesAndAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "VIE consolidated amount of other payables and accrued liabilities.",
        "label": "VIE consolidated amount of other payables and accrued liabilities"
       }
      }
     },
     "localname": "VariableInterestEntityConsolidatedAmountOfOtherPayablesAndAccruedLiabilities",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_VariableInterestEntityConsolidatedAmountOfPrepaidTaxes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "VIE consolidated amount of Prepaid taxes .",
        "label": "VIE consolidated amount of prepaid taxes"
       }
      }
     },
     "localname": "VariableInterestEntityConsolidatedAmountOfPrepaidTaxes",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "AATP_VegeFruitFiberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vege Fruit Fiber [Member]"
       }
      }
     },
     "localname": "VegeFruitFiberMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_VehicleMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vehicle [Member]"
       }
      }
     },
     "localname": "VehicleMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_VendorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vendor [Member]",
        "label": "Vendor [Member]"
       }
      }
     },
     "localname": "VendorMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_VendorOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vendor One [Member]",
        "label": "Vendor One [Member]"
       }
      }
     },
     "localname": "VendorOneMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_VendorThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vendor Three [Member]",
        "label": "Vendor Three [Member]"
       }
      }
     },
     "localname": "VendorThreeMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_VendorTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vendor Two [Member]",
        "label": "Vendor Two [Member]"
       }
      }
     },
     "localname": "VendorTwoMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "AATP_YoungFormulaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Young Formula [Member]"
       }
      }
     },
     "localname": "YoungFormulaMember",
     "nsuri": "http://agapeatp.com/20221231",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_HK": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "HONG KONG"
       }
      }
     },
     "localname": "HK",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesDetailsNarrative",
      "http://agapeatp.com/role/ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_MY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MALAYSIA"
       }
      }
     },
     "localname": "MY",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesDetailsNarrative",
      "http://agapeatp.com/role/ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails",
      "http://agapeatp.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesDetailsNarrative",
      "http://agapeatp.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r544",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r544",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r544",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r544",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative",
      "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative",
      "http://agapeatp.com/role/ScheduleOfInvestmentInNonMarketableSecuritiesDetails",
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative",
      "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative",
      "http://agapeatp.com/role/ScheduleOfInvestmentInNonMarketableSecuritiesDetails",
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://agapeatp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r210",
      "r393",
      "r394",
      "r397",
      "r398",
      "r429",
      "r493",
      "r586",
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfEffectiveIncomeTaxRateDetailsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r210",
      "r393",
      "r394",
      "r397",
      "r398",
      "r429",
      "r493",
      "r586",
      "r589",
      "r590"
     ],
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfEffectiveIncomeTaxRateDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative",
      "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative",
      "http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative",
      "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative",
      "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails",
      "http://agapeatp.com/role/VariableInterestEntityVieDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r257",
      "r520",
      "r594",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r354",
      "r434",
      "r467",
      "r494",
      "r495",
      "r517",
      "r523",
      "r532",
      "r591",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative",
      "http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesDetailsNarrative",
      "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r354",
      "r434",
      "r467",
      "r494",
      "r495",
      "r517",
      "r523",
      "r532",
      "r591",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative",
      "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r257",
      "r520",
      "r594",
      "r624"
     ],
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r254",
      "r440",
      "r518",
      "r530",
      "r583",
      "r584",
      "r594",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails",
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r254",
      "r440",
      "r518",
      "r530",
      "r583",
      "r584",
      "r594",
      "r623"
     ],
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails",
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r352",
      "r354",
      "r356",
      "r357",
      "r358",
      "r433",
      "r434",
      "r467",
      "r494",
      "r495",
      "r517",
      "r523",
      "r532",
      "r582",
      "r591",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative",
      "http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesDetailsNarrative",
      "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r352",
      "r354",
      "r356",
      "r357",
      "r358",
      "r433",
      "r434",
      "r467",
      "r494",
      "r495",
      "r517",
      "r523",
      "r532",
      "r582",
      "r591",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative",
      "http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesDetailsNarrative",
      "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r224",
      "r355",
      "r553",
      "r572"
     ],
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative",
      "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative",
      "http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative",
      "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative",
      "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails",
      "http://agapeatp.com/role/VariableInterestEntityVieDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r255",
      "r256",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r519",
      "r531",
      "r594"
     ],
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesDetailsNarrative",
      "http://agapeatp.com/role/ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails",
      "http://agapeatp.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r255",
      "r256",
      "r478",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r519",
      "r531",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesDetailsNarrative",
      "http://agapeatp.com/role/ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails",
      "http://agapeatp.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r224",
      "r355",
      "r553",
      "r554",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r574",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative",
      "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails",
      "http://agapeatp.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative",
      "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails",
      "http://agapeatp.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "AATP_OtherAccountPayableAndAccruedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.",
        "label": "Others"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts payable \u2013 intercompany"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableMember": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations incurred and payable to vendors for goods and services received.",
        "label": "Accounts Payable [Member]"
       }
      }
     },
     "localname": "AccountsPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Other payable \u2013 related parties"
       }
      }
     },
     "localname": "AccountsPayableOtherCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesCurrent": {
     "auth_ref": [
      "r19",
      "r138",
      "r139",
      "r568"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable \u2013 related parties",
        "verboseLabel": "Accounts payable, related parties, current"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets",
      "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r1",
      "r19"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.",
        "label": "SCHEDULE OF CHANGES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/PrepaymentsAndDepositsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r181",
      "r258",
      "r259",
      "r499"
     ],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfAccountsReceivables-RelatedPartyDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfAccountsReceivables-RelatedPartyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r258",
      "r259"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://agapeatp.com/role/ScheduleOfAccountsReceivables-RelatedPartyDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets",
      "http://agapeatp.com/role/ScheduleOfAccountsReceivables-RelatedPartyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedPayrollTaxesCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "AATP_OtherAccountPayableAndAccruedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Payroll"
       }
      }
     },
     "localname": "AccruedPayrollTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "AATP_OtherAccountPayableAndAccruedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalesCommissionCurrent": {
     "auth_ref": [
      "r22",
      "r502"
     ],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "AATP_OtherAccountPayableAndAccruedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Amounts held in eWallets"
       }
      }
     },
     "localname": "AccruedSalesCommissionCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r81",
      "r177"
     ],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r31",
      "r32",
      "r33",
      "r183",
      "r461",
      "r472",
      "r473"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r30",
      "r33",
      "r115",
      "r422",
      "r468",
      "r469",
      "r559",
      "r560",
      "r561",
      "r569",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r11",
      "r529"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r11"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Paid in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r359",
      "r360",
      "r361",
      "r569",
      "r570",
      "r571",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit": {
     "auth_ref": [
      "r86",
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.",
        "label": "Additional paid in capital stock split"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r363"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "verboseLabel": "Advertising costs"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables": {
     "auth_ref": [
      "r575"
     ],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfPrepaidExpensesAndDepositsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet.",
        "label": "Allowance for Doubtful Accounts, Premiums and Other Receivables",
        "negatedLabel": "Less: Provision for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfPrepaidExpensesAndDepositsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r184",
      "r262",
      "r268",
      "r269",
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfChangesInAllowanceForDoubtfulAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r184",
      "r262",
      "r268"
     ],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfAccountsReceivables-RelatedPartyDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts receivable, allowance for credit loss",
        "verboseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfAccountsReceivables-RelatedPartyDetails",
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in allowance for credit loss on accounts receivable.",
        "label": "Addition"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfChangesInAllowanceForDoubtfulAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Wrote-off allowance for doubtful accounts",
        "negatedLabel": "Write off"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfChangesInAllowanceForDoubtfulAccountsDetails",
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r49",
      "r70",
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Potentially dilutive securities outstanding"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StockholdersEquityDetailsNarrative",
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative",
      "http://agapeatp.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r143",
      "r155",
      "r180",
      "r206",
      "r245",
      "r248",
      "r252",
      "r266",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r306",
      "r393",
      "r397",
      "r403",
      "r529",
      "r587",
      "r588",
      "r615"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r172",
      "r187",
      "r206",
      "r266",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r306",
      "r393",
      "r397",
      "r403",
      "r529",
      "r587",
      "r588",
      "r615"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Total current assets",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets",
      "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r206",
      "r266",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r306",
      "r393",
      "r397",
      "r403",
      "r587",
      "r588",
      "r615"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total other assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER ASSETS"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r391",
      "r521",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r105",
      "r106",
      "r391",
      "r521",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r0",
      "r55",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "ORGANIZATION AND BUSINESS BACKGROUND"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/OrganizationAndBusinessBackground"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareGross": {
     "auth_ref": [
      "r626"
     ],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfIntangibleAssetsNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.",
        "label": "Computer software"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r475",
      "r476",
      "r529",
      "r555"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash in bank"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r51",
      "r175",
      "r497"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents (Included $1,609 and $17,493 in the consolidated VIE that can be used only to settle obligations of the consolidated VIE as of December 31, 2022 and 2021, respectively.)",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets",
      "http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative",
      "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.",
        "label": "CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/CashAndCashEquivalents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r46",
      "r51",
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS, end of year",
        "periodStartLabel": "CASH AND CASH EQUIVALENTS, beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r46",
      "r134"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "DECREASE IN CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommissionsExpensePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commissions incurred in relation to revenue generating activities or operations.",
        "label": "Commission expenses"
       }
      }
     },
     "localname": "CommissionsExpensePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommissionsPayableToBrokerDealersAndClearingOrganizations": {
     "auth_ref": [
      "r141"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount payable to broker-dealers or clearing organizations for executing or clearing trades or orders.",
        "label": "Comission payable"
       }
      }
     },
     "localname": "CommissionsPayableToBrokerDealersAndClearingOrganizations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r85",
      "r290",
      "r291",
      "r480",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r569",
      "r570",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative",
      "http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative",
      "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheetsParenthetical",
      "http://agapeatp.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheetsParenthetical",
      "http://agapeatp.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r10",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheetsParenthetical",
      "http://agapeatp.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r10",
      "r529"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, par value $0.0001; 1,000,000,000 shares authorized, 75,452,012 and 290,460,047 shares issued and outstanding as of December 31, 2022 and 2021, respectively."
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r34",
      "r189",
      "r191",
      "r199",
      "r457",
      "r464"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "COMPREHENSIVE LOSS ATTRIBUTABLE TO AGAPE ATP CORPORATION"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r110",
      "r111",
      "r123",
      "r189",
      "r191",
      "r198",
      "r456",
      "r463"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Less: Comprehensive income (loss) attributable to non-controlling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r109",
      "r123",
      "r189",
      "r191",
      "r197",
      "r455",
      "r462"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "TOTAL COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r524",
      "r580",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software, Intangible Asset [Member]"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r60",
      "r61",
      "r131",
      "r132",
      "r257",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r60",
      "r61",
      "r131",
      "r132",
      "r257",
      "r474",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r60",
      "r61",
      "r131",
      "r132",
      "r257",
      "r479",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "CONCENTRATIONS OF RISKS"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisks"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r60",
      "r61",
      "r131",
      "r132",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentrations of risk percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r58",
      "r60",
      "r61",
      "r62",
      "r131",
      "r133",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r60",
      "r61",
      "r131",
      "r132",
      "r257",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r112",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Principles of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetGross": {
     "auth_ref": [
      "r263",
      "r273",
      "r592",
      "r593"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time.",
        "label": "Comission payable, threshold"
       }
      }
     },
     "localname": "ContractWithCustomerAssetGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r338",
      "r339",
      "r350"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Customer deposits"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r39",
      "r440"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "negatedLabel": "COST OF REVENUE",
        "verboseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss",
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldAmortization": {
     "auth_ref": [
      "r562"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.",
        "label": "Amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsTotalMember": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of product sold and service rendered, when it serves as benchmark in concentration of risk calculation.",
        "label": "Cost of Goods and Service Benchmark [Member]"
       }
      }
     },
     "localname": "CostOfGoodsTotalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r567",
      "r601"
     ],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "negatedLabel": "- Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r567",
      "r601",
      "r603"
     ],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "negatedLabel": "- Local"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r59",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r25",
      "r87",
      "r88",
      "r89",
      "r90",
      "r135",
      "r136",
      "r137",
      "r153",
      "r210",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r413",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "verboseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCosts": {
     "auth_ref": [
      "r142",
      "r154",
      "r556"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.",
        "label": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "SCHEDULE OF PREPAID EXPENSES AND DEPOSITS"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/PrepaymentsAndDepositsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred:"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r104",
      "r567",
      "r602"
     ],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "negatedLabel": "- Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r49",
      "r104",
      "r376",
      "r382",
      "r383",
      "r567"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred tax (benefit) expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r366",
      "r367"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r567",
      "r602",
      "r603"
     ],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "negatedLabel": "- Local"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r599"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "negatedLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r102",
      "r600"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred tax assets operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "auth_ref": [
      "r102",
      "r600"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.",
        "label": "Net operating loss carry forwards in Malaysia"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r373"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred tax valuation allowance",
        "negatedLabel": "Less: valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesDetailsNarrative",
      "http://agapeatp.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined contribution plan expense"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositLiabilityCurrent": {
     "auth_ref": [
      "r22"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current portion, due within one year or one operating cycle, if longer, of deposits held other than customer deposits.",
        "label": "Total"
       }
      }
     },
     "localname": "DepositLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfCustomerDepositsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Deposits": {
     "auth_ref": [
      "r147"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.",
        "label": "Deposits"
       }
      }
     },
     "localname": "Deposits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r49",
      "r79"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/PropertyAndEquipmentNetDetailsNarrative",
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "SCHEDULE OF DIS-AGGREGATED INFORMATION OF REVENUES"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueFromRelatedParties": {
     "auth_ref": [
      "r146",
      "r161",
      "r182",
      "r298",
      "r299",
      "r300",
      "r304",
      "r305",
      "r306",
      "r426",
      "r568"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.",
        "label": "Due from related parties"
       }
      }
     },
     "localname": "DueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r182",
      "r298",
      "r299",
      "r300",
      "r304",
      "r305",
      "r306",
      "r426",
      "r500",
      "r568"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).",
        "label": "Amount due from related parties"
       }
      }
     },
     "localname": "DueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r148",
      "r160",
      "r298",
      "r299",
      "r300",
      "r304",
      "r305",
      "r306",
      "r426",
      "r568"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r200",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r225",
      "r227",
      "r230",
      "r231",
      "r232",
      "r234",
      "r401",
      "r402",
      "r458",
      "r465",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING"
       }
      }
     },
     "localname": "EarningsPerShareBasicOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r56",
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings (loss) per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r608"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesDetailsNarrative",
      "http://agapeatp.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r208",
      "r369",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "U.S. statutory rate",
        "verboseLabel": "Tax percentage"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesDetailsNarrative",
      "http://agapeatp.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r597",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r597",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Differential tax rate in Malaysia"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r597",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Tax percentage"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfEffectiveIncomeTaxRateDetailsParenthetical"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r597",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Permanent difference"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r86",
      "r169",
      "r193",
      "r194",
      "r195",
      "r211",
      "r212",
      "r213",
      "r215",
      "r221",
      "r223",
      "r236",
      "r267",
      "r337",
      "r359",
      "r360",
      "r361",
      "r378",
      "r379",
      "r400",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r422",
      "r468",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative",
      "http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative",
      "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Proportional of ownership interest and voting power held",
        "terseLabel": "Equity interest percentage",
        "verboseLabel": "Ownership interest percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative",
      "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative",
      "http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative",
      "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative",
      "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails",
      "http://agapeatp.com/role/VariableInterestEntityVieDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r129",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair value of financial instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Estimated useful lives of intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r178",
      "r280"
     ],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfIntangibleAssetsNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Less: accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r281",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r71",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r74",
      "r441"
     ],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfIntangibleAssetsNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyExchangeRateTranslation1": {
     "auth_ref": [
      "r410",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.",
        "label": "Foreign currency exchange rate, translation"
       }
      }
     },
     "localname": "ForeignCurrencyExchangeRateTranslation1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign currencies translation and transaction"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "negatedLabel": "GENERAL AND ADMINISTRATIVE"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r38",
      "r206",
      "r245",
      "r247",
      "r251",
      "r253",
      "r266",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r306",
      "r403",
      "r510",
      "r587"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross profit",
        "totalLabel": "GROSS PROFIT"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails",
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r49",
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r76",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment for long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r207",
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Local \u2013 United States"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r35",
      "r140",
      "r149",
      "r163",
      "r245",
      "r247",
      "r251",
      "r253",
      "r459",
      "r510"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Loss before income tax",
        "totalLabel": "LOSS BEFORE INCOME TAXES"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails",
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r207",
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Foreign, Tax jurisdictions"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r208",
      "r370",
      "r371",
      "r375",
      "r380",
      "r386",
      "r388",
      "r389",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationDescription": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.",
        "label": "Income tax examination, description"
       }
      }
     },
     "localname": "IncomeTaxExaminationDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement": {
     "auth_ref": [
      "r95",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.",
        "label": "Income tax description"
       }
      }
     },
     "localname": "IncomeTaxExaminationLikelihoodOfUnfavorableSettlement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r598"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.",
        "label": "Income tax examination, penalties and interest expense",
        "verboseLabel": "Income tax examination penalties and interest expense"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesDetailsNarrative",
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r209",
      "r222",
      "r223",
      "r244",
      "r368",
      "r381",
      "r387",
      "r466"
     ],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income tax expense benefit",
        "negatedLabel": "BENEFIT OF (PROVISION FOR) INCOME TAXES",
        "negatedTotalLabel": "Benefit of (Provision for) income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesDetailsNarrative",
      "http://agapeatp.com/role/ScheduleOfProvisionForIncomeTaxDetails",
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r192",
      "r364",
      "r365",
      "r371",
      "r372",
      "r374",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Accounts Payable, Related Parties",
        "verboseLabel": "Accounts payable \u2013 related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Income tax payables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r435",
      "r563"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Customer deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in related party receivables classified as other, due within one year or operating cycle, if longer.",
        "label": "Increase (Decrease) in Due from Other Related Parties, Current",
        "negatedLabel": "Amount due from related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in related party payables classified as other, due within one year or operating cycle, if longer.",
        "label": "Other payables \u2013 related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueToOtherRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r563",
      "r611"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Increase (Decrease) in Other Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.",
        "label": "Other payables and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.",
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "negatedLabel": "Prepayments and deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidTaxes": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods.",
        "label": "Increase (Decrease) in Prepaid Taxes",
        "negatedLabel": "Prepaid taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "INTANGIBLE ASSETS, NET"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/IntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r73",
      "r437",
      "r438",
      "r439",
      "r441",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r69",
      "r72"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r557"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r186",
      "r498",
      "r529"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r174",
      "r185",
      "r235",
      "r274",
      "r276",
      "r277",
      "r436",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r275"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory write-down"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r41",
      "r243"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedAtCost": {
     "auth_ref": [
      "r164"
     ],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_MarketableSecuritiesNoncurrent",
       "weight": 1.0
      },
      "http://agapeatp.com/role/ScheduleOfInvestmentInNonMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "AATP_InvestmentInNonMarketableSecuritiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of the investment.",
        "label": "Cost of investment",
        "verboseLabel": "Investment amount"
       }
      }
     },
     "localname": "InvestmentOwnedAtCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative",
      "http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative",
      "http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails",
      "http://agapeatp.com/role/ScheduleOfInvestmentInNonMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "auth_ref": [
      "r165",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance held at close of period in number of shares.",
        "label": "Shares purchased during period"
       }
      }
     },
     "localname": "InvestmentOwnedBalanceShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative",
      "http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "SCHEDULE OF LEASE COMMITMENTS"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r421"
     ],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfLeaseCommitmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r421"
     ],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfLeaseCommitmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r421"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r21",
      "r206",
      "r266",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r306",
      "r394",
      "r397",
      "r398",
      "r403",
      "r509",
      "r587",
      "r615",
      "r616"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r15",
      "r145",
      "r158",
      "r529",
      "r566",
      "r577",
      "r607"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r24",
      "r173",
      "r206",
      "r266",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r306",
      "r394",
      "r397",
      "r398",
      "r403",
      "r529",
      "r587",
      "r615",
      "r616"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Total current liabilities",
        "negatedLabel": "Current liabilities",
        "totalLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets",
      "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r206",
      "r266",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r306",
      "r394",
      "r397",
      "r398",
      "r403",
      "r587",
      "r615",
      "r616"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total Non-current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NON-CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.",
        "label": "ACCOUNTS RECEIVABLE"
       }
      }
     },
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/AccountsReceivable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Investment in marketable securities",
        "totalLabel": "Investment in marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets",
      "http://agapeatp.com/role/ScheduleOfInvestmentInMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Investment in marketable equity securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "SCHEDULE OF INVESTMENT IN MARKETABLE SECURITIES"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/InvestmentInMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Unrealized holding loss on marketable securities",
        "negatedLabel": "Unrealized holding loss on marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows",
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r28",
      "r144",
      "r157",
      "r206",
      "r266",
      "r296",
      "r299",
      "r300",
      "r301",
      "r305",
      "r306",
      "r403"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "NON-CONTROLLING INTERESTS",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets",
      "http://agapeatp.com/role/ScheduleOfNonControllingInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of noncontrolling interest which might include background information, terms of the ownership arrangement, and type and terms of equity interest owned by the noncontrolling interest holders.",
        "label": "Noncontrolling interest, description"
       }
      }
     },
     "localname": "MinorityInterestDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestDisclosureTextBlock": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "NON-CONTROLLING INTEREST"
       }
      }
     },
     "localname": "MinorityInterestDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/Non-controllingInterest"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r203"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r203"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r46",
      "r47",
      "r50"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r36",
      "r50",
      "r150",
      "r162",
      "r171",
      "r188",
      "r190",
      "r195",
      "r206",
      "r214",
      "r216",
      "r217",
      "r218",
      "r219",
      "r222",
      "r223",
      "r228",
      "r245",
      "r247",
      "r251",
      "r253",
      "r266",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r306",
      "r402",
      "r403",
      "r510",
      "r587"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "NET LOSS ATTRIBUTABLE TO AGAPE ATP CORPORATION"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails",
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r113",
      "r122",
      "r188",
      "r190",
      "r222",
      "r223",
      "r561"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "NET (INCOME) LOSS ATTRIBUTABLE TO NON-CONTROLLING INTERESTS"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r219",
      "r225",
      "r226",
      "r229",
      "r232",
      "r245",
      "r247",
      "r251",
      "r253",
      "r510"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "NET LOSS",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows",
      "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity",
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recent accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL NON-CASH FLOWS INFORMATION"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r107",
      "r337",
      "r569",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "TOTAL OTHER EXPENSES, NET"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER INCOME (EXPENSES)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "negatedTotalLabel": "TOTAL OPERATING EXPENSES"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r245",
      "r247",
      "r251",
      "r253",
      "r510"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Loss from operations",
        "totalLabel": "LOSS FROM OPERATIONS"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails",
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r609"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating lease, expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r415"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Present value of lease liabilities",
        "verboseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://agapeatp.com/role/ScheduleOfLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r416",
      "r418"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating lease payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r414"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets",
      "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r564"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Amortization of operating right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r420",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating lease effective interest rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r419",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating lease, weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.",
        "label": "Other payables and accrued liabilities ($1,090 and $1,548 are included in the consolidated VIE that are without recourse to the credit of Agape ATP Corporation as of December 31, 2022 and 2021, respectively.)"
       }
      }
     },
     "localname": "OtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r109",
      "r110",
      "r114"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "verboseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other liabilities.",
        "label": "OTHER PAYABLES AND ACCRUED LIABILITIES"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/OtherPayablesAndAccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other expenses, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Purchase of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMachineryAndEquipment": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for acquisition of machinery and equipment.",
        "label": "Payments to Acquire Machinery and Equipment",
        "negatedLabel": "Purchase of equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireMachineryAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of interest-bearing domestic time deposit liabilities to total deposit liabilities.",
        "label": "Percentage of Interest rate for time deposits"
       }
      }
     },
     "localname": "PercentageOfInterestBearingDomesticDepositsToDepositsTimeDeposits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r9",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheetsParenthetical",
      "http://agapeatp.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r9",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheetsParenthetical",
      "http://agapeatp.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheetsParenthetical",
      "http://agapeatp.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r9",
      "r529"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock, $0.0001 par value; 200,000,000 shares authorized; None issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r558"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://agapeatp.com/role/ScheduleOfPrepaidExpensesAndDepositsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepayments and deposits",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets",
      "http://agapeatp.com/role/ScheduleOfPrepaidExpensesAndDepositsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidTaxes": {
     "auth_ref": [
      "r501",
      "r511",
      "r579"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid taxes (Included $1,741 and $1,357 in the consolidated VIE that can be used only to settle obligations of the consolidated VIE as of December 31, 2022 and 2021, respectively.)",
        "verboseLabel": "Prepaid taxes"
       }
      }
     },
     "localname": "PrepaidTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets",
      "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": {
     "auth_ref": [],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.",
        "label": "Advances to related parties"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Product Information [Line Items]"
       }
      }
     },
     "localname": "ProductInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails",
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r171",
      "r188",
      "r190",
      "r202",
      "r206",
      "r214",
      "r222",
      "r223",
      "r245",
      "r247",
      "r251",
      "r253",
      "r266",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r306",
      "r392",
      "r395",
      "r396",
      "r402",
      "r403",
      "r459",
      "r510",
      "r525",
      "r526",
      "r561",
      "r587"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "NET LOSS"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r84",
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "PROPERTY AND EQUIPMENT, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/PropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property and equipment, useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r80",
      "r176"
     ],
     "calculation": {
      "http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Subtotal"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r82",
      "r159",
      "r460",
      "r529"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets",
      "http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r82",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "SCHEDULE OF PROPERTY AND EQUIPMENT, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/PropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property and equipment, estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r201",
      "r270"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Provision for doubtful accounts",
        "negatedLabel": "PROVISION FOR DOUBTFUL ACCOUNTS"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows",
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r353",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails",
      "http://agapeatp.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Purchases"
       }
      }
     },
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r353",
      "r425",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails",
      "http://agapeatp.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r423",
      "r424",
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "RELATED PARTY BALANCES AND TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/RelatedPartyBalancesAndTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r12",
      "r91",
      "r156",
      "r471",
      "r473",
      "r529"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r169",
      "r211",
      "r212",
      "r213",
      "r215",
      "r221",
      "r223",
      "r267",
      "r359",
      "r360",
      "r361",
      "r378",
      "r379",
      "r400",
      "r468",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r241",
      "r242",
      "r246",
      "r249",
      "r250",
      "r254",
      "r255",
      "r257",
      "r348",
      "r349",
      "r440"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "REVENUE",
        "terseLabel": "Operating revenues",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails",
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss",
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r257",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r351",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "verboseLabel": "Customer deposits"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r196",
      "r206",
      "r241",
      "r242",
      "r246",
      "r249",
      "r250",
      "r254",
      "r255",
      "r257",
      "r266",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r306",
      "r403",
      "r459",
      "r587"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Total revenues \u2013 products and services"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SalesCommissionsAndFees": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).",
        "label": "Commission expense",
        "negatedLabel": "COMMISSION",
        "verboseLabel": "Commission expenses"
       }
      }
     },
     "localname": "SalesCommissionsAndFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails",
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss",
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "SCHEDULE OF ACCOUNTS RECEIVABLES - RELATED PARTY"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/AccountsReceivableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "SCHEDULE OF PROVISION FOR INCOME TAX"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "SCHEDULE OF DEFERRED TAX ASSETS"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "SCHEDULE OF EFFECTIVE INCOME TAX RATE"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r71",
      "r73",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r71",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "SCHEDULE OF INTANGIBLE ASSETS, NET"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts.",
        "label": "SCHEDULE OF FOREIGN CURRENCIES TRANSLATION EXCHANGE RATES"
       }
      }
     },
     "localname": "ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAX"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r2",
      "r16",
      "r17",
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "SCHEDULE OF INVENTORIES"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.",
        "label": "Schedule of Product Information [Table]"
       }
      }
     },
     "localname": "ScheduleOfProductInformationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfDis-aggregatedInformationOfRevenuesDetails",
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://agapeatp.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r138",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfRelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "SCHEDULE OF RELATED PARTIES"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/RelatedPartyBalancesAndTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the key aspects of a subsidiary (partnership, corporation, or other entity) of the limited liability company or limited partnership.",
        "label": "SCHEDULE OF SUBSIDIARIES AND ASSOCIATES"
       }
      }
     },
     "localname": "ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/OrganizationAndBusinessBackgroundTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": {
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r119",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "SCHEDULE OF VARIABLE INTEREST ENTITY"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/VariableInterestEntityVieTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingExpense": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized in the period that are directly related to the selling and distribution of products or services.",
        "label": "Selling expenses",
        "negatedLabel": "SELLING"
       }
      }
     },
     "localname": "SellingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss",
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares issued price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative",
      "http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Shares, Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShippingAndHandlingMember": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Packing and transport of product.",
        "label": "Shipping and Handling [Member]"
       }
      }
     },
     "localname": "ShippingAndHandlingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r55",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r26",
      "r86",
      "r169",
      "r193",
      "r194",
      "r195",
      "r211",
      "r212",
      "r213",
      "r215",
      "r221",
      "r223",
      "r236",
      "r267",
      "r337",
      "r359",
      "r360",
      "r361",
      "r378",
      "r379",
      "r400",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r422",
      "r468",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative",
      "http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative",
      "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative",
      "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative",
      "http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative",
      "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative",
      "http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesDetailsNarrative",
      "http://agapeatp.com/role/ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails",
      "http://agapeatp.com/role/ScheduleOfDeferredTaxAssetsDetails",
      "http://agapeatp.com/role/ScheduleOfEffectiveIncomeTaxRateDetailsParenthetical",
      "http://agapeatp.com/role/ScheduleOfInvestmentInNonMarketableSecuritiesDetails",
      "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails",
      "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity",
      "http://agapeatp.com/role/VariableInterestEntityVieDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r236",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative",
      "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative",
      "http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative",
      "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative",
      "http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesDetailsNarrative",
      "http://agapeatp.com/role/ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails",
      "http://agapeatp.com/role/ScheduleOfDeferredTaxAssetsDetails",
      "http://agapeatp.com/role/ScheduleOfEffectiveIncomeTaxRateDetailsParenthetical",
      "http://agapeatp.com/role/ScheduleOfInvestmentInNonMarketableSecuritiesDetails",
      "http://agapeatp.com/role/ScheduleOfSubsidiariesAndAssociatesDetails",
      "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity",
      "http://agapeatp.com/role/VariableInterestEntityVieDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r9",
      "r10",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock issued during period acquisitions, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r9",
      "r10",
      "r86",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock issued during peirod shares new issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares (or other type of equity) forfeited during the period.",
        "label": "Number of shares forfeited",
        "negatedLabel": "Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity",
      "http://agapeatp.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited": {
     "auth_ref": [
      "r94"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Forfeiture of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationForfeited",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r10",
      "r13",
      "r14",
      "r67",
      "r529",
      "r566",
      "r577",
      "r607"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Net deficit",
        "totalLabel": "TOTAL AGAPE CORPORATION STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets",
      "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r107",
      "r108",
      "r121",
      "r169",
      "r170",
      "r194",
      "r211",
      "r212",
      "r213",
      "r215",
      "r221",
      "r267",
      "r337",
      "r359",
      "r360",
      "r361",
      "r378",
      "r379",
      "r400",
      "r404",
      "r405",
      "r409",
      "r422",
      "r469",
      "r470",
      "r566",
      "r577",
      "r607"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "TOTAL EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets",
      "http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r93",
      "r205",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders equity reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r410",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r410",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r410",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r430",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL CASH FLOWS INFORMATION"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.",
        "label": "Supplier Concentration Risk [Member]"
       }
      }
     },
     "localname": "SupplierConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://agapeatp.com/role/BalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Income tax payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TimeDepositLiabilityUninsured": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of uninsured time deposit liability. Excludes uninsured time deposit liability in excess of Federal Deposit Insurance Corporation (FDIC) insurance limit or similar state deposit insurance regime in United States of America (US).",
        "label": "Time deposit uninsured"
       }
      }
     },
     "localname": "TimeDepositLiabilityUninsured",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TimeDeposits": {
     "auth_ref": [
      "r147",
      "r152"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of time deposit liabilities, including certificates of deposit.",
        "label": "Time deposits"
       }
      }
     },
     "localname": "TimeDeposits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r260",
      "r261",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TradingActivitiesGainLossByTypeTable": {
     "auth_ref": [
      "r127",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of gains and losses on trading activities (including both derivative and nonderivative instruments) recognized in the statement of financial performance by statement location, separately by major types of items (such as fixed income/interest rates, foreign exchange, equity, commodity, and credit).",
        "label": "Trading Activities, Gain and Losses, by Type, by Income Statement Location [Table]"
       }
      }
     },
     "localname": "TradingActivitiesGainLossByTypeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradingActivityByTypeAxis": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of trading activity.",
        "label": "Trading Activity [Axis]"
       }
      }
     },
     "localname": "TradingActivityByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradingActivityByTypeDomain": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gains and losses on trading activities (including both derivative and nonderivative instruments) recognized in the statement of financial performance, separately by major types of items (such as fixed income/interest rates, foreign exchange, equity, commodity, and credit)."
       }
      }
     },
     "localname": "TradingActivityByTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradingActivityGainsAndLossesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Trading Activity, Gains and Losses, Net [Line Items]"
       }
      }
     },
     "localname": "TradingActivityGainsAndLossesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative",
      "http://agapeatp.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r63",
      "r64",
      "r65",
      "r237",
      "r238",
      "r239",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableIncomeInterestRateMember": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading in derivative and nonderivative instrument that provides fluctuating return in form of periodic payment of interest based on movement of benchmark rate and return of principal at maturity.",
        "label": "Variable Income Interest Rate [Member]"
       }
      }
     },
     "localname": "VariableIncomeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfVariableInterestEntityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.",
        "label": "VARIABLE INTEREST ENTITY (\u201cVIE\u201d)"
       }
      }
     },
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/VariableInterestEntityVie"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VehiclesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment used primarily for road transportation.",
        "label": "Vehicles [Member]"
       }
      }
     },
     "localname": "VehiclesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r225",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "184",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5634876-113961",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41256-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10(3))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.12)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(f)",
   "Publisher": "SEC",
   "Section": "1406",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r533": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r534": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r535": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r536": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r537": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r538": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r539": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r541": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r542": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r543": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r544": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r545": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r546": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r547": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r548": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r549": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r551": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r552": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/subtopic&trid=2196772",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "https://asc.fasb.org/topic&trid=2122478",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2611-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "c(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121825205&loc=d3e27249-109313",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>121
<FILENAME>0001493152-23-010029-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-23-010029-xbrl.zip
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MLG9)-9X5=U<4%R*.HS._%<_=A"C;=9>0J7$JN$JR.^SB]8E6#[&]MJOO1I3
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M"=722NG_M"*+$<=#L10O8=2)J^7IZ?=[*OAS*46>FO'='5+PSZ4$DU6,]9A
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MP?8N)K[#;J1*BU.':O/H,!---:"!T&DULR8[%R3)-&]ACO=BN_)7J[\C87G
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M9.PJFFNU_$+D '35*'R1S!AS-*'3T-ME?O:UIWF)>5E^84>-HA=P_DN@!9V
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MY@6!M"6KH;(E04;7U1+JM*87I2$F)KVS)DGG"%=R4&?5KIF$A </"E3#K!&
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M/^^/\RH%:*WZ6-K2$[Q/4;5B96+3?]T1I9*?_ M02P,$%     @ Y5Y_5K*
M=(M;-0  >2T# !4   !A871P+3(P,C(Q,C,Q7V1E9BYX;6SM?>MSX[BUY_>M
MVO]!VZE*3:JNI]ONZ==,9F_1,FWSMBPI(NU)[Q<534$2TQ2A\.%'_OH%*,DF
M1>)%@038HUNYB>T&P'/.#X_SPL'?__MI%?0>0!3[,/S]S>G/[][T0.C!F1\N
M?G]S:Y\8=M^RWO3BQ UG;@!#\/N;$+[Y[__[O_]7#_W?W__/R4GOT@?![-?>
M!?1.K' .?^L-W17XM7<%0A"Y"8Q^Z]VY08K_ B_] $2]/ERM Y  ] ^;#__:
M^_#SZ6>W=W+",>X="&<PNIU8+^,NDV0=__KV[>/CX\\A?' ?8?0]_MF#*[X!
M[<1-TOAEM'=/[[;_M^G^]\ /O_^*_^O>C4$/R2N,?WV*_=_?X.]N/_OX_F<8
M+=Z>O7MW^O:?-P/;6X*5>^*'6&X>>+/KA4>IZG?ZY<N7M]F_[IJ66C[=1\'N
M&^_?[LAY&1G]ZRQYZ9!O_.'MYA_S37W*T#FB8__7..-D #TWR68(DZ(>L07^
M[637[ 3_Z>3T[.3]Z<]/\>S-#J=,V!$,P 3,>_A_$= O7W47[AJXR1IC^Q;_
MX]L^1',749IU6T9@_OL;%S5 HY^=G9YMQOY+H5'RO$9S./;Q%'S3>UOSN^=N
M@&5D+P%(8M;W*QLW0,?8C4"8+$'B>VX@1%1E3SD4XM4%5FCT>#0?K?&.@.91
M;(0SO M$8 G"V'\ %MIS5F  8Z8PZXXGGYO^T@T7(+9".X'>]R4,9F@W,_^=
M^LFS"!,<PS1 NQLO+P/X*"3N4B<Y=(VBA1OZ_\F 1#B>I[$?@C@^=[WOBPBF
MX8Q%(_< DN28KE9N]#R:V_XB].=HR82)X7GH0PDZ-<<P\#T?L 4K-(H<RN_<
MR'?O [0Z$A"!.#'1MY+G.Q^PB&5VE$,?GF!X):/_P0O@P0WPQ&-N[]1><BC;
M(A-/@ ?0%^X#ILC(/>109(4/B$T8<4RUBJ9R:!A'8.T^9[L# N "K&'LL_&B
M]Y)%&41G0_*,/H#GQ!I_;0@2-FG4;K*00_K5PD<SPHAC=/ART$7I(F\VQ0EF
MUPIOW.@[2/",M8&71G[".<5X^LNG=@C#D]6!%+/&D+2[I7&"E)*(=YV0VDLZ
M=9&Z%XW=9\PQ7H=HOXI2,!N@?=X/N"3(/X(<BB<@0+K(#.FJR?-6>\6?=2(W
MC%TO4P-9) L,(4OG$E<-F]4"\5SW8)B@7U#/Q>Y$9Y'%Z"9K76.MW7&?>)9O
MJ:FD50K1I$!\;NR*T7SBQ]_92Y76219=JY6?[$Y-]$&L)H*01]7DZ"I+,[Z/
MP;]3]"'S@4=S([5O4T^7JZ\WH[<S#1PGVX,/MI.*P[2) A\#=<9JV'+B(YRS
M>U.V"A^1K'[2[18^LH@=FK1A^$CCZ=NH/<-+)D?GQFP;7I09'=NQ<_BG)/\H
M[=D\XM3SC=2,_<-'+;U76[80YP$K.$YK=A$?^<(#-6J1\-',U5FZ=<*[T @=
M&K<(.)<6[P"2-$%O"69I )#ZAO1^?^:[^$S'RR2.H>>CJ1=?H'W(#]AZH/!(
M+>GAVZ\.W0B;@@],)W'M 64C8L:)O\*+_S8&\S08H$\A,[9*<1"&J/;0[?!8
MH7A(8I$]LFP.+_SXQ%TL(K# Q. <AVB5S:W1? *0%IW66&'B8\KFZA)& -E[
M_32*MIL3/I""C CSR<O"IY-:NT?=D=NTC$6WE,-&E8U=M>$K#!37, U;^J)
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MT%S03,I;4A6S(O!>&K@1KNV=78[;UNT@B9S807>),P@G*HF2!1[YH>>OW<#
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M3",D1Z3*(@XO_2?\$S.\0>ZCZIG&^E@Q>)$>BC\8L %PX^SE%6NUCN##)A3
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M.[37\QCA/+U51=L.T-ZXV>(PQ-48:,BL.G$7BP@LL)5FA7,8K;*,YM%\ AY
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M>[02I2C[K/H&TW!QB6RL-'"ITBPWG)[J?E21:"9*5_I9E96-]A =R;+O1OT
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MW.;GZJS'RU@\6.W?0N&6C$9&,)E5CFOD7)W5W/H708,31[WK #0-I)9!A3;
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MGCNIMHZJ"C"*VI558W0)[)K,D1#^K-.93#<N*2=41XU-$8Z( 5YE+Q+-9IE
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M"KAG<KVF9[HXIP>BMT9*7)#PDKT*</8L"&?VTHW )8SHER2SR47NT0'Y<W%
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M4,0="_H:\,B:"JU@'0QN/XTCLX;?(\*->3"<N+)5]L=ADT%J%JLT@?+8 -?
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M7='73Q'^O"<)FZ3'Z\,J&\:'?1Q)NUPIZJSG#6 K BCDO,>.%N#$[;E"FMV
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MR\+J&C-0X80@T^"K-&P?@ W\I*GE9YD_2#*R.H1!DE(CTO2 UT5M3;%GE*+
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M(.?*&'EDUKK'Z)J')AK.'>ZG@0.W71DUSV.80X?O0^?;Z,Q>T&:1U'?KJH2
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MZ$4C!7 0F09APR/=F6K-.VKORALSIH!EY1F,T_JTQ:,8JW<8F]*/%>1'\<2
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MPBH19BUM0?]HQ?[&/E8?L3]NF6WVR?\ 4$L#!!0    ( .5>?U:Z[@GDK58
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M]K"1FKG_P&8K[W6NNQ#P@-4<YVSW(MCTM0=J]$8"FS.H<^VW$ZB@"3HT?B,
MBA9T@)HT06=)9K%+F/K&]'XZHS8_T[F8A*'O4+;TPB[;AZBKU@.U1SJ3'K[]
MZL .^%7P26DD+CU@W1RQPHBNN/#?AV0>NWWV*7:-+5(<M%E4>NCST%B@>-1$
MHGKDNBGLTO"-O5@$9,$GPQT7@E6RMH;S,6%:=%Q"PO3'K)NJ6S\@[+[7B8-@
MNSGQ \E-)F&].,GSZ;C4[E%VY'/>C'6WE&JCULV[XHNO-J- PS1\T]=EA/9
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MR8[]QEE2=\_E>>"O1.ALD? %$\T"Q3YQ'C3;[/LS/H=;UUX4PWG2!(CG.PQ
M"ZG!0K1+0B>@:XZ+ MBCED!\WZ/B6T#;F6'>R<Z8+&BX/3_WX:SR?4'0!0C\
MMY@[A91:) ZT/2^VW3%9^X$"^..60+S_AHEW$6U(,/\KM@-VDW8W$*1SC8%@
M?X<)MH!")+P3;Q'*\8$ GF\-1/Q[5,5#0",2Y),E<5UN<K$]T"HO:@^$_0=,
MV,5T&@!\$JS594<+'/M,%R#\/YH"?XY:) Z,2$#]&3O2 P#VN<9 U'_"1%U
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M%:%/\N!:6&_TH@XE^*)BK!BEBTX#FR>TFU8.3GPFQB0)F!C9 1>&U$=":YL
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M\?1S(@S\.C3BLO%?K8$UQ3E1=N2,7&Z+RM"D/E< 7=$"$(HGIG7:Z(V"?/J
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MCS]SR\6D]V'0N^UUVH-IJ]WI#.\'T][@0VLT[/<2,\:UW&.M5%P#. JVR6L
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MV&0FUN4V7'.9CJO;\-5M^/S7A*O7\!_5:[CFJ(>KU_#5:QCS*OPZG(:-]%Q
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MWXE:!D/.2 :GU?;TF+OK@^TFB,398\B,Y.HPCL+(]KA:I<?:HX[83HA(_"T
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MV)I,L;..)PLA1Z?:!U'5K\X]O9@7(YLM/:]CKVEDNX)='=03V10&XT!VH];
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M7G]6D_'DS7$(  !/3@  "@   &5X,S$M,2YH=&WM7.U/XS@3_X[$_^"GTJU
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MY=A>.;97CNV58WOE9^'RV%XYME>.[95'M%=L/I>X9D@I7)$5] A_IBV6H>/
ME?T>>O;H&:)/^RF];8C)^BE?M^38WSCV-_Y/_8U:$]PHR:L-&!*L#X_MC@?:
M'?^EYD/9_.XD_2&*^;W*WU!+ P04    " #E7G]6YBT,A;ZA @!/IAL #
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MG\CQ&HP/SXR%VY0!O.*&W7#1I#YU2PZN!T*=\H9JT3)5C)Q%R^+04KZHE*.
MB@[[FWJ@9%-!_ ,>N# ! BA8:N@\.&[+=:;B.A9'1<11^?C1"0]P-@^(?TJ6
M-K12(2=GI);G3,5S+%8L7WDL7SGOT0[YZ-.R1V(\ )3185J.,A5'L2BQO.1A
M7O*11N24W-TM-4:&!VGYR%1\Q"+$\I#[><AWVJ''(F;1,8-96FJ<Y W5\I.I
M^(E%B^4M4]A01-ES"A]2AX5-(7R:Q<0BP_*,7)[Q@\=!YY@+[(ZUU @9'ZCE
M(5/Q$(L4RU,>:7-5&?\NS&/4/2#BP*<$9C[H?"3++<(^.&[+<::SREH<%1!'
MY>-',*>7IR=7YQ=^7/*0WP> ,SY0RW&FXC@6*9:G/(ZG?&4A[Q%YO=0H&1ZD
MY253\1*+$,M#'A&#2R/V5_P"8B6SX[2<9/H86XL3RT\>X"=7@O667G(='J3E
M)%-Q$HL0RT/NYR%F7G7I\:LN%21D94^4?@ O]PW9\I>I^(M%3W'04S[><Q[!
M]"TW6K)#M+QE.F^018?E'9-+<YAI759\9(J]#(9I.<AT73PL1EX\'\EO:'>A
MGG44>*<_+LN-CK3.$Q&,M'QZ"5.7E5;'!OK<^'BNMG1FH4<5%+O0"UCHVC,L
M]*0=_?G+X<M8Z'2@+W1'VX5>EAW]H(U2/;5Q0P7IT)?!R$<':R7_Z>R2%C%6
M#W@ZCWD91\OH8"V/>3J/L8BQ/&:"9C+6(OZJ*^@2!/8T@0XO]NEY&PM01_U3
M&G6Y=Q+<4!GA(\>_I?2,](;K>DZ>FB77:L9*E)M]=Q*XO(?5E*F &<-=6&ZD
M)'SE2A /FPN[$;L!NG-+E3\P!4N.B%'CM45$D1&Q&(788J.PV"BK-&LA50Y(
M%5[<79IV:47K3+8@R71INH85K4'7@M;3J*-)XY9&X)VWV\RE(VTJR[K*4W5'
M4MKG0S.QY+BH65R4#A?/Z5A_N+'DBX#$+-I(+@6?L'@H/AX6P1]LO\["]>M<
M,(>PB"@R(A80G&>:D+X@")@2QYEAOQ >8%>\""O^#'N\]K92W:[4=I,5_R0H
M#8#-'9"01=@?383E7GV/,N#@'>(?*7HSJSQQJ(M;\60UYKWBNY7-JEWQHJPX
MKL:<5[Q6K=1V[(H79,75:LS;Y[Q;J;U-_]I;V-+.Q@V+@YG6#:O&_2P^,[NO
M"K"OGLD+HU!E5[P@*SZTQ^>RXL"J:Y7J9K+BA\U;)N5)X"[K.H\,<(&K:V9^
MWJL+(-JSJ[N(U<69G[,UH[I7J:>Z;?.H<47=[G>@&<W\R\RM)PYUH=8,M1IS
MU73V*M6M#+>^Z'(:L#LL*U?^U9Y1M'[NG"Q0'3)+]BRP2%P;![S7XT$SXJXI
M@;R4@$D,G\T(-)\!.C P@@?HQ!CV<XQ-RL.@L+"=JQ9?4]9 U.(WX54HITP&
M</(+)N/0OV*<U!NZ+%$_BT5P2L7PU(Y["G/G_KDQ.AINO#VUZ<2 [3E-)TO%
M=R>+905C8@LI_&%7>NE<B0]6./^\B=I(P'W>Z3>]X&/7*_>Z)PS_DOK &;T+
MX*K]*T$"2=P(+I ?^]E?LD6N)\W$0D^)$N4Y6425 E&%3W.R."HJCA8KGEA
M%!D0"Y5B#IL_/E(21R\;%KFS8*67J:07BZ1B(JDL4HO%3V'PLUAIQ0*AB$!8
MJ)32Z)"0PJPT)"-?68_!?+U06$R<"2NM3-==VR*JT(@JB]1B<50X'"U6>K&
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MB:_)P9_N61G+<Y^J!=L=87>$/2,>OR,LXI^.>,N#+>*6!G'EXW'CWB=[O,_
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M*^?JW(&S\ K..Z>VZ9Q?.K7M5]YKY_S8N?I\Y R.R<$)V3BXPI]K>YM;H[,
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M6@J)[^JR<=8\0:G.2GW+S<F5U!>!U!>E>':TSTC9MYV?]_W?\AT"9:$>5NZ
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MCH&@89:HXVE^ZSSD;T CD3(- 5M%O1*4M%AJP1M&0%7ANIRB)B"]X[O\OMH
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MM$O.IQ'U=1!L"A$@B0H9P7?HRHNZ!'"E0_%-XD 2D8\Y&"V:#<?7 ?JHB*C
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M9(:>CX+2,H=EX&WY1]"(>6O4H)9_T[VV-2 B[MUK82OM/)8<!JJFZ8,KJL\
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M+>U,,R'TF,NO'I53:B!QZQ%\-K!AFH("V3!G'L8BNP-<@.@ FC\/,0(,7TY
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M+U?MLOZ*!T5"DYL51_'CEH#CQI1#39J\ZFJHDK>C@$J9-"#0+*C+_+00*0X
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MOFU-XK,UB6];D_@0JJV]^1GLS9O:WGS,1,]:FXME;1[*:#C\,_:9=%X==&G
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MD2H-.U$2:8FL2QV1']>4JS%]<&M/F"UUR\*IOF[/O\W7;.-"!U;(HUM+G41
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M3A=>]>F"QK:Q@887="(C08[__I&W9!R]2/)D4V=\+'/L(#3=Z#L09.<*7W?
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M'3VX__";NSR+>Q3ZVM\(UIU,*#WJ))3T-18U\.!H_6Z_LTQ;:W8GM_\GS,Z
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M-<D@WL.!H@7RH5:+QDQ*.1TRL%@CLXY+XIW6&PV],HH7UJAP&"$7:\?S)=J
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M?9-NV+'#'$WG*,BC)P=?X;^8/9H;X/BGQU=EX(6%D&[QYUZ%(!J__FQ3^K\
M\4/F<,M*U[X-$-%3:="TDT[:97F>2,K4V2LA$<DN,NS_D0E'O&2A]A=/!A!:
MG*=I!+[[)PX]S 10:NF>8+-(65./+XP1KTJ0Y"F.I64'EM9:2!SV8+,:!C Z
M9-7"XSUGG*F'QGH,0XD\<0R:(RD@BCM89L;#K,"1X0*:H0FZ_]3%>ZX)OD<5
M&!?&8CF\+1^[9;J@98;$OI'LWZ(%V9:_L.<-B5"J".NV4.PA0M69Y#"J=64:
M'^?;X8O(QJ;/8UQ$IOVL*K8IX@"JV$L8Q&ZWD%SF+,V=6+L=].2 OLRZ1!*2
M]!PNZD<&%>GQ4(Y T9L@E!<B,B!!$T:97WIS'TX.3@.L(Q.)=EC+@FV\M4;P
M>!:8-/;8@=G!M\7]*5T;TGB65>U/XGQSQ)B70'R^R4'[?D<J3!T,N5([T.KC
M]K]9FVV9,*KL#"=/+ER6QA5QP@1@@>:M"9Y!.-U ]9XNDK6)7A\^.SP]C%ZG
M1?3],HT[9WZ?^:2#DO6R)/A(YOCR&3-[ DGQ3P"VFUF[ (02-#*/KJ6#C5D@
MZ(H2_'A34Y@Y5V-[N!@G+4'\HK7]>!0_ J<;MSR2K\3&^VV9Y:S5BI+Y&(4*
ME'.M0]_N/K?SE1+L2$O2J-V$XV@"WV1M.-9O<M!=0&>IJ2R@%@H\S>=LR@8D
M/Z))!>")2B9WT$%T/3]EUJ@( \>6Y_;([-F%=-(XJDUM \I"DM4P/*4!VS"'
MYY%P[1X=/^X!B>C%6<VE7YG#^^!<VKF9R1!7R-7_/'_F6NK9LT\'C&<J%(\;
M4LGV(A6/GE293$9$WR%-,5W"*L_+<\8ND46-=%L%3K89K<U7R=?R/*X$1Z0W
M)?M2N3B"J=0GT<@DKKL""&J0N%HO\^MH-4$ -I0N=E]-Y=TEZ0]-PF$ R;0N
MJZD-NO=?++G!$-T_[?+U*D(3-UA"#.11-3F),@FODYQCTGT\2<-EGA\@VL(5
MZB@J5>+V'<F\4<,_$*T!R9H<0+0.R6'R)+*[)/!$)?#D>/@XB-(L9?6N^T#"
M[S9'JI^C@^]5>(2/<PMJU[FTI,T<HDN8(=(;'#79(.JGX!(2<'"O1KG@-4B#
M''_9I:,.'P2#T7"M)6O_<':ULR%HY'J?TEO.R_'OZM$ JUMI<#R0VZ-Z3E__
MY#X_W''^(",[KITQA(5MPLXZ8*8&3'(+!K:E9^[-S,UT]==T#C;6/QV"IO?D
MI\>L]%X,GZQ%CASQV1%88B[-1<N8HC\J0D A>9ZTC.ZN-+D*965SSYSA8PIU
MG$T",DGXU%HACL"JFW7TU##5:T9;5!-_K@.J9+5'H^JFXXH^4:>P%FDFG0OZ
MF4P.F.RD4#0Z9(NA^+]5>J*^A$6NG'I @-CV2<V<FVF1(GKV3E@ R'$F%?.J
MI3<?WT_N'3_X:OYUO./10W*9P:)2RBIZ/LYA#HIR67C0U+==HSQ&:=%C:R%)
M/!7-;N%'GVEABO^#?V,)LY+QD!8PZ-NP3\ND2AF1S981%W@$$^RAG)*M+DP>
M*XZ33UO4UY2"CW),F1Q:]!Q@TKE T]@@7AB8"5^#8=9)Y<(E@P<N+_([G6,Z
M'M'_1+@#N,U?(F5+:):H?%WY1JOS<?3..!"J!+&8*<L.I&1JM?(MK$L@6/1O
MO$:IU N1'?5G3(;4>Y8:H,:B%Y9+$#"Q*M46MG9^R/8T#0[##J\$$QE6[!+/
M<VN9-C2-M<N(@TDAJQE<%H;%Q(CH6?S?7;@P/'C&T0:/Y\@MQBL-(WT(":ML
MJA6[&.]?E>WYCRZ<?E!DV/FW, 1FAF!2[(#/P!9J=3^4QRVZFDVELN!ZKZTQ
M]%K=T4.ZPOTG@%"<Z&_-IB[^[AGUDH[PAH %V#)GC"Z3P[J 7EO8T?!,D =8
MJR5*AY>@/_PZ[W#E[+('WD+? O*6CUCBVXLUVC?#P[\I!,'C$4%PO0B"QY\I
M@N"+V[TG]MSX?%YP)72A&MVG1UHZHWQE;^#H#YZ4"1\SP]ZZLC=P(0N7JVC,
MS"IW5$ F;PNF.'5UB]Y&LQ9G:B2..!/DGB6X"@,]O4L<4/\"RQ5VG;>(^T.+
M[,AT7&+=NM>(49OTFU^'P^#(_N7'H"" @)4]DPBE.Z;I+"6_0'FW<%EP2J+/
MD%T3W^ZC=]86!<H#2IV9;+4C!.2*?J;&F@$",97C7X)DCMEJFM29]#&*MN8.
M:^%%P--[AJ8 9  JZ:OLZV[,&-10]SA?Z6QU-8*"WK^>CS,PA=\6Y7ENTH5Q
M9I<"+N$?EP6*6*6.G^Q7%/P8VZ\;$Q=8D[$K6N(4HGD7_7KX^C#ZZ^GI+^'K
ME.M7JFG5NC2:6CS+:#\.[YO"S0A,MAJ@4[8,Q5-R;_J.9H:FAL](?";-2S'3
MS(Z3+MFS*=[<K)0AP\^:!H$+J=ZU;*$H*I/](O+"+&]L\YT-.)2!S\#A!CL<
MZX'N<C#"/2"CM.,7K@+.-5NAGQQL04!V/):MQ*DQ131+JHH#MRU2UTBOTS>G
M/&O!M$E-3/3\S<XG*KT;!T;156!#T[.RI,;>RF;KEGM-02["WZ?TJG;=]S:5
M"H(69)$4%F/CKSF,]O;\V//C3_*X@$TG;TF,5J1GG71#B'KQ98%YNZLX0;$R
MZ49!^0.J3W6BNT/K(J$;6$@EE$?^*QZL[CI)$8DQ="^72;&RC*-E5JEV0JT]
MGP409+^_?=, Q0\)3N,24C_G)CB?1M892;)"&6M7(]"&LRK!8=D%2P)^EJPR
MO>M+8:FR=#!&20'/V#N/%OA'(4R'IWE?1Y:V(0Y'7P.*F;GPL?2P_7RI'-$:
M4<H=K8AH,SH9:*$:(VB: 8R,RH<5 YN^%^+#H"@VH%8.C\]+F3)18$5T>%6X
MB2Z3ZEL5NPE4IR5?!)<+*D(X'-D!SE0VO5CST+?'IPG\L'T%'64\.H$BR?=Q
M 0O;=$,/Z=%,(V N4:70FMMYB 8%B,AV956?H#3$_W!=]8RWT,#LP18(,'O!
M$1U27LXSX!_J 2MH;Y7AGNORTQK<(9+0\,0['F#&O2$"0!VV[^NDFB8D@/=>
MOLMI5RC(]N3HZ.20WB/JZ)NC;ZPQO7TY>P"O7_Z_N"JVFH*E1VEASYU:9SN>
ME0AG/0.UJ6&M0<K;*T3>98NH@:^O0D[P!RC<XZ-[?]>8,%]&!EM%3^:MKU=&
M]L)_!*V^N"2-+7>T>N!@I,DY-0I7,$<9W,M.H9$43W4T3CF4_[HPA0"MY:8C
MI**";6K9:()WVO<%O=T&WQ<Z.YT7NI?%>K,_%0+N!A6NP.R?9]4J5I"  HEM
M;SI4CH7/:4S=V"8=-!WP%[Q(\+!I''ZZA51!YT+8J_"SZ[NUG4]4AT;[L32:
M3%0'7B[A:L%RUJ[8G8L1OY<,36P3WJG #>&R\*^5'8B%F%KZ E=;%^A*QP(-
M"D<(>5OW&2AYILZ-W8]VPR(*$5!E^;7Q4!,Y-@4YVZ7@ 2038EWTQ"*.=M/-
M^;HW-EK8^%'(MJT8KXV1,T* 9[;<LU,]KYI?7$.%"QAP>BHZ1M9<CL'"$26G
M>MZ..,X]*8B[?S2&LZ\UG'W_Z#,-9X^;\N+A/V4L)[<RAU%?2?VY/;-<7EWU
MZN!![SU;CKXZZDTY1#=Z?H5E.?/ A-,R:Z4<)H>0/9; 49$V %>.-(?0B\Z1
MF'4P91W:90FLS81W^:HN8*U>)\A#TP2Y>YS^JS)E^R(6'@.S<H%=+C"!5=<O
M$?%,U#U*7F?EL=-._U<X5M@-<J$.]C1#@/H5[-E^YEM7Z7!RT 7B);,E4[^&
MT!B,Z(+7FN(LJ\I"S(1SVRY*B3D'(^K;3B@Z&'>\4+>((/K>:<=8F-<YOU+)
MZ 7MY1A)\10F(-CNWB;/-!V>H #MA1!$9MUIRT'%@21Q#R2.@]5SW<11B4BC
M8K9N><, @##N(,R2?L,X<)!9"$2?<O0P.G5\!>C+3+=]@#S(%Z%W=&TL,;AK
MR<6(<^ XJJ1-F87#DU>0#*U+!G,JT( M/G4$Y4$./<Q]T&M/&:+E>G26&P5(
M0=A=PV5<&X=A 5E N]("7YIE9QEG7&95!OQ=3II(0EV^-XFEFG0&HO16:RP$
M=1@U)*0FF<3YLS(=@P\WB/+\R2RP%8%W8>"T;=UH4@X4#8BO@Y#%E^7L8-'=
M(OSM59&-:,Y;P$.$0"O?RC%FW[?3:YH<\A+M$I>@IH7SDD"O>7MHH#2L0TNE
M]96^QW74D#G.&CT0.D-.:[DQDG8G05/^':Y+5N26'1IKYT38?^3'"]!: 56M
M'L&N6#:L=71CWT6$:_'V&BL(I]&]2Z;-4=+QG(;SZ"8@[VW/'OB>)[IM9EK
MRVGX[>W+OK_M^^'CSI[SCLZ7)K=F966?:'F@7/DG'0R^_G/XR_M].P+BN[(:
M^%![X,^8HLI1QNN5KHT2F87G8)M..GU^R=[.M'.NUS5E/\QFU90G[O,7.\Y
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MM>HMQ0E&X?F[6.\J#XIWQRJA;JV,(&NULWB:&8E&(W0[:K\;9//>%CM[IH+
M14IAGRB4Q)+11.Q$5IQ94%K<E+QY&SW1JP=:0$A%JF]VT.$C0:$M"$F"FG2R
M7#);%IEG;TUN=644JDJA3.VKR3ZH_SQP0@KG?#AOQ$'>I(Y@!P%-:-[(R1V]
M*=V.%X3<629%][Z&IS\K0>*D:JWERJA8Y?&18(O@? NX^70-\[L8Z:-T&)VZ
MDE3&M,\'U$?T>YD5M1J]TGD".[!T9<:UR__8.;-A&J@/-MQ=PXK) 1=ZL^Z2
M+^D%YURE\M1L\XB.!4,W>V!IK8$]MP(CAROR%?Z/.*&T-M7P"Q=*,Z,0:KYX
MU]\#R!G>TGPN&YK\FA6W"I-T>V-FRZ+,R\4FEDK!V(/ %/1L^< \0Y3=8L'9
ME$AQF]3=(WCEAR%-4R5ZV^TTH]\W;W/6#_(M'.E=,L=U')R).ACY2)OIE4=[
M'C-;3Z(/'H7XYLQTG%5JV+##IR<*.;Q,9<$&AP)!O)QJFXIR^KLTD9/:!^]W
M<FC?9I]MV:;5U"[=$*BSH'G<:(/?9%"*E00M',E!5B\UV2]4_DQR7I0M,]$J
MJN,BF;"I ?^+8.]MAX!AOE^.>!A(4F(Q]T%C%-?/) XJI#WG85K1:PJ;M)**
M:E\<1(]:A5T04(&,7!%")^PUV@=R5:XPOPBO+@?2>)R:/F"SA:-.=1W6(/N7
M2=L4GCU]W2I[9R$F9 GR!B@EP"(N ?-)* T-Z>B<5F;H,WR%R^ K:%=!I:+N
MI;>-+UJJO979&]ARWY$$S]XN&,H$:$)9_1FRTYB/P% %"&HD;2<"%)26(P>9
MV-WYSB"SZ+*8GUS)?I(INZNB@,3]S=891K[,<')P8W6&4;_,<')PG76&[RTM
M=.'UK<I"1CN^M[20K5[-%$>V%^.H> >'?U.HMP<CZNUZ46\//E/4V\<4X%%'
MW/")_.EJE>$+:( VQ.?%2L/2:^D8V[Y3A@Y41</3%+DD0A=T+S3O8AL&IR+X
M3,,JYA#N;9EO?'NDP^@4!WJ/@('9\,//X@]1<BF.W((?A$[KA1U@;'D[.H1/
M>'5!RQ(VD1.2<( EN-,O@'%)Y6H*TM:SS9.M K-8&3BZ5H$>Y<JSR&3N[#<&
MO8:3MEF6RF_HK6A\IS)U"L.%IOC#>6TXQ ;DF$P'UB5?@?!=1<6[FE.S*;60
ME+-:)<WH+[W9K&TIN,3F;*BFCZZ<TRE1GM-$?-J"\1NT[?VI&IZB_5/VCQ74
M[3R,O^"SY#K+Z?AD^@.5<"??K-]]Y#JX/S#(3UN4NEW>O<.HWZHV4DWNNFM@
M0P>EJZY>5=AK>Q',V/.'ZCAL"JLIAZZ^@&-ONZ;[ELC;1]S7MUK"ML=Z=U=E
MCS8^!XQYJ]G\ET!_I/M-0#&,;#BS-2>VBPX:]P2_2'*\T[RE7P*G*+\>R7(R
MX_A*+>- K"8[XZ-),F$R$NG?JC5]P; 2G-K<P9150%JVTP:9-OO0K;) UV4H
MZ.@L,>*,[4T$=&4DEBNYQ"EI9T=!CF$EY?M:FPYU+]D%+M_*Y'\F.V;48[=Q
M5?9(CY$S)H,+RG;4%@EI+^)!JHHR-%@NX)5VL)*==2"=RAM6JXF@RWWC,<^<
M 1^(]2%]8 N21]\R.^F5PD3<,LWI%*'1<*V.5%.Y;P@TDHR"(3"VOLGB/#NW
M#!-PW$FI'G7-;5R5/=(UCCID=QF_[[*1^FA3Z,WX"^*.*6(91+C$;9#FP45?
MY(628L=H@H82-AO.8Q$LB031''KD @,%0_86C:N*# 8YS)T@HV 4B],O(8N"
M5.)<LWVT35S"N\.1EXSAWD\'AGJ%3/ODX)5/M6,IGRNQ_(A-ND4%)6+ V-:6
MKM%D4+=N03&^^^LL3[(55P8WVN\E]GX10+DYB&I0M&010LD*2@X(QWE9HG'-
MW#0;-)2JN0(+/]Z31J0!&[+",YHEPL#TW[9WI 9X)2]027\BBY<6B!6N8IR'
MHK_#>-!A]$O_@U#98N%#H:F8J1.,*+&4&91!]> FZ""EK;C'3F4W/?R?LK>
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M#!,Y@@,U7\LY)5TTM&_4*JMK-45=MTG)5.O0'LG0<&*=KBLZ'$\>\B\G,MB
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MQGHKEU^PG05R[S@*O\(( QH<G>QDM:7RBE^NYTF[Y3.FH&801?[7U M]5"J
M8QU?,%"LK]=4"PN4U 8!K[9.F;<2P6,-A@<EBEE378/2?PW'VQ"N,UVY%P5
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M*#QLE?V\M>7V=O9JPBR;V[^4 B!%559%2-59=)D7J:KF&)P <3#BA+-"K*4
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M/BL=J:QZIO3;T4U)QFCHJEZ]/G6/4-K>&^=$S-U?\88S,4]-?&U[KPFP/42
M;>\'#;"]4I'P.*E/SYA$]9D.[; FRWI%IW75=X4RB#G1![$CHQ8T9NT+,FL]
M/YG" 6>=H[.<=#,/ <PO4T[Y6D,"5:_S9G#VA?_5?;/N]#K=[8W.ONNH%19$
MA0-Z5^K!2N9DMP--B^NL#<X.G/-D&@Z=G<[.NL <T-'FK#JRN\)I%*@#?E.X
MRJ7EBD;)U*G4%?&E9*6(!1?,Z/CFAFF!->TT4-YH^0D;O6"XIR8O$](ZQ?67
M":TO!SX,JR^',PRZCFJ-<\TRDPP'%5^463!G&B5=]TRT;:DF"+A(+(_$<!<5
M5\&*;K9;YQB?XOUC\[XZ0@!98$]P\AYF&\03I#HCSU!(*6S6"S9DQ28-3+A$
M3TPV9@?^1=E\R1V/EB4)X:.-A;,S4>RQ^,,E^U)%P%7HFKJ11&8BG?(\JGGF
MH7MF3DNLGG.TAUE.>L)$,3Q7NN:4>Z:+M*I-99X0X(T#+\K'"CHDBMA;8V+Y
M*WN&7X,(PADV2;#L6U*H&TY,#8W"JV CRX.I,TG\("H?[=06.@8@0Y\'\7#-
MM6"]J\PZTVZMA>O%L5(GFIL2.<:?J+>XSEI8?7K1X3.4XM(8_Y1^6YQ'(XC$
M^\;"D+-*39@.Z2=B<%1EC-CP>: E4IUWP2N54J@P)=.)TO$0(8-J*(["HG=7
MZRQ5A^+@*W?.X;[I-Q>QEN5'CS.X1J^87T>6(VN( 6?K93X@:BL;D5(GW:E_
M57.,7X0FH<%R()&]R@DJ!+^L=>F,A9RG-0ESE;J-7"3:^PHT!T$ZDX*NRF#M
M$Z+J:VF#T*%"UA?<OW(Z0YW18%XUEIRP"3(:D/D]N\ARWDWL]BX=,?LPT=O5
MH\JK##->W S-YGLN R/\YQG=\1*__E#<\G]4;WFQ-U9TE*N_2!OMUN<%-X26
M[G6*7;-J+T2NDT $DQ_'.TW=#BM>4+&S0NL228_'"L.)/S*_N@@$"]+H\U7[
M ;*Z1F&'7B1GF:6[-BE47J_]1J>LV1EK( &7()LQV5BE<:C7L<DB"J/61L+,
M1 TYBPFX.D5.N4Z:$CLG#4BGBHNX/C7UV>[K)<U=3#:OXWLW<C7*+U2EJ*XM
MG6,8U* ^F\Z',$/.^A#WCN831(P3*'&V=B>KH5IO;J5[=?\+/ ^U&X?6'UR3
M"KT0VU>'KLNYDF"$#(J-BE#WE,OU0%J)O"!3?I>GX<6,,QRU)I0%UHE!O-BL
M?J88-4TT<DQZ-TI]2786>(^J#YO.NX"+B)'EJ=+3\YNI;*=*M[B[1CF2SSC'
M"P9'D42ITP$DB)@5B9-%?V5+HW$KD#=OT]B=*$9G4=A++_!:+HU6L4 YF";1
M4B4VU RE=&A)R?.L3LD/C42;\S8HS=7A#FAJSS>J5RDLG81G53N ! E"A(\]
M&05"HVIQTQF8%$_S% ,2RV,ZRBL6F9:']II A&#>Z]TE^BE5WEZ9.\ZSH.T;
M4)M9*#D-)5[3S7;K:%1?*&F6UP]]-A%5!+G<N5&N3DWES>6C<<T^IL+HXUR/
M)!T%7.W."*!6L!GS*J*LM.KFG7PDS96RV0BXQZL&(^7MLTY[6:AE:T=?HZ\M
M[/YFKQ_&"U)U^,,PAKWZJ[,ACS[DR$C[QC(V"OA*=;^<>4CW,I<LSH3[VC9P
M+U-OPA5DY3"!$>0EO?EB%OL(.K!2KM3LC"ZS0)(&2<>5'%7]W=";3%FCP5OD
M!EK\*TMUQ^]TY^3-VK,B=W,F, H+/8?R*FI@$F82B?$#%#>E<E'4]T%@!DQ7
MD# 8^^+:R><ZQ]4UJA>H5E'N(OAZ7+MV@T'#AX7:,Y(L)R^7GN@5XN1 /[!&
M9L(?G +%G==AK3N[[VFZ:<^G"<@*#<:ZEA%+X1&6I@1C*VD*CV^\22):QF6*
M&(%>[\DT"KAXB>-// 'SUIH-^<![9!:IA+0L,/HD;9(LB<O#\J(LL1?0&B:7
MD#[..&NV-\/_%:/5A/)(FB,]S[NI&+6\0"LKE59<J-XGI6R_R1Y[X.RQ_29[
M[&FV]8NT).P^_IT>UNU)>^4[(#&L'+C.PR:G/8[T>RH\:B\D[:DH6#781\@I
M3V<*&?%Q\K)6]%YZ&B7? K+*5-X5Z1Z77LH.IQ$MFW/[JBDOM!2$6\]/ @\H
M7_*,'XS@LUS< K0FE1U1((1IY6697HR#R*_Z(U=N15[91M+K;BV@BT@&W;$A
MB'_9G1QL1*3Y1ORUZ-[C,$B]=#@6AH$*8%S]#I,*V7@LH*O6#BJAK*"Y^=\K
M<X_[XG!?Q(:0OK/!.&* M%]7;F'J]U.A MHJ7U4EO/?02AKA0LWQIRH/]?(O
MJ-$D:ZBH[]WAA_=Y5::]CIKY1?1R?V=W_Z&Z^<@[^2/.I72O2W)_.I-45N7[
M5X)#0 N3*+F\X1/\W[.$H>M3]H2LS6+/1]<"?UUJ4MGK0AO*L(FE);A*IA3D
M##,)OEE!S06<ZL^UEU_HYFUVJ^/TEMJM"O:SLF.Q2;.0NN"EBR!5Y_:HJS@J
MY9WL*40W<!R2"W@%6?CKI.7YC7]#-W3(.=H^W9O#'.1^*</BR%^N]*J4C,8Z
MVBR*'&3 &:6M3DUK3E!S@NY[@K:6EO>SV-KB7 1@I:>H7Q?ZWX*]J%Q #Z#>
M-9:!IJ&",]HVUI2X\R4M03#Q+0&G/RJA0*<6DG.1V5W *9<P^C,$74;>T*1N
MI QAY@)]C(,K0++Z)D7=ED5P$0P]5020,QHC0B)%,@.BDB:CP4X94"$2KJ2I
MFL;T7)@6B(H*3%$R4XKO]9!%BFL\+ "XD$Q]#'RJQI;]SA+0TV H_(>%W4M[
M*DZ 0/*81!_-PBT1LD::O2"C!AS/9 +=&,J,3CR[F.6<5W1#ITTX.$B)<BVP
M#%:/IM.(;@]1C S X9 S,M%JK<]CQD6+6;MEE2UFNFYQT_E4('.(9)',2D<#
MSZ+VJ+9=P[\A0V@DPA-U^X@$]7%R)>!JO8ZF27T_.'NK<_]027:<;/*W&]V.
M#N&3RB&;06JE]"XS.;;6SW8VNENL69/J?X6O&3@XYE(3VJ8;]-6&0+.T6TEZ
M2=_(':(N3)6>F4UH*W%Y)2Y*!G34S?!>YL1*O$6Q3@E(B^LP);@R'<:!?VEO
M/,T(?ET90+NEC(@L$#KI5 $DL9<MS&!7"S[P14 -<J:!).P9I+IN7Y#J-GDF
M>/(Z?311O*E272FU/7&,BE-%/$NK-M'!?Q;""L.E>.N_/'H^O7$$%V\+#KUR
MYBR97;1]) T)F9N+IO&FG 2 LB&YMNGX!DHM1>ZKQI<D08&S;]97 /EDE  6
M%=J@6+(![J*&:,[[$W7[\-LPF.9F>TL&] ;6@,X;&^?V+:\SXB&8XX3/B=PU
M6C8LEN6<?:M29PVGDKY@YC5<ZI'9%IR_RZBW%G=(B>5))4YK0-AF]SQ"4/E"
M-1;Z__&3-_VO3J=K(LU'YX>?VJW=P:;SGU\&Q^='YX/SHW\?.H/C=_C@H_[[
MW='9P<>3LR^GAV?.X.W)EW/GT^#T]\-SY_3H[/<F%GI[MY\$9PZQZR0-Z+W@
M2)-R&2<-LZ^(5F\Z9R5'V$21J8(1IZ 8XEA2G$Q4<KDR7C5&8^R<DFRX#!E9
M+0I*;1AFHDH;L*;G&W"%W,E'I"6M0#^^XP\WG3^H'6&@O BBD+JH,0NMJ\QP
M4]KN$_'_X?[%7)C*(<"+9U]%<1#RO)PU""$14&&[RNAU&_+&H>*\Q N%]Y*3
MZ3RY_FN=B,X@RL?)[!+&MG,9Q"3S(C+MU8Q)X ]\"Y6^\K)E%N9$%$Y01N$:
MMY(&[1;.= $)%M(]NO,G))//0'7'=S>P\5A+L9(SY_<)-#GM,*@NSMSZO>&/
M[UI#XZ0H=1I]-&"@M@85W:#>HS3_\SNO[CVNVH]*52I&'S*FAO+>6+U]HCMF
MA=$EGZ+:59/^%B+J?6V^A+$FIPD@'$1^6<BPRD+@T\U&<08T=4;*X4=Q4'3!
M/12>D+VN9059B1B%G4"M0"^R^.NL5X2B!?/&LMK+%%ZM+6-)\;GTU+'#;VC+
M)JRC2W-!X1\F38T9=$V&BCH/XM<K2N@Y;I%5$I<3>CFDF9(O;*$+' Z'LG-\
M6,;_J+2@.A)D"HT^\)7U4A1KBI+I)[.+?#2+B@D5?!LN!T/&-VKU2*CQEC?9
MRM;DP?4X#880U45G7&=L"C=I7H-8 >.(C V9%=![% "!YX(%ORVAMM]I$FH?
M-J&VW_G!$FH?V'30W5]!'7_>\.E5#)\]NG:.C@?'!T>#C\X9&3N'GPZ/S\_8
M_CG[\OGS1_Y[</JG\VYP/EC)25A1%8'=Y+74HP;,G=59D/+0-ZPB"" 3ZWN?
M!Z?GSM&_"QP\\<6=LJ?LE=PD+[_;\P=PJW( ]S>=@P^#X]\.SYRC8SYV[X[.
M!K^='JJ#^,?1^0=G<'!P\H6.(3XX.=9_'AW_QC\H#G#AI6A.ZM-U^SB)'QZX
MOYGL94_4=O5$#>A(G1R?GYY\E'OL\^G)P>$[N.Z:4_$"X_.'Q@X4@JDB)YQ!
M8I-(S*'/L!%]N*F:>/V3=EL1?W%D-/8-N(HDVS!'G:6*B'[ALI^2J]%]KD9G
M+C^]S*ZLOF3NS*8H@,XT+Z%!T122P'!JG!#)+&VW)B8F;P/[P:<V'(?!" R$
MPQD[) 7'23QS\EVA2ZGO7#T6XX-CIYSFL _@515+7 =K3#^LPH6AO4FG9I.N
M>9DI3%".Y$/M;1P,<^=T!J=)=\O;Z/;7@G7^=;?ORU_K%>Y86%WB.[%F4?RH
M?V/<[."1M"XXE]Q%O&0N3^S=0VVWF$D'/I@B'NQID@\O2V+)\\NH$<[\DCH2
M?V8P0DU0[9JL3"P"^Z*S81I>8&\%47+=7+ O36X?P3_!Y>M*3CLG 'XNO)BG
M.BK?".PG[?;)(TA*!LT"O%46ZK1T4Q\6*L:RB1?&R&X11 HR4CGY)%3;I$#O
MPRXI7F%R-T! N^2C3$-4"%?(4BU*1^N(42E)2G\ '&0674HPKKAW2K*8<TFT
M#UKD/E]IKO"%U]U5R4A#HE7PL):?7-RJQ9=!)495;?@B0<$G0$(XOI? ;URL
ML>4P%A2,.(A<2%<%.%(OATWYJ/C]T\#4%I3+-XMYUZ IDD=D[L1:-P7OD6]J
M1:>S=)IDN@X"Z&O< X'\-8D7%L9_9OGSZ8%@:D5DO\0,JG:6Z^3;P22 ^UQE
M&O'=!F=^@HPGQ?51N;/XYFOJ!&]]>U,GV-0)/MI._BR9D-)!HP;BLH@%Y6FD
M4!I5!)2.OB7#_(!^S'&XF0+VP?%&@0"'_YAQHXHO:7 U=4Z64?4UHR^Z8E $
M6?R6)O,Q2D\:B=%(C$9B+"<Q1)61#M;J,T+743KQBA5&@[W& 70\Y!A#-P*W
M1KZ4+C.OM:AJ3;NFY'LU%T47- S"J2I)XK0RG]%/LXID$IR^@)4F](31@),8
MA1,U&M:,E*'49*)32Q75T2B55?F';YM2T-?0K:>^:9K-TM0-?Y<T+\"-IIRB
M*P):F,48R3$/#&KW+-8BCA/Y_WL6ZK1[KA)-;;6O(N*TA:T$NA2WLB@><OII
M->]?#'7CF;VU .15*8UWY&UUF[RM!\[;ZC9Y6S^:Z_:MI(QSP"UDO7,<J I[
M4E5%?7.=I5VJG "/N(R2H"P)66YR52Q @PNIA0CK7\'0J(C,=V<EZ8+<I!0H
M0^:^$,7I4CY&2RY2DX65*_NJQ:F*'DE6/HG?@$:B'<5V2;_F.@F9\L478QWQ
MKM0QC'Q^< D8,#P-4-VP4';9/ZF]?ERH:9Q^>#-SZH4(: 2H3XCF9S.[R6A.
MN)X38A^5D./DFCEFC'>8>L,70]T"<79QRD?.=3#ORA6IVBU8_7Q-\FFB9B#0
MT"Y;5N9K;T8%0\R\>NT6EF'^%BJ9->+[9$Y3_F#3>5L&4*@;AD$UL.9&%]&%
MS)MAEE9?CNU6:4N9[7<1Z!V(F*;>@Q+?]/2%?N%EU"QRQ9>/&'Q(KL&(X:KR
M5CV,=LL>!W;EUSBYCIU1X)5LJ;HCH^( I454C(E))M$/QAGGZ#!U-=%<(QP]
MR+Q1<#F3TL$$U:[^##2-J@J&0Z3H&DH\7(F88Q:;X.;3YC(L"'4_<,P,NF26
M!7YMCH%$[Y>7Y(9)5VH*0CYP$F,QTF/YUDSL3I6HF<B;"N6R4MQ[@X\O4TXI
M?9^2>L($1VN]3G=K75?-%DB>3,O($N4,<<*$\=I/2B7PZMB=DU3SKTDV\*\R
M80W1( P')V<GACP:\WMV>.!<SD)Q9R1R)8"O!W6ZP'&1:59WF$F;$+)D*^>D
MCO2@=L'_=EZ%.Y=888'6WY$O4UTZ13)MW5T+UW(^^0*R"]302$&9*7$UPGTH
M-7PLLH-O868YII0\ WOS7+++7-\6]T6*E7PF*8+[2P<UZ_9Z5CB]5)V>1?X@
M%V--7D@C*E]<'HBA4&VW/ND%^T,M6)/Z\;3W&Q(_*F>&2_;NDUGAF:>,V)!4
M"-*T+RP4K;FG& 1%H Q)8LTB<9Q/$J:<03D=O6>2Y*CG_4IJT#A)U/FWW"NV
M CFOIEFZI>&D7J1<-I+BB;I= "6YN"R^/]?("!25_*AI;N:WMKI@F4G/J &L
M7=WCTEJ0_OA:LD->?+?7PG5&'9R-1([DC%&Z ;.PR&92@2S  4YI#^0& ;RH
M;\9:PLZ+ &M@XF=IR%XST&LF<9@KK!C?"]FZ1IR,-^NH%#BDC>SY?HHM)IP]
MWZ2 _K?!X+/].B'S%$4FT>A*JHP9*&'UHLL&XK=1TR75S+SHC;,68FK83XIA
MTKS$W#_/\EIX,Y07^WBS "$D5@Z84J]DX)E!JH'JI_ <-%6F>-CKC @[T9=1
M;75WM.=F48J5?>](+W7_,5E!+/ /XP5$O(M:A=NEW;H 4$,IPYQ^$7DT9I^G
M+5PW_<2.H6D].E_8I(^=1 ])W;>X:903JF0B ,]@-BU]-,L@S89L^U=BJIDP
M>SDV"IB=E_E*[J<[P@*])BSPP&&!7A,6^-%NR,%0W5/1C5LF%"Q[')0;M$XQ
M=T0C%XO?L_W*XM:4M-]EM'%!]6-OO$+U^YL*>KWWMR[Y>4Z9>R6R\^5W>VDO
M0&$$% 'U4_K;#\5>/"(5!/^\:NKWG@$6%?5WHQ' =$CS2M6R"&2496W5E6$5
MA04E:6+1^-0[][@$D$6 UHJO4SB(0?.^0 UCT)U"M^:,WCI_IQ7],E%&FSV(
MJ5$%$%B[*DAU&#M?SI3^+D[E=@M>Y0#;-^-:"9OPB$%W(A/6 <Y2A!@>PW<E
MR==,F-&!KQ0S4M!PF )?0<08]T!QQ?.HHJAL7MC>9G1=@1;[P44Y@;&1<T^%
MMI&T6Z-9RAL] PC39:[)7*N&2?U6A_'!K+4BYX*JZT)16#E2QDF;XMI+_=?B
M8FC2R1\Y4;N[N1I9?7^HA#ZNX_ K0G6Q.T!\.[8#SSGST@N/)//&R;<HN+&3
M/.9D?3A!RH314>'G(X%;=,0^K VOS0O;,3].UG!O1<[P">,=HG=TK8V!HP@9
MKMR. 1W#Y"8(Y-(KCKFY]CP^JFE MV<&=R)I,U(1K'G01<]AAYOD*:F+LTA[
M4BB1<NUN7)LL8=U49J4&SWDKQ;=J20B2"(7K]C[N6%?$D@!1S"(OE5[0#(Q9
MR4L$<+8,&SX:-1+FA>WG'T?";#VNA)EW!_[TSP\AIWR&H@'"QUZ$'A)]SO4M
M'>G,Q*I#?B[9Y9Y^^(7^=NN93?%8OJJ4_)??;2B$0 1F))_ =E*&A4-(_ 07
M#!H#AI-<A"XJZ,A2'K$3$2%!_*5W49%ZID")+"839@]I3.>7YB(\D+1N3CA<
M/CS?> N?&G8T#0RB4XE9P$K+K\_GNSTM,!DRCX"_?%:D)@$$29CV35I9A9R3
MQ, T*I9Q(XE%7-P[][Q[STZ_%M_,B^\V<E5Q23 ^K4Q_ >JN^7;A8LUS.!/X
M6E>/J8A4U4-'Y@$R'%(.=OD!:JA9[YA=D+IA*^RC,)W4&!/MUMV5!_/Q#MTI
MI-VBZU8AC-WU(F%ZB3ZW6PLZ/9VEV4RQI:8,):?FXBR@4Z:8..EB-#A'1:JU
MG$95_&['$DM&& #\:T(Z:HR<-5Q%%89%]#ZASG4[&[\WU^^S :+VJX"H;S>=
MD_,/AZ?.T?'[D]-/@_.CD^,&"K4!"/X;DWU'ML]6D^WSP-D^6Z\_VZ=NXNSN
M41-SNV+>\GCQ@D6&]BBB?PGCJW)'[)@[ D0![=;1T9$9_6-?# \_$2MZ+\Q?
MW;N5J[O;V73>'9T>'IR?G)ZYSN'_/3SXPGR$)^_?'QT<G@K ^<')Z>>3T\'Y
MH?/;R;\/3\$&T!  O 1V,D9BG:M^,#J_C;Q4^E"HYE6."Z,IP^[V"FQJ^-)@
MJ",-&P&:3*4:9$]CM3XCM=OK3C6H:$<7\]K1O8>TA1$]^CUT//A4%CD/@GC7
M>_2N+Q'(>H0UV7F*)1G\UJS(\BOR)*?D\\G9T9SQ_8H#DA^2:^G'[\E7YV"<
M))8[_^$BE,^R!U]*5_O[*]'-%PJ9=X :5.G)H5'33G0AZF?2P#@]VG7>*37-
M=?@GSHF@) #A0C]],/;"E%ZJE32#V/[.@&MRYG$P3(/<2V]^! $PB/TT4#+@
M8Q XOWL3Y[T7_VA;]K&[NM-=B6Z^?"%0D)>H8_TL4(ZOC3G[2<9S%N3,TIR/
MA3!(D"PN4DAKX1*:VNB?18]8*AM*=JMD7+&UUZ,7:+N=4Y6$L"K+G5&(XF3D
MH#0DZ\_N38)[+?SGNW2SW2)%M*2#ANSFQ!;!"H\2J;S7663*UT+?R&6_G&IP
MMV9@>-3>WJ$:.+09:0/V.MV=38<& )P[1J!+0YI"02XHD_&HI/=29FUI7V?@
M<P\N =%BT<JZCN=/PCCD;]G11+\9SZ#%T!MH!H:8BQ&(%;)*M+WH&*=G&)"7
M7H=SL/AQZS IG*DLB,/$1EIKM](DDJ02?#\.O BU *"""Z)(X=?XM#E2>N/[
M-)DXW?V]7<2J,3NNZ02B[@;^\8SZ\8%:_(W.Q10=D3[KH#@BUQ&GF6E(X'$0
M^>T6VL#/+_EGB[!+]('GIS:=,UZJP>R2^DA]ZFP5?;H(+B6WF7'3\+O!;X//
MA\[9C/->4N=C>(6-HM#7),6ZW9)>Z[Y$R047HJG])M I"5(!@#Q!C8^3R)=H
MO!X.3924,KEJ(YT!A)[!3:B#^VYIY= WA7QP_F&+/H[@1<O:K3,_=MZ.&3;?
MO+U8].0"]!U 6Z;%1.*"<6 J9$ZN@7/\!-L;[DKU,:W*6[TG!^6]-\+JTO'F
M7((O<0@4L3!'Q?.7LP%^:"!:NOO[N_P"\PF-J^-:'M/H!G12SB<O\FZRT"N&
M7$@!WC)  +F,&39:)6;\:\8[E,XL-ZQ;<-;^=?!IO=T"5U3LG,SR+*<.8/7^
M).EQ:9Z+U1[@'8R'4>>ED&SR,(_X6OD7A)W<,)\#3_YA7J3/?J>_6==K)@BX
M M@6FK0[,N#7(]&#AI#?")9?>#'C'3Y /S")=&RZ;O&V\V3JG >DEO<[SB'V
M(<F8+"@_SH.1XW8^#HIVL:'Q7+NU]BGP88'PDQ_D#)\&&<F!X7A=-=-S'07Q
M]TF,)+3U)SVBT/[PV!])&OG(^$?B"IU_%AUV7_IW-,+)A9^&G\((906_R>&Q
M&U!C>$?;CN9LQA"(/'/.9V^(3+?2E-*,I 'M_CB8X;2.@IRN'&< T: *CNRV
MZ63Q .PFVBVZ%F(DO"YHR_X]3]\!K#FNQ_V<)J. <W9H$.>H?J -J<9<DAGE
M)R4UB23P(,N2H=1?\[S@%5HM*>*ZCWF9E]]R1_+ =I,\\,#) ]NO/WF@@0JI
M4WH_0>DM.5Q$XW4=\<A4U-Q%1+%5C>\S:RVD<_R52%&7G3Y( N9?7CR#^MKK
M]'#'T.5%?0!2=B;(7=_"B;!U;>T52F)MR7]@*K(*'5+K6O^:17A%=]N\@A49
MAH126,QTB06XGL"P(P/FCOPO;T('T0Q'-Q>SJMTIFN/98<T'>:?^7ZA3=< I
M-DN+6?GP^]'!YT%9]!Y^\R8*(3&#C< (W G-R&>I?IN@QH',D=^_.&<D>@*E
MTA;S1I<M3>\)*4VBU>#"F^^5D*61E,>D&4O4H]OHF#0E].HC\*\#7[5OZW_=
MCO6&=DLNYMJ!V[FS<1)O%*JP_<JS6<P:PQKN.6^=E(GA."9#]/)&J=^J*\X:
MIW_'N3"T!:F">:5W_7XR^#AHMPKG2^6''Z#W_)YPA5U"$G^8^+3?.W3A[X J
MF8?X":H&M*8=-#J@#1!AL+O%V*"-,:)\@7#+!L-[8(C!XOGX\3.#=B<,7[L
M=A+A=H5HX==1+9E:0]6O8BD[//&6QKIXQZ$Z6D.%*;-T=I&Q^,;T>5P? V6
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M=ASDS$^14T_3] 8] LD%R\?!V4>0?D!"";Z)2@/M"-W%HC[@=4@;SQB ^T(
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M>OX,:0*P(M!UJ-/A/P,=0H+.,!>&\S.H*Z!#LR1+R .DX=_J\$#P9?!40'V
M^@;_TCX7\A/L<]D.@HPB%BJ$!15)ZYI"H1'YKB-8$TJAV%]2O$&-!:N^<TZ(
M\[-GL";5%K[0JZRII0CM2'&@5P9]'=6'6$5'=%R4\02ZI@;&GZTBT:<66G)^
M&0&#@>7@J4B-^JCB78Z-^0S^B/PWA%5;0:L:94S$H?-^H@HB!AE:3.C#VM(O
M*A.TH,%F:\LGU40@370KPP+E$]$(VV;9>#1\Q<YA$"^A]15):'J13-)NE;$*
M ](LEH&7+%.&F!?#<DEU$-^X/CP_#WB!R%'AHVADP06(4L-$%EV&L( G-$U&
MQ$.%!<R0UFU+&"'#;!DL239$>(6R'^I[,,O]L' I*(;F N!)4"8"%D#G$KGN
M\^/YQ>AU:!XQ7FV(9B5#4.41]O5'@@2H_M3E[]#HXO(,X,T'_G?E'4CRT)UH
M[%ZDLH$JV)WI T4&3[8"7Y@%B%.$)739H5S:&F,0:Q+7M2U4@8VW;(9\Y2@A
M%TE$_A;NDZ%N!1-*5N@1GWCC-/IE-7,L6[P]LK",K>WB9QF;P8&N63X+=%]U
MI-6@4I(U:6'J??T2VP."SQ2ACSM1T9Y2Y&GI*WXZ<L-<O[>=<^OYZ#<R! C8
MSK$ <?F.?6^'7K ZMO2(@9[KUE'X[?:!+-UL/]C;AU+198-[#]75DZ8\V0XA
MOB[(. 0!O75%@5X/5J#&I/_'<@1H]%H49U+ "Z24]+#0(Q* [X4J%UAP6Y/5
M,430O(LV!:@E A"]L1=T> 02&CLU&4%/4A:H4@LZE.O/?X(\+2!(C1$D9DH4
MQL;%EWJ]M=)O%]'QW*\-\+"X(]W"-]JF0Q >@_B\ 72DM>Q0\^J=1+":3J%7
MA;P\CF&+U#M\PY"P%A4>L5.WT*:VAP:U]")6+ +=NGM!_]>* E=U&4@02@J2
M]/P,>F5K,@A_L;@TP4.,32NX;,>6W\>5N>,M>O"3YV>_-/V1QE]"/WWNZ]2'
M+Y86]!B^-]ZS$BH&)16ON3QD4XU7D11QA5+$Q9$BKB1):0"X/?DH/!F51P^4
MH8OH,?J(95*//6BI+O^,'RXH03'_N[B BO84!TW&#JWC;S3+QJYH;14+B0BR
M^@.=$)0XU6C>\ZT31E]W6QT>?N-92).P0QV3::.L20O08T$4RC& CDMU&NM1
M%!:@0LU*K'A5J8F+!MN@!6LH!V$I0%QQA8NM/ "E]BQ>6SJ.5PAUO7;-@F;K
M%ZEH"]G.S[S.CBK9U@O9J+4ZMN4R-E^D!JUI.S\[<5$;T20GK'8CR-]8!K==
M4QRE)LYEYI>?MQV^< ODSL^V5\A1QRB0.S\+4"%'15\@MS"RX5?($=E\/55R
MP13)025SYV>NFCGJA"5S^'(X)PNN(HNB9HX.5C2')'2UMO@U%,T1[7"*PKFM
M<KPDI?"ZL2JFIZFB0WK*+J.C E31;3WE825UYV=>-754%"5UVT]R?K:UP([:
MM;PN[C)RC"4<$8"-BVJV3,U&N3;OF=G/0Z'!J>F*>54(;V8V>MW%%W?5P9;)
MV8E!=D)Y9/_J$W.H:Y.'(:X"2=RQ$TJM56$N+PMS71.Q-O<6Z!?EL?Z[6O^E
M=L7P!-IYI7=)RRN1;5R2<W[&%>@WSNW[EREXI>332REY&Y@A0*&1CU0^/WZ9
M5X_D\LSX!6?MH\7)YH*>/$,*>D(IZ$F3@I[D%?0<;W4<?\VW*O;DEF:[U6SS
MW5JS$<5FN..7NN3FI2ZE9J/3K-?*?+=2/C^[XNM\HU2A.C>52C1;\(YPUG<E
MW& B3L_/[)".E1M;SHN5D>;2C7F<^Z[SCQ/EAC?P%Y12P]=%=8)3=/!F:J#I
M1,;[Z+%R@E7FFW2_X^BEH2/'LM"%&SRD,S\J^5:CVH>683*"1YGBCWQ<E"Y0
M*6K#6H8]MA &,SUK6P@EV1@K L08= "!WZ1)GQ&=J6?;"^AKBK2\"6?#!S]1
M-C+G&A4;89_=/? 4B";_77 +1&>*K,MA_CJZOWULZR5%!:MV>(.M]P#+2_ L
M1W+Y1)[@>SSQJ!C)(HRP%D9R&7&<&=P-OLJ1((0-!R'6"-$-CL\:[T6,SUSX
MV.+7JEC"Q-V2(,=:<M^86,9=Z"S&F2L/IM #$R/U( CC5(K'74=\WS!U031[
M\E5OUA]D.:'^7/R;%2\VL]L!\YY7@.8['>QA68?>N-=M_6[D36#WYW3TKB ?
M]'I@G*#Q)BBW1E#+YS,7=&582-F)G%:$BI(1;^0]*.LWCWT=XM)=NXTJQ E5
M#Z$J[Z(JVAK JQ+Z#]H"\B0H*._#FR5!UU%!)IY0#:G,U7HC@2_-2@;HS9[:
MM>_BKT=&?N"B$61'*:$366[K(CB4^=<KC(&W'\SK*\'B*-2[FI-]^V<UH,KT
M@ CO -HHE;I'G:_02Z\A30D,LZ*:LCEUN]8\S@HV!]X8Z\FUWGC,C!DK&FLY
M4(5K3O[U,%;N9M(%!9^'CG9?JRSGW:QL(V[8]#O#/(!;13*'$GA69):'E^:/
MAT)^L10.YHWFP!T"1@$\P?SO0GXQ/\(KFJ29$A#ED:!<4/8/AA6X@J0'^*<)
MO/[A1]UURA=?6#K'%)W(L .^<Z_#AUVC2B4JJMAN[8_'OT\OTJBDY0L)HPH;
M&E7R=*:8]B6+5Z(;80@G@$5(K#ZP!K]HJC)%N7AH&2 :*:T/17*Y2&SM&3Y3
M*S&&K=I<NZ8-5S9?OE]5>+8:X/[=O*35N:MZ*HM_?![*KNH66_5ZT]G6H1\#
MJ=!PI&Q5MC)0A6;2C <AO<_GB0UOP_*:\+RSW"SCF:.SQ3Q=R!3"P[.W8<ZZ
MW2U[3$H;2@H\*U0E#6#:WM>J/;Z=76=J?Q_N<J5^B.Z7EQ%>/Y4#)Q1;!]"H
M/:'-;+()<5%((4<7N-Q6SCB5U[@4VDP90$S)+ZFA+$D ?@9R'2>_]'6%8;+%
MBR^II=4LA_F811<KER< 99G;5@-+2]!1S; /*POWZM6SHC^VJT=T+3VXVC+_
MJ)84SU-RFF_&%O"GY?!-^(S$SC!T-IV)+XN'BZP#C46>9IA#<;7]VE93GR#\
MFCZ%NFU5A+XU[OO-PLAL/(9Y&5^7FXLO#A0GEP@W.J*0@$R.YO+YA$K 5N0<
MR/'I?!;JAVPD/._VB%HZ& NRU!5>@+'*\P5%4M/:TV^-29_2;-@@4B:"<5/D
MH;C/'7<9 1[QAEHS][7-?M,XH1CD9CMV0QO2;=8-8]21A7R&W2VRD \7ZW8\
M =P]C=*%\=5(DV.+]? B!W0ZZZ4(XQLX.(W2#5\.5I1NNDBG<TDU2>'SZS)V
M<FEHL-GM]_5]3!*[;I(J+V.@&H!7I29J;EG*E*Q:JMQ3E5%?KB;??^QSP3GD
MKNZ;A\2GF,[GJD+$XDY]8Q5;NZ0Q Z<N@_+8;D_:A0LW42^2ZU21I5EF>]#.
M)S,;%&&$6N$$_XK0NV6W*]J]J.6M8:[\LJY(EW2A,C%M90*URNPYS?5F/^[J
MXVQ9;]^W(G)_ ^N2KF8*"F7#2UG0OW;.C%QC<#3#%0+%8(C.V)$RA]Y]Z2++
MT2RJ(HI:/QSL*\2X3B%>T'AKY?R:5FYHJNA9#G-=?&$;?U\R]S\'QU''%U^:
MW9M*F]3%A):S:.EHRI0Y;2D")*\JH8SC&+G([H!K8_:]*/=FC/CC]NE%>VIU
M"T=/OSEP8L<=.$#2E K,4U_Q_!$8B5>=@7HXXU5J$@\V#1E;AWJU;);.%P_%
MEK<8Y9;R%*:@/LA]!=@J$YB5%Q04A9Q]K6G2LZPHJ^)TJWS[6<Q??V^^#$\9
MRUV ;D_0CX%0!4%G) YHAF8R2<T [HVT@WW#7&[[+7\?"6-<$M:TAB&J#W4@
M&*"-$-(<W!G665=%2^X4OXZNO[5'VCZ.R6&6:@ZH1;64-DA-#$>V3LLA&W$8
MA3P56)I->]7?)4&>=L?6H<8JG:?S$45STRY1NA7T1X![]1:C[18^_JHLS0KE
M]K7Y^[[BZA<[B9EZ H:)6P%E%74[VD=PC?<[+;MLQFHDKF".SA62FAK9 UT'
MBE>A2#.,5R;U<.DJ+Q*N"SZMJ? \N\G:P^11UQN_RX9T_!O6LH!!#*5.(V0!
M"_F*V7T+^8[-\3C'O1-;1,']+)T-D(LYU+24[0'=)<TPC57N-N\[L\Y?9?(\
M/6'-HV]$WP&=T@;P!VM&N_'Z@_I+%(NDIJQ8I.%32$@_;+H<ZFWF,G0^0#E;
MB D_9D-H>9'SL[3%/.?WHCZ6I;N;:G%4C+#G<DNB3\/#/(4WE.:+UG7-Y](T
MQT;$?&^<-(>ZR2Q'9]CME_;C)_HV>  QSL'$"YKM+IS%8RC#9ZEC2POKOYN3
M\5?0^#7Z$Z(6WC+/P5LQ<[9B;G;Y^DHFT(\WN3WE'G^/DK0)=-0#-?[M^)0=
MA#Z:>HM\$947;\^/>")T?SW\6NEQH.J%#AF7"=1CL!<]B/*-I?)U%US490%O
M@9&!P:N2>]E>!:_66IHS<S_*W/$/G6YG&F:6(X!.OOA2K_%7M7JM6ZMT*+Y1
MICK=9NG;3;->KK0[SC*PRO>[6O=7'.D0+VA\0XI>7.$]E^;Y[XLR_?;ME]Z)
M:.+0^@F<$34N3H@C<N,%S?9" J>KNR5,472PJPL26*FPKY=FK%+JS1[;?T;R
MW_M?M;IPNF[XL07GGLA>L]>[&V-_?$7B,17HPO$3FL='TZ'!YC2=#W"[WT=8
M>']AV=!X;S6S+62'^ZM6ZG7CE_C[X:3M]RMBA+=[LNRG>/7A!T%SM#V07);.
ML8>F[DZ>LV+9?+C#)Y8&G*']5! O/V1S6,*Y2* [?L/4QX)4M(?9]4WASS,(
M,[0:C/4=&->ZL$[#XT'0%TE_8RY-,P?7?"0.:X?F+O)%.E>(IJR3\RTZVR9.
M=_>W"M"5Z8V\SWBBT(S*H@!-05!3RN+V$*>"JF-(5X&C\TQ2A6L/=!WJMF7S
M-%.,9JK+4BTG[FA<]BIX58)_HT^ Y+KMKDK8]X>'PM?R[.G[Z 1UG3@%:#MJ
M5@.Q8 'LEC#J73AS'O';;-08/KCQF(SQM?(TFMS__J&TQ" S&K1 9PII>,/V
M(T4]2(,I>E7 ;!BDL=?@U%U)9X_7N'H4OK?[ (CUW&LA78C3.+*>4PEMTNE@
ML7IRXV@.]$FT$A@MYM4!U#^Z 9R=TJ(.[(6W_(,P!A1>U*+I8TVW=DDF:RY'
M8!4;278?WO^3.T?J,-0=FGW/%NAT-IK0R88X(S[SQHC)W]K-2[=>O$K_.6FW
MTI(53D2XQ(W:: U<ABX4#BWQ/'V0))T.-TA2=7$]'L1CT\7G$C<JW>3&Q2=9
M,X]=@NU;@E9317BQ1H.T5L/MK[7.R8-.$0W\+.:V7P])$=I>Q#E\Y$0A(MKL
ME(=?G4EC*PJH,6:_> />26N&^D=I?VU)$45]=BQ5=6;2U-?#/J^5(]>I%<T8
M>HXKTER15*U&0YZ#&US2+$<7/&=EAJPS#G8+8ERB$"]HMH\F=#&7[YP:7:ZT
MGZ_!'ZY[I+%A%U\:S4:*E,B$1G'_20#SN/AZ5V6],>N#<F_&L-/Q4*D\-+/'
M[ZH,/QD3J!@DX%TKDSE:$^7A-2Q;Z1Y)/"9-9PK19$3R'GV3UE4/>MANM0;6
M.'H@WS\,P-W-C_8^B?NC=5*B&ZL'PR?8SPDJ5QL*/8ASZ-GGZ,/YT:0YZ6P^
MHAF3VPMU/!V6Q>W2DO#Y[;)Z:S[4\^#G1&5/U_T(X4R)K_):&5">LPR1Y]TO
M>]%:YF*19K)'"!"%:5YC['?'"YKM@RN7JT2L7D5+9T+=R7<JL\*5V9O5=;DT
MRTYOOXU/W;7H*%3<M>AQ(SRR/@C6*1>:*B#QN&20Y. 87(9EZ4* @9M$+;\>
MM>QN5=O4LHAC<8/,%+1^_-"4EWRD*]1)1V*4;6HMW;ZV87HO+4^'IK>:SO5F
M;+/S4KR6C9O62:NAYY#"KT%0:<]M63[G:@EZ4^^8J+0$'[$%],Y0T &JWW,5
M7?[EQ2NEHY4'>3"OW%M[[5C0J2>\N??+*@"EO0&P2P?3??YKNOOUYJY=# ;
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M@#\@MT5$,,?DGNR!S<@G7:0S=&:O.0UQ"2X$15IXC599FF.W[V4Y)*2@:R(
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MMC1X.95]"VTRC_PA1;>IO<FI;@ZZULP/QA.?O 6?"*RDG%VVM(A\027Y%C"
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MTHGFBU_')<R7</W@6ZE;64T#)D!<T%&2+P>_!BVFK(,!$T/:"0:,6Y2^-]&
MJ9V^SWZIK)C]$J"P?-O3],O^Z8WVN,+V2PQAH^R7XPD&RVSVBO2L1M2,+]N*
M2:V'%1-@G=JADW\YV+O/YSI?UHKYH#8'&SMFL^9?;\=DX^V8S$K9,5V3>:Z<
M@\OZZ^6Y<GIXDU]Q2\:'>C9;9J3@ZLN9,$$J_GI4NA?[)?W@-;\F1DP,-><S
M8WB669:LF.Q;"9Q:42LF2-_+&_71&73JK?S>6M@Q<=2=8,FDEVK![*^:!1.D
M[FM1'RK'5K=<7&43)HZF44;,3;6,5%NH5^G]NL7B:O%@?S%C@9:HJ6P4X+59
M\^]4@'-KDH]4,1S3E;TW@U>EU3RSRR_9U=9_?:"GJ+_S= E;1$+#*BG%0<I>
M#L]K^Q>6UL\WUT,GCJ'P?"KQ>$.Y+^;=#Y)X>'"6?K[J)<_,AW50B^,(_(XZ
MB_?JQ<D5TXN#U,V^%/<KG<>'EMQ>8;TXCJA1:C%OLT3]$G&@0WM1+1.E=W9,
M7'9L(+<>L8$@\YDOW3.U_Z3=Y;I?-C@09-U-CM.:FQSKLN;?:1KEXTVCU$J9
M1H&NGA=GA[]_G=[_OCEHK[AI%.CG.=$TFMSW]5UA@L*J6D0!@C[VGQZ.;N_S
MU=Z:5&K$$'8^BVBL>_ B(D&K9! %*%RWSOYT3P\RCMQ<"X,HAK[3*C:6:A*E
M5\TD"M W]_#GI5/+E^S\*E=KQ)$URB2Z0&/&$N;0M'['R[52TFMBI03XX?9/
MMJGIQ<)#>>_K6BD?T:U[7B-%#/FFAHBC;!GH&EI*-H:&<G_]8-;33/91O$[S
M@'G'5O9*SH6?$^?,YS9SYA<R9WYO?>;,$_>[S+$9.K\0J+_:T/FSS6SYS6SY
M=>G\S*>OSS)=7?H.['PE.EX??@"1UGO*^H*IM"]&I@"MGC$,PEXVI^3#\!\S
MHIQFU[E^08I)\5@5K#VI#G_&LA;;D S'E%J:BA$L/K1$V C;6WT3M'\3-@/
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MG)I+92>@.+11JA8;$[T?E([U!4PK5]1?T 05>W"A84]<7<$2I#[>Q9,-K%)
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M, <5E?B.=Y^2L600G1<3OAOJ-L5US[8*UHK7XX:L#68[IAZP-P*PA!0#[GS
ML!@@ERNU7T^[_)#.?*!=@>EAP<GETFZ6UGSAN1.S+=$8EJJ7A4X[DS_J/GQ=
MK^Y>8_AR7[$?]R]/GBLR]7CST4/=)5'&?M<,"T-!&R?OIW3=BZ4(N:2\%F8O
M!CF5#!U]40ELN":%GT:!:6 G.CY\RETT_-0NP#;Z(C63HR87HG%7PN\ F)#(
ML<.=9@8ZL;@X)*;C/F;7HX0*,%EN(**Y'D^!1NSWU34T1;2BPZX>W$$!<MEU
MXXB^IN31\S<&YO_YM/V$<"1[,K@EHJ;8V$RW-.'@()>UZ/R!%X3G10Q>!F@7
M^+Y*=*5O;RD47Z66Y.@2!QN6VAMH[G<V8G[6-D]GADYU_ :UKW55ULD"?L_/
M5)OI]<;PNO?ZRZBGSY[R\M<5[NG&,-.OU^\N#ZKY;/?;3\#-3@ Y*$PX>C:2
M_?/HZMN?P5CSJ:I3,U&7@0]]OTNTN9]I[CO]W&F/W?F%,.&SX%E7B25X<2;
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MNJ(F&K/N]A9_FS;V/8,3H50:%,3U6!+\UJ0%Q-?Y;!W^==1N>;O[%Z:AQ@V
M=DEY;K,79@(2X4&4&-@T%RZ(GFI33!)PTI,?^20BWTG6)X'"D4Y)AP;I*-@!
M%I26(1,?C=;[0YVD>9=6(KP51SR,@V'S5HV:JW(PN48%Y.*M),7WX$,X(%@@
MW&T\2_N6/9BP.2UL0G/?\I[;E>HT@S@4N/-:77.<XK7/S1UX!='7,] Z$7.D
M" <Z>PGV Q_T<3>:-YI@K(6VH3%R%)J,SQ\(8L=D'0<L*'B;<=616;PK+GT&
M9T?Q+],AP*_"/8Z]SRWB9$,'=7 @M<#: *;$C;G1PP0^16UJW>WP?IM\4:$@
MJ#HU6_89:)<.-O^Y9R@>,U-K7&PEC*^8;"?HW!38I&Q5_ &U$3>%IG9^[7=M
M#_ *GU45Y)AS+U()[TQ\%G00T8N8.-&;UX4!2 PV$E!\&%=3MOQ>ONY@-,]]
MSU?NRP/1>]@-K ;145=10</?JCT<T*!R10?/)@_>1C.1VY@::*1@:V"%X7(J
M4HLE0E%CQ);*]4N.3Z!.TS!-WC:5OA7:A:KS9%P:@X+MH&6:>1:' Z27^W&_
M*?Y$1'#^G "/Z('/NUS[^IZPYX.;>S$<3>&]87$RG3R@X#*MEN #W\CQ:F.W
M<"(E37U+D"RBELS8^1D $-91&$[>V-MS042U].?J*A'6?Y (^R72M>;($LYM
MLH07DR6\M\D2WF0);[*$5R)+^$/LETWZ\!=R[FW2A[^ 1X$<!:!HDL'K6#QE
MT9UHRV;2]<6$&M3,#5+472,)M=: K0<[9&AV"9O/X-HCC8;S-=($J)E62*GW
MO!"D^GJ&&G,--9ML1<T=Y\OH@]R! <M8OKE)!ER3>5:=$C8>_6VX^9L65\ ]
M95A3V\R=J>,G@_(O!PPMGO-)D\!, E1HW(#=MJ-YJ[@JM/'"4T_PW3!$F 0K
M/#4<$G)([U#HC7^52T+876 "RR30QH;SA0DF["V:NB('3#??$[*]Y;M"T+6P
M*U5MSTX;8X2^:>#P:U@+6(BR@*6.(^/<:,;X5F-AY9X.H7!9 ?+J& *U0.Z<
M" S0P!]NPWM6+)E#EFW*:$?OH,/3G8$=89=N9- 'YH[YKIIGE;U8KC= 5DW7
M_X&G*\"R=!@MG+?,^5+,=S0-F<=Q-!43%#%P;;LC)35#[P#1GV..E?@T/U+(
M-%BBRR/B[O?'5N"^(IPTQ6/H@9E$+=5L.3V,D=,8HE;+,=TAXPIZ?)@GBT"N
MFB;-!O1$*7FG.,/WP*+'0],, *6)8\+=K"Z&^H9EX73V(.* MSW7!N[ W9#P
M,[IL'PD!W^/VEC?1W(M6P<VC6N3'1"0[-N;9P76P8\NOP0E.KM=*I(OZ4R]C
MY1F-S@OXTCRXN*N"9N2,RH;19 A8$51%VZ61A#=E7^1$"+$A-F>TU"!@WHK>
M%28"BA';W=X:W^]7D1C+#\8!A"7/#WYAPCWJ"(>:B++-/O9YWJ4:P_/RDU$\
M2?<?KQZ_;MCNH#%\O'RZK_0+SY:=Q?*H%O?5!<(/(61M(GJ??O>A'.27$,HN
M4$I-(IJ&(Q@MAX&*W'1LN@L&(-98N\VG>B5\Q30TY9@+>I)[L'Z+3PZ$52/3
MM)T^33OV!YN6ZM>6/T_U5-;E#O=X\["&B,:XUS5H[M'K\IB3R<06OHJ(7'FP
M<43H&5SOY 9))U-%'A&IE.K[@A04'SXS=NFO.ZFD&VV#&Y@S [_R72[CD0Y@
MH<!K^9U4AG2LOJD^NU,JJ>HM@6RZ W_: 2G3QM&]AMF!O_ ,%Y'.(P)J5@]8
M": ,#%_VB^> E_G49%2N3*:HMAB[Z0>'<:TN4SI!QN,*!G)E> .@S/"\1XL4
M%K#$\-2HHC  +GDP17A;TR:#!2F<([?!'/ ;G*9R"0GON5TWP%[<2>9P"?]+
M;FZE>[!YD%EW1,$@!7/47G#<M!C,%_CJ+QF>-P=2BKZ6D4:L7_@>1FW4MNJ-
M"HU!8WCF,+XHDHK\<"A%RUV-&P0%GGV/O@BQNTO41<G<%MID*-,J:M#IYKQ_
M$-AELO@]]@8]'P[_#M( SAOE$P<O>^$6(,&L&W1.^%WCRH9X64[>$N(!6<(\
M.9/R>\4%,YY_!Q!Y;-$7 SL34G@:K6\7<+D0KU!/:$F4.VP,^TKAX'KOA-TK
MV977[#Y+]7;;N55%1+E,,]@/O7JI&)T;NT".M82;N@:.I'J]K*4JYX6NNO(D
M^=_FS\PN$"&L2J>SC>%#6DG]RAPU7Z_:WW[>E&K5TOY)6:J>795KY?J55#Z[
MJE[=>T&)FVK9U9P\^FY<VA\%=KU<VMY2\4:T35D)W(,T%IMW(>#^D%,L,92R
M>,$FX;_)FN).0)D[+TYE31Y8JKPKP:*NUU*!_3P8IO *E>HG7EI*WX'U>,H8
M>C_Y0&U*&S%5ZU%ZD=&A8#GMMMK"A"S4M+APY-DI5,4ALII!#(;9L)C,!PY@
MF98^I>3WJOX,1Y!F([_HH,UTU?X%,U&88Q]'M=KHJTI#Z3<<[!;7:'G3!AJ6
M:0='+T>O.?Y;QC!>'^X$6?=FF LUXPI+*=U^D/NEX\ZKMG_2[(!8!DF!)/9@
M]5-;^A[4TP:%S+S]6::O3()]GJY\J#L"C#OIL09]J634^! Z5O^XGL4FCKAG
M%NFB-.I&)G<8N3:!QTB'<R>I8]*9;(WUS !.DT#T$// *VX*$>CF/50DFTQG
MR'GX;TOE3$<F9]. ;[@E.]XP:>!DA!4.&9S0UAJ.C-Y4OLY<4_K1M%A@.>S2
M09=W%P3V4N&<$!,F%Q-"W3=>\'XSW 1H,A/\.T=( )0@I.CW#)#)@?(I=$-Q
M-5\\YMU[7B 4)#C)2\KQ C&TJJ5^Z\7O2X:U^648W&C"QV4>YC?  K8,LRF\
M16/<W:*LV;Z! 41>PMID4<6"^((PJ7GR-0^<,73S\!L5BPA$@(R#\99ON"18
M&%677MJXL31^8MR)&N=H@P3WGPFW";$;F@SJB(M,Q!/Q,5(UP\W$/LQMMGJI
MT_E-ZO1B4J>+F]3I3>KT)G5ZDSJ]3JG3&^?EB MZ'A?SY.SIU=]R-*46'_CP
M/9V1X0LP@6-"'\5@Z&..51K#,Z56JF5?ALW[U>\ 2E;42+I=P&KRC/V8C.$7
M"B>Z??+6UUT8COWLIQK#RPI[K=P>_AYF6]'3C+[]K!\<EP^OX;B>5Z2XHQN3
M6+6&PY3?,Z5IEGFCTP: 3IX/.-UDF#HFR!]%7/*',S<\$7#%PTHE[CH;[ ]0
M)>?QD(@(*5AZGHC F4%N4"2GW6@O^8J>L5MS#%.-&%TT!^9F'YGXV8C/^).?
M%XWX:O9P7[W-[^FWG95!_-\P-;I$7I'5F!.]EN.1-].@UVD:=*20F'?A^2<^
MEP*Z:HE4-6X<VI@),+SN7=ZWNJ7K@_W<9XQI/@CU=%O& .#_6<CL7]=D""%P
M8BZ!>*,Q[?J9,:$@&<@AN*X??ON9261R44D$*S%U^:.1GOH@I*?V$GN+Q/KT
M$WOB6U3>L3VK-A2U,?Q3?U#V]H^=NK6WQ-G(L3? P7COQ=70&=^CP7V?S(GC
MU/A4&9#-)'*I]%1VG%D!_7=#P(^5)[E4(EU8/ &CQ4HFZ+2RC=9C%U0C9EH\
M=XZT@72VUJE<J)W4_L-RM('ITB7-6>R,V31LH:7:T["1?B-3TGN28CA V)DN
ML3E7F8TCQRGQP2(%TP_^[[>=,=F23*3R\[-F^LVRY:\@X_($2PP9,^E$-KUX
M,D:.AUX7C^[?X7!=Z)QTWP]769X#M/HG9^CW%4MY2<UN0,^ZA47MO[@\/V3Y
M_OXY5]V_;%XU%[W_C3MQXT[<N!,W[L2WNA,_PA88]0;^6(SH7JV+9!EB?=30
M.PP8>@>RU2WI"OX/JJ7/LH;9I"7[0,3U:6HIV7YVZ_:,6:_G?Y[D!;J3?/<O
MD!> 6'UOXTP8^U2W3RJ13Q;_#M?OVXGQ82[A0B);S"S;)9P*'.D+[%*A*E?R
M*[/HY":3][]:<K5_KRJ?Y;41U[@ 3;(1MO5W)D[FS2 =/ED>%+*IQ3D15RG_
MXQ.I]V$"))')%99#O6A9DI\<$.[(K:/[I\NRKGY&5.G*P-$'K8EAX0]BQ=D<
MA^_CPG6+)Z^'$%D-RJU84/K=$F21FL4*VU2K!<V["#"K-(X,YF_,[S>:W\$X
MJVA$:EW( SSZ8,J<8Y\M^+7I,"4JN0.NX'J]?U)H_\G>#C(?H\_SPE4J4^US
M0&DZ7"KU'^_%(FI3WTB",6D\OZR=$XN?FY0Q6\1MP7R^(DC^J#LO6TP4TMEW
M(CGZ^)8;S&UB1 @0^+!JO&?UA6S:@^!I/5 OAL?%N^N'YJ<HS 2C>VQY%8[,
M2?:U,K.BF;=4NKKX,8U,GVR<)XM?1:]>87)^G+6>R^Y]I+6>FY(,"A*HUF6#
MW_WG6J]2^&3_7]AZ_WSY\Q&&X*JI'PO."?WRAOR*:3:+3@E=FC&YPG;9:D$3
MJV9.R\;]?5Y0S.L_RMU9:Y.-NU)IG)MLW"]!QDTV[NIEXZX\V-06PW)Z\%4^
M0<X;%<5GM5N1/3*6VPMCDR3]=W>E.*2D[&0JF6HL+SW[];=1O=8N7[O=[,JT
M25@=$N0H+]PCP7(RQ).7:JW>K)^SOK8R)/@;4LLKHN$K'P3$=.SYOTDTWR2:
M;Q+-9UUX_KX5>P$#N8;S5!V&C=X. $FH-]^J=O> XC3,+%/+4!2O-/V48597
M8YBN#+/U_$&[]"?[\:TM8DWI\X"Z2)N*[WH1N\8[K;+Y\G?G6# NQ3>HF^Y8
MK+6CONYT545A\ P0.ZV^-DTMN9<K?/NY$^I2'9D_.[-U-"7)^:]#[][RT#L]
M:_G(-"SK@D;_-8:/0[50>VG7[L[?4F?^;B6>8)'X',+U]FS/2/I\,I[TZZ%W
M?S"^4@O&U_3SX=T+7/L_ 0YM#.V[_#!IW+W^>EK2%3;SM87P\*D&_FR^K^U#
MC"!(V(D8;CO[&5[A8B*;V3B%%TW0E$?0#_</IU.)8CZ_//]P;&;!&;.#<N<F
MFS8>#G]?=E_?$GEZ^_T<"#?AE):OS8\AG&]$R]<FY6<*E<)RA4HPZ#1A'&^I
MU!@>G^I=)O\9G.G*&X(%JQ">6OXXWNB2U^GC> ^F5GU'CN-U'BHO1Q?I)[65
M6GF2_&_S9S9B'&^J,<PI3Y569G#:>BA\^WE0JA]+I;-#B?Y1OKRNWI1.^)B/
MS>S=&<#^@"DE$SY1LK:W1OJXX+S[M!@[GTZ%IMYW947ZG]'!N.FW-$#H]Y/]
M9& :[M H']_>%4W5?/)FU.(J_D1RYJ^W]*8"<]P"?.IL1.9J%NS ;"9V\BQM
M; R7E??ADL?!AC</I_FZRAY_7;4^$YFI12$SG<@5"XF]R%1@0F8"LP'Z#,-]
M3!LD,">@%;??!+)^J\O']UHTBKJ]O35&B?T12D0R;2%U5%::A;W^Y5X8T:H.
M1TY_G 6WR^7#7"J32.6B=,L)7)B=N'?!9(?GSS=GPV%5<QX6N_>%L4TNETWL
MY:/J5B8RC8!?3 %?]&#(,60'^P_CNX>L;UBJ;44RW&UA<),K*K\[E;2'='P)
M$,+?FH;UX!>6RWG%%& _%=4I@3#J*A:NH1!W07$&#5(A^HS&HT[PZWW5NF$W
MJ?)--K,DU"V,<5.)8B&7R&2C&A6,LV,LZB(8W YN6.J#.<:4[2V:<LYYWC E
M@VJ<_+&8J@YZBNV0$Y)7/&%ZE:9)7;#6M(&DJ2!<<>"9.PC>XF/3 4(###I8
M1P,UR'9,U1[P;"V3,:D'^.O2]S1F631??7N+M=L<7'\JO0FF&<U%0STD#+XI
MZQTX>TUFOS"F2Z/<$<SY]4?2G[==HV^?@2VH=P[!#L01ZRYIKPSO7Z,LI2H-
MI=]P<*I\X% V+-/>V:DA,#S%A'X^576UY_3<7)):ZJQ7NTZ5#_*:QWT^4(B6
MZOB.Y^'.=^]P8NHM;*D1VM&,3%X]JWALOI,.\#GB$!A]-Q6K(/V#XWDGZ9J?
M0%/Y-4C3TS][R?V2_+NI/*PM38,[6A1-]V+UM']P1#D(!EA[5QKO(!FV/!+C
MBLEAM,!WBTH&USH(*X!"0=(&KLU?*4N^*U7[%_UHV8][X"_.<0F,?W4Q%^J(
M[@MX2>W%W@2(K0CM]6!>1(E+LGG]V'7NJ]?U@^R'(VKNZW,$4<5<HI"/U3=$
MGK#%X*+3X&9C/$U8-W!.^#,<+45J#KQM$ISX5/@.W8V9(K?R&<5SC((N;$9!
M+V04=#KYEXV"7AI'_V_3V\M:CD;>S'E>JQUNQCFO3GCFQ)!UZ\P A&-*O]<F
MI09*H_I,+0NFAVJ2P9K^MZS7&.8NTY>_7MO6_7-V*6&;SXT! ,_G(@(]Y<:0
M:37]N#*4;VJ U-+!P?DU'&NI5CXH5V]HR.Z$&,\R)TB[W7.(DD13H&2%>RST
MCD_-&)8H[D5.E)Y[U<;0>/YC6<?R]7XW\SF,X8]*WFL,TR?-?*M\GGFX\$<:
M3!B5'$'0NK0#/YV02+\HU?RQR9N"M[^XX&W/+W,;=IU7Z^54N:NW5J<H:G4P
M5?*KT899Z^+ROE*]K)T\K@RF_H;RL<UDDDW!V"<7C$6G?;KZA:])4&E$H+D4
M#UKUY%*M5*H-:[6#QO#VN?S[=U$]4.3TQ]=5!5I5FA[0L24^*S/'8#*BEQOV
M3"?VTM/3_]9E7,2,%1S%_$S%3F^IV@A:;R7LYX!>V8IA'AI.TVX[VCBMQ\^3
M%3A/1\VGDZL_]X?UI[>T;WNW@N=M@9P#BM@$-I&D7:R&/O,113_%"?5Q:ZD$
M?@C2BA]2*;4_\=(Z8[9WQ*Z\,V8'SEC3OG[H'#V5<TNZLF+2V:D?XIJGOL][
ML?G$6(5K[9W%PNM&J]E.;3&9GOW4SE?_.VLQP#[<>[TCY?ZU^)26U75U87Z>
M&[JJ/\,),\S!=&]ST+4XZ;7&T"PZ]D7IHE,<:N^ER((C(/D(;S"P4$8]=PK[
MO:..!:9/]>RF?'9U7JN6OV"B_S)]UQY3"+E]-<E1O1_IJ)Z\1&-HV >_+SJ7
M=Z]+"E<LD@#N7E1F;6^)G&RWIQMOX ;B<>$MW#Z*KT9\],G&\'IO/W,Y4#H7
MAYU9?/11QVSM7>=3#"@W"6,N'WG4 N_T.RW:US39:RS\Z_MR[;69MLZ9U5DM
MY]Y,>_H"Q"@'7/BUVU1>R]?/"F=LM5R/T_>T\?1_K*=_AFPR<K&^6Z@%.BI]
MU)$*N/#>)19F_U)V]D]%R;0)#9:6)=XV9)DNW99"EF@75C;*#*NHNFJ!$GUD
M& H?YCNXVD^67UKZ'R7WR2U_7-BD#@*W[IZ1B5ZL:'HL(WD^FT^D"_./>_WB
M;JM%$>>="?N90BZ1R^260YVY762@[94?;CO,,J_S7?FKN<C6M7,!-0/>WIK4
M#7BT:"C8K\!D+:.C4^/XL1*9@C]YCO,\NB!N30#_T'C1>?702(_O8>&ZV+TM
M= =FTZ_B\PZ,]((O[RCP]L2)6Q%?F]2/*.QC>N.8FT0F.;&$:!P]I>GH&>V_
M/;Q1_YP=5G+GI79G^>@9Z_'S9CD$ET3D1'>.'35B _]%XVR,I> MVL1YNQVL
MY1YE*ZN5VF?IVT?E()ZMC'9[!K0%/KAXGHHM5\8AG)$]CR;PUPRX4EY/HOE,
M-DOY?"Z?MHK%6'R!9=C^\>/N\.['CYW90S6IPK>?R;"CS6> [2V/%'%E86LO
M;C\ZPD*\>V&ROCR@TO&2KGB%K#$1EL#(T"DO-H8GA99R7']Y>3I*K^N5/CEQ
MOQ =JGE1!O>I9EMYLC+??E[4RA>E>RK)H49-A^6+\WIU8H.FQ0= #EF;F293
M#@S+M@[DOFH#)N%B)A*JBC< EP:]3PVS%8.-<MZ[=&/XH-AR^:C2L?8?UY5-
MXD(.A<8PUS\IU*X!#[=LEI #L4OU4"K?793/ZN48GEG[(,1?E+]?">@:M>Q=
M[;[U='G5?EB9K/35P=1>0,O02Z<GPXNSW-5)=V4PM?'J;_+W-_G['YB_O^\K
MFX$B452"ZC*O%@53M>F >4 .Y9Y\,*Q<W#2&!]=J[OFZTVS_ZGY&VGX 5MY'
MWD)H)24 [DKDE\?;L].PO11W<2:1*WZ=Y/T%(_>=;I94*I?(%(J+PV[T@<WX
M!];OC51W^GU-96;HB*JIVY)UJ;7V?KTE3?G=JJ(+';:YL@1\7R'_/Y[KQNFQ
MC$.<RA82N614U\<OH*E^+F7>ZVA-IN!&RRQ_VKHO#8HCOB)5*;_VF6XQBRK"
MJ( !!<)KR6[T;"$87O=RJ8NSB^%%;<%S8'[6G:8=+%*8R"ZS,L-\I(Y"PU*.
M83&5 .-\*K&G[7*54?3.\Y!-Y1/YU/2Y#V]A_,J,97.PUY[J]*R(3B@-]:S:
M4-1&S^+G8VC_SA;*QX\GBOHI<\1.F&7]D"Y,XUFUD&)_=P%=,3-'5<F7O]NF
M3 QYXPE8BAJ<3B62Q?FS'F)).''J4+!A9EBLA;WBP8(^O ?IO'=S\E#?3ZM_
M;MN;.KZ%)MG,0(K/O),W^5#O)]4"NIGF4DM*79L[.2K9&&:KSE.U=WAQ>O/E
MDJ,6'^P<K],-WD ')E-4&X=73:S].IQ8A3W+@HUA33_I[!7OT^KQ<N+?BR3.
MJ?',*)1/$VGDR8T2>!-Z2Y2(61]3(/:)8=Q28UAU[EX/'N\JC_N96<*X!\>E
MLZ-R7:J>2:63D_/;TME!6:J<UZ3#\^O]J\KUB=?_;1/37<.8;K$1E4E6/1UJ
M5W(WT[_;6YF8Y>K@+-N(RB9[N.]<JU4MU913*X.SOR'.6Q%#/>(2>S=1WTW4
M]Y.BOH=S-YUJJ/7&<*^JWCS\N6H]*TL:(#XYZ+O/0'_1 0?_C[TO:TY<6=9]
M=X3_@V['7C>Z(["W).9>^W8$HXW-9,#C"R$D 3)"PAJ,X=??*@T@0#.2$&Z=
MV*=7MPU25DZ5E?5EIC[B(+ZWD&X2,UOFGC(/<RZ7O2ZSAADL1IW:NB BY*D&
M1PHT(=+ ]RO_!3MR;[KZ*M%WT\]" (GF/R7@&*!L0[]2<"N#M+4,XG4=XLU,
MS<49;O$&-.,LYGS;ZQ-*X%&A]0(&>'<"KT[6T]GXYH/O-$N58C3UI3_^*#3
MZH>P5>:(G+L)Q\(N@0*ZEDKG_5RV_8J-W\C[]1OF^HUM+\?=":OV14[A2#0X
M+KVFC.H;KF<EGKK]'+=7Q9/TT]1)4B>LJ?,#XW'L#.$Z2[F=]BNJ$.K! ,E
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ME"[@'1'\A9-H+$F.WJJ 6+JZ99E53BAR4?W@9GG71O]M=A=\J@TWMCMLM,>
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M2,8).>;///PI3;?!YK.[TW6G/,TQ7UU6WMGE:K)P)\R>QY_-+1Q4?2!$+M+
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M64R[,ZCU+R\&';"6=K_3;%1+@UH5J3?:I7:E46HB_0'X 6S>W3_3%?ZLR((
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M MN,FIXK)VWU&10C2@(SDB5>$/59U1PM+7EAIEV50PCY2!89CA8A0'H1Q)"
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M0@@TD/48[H)JGW0H*DT7+B]$V/<=(<#'$*T_$<+J922;MN>QQ>2?)MA2 =U
MMUF9HO_\[_]<72%U!K#]-](E)B D[T/+ MS]C111Y.I*/QQ0S*?[#(VZS,TG
M<@KW/.&&W:&!S81DG0"1^(59^&UQQ%=Q:'O@X_J5D6$ZJ_Y%!JL%H* D -TC
M_T7@U B5G6T>LA!/&[_U7_UK\%?;J%^/^/_W7\!J,ZX+-#&[&M' ^,##%XJL
M-#Z#A>E,WNBD0=.,94 [3S<2!:E5"3)HAU\U-^.CD58EKMY3$D/G_'@>- Y-
M5H<J!EK34;HI=6N7%R#\12J=7K?3*PT:G7;X8\="64R[,ZCU+R\&';"6=K_3
M;%1+@UH5J3?:I7:E46HB_0'X 9QST#_3%?Y4+Y[(%0Q48>&;J,15R".G1%C*
MC"D1J4+O!2(<?:C(8_\_^E"1E!)G &KAF07LIA 9#2=?*4-7?ITC5TY5']:C
M6<!LJDL(TDKI#JM&&2[JQ(S3Q#P\9;@F7L>#5F/RV*F]QS[U NO%,B;U8KGA
MNCQA"4+\6+Y6F!]_>K6F8J3=4F_PBI1+36"J6I'0H%=J]TL5Z)#L"L9""8QL
M$C'GM6N$-G#&&,2 .%P;8/ ;A.$@E&(96 2F*??EQ0*JMQY(BQ:57K%?MXFX
MXD\TW..5X\[E!273R!AX.W#$4>2"0+$H37K#K,+<C!C;%$U:^3S;\DLC,L[K
MHX9K%N5?GYNETOM93)(-NX2S.ESG\?Q:>I,;;YRK"5%&+VU2JWFH/_$JVW3=
M#=#B-MSJYM-E<1$\H<$H2]-6'U?P^K'&:B%VUVL>UV2V -^5A^=.MXF /2W%
M5WWCD=KFN^XQ. ;XJI&,C$'*;F&'M[!9O">E/!;$=.0Z%7<#=\,IL_@+EMLF
M)'!<.N%"?=6G'KEHLS)=LR6[K65U9]Y_$WL/RH+#9^\QWM-E&MH#M,WQB>:[
M;73/-"B&S>>/_7I8F$=;ENC5OKAIX>K@-HT,:'+*@9=,5DB?XI#RE-JD_<"O
M];2?SRIB3S3MIO9VKB]U-(CAN ;.G<;]R0BU,$6%#!U39N65\3>[<SP!*[:,
M GP";-(O/YEF)4?6"QWT=K2Y_#12=KB@HJ\%89L%8>$N:-U?9ZGLJ/$Q+UHM
MR.WI_G!RE>5[=Y T[MCBAA!L0P@6)B$MX1JYY9?(/3]#*E.>YR8IM>U;K:/!
MJ@2:E'A!O[[7<5@,1&")/$+L? +0=@@Y,86@6 P,"L \L9R%>78%6H<I %(;
M@X-*<8]$N.PTL#&?@A%!4Y5I*.A=,6WK3,CPS?^M]-AH#0:%<>=]8RU5BT39
MC_TU^^J78+IF-U/C;%3^6)0IEL+SSL7R)V]7L56BC#<E"MGERK-E3<1>N<D@
M$YP2N1L\AF4SUH/'?+6]" SM[S(4K?9?D3)-R-)A!+/]U7X@$TQTN;^SIV,0
MJH UJTO>53$T5\P\#^Y'TBOF,DS!8A"F6"R&?INSKWTFG\YG@P]13-\9=7@2
M'!$0\*@'%RK&6[FLAS@\6L5X&PQ(!;#M^!N(@83AS2NQ0.H\#\(;"'G\V9?H
M3QK^\%=J+WJ!CWNF658!B#>@H7"$"K+4[=-?<!.0R>YACC2(SR' !S@6O4<P
MQ#IHX$]1O:% ?/Z?A[<O9(&<$DI<M7#' \<]=;O]8=''4!:FO*R^/7*=:2%-
MD>ZWONAB)@L[/#9>*J;PW+'=#(+3ADKTP9"%-I17'SWF\_WF:WZD-K@,?G*X
M=?!SFA)6C\%/:4(L: 3"[WZ61(;XA329N0+ETD,@N%<@\%?11$!H#"(@A2=@
MV7#5&CMT_;I]GK\N2CD<_[#,;>PM"(]!%&2SH&YZPK1%[+:>H8*/A"S?&W4T
M%"PAQR9KX,]$'LZIW@92!U_<V-U)@YT]92Y;*;-Z]W4RL_QLY6^GV+R>76R3
M*"I)AVO(>EM#9)9X]UB?OF:%>N8).UQ#M#9XP(G(C<^$ KT-(=B^&4H)J<,T
M$0_1C\=44,BFL!IU5^UQ9[+,YB*)@/*^(Z"322!D0V;Z_*R6O6V]=/.Q.)&X
M-\>CNZRE<"S(WIW19@(MFX'?\J)$@/\I^<%KF("X1OXW$I#__M%BY,T'M!@Y
M@ Y#+K=H2YKC> FZ8=/NF:WXW*QTGB2<Z!(N8^IZ#&)JB\6DG\1/KK'HE.9X
M\/&TZ3NCCJ6#(R*(.-KXF0UEU\CAHX'!$*(Z3VM$6W\5EM?"Z'LA,"R"8RE$
M1> <<YD: ^NWO%>((FZWL!3J/3_B'U;Y-[3@&+/G3AFS6]#_^-IA;C)4O?.8
M#C)>]VI>P<;J ;R]#WL= 5-#E +U3<W'YLF1&U. @W6*A73TP;Z%_BU>J.<7
MHE=;C7#W8::_=H,NCP(%FYO@L^S1>-(3AH787QCYYJ%<Y\A[.FRQAW/^L' Q
M1T_B2.6+9]9MTNI =+BMX^9P91 6!->\T'?,<?CL;T+(D7T!?=^/:<V:ZAF^
M/GC,D]U[ZDA+/W9DL=?+SP#P8&@JFW9.)9Q=K\BM3J!^=I1UMEEK- KS-54Z
MUOM'IA/!M2-/H6A(*G'8AS+^A=7G6KP_^J,WJ(9U^4IK+T3IN8;]ZZ8P/*0%
M;GL&A<K&I#PY*4_^1G0GY<E)>?+9UNLFY<G1+C0I3_Z.[#VS\N3#7(MI4L4G
M3L%J/_?ZS)B6)]N %<ZK<+DR*"%M61(8DI:5[XHZ_'6_ @A\,@XUS)878!%>
MWP-6[/)LKZ9&>'D5RW=53')[C5^+P36^PZ(^>.&]U[MM?M#3X*_S;=\=];5^
M\,0X%PY!,PRJ8FBW4&A3/W14Q5 4Y="N ?!17-4[6$/CF9],*HO/U;H8;YBM
MPSINIU^]STRAWUV,@KRZ]VM"P5[A!TA%5R\A@T:F%[!MIHTHPP64#OW@MR0_
M7[ TK.HGA!4RI0E6FL)/"<1"2>1%8'Y'U7#O#<W;9<W!%->@KO8=]+1;K^9S
M[Z,W(YA,)W0[%F'/>Z;TX0#!= MPPQ@WA7 .:GDT]#2;2A><AXO%J(- _BCM
MB\!+MJG18Y.=%E92(4SM<P<N 4L^ZS8#EE ]7]T'8@0M+,3@9&)1#-K"UO@M
M6;N9R>\N3R3^CEF1M"PH-#IOXU[O8= - 5B<M"R(9\N"&-FY90%!%/&\A4V0
M>7Y)/U0[K^FQCS@^,$5TBIQ'JJ)M.T!8B#Y>D,?ZR:-C"ZF/']/MQ]<,WAZ/
MCHE+PI^\[3M6#JEI!(Y[A\^<&4ZW=O*@VD)IG[+T0S&-/Q3P;/1*ZS+$QFQ"
M[ 0X&W^\:FP("0PDB06P!ZUORF7LKIRK/'UD C>](U&4QVX8@>1-<IAS)Z$S
M!MH6 ]@2UF\EJE'/?^;?".($.N36?^?<^V__X]G/ 6&J+^( /NIA'"B6C ,-
M9AQHYB\;![JC[>>&^$Z&?"9#/I,AG]^HV$(9@NERR"7R$ZCT0"G&R/];C4!0
M$>_^9T!],MKRG,@&RM:!( ?]"(!<G;"$*2(;.M/2):O$DWMHLH_2)0]8:#\U
M Q[7Y+X$Z"^@^WN6+L4;?)^4+B6E2TGI4E*Z%!/V)J5+2>E24KKT5Y8N08ZI
M%_0=CM;OZ'MO[TT97ZSD_NR,)C&Z6UNE*%'9%?/P/K<<WQ1@X8,)"2>O9PJ*
MIJ2LR4]9D^4PL).4-9F:R#K72K>K:^HM2SE6-Y5B5=UDOISE5_/I<7J7OS&9
MB7 R6P^YUNEH8G3@YD'%TX3F: &8H"S2\:QFVAMK.N!-T0TECFKS'!E909.I
M:F9:GV_CVU'M8YK=Z6(&'*15#[-C)YZZ88>O,B93C3N^D3Z6*9Y3,5/M6.6+
MSB_6:IDQ,1&:V)@*2OE<XG/PPEF7,,5J4FH<YH3M07T-.O;^DI\QN3(_<#TL
MU=_DUU"K+(RQA#1B7ZMW0HD.84J8U6M/7'\4]BGA3$J0PC'?DQX'K/4<93IR
M;W[7>BJ;%!3%N"#*L(3;I[?LH'U726?8(,-^'\81;*@?# 'AA?=!S;+*Q2&,
MMU:OPO-\.D]/'QN9M-OHZ93ANK76!!&B._<;<!)\4%J3C4/\;:TUQ#3_]OC^
MV&@W9L=HC<LX.X.>]5!>RY+<PZ%&,:P3MMS9(PS, 9, CU06;4+8\>WK(O\T
M;LUS+D/R2@Q"<K.5O(QZRVI3G!6*V>"#\<,71C]?+! *? X7._LZ?<LKJ6A&
M?1VJ:XY:<N,.+7<^)HXQ=?ZT<[X.B;]9OO#XO%(@[TWN!"*RLJ G?!WW:F G
M<T94VG[1ZD3>\Q[HA<<AWC93O=M,;SG/BNEB9^(V9@IGS%-0L;B9YAT;A6<+
M?U5+@Y.%]F8*^LX-F'6EN[@MA*R@+L/^;*S:%UBEVI.>!?$D)+!Z\Y)/>Z5V
MNQ;<C;XPN3B7LY7B4=9U_)RG8_U_$+/]"@7OL_W.M$>!'YW1NA3TL?)T]9 N
M,T4F9)UQZY*3C@3G7-WFLQA1,@052%*1&'7IWJ;W7%)[F-0>1E[#%_LBP^,(
M#+L")L)JPKK6QWU%PS8.-'#G5%);F-06)K6%)S+]I+;P&['WKZ\M#+0.,-ZU
MA4D%8;@5A/ZJ["*=C'13'$FWW)*@*I;=^0.9FQ#IF"1";JX+X\K;8)9/AI\E
M58(15 EZ+*N+U,27#^QT24EI4<H[XA@LH4,Q&'[V.+A9WK3G=^M')M2ZP&3X
M6:R'GQG'3UEHV88#D.O&SQC1#U&:8*UZMR#7N8?'ZA9\O"$RF%)!KZSX$:21
M''M/AA4+J70^=TZ%@\5@U#!2#_K>?LQ3-_-,)L\>H88NK]!R2=%@8%5',9Y5
MUKBAOHKE)39B+0<-QQ">;+&8;ETNXTQV@.4LL=;)K+*D4-"-R99C5"BX4>]/
M=-'MK9<RF7,\"5BZG!..37L5[C]F;:K$9[,AE@B>MCXP_*%M418%%N(8K%MH
MESSY&'WVGC_EM%UT%+/ /*2):^E4,9^-39%@)8ZQMI46Y1;9USNYS4]GL=,B
MKS[H6"W*8X4C=2C>=8T[$<G_)>;@NTV>F]"?#'# %24P,#LZ/#<K,9Z+'(>V
MAY!)&E]!8+GAJ<I254<'2UXWN='3B+]?H#=,P[*N,)Y-2SRLD>E7[YA[NOS^
M&,[)Q#4I)SBPA$M;P&<0A &'(5;D#[\(S-Y;,'8=0^]@V;XHHF.-!Y-YE)G&
M8E[L/M CQ]..QV6=TA.\];KRNOQ$W)FU>CFY#PC\;!0243&Y)#EUC5XFIN<S
M#_;P7BZ@;[D/\.JQ3< =0H5IZ <[#ZI_] 7,]Y^PG8WI(=++CM;MBE^C]F@D
MYP-7=9>W.L6D5O7\2D1C0TA@=8=X./O6NO'V\5:H4<5BF_)J84?6JP:YFTA\
MD$6LX%FIC(MLX!F7L0:D3OM[P_HK3;](A:(XZ>#GJ$X'<7DT*<&_J, VH)'?
M>#+R.YB1W]EDY/?93;--)G\GD[_/?O)W,E ZF0!^Y@(+H.G&N?;<.'/):</
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M%ZV)%-;X>YI N:?N?CL>/7$8\."/G;5ZN^JQT1A_6>]L+I7)>D)(>(9"!*Q
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MZC;9MAL]TB))+* [%F3ZQWX; (DG9U.>!;N#6/N0P6&TS4MTE1%)EA=E@1Z
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M!4^IIJ;\629$FH*KH#E1.0MHI ,O:X]%A/?EG7%)$ ANHK!Z%W:H/'PKD:U
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MG9<7IG>XQBN0$B<Q%,,J4\WZP+X$!M;YU]3J#@HJ&31A65)<66=<(P0.QMS
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MA':*+@-8LLN2&>V-0X=%N0QZE*'K6MASA1OB'LCW'W\@4L)\V/H_". !W'&
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MQDLJ:S>#!>1T!<%ARJ6B)")C!DH<?@Y5,YL[32"@;5$T".KG#*=]091X<H:
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MJ);S@<C%";&F)4GS6R0P<A@+\=O\*L2-W!&<#"',RM:$%<%*.0I>F9/*?L1
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M7AQ>/):H.<,Q<(R'>G;MT1/E\E=403(.6@M?N.E"%$D+EM,Y)0^]6?));Y9
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M>O82BP4+YP#!#_%CA($WS[0H*3C*!<T1+'0_OP M<*(:KV(F)9J<<G WO;R
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MWV0M$B@GB-W/5X_M#Y:NRE$N+[:H-!"5+-2^].PJB?1/#I+P?Y6%GMM5E@X
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M)E7(F37*5=>_A 6X_[^]*VM2%-O6[Q51_\'H.#?BGC"K%12!/G$[ A45!2=
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MSV?[G>#<?\<:W[(/&*LKD0X3>F>N_]T![+LN>^(!>Q^$ME,I[YOJ3^ ;-#^
MMH3B.Q6BB1:&@N+9\Y6Q;Q@@Z*A WU@'GBHXS")2*:LDX&]Q""+#(FE6Z'KX
M=!R.7WX4'COT,>'!?_P HZ4R%04_40!''%N+ 9L$)GV<]+IJDU4.=M7\\OF[
M[V=I_FL$FTM#>#C0J2=B!G/],,M?K\,FH9>JAW82%9EEZK+"Q]4-E GL!)\4
MH6G(VBD8^53=,*#[."!92./&^:K@//V3C61?NIFZL^Z;MP;U3_4FL&BG^H.[
M2_S:/H]-LOY0OU\&^E#>6"E@:2&\GO++<+=H6_G)-SXE4 N</)3Y1#QY*+"?
MFUY ##S-"CQJ%W<$K"C:AU_B_R2&O>)<P']NXE9@\@*" RA9&3<?/U70_*$"
MS]0$' M<*<,H+\\NK=1.,?]+S\,>'X:DPYWI&@7".Q"S0-,-5ST' QU+3V[B
M8+PGJT6&2N+3;2;+=SGMSE;?QG=?WNKW8,@O 5W^B;V <PGLGVH5\,::#C/T
M-@2C*#GB5IT,H%.A5Z"SK8:%]H*%R("S_7W!U3#M\\M9@E_8@'%*=@VM=WTU
M4O U/*C8+U*'D0XSAT"<P3\^%:5^A2B 0SW$NE=4/9W[1KJ^9AOVV<" &,L.
MX?D^50/HY<JXD @:?K#P=03 3)^U$X(1UJB7%7S@-^1SC@WF:M#?S)9Z\RRA
M[&6F\F8)LN,?KXA80+B"?6K4S[\]N1^&MM4%W[(T)8.[UKT_KN^>;RS[C[^O
MJ-IX%D(=[XB+Z^WXY =\_% Z D6R\AZU6E]%K8M.G(8^T!)Q-G44+P8Q$L3=
M": ,7M<]GF80CNY'IV"$DVHT);\AR^RHO?T6E#^IM%MS__-3H1(3#/_J@WGB
M?Y4^5,G/)7L?&[,>KQRUI[5-H?[INNDJ,,VE28[*1ZC/7:]'=OFQ!$5W/3CX
M:$]+U).S]\Q;PR\\PT"5"P;KZN5/Q@-K*KM9 V:X:FA]<M^.TL:YR,A>(.+$
MN)1 S<^3 @?CLK6"?Z_V]&+9QJO7<Z>8XX:POM[K:CR@V'W KQN;>GI<'S\4
M#O=SAHB^E8-US^DH;NI?JI=^%P?KJ3+Y)P[6JK?@S72_%>?.3^EA/5%'OSVL
M'^VJ_+]>\)W%7BY]OM4,$Z\R46,?YK:_["(J+V+>LS#%KC\63FB5)P9,U$*N
MATI'.[#'ZL ZB&_R_:1)[@9)WO#PNVH"BL1??\E=^:^_INCRR1%^BG3UDWWX
M9-F:IH.=@76A]F$=.DBK1?[Q]\F1?9(Y^_BA'/I4"03<WA*N#Q8LZV%:]&J)
M8L4HZZM<H/R/13KOF&4A7I]E.5)K9APL(IFQX[K]J@3)J],Z<ZA#)X88Z85Q
M?C*M/YDH*U0WMFW]QK37:8JC.7W/W SR"0'1\%<[ 6]9R!,J?(OED \X?JOF
M]L7WP;?S0Q\_/*+\#\P/ 3_I"_[+K?P0\N[N2\FM-I&S[8,9N>DM;OT9/(^W
M<-!/Z%C<L4;HSV#O;M[IG*<M[-W83\MWBU]C\*A_8/#@&\5\J'?=V9YI<-+V
M273]M68.Q^^:N<J5E:NL80&Z!2.)XE:B*$(]BT51%*R_JWG#WV+>"MH$;7'%
MKB2475M?8]ZZ;S=OQ;3F8CLGMQ)E*,T?8MZ0G\N\_9/E(/4[[W2^PKY5OF3>
M/G[XWO<?;PK/[WM;7VW?"G85*7??#YN9M+[O!/Y@^_8&%OI)[=O_K_#S]Q7*
M5U2&OX3]JE?V1^$YEG\7+ DX])%B*4J_7PV)\*)PSD^SG+T0I' ^XN752\7W
MR>S)<US4.H?)8D[>TS\/E^TKY?JNR' )ZE^\0'C\WO%M>3KH+?VE)2%TB9X6
MH[V5C+ S -:\=Y-0.%W?)]GV VNMWK\D\);O?':4."6&71(R 593WZD+))M?
M\,2_,-KG'"$/NMUL\<F2^.F+ XM7*+#O=GDKZQZW=*_QCW_':8:..]0Y$9@!
M/G[[Z[MJX_/9M8G/^33?JW&K(^6Z?::^9D>!HP#R &8#7,UW!G179.G*I%=A
M:8JG*U>UC^\.G7:;\]_TXN'U1/ORVP@"OE6 1?Y7KR$>T><_E:>/(\JW&K?4
MA%2JB>.;@<MCB>.>SJ\\BA<@%U+ =PUO^?"S\;_\S.3Y6XXGDY^8IDD2%^RK
M7'=$,<QZD3LFG[XW>>5D17#QIJU^:;'P!0CDF+N/5\K1;AS#EU=><&MI4^$X
MC@94PEYW@'_/P1ORJ$*7(=.U,_)T4\_&^$_E+4<*6 F*QO_\@;Z!XC?FO%7B
M?B_(!_KJE4=S@T#/S^:1,'WQ=)[PQA>I\L+G'\U_YNA'I>TOFK#I,2SM)OH8
MD*\\^O+D+Y@+KL).6'::4XCP.??&E+(63%5?7P3D]?HB--?_C=:;#VB#>$ Q
M[-\W>/:BIF[)15E\\?CDCM] _^MEG7%ZK'5SW'_=&11I_==-\7XYW/U:FG];
M8 ZB^8 T;R'[W][Y33I]F?=ZUX5&KR,#90!A?27_+:2%-I?ZJ;57OH+_WFBO
M!/B.5H&K^SELUC\Q2*_-^I(@,/ET]E;>S7P]99/&5ZBHS[9PYHGXBB="9&.G
M@]9,/&#?1B<]WV !+G<T*J?<WLL*_>Y0M\_XF^F<GT+'? W'O-JHB<!EB8[H
MD/0!(H101?+VLST^L8]F?\X/4X5;&KTTZ9COJ$F>[NRN+P2W\-<YB_KKZY?_
M_@?L>>_$OBVO(@_-QBV\QJ_4>?]^B7FIU]U9E=R9KRT>G1(\M[3U;Z/0GFX*
M+=EK^O1"X\U>,_J5?%I\KX#*<?17^6=O'.55*O0MUVOOIS'1![Q^JW+C%81^
MM>D]X@?<?)9[E?NBJ,_YR)<"+2-C5MW\]-FK7S+S_P3Z!6*KE7*F%5#'SV_1
M(3I)$<\^E'^%>,B6'U@^O+XL+SB]2^'_^3*@#./=,HR',"LZ; -[O-F"^#"J
MHT1142@.+SRO9CN5C?,V1**XW"H4,%JG!H*1?GK#40QV9SJE^*D7-Q(!O$B+
MCX M.@3G*J"GBG+W8T' J7SN=D7XXRH""ZRY&$77GHU3>6F8X_7M>0.W>G9\
M_'"Y<7F:!+T\FRUH<;KI?>0,EJ]MC],\R9J6X#''RV4/L-H3XA7T?%;UT+IK
M04[.W4TT][S/] 8\M<5&&7+W5O?DP;Y-09[F?0GF_''B_NON_K'673#)7Z\:
M^1=56?/BK? 1F?IU/43/$+K%/?HS?N[<Y>=C'XMK/-2G3*T>)KC4/;0'AG;_
MJO"XVK<Q]7'R]^?INUXH67_ [C<WN@N7^FKB/<6PS_'.J+Z0.QMK8'Y'XCW#
M=G\'TN'D ]:ZBU[\(UK7_E_#K?@A\!2/\%=^(U-\;[28HF_W=T-Z^4WSOZ&&
M_/@A!A^"3BS\^;AT&/K.2A@7+T-5/8PAZJ,##ZE$P-5A8 A];>@Z.@[\>?H4
M=( +B$1H11+OT_G?P/>W(21NF6<I8%[#1-<>BDC@-,JEW=<%$Q*^MO0]$$UF
M1VA)![C1X)>C5WM2N<5[EP1$&D#!QP5:K>UI=FIK)0(D7,[1 59,,]0AX.]#
MY81SK>FZ"X,2,,8:(EJ# 2!B-:1-B31<9*&*>KL+GG4$<;<*?_2W4_C]=$5G
MLF"ZGQ#RM[KX"?P"3G&4++(5(,7[ @$6BLLYK(^>%/7 \F7-=Z$ Q07Z=61K
M0 B+_$,)Q1V'BE?6\)4Q._PR=/8A&&I@*27FZXD#KDJ#3\A&91#]9V6NPW8[
MZG$17F5]+!(\@A4%NA\ +:*<JJ85Y\\*IRO>'@+:EYK0A,CW!?)JY8A"7[:Y
M RZ"GQ1E@+;GJXE3YB_*\,2'&/HZ"*UUK\2\!A\K:( 5LR+(,7PI=!%4@9KO
MZ!',M%3@.07'5 E$O0WMJ'BC?S5DY3PB4D8Z" ZTJ98X$!O6\DM [37\H)%
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M6<5\E>"FO"XK(W\82T',-N?X(D0)O,YWTTSHUF@S%7)+&_9,C&HN#"E)=[N
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M;PV;02P*/7OB&USN=&5I4-W4O6&N2\3"3_)13!'U_#".:K-.?6.+9KT6D;V
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M#P5$WBR3\)PED]]!IA'J21# ;O'<!O_QQ[U: @GY^2GY8]Y+[7/ OYTRN\.
M\%.5T6Z7$+J%N(625P((R-_ [ ^:V9JQ3_J&=\G:Z>!!=/!FCY\ !D?I:P/W
M'+>^!3B;XA.W(#1N0E,8X.;Z</TPZVGMA+3$ &HI9K09C_'#I0R/FVL(+)0
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M5#39\J'2*L!GM&"H*MWGXLMV!:9#,R&YW,2.G;%W+13'XV/U>>2*P/C>@N=
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M[[/:]$7?/^F,V;&.[9'"5PB4%R4ZX*"*6@&*C8>I((NO"U]Z&5E>][8)\,$
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MCVF[P20@W:3AN.SWGNJOCTBKHZU1JY/F&K8]+52A4]&QTB S)ND[0I Z([$
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M3Y]-%F^>5Y6+XP=OU!"=%Z/;'IL7-N0L9I@P79#J>DNSDSKQ2.=]Z?I92N*
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MR5-0U5#>UJ'YK:O3SCY\MI)*T:[*OZ.OKV_:"-!]HZ)4^*[D(9DJQ^B/MVF
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M!VZW[!TI;CIJ!T!_+9X/F6@K7 .ZOP?U0"?'J6XX$5LCFTKI1\.C6FOZU;S
M'+\+7]_GM-P4(KJUP#T:O%?V-8#BZE>IZ_*IRREP+R+S"51C4H;;6JBP^6^'
MR:PIQ2;ZX#*N;*6&AQGCG6K'.=9VDX%1.P4<:M6S3$A#/)U?1OP1BT#DZ#7
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M_&F6K*<7C^ EK=(VA@X=_KV[5R/7 /T54=$L!Y7<'XV8O3/D.>O;O<@%G9!
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MFI/*5DEYW,Z4SHTV_L1W4(/(9 &BVF3N]$.5E]-9_%P".^U%Y!H/P]JM?</
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M8BW[ON_=R>E5F+NG.MB.$0;/FG<54O$<TIKON\XX,^:/.V'-+ [7 .<ZU%P
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MA0V5?<!D9CU6C+P\6N$.6/'939%\[1&B_$*L"ZF5,[ER,.HJWA1_S7#JY3L
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M=!V/3(W6PW[5_),A5"E58:N$Z'#>"002,>\<ZH:W0JJ21[S:G)S!P#K9[5/
M\P#EFPT$;Z_T,,%=;&*;88A]YY.=9*]U242A$7(\-!OT^X!Y0V-(HSP^H"#I
MSC#"[KT5D*07 =N.7\VT'C(_N=' ITJ#:9/UN)%F8TB/-Z:KQ.\XD86JJ*^0
M4GH?@<D=J8JXGHVX'-$+3A-OA_<6!)LIN.%\"C:)I>Y $X/O%2I')[$;/54M
M 8DV']S.M'7L8'UOW= ?T.<CV$<1D-7O5_C;@JN,A0F'P5;),'9#BT%/E1VQ
M1*$SV?WZW]VG9+"+.^OOR;PPQ+>.SE<!FDSUEQ1#]1I0VD<Q>(D(JW.1)-D/
M6Q7>8C=;KDA-FB['8T7UJNS6G?)>7URJ"F_@<6IXB ,YB[ZXR)%/1^SJM4J\
MJ]D*<<M-G9PI6>^<!CWX"ID OV[8WLQ622@RK\_(<CD6"GV!IX"^42XVP+V!
MOIO?)Y=+\LJ9]M_@0RP$ATS&=\@I@3=L#RH"!P[3A8LF2E]RQ:L.2S9Q*6=@
M$(XMW2GO]OJX#I(C3P$.F2R^ S]\*HZENU'=ST+%VNKTCOE6]^\-.AXX(:XN
MO0IFA<'">M_@WJ8M!#FTDZ2>FXA5WT<LX.<44%&Y^BH#'-J*&90\O[FB8.?K
M78L!AKX(TS\1/N$JK+YYS9Z2M8,E+(]1Q=',$HMBR4F]<,3)O![OGK5ZP%[V
MDS+#D)3=Q$#,94]M,LJ#POV.YOZC)VN\=6P@W.":5"E@Z<:86I&OG399G635
M42!=WXGNOL(98]KP^%U9K'&BX"Q.'!%PC.3!WD9?I%J,"97E]?2]\ X*Z9!<
ML, )O@TT)X(OZ!&U!#^PFFRZ<,J%?_9?DC\:TR3U,7>2(B]]TXK_.TS>OI,F
M-J_C#O(-)8"L,)X7CP\Q ;!(*[$J]V33SZ> .H9B$"1\R410VDO]"_'PIKSJ
MSE$FU)$,Y+$M\WLH!)_J]S!R[B_]F<)LY_EUK,N#]HH,K3P%;/!_C7(;?_CT
M%,!=9^(!%$J-O*JALIP?8Q#NN>AZKMP"+"&J=W;Y'Q:,T#@1 1BK&I'-%!6C
M:6EC'#6@0$V@:Z<]C^<((BR"EIYXF'9XP7_C5[X06:5(4G%K\>_]&9@6'V(#
MGCT_^3U]I)=^)<R;_9_SE%D#?%?L@XAY)0/[7*B%DJDLP_XK-S=*B/!)=ZF$
M4LRSS?;"!NV,W,IHT?!93_Q7O%!\E(M^$L0E#' \2@\F PVV*[^XNGQ@]#IN
MYVUS4/M.6"T[5UZ>0>Q3CY B=-6> B[3N^G*Y( L70$=19]30%(5_QU:4=C5
MGQ6):YW(B?4_RV.%IP"/ZX2XA:.J"(2N9>:&;-GO8D^(1\?"\WZD>*%OQHYB
MH$(7/(5G;OX)?/T4P$!O\C;MN4$7&N:;C^)D$?QK!:;NJT?4"Z6QNL4Y05TD
M77D(%=?!T<A>L4^2PY#[-[W >'Z;8.*T.BS@ZB'W;-_G(!9ZAU112Z'O-U<K
M7M?&]H:"024)UM3)%:A]33O/IP$N>$[-% >HN1852N>$HZAIENV&FCSO>3RO
MG0*N*Z\1/<Q6QSMW35""6V^^B/+P>!K 5(K7WRJ+BE_1PI5^M+GUN-%H>N3H
M3LE?/_]3=! QZ#;RUH"*\.1F+7I]\L<S4]8GM\+T'A-F+?;!(<@>$O;<VBF
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M0JI.A,Z*>79W,WBN[Y916.!L@&Y#ZCU2#$"#.N$7>K=P9 @#P$%_)6_& +"
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M=KT_5.,7998'!]0^KIV/(_(3R$GQ 99015B&^M!&FK+'K25),K^WB/^.]<:
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MHK-8S]995Y>:/,7^U,79A_4WHLKR/@,2?U?N^?HMC@T9))6RF/P9E*MZ6/Z
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MHL@,?H*N^:[VI&:\2I"^[54Y(=JQ=;'%?67HZ?0"G^7@5P,:.GA.3DK:=U3
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MCQ<_F'QC%R.OOELO2%G=TYMV_,SSB2)_6>N5-PU[VJ]&YXX<PM1=84*=@?"
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M/DKR.KQAW??P'';7\(0_L:V3$3!*=_"4L#?[L2BX!X^8N0;8X@(+X>>%(M>
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M9IU%TI^.&I'UK^!P(H/L^';(IKAK)7M*N8Z?I(>6L6!4AT2WC24;\W9(>F!
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MN1W64;TXDEKC:ZOU$_XW(((Q-D*G>A6C2D3/5Z[L@/I7PWSQ2P:?X?N1\'L
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M\69TZB=/R<F]#,(J1H+.#W3:P?M&TC:=YAFY7G<$=3S#/^OR@M!YZ%B4Y3T
M%]1.+6S8,62R]<:<0OJ,"T*[G.CGX6]\#\ Z06#5D(EVIQA?&;T?!"U^PK@'
M9%+=O@_^_9_G4%O-S,H.=]3(LH^*W\8<9YX[R[YT>R#ZYV7**3%]+$SEP-+
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M4[\.&\^$[/W1(]6QT;G468'@37M[8U6/F([F5?-G[BX?KGQ*:=W>UQ<X_<E
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M@TEG"B+S@QR8UEXENB\2TM:7<;;5-(Q[)Z<G\+';)AHHBPTK]&QX!63DOR4
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M9\OSM[^YN*-/AVS/N>/6.T7/)56[(5TUGQZ3VNLCILXE924M36&AFW?-<_<
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M,57-SWQ89S'8A=$]U:<-;^3N64/5>U>:6CL?_$S +?_8NIYR07E00U0O@L@
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MT:I9WE'A>3VB+J?B4XM30WVL8^*UU3>% $@,]M\TTG]R(!D3_P)02P,$%
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MZP/*-S'951T/6?DUCJ@^NHX24K,)K#P__L>T_[#L_\RP;_]/EOT/P_ZG7;,
M8ER<NX^'2P8  6XU<\(X /__]4V'W/L_67@YC1#-5?F0VA BJ0K'P]AF[K[D
MKTRNCQG!@OUV+,P"6\C 2EO=>E?\6>(Y\[>':7%80-0(09&ZR=/ XP&3%/-S
MIE>P60G7%]9)& N'CX/'_+#Z.(&8'2+']%@&F_/HFRV*ZXG3I]/7+WY5,JD"
M-T2A(*H%Y9/!<CM@PRGF]VC1-=X3'=GS=,&U\!?9)<FI(G^G\-^BUE*,>OW+
MKNLVKA>'6)]W'\O0[IR(J%^E]#LQ7KJH,IB.XUPT1Z/MU_W"F<1H84XQ<UY
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M"^SZQ;W*M&=]PBU1(-E*)3_>>#W^]$-36N#9$/Q:T\'M7)+,CRXI1=HT)C#
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M<IUDC06L<N5BIC/Q'6823%EL1^-WZ#FQ@,N%1VF([90NFM#B(ZWP,YMSCV)
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M^$$76O48/TZLMBXEHD;^6530AL0=Y[BMJ("G2[KO4^]VIRP@IM.=K$CY/3_
MOQK(6[DBPG_G6IG,9?L+'@T<>.^5(343G%I9R:ZJ*D2/ZB!,/2U\,(6?(;K.
M'3V6:/?Q3Y,.M8<4!O,J'OE&W91 BCK6Z:]SH*%J-+N[Q;B#SZP0X9ES[:'G
M=<8KX.-)4TO:6=YI%$1JDY\L[IM]5GW3E<^6^-3#O$5KDK0,:(U0WM%;^+.Z
M>$F%R(!70Z=J;7/0&K@_8@%R9 M8Z$#M&S&'%OD@L #>#@B#WV ]4<@3W-G&
M]7=;42_Z^,<@;9;$8MJ[MO'>CD!6I21HT\WXX0O>OOT1719@:[3N['.&=(&7
M;.K1%52.O+76<Q SVZFY&#D?9FC)U%N;CHLB%S]ZN1R[C3P^@+/=FBOQ9E;9
M@_*ZRKYAI [BS*%74"+W_,<6A VORJ X^J4N:\&.3$&'Y&Y!6,!HQ,1[AC>*
MLM5+/%2T%K.)7@?75EFGHN?%W-5[/I+;6$"D+(7[H,*?_>5C:?)28J2@@,,I
M[J6VK)GO1-CRZ\U6@.FIY%6NLT5'2:QRR<2[N2;?\<IR??C@-SOIN8!!F2&.
M4VTY_3\F:VGJ'\OU=0_5-^.6=M4%E_^<?+1]CV3-NH[3?J%4/'T5^T/SILH#
MK7:I_7S^X4'%4RBH-5XK(TR4_:CLZM7!(0[U<4#*'9?EMF017N;Z2^T\E][?
M"&Z>2T!OG[R^?U'29'S?NBNOA^BJ?-"%=Y>M);-K+%-X81.B%Q\U6RC\)"41
M>, OM=E(V<8"N(Q3_F=_)PD+.'NJG'9DI_8("^CM*\ "IOX&7C\NP=TSX,C)
M^R__.0&/,E<+(*ZSB-+\T#E[)O205B"%DZ3]Q<?V!^!7!GTTT6BY5+WXMK2T
M1T%_[183KC-,S&8+LT?\GTYR^VMF[Y@\FL!XKT5F$&<X^WX]()6:'#"83B<K
MJ+1>1%37BE=-V<+LX\8\BM&@,H,='<A/R+P(%F#C13 ]I>)16@[Q<"OBJK7W
MX/];LE#M%H:J'%TONN'?!%>6:*@'4@:R%HUZL&F\)3,F[WU%^=B5=]?$G*FK
MLU.ZFW&C>8'9@HVC'WQ$0%?QQMDPS:X<PB28/@*-X+&K8L[R7_Z#)$!4S2('
M3/R.>_2@7</U['%&!QSUZGO1'XX.?\9#WBB^UD1!;*&420<Z#"HN=2YE.LM%
M>%73VA#0!U/^/L_9'9]R3@W=)DF1U1<YN:R0D#V8#!-0D>'P-?XPTBBK95;5
M4& +I<:#ZXD<'ZMQ[]>+IX :#EZ>'Y 8&'X930M;Y_:@-")?.)X*FZ]LH. A
M^*HG,KT=# ;G[U)[._(QX$I,65K[&@BRGY8S+VX]K(O[IN:[O:>?%^GY;3&)
M48=/WI)N9H:)< $_/(JK-E&:T2K7T)8P%JP<Z+U:9"2A<V7[BM*M5SU./R^J
M3U5G8IO;43ZA!844+963=HGK<:.^1OUV*=^6E@ROI"O--?GZFW8X34V&_B"_
M_X8>EF/OIOB>SC0J*5^_KA+ORV:^VU0*=&+P^P_V7(6EOX0A\T-_B>NYIT2D
MJ2'RC1&E;&=BMA7/0O%28P/#PU*F/A"W/XL59_XR)61 :\B1RY8@NADW,1GN
MM]P25J[YW% S)_8]&\C_R?G::NR"ND(O'W.R6\H S8QZ%%>WL EZXB25JS@5
M[#B)T=8QC%(1WB>JKT 4];GS(_+?3<VRRGZ2])O04! _*RGU%)K@=F6(JG7]
M7?)L7% WOBE(Q384\I8M T5"STFU:3[LII3#:_IX.]_WMN15YF&891<)5#BD
MBX7<-HD.9'='*E:_JY]+4JK+)/W[_]"Z:W6E>;-PY#!-:M*JE8.<7KLW :N?
MRR"X=FK-&DXKF]G#[<NLK=G]2$T$PVH@7R*Z,Y P9DV$)/UR9)=ZX,Z9,&;5
M)S066.J4O6]BA7#==K[]MH:7@9#[V9D6$30LN+?(<KR^WOX#)<FW#YZ@RK,W
M ^CTG]9(BC(!?V3*1'<CJG=<'.MB=U;UWP@/1E3!7(PO[:+X:Z.)Z$+S!?<Y
M2I6*>V,-Z+=:A(OQ@C4]Z;Q+=<#WDC'RC1]X@Z"N]J9*EX%W*(?>L%B/F?=/
MA24BN%[BH7FIR39IRA'MQ'%=WKC'2Q/\EUD4BTVT DNDV[LW5Q:SH,V\Y%NN
M]?+2E5(A4\ZG_FF1Q3'74ZRE-#FRMR;O;\84YL?K)8LL&:+X_PQ^2%69>&6M
MOP]9MTA[C,]E=0DQ+\0< +6147HXUSHFV<=A/O5$'E&\45+&2]&"9.>1VQ0%
M.;G]<8GS4>TJ(RCQHJ_>":P1'^4Z()9':3'EVX?<R[1]\[ZZD8&=$Y.%_C[C
M"OS?&O_<<J%]AZK*Y--((D=XAT!B]8JED[51@?9O@"M.DUA S$Y=G9AD7M?@
M9,MMJX84:GQZIXD[S4?6>IBEQ1GTUD2XT,;K@HYB(6DR]*DHNE0'+EOW[2W3
MWS%5^8LHX$-U4SNYLRKUH#%.YG@?Y*#47]XZZD[MG7:?XCH0&<^K9-80NN?L
MF0OE'48]D-;()BL1BS==";B"N1;%,I1?>K5P1B!NBH^-7SFA^AJ!XDS+$U"E
M.>=W+M+?G8W[S"]U^2$!1776K6X=#,\89/6@"")@I;-NO6_OI"/)6/,A2_19
M&3)W>HHL;".T26\4@:"^7])L<:B@Q()H)@JPD7^L;48SXE[Q##/K(/6N[Z;K
M&132HKXA'^N2.5;[F[%>8E8T]$5D1M"+VN::!F8?03OX!QK:H8<5H/I)O+4@
M6X::2YW!_/'97ZK\&CD>;VG7#L[%'>8N-5$%=/YQIXR,UPCCC+QJ5\,,*'-N
MT;T6LAXIS7+M^ HWMQMI3ER1C4SFO.PO)!T7Y>+[>W]?3Z#:S+K2@L:B-*@Y
MSDCW94]JFNL9)Q\*JHPQOA8<B)3IQ76&YS]OR][@/=M6[_<(L-O4:?IJ"7.5
MW%$X:#5,V5QI%&4'(<H-FWO!LM8@Q5"* BI'!\B?CLTYB& !L<BSW!"8/LU+
M3U+?VKIM6I;N1=3W,E_WB8QUSP$>J(,W_KR1][A".&*=='WXK*PX"<>8H#/_
M5.J932,3.SL6P&@75/$IP%"6\H/5OV<"J*[8;S3Y]-$?CSN!1;&2EGG:PVQN
MXZ<5B'ZTYVW5*UKPB)0@$6SAC:H?"E)<6A-' 59Y)*Q1(^;4#1&PC)XM_YC,
M)W4DTHL61[0DZLQ*]J#*2K1Z/)Z2%2%M/W^]TE4Z6M*I/F8/_?S)(TII[NFZ
MN *..VN;;\043ID1B;W)Q.;/23/^:E;<]#E5_DO$V:Q;;1/C6,139C^TZD;?
M\4L]JZCYH.FJLO2WW32ZD34?]T"=^':P1,M[,/*/8XQKS-^:]EE4H*>_R]17
MY'QULVD>[%I$:6A3Q4H@U(CF[>921#;U28US<5$0",U*/+J$JH*:%PM0X5-;
M T[6WG@[?B]R:963%31_//_RAS.!J6^@GOV*B&5HV&3ND*,4W8[GI5FI<^ZE
MA?F@?LU1!*(J)%/M-\5"H@BZ=+QMA'$Y+<!7>\!PA?P+*5*CBF+'_"4CVUF<
M?(SQ5J3=HE/L:#868$UEK]AR(_'5RSS Q:1_7-:% 0B+(F5U#1JTQ@*LIM5B
MN,OX_*CH6.)MJAZ6"CA/## =TF'PF5,#*6.*E[X5IA27*']J<B-R-!/9-X94
MA+J7 ZHCU0(:J>Q !-O$>S!.7&'C:OI.;0M73+:!.G1T\]RKWLI2V7_^4?*@
MXX*MLL/KY\^,*'H\=:0(QU+<':J_/7)K/X/\E* HK%[_E+BT4<:N0S,RFZ%O
M&G\J@+&.-=A5L0NA_E5*NO*B3F-YT2#WD:JH8*#&I7VAT0Y>\&0G(S)"US0?
M+54%'4<(9N@B#QDU/)Y:T/N .?MZ]G>\ZQI=ZKPG+)/E7T0*[?[55ID/6FSU
M1:XP)Q<9 05.<<>AQJ9!OI2<,9O4N'2D814.*D#^]+7I1I4^PT,1TT?=8<RJ
MOAYPJEQ)I =)AMI@5/S$["6+XOA%R14:=7LLR'5IJ!!9M<Y_L'>@H@:-'"I:
M!L*XA!4V/GNH+: .M5$D[Q?>A "FLO6WQ!0Y6#[^L)B>7*^I"7Y==^R !3AK
M^^F="^L'Z#*(Y@Z4?6J("PZ1@ZN4^$#" X2UDK*I8Y>Q #*# V2,%KHDZU$_
ME\W:@)98X@R3U@F*)<PA;;#]N]/:W :EM-_!\+:!4 :9PE6LI\563M.#-9+9
M&%/B0(.^?OE\8FZ.LT:FMG!;QQ;Y!BP .FAL7-2@C;O%]=QB*E_\;]G"S-;;
M!!!AY<DE$]<]WY$3Z[&DP<S\3T-%5=6OYP;=081$@9WPD3^@DYD:+,!?T$U#
M"%AT*8\%/*>1PP+*(5A EN#[;)3Q71#&^;<D.XYI[%(=>] &B$'"N+@S4H+4
M[VF,UJ?B8=/\NRB\H;M/MVI3FQD%?O'M=+TVY5I6OQF(.UJR/.M+.QEAR?!^
M^HK=I5Y':*SOT4H(+Z]1]-NPA1$+LNTJ/%HZ";#@%N;)I6F^]T__&_D;DH&(
MGV9/<@-TL]' [Z'O,V53 J1696,5V("M?#C,T)&"Y-5A4C'5_07ZQ^L^&]"S
M?97]-9'>LJ*OLUSSBMZ2DO8Y+S<2FXM';:78A#3IB,'FDC4&K(:Z&LXN:3=3
M0&)+PR^O W;?O/*-2M,6L-QGALV9.EG.PIE43.J;AOCLR3E.@X8941 &'V$S
M]V%-?>.HO2T')P9"G-X+R(/?-6M8 (V$1YF]B/[OUW)PL+W=P,LO9*>>)9Q"
M@W<=G(L9OU>;[23S3?;37.7]C+9&B+@UL9V!\N++=D>8T++.]ZG+(!N)E'SZ
M!-SHH3R;:UV!F$DZ@5K.N%-'R]4ZB$<1LOZ!//!/V5^7L(C25RZ7&M7\&K\]
MQ5))U%^8!S\) *K:?S]1<H3AN3PV?>^X.X2G>G&BV/IG4$EA5B222)=&-FG2
M*GTRD?6D*,%SB"'3P'[@%ME1$B;/6'!@VQ4P5F!?9PY7[-$GK/.=*.9EJCF\
MM9?A"FG18(8Z4C,TI<#UPY 2VKT%6Z0FM0PPJWYE?-'57WT)PXJ%C%U>[((\
M24I@YMH])SJ:!)7IO'G2SQ.$2SS*],8SUUIZ6Q$_7:5J(Z\UW;9LZ17[<@OX
M&%C-K*^FY(\RS%FZ(0]5P3[)\E,#;D9_(\ A39E!QR\SR04TNN*]S.]\\#4&
MBK]UW13&D?7OVSHXIK\S:X/8?X!%_&5'C;" ?/FB]X)U?LLG0)1C.U.@O8-&
M( EF',/3&OIT=4+_^JA?6@0=:4LR9'?R(7(1GKHMQ3>)9N=4>E_?6;@!S7SN
MMC^O$UE7C7G6W-06^_1^;/L@LQ=.#WLW$4/ 6Y7P'@.S)0MGG :M-=AB7J!8
MX7)2ST+\8+=C/N6:VT7#ON'6E& TRU+$;9R7\:,$VDO M7:1A6B7LYC.9]\\
M\R]<"I!P4?(M(.<PU$#%D3SL111%%)Y1R.L&]JD4\OD(BWRCD*48F+V)?6ZL
M^D1C_FQX>!&2[3&<#C*W0.* U-=\SA^4 A]'VJP1)\\7AFU]FF ^F9#[<T\L
MTZ"GQALFY,6S=9*G8]? $+K(,O8C]6)&CI!_G%%'F?/9UR XQ&:&>I[O->>\
M1ML/A-ZY6Q2M=JFG>)MYYMN4$'(#_DQ53L2M6X\&_GY5LW6:!:-GJ7*S+GZI
M8<"(W[5U2@.#ZRFB.G9BSY!J 3?-5?)4O8]TX)M(J08[^"S5;>JTK"^6(PEC
M1GA\Y[!$/T[PI:#\AN@!F$BN+:'(>;$5=95A7!JA?=7,5H"=_)7;GY+#*+^(
M#Q&?A+WN5I,RF:=&FS$I>=UKR)BHSKR(>*-H&%2.<3:Q&^[,+E*,3&S8;+7D
M-SN^GOSQZ3,2RJ\P8*Q25+"&VU&J]/IPT.(M*]"]M_2C4RI5=HN5_4]ON(%O
MKS?N%<*=+VZQK(<3E6]13O[*<5]N)^CO0$# =B)-C$&Q[2<]>*O9Z R=H:O.
MLV;3;RYE2V2UR+0]_0=80)M]O_54V\C-TQ7QN(FI$LP0;W@T"S N/6&L'?,-
M!'F7,R;&.1F1GA.@(DNI8]7Q7YPQF07:WKG/;W*YO6J8FA##;$LU!/MSD].N
MLGMJ?WY2/[D'!MIY-3T?9QN5H1APS!7_*C,D:8=L3'^7%K#NUN?_].AZJO-H
MT5#>@QN1Z=YL@'"FDY&$KYC8U1U=\A@A! ;4,6%QEE1-1>9I8*J^!7^S8X,J
M[0G_:I'5UR2O0DM-[']Z^06*-C0EJ*7(,:8] A:\CO6RCD:E"#ZGU=2QV57K
MER$07=-N%N][N:;_^":^3-P/<26Z;H<%S!+Q6NTN42U]&E$D=1L[2Z;0J-=G
M995\< :Q,8?+Q(U,97H[&=-;\)H-1<)&_*8LG5;GA/\X'\=-/6NTI*')#O^M
M$RL,63;K=P9LJ;@+&? M&!P.,4!=$6W/Q@NB\0/:U37GT'I'!^&>YS3T>2Y*
M7T\:GA"?B9;[&"'(\S);SE!"*?.POY)BDSS[11]C<J(W@6CY TS H(4]R^-:
MI693+K@^-,4V2DH?('*HAS!H(9__,68S?.%9*9C/<>IHH5Y15;PEE-(=YQ),
M, ;E_C3WY/,G7UU.B]?:C,O7B-MF+ #WM17CNJ^N[C-#6OMFL1L=XJR@E$9F
M'\G05C/;>GFB82:8&.+Z]33AF>#P<RO/3MUWI:?<K*]\?<=9?X4,&FCCB4CH
MJ%!#N1Q8Z00B,GD((LY*B1N=?"-#YA$.=+_3"8,62Q4:3,0GIXQGBM@T1RP$
M8@:?Y< CKM4;8-V,9(B\.,)"49.;:+OA5)V:4/&#92./!:[H78/<! ,:8<;-
M N][A?I"J*?@^/X%_W='"\DS+VKLRD6Y6%Y4.K6)>-M-LO3'KFY/946]Q+^F
MT(H_EY>HHLPNRTO\>S:]81<W)![L[;&Y3RQR0QVK9Y%9^S[Z%K\Q70GI] -%
MLI5(-@/S]>']TH7!,X"1!SPR2"Y@3AFMWPH G4]#IOQCRY3F:\QTC#>[':@[
MZFXKC4 7YE>1_J7"/U%,BF^F$FOFJT"PM>A^Z%FZTH9ZK-MB4ZY,0(&+DD3<
M6!KWCM\"O+O8<<XA3XD\$^F64(*KG8)*WHC)8V\4[-C6#>Y<FU(I5/#\;[V]
M5SC<7]3W/8DD(H)$C#Y$"$$0O9LDH@=1A]$2G5&B=X(@4:-W(GH9$V7TWGL9
M9?3>1V<8#-[<]]%S/?_W/7T/ULF^]K6/?FNMS]KKN]</NS:A^"2XJ](A'E8_
M'CVY[4A)((+PN4X*]K;E%6'15;H%9,D926S;5H:G,2!/>7:;VF^>B39C^E2O
M'XF=P!A-OMG"50NV_H2N2?[^O\<)( ;)9OTZ5]N:*]=1<XRG=!%2XPI;S6P+
M"-0E/N=_M%3<8$OVJ-+4?^#U.Z5FWVF%99G4U(.J@_$[KWOD@PF\1 _;+_LW
M['0LYT:>RWC./_/0K;J X7N_YF;F5N3G/ON'9K: *;D;:-Y4-I"XY3[K(SB1
MV6]:F-@6$JM*7TDWT:BKB+>S9=,Y7FA^WB.%K7<,J)@Z8>< [G#\11FH;9(N
MZ'^+S(?K5Z<7UN6EGGE=?#02L,81S.153W7OFZ(U+4SMUFFX2&PYA&IJ?M[I
MVKA;O]T@9NK_V%L$<P)A7_:B8:U12C3XU>7(/X>V!1W0O>O\4"1T*G%9ICXI
MZRP%JJ6/Z1ZC1K#@HO\8=*_T-CL.2%2N\2"]<AO/1%@;NE>$<M=Q?XQ2;W3S
M_:RM5:X8M#F>GGGR]POZL+K;M/<$023(.?GH?L)O3*-'&]5^@',]OT>05N?V
MPWC^)9!3R0B/1NSW&;.Q=K[/D1DA<]KCFX7]TO,1",>]J% DI[K0#M7SJ$OK
MQ54#\\0C\0ZAV0^>@VU+)@5@5 U913%)RYYUM;T-9K3.%SF32U4G]K(JQA*[
M)[R"_K%L:K_'SJ)QO7[/O)&_'4R![!_D'/"(G^*E2^$=XNQI$+>P]?EC8]HQ
M"W:;VL>6MK<)4P[GYI8+]:XR-L@N;>09#FZ;#!1KP\'!]@?B/Z5>80*S9\/=
MCILOL<;HE:ZJ;!-DLP3!NO,U+*JFFFN*="5E))/+*Q0]A8J9.EZ/Z)3YA]?7
MFT8^1](=3TUL?EDPGO3? A Z;GZ4#4H!E/LB%SMECR?%Y@@UZ$,>$_;OP#B.
MQAPN3ZTWG3]7.KQ)$'_67.GGX;FY8A1J.@>N8OL8M?0(G&N^X'[5 5&SR=2I
M^S(F_NWF?;'RH_)]:CPGQ^%]Z.!8R'%V*D9KL5/M>C?@Q'#"_.HR8O:!Y*:-
MGUAW7$,YI:N%S5J"J*"YRH6$><IG:C8)+^>2F:J.$R>[_0\EOD:3:</5OSR&
MV',?7FK:3CFSYITQONR%2O<^2"J/:8E5-F/.:BD8UAA>5DJ>FY"65EEP:C&&
M&:DVL#]O[71RX.60A,D.]G[F(T3:TK@Q)R::C#JGOVLR4H6[S/BL"I@0$LXT
M="O4<TP-2197H^P>=&RFC<5*2DB4>))&\;KJ;Z*:?ETGM/NUV;+W,N_R;6:>
M92.2*T4?G/8B\OW,DH;Q+\=$".VGU@EO+B-K.#.]XC&%6"X*-7VYD2 *M;?W
M_T_S_>R[N$ O]>HZ+R@JR5A[C*M?A*9E!G9ZTRSH9V<K?<5V%M/4,,5BZ:RC
MS^WY*Z]4/&E24:VR2HKMZ*"]4;6-ZO&Q[-A4V07W)X=3J> Z<,#YW46YB<6K
M4K(;<</&/[CBCT= 9'K\880=@JMCT2S.3(?AMP7<88%EQ/G@H5*Q=%X;ETDZ
M<,#:O7<U=#:]U[%B0$=^K*A8PY/BM;$>ZIA]?ASI(B85E&^@6[)H;L3K;C(L
M*+U\':I@[\%2[_I:3TD0>K@!MR+I[*Q,?)0/YE:E 9(W[CT3<W"P-@ -*@4_
MZ49^+1(#<'!^2-A?-@Y+M)NPWF=Z_CKG27L B47'H/US9^-P21(#,#_MC=G9
MR7-S64:^-.#I/]>- ..U^$Z&$S+[&K7L4I;#A(@9\AI"5M23\%I,S#01'I*X
MTIX,5LXE_A*7!_Y-6*N>JIE*Q<1'C""ZFE(SIQK:9GLFG7.[[9D\M1T/:_VZ
M/W,9#T^2!!O[]FYV TJW,\GL6.P7YCO"%FE8_P2JO_J#M'')TQ[RXU<;EHR0
MK/!*YTK\GJA<=@OX$)T3[7N>XGL^ABJSR\X8LI>@^CER# DV*H!?,^N< .Z=
MPR\JZPV,^>AMXTKOA8W[^,@8B UQHT1AHUK76UL#ML\ZV3W*B2O6Y=UU/3E]
M?#B+K]B/G<89DM8@J1@&QKI1NT=B7U3GF??E)>7R44@)\,JVLWO',TYEV]'X
MJ(%,16S3L("K1-*X_E"ZEKFM=<+K9F$5K&HOU=\$^KYF#P?T0EV/;V^I+KPS
M+8R#X3?#NW-04=39,[T^D -26;H@A6@Y?3]2!>8F[9_&,)'J8;/\4Y(0>DH,
MYYXQ(RWO^H;M#P_4N0P.I=')TI8JFBX5UJ@UTK:XX\ PV5I0==KE8'!_,K)O
MZGE*/FL&A&T1R)4MS&#PN/-;#Y%:BLZN[AH-8Y#U[-0O1T)&Z)@>M>V>:?(W
MAJX*UX\UG5.;+&,#L, @!JR.7I?>'7_K41_N@T^.LWKF[A1=(^;A)YWVM'PQ
MM:T2IDS<ZK'0)+0D&=0;S!EYC<F]!7PWW_$2F2+9E3$<\7V&:7H^3KZ NE-S
M4CL$ $K 04>^H[DD>KR[IO?NBD@>&02'??4U= ?^6""9%+A^MPL=7%@1FND+
M9&UD:[T%/.;1SZE+OGKMXYW5SXC(99<R&)8CEG7)[;_OZLQ 5A%S^?8)K^$F
M_:-+])G)WV.7_DVM"Y-*XLQB/VQQFT JM0!.F\[Y8:C(^25Z-+."-MC6X:A'
M_BW^7UX.\L"^'/"-^I:URV2.E5P)?57J-/'?EF?7OT0; &JN!.WZG8Q)_X^:
MP/X0,9:";_JW'J^OE(MW1-:'W)E5_.E!_S0!Z##75K$>:-%[P]Z4J!S2)I9S
MK[@3<">DJ%H1?40^%_5D7O&DGRM]36VN?4/H*[6I_RZ)T>%PT HN>NE>F4+"
MPG';6GDM#8!A41&-"\HI315*M(NH[RG7"6,TF:S+LG.A](BSZEW(E[,_-C>]
M[*D^W)$F7EYS1'WS6/U=TJ] ('2P(JD,68[/ENP&:J-VE'0?B'P9DT![&V>?
MB*\JOSK.;AS!AB"_Q@CA=%8)TR"Z+Y.BM3^T<P(<.7OWL&PB0_P9/IAQ"5#)
M.Z?<AQN)Y,P.&2NUQ>\7CD4XVA-7@%SXZFU#M:-WX)4<-C:WA.:^QM&2CFGG
MUN&LE0;82GRAT=,[D66!BFFEP\1TI%#;-(Y(7#ZB;Q&:SK07R7X+L.C;!(Z^
MFKM8,'UANK096O$XQ($YQ?33/GU4%[S=>G&^I]2<\-WOX9,@MD.$XJ@ND" &
M"$G@&H&D;VG+#= \0'I;>'!%1MM36)@Z"3'>0PL@7<79K\H<Q0U4NZ7H86[(
M=(9S>J&.'CPFM&'L=%Z^#+46W:UV+_L96?YYD*.0&XSA'XHB#6"W@-<ALC,[
MCKFJS]'%T@EI=LG'[G,&UA.B+X%F%579?E7<#6SNU4_Z1OI4 ""Z<6 .6HK%
M&GH2[X&OO-D%_\-:_?.P!@7AGRY$I?D?()I$5\@NA\4=+S37@ZSUWF";:K]#
MA"J92EKZC-08P3??]@7;BA$;[!/(X\YR49N)X6I5FS9Y"V?P+M+14PIN>W]<
MU>%.G;_O*=,9)=Y+.[YDSRG>*)HZYG?:DD6N9VP6$:<.Q^>UQM71!AXX=],&
M:EV+.\[T#3WX%F!8:8KZ8O7#PR184**>_HZAGP4=M,$Q&_B+@4:%Q/D0YZ4]
MF:<9.8UFPU48"8:V7]%LERV9<"C&JGWGGEZP]*5 (:=>!JI$YS5JS=%G_KJ"
M/"VQ\DP5GBY]KN-=O<8F@OAXR-,6]51G3HZW!B;0/4"]^J(Q51EGD+LP+2$L
M;AKS[@1(?^.RV=MU65$:;!3>I:$@%WVQ.YSB/$7+J1F%*QO4BVKGWW'DD",>
M&'K; 8N]A(Q,+A(+<'$%=%N7OY$T?QGA0FN>:I7/_2)4))6Z[SFP"-'7.%9*
M+\X1=8Y2.I*HE\;I<4S-LE3=J&G26(EM-)*U^U*5C]BVY8VQN1J2V!C*,;.;
MT71^JHB$A>5&2;B %;NT7@H68JEM[C]F262Q&]@S'EJ0E,F/?#BZ1F.AM98R
M6(/D)$JTNV-'XN*96V!<MKK!U6GBGI4P*>ZEN?-@H\3.DSPO>Y"9>[[)7O&2
MY^R+J++;F WCD.)%VWP=0UY3Q'6BGK/8P=5?/U%.49"ST/^$BY*AO_\E=C".
M7>J'BVHXK>*#AZ:H]@?,5[G%I^5-%-=-SCH'4B\LU8'7&"M'&ZFKHVOKU6R^
M0@;W*?S^H5P4VR$I@J4-7 GM/1Y\*,(&ZFZTWF&0]&-P#]@YZ(-YN:\247PX
M?N"9LN+]+G_.*N7[&9I7@*\X&AG2:+O=1#/N+?Q*.-H?-$<LP!W"%(?VUK3+
M';^8DU0LRJ^X8D_EN 6(2.%I$[Q$%DR"9U1/!+7GH0H4C-#33!*<^;#^:'K^
M^W*B-^4\^I^UL=:OBBMF;1=ZEIG*O(_?,B#'MJ('[>_\<HKD+!CS!4UW?D4(
M#L1TD;J:T.2@G37'L 1GS[Y_?M2]!8O1BAU9Z712I$WP!L,]G'(<O<MX6UD.
M.1-P^<;E[@'L3X)E?SP.W:E<)%DP>F#U_/@AHWN:Q2QP_19 /G@3N/(J(%%M
MW9$N'J-%8C F0:^\*IV@]+[Y3&7UW'K DS%)KE_+V8BF95;[DC+JNJ!+;EWE
MB*KCU6M(/^JL-[(BNGODT;8^ZEQMM2NTX!IUW1PRZZIX$^\K>0_17QV[9_CE
M%D#45.8B\N+R@]V<OP%K[-'[6X!*C6:S5G,(_2^AOWC+!-IBB)QQFV#MENO9
MM@E1@L7#(OY8_?.?WO(I:U96CZ5[-'[-3UUIVT[6>JP2!^DPVW-%]3XB)9RL
M9R3%*0BDJ;K>&SLS[//K:LA+M4^5[D_;T8S-5Y692--<()OD.NM+<3X@""]^
M->C<] 2G4>J>L4VN Z[8(UQ,\"65#'$RP%:5V[;</S/)=9Z!_-1-]G79++UO
M12,")RT8R6)MS*X]SO]Y:H477XF04XV]T5'I<7L,RL["RSAY!OE'*A_1!WA!
MQL&43?3=J_(K$\XCQ85_]ERV7AI.GR,R2RN+]UBO>FHKW4V'A'J^.QF>T>8+
M/-U#E1;VC;[A,EA=0ZP:9 8[^T@;UN@X7[G5)M:J'2-J)8-<F^[@Z!P*Y7FP
M6R^1%6"QF5*WFO.;+4067GSY8<F><05*8-3^(<$=#8(=54],AGBT+D/:GZ+B
MJ9-;0,@B@<SU>N;91&N"[7($LOD152V7D;1<[I059SEJYM7[HWBUS*'LPYM@
M >I>UQ,[O0,1^CM;'!-79KK?5K>-1'_ Q5 -&8$1',X3J/'LE].ZA!(NQ55B
M99%OI3]/"D2<:%"N]CNJ,L0/A<_+43DUAJZ@-9>3Y$08O<H*UI QC\T<^<]#
MI/4_CT/)I8S%)Q=B5^Q?7SBN1]=Y:?=)1F0;\KLF;,PL&H-?L[$%6$^DU^EQ
M?I3O+6!)M^/J#8%9I/FKZ;4[21%4=5#D5(JO8 WD[9"6V0T><^0_I*#+6(-W
M" 2#-MA]HVZ10B\77O<G,[DX-)IT-1YO#:P6P2BZK9M6(78<)8NWP=/FRB.8
M_JWG-XZ0P:]"[EV<VT;36G)3V/,NTBW(J<DU3!3D;K)0\"=T8/\_T($SN7E$
MY7YI'R5!+%8U#A.=N&YQN!$\E_3UN06TJM.L-ATZR;J6S\P]:4<L*M;LFV@=
MMU9L2NJU+3#BDO.['>(M-/P%6 BI=V%4*]JIH'"H9*7T6@!Y(-H2 1KQMBUR
ME_XD3*EAX7"]IMH''H? EC,9#7$GG7RJ7H^MZ+\^1-U?<UD[T3NNP8R<,(?E
M:QW/C)F)?/:9_6/H%&A8NTP$GY4)>BY1T$[F.9RI4-U0;AH)_'D9D0T,^[-#
M[NZF_C+Q#6]'\?8^NZ+AJ,[$D.9:;95%CBR\YK.##H1<X'+)J('BO*0?\:--
M/.#7;$#@57=*;+M8)30R9V#W173P6SNGTP+-/&19!I-33O1\^U<1FFX'0XLC
M=?F\2:Y)3=((QB,?6+,91P,6P88K=.Z'0]=N ?W,> P4MB"7&I6X#[60=%O6
MLRJQ8ZOZU36:99O4@^"M6PBK/^#VX\!*,JK1A8HN!Z/$G?2EFK-Z<Q:5"/*V
M=!)D=^60GJ>FJURJ5$2O9)5+\T5B7Y17<*\31J<DER8.LY+W$X$Y:GN!]#/.
MT>0:FT;6H=2&LM1TJ;F>I7_*3CEC%+<S?AY6=Y!;9;R(H!F.!^]/^7A":O1W
M(LS+\Z;F1%I?\_EFHQKXEQ$A=BXDCO-:Q$D_$MYG!ZD-0\](G)..=6Q9'#(5
M+QJT<K4$W-T+983[3!>L@^7HC&>CI%-&4%CMQ_PU$&$'IKDW7WTX!L.[% !#
M3IV/V!G!>Z!323J9R8B.66%'%5[#WF7PG5G!@H8)^//:-)+#DK( C<4,[(;?
M?3PC:U8!2'&#S_:WS8N,\,5KZ\L7[\MTA1WO?]SLW^_,A,0OIV7M%7E']R#3
M'(G>184O.1ATECS5FY&A[0)JO=W69TGTXR<[$*'!PY#/HFE/\&!47./J;'ME
MK%E0L"BUJ7DFZT]0W]\NX4>A7<;'X9<G>K_*XY<T595)"V3YYT[2G:1K4&OB
MU1(6V1#PB[\V)U%P+YGU$L^([/;G]U9#3[CTE,5\VKO: 0R<+$./51BCYR5)
MS7+$*P)X-62<1Z)[:6Z8!LD_?)@FV/XDM6[.*.2+'*7T2*43JNOX6_AP@,QS
ML0R=LC#>4**3 ?2ZAOWZ;DL@,9$85Z8_LGLJMCT>)_@1W33.J)Z<?/--VZ##
MPJKE0&,VN_=;MNA9\7#VP)%=I_%$9%*AYGA+1"@Y,60LL]P[3,J_5+XAJO*%
MQ5;FM2=NL]/PC1YG2$6%:++*-".CVQ0$;50&K? 6&F>U*S=B\/W1O*K;:VD?
M5$RCN196>_J20DTGX^]_!#RMS8?JJ<!Q_+LE+XNA7JY-C5N 3Z[/NM&C?TXM
MQW*,5UNR ,D@6QG/9R:ZG3CJN@9P="OH]EG&QU,SBU,'6M%5$C:._)&UI7K+
M#:AW)7W&MO *S$(=(] :[5GM_]*K%BH;]8E)B2$05>7-NTS'Q8KY,,[5J]E4
MT1]B<W/2Q%DH+CMPR*:@V<$^IFV$$@M<(9[56;ZC->7RFJ,TU_&R@LKR.]^;
M[OZ1E"W;I7!\:6@[N!-BAK*U8W:/OEM+K0V*,,VE.# IU]P9U$LZT=WK*RJD
M,W"_!6 TX-SA?)S,](CY+ZV#-@O;Y;Y'K%%4O%_[KY=W.!F\(',/6R1]F[#S
M*E"=3_'7O0P5R^GOD.D@@^$#$W&=RTO:X\5P^5%80LA-,N.F8>QAT^"L<IW-
MNM)]?<^56I[P%"6A?*MN? 5XJ'8B6[UGJ5O#+M#R>(O5S"823+M3N<6%Q1B]
MV& 4)?1;,?H*2X51A<?/0L5 :RG.F_1DBF=,0,'"([Z"[;ZM9G#K57(N:]?1
M78;W']_XB;5,-H'F<*[+]]?"$FE(R)ZC"Z9@ 1C3D/6+MUW6Z)^[8]"1J7LD
MKTT<,[!<-8HH3Q!?IU8ZV^Y\LMZR5+Y9GJ4JA39F,WCVZV"_R*X3]+)!2+CS
M7/$,CG]9:Y0'&_#F+P0Q:OWH/>YDFEJ]1.<8Z-'E]%R4H1KZ1K^F]V<;S:+.
MJ]^H=ZLBDYM&^8?Z\0_O$![!23A5:3NQ\,;<YIB!6<^U,C8\>[8,QS2[X<_#
M8NE0+IT=*CWF@ EA[^ND0Q(SCJ#EP])<&=+-"G<]A3"9,2[XBT^4 @12^;5X
M99L=U$/G<_,+&0>J!2%WG3 SG;'?T769OTLXHYXL+%9-[^<D,.,?.^ +-;+4
M\_(7N]BE8U@O>Z ;#*UYAF#:4\*(U.@6! NR+MI4^^,#]4=EHFL0A]^X-KVD
M .M'?U0&&CGSG#=!X>QC9U:%('IND^BO#E!7=)!#[)XN8P<U?> P!3:UWVZ"
M<H,\-E#LU7ZYYXDN \>8S#HB(^P$ 75IZ/SK-1GW\>6/8A/"0)T^B;IT-RWC
ME>'7,20#*J)%@^:="D.<14>D,3:EQ!PW>[7 @3EK[4MUNK!"YN!70[HY(A3H
MZ.7Q$&9K&2L3F O]YDSFHV13QF'!#08!W)YYK#)E+.%,SBT@8[C#+\1)YP9X
M%(Q8(:)=.=O-4?35^7.A7<>DHFX1K?$F6T6_S$TJM+J^<NQ/.U]#2/D)A+D9
M5G#\8&([]!@FZ:+W$!Z+2=D]E30:^EXL1%NJ&:<*(8G2,NNKE$O#2Z,Z\W_,
MKWQDR12^VX2^#L\F/DPP)F3[Y'T+6*S!K),Q3%T7/14K5:3?:"J_CD#;M^F&
M7']@N06,.D" )A7W23]^*/%"4JCIYS?]1R=T&(6GB YP#VM9.[V2N 5<TJ+G
M)P[=\!1MK ;2K;&KZY3GQ+A]:0C) ,S[,8ZM<Y+$9%E2Y6Z]Z^(#QO=B:#GD
M+6#YWF&QW<P.G=6^2&F,/=FL]X?#$NT-^Q=O^S?X  K,X]H6'485ED(I#-%W
M-BB,LR6_=<'^\$VP?BW2+W>A:D/A^TD*^UE3"5YU)+?_Q0+]WD^8626PDV[0
M!\!248+W;OI3B(YS?O5<^Y_"X81*]5?0.9$.D1Y1C)I K!7-<.H,)S^BKK)J
MHFPCC_XK"T@.AV8LVG*$SDG8O6E9U_5D=##T_Y+7V.%K?+:7@ECE=*X>2=&5
M.XA;X2,4+?Q>LMM7*#.NW^\4=WCP(V=T0^/A[&L+F^A; #$"A^8]<EKY=N62
M@HS3X8V-P6,O->B<A>\[M=)@#$V.K-_7Y89N^C\].# <I!=@>SG %M+(1K=O
M.X-;5&UFLO#/$KWJ<3( IH?3QL$$<\)>@5RQC- C3BO8[Q&\M%/V?+< WQL.
MC\W 7=C$97%H \V)3EJMXIEDM_+8@J!1W.:V041$L<#;I_Z1,.86S\[$<('1
MU\QF?2:#86-S7A /6$Y\V/ZAK!@Z%FHKKN04D/"T<\O=/D)"RGE088J;*7%#
MG;,!Y^";LA]2!;F[,MU0/:PN3INYDB/FDQ=8M:*S6J>1M*J:/CO^V1FXWD1R
MY'/^'1OH=_]W#*L!XC$<J>^G^+--:WN[ME<QMFT%=$-UF8%+N6/^^$G-U@-V
M"7#!SP/$GN;*PJ0:W=5?&G"\DYC]'EF^-(,+URN]Z)YC-K+,8:!&JR]354WH
MRJ70(FA]H.).VA*E"'!S+/>5RL13K C/%^W\_?2;CWO[6&D'3XT_KH+F=+$M
M\['ZR(D6;>[ +X1,[Y8F^B4_R1/:P[WB4&78D9R22O'JD%TN:O)N7F>2I"&'
MC E7NF^+G0&BYZ5BZ$]==S[S'D YB^Y]>F+OU (X2;$3@J9A"\\D[=NK(UR,
M@;6<^.(/$7",#@.!1<SD\O17BJ ASS1'3E?=JC5T--M55_1FS8(P5]O:20:G
M^D0UCZ"__=?96IIB-]I*5R%[?E"67V:NYI^%P._CP,7WJE0&<O9_YG@9S-J8
M+,==6""=AH)'K/"5B/?2/KP/2][ZNVOA.7>L7(A<J&(4]!*PDHV<F\T,5KPS
M&(CM0X/2]7+./Q2-,6BG5?XB5,=Q3;U<M=,01&D^<**1T[<+MWWX6MX!,RA?
MY:MI+K?TU%]_+5%Y\]E!:"ZK]^*+NK)M*$,U=83TFSE5P:T,QB:NLD S6*MS
MZL0<'VZC,6QY+S(;SI';\'CT].1A2X'C^J1<O7]XKIHL;453?2<VO+7V0H5S
MAV?JVM6;,]U'D(;P1CJRR;2FS)9;KBIZO XQ(.,C??52;AW/6WL^G@O&K;ET
M0H?8LP_>'#H4EFXB1V6 '9[^_VG34_JURE?J"I)0M3EU\/6R]-X"(@.O.??$
M+C1N'A$)N/H2' Z.E;KNO [9,K8_+(I<4V:7R?,U(J.S]B4:'T@(,F1_P$ C
MM=V-+9$[TKH%A#5\LD> O =3U2#?LD<@>8;>7&&=0M75=[5#;==:MW'H&,LJ
M=2M?M@34NJ+"4U,'@],+4_QP6B'M:?Z]Q;KI+4_?,OHSF)F 4KVKM/^@LZ<M
M=C^X., ">7.0^S7HHUTIF>@2.@?W$8X-_@< WUW^(*4,O#(BY.M/9*;V\?PK
M@V*V@M,;3_FPVI@+;9X("36S$FBG+8'0J4\W<T&GD^'SO\I\\H:+SX54.!^9
M+]2W+V$+<V64%F3_QN4RZ#XH9$L4ZQ$!8?JD>.3IU,L^.R6E7J"+:ZD2:D ^
ME^AP/'3Q0;9I1-<3["6Z[+V5 N@-Q/^G@X_QC$^*WFPOR8K=R89%7^^V_TR6
M7ALAM%>WSDF5WZ*)<R+B@QD'AP'I5:NOR+BWN$,J\<_GT5TH"&%45SWL@!Z6
M^&G?1WTY$[0V U8\NGX9U-A0_9ITG9$G2W#;EPB%S:2SK!C,WX8+C-ZER8H*
M6@TT5!%39-=$3A\GYY'K]WV=.3/C3(5;J-M<5SA%3W\,.1%4<)94M!(V-!)X
M>GY"SX2OT'7S3,AZH60O.1"M1/SY6Z<JZ%VG:5@(2S)U3W<V[R#%WZ/TM(P0
M9?HF[])!MG6Z6T#TC,%6'4- 'T^IMD(ZP3=^UG<'W8IGPP0[4+-S_]-6*^N=
MXAJ";\V=DTT&*;+IOB89;4U).#H+E@QRU!3[UY*.R'GK,HK"]V(,"<_NT/*?
M(3D45>8-,QVV/I504>Y0V.F;L!AG)4ISN+U=O7<JN-"Y7"]>3$%")\VTZ7@*
M#GK9'"@W3Z7$0*;]H,%RY7==^NE1="/")+@*9>>V%$\X/KD0;R(@K-95X\;V
M?/5%(Z$,SLV$N;!A(JX(*X^^=\-:CU$EW:JJ\XM^S%MB$G-Q/ZK)2K-SVQ)$
M'E?4>5SIF$$]F8W:7:U(?O]-@3N[4%*A]&=#;=<ID__6NU+PI\AINQPEMT5J
M"7+V2>CWLX]"9;/78ZB:+T*9#>YO.D6:%%.F=JKB[3B3CLR+JVZ(GQ-]JI^]
MA$B;E+2[_Q8B5U7<$"1A55;JB%7JU6J+RO6,X^"&E?,FQK,4PER%9D1+@=,B
M^IZ0Z)TZ[Y20'Z4Q&G$DWV +/.\MZS["(]\?[<,ZD,595!D7'>%*_)X0-[!4
M2+^YP,2KKJLTG@@[F>)4><#< ^K0-5OGLYI?)-.2&".=FBN9=M$>=8]A#=U^
M]Y'-?MM ;&D22L$@DTB/=IU;9]?&G5_ZRBW".5U,IU]&LJW0R Y[Y@HOMLRX
M,V;RP^-3CRQS$.#Q8I!WXY7DK$*IMVJ%%=@]86M( 23).=7TW)U ^T@X*E5[
MV8;+Y&'8>)6HX.I*G(&A]FZ);V)[.?QQDU9A=XIZ?)-,,H_I1 H,30<U6@8!
M$/!FLUD-V&'I"]G'U4Y@]"]PKG>6%6QM9O?LP,@"3U*I!PZZY$,<$5%?>W?=
M AYM%!\6,^H%A]?6YM8NJ,D ^SS_*VQC^9^RIWDM'N=^:9U_"_C0Z&-K]-JO
M]1U<_?Q?G?S%E\ ZQV^-AB.[E@\2)K<Y?Q[%<CA1FM!/JT#\G-^BE#^2,QJ7
MG-^2P5TVL=<\;M3:[&8SD?F#UFMZMMV>B4;GQX,_=1J%WI*'>_UF*0MR/ZXY
M2X4B<J) 0QIIA<.Y*1<ZG;+DC\T;"5O<U+IA+#*'LQ75$FA">[O@MX"Y[M]P
M')?A8.P!2_H[0N"HMK5#&5RWH#@CI'A[<6;&MZ<VF12R.%-#W,-2O5##T;(<
M7?.B3IFPDY7RZ?QZ+!A#:-15+X2JS'PBO=F@-N2Z))8FO*HS5K!]^8PHOT@B
M7Z&J-BT^DC4NXSV"A0QZ? N(>)J3...YRW%%)\J /5WT3R&ATJ^MLHPCO()'
MRHI#8F]&>FV%*NP*[SZ/3GU^1]>8-S(HYY<213:IE[4WAB%]X[B4<!*NMVU-
M3</X]11A>MC<<@L@<X]54JK/I)G><N(512;>;\$K._&Z"ZM&=4S.F"';#;M?
MSK2PKF[JKSXGL\9:&3._*M09RA.5?9K1=-;-?D;#$__\.^_]@!\C9JE3CZ[X
MEX9B"5L9@_F,,$5<^X@D1=M9NI;NOAHLG$B"?XDL .IV%B[VD4U]]D?#V(;\
MX [_&,80N*H*VO$5F6@?VA/8=6VU#EE_=UJR+AR&FI1+C>R^UBIROMY)IY+9
M&/);T10R%#@"[>>:F;XVKW/LO6>@-Q>ZF77H,Q'NJ[67%MV+?OT=,FI$ZDNG
M9\F;EUW$,6>MP@>L)3+HRG:[HZ] ;U?31?,.Z+TP6-#*8,X(-!18K$R_O 48
MRO4*^9(H!1/3\_5UX[04!GUB#XE;;//=Y52\MKX_3$VVG2T4W8$E)5PNT%]G
ML(3? CPT>8X1VH>@Y=AVUYPTEQN7X1^%HA]._XKD:U>HQY^*35=>B?K/DQ/<
M# -U*_4L>M[W\*/ALA;SD4X8E:MWVH2"JWUL===I&65/<#Y3Z3%D.*#&>.5L
MNM1\4I7)UE>8.ET;'*,QIPR:J/^ #Z;>*%^'\,4_4H=:.HR6EQ*)%G8$O,/L
MI:1@I*/EGWY)%"WVA(0LZ$*&S3X0_L$*SN3F)J_[0.VTY0,65:,#^O[ADI-^
M$?Z]_6-< ):G)68<O #2-&Z<02M_AQ91W &T4"-BFBT->"L1E$KVU@?K/4TV
M89$9 ?&";)QOUP:W)UI&(JQ5+1#SN 0I)F^W1.T:F '-/>TBO\D>OL&#R(D-
MM-2K<6Z"G^8GP$AEM</A8&S4,WT%TN3\8<_M]J0Q)J<=+XCM$B+@LCN"YP >
M_G<[KTL-V#U#-D W!:DGTLBG:PK9F* T2]'65O<>5@G#5TG<[& &>K';FF=]
M2S5RO.<V])!&6"8AGFFI>%[\8^-$J@:ZE.V'SR]0<5F2Z2\QAPSL_ Z5-B5S
M9QW1X75C0F">3LC5)WU[QT;^</.*#"[A_>*,)L;@HE?5AG_"#*@:X:D556%V
MFQDWO4>STQAH5[$+1ZO]XW?"M2U81&YE)J65U"O=KG074)]<._60C*]7NY\+
MJ'Y&QN$%M.=J0''JWM7ED9'JS0#49E),%N[S_ 7]_7OGS\UK'32=7?2D$D/X
M97@LOGT74*C"GXLGT_B.?LW^1A_9A#T#MR(N6%/8KF+\MM"(G\[U$PTIVR&B
MOS(GF^9PX.[V"*KK7O"I"1JH#(RJR7KY<B"R+_15">E_NT:QS4O9SQH1;0<D
M?2&/Z[KDKB]BFLH0T7Y+.6,>8")OB<W\LYKA?XM%XMEBF<12S# 0N'N&N_L+
M"/7XP<U+\+(.-"3XY6'SM^6R] 0%RJV_9EOO! >F,<)BRBOS4(7J<8L 21)G
M*5:<O\F*,BFQVE7JT7,N,BS#Q,C*Y"R#.ES%S1&EX+,I:1=,26A'!K=_H_<#
M G9W%BVJ:OHPV3<;)YSG,:C*N#\[B^12"T?.C524!ZI%65W/K9:*CV-L"RV5
M-V;K323K:+M3/\%$@2-[#H/0LJ/UP;C5/=Z2PXPB.>A6.'W\Z)-<=LYL11)/
MO8CW-#D:P+:_O8;!-8P1&C^1@V_(E8"O'6'HE&'%B4KL^.[0B/R Z?DIXAFN
M9=9%OI10)_LST24D_:>BNIJ%H YRD$Y/NA-KJ^V!)!I.KGS '*6(_(V+^C3J
M0NPUJ]N3,1_8M1D#QT!.$:33F!1+][59[Z?KOV@>\*:1@M/U&@ZMMWL%HN<[
MCF18'(0':X)-PH^V9'RT.'5E*B;5<ZDY;&W7W"@-N2=NF Q#ZJ-+D0KR6J"H
M$4B].]TR5W/0:Y4LWS^K6B[SPU)&2.^KY4;2@_;SKW/=$N;NLU^U>GS)J%>;
MH9=AJD?8/'A>1T5PJ&I%<(PLM?XY_7D!G+J3QWPX%JX2)%:>9KC.F;HI:^<U
MX=7?SF98[UXBGNY(8Y?L9FJQSIR^=#H;.AILB;#]XQY:7GWTJ,XYOM1[W1JU
M80E_V<67C[ ^LP_AJF^K"KD^V#24?)EPD"IZ+KB[2+)W"UA)1 (<$OX%K]#0
M3R-8/EU%G1#?;B4*LUD&9!9#&LJ$.5=L9MK]0._,%5/IO&WX.MMD_Y]+#U>,
MMK8^WT2J\H3H69F98$+GD3^U0H#F;QMY=2J0:MKC)ZFW +XAXZCH;8BS57C%
M;T9A021B^VBN9;#2;D]_*-TU1=RL:R4_%ZJ0'>"6JP')VE:SU8DC4[PP.8O[
MIH?IVKJ>IC+WZ?3Z@^M1/G[A;_ATM;]'0KG$2-< D42K'!:+JLRE&LS:V-0J
MG&SGL-J91OD."QWAP,L83$Q;EX'BGKID-DOI5S#<J9FR<G:1%/\5M3#C\?GO
M!&NH>:0P1VG+<KGX&4)^LD$Q\Q&>*LL*:J.])S04$S$K9G%42K6RV3%,BJ%B
MH&M0@&(T_T:;QINH\(Y_\T6.*O+'JW@9B&>'@+ V4H]$K#35XJ4@L^C)RZ1%
MX-_%RN"XAYO7M!5@RX,?*<C%GP<-@O0_[7/;*RN_EM)J=_F:+-0<,.(_U!RY
M143]L%T6\]X"?IEQ \Z.-B&'!=!B^_"SXFG##0]]&O-?:YG0@_P0M[#$#]YV
M_,+?LW]DOU<]CVT\4Q'WW/%$M"].(]2/6#/S=RKF2UQC"WX5, I)<L[A]80R
M#\=:MG.F?Y7W"+TBC-V!@=_A&O.G<-:H=L5JJYQ@7NK7;^YT>EA$"J;..T')
MY^5-G49<U;8X?Q8A<Z\&R:6Z,L<=!\!7H+2U&+OSF\:G4^ZD2_VM)KW[L(/%
M[^!C%6>[6\#KS$M!S,EFZ_DG*\IR WV^/[+)+"E7!TO*T^-2Y#B[K7"/R3U6
MJ=+N2[2@SW!6O]&^NE?Z^O_<797^Y^[JN!I/(2?MX[5TDTCQ.?F9V@+O+4 _
M!U$$^X<D-NX?,LD$VF3?[[!G=NIHO(-M^4I(%]$IY575]MG:UDH6M<DVSVJ/
M80U*P(JG1I&,#RVJK03W6)E9V#8R*.@15^\;5+KU4U6C"4B."J_R"Q"RF<T@
MLN@.F64,-*];2[ CC/U1AU/*),HED;1,Q?'[>0FQ)!1U4<V2EJ$H_ #17^&Z
M=N%37#'-&N4J$?]E?R<2\4GM^*_$T]"^NC0!<5YD!1HH&)R#IES0Z&Z4\ZRW
MR._VZ&][.*PMF"Z6,704W5,L&UAY225!5=_O:% 5&2CQ:/F&ZPU,<FAJKO/.
M)3I71Q>>TORKB#C<.Z\!O>K2,+*E_;3(;" 'Z8%]L0,)DU^.UT$7[)ZZ2L0,
MOR<Q9X,%$IUTZ)I= "1/4N9BWTUPV=JQ>"58:L32\=Z?>"M>MG6'^O)(-F1Y
M%C/XDD==AJC9/N&"AGDQSZ=8RP9[1O5T/;?JR]6$#6B:X)NJ)&#)$U)3["5I
MYS91,C:1;=0N/),]2&P@L1-"SBPO:OS@#B'<A]EBB2[^L#&NGU_PI"#&M,Y8
MRW^3INO=]@4D'L^&#-,\NO\3;=M!Z8K9+*D %3,![@^/ 4\-SLJL)&RBY[JF
MJ)FHO1L<+K5=BKUDLRG<G8+$BC02YSRX)C/=\N<8%[L;J=]<+[S_Y=0M:-^^
M;+.K3<.B':V3YE\M*@KG<H01.*TCYQA,7+GY=<KU+DSC73BG_0>ME'/+3N(+
MZRM^1_$+?PP]BP+,QA_N(9AKMP\,B4P\SW) %V\](<UX<(IX%,FL?(Y)!O^!
MSDKJVOCIL<XMH!(L71Q('#X)SVF5)?RH_?XO8\<;264I6-:C9[5RJZB&Q -+
MGSKONM31Q5>?*39*?+('0'ZTZQ#-('?^+I%A;C$MC.T[\PA#4<H/=M+L/<SC
M:KN#V=!+6D@X2_A)!F?\Y*Y6]NML_QUQM!Q]?:=&734Y9X#(B_RXH7(-B$B!
MN8ZI_I$A\TI_-$.MCUAMWX#K[E*4Y]G>^Z>@=M(DR>(6)+$'R]&#' )"+GY
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MN$L'=W=W=W=HO(&6X?VOF;GO^MU9L^Z=K[//V5].[:ZJ9U7M7<]S^J 64!N
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MC69-A,FOW2?>@4G@4!';GE9/D2)@W4_-;"J0,FKUT/E0(7HLV;&=)%"\%4M
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M)O]Y[7P;ZL[&-*>(JWG_/\G7O>3MGYE7/6"1&5:TA24W9_W?.#&]F(T/2&B
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M^0B,B&<Q/>X6#&E" ;P-Q*Y)\W'Z,HC_Z-K?,#Y# <!)*T0#DZ?T*ZSC4K'
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MS-O4MVEQ.UD"43I][^,)9R['DQ"OPQ!-.(=I"EK%4\E3\$_#-/\,WO .VJ
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M@K- E4:1&^Y,W5)6K\R2^]F!BT:%4.KC'B09'+<95K[1:M6'Y.6RI5B#6*,
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M29]-F)P<^/Q*P06X_(-H0-6\WL0@3:<V-)@NZ:02/@)D=C$:%^/4%XP^E_=
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M#PWQ)4#$FR_]=]SV0BMFRLOEF"^30XWN_7=A:@+@Q-9^; #WH>D):2Q;BJS
M*1#WK9&5!C8Y]!N6)L1=B/Y#?;2;\FA@Q2J;$X-=FQXG?=SJ1V' (*'#29P/
MH;WG+S&)ACSTV&./J!XL^X!G]UV)Y6R/OF'#%L8%?ZG="49[30!UNA117WE/
M$#/>C[:;3KP^B(NJ)$Z4L/*2B'-_"O.6QZF]!&U\=W?3Z-]>"YY]9_9_OH*?
M60O'_0P_]. J63R^B4(.=(.Q>M+P>R* !<9MR3R#Z>^?#8ZRU/87QDCDN)-L
MF#"/'351EHJ'G19;JS-HRF=S:(F3J^6[#;D"7[I+%]\K7 @U6288=CM^S*RN
MV;DB"5X2=YGM+:.6=3)K)?517W[VL3 4,/BV9>'8JYQ6[017ANRF4G1:)G_O
M[Z$L$5%= (*[[,BFN)")HV="@C-2P: ?5ZVB\XPDQLZC2L!G:WH,AESK22:R
ML..+3Q$=K%)+U! 6ON#O]VIL%_2-@>4O>'N<<MX::63<B,7H3MB<ENGQ WWU
MRXVB?.== <JUTLT$XC'<QOAUNWV5T)&+!TX3N^IS_,UH.1OZ[Q"T[.-I6K"?
MG,&FWG,59L@:ZUQ3H\S)&V4\ 5 ?5\-2FY$*-W?1_FN"D(8#7N7Z3,?NA9_%
M[IU.L]X.-#F$)O_!0=F@5<723L-?&1<#J9SRE\3N3X"]<3 AB7^6WTLZ,(L(
M+<Q-XM/8(5]4Y\=2A9&>/]J)%T@I(*'B5.&$$\V<@DPO4C0]YZJLQ&0+#U8_
M;^15+Q9NP>#VY>5T=!P5K?W[:9A5O/7LS\@5^!(NDB3)>;415VC3;OWL%V7;
M5NB!?JUGFL/W7%:V=(\JYSE)(J.%A>'>[ME]3UT3NNJ:FK/'B9%#C4YG>L M
M84?.$^!'#<E,-*Y1:32*>*"7P1+/ \YU'%!TJP99&7=66NAT1ZT?F6J+8DL:
M81@3CPX4,D3C-,$&H H?TUN9EC)VBO@W7_%Y+,_'PF?()7K^+4C'$7P. 0R+
M]PYICQZ54RP)#RI3A;H>6H1P+;;MLD:/'USDCY33"#'\&HQ^#UT/4GK]4EM:
M-(CN_ )V5&U,S3$W)UHTM  J9P#3<MWZ$O:4J+N,0G;Y]M)+!WIU3D8ZB)VX
MRTE47_+(NXK>3MSV--M]'\UADNRBW_:O,LJ0$ R9UJJO.IU3A/4J"@0]<VP*
M/B^]M>JB8:U/ILPY[BCT-IY7AN<X>*Q=E.6C?%5>E/?R_V(_XA/]55;3,W@7
MJKK^>^)T,)!@LE_?0,6;&PK\O0G](F'$@GTZL[;AMBM-+6+=X.^L7#6RY,M*
M*[I_ZF"E3Z @U(=$DX;JWP:&C>$*6$Z0#50W]KUN%Q*>CS41T?V<:%XF.A.^
M=+*:[+UD61..M'7D_T@YL *E%'_YPGW<R- KMR-M,Y\87RSY\YN:;217LA4F
M5"2N:<5G.AL>FGTPIL;?,[/A,4\\U*"YF-D\S'U.LOL$P'9TJ&X4-Y@8V)0'
M<P[1".'HVF'>TNX8\R4)JQA5U_]N)9Q<J8C4?R,#!D57# 6-_F&B\KU@&@G6
MO=<F*&GY,);[:V9GK)Y4L?W;-U+3' ;SAJDQQ[(#Z;%W0GFQ"92N79Z=X/9R
M^2Y=S04YAN5*O2 Z3_Y)-J7.?,QJT5S#6009#'?<'MFOTT0C.P$9&-@(HDZ\
MQ+J=Q@>!\NUJWV5;-M5#YX%/@-P^>JXW9AZ973946>*E*2=9S<7R-F[<9YCQ
MN>9?=ILN:'Y?P$6.6V"PW64@U#OKE/5;GC*]WT#6KZRM>WRG$Q9@6E9A*1;Q
M9$/6@!O:K9G!)G[#LI\@R.;?@\AYN9K,=?A5&J(E_*0N-9^NDK89Q;17R]C
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M*Y#?1W_E'@8U*&V42%RDRB!U&B3RG4DZ=]7G2T+\NIV;1+YOUHDS(;/(P]'
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M0(@0EU$?_S-U?CY7-?=5D"U2%6M\:Q[EA-BN.7T"6)>]EB/^_!-[1I[N0M*
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M2KX6WU+'DYQ MX0]I*SSV+.I:5HBGP"T2I?'\,7/-J,3ZK(^#/^[$_-%@%O
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M^NJD3^%2!*14Q65[*L\3CGF/IO6VJJE?9NG1'YJ\JP-N5[^Q9?Y%=AU(67(
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MVD_&*7FB[JOU?*K#5'F6?])$V,J4_WG M*+U1EH]2H;P/9.S"5.AZ!L(Z2/
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M7.(9WD@DU"MZ,M84VSO5D#8=6G+(>"L0>-1Y33[MEF]2T1!*]/HJ*W&CLW;
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M8)5L_6%&W2G5U'2(!XU9P0K)4B68EEPHN^7E?5K)6EVD0,TAK9\'WFS$1P:
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M1+?63-UM7N*&=513=R#147.3@UZH&BH^,NW^_ /OAQ$K\)A>%O6K:XVUEZN
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MKM[28-KT<EKA@[5KM&H7BUHM6G$@@'W#<K0SFP81EO]_$P!02P,$%     @
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M%(0(RP['])W( P";>:P@=DD"V"4: NM^HU]0W2 7@G,58,=[:];X]7V>-YV
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M4)L9!;/&G^\;=.MU:W]"^@"PM8V)MA2@O-AJI([U&I'8K[Z6!4U"'P#[J0\
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M V"LU[PG][J!K&K58W:-BRG\6=T1)VC9++^54.$!\.R6OL1IB!I(=^'%0AV
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M,]+*,(F-:-+"(;:\VW<_%KC.7%/?HKG52=,(7U*S7:!BC</"DY@P[!]L(VT
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MTO@R(!$]Y90'%X9/HLND/-RH0I*8X6I=;5C7*<AE]6O=]8AO' ^ )6PW'Y\
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M%R5,!MRC>S#X6>[H9_K-T@- \=90:Q:8/\2 &QGW [ [T6:%-(7;BZW"#QX
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M;@<L!#/U><W,J?$\W/T1+G\=[S(U]?<&0Q5*PC\Y?,&X?JB\W9DBOL)68?/
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MO<ZU_.K_>\KF_P[FD['_ 5!+ P04    " #E7G]6'F!7U*R?  "'I0  $
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M<@CKV"H3N ("-SB!K^7+5HKCJ P."63ZJT4KOO3#(\#.M@HI>Q+%L#+W-S^
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M(Q[> SBLII #Y_,Y06177S"1EFN:L+&C0SWR 9#R8Q.F=^*1C53C%H =:#P
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M140H*02[2_8\#.,L)LPC^7> 1[LXJ*O-3U[4+H:![H2=!%0NB-U?_T>$FE;
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MU1S,>^;51)9VO]HGXH#LP*(1RLT%%6PW1,VM7;QJ/*./@5_P,J$JY&9F[4O
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M.DB("51;G]8J-E-)U2[,5G#@=(62M>2M?MSK2T8I)^S9:9PO)JL; 2>I+Q\
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M.81])LE$2\WPZ/%R: V M9P9:=.>]#X[&SV!7FP?"1O<:&<)#**Y+8:BN/I
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M'[!ID#6MNHQ%_?;X(1*FZ8W!AMM_$Q;TXS9+5(+W6F21?AL4?:L\N!N O5'
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M5D%^G^QT()7YZ/?AEH+WTW($,[/=MQX8/_5>,R_G*:5+ -ZE1]7]HWR2T;F
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M35?H*^&5%ZPUJFIO!RIA2P&/L=?43"_L>8Z-SJ1EMER=#)7M,P=X$[K<*EF
M/,G]O@!_?*.*LKPLVQ)8OCL3[@TM-0O J4LGI7^O_F7O(=8]+L&6OV,.^6TP
M\X3YWA(*-C:S86%\VZ)06(U,+M"6)/ID8VVF,J=2QLC@BH>+UIYC9+5H88NV
MYNA**:MM7*K8'Y]^:6(<7++5"UH^J)KL%Q>92>,4ZI T9-@S<;#9/5=]*6Y\
M3^ 03<N(CLCXN[94:53@;:Y)F6R2(1]'UM8[Z[OKI PT_E1HW.4&O?VH%>P7
MM8_C'/T:5:SR[ZTR(YX_#_RHVNKV6])$\969!LHTM]W,HT@]?04TDWJ4,5\
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MF<]B>E[VB8EOI:KQ/'EFIJN.T+:T?, #*,IL2B%O^%'F<'WP<>!IEVA4_@W
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M?B_R%5KOX/_I$/J?+X,^M\EU_.8-@#$W2#'#VHTS^';C!9_OW<C[6Z=T \A
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M\\P5([V^#:Y!><E1)K*G@@]D6"[>8!36I9](B_I7X4]'%7.<?HII%2I=5![
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M"*2SNJU!V%.[J,IRD8'368(+Q@APM'].JIZ/I(=21[=V.[.@^_6(Z=;QF1&
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MC[]KG@75,.7=_QA;)BMI'1<Y,S%WP?OAP_$@9T,0<4F9 T1+^N2W 'FA.97
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M*?:G1:)[@&68H/$>,$CU-DO#"6>WNI2_9L'<?^E(3!!)S]J>$$CPVZKE.BX
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M_O5:+F73UQ!;NAKXPWD-Q'D*S@&L8=ER-YLG,)JH6<.LDR'&! W-9H<-KSL
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M<G6U0>T _1KH=W0@0;%_+6#Y\!$94(*R.1<KY5X*T[=0^\O> (^LL@%CK!+
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M"J<RVP:0CS?PTO"*'QNJ-E]N^N?B^[1DX;;S-8EK$4O](67>"#*@5P'6H7.
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M&; &1BJ-7]<F_9SX)9+3AB2+N#4TC4K>DGEDVS&?4.WQ]O>B:-_"_*[Y7./
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M^,Y%\;JSDTR8621<.! I(X2,;U[,2:F>#*.:G*8\LG0N$U!ZH@9>@AJC6\F
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M'6*CDB15?O2;1A?]=#/B=5Y[_+4,Y05E:[B:<:L)N,T1E.>Q!*TT!?O&!@*
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MI[BGW^5]<%I"M_\8]$2X3F;O64*F%5[5S]9WOG";I*@7R4,X3C%O%XC0_L*
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MLM)J+HQM6TU$$N8.AX, O='@'^,-(M7DIKT^.W,LCSQ\19:-_!M02P,$%
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MV3JJXL:&$DVM^8N=3Q9.[.X_&.2] 'S1)US _*#&T>>;9_,=ZUK8NK[A%?J
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MFT=7Y2=O'2\5AM;SK=N#3FZ]X[T@+R?_P9G:X)<D9:S1/X6)TK(E%DQ4J2\
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M,%::J;:2UA15PSYJ.1?[X]W<)T1:?)%BQTI4]2FJ@%5%"%9R8)@^X/2^:'"
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M[<6F0/DUXTG*=6#9KO2V-;,W/+<HP,GR;4Y,T1 0[9WMK?9&H:KX7_X9\0V
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M]D&8?NKS6O:LA?^LBCG-WF$OD%7L)Q7;G+'E;B@ZF'_ #5TL:3=2/?OZ5Q!
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MI?B=0#7/O])K%UU3O'-W PM/#<'_-P%02P,$%     @ Y5Y_5KIY5X*S>
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M9 <J'I-GY"!'76"L?7=%_:[% 7SZ0P>FYY]PP=')(0UL<:R("-L^B@/H]'%
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MK[B3%];8\Y6U*QZY%?&E_3%2AIL:I\SFL"FRRW*7WV!]9+8<6(Y9WURKR&0
M#N0^:3,3)6:KJE)\U[8+#3T7N!I[H;\[S)8"5:,6X[6WRUR>4@\9$N48*#M4
M]*,QR_"9/SD0L"#-^OWJ3D6[]AK9P&<-@MAE\7WMQH*,YC'B!/)Y&M=?X_#\
M_D)'GO=^BL9,DJ/R# 2RLWYB9-)LCLVYQN\K;_FT&O,6?#LKL^>T?&;CG&L<
M?NZEL/KYZ<3@J,J9#'%DKJ$]B#61<![DYMO)IQR*_NTM/_2,;,BH9IOBL!!H
MB:51"#7<%)'0U!<PI_A55!8^Y3'N-2#5R>; T;DO=>9][O]XOJI]:K\HKTJ#
MGR!IB"AQ,IB#5NKDS0@90FMH/N"3FN"WBLO:Q;1,J:;[B9SI"4T97UT(55N3
M71\@ %]#3]Z7@PRHJ6-:'<)-@Z.NA'"=HXZ?D+6[7I!C[IG3!X4X8("I!]N&
MSSECZA E"&5@8R^,,CD.K;&4@D<B3!V%USS8!S(6VVM\V&C!PA_Y?<W\G[]S
M"> 1J94&NO05F!CB)HT#$M"(R-XER-[GUH]K_40R>J&'^X_F(I6"ER_0KIM8
M0J'^[DS_Y(\U(>&/FR'$$3=_!T8,#8"L0N%-/OXQ^C\_+QO5?WPVPF#"0,G<
M-2SZX=B'5%(OU7'A.&EI;R(D!Q+';LP<GY-U0/CA)Y$PC;) K(:7;Y]H+D52
M9P4'/_.GJ^0PSJF: A'??36.W0SO\L(?9]S16M&5%5U<D^&E('B?-G<F2[_F
MKM[LEUQ.%P+J]H.@2"E/K:[!THSP%YRNQ,(]::.A .-O?04CQ8]R9% WT\;!
MM:G$\5[P[*$JL5BB%_A52:8Z-.JB4E0VB*C,32EO^.<8H6.QW"#X9XDX#4&A
M_Q@5P:-4_[01%X"-<$U4Y8Q[WZOP@;3YKZ>]-.E?%+U&) 02ZW@%9CH:Q(1$
MY3$"!2Z"\\F*K&8_:.9??GJ(<F)FG^0PV50"N46N](=<&?OF;A239TH.4O\P
MMK2I7>CC6;$F6I/_=.CQ?I["GI*\<\A7I_;SIN_F1%9E5_/F1/:=^>7\O.$G
M#?=<"6O(;*<6AD4?]"D.F>X.X".C/0/6A,JGFQ]NI9&S0<3,O/O8WO)2KH+%
MA%]9[A.QJ?!RM$&#$+_1C>*E1M#(^\$W79\>OK870R1.+5HX\E(7-9B;+XP:
M&]!SE.7F9WTB\]S=?M OC^$7;HE\F&O$J;J9-DS$X[B0*D%"!WNBS<@UJ*@G
M\;"A;?MMX$*'C&O5\)C_KH[-LKU7(3[D,!#,8.XFRO;14A#!,8^KL06[9AV%
MPWS8!V:0LS[P*9W=*&WWF_M(S>Y>R)@&(>0&P\PIN$1D6&0XX@X>#"7'^\S?
MK76+YZ].[,8GZI)B[V87HB/=\S([4<1,DN(&"@^D7IB_7X-Q[,[@ +?7X*-V
M)9<RV!P4?,0(XQ%H5'K>M':]80J.5GG]."<T7T]" WBEKZ?C,S3#UR FL9(L
MOV]DT<6GK%*/ R2]]!4F/C):)/T8E0KY IW.Z^=/>U5&^,[TJ>K%OO97N4ZB
MZ<_'LY*[VUID(6$A[(&%3I=?X2EJ RSM#MK<L2.3JN\T%&+ZI%,L0WUW3:V<
M'A=T%^N^2?'1IP9X"ME)1]W<;P!RN\9U00RCK3_  BKUY'%#Z?GZ_,>C\H/2
M/&&YQE37XGW*I+J<O_LUI84(WKL19 (I4?HI<RZF<E=C1([IN8BHQ4)+\T _
MJ]CW!(.CU;S>S%[IP.9'BUQ1J2\2)S_L5_,VA)93H-T915!7^8TDX'GSXZ:2
MXZ$7 L-BW;>9I6J;DEZM.6515"%]+Z=B[3O]A]EU(L\?[#[19M$0EF<@SW)X
MQOMBLTW2E8.&A-=?5 .SC8[C91\CTK+_.T);(FUYN?R\Q$-6>?M-<C#+U1/Q
M:!DO!;3Q]#S1CY3\K K&Z/(] V,M%:2@*WG@V)^SPMJ8_'HL8;2F?/E"VW84
MO4I8%'3DS5R_OI[F\6:^GGQ@+M%, R&O&7ZED,AG^>HEDOI.I*1+^O:)43<I
M0RC\SKODRG]_7\L/Z=-C3]B.TGKNQ7+9?O$@WE>>9<>U)B$E9C&[>HP^T9@
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MSO][1EFR"D)JTB>OG$YP0#:Q8MM T;KDX29A&)'!96 T6^ZX/>?X@?%9>4Z
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MCQ,A27IY33K-7IO2SLAO2UA6RTB>!"+&+SL:_E[[ TG)-_C^L,\T1LXL432
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MC_V)NK]@@H&IWQ&G/IDKF9@'OF5_R[NXTD^6DU,=4KF->$33U"A4B.!VF^8
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MAVR7_W;5ELSY>PG/WB5[SY06/F<ZJ660]9S,9CGO-,^G5CKQ<H=- /!Q 66
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MGO=P;K@,7VJR4H'9&ET+N&K)>CZW9R=A>;CX"<OM[ MPO.SF@I] F4%]_>Y
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M@BP*285A >RDC:-?E(Y<+B70>'K#8;_NLU/21C^W)9#5\5W349,-YHD85/D
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MT&Z^TW32(V$)]YY<%DV!<8P14\P'_PZ/&-5^W[6N/WKQSC+1Q$4R5*_LD?[
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M__ZA206\I#&P/T<,<TNB J"GX_WV##AI%:]OF7+N:)OEE+R*1IYY2@Z9FT$
M,"O_AQI7V'<Q))6M61"98QU&.H^B F(+0-M0=+C>X-P^FG(&2@5TC/R1-78$
M]N$HYPZWSVD"V_Z7D*9_*(F^#S$'^R]+#HTKZJ&;D%D4 O":-/@_I/FGRC-3
MWOZ7)>=_60:'_M>D?W6D OXO)6D<$:<<8_ T?![FDGA\?,J4!M9?PTD,5,#'
M,!<J($+F7^O5.!\%@/U//1M*OTR1_!^! U3 J5\]L"2)=6O$R-#_CS--5PP
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M-,@O*8SE3""VC<@+J*8LFG/0B(^Q5Y><7R+:SI%8)J&DJU>4U! A4C21AE1
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M:;V4.Z;<RRB^;UA@9EL$]XX<^\_,9,1?(OTN2(/.?!F]OT8%]I[#MJ2I+]K
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MM404F]1JN:/%[7W)A]\'7<*TOH[%P0,"RN]]_#V3W\5@D7JR1P)BA',JO)*
MV]XAR\ER&P8$74:'FA@%U4T\NA =RG$4 Q-M]]A-2L&J)')$DD<)X7MFB5>B
M-$Y1#\UDN=8U3L#G7,/4H0RD#0W*J*69+O^ES[,:CV&)XLBP<S(UC9!$BD],
M3B6"2B5+DL=+ME\HL0"!\&TVQFMISKY2QZG+RDN:GT^'FF0ZQ,MVNDR.;ZUY
MEAL_,EOS3]JZ0!5=0SG]>%7]NZ5+(\4W#X5ZH(^KAT6#B@E]QZ_'86P0*G&2
M9]O\OWX](K8H\$(5\RAUC:K7MC21^@S3WL-W2U@,B=$#>W44/G&;B_%5F^./
M4RYP&&#P*"!05R<7W(DT_/-!3!Q%]7M@@(%\<;*L6*:X.N?%+ZM%X_U-@>*;
M]UP%Z+QRBIX82L[@^WMJ#6\[(6^W]DQJK:)B$5Y.6F8)3[(=CHSEZ]-&O/=:
M7Q;-L=Y_.3](Z91K1HVT[B07[)>V5T2D"D_VN;K$)_SI.<R.6JT>Y_$7KU!P
M\A?WG(L,V*Q-KAWSNX2O-K0*'LGU9H.2^\>=D+^%1-D&C,-Y'7U=)<LMZ^T_
M)/R0V&MY]=<W8ED94__]K@\"Q'!#[:91-[6K?Z[N)_XH//^^J9%9#&^X%!]9
M**U;J/A&750QQ1,;"?=MMF'KU+US\WJ]B:TK!XQ8]9+E];L:XABQG8:O7$,8
M>:2:^>J;[IU%_M:W*$FO.>KP:O8:I9A3+=YMPTVZ"GZ;_%YGMF]97"UC K3N
M6X)KRUB _.3\FS?+-S*K;1J)84R"J9J-FY26)$2%0?57G]OY,X*W!!?Z\>7:
MRA-> L7A^4J+&>]ZCD ?O_HK>2<HESLYD%SHU\>1PAS 5N;;?A,8P<+"T^&U
MDR<[]L8O39>^BYO'9I<6VP923 LWY:DP/CI>'OC1&!YJL] _*U,PK;9J;P_&
M1YMID'?Y,-ZTE JY;L?+RG43VI_ 2+YM=S6Q!G )%0;ZT"OU\MJ0C<K0<19>
ML-7Q+"Y\$.+G'G(;S"(3MEI(VY1PE(3S"?;RMYL7%RK5"@(RFG[:+BU9DI9"
MI!:.[]902"$,N&U2J\N$?>TA'7Q1'G_28CUX3XY\H67<;7W-15DB&N&R(WM[
ML$JHLI]>G:+M$>9GO"OLG?;U1L[SAD&8'$)HJ24NTG.B<2THFGDPWF4J-,80
M_2D;K06]<^,P:+3)>GEI$-_^4&&NZ\"LYHCC&?K^84O9B5M8MN^QO&1Z6%SV
MR/?BFM.@U$*-3[Z\_:9+O!""-@*K3&)YKLPV<<9>4=]@8I(PXU3XX%<*8,*+
M/,P+F@A12(>)$63$K*O4TM")H39"2,".BK14&?5X4![?<R%,\8KZR5T^%%,M
M4;C>+-X(66!B4!>S7N $4@$4=Y?0\KJ@:EC>PEA\M4,Y:#EFI,/VJ"P8[W@2
M"R '5,HXWHU.D+#G-?#_STG5T@T)('C%CAZ]6>A Y4E</FKWONX(<9J!]063
MS1N[8 $GRDF-E3>P5=@JU9"H"$5@:#EFWP51+&RAZ N09-R C3ZEL&^%F&RE
MD<OKF3 I<&2X@C1<M&K?9V4KZVDOB3+K4/+%N45YCE+UI;K"6'U_C04+_IH0
M.>-DQROK^JX$-<)5F+90C,EXS=72PC!<\8;DQ.%S='%$%>PZ4R]HQ>GMKB_A
MER!D8J9&" X[,Y"78@$6^U57BMG'DD'+UN4-PR%1#ZM+^1S44:&*5R\:N24P
M>WH%A%Z0'0/&V*S5-7R_LY*7"KOW@Q'C<86!LB9!;8L9QH2^2$R:E0G%8"?Q
M IS]S7S;;4B#'=5Q@-_X_D6[66,7J) 9TF7BT@OQ8%0\+6XZAX8+.OV,%6>L
M4264%B#7CW@<##HNYG+\$1(<4&J\;@$;>HN'O_?7!W18/!#R0+V-HI 6[]-5
M]U*=[X>NA3NR]0V3_L9(6J03F7'C^.K+R0O7^2$^=9AD7E0J[.N0YHR2R?$2
M]]YB9\CUMEK7-V]_MV$_GL^'$^J'1.=PCQB:V9_E?]#R>_%+&A353EEKV35*
M+%@@ZXVL1=NY12;2E.:D!TRV=J30L/Q4] <E]QV78KLLQN/\T)7;6,! BNFU
M(TS&6H _R@TF\,QR$'GDV4X-N5F<_'U_GW=V[0>R2+S,-R+7H]R$SJGJ26MF
MQWIE3^'\#5O:6;EYA"]W-ME<M_:/\B..BKF>N-ILB)PC:/@M%EA<('^BZJIB
M47Q(U'H6=,<?<AVR;$Z&+N[QG2HOD8?8)_UD;7E$N:O'O4U%AJB4\=OGD6]:
M+K 4VY3RT]L)L+N\(_C&*<B-+,YAV(EAJ$2C5-/%7&4&K:&B\?&&W.F>-[3[
M,N@CM+K.ODVC>RJ.:X8X0M3>,U[(%8^9('C^=+45"ZP*9T>EKPP]C*@[7/H1
M^'!L_^%MXLK\.7F&32_._'<57<9248&ZD\G/&K/,G;[:)=5O+#)JWTBZWN)[
M^O,]\RDA05C:\/&/JD$JMG,8?IMYY^*ML:^MX#-I0P'OSSW/1CZND7V[,/5R
MZ[OYK-=.MZV_>YD54^KMIM2<K%[=G*'BX=#^FI-#S"U+5LK@><%"4]8FN#YR
M8]V8R7"G]E"Z>?(MC)D'D.;ZXW\_P++*VZ!/ G-#.U;06@-?<*B,G[L+X6?.
M;&G.$AQ^XWVB:A]$/#>_/<N4GF-?A 4&(QFE]5[47]WF[C)$.;*?F1T(O-YK
MN]&/$>EV'-69*.30(R%?6"Q>3!N>NWA(P&'")+DYU8220%1]VYJ*5^5 BNVE
MV0U@8$7L\U:(+5409S))6\!?CO6,J'@.??6PQVILX![/!/2O'B'+K-:S7C;)
M:OCDKN-?<O9UMSX73<G;@TR9I0:,_%WBR#3[P!/66-FBY<WUIZ@B4 4&=HQ#
ME"\P?.]$]+Y^&)X0W]LSDSMN6)!T,>L](M-K)\3P:Y?1BXHQ8P&)8^)HPV,^
M6.$;E97 JA.>POVO9+%0\MITTM1W-@3[$SUO=%\=;2EW]&9)'AG3W5T1ZT14
M2@[NDV^[R3?N@S_F>IN4.UR>Y>323*)8G7UU/SNU%!-Z%.@%:BA[)<UGG"Q^
M#EZF!)ED')D7+!TJ$H'?'96[W)3"P >/ ^T+_")N20;X36\98"@Q1.E]C;@T
ML<1U\LH2N2B;+0\J+5-BEO\^XY,)7$2 OW=$72!^.F&!?&15SLYF]MR15^!@
MH!#MZ'_=*\G^\3.F)Z9'Y7-(K,9X&0\KE&^UV$J*6.QR@LZS"NQM("ZG0P")
M0!6R>-UOJ2,[7MX#2%Y;)X!HB_A57IV@2>3C8(/%4+,O?9I\2L549L4)![+A
MMM01;L.^&KM_!Y=H4#'I8-:.2R*?LI[<3XPR=5O0FE;.I0="@2V>:L&P*^I,
MM5<_/_3$2+>LWNR G*]46R\Q>YJI=_C[A]5*5J653P"J!_=6@I8=-,O/"(25
MSQ[O0XX[LZZW*D I?#+MJ(-V)80T^^OC,"RP4_8M8H^@7E#9>].+RM4-?E.;
MNA4R761K2-S O.:FLAY^>CK,Y3C?>HJ#!-%\ W!UP0P7^6 7G82^H!\9^6+Z
MK)$68;^8,B9&9 >8-PLE@77S#'A?VR/$ZE0"%K@EDKRB9M#9'%A-GF'MO6]T
MZ?T0YCER04D^]>;O[4T&@_3^3C?TPX_U\_?/2[Z-OL#U+V,E2D]2>% MQCNT
MW$$U3I4\C(/;^BN?V;^<DC?]Z)=Y0Q!I77HD*1<_N#@MA_;+0_L2M4;N(^__
M]#Z7)'_QIG#@A?0MLZ8JF06X1I#9EPP:5H9SL4TJ0_^A4S4_9,'#ADC($4_F
M<J6DW!&#@=9\;TE7D(MH\K<CVNB1A90+3Q1!H6L[Y]':#?OA=5+DI4-E>&96
MKE<I;$V2?\E9MSGCC,A5IFZP_%Z3M!NBC2P+<[6:S?[5O8/,WQD+D/F;DK>0
M9SN5?=PKKO.3+*6#)(E;\C<GF:<P5OA0\WYL?;F2::QD_!2RLI^]TE(81VMN
MM"TJV*BWG6XEZ1Q@'ZMM)!^-9\NPHJ5@> WR;9V5*7XH.%!D#J.EXY[Z#H!*
M'WL7,0SM8.2.)!A]58R3#]NBL_+?4&G.FAHOJ%R%@.=9!&MOA+.QP)V'6_[R
MY?9*E@Z,?<7VC^MZ.&)3/6:/\:Y779=T3(I6^YV]3_,)C]4I['[_SFBPD<@G
M^BY:2_' Y*\,W;2[F,-J$IFAPG?5M8,8FW,7A/B!(4!M 5R.N[.)0Z1MKR*0
MH]2?'?;M\A)G:>=?A6"!Z0(2NICQ[..<-T*C+5F+[W7_Y.HZ+<,IGBDLM"D0
M<;%O4["E.2UBR P_0:XZ,UY=CG6]NW'O=!;,\M.*_B/^Y#,>ZWL/L/*'0/II
MZ1*V4M#3ZZE< S^W2VU:=VGQ@U&JZN5E\M0#.7:SC(R)WYX>4KY:)772-JLR
M?VX(<07G<-A5D7&G_YQ#?-0,6>>[U!,=?0A9"510=_1F*Y;FZL?4K3$M)D:#
MPR\[AJ:*+L_,8__^X7F^TN*KV8D:50[/Y0IMS993M7W(NV6<DD0'T_KU4"0L
MW/+@>-+%U*?1[$'6J<U;3N]-Z;?L(98>3E_6_"93WQ" ^5$% ,,RY?RKB61?
M9(<OX#A##1<3OM3! H0!KZR.2J!^%D=[7ZJ&L_E3G?V8&JO&L]&L)#P'#^L5
MKG/P]KYL).MJSV07NFO)NZ<046G)_H?\L<"5]]>#&9N^H'U<C_<7O?.7Y-!I
M+HE%=+<#*?PZ;OU'T+& [G\AK96VKDW&DZRZVY(UH^LZ)FS)HPM/<DX(W->F
M;GT7?[R @;)3C355)XEM[2F+9F1]*&)_^]* J%%:7K/WN%N43:C;,:AMM,,H
M5L'S],).Q'HMY,>Y\"/PF>L#2,>[Z8*;D:'NU:E(/.2]$RR 5R4"MQB\8Y!_
M,UK9L%H?'97PB=CM9MA&9_E-]RJ,J)RSJ-H_5V&I]F?,U>[OITWO4 =I+67(
M*Z.KC&]-R55!&;\5=,Z38[HK[>J?^U47'Y!25+*SE@):M(PW7W8=):MC[*Q"
MHZK%1ND@A4_F16!%+MHBSR!'6W) ZPI<O("0D.XV*V;!=UQ@,R/JG%J0EPW4
ML:ZY;&6S(12L=_'!Q!,TGE&=V=2GN+P1EVPCC1 KE?G+$+<8_'#(FU$F\0]:
MM//2X3IAIYUK<OV7/W?%:[@WY)ZIF4K4A>=?[W=>EL?PU%'J/M&%KFO[\=76
M\786-.C'(F.R0<.8QQXPZF3=,*@]=?0D><C:IUFN]FC4B*?O<_9A=3LUVDD?
MKL:V\JZYK8"$TK&NTEK7IW&](!Q/5FF7S&,JZQ$ZH%*-.!_)&^Q;'Y=#M-BP
M"&YKDOWY)WZ;*L;_=Q4AAFTR\*&WJ,Z16E+-,IFQJ8_1R.+^IB'\K?LI</^1
M%94/?8ZV6)_?5'3#GNVJ*9MRC9K3JEGI:KHE'3R(8BO-BF;+$5E\P/H\'K9-
M11JF?&!_\^3]0^@/+! <Q" L7W?(&UE71;QS#NN?:!4N>W;6(:+>,JLW<&=G
M2V,*^CK K^L&W'XD4E/>NVI._O)>?%7H]%ZRZD4?M7$HWLH'K:Q$&Z7K>J%,
MTZ)O1\D_ALEW5*S,'V/$B+-]OU*0OC$!EYA8M\1$+)'N>B@N'T$[LS^G3;]_
M<Z7R$@O8H#-);84GLP7E 39;9AMNF-B.SM"T>0<&D2]C/B4#>9:'<,M'N_W0
M-[O/U;!W;Y&C:=(RT5<QOI] -D#7Q90G>37F,Q/+Q!W[+*E)5 R%6+0CC_!<
MS;H0MS-M;_1QGV+7'[( Z2,=1 (&^EMH[,A@>3)0R(%)GJUO5O4.Z0/!ZE7+
M8*_8#A]CYCH?XNK#XF5$[\^(27_)HR13XHV%S*]/,6[W>19V#>4=B45R6*/(
M^?4\'.1MQK+\P,&MXDC6CM\L#4=)=25JKOV.K9 <B"UY=RC+*"=T!O*H:>I7
M('U5NJ5;.;I<<?I%E@9&M8+%V-YS*S4T<YD<35?E=H3H!,,W-3[HCQD-_I1O
MJ(,OCOSLNEQ1W/A$3*,7;GAO+R/>1W@4"_Q(1*<>Z70V5Q\]"!,6\S?($V[>
M:@X?_M[]>%= J7HEKB;B]LVW%O_YT[Q+,RP06[GFS1O=>M]K.4";2R7]L_U?
MQT?&Z<8[H@MDDT_/K<R6G;W%((T54O='?#VJ5-%U]@_"I'A7LO&&O5Z7;5^J
M-CQH2&YVSS-$VIZ%V'>@H_PDX#)V)X]?M7QS_JVB*S<6<WQC1B'VER,R9<3[
M26;<Y*$T![%+YL+5+Q;J0!/PBM!"!]0L$<(G+8:D^DA2BB2HXX\&\]+VCQJ9
M4*\$L%O/Q<VU4;8;,\K4WHHAK&:C0U"A#7+%J!PN+B 8#L2=I6 .H&#M\OKM
M'^]>?H/X?W]O76]_1[K9;ANRW7'/4M#_-MJJT62_27Q4^9A-7SV?=K]NQ_S>
M[0_+YMV0V-[9M:/9UGC)Z''+',9R3C])+UR#K':C<OQ@1(I@>E(;$^\V77=/
MP52)@:G._%U</[]12CQM9":RP2B-CH"=+<JK(/K#@F.FVCU80B>BD#_A*Y\A
M>"0J8-%EM-" 9#M_8\V+FMO- 0P=5K2::S?!ZPU,P'7(F@J+0O2?'#['!I::
MI]F+CF[3%]<%)@5U@8\UHN$ GFY@J?+@W\(:J'))7N06WW_WQX=!<PG0PR$9
M003FY ,6@#WVZ_5FVQOO"GJS]/!^AH_S?WT)QI7+?V6[!R&5T&O /7QNP'#C
M(36$'\5+;3!B,4]Z]M7*D,:A9S/&SMZ1VRW#L_ D/:3!&13*J1#P1YKS#%\H
M96\N"KZ10<O'TJZ3Q?D\]P-A )%P+MMB;&=?2\##EH-@ ?J@SP_I. ,M=N)N
M]GRV6R"6WW;MQV[PO@?]F!R+T4DEEBE_.?J?O8.LG"O(SCPAR_$-(W],QF^S
M5KT%18=)GF,EZ-OD]J"HWSQ45U-Q?S0\Q8/?;-(-LV@V0;(XYB*__F;@&X44
M"GIBPD;'0XVH:9W$Q=]IUX 1%[I^D2AHH?A)@\S\B>SM)KTF<8R$CF?2I@=(
M?)1V[T"1EB%I)VN2-,Y9<-N'..\=IB?[J^1D;GI"S$C*7FV AAVA8#1"7*@5
M2;CFSASY]G7+UHY*7^!9P!;>+S2T;_H&%+_^+K>VK;I%L\'(.A_(FO(/&#_*
M*E1B9?H];MO.A[:GKK#40CL$!/GGGS?<]8Y0I)QK,OQQ-W^V]2^_F6!\0)GH
MR"%QP-\[F973</=,B1U-&<;#RJS,-S[@),AOAJ51QZ6E"/TN!0Q7UI244CDZ
M3#,>"VA.?G7B9>VR78N-8"4EZ!/OW(D<DCMQ6_PB0NXV.I[YP6U*AC%P @O<
MNWF <'(J\$Y2&1:AYB)/+2MIKHN1QM0?9/MNG<;$F).UL]1%F0F@H9;4/Y4V
MMB66/GR='5_UDC9D)G3;,B/N\,LL_O-KD!SFV#JN90H:&@V8]*B:V;(VSN3&
MR'UZ?9%?';\6SG;5;HT)R4)_%44L,?)@8"M__(5SYA;1?MVEO-E"@G8"IB;S
M V/^ W#R7Q*\EF9F,B:75V-_846*Q8/-GU.C7R=92VUF;(H7Q7IB ??3XI31
MB0ZJ\$!M0S==EO3F_36+C/(3E]$Z^F? E=>6G&_)SH$LB;'7.T^AC)A"7ND/
MDV.UYU+N5$!V]\3&#DS:5[LL+B$KLZ1O6<75=S66W!KY:US0<8U!JRX"H,/8
MYJKO7@9LOY)T7AAQV7E^<MHKAN^-8(R6$*Q=IDB?J,2W*?6'1?%V@2/\X,]$
MI9L-8B^X)FT(TDZ7/LV8AP21ROC'.[IJ?/4UB$>(>/OSGE9L[9T$I=;]2_Q'
MV@9_.16G/5U=I6T/R-=9^4 3U/<Y8LKU(T19^;\GC"A235HCP^"[MCO.94NB
M,G6/OHNX3?_Z)2#\Y9)T\[!8Z&,%<1"):<F#A&'A1+>$TQR0\EAHH>N\6]SB
M?T[!MI*.*H*/JA66>KE.=-;G^>/,"[' H2(-DWG4-*T8:*E,N[W$WCKPBY8\
M];C%?Y_*KX ;2)*N4_QMHURHV#:V;IJX%G:Z@QS"#:Y3,=:TR[066&!LX.4D
MFLX9'8<VY^+B<796\-4E2FQ@>*4W0ZD@N^+G,E767%:/?WI>03(9U5^\#@!0
M$JE8W;C^L]P5K>@V4)6O70TO=R-X(8<HCNZ9I,O!GOK+-MV$.<8M_[$&AAA+
MU;B@CRZ1EJR-I@NWYHF\@H _B"-[.5;'QQDNN"KP-Q8U BOT!7>2)?@;C%&M
MW37' L\JB@/U=65878R*]T_]3D&OKEXTZMQ<E*7[;;)5"=OH@ZZ,,#4^V5L"
MF*5#03V#6_/Q >6*&';MA=#X"K%>*<[2_IW%>A04WSZ0[9=PF]V/6<&BM]4%
M#>?WAJH_=L??)4-L6#S[ ;?'NR6IG)'MHJNX?,M"<*Z0WS4Z7C M05J)82,9
M_4&8630DE!SF/R&RCZ0]+TZ<Z\0X<]R3(U^EXGL#R5I<32$#\\HI&XKP.4,S
MA?J,-RPOQY&L81/5.<1"EE+(+35-+]^H5[H9@B>CIP4DZHI;TVF T\^=$W>A
M$:CZ;YZQ:>K[7!RO8!U"M]1:4A(F%K,[XA+"U'02"4G!OJXK*2X#RQ.-)H;S
M&4>U67U?OLWMI/V58EF6=D+P[SS-GX,)&4GGMK?%*\4_CKSKTL*MH"0%B#]I
M&DU,=(NE@ CUD10[DSK?WM%8\;($U0?8"FX+CDBX/.N\<#N0?;^B@&NH.9KP
M:J9E:L^Z,Q+!<JK@U$OMY_<S[JI+:O,OA&1)EPZ<1]P:U=$0VVPZS_&$F*^N
MA2TM)CO]#(LQ]]6[^"[AIG+N^FS@2?"WR);O@HA*820BEZF]CN?@R]W:J4U:
MJ-_7M[3S&<<N:$V9LSNDYYMIYKP;TH)F(3Z5AJ*=DL9@SBZ/WFDCMCB'29/K
MV!>,ZC>-)P*"6[U\L*Q]<U-$22GUEV!R6&.5V9%NUJTFM%;9DK&\$T4T;]7N
MOO8=U0N1^EY#*8XL+_R<ZJT3DF/2_<WB.OH(1 7F!<D2W@V=:_%&TXT'<N\V
M\_<3LYHC+F?T_<,>7E# P)/_@XKWCF?[B_['TRJI&BFMHF9+:]7>A-"^:Y:H
M6=1HJ5&U=X0H-:I(4:.H4:MF2NV]*M3>>R5&[<0,DOCI=WQ^C^\?^2./W-Q[
M[GG=<\[S><]YG<;$!S<*W*6_B?XC62/Y%X 'IU>5QS?0+6]A%8D]FUTAD5NM
MW5F=UT]UQ6<J)6ZKLXEW44N5M\O+M_9+;J^J*K9P:1G%-,AJO7IEQI">E&UC
M4<"'RYNYC"2%/-%BK<3N7 H9G$P94-?IL(5,3554C)50/AXG.UJEAO4Y^,\?
M_B]ZQ7#-;[",]"FS7Q#V/><R2O-_C]K\_V^Q<:C9 %^B)'.,#[ML K/5V7;B
M;A6&JSH]R'Y[%*L:3<9(GFHEWB*8_K-4$]Z5G25#)QG)6H,%U;8;5[$\(]_M
M395Q1"&:.YIM9';1EU'@%G&-\ZX<K,N0FV?Z6%Q-T)<7_]TJ=C&89!^RI0M&
M@VW9#?ORT@ X==9\39?2DUB0)?^5%B&YO2ZG)@*#RR*NJO(Q""];\W9)IM&Q
MUG- KNQ\2?$.H3A;@(73AE,I3.=_7V4'H2X ]Q1W6_ '(JKLI..RT:7D]EFN
M:$NY*EP3.K)EF:NE\9II]X2S6[P<J^"LQBP:AJTREG!B7@FF>?E'A:/9!V5.
MBOEX 0A/PKW]3'U@NW,!>-;/X!,%Q'.8=$'?P_A:6RK\*'YG,JU%L>)+'I0B
M(_)2983WJ>SH)=06KFR,F:00%I<M([*(2N7XB'"X73/?S]I&)U;AA;:2]?>M
M Q:F2+I8ND#Y"P#E-9S+)PPT.O6_,R32"T2C6P]V+\TH^O75 M[5$1*IIN@]
MR+2?_%N4LJ;#PGA6I1)/"UO+]'WC7%AY''%G7V/3S=";F_Z*''B8N2\J*>(G
MD944@R'@E\PO #?]#-#/-?UMX1^]9N>EE_N[^LGZW>;7/$_*HTXO .:XA;QE
M"X\MM0EGWI$C(?D^9IF#;#I68$(LEAUI=B(:1I8=)[,%]9TH\PZYK%2,>5T
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M2)C)%5_Z*YADH5Z7MM\/6VOEY@+T0YC!'K A"N:U=T<G.[H4/FJZ2H%.683
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MNG^+C-9ZJ)SI 7;]LB.= K<YGXK(Q )[U4::O^3% @:4"FF/0-/O;(XC"7[
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MJ@DOO=@.]ILO. ,FYX,D"'Q8:/@%@&(GB(/(.B*U(2K-*U2R56,R/-O *$8
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M"/9E#-"3D>HJ[6:3&QQI (7^W< +=:RRW#K.PX[!3-@B8G[J4LE+3\'OI5\
MVO_@"%V0D4G.;X[091MD9S2"L5@T4OIQMZJL![%$GDN\!%DOD>-6NL?2W8]Q
MMO%<C9G[.FC5Z'1[U6]341_9'B8\S>F#'_.Y'=9LC: U6%GGDF4]W-%+$O2S
M;-(QY2Y9Z*2 .O_) 8^(+EP)5[=,?#BW&K$D<(5-E'5 KDUJ0M%-3%-:4%1?
M3=TL9O21&RQ@="@[\['GF4%R!O7.U'"M C9])!(_R$OBOUG4 +5HCWN_TU-
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MB)+"Z+%8(/#?'GU)N<K<_C9W?S<S3W0IJQ=HQ4)G;-";IQ;Z4S)R%X#'T1<
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M/;&WI-M,6QG4E(645VWU-.GW]7BN6;W[KU33,L,:UV$",/L0,X^V$U*0Z_W
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M.=5?NQ@%?X\FZ9WN&57W6MQ9DH#FF-N]6QT<"OF_E]*V4?(8@'0049T!&$Q
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M/BT2ROJ^93CDC[R<Y*9H^GY:HLB58JF*J+D7-=_B2NFE^GP.Y?0LE=(K5A!
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MK\</B=@!$S \QP&-IWLT1LQE+#I=P0Y7MA8(ZV:!'MG"B11_X?$R&B+P!0X
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M!XR>:'.W"7/U^S<=@2^NRMZ6Y[\,?7KLR%\-DNWB+AI:5^?Z#6N+O]6@"NV
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MNXC ["UT9PV4T_@ZNR2S8V67T-0A7HL]QO#%@**KFB[.=F;?U'2^5?'5+,0
MF763]D5AV#"P*KL47_%/5/LG2PU$3*,P;:1=P6QA7^U9'9*==SRUZ4AF1(R)
M-H'.*"C@?%1?0$N!R)[W ^<K>\&<$VLO@Y,]!K,0$L/[VBT_H[8,6IQPFEY/
M+K/@)W(47Q/G1G=N:]&P=*[3[JN?%VX9U"D0O="]>9"[3,<=9 203%6_SKKA
MDV'S78MC0#//[-:^@<>7A[;W:B]BAKWT6@&I3T2;FAA$ESU[5)XJ\\[B*8
MXFT$XU%R^IERF6C'M#%WPF1EV,AU%=N;!-_:$VAY:R<DRMJ=3']E;P^]&+)Z
M4A&TA3Y#W-JK3JF!6WIW@V_A#W(M4G?V#9X"C@:""AX,U&(;4!.9J\4!LX=%
MOR[(AJN:X7?5Z1]$160-NS4;29W+NSS4.XT,XK$*!['L*',&7<&.5V*RUM;N
M0'>_@X?!;1=F<>L:=&3(%7)HI57@G0F9"?L]4KZX:I@=>-BL[>8\;E<3>-!A
MJDN>#P(.UQ#E__C+&&H$</^?ZM@Y_$EU" <^L NZ!!8"_>WT8[F<91\^\+>Z
MO7RT2S#FE9B20D_O/0\S(5SVC,Y-J7AO3@$H8=+QJU3-R<-,8(.?,#_W#!I[
MW? 9-:,?1?OBFY^IHD#"4:G,M00S?^[4P7NFE[\6UV<U6_[FSE9&U2 _.#&?
M[_:IA:M]I  4;K92)7O*+Z@(2,!?AOX(-LUA2)8V_X5U^[<1L-$01M"M2D)O
M?J!ZGT;V#[C\OD.8G#GS<=B G!<9 W^ -QM:2K0^X'N=7G/VJK'0:NN0[Y@J
M-@.AEX,J^'<JO RV!I6,IQ^MV"L4[FDO[V0<TFM0 *X*W?EI\TG"T_-(4)"W
MJ,C* 4N'9O]3[E/CP#\7GDSY#=TR9DN*S%7_&B.IW>[J,Y'=_'53CCB7%(0Z
MQU:+'$WY?+QBW/L547IGO4D,$!^ ,;IXHI['[.[ME5PJ;$!2S&?C?XZ&',B<
MVP<PL1=XTG$L1^G3BM(_I:GA?LEXD!G!?BO)N;?E-_L ]TZ/==SCVL2(E(64
MC^LT$08I/KN=LOPJ^.Y\-C;GU@$1K%!=$9?R[^%09Q:&Z94PEFVI.S0WNNX-
M*:QO&7W<2K9,3+?;6GA?(N^^$X3R]HIJ*9I<LTZ9^<%\. 1,O/4+W9C#SU]U
MS^"!)JA4T0?%#1M-"\.W+!H#IL,E44UW]AJ/\F8>>XVAJH-?O(]A/5PT>LT5
MNM^IW0MJXI,8/C5A"=;"<O?QQ9)Y^&&99P(^<3ALH14LHVGHZ$,BUT."[Y?U
ML]L&HFV6U[/@=QH;:TCH=8F!S$G"X1[O1,[7 M8KQ>U(RT^*%F&F!3O[Y0 ^
MW4/&%[+/UVMEQ8>1M-YT8,O$)<E(+7>G)(^/UP._B2OW 76=3:W=%%GY^:0%
M#9CRKC"IDC0D,VRI(7'B2VKJ46TM!1 11XX@,R\2E4>TJ0K^UN0^"5-) <1%
MZ=JAL%[>0#0KZ5P(_U,$HZ^*K]P?J&X/M%%"Z^3'ZE_@L_P%_O?_!OX%_&H"
ME$[%NKT0M0)OL:K>F\JN\Z&B?FMYDIB"8,/#".D]X'#IW0"[KU$^?J>3M(A_
MVS 6@.</H=]IX\"WWW+O/V4%/\A:R_6C_=HQ]HIUVVNFZMJAT^SF1+:]<<*+
M+RN,X2MQ]&*5K)LZYZ^U :.B=@U_0P@LJRECRXI%:5%1>\L37UN.H-.,;A0
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MC#N>)[?_ZTP=JE42L>840/<5JMB8O9!;6Y^TT$/"_&<_4H' VL]\_XXPM2Y
M7J-._GJ6ZLUK!+;VO')?,2#PL-49V:+&=2OEVQ04'9U#>IU' :C!%O@,H?UA
MJJ'9KXDCVG0D'P]<8?.0'.:LZ!(WM!B( ?]"X$J)XM.#T7:[9RF&->W *S>2
MMZ_RG>T)0TL_(M919^U_)$Z2D0>5J6MB+''-&T[3-?PIF^!B-',8"\1VM^6T
MW\LY*#2AU+U5G/.6G)R"+/XXH9EM@P)@(NI@$O4ZG.G?7W7Z$=DUEWQ0%\#W
MF0*H2# KC1HJLA?_: G]$OWD?M&AV@O[2)9BB6K%_&K69.ZD(+,)2W1$B#*>
M:_E"I:5^+J<_W,FP3&8_@K4C.*CP\"?Y B[Y30CK$OSZYDSB1Z6UBI4!E=^'
M23,JL(_0JKA=,BHREDJ!X>Z(R2^P7Z$':L\L:+]>SW@F_>'R0"@_!A;%"8Y3
M45PJ-7Z<09.CSUFN[]DBFT*[:VQZ%Z7&30&T_:I&C:+Z(H.KJSE'* "+M>1E
M"B! -J>_:&$DWOTH[)^?8CM#&6,WEUE03$\2CN&YLLE12F911%%,HEE'ZF/6
M-[=K3NZK].U9K=),)9@F)ZO083QX(&OM^CA229 :W&WEP6^ARW[,M]X#9SI!
M1VE" A_J)VWC6K?!-D/IGG7+N *LH&[40*BA,^ZX38V&4 3U*)W6^/GGAI;,
MQ*GU:Y4&7XU!\-RI*3@JC'&#K%0_*8MF>.N($BK_'/K)_UR)4/?9PKRG$WFT
MH,%@HNF4=5NP/ @F*V/G*9TZFO$;DP1A/2A+S"$J#(?QNGQBFT#/>&L%\Z1-
M5!=\SGTYN,(;/L89VR(&U"+X>12Y!/CCG3\=C^J>EKA?M9[%7C"A\W;Y9&^
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M6M>9NJ9*$J:BALJG<XYOK:?[H*@Y,4]-4+-.[?X8':E2!G6F&Z+GGBTQ!J
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MT 5ZP]G8T;*9!1N9%NEOUL/;4!8JGBV%GZGT7@_E=W1!5Z W%S[W'?!0+!]
M$6,"A^4;8EB9S:IE5ES+8?W,/6D/+%>$<M>83$O:B#Y^]&Z<.O\1,!9#;*B;
MSC^\*URBH*);4PP))Y>]1P]C7)ZA1>F5H0IW^=F-DTS5H,]PQ9U;P?CE:_\J
M[IFIKV:HT55.Q]#L:W71^(\<(!K&%NOO,"7S/]L$U>!GQ1;;N1QTKQXB:*.%
MU4 M>3",Z8?0<Q;#_*S:'K88K,TEUCR=H>'4(L4!,%*&;?&"<^%]&<A$%4\9
MH\WYQX]YID4P[5P@Q/&L:Y""+HBB0?[B&AV"8,C^6!H0@!XX!>I''8]\;[_R
M-$ UP/1"E\6C51H6']]*\ZP-0+&>6=&RFL49:\'H::%]F>8<H&.PXG!ZW^5P
M&'P[]XY.C7];O1+#BO(7UW[AE=--]&*;"ULI$R<0'EC#OKSJ ^YQO'K!1=\\
M)>"$CU^LM#[LE)/K50TD&,M^WZ98R#)? Y ^>[_7% 6)9Y[<'5GE '([:$::
M4XF@T!0D(C\WT=[Z.<&_K-U01A4D(,^S#__D #.(Y'!=>G(Y_H5V%Y[U1_[^
MS(C@\3Y-(4E]$])8.)Q>Y 1NF4Y^.CK,-AX$05XB$3?-1<^>@KUX3,2S>'XO
M.*66>HJG+P!QZY4$7_7=:0Z08/TE_.2G=2);D8BF:PW31.+IH( !](H,C ,<
MLW.M/R<S"]E84+6NIJ&-'3D +8K15(X]Z-V!'M'Q9RMA&,9Z3J/\;2BJ/KI"
M:5_"@:]O9@53_MS.]1Q+T"SUI&G$1[@P<A^/HSB IP6HEH$)/OJ]Q6D+) <X
M4 &*W'%PZD%8&E3^=)],&Y(]2'?<I.7712WG$_95"'Y&_SB[+WK*G[S8K2"U
MMFHP#RSXB0>QQO=FX'/R)]B+<#OLQ[;Z$5 AGJ#TAU=HV#AX?W15MB'X E#&
MZFVU$[T3XO,=CL?>\+PVF2Q@/=K/SF)CC2>S03\Q^!T/^0W$P\_1L7'-\J&H
M=BM:=9EBNXO)V/V*9.V6 #/U%JX6[;VQZ3TIK1^'K2H_ROH<.>5?DV\2B>@R
M8#&CE:DC ]EQ:G]U_&=_G?_64%5]\&_D\+\>(IS1_P-02P,$%     @ Y5Y_
M5C% .EW=Q   1M(  !    !F;W)M,3 M:U\P,30N:G!G[+IG7%-!%SYX$1&E
M2I-.I"C2I @""D1 NA!Z+RH@34!Z3T $%(%(5ZKT3J2#-.F]]]Y!>D(-)"2+
M[[_LE_WM;]_]NCOWGB]W[ITYSYF9<YXS=_#3^&7@KJJBBB) 0$  S%]? 'X.
MD <(;]SX=U^7F]<WT6TBHILWB4B(B6_=)B,A(R,E(24EIZ"^2TY!14%*>O?>
M72H:6CHZ.C)*>H9[M S4M'2T_QHA(+S^YB;1'2*B.[3DI.2T_W7!_P&H;M]X
M0,A(2, !W* B(*0BP+<#(  @("+X3P'^9R&X<:WC+>+;=TA(KU^HN@O<(" D
MO'&3\)_6U[4!U_7 32HB:G9AV5LT6F^(.5QH18*B,VYSRI6UT&F/(+F>O'7]
M>(?D'CT#(].#A]R/>'A%Q9Z*2T@^DW^IH*BDK**JHZNG;V!H9&QI9?W.QM;.
MWLW=P]/+V\<W^%-(:-CG+^$QL7'Q"8G??R1E9F7GY.;E%Q265U165=?4UOUN
M;6OOZ.SJ[ND='1N?F)R:GIE=65U;W]C<^KN]@SHZ/CD].T=?7/[#10 0$ORO
M\G^)B^H:UXV;-PEO$O_#17##Z]\+5#>)V(5O4<MJ$;]QH>$0";I-*Q>=4=9R
MA_.)-I+NK>L(R3TNT94'J'_0_H/L_QFPC_^OD/UO8/\GKEF C)#@>O (J0 P
M<*63&?X(^/_E_[-"D+>MEC()+2LQM+WGZ%6P.#=MC%A,VM%BHFQ/VFQ><4<3
MX\*D2?' +2I8I(S^V<NZ!_7/3</%#:CP &G%"AZXHDBBQ)%QX $F"[19.F7S
M7_=A&-*2'CVVD?AZ$^Y6M:#H$(8'0E:0A[@P9TH\L-PJB..%H\W!%'C@K^<P
M&/F&'@_0*?'ML8P<>$F>9Z%*:7#T>6UE>.!)9R#X@),>/5K3!0ESF.IB X'.
MJ;[B@?"L!+/@).G!75266"NL]13MN2#EMG*,!UP8FM&%S&MY;3F814DD&@_4
M1EA@]5C*]QY[GS\O'C'EQ@K"PD GTMZP:SC",)1N.K))AL4+-176?*WQ/RWX
MZRFO&S[W>'AHOT*_UM46NKV&H$S'?.[  QU:UX#75KH@:(T&,!X(_M>7I/6T
M9-;\X9-#Q8#=3]<@MY&[N+#T?R [KT$F_^>#/[MKS92P_SR(,O*DN-9D'C.2
M[KO<O.+O+XX',@[;EM B_T&%HQ]J@UVR8:6O6W_TKW6+-VY==8N;$5-$_VEI
MR.*Z:VDXYO8_;;3A<! %<UY4@_3_J8O_M05_9"%+R;">:%?PIB\2#^#(WN*!
MU8)F9%,3,QX8/E\YQ#(J_ /3][AE@&W+K^/!AVLC0)GA%VG_NU_BKO30_;$N
M*!L>:(G['P;\-S;)^0NF]%A!1.A,"VKKVF+6_RRF<8T:A5S"A37_+]11!O]L
M<G!DVW.MAS?Z?:._U\K*_QP;!?0I<B:*. HK!;GZ]$^Q_/7_3)+& 8$/7U%3
M*V/NJ*ZPH:OV?U6%$_".PYOVB<)S,^AZA;HT^9"HYW_[A,\8<WK^H[JU@LA3
MLHR*;SZ[D&Q-+05:X+\1'<,5N_$(D4<WN*,MU0=[OUYM2M!NO-ZMO=NV:ZZ"
M43,UE;^VG6-#R9V8U\6:T='!IO1[>:AJ ?M%"^)=>J/QDM2F'OYBE52W<U>_
M\$WOSX5-W2><'U-^+1E&Y8T9Y>G01HR5\V4?=V3&) 22\#S95WM!1/OC+.?G
MC?!'_^\ENC8G^R=E'QC-1]^NKJ:!+EB!47[=7ANC41-7>U_\$FJI+/M6^H-P
M$EH'1Z,0TI6RJ),F3[8\-0U"&I@M(8=EF#I98*\C,@XQ8Q8W=[RI@^IM.>.^
MN9AG\_YVGX"+N%MJ%]4M"48(6+=XO,<#/CZW\MAX?^GUW>JJ[? 9%\XLA5J@
M29F2[6OX/1$Y2E/<TXB"MKJ_PNAZ=<M8RK[98D2$:#\L'XR\1[?%5_9;PJ)P
MM.LVKQI9!!XHAE>)??V61G''?NAZYGWJ4WV_NF#-6?BK)<>"T8ZLUD3/_2 O
M'_%,**I8Y23Z&4YT4K86VXW#!JN_W3R3/7WD)<V)HUZ@/:FP/N.3]VY3-"=/
MVSSIY!LR%]-=*WUF-28PX55]?C-M/@E1,E0&T@D]EWX@99WU<[7%#4T"PW(S
MR94:M^<U$=!M=FAN6?+(?'J;$GTRJRHCJ2C%!#-.?!.@P3Q_XHDJC2B^\TLK
M+480TAG?8)-UZB@*.AN.,$CK8BI,7Y;<8/A@5W)WBUD7]FN<7S?D5)DM5.I-
M-EB-<O3;M4;OUM2)6344?$97@IC+HD347S49:HH'H9F:BY4A=XC&3_10GC'T
MD4_@;WG *T*C5@\4TXIA=?<9L7R!5 7 LLBUL27$.!69G53<<9>GM+BRQ^U7
MQL3N3?RCG_G84H2Q6F6@'"4\<.?I-P@VN-]FV]0V0JC'.I;U.%B;%R#@GSY9
M2H(9)KZ%(NC*)FN^B!;[3RJQQ164V@D,3<ND\L7I:L^\(QSVU8GC2[EU/1H-
MY&+F9B&GWN?/JE&W$I[-T+'5*RC.3B9 WY5I-Q^/$$-*W%RZ0O\\Y-Z[TYL4
MK:<%QU8XK31M%YX-_;J*\$L>*-B.(6O\]F9F'/8,CI&'@%V7V*:+XR.<EE_C
M@7)T@6=4X/KE)MRVY\S%3"W&S+ &]&Y^\?3MI(/HMBV,J'CC=NH4JD@?5?18
MKHCL5+Z[,&+A0"TW<LZD3[U%GRK]X/=J=;%-S?P-14NG-2D#<?NBJ:NW7J?&
M?RN[7Z;XEPK_D:(R#^$.&'I6N#'QY QR9CSQ^!01*$/VNR%-K6#@FSQ_20)O
M=E#L_#+):;HJZG"& RQXYHU\O?U5?NDJ%_$&$5=BK:WB)5/ZU2G%>=KX46;Y
M4Y)'F8'_CT75^!%A3[,=LRRX;<JUP[\@+L*KF_-R:@/QN>G!SB(E*GY@,A8\
M<R"P=<P1YZ%]!S$!FZ6>-O47'/_BV&1D  I"]"XQ>O/.:4X*<MLQ>@D3.T-]
MIP;6"GD]#C @O^@QCU_EX6:0G_S-R[E-#Y#%SQ2::E;\I'4&*HVXDAB-Q=UV
MA\/WW&%HWL30S>^/"Y9W,8:H_F^F_"E7M^F.C+&"8U*6UK937C7"/99,<WDQ
M0&^,S_M+[27H0,)P/3_3_!\/YA7B")?%^D>;HG2BA=(04N$>E&I#ZNV_ 4NY
MUYY>%4=E#F%QZRF<X2.KC)G=,)A>WJP7$#S;10L4FGQ1BGA3W=.5Z$*3%> 2
MCNV,/7,8MUI8W]7_=":2]1'&/^DQM+>U6CO3+FCI$95L,ZN,!X((S(J80V*:
MA=?4"*."*_+<3KN4KPIE:'832<GSHDX\HT-?Q'Q(O[S'5SX"Y42;M(<SOT+=
M2X3F5,,Y]IFYQTJ@' O^]U E:088JG7211ZZBI.60C#R$[I/P5G8/55[(@XY
MPDD&:BW:%;5HXTS3==%$%U2<ISI1*_0J1S45_AF?OS18/FV.:N*P%2JF<I!A
M+_^B\=)!M)?@4G\#L2^+<E"W$D;OFGS^.4O8JPSZ7C*^/#H^T.N"_CDTKS6D
MI4@$E?"V.+M$]ZW\"O?7^)W)N_PXXX8*>@N8<LNZ-A:DZ9$=JK9A[,3L9>RW
MHQ?=2K]F)U0'_G:?]16"]0KXCAT@>.!CL0.J6.ZXQ=B_F/B03)RB[IR%Q4 G
M!]:B+[HM,(61_S/%\_0 .N2>XX)>#2H<MEEJ&+'@L&U&ZH!#C$.:,'_%(D7\
M@S;$:F%=]Z=<\G +2T2G/.RRJQM!ZUV7NSZT@N.K'Z^R+73^RMAN-B#4K_)E
MZ.PCOCJOE;#_2+8EES!-[ZQGIOR<QC!Q_[A$2B'75"'%22V;$YQ*Y,8]OOVH
ML/HRLF0T2]Z-+*-3M^O^_2MA?04B4@7:%-_A&R/J:Y,1<&/ @U;K.F[]W\@#
M@0< 5![68GX]W*&!R.Z9>AP79\;6E1WBXZGDQ_[@\["HT*:3:TLT\CC/$K9Q
ML8#V!*\*'98;5>5&']XA9L%.ERY=>$8)7OBVWAT(9I].+;>?6M!\83@V4?>P
MR"3B];(-9G"FB'/S/>*0"W?!0K+Z7&'6BI4!;I89<\]6_)O0\^ 7S%\81"[+
M)+0@8<R&UC"RB4PNWN[&#R.Q5V/16I4A<W?JX 6T5IWSKKG1Y29%(,?6PK0-
MZ:_,-PKF2;N5%FBK\0#_)^HL^.^B)+.YMYWZ[/ ",=9ZLMAT'C!JL_"OY;#_
M<.C-9026F);_4[Z2&9K%=RP;<*NP/7T'[HT.M&:XS^)QZ[O 5ZK^PMKY95^A
M <7^8R<2H?1%^Y@[=UZ(R%/Z.I0>&#ZY=KIMM$JN^FOL6F75^:^?U;L7Z% _
MP@F>:V=&8&LM&\XB?76+4G\*\\]@O@[KM[#/D<%$K*CV(4:WY!VMMF)2P;P:
M]$"(SO;OX",ASKR?A<)6N\^P2^VP!3K>C]-V&L36!_9TCGTMSFUT_/8&-Q]3
MGL]O%F5PM6WL%+'YL:ED'TU\3ZV[9*=5F,\8<N/4C&! ,N*!V7?W=5Z>WE[G
MK6=P?G4Y$71_W>F]K\AFUBRK2S0>"'B70L%0L#L]^=E,)?[KAZ^Q.[=X;8?)
M(GS@\S;AGZVVGG>?%=02WOQD<1"E4BC\MOJ9-6Q!;P!"LO\*0?S7_EXW(?=K
M:5H/,='W>BXUSI@!XY<)MD8:3.KM=,Z' IY,=XR,?!:&SGU*'_Y)?\(W5^TP
M+/4PT\ 4&LAT\@&3YL3]$MJ,ZRVJ6:8,[H*<6%Q]GRHQB,?UD]8L&WR2W7>8
MAU4Z3#AL[,*HS?/&AG&T 7>U%.B^U/Z7#)#@C[]K%<:@==_'[>.O0VPDU,H[
MT,>K1AG6:)'?3,_^Q%]R*LX#\P3ZL5G07X_T<95W8&H]YHIOO0*^JMCU=UZ@
M1#)O7HJ;8KH5O!BS*O1"BDX@PN#GPINM:.8(2SPP8>Z2,UO5\3W>QO:'7B#A
MU<?;8M.-'?V9DN+^_3]KV"96^ZP"GG(\6Z!7C;IQMH^>F(.97Q1[OZLU5]9N
M/[J];>Q9T6T2-T^LVGDVO;8A.N%%$*W3%4/,Y=9=&.FZ.RH]CCX@B=B3J8Q]
M+ZE6UE7GZZ9I9NOK^+=C,-GN Z4.U^VN4UKT02(\#KZMP]^6ZW-..[Y>51>;
MP^@4Y;NV8O/)N7G*VPO"/?&&!"9L>&Y1<1A46D.5>5L--L23 C,^7(OWO4<8
M7L&<N]3$9[MJWV7'H$8JY]<2T!5M"NU;I$B.,]F%01ZOP<?US;KV$C.4*6=.
M&^7FS\B9)'!O&_OZR3XPI=0N3-88[LEAE#C[A&(6DV2<&ZZBG834T[]H)4OQ
MGW6X7= 8>L'*X>$KF^3RKVJW,CPM-OEVB4S9*@\M391$VP6<7/NX6OKV0*QF
MT &H9$WGW'.C7["-^-[CB]6*330WBA32FQOFVX,'- 99H*%-4ZRUVZJ-/B63
MCF9.;I P9(E?C5([!^A+&FT,MS)6+:]2*HO].]'EZ\GXYGU"E*62%@,J\?//
M-J>Y!^VI,":,@LK> +Q$B5]8HS9!]!NL.JC(.F6H6$/EPYYXQ%#\2?-<\-K3
M9#=F6*NE&SCQC]&:HLXIPV8CS<MKQ_;=7V=L/<+<9)LI)G/?.N9&"+S@_BE"
MJQ89%>83^Q3^1EA:S>0A+-YRP9\=:8:R% PM%A?7-SQ+'P[?P<U^77Q(O;*-
M^)AA<$WO/N9ZEX*$[,WOCCV&,[]Z\LQRMZ5TZ%\7!7:N"4PU'Q^_ 3Y,UK"7
M^R%?(*2:KU*EB/U5<)U/NR875Z8N8@T-TLOS/KU;73S4K9(9*X)WE]A7^)II
M#?%_I0.%JJ1K&%['K%=-]\RD^,32*FQ!A_5S!;K8I'H0!731XHZ_5K')=G52
MR>R09&ME=7&A=,\>WTHR8H9>(Q;\#D4^ZNLS7 3CX(M&T;?Z#073*!2;[-X)
M:/8GDDHMEC%O5+<_5J4@;\&TMJU/]^A'V MZ%2GM)207&MM/NBP8F79X.=Z?
MCVEMB8-;Z@=3.!R/G>FA2TIM\0!Y^Z3!BPZW)T*17X7@TS9!0SE^UH@N.(U)
M7V/.1[TNWNT.&Y;9A%'%TW+C\<UQUI'36SMFK4W7J4EH& IDRX\'#H-Q8DJZ
MZ(W5 (T'D0]"AX@?9)A#-AV<]Y_=&]WB[=U='.P:9^Y@[BKQ_[A$TZ!A&%NH
MDFYO@^5/IZY9G-C""IM>>T$D3@>V%Y[>#__EWW&:O9B6=8R(RD9_6167VCF_
M?]:F![O.N%_.D!<MN/T=ASDH0>42(.!-F8%C'4S;<=8 Y%!PDV]U6^I-B;*,
MH_8V_,I=#(3EFJT,][(WL/A4HO[NRU4@KCOQ.-V.^7MB<2'EN'9)OWIK;S:&
MRH(NU4\[]M!BOFP[X=NH"3I8I]IUQ&*>T_+PSNV<JX)%@JL8/)""L>RWT%+Z
MWKP(2O4W;7H\63%8Y(,'8,E8NY)51[UD-WL#H_-X^&D1;AQ^%'L5*[@E,WJM
MV>[%F/&JJ&FBIK0KW^HFZE[N'UA[Y^[. V=4IKJ?MFUOU55;P7*1ZOPX'K 7
MW*#<^P&3/$K'TE5HUHS+@+WM]DM'#:?D23Q9(BYRF^Y.M!6/-)O+'$V--]=8
M17)W"#"??[?,I0!]@[I9/-[Q-WV\M- D8^7\>^*DTM[/5.K=9;J8?GIY>R_I
M3^/?/5$ ^"!8_^+-1U8\,*,5I)OY27BP2WZ_NTC!4_!Q.U0OZ-=9ZW5^V%5I
M#TOE$I'4":5Z["OP5 +I1067U9:/UY?PMRG\9O^;AEW&\ZU4!\Q2LX)AG3V1
M<'@B]"(N]DOL.)E0?C9SN? F(E]J8FS>^>W40D1TR%K^JS&!\8L(/97W-O[7
ML=."SQY;O!;U78R6#]-:)S 6XZMC\N1QA'\47;+S(:A>'-*:QN4J&2?(RL/X
M=/T1V#3<<[66>8;2<8TC_QEU"$P 0B:M'\OQ*N(Q-.[DXH-$N,;2@GV4\I$*
M;[=?/".M0+=)U%<9(^9P^$MS^Q=/.W_BMBDW[1M\=,$-CDTS=%SV7)H+C;MO
MNN,-EWW>6++EE:@=5U"F&EXRO:!D6, #!"UY-IXR>VW-#!SY+9^?, M9=]78
M5[#-\Q# Z,2HL=URFR]QAR@27T6)V;T&=XZB#/Y4J%-]MG0<&8EE !Y(WG+J
M?D8BJ2GK^=;//?/168U\>JY=>WP=1V6J. >E:BR%;@H?7&]?79\OHH(;L]LA
M129^7]'OV=68,;L'B*:(F@$(V!E=<?M8=$"DQTOJWRL/\_%E2A-::F/OT(I]
M> Y$G'KAXC+*S@W ^U4*E3V=F^^]"A3U-.B:"9(FN1(J-SW3F1/%MF5(M<OS
MK3O]#)*V]W\O6Y+!?BN2^^8%3KF'T\<//5I0\)6P^'PL;''G\APC6KKT48:6
MH5.@^<S2/,/<!B.!2$1:M&;5S/A=LR2',;Z-(CQP[W\&]AOACXK56_^;+9)O
M)SG9TH\(X]$9Z6B#R_,K7Q5LT1$>Z%@Z8JD?>K>+)KG20GV\(\57Q ?(5L=R
M@O:2L&6HPOVITD[A[A9$_*!^F<U?4WZ<Q/?=9R55$9H)D8;E,L3:$.ZC#B_A
M]&]D6X2$D[5F,F\XC>5VNU(T? F#D@ZMK*T7);1AW8@T5T>0V9<Q.4/=YV1L
M$QFW'V415UFW10=?Z.<T!"7>]-PVJG:YMQ8+4+NJ&Y(PAGX@H#,')]\HYNY;
MDLC^3ET,BX?06D9$C#^:N1Q'(9]L*[3 J8I<@K1][/O"W]ML<"'M=A<_$KS1
MBF#1F;Q+X>6F$KNK07C3)@FP$*@X+].8Q0.+'8_]@M&C6TNBWX/\^Z^P8U-0
MM\EH2(YRF,QXT 5IW141.:?+D4YY@.V"K@J-:EMJY8K+V(8H=J1K-/&G[Y>S
MH#194,CS09U86:U.G^S6\P*"/I'XY?U]<V;,JT7"E=,@%L;XV5<4;6\8$<Z.
M)=,&0Z!*D88Q^[U4 4=:Z.M8 \B:XGC"OOMSV(PC>'7 MAUY6#=4RS55@F!Q
MA3&AKCW VF %&KQB][8M^KT\NP29.&BRD1IRSZ2K/:$FNOG#KP30]](H9Y_+
M%!T-XU1BJ#J+[U2Z]]?5 _B*>R2B?UAQZ\JJ+$YK3Z74%3+KUO(A(E7[\7,>
M[DO]\$,K-XESFS)JB*]<BZ[;@'?*4I5SL"68?V]M0JNYM5 %8^(-\>JMJ''B
M<$:6Z%J/<IGD#'F\9PN-XOO#?-:$[#VIK@.?]8]30Z?9V$SW*NO A@,R1I[$
MO34VPS/[EZ,'S\OF)IO<K@-/VW"8"5\$;.J))AYHL[)[GOR4GMG/418G>F$]
MG:9[9C.:W+A='_HDS6'3"/8^5=ID8RQO9D?3YF(<AIQ),@G^RAAW^;T%5^DG
M>?AZW6PH3RW&6VI,#73XKLG$>0ZB;K Z"L&<XX&I_*FSD8KH7]6N*2<7]%B[
M_*%,[GF-0>7+$JO]E.%B+S^#OFC<%!D><.V&%\)1.>"JD#:>CM*QN?NPR(?9
ME;;-5LT_V (PGM9-W':$MNZX 4;"_(M(_Y9"H>.[SOH,F'(*AZEF6_!G.(JS
M(X$IXM?W6699"MVU)H>N4Q6U5S]](KODPS%[#W %I.G):Y9]D4FUW[X5I9#!
MRC5X7_?5WI/" UXE!B$:>CE@!5;[1=6UYV_Q@!59%3N%D=[O9\&XT;&,/SU=
M"7XB)V)L"VWQ[]AVB+CX1YPL&CZ=V-?NO?Q*O/&^VA+:3]QK3]\FC/ET6= A
M^)W^X.++'H6"<'9T,DDQY#PYO- OKL]IZ3&QJ0=WCH)]=['L>]2V-D=A9!&F
MLU,%[*YMDIY:-T3XR72X6N0O__=OJ1E<9YUC$"U,10U_XYI39F8MO$!3/D!8
MXU@\J%'EM<Q1FH.LP->[T1LA9"1XP%-#^-5[00V9*#O+1*JKK;<2+82B7?K^
M"?TN>*!*9SQ.Y"E9=FS($/3T6;DC2 0/_(D;8]?D?'LC'W=\I*Y<^TABZ41U
M@>)ERN,[S,3GPRCM"O]>BPUP&\?YY03TC91K4VCV\8WH2-36KW4]!I$/<U$:
MG>!%_9:"X'BMCRHG"TE%FTZ#PX97PMJ\\:^MN.K^9ET.JW$KDL98;&(U> S(
MEAY%#N7='PV=:_.Q#Z"U&F5H<QN^7 ZOC:EY"!]YDH8J&]J Z(-$"@"VLL87
MY:P_GR7PC01MYADEIM13_>TEM_W4PWEADCN$!M'Q.,X *5Y<XZ2_=8XBBZY6
MA?4YM;I)FUF-?NL\L9P(U!;YJ8W-.B2C/.3),765T=DK4M]\^C@/KCK)=6_/
MY'R[=AU&%IR/,$/[YZK<Q2*&-#\X=!4_M*B\(:ZHLC]VA+!$N\H_.Z($+R @
MI'6;;W$TI[MG7F;-M[!"PO 3YQV'D=U!/&"S*$.)MHF 9<%TS+]8\%F@RT]M
MQM[@@1#02P%:+<-4 @5:S?]"X@C4]+4>)KL7B^0^O G*0/0N?=;ZA'JP.-;"
M1:G!,+73,>I<$T^Y8'T?Q]$L(".D1-X<(?CFTQO+) 5.F<CKI87X,:@?+7,8
M8HWIC99 D/57J-^.)KT0_^1XF=&"[? 5:"V^YT(6^MXU(&!W2-1$4A1CF:_<
M^=Q'4,]5!@7<G<8#32%>!J^:+0/)9_3N])RL-MFKR>^AP-0/*IQ^E"@O">P;
M/?7YBI"4=E#7I4A]/LF_4:.]SJ]#YK-OP.DXK^_1]$&OJ:ZHS+_V1K9O@N7@
MH7V*,)V98:"]]Z#M$ZO>JTN=MFO6IQL BY<T<+S!1:Y!KA4QUAR&$#/@B:$@
MDE*9)HF471M-(5+A2HZ4-#R3&G_A/WYZJ/2->GTL6-<R2+GV5/3[%\:S)'$=
M[X>).<\#?Z;^V4ST9O'(Q0-W15N6HDY*1=2OBK9@D8D"]9WV:[S5?V[A@<"I
MX9D._Q%43[9=@^W/98;J=,QJ:5J%DCIYSE]?V!^].TB_UGG+J[N@\2G/OOKT
M;5.E%MHY9'+K&BXE#@\\._">&[I5&7L^T\+9 G.PG6A@SE$$R,X;TE_7(7Y4
M-A,OV@\POHSMC?:Z(]$10(\Q6^+X>\DEC=UFQ@.L'==LMJWNWEI;M4_G!L/<
MMODFQ<[MU11.R9F44WC+Q<%W]C0]\SJ&:TJ S'!J^%/@Q@YGJ;A+N<PW43E!
M%3D/./R,^BOW<U^Q^Z]#:7G\52L.H6[O;80F]C9ZZ98 ZMA4ICG*-?<G:H([
MQSQ\#3W;)MX./[=[_#I.F*Q;2?<-ME#BH#F$89\S?K,!#RSELG4FZOPY@-Y>
M4&+@V2)F21<.!:MZP%M-^A@&'?M+-5;5UJ&9C0<J<\[]/B=Y+X?]ZT< Z?.W
MZ8>.;S!,?#I;)99_:F8#BL^II\&)3 EOA7%TL] ^&9H*U#T$PF+G7G0?>;$*
MB1+_F]!-22G+4KYA*<<'26BP$1FRX-Y S7FP=&'B7H]7KAT;S?BBWZZ:S\'!
MT3V5>!/ 4F) D3-5T[D@+B"IL/A$FED7*1BZ O<>KMQT=4FHDK_BBYF484"K
MN&-V$Y&;:9@WT3UW]UI(E#OG=;"RJ(\#4'[;M-M55;AA\0[_OMH'-U\:4C=K
M=4E-GK=O=WY=EG8R76F(9>"LXZ;;5-#/74W7R4L*T=\?OD"T+-VQG*RTJ*XL
M86HHIJ.E^0,V_FNP7%6^?[67#:N_7DJE\!7KD[YE4O*_)3^L);LD%LQ@9QFS
M/SO0P6:G?%4/HWE3'-W6AR*@3! 2=/CD;;4WRTNAEU/)]HZ_E2^<4@G?-J:?
MQ7X;6N.[I6^(LKTU"IM%T$Z<MXE0-UC6R%L$?$I\2DW9C6UFB^G2)76IR+U.
M5FRKU8VU:N*7/41J+%H+Y\1[KUWYW_L3#4Z=>MG2-1^JN.X$SH<\@#6R<R2P
MUEL0*9\P9OO<.%IJ@/9A.3X;Z^L_KR:<RS'U?"A7Q( D=9G>C'G53.P&^Q-(
MVV0:T45D=38D1H$'OA>1L<W0:5XG$VN6[R;9#<J5>D2_"9/)4V>Q<)SF,,ZU
M=(%:X^9,"]YFO8-%7N+HU!P8!<)4,!7'O+F^UE]$5UM^Z48N=F;&O"CYG,A=
M_ZM'])J7B41T9^TH:+H+S'6K1E +3]U*VCV^-Q>[R^F.Y:6CY@WEQ-ULY)EK
MLPF1\J+-JKO-?E&N= B:^E40UO^3?%0<^J'JYGM&Y0?)5_&FNO.WIZ"T%)_S
M+B9;V+$NJ<WJG:FQ-(\INP-XI0^6W&]/(>D>SC"&\>+F]1A%/![$1=2,?.#I
MS95I?7#0OC[A\;:.3/B4L>A.Y)_(GY?[8LJAZFQT*A8+>>>?+R(?CRIZIE@>
M/E\-Z>$*'!4_3P_D0=PWA?79G$K+Q(VP*JS\(@06/DL6K,2E!$\A"W<WRR/N
M9HT%:8O4]O#A@1O&(TYD-8,^U$(G4B2)SVN=DT?%<%5:#$+[Z;[E%/0$'_%
MK621XONRV CA^WC A4?2=-URNDK,E39-R^\R2=P)Q!'AFU:E\DTMCSKQ!8(O
M[<5F8\T*HK\'/DR"8I6VPLBM.1N?+86"^7[R!2>=(.O3WCU9 9O+ !'^',BI
M*S^ORZ03WN/#P&#0G7\_U<V7QJ=^3O49X/@;(;G7/I5$YK/QH\RR9__=/U<>
M2E4@2D,OK IJX>]?I0Y>U<^[8>.<^E!#$BP&S;B>I3^N^0)1@V<S797MVC)_
MR=32S:DA&])S%ZC-#/)ZB=C%'$F5'))WA8T.6$I&H2R\)L+HYG>8]?7TF&\1
M@XR/;0^:^O)V5'T3(]M FC.KC=2>3V2=!<W^,H._(.*JPQ9793B\33;V QU4
M[W$"1Y32#B(32@D$NQ$3TPP'K&6:@VYR_($!S_2Z,6ZZ6K4DODEU%,*C/T.-
M(QN5?'_XK-&1>=O'NW2PBWA/NXOQ./W1Y8M(\<CCL_PY<-,PUNO5V(YT2U/E
MADSEK>R, F@\TZ\\I_T784ZDVGS^$Q30-]N0>7&HZ._Y.^#/'^RZ9G]LNF]^
MG,EZP;IG=Q4I?Y*'4.4GK!^V$W?:5SG-!M0,!L"59!_I4 [PN&*)M3H>"]4*
M,H,^/% YQN6YR,Z+2>Y3\/=#P$:K<DJ4DT='GYS8E&&9S=))I1X_([#Z@2U"
MQ&,,!)"I_HA0*).IVQD#'HCWH'YZ,#_>@^G?='CI/X8QWM[</&Y3#3GJX^'-
M"^ZF6ZM)FECZ9&G"K%[D4R57D1[OMCO;F'66_;VCR-O[WJO;&R#A/67$;=2T
MR=?L^E_48K\SG75"W_YY'1TU<8)6XQ5^?_%*=T>QH4Y=N<%G=3#,-(2>A2A2
MZ:1@SAPU<?I[X%Z!"_\K9?W0^VY1C??J^$R">+M?1:0_?N$]M)&T+9K.:F8X
M;632Y5FMGA=V]U5]#>L6]\^STD&/@8*PRN)7O] '2':FT.P>]M8X^6.0;)?Q
M5QP5'F P->52S[?OXZOND&U@.5\3NXYKI-*SFX/ZOZL,*NO]NG\XSMEZ$GH:
MC,T6B;>O1UU4W4Q@=.9<Y8ZY)<'8 \1V<1UO=\C8GHO$%55;@VZC$U:\2!>,
MK448VKBB9%^+O+AHO&7/@Z4KX7<Z5BERC/22V7PO*#MH@N"$^Z;U=6K9H?W\
M(J,JJF8=@WYQ/=)A]7V=WEEJ[B\7ZN#SXO?S=?ZQ1S6.-61R'_N?M)%GY>6P
M='=J%UG2Z"*UQO8<K<>YFQ33'UA^.]5T2=E*<^!'P]0B]6KFZ7=3@@P:]-;L
MQ+XZ,!M\FY\S+J#J?BM<.^_ZYSBJ<:<J+0AAGU!F-N/MI]M0]<T_5M9IL"2J
MEJ- Q<0L2K^P9]>EANG5,XMXZ4_G5'W<?9O\M6]..+_!F/:E0&QY[C&&9O:_
M0R:2HW]+YMD0([FF2+E\0SK+V.)^6Z_[IJW@0D>B>23VFJJVH?1(V!?1[HUQ
M,6E*S;']+$Z1(=)'A&4/RXM7^@Y9IQ7 #MYI(RL"3UG!LE45RC-9<(G!9[&+
MO^^-K<[2RC&L2;%8GI0:R$Y8U8R5S*B\_LOB1%<JI<5E^<!UL;7)/#MS?:@<
M+@9/OE[/^0K-D>ZG"H#8=QF3\PNX+XI<Y\I^;PV>]! 7OV]16?US-C&"G\O]
M0B%7)"OZV"!\Y[L=S0.NM8_>',W*+28[F@YE%^_ 5Y?0;*J7C8KK,LL3,?4&
M_.OAH?1'4UPX=>T"YIKG 02Y[V08ZA8B?'5'8FBW7.&F-WA9>Q?(;&8J- +W
M!I^0GFWQVD>+</']X2=\")ODOJFK_?BP(:?+QKPY$OQ!9ZK7;0J3^]VEGET7
MI.=/:$#>>?: :@5J=)MA^R//-\3A[1ZW\!_9,N83DA);*>%1$S%/[__J83W6
MF^]YK[*Q/TB )0)[R7YC!GG*AEL%"G'QUN*!U]_LH$?!_65K&9C6[^[<GQTE
MM,HP!9C<S 2Q/E#2PQ-.>&M.1&B$:_FCO:Z;.I!>"#^PWRRJY'IO72O+Q^HB
M16<-[AMA%:15Y%.H\ESWVLF_,3(6HHM%R"=-NSX$/<(]N*:@[U)KGS($;B\D
M!FO!BOA2.@-DNPMD]@+3%YK?[=E'&#UBSKJ/.WTNA&F--R![V@>WC%;7 PO/
M!5_]G4W?8D#U"9]PZ7&HD-2@ZF"R23$2JH'*_- ?'4K,CXU2 J&-O$Z,WM=4
MX:!L0-1F7+/%I7LH*Y=7P:QX^FKL;&M#C-HZ<>-JF3@.6L6;.O=Q)?$W^*;^
MUP^6V0KO^BAYZB]U>YIMVW^PU>6ZS?G"Y61ID1WE/T\.[$>HV0H-HV,@ONG,
M.B#,8[O/<E'7?2P9YG6KYG.[PBKS.'[$@EY[S1.&?*!46)ZJ\Q=@CA<^SO5E
MRVQXW :RU^ZRV^<XP3HL--U[[,E:)XGI]9TJ^#1_[))^YW(-26NY(AC:Y5R!
M!W3,@TSI_R NN' L0U@,?-.A$9& P!KYID/"<+0!1)GA?#0?_KOS?JJ (MU%
M#<;$Y"LL_#*9JD]9#?IB:IO38(MR_U,>[EX5[GD//*_'G,(9RW"9;M)F<>@\
M?'&@%B10G5_;FVFU5=,\V4BJ-BZS\'.[/#AR>/E*%O&D)O1IK*Z!I$5% J>T
MS^IUX"-_*= @[A1SHUY"T_>;#R+&SQ8::>3Q[/;<<]4CE_!ZI_9JR"M]Z^0(
M&VET"8,:WP=7\K=+\M]&O@0+W3\I4EUZ5*@IY&2_[C,7/<C[LF?U_1K(N*S6
ML]"%/,6=SEY*9 N=S_7#@I57$P\(&$",DPDG@PRA._'&&::>HJ?.OC=5HI,\
M?>C8[/R2@,2$#/LGZ+&II)?3T<:IM6RA66L?3O)0RF+T7O9Z[\-M4'ZC%.3"
MU.>L!?7AH^+(T2,>(7K&+6S2A>!97&(?O'V'4H #A0<(Z$[3#@*GNIHKCWV\
MDHX(SW,LMDU63HMH;.WN7(*4L&(7,FQH#PAR1@D/_)Q2[&?.6*U; A*^_KFD
M3K\X@N,!6;I*F:H.'K&'2H_#!M*K/E[,AD;6%':B3S&M=8>$:$7NU_WBMR)5
MAAK=095[R54E/! (3_,)NT'#[:P^TN'/"8W>XS$_8R0V%$7RYQ3GH905]64Q
MQ-5?)A(!T=?'%P:BS925?Z>S#/^0I,E&N)AGO<VP)"[23?0U]8*!YV,QN&;C
M50_N ,;," /Y_L25@Y@YV+# \>Y&N!>6;X G_/[8_LST,N4C5\B*V8YM*?,7
MFMT!L_*QE8J+)FQ><=BEKI]J:N]ZV,L/4R!*T3GMPO>.0PQ#<<TK>O @]PFG
M]Z^[KESI_B9]%$QH."_>4S1)QP-F:@5BXW02%I:]3=S>$,@HEM[/@SR;AZ/R
MM4@GP4;1..[6O(H#LN;5"V6SH[O$#!=%$>@EC@[DV0?BR[[O!O#SHG+TTYLP
MTI/8M*8W>*"K*)?NP1Y-0/_\_4(QIY  DY7'(?G^<O#.F$H\,,L;R!#?I/B-
MC/AT6P7%>ZF,8]G]S/KQO>8MV&QIZTI-Z9W6I!49@;>@L&=M[F0HRO')M%F=
MF-IX"05Q6AMO5^HFZN%?XC3V#><E@EPW!^<GG"D$$U<"Z.2PF2.4FWR:5QT,
M=%W@+TGNKR[2SZ+F0!'\4'V=,]E>/-!H+E@T*-7.Z<8"<W_76'069XD'[L0'
M$>-,NPBO=E"16E_<[]= 5CJ@.8G7W+=M&)L,PEV!M2MY#8M4/1'6K/;+%[ 0
M2PLY$?M*3O)O]9#SU'+[T?.9GD,^O6^WA'93;/[6YO[I%+.R7ORQK!-WL.X$
M._OQBT?'@>^& >+=@#&'">EF(9*U"\/U+C-&;K]:2.7R;;8^^Z^NM/&I>1/B
M_C=_A7C:7'\\RUP#[8)8(I \ KT'UL^?1(7?R7M\3^HIYZN "4E+E3M\Z1=6
MC?%05*'(WZ<*<S$BE&-TO-V,\D+6SH?<:!TK+L)OFK!*[*AEB)746@I3N7.&
M]3NY8,'FG93Q66@BK'21U('9J/2!DW^M9MD5;Z4;=9;=)?9GTMGS &T+P)]J
M[- ]HJ-H][B[PIPP3'E\S5:Z7G^\H*!ZL?OH"9D5LI J&R%9_W@Q[\<26M!X
MQ/)=X\B!@"Z,I6\,2:<ZV&DFF_#<V]B'$MD9BO@[:UY2:J]&5VAF[UNY)-)!
M4T%UT"5%LGV*"&D2'G8_=BNP2Q1PC!QTM"+?P/RRV#7A=3+N>,XXWL\S8A]O
M'ZT#]10ZD"):57_6OM"39<;\ #/*>ZAWN5JFKV *] =CBI^800*Q1OG>G.W5
M3TQ,RZIB]%0RCD5B%=MO/+T"\]:CDI6JAZ%<]D_//I?-J91[1"K=-I.G.LE=
MH:>P_:'=J6]8%5(8G_3;H2]+HEE8R#-R ->[FJT[*_LM)>US5I+"0N51V]5$
M 2U=Y\31E=GEI.UI5V'(H![-L*NZI"4+G83,^#1:V^!V5E&-SDG!MP1"YFG+
M(A82*^%,]7DA]C"4H''BD/[@EOXE0HRF:U"V#=; JSSGJ<1<'_ES\O,SZB*?
M/"K$6G@JU0>YR*VZ?<U2B-D>^#?]C6SS=''"2@?]S]$R$RW$-BM)^LX"BA2Z
M9]GZO$(:TG3$8IRN6;Q+2 Z>'Q[TZM;TA.055S$B? M0VKTYQ@N5H=<.+2?8
M+G>)"VC\(>P.JOQQJN\^0NU.W>;:4[!ITTT\T,.-W+KRNXY)370M_J1X($9G
M9? Z(U^[2#I4\.^ K?:-7[X'([/^_O?[?"IJ"H#H5CCV]*J*/7QJ-?*/;IMR
M/HRU(>F*I,.?%.-I^-7B\],:YAK1[LBQ@ZCTT897<VC2\<LHUOBRZB,9B.'4
M?F*A2WJ%9,L9XXU&8K78?7/:2G_<,0/X9X?/&.'#_-W(CDPHF.1 BFNT)BQZ
M&L3CH[/G!WMVP1:V79M*7B1YB]-T+<=Q[FKT28M8_YSPH,H@)5VSM3#/$,LD
MM?[XJB"BK\M_8LZ')/#.[KZNB%'MY<1?9%]4U0T!GH5H[;R^BPF]WA2*>#O*
M/OD;WC@G.S6VL*3PI[.-;I"A_%P.B'UL:@-3A,<NQ*)1.4&Y[L"NK=0N6+J@
MMQVE\(.>32(SZ1EJ-%5;\S _CVS,2R>1)8F? &LT(,"]HMJ4^NA!E.@BF$F?
MW9?-KB$M-UMN"V2,7CO+B,5Q&Y=;%I?A 54,7=&:Q6P2!%U01<1"(\5Y2C<1
M8E 8^31/4'[[VD51"K;ZBAP?S;2#42/&U&9<JJX3.G)FORF2L@Z^VG:"ESFR
M?D>0(0,<>O.3WX^8J*5+0D>9BMV\BR#5)(>\+?7V43^<*& D7D%2\@Z6-&I^
MKM7=90';%,1;>C)@]76LW"^R<*H2&L\#;-KI5CJU8&1C^U.A>@6GD;QD*M-;
MV-U=VY6L9W=?7:C.?-J>3/%[LO@&W;:BYK%E'#24N8[3C?'W0!;[P^P*\( '
MN?^:LP>+%71UV@4/2.TBQMS5V8[5Q_+JFZ.&]B'<R5R>A:MTVD#WH,]#Q([F
MS ^8[?AB5Z$*"M,Z@@?Z3L*VJ0J/H"/F#%\@B5+[NYA84ZXTXM&!A4_@.:K5
MU8N]1>7]X2ZF_)LJ]=(4=M6+I.6)NB;.^W(<1L)<D<Y,*VZ1M=P)X.Y-Q([H
M[^\-@QG3YM#A1;8DH;L+-/,7W'3708Z<()/RNY)W.UN:2JD.9.1D]XS@L)3_
MZT(/P2T&%!._=3";V_C;[ 9D8[&*)%PW>A.X$-Z7/0LADHV&S;2!H#Q7BE]B
M!WA+?M"WIW\]:^(=OI7LZ.#.=1QCUO_=E,*A .F\+[N23H(&JXT<N ]H.Q3I
M\G$J,>WS:VA(EG)VN'5DSFY'6OH]F$X0V>=.R":,N;'NL4QH6KX3*?#'CE/?
M4RK]D=5D$9%"5WS1]X;)9K%57_I/>,#VT0KZ!\+!M]R^W!NZ,ZE<4OQV[K?X
M6M][F@@*MRB?DBN_U9+F=M"M':: R)+9RG*^@A\O.N<W&Q(N_YJKO1;IX>W[
M,RVQ5N+KW,; LN-$WL9OPV_8<FE)6_3&;D:T2G'ZE8<YU$B:<8>)U&G8/5MS
M.GQ25,JKPU:9)/_"!*RZ^SZKH^'=\Y7S%W@ ;MD%4AU63K81_RP-F<$#EQ/+
M?12';G\3V!]8KA[.JH&1WPW]=_+V4AE@5>;<Q4ZA5O,-5&B#$5#5: V6^]+^
M2\S6%4#=9+ZTBD@[-776>_5L[<J$A>H$,2JDM=$B/XSM8N5;R\5V.R+_W*4-
MT$VJ:5MF'51"!@7I9GPEYN6*N.+M$^Y<V!OXJWZ#K0L,VW+J;B3RI0QLHFM;
M;;ZSA/ZJC?),7)%^MGCQGJ#QHQ%93+DS\)ZXRF?=H28ZXNJ:8N7&X@&RN?SU
MZ[R>3E>BSP9GAM'MJ:Q\]DCN27SVE^1E/!#"?.AO@;R&5L/\$W9" D'K0&D.
M4; V1SS@)&Z!5?!9WBH1>%>7=1:UJ&K1@TZ+DJ%"JRL2=RR1Y[$JA$SA :J7
ML-O^#]@V00Q24H9X@,;(C.::7AHD+_MJHPQ\\(!08ZK@AC1CTUVT@JO!ZGF8
M$5S?CSD+#Y1KX0&2V-8&6,<R<@D'F,%0=%L,68[TZ<>D,Z,XG3Q4>M"),]G,
M'"0'/:>*>E6NK*WFQ^R3:1M'=B#S-BAJ7G\Q\0/N 5K>*S?DV D+]CB;SCH-
M0L,PZ]$74VE/^7S[M.N0Q4EBIZ7B*J3=.TN>UN]XNQ=_1O$5AB@Q'TM3TCQI
MD:=B\!.SX_8XDJF^BFJB;5FE#/5-^/U'2;I]@%HC^+"?LH\9M&)*T53,-Y.!
M+ T2CNNCG=RE2&9=+Y(>GFN<YI'S1-Z"V*.'5M([ZIW#D! GZ 1WB/,#D:X-
M89$99>B)4U;^"3C2]U811AZMOSCUS'^*J6,OF&JV@X9\X&^_+\FEOYB]:HR&
M)YA@2*2X-==J"T*VU7^24'T24.RS!&^@RKIVA)5Z9U\R>DM6LNM,5OA*;WX(
M9.TY86VF,HW?FX6U+WV>;1S,6R4%D\TH]Z/,ECHX,_1:,X' E&BTBUZ#T>K%
M9JPN.:]:T0XB57&3,_[?\=<%RI\'?M%1$WV[]_" 30,<ER1/VWP^2FA.[CLX
M*!0 F3E*(8THF.@0\/$QV!E2@J_ /@'WL6;("];FX=)F=/@W?V&D[S?8BJ.W
ME\S9OP-A5HA''<\:-K3SW':O0MB^82%&%J%-%)@!E'/;P4*%M0?\ZD9*,SF6
M=:)) !TP-SQC]AJV%K\>IW,6_SSL5P:V^<NN!;+4GW-N=2KL>KTAF!$XCD0<
M77/P.0A=#P41S_;NXH'/"*[<]$:EJB)LZQDM.!8E'04)\97>_%J\]#<-/')Z
M47GM]B'6CLXNS-_;"JE)'S_[=6AZ\_VM#WK0E*0=*(D@5JV)\T@)J^,\=-4@
M;UKY(-YMTV4W_*!--^5PT,=[1S.GK[O$M96,L&9=9R*Y(*,,RTN,@?3DYHL(
M"\1N#ZAQ]Z:W@P&'RJ.78\=G08'% 41^4ZT6T6]OOMXZ0A"-(9U$7GC@D"SA
MYX>?^GXSP"+=SNO#3X62TYR>6)YV+5M@8](I\,!4+>Y=?>\RC@B.KF)C 9T<
M@'^4'C49-Z,>[ 2(4:XH#?_;^17_K\[Y7PM-H[\X)L"XA_)S95\H86^,J*8?
M<N+\@;\9'B "=+9L!R)6;H$/"X^>*/@_#X!G=%OW17U!@6(W'<"PMSX:D(+5
M>@CA(83TPNG%"@F\'S19IY#T2"S?6.NW&'DM15[X+%)JX"J=]]92I=-<6K"'
MO^L$J&#5K$J<U?BIUIR'^[='MIH43?&Q]OHH)=!36+R]G'#@,P_&?=.C1/DO
M:FH)*Y9A-T__\NXWA$#&PO,+JF6CYTI4V,2?4OI/^I*-Z///4_"VRW_8+&AU
MG>&F<WW:IT/S0*&EP&6I1#$W=?*C"J?V'K#QI9-/X[F?@\2D6N;!5O3=PK.S
M7;KD>57Q&R2%6\TGI46M,G3TFI'RFFR>.,O(NL'GZ<9[;2L;YJ9E4OYMK&K$
M*A/Y)]A^OW>-]9^^JDNF25&F.V>LQMC\KO8>N KN8JI>5;64F3E!0/1:]QE(
MGE$$0FFEU#CBH@FS//09;S6>QV'J=_REO/.6:BK. R"\OZM"%8P$K.9O]VBL
M31;P&1BL"E)$WG+)G\EU9%A5AK,_N>)+'V>'2#Z,K&#Y\VN- 7&CB4WW00_G
M =*PU_NW?8ZXQY6MP<*A:I[K*%24H+IV,2P7+$W$^PM7V7^>@P=.QS^[^;=^
M']_D'-?QIB.DR3./1X7M2VTTV+B'9?S^!,UL&N*Z-.C  U4B(>A/]!6F?V#Q
MGBO@\"_Y^ZI*D[]%7]O=(V2XL2B,!Z+"QT,[9^4Q\^E.$_(J%^[U]Y6P9;+_
MGE>/$<DI^/CWJ$3FSAQ3[FN)I3:W,Q/:D33 7D<RJN*!>VLQTD41%D0]:T6N
MW/&9<1Q[<1'1?R5+OYY]CMUGD_D%;#E6P@K$&I>]VQ/:;\W.&4CY&0SSO\Q2
M%& S&-_V4WD:]9@RZ#+9U</6),*R6\QI;+D3867:46!<YO_A;".,[<>V>9>S
M T?^\W.]S^N<&U;W+Z?X.B>;-JY4X98=7:VICN]Z=SR%Q<%'V]$7.D,M YX[
M]/(E1B%O@JO'0(GHJ?)*QR?6NBQ>1?I(NK-5.$+_@)1 WH^-T@/I9?Z)"#==
MT?9XGE1C:>U02[QUB$J-](7'5V%&R98*G*F+^7:^HO@C[BH]0T5>MC?FTDI7
MJ;('\!]0=G^1"??G8A./Q6R=F(SNL4;+;QQ'293VJ5S%.8LU,FM,L*," \WE
MRB_4[35:_6RDIN11LT)-S*-C=8T]>*#)80;+$;K4,BOB=:\ WEOC$^D]&C&V
MD(('9KSM!G*K9621AZV.\B;H+T5HE],O-!@A8=SPT1V6NS*'[Z>RS+QE+$)\
MJ1=SJV=3-M=Z+][RI"QO@57/ S05B_BRM;@.A+F^,%"@<2B6],Z&V-5)\ JH
M["MHU[D3QJYWE2'U,LZ7B+\ZGG9K?-_97\$W$6CSXLU08'^R0R3< "FH?N(C
MJ!%4]$3SPDDU* (01I.\38^;(HR#RRH(\'N#]T$^+OG>K:UJ,4<BLP#BF_)%
M4<=IZ +'+5ZLQ_U@\V:,K)#%/2/6$CS %APO+8E@F\B.SM8,@K,:3NTP$./:
M7F'S0+@KG?$095,B0J]J>P]WK3[JQ=H!@YH7S S4?=O3>HU=N7LU'@K+>G=Y
M:]U"K*7</3I\H8DA5\D>[!5O\,"G4I;CZ.O6KXKZUL,\78O!)"<+[-]Q [^3
M:B10IA)XX(_OCSV/-\U?CB04\G3T4Y5W_X?;R_YYTQ(].1%_&H*+O9=:T/.@
MK.:=@T/WF'>$<(^B>8[;H-*KI#TI,#*7W.;/QR.5 PZ4V(7#P-.Y/AG9\LC6
M5P>P!A5^ $=K:6)^'ZV4M6B<F_S3Q,QHU\7>Q2[3I+Y9="%T<#N-/*OW!8$'
MKPDOA7W68YVT$HE)%>F1#537K1]\4K[9KD7^.1PA@ZB_LFO'.5%G4PXYU?NB
MS48,SFN8.I:@$^SN.!Y8,?9676I/K!E6\H.M$.:H>-AZ\&59K:Y*:C/J&\E5
M3Y#U+\AL6QC7409"V;H%#_;>PO6JC-Z$N2>MM=DX\GR2BL[Y\_E'DV7+?7<Q
MT[V>8>V%- 6;W&W-L@2,GA&[.73(AIF1Z^QFA.!DP<YE]$053^DK.2()W4A?
M#H(0BS\&2GEHQ5E'BM4CJQ^ELXI)DY,<GHT-CE]N83TX\S#9D]DR(.3"9@D+
MSQLO6KYKUV.GLFG^889$;LL9<-HUP?!(3!\U-<JE&G#[B.7%G$AAI$8G:\(%
MW(NDY1Z,6E.WCO I%X!3\K<*P_XL&(D-/#JJ_G$P4EBDH\=1_%U+@>YAACJ.
MUT,<G?^7.,^?YKG[=0B_P ,9=GC@))-I?:4M8 UN:6;1XL\JOBKC#4)&@G%Q
M\J:9Y&4?"\L0Y\DQ#LUWSN!\PABVD.M)XR1_>BME6O-9IY](2GBDQLKN 3UM
M::=P#2/D8,IGE7J:M09(7Z@YKV<Z'_K4T$7%#I'6G0JT&^6=!T@1*]'FY\C(
M<Z7;6K'IKPP*0N:/R]+O7**0XC@5BS#8[M)ETL'N)S1].EI/AG4(B\$#.F8+
M_E7.JVKCE\:@5GCFO?_Z:.>UW$1\PP/.W6,8P1<V+/YKTE=%N[T7S\\NJJB]
M=5XE>C)ZD4$Y&OK[KF:5:F+P0/,+]+T-$XSK5)_ZWJ@CZ:[)(J%U^.(V%QXP
MJHM[#:.0I1NR4'TSR7\T=_N[_^*/TN2540476,':IJ'N\73*5+MY]Y4E5:$Z
M*\4// #J%/)[]_OVMPW4$ /=H"*9<3!X@>LUE*Z&?/B88$AK]%?"[Q1[C.$8
MMQN=>5:)<!,*\*518<8=NZQ)V_?NOUO+*Y%CE"[<7SXM*L,V&V>!%KN+HF.K
MOR=SFWN+W5_-LC#V$I!]&!(=JUU74>GZE)[T#[ FME-#3PBYV\8"8]<G(9:M
M=+_BZVMXEE,U=[_1O\4\M5"%_\.MCV(QUA>_VL""*,H"%H.Q#6'_V!BP^*I^
MVL-X^HI:<I5DKX/R5;%X [ WU=AN&@^X.K'O,2?7;:F%QN,4QVS,:\=LDR<N
M1ZBQB/&O'^9J*[DC@KLN!ORB=1)UUD#E&H.$<*RZP,%^CJ9F9'*8?/R CWSG
M<#>JK(^3#ELT[6CMJ?,=^XL"P%6MS^;4F^Q,13=K\4%?QIJS.9(^4L:8TQ?6
M[>B8V,J) +25W[/$CO:N[AH_UPJG4[A/\BK=V&LT:7I[-"?PR74Z1((N.LMX
MCGN8SWB=%^8K'2&J;K>FG:(@^S*AX*]W'T-/Q[E!\9[7*=67(Y'"?0T+SMT%
MP<BG4]S9/%W8F[HQRIYIWKFS^68R\UY4@D>%])CUR&]/9Y'95YN>Z4+^ ?4*
MZ""RH%".FJ\1IYB)8>\;%Z\T5(9Z?ZYMFX9U\%G]1N?DM^\AUB^$\[XO>6V4
MNK7/KL]29"=Y)GI/CL:(F_V\\+5:]CU#(')"M[)H,2 !J4ZAHD?3E\93VN$2
MH9!FX[A=_94F=(=_K8>CG-Q+'%>M->=/;<F<&+7N?OO+QF7*CPQ9KI3RAE>R
M7GP863$_D&93G7,4JT&5 AZX<Y/$99.RWZ!?1,F5T,:PWE0<S'F2+]/WH=^E
M>('E_^#L/:.:B-Y^T2 (BB"B@C2)"H)TZ9V "J&(2 V]B-1([Q! 0$"Z@H"
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M]8/]QQ"SUN[CS/?HZ.HLW&=K2)W10$YY _N4Y?NR?>F'T5U3R,7T!Y^*[*X
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M(V3U[+VM6BUF<_ *Q,0$CERF*P"R0[BG\$8-S^$5P)W?R*HU\@I@@0>W7@/
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MP_T_YWQYW_5\N,_S8;+6;ZW,GCU[[=G[NF;-S.X",AOY6L _=_1(/'U2AMA
M]@LF]_?_.#AS:F\V\C@O-E;1#*  ';Q4[DC/?E !:NK,.\.CQE[P1=!MQA"X
M*35U]3-E8R7P3'NQK&U%B%+O>/I80/T?D9)QX86]:JB)7M41XPUYT-&!(.EG
MP7[$-)1_]&D1@NOF]PZO%1N\QR:]*EE6:EPHQW9BF0OIDD-N7TQP+Z->ZF(
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M\P!R;JNY-=EC_1M:(SD7H+ 9>6M1_=[#/YC),)?)8");M"$3QVW;:@L#F%9
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M>=<BH7]J(4O\Z]/)]XVNJ3[Z=,GJC?X?N5P:?W'RURU@QUG@JGE/1X828?6
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M%>,R=(AX'7BAM&!*-UC]6++;/W%++[TP44BTD>KJ>NNY=QM=T&$BS7I#<EJ
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MU6SHZD4_-=W99YIB>[!P,O[#NZQ8JYI"9*W"YWZ=RQN>AA^],52<V67EY/1
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MUU@2/*' _"-18?3PF++Y_JN['Q5./X)_@;\C_VZR:+&NYJ"/]W!F<U?Y*D@
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MX*9CK ',",H-!Z)>7E$<1X=?G-S1$Y:JW"3"R%WQ+(HBWMV][>6%2P_3ZWL
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M9=& H7.8$T.N#L^W'$)\ ,GVK<N&T!J+L.&7^@"E,X%=%/O-^*&L6J!(;+^
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M"LTQD,E45(C9S(D(4>G=6)AK)T<W.7O\OB9<TW*2C_8ZAC9>;,CBY!?IB>3
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MC-OK'[= M5R6.TW0'JBF/C+!-]6S*&TUA.@YOU/!7T;JMJ[8C)8?%+\_ %#
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MVZUVOP=T_P"Q^$5G8'S;F5G9CU(' JAXX\*V7A_59?%<$#!679>QPKU!X\S
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M&5WXIL5LULQ9P%LLN=Q;'J:Y'2/'&FZC.D!A>V=N%,@X)]*Z.Y\NVCW.2JY
MX&>M>?A.%L/A)JK*G>2^Y'LRS3%XJFX3K<T7N<A>Z5-8WLTT,K3M(H&T_<3Z
M>]):>&#,_F.,LW)S7;6]O;W5Y';"2/SFX$98 G\Z7XD:?;>#?"\A_M*!M6N
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MV*5VQSJHS%X-K8^>H/@A<>6C->R CC!S5ZT^"J0L"TLDG/8FO=O[#W=)G/\
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MMXEZ1K^5648+V KYJM4]K+F2L>Q2C[.-KG.MJ\$?5)O^_3?X4T:[:[<XF/\
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M''<UHQPBI%CKPZE252;G)ZLZUHK(@CBV]/Y5-MJ0*%J3;6)1_]E02P,$%
M  @ Y5Y_5O CZ,>6#   ,0T  !    !F;W)M,3 M:U\P,3<N:G!GG99Y.-1]
M]\>_F+&O,61+498\Z;9+F.A&"#>2K4R,?<CMEB@SHT1D#;<]!B6RC<'8&B9,
M=LK8$S+*+@9C:\;\>*[?]L?SQ_/[O3_G\]<YG\]U7M>YSKD.<X+Y#1 T-S$S
M 5A86(![QP=@3@'7 396UA,[%NC8P)Q@, @$YN;@8.?DY>;EY>'FX>'C/R7(
MQR_$S\,C*"HH)"P"@4!X!<1.BXJ</B4"$3GYA(7M^ T(S 4&<XGP\?")_)_%
M_  (<0)PP(^-119@%6)A$V)AD@ 9 & !L_Q3P'^*A?4X1W8.3BYNGN, O"#
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M8;?[*M,@^4&5GC?,CON7[VH;<LE"P2=J#CBZI3&9(U0]M"H>,($__*D\D:M
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MH=S*U,"WE*(QROW;)3- <O^;:-V-Q'@&\,,<G,H@ +"B9N$ZZ>G4'S88<#2
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M;WXZC]1,Q4.=,P#MK8GJ/9GDR4D;OB]?$I75%K%K*]@2V-73*>$;YSH;O5]
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M(8DM=^F483!9 MBW3;8Y#TT9_QDECE68X!N;KF)*J?89P/ITK^W\;IODRV>
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MH5Y) /\JVW=O)T^1+CCXV)P']RL= U_UWAU6GY+A\/8#OG6R<?UXZ7;A]AF
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M7O4!JOGI8"\S)X9:_9HLV_[[EC<2PAP,L:TC82B<6:=K78>UJZ'ZHX].G@\
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M*J)#DD50F5:WJ5\*)&=0G4W]&U!+ P04    " #E7G]6) D?+Z4>  !I'P
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M _%\D3?'&\A6KBHR]R2=:PM7\,LH\Y,&B)>CW[S4ZDA9+$7\=7/B/E#6<]1
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MJ^K, -H_$YS"2XEEC)*2#EJ))07=;8X5D8HF#<3**"ED3TBY1,/,S5[\L)'
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MW;PPS_R^H&/ H?XL@-<QZ5&=7(>UF%/ I[(/B0#I,S^=_V]02P,$%     @
MY5Y_5B0)'R^E'@  :1\  !    !F;W)M,3 M:U\P,C N:G!GG9=G5)/!]^=#
M[R!"Z! %I4B3WA,4:2(B14 0(@)2(DU 0HVH="$"@D@5:2)-.E(2.B@E]"H$
M$@M%()$62 B+O_^6%[LO=O?.W#?/S#SG?LYWSIU[3^=.5P#G;AJ9&@%H:&@
M#\X&X'018 "@HZ7]-\^,_FPR,#,PT-,SL#(Q,3*SL[*SL[&RL7%PGC_'P<G-
MR<9VCN\<-P\O$ ADY^(7X.,5.,\+Y/WW$QJZLS/T#"P,#"R\'&P<O/_/=MH)
MX&8&; )"Z&C$ ;3<-'3<-*>] !  0,- \Q\#_'>CH3V+D9&)F865[6Q#XSD
M+0T='2T]W;^HSU8CS]8!]-P,YR\J76/DL71A$@_@58Y.+626N%[;!;0:)UQ2
M>?CD.0LK'[^ H-!E22EIF2NJ:NH:FEK:!C<,C8Q-3&]:V]RUM;._Y^#JYO[(
MP]/+.S H^&D(/#3LQ<N8V+CXA,2T]#<9F6^SWF5_*"HN*2W[6/ZIKKZAL:FY
MY4MK=T]O7__ X-=O$Y-3TS.S<_,+JSC\CY^_?J^M;Q#_[N[M'QR2CH[_<=$
MZ&C^A_T?N;C/N&CIZ>GHF?YQT="&_-O 3<]P48GQ_#5+)I< 'G'E:&;>ZZF%
MM5TL$BI6!.##)^.L?)=45R\3_Z']A^S_#NSY_Q?9_P3[7UP+ '8ZFC/QZ+@!
M$,")=;'OFX;DB6<2.AU>51>W_3U3,==F4$8G#6C8.Q2G'!A(:$E!\#HKK+NG
MIWKQ'Q(W'0SO_^ZUM;DXBOE4O3\DJD&%J#'[/$'\;$A$#T_#H'Q>&I.J3Q<:
M\WK*?[KFF8*JHD(H3">Y$7YDDZ,H12(V?E]:52LGZ,KDU<S?HL1\ADC'0NI
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MF#&&>ZYZ;GU_=L.;5XEN 7WS3/A<*K]%7$']=BW.R6NA?_%.:]I1\>LM6J
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MDR(YYKV/VVCO'9!4=X>WS62#9[M?,2D%PC4D(9LC<V^1II,)$@M3.? X>=N
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M$J9E)*IX&/X#GX_*6(&(Z J61$WP4:5)(?ZN:1,38SP2BDK+GX?=Q.;>&U?
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MI6D_+8A_[.5.+KNBSLG5*-V\,,_\OJ!CP*'^+(#7,>E1G5R'M9A3P*>R#XD
MZ3,_G?]O4$L#!!0    ( .5>?U8&_1J$G10  - 5   0    9F]R;3$P+6M?
M,#(Q+FIP9YV7>334W__'WV,P]GT+F19;UK(79I0*^<A2HK&,+%DF)F6M:49D
MWT(E2F0I2H;,D&WL0XNL$;+,#"D99H0FQOCI>[Z_Y7S/YWO.[_=[W?O\ZR[G
M/E[WO.[K=7<^[\P"8F=.VYP&0" 0X+7;@)U)P!( <W']Z;O&O=MY^'AXN+EY
M!" 07CXA 2$A00%!06$1"3%A$7$104$Q&3%Q22EI:6DA45DY&2DY"2EIJ3^;
M@,"[:[AY^'EX^*6$!86E_L^VTP:(\P%W@0HPZ # )0X"BX-VN@ H (!X0/\P
MX)\&XMH](R^$CU] <'<"40S@ H'!7-S@/Z?>';VU.PYPB_-([#]RG%?2\1+D
M0*B4WNVLIWP'3]2T2SL-,I3UO:_%\@O(R,KMD5=155,_I&%@:&1L<O28Y<E3
MIZVL;<Z<.^]\P<7U(L+'U^^R?T!@T/6P\(C(J.@;<7?B$Q*3DE.R<^[=?Y#[
M,"^_N*2T[-GS\HH7KVL)Q+KZ-PV-'9U=W>2>WK?OAH9'/HV.?1Z?H%!I<_-?
M%[Y]7V2N_EQ;W_C%^KWYAPL$@$'_:7_+);[+Q<7-#>:&_.$"<47^F2#.S;/_
M"*_$<4?(I5#) WJW^:1.9#VM:><_J._$D/:^-B@@HVQ 46'^0?L'V?\.+/;_
M1?9?8/_--0$(@4&[EP<6!^# ]KGB%'7@?ZI438H81\-+]LRV0GX@UMXI:1N]
M0Y&=0N\FN4'+ !=F;E>F( 9>)\G*Z4)$Q"L(OT.'7-"S*N>>&WO2ON6%V=O8
M?#. =#" Y!LUU>A=A%7V;M7'V# FG5C):+7NF4PE YA$]9@OJL#81B,D7/.A
M7$$J3X/)2;!<_V@SGCR1V%$V[#G9(0]-FFOPY-FH"9=S_P5SPM-&\QX5U,'#
MFLUI=I#N"\SW)3\0V!?9PN]&<P^I6E6!^H(U$S["[K.TM^!1DN16"9C*=T]%
MQE[Z<M[+#Y3Y$>TJ)4/"'<7FRO.SH,^19B[+Z%B,*3S>3+<LT%C^_L=:\X+&
M;I5M6DA^!#C79S%0IN!3WZ)Z\>UX*4<+GK^5DS\I (2*98W3?H@F[ #"Z^DA
MG)XM5RMH#KKL!1HUF6CJ$Z-[ZX/%YF4"^Q;3M*-5R.#!"/L<_O.WB)BK8]?B
MM3F+Z_ 8?!9,:P=H/P.3^+Q=$-8GLT7.;<3,!!!RWHM-:I7L,_%?2'MB4625
MR^KD\(\QD;1335&3722-86]F^L_H5R5_0=^]3LO,YK[407<7 F5H/F;@V1*Y
M5,,IIIU/UPV='%1A?H"M^]'UCEF![X;VK$,]W:*2ZCO '2O*8R.F7N;TNQP/
M]A1G,2VE)V[CX3:^.5SQN2WCT_R]D!U@/W'0K+IP:?Z;/J;%OA'G7SB>VKX#
MU.(2)NT9\[7NR"_JQHVO!J;,WXN>8VM^*TE9IQR>#5;[WH?U_CS.^8+5R;I@
MF^YV-CWC^-WV$,C(6#E+<B-PN\*P(ALGPPYXU#DH(6CIHS;AVQ,ZH&X@55IG
MO?7RHT),>X5F"@O%F.= OP?S]">%XR2FW\9I;^#A#Y>LPL'QT#-T=2V$>G&,
MP-_I]\Q&S_:+77=>;@6T1@<[;U);' @(Y\?/YWNWADTX5,XS4A*^;P>8D*7$
MC_6@68<@B68J+[[>XNJTCMUT?73?:-&VD;;]O,T 1,9(;M_%W-Q"3F<FS4B;
M694C L8J+]=/'V]H</\Y_Y0JMWWXJ/1Z9.>N)W&UN(Y6*3O*RYM[^3'G@B3[
M.%/[EUVSVH75)W"SAM\Y^LADV-Z15[X,SSS*-K*SVJ(&EA[1C[I:&IGA>+]-
M#F3-1L4S_<FZ8$^#&Y'=>& F*G#N-_9396#L8C^CP:)-]'H*=W'CDUJ::&($
M3)?A\3&U+$B?Y7QY8C ( ;+VNU/1JV%!-F]*F=4VA*>V"OG7)[K*(S/9^N+;
M'+Q@JL)6@,57FX-PY8= 3II\Q5.V,"-]38:CPD+3/'PZ(ZZ+FSPZ-4(:O*0G
M4M2M.@<&,HZD_/;9^+B-+V458 IY.+(>MZH7QQR_-SXABAS/R^L@B-'JG?KH
MMRWZ223IJ$5XLB>DFJG=#+-[\I3D=F5!E^]:.7L'B!+B&(ZYF#)^=51'0=OE
MH8GT>UKR?O>,D@ .E8?C-7;JWX34/Q5-)C+J%/!I3Y28ZZ6.SYX&^H2631^E
MS-??37!<(>:N&WX;K]*DYG;W"[#W,CYLKJ0:)AFD\MVKUE-\>PC:*;]^>4-*
M8,&8J7^*E>>'MZ3"N5 RD:&6LKG7*78(\[I?*2*15H=_E^3LY>^%W?_ ZMFH
M9KATV@/'*]BG[%FGPU'Q7M/2>4.+ZP\EC.*=CD-J3*BD@]M%\-EG2CK,M952
MC%D"FC^@-@<ZZ6LQ]A/<=I 0O3;WTQ4)V@%F"SEPUG=CMC)6N[&10<H*HUI&
M5_!F<YC7L]M=V0WK\/N.CY]M'A2DM=(SJ3M AA+NCMG>9X40EI&+7]U F&MH
M9'3.XUZ'T.QH9^@YI"VV'5?]Z5?,NB TB0,G'$:I/QPB7 3@E[_ Q][!%YX7
M;^#+.'R<]W A#A=YD(6VBB<^L)\)BKQC&ZYZXV[/<MRW-WB_=*/9\%*3JLIK
M.E]2PJ6<#/XV</[(TM9Z!/053K#JT1;=N,E"X:@M 03R@0.$FC2J;4/_5#JV
MI=]+DUE/5>O"*V)'D!)%S2/YP?YN(\]7#?IDA!X6<3,540->X?!D_(M=3[PZ
M-ETT;<#"%1_."@L-# T[;"-\U*NUB!.VPE*%M#-?6-'@2;>U)\^_5K,9]*08
M5TI<^;(JOJYA0L^_;-?T><T^%EZSG+.ES[K10R:I,^ZO=!4JO#V KAT^:.-B
MRWUMD-P%N310/X^T1&!'H2+T*IYG3>6>K-,,L829K@L2$UZT9]0FG+NS%#.R
MQYX_7KX^AFU.?>_KH$3KW'SD]H'S:OZO(ZR0"IT=(  J2JP?;[X^BQ,/4!__
M8AB\;VHR372%K.B=53RH^(N^GZFAR\]2&J9!8M=-S4/-]#5VUTR.>VC5> :N
M'I8X&*SVU7./O:?FM-D>:I]QCY+L$'%;:5[7H._,N(Y7OM$7@>I^I.=,/&:2
MF>/$<L-MJ;,1GYH%1>X^N![X6K!NF,XNG)D-%GDC%W)+4Y##CZ0FK_>//S,W
MLI$_-;B^AWXN=.Y09SS;6)YK\_.67HIZT:53>A8]RX\5A[\!_YJT_Y&X+[WQ
M?I "_,[<6-G.7^; ,5K)!+YBM/2W:X^:I.]Z?;SC;1T9H7S-U%> ,<-2J4\E
M]9>P3[+\RT.&B.\5^NM[)#&UJG.K<[,[@(1>YL=6RS-Q2'.V[W:N-G%%P15S
MEJ'%9*&H%_*OU?,930:%[@!2LAK'$A31B_K3MR^&H-S81U@5E'DU&U;E!,'T
M:G54ZIF,X)F+!S5.&3;;,/M//!3LAT3Y=,LT.,\\"T*CU/> ,MX>AX"?$,_V
M4'1*F%RKM"Y(-_880Z9QE:=IB!ZNDOWQ$ #\MEY\-_BD*[SJ24>_ VL_!2[Q
M@Z/#W'A*?76 /(4WZW.:5I^>$K?Q$Y93J)T\V *&N>\ L05LQ#!;C5'72:'?
M$;-\%97AV]*2 %2\GM#/=@N8JP6._HCS6&!+0MM=8++;C_>-A'@'*'B,J)+2
M]US%D*3=F%RM\&;M9U%Q&S^VGZ?,V*O+=]%#HXVB7@_?W>Y>^WT56%=M#3([
M0NF#=V"5A@T\=*:"#:9@4]ITREFN S$ NWP_2C.?0' \?NF4E /HW\DZ6JZL
M.$8,4R*]NL"6RJ=NS&R<9B(__Y5*0IU_$]!.E=18^6@:UG?+QI6CQ2#ETG1%
M%A$Z-0'U$Y>?AHR.&:T*5695MTN!?G?O -Q)@UJ^3-FN6PAG)-UZ'[$^/NI=
MQV1>TN9=S;5![#=\OX?@1C K>4L,X][ K.^D'T,GP;A&I"87$=H5@CAATE*5
MU..C9[O"]Z+HN,16&3-CIE+'GK!'V_6GP+;/I\@#'B=PC4SC?9GO8KTK*R/N
M.0D@!/[U!=G_ICFVS]+>X&K%K$&&%)9P=]KMB\^[)T>OZ1F9'&6_I"%9ZJJ)
M?M1^*!O"V,";#7S++TQ2KF]QK?H+5*+>P'-;;G-K;/_664[_;BW%X<7H/NI&
MBC8C7T:AR/)A-74Y/%5$[?&F>]5=!R2Z'F^%K5A L83>%-O##L<>F'"5; 6W
MLG]E<K:D5Y_3G:FBXN[8ME^;I"J_83-;6):?X6Q\VI6<(VEO:,^51^&=HI_A
ME-9DDF*4O_-(.%YR"CD3..#>;R"_]B)C^78RV$PD +SDFZ?LX!B7Z7Q4BC[=
M-2;.P%%TTAG(=EIGOO1T2?3SU&0=[OR"\89[LF27:(YX!@_FT18"I:3/HC//
M.3!$._M"/#1T@>]H_&*DT>O#^E.W'](SADQ%$D<&(%,67V/&\;K;^5B=;F;3
M;$^BV?DBE;F!W[),$;.F<LY%%\[F'C:JI_D@5?L"C2.@0A,^X''F^UHYQE H
MRY50>>FTBE[[,? NO^O7]$]S.P QHB+Z*>=CH9CNVE9%)=YKJ#2J:M\UO$)H
M[\&G>%EF:WHX79?#WQI(-0WVWA".Y(B_MSE;FB,.6W71;JTZ:V\ 6O^I'F(]
M=],9NN2F2Q?'!.]'M1W6,2O[":Q-C9*TMQ-AQE&%G3<(2 &8VHP=#%^.4*VA
M3#FMGB!O3#L+>8M@F8HTIO0$]M,3;29O^I8E!CQ(*(C8LADFVIWU(]43[KWX
M\F)IOWODW@#P8O>E?D2H%W'5A;Z7!I<,A-?)MJ5#K$=UE]9NG;!!<,@33C7N
MZCZ_QMYP$7"!\ R.5B,KMP0CS7)6-N(8?_+>LN/4'/Z2[XSW:(N\=G2#-AH#
M*YVR>>/2V\IHWWQ%[CN[0LO,*&,Z]>Q6K^K+)[I>WSRU/>,=U-,&35<R9NB2
M4:VQ4!F\I,LH)B>\B'7_W'OY>X#O2]$54"&6KTBT\I<C4I-UO6=:<P0^6^2I
MRL@;#4%V1&"54N8"XQ.SL\5:390:#)=:"48-.$KA;9+)I["7%5KA"N:JT:^6
M#Y@$?#FT/_%-D>B)J=.441*\@=5"I1MS^-^*9AX875;H?EFLW;-10BG3VW/5
M+2N-^IHMO 5GWV1F)AC82XE.Z#H1<YRK$U:6=H#QH/?0A[?KMI<4_:O4P73G
MX!%B&UN:@4XU$YS=&#;SIZDQ/^(W\E3D2Q]T\(H_#DXK5UO^V=\2.0)BHME2
MD(Y-=#I,&0,>(-[3+5U4VO=@>HY?R)?<6Y3>N;P=E$O&CXO.SG1 $V_TI)L=
MK?C"<NG:5!:.+ENTO*#SXYC0BQ<-^^:8:?[YF\:TW*69V=8)F4GKQ&Z&9V]8
M'@)E<R4D'Y+^T.MQ1C/(,[04UVY*$@YLO-\R-9KW$I4*3I89N_#)[PE7VX(*
M?SL[ /R!H\L^/H8]A&O7\V=:)=$$*V>^#S0OO:S_<.#J4V:&,:B0W-BZ^W6J
M1G;8W:2,)80KI I[5*$-WD?/11&31]!1(S6 $429H?D-G33#QS[*M*30%V+#
M'[ED=HXYEMJC+W-LG)T$X@\6S;K$[9;UW#06NN'"<)>24?7M\QJ3[7B;&HNU
M7FJ,.=3S#:-^Z>:6^:+D16+'MT9A0GI0?0YA]:UFMJ.ML99M%E(%^^&)%FN8
MT=_9.%T-XUF$:8RP/:(FB*.UVHLG?XGWZJ42TN(!AOF/[Q=;O>W!TQC=.H;T
M\DNJ[3:ON6.XORPB*_MB*0!DS/D6]4SAL:]?I]H38B=X5F<3#%,,]DJ?]Q+M
M=8"TM=:@TX@[0#R<()N*58KJ[,Q5XB4PKY/JBP-^.?%:^[[5R:JWS'I2,-H$
M%YK&7=K]%OYEYI!/R!HO.-<9JEKP%=,:0!XZD3/"F#+7G.9H8_M)2JP&Z@IO
M5(YC0TOU*$8S2F>IZDJI@*NOI +SW6/<L43:V-(X!9TY>L,')>$9B!B]OS_7
M?I30@'G4=-G<(F3QEC#@@YV4IV<D;NFR.+8_[M5+?N]#BUV/4TZS<';\4GB&
M:9^FQ5':S:?(";>9=BU9*"/C<X>/7Z>FOJJ>9NTP_)*",+++2#ZW"Y>$56?E
MHI_U*M<.&P9V3&J"[WJXK+B\9H>Q=,O8H2R7"A;4H>G-$.$'14[_HL9*I@^O
M0Q$S\YX P"A,@@(AL".<]S,B1)S(F2MF.$JZZIC#P J5\B%5(H??/*+NV(VQ
ME* 9Z#[6.A.U$3BBXWP%X_QL,=<(\?5AIVCPM2:0RDW>?5G(IUAA1DMK'$:E
MY)O1:QO#NKS O:5.MND?RI\>-UGICHI,@GLC>7] "3*%S*"AC9\VH]H+;A65
MP<ZP_E"--/25M-B;U!B3P@D)YQT@89G%??OV)73D?4C6XU&543R:4<(1L N_
M14T>&K9G8A,>3-C-D[D@#B7O(747K1=&7 9(!BQP&8M&<XG#*GL$N5S83$PX
MD&UZT\01TU"_D*OVE6;^\AP-WH;F94<S!@:;W9YMOS"9O-4RHCW_Q0W^J^3N
MM=:S"3'F/*[!_>@AD@K3;@2Y!SY;#!.&R8:/7&$+/^^=Z%OR/]Q!?\,M=*S.
M5>@6JNS-=BR>-N@_= 5FPK8@#'T.MC5N$977M2"5^DR78_1WKPWW \I?E=5L
MR"SLNN'\TKWLTR<BL3FH7EG,^OK(7&@?8-H1Z1@XPW!:D>L.VP'\L[<Z&(+.
M.?,_-^C:M6-R\/LWD?2+Y6ZNG-WH$E=MR/-*W9(/G]G?]M8=Q,K65-N(V\Z[
M C.:"KA!3VB(ID 5 ]0B"JA[S40-(1X9\&2;!2CBI^T.\+F_!R=95:D-TV9?
M(C$CX^E^%Q^=K"&XG6ST6Y#06Y<"]49EDV_MYBA[*1<'@M,.T&$JE6 L9XIP
MZ(0[6"VX(07A?OBDB?I.N, ,@C/ .3Q$KPIKBBZNJ8^55!08K!"O,)L%9W:0
M$EB#C(@Q:D][@3]EG3CQ+2)RM")0<?"DHD7*:< ]XW"12^)WY&LKLIWH7\3A
M2GC@WH@A\JA*+)^D;>*5T'+0>?]JP $RB!-@0U]$";9?0.C44A^M[%D4T\\=
M-51VSO?Z8"TDFP'JH7A$G(J>:8>#6+64E00=@Q59UN*/GLT[N=H&B/3YQA-,
MLD57E"<?MV3AC36[XACXSOA_ %!+ P04    " #E7G]6@=O;_OX6  !3&
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M<]H@7$#KRV<3%6A<%EP#&: 5PF*-/O$U(4:2<J79SPBAD4&_GB88V(;TT%W
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M_'J9%,Y/-Z:P*,*/!\*NY^5O!EASE :SS!OZ./C$GL^L4F@JZ/* /@,F9/"
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M W6D<B<\L.*1XY?)WF:=,$)LR=.QX!0FTX03!F>Q0DVZ).9*X\5-UN>2(\;
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MX?\3_YCXGZFZ\J'_!5!+ 0(4 Q0    ( .5>?U;]",69I1<   <) 0 1
M          "  0    !A871P+3(P,C(Q,C,Q+GAS9%!+ 0(4 Q0    ( .5>
M?U:"O!,PMAH  -)< 0 5              "  =07  !A871P+3(P,C(Q,C,Q
M7V-A;"YX;6Q02P$"% ,4    " #E7G]6LH!TBULU  !Y+0, %0
M    @ &],@  86%T<"TR,#(R,3(S,5]D968N>&UL4$L! A0#%     @ Y5Y_
M5D?ZM-^B?P  FNX& !4              ( !2V@  &%A=' M,C R,C$R,S%?
M;&%B+GAM;%!+ 0(4 Q0    ( .5>?U:Z[@GDK58   EZ!0 5
M  "  2#H  !A871P+3(P,C(Q,C,Q7W!R92YX;6Q02P$"% ,4    " #E7G]6
MD_'DS7$(  !/3@  "@              @ $ /P$ 97@S,2TQ+FAT;5!+ 0(4
M Q0    ( .5>?U8W;_ 7EP4  +8B   *              "  9E' 0!E>#,R
M+3$N:'1M4$L! A0#%     @ Y5Y_5N8M#(6^H0( 3Z8;  P
M ( !6$T! &9O<FTQ,"UK+FAT;5!+ 0(4 Q0    ( .5>?U;EA[V;_%(  /=6
M   0              "  4#O P!F;W)M,3 M:U\P,#$N:G!G4$L! A0#%
M  @ Y5Y_5K'ED&HD50  N5@  !               ( !:D($ &9O<FTQ,"UK
M7S P,BYJ<&=02P$"% ,4    " #E7G]61I"B?\=G  !I:0  $
M    @ &\EP0 9F]R;3$P+6M?,# S+FIP9U!+ 0(4 Q0    ( .5>?U9WFV=_
MX(X  #:2   0              "  ;'_! !F;W)M,3 M:U\P,#0N:G!G4$L!
M A0#%     @ Y5Y_5GU'AXX'?0  )X   !               ( !OXX% &9O
M<FTQ,"UK7S P-2YJ<&=02P$"% ,4    " #E7G]6ZP/)3X/%   YR0  $
M            @ 'T"P8 9F]R;3$P+6M?,# V+FIP9U!+ 0(4 Q0    ( .5>
M?U971,BFY%(  )%6   0              "  :71!@!F;W)M,3 M:U\P,#<N
M:G!G4$L! A0#%     @ Y5Y_5AY@5]2LGP  AZ4  !               ( !
MMR0' &9O<FTQ,"UK7S P."YJ<&=02P$"% ,4    " #E7G]6-_<L+9I+   I
M30  $               @ &1Q < 9F]R;3$P+6M?,# Y+FIP9U!+ 0(4 Q0
M   ( .5>?U;T66,1VT$  *I"   0              "  5D0" !F;W)M,3 M
M:U\P,3 N:G!G4$L! A0#%     @ Y5Y_5KIY5X*S>   H7L  !
M     ( !8E(( &9O<FTQ,"UK7S Q,2YJ<&=02P$"% ,4    " #E7G]6L*@V
MRL>B  ">IP  $               @ %#RP@ 9F]R;3$P+6M?,#$R+FIP9U!+
M 0(4 Q0    ( .5>?U9]9D8JWX\  !B4   0              "  3AN"0!F
M;W)M,3 M:U\P,3,N:G!G4$L! A0#%     @ Y5Y_5C% .EW=Q   1M(  !
M             ( !1?X) &9O<FTQ,"UK7S Q-"YJ<&=02P$"% ,4    " #E
M7G]6N?.>:Z4D  "A)@  $               @ %0PPH 9F]R;3$P+6M?,#$U
M+FIP9U!+ 0(4 Q0    ( .5>?U;IBN$5*5X  ,!>   0              "
M 2/H"@!F;W)M,3 M:U\P,38N:G!G4$L! A0#%     @ Y5Y_5O CZ,>6#
M,0T  !               ( !>D8+ &9O<FTQ,"UK7S Q-RYJ<&=02P$"% ,4
M    " #E7G]6U)>+6<(K   L+0  $               @ $^4PL 9F]R;3$P
M+6M?,#$X+FIP9U!+ 0(4 Q0    ( .5>?U8D"1\OI1X  &D?   0
M      "  2Y_"P!F;W)M,3 M:U\P,3DN:G!G4$L! A0#%     @ Y5Y_5B0)
M'R^E'@  :1\  !               ( ! 9X+ &9O<FTQ,"UK7S R,"YJ<&=0
M2P$"% ,4    " #E7G]6!OT:A)T4  #0%0  $               @ '4O L
M9F]R;3$P+6M?,#(Q+FIP9U!+ 0(4 Q0    ( .5>?U:!V]O^_A8  %,8   0
M              "  9_1"P!F;W)M,3 M:U\P,C(N:G!G4$L! A0#%     @
MY5Y_5O]74[77*0  PS0  !               ( !R^@+ &9O<FTQ,"UK7S R
;,RYJ<&=02P4&     !\ 'P"'!P  T!(,

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
